Any feedback?
Please rate this page
(enzyme.php)
(0/150)

BRENDA support

Disease on EC 3.4.15.1 - peptidyl-dipeptidase A

Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
Aberrant Crypt Foci
Preventive effects of the angiotensin-converting enzyme inhibitor, captopril, on the development of azoxymethane-induced colonic preneoplastic lesions in diabetic and hypertensive rats.
Abortion, Habitual
Lack of Association between Angiotensin Converting Enzyme I/D Polymorphism and Unexplained Recurrent Miscarriage in Saudi Arabia.
Polymorphisms in NOS3, ACE and PAI-1 genes and risk of spontaneous recurrent miscarriage in the Gaza Strip.
Significant association between angiotensin-converting enzyme gene insertion/deletion polymorphism and risk of recurrent miscarriage: A systematic review and meta-analysis.
Strong association between Angiotensin I-converting enzyme i/d polymorphism and unexplained recurrent miscarriage of chinese women--a case-control study.
Abortion, Spontaneous
Angiotensin-converting enzyme D/I and plasminogen activator inhibitor-1 4G/5G gene polymorphisms are associated with increased risk of spontaneous abortions in polycystic ovarian syndrome.
Haplotype-based association of ACE I/D, AT1R 1166A>C, and AGT M235T polymorphisms in renin-angiotensin-aldosterone system genes in Korean women with idiopathic recurrent spontaneous abortions.
Increased rate of birth defects after first trimester use of angiotensin converting enzyme inhibitors - Treatment or hypertension related? An observational cohort study.
Insertion/deletion polymorphism in intron 16 of ACE gene in idiopathic recurrent spontaneous abortion: case-control study, systematic review and meta-analysis.
Polymorphisms of plasminogen activator inhibitor-1, angiotensin converting enzyme and coagulation factor XIII genes in patients with recurrent spontaneous abortion.
Abscess
Tongue protrusion as the presenting symptom of parapharyngeal abscess.
acetylcholinesterase deficiency
An acetylcholinesterase-deficient mutant of the nematode Caenorhabditis elegans.
Acid-Base Imbalance
Effects of acid-base imbalance on pulmonary angiotensin-converting enzyme in vivo.
Acidosis
Amelioration of metabolic acidosis in patients with low GFR reduced kidney endothelin production and kidney injury, and better preserved GFR.
Association between vitamin D receptor gene polymorphisms and tubular citrate handling in calcium nephrolithiasis.
Automated determination of blood metabolic acidosis, total acid phosphatase, angiotensin converting enzyme, fructosamine and urinary oxalate and citrate on the ABX Pentra 400.
Diets for patients with chronic kidney disease, should we reconsider?
Gadolinium-based contrast exposure, nephrogenic systemic fibrosis, and gadolinium detection in tissue.
Life threatening hyperkalemia and acidosis secondary to trimethoprim-sulfamethoxazole treatment.
Mesenchymal Stem Cells in Renal Fibrosis: The Flame of Cytotherapy.
Practical Approach to Detection and Management of Chronic Kidney Disease for the Primary Care Clinician.
Regression of left ventricular hypertrophy in hemodialysis patients is possible.
Type IV renal tubular acidosis presenting as dyspnea in two older patients taking angiotensin-converting enzyme inhibitors.
[Laboratory markers of nutritional state in patients treated with peritoneal dialysis]
[Plasma renin activity, angiotensin II, angiotensin converting enzyme, thromboxane A2 and prostacyclin I2 levels in pigs with severe hypoxia and hypercapnea and acidosis shock]
Acidosis, Lactic
A Unique Case of Metformin-associated Severe Lactic Acidosis Without Preexisting Renal Disease: Perspectives on Prolonged Dialysis and Education for Prevention.
Acidosis, Renal Tubular
Association between vitamin D receptor gene polymorphisms and tubular citrate handling in calcium nephrolithiasis.
Life threatening hyperkalemia and acidosis secondary to trimethoprim-sulfamethoxazole treatment.
Type IV renal tubular acidosis presenting as dyspnea in two older patients taking angiotensin-converting enzyme inhibitors.
Acne Vulgaris
Angiotensin-converting enzyme gene insertion/deletion polymorphism and family history in severe acne vulgaris.
Acquired Immunodeficiency Syndrome
Angiotensin-converting enzyme inhibitor-induced renal failure: causes, consequences, and diagnostic uses.
Proteases as drug targets.
Sarcoid and erythema nodosum arthropathies.
Serum angiotensin converting enzyme levels in AIDS.
Spontaneous reports on drug-induced pancreatitis in Denmark from 1968 to 1999.
[Drug-induced oral ulcerations]
[Serum angiotensin converting enzyme in the acquired immunodeficiency syndrome or related syndromes]
Acromegaly
Angiotensin converting enzyme I/D, angiotensinogen M235T and AT1-R A/C1166 gene polymorphisms in patients with acromegaly.
Effects of angiotensin-converting enzyme gene polymorphism on the left-ventricular function and mass in patients with acromegaly.
Pharmacological management of sleep apnoea.
[Angiotensin converting enzyme (ACE) activity in acromegaly]
[Drugs affecting obstructive sleep apnea syndrome].
[The activity of renin-angiotensin-aldosterone system (RAA) and possibilities of application angiotensin converting enzyme inhibitors (ACE I) in selected diseases of endocrine glands]
ACTH-Secreting Pituitary Adenoma
Presence of renin, angiotensinogen, and converting enzyme in human pituitary lactotroph cells and prolactin adenomas.
Activated Protein C Resistance
Atherogenic, hemostatic, and other potential risk markers in subjects with previous isolated myocardial infarction compared with long-standing uncomplicated stable angina.
Acute Chest Syndrome
An evidence-based approach to the treatment of adults with sickle cell disease.
Acute Coronary Syndrome
ACE inhibition modulates endothelial apoptosis and renewal via endothelial progenitor cells in patients with acute coronary syndromes.
Angiotensin converting enzyme DD genotype is associated with acute coronary syndrome severity and sudden cardiac death in Taiwan: a case-control emergency room study.
Angiotensin receptor blockers vs. angiotensin converting enzyme inhibitors and acute coronary syndrome outcomes in elderly patients: a population-based cohort study (UMPIRE study results).
Angiotensin-converting enzyme gene polymorphism adds risk for the severity of coronary atherosclerosis in smokers.
Angiotensin-converting enzyme inhibition is associated with reduced troponin release in non-ST-elevation acute coronary syndromes.
Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Acute Coronary Syndrome: Implications for Platelet Reactivity?
Angiotensin-Converting Enzyme Inhibitors Versus Angiotensin II Receptor Blockers in Acute Coronary Syndrome and Preserved Ventricular Ejection Fraction.
Association between angiotensin-converting enzyme inhibitors and troponin in acute coronary syndrome.
Association between the use of 4 recommended drug categories and patient perceptions of health status following an ACS event.
Associations of Guideline Recommended Medications for Acute Coronary Syndromes With Fall-Related Hospitalizations and Cardiovascular Events in Older Women With Ischemic Heart Disease.
Coenzyme Q10 Modulates Remodeling Possibly by Decreasing Angiotensin-Converting Enzyme in Patients with Acute Coronary Syndrome.
Comparative effectiveness of recommended versus less intensive drug combinations in secondary prevention of acute coronary syndrome.
COVID-19 and cardiac injury: clinical manifestations, biomarkers, mechanisms, diagnosis, treatment, and follow up.
Effect of therapeutic interchange on medication reconciliation during hospitalization and upon discharge in a geriatric population.
Effects of captopril therapy on endogenous fibrinolysis in men with recent, uncomplicated myocardial infarction.
Genetic polymorphism of angiotensin converting enzyme and angiotensin II type 1 receptors and their impact on the outcome of acute coronary syndrome.
Identification and treatment of vulnerable plaque.
Impact of Optimal Medical Therapy at Discharge on 1-year Direct Medical Costs in Patients with Acute Coronary Syndromes: A Retrospective, Observational Database Analysis in China.
Impact of Prior Use of Four Preventive Medications on Outcomes in Patients Hospitalized for Acute Coronary Syndrome--Results from CPACS-2 Study.
Impact of renin-angiotensin system blockade on the prognosis of acute coronary syndrome based on left ventricular ejection fraction.
Improving care for patients with acute coronary syndromes: initial results from the National Audit of Myocardial Infarction Project (MINAP).
Increased angiotensin-converting enzyme activity in coronary artery specimens from patients with acute coronary syndrome.
Interhospital Variability in Drug Prescription After Acute Coronary Syndrome: Insights From the ACDC Study.
Managing acute coronary syndromes in the elderly.
Medication Use Pattern and Predictors of Optimal Therapy at Discharge in 8176 Patients With Acute Coronary Syndrome From 6 Middle Eastern Countries: Data From the Gulf Registry of Acute Coronary Events.
National survey of doctor-reported secondary preventive treatment for patients with acute coronary syndrome in China.
Nationwide dispensing of cardioprotective medications during the first year following acute coronary syndrome (ANZACS-QI 56).
Noncompaction cardiomyopathy and multiple coronary-cameral fistulae in an octogenarian.
Omapatrilat limits infarct size and lowers the threshold for induction of myocardial preconditioning through a bradykinin receptor-mediated mechanism.
Optimal dosing of angiotensin-converting enzyme inhibitors and ?-blockers for acute coronary syndrome: up-titration remains a challenge.
Oxidative stress in patients with acute heart failure.
Perindopril vs Enalapril in Patients with Systolic Heart Failure: Systematic Review and Metaanalysis.
Pharmacological approach to patients with non-ST segment elevation myocardial infarction: does sex make a difference?
Prescribing Performance Post-Acute Coronary Syndrome Using a Composite Medication Indicator: ANZACS-QI 24.
Randomised controlled trial evaluating the role of tirofiban in high-risk non-ST elevation acute coronary syndromes: an East Indian perspective.
Relation between previous angiotensin-converting enzyme inhibitor use and in-hospital outcomes in acute coronary syndromes.
Role of angiotensin-converting enzyme inhibitors in the coronary artery bypass patient.
Self-reported use of evidence-based medicine and smoking cessation 6 - 9 months after acute coronary syndrome: a single-centre perspective.
Soluble angiotensin-converting enzyme levels in heart failure or acute coronary syndrome: revisiting its modulation and prognosis value.
Strategies to achieve coronary arterial plaque stabilization.
The angiotensin converting enzyme genetic polymorphism in acute coronary syndrome--ACE polymorphism as a risk factor of acute coronary syndrome.
The II genotype of the angiotensin-converting enzyme gene delays the onset of acute coronary syndromes.
The Modification Effect of Influenza Vaccine on Prognostic Indicators for Cardiovascular Events after Acute Coronary Syndrome: Observations from an Influenza Vaccination Trial.
The physician-hospital team: a successful approach to improving care in a large academic medical center.
The role of inflammatory stress in acute coronary syndrome.
Treatment of acute coronary syndromes in patients with type 2 diabetes mellitus with beta-adrenoblockers and angiotensin-converting enzyme inhibitors: cardiohemodynamic effects and impact for prognosis.
Use of evidence-based therapy for the secondary prevention of acute coronary syndromes in Malaysian practice.
Use of medicines recommended for secondary prevention of acute coronary syndrome.
Use of secondary preventive medications after the first attack of acute coronary syndrome.
Use of the recommended drug combination for secondary prevention after a first occurrence of acute coronary syndrome in France.
[Acute coronary syndrome without ST elevation during pregnancy. A case report]
[Angiotensin converting enzyme inhibitors and angiotensin receptor blockers use in patients with acute coronary syndrome]
Acute Kidney Injury
ACP Journal Club. Review: Aliskiren plus ACEIs or ARBs increases hyperkalemia more than aliskiren, ACEIs, or ARBs alone.
Acute Kidney Injury After Cardiac Surgery in Infants and Children: Evaluation of the Role of Angiotensin-Converting Enzyme Inhibitors.
Acute Kidney Injury after Heart Valve Surgery in Elderly Patients: any Risk Factors to Modify?
Acute kidney injury and infections in patients taking antihypertensive drugs: a self-controlled case series analysis.
Acute kidney injury complicating minimal change disease: the case for careful use of diuretics and angiotensin-converting enzyme inhibitors.
Acute Kidney Injury in a Case Series of Patients with Confirmed COVID-19 (Coronavirus Disease 2019): Role of Angiotensin-Converting Enzyme 2 and Renin-Angiotensin System Blockade.
Acute Kidney Injury in Elderly Patients With Chronic Kidney Disease: Do Angiotensin-Converting Enzyme Inhibitors Carry a Risk?
Acute kidney injury in the setting of knee arthroplasty: a case report and discussion investigating Angiotensin-converting enzyme inhibitors as the culprit.
Acute kidney injury in type 3 Bartter syndrome: Angiotensin-converting enzyme inhibitors as a cause.
Acute Kidney Injury Post-Major Orthopaedic Surgery: A Single-Centre Case-Control Study.
Acute renal failure after the use of angiotensin-converting-enzyme inhibitors in patients without renal artery stenosis.
Acute renal failure associated with use of angiotensin converting enzyme inhibitor--a report of two children with Down's syndrome.
Acute renal failure from multiple myeloma precipitated by ACE inhibitors.
Acute renal failure induced by angiotensin converting enzyme inhibitor in a patient with polyarteritis nodosa.
Acute transplant artery thrombosis induced by angiotensin-converting inhibitor in a patient with renovascular hypertension.
Acute tubular necrosis in kidney transplant patients treated with enalapril.
Analytical review of the evidence for renoprotection by renin-angiotensin-aldosterone system blockade in chronic kidney disease - a call for caution.
Angiotensin converting enzyme inhibition and renal insufficiency in patients with bilateral renovascular disease.
Angiotensin Converting Enzyme Inhibitor (ACEI)-Induced Acute Renal Failure in Premature Newborns with Congenital Heart Disease.
Angiotensin converting enzyme inhibitors induced acute kidney injury in newborn.
Angiotensin converting enzyme insertion/deletion genetic polymorphism: its impact on renal function in critically ill patients.
Angiotensin I converting enzyme activity in uranyl nitrate induced acute renal failure in rats.
Angiotensin I converting enzyme in glycerol-induced acute renal failure in rats.
Angiotensin I-converting enzyme activity in rats with carbon tetrachloride-induced acute renal failure.
Angiotensin II Receptor Blockers but Not Angiotensin-Converting Enzyme Inhibitors Are Associated With a Reduced Risk of Acute Kidney Injury After Major Surgery.
Angiotensin-converting enzyme activity as a prognostic factor in acute renal failure.
Angiotensin-converting enzyme activity in renal disorders: influence of disease pattern, hemodialysis and transplantation.
Angiotensin-converting enzyme inhibition or mineralocorticoid receptor blockade do not affect prevalence of atrial fibrillation in patients undergoing cardiac surgery.
Angiotensin-converting enzyme inhibitor usage and acute kidney injury: A secondary analysis of RENAL study outcomes.
Angiotensin-Converting Enzyme Inhibitor/Receptor Blocker, Diuretic, or Nonsteroidal Anti-inflammatory Drug Use After Major Surgery and Acute Kidney Injury: A Case-Control Study.
Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers after Acute Kidney Injury: Friend, Foe, or Acquaintance?
Angiotensin-Converting Enzyme Inhibitors and Contrast-Associated Acute Kidney Injury After Coronary Angiography and Intervention.
Angiotensin-Converting Enzyme Inhibitors and or Receptor Blockers After Acute Kidney Injury: Rehabilitation of the Supervillains.
Angiotensin-converting enzyme inhibitors and risk of acute kidney injury after cardiac surgery.
Angiotensin-converting enzyme inhibitors predict acute kidney injury during chemoradiation for head and neck cancer.
Association between angiotensin converting enzyme inhibitor or angiotensin receptor blocker use prior to major elective surgery and the risk of acute dialysis.
Association between exposure to angiotensin-converting enzyme inhibitors and angiotensin receptor blockers prior to septic shock and acute kidney injury.
Association between peri-operative angiotensin-converting enzyme inhibitors and angiotensin-2 receptor blockers and acute kidney injury in major elective non-cardiac surgery: a multicentre, prospective cohort study.
Association between scleroderma, renal cell carcinoma and membranous nephropathy.
Association of Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use With Outcomes After Acute Kidney Injury.
Attenuation of nephrotoxic acute renal failure in the dog with angiotensin-converting enzyme inhibitor (SQ-20,881).
Benidipine inhibits apoptosis during ischaemic acute renal failure in rats.
Cardiovascular risk in patients with mild renal insufficiency: implications for the use of ACE inhibitors.
Characteristics of atheromatous renovascular disease in Dubai: a single-center experience.
Chronic kidney disease: cardiac and renal angiotensin converting enzyme (ACE) 2 expression in rats after subtotal nephrectomy and the effect of ACE inhibition.
Cisplatin-induced acute renal failure in mice is mediated by chymase-activated angiotensin-aldosterone system and interleukin-18.
Clinical characteristics of atherosclerotic renovascular disease.
Concurrent use of diuretics, angiotensin converting enzyme inhibitors, and angiotensin receptor blockers with non-steroidal anti-inflammatory drugs and risk of acute kidney injury: nested case-control study.
Contrast-Induced Acute Kidney Injury in Radiologic Management of Acute Ischemic Stroke in the Emergency Setting.
Correlations Between SGLT-2 Inhibitors and Acute Renal Failure by Signal Detection Using FAERS: Stratified Analysis for Reporting Country and Concomitant Drugs.
COVID-19 and Kidney Disease: Update on Epidemiology, Clinical Manifestations, Pathophysiology and Management.
Diarrhoea, vomiting and ACE inhibitors:--an important cause of acute renal failure.
Differential renal function during angiotensin converting enzyme inhibition in renovascular hypertension.
Direct Renin Inhibitor Induced Renal Failure.
Diuretics potentiate angiotensin converting enzyme inhibitor-induced acute renal failure.
Drug interactions and consequences of sodium restriction.
Drug interactions between antihypertensive drugs and non-steroidal anti-inflammatory agents: a descriptive study using the French Pharmacovigilance database.
Drug-induced renal toxicity. Help in recognizing offending agents.
Effect of Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers on Serum Potassium Levels and Renal Function in Ambulatory Outpatients: Risk Factors Analysis.
Effect of benazepril and robenacoxib and their combination on glomerular filtration rate in dogs.
Effect of benazepril, robenacoxib and their combination on glomerular filtration rate in cats.
Effect of captopril and the nonpeptide angiotensin II antagonists, SK&F 108566 and EXP3174, on renal function in dogs with a renal artery stenosis.
Effect of Renin-Angiotensin-Aldosterone System Blockade on Long-Term Outcomes in Postacute Kidney Injury Patients With Hypertension.
Effects of withdrawing vs continuing renin-angiotensin blockers on incidence of acute kidney injury in patients with renal insufficiency undergoing cardiac catheterization: Results from the Angiotensin Converting Enzyme Inhibitor/Angiotensin Receptor Blocker and Contrast Induced Nephropathy in Patients Receiving Cardiac Catheterization (CAPTAIN) trial.
Functional basis for the glomerular alterations in uranyl nitrate acute renal failure.
Hypotension as the Etiology for Angiotensin-Converting Enzyme (ACE) Inhibitor-Associated Acute Kidney Injury in Pediatric Patients.
Impact of acute kidney injury in patients prescribed angiotensin-converting enzyme inhibitors over the first two years of life.
Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers on Acute Kidney Injury in Emergency Medical Admissions.
Impact of angiotensin-converting enzyme inhibitors or receptor blockers on post-ICU discharge outcome in patients with acute kidney injury.
Impact of benazepril on contrast-induced acute kidney injury for patients with mild to moderate renal insufficiency undergoing percutaneous coronary intervention.
Impact of Renin-Angiotensin-Aldosterone System-blocking Agents on the Risk of Contrast-induced Acute Kidney Injury: A Prospective Study and Meta-analysis.
In vivo renal angiotensin converting enzyme activity decreases in glycerol-induced acute renal failure.
In-Stent Restenosis of the Renal Artery in a Single Kidney Patient: The Role of ACEI in the Therapeutic Choice.
Ischemic nephropathy: clinical characteristics and treatment.
Ischemic renal disease: an emerging cause of chronic renal failure and end-stage renal disease.
Long-term follow-up of acute renal failure caused by angiotensin converting enzyme inhibitors.
Metformin Associated Lactic Acidosis in the Intensive Care Unit: A Rare Condition Mimicking Sepsis.
MicroRNAs mediate the cardioprotective effect of angiotensin-converting enzyme inhibition in acute kidney injury.
Mineralocorticoid Antagonism and Diabetic Kidney Disease.
More on the "Triple Whammy": antihypertensive drugs, non-steroidal anti-inflammatory agents and acute kidney injury - a case/non-case study in the French pharmacovigilance database.
No Association of Angiotensin-Converting Enzyme Inhibitor or Angiotensin 2 Receptor Blocker Intake with Acute Kidney Injury in Patients Undergoing Kidney Biopsy.
No Increase in Adverse Events During Aliskiren Use Among Ontario Patients Receiving Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers.
Obesity, Angiotensin-Blocking Drugs, and Acute Kidney Injury in Orthopedic Surgery.
Pathogenesis of acute renal failure: new aspects.
Perioperative management of patients treated with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers: a quality improvement audit.
Pre- and/or Intra-Operative Prescription of Diuretics, but Not Renin-Angiotensin-System Inhibitors, Is Significantly Associated with Acute Kidney Injury after Non-Cardiac Surgery: A Retrospective Cohort Study.
Predictors of Acute Kidney Injury Following Surgical Valve Replacement.
Predictors of Perioperative Acute Kidney Injury in Obese Patients Undergoing Laparoscopic Bariatric Surgery: a Single-Centre Retrospective Cohort Study.
Preoperative Angiotensin-converting enzyme inhibitors and acute kidney injury after coronary artery bypass grafting.
Preoperative angiotensin-converting enzyme inhibitors and angiotensin receptor blocker use and acute kidney injury in patients undergoing cardiac surgery.
Preoperative use of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers is associated with increased risk for acute kidney injury after cardiovascular surgery.
Progressive acute kidney injury following myocardial infarction: cholesterol embolisation.
Rate and Outcome of Acute Kidney Injury Following Hip Fracture Surgery in Diabetic Older Patients Treated with Renin-Angiotensin-Aldosterone Antagonists.
Re: Wynckel et al's "Long-term follow-up of acute renal failure caused by angiotensin converting enzyme inhibitors".
Refractory hypertension after renal transplantation.
Renal artery thrombosis with acute renal failure after withdrawal of angiotensin converting enzyme inhibitor: a case report.
Renin-angiotensin system blockers and 1-year mortality in patients with post-operative acute kidney injury.
Renin-Angiotensin System Blockers and Statins Are Associated With Lower In-Hospital Mortality in Very Elderly Hypertensives.
Renin-angiotensin-aldosterone system blockade is associated with higher risk of contrast-induced acute kidney injury in patients with diabetes.
Resistive index as a predictor of acute kidney injury caused by an angiotensin converting enzyme inhibitor or angiotensin II receptor blocker in chronic kidney disease patients.
Resistive index as a predictor of renal progression in patients with moderate renal dysfunction regardless of angiotensin converting enzyme inhibitor or angiotensin receptor antagonist medication.
Reversible anuric acute kidney injury secondary to acute renal autoregulatory dysfunction.
Reversible impairment of renal function associated with enalapril in a diabetic patient.
Reversible Nephropathy Associated with Jet Fuel Exposure.
Reversible renal failure due to the use of captopril in a renal allograft recipient treated with cyclosporin.
Reversible renal failure in hypertensive idiopathic nephrotics treated with captopril.
Risk factors for postoperative acute kidney injury in pediatric cardiac surgery patients receiving angiotensin-converting enzyme inhibitors.
Risk of postoperative acute kidney injury in patients undergoing orthopaedic surgery--development and validation of a risk score and effect of acute kidney injury on survival: observational cohort study.
Stopping renin-angiotensin system blockers after acute kidney injury and risk of adverse outcomes: parallel population-based cohort studies in English and Swedish routine care.
Study of Acute Kidney Injury on 309 Hypertensive Inpatients with ACEI/ARB - Diuretic Treatment.
Successful stenting for renal artery stenosis in a patient with Alagille syndrome.
The angiotensin converting enzyme inhibitor enalapril in acute ischemic renal failure in rats.
The Concomitant Use of Diuretics, Non-Steroidal Anti-Inflammatory Drugs, and Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers (Triple Whammy), Extreme Heat, and In-Hospital Acute Kidney Injury in Older Medical Patients.
The effect of Renin-Angiotensin-aldosterone system blockade on contrast-induced acute kidney injury: a propensity-matched study.
The natural history of renal artery stenosis: who should be evaluated for suspected ischemic nephropathy?
The oldest reported patient with fibromuscular dysplasia of the renal artery.
The renin-angiotensin system in aminoglycoside-induced acute renal failure.
Trapped renal arteries: functional renal artery stenosis due to occlusion of the aorta in the arch and below the kidneys.
Tumor necrosis factor ?-converting enzyme inhibitor attenuates lipopolysaccharide-induced reactive oxygen species and mitogen-activated protein kinase expression in human renal proximal tubule epithelial cells.
University of Miami Division of Clinical Pharmacology Therapeutic Rounds: ischemic renal disease.
Urinary angiotensin I-converting enzyme activity is increased in experimental acute renal failure.
Valsartan Effective for Malignant Hypertension after Aortic Dissection with Renal Artery Involvement.
Variance of ACE and AT1 receptor gene does not influence the risk of neonatal acute renal failure.
What is the association of acute renal failure, angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker in a young patient?
[Acute renal failure, renal artery stenosis and angiotensin-converting enzyme (ACE) inhibitor]
[Acute renal insufficiency after flurbiprofen treatment in a patient treated with angiotensin converting enzyme inhibitor]
[Acute renal insufficiency secondary to the use of angiotensin converting enzyme inhibitors in 2 patients without renal artery stenosis]
[Aggression to the immature kidney]
[Angiotensin-converting enzyme inhibitors and acute renal failure]
[Captopril use in pregnancy and its effects on the fetus and the newborn: case report]
[Changes of angiotensin converting enzyme activity in rats with gentamicin-induced acute renal failure]
[Diagnosis of renovascular disease by heart catheterization]
[Effect of early postoperative use of ACEI/ARB or diuretics on the incidence of acute kidney injury after cardiac surgery in elderly patients].
[Kidney disease: therapeutic implications in heart failure and coronary heart disease]
[Non-steroidal anti-inflammatory agent and angiotensin converting enzyme inhibitor: a dangerous combination during postoperative period]
[Pharmacological studies on the diuretic action of azosemide [5-(4'-chloro-5'-sulfamoyl-2'-thenylamino)-phenyltetrazole], a new diuretic (3). Effect of azosemide following pretreatment with SA-446, an angiotensin I converting enzyme inhibitor, or propranolol, a beta-adrenergic blocker, in HgCl2-induced acute renal failure in rats]
[Revascularization of occluded renal arteries. A case]
Acute Lung Injury
ACE mediates ventilator-induced lung injury in rats via angiotensin II but not bradykinin.
Age-Dependent Changes in the Pulmonary Renin-Angiotensin System Are Associated With Severity of Lung Injury in a Model of Acute Lung Injury in Rats.
Angiotensin-converting enzyme 2 (ACE2) mediates influenza H7N9 virus-induced acute lung injury.
Angiotensin-converting enzyme inhibitor captopril prevents oleic acid-induced severe acute lung injury in rats.
Angiotensin-converting enzyme polymorphism affects outcome of local Chinese with acute lung injury.
Association between insertion/deletion polymorphism in angiotensin-converting enzyme gene and acute lung injury/acute respiratory distress syndrome: a meta-analysis.
Diabetes, insulin, and development of acute lung injury.
Effect of acute lung injury on angiotensin converting enzyme in serum, lung lavage, and effusate.
Effect of angiotensin converting enzyme gene I/D polymorphism and its expression on clinical outcome in acute respiratory distress syndrome.
Ethnic and age-specific acute lung injury/acute respiratory distress syndrome risk associated with angiotensin-converting enzyme insertion/deletion polymorphisms, implications for COVID-19: A meta-analysis.
Glycyrrhizic Acid Alleviates Lipopolysaccharide (LPS)-Induced Acute Lung Injury by Regulating Angiotensin-Converting Enzyme-2 (ACE2) and Caveolin-1 Signaling Pathway.
Hypoxia induces expression of angiotensin-converting enzyme II in alveolar epithelial cells: Implications for the pathogenesis of acute lung injury in COVID-19.
Inhibition of angiotensin-converting enzyme by perindopril diacid in canine oleic acid pulmonary edema.
Lipoxin A4 attenuates LPS-induced acute lung injury via activation of the ACE2-Ang-(1-7)-Mas axis.
Losartan attenuated lipopolysaccharide-induced lung injury by suppression of lectin-like oxidized low-density lipoprotein receptor-1.
Pharmacological Effects of Verticine: Current Status.
Pulmonary angiotensin-converting enzyme kinetics after acute lung injury in the rabbit.
Pulmonary capillary endothelium-bound angiotensin-converting enzyme activity in acute lung injury.
Residues affecting the chloride regulation and substrate selectivity of the angiotensin-converting enzymes (ACE and ACE2) identified by site-directed mutagenesis.
Studies on the mechanism of decreased angiotensin I conversion in rat lungs injured with alpha-naphthylthiourea.
The value of serial serum angiotensin converting enzyme determinations in hospitalized patients with lung disease.
[Epidemiological features and mechanism of coronavirus disease 2019 in children].
[Immunohistochemical observation of angiotensin converting enzyme in acute lung injury]
[Serum and pulmonary angiotensin converting enzyme as a marker of acute lung injury in an experimental model of adult respiratory distress syndrome]
Addison Disease
A chronobiological approach to circulating levels of renin, angiotensin-converting enzyme, aldosterone, ACTH, and cortisol in Addison's disease.
High serum levels of angiotensin-converting enzyme in untreated Addison's disease.
Adenocarcinoma
Antihypertensives as novel antineoplastics: angiotensin-I-converting enzyme inhibitors and angiotensin II type 1 receptor blockers in pancreatic ductal adenocarcinoma.
Enhanced expression of angiotensin II receptor subtypes and angiotensin converting enzyme in medroxyprogesterone-induced mouse mammary adenocarcinomas.
Inhibition of matrix metalloproteinase activity and growth of gastric adenocarcinoma cells by an angiotensin converting enzyme inhibitor in in vitro and murine models.
Inhibition of proliferation on some neoplastic cell lines-act of carvedilol and captopril.
Kininase I, kininase II and aminopeptidase levels in patients with gastrointestinal tumors.
Adenocarcinoma of Lung
Analysis of the susceptibility of lung cancer patients to SARS-CoV-2 infection.
Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers might be associated with lung adenocarcinoma risk: a nationwide population-based nested case-control study.
Structural variations and expression profiles of the SARS-CoV-2 host invasion genes in lung cancer.
Tumor growth-inhibitory effect of an angiotensin-converting enzyme inhibitor (captopril) in a lung cancer xenograft model analyzed using 18F-FDG-PET/CT.
Adenoma
A case of aldosterone producing adenoma associated with high PRA after long-term angiotensin converting enzyme inhibitor treatment.
Effect of the circulating renin-angiotensin system on prolactin release in humans.
Effects of corticotropin-releasing factor and other materials on adrenocorticotropin secretion from pituitary glands of patients with Cushing's disease in vitro.
Insertion/deletion polymorphism of the angiotensin-converting enzyme gene and loss of the insertion allele in aldosterone-producing adenoma.
Local renin-angiotensin system in human adrenals and aldosteronomas.
Presence of renin, angiotensinogen, and converting enzyme in human pituitary lactotroph cells and prolactin adenomas.
Sarcoidosis following Cushing's syndrome: A report of two cases and review of the literature.
[Detection of primary aldosteronism using the captopril test]
Adrenal Insufficiency
Important Management Considerations In Patients With Pituitary Disorders During The Time Of The Covid-19 Pandemic.
The management of hyperkalaemia in the emergency department.
Ageusia
Effects of zinc supplementation on serum zinc concentration and ratio of apo/holo-activities of angiotensin converting enzyme in patients with taste impairment.
Serum zinc is unaffected by effective captopril treatment of hypertension.
Aggressive Periodontitis
Angiotensin-converting enzyme (ACE), angiotensinogen (AGT), and angiotensin II type 1 receptor (AT1R) gene polymorphisms in generalized aggressive periodontitis.
Agranulocytosis
Agranulocytosis associated with enalapril.
Benazepril-Induced Agranulocytosis: A Case Report and Review of the Literature.
Captopril-induced granulocyte aggregation. A possible complement mediated mechanism of peripheral leukopenia.
Granulocytopenia after combined therapy with interferon and angiotensin-converting enzyme inhibitors: evidence for a synergistic hematologic toxicity.
AIDS-Associated Nephropathy
Effect of angiotensin-converting enzyme inhibition in HIV-associated nephropathy.
HIV-associated nephropathy: clinical presentation, pathology, and epidemiology in the era of antiretroviral therapy.
HIVAN and medication use in chronic dialysis patients in the United States: analysis of the USRDS DMMS Wave 2 study.
Long-term renal survival in HIV-associated nephropathy with angiotensin-converting enzyme inhibition.
Optimal management of HIV- positive adults at risk for kidney disease in Nigeria (Renal Risk Reduction "R3" Trial): protocol and study design.
Response to inhibition of angiotensin-converting enzyme in human immunodeficiency virus-associated nephropathy: a case report.
The Kidney: An important target for HIV infection.
Airway Obstruction
Airway obstruction due to late-onset angioneurotic edema from angiotensin-converting enzyme inhibition.
Anaphylactoid reaction to recombinant tissue plasminogen activator.
Angioedema from angiotensin converting enzyme inhibitors: a cause of upper airway obstruction.
Dyspnoea, asthma, and bronchospasm in relation to treatment with angiotensin converting enzyme inhibitors.
Late-onset life-threatening angioedema and upper airway obstruction caused by angiotensin-converting enzyme inhibitor: report of a case.
Losartan Effects on Emphysema Progression Randomized Clinical Trial: Rationale, Design, Recruitment, and Retention.
Predisposition to and late onset of upper airway obstruction following angiotensin-converting enzyme inhibitor therapy.
Upper airway obstruction following angiotensin-converting enzyme inhibitor therapy.
[Life-threatening displacement of a tracheostomy tube in a patient with severe angiotensin-converting enzyme inhibitor-induced angioedema]
Albuminuria
2 year followup of patients with diabetes mellitus nephropathy showing albuminuria reversal following angiotensin converting enzyme inhibitors.
A longitudinal study of risk factors for incident albuminuria in diabetic American Indians: the Strong Heart Study.
A Pilot Study Linking Endothelial Injury in Lungs and Kidneys in Chronic Obstructive Pulmonary Disease.
A Population-Based Analysis of Quality Indicators in CKD.
A randomised controlled trial of potential for pharmacologic prevention of new-onset albuminuria, hypertension and diabetes in a remote Aboriginal Australian community, 2008-2013.
ACE inhibitor intervention in Type 1 diabetes with low grade microalbuminuria.
ACE-I/ARB treatment in type 1 diabetes patients with albuminuria is associated with lower odds of progression of coronary artery calcification.
Adverse effect of the calcium channel blocker nitrendipine on nephrosclerosis in rats with renovascular hypertension.
Albumin metabolism in the nephrotic syndrome: the effect of dietary protein intake.
Albuminuria and the renin-angiotensin system gene polymorphisms in type-2-diabetic and in normoglycemic hypertensive Chinese.
Albuminuria in diabetes mellitus: relation to ambulatory versus office blood pressure and effects of cilazapril.
Albuminuria is Not an Appropriate Therapeutic Target in Patients with CKD: The Con View.
Albuminuria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT): a randomised, double-blind, placebo-controlled trial.
alpha-Adducin and angiotensin-converting enzyme polymorphisms in hypertension: evidence for a joint influence on albuminuria.
Alport Syndrome in Women and Girls.
Analysis from the EMPA-REG OUTCOME® trial indicates empagliflozin may assist in preventing the progression of chronic kidney disease in patients with type 2 diabetes irrespective of medications that alter intrarenal hemodynamics.
Angiotensin converting enzyme gene polymorphism and ACE inhibition in diabetic nephropathy.
Angiotensin converting enzyme inhibitors in diabetic patients with microalbuminuria or normoalbuminuria.
Angiotensin Converting Enzyme Inhibitors Reduce Albuminuria More Than Angiotensin Receptor Blockers in Patients with Type 2 Diabetes.
Angiotensin receptor antagonist vs. angiotensin-converting enzyme inhibitor in Asian subjects with type 2 diabetes and albuminuria - a randomized crossover study.
Angiotensin-converting enzyme genotype, albuminuria and plasma fibrinogen in type 2 diabetes mellitus.
Angiotensin-converting enzyme inhibition in diabetic nephropathy: ten years' experience.
Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use Among Hypertensive US Adults With Albuminuria.
Angiotensin-converting enzyme inhibitors versus calcium antagonists in the progression of renal diseases.
Angiotensin-converting enzyme insertion/deletion polymorphism and diabetic albuminuria in patients with NIDDM followed Up for 9 years.
Antihypertensive therapy and progression of diabetic renal disease.
Antihypertensive therapy in a model combining spontaneous hypertension with diabetes.
APOL1 associations with nephropathy, atherosclerosis, and all-cause mortality in African Americans with type 2 diabetes.
Association of angiotensin-II levels with albuminuria in subjects with normal glucose metabolism, prediabetes, and type 2 diabetes mellitus.
Association of C-reactive protein and hyperuricemia with diabetic nephropathy in Chinese type 2 diabetic patients.
Awareness of albuminuria in an Italian population-based cohort of patients treated with hypoglycemic drugs.
Beneficial effect of alacepril, a new angiotensin-converting enzyme inhibitor on albuminuria and glycemic state: an open multicenter trial. Alacepril Study Group.
Captopril acutely lowers albuminuria in normotensive patients with diabetic nephropathy.
Chronic Kidney Disease Diagnosis and Management: A Review.
Cigarette smoking and increased urine albumin excretion are interrelated predictors of nephropathy progression in type 2 diabetes.
Cilnidipine is as effective as benazepril for control of blood pressure and proteinuria in hypertensive patients with benign nephrosclerosis.
Cognitive Impairment in CKD: Pathophysiology, Management, and Prevention.
Combination of Angiotensin Converting Enzyme Insertion/Deletion (I/D) (rs4646994) and VEGF Polymorphism (+405G/C; rs2010963) Synergistically Associated With the Development, of Albuminuria in Iranian Patients With Type 2 Diabetes.
Combination of half doses of angiotensin type 1 receptor antagonist and angiotensin-converting enzyme inhibitor in diabetic nephropathy.
Comparative Efficacy and Safety of Antihypertensive Agents for Adult Diabetic Patients with Microalbuminuric Kidney Disease: A Network Meta-Analysis.
Comparison of spironolactone and trichlormethiazide as add-on therapy to renin-angiotensin blockade for reduction of albuminuria in diabetic patients.
Cost-effectiveness of screening for albuminuria with subsequent fosinopril treatment to prevent cardiovascular events: A pharmacoeconomic analysis linked to the prevention of renal and vascular endstage disease (PREVEND) study and the prevention of renal and vascular endstage disease intervention trial (PREVEND IT).
CS-886, a new angiotensin II type 1 receptor antagonist, ameliorates glomerular anionic site loss and prevents progression of diabetic nephropathy in Otsuka Long-Evans Tokushima fatty rats.
Daily oral sodium bicarbonate preserves glomerular filtration rate by slowing its decline in early hypertensive nephropathy.
Diabetic Kidney Disease: Diagnosis, Treatment, and Prevention.
Diabetic nephropathy and antihypertensive treatment: what are the lessons from clinical trials?
Diabetic nephropathy for the primary care provider: new understandings on early detection and treatment.
Diabetic nephropathy: hemodynamic basis and implications for disease management.
Diabetic nephropathy: What does the future hold?
Diabetic renal microvascular disease: the role of hypertension and ACE inhibitors.
Diabetic vascular hypertrophy and albuminuria: effect of angiotensin converting enzyme inhibition.
Differential effects of enalapril and irbesartan in experimental papillary necrosis.
Dual blockade of the renin-angiotensin-aldosterone system is safe and effective in reducing albuminuria in Asian type 2 diabetic patients with nephropathy.
Dual RAS therapy not on target, but fully alive.
Dyslipidemia, kidney disease, and cardiovascular disease in diabetic patients.
Effect of ANG II receptor antagonist on albuminuria and renal function in passive Heymann nephritis.
Effect of angiotensin-converting enzyme inhibition on renal function and albuminuria in normotensive type I diabetic patients.
Effect of angiotensin-converting enzyme inhibition on survival in 3773 Chinese type 2 diabetic patients.
Effect of captopril on blood pressure and kidney function in normotensive insulin dependent diabetics with nephropathy.
Effect of dietary protein and enalapril on proximal tubular delivery and absorption of albumin in nephrotic rats.
Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial.
Effect of losartan and spironolactone on triglyceride-rich lipoproteins in diabetic nephropathy.
Effect of PF-04634817, an Oral CCR2/5 Chemokine Receptor Antagonist, on Albuminuria in Adults with Overt Diabetic Nephropathy.
Effect of spironolactone therapy on albuminuria in patients with type 2 diabetes treated with angiotensin-converting enzyme inhibitors.
Effects of ACE Inhibitors and Angiotensin Receptor Blockers in Normotensive Patients with Diabetic Kidney Disease.
Effects of adding tripterygium glycosides to angiotensin-converting enzyme inhibitors or angiotensin receptor blockers on albuminuria in patients with diabetic nephropathy.
Effects of additive therapy with spironolactone on albuminuria in diabetes mellitus: A pilot randomized clinical trial.
Effects of angiotensin-converting enzyme inhibitor (alacepril) and calcium antagonist (nicardipine) in hypertensive non-insulin-dependent diabetic patients with microalbuminuria.
Effects of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on All-Cause Mortality and Renal Outcomes in Patients with Diabetes and Albuminuria: a Systematic Review and Meta-Analysis.
Effects of angiotensin-converting enzyme inhibitors in experimental diabetes.
Effects of manidipine and delapril in hypertensive patients with type 2 diabetes mellitus: the delapril and manidipine for nephroprotection in diabetes (DEMAND) randomized clinical trial.
Effects of verapamil added-on trandolapril therapy in hypertensive type 2 diabetes patients with microalbuminuria: the BENEDICT-B randomized trial.
Enalapril reduces the albuminuria of patients with sickle cell disease.
Enalapril retards glomerular basement membrane thickening and albuminuria in the diabetic rat.
Enalapril/amlodipine combination in cyclosporine-treated renal transplant recipients: a prospective randomized trial.
Farnesoid X Receptor Agonism Protects against Diabetic Tubulopathy: Potential Add-On Therapy for Diabetic Nephropathy.
FGF23, Albuminuria, and Disease Progression in Patients with Chronic IgA Nephropathy.
Genetic hypertension accelerates nephropathy in the streptozotocin diabetic rat.
Glomerular hypertension as one cause of albuminuria in type II diabetic patients.
Glomerular localization and expression of Angiotensin-converting enzyme 2 and Angiotensin-converting enzyme: implications for albuminuria in diabetes.
High glucose instigates tubulointerstitial injury by stimulating hetero-dimerization of adiponectin and angiotensin II receptors.
Hypertension in patients with type 2 diabetes mellitus: Targets and management.
Impact of a Primary Care CKD Registry in a US Public Safety-Net Health Care Delivery System: A Pragmatic Randomized Trial.
Impact of blood pressure and antihypertensive treatment on incipient and overt nephropathy, retinopathy, and endothelial permeability in diabetes mellitus.
Implications of albuminuria on kidney disease progression.
Increased 8-hydroxy-2'-deoxyguanosine in leukocyte DNA from patients with type 2 diabetes and microangiopathy.
Influence of angiotensin converting enzyme inhibition and angiotensin II type 1 receptor antagonism on renal sodium and water handling and albuminuria during infusion of atrial natriuretic factor into healthy volunteers.
Influence of microalbuminuria in achieving blood pressure goals.
Inhibition of angiotensin-converting enzyme reduces urinary albumin excretion but not regional albumin clearance in experimental diabetes.
Intervention using vitamin D for elevated urinary albumin in type 2 diabetes mellitus (IDEAL-2 Study): study protocol for a randomised controlled trial.
Is a reduction in albuminuria associated with renal and cardiovascular protection? A post hoc analysis of the ALTITUDE trial.
Is microalbuminuria a marker of early intrarenal vascular dysfunction in essential hypertension?
Joint effects of hypertension, smoking, dyslipidemia and obesity and angiotensin-converting enzyme DD genotype on albuminuria in Taiwanese patients with type 2 diabetes mellitus.
KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update.
Lack of association between endothelial nitric oxide synthase gene polymorphisms, microalbuminuria and endothelial dysfunction in hypertensive men.
Long term reduction of microalbuminuria after 1 year of angiotensin converting enzyme inhibition by perindopril in hypertensive insulin-treated diabetic patients.
Long-term ACE inhibition in Alport syndrome: are the benefits worth the risks?
Long-term comparison of losartan and enalapril on kidney function in hypertensive type 2 diabetics with early nephropathy.
Long-term reduction of microalbuminuria after 3 years of angiotensin-converting enzyme inhibition by perindopril in hypertensive insulin-treated diabetic patients.
Long-term renoprotection by perindopril or nifedipine in non-hypertensive patients with Type 2 diabetes and microalbuminuria.
Low-dose angiotensin converting enzyme inhibitors: effect on renal function in normo- and hypertensive type 1 diabetic patients.
Lowering of microalbuminuria in diabetic patients by a sympathicoplegic agent: novel approach to prevent progression of diabetic nephropathy?
Management of diabetes complications in youth.
Management of hyperkalaemia consequent to mineralocorticoid-receptor antagonist therapy.
Management of Hypertension in Diabetic Nephropathy: How Low Should We Go?
Managing hypertension in high-risk patients: lessons and promises from the STRATHE and ADVANCE trials.
Measurable Urinary Albumin Predicts Cardiovascular Risk among Normoalbuminuric Patients with Type 2 Diabetes.
Mechanism of decreased albuminuria caused by angiotensin converting enzyme inhibitor in early diabetic nephropathy.
Micro-albuminuria and the organ-damage concept in antihypertensive therapy for patients with insulin-dependent diabetes mellitus.
Microalbuminuria and cardiorenal risk: old and new evidence in different populations.
Microalbuminuria and cardiovascular disease.
Microalbuminuria in essential hypertension.
Microalbuminuria screening for patients having type 2 diabetes mellitus: who wants to participate?
Microalbuminuria, insulin resistance, diabetes, hypertension, and kidney function: the latest concepts in pathology and pharmacologic treatment.
Mineralocorticoid antagonists in chronic kidney disease.
Modifiable lifestyle and social factors affect chronic kidney disease in high-risk individuals with type 2 diabetes mellitus.
Natural history of early diabetic nephropathy: what are the effects of therapeutic intervention? Melbourne Diabetic Nephropathy Study Group.
Nephropathy in model combining genetic hypertension with experimental diabetes. Enalapril versus hydralazine and metoprolol therapy.
New Areas of Interest: Is There a Role for Omega-3 Fatty Acid Supplementation in Patients With Diabetes and Cardiovascular Disease?
Nitrendipine and enalapril improve albuminuria and glomerular filtration rate in non-insulin dependent diabetes.
Not all proteinuria is created equal.
Office and ambulatory blood pressure are independently associated with albuminuria in older subjects with type 2 diabetes.
Persistent albuminuria in normotensive non-insulin-dependent (type II) diabetic patients: comparative effects of angiotensin-converting enzyme inhibitors and beta-adrenoceptor blockers.
Potential implications of the 2021 KDIGO blood pressure guideline for adults with chronic kidney disease in the United States.
Practical Approach to Detection and Management of Chronic Kidney Disease for the Primary Care Clinician.
Predictors of angiotensin-converting enzyme inhibitor-induced reduction of urinary albumin excretion in nondiabetic patients.
Prevalence of and risk factors for reduced serum bicarbonate in chronic kidney disease.
Probucol in Albuminuric Type 2 Diabetes Mellitus Patients on Renin-Angiotensin System Blockade: A 16-Week, Randomized, Double-Blind, Placebo-Controlled Trial.
Prognostic value of albuminuria on 1-month mortality in acute myocardial infarction.
Progression of diabetic nephropathy in normotensive type 1 diabetic patients.
Protein kinase C beta inhibition: the promise for treatment of diabetic nephropathy.
Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. The EUCLID Study Group.
Recent Advances in Pharmacological Management of Hypertension in Diabetic Patients with Nephropathy : Effects of Antihypertensive Drugs on Kidney Function and Insulin Sensitivity.
Recent advances in pharmacological management of hypertension in diabetic patients with nephropathy. Effects of antihypertensive drugs on kidney function and insulin sensitivity.
Reduction of albuminuria after angiotensin converting enzyme inhibition in various renal disorders.
Relation of albuminuria to angiographically determined coronary arterial narrowing in patients with and without type 2 diabetes mellitus and stable or suspected coronary artery disease.
Renal protective effects of angiotensin-converting enzyme inhibition.
Renin-angiotensin system blocker discontinuation and adverse outcomes in chronic kidney disease.
Renoprotection by direct renin inhibition: a systematic review and meta-analysis.
Secondary prevention of renal and cardiovascular disease: results of a renal and cardiovascular treatment program in an Australian aboriginal community.
Serum uric acid level is associated with metabolic syndrome and microalbuminuria in Korean patients with type 2 diabetes mellitus.
Short- and long-term treatment with angiotensin-converting enzyme inhibitors or calcium channel blockers for the prevention of diabetic nephropathy progression: A meta-analysis.
Sickle Cell Nephropathy in the Pediatric Population.
Targeting albumin excretion rate in the treatment of the hypertensive diabetic patient with renal disease.
The BErgamo NEphrologic DIabetes Complications Trial (BENEDICT): design and baseline characteristics.
The effect of beta-blockade and angiotensin converting enzyme inhibition on kidney function in diabetic nephropathy.
The effect of losartan and captopril on glomerular basement membrane anionic charge in a diabetic rat model.
The evolving science of apolipoprotein-L1 and kidney disease.
The glomerulopathy of sickle cell disease.
The insertion/deletion polymorphism of the angiotensin-converting enzyme gene is associated with progression, but not development, of albuminuria in Iranian patients with type 2 diabetes.
The Long-Term Impact of Renin-Angiotensin System (RAS) Inhibition on Cardiorenal Outcomes (LIRICO): A Randomized, Controlled Trial.
The need for combination antihypertensive therapy to reach target blood pressures: what has been learned from clinical practice and morbidity-mortality trials?
The role of adiponectin in renal physiology and development of albuminuria.
The roles of angiotensin II and prostaglandins in the regulation of the glomerular filtration of albumin.
The selective vitamin D receptor activator for albuminuria lowering (VITAL) study: study design and baseline characteristics.
The short-term effects of angiotensin II receptor blockers on albuminuria and renal function in Korean patients.
The Use of Renin-Angiotensin System Inhibitors in Patients With Chronic Kidney Disease.
Therapeutic Insights in Chronic Kidney Disease Progression.
Time course of the antiproteinuric and renal haemodynamic responses to losartan in microalbuminuric IDDM.
Treatment of arterial hypertension in diabetic humans: importance of therapeutic selection.
Update on current management of chronic kidney disease in patients with HIV infection.
Update on the ROADMAP clinical trial report: olmesartan for the prevention or delay of microalbuminuria development in Type 2 diabetes.
Urinary albumin excretion and the renin-angiotensin system in cardiovascular risk management.
Urinary glycosaminoglycans, sialic acid and lysosomal enzymes increase in nonalbuminuric diabetic patients.
Vitamin D receptor activator and dietary sodium restriction to reduce residual urinary albumin excretion in chronic kidney disease (ViRTUE study): rationale and study protocol.
Vitamin D, proteinuria, diabetic nephropathy, and progression of CKD.
Waist circumference and the metabolic syndrome predict the development of elevated albuminuria in non-diabetic subjects: the DESIR Study.
What is the evidence that microalbuminuria is a predictor of cardiovascular disease events?
[Long-term decrease of microalbuminuria after one year of treatment with perindopril in hypertensive diabetic patients]
[Renin-angiotensin system inhibition and cardiac and renal alteration induced by a high sodium diet in rat]
[The effect of trandolapril, in monotherapy and associated with verapamil, on arterial pressure, albuminuria, and metabolic control in hypertensive patients with type 2 diabetes and albuminuria]
[What do large clinical trials learn us about cardiovascular and renal prevention in patients with type 2 diabetes mellitus and hypertension?]
Alkalosis
A new syndrome: angiotensin-converting enzyme dysfunction syndrome: differential diagnosis and pathogenesis--case reports.
Effect of angiotensin converting enzyme inhibition on airway conductance during hypocapnic hyperventilation in normal subjects.
Predicting the safety and efficacy of buffer therapy to raise tumour pHe: an integrative modelling study.
Alopecia
Association between angiotensin-converting enzyme gene insertion deletion polymorphism and androgenetic alopecia susceptibility among Egyptian patients: A preliminary case-controlled study.
Expression of neuropeptide-degrading enzymes in alopecia areata: an immunohistochemical study.
Alopecia Areata
Angiotensin converting enzyme activity in alopecia areata.
Serum and tissue angiotensin-converting enzyme in patients with alopecia areata.
alpha 1-Antitrypsin Deficiency
Serum angiotensin converting enzyme levels in patients with alpha 1-antitrypsin variants.
Altitude Sickness
The association of angiotensin-converting enzyme gene insertion/deletion polymorphisms with acute mountain sickness susceptibility: a meta-analysis.
The effect of angiotensin-converting enzyme genotype on acute mountain sickness and summit success in trekkers attempting the summit of Mt. Kilimanjaro (5,895 m).
Alveolitis, Extrinsic Allergic
Serum angiotensin-converting enzyme and lysosomal enzymes in tobacco workers.
Serum angiotensin-converting enzyme levels in patients with pigeon-breeder's disease.
[Angiotensin converting enzyme at different stages of extrinsic allergic alveolitis. Serum and alveolar study]
[Serum angiotensin I converting enzyme activity in extrinsic allergic alveolitis]
Alzheimer Disease
A clinical dose of angiotensin-converting enzyme (ACE) inhibitor and heterozygous ACE deletion exacerbate Alzheimer's disease pathology in mice.
A pilot clinical trial of the angiotensin-converting enzyme inhibitor ceranapril in Alzheimer disease.
A Role for the Brain RAS in Alzheimer's and Parkinson's Diseases.
A?-accelerated neurodegeneration caused by Alzheimer's-associated ACE variant R1279Q is rescued by angiotensin system inhibition in mice.
Accumulation of Insoluble Amyloid-? in Down's Syndrome is Associated with Increased BACE-1 and Neprilysin Activities.
ACE gene is associated with Alzheimer's disease and atrophy of hippocampus and amygdala.
ACE I/D polymorphism is a risk factor of Alzheimer's disease but not of vascular dementia.
Altered angiotensin-converting enzyme and its effects on the brain in a rat model of Alzheimer disease.
Alzheimer disease risk and genetic variation in ACE: a meta-analysis.
Amyloid beta-protein is degraded by cellular angiotensin-converting enzyme (ACE) and elevated by an ACE inhibitor.
An age effect on the association of common variants of ACE with Alzheimer's disease.
Angiotensin as a target for the treatment of Alzheimer's disease, anxiety and depression.
Angiotensin converting enzyme and endothelial nitric oxide synthase DNA polymorphisms and late onset Alzheimer's disease.
Angiotensin converting enzyme deletion allele in different kinds of dementia disorders.
Angiotensin converting enzyme density is increased in temporal cortex from patients with Alzheimer's disease.
Angiotensin converting enzyme gene polymorphism in Alzheimer's disease.
Angiotensin converting enzyme in Alzheimer's disease increased activity in caudate nucleus and cortical areas.
Angiotensin Converting Enzyme Inhibitors Ameliorate Brain Inflammation Associated with Microglial Activation: Possible Implications for Alzheimer's Disease.
Angiotensin Converting Enzyme Inhibitors and Alzheimer Disease in the Presence of the Apolipoprotein E4 Allele.
Angiotensin converting enzyme inhibitors and cognitive and functional decline in patients with Alzheimer's disease: an observational study.
Angiotensin converting enzyme inhibitors and the reduced risk of Alzheimer's disease in the absence of apolipoprotein e4 allele.
Angiotensin converting enzyme insertion/deletion polymorphism in sporadic and familial Alzheimer's disease and longevity.
Angiotensin Converting Enzyme Serum Activities: Relationship with Alzheimer's disease.
Angiotensin II-inhibition: effect on Alzheimer's pathology in the aged triple transgenic mouse.
Angiotensin-converting enzyme (ACE) levels and activity in Alzheimer's disease, and relationship of perivascular ACE-1 to cerebral amyloid angiopathy.
Angiotensin-converting enzyme and alpha-2-macroglobulin gene polymorphisms are not associated with Alzheimer's disease in Colombian patients.
Angiotensin-converting enzyme as a potential target for treatment of Alzheimer's disease: inhibition or activation?
Angiotensin-converting enzyme degrades Alzheimer amyloid beta-peptide (A beta ); retards A beta aggregation, deposition, fibril formation; and inhibits cytotoxicity.
Angiotensin-converting enzyme gene and plasma protein level in Alzheimer's disease in Taiwanese.
Angiotensin-converting enzyme gene in Alzheimer's disease.
Angiotensin-converting enzyme gene insertion-deletion polymorphism is a risk marker for Alzheimer's disease in a Chinese population: a meta-analysis of case-control studies.
Angiotensin-converting enzyme gene polymorphisms and risk for sporadic Alzheimer's disease: a meta-analysis.
Angiotensin-converting enzyme genotype is associated with Alzheimer disease in the Japanese population.
Angiotensin-converting enzyme in cerebrospinal fluid and risk of brain atrophy.
Angiotensin-Converting Enzyme Inhibitors and Alzheimer's Disease Progression in Older Adults: Results from the Réseau sur la Maladie d'Alzheimer Français Cohort.
Angiotensin-converting enzyme inhibitors and incidence of Alzheimer's disease in Japan.
Angiotensin-converting enzyme insertion/deletion polymorphism and the longitudinal progression of Alzheimer's disease.
Angiotensin-converting enzyme insertion/deletion polymorphism is associated with cerebral white matter changes in Alzheimer's disease.
Angiotensin-converting enzyme insertion/deletion polymorphism is not a major determining factor in the development of sporadic Alzheimer disease: evidence from an updated meta-analysis.
Angiotensin-converting enzyme levels and activity in Alzheimer's disease: differences in brain and CSF ACE and association with ACE1 genotypes.
Antihypertensive drugs decrease risk of Alzheimer disease: Ginkgo Evaluation of Memory Study.
Apolipoprotein E, angiotensin-converting enzyme and kallikrein gene polymorphisms and the risk of Alzheimer's disease and vascular dementia.
Association between ACE gene polymorphisms and Alzheimer's disease in Han population in Hebei Peninsula.
Association between ACE polymorphism, cognitive phenotype and APOE E4 allele in a Tunisian population with Alzheimer disease.
Association between an angiotensin-converting enzyme gene polymorphism and Alzheimer's disease in a Tunisian population.
Association between angiotensin-converting enzyme and Alzheimer disease.
Association between angiotensin-converting enzyme gene and late onset Alzheimer's disease in Han chinese.
Association between angiotensin-converting enzyme gene polymorphism and Alzheimer's disease in a Chinese population.
Association of Angiotensin-Converting Enzyme Insertion(I)/Deletion (D) Genotype in Alzheimer's Disease Patients of North Indian Population.
Association of Increased Serum ACE Activity with Logical Memory Ability in Type 2 Diabetic Patients with Mild Cognitive Impairment.
Association of polymorphisms in the Angiotensin-converting enzyme gene with Alzheimer disease in an Israeli Arab community.
Association of PS1 1/2, ACE I/D, and LRP C/T polymorphisms with Alzheimer's disease in the Chinese population: a meta-analysis of case-control studies.
Associations of angiotensin targeting antihypertensive drugs with mortality and hospitalization in primary care patients with dementia.
Associations of Anti-Hypertensive Treatments with Alzheimer's Disease, Vascular Dementia, and Other Dementias.
Associations of Blood Pressure with Functional and Cognitive Changes in Patients with Alzheimer's Disease.
Associations of centrally acting ACE inhibitors with cognitive decline and survival in Alzheimer's disease.
Attenuating effect of lisinopril and telmisartan in intracerebroventricular streptozotocin induced experimental dementia of Alzheimer's disease type: possible involvement of PPAR-? agonistic property.
Beneficial association of angiotensin-converting enzyme inhibitors and statins on the occurrence of possible Alzheimer's disease after traumatic brain injury.
Brain-Penetrating Angiotensin-Converting Enzyme Inhibitors and Cognitive Change in Patients with Dementia due to Alzheimer's Disease.
C677T Methylentetrahydrofulate Reductase and Angiotensin Converting Enzyme Gene Polymorphisms in Patients with Alzheimer's Disease in Iranian Population.
Cerebrospinal Fluid Levels of Angiotensin-Converting Enzyme Are Associated with Amyloid-?42 Burden in Alzheimer's Disease.
Cerebrospinal fluid levels of angiotensin-converting enzyme in Alzheimer's disease, Parkinson's disease and progressive supranuclear palsy.
Cerebrospinal fluid levels of angiotensin-converting enzyme, acetylcholinesterase, and dopamine metabolites in dementia associated with Alzheimer's disease and Parkinson's disease: a correlative study.
DNA polymorphisms of apolipoprotein B and angiotensin I-converting enzyme genes and relationships with lipid levels in Italian patients with vascular dementia or Alzheimer's disease.
Effect of a centrally active angiotensin converting enzyme inhibitor, perindopril, on cognitive performance in chronic cerebral hypo-perfusion rats.
Effect of a centrally active angiotensin-converting enzyme inhibitor, perindopril, on cognitive performance in a mouse model of Alzheimer's disease.
Effect of the Casein-Derived Peptide Met-Lys-Pro on Cognitive Function in Community-Dwelling Adults Without Dementia: A Randomized, Double-Blind, Placebo-Controlled Trial.
Effects of Centrally acting Angiotensin Converting Enzyme Inhibitors on Functional Decline in Patients with Alzheimer's Disease.
Effects of prolonged angiotensin-converting enzyme inhibitor treatment on amyloid beta-protein metabolism in mouse models of Alzheimer disease.
Enalapril Alone or Co-Administered with Losartan Rescues Cerebrovascular Dysfunction, but not Mnemonic Deficits or Amyloidosis in a Mouse Model of Alzheimer's Disease.
Frequency of APOE, MTHFR and ACE polymorphisms in the Zambian population.
Functional regulation of Alu element of human angiotensin-converting enzyme gene in neuron cells.
Gender-specific association of the angiotensin converting enzyme gene with Alzheimer's disease.
Genetic polymorphisms in older subjects with vascular or Alzheimer's dementia.
Genetic susceptibility factors for Alzheimer's disease.
Higher activity of peripheral blood angiotensin-converting enzyme is associated with later-onset of Alzheimer's disease.
Interaction between apolipoprotein-E and angiotensin-converting enzyme genotype in Alzheimer's disease.
Is inhibition of the renin-angiotensin system a new treatment option for Alzheimer's disease?
Lack of association between angiotensin converting enzyme polymorphism and sporadic Alzheimer's disease.
Lack of association between angiotensin-converting enzyme and dementia of the Alzheimer's type in an elderly Arab population in Wadi Ara, Israel.
Large meta-analysis establishes the ACE insertion-deletion polymorphism as a marker of Alzheimer's disease.
Methylenetetrahydrofolate reductase and angiotensin converting enzyme gene polymorphisms in two genetically and diagnostically distinct cohort of Alzheimer patients.
N-domain of angiotensin-converting enzyme hydrolyzes human and rat amyloid-?(1-16) peptides as arginine specific endopeptidase potentially enhancing risk of Alzheimer's disease.
Neurotoxic Effects of A?6-42 Peptides Mimicking Putative Products Formed by the Angiotensin Converting Enzyme.
No association between DCP1 genotype and late-onset Alzheimer disease.
Perindopril ameliorates experimental Alzheimer's disease progression: role of amyloid ? degradation, central estrogen receptor and hyperlipidemic-lipid raft signaling.
Perindopril, a centrally active angiotensin-converting enzyme inhibitor, prevents cognitive impairment in mouse models of Alzheimer's disease.
Pharmacogenetic effects of angiotensin-converting enzyme inhibitors over age-related urea and creatinine variations in patients with dementia due to Alzheimer disease.
Pharmacogenetics of Angiotensin-Converting Enzyme Inhibitors in Patients with Alzheimer's Disease Dementia.
Pharmacologic management of Alzheimer disease, Part II: Antioxidants, antihypertensives, and ergoloid derivatives.
Pharmacological strategies for the prevention of Alzheimer's disease.
Plasma angiotensin-converting enzyme in Alzheimer's disease.
Protective effects of perindopril on d-galactose and aluminum trichloride induced neurotoxicity via the apoptosis of mitochondria-mediated intrinsic pathway in the hippocampus of mice.
Protein processing mechanisms: from angiotensin-converting enzyme to Alzheimer's disease.
Re-evaluation of cerebrospinal fluid angiotensin-converting enzyme activity in patients with 'probable' Alzheimer's disease.
Shifts in angiotensin I converting enzyme insertion allele frequency across Europe: implications for Alzheimer's disease risk.
Soluble adhesion molecules and angiotensin-converting enzyme in dementia.
Structure-activity relationship of hydroxamate-based inhibitors on the secretases that cleave the amyloid precursor protein, angiotensin converting enzyme, CD23, and pro-tumor necrosis factor-alpha.
Study of the association between Alzheimer's disease and angiotensin-converting enzyme gene polymorphism using DNA from lymphocytes.
Tempol and perindopril protect against lipopolysaccharide-induced cognition impairment and amyloidogenesis by modulating brain-derived neurotropic factor, neuroinflammation and oxido-nitrosative stress.
The ACE gene and Alzheimer's disease susceptibility.
The angiotensin-converting enzyme gene as a possible risk or protective factor in Alzheimer's disease.
The association of angiotensin-converting enzyme with biomarkers for Alzheimer's disease.
The associations of apolipoprotein E and angiotensin-converting enzyme polymorphisms and cognitive function in Type 1 diabetes based on an 18-year follow-up of the DCCT cohort.
The Impact of Angiotensin-Converting Enzyme Gene on Behavioral and Psychological Symptoms of Dementia in Alzheimer's Disease.
The Implications of Angiotensin-Converting Enzymes and Their Modulators in Neurodegenerative Disorders: Current and Future Perspectives.
The insertion polymorphism in angiotensin-converting enzyme gene associated with the APOE epsilon 4 allele increases the risk of late-onset Alzheimer disease.
The role of ADAM10 and ADAM17 in the ectodomain shedding of angiotensin converting enzyme and the amyloid precursor protein.
The role of angiotensin II in cognition and behaviour.
The use of angiotensin-converting enzyme inhibitors vs. angiotensin receptor blockers and cognitive decline in Alzheimer's disease: the importance of blood-brain barrier penetration and APOE ?4 carrier status.
Use of angiotensin receptor blockers and risk of dementia in a predominantly male population: prospective cohort analysis.
Variation in the DCP1 gene, encoding the angiotensin converting enzyme ACE, is not associated with increased susceptibility to Alzheimer's disease.
Voltage-programming-based capillary gel electrophoresis for the fast detection of angiotensin-converting enzyme insertion/deletion polymorphism with high sensitivity.
[Activity of peptidyl-dipeptidase A and carboxypeptidase N in the serum of patients with Alzheimer disease]
[Angiotensin-converting enzyme gene as a possible risk factor or protective factor in Alzheimer's disease]
[Association between angiotensin-converting enzyme gene polymorphism and Alzheimer's disease].
[The association between angiotensin I converting enzyme gene polymorphism and Chinese late onset Alzheimer disease]
Amyloidosis
Angiotensin Converting Enzyme Gene Insertion/Deletion Variant and Familial Mediterranean Fever-related Amyloidosis.
Effect of indomethacin and selective cyclooxygenase-2 inhibitors on proteinuria and renal function in patients with AA type renal amyloidosis.
Primary systemic amyloidosis and high levels of Angiotensin-converting enzyme: two case reports.
Amyotrophic Lateral Sclerosis
Angiotensin-converting enzyme inhibitors and amyotrophic lateral sclerosis risk: a total population-based case-control study.
The Implications of Angiotensin-Converting Enzymes and Their Modulators in Neurodegenerative Disorders: Current and Future Perspectives.
Anaphylaxis
A variety of clinical applicabilities of immobilized dextran sulphate as lipoprotein adsorbent and avoidance of anaphylactoid (anion-blood contact) reaction in its use.
Acute angioedema response to topical 5-fluorouracil therapy.
Adult food allergy.
Aggregate anaphylaxis and carboxypeptidase N.
An 82-year-old man with recurrent angioedema.
Anaphylactoid reaction to recombinant tissue plasminogen activator.
Anaphylactoid reactions and bradykinin generation in patients treated with LDL-apheresis and an ACE inhibitor.
Anaphylactoid reactions during hemodialysis and hemofiltration: role of associating AN69 membrane and angiotensin I-converting enzyme inhibitors.
Anaphylactoid reactions during hemodialysis in sheep are ACE inhibitor dose-dependent and mediated by bradykinin.
Anaphylactoid reactions during hemodialysis.
Anaphylactoid reactions, angiotensin-converting enzyme inhibitors and extracorporeal hemotherapy.
Angioedema: A Life-threatening Complication of Tissue Plasminogen Activator.
Angiotensin-converting enzyme genotype is a risk factor for wheat-dependent exercise-induced anaphylaxis sensitized with hydrolyzed wheat protein.
Angiotensin-converting-enzyme inhibitors and anaphylactoid reactions to high-flux membrane dialysis.
Antihypertensive medication use is associated with increased organ system involvement and hospitalization in emergency department patients with anaphylaxis.
Are ACE Inhibitors and Beta-blockers Dangerous in Patients at Risk for Anaphylaxis?
Arginine vasopressin as a rescue vasopressor agent in the operating room.
Biphasic anaphylaxis to gemifloxacin.
Bradykinin generation by dialysis membranes: possible role in anaphylactic reaction.
Changes in bradykinin and prostaglandins plasma levels during dextran-sulfate low-density-lipoprotein apheresis.
Cofactors and comorbidities in patients with aspirin/NSAID hypersensitivity.
Cryofiltration apheresis and plasma fractionation causing anaphylactoid reactions in patients receiving angiotensin converting enzyme inhibitors.
Effects of losartan on low-density lipoprotein apheresis.
Efficacy and safety measures for low density lipoprotein apheresis treatment using dextran sulfate cellulose columns.
Evaluation of the Losartan in Hemodialysis (ELHE) Study.
Evidence Accumulates Against Angiotensin-Converting Enzyme Inhibitors and Beta-Adrenergic Blockers as Important Co-factors for Anaphylactic Reactions.
Fatal anaphylaxis following jack jumper ant sting in southern Tasmania.
Haemodialysis-associated anaphylactic and anaphylactoid reactions.
Histamine, tryptase, norepinephrine, angiotensinogen, angiotensin-converting enzyme, angiotensin I and II in plasma of patients with hymenoptera venom anaphylaxis.
IgE-Mediated Anaphylaxis to Foods, Venom, and Drugs: Influence of Serum Angiotensin Converting Enzyme Levels and Genotype.
Kinin generation by hemodialysis membranes as a possible cause of anaphylactoid reactions.
LDL apheresis with dextran sulfate and angiotension receptor antagonist (Losartan).
Life-threatening anaphylaxis to venom immunotherapy in a patient taking an angiotensin-converting enzyme inhibitor.
Losartan associated anaphylaxis and angioneurotic oedema.
Management of allergic disease in the elderly: key considerations, recommendations and emerging therapies.
More about anaphylactoid reactions in patients dialyzed with AN69 filter and on angiotensin converting enzyme inhibitors treatment.
Negative penicillin skin testing induced anaphylaxis with concurrent beta blocker and angiotensin-converting enzyme inhibitor use.
Plasma renin and angiotensin I converting enzyme activity in anaphylactic shock.
Relationship Between Anaphylaxis and Use of Beta-Blockers and Angiotensin-Converting Enzyme Inhibitors: A Systematic Review and Meta-Analysis of Observational Studies.
Response to life-threatening anaphylaxis to venom immunotherapy in a patient taking an angiotensin-converting enzyme inhibitor.
Risk of severe anaphylaxis for patients with Hymenoptera venom allergy: Are angiotensin-receptor blockers comparable to angiotensin-converting enzyme (ACE) inhibitors?
Role of bradykinin in anaphylactoid reactions during hemodialysis with AN69 dialyzers.
Salmon caviar-induced anaphylactic shock.
Therapeutic selective adsorption of anti-DNA antibody using dextran sulfate cellulose column (Selesorb) for the treatment of systemic lupus erythematosus.
Transient myocardial dysfunction associated with angiotensin-converting enzyme inhibitor-induced angioedema: recognition by serial echocardiographic studies.
[Recurrent anaphylaxis and angiotensin-converting enzyme inhibitors]
Anemia
A novel nomogram to predict all-cause readmission or death risk in Chinese elderly patients with heart failure.
ACE inhibitors do not induce recombinant human erythropoietin resistance in hemodialysis patients.
Acute Exacerbation of Chronic Obstructive Pulmonary Disease in Oldest Adults: Predictors of In-Hospital Mortality and Need for Post-acute Care.
Acute Kidney Injury after Heart Valve Surgery in Elderly Patients: any Risk Factors to Modify?
Advances in nephrology: successes and lessons learnt from diabetes mellitus.
Adverse safety events in patients with chronic kidney disease (CKD).
Aldosterone blockade as an alternative renin-angiotensin-aldosterone system blocking agent in cases of treatment associated anemia.
Anaemia after renal transplantation.
Anaemia due to ACE inhibitors and losartan in patients with renal failure.
Anaemia in chronic obstructive pulmonary disease. Does it really matter?
Anaemia in chronic obstructive pulmonary disease: an insight into its prevalence and pathophysiology.
Anemia after kidney transplantation.
Anemia and angiotensin-converting enzyme inhibition in renal transplant recipients.
Anemia and diabetic nephropathy.
Anemia in kidney transplanted patients.
Anemia in new-onset congestive heart failure inpatients admitted for acute decompensation.
Anemia in pediatric renal transplant recipients.
Anemia in renal transplant recipients caused by concomitant therapy with azathioprine and angiotensin-converting enzyme inhibitors.
Angiotensin converting enzyme inhibitor induced anemia in a kidney transplant recipient.
Angiotensin-converting enzyme (ACE) inhibitors have been reported to induce or worsen anemia in patients on hemodialysis.
Angiotensin-converting enzyme gene polymorphism is associated with anemia in non small-cell lung cancer.
Angiotensin-converting enzyme inhibition and anaemia in renal patients.
Angiotensin-converting enzyme inhibitor and anemia in a patient undergoing hemodialysis.
Angiotensin-converting enzyme inhibitor as a risk factor for the development of anemia, and the impact of incident anemia on mortality in patients with left ventricular dysfunction.
Angiotensin-converting enzyme inhibitor therapy in chronic hemodialysis patients: any evidence of erythropoietin resistance?
Angiotensin-converting enzyme inhibitor-induced anemia and treatment for erythrocytosis in renal transplant recipients.
Angiotensin-converting enzyme inhibitors and anemia in chronic kidney disease: a complex interaction.
Angiotensin-converting enzyme inhibitors but not angiotensin II AT 1 receptor antagonists affect erythropoiesis in patients with anemia of end-stage renal disease.
Angiotensin-converting enzyme inhibitors slow recovery from anemia following cardiac surgery.
Angiotensin-converting enzyme insertion/deletion polymorphism is not associated with vasoocclusive complications of sickle cell anemia.
Angiotensin-converting enzyme is required for normal myelopoiesis.
Association between anemia and outcome in patients hospitalized for acute heart failure syndromes: findings from Beijing Acute Heart Failure Registry (Beijing AHF Registry).
Association between gene polymorphisms of the components of the renin-angiotensin-aldosteron system, graft function, and the prevalence of hypertension, anemia, and erythrocytosis after kidney transplantation.
Association between serum Na-Cl level and renal function decline in chronic kidney disease: results from the chronic kidney disease Japan cohort (CKD-JAC) study.
BP Control and Left Ventricular Hypertrophy Regression in Children with CKD.
Choosing Wisely: The Canadian Society of Nephrology's List of 5 Items Physicians and Patients Should Question.
Clinical characteristics and predictors of in-hospital mortality in acute heart failure with preserved left ventricular ejection fraction.
Comparison of frequency of new-onset atrial fibrillation or flutter in patients on statins versus not on statins presenting with suspected acute coronary syndrome.
Competing Effects of Renin Angiotensin System Blockade and Sodium-Glucose Cotransporter-2 Inhibitors on Erythropoietin Secretion in Diabetes.
Contribution of systemic blood pressure to myocardial remodeling in uremic rats.
Discontinuation of the renin-angiotensin system inhibitors improves erythropoiesis in patients with lower-risk myelodysplastic syndromes.
Disease progression and the application of evidence-based treatment guidelines diagnose it early: a case for screening and appropriate management.
Early and long-term outcomes of decompensated heart failure patients in a tertiary-care centre in India.
Effect of angiotensin-converting enzyme inhibitors on anemia in hemodialyzed patients.
Effects of angiotensin-converting enzyme inhibitors on anemia and erythropoietin requirements in peritoneal dialysis patients.
Effects of angiotensin-converting enzyme inhibitors on the treatment of anemia with erythropoietin.
Effects of the Renin-Angiotensin system blockade on hemoglobin levels in type 2 diabetic patients with chronic kidney disease.
Efficacy of captopril on posttransplant erythrocytosis. Long-term follow-up.
Enalapril reduces the albuminuria of patients with sickle cell disease.
Enalapril-induced anemia in two kidney transplant recipients.
Factor deficiency in the anemia of renal transplant patients with grade III-IV chronic kidney disease: baseline results of the ARES Study.
Haematopoietic effects of Angelica sinensis root cap polysaccharides against lisinopril-induced anaemia in albino rats.
Health care resource utilization and the impact of anemia management in patients with chronic kidney disease.
Heart failure in the outpatient versus inpatient setting: findings from the BIOSTAT-CHF study.
Hematocrit-lowering effect following inactivation of renin-angiotensin system with angiotensin converting enzyme inhibitors and angiotensin receptor blockers.
High dose enalapril impairs the response to erythropoietin treatment in haemodialysis patients.
Hypertension after kidney transplant.
Hypertension, Living Kidney Donors, and Transplantation: Where Are We Today?
Impact of chronic kidney disease and anemia on hospitalization expense in patients with left ventricular dysfunction.
In-hospital and short-term prognostic factors in acute pulmonary edema: clinical and morphological features.
Inhibition of the renin-angiotensin system in the cardiorenal syndrome with anaemia: a double-edged sword.
INVESTIGATION OF THE EFFECTS OF ANGIOTENSIN CONVERTING ENZYME INHIBITORS AND ANGIOTENSIN RECEPTOR BLOCKERS ON ANEMIA IN PATIENTS WITH NORMAL OR MILDLY LOW GLOMERULAR FILTRATION RATE.
Level of renal function and serum erythropoietin levels independently predict anaemia post-renal transplantation.
Lisinopril pharmacokinetics and erythropoietin requirement in haemodialysis patients.
Mechanism of angiotensin converting enzyme inhibitor-related anemia in renal transplant recipients.
Meta-Analysis of Risks for Short-Term Readmission in Patients With Heart Failure.
Peripheral sea-fan retinal neovascularization as a manifestation of chronic rhegmatogenous retinal detachment and surgical management.
Pharmacoepidemiology of anemia in kidney transplant recipients.
Prevalence and association of post-renal transplant anemia.
Prevalence and management of anemia in renal transplant recipients: a European survey.
Prevalence and Prognostic Significance of Anemia in Patients With Congestive Heart Failure Treated With Standard vs High Doses of Enalapril.
Prevalence of and risk factors for reduced serum bicarbonate in chronic kidney disease.
Prevalence of anemia and effects on mortality in patients with heart failure.
Prevention of nephropathy in patients with type 2 diabetes mellitus.
Prognostic significance of nonsustained ventricular tachycardia in patients receiving cardiac resynchronization therapy for primary prevention: Analysis of the Japan cardiac device treatment registry database.
Progression of renal failure with anaemia and multiple effects of angiotensin-converting enzyme inhibitor in rats with renal mass reduction.
Proven strategies to reduce cardiovascular mortality in hemodialysis patients.
Ranolazine, ACE Inhibitors, and Angiotensin Receptor Blockers.
Regression of left ventricular hypertrophy in hemodialysis patients is possible.
Renal failure and hypercalcemia as initial manifestations of extrapulmonary sarcoidosis.
Renal Failure Is an Independent Predictor of Mortality in Hospitalized Heart Failure Patients and Is Associated With a Worse Cardiovascular Risk Profile.
Renin-Angiotensin System Inhibitors Linked to Anemia: A Systematic Review and Meta-analysis.
Risk factors for pacemaker implantation following aortic valve replacement: a single centre experience.
Role of the renin-angiotensin system in primitive erythropoiesis in the chick embryo.
Severe refractory sarcoidosis in a 64-year-old man with persistent leucopenia.
The Effect of Anemia on Mortality in Indigent Patients With Mild-to-Moderate Chronic Heart Failure.
The effect of high dose losartan on erythropoietin resistance in patients undergoing haemodialysis.
The effect of losartan on hemoglobin concentration and renal outcome in diabetic nephropathy of type 2 diabetes.
The management of cardiac disease in chronic uremia.
The prevention of pain from sickle cell disease by trandolapril.
The Role of the Renin-Angiotensin System in the Regulation of Erythropoiesis.
The value of pre-dialysis care.
Vitamin D deficiency and anemia is highly prevalent and dependent on the etiology of heart failure: A pilot study.
Worsening of anemia by angiotensin converting enzyme inhibitors and its prevention by antiestrogenic steroid in chronic hemodialysis patients.
[Anemia as a new predictor of mortality in patients hospitalized with congestive heart failure]
[Anemias in chronic obstructive pulmonary disease].
[Angiotensin converting enzyme and left ventricular hypertrophy in uremic patients: correlation and therapeutic options]
[Chronic anemia in heart transplant patients: prevalence, predisposing factors and prognostic significance]
[Etiology and clinical management of anemia in heart failure. GESAIC study.]
[Non SLE connective tissue diseases: general aspects and kidney]
[Pravovirus B19 infection--the cause of severe anaemia after renal transplantation]
[Successful treatment with enzyme replacement therapy for pelvic fragile fracture in an elderly case of type I Gaucher's disease].
[The effects of ACE inhibitor treatment and ACE gene polymorphism on erythropoiesis in chronic hemodialysis patients]
[Update cardiology 2006/2007]
Anemia, Hemolytic
Antihypertensive medications and anemia.
Anemia, Iron-Deficiency
Proteinuria Induced by Parenteral Iron in Chronic Kidney Disease--A Comparative Randomized Controlled Trial.
Anemia, Megaloblastic
Circulating and local bone marrow renin-angiotensin system in leukemic hematopoiesis: preliminary evidences.
Anemia, Sickle Cell
Angiotensin-converting enzyme (ACE) inhibitors for proteinuria and microalbuminuria in people with sickle cell disease.
Angiotensin-converting enzyme insertion/deletion polymorphism is not associated with vasoocclusive complications of sickle cell anemia.
Enalapril reduces the albuminuria of patients with sickle cell disease.
Impact of renal function on hydroxyurea exposure in sickle-cell disease patients.
Levels of angiotensin-converting enzyme 1 and 2 in serum and urine of children with Sickle Cell Disease.
Peripheral sea-fan retinal neovascularization as a manifestation of chronic rhegmatogenous retinal detachment and surgical management.
Prevalence and pathologic features of sickle cell nephropathy and response to inhibition of angiotensin-converting enzyme.
Prevalence, prevention, and treatment of microalbuminuria and proteinuria in children with sickle cell disease.
The prevention of pain from sickle cell disease by trandolapril.
Aneurysm
A combination of PPAR-gamma agonists and HMG CoA reductase inhibitors (statins) as a new therapy for the conservative treatment of AAS (aortic aneurysm syndromes).
Abnormal mechanosensing and cofilin activation promote the progression of ascending aortic aneurysms in mice.
An evaluation of the effect of an angiotensin-converting enzyme inhibitor on the growth rate of small abdominal aortic aneurysms: a randomised placebo-controlled trial (AARDVARK).
Angiotensin I Infusion Reveals Differential Effects of Angiotensin-Converting Enzyme in Aortic Resident Cells on Aneurysm Formation.
Angiotensin I-converting enzyme gene polymorphism in intracranial saccular aneurysm individuals.
Angiotensin-converting enzyme inhibitor helps prevent late remodeling after left ventricular aneurysm repair in rats.
Captopril versus atenolol to prevent expansion rate of thoracic aortic aneurysms: rationale and design.
Concurrent pulmonary thrombosis with systemic embolism: a case report.
Current theories and clinical trial evidence for limiting human abdominal aortic aneurysm growth.
Effects of two inhibitors of renin-angiotensin system on attenuation of postoperative remodeling after left ventricular aneurysm repair in rats.
Histological and genetic studies in patients with bicuspid aortic valve and ascending aorta complications.
Increased angiotensin converting enzyme activity in left ventricular aneurysm of patients after myocardial infarction.
Medical treatment for small abdominal aortic aneurysms.
Novel findings: Expression of angiotensin-converting enzyme and angiotensin-converting enzyme 2 in thoracic aortic dissection and aneurysm.
Pulmonary injury follows systemic inflammatory reaction in infrarenal aortic surgery.
Relationship of genetic factors with development of aortic dissection and aneurysm.
Reversal of Aortic Enlargement Because of Increased Biomechanical Forces Requires AT1R (Angiotensin II Type 1 Receptor) Inhibition in Conjunction With AT2R (Angiotensin II Type 2 Receptor) Activation.
The role of angiotensin converting enzyme genotype in coronary artery ectasia.
Thoracic aortic aneurysm and dissection.
Aneurysm, Dissecting
An angiotensin-converting enzyme inhibitor, not an angiotensin II type-1 receptor blocker, prevents beta-aminopropionitrile monofumarate-induced aortic dissection in rats.
Angiotensin-converting enzyme I/D polymorphism and the risk of thoracic aortic dissection in Chinese Han population.
Angiotensin-converting enzyme inhibitors reduce long-term aortic events in patients with acute type B aortic dissection.
Association of Long-term Use of Antihypertensive Medications With Late Outcomes Among Patients With Aortic Dissection.
Lack of association between angiotensin-converting enzyme gene polymorphism and type I aortic dissection.
Novel findings: Expression of angiotensin-converting enzyme and angiotensin-converting enzyme 2 in thoracic aortic dissection and aneurysm.
Relationship of genetic factors with development of aortic dissection and aneurysm.
The deletion polymorphism of the angiotensin-converting enzyme gene is associated with acute aortic dissection.
Aneurysm, Ruptured
II genotype of the angiotensin-converting enzyme gene increases the risk for subarachnoid hemorrhage from ruptured aneurysm.
Angina Pectoris
Angiotensin I converting enzyme gene polymorphism and insulin resistance in patients with angina pectoris.
Angiotensin-converting enzyme in acute myocardial infarction and angina pectoris.
Angiotensin-converting enzyme insertion/deletion polymorphism in angina pectoris with normal coronary arteriograms.
Anti-ischemic effects of cilazapril in patients with both hypertension and angina pectoris. Preliminary report of a pilot study.
Association of chronic kidney disease with periprocedural myocardial injury after elective stent implantation: A single center prospective cohort study.
Captopril potentiates the effects of nitroglycerin in the coronary vascular bed.
Clinical effects of calcium channel blocker and Angiotensin converting enzyme inhibitor on endothelial function and arterial stiffness in patients with angina pectoris.
Dose-Related Hemodynamic Effects of Enalaprilat in Patients with Ischemic Heart Disease.
Effect of captopril, an angiotensin-converting enzyme inhibitor, in patients with angina pectoris and heart failure.
Effect of ramipril on postrevascularization prevalence of angina and quality of life.
Improvement of coronary flow reserve after long-term therapy with enalapril.
Nifedipine retard prevents hospitalization for angina pectoris better than angiotensin-converting enzyme inhibitors in hypertensive Japanese patients with previous myocardial infarction (JMIC-B substudy).
Residual coronary risk in men aged 50-59 years treated for hypertension and hyperlipidaemia in the population: the PRIME study.
Response of symptomatic myocardial ischemia in ischemic cardiomyopathy to intensive vasodilator therapy.
Role of calcium on excitation-contraction coupling in cardiac and vascular smooth muscle.
The Angiotensin-converting Enzyme Inhibition Post Revascularization Study (APRES).
Trials and tribulations associated with angina and traditional therapeutic approaches.
Verapamil and angiotensin-converting enzyme inhibitors in patients with coronary artery disease and reduced left ventricular ejection fraction.
[Angiotensin-converting enzyme inhibition and angina pectoris]
[Angiotensin-converting enzyme inhibitors in angina pectoris]
[Causes of death analysis in 133 congestive heart failure patients]
[JMIC-B study and its sub-analyses: effect of nifedipine in Japanese hypertensive patients with coronary artery disease]
[Risk factors for mortality in abdominal aortic surgery]
[The ability of captopril to enhance the anti-anginal effect of isosorbide dinitrate in patients with stable exercise-induced angina pectoris]
[The angiotensin-converting enzyme inhibitor in the treatment of angina pectoris]
[The anti-ischemic effect of angiotensin-converting enzyme inhibitors in treating stable stenocardia of effort in middle-aged and elderly patients]
Angina, Stable
Angiotensin converting enzyme inhibition in chronic stable angina: effects on myocardial ischaemia and comparison with nifedipine.
Clinical effects of calcium channel blocker and Angiotensin converting enzyme inhibitor on endothelial function and arterial stiffness in patients with angina pectoris.
Effect of apolipoprotein E alleles and angiotensin-converting enzyme insertion/deletion polymorphisms on lipid and lipoprotein markers in middle-aged men and in patients with stable angina pectoris or healed myocardial infarction.
Effect of benazepril on myocardial ischaemia in patients with chronic stable angina pectoris.
Evidence-based management of coronary artery disease in the elderly--current perspectives.
Long-term impact of secondary preventive treatments in patients with stable angina.
Prediction on admission of in-hospital mortality in patients older than 70 years with acute myocardial infarction.
Surgical, medical, and percutaneous therapies for patients with multivessel coronary artery disease.
The variable effects of angiotensin converting enzyme inhibition on myocardial ischaemia in chronic stable angina.
Trimetazidine in Practice: Review of the Clinical and Experimental Evidence.
Update on the medical treatment of stable angina.
[Effects of inhibitors of the angiotensin-converting enzyme on endothelial dysfunction in patients with stable angina pectoris]
[The angiotensin-converting enzyme inhibitor in the treatment of angina pectoris]
[The effect of intracoronary infused captopril on luminal width in coronary stenosis]
[The genes of atherosclerosis and cardiovascular diseases].
[The practice guideline 'Stable angina pectoris' (second revision) from the Dutch College of General Practitioners; a response from the perspective of cardiology]
[Treatment of chronic stable angina pectoris with angiotensin converting enzyme inhibition--a randomized, placebo-controlled, double-blind cross-over study]
Angina, Unstable
Adherence to evidence-based therapies after discharge for acute coronary syndromes: an ongoing prospective, observational study.
Angiotensin-converting enzyme gene polymorphism adds risk for the severity of coronary atherosclerosis in smokers.
Angiotensin-converting enzyme insertion/deletion polymorphism and restenosis after coronary angioplasty in unstable angina pectoris.
Captopril administration reduces thrombus formation and surface expression of platelet glycoprotein IIb/IIa in early postmyocardial infarction stage.
Does long-term angiotensin converting enzyme inhibition affect the concentration of tissue-type plasminogen activator-plasminogen activator inhibitor-1 in the blood of patients with a previous myocardial infarction.
Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions.
Evidence-based management of coronary artery disease in the elderly--current perspectives.
Hypertension and coronary artery disease: a summary of the american heart association scientific statement.
Ongoing clinical trials of angiotensin-converting enzyme inhibitors for treatment of coronary artery disease in patients with preserved left ventricular function.
Reinforcing a continuum of care: in-hospital initiation of long-term secondary prevention following acute coronary syndromes.
Side effects of using nitrates to treat heart failure and the acute coronary syndromes, unstable angina and acute myocardial infarction.
Triggers and Timing of Acute Coronary Syndromes.
Usefulness of losartan, captopril, and furosemide in preventing nitrate tolerance and improving control of unstable angina pectoris.
[Renal failure in patients after acute coronary syndrome--does it change the standards? From theory to practice]
[Time course of changes in brachial artery function in patients with unstable angina pectoris during perindopril therapy].
Angioedema
-
"Nuts and Bolts" of Laboratory Evaluation of Angioedema.
3. Drug hypersensitivity.
A 47-year-old man with tongue swelling.
A case of left atrial compression secondary to angioedema.
A Case of Life-Threatening Angioedema Occurred During Prolonged Angiotensin-Converting Enzyme Inhibitor Treatment.
A case report of angioedema during long-term (66 months) angiotensin converting enzyme inhibition therapy with enalapril.
A Database Cohort Study to Assess the Risk of Angioedema Among Patients with Heart Failure Initiating Angiotensin-Converting Enzyme Inhibitors in the USA.
A focused parameter update: hereditary angioedema, acquired C1 inhibitor deficiency, and angiotensin-converting enzyme inhibitor-associated angioedema.
A Forgotten Cause of Allergy at ER That Is Still Difficult to Diagnose and Treat at Poor Resource Setting: Angioedema after Using Angiotensin Converting Enzyme Inhibitors for 4 Years.
A Novel Approach to the Treatment of Orolingual Angioedema After Tissue Plasminogen Activator Administration.
A randomized trial of icatibant in ACE-inhibitor-induced angioedema.
A Rare Cause of Abdominal Pain: Intestinal Angioedema.
A variant in XPNPEP2 is associated with angioedema induced by angiotensin I-converting enzyme inhibitors.
Abdominal pain, angioedema, and angiotensin-converting enzyme inhibitors.
ACE inhibitor- versus angiotensin II blocker-induced cough and angioedema.
ACE inhibitor-associated intestinal angioedema in orthotopic heart transplantation.
ACE inhibitor-induced angioedema causing small bowel obstruction.
ACE Inhibitor-Induced Angioedema following Cervical Spine Surgery.
ACE Inhibitor-Induced Angioedema of the Bowel.
ACE inhibitor-induced angioedema of the intestine: Case report, incidence, pathophysiology, diagnosis and management.
ACE Inhibitor-Induced Angioedema of the Small Bowel.
ACE inhibitor-induced angioedema.
ACE inhibitor-induced angioedema. Incidence, prevention and management.
ACE Inhibitor-Induced Angioedema: a Review.
ACE inhibitor-induced small bowel angioedema, mimicking an acute abdomen.
ACE inhibitors and chronotherapy.
ACE-I Angioedema: Accurate Clinical Diagnosis May Prevent Epinephrine-Induced Harm.
ACE-I induced angioedema: a case report and review of literature.
ACE-Inhibitor Related Angioedema Is Not Sufficiently Reported to the Danish Adverse Drug Reactions Database.
ACEI associated angioedema - a case study and review.
Acquired angioedema induced by angiotensin-converting enzyme inhibitors - experience of a hospital-based allergy center.
Acute abdomen due to intestinal angioedema induced by ACE inhibitors: not so rare?
Acute ACE inhibition causes plasma extravasation in mice that is mediated by bradykinin and substance P.
Acute upper airway obstruction from acquired angioedema.
Adverse drug effects and angioedema hospitalizations in the United States from 2000 to 2009.
Airway compromise due to angiotensin-converting enzyme inhibitor-induced angioedema: clinical experience at a large community teaching hospital.
Airway management in angiotensin converting enzyme inhibitor related angioedema.
Airway obstruction due to late-onset angioneurotic edema from angiotensin-converting enzyme inhibition.
An 82-year-old man with recurrent angioedema.
An Unusual Case of Angiotensin-Converting-Enzyme Inhibitor-Related Penile Angioedema with Evolution to the Oropharynx.
Analysis of recurrent angiotensin converting enzyme inhibitor-induced angioedema.
Anaphylactoid reaction to recombinant tissue plasminogen activator.
Anaphylactoid reactions and angioedema during alteplase treatment of acute ischemic stroke.
ANGIOEDEMA AFTER ANGIOTENSIN-CONVERTING ENZYME INHIBITORS.
Angioedema after local trauma in a patient on angiotensin-converting enzyme inhibitor therapy.
Angioedema after long-term enalapril use.
Angioedema after long-term use of an angiotensin-converting enzyme inhibitor.
Angioedema after long-term use of angiotensin-converting enzyme inhibitor.
Angioedema after nonsteroidal antiinflammatory drug initiation in a patient stable on an angiotensin-converting-enzyme inhibitor.
Angioedema Among Hypertensive Patients Treated with Aliskiren or Other Antihypertensive Medications in the United States.
Angioedema and angiotensin-converting enzyme (ACE) inhibitors.
Angioedema and angiotensin-converting enzyme inhibitors: are demographics a risk?
Angioedema and photosensitive rash induced by valsartan.
Angioedema associated with angiotensin II receptor antagonist losartan.
Angioedema associated with angiotensin II receptor antagonists: challenging our knowledge of angioedema and its etiology.
Angioedema associated with angiotensin-converting enzyme inhibitor use: outcome after switching to a different treatment.
Angioedema associated with angiotensin-converting enzyme inhibitors.
Angioedema associated with candesartan.
Angioedema associated with lisinopril.
Angioedema associated with the use of angiotensin-converting enzyme inhibitor.
Angioedema complicating lisinopril therapy.
Angioedema deaths in the United States, 1979-2010.
Angioedema due to ACE inhibitors: common and inadequately diagnosed.
Angioedema due to angiotensin-converting enzyme inhibition: an association frequently unrecognized.
Angioedema due to angiotensin-converting enzyme inhibitors.
Angioedema due to fixed dose combination of telmisartan plus ramipril.
Angioedema due to losartan.
Angioedema from angiotensin converting enzyme inhibitors: a cause of upper airway obstruction.
Angioedema from angiotensin-converting enzyme (ACE) inhibitor treated with complement 1 (C1) inhibitor concentrate.
Angioedema in a patient with renal cell cancer treated with everolimus in combination with an angiotensin-converting enzyme inhibitor.
Angioedema in heart failure: occurrence with ACE inhibitors and safety of angiotensin receptor blocker therapy.
Angioedema in renal transplant recipients on sirolimus.
Angioedema in the emergency department: a practical guide to differential diagnosis and management.
Angioedema in the emergency department: the impact of angiotensin-converting enzyme inhibitors.
Angioedema incidence in US veterans initiating angiotensin-converting enzyme inhibitors.
Angioedema induced by angiotensin converting enzyme inhibitors, potentiated by m-TOR inhibitors: successful treatment with icatibant.
Angioedema induced by angiotensin-converting enzyme inhibitors.
Angioedema likely related to angiotensin converting enzyme inhibitors.
Angioedema may not be a class side-effect of the angiotensin-converting-enzyme inhibitors.
Angioedema of the airway: an unusual case.
Angioedema of the head and neck and angiotensin-converting enzyme inhibitors.
Angioedema of the lips and tongue induced by angiotensin-converting enzyme inhibitor. A report of two cases.
Angioedema of the small bowel caused by an angiotensin-converting enzyme inhibitor.
Angioedema of the small bowel caused by angiotensin converting enzyme inhibitor.
Angioedema of the small bowel due to an angiotensin-converting enzyme inhibitor.
Angioedema of the small bowel secondary to treatment with angiotensin converting enzyme inhibitor.
Angioedema related to angiotensin-converting enzyme inhibitors.
Angioedema Related to Angiotensin-Converting Enzyme Inhibitors: Attack Severity, Treatment, and Hospital Admission in a Prospective Multicenter Study.
Angioedema secondary to angiotensin converting enzyme inhibitors is not due to C1 esterase inhibitor deficiency.
Angioedema secondary to angiotensin-converting enzyme inhibitors.
Angioedema Secondary to tPA Use in Acute Ischemic Stroke Patient with Hypertension: A Case Report.
Angioedema Spotlight: A Closer Examination of Sacubitril/Valsartan Safety Results.
Angioedema Triggered by Medication Blocking the Renin/Angiotensin System: Retrospective Study Using the French National Pharmacovigilance Database.
Angioedema without urticaria: a large clinical survey.
Angioedema without wheals: a clinical update.
Angioedema, angiotensin converting enzyme inhibitors, and angiotensin receptor blocking drugs.
Angioedema, lymphoproliferative disorder and angiotensin-converting enzyme inhibitors: masking of diagnosis by corticosteroids.
Angioedema.
Angioedema. A review on the acquired, allergic or non-allergic, and the hereditary forms.
Angioedema: a rare and sometimes delayed side effect of angiotensin-converting enzyme inhibitors.
Angioedema: the role of ACE inhibitors and factors associated with poor clinical outcome.
Angioneurotic edema as a reaction to angiotensin-converting enzyme inhibitors.
Angioneurotic edema attributed to the use of losartan.
Angioneurotic edema of the upper airways and antihypertensive therapy.
Angioneurotic edemas of the upper aerodigestive tract after ACE-inhibitor treatment.
Angiotensin converting enzyme inhibitor induced small bowel angioedema.
Angiotensin converting enzyme inhibitor-associated angioedema: higher risk in blacks than whites.
Angiotensin converting enzyme inhibitor-induced angioedema more prevalent in transplant patients.
Angiotensin converting enzyme inhibitor-induced angioedema: a report of two cases.
Angiotensin converting enzyme inhibitor-induced angioedema: report of a further case.
Angiotensin Converting Enzyme Inhibitor-induced Gastrointestinal Angioedema: A Case Series and Literature Review.
Angiotensin Converting Enzyme Inhibitor-related Angioedema: A Case of an Unexpected Death.
Angiotensin converting enzyme inhibitor-related angioedema: onset, presentation, and management.
Angiotensin converting enzyme inhibitors and delayed onset, recurrent angioedema of the head and neck.
Angiotensin converting enzyme inhibitors are not associated with respiratory complications or mortality after noncardiac surgery.
Angiotensin II receptor antagonists in arterial hypertension.
Angiotensin II receptor blocker-associated angioedema: on the heels of ACE inhibitor angioedema.
Angiotensin II receptor blockers are safe in patients with prior angioedema related to angiotensin-converting enzyme inhibitors - a nationwide registry-based cohort study.
Angiotensin II receptor blockers in patients with ACE inhibitor-induced angioedema.
Angiotensin-converting enzyme (ACE) inhibitor angioedema requiring admission to an intensive care unit.
Angiotensin-Converting Enzyme (ACE) Inhibitor Angioedema: The Silent Epidemic.
Angiotensin-converting enzyme (ACE) inhibitor-associated angioedema of the stomach and small intestine: a case report.
Angiotensin-converting enzyme and dipeptidyl peptidase IV inhibitors: an increased risk of angioedema.
Angiotensin-converting enzyme and dipeptidyl peptidase-4 inhibitor-induced angioedema: A disproportionality analysis of the WHO pharmacovigilance database.
Angiotensin-converting enzyme inhibitor (ACE-I)- and angiotensin receptor blocker (ARB)-related angioedema: A neglected issue in daily practice in Greece.
Angiotensin-converting Enzyme Inhibitor and Other Drug-associated Angioedema.
Angiotensin-converting enzyme inhibitor angioedema in a pediatric patient: a case report and discussion.
Angiotensin-converting enzyme inhibitor angioedema of the intestine: a case report and review of the literature.
Angiotensin-converting Enzyme Inhibitor Angioedema.
Angiotensin-Converting Enzyme Inhibitor Angioedema.
Angiotensin-converting enzyme inhibitor induced angioedema of the head and neck.
Angiotensin-converting enzyme inhibitor induced angioedema: a new trigger?
Angiotensin-converting enzyme inhibitor induced angioedema: not always a class effect? A case report and short narrative review.
Angiotensin-converting enzyme inhibitor induced angioedema: predictors of mechanical ventilation and treatment approaches.
Angiotensin-converting enzyme inhibitor related angioedema and the anaesthetist.
Angiotensin-converting enzyme inhibitor-associated angioedema in a cohort of Caucasian patients: from bed to bench.
Angiotensin-converting enzyme inhibitor-associated angioedema is characterized by a slower degradation of des-arginine(9)-bradykinin.
Angiotensin-converting enzyme inhibitor-associated angioedema treated with c1-esterase inhibitor: A case report and review of the literature.
Angiotensin-converting enzyme inhibitor-associated angioedema.
Angiotensin-converting Enzyme Inhibitor-induced Angioedema - A Dangerous New Epidemic.
Angiotensin-converting enzyme inhibitor-induced angioedema and hereditary angioedema: a comparison study of attack severity.
Angiotensin-converting enzyme inhibitor-induced angioedema and icatibant: a new hope.
Angiotensin-converting enzyme inhibitor-induced angioedema associated with endotracheal intubation.
Angiotensin-converting enzyme inhibitor-induced angioedema following carotid endarterectomy misdiagnosed as cervical hematoma.
Angiotensin-converting enzyme inhibitor-induced angioedema in a community hospital emergency department.
Angiotensin-Converting Enzyme Inhibitor-Induced Angioedema of the Small Bowel-A Surgical Abdomen Mimic.
Angiotensin-converting enzyme inhibitor-induced angioedema worsened with fresh frozen plasma.
Angiotensin-converting enzyme inhibitor-induced angioedema.
Angiotensin-converting enzyme inhibitor-induced angioedema: a multicenter review and an algorithm for airway management.
Angiotensin-converting enzyme inhibitor-induced angioedema: A review of the literature.
Angiotensin-converting enzyme inhibitor-induced angioedema: epidemiology, pathogenesis and management.
Angiotensin-converting enzyme inhibitor-induced angioedema: late onset, irregular course, and potential role of triggers.
Angiotensin-converting enzyme inhibitor-induced angioedema: still unrecognized.
Angiotensin-Converting Enzyme Inhibitor-Induced Gastrointestinal Angioedema: The First Danish Case Report.
Angiotensin-converting enzyme inhibitor-induced isolated visceral angioedema in a liver transplant recipient.
Angiotensin-converting enzyme inhibitor-induced small-bowel angioedema: clinical and imaging findings in 20 patients.
Angiotensin-converting enzyme inhibitor-induced unilateral tongue angioedema.
Angiotensin-Converting Enzyme Inhibitor-Induced Unilateral Tongue Angioedema.
Angiotensin-converting enzyme inhibitor-induced visceral angioedema.
Angiotensin-converting Enzyme Inhibitor-mediated Angioedema.
Angiotensin-converting enzyme inhibitor-related angioedema: how to deal with it.
Angiotensin-converting enzyme inhibitor-related angioedema: recognition and treatment.
Angiotensin-converting enzyme inhibitors and angioedema.
Angiotensin-converting enzyme inhibitors and angioedema: estimating the risk.
Angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists.
Angiotensin-converting enzyme inhibitors as a cause of isolated angioedema in a Slovenian population.
Angiotensin-converting enzyme inhibitors as a cause of unilateral tongue angioedema in a 68-year-old woman.
Angiotensin-converting enzyme inhibitors, angiotensin-receptor blockers, and risk of appendicitis.
Angiotensin-converting enzyme inhibitors-induced angioedema of the small bowel mimicking postoperative complication.
Angiotensin-converting enzyme inhibitors-induced angioedema treated by C1 esterase inhibitor concentrate (Berinert®): about one case and review of the therapeutic arsenal.
Angiotensin-converting-enzyme inhibitor-induced angioedema.
Angiotensin-converting-enzyme Inhibitor-induced Intestinal Angioedema.
Angiotensin-II receptor antagonists: a new class of antihypertensive agents.
Antagonizing the angiotensin II subtype 1 receptor: a focus on olmesartan medoxomil.
Antihypertensive drug associated angioedema: effect modification by race/ethnicity.
Antihypertensive efficacy and tolerability of once daily losartan potassium compared with captopril in patients with mild to moderate essential hypertension.
Are physicians aware of the side effects of angiotensin-converting enzyme inhibitors?: a questionnaire survey in different medical categories.
Asphyxia due to angiotensin converting enzyme (ACE) inhibitor mediated angioedema of the tongue during the treatment of hypertensive heart disease.
Assessing the impact of the new ICD-10-CM coding system on pharmacoepidemiologic studies-An application to the known association between angiotensin-converting enzyme inhibitors and angioedema.
Association of angiotensin-converting enzyme inhibitor-associated angioedema with transplant and immunosuppressant use.
Association of Variants Near the Bradykinin Receptor B2 Gene With Angioedema in Patients Taking ACE Inhibitors.
Authors' response to is angioedema a class side-effect of the angiotensin-converting enzyme inhibitors?
Benazepril induced isolated visceral angioedema: a rare and under diagnosed adverse effect of angiotensin converting enzyme inhibitors.
Biochemical basis of angioedema associated with recombinant tissue plasminogen activator treatment: an in vitro experimental approach.
Black Americans have an increased rate of angiotensin converting enzyme inhibitor-associated angioedema.
Bradykinin and the pathophysiology of angioedema.
Bradykinin-mediated angioedema.
Bradykinin-mediated diseases.
Brief review: Angiotensin converting enzyme inhibitors and angioedema: anesthetic implications: [Revue sommaire sur les implications anesthesiques de l'oedeme de Quincke et des inhibiteurs de l'enzyme de conversion de l'angiotensine].
C1 Esterase Inhibitor (Berinert) for ACE Inhibitor-Induced Angioedema: Two Case Reports.
C1 esterase inhibitor for angiotensin-converting enzyme inhibitor-induced angioedema at a community teaching health system: A brief retrospective propensity-matched cohort study.
C1 esterase inhibitor use in the management of lisinopril-induced angioedema: A case series.
Can an angiotensin receptor blocker be used in a patient in whom angioedema developed with an angiotensin-converting enzyme inhibitor?
Candesartan cilexetil in cardiovascular disease.
Cardiovascular events in hypertension trials of Angiotensin-converting enzyme inhibitors.
Case Report: Compromised Airway Following Anesthesia and Its Correlation With the Use of ACE Inhibitors-An Unexpected Clinical Event and Review of Literature.
Changing trends in angioedema.
Chocolate-induced prolonged angiooedema in an elderly patient.
Choroidal detachment after uncomplicated small incision cataract surgery.
Chronic Urticaria and Recurrent Angioedema: Clues to the Mimics.
Clinical characteristics of angiotensin-converting enzyme inhibitor-induced angioedema.
Clinical experience with angiotensin-converting enzyme inhibitor-induced angioedema.
Clinical experiences and case review of angiotensin II receptor blocker-related angioedema in Korea.
Clinical Features and Outcomes Associated with Angioedema in the Emergency Department.
Clinical features of angioedema induced by renin-angiotensin-aldosterone system inhibition: a retrospective analysis of 84 patients.
Clinical Practice Statement: What is the Emergency Department Management of Patients with Angioedema Secondary to an ACE-Inhibitor?
Comparative Risk for Angioedema Associated With the Use of Drugs That Target the Renin-Angiotensin-Aldosterone System.
Comparative risk for angioedema associated with the use of drugs that target the renin-angiotensin-aldosterone system.
Comparative study of effects of angiotensin II receptor antagonist, KD3-671, and angiotensin converting enzyme inhibitor, enalaprilat, on cough reflex in guinea pig.
Comparison of Clinical Factors Between Patients With Angiotensin-Converting Enzyme Inhibitor-Induced Angioedema and Cough.
Complicated orolingual angioedema after recombinant tissue plasminogen activator treatment in stroke patients under angiotensin converting enzyme inhibitor: Report of two cases.
Concomitant Angiotensin AT1 Receptor Antagonism and Neprilysin Inhibition Produces Omapatrilat-Like Antihypertensive Effects Without Promoting Tracheal Plasma Extravasation In The Rat.
Congenital angiotensin-converting enzyme deficiency presenting as recurrent angioedema of upper airway in adult life.
Continuation of angiotensin converting enzyme inhibitor therapy, in spite of occurrence of angioedema.
Cough and angioedema from angiotensin-converting enzyme inhibitors: new insights into mechanisms and management.
Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. A review of the literature and pathophysiology.
CT Findings of Acute Small-Bowel Entities.
Current concepts of pharmacotherapy in hypertension: ACE inhibitor-related angioedema: can angiotensin-receptor blockers be safely used?
Current pharmacotherapy of bradykinin-mediated angioedema.
Cutaneous effects of antihypertensive drugs.
Days Needed for the Disappearance of a Cough Due to the Use of an Angiotensin-Converting Enzyme Inhibitor and Identification of Predisposing Factors Associated With Its Appearance in a Clinical Cohort of Hypertensive Patients.
Delayed diagnosis of angiotensin-converting enzyme (ACE) inhibitor induced angioedema and urticaria.
Delayed onset of angioedema with angiotensin-converting enzyme inhibitors: case report and review of the literature.
Development and validation of the angiotensin-converting enzyme inhibitor (ACEI) induced angioedema investigator rating scale and proposed discharge criteria.
Diagnosis and treatment of bradykinin-mediated angioedema: outcomes from an angioedema expert consensus meeting.
Different patterns of angioedema in patients with and without angiotensin-converting enzyme inhibitor therapy.
Dipeptidyl peptidase IV activity in patients with ACE-inhibitor-associated angioedema.
Dipeptidyl peptidase IV in angiotensin-converting enzyme inhibitor associated angioedema.
Dipeptidyl peptidase-4 inhibitor induced angioedema - an overlooked and potentially lethal adverse drug reaction?
Dipeptidyl peptidase-IV inhibitor use associated with increased risk of ACE inhibitor-associated angioedema.
Discovery of TD-0212, an Orally Active Dual Pharmacology AT1 Antagonist and Neprilysin Inhibitor (ARNI).
DPP-IV Inhibitor-Associated Angioedema in Patient With Known History of ACE Inhibitor Angioedema.
Drug safety in Aboriginal Australians: three cases of angiotensin-converting enzyme inhibitor angioedema.
Drug treatment of systolic and of diastolic heart failure in elderly persons.
Drug-induced angioedema: experience of Italian emergency departments.
Drug-Induced Inhibition of Angiotensin Converting Enzyme and Dipeptidyl Peptidase 4 Results in Nearly Therapy Resistant Bradykinin Induced Angioedema: A Case Report.
Drug-induced urticaria and angioedema caused by non-IgE mediated pathomechanisms.
Drug-induced urticarias.
Drug-induced visceral angioedema.
Drug-induced, life-threatening angioedema revisited.
Early health technology assessments in pharmacogenomics: a case example in cardiovascular drugs.
Ecallantide for the acute treatment of angiotensin-converting enzyme inhibitor-induced angioedema: a multicenter, randomized, controlled trial.
Effect of bradykinin receptor antagonism on ACE inhibitor-associated angioedema.
Effect of C1-Esterase-inhibitor in angiotensin-converting enzyme inhibitor-induced angioedema.
Effect of enalapril on the skin response to bradykinin in man.
Effect of icatibant on angiotensin-converting enzyme inhibitor-induced angioedema: A meta-analysis of randomized controlled trials.
Effectiveness of C1-INH therapy in angiotensin converting enzyme inhibitor induced angioedema.
Effectiveness of ecallantide in treating angiotensin-converting enzyme inhibitor-induced angioedema in the emergency department.
Emergency department evaluation of patients with angiotensin converting enzyme inhibitor associated angioedema.
Endogenous bradykinin and B1-B5 during angiotensin-converting enzyme inhibitor-associated angioedema.
Endoscopic Visualization of Angiotensin-converting Enzyme Inhibitor-induced Small Bowel Angioedema as a Cause of Relapsing Abdominal Pain using Double-balloon Enteroscopy.
Epidemiological study of angioedema and ACE inhibitors.
Epidemiology of ACE Inhibitor Angioedema Utilizing a Large Electronic Health Record.
Epidemiology, pathophysiology, prognosis, and treatment of systolic and diastolic heart failure.
Episodic macroglossia as the sole manifestation of angiotensin-converting enzyme inhibitor-induced angioedema.
Esophageal Foreign Body Sensation: A Rare Presentation of Angioedema.
Evaluating for seasonal variation in angiotensin-converting enzyme inhibitor- and angiotensin receptor blocker-induced angioedema.
Evidence and evidence gaps of medical treatment of non-tumorous diseases of the head and neck.
Examination of baseline levels of carboxypeptidase N and complement components as potential predictors of angioedema associated with the use of an angiotensin-converting enzyme inhibitor.
Exome Sequencing Reveals Common and Rare Variants in F5 Associated With ACE Inhibitor and Angiotensin Receptor Blocker-Induced Angioedema.
Expression of metallopeptidases and kinin receptors in swine oropharyngeal tissues: effects of angiotensin I-converting enzyme inhibition and inflammation.
Factors associated with hospitalization of patients with angiotensin-converting enzyme inhibitor-induced angioedema.
Fatal angioedema associated with captopril.
Fatal angioedema associated with lisinopril.
Fatal laryngeal angioedema: a case report and a workup of angioedema in a forensic setting.
Fatal outcome of late-onset angiotensin-converting enzyme inhibitor induced angioedema: A case report.
Frequency and recognition of angiotensin-converting enzyme inhibitor-associated angioneurotic edema.
Fresh Frozen Plasma for Progressive and Refractory Angiotensin-Converting Enzyme Inhibitor-induced Angioedema.
Fresh frozen plasma in the treatment of resistant angiotensin-converting enzyme inhibitor angioedema.
Genetic analysis of Factor XII and bradykinin catabolic enzymes in a family with estrogen-dependent inherited angioedema.
Genetic variants associated with angiotensin-converting enzyme inhibitor-associated angioedema.
Genome-wide association study of angioedema induced by angiotensin-converting enzyme inhibitor and angiotensin receptor blocker treatment.
Gram-negative pneumonia among patients undergoing dialysis who were admitted to the hospital with angioedema secondary to angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists.
Hemi-orolingual angioedema and ACE inhibition after alteplase treatment of stroke.
Hereditary angioedema first apparent in the ninth decade during treatment with ACE inhibitor.
Hereditary angioedema: how to approach it at the emergency department?
Hereditary angioedema: treatment, management, and precautions in patients presenting for dental care.
Hospitalizations due to Angioedema without Urticaria in a Portuguese Center: Five Year Retrospective Study.
Hypovolemic Shock Caused by Angiotensin-Converting Enzyme Inhibitor-Induced Visceral Angioedema: A Case Series and A Simple Method to Diagnose this Complication in the Emergency Department.
Iatrogenic angioedema associated with ACEi, sitagliptin, and deficiency of 3 enzymes catabolizing bradykinin.
Icatibant for Angiotensin-Converting Enzyme Inhibitor-Induced Angioedema in Intubated Patients: Case Series and Literature Review.
Icatibant in angiotensin-converting enzyme (ACE) inhibitor-associated angioedema.
Icatibant in the treatment of Angiotensin-converting enzyme inhibitor-induced angioedema.
Icatibant Use in Angiotensin-Converting Enzyme Inhibitor-Induced Angioedema.
Icatibant: a novel approach to the treatment of angioedema related to the use of angiotensin-converting enzyme inhibitors.
Identification of Human Kinin-Forming Enzyme Inhibitors from Medicinal Herbs.
Image of the month. Angiotensin-converting enzyme (ACE) inhibitor angioedema of the intestine.
Images in emergency medicine. Angioedema as a result of angiotensin-converting enzyme inhibitor.
Imaging findings in angiotensin-converting enzyme inhibitor induced angioedema.
Imaging Review of Angiotensin-Converting Enzyme Inhibitor-Induced Angioedema of the Head and Neck.
In vitro comparison of bradykinin degradation by aliskiren, a renin inhibitor, and an inhibitor of angiotensin-converting enzyme.
In Vitro Modeling of Bradykinin-Mediated Angioedema States.
Incidence and characteristics of angioedema associated with enalapril.
Incidence and predictors of angioedema in elderly hypertensive patients at high risk for cardiovascular disease: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Incidence and risk factors of angiotensin-converting enzyme inhibitor-induced angioedema: A large case-control study.
Increased reporting of adverse reactions to ACE inhibitors associated with limitations to drug reimbursement for angiotensin-II receptor antagonists.
Increased sensitivity to bradykinin among African Americans.
Increasing hospitalizations due to angioedema in the United States.
Inherent inaccuracies and potential utility of race/ethnicity labeling in the treatment of hypertension.
Inpatient Initiation of Sacubitril/Valsartan.
Institutional Incidence of Severe tPA-Induced Angioedema in Ischemic Cerebral Vascular Accidents.
Intermittent visceral edema induced by long-term enalapril administration.
Intestinal angioedema from angiotensin converting enzyme inhibitor.
Intestinal angioedema induced by Angiotensin-converting enzyme inhibitors: an underrecognized cause of abdominal pain?
Intestinal angioedema misdiagnosed as recurrent episodes of gastroenteritis.
Intraoperative angioedema induced by angiotensin II receptor blocker: a case report.
Intraoperative angioedema induced by angiotensin-converting enzyme inhibitors: overview and case report.
Investigation of angioedema associated with the use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.
Is angioedema a class adverse effect of the angiotensin-converting enzyme inhibitors?
Isolated Intestinal Angioedema in the Emergency Department.
Isolated Intestinal Angioedema Secondary to a Food Allergen.
Isolated uvular angioedema associated with ACE inhibitor use.
Isolated Visceral Angioedema Induced by Angiotensin-Converting Enzyme Inhibitor.
Isolated visceral angioedema: an underdiagnosed complication of ACE inhibitors?
Late onset angiotensin-converting enzyme induced angioedema: case report and review of the literature.
Late-onset angioedema after interruption of angiotensin converting enzyme inhibitor therapy.
Late-onset angioedema due to an angiotensin-converting enzyme inhibitor.
Late-onset life-threatening angioedema and upper airway obstruction caused by angiotensin-converting enzyme inhibitor: report of a case.
Life threatening tongue angioedema associated with an angiotensin-converting enzyme inhibitor.
Life-Threatening ACE Inhibitor-Induced Angioedema After 11 Years on Lisinopril.
Life-threatening airway obstruction caused by angioedema in a morbidly obese postoperative patient: a case report.
Life-threatening angioedema induced by angiotensin-converting enzyme inhibitors: Characteristics and risk factors.
Life-threatening perioperative angioedema related to angiotensin-converting enzyme inhibitor therapy.
Lingual angioedema after perindopril use.
Lingual angioedema with macroglossia during the treatment of acute ischemic stroke with alteplase.
Literature reports of angiotensin receptor antagonist-induced angioedema in patients with a history of angiotensin-converting enzyme inhibitor-induced angioedema.
Long-acting ACE inhibitor-induced angioedema.
Long-term follow-up of 111 patients with angiotensin-converting enzyme inhibitor-related angioedema.
Losartan-induced angioedema.
Macroglossia secondary to lisinopril-induced acute angioedema.
Management of angiotensin-converting enzyme inhibitor-induced angioedema.
Managing Chronic Urticaria and Recurrent Angioedema Differently with Advancing Age.
Many faces of angioedema: focus on the diagnosis and management of abdominal manifestations of hereditary angioedema.
MDCT Features of Angiotensin-Converting Enzyme Inhibitor-Induced Visceral Angioedema.
Measurement of Bradykinin Formation and Degradation in Blood Plasma: Relevance for Acquired Angioedema Associated With Angiotensin Converting Enzyme Inhibition and for Hereditary Angioedema Due to Factor XII or Plasminogen Gene Variants.
Metallopeptidase activities in hereditary angioedema: effect of androgen prophylaxis on plasma aminopeptidase P.
MR imaging of intestinal angioedema related to angiotensin-converting enzyme inhibitors: Report of three cases and review of literature.
Multicenter study of patients with angiotensin-converting enzyme inhibitor-induced angioedema who present to the emergency department.
Neprilysin inhibition in chronic kidney disease.
Neprilysin Inhibitors and Bradykinin.
Nine year follow-up of a rare case of angioedema due to acquired C1-inhibitor deficiency with late onset and good response to attenuated androgen.
Non-histaminergic angioedema: focus on bradykinin-mediated angioedema.
Nonallergic angioedema: role of bradykinin.
Nonallergic Hypersensitivity to Nonsteroidal Antiinflammatory Drugs, Angiotensin-Converting Enzyme Inhibitors, Radiocontrast Media, Local Anesthetics, Volume Substitutes and Medications used in General Anesthesia.
Not all ACE inhibitor related angioedema is always evident: a case which is misdiagnosed as panic attack and speech disorder.
Novel Pharmacogenomic Locus Implicated in Angiotensin-Converting Enzyme Inhibitor-Induced Angioedema.
Novel therapeutic targets for hypertension.
Novel Therapies for Angiotensin-Converting Enzyme Inhibitor-Induced Angioedema: A Systematic Review of Current Evidence.
Novelties in the Diagnosis and Treatment of Angioedema.
Off-Label Use of Agents for Management of Serious or Life-threatening Angiotensin Converting Enzyme Inhibitor-Induced Angioedema.
Olmesartan medoxomil-induced angioedema.
Orolingual angioedema after alteplase therapy of acute ischaemic stroke: incidence and risk of prior angiotensin-converting enzyme inhibitor use.
Orolingual Angioedema After Tissue Plasminogen Activator Administration in Patients Taking Angiotensin-Converting Enzyme Inhibitors.
Oropharyngeal angioedema associated with the use of angiotensin-converting enzyme inhibitors.
Overcoming Cough and Angioedema: Advocating for the Use of ARBs Over ACE Inhibitors.
Pathways for bradykinin formation and inflammatory disease.
Pattern of hospitalizations for angioedema in New York between 1990 and 2003.
Pediatric angioedema.
Penile angioedema associated with the use of angiotensin-converting-enzyme inhibitors and angiotensin II receptor blockers.
Penile Angioedema Developing After 3 Years of ACEI Therapy.
Perindopril-induced angioedema of the lips and tongue: a case report.
Perioperative angioedema in a patient on long-term angiotensin-converting enzyme (ACE)-inhibitor therapy.
Perioral angioedema associated with angiotensin-converting enzyme inhibitor.
Pharmacogenetics of angiotensin-converting enzyme inhibitor-induced angioedema.
Pharmacologic management of angioedema induced by angiotensin-converting enzyme inhibitors.
Pharmacological and clinical profile of moexipril: a concise review.
Pharmacological profile and clinical use of moexipril.
Pharmacotherapy for Angiotensin-Converting Enzyme Inhibitor-Induced Angioedema: A Systematic Review.
Pharmacotherapy in congestive heart failure: ACE inhibitors and anemia in congestive heart failure.
Phenotype Standardization of Angioedema in the Head and Neck Region Caused by Agents Acting on the Angiotensin System.
Point-of-Care Sonographic Findings in Acute Upper Airway Edema.
Pollen count and presentation of Angiotensin-converting enzyme inhibitor-associated angioedema.
Possible Angiotensin-Converting Enzyme Inhibitor (ACEI)-Induced Small Bowel Angioedema.
Postanesthetic Severe Oral Angioedema in Patient's Taking Angiotensin-Converting Enzyme Inhibitor.
Potential Biomarkers for the Diagnosis of Angiotensin-Converting Enzyme Inhibitor-Induced Angioedema.
Potential role of vasomotor effects of fibrinogen in bradykinin-induced angioedema.
Potentially lethal ACE-inhibitor-induced angioedema in a child.
Pre-operative cessation of angiotensin-converting enzyme inhibitors may not necessarily protect against angioedema.
Predictors of Airway Intervention in Angiotensin-Converting Enzyme Inhibitor-Induced Angioedema.
Predisposition to and late onset of upper airway obstruction following angiotensin-converting enzyme inhibitor therapy.
Presentation, diagnosis and treatment of angioedema without wheals: a retrospective analysis of a cohort of 1058 patients.
Prominent features of allergic angioedema on oral mucosa.
Randomized Trial of Icatibant for Angiotensin-Converting Enzyme Inhibitor-Induced Upper Airway Angioedema.
Ranolazine, ACE Inhibitors, and Angiotensin Receptor Blockers.
Recent advances in drug-induced angioedema.
Recognizing a Rare Phenomenon of Angiotensin-Converting Enzyme Inhibitors: Visceral Angioedema Presenting with Chronic Diarrhea-A Case Report.
Recurrent angioedema associated with pharmacological inhibition of dipeptidyl peptidase IV.
Recurrent angiotensin-converting enzyme inhibitor--associated angioedema.
Recurrent Angiotensin-Converting Enzyme Inhibitor-Induced Angioedema Refractory to Fresh Frozen Plasma.
Recurrent episodes of skin angioedema and severe attacks of abdominal pain induced by oral contraceptives or hormone replacement therapy.
Recurrent severe angioedema associated with imidapril and diclofenac.
Renin inhibitors.
Repeated subileus due to angioedema during renin-angiotensin system blockade.
Risk factors associated with intubation and readmissions in patients with angioedema: A single-center experience al. / Ann Allergy Asthma Immunol 127 (2021) xxx-xxx"?>.
Risk of angioedema with angiotensin receptor blockers in patients with prior angioedema associated with angiotensin-converting enzyme inhibitors: a meta-analysis.
Role of angiotensin-converting enzyme inhibitors in visceral angioedema.
Sacubitril/Valsartan: The Newest Addition to the Toolbox for Guideline Directed Medical Therapy of Heart Failure.
Safety of drugs commonly used to treat hypertension, dyslipidemia, and type 2 diabetes (the metabolic syndrome): part 1.
Safety of thrombolysis in acute ischemic stroke: a review of complications, risk factors, and newer technologies.
Safety surveillance and the estimation of risk in select populations: Flexible methods to control for confounding while targeting marginal comparisons via standardization.
Serial measurement of serum tryptase in angiotensin-converting enzyme inhibitor-associated angioedema.
Serum metabolism of bradykinin and des-Arg9-bradykinin in patients with angiotensin-converting enzyme inhibitor-associated angioedema.
Severe angioedema after long-term use of an angiotensin-converting enzyme inhibitor.
Severe Angioedema Associated With Angiotensin-Converting Enzyme Inhibitor Therapy in Two Patients With Pollen-Food Allergy Syndrome.
Severe angioedema induced by angiotensin converting enzyme inhibitors: role of precipitating factors.
Severe angioedema related to ACE inhibitors in patients with a history of idiopathic angioedema.
Severe migratory Angioedema due to ACE inhibitors use.
Sex-dependent and race-dependent association of XPNPEP2 C-2399A polymorphism with angiotensin-converting enzyme inhibitor-associated angioedema.
Simultaneous acute pancreatitis and angioedema associated with angiotensin-converting enzyme inhibitor.
Simultaneous mucosal and small bowel angioedema due to captopril.
Six years experience of angioedema at the University Hospital of the West Indies.
Small bowel angioedema associated with Angiotensin converting enzyme inhibitor use.
Small bowel angioedema from angiotensin-converting enzyme: Changes on computed tomography.
Small bowel angioedema induced by angiotensin converting enzyme (ACE) inhibitor: US and CT findings.
Small Bowel Angioedema Secondary to Angiotensin-Converting Enzyme Inhibitors.
Studies of the mechanism of angiotensin-converting enzyme (ACE) inhibitor-associated angioedema: the effect of an ACE inhibitor on cutaneous responses to bradykinin, codeine, and histamine.
Substituted Benzimidazole Derivatives as Angiotensin II -AT1 Receptor Antagonist: A Review.
Successful Comparison of US Food and Drug Administration Sentinel Analysis Tools to Traditional Approaches in Quantifying a Known Drug-Adverse Event Association.
Supraglottic swelling may not correlate with tongue swelling in angiotensin converting enzyme inhibitor-induced angioedema.
Tacrolimus-Induced Intestinal Angioedema: Diagnosis by Capsule Endoscopy.
The Angiotensin-Converting-Enzyme-Induced Angioedema.
The Fine Page: angiotensin converting enzyme angioedema.
The Importance of Complement Testing in Acquired Angioedema Related to Angiotensin-Converting Enzyme Inhibitors.
The Influence of ACE Inhibition on C1-Inhibitor: A Biomarker for ACE Inhibitor-Induced Angioedema?
The role of ace gene polymorphism in the development of angioedema secondary to angiotensin converting enzyme inhibitors and angiotensin II receptor blockers.
The Role of Angiotensin Receptor Blockers in Patients with Angiotensin-Converting Enzyme Inhibitor-Induced Angioedema (April).
The role of angiotensin receptor blockers in reducing the risk of cardiovascular disease.
The role of icatibant-the B2 bradykinin receptor antagonist-in life-threatening laryngeal angioedema in the ED.
The role of TRPA1 and TRPV4 channels in bronchoconstriction and plasma extravasation in airways of rats treated with captopril.
The use of intravenous tranexamic acid for patients with angiotensin-converting enzyme inhibitor-induced angioedema: A case series.
Therapeutic Efficacy of Icatibant in Angioedema Induced by Angiotensin-Converting Enzyme Inhibitors: A Case Series.
Tongue protrusion as the presenting symptom of parapharyngeal abscess.
Tongue swelling in the recovery room: a case report and discussion of postoperative angioedema.
Towards a specific marker for acute bradykinin-mediated angioedema attacks: a literature review.
Toxic effects of drugs used in the ICU. Nitroprusside, nitroglycerin, and angiotensin-converting enzyme inhibitors.
Toxicodynamic analysis of inflammatory reactions by an angiotensin converting enzyme inhibitor (lisinopril) in guinea-pig skin.
Tranexamic acid for ACE inhibitor induced angioedema.
Transient myocardial dysfunction associated with angiotensin-converting enzyme inhibitor-induced angioedema: recognition by serial echocardiographic studies.
Treatment of Angioedema Induced by Angiotensin-Converting Enzyme Inhibitor.
Treatment of angiotensin receptor blocker-induced Angioedema: A case series.
Treatment of angiotensin-converting enzyme inhibitor-related angioedema with the bradykinin B2 receptor antagonist icatibant.
Treatment of heart failure with decreased left ventricular ejection fraction.
Treatment of Life-Threatening ACE-Inhibitor-Induced Angioedema.
Treatment of systolic and diastolic heart failure in the elderly.
Unilateral angioedema.
Unilateral tongue angioedema caused by angiotensin-converting enzyme inhibitor.
Unilateral Tongue Angioedema Induced by Angiotensin Converting Enzyme Inhibitor: A Case Report.
Unmasking of acquired autoimmune C1-inhibitor deficiency by an angiotensin-converting enzyme inhibitor.
Unnecessary surgery for acute abdomen secondary to angiotensin-converting enzyme inhibitor use.
Urticaria and angioedema.
Use of angiotensin receptor blockers after angioedema with an angiotensin-converting enzyme inhibitor.
Use of C1 Inhibitor for Angiotensin-Converting Enzyme (ACE) Inhibitor-Induced Angioedema Decreases Mechanical Ventilation Time.
Using Bronchoscopy to Detect Acquired Tracheoesophageal Fistula in Mechanically Ventilated Patients.
Valsartan and the kidney: review of preclinical and clinical data.
Valsartan-Induced Angioedema in a Patient on Angiotensin-Converting Enzyme Inhibitor for Years: Case Report and Literature Review.
Valsartan-induced angioedema.
Visceral angioedema due to angiotensin-converting enzyme inhibitor therapy.
Visceral Angioedema Induced by Angiotensin Converting Enzyme Inhibitor: Case Report.
Visceral angioedema: an under-recognized complication of angiotensin-converting enzyme inhibitors.
What's New in the Treatment of Urticaria and Angioedema.
When Nothing Else Works: Fresh Frozen Plasma in the Treatment of Progressive, Refractory Angiotensin-Converting Enzyme Inhibitor-Induced Angioedema.
[A case of angioedema with dysarthria mimicking transient ischemic attack].
[ACE inhibitor-induced angioedema in the head and neck region. A matter of time?]
[ACE-inhibition and bradykinin-mediated angioedema].
[ACE-inhibitor-induced angioedema. The most frequent cause of oropharyngeal edema]
[Acute angioneurotic edema due to ACE inhibitors]
[Acute non-allergic angioedema. Rare cause for intensive care unit admission].
[Age-specific aspects in the treatment of angioedema patients].
[Allergic emergencies].
[Angioedema and angiotensin converting enzyme inhibitors: a report of 19 cases]
[Angioedema and angiotensin-converting enzyme inhibitors]
[Angioedema caused by angiotensin-converting enzyme inhibitors]
[Angioedema caused by inhibitors of angiotensin converting enzyme (ACE) and angiotensin II receptor blockers]
[Angioedema during ACE and DPP-4 inhibition]
[Angioedema of the tongue and oropharynx after treatment with sublingual captopril]
[Angioedema]
[Angioedema].
[Angioneurotic edema caused by angiotensin-converting enzyme inhibitors: incidence, clinical characteristics, mechanisms of action]
[Angioneurotic edema caused by angiotensin-converting enzyme inhibitors]
[Angioneurotic edema in relation to therapeutic use of angiotensin-converting enzyme inhibitor]
[Angioneurotic edema induced by angiotensin converting enzyme inhibitors]
[Angioneurotic edema of the tongue, induced by administration of ACE inhibitors]
[Angiotensin-converting enzyme inhibitor induced angioedema : New therapy options.]
[Angiotensin-converting enzyme inhibitor-related angioedema: emergency treatment with complement C1 inhibitor concentrate]
[AT1 angiotensin receptor inhibition as a new therapeutic possibility]
[Blood and tissue eosinophilia in patient with angioedema caused by inhibitor of angiotensin converting enzyme (ACE)--case report and a view of literature]
[Bradykinin mediated angioedema with ACE inhibitor in combination with immunosupressive agents].
[Bradykinin-mediated angioedema secondary to angiotensin converting enzyme: initiate treatment from the prehospital phase].
[Case of facial edema and tongue swelling after aortic surgery in the lateral position]
[Case Report; A case of tongue angioedema induced by angiotensin-converting enzyme inhibitor].
[Classification and pathophysiology of angioedema].
[Cross-sensitivity between angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonist]
[Delayed angioedema during therapy with angiotensin-converting enzyme inhibitors].
[Drug induced angioedema (ACE-inhibitors and other)].
[Drug-induced angioedema : Focus on bradykinin].
[Drug-induced chronic urticarias]
[Extensive head-neck edema. Angioneurotic edema caused by angiotensin converting enzyme (ACE) inhibitor]
[Gender aspects in angioedema].
[Iatrogenic angioedema: the role of angiotensin converting enzyme inhibitor and angiotensin II receptor blockers]
[Icatibant is a new treatment option in life-threatening angioedema triggered by angiotensin-converting enzyme inhibitor].
[Impossibility of intubation due to angioedema secondary to an angiotensin-converting enzyme inhibitor]
[Is tracheotomy of angioedema associated with ACE-inhibitor therapy?]
[Isolated intestinal angioedema induced by enalapril].
[Life-threatening angioedema as a side effect of angiotensin-converting-enzyme (ACE) inhibitors]
[Life-threatening displacement of a tracheostomy tube in a patient with severe angiotensin-converting enzyme inhibitor-induced angioedema]
[Life-threatening postoperative angioedema following treatment with an angiotensin converting enzyme inhibitor]
[Life-threatening swelling of the tongue in antihypertensive therapy with ACE inhibitors]
[Management of angioedema. Guidelines of the Angiology Section of Slovak Medical Chamber (2013)].
[Management of angiotensin-converting enzyme inhibitor-related angioedema: Recommendations from the French national centre for angioedema].
[Postoperative angioedema induced by angiotensin-converting enzyme inhibitor: case report].
[Severe oropharyngeal angioedema caused by ACE inhibitor. A case report]
[Strong and Deficient Evidence in Drug-Treated, Non-Tumorous Diseases in ENT].
[Successful extubation in a patient with alacepril-induced tongue angioedema]
[Tongue angioedema associated with angiotensin-converting enzyme inhibitor (diagnosis, differential diagnosis, treatment)]
[Tranexamic acid as first-line emergency treatment for episodes of bradykinin-mediated angioedema induced by ACE inhibitors].
Angioedemas, Hereditary
"Nuts and Bolts" of Laboratory Evaluation of Angioedema.
A 47-year-old man with tongue swelling.
A focused parameter update: hereditary angioedema, acquired C1 inhibitor deficiency, and angiotensin-converting enzyme inhibitor-associated angioedema.
ACE inhibitor-induced angioedema.
Acute upper airway obstruction from acquired angioedema.
An adverse reaction to angiotensin-converting enzyme inhibitors in a patient with neglected C1 esterase inhibitor deficiency.
Anaesthetic Approach for Patient with Hereditary Angioedema.
Angioedema secondary to angiotensin converting enzyme inhibitors is not due to C1 esterase inhibitor deficiency.
Angioedema without urticaria: a large clinical survey.
Angioedema without wheals: a clinical update.
Angioedema, lymphoproliferative disorder and angiotensin-converting enzyme inhibitors: masking of diagnosis by corticosteroids.
Angioedema.
Angioedema: 5 years' experience, with a review of the disorder's presentation and treatment.
Angiotensin-converting enzyme inhibitor-induced angioedema and hereditary angioedema: a comparison study of attack severity.
Calcium channel blocker-associated small bowel angioedema.
Clinical features of angioedema induced by renin-angiotensin-aldosterone system inhibition: a retrospective analysis of 84 patients.
Hereditary angioedema first apparent in the ninth decade during treatment with ACE inhibitor.
Hereditary angioedema presenting in late middle age after angiotensin-converting enzyme inhibitor treatment.
Hereditary angioedema: how to approach it at the emergency department?
Hospitalizations due to Angioedema without Urticaria in a Portuguese Center: Five Year Retrospective Study.
Idiopathic non-histaminergic angio-oedema after routine extubation successfully treated with fresh frozen plasma.
Intestinal angioedema misdiagnosed as recurrent episodes of gastroenteritis.
Measurement of Bradykinin Formation and Degradation in Blood Plasma: Relevance for Acquired Angioedema Associated With Angiotensin Converting Enzyme Inhibition and for Hereditary Angioedema Due to Factor XII or Plasminogen Gene Variants.
Membranous nephropathy in a patient with hereditary angioedema: a case report.
Metallopeptidase activities in hereditary angioedema: effect of androgen prophylaxis on plasma aminopeptidase P.
New insights into hereditary angio-oedema: Molecular diagnosis and therapy.
Non-histaminergic angioedema: focus on bradykinin-mediated angioedema.
Plasma bradykinin in angio-oedema.
Possible contraindication of angiotensin converting enzyme inhibitors in patients with hereditary angioedema.
Prominent features of allergic angioedema on oral mucosa.
Recurrent episodes of skin angioedema and severe attacks of abdominal pain induced by oral contraceptives or hormone replacement therapy.
The Importance of Complement Testing in Acquired Angioedema Related to Angiotensin-Converting Enzyme Inhibitors.
The role of icatibant-the B2 bradykinin receptor antagonist-in life-threatening laryngeal angioedema in the ED.
Therapeutic Efficacy of Icatibant in Angioedema Induced by Angiotensin-Converting Enzyme Inhibitors: A Case Series.
Tissue Plasminogen Activator-Induced Angioedema Involving a Posterior Cerebral Artery Infarct: A Case Presentation.
Tranexamic acid for ACE inhibitor induced angioedema.
Urticaria and angioedema.
[Angioedema].
[Classification and pathophysiology of angioedema].
[Gender aspects in angioedema].
Angiomyolipoma
Evidence for pericyte origin of TSC-associated renal angiomyolipomas and implications for angiotensin receptor inhibition therapy.
Anthracosilicosis
Serum angiotensin converting enzyme, ceruloplasmin, and lactic dehydrogenase in anthracosilicosis and anthracosilicotuberculosis.
[Serum angiotensin-converting enzyme, ceruloplasmin and lactic dehydrogenase in anthracosilicosis and anthracosilico-tuberculosis]
[Significance of elevated serum ACE in pneumology]
Anthracosis
Serum angiotensin-converting enzyme in coal worker's pneumoconiosis.
Antiphospholipid Syndrome
Acquired Angioedema Associated with Primary Antiphospholipid Syndrome in a Patient with Antithrombin III Deficiency.
An evaluation of an angiotensin-converting enzyme gene polymorphism and the risk of arterial thrombosis in patients with the antiphospholipid syndrome.
Primary antiphospholipid syndrome associated with anti-phospholipase A2 receptor antibody-positive membranous nephropathy.
Antithrombin III Deficiency
Acquired Angioedema Associated with Primary Antiphospholipid Syndrome in a Patient with Antithrombin III Deficiency.
Anuria
A role for the extracellular matrix component hyaluronan in kidney dysfunction during ACE-inhibitor fetopathy.
Adverse effects of drugs on the immature kidney.
An unusual case of neonatal anuria.
Neonatal anuria with maternal angiotensin-converting enzyme inhibition.
Oligohydramnios sequence and renal tubular malformation associated with maternal enalapril use.
Pregnancy in chronic renal insufficiency and end-stage renal disease.
Pregnancy outcome following exposure to angiotensin-converting enzyme inhibitors.
Transient anuria following administration of angiotensin I-converting enzyme inhibitor (SQ 14225) in a patient with renal artery stenosis of the solitary kidney successfully treated with renal autotransplantation.
We Avoid RAAS Inhibitors in PD Patients with Residual Renal Function.
Aortic Aneurysm
Abnormal mechanosensing and cofilin activation promote the progression of ascending aortic aneurysms in mice.
Alterations in angiotensin converting enzyme during rodent aortic aneurysm formation.
Angiotensin-converting enzyme I/D polymorphism and aortic aneurysm risk: a meta-analysis.
Angiotensin-converting enzyme inhibitors and aortic rupture: a population-based case-control study.
Angiotensin-converting enzyme-induced activation of local angiotensin signaling is required for ascending aortic aneurysms in fibulin-4-deficient mice.
Associations between the insertion/deletion polymorphism of the angiotensin-converting enzyme and susceptibility to aortic aneurysms: A meta-analysis.
Impaired Abdominal aortic wall Integrity in Elderly Men Carrying the Angiotensin-converting Enzyme D Allele.
Large ascending aortic aneurysm and severe aortic regurgitation in a 7-year-old child with Marfan syndrome and a review of the literature. Marfan syndrome in childhood.
Meta-analysis of the association between angiotensin-converting enzyme I/D polymorphism and aortic aneurysm risk.
Pharmacologically induced thoracic and abdominal aortic aneurysms in mice.
Possible roles of angiotensin II-forming enzymes, angiotensin converting enzyme and chymase-like enzyme, in the human aneurysmal aorta.
Aortic Aneurysm, Abdominal
Abdominal aortic aneurysm in normotensive patients: association with angiotensin-converting enzyme gene polymorphism.
ACE DD genotype: a predisposing factor for abdominal aortic aneurysm.
An evaluation of the effect of an angiotensin-converting enzyme inhibitor on the growth rate of small abdominal aortic aneurysms: a randomised placebo-controlled trial (AARDVARK).
An evaluation of the effect of an angiotensin-converting enzyme inhibitor on the growth rate of small abdominal aortic aneurysms: a randomized placebo-controlled trial (AARDVARK).
Angiotensin-Converting Enzyme (ACE, I/D) Gene Polymorphism and Susceptibility to Abdominal Aortic Aneurysm or Aortoiliac Occlusive Disease.
Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers in Patients With Abdominal Aortic Aneurysms: Nation-Wide Cohort Study.
Assessment of insertion/deletion polymorphism of the angiotensin-converting enzyme gene in abdominal aortic aneurysm and inguinal hernia.
Association of 1166A>C AT1R, -1562C>T MMP-9, ACE I/D, and CCR5?32 Polymorphisms with Abdominal Aortic Aneurysm in Croatian Patients.
Comparing American, European and Asian practice guidelines for aortic diseases.
Deletion polymorphism in the gene for angiotensin-converting enzyme is not a risk factor predisposing to abdominal aortic aneurysm.
Does the angiotensin-converting enzyme (ACE) gene polymorphism affect rate of abdominal aortic aneurysm expansion?
Downregulation of Remodelling Enzymatic Activity Induced by an Angiotensin-converting Enzyme Inhibitor (Perindopril) Reduces the Degeneration of Experimental Abdominal Aortic Aneurysms in a Rat Model.
Impaired Abdominal aortic wall Integrity in Elderly Men Carrying the Angiotensin-converting Enzyme D Allele.
Inhibition of AAA in a rat model by treatment with ACEI perindopril.
Renin-angiotensin system blockade does not attenuate abdominal aortic aneurysm growth, rupture rate, or perioperative mortality after elective repair.
Significance of Matrix Metalloproteinase-9 Inhibition by Imidapril for Prevention of Abdominal Aortic Aneurysms in Angiotensin II Type 1 Receptor-Knockout Mice.
Suppression of experimental abdominal aortic aneurysms in the rat by treatment with angiotensin-converting enzyme inhibitors.
Use of angiotensin converting enzyme inhibitors is associated with increased growth rate of abdominal aortic aneurysms.
Aortic Aneurysm, Thoracic
Angiotensin-converting enzyme insertion/deletion polymorphism is a risk factor for thoracic aortic aneurysm in patients with bicuspid or tricuspid aortic valves.
Captopril versus atenolol to prevent expansion rate of thoracic aortic aneurysms: rationale and design.
Aortic Coarctation
Angiotensin I converting enzyme genotype affects ventricular remodelling in children with aortic coarctation.
Effective use of captopril in postoperative paradoxical hypertension of coarctation of the aorta.
Nitric oxide and the depressor response to angiotensin blockade in hypertension.
Role of kinins and nitric oxide in the antihypertrophic effect of ramipril.
Role of the renin-angiotensin system in hypertension after coarctation of the aorta.
[Effect of angiotensin converting enzyme inhibitor on arterial wall thickening in coarctation hypertension]
Aortic Diseases
An underused opportunity to introduce ACE inhibitors and influence prognosis: observational study of patients undergoing aortic surgery.
[The treatment with statins and angiotensin-converting enzyme inhibitors in degenerative aortic stenosis--up to date]
Aortic Rupture
Angiotensin-converting enzyme inhibitors and aortic rupture: a population-based case-control study.
Commentary. Angiotensin converting enzyme inhibitors and aortic rupture: population based case control study.
[Update cardiology 2006/2007]
Aortic Valve Disease
(Pro)renin receptors and angiotensin converting enzyme 2/angiotensin-(1-7)/Mas receptor axis in human aortic valve stenosis.
Aortic valvular heart disease: is there a place for angiotensin-converting-enzyme inhibitors?
From Other Journals: A Review of Recent Articles in Pediatric Cardiology.
Aortic Valve Insufficiency
Angiotensin-converting enzyme inhibitor captopril prevents volume overload cardiomyopathy in experimental chronic aortic valve regurgitation.
Aortic Cross-Sectional Area/Height Ratio and Outcomes in Patients With a Trileaflet Aortic Valve and a Dilated Aorta.
Assessment of hemodynamic effects of angiotensin-converting enzyme inhibitor therapy in chronic aortic regurgitation by using velocity-encoded cine magnetic resonance imaging.
Beneficial effects of 1-year captopril therapy in children with chronic aortic regurgitation who have no symptoms.
Clinical trials in heart valve disease.
Effect of the angiotensin-converting enzyme inhibitor alacepril on ventricular function and beta-adrenoceptor number in rabbits with aortic regurgitation.
Effects of perindopril on left ventricular remodeling and aortic regurgitation in rats assessed by echocardiography.
Large ascending aortic aneurysm and severe aortic regurgitation in a 7-year-old child with Marfan syndrome and a review of the literature. Marfan syndrome in childhood.
Long-term effect of angiotensin-converting enzyme inhibitor in volume overloaded heart during growth: a controlled pilot study.
New insights in the pathophysiology of mitral and aortic regurgitation in pediatric age: role of angiotensin-converting enzyme inhibitor therapy.
Risk factors for pacemaker implantation following aortic valve replacement: a single centre experience.
Statin Use and Aneurysm Risk in Patients With Bicuspid Aortic Valve Disease.
Aortic Valve Stenosis
(Pro)renin receptors and angiotensin converting enzyme 2/angiotensin-(1-7)/Mas receptor axis in human aortic valve stenosis.
A prospective, double-blind, randomized controlled trial of the angiotensin-converting enzyme inhibitor Ramipril In Aortic Stenosis (RIAS trial).
ACE inhibition in aortic stenosis: dangerous medicine or golden opportunity?
Activation of the cardiac renin-angiotensin system and increased myocardial collagen expression in human aortic valve disease.
Administration of angiotensin-converting enzyme inhibitors is associated with slow progression of mild aortic stenosis in Japanese patients.
Angiotensin AT1 receptor inhibition. Effects on hypertrophic remodeling and ACE expression in rats with pressure-overload hypertrophy due to ascending aortic stenosis.
Angiotensin-converting enzyme gene polymorphism influences degree of left ventricular hypertrophy and its regression in patients undergoing operation for aortic stenosis.
Angiotensin-converting enzyme inhibition prolongs survival and modifies the transition to heart failure in rats with pressure overload hypertrophy due to ascending aortic stenosis.
Angiotensin-converting enzyme inhibitors can increase the transvalvular gradient among patients with aortic stenosis.
Aortic Cross-Sectional Area/Height Ratio and Outcomes in Patients With a Trileaflet Aortic Valve and a Dilated Aorta.
Aortic stenosis and angiotensin-converting enzyme inhibitors--rupture of an ancient paradigm?
Are angiotensin converting enzyme inhibitors beneficial in patients with aortic stenosis?
Cardiac renin-angiotensin system: role in development of pressure-overload hypertrophy.
Clinical trials in heart valve disease.
Determinants of left ventricular mass in aortic stenosis.
Does angiotensin-converting enzyme inhibition improve the energetic status of cardiac and skeletal muscles in heart failure induced by aortic stenosis in rats?
Effects of angiotensin converting enzyme inhibitors in hypertensive patients with aortic valve stenosis: a drug withdrawal study.
Effects of long-term angiotensin converting enzyme inhibition on myocardial hypertrophy in experimental aortic stenosis in the rat.
Emerging medical treatments for aortic stenosis: statins, angiotensin converting enzyme inhibitors, or both?
Genetic variants of proteins from the renin angiotensin system are associated with pressure load cardiac hypertrophy.
Hemodynamic effects of the angiotensin-converting enzyme inhibitor, ramipril, in patients with mild to moderate aortic stenosis and preserved left ventricular function.
Impact of renin-angiotensin system inhibitors on clinical outcomes in patients with severe aortic stenosis undergoing transcatheter aortic valve replacement: an analysis of from the PARTNER 2 trial and registries.
Increased rat cardiac angiotensin converting enzyme activity and mRNA expression in pressure overload left ventricular hypertrophy. Effects on coronary resistance, contractility, and relaxation.
Intracardiac angiotensin-converting enzyme inhibition improves diastolic function in patients with left ventricular hypertrophy due to aortic stenosis.
Is the use of Renin-angiotensin System Inhibitors in Patients with Aortic Valve Stenosis Safe and of Prognostic benefit? A systematic review and meta-analysis.
Medical Therapy for Calcific Aortic Stenosis.
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in aortic stenosis - Is this the light at the end of the tunnel for patients with aortic stenosis?
Renin-Angiotensin system blockade therapy after surgical aortic valve replacement for severe aortic stenosis: a cohort study.
Safety and efficacy of angiotensin-converting enzyme inhibitors in aortic stenosis: A protocol for systematic review and meta-analysis.
Safety and efficacy of angiotensin-converting enzyme inhibitors in symptomatic severe aortic stenosis: Symptomatic Cardiac Obstruction-Pilot Study of Enalapril in Aortic Stenosis (SCOPE-AS).
Short-term hemodynamic effect of angiotensin-converting enzyme inhibition in patients with severe aortic stenosis: a placebo-controlled, randomized study.
Simvastatin inhibits cardiac hypertrophy and angiotensin-converting enzyme activity in rats with aortic stenosis.
Statin Use and Aneurysm Risk in Patients With Bicuspid Aortic Valve Disease.
Statins but not angiotensin-converting enzyme inhibitors delay progression of aortic stenosis.
Therapeutic Controversies in the Medical Management of Valvular Heart Disease.
Vasoconstrictor role of vasopressin and angiotensin in experimental aortic stenosis in the rat.
[Blockade of renin-angiotensin system attenuates cardiac remodeling in rats undergoing aortic stenosis]
[Medical treatments in aortic stenosis: role of statins and angiotensin-converting enzyme inhibitors].
Apnea
Eighth European meeting on hypertension.
Appendicitis
Angiotensin-converting enzyme inhibitors, angiotensin-receptor blockers, and risk of appendicitis.
Arrhythmias, Cardiac
Angiotensin in the brain suppresses epinephrine-induced cardiac arrhythmias through CNS opioid mechanisms.
Antiarrhythmic effect of carvedilol after acute myocardial infarction: results of the Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction (CAPRICORN) trial.
Antiarrhythmic effect of converting enzyme inhibitors in congestive heart failure.
Blockade of the renin-angiotensin-aldosterone system in patients with arrhythmogenic right ventricular dysplasia: A double-blind, multicenter, prospective, randomized, genotype-driven study (BRAVE study).
Blood pressure and the risk of complex arrhythmia in renal insufficiency, hemodialysis, and renal transplant patients.
Cardiac arrhythmias are ameliorated by local inhibition of angiotensin formation and bradykinin degradation with the converting-enzyme inhibitor ramipril.
Carvedilol's antiarrhythmic properties: therapeutic implications in patients with left ventricular dysfunction.
Clinical characteristics and four-year outcomes of patients in the Rhode Island Takotsubo Cardiomyopathy Registry.
Current treatment and management of dystrophinopathies.
Effect of an intravenous angiotensin-converting enzyme inhibitor on the electrophysiologic features of normal and hypertrophied feline ventricles.
Evaluation of antiarrhythmic activity of captopril and enalaprilat in experimental cardiac arrhythmias in rabbits. Part I.
Matrix metalloproteinase 1 1?G/2?G gene polymorphism is associated with acquired atrioventricular block via linking a higher serum protein level.
Mice with cardiac-restricted angiotensin-converting enzyme (ACE) have atrial enlargement, cardiac arrhythmia, and sudden death.
Significance of arrhythmias in congestive heart failure.
The influence of iatrogenic atrial septal defect on the prognosis of patients with atrial fibrillation between cryoablation and radiofrequency ablation.
Treatment of advanced heart failure in a young man with familial cardiomyopathy.
Upstream Effect for Atrial Fibrillation: Still a Dilemma?
[Circulatory insufficiency, ischemic disease, arrhythmia and the renin-angiotensin-aldosterone system and angiotensin converting enzyme inhibitors]
[JMIC-B study and its sub-analyses: effect of nifedipine in Japanese hypertensive patients with coronary artery disease]
[New strategies in the treatment of atrial fibrillation]
[Nonocclusive acute mesenteric ischemia]
[Risk factors for mortality in abdominal aortic surgery]
[Vasoplegic syndrome after cardiac surgery with cardiopulmonary bypass].
Arrhythmogenic Right Ventricular Dysplasia
Angiotensin-converting enzyme gene polymorphism in arrhythmogenic right ventricular dysplasia: is DD genotype helpful in predicting syncope risk?
Arterial Occlusive Diseases
Angiotensin converting enzyme inhibitors and angiotensin receptor blockers have no effect on the outcomes of endovascular revascularization in tibial arterial occlusive disease.
Angiotensin-converting enzyme gene insertion/deletion polymorphism and carotid artery wall thickness in patients with peripheral arterial occlusive disease.
Angiotensin-converting enzyme gene insertion/deletion polymorphism and peripheral arterial occlusive disease.
Lack of an association between angiotensin converting enzyme gene polymorphism and peripheral arterial occlusive disease.
Arteriosclerosis
Beneficial effects of combination therapy with angiotensin II receptor blocker and angiotensin-converting enzyme inhibitor on vascular endothelial function.
Effect of angiotensin-converting enzyme inhibition on growth factor mRNA in chronic renal allograft rejection in the rat.
Hemodynamic cardiovascular risk factors in chronic kidney disease: what are the effects of intervention?
Monocyte Angiotensin converting enzyme expression may be associated with atherosclerosis rather than arteriosclerosis in hemodialysis patients.
Novel anti-inflammatory actions of amlodipine in a rat model of arteriosclerosis induced by long-term inhibition of nitric oxide synthesis.
Regression by ACE inhibition of arteriosclerotic changes induced by chronic blockade of NO synthesis in rats.
Arteriosclerosis Obliterans
Angiotensin I-converting enzyme inhibitor improves reactive hyperemia in elderly hypertensives with arteriosclerosis obliterans.
[Arteriosclerosis obliterans. Treatment with angiotensin-converting enzyme inhibitors]
Arteriovenous Fistula
Arteriovenous fistula patency associated with angiotensin-converting enzyme I/D polymorphism and ACE inhibition or AT1 receptor blockade.
Is AV fistula patency associated with angiotensin-converting enzyme (ACE) polymorphism and ACE inhibitor intake?
Risk factors of vascular access failure in patients on hemodialysis.
The presence of PAI-1 4G/5G and ACE DD genotypes increases the risk of early-stage AVF thrombosis in hemodialysis patients.
Arteritis
Impact of diabetes, angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker use, and statin use on presentation and outcomes in patients with giant cell arteritis.
Labeled lectin studies of renal tubular dysgenesis and renal tubular atrophy of postnatal renal ischemia and end-stage kidney disease.
Polymyalgia rheumatica and giant cell arteritis--rational diagnosis and treatment predicated and disordered prostaglandin metabolism.
Treatment with angiotensin II receptor blockers is associated with prolonged relapse-free survival, lower relapse rate, and corticosteroid-sparing effect in patients with giant cell arteritis.
Arthralgia
Sarcoidosis following Cushing's syndrome: A report of two cases and review of the literature.
Sarcoidosis: a journey through 50 years.
Arthritis
A comparison of Blau's syndrome and sarcoidosis.
Prediction and primary prevention of major vascular complications in systemic sclerosis.
Ramipril attenuates lipid peroxidation and cardiac fibrosis in an experimental model of rheumatoid arthritis.
Serum and synovial fluid levels of angiotensin converting enzyme in polyarthritis.
Serum angiotensin-converting enzyme levels in sarcoid arthritis.
The 6-min walk test: a quick measure of functional status in elderly adults.
The non-thiol angiotensin-converting enzyme inhibitor quinapril suppresses inflammatory arthritis.
The receptors and role of angiotensin II in knee joint blood flow regulation and role of nitric oxide in modulation of their function.
The renin-angiotensin system in the synovium promotes periarticular osteopenia in a rat model of collagen-induced arthritis.
Arthritis, Experimental
Influence of the new angiotensin converting enzyme inhibitor ramipril on several models of acute inflammation and the adjuvant arthritis in the rat.
Arthritis, Juvenile
Angiotensin converting enzyme gene insertion-deletion polymorphism is associated with juvenile rheumatoid arthritis.
Arthritis, Psoriatic
Angiotensin-converting enzyme gene polymorphism in patients with psoriatic arthritis.
Carboxypeptidase N (kininase I) activity in blood and synovial fluid from patients with arthritis.
Lack of association between angiotensin I-converting enzyme insertion/deletion polymorphism and psoriasis or psoriatic arthritis in Spain.
Serum and synovial fluid levels of angiotensin converting enzyme in polyarthritis.
Arthritis, Rheumatoid
2012 Brazilian Society of Rheumatology Consensus on the management of comorbidities in patients with rheumatoid arthritis.
A clinical and biochemical assessment of a nonthiol ACE inhibitor (pentopril; CGS-13945) in active rheumatoid arthritis.
A DNA polymorphism at the alpha2-macroglobulin gene is associated with the severity of rheumatoid arthritis.
An Extensive Study of the Functional Polymorphisms of Kinin-Kallikrein System in Rheumatoid Arthritis Susceptibility.
Angiotensin converting enzyme in human synovium: increased stromal [(125)I]351A binding in rheumatoid arthritis.
Angiotensin converting enzyme in rheumatoid arthritis.
Angiotensin converting enzyme inhibitors and rheumatoid arthritis.
Angiotensin-converting enzyme inhibition improves vascular function in rheumatoid arthritis.
Angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers and the risk of developing rheumatoid arthritis in antihypertensive drug users.
Association of angiotensin converting enzyme (ACE) gene I/D polymorphism and rheumatoid arthritis.
Carboxypeptidase N (kininase I) activity in blood and synovial fluid from patients with arthritis.
Effects of Angiotensin-converting enzyme inhibition and statin treatment on inflammatory markers and endothelial functions in patients with longterm rheumatoid arthritis.
Evidence for the presence of dipeptidyl carboxypeptidase and its inhibitors in inflammatory synovial fluids.
Patterns of angiotensin converting enzyme insertion/deletion gene polymorphism among an Egyptian cohort of patients with rheumatoid arthritis.
Pleural fluid beta-2-microglobulin and angiotensin-converting enzyme concentrations in rheumatoid arthritis and tuberculosis.
Renin and angiotensin-converting enzyme (ACE) as active components of the local synovial renin-angiotensin system in rheumatoid arthritis.
Serum and synovial fluid levels of angiotensin converting enzyme in polyarthritis.
Significant association of insertion/deletion polymorphism of the angiotensin-converting enzyme gene with rheumatoid arthritis.
Spontaneous release of angiotensin converting enzyme and interleukin 1 beta from peripheral blood monocytes from patients with rheumatoid arthritis under a serum free condition.
The angiotensin-converting enzyme insertion/deletion polymorphism and susceptibility to rheumatoid arthritis, vitiligo and psoriasis: A meta-analysis.
[Drug-induced interstitial lung diseases].
[Drug-induced oral ulcerations]
Asbestosis
Angiotensin-converting enzyme and lysozyme in silicosis and asbestosis.
Bronchoalveolar lavage analysis, gallium-67 lung scanning and soluble interleukin-2 receptor levels in asbestos exposure.
Lack of correlation between serum angiotensin-converting enzyme levels and asbestosis in man, sheep and guinea-pig.
Serum angiotensin-converting enzyme and lysosomal enzymes in asbestosis.
Asthma
A pharmacist-led information technology intervention for medication errors (PINCER): a multicentre, cluster randomised, controlled trial and cost-effectiveness analysis.
ACE gene polymorphism might disclose why some Taiwanese children with allergic rhinitis develop asthma symptoms but others do not.
Acid regurgitation associated with persistent cough after pulmonary resection: an observational study.
Activation of angiotensin-converting enzyme 2 (ACE2) attenuates allergic airway inflammation in rat asthma model.
Activity of angiotensin I converting enzyme in sarcoidosis, atopic bronchial asthma and acute bronchitis.
Airway inflammation as an assessment of chronic nonproductive cough.
Allergen immunotherapy safety: characterizing systemic reactions and identifying risk factors.
An Angiotensin I Converting Enzyme Polymorphism is Associated With Clinical Phenotype When Using Differentiation-Syndrome to Categorize Korean Bronchial Asthma Patients.
Analysis of medication use patterns:apparent overuse of antibiotics and underuse of prescription drugs for asthma, depression, and CHF.
Anatomical diagnostic protocol in evaluating chronic cough with specific reference to gastroesophageal reflux disease.
Angiotensin converting enzyme activity, prostaglandin F2 alpha- and immunoglobulin E level in childhood asthma bronchiale.
Angiotensin converting enzyme gene polymorphism in Turkish asthmatic patients.
Angiotensin converting enzyme inhibitors and asthma.
Angiotensin-converting enzyme gene polymorphisms might be associated with childhood asthma in East Asia.
Angiotensin-converting enzyme inhibitors in patients with bronchial responsiveness and asthma.
Angiotensin-Converting Enzyme Inhibitors, Asthma, and Cough: Relighting the Torch.
Angiotensin-converting enzyme insertion/deletion polymorphism and susceptibility to pediatric asthma: A meta-analysis.
Arguing the misconceptions in allergen-specific immunotherapy.
Association between angiotensin-converting enzyme I/D polymorphism and asthma risk: a meta-analysis involving 11,897 subjects.
Association between Renin-Angiotensin System Gene Polymorphism and Recurrent Wheezing in Chinese Children: a 4-year Follow-up Study.
Association of angiotensin I-converting enzyme gene polymorphisms with aspirin intolerance in asthmatics.
Association of the TNF-alpha-308 (G-->A) polymorphism with self-reported history of childhood asthma.
Asthma susceptible genes in Chinese population: a meta-analysis.
Bronchial effects of alpha 2-adrenoceptor agonists and of other antihypertensive agents in asthma.
Captopril-related (and -induced?) asthma.
Chronic cough and a normal chest X-ray - a simple systematic approach to exclude common causes before referral to secondary care: a retrospective cohort study.
Chronic cough with a history of excessive sputum production. The spectrum and frequency of causes, key components of the diagnostic evaluation, and outcome of specific therapy.
Chronic Cough: An Update.
CICADA: Cough in Children and Adults: Diagnosis and Assessment. Australian cough guidelines summary statement.
Clinical Practice Guidelines for Diagnosis and Management of Hypersensitivity Reactions to Contrast Media.
Cofactors and comorbidities in patients with aspirin/NSAID hypersensitivity.
Comparison of the effects of an angiotensin converting enzyme inhibitor and a calcium channel blocker on blood pressure and respiratory function in patients with hypertension and asthma.
Cough: a worldwide problem.
Development of persistent late onset asthma following treatment with captopril.
Dyspnoea, asthma, and bronchospasm in relation to treatment with angiotensin converting enzyme inhibitors.
Effectiveness of amitriptyline versus cough suppressants in the treatment of chronic cough resulting from postviral vagal neuropathy.
Effects of prednisolone on angiotensin converting enzyme activity.
Elevated ACE activity is not associated with asthma, COPD, and COPD co-morbidity.
Endothelial dysfunction in patients with asthma: the role of polymorphisms of ACE and endothelial NOS genes.
Evaluation of angiotensin converting enzyme gene polymorphism and susceptibility to bronchial asthma among Egyptians.
Evidence-based Evaluation and Management of Chronic Cough.
Expression of SARS-CoV-2 receptor ACE2 and coincident host response signature varies by asthma inflammatory phenotype.
From a prospective study of chronic cough: diagnostic and therapeutic aspects in older adults.
Gene polymorphisms of endothelial nitric oxide synthase and angiotensin-converting enzyme in patients with asthma.
Gene susceptibility in Iranian asthmatic patients: a narrative review.
Genetic polymorphism of the angiotensin-converting enzyme (ACE) in asthmatic patients.
High frequency of a deletion polymorphism of the angiotensin-converting enzyme gene in asthma.
Identification of independent risk factors for fentanyl-induced cough.
Identification of risk factors of severe hypersensitivity reactions in general anaesthesia.
Immunotherapy safety: what have we learned from surveillance surveys?
Intolerance to Angiotensin Converting Enzyme Inhibitors in Asthma and the General Population: A UK Population-Based Cohort Study.
Laryngeal sensory neuropathy in patients with diabetes mellitus.
Molecular studies of bronchial asthma, sarcoidosis and angiotensin converting enzyme inhibitor-induced cough.
Omeprazole-induced cough in a patient with gastroesophageal reflux disease.
Pathophysiology and clinical presentations of cough.
Pathophysiology and therapy of chronic cough.
Pharmacotherapy of chronic cough in adults.
Plasminogen activator inhibitor-1 and angiotensin converting enzyme gene polymorphisms in Turkish asthmatic children.
Polymorphism of angiotensin-converting enzyme gene and genetic susceptibility to asthma with familial aggregation.
Prevalence of tumor necrosis factor-alpha and angiotensin converting enzyme polymorphisms in mild/moderate and fatal/near-fatal asthma.
Protocol for the PINCER trial: a cluster randomised trial comparing the effectiveness of a pharmacist-led IT-based intervention with simple feedback in reducing rates of clinically important errors in medicines management in general practices.
Role of neutral endopeptidase and angiotensin converting enzyme in asthma.
Serum angiotensin converting enzyme activity in human bronchial asthma.
Serum angiotensin converting enzyme activity in pulmonary diseases: correlation with lung function parameters.
Serum angiotensin converting enzyme level in bronchial asthma.
The aetiology of chronic cough: a review of current theories for the otorhinolaryngologist.
The I/D polymorphism of angiotensin-converting enzyme gene and asthma risk: a meta-analysis.
The Microbiota and Health Promoting Characteristics of the Fermented Beverage Kefir.
The pharmacologic treatment of uncomplicated arterial hypertension in patients with airway dysfunction.
The PRICE clinic for low-income elderly: a managed care model for implementing pharmacist-directed services.
The relationship between the arterial level of angiotensin-converting enzymes and arterial gas tension in bronchial asthma.
Usefulness of the Guidelines of the Spanish Society of Pulmonology and Thoracic Surgery (SEPAR) in Identifying the Causes of Chronic Cough.
Venom Immunotherapy in High-Risk Patients: The Advantage of the Rush Build-Up Protocol.
[Association between indoor coal-burning pollutants associated with asthmatic susceptible genetic polymorphisms in childhood asthma]
[Changes in angiotensin converting enzyme activity in bronchial asthma during physical exertion]
[Changes in the spectrum and frequency of causes for chronic cough: a retrospective analysis]
[Etiological diagnosis and specific treatment of chronic cough in 106 patients]
[Polymorphism of angiotensin-converting enzyme gene and susceptibility to asthma with familial aggregation]
[Serum angiotensin converting enzyme (SACE) in patients with atopic bronchial asthma]
[Unrecognized causes of chronic cough]
Astrocytoma
Hydrolysis of atrial and brain natriuretic peptides by the human astrocytoma clone D384 and the neuroblastoma line SH-SY5Y.
Ataxia
The Protean Neuropsychiatric and Vestibuloauditory Manifestations of Neurosarcoidosis.
Ataxia Telangiectasia
The expression of genes related to adipocyte differentiation in pigs.
Atherosclerosis
2012 Brazilian Society of Rheumatology Consensus on the management of comorbidities in patients with rheumatoid arthritis.
A study of gene--environment interaction on the gene for angiotensin converting enzyme: a combined functional and population based approach.
Abnormal flow-mediated epicardial vasomotion in human coronary arteries is improved by angiotensin-converting enzyme inhibition: a potential role of bradykinin.
Abnormal taurocholate ileal transepithelial transport in atherosclerotic mini-pigs and effects of ACE inhibitors.
ACE and ADD1 gene in extra and intracranial atherosclerosis in ischaemic stroke.
ACE gene polymorphism in peripheral vascular disease.
ACE inhibition lowers angiotensin II-induced chemokine expression by reduction of NF-kappaB activity and AT1 receptor expression.
ACE insert/delete polymorphism and atherosclerosis.
ACE-inhibitors and atherosclerosis.
ACE2-Ang-(1-7)-Mas Axis in Brain: A Potential Target for Prevention and Treatment of Ischemic Stroke.
Acute effect of captopril on serum lipid peroxides level in hypertensive patients.
Aggressive treatment of atherosclerosis: the time is now.
Aging increases aortic MMP-2 activity and angiotensin II in nonhuman primates.
Aldosterone administration to mice stimulates macrophage NADPH oxidase and increases atherosclerosis development: a possible role for angiotensin-converting enzyme and the receptors for angiotensin II and aldosterone.
Aldosterone blockade in patients with chronic heart failure.
Aliskiren effect on plaque progression in established atherosclerosis using high resolution 3D MRI (ALPINE): a double-blind placebo-controlled trial.
Allele and genotype frequencies of polymorphic DCP1, CETP, ADRB2, and HTR2A in the Egyptian population.
Angiotensin Converting Enzyme and Subclinical Atherosclerosis in Psoriasis: Is there Any Association? A case-control study.
Angiotensin converting enzyme inhibitors and atherosclerosis.
Angiotensin II activates nuclear transcription factor-kappaB in aorta of normal rats and in vascular smooth muscle cells of AT1 knockout mice.
Angiotensin II atherogenicity in apolipoprotein E deficient mice is associated with increased cellular cholesterol biosynthesis.
Angiotensin II reactivation and aldosterone escape phenomena in renin-angiotensin-aldosterone system blockade: is oral renin inhibition the solution?
Angiotensin receptor blockade decreases markers of vascular inflammation.
Angiotensin receptor blockers vs. angiotensin converting enzyme inhibitors and acute coronary syndrome outcomes in elderly patients: a population-based cohort study (UMPIRE study results).
Angiotensin-converting enzyme and endothelial constitutive nitric oxide synthase polymorphisms in Turkish renal transplant population and possible influence on renal artery atherosclerosis and graft survival.
Angiotensin-converting enzyme expression in human carotid artery atherosclerosis.
Angiotensin-converting enzyme gene and atherosclerosis.
Angiotensin-converting enzyme gene polymorphism and carotid wall thickening in a community population.
Angiotensin-converting enzyme inhibition down-regulates the pro-atherogenic chemokine receptor 9 (CCR9)-chemokine ligand 25 (CCL25) axis.
Angiotensin-converting enzyme inhibition improves vascular function in rheumatoid arthritis.
Angiotensin-converting enzyme inhibition prevents arterial nuclear factor-kappa B activation, monocyte chemoattractant protein-1 expression, and macrophage infiltration in a rabbit model of early accelerated atherosclerosis.
Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in atherosclerosis.
Angiotensin-converting enzyme inhibitors and atherosclerosis: relevance of animal models to human disease.
Angiotensin-converting enzyme inhibitors in patients with atherosclerosis and preserved left ventricular function: clinical outcomes.
Angiotensin-converting enzyme: induction by hypertension-induced vessel distension.
Angiotensinogen and angiotensin converting enzyme genotypes and carotid atherosclerosis: the atherosclerosis risk in communities and the NHLBI family heart studies.
Anti-atherosclerotic and renoprotective effects of combined angiotensin-converting enzyme and neutral endopeptidase inhibition in diabetic apolipoprotein E-knockout mice.
Antiatherosclerotic and antioxidative effects of captopril in apolipoprotein E-deficient mice.
Antiplatelet effects of angiotensin-converting enzyme inhibitors compared with aspirin and clopidogrel: a pilot study with whole-blood aggregometry.
Aortic atherosclerosis in diabetes mellitus is associated with an insertion/deletion polymorphism in the angiotensin I-converting enzyme gene. No relation between the polymorphism and aortic collagen content.
Approach to a Successful Selection of Antihypertensive Drugs for the Patient With Atherosclerosis.
Arterial protection: a neglected but crucial therapeutic goal.
Association between Genetic Polymorphisms and Sites of Cervicocerebral Artery Atherosclerosis.
Association of Angiotensin-Converting Enzyme Genotype, Insertion/Deletion Polymorphism and Saphenous Vein Graft Atherosclerosis in Iranian Patients.
Association of Angiotensin-Converting Enzyme Insertion/Deletion Polymorphism with the Risk of Atherosclerosis.
Association of angiotensin-converting enzyme with low-density lipoprotein in aortic valvular lesions and in human plasma.
Association of the KLK1 rs5516 G allele and the ACE D allele with aortic aneurysm and atherosclerotic stenosis.
Asymptomatic cardiac involvement in Thai systemic sclerosis: prevalence and clinical correlations with non-cardiac manifestations (preliminary report).
Atherosclerosis in chronic kidney disease: the role of macrophages.
Atherosclerosis in Marek's disease virus infected hypercholesterolemic roosters is reduced by HMGCoA reductase and ACE inhibitor therapy.
Atherosclerosis of carotid arteries and the ace insertion/deletion polymorphism in subjects with diabetes mellitus type 2.
Atherosclerotic risk factors and renal function in the elderly: the role of hyperfibrinogenaemia and smoking. Results from the Italian Longitudinal Study on Ageing (ILSA).
Beneficial effects of ACE-inhibition with zofenopril on plaque formation and low-density lipoprotein oxidation in watanabe heritable hyperlipidemic rabbits.
Benefit versus risk of calcium antagonists in hypertensive patients with concomitant risk factors.
Blood pressure lowering, not vascular mechanism of action, is the primary determinant of clinical outcome.
CAC score as a possible criterion for administration of angiotensin converting enzyme inhibitors and/or angiotensin receptor blockers: the MultiEthnic Study of Atherosclerosis.
Camel thorn extract reduces activity of angiotensin-converting enzyme in rat aorta increased during aging and treatment with NO-synthase inhibitor.
Can antihypertensive drugs reduce atherosclerosis and its clinical complications?
Cardiac allograft atherosclerosis in the rat. The effect of histocompatibility factors, cyclosporine, and an angiotensin-converting enzyme inhibitor.
Cardiovascular antioxidant therapy: a review of supplements, pharmacotherapies, and mechanisms.
Cardiovascular disease: much more aggressive in patients with type 2 diabetes.
Carrier-state of D allele in ACE gene insertion/deletion polymorphism is associated with coronary artery disease, in contrast to the C677-->T transition in the MTHFR gene.
CD143 in the development of atherosclerosis.
Chronic treatment with sulfhydryl angiotensin-converting enzyme inhibitors reduce susceptibility of plasma LDL to in vitro oxidation, formation of oxidation-specific epitopes in the arterial wall, and atherogenesis in apolipoprotein E knockout mice.
Clinical impact of angiotensin I converting enzyme polymorphisms in subjects with resistant hypertension.
Clots, kinins and coronaries.
Comparison of the effects of AT1 receptor blockade and angiotensin converting enzyme inhibition on atherosclerosis.
Contributions of leukocyte Angiotensin-converting enzyme to development of atherosclerosis.
Current perspective on the use of angiotensin-converting enzyme inhibitors in the management of coronary (atherosclerotic) artery disease.
DD Genotype of the angiotensin - converting enzyme gene and stroke in Slovenian population.
DD genotype of the angiotensin-converting enzyme gene and stroke in Slovenian population.
Delayed intervention with AGE inhibitors attenuates the progression of diabetes-accelerated atherosclerosis in diabetic apolipoprotein E knockout mice.
Deoxycorticosterone acetate salt hypertension in apolipoprotein E-/- mice results in accelerated atherosclerosis: the role of angiotensin II.
Development of a sensitive, accurate and robust liquid chromatography/mass spectrometric method for profiling of angiotensin peptides in plasma and its application for atherosclerotic mice.
Differential effects of renin-angiotensin system blockade on atherogenesis in cholesterol-fed rabbits.
Dissociation between the antiatherosclerotic effect of trandolapril and suppression of serum and aortic angiotensin-converting enzyme activity in the Watanabe heritable hyperlipidemic rabbit.
Downregulation of angiotensin-converting enzyme by tumor necrosis factor-alpha and interleukin-1beta in cultured human endothelial cells.
Early sign of atherosclerosis in slow coronary flow and relationship with angiotensin-converting enzyme I/D polymorphism.
Effect of Angiotensin-converting enzyme inhibitors and Angiotensin receptor antagonists in atherosclerosis prevention.
Effect of enalaprilat on nitric oxide activity in coronary artery disease.
Effect of losartan, compared with atenolol, on endothelial function and oxidative stress in patients with type 2 diabetes and hypertension.
Effects of angiotensin-converting enzyme inhibition with perindopril on hemodynamics, arterial structure, and wall rheology in the hindquarters of atherosclerotic mini-pigs.
Effects of captopril on platelet cytosolic free Ca2+ concentrations and on suppression of cell proliferation in culture.
Effects of combined endothelin and angiotensin II antagonism on growth factor-induced proliferation of vascular smooth muscle cells isolated from uremic rats.
Effects of natural peptides from food proteins on angiotensin converting enzyme activity and hypertension.
Effects of ramipril and vitamin E on atherosclerosis: the study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E (SECURE).
Efficacy of cyclosporine and angiotensin-converting enzyme inhibitor to inhibit cardiac graft atherosclerosis in the rat.
Enalapril attenuates angiotensin II-induced atherosclerosis and vascular inflammation.
Endothelial function. From vascular biology to clinical applications.
Enhanced reduction of atherosclerosis in hamsters treated with pravastatin and captopril: ACE in atheromas provides cellular targets for captopril.
Eplerenone inhibits atherosclerosis in nonhuman primates.
Evidence of suboptimal management of cardiovascular risk in patients with type 2 diabetes mellitus and symptomatic atherosclerosis.
Flavonoids decrease the radiation-induced increase in the activity of the angiotensin-converting enzyme in rat aorta.
Fosinopril reduces ADP-induced platelet aggregation in hypertensive patients.
Gene polymorphisms of angiotensin-converting enzyme and angiotensinogen and risk of idiopathic ischemic stroke.
Genomics and the prospects of existing and emerging therapeutics for cardiovascular diseases.
Hypertension and atherosclerosis: clinical implications from the ALLHAT Trial.
Impact of genetic variants on the upstream efficacy of renin-angiotensin system inhibitors for the prevention of atrial fibrillation.
Impacts of Lisinopril and Lisinopril Plus Simvastatin on Erythrocyte and Plasma Arginase, Nitrite, and Nitrate in Hypertensive Patients.
Important causes of chronic kidney disease in South Africa.
Improved treatment of coronary heart disease by implementation of a Cardiac Hospitalization Atherosclerosis Management Program (CHAMP).
Inflammation may be a bridge connecting hypertension and atherosclerosis.
Influence of the angiotensin converting enzyme inhibitor ramipril on high-sensitivity C-reactive protein (hs-CRP) in patients with documented atherosclerosis.
Inhibition of renin angiotensin axis may be associated with reduced risk of developing venous thromboembolism in patients with atherosclerotic disease.
Inhibition of renin-angiotensin system attenuates periadventitial inflammation and reduces atherosclerotic lesion formation.
Inhibition of the renin angiotensin system: implications for the endothelium.
Inhibition of the renin-angiotensin system ameliorates genetically determined hyperinsulinemia.
Inhibitors of angiotensin converting enzyme decrease early atherosclerosis in hyperlipidemic hamsters. Fosinopril reduces plasma cholesterol and captopril inhibits macrophage-foam cell accumulation independently of blood pressure and plasma lipids.
Insertion-deletion polymorphism of the ACE gene modulates reversibility of endothelial dysfunction with ACE inhibition.
Intermittent claudication: an overview.
Low potentiality of angiotensin-converting enzyme gene insertion/deletion polymorphism as a useful predictive marker for carotid atherogenesis in a large general population of a Japanese city: the Suita study.
MAS receptors mediate vasoprotective and atheroprotective effects of candesartan upon the recovery of vascular angiotensin-converting enzyme 2-angiotensin-(1-7)-MAS axis functionality.
Microarray gene expression profiling reveals antioxidant-like effects of angiotensin II inhibition in atherosclerosis.
MMP-9 inhibition by ACE inhibitor reduces oxidized LDL-mediated foam-cell formation.
Modifying the natural history of atherosclerosis: the SECURE trial.
Monocyte Angiotensin converting enzyme expression may be associated with atherosclerosis rather than arteriosclerosis in hemodialysis patients.
Monocytic angiotensin-converting enzyme 2 relates to atherosclerosis in patients with chronic kidney disease.
New therapeutic potential of microRNA treatment to target vulnerable atherosclerotic lesions and plaque rupture.
Omapatrilat decreased macrophage oxidative status and atherosclerosis progression in atherosclerotic apolipoprotein E-deficient mice.
Omapatrilat, a dual angiotensin-converting enzyme and neutral endopeptidase inhibitor, prevents fatty streak deposit in apolipoprotein E-deficient mice.
Omapatrilat, an angiotensin-converting enzyme and neutral endopeptidase inhibitor, attenuates early atherosclerosis in diabetic and in nondiabetic low-density lipoprotein receptor-deficient mice.
Overexpression of myeloid angiotensin-converting enzyme (ACE) reduces atherosclerosis.
Pathogenesis of the acute coronary syndromes and therapeutic implications.
Pathophysiology of atherosclerosis: the role of inflammation.
Patients undergoing infrainguinal bypass to treat atherosclerotic vascular disease are underprescribed cardioprotective medications: effect on graft patency, limb salvage, and mortality.
Peripheral artery disease: potential role of ACE-inhibitor therapy.
Pharmacogenetic interactions of three candidate gene polymorphisms with ACE-inhibitors or beta-blockers and the risk of atherosclerosis.
Polymorphisms of apolipoprotein E and angiotensin-converting enzyme genes and carotid atherosclerosis in heavy drinkers.
Potential anti-inflammatory, anti-adhesive, anti/estrogenic, and angiotensin-converting enzyme inhibitory activities of anthocyanins and their gut metabolites.
Potential role of angiotensin converting enzyme inhibitors in treatment of atherosclerosis.
Potential role of angiotensin-converting enzyme inhibition in myocardial ischemia and current clinical trials.
Premature Atherosclerosis Is Associated With Hypovitaminosis D and Angiotensin-Converting Enzyme Inhibitor Non-use in Lupus Patients.
Preventing atherosclerosis with Angiotensin-converting enzyme inhibitors: emphasis on diabetic atherosclerosis.
Prevention and treatment of diabetic nephropathy.
Prevention of accelerated atherosclerosis by angiotensin-converting enzyme inhibition in diabetic apolipoprotein E-deficient mice.
Prevention of atherosclerosis by interference with the vascular nitric oxide system.
Prevention of heart failure: effective strategies to combat the growing epidemic.
Progression of atherosclerosis in patients with peripheral arterial disease as a function of angiotensin-converting enzyme gene insertion/deletion polymorphism.
Ramipril administration to atherosclerotic mice reduces oxidized low-density lipoprotein uptake by their macrophages and blocks the progression of atherosclerosis.
Randomized, placebo-controlled trial of the angiotensin-converting enzyme inhibitor, ramipril, in patients with coronary or other occlusive arterial disease. PART-2 Collaborative Research Group. Prevention of Atherosclerosis with Ramipril.
Rationale and design of the Cardiac Hospitalization Atherosclerosis Management Program at the University of California Los Angeles.
Regression of early atherosclerosis in hyperlipidemic hamsters induced by fosinopril and captopril.
Regulation of angiotensin-converting enzyme production by nicotine in human endothelial cells.
Regulation of vascular smooth-muscle cell growth by angiotensin II.
Relationships between blood pressure, polymorphism of angiotensin-converting enzyme (ACE), body composition and biochemical characteristics in elderly Slovaks.
Renin-angiotensin system as a therapeutic target in managing atherosclerosis.
Residues affecting the chloride regulation and substrate selectivity of the angiotensin-converting enzymes (ACE and ACE2) identified by site-directed mutagenesis.
Role of Renin-Angiotensin System Components in Atherosclerosis: Focus on Ang-II, ACE2, and Ang-1-7.
Role of the renin-angiotensin-aldosterone system and proinflammatory mediators in cardiovascular disease.
Specific and Pronounced Impacts of Lisinopril and Lisinopril Plus Simvastatin on Erythrocyte Antioxidant Enzymes.
Stage A: Can Heart Failure Be Prevented?
Study design and baseline characteristics of the study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E: SECURE.
Study of angiotensin-converting enzyme insertion/deletion polymorphism, enzyme activity and oxidized low density lipoprotein in Western Iranians with atherosclerosis: a case-control study.
Sulfhydryl angiotensin-converting enzyme inhibition induces sustained reduction of systemic oxidative stress and improves the nitric oxide pathway in patients with essential hypertension.
Systemic hypertension and the renin-angiotensin system in diabetic vascular complications.
Targeting redox signaling in the vascular wall: from basic science to clinical practice.
Telmisartan and cardioprotection.
The ACE inhibitor alacepril suppresses atherogenesis independent of serum lipids in cholesterol-fed rabbits--critical analysis with new ultrasound technique.
The Alu polymorphism of angiotensin I converting enzyme (ACE) and atherosclerosis, incident chronic diseases and mortality in an elderly Chinese population.
The angiotensin-converting enzyme inhibitor, fosinopril, and the angiotensin II receptor antagonist, losartan, inhibit LDL oxidation and attenuate atherosclerosis independent of lowering blood pressure in apolipoprotein E deficient mice.
The antiatherogenic potential of blocking the renin-angiotensin system.
The association between the insertion/deletion polymorphism of the angiotensin-converting enzyme gene and the plasma fibrinogen level in women and men with premature coronary artery atherosclerosis.
The D allele of angiotensin I-converting enzyme gene insertion/deletion polymorphism is associated with the severity of atherosclerosis.
The effect of ACE inhibitors on atheroma formation is potentiated by association with a calcium channel blocker. A biochemical and ultrastructural study.
The effect of angiotensin-converting enzyme inhibition on endothelial function and oxidant stress.
The effect of antihypertensive drugs on carotid intima media thickness: an up-to-date review.
The effect of myocardial bridging of the coronary artery on vasoactive agents and atherosclerosis localization.
The effects of ACE inhibitors and other antihypertensive drugs on cardiovascular risk factors and atherogenesis.
The effects of renin-angiotensin system inhibition on aortic cholesterol content in cholesterol-fed rabbits.
The I/D polymorphism of angiotensin-converting enzyme gene but not the angiotensinogen gene is associated with insulin response to oral glucose in Japanese.
The level of hs-CRP in coronary artery ectasia and its response to statin and angiotensin-converting enzyme inhibitor treatment.
The possible therapeutic actions of peroxisome proliferator-activated receptor alpha (PPAR alpha) agonists, PPAR gamma agonists, 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, angiotensin converting enzyme (ACE) inhibitors and calcium (Ca)-antagonists on vascular endothelial cells.
The QUinapril Ischemic Event Trial (QUIET) design and methods: evaluation of chronic ACE inhibitor therapy after coronary artery intervention.
The QUinapril Ischemic Event Trial (QUIET): evaluation of chronic ACE inhibitor therapy in patients with ischemic heart disease and preserved left ventricular function.
The renin-angiotensin-aldosterone system as a target in coronary disease.
The role of the renin-angiotensin-aldosterone system in diabetes and its vascular complications.
The vascular biology of hypertension and atherosclerosis and intervention with calcium antagonists and angiotensin-converting enzyme inhibitors.
Therapeutic potential of nitric oxide donors in the prevention and treatment of atherosclerosis.
Tissue angiotensin II generating system by angiotensin-converting enzyme and chymase.
Tissue angiotensin-converting-enzyme (ACE) deficiency leads to a reduction in oxidative stress and in atherosclerosis: studies in ACE-knockout mice type 2.
Treatment of Stable Angina Pectoris.
Use of angiotensin II receptor blockers in animal models of atherosclerosis.
Vascular renin-angiotensin system and vascular protection.
Vasculoprotective and cardioprotective mechanisms of angiotensin-converting enzyme inhibition: the homeostatic balance between angiotensin II and nitric oxide.
What should the role of ACE inhibitors be in the treatment of diabetes? Lessons from HOPE and MICRO-HOPE.
[Angiotensin converting enzyme and Alzheimer's disease].
[Angiotensin converting enzyme-angiotensin II system, atherosclerosis, and angiotensin-converting enzyme inhibitors]
[Anti-atherosclerotic action of hypotensive drugs]
[Anti-ischemic and infarction-reducing effects of angiotensin-converting enzyme inhibitors]
[Association between angiotensin converting enzyme I/D polymorphism and high-sensitivity C-reactive protein in type 2 diabetic patients with atherosclerosis treated with ramipril]
[Correlation between polymorphism of angiotensin-converting enzyme gene and the lower extremity atherosclerosis in type 2 diabetes mellitus patients].
[Inflammation and atherosclerosis: the role of Renin-Angiotensin system and its inhibition].
[Inhibitors of angiotensin-converting enzyme and processus of intima proliferation in atherosclerosis]
[Management of patients with intermittent claudication]
[Pleiotropic effects of therapy in endothelial dysfunction syndrome]
[REGRESSION OF ATHEROSCLECROTIC LESIONS: MEDICAMENTAL AND ALIMENTARY FACTORS].
[Therapeutic strategies in the treatment of endothelial dysfunction: facts and outlook]
[Treatment of hypertension in postmenopausal women]
Atrial Fibrillation
A multicenter risk index for atrial fibrillation after cardiac surgery.
A985G polymorphism of the endothelin-2 gene and atrial fibrillation in patients with hypertrophic cardiomyopathy.
ACEI and ARB did not Reduce the Incidence of Dementia in Patients with Atrial Fibrillation: A Nationwide Cohort Study.
Angiotensin converting enzyme inhibitor and angiotensin receptor blockade use in relation to outcomes in anticoagulated patients with atrial fibrillation.
Angiotensin converting enzyme inhibitors and angiotensin II receptor blockers in atrial fibrillation.
Angiotensin-converting enzyme and endothelial nitric oxide synthase polymorphisms in patients with atrial fibrillation.
Angiotensin-converting enzyme gene 2350 G/A polymorphism and susceptibility to atrial fibrillation in Han Chinese patients with essential hypertension.
Angiotensin-converting enzyme inhibition in hypertensive patients is associated with a reduction in the occurrence of atrial fibrillation.
Angiotensin-converting enzyme inhibition or mineralocorticoid receptor blockade do not affect prevalence of atrial fibrillation in patients undergoing cardiac surgery.
Angiotensin-converting enzyme inhibitor suppresses the incidence of prolonged and fractionated right atrial electrograms.
Angiotensin-converting enzyme inhibitor therapy inhibits the progression from paroxysmal atrial fibrillation to chronic atrial fibrillation.
Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers Are Associated With Improved Outcome but Do Not Prevent New-Onset Atrial Fibrillation After Acute Myocardial Infarction.
Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers have no beneficial effect on ablation outcome in chronic persistent atrial fibrillation.
Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers decrease the incidence of atrial fibrillation: a meta-analysis.
Angiotensin-converting enzyme inhibitors and stroke prevention: what about the influence of atrial fibrillation and antithrombotic therapy?
Angiotensin-converting enzyme inhibitors are not effective at inhibiting further fibrous changes in the atria in patients with chronic atrial fibrillation: speculation from analysis of the time course of fibrillary wave amplitudes.
Angiotensin-converting enzyme inhibitors as adjunctive therapy in patients with persistent atrial fibrillation.
Angiotensin-converting enzyme inhibitors to maintain sinus rhythm following cardioversion of atrial fibrillation.
Angiotensin-converting enzyme insertion/deletion gene polymorphisms associated with risk of atrial fibrillation: A meta-analysis of 23 case-control studies.
Angiotensin-converting enzyme-2 overexpression improves atrial remodeling and function in a canine model of atrial fibrillation.
Angiotensin-Receptor Blocker, Angiotensin-Converting Enzyme Inhibitor, and Risks of Atrial Fibrillation: A Nationwide Cohort Study.
Angiotensinogen and ACE gene polymorphisms and risk of atrial fibrillation in the general population.
Anti-inflammatory effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: potential benefits for the prevention of atrial fibrillation.
Antiarrhythmic Effects of Losartan and Enalapril in Canine Pulmonary Vein Sleeve Preparations.
Antihypertensive treatment and risk of atrial fibrillation: a nationwide study.
Antihypertensive treatment with ACE inhibitors or beta-blockers and risk of incident atrial fibrillation in a general hypertensive population.
Association between angiotensin-converting enzyme insertion/deletion gene polymorphism and atrial fibrillation: a meta-analysis.
Association between elevated fibrosis markers and heart failure in the elderly: the cardiovascular health study.
Association between the use of non-antiarrhythmic drugs and postoperative atrial fibrillation.
Association of angiotensin-converting enzyme gene I/D and CYP11B2 gene -344T/C polymorphisms with lone atrial fibrillation and its recurrence after catheter ablation.
Association of pretreatment with angiotensin-converting enzyme inhibitors with improvement in ablation outcome in atrial fibrillation patients with low left ventricular ejection fraction.
Associations Between Outpatient Heart Failure Process-of-Care Measures and Mortality.
Atrial fibrillation after radiofrequency ablation of atrial flutter: preventive effect of angiotensin converting enzyme inhibitors, angiotensin II receptor blockers, and diuretics.
Atrial fibrillation and morbidity and mortality in a cohort of long-term hemodialysis patients.
Automated review of electronic health records to assess quality of care for outpatients with heart failure.
Blockade of the renin-angiotensin-aldosterone system (RAAS) for primary prevention of non-valvular atrial fibrillation: A systematic review and meta analysis of randomized controlled trials.
Candesartan in the prevention of relapsing atrial fibrillation.
Central retinal vein occlusion case-control study.
Clinical factors associated with early readmission among acutely decompensated heart failure patients.
Clinical Interventions and All-Cause Mortality of Patients with Chronic Kidney Disease: An Umbrella Systematic Review of Meta-Analyses.
Clinical trials update: OPTIME-CHF, PRAISE-2, ALL-HAT.
Clinical trials, the renin angiotensin system and atrial fibrillation.
Combination therapy with amiodarone and enalapril in patients with paroxysmal atrial fibrillation prevents the development of structural atrial remodeling.
Contribution of the ACE (rs1799752) and CYP11B2 (rs1799998) Gene Polymorphisms to Atrial Fibrillation in the Tunisian Population.
Demographic determinants and effect of pre-operative angiotensin converting enzyme inhibitors and angiotensin receptor blockers on the occurrence of atrial fibrillation after CABG surgery.
Digoxin and clinical outcomes in systolic heart failure patients on contemporary background heart failure therapy.
Digoxin therapy in the elderly: pharmacokinetic considerations in nursing.
Does treatment with ACE inhibitors or angiotensin II receptor antagonists prevent atrial fibrillation after dual chamber pacemaker implantation?
Does treatment with ACE inhibitors prevent the long term recurrences of lone atrial fibrillation after cardioversion?
Effect of a do-not-resuscitate order on the quality of care in acute heart failure patients: a single-center cohort study.
Effect of Angiotensin converting enzyme inhibitors and Angiotensin receptor blockers on patients following ablation of atrial fibrillation.
Effect of Angiotensin-converting enzyme inhibitors and Angiotensin receptor blockers on risk of atrial fibrillation before coronary artery bypass grafting.
Effect of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers on the frequency of post-cardiothoracic surgery atrial fibrillation.
Effect of angiotensin-converting enzyme insertion/deletion genotype on collagen type I synthesis and degradation in patients with atrial fibrillation and arterial hypertension.
Effect of preoperative angiotensin converting enzyme inhibitor or angiotensin receptor blocker use on the frequency of atrial fibrillation after cardiac surgery: a cohort study from the atrial fibrillation suppression trials II and III.
Effect of propranolol versus no propranolol on total mortality plus nonfatal myocardial infarction in older patients with prior myocardial infarction, congestive heart failure, and left ventricular ejection fraction > or = 40% treated with diuretics plus angiotensin-converting enzyme inhibitors.
Effects of angiotensin-converting enzyme inhibition on the development of the atrial fibrillation substrate in dogs with ventricular tachypacing-induced congestive heart failure.
Effects of angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker on one-year outcomes of patients with atrial fibrillation: insights from a multicenter registry study in China.
Effects of lisinopril in patients with heart failure and chronic atrial fibrillation.
Effects of preoperative statin treatment on the incidence of postoperative atrial fibrillation in patients undergoing coronary artery bypass grafting.
Expression of extracellular signal-regulated kinase and angiotensin-converting enzyme in human atria during atrial fibrillation.
Genetic susceptibility to atrial fibrillation in patients with congestive heart failure.
Geriatric heart diseases in dogs.
Higher On-admission Serum Triglycerides Predict Less Severe Disability and Lower All-cause Mortality after Acute Ischemic Stroke.
Hospital variation and characteristics of implantable cardioverter-defibrillator use in patients with heart failure: data from the GWTG-HF (Get With The Guidelines-Heart Failure) registry.
Hyperuricemia treatment in acute heart failure patients does not improve their long-term prognosis: A propensity score matched analysis from the AHEAD registry.
Impact of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on the long-term outcome after pulmonary vein isolation for paroxysmal atrial fibrillation.
Impact of genetic variants on the upstream efficacy of renin-angiotensin system inhibitors for the prevention of atrial fibrillation.
Impact of ramipril on the incidence of atrial fibrillation: results of the Heart Outcomes Prevention Evaluation study.
Improving evidence-based care for heart failure in outpatient cardiology practices: primary results of the Registry to Improve the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting (IMPROVE HF).
Incidence and prognostic significance of atrial fibrillation in acute myocardial infarction: the GISSI-3 data.
Incidence, trends, and predictors of ischemic stroke 1 year after an acute myocardial infarction.
Increased expression of extracellular signal-regulated kinase and angiotensin-converting enzyme in human atria during atrial fibrillation.
Influence of dedicated heart failure clinics on delivery of recommended therapies in outpatient cardiology practices: findings from the Registry to Improve the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting (IMPROVE HF).
Influence of patient age and sex on delivery of guideline-recommended heart failure care in the outpatient cardiology practice setting: findings from IMPROVE HF.
Interactions Among Vitamin D, Atrial Fibrillation, and the Renin-Angiotensin-Aldosterone System.
Intravenous enalapril does not prevent tachycardia-induced acute atrial electrical remodeling.
Left ventricular systolic dysfunction and atrial fibrillation in older people in the community--a need for screening?
Long-term efficacy of upstream therapy using angiotensin-converting enzyme inhibitors and statins in combination with antiarrhythmic agents for the treatment of paroxysmal atrial fibrillation.
Matrix metalloproteinase-9/tissue inhibitors of metalloproteinase-1 expression and atrial structural remodeling in a dog model of atrial fibrillation: inhibition with angiotensin-converting enzyme.
Meta-analysis: inhibition of renin-angiotensin system prevents new-onset atrial fibrillation.
Molecular genetic studies in atrial fibrillation.
National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand: Australian clinical guidelines for the management of heart failure 2018.
NT-proBNP Response to Sacubitril/Valsartan in Hospitalized Heart Failure Patients With Reduced Ejection Fraction: TRANSITION Study.
Optimising stroke prevention in non-valvular atrial fibrillation.
Outpatient cardiology practices with advanced practice nurses and physician assistants provide similar delivery of recommended therapies (findings from IMPROVE HF).
Perindopril decreases P wave dispersion in patients with stage 1 hypertension.
Perioperative management of patients treated with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers: a quality improvement audit.
Polymorphisms of the angiotensin-converting enzyme and angiotensinogen gene in patients with atrial fibrillation.
Prediction on admission of in-hospital mortality in patients older than 70 years with acute myocardial infarction.
Predictors and Clinical Impact of Late Ventricular Arrhythmias in Patients With Continuous-Flow Left Ventricular Assist Devices.
Predictors of Acute Kidney Injury Following Surgical Valve Replacement.
Preoperative angiotensin-blocking drug therapy is not associated with atrial fibrillation after cardiac surgery.
Preoperative treatment with an angiotensin-converting enzyme inhibitor or an angiotensin receptor blocker has no beneficial effect on the development of new-onset atrial fibrillation after off-pump coronary artery bypass graft surgery.
Prevalence, predictors and prognosis of ventricular reverse remodeling in idiopathic dilated cardiomyopathy.
Prevention of atrial fibrillation by angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers.
Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis.
Prevention of atrial fibrillation with renin-angiotensin system inhibitors on essential hypertensive patients: a meta-analysis of randomized controlled trials.
Prevention of Recurrent Atrial Fibrillation With Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers: A Systematic Review and Meta-Analysis of Randomized Trials.
Primary prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with end-stage renal disease undergoing dialysis.
Prognostic value of the QRS duration in patients with heart failure: a subgroup analysis from 24 centers of Val-HeFT.
Quality of Care and Outcomes in Women Hospitalized for Heart Failure.
Quality of care for patients hospitalized with heart failure: assessing the impact of hospitalists.
Quantification of the risk and predictors of hyperkalemia in patients with left ventricular dysfunction: a retrospective analysis of the Studies of Left Ventricular Dysfunction (SOLVD) trials.
Reduced atrial fibrillation incidence by angiotensin-converting enzyme inhibitors: a possible contributing mechanism.
Relation between angiotensin-converting enzyme II genotype and atrial fibrillation in Japanese patients with hypertrophic cardiomyopathy.
Relationship between Angiotensin Converting Enzyme, Apelin, and New-Onset Atrial Fibrillation after Off-Pump Coronary Artery Bypass Grafting.
Relationship between the long-term preventive effect of combined treatment with antiarrhythmic drugs plus angiotensin-converting enzyme inhibitors and circadian variation in the onset of paroxysmal atrial fibrillation.
Renin-Angiotensin System Inhibitors Prevent the Recurrence of Atrial Fibrillation: A Meta-analysis of Randomized Controlled Trials.
Renin-Angiotensin System Inhibitors Prognostic Benefit in Older Patients With Atrial Fibrillation.
Review: Angiotensin converting enzyme inhibitors and angiotensin receptor blockers prevent atrial fibrillation.
Reviewing the future of renin-angiotensin system blockade: the role of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in the prevention of atrial fibrillation.
Risk factors for appropriate cardioverter-defibrillator shocks, inappropriate cardioverter-defibrillator shocks, and time to mortality in 549 patients with heart failure.
Risk for incident atrial fibrillation in patients who receive antihypertensive drugs: a nested case-control study.
Role of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in the management of atrial fibrillation.
Role of angiotensin-converting enzyme inhibitors in the prevention of atrial fibrillation.
Role of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and aldosterone antagonists in the prevention of atrial and ventricular arrhythmias.
Role of the renin-angiotensin-aldosterone system in atrial fibrillation and cardiac remodeling.
Sex-Related Characteristics, Quality of Care, and Short-Term Mortality Rates in Patient With Chronic Heart Failure.
Shock efficacy of single and dual coil electrodes-new insights from the NORDIC ICD Trial.
Short- and long-term mortality associated with new-onset atrial fibrillation after coronary artery bypass grafting: A systematic review and meta-analysis.
Statin use is independently associated with smaller infarct volume in nonlacunar MCA territory stroke.
Syncope in advanced heart failure: high risk of sudden death regardless of origin of syncope.
Target-organ protection with combination renin-angiotensin-system blockade.
The changing face of postoperative atrial fibrillation prevention: a review of current medical therapy.
The impact of suppressing the Renin-Angiotensin system on atrial fibrillation.
The Prognostic Value of High-Sensitive Troponin I in Stable Coronary Artery Disease Depends on Age and Other Clinical Variables.
The renin-angiotensin-aldosterone system (RAAS) and cardiac arrhythmias.
The role of angiotensin receptor blockers and/or angiotensin converting enzyme inhibitors in the prevention of atrial fibrillation in patients with cardiovascular diseases: meta-analysis of randomized controlled clinical trials.
The role of renin-angiotensin system blockade therapy in the prevention of atrial fibrillation: a meta-analysis of randomized controlled trials.
The role of the renin-angiotensin system blocking in the management of atrial fibrillation.
The underutilization of cardiac medications of proven benefit, 1990 to 2002.
The whole nine yards: multiple cardiac surgical and percutaneous interventions in a patient during 30 years of care.
Therapy with angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and statins: no effect on ablation outcome after ablation of atrial fibrillation.
Thrombosis and occlusion of vascular access in hemodialyzed patients.
Treatment and prevention of atrial fibrillation with nonantiarrhythmic pharmacologic therapy.
Upstream Effect for Atrial Fibrillation: Still a Dilemma?
Upstream Therapy for Atrial Fibrillation Prevention: The Role of Sacubitril/Valsartan.
Upstream therapy of atrial fibrillation.
Use of beta-blockers, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers to prevent atrial fibrillation.
Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: a prospective and randomized study.
Usefulness of acute delirium as a predictor of adverse outcomes in patients >65 years of age with acute decompensated heart failure.
[Characteristics of the patients with heart disease in a health area of A Coruña province. Barbanza 2000 study]
[Effects of angiotensin converting enzyme inhibitor on short time prognosis in patients with chronic heart failure combined with paroxysmal atrial fibrillation.]
[Effects of angiotensin converting enzyme inhibitor on the expression of angiotensin converting enzyme 2 in atrium of patients with atrial fibrillation]
[Efficiency of angiotensin-converting enzyme inhibitors in the maintenance of sinusal rythm after conversion of arterial fibrilation]
[Genetic aspects of atrial fibrillation in coronary artery disease patients].
[Intravenous enalapril does not prevent tachycardia-induced acute atrial electrical remodeling]
[Long-term efficacy of combination therapy using antiarrhythmic agents and angiotensin converting enzyme inhibitor in patients with paroxysmal and persistent atrial fibrillation: importance of the timing of administration]
[Modern therapy of cardiac insufficiency]
[Preventing cerebrovascular accidents during atrial fibrillation]
[Preventive strategy for atrial fibrillation in arterial hypertension]
[Recommendations for the treatment of heart failure : What's new?].
[Stroke and other thromboembolic complications of atrial fibrillation. Part v. The use of drugs without antithrombotic or antiarrhythmic properties.]
[Study on levels of angiotensin converting enzyme and C-reactive protein in peripheral blood of mitral valve Replacement preoperative patients with atrial fibrillation]
[Update cardiology 2006/2007]
[Upstream therapy of atrial fibrillation in patients with heart failure]
Atrial Flutter
Atrial fibrillation after radiofrequency ablation of atrial flutter: preventive effect of angiotensin converting enzyme inhibitors, angiotensin II receptor blockers, and diuretics.
Atrioventricular Block
COVID-19 and cardiac injury: clinical manifestations, biomarkers, mechanisms, diagnosis, treatment, and follow up.
[Angiotensin-converting enzyme gene polymorphism in patients with primary disturbances of cardiac conduction]
Autoimmune Diseases
Advances in upper airway diseases and allergen immunotherapy in 2007.
Allergy immunotherapy for inhalant allergens: Strategies to minimize adverse reactions.
An insertion/deletion polymorphism in the gene encoding angiotensin converting enzyme is not associated with generalised vitiligo in an English population.
Angioedema without urticaria: a large clinical survey.
Angiotensin converting enzyme (ACE) gene polymorphism in sarcoidosis in relation to associated autoimmune diseases.
Arguing the misconceptions in allergen-specific immunotherapy.
Association of angiotensin converting enzyme gene I/D polymorphism of vitiligo in Korean population.
Clinical Practice Guidelines for Diagnosis and Management of Hypersensitivity Reactions to Contrast Media.
Incidence and Risk Factors of Dry Eye in a Spanish Adult Population: 11-Year Follow-Up From the Salnés Eye Study.
Inhibition of renin angiotensin aldosterone system causes abrogation of obliterative airways disease through inhibition of tumor necrosis factor-?-dependant interleukin-17.
Pathophysiologic implications of angiotensin I-converting enzyme as a mechanosensor: diabetes.
The role of IL-4 gene 70bp VNTR and ACE gene I/D variants in Familial Mediterranean fever.
The serum angiotensin converting enzyme and lysozyme levels in patients with ocular involvement of autoimmune and infectious diseases.
Azoospermia
Association Between Polymorphisms in the Angiotensin-Converting Enzyme Gene and Non-Obstructive Azoospermia in the Chinese Han Population from Northeast China.
Azotemia
Advances in noninvasive screening for renovascular disease.
Atherosclerotic Renal Artery Stenosis.
Azotemia during chronic converting enzyme inhibition with enalapril in sodium-depleted rats: role of renal circulatory changes.
Concern for azotemia with angiotensin-converting enzyme inhibitors: public health implications and clinical relevance.
Ischemic renal disease: an emerging cause of chronic renal failure and end-stage renal disease.
Pathophysiology of experimental nephrotic syndrome induced by puromycin aminonucleoside in rats. I. The role of proteinuria, hypoproteinemia, and renin-angiotensin-aldosterone system on sodium retention.
Renal artery stenosis: a common, treatable cause of renal failure?
Renal effects of angiotensin converting enzyme inhibitors in heart failure: a clinician's guide to minimizing azotemia and diuretic-induced electrolyte imbalances.
Safety of angiotensin-converting enzyme inhibitors in patients with bilateral renal artery stenosis following successful renal artery stent revascularization.
The natural history of renal artery stenosis: who should be evaluated for suspected ischemic nephropathy?
The role of laboratory testing in the diagnosis of renovascular hypertension.
University of Miami Division of Clinical Pharmacology Therapeutic Rounds: ischemic renal disease.
[Worldwide experience with enalapril]
Bacteremia
Release of angiotensin converting enzyme by the lung after Pseudomonas bacteremia in sheep.
Bacterial Infections
Incidence and risk factors for early renal dysfunction after liver transplantation.
Bartter Syndrome
Acute kidney injury in type 3 Bartter syndrome: Angiotensin-converting enzyme inhibitors as a cause.
Angiotensin-converting enzyme inhibition as a therapeutic principle in Bartter's syndrome.
Hypotensive response to angiotensin I-converting enzyme inhibitor in Bartter's syndrome.
Independent roles of prostaglandins and the renin-angiotensin system in abnormal vascular reactivity in Bartter's syndrome.
[Case of hypokalemia similar to Bartter's syndrome, suggesting deficiency of angiotensin converting enzyme]
Behcet Syndrome
The serum angiotensin converting enzyme and lysozyme levels in patients with ocular involvement of autoimmune and infectious diseases.
Tumor necrosis factor (TNF)-308, -1031, and angiotensin-converting enzyme (ACE) DD/II polymorphisms' role in Behcet's disease with and without uveitis: a meta-analysis.
Berylliosis
Angiotensin-1 converting enzyme polymorphisms in chronic beryllium disease.
Serum angiotensin converting enzyme activity in chronic beryllium disease.
beta-Thalassemia
An angiotensin-converting enzyme inhibitor improves left ventricular systolic and diastolic function in transfusion-dependent patients with beta-thalassemia major.
Bicuspid Aortic Valve Disease
The Effect of Angiotensin-converting Enzyme Inhibitors on the Rate of Ascending Aorta Dilation in Patients with Bicuspid Aortic Valve.
Biliary Tract Diseases
[Activity of angiotensin converting enzyme I and levels of acid alpha glycoprotein in selected liver and biliary tract diseases]
Blister
Angiotensin converting enzyme and substance P changes in blister fluid following afferent nerve stimulation in the rat.
Oral bullous eruption after taking lisinopril--case report and literature review.
Bone Diseases
The skeletal renin-angiotensin system: A potential therapeutic target for the treatment of osteoarticular diseases.
Bone Diseases, Metabolic
Forearm endothelial function and bone mineral loss in postmenopausal women.
[Epidemiologic, clinical, biological and therapeutic aspects of Gaucher disease]
Bone Resorption
Angiotensin II is generated from angiotensin I by bone cells and stimulates osteoclastic bone resorption in vitro.
Zoledronic acid decreased osteolysis but not bone metastasis in a nude mouse model of canine prostate cancer with mixed bone lesions.
Brachydactyly
Quantitative trait loci for blood pressure exist near the IGF-1, the Liddle syndrome, the angiotensin II-receptor gene and the renin loci in man.
Bradycardia
A facilitatory effect of anti-angiotensin drugs on vagal bradycardia in the pithed rat and guinea-pig.
Atypical reactions associated with use of angiotensin-converting enzyme inhibitors and apheresis.
DuP 753 is more effective than captopril on baroreceptor function in high-renin hypertension.
Effect of long-term treatment with enalapril in streptozotocin diabetic and DOCA hypertensive rats.
Low-density lipoprotein apheresis for prevention and regression of atherosclerosis: clinical results.
Overexpression of AT2R in the solitary-vagal complex improves baroreflex in the spontaneously hypertensive rat.
Reversal of bradykinin-induced reflex tachycardia to bradycardia by captopril; evidence for prostacyclin involvement.
Short-term lisinopril treatment in old rats worsens impairment of angiotensin-induced reflex bradycardia.
Syncope caused by iatrogenic hyperkalemia.
Brain Diseases
Angiotensin-converting enzyme genotype and encephalopathy in Chernobyl cleanup workers.
Long-term prognosis after out-of-hospital cardiac arrest with/without ST elevation myocardial infarction.
Role of brain renin angiotensin system in neurodegeneration: An update.
Severe hepatic encephalopathy in a patient with liver cirrhosis after administration of angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker combination therapy: a case report.
Brain Edema
Losartan versus enalapril on cerebral edema and proteinuria in stroke-prone hypertensive rats.
Brain Infarction
ACE I/D polymorphism in Korean patients with ischemic stroke and silent brain infarction.
Comparison between angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on the risk of stroke recurrence and longitudinal progression of white matter lesions and silent brain infarcts on MRI (CEREBRAL study): rationale, design, and methodology.
Polymorphism of the angiotensin-converting enzyme (ACE) gene in patients with thrombotic brain infarction.
The Association Between Small Vessel Infarcts and the Activities of Amyloid-? Peptide Degrading Proteases in Apolipoprotein E4 AlleleCarriers.
[The relationship between angiotensin-converting enzyme gene polymorphism and brain infarction in Chinese hypertensives]
[The role of polymorphic variants of renin-angiotensin system genes in the development of ischemic stroke in Moscow population]
Brain Injuries
A Comparison of Ramipril and Bevacizumab to Mitigate Radiation-Induced Brain Necrosis: An Experimental Study.
Arginine vasopressin as a rescue vasopressor agent in the operating room.
Oxidative stress-associated hypertension in surgically induced brain injury patients: effects of ?-blocker and angiotensin-converting enzyme inhibitor.
Perindopril, a centrally active angiotensin-converting enzyme inhibitor, prevents cognitive impairment in mouse models of Alzheimer's disease.
Radiation Increases Bioavailability of Lisinopril, a Mitigator of Radiation-Induced Toxicities.
Renin-angiotensin System Blockers and Modulation of Radiation-induced Brain Injury.
Brain Injuries, Traumatic
Angiotensin-converting enzyme (ACE) inhibitors exacerbate histological damage and motor deficits after experimental traumatic brain injury.
Association of Angiotensin-Converting Enzyme Inhibitors with Increased Mortality Among Patients with Isolated Severe Traumatic Brain Injury.
Beneficial association of angiotensin-converting enzyme inhibitors and statins on the occurrence of possible Alzheimer's disease after traumatic brain injury.
Effect of angiotensin-converting enzyme tag single nucleotide polymorphisms on the outcome of patients with traumatic brain injury.
Influence of Angiotensin-converting enzyme polymorphism on neuropsychological subacute performance in moderate and severe traumatic brain injury.
Brain Ischemia
Blockade of central angiotensin AT(1) receptors improves neurological outcome and reduces expression of AP-1 transcription factors after focal brain ischemia in rats.
Candesartan but not ramipril pretreatment improves outcome after stroke and stimulates neurotrophin BNDF/TrkB system in rats.
Captopril improves neurologic outcome from incomplete cerebral ischemia in rats.
Effect of antihypertensive treatment on focal cerebral infarction.
Enalapril and moexipril protect from free radical-induced neuronal damage in vitro and reduce ischemic brain injury in mice and rats.
Influence of on-going treatment with angiotensin-converting enzyme inhibitor or angiotensin receptor blocker on the outcome of patients treated with intravenous rt-PA for ischemic stroke.
Neuroprotective Effect of Scutellarin on Ischemic Cerebral Injury by Down-Regulating the Expression of Angiotensin-Converting Enzyme and AT1 Receptor.
The angiotensin I converting enzyme inhibitors, captopril and Wy-44,655 attenuate the consequences of cerebral ischemia in renovascular hypertensive rats.
[Neuroprotective activity of angiotensin-converting enzyme inhibitors during cerebral ischemia]
Brain Neoplasms
Mechanisms of zoonotic severe acute respiratory syndrome coronavirus host range expansion in human airway epithelium.
Breast Cyst
Angiotensin-converting enzyme and enkephalinase in human breast cyst fluid.
Breast Neoplasms
A Cohort Study of Antihypertensive Medication Use and Breast Cancer Among Danish Women.
A cohort study of antihypertensive medication use and breast cancer among danish women.
A narrative review on the interaction between genes and the treatment of hypertension and breast cancer.
Administration of angiotensin-converting enzyme inhibitors and ?-blockers during adjuvant trastuzumab chemotherapy for nonmetastatic breast cancer: marker of risk or cardioprotection in the real world?
Angiotensin Converting Enzyme Inhibitors (ACEI) and doxorubicin pharmacokinetics in women receiving adjuvant breast cancer treatment.
Angiotensin Converting Enzyme Insertion/Deletion Polymorphism is Associated with Breast Cancer Risk: A Meta-Analysis
Angiotensin I-converting enzyme (ACE) gene polymorphism and breast cancer risk among Chinese women in Singapore.
Angiotensin Receptor Blockers Associated with Improved Breast Cancer Survival-A Nationwide Cohort Study from Finland.
Angiotensin-converting enzyme gene insertion/deletion polymorphism and breast cancer risk.
Angiotensin-converting enzyme inhibitors enhance the effect of cyclooxygenase inhibitors on breast cancer: a nationwide case-control study.
Angiotensin-converting enzyme inhibitors, calcium channel blockers, and breast cancer.
Anthracycline-induced cardiotoxicity prevention with angiotensin-converting enzyme inhibitor ramipril in women with low-risk breast cancer: results of a prospective randomized study.
Antihypertensive agents and the risk of breast cancer in women aged 55 years and older: a nested case-control study.
Antihypertensive medication use and incident breast cancer in women.
Assessment of risk factors for mortality in patients with cardiovascular disease and a history of treatment for malignancy.
Association between polymorphisms of the renin-angiotensin system genes and breast cancer risk: a meta-analysis.
Association between the angiotensin-converting enzyme (insertion/deletion) and angiotensin II type 1 receptor (A1166C) polymorphisms and breast cancer among Brazilian women.
Association between the polymorphism of the angiotensin-converting enzyme gene and tumor size of breast cancer in premenopausal patients.
Association of angiotensin I converting enzyme (insertion/deletion) and angiotensin II type 1 receptor (A1166C) polymorphisms with breast cancer prognostic factors in iranian population.
Association of angiotensin I converting enzyme insertion/deletion polymorphism with breast cancer: a meta-analysis.
Beta blockers and angiotensin-converting enzyme inhibitors' purported benefit on breast cancer survival may be explained by aspirin use.
Breast cancer and the renin-angiotensin system (RAS): Therapeutic approaches and related metabolic diseases.
Cross talk between COVID-19 and breast cancer.
Genetic variation in angiotensin I-converting enzyme (ACE) and breast cancer risk: the multiethnic cohort.
Hiding in plain view: the potential for commonly used drugs to reduce breast cancer mortality.
Inhibition of proliferation on some neoplastic cell lines-act of carvedilol and captopril.
Insertion/deletion (I/D) in the angiotensin-converting enzyme gene and breast cancer risk: lack of association in a meta- analysis.
Insertion/deletion polymorphism of the angiotensin i-converting enzyme gene in patients with breast cancer and effects on prognostic factors.
Lack of association of angiotensin-converting enzyme insertion/deletion polymorphism with breast cancer: An update meta-analysis based on 10405 subjects.
Lack of association of genetic polymorphisms of angiotensin converting enzyme 1 and angiotensin II type 1 receptor with breast cancer risk in Iranian population.
Polymorphisms in angiotensin II type 1 receptor and angiotensin I-converting enzyme genes and breast cancer risk among Chinese women in Singapore.
Potential role of Renin-Angiotensin-system for tumor angiogenesis in receptor negative breast cancer.
Predictive value of soluble ST-2 for changes of cardiac function and structure in breast cancer patients receiving chemotherapy.
Prevention of Trastuzumab and Anthracycline-induced Cardiotoxicity Using Angiotensin-converting Enzyme Inhibitors or ?-blockers in Older Adults With Breast Cancer.
Risk of Breast Cancer With Long-Term Use of Calcium Channel Blockers or Angiotensin-Converting Enzyme Inhibitors Among Older Women.
Role of the renin-angiotensin-aldosterone system and the glutathione S-transferase Mu, Pi and Theta gene polymorphisms in cardiotoxicity after anthracycline chemotherapy for breast carcinoma.
Statin Prescriptions and Breast Cancer Recurrence Risk: A Danish Nationwide Prospective Cohort Study.
The impact of renin-angiotensin system, angiotensin ? converting enzyme (insertion/deletion), and angiotensin ?? type 1 receptor (A1166C) polymorphisms on breast cancer survival in Iran.
The Role of Angiotensin-Converting Enzyme Inhibitors and ?-Blockers in Primary Prevention of Cardiac Dysfunction in Breast Cancer Patients.
Use of ?-blockers, angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and risk of breast cancer recurrence: a Danish nationwide prospective cohort study.
Use of antihypertensive medications and risk of adverse breast cancer outcomes in a SEER-Medicare population.
Use of beta-blockers, angiotensin-converting enzyme inhibitors and angiotensin receptor blockers and breast cancer survival: Systematic review and meta-analysis.
Bronchial Hyperreactivity
Angiotensin-converting enzyme inhibitors in patients with bronchial responsiveness and asthma.
Bronchial effects of alpha 2-adrenoceptor agonists and of other antihypertensive agents in asthma.
Bronchial hyperreactivity and cough due to angiotensin-converting enzyme inhibitors.
Bronchial hyperreactivity in patients who cough after receiving angiotensin converting enzyme inhibitors.
Bronchial hyperreactivity induced by angiotensin converting enzyme inhibitor.
[Bronchial hyperreactivity in cough associated with angiotensin converting enzyme inhibitors]
[Cough, bronchoconstriction and bronchial hyperreactivity in relation to treatment with angiotensin-converting enzyme]
Bronchial Spasm
Angiotensin converting enzyme inhibitors are not associated with respiratory complications or mortality after noncardiac surgery.
Bronchospasm and cough as adverse reactions to the ACE inhibitors captopril, enalapril and lisinopril. A controlled retrospective cohort study.
Drug-induced bronchospasm.
Dyspnoea, asthma, and bronchospasm in relation to treatment with angiotensin converting enzyme inhibitors.
[Iatrogenic drug-induced bronchospasm, cough, and bronchiolitis. Etiologic and physiopathologic aspects]
[Serum angiotensin converting enzyme (SACE) in patients with atopic bronchial asthma]
Bronchiectasis
Airway inflammation as an assessment of chronic nonproductive cough.
Pathophysiology and therapy of chronic cough.
Revised Korean Cough Guidelines, 2020: Recommendations and Summary statements.
The Korean Cough Guideline: Recommendation and Summary Statement.
Bronchiolitis
Revised Korean Cough Guidelines, 2020: Recommendations and Summary statements.
The Korean Cough Guideline: Recommendation and Summary Statement.
Bronchiolitis Obliterans
Targeting the angiotensin system in posttransplant airway obliteration: the antifibrotic effect of angiotensin converting enzyme inhibition.
Bronchitis
Activity of angiotensin I converting enzyme in sarcoidosis, atopic bronchial asthma and acute bronchitis.
Approaching chronic cough.
Chronic Cough: An Update.
CICADA: Cough in Children and Adults: Diagnosis and Assessment. Australian cough guidelines summary statement.
Cough: a worldwide problem.
Effectiveness of amitriptyline versus cough suppressants in the treatment of chronic cough resulting from postviral vagal neuropathy.
Pharmacotherapy of chronic cough in adults.
[Changes in the spectrum and frequency of causes for chronic cough: a retrospective analysis]
[Efficiency of ramipril treatment in patients with chronic obstructive bronchitis complicated by chronic cor pulmonale]
[Etiological diagnosis and specific treatment of chronic cough in 106 patients]
[Novel approach to respiratory pharmacology--pharmacological basis of cough, sputum and airway clearance]
Bronchitis, Chronic
Airway inflammation as an assessment of chronic nonproductive cough.
Chronic Cough: An Update.
Kininase II in bronchoalveolar lavage fluid and serum of patients with pulmonary disorders.
Pathophysiology and therapy of chronic cough.
Revised Korean Cough Guidelines, 2020: Recommendations and Summary statements.
Serum angiotensin converting enzyme activity in cigarette smokers.
The Korean Cough Guideline: Recommendation and Summary Statement.
[Unrecognized causes of chronic cough]
Bronchopulmonary Dysplasia
Angiotensin-converting enzyme D allele does not influence susceptibility to acute hypoxic respiratory failure in children.
Deletion allele of angiotensin-converting enzyme is associated with increased risk and severity of bronchopulmonary dysplasia.
Genetic Contributions to the Development of Complications in Preterm Newborns.
Polymorphisms in the Renin-Angiotensin System and Outcome of Very-Low-Birthweight Infants.
The Angiotensin Converting Enzyme Insertion/Deletion polymorphism is not associated with an increased risk of death or bronchopulmonary dysplasia in ventilated very low birth weight infants.
The ontogeny of human pulmonary angiotensin-converting enzyme and its aberrant expression may contribute to the pathobiology of bronchopulmonary dysplasia (BPD).
The role of plasminogen activator inhibitor-1 and angiotensin-converting enzyme gene polymorphisms in bronchopulmonary dysplasia.
Brucellosis
Severe uveitis in an HLA-B27-positive patient with ankylosing spondylitis.
Bundle-Branch Block
Absence of left bundle branch block and blood urea nitrogen predict improvement in left ventricular ejection fraction in patients with cardiomyopathy and wearable cardioverter defibrillators.
Effect of antihypertensive therapy on development of incident conduction system disease in hypertensive patients.
Heart failure in patients with preserved and deteriorated left ventricular ejection fraction.
Prediction on admission of in-hospital mortality in patients older than 70 years with acute myocardial infarction.
Prevalence, predictors and prognosis of ventricular reverse remodeling in idiopathic dilated cardiomyopathy.
[Prevention and treatment of ischemic heart disease in patients with diabetes mellitus]
[Recommendations for the treatment of heart failure : What's new?].
Burning Mouth Syndrome
Burning Mouth Syndrome Induced by Angiotensin-Converting Enzyme Inhibitors.
Calcinosis
Labeled lectin studies of renal tubular dysgenesis and renal tubular atrophy of postnatal renal ischemia and end-stage kidney disease.
Carcinogenesis
Amelioration of carcinogenesis and tumor growth in the rat liver by combination of vitamin K2 and angiotensin-converting enzyme inhibitor via anti-angiogenic activities.
Angiotensin II Type 1 Receptor Antagonist as an Angiogenic Inhibitor in Urogenital Cancer.
Angiotensin-converting enzyme insertion/deletion polymorphism and the risk of prostate cancer in the Han population of China.
Angiotensinogen polymorphism is associated with risk for malignancy but not for oral cancer.
Combination of interferon and angiotensin-converting enzyme inhibitor, perindopril, suppresses liver carcinogenesis and angiogenesis in mice.
Inhibition of renin-angiotensin system affects prognosis of advanced pancreatic cancer receiving gemcitabine.
Inhibition of renin-angiotensin system attenuates liver enzyme-altered preneoplastic lesions and fibrosis development in rats.
Interaction of renin-angiotensin system and adenosine monophosphate-activated protein kinase signaling pathway in renal carcinogenesis of uninephrectomized rats.
Lactobacilli as multifaceted probiotics with poorly disclosed molecular mechanisms.
No association between ACE olymorphism and risk of nasopharyngeal carcinoma.
No association between angiotensin I converting enzyme (ACE) I/D polymorphism and gastric cancer risk among Japanese.
Role of renin-angiotensin system in gastric oncogenesis.
[Combination therapies using cyclooxygenase-2 inhibitors and angiotensin-converting enzyme inhibitors in colon carcinogenesis]
Carcinoid Tumor
Arginine vasopressin as a rescue vasopressor agent in the operating room.
Carcinoma
Analysis of the susceptibility of lung cancer patients to SARS-CoV-2 infection.
Angiotensin Blockade Modulates the Activity of PD1/L1 Inhibitors in Metastatic Urothelial Carcinoma.
Angiotensin converting enzyme. A possible histologic indicator for human renal cell carcinoma.
Angiotensin I-converting enzyme gene plays a crucial role in the pathology of carcinomas in colorectal cancer.
Angiotensin system inhibitors and survival in patients with metastatic renal cell carcinoma treated with VEGF-targeted therapy: A pooled secondary analysis of clinical trials.
Angiotensin-converting enzymes (ACE and ACE2) as potential targets for Malignant Epithelial Neoplasia: Review and bioinformatics analyses focused in Oral Squamous Cell Carcinoma.
Angiotensin-I converting enzyme inhibitors suppress angiogenesis and growth of esophageal carcinoma xenografts.
Association of angiotensin-converting enzyme gene insertion/deletion polymorphism with decreased risk for basal cell carcinoma.
Association of Polymorphisms in the Genes of Angiotensinogen and Angiotensin Receptors With Risk for Basal Cell Carcinoma.
Association study indicates combined effect of interleukin-10 and angiotensin-converting enzyme in basal cell carcinoma development.
AT1 receptor and ACE mRNA are increased in chemically induced carcinoma of rat mammary gland.
Biochemical and functional markers of lung damage after bleomycin treatment.
Cancer stem cells within moderately differentiated head and neck cutaneous squamous cell carcinoma express components of the renin-angiotensin system.
Characterization and immunohistologic demonstration of angiotensin-converting enzyme in human renal cell carcinoma.
Choroidal granuloma in sarcoidosis.
COVID-19 and Kidney Disease: Molecular Determinants and Clinical Implications in Renal Cancer.
Effects of the angiotensin-I converting enzyme inhibitor perindopril on tumor growth and angiogenesis in head and neck squamous cell carcinoma cells.
Hypertension and Angiotensin System Inhibitors in Patients with Metastatic Renal Cell Carcinoma.
Insertion/Deletion Polymorphism of Angiotensin I-converting Enzyme Gene Is Linked With Chromophobe Renal Cell Carcinoma.
Localisation of renin-angiotensin system (RAS) components in breast.
Melanoma and Non-Melanoma Skin Cancer Associated with Angiotensin-Converting-Enzyme Inhibitors, Angiotensin-Receptor Blockers and Thiazides: A Matched Cohort Study.
Oxidant, vitamin A and angiogenic markers in laryngeal cancer patients.
Prognostic impact of renin-angiotensin system blockade in esophageal squamous cell carcinoma.
Renal therapeutics: patent highlights January to June 2003.
Risk of Nonmelanoma Skin Cancer in Association With Use of Hydrochlorothiazide-Containing Products in the United States.
Serum angiotensin converting enzyme activity in cigarette smokers.
The association between ACE polymorphism and risk of colorectal cancer in a Chinese population.
The role of drugs and selected dietary factors in cutaneous squamous cell carcinogenesis.
Transforming growth factor-beta-1 is a serum biomarker of radiation-induced pneumonitis in esophageal cancer patients treated with thoracic radiotherapy: preliminary results of a prospective study.
Use of antihypertensive drugs and risk of keratinocyte carcinoma: A meta-analysis of observational studies.
[Matrix metalloproteinases 2 and 9, their endogenous regulators, and angiotensin-converting enzyme in cervical squamous cell carcinoma].
[Serum angiotensin converting enzyme in patients with primary liver carcinoma]
Carcinoma, Basal Cell
Association of angiotensin-converting enzyme gene insertion/deletion polymorphism with decreased risk for basal cell carcinoma.
Association of Polymorphisms in the Genes of Angiotensinogen and Angiotensin Receptors With Risk for Basal Cell Carcinoma.
Association study indicates combined effect of interleukin-10 and angiotensin-converting enzyme in basal cell carcinoma development.
Risk of Nonmelanoma Skin Cancer in Association With Use of Hydrochlorothiazide-Containing Products in the United States.
Carcinoma, Bronchogenic
Alterations of serum carboxypeptidases N and angiotensin-I-converting enzyme in malignant diseases.
Plasma angiotensin-converting enzyme activity in patients with bronchial carcinoma.
[Angiotensin-converting enzyme activity during cytostatic therapy in patients with primary inoperable bronchial carcinoma]
Carcinoma, Ductal, Breast
Captopril modulates hormone receptor concentration and inhibits proliferation of human mammary ductal carcinoma cells in culture.
Carcinoma, Hepatocellular
Activity of serum angiotensin-converting enzyme as a tumour marker of hepatocellular carcinoma.
Angiotensin converting enzyme inhibitors and hepatocellular carcinoma incidence in the General Practice Research Database.
Angiotensin converting enzyme-independent, local angiotensin II-generation in human pancreatic ductal cancer tissues.
Angiotensin-converting enzyme inhibitors have adverse effects in anti-angiogenesis therapy for hepatocellular carcinoma.
Angiotensin-I-converting enzyme inhibitors may be an alternative anti-angiogenic strategy in the treatment of liver fibrosis and hepatocellular carcinoma. Possible role of vascular endothelial growth factor.
Combination of branched-chain amino acids and angiotensin-converting enzyme inhibitor suppresses the cumulative recurrence of hepatocellular carcinoma: A randomized control trial.
Combination of interferon-beta and the angiotensin-converting enzyme inhibitor, perindopril, attenuates murine hepatocellular carcinoma development and angiogenesis.
Combination of vitamin K2 and angiotensin-converting enzyme inhibitor ameliorates cumulative recurrence of hepatocellular carcinoma.
Comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in chemoprevention of hepatocellular carcinoma: a nationwide high-risk cohort study.
Ectopeptidases are differentially expressed in hepatocellular carcinomas.
Effects of angiotensin II type 2 receptor overexpression on the growth of hepatocellular carcinoma cells in vitro and in vivo.
In vitro evidence for an intracellular site of angiotensin action.
Influence of angiotensin I-converting enzyme gene polymorphism on hepatocellular carcinoma risk in China.
Possible Involvement of Angiogenesis in Chronic Liver Disease: Interaction among Renin-Angiotensin-Aldosterone System, Insulin Resistance and Oxidative Stress.
Relationship between polymorphism of angiotensin-converting enzyme gene insertion/deletion and risk of hepatocellular carcinoma in a Chinese Dai population.
Soluble VEGF receptor-2 may be a predictive marker of anti-angiogenic therapy with clinically available safe agents.
Synergistic inhibition of hepatocellular carcinoma growth and hepatocarcinogenesis by combination of 5-fluorouracil and angiotensin-converting enzyme inhibitor via anti-angiogenic activities.
[Intrinsic angiotensin II-generating system in human pancreatic cancer tissues]
Carcinoma, Non-Small-Cell Lung
Do angiotensin-converting enzyme inhibitors reduce the risk of symptomatic radiation pneumonitis in patients with non-small cell lung cancer after definitive radiation therapy? Analysis of a single-institution database.
Renin-Angiotensin system blockers may prolong survival of metastatic non-small cell lung cancer patients receiving erlotinib.
The Angiotensin-Converting Enzyme Inhibitory State Promotes the Transformation of Non-Small Cell Lung Cancer Blood Supply Pattern Toward Vasculogenic Mimicry Formation.
Carcinoma, Ovarian Epithelial
Assessment of serum angiotensin-converting enzyme in patients with epithelial ovarian cancer.
Association of angiotensin-converting enzyme I gene I/D polymorphism with endometrial but not with ovarian cancer.
Carcinoma, Renal Cell
Angioedema in a patient with renal cell cancer treated with everolimus in combination with an angiotensin-converting enzyme inhibitor.
Angiotensin converting enzyme. A possible histologic indicator for human renal cell carcinoma.
Angiotensin system inhibitors and survival in patients with metastatic renal cell carcinoma treated with VEGF-targeted therapy: A pooled secondary analysis of clinical trials.
Characterization and immunohistologic demonstration of angiotensin-converting enzyme in human renal cell carcinoma.
COVID-19 and Kidney Disease: Molecular Determinants and Clinical Implications in Renal Cancer.
Hypertension and Angiotensin System Inhibitors in Patients with Metastatic Renal Cell Carcinoma.
Insertion/Deletion Polymorphism of Angiotensin I-converting Enzyme Gene Is Linked With Chromophobe Renal Cell Carcinoma.
Renal therapeutics: patent highlights January to June 2003.
Carcinoma, Squamous Cell
Analysis of the susceptibility of lung cancer patients to SARS-CoV-2 infection.
Cancer stem cells within moderately differentiated head and neck cutaneous squamous cell carcinoma express components of the renin-angiotensin system.
Effects of smokeless tobacco on chemically transformed hamster oral keratinocytes: role of angiotensin I-converting enzyme.
Effects of the angiotensin-I converting enzyme inhibitor perindopril on tumor growth and angiogenesis in head and neck squamous cell carcinoma cells.
Melanoma and Non-Melanoma Skin Cancer Associated with Angiotensin-Converting-Enzyme Inhibitors, Angiotensin-Receptor Blockers and Thiazides: A Matched Cohort Study.
Risk of Nonmelanoma Skin Cancer in Association With Use of Hydrochlorothiazide-Containing Products in the United States.
Structural variations and expression profiles of the SARS-CoV-2 host invasion genes in lung cancer.
The role of drugs and selected dietary factors in cutaneous squamous cell carcinogenesis.
Use of antihypertensive drugs and risk of keratinocyte carcinoma: A meta-analysis of observational studies.
[Matrix metalloproteinases 2 and 9, their endogenous regulators, and angiotensin-converting enzyme in cervical squamous cell carcinoma].
Cardiac Tamponade
Total peripheral resistance during cardiac tamponade: adrenergic and angiotensin roles.
Cardio-Renal Syndrome
Addressing the challenges of cardiorenal syndrome.
Impact of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers on Renal Function in Type 1 Cardiorenal Syndrome.
Cardiomegaly
A local kallikrein-kinin system is present in rat hearts.
A newly developed angiotensin II type 1 receptor antagonist, CS866, promotes regression of cardiac hypertrophy by reducing integrin beta1 expression.
ACE inhibitors and cardiac ACE mRNA in volume overload-induced cardiac hypertrophy.
Acute and long-term effects of angiotensin converting enzyme inhibition on larger arteries and cardiac hypertrophy: mechanical and structural parameters.
Acute and long-term response to enalapril in congestive failure.
Age-related increase in sensitivity for ischemic ATP breakdown in hypertrophic hearts of SHR normalized by enalapril.
Angiotensin blocking drugs and the heart beyond 2000.
Angiotensin converting enzyme inhibition for cardiac hypertrophy in patients with end-stage renal disease: what is the evidence?
Angiotensin converting enzyme inhibitor, captopril, inhibits cardiac hypertrophy without changing collagen types and concentration in spontaneously hypertensive rats.
Angiotensin converting enzyme is involved in the cardiac hypertrophy induced by sinoaortic denervation in rats.
Angiotensin II type 1 receptor gene polymorphisms in patients with cardiac hypertrophy.
Angiotensin-Converting Enzyme 3 (ACE3) Protects Against Pressure Overload-Induced Cardiac Hypertrophy.
Angiotensin-converting enzyme and angiotensinogen gene polymorphism in hypertrophic cardiomyopathy.
Angiotensin-converting enzyme and heart chymase gene polymorphisms in hypertrophic cardiomyopathy.
Angiotensin-converting enzyme gene polymorphism, left ventricular remodeling, and exercise capacity in strength-trained athletes.
Angiotensin-converting enzyme inhibition and salt in experimental myocardial infarction.
Angiotensin-converting enzyme inhibition, intracellular Na+, and Na(+)-K+ pumping in cardiac myocytes.
Angiotensin-converting enzyme inhibitor suppresses activation of calcineurin in renovascular hypertensive rats.
Angiotensin-I converting enzyme genotypes and left ventricular hypertrophy in patients with hypertrophic cardiomyopathy.
Antagonism of the renin-angiotensin system, hypertrophy and gene expression in cardiac myocytes.
Antihypertensive effect of Carica papaya via a reduction in ACE activity and improved baroreflex.
Augmented sphingosine 1 phosphate receptor-1 signaling in cardiac fibroblasts induces cardiac hypertrophy and fibrosis through angiotensin II and interleukin-6.
Captopril prevents ventricular hypertrophy in sinoaortic denervated rats.
Cardiac angiotensin converting enzyme and endothelin receptor in rats with chronic myocardial infarction.
Cardiac hypertrophy in experimental hypertension: interaction of the sodium ion, blood pressure and lisinopril.
Cardioprotective action of perindopril versus candesartan in renovascular hypertensive rats.
Cardioprotective effects of an angiotensin-converting-enzyme inhibitor, imidapril, and Ca2+ channel antagonist, amlodipine, in spontaneously hypertensive rats at established stage of hypertension.
Cardiovascular adaptation, functional capacity and Angiotensin-converting enzyme I/D polymorphism in elite athletes.
Cardiovascular adaptation, functional capacity, and Angiotensin-converting enzyme i/d polymorphism in elite athletes.
Cardiovascular effects of captopril and enalapril in obese Zucker rats.
Carotid thickening, cardiac hypertrophy, and angiotensin converting enzyme gene polymorphism in patients with hypertension.
Chronic AT1 receptor blockade and angiotensin-converting enzyme (ACE) inhibition in (CHF 146) cardiomyopathic hamsters: effects on cardiac hypertrophy and survival.
Chronic captopril and losartan (DuP 753) administration in rats with high-output heart failure.
Chronic low-dose treatment with enalapril induced cardiac regression of left ventricular hypertrophy.
Cilazapril prevents the development of cardiac hypertrophy and the decrease of coronary vascular reserve in spontaneously hypertensive rats.
Clinical characteristics and prognosis of hospitalised inpatients with heart failure and preserved or reduced left ventricular ejection fraction.
Collagen phenotypes during development and regression of myocardial hypertrophy in spontaneously hypertensive rats.
Combined effects of low-dose spironolactone and captopril therapy in a rat model of genetic hypertrophic cardiomyopathy.
Combined renin-angiotensin system blockade and dietary sodium restriction impairs cardiomyocyte contractility.
Comparative effects of angiotensin converting enzyme inhibition (perindopril) or diuretic therapy on cardiac hypertrophy and sympathetic activity following myocardial infarction in rats.
Comparative proteomic analysis of rat left ventricle in a subtotal nephrectomy model.
Comparison of irbesartan with captopril effects on cardiac hypertrophy and gene expression in heart failure-prone male SHHF/Mcc-fa(cp) rats.
Comparison of the angiotensin II type 1-receptor antagonist YM358 and the angiotensin-converting enzyme inhibitor enalapril in rats with cardiac volume overload.
Continuous versus intermittent angiotensin converting enzyme inhibition in renal hypertensive rats.
Different effects of an angiotensin converting enzyme inhibitor and a calcium antagonist on protein metabolism in rats with right ventricular hypertrophy.
Different pathophysiology of cardiac hypertrophy in hypertension and hypertrophic cardiomyopathy.
Diverse effects of Ace inhibitors and angiotensin II receptor antagonists on prevention of cardiac hypertrophy and collagen distribution in spontaneously hypertensive rats.
Early expression of monocyte chemoattractant protein-1 correlates with the onset of isoproterenol-induced cardiac fibrosis in rats with distinct angiotensin-converting enzyme polymorphism.
Effect of an ACE inhibitor and an AT1 receptor antagonist on cardiac hypertrophy.
Effect of angiotensin converting enzyme inhibitor on regression in cardiac hypertrophy.
Effect of benazepril hydrochloride on cardiac hypertrophy in spontaneously hypertensive rats.
Effect of valsartan and fosinopril on catecholamine-induced cardiac hypertrophy.
Effects of alatriopril, a mixed inhibitor of atriopeptidase and angiotensin I-converting enzyme, on cardiac hypertrophy and hormonal responses in rats with myocardial infarction. Comparison with captopril.
Effects of angiotensin AT1 receptor antagonist on volume overload-induced cardiac gene expression in rats.
Effects of angiotensin-converting enzyme inhibition and angiotensin II AT1 receptor antagonism on cardiac parameters in left ventricular hypertrophy.
Effects of angiotensin-converting enzyme polymorphism on aortic elastic parameters in athletes.
Effects of captopril on cardiac and renal damage, and metabolic alterations in the nitric oxide-deficient hypertensive rat.
Effects of captopril or nitrendipine on left ventricular collagen or laminin B2 gene expression.
Effects of chronic ACE inhibition on cardiac hypertrophy and coronary vascular reserve in spontaneously hypertensive rats with developed hypertension.
Effects of combination of irbesartan and perindopril on calcineurin expression and sarcoplasmic reticulum Ca(2+)-ATPase activity in rat cardiac pressure-overload hypertrophy.
Effects of enalapril versus losartan on regression of volume overload-induced cardiac hypertrophy in rats.
Effects of eprosartan on renal function and cardiac hypertrophy in rats with experimental heart failure.
Effects of Medium-chain Triglyceride (MCT) Application to SHR on Cardiac Function, Hypertrophy and Expression of Endothelin-1 mRNA and other Genes.
Effects of quinapril, losartan and hydralazine on cardiac hypertrophy and beta-adrenergic neuroeffector mechanisms in transgenic (mREN2)27 rats.
Effects of simvastatin on activities of endogenous antioxidant enzymes and angiotensin-converting enzyme in rat myocardium with pressure-overload cardiac hypertrophy.
Effects of subchronic treatment with trandolapril and enalapril on cardiovascular morphologic alterations in the aged spontaneously hypertensive rat with heart failure.
Effects of temocapril and olmesartan on myocardial sympathetic nervous activity and fatty acid metabolism in rats with chronic beta-adrenergic stimulation.
Effects of the novel dual inhibitor of neutral endopeptidase and angiotensin-converting enzyme, CGS 30440, on blood pressure and cardiac hypertrophy in spontaneously hypertensive rats.
Effects of two angiotensin converting enzyme inhibitors and hydralazine on coronary circulation in hypertensive rats.
Enalapril induces regression of cardiac hypertrophy and normalization of pHi regulatory mechanisms.
Evaluation of the renin-angiotensin system in cardiac tissues of cats with pressure-overload cardiac hypertrophy.
Expressions of bradykinin B2-receptor, kallikrein and kininogen mRNAs in the heart are altered in pressure-overload cardiac hypertrophy in mice.
Extracellular matrix and cardiovascular diseases.
Genetic variation in angiotensin-converting enzyme does not prevent development of cardiac hypertrophy or upregulation of angiotensin II in response to aortocaval fistula.
Heart failure in patients with preserved and deteriorated left ventricular ejection fraction.
Human cardiac fibroblasts and receptors for angiotensin II and bradykinin: a potential role for bradykinin in the modulation of cardiac extracellular matrix.
In vivo evidence of the importance of cardiac angiotensin-converting enzyme in the pathogenesis of cardiac hypertrophy.
Increase in nitric oxide and reductions in blood pressure, protein kinase C beta II and oxidative stress by L-carnitine: a study in the fructose-fed hypertensive rat.
Increased brain angiotensin receptor in rats with chronic high-output heart failure.
Influence of ACE I/D genotypes on left ventricular hypertrophy in aortic stenosis: gender-related differences.
Influence of angiotensinogen and angiotensin-converting enzyme polymorphisms on cardiac hypertrophy and improvement on maximal aerobic capacity caused by exercise training.
Influence of enalapril on established pressure-overload cardiac hypertrophy in low and normal renin states in female rats.
Inhibition of the renin-angiotensin system ameliorates genetically determined hyperinsulinemia.
Interaction between neutral endopeptidase and angiotensin converting enzyme inhibition in rats with myocardial infarction: effects on cardiac hypertrophy and angiotensin and bradykinin peptide levels.
Interaction between the renin-angiotensin system and insulin-like growth factor I in aorto-caval fistula-induced cardiac hypertrophy in rats.
Intracardiac angiotensin-converting enzyme inhibition improves diastolic function in patients with left ventricular hypertrophy due to aortic stenosis.
Isoproterenol-induced cardiac hypertrophy: role of circulatory versus cardiac renin-angiotensin system.
Long-term effect of N-acetyl-seryl-aspartyl-lysyl-proline on left ventricular collagen deposition in rats with 2-kidney, 1-clip hypertension.
Low and high doses of oxandrolone promote pathological cardiac remodeling in young male rats.
Managing hypertension in high-risk patients: lessons and promises from the STRATHE and ADVANCE trials.
Modulation of adrenergic receptors during left ventricular hypertrophy development and after regression by captopril.
Modulation of in vivo cardiac hypertrophy with insulin-like growth factor-1 and angiotensin-converting enzyme inhibitor: relationship between change in myosin isoform and progression of left ventricular dysfunction.
Myocardial blood flow in patients with hypertrophic cardiomyopathy receiving perindopril (CARAPaCE): a pilot study.
Non-corresponding effects of an angiotensin-converting enzyme inhibitor on cardiac and vascular hypertrophy in spontaneously hypertensive rats.
Oestrogen action on the myocardium in vivo: specific and permissive for angiotensin-converting enzyme inhibition.
Overexpression of angiotensin II type I receptor in cardiomyocytes induces cardiac hypertrophy and remodeling.
Paricalcitol Downregulates Myocardial Renin-Angiotensin and Fibroblast Growth Factor Expression and Attenuates Cardiac Hypertrophy in Uremic Rats.
Plasma aldosterone concentrations are not related to the degree of angiotensin-converting enzyme inhibition in essential hypertensive patients.
Pressure overload per se rather than cardiac angiotensin converting enzyme activity may be important in the development of rat cardiac hypertrophy.
Prevention of remodeling of the heart after myocardial infarction.
Prorenin/renin receptor, signals, and therapeutic efficacy of receptor blocker in end-organ damage.
Protective action of angiotensin converting enzyme inhibitors on cardiac hypertrophy in the aortic-banded rat.
Protein kinase C betaII activation induces angiotensin converting enzyme expression in neonatal rat cardiomyocytes.
Quinapril, an angiotensin converting enzyme inhibitor, prevents cardiac hypertrophy during episodic hypertension.
Ramipril prevents left ventricular hypertrophy with myocardial fibrosis without blood pressure reduction: a one year study in rats.
Regression of cardiac hypertrophy after therapy in animal hypertension.
Regression of cardiac hypertrophy in spontaneously hypertensive rats by enalapril and the expression of contractile proteins.
Regression of left ventricular hypertrophy and prevention of left ventricular dysfunction by captopril in the spontaneously hypertensive rat.
Regulation of atrial contraction by PKA and PKC during development and regression of eccentric cardiac hypertrophy.
Regulation of extracellular matrix proteins in pressure-overload cardiac hypertrophy: effects of angiotensin converting enzyme inhibition.
Regulation of insulin-like growth factor-1 by the renin-angiotensin system during regression of cardiac eccentric hypertrophy through angiotensin-converting enzyme inhibitor and AT1 antagonist.
Relevance of blockade of cardiac and circulatory angiotensin-converting enzyme for the prevention of volume overload-induced cardiac hypertrophy.
Renin-angiotensin inhibition reverses advanced cardiac remodeling in aging spontaneously hypertensive rats.
Renin-angiotensin system and minoxidil-induced cardiac hypertrophy in rats.
Renin-angiotensin system, hypertrophy and gene expression in cardiac myocytes.
Reversal of cardiac hypertrophy and fibrosis by S21402, a dual inhibitor of neutral endopeptidase and angiotensin converting enzyme in SHRs.
Role of the cardiac renin-angiotensin system in human heart failure.
Significant target organs for hypertension and cardiac hypertrophy by angiotensin-converting enzyme inhibitors.
Simvastatin inhibits cardiac hypertrophy and angiotensin-converting enzyme activity in rats with aortic stenosis.
Small gene effect and exercise training-induced cardiac hypertrophy in mice: an Ace gene dosage study.
Sub-antihypertensive doses of ramipril normalize sarcoplasmic reticulum calcium ATPase expression and function following cardiac hypertrophy in rats.
Substrate metabolism, hormone interaction, and angiotensin-converting enzyme inhibitors in left ventricular hypertrophy.
Sustained haemodynamic effects of enalapril in left ventricular failure.
Synergistic effect of angiotensin-converting enzyme and angiotensinogen gene on cardiac hypertrophy.
Temporal relationships of treatment with angiotensin converting enzyme inhibitors on the hypertension and cardiac hypertrophy in spontaneously hypertensive rats.
The angiotensin-converting enzyme inhibitor, perindopril, prevents cardiac hypertrophy in low-renin hypertensive rats.
The benefits of soluble non-bacterial fraction of kefir on blood pressure and cardiac hypertrophy in hypertensive rats are mediated by an increase in baroreflex sensitivity and decrease in angiotensin-converting enzyme activity.
The need for combination antihypertensive therapy to reach target blood pressures: what has been learned from clinical practice and morbidity-mortality trials?
The progression from hypertension to heart failure.
The renin-angiotensin system and experimental heart failure.
The renin-angiotensin system and volume overload-induced cardiac hypertrophy in rats. Effects of angiotensin converting enzyme inhibitor versus angiotensin II receptor blocker.
The renin-angiotensin-aldosterone system (RAAS) and cardiac arrhythmias.
Tissue Angiotensin-converting enzyme activity plays an important role in pressure overload-induced cardiac fibrosis in rats.
Trandolapril dose-response in spontaneously hypertensive rats: effects on ACE activity, blood pressure, and cardiac hypertrophy.
Transforming growth factor beta 1 and extracellular matrix gene expression in isoprenaline induced cardiac hypertrophy: effects of inhibition of the renin-angiotensin system.
Vascular smooth muscle polyploidy and cardiac hypertrophy in genetic hypertension.
[Alteration of atrial natriuretic peptide in progressive muscular dystrophy with congestive heart failure]
[Angiotensin-converting-enzyme inhibitor and heart hypertrophy]
[Regression of hypertensive heart hypertrophy caused by chronic angiotensin-converting enzyme inhibition]
[Renin-angiotensin system inhibition and cardiac and renal alteration induced by a high sodium diet in rat]
[Synthesis of renin and angiotensin-converting enzyme in human heart]
Cardiomyopathies
A randomized, double-blind trial of lisinopril and losartan for the treatment of cardiomyopathy in duchenne muscular dystrophy.
Amyloid Cardiomyopathy in the Emergency Department.
Angiotensin receptor antagonism and angiotensin converting enzyme inhibition improve diastolic dysfunction and Ca(2+)-ATPase expression in the sarcoplasmic reticulum in hypertensive cardiomyopathy.
Angiotensin-converting enzyme gene polymorphism influences degree of left ventricular hypertrophy and its regression in patients undergoing operation for aortic stenosis.
Angiotensin-converting enzyme in the human heart. Effect of the deletion/insertion polymorphism.
Angiotensin-converting enzyme inhibitor captopril prevents volume overload cardiomyopathy in experimental chronic aortic valve regurgitation.
Anthracycline induced cardiomyopathy: successful treatment with angiotensin converting enzyme inhibitors.
Anthracycline-induced cardiomyopathy.
Association of angiotensin converting enzyme gene polymorphism with tachycardia cardiomyopathy.
Association of angiotensin-converting enzyme activity and polymorphism with echocardiographic measures in familial and nonfamilial hypertrophic cardiomyopathy.
Beneficial effect of angiotensin-converting enzyme inhibitor on dilated cardiomyopathy induced by autoimmune mechanism against beta1-adrenoceptor.
Beneficial effects of angiotensin-converting enzyme inhibition in adriamycin-induced cardiomyopathy in hamsters.
Bromocriptine use for sudden peripartum cardiomyopathy in a patient with preeclampsia: a case report.
Captopril prevents experimental autoimmune myocarditis.
Cardiac management in neuromuscular diseases.
Cardiac resynchronization therapy: A comparative analysis of mortality in african-americans and caucasians.
Cardiac Toxicity: Using Angiotensin-Converting Enzyme Inhibitors to Prevent Anthracycline-Induced Left Ventricular Dysfunction and Cardiomyopathy.
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Carotid thickening, cardiac hypertrophy, and angiotensin converting enzyme gene polymorphism in patients with hypertension.
Catecholamine-induced cardiomyopathy.
Changes in levels of angiotensin II and its receptors in a model of inverted stress-induced cardiomyopathy.
Chemotherapy induced cardiomyopathy: pathogenesis, monitoring and management.
Clinical aspects of cardiomyopathy in dialysis patients.
Clinical characteristics and prognosis of hospitalised inpatients with heart failure and preserved or reduced left ventricular ejection fraction.
Cloning of the gene and cDNA for hamster chymase 2, and expression of chymase 1, chymase 2 and angiotensin-converting enzyme in the terminal stage of cardiomyopathic hearts.
Contrasting effects of steroids and angiotensin-converting-enzyme inhibitors in a mouse model of dystrophin-deficient cardiomyopathy.
Deletion polymorphism of the angiotensin converting enzyme gene is associated with an increase in left ventricular mass in men with type 2 diabetes mellitus.
Deletion polymorphism of the angiotensin-converting enzyme gene is independently associated with left ventricular mass and geometric remodeling in systemic hypertension.
Development of circulatory-renal limitations to angiotensin-converting enzyme inhibitors identifies patients with severe heart failure and early mortality.
Effect of amlodipine on mode of death among patients with advanced heart failure in the PRAISE trial. Prospective Randomized Amlodipine Survival Evaluation.
Effect of tensiomin in ischaemic dilatative cardiomyopathy.
Effects of angiotensin-converting enzyme inhibitors and/or beta blockers on the cardiomyopathy in Duchenne muscular dystrophy.
Effects of Calcimimetic Combined with an Angiotensin-Converting Enzyme Inhibitor on Uremic Cardiomyopathy Progression.
Effects of cardiac versus circulatory angiotensin-converting enzyme inhibition on left ventricular diastolic function and coronary blood flow in hypertrophic obstructive cardiomyopathy.
Effects of enalapril on the collagen matrix in cardiomyopathic Syrian hamsters (Bio 14.6 and 53.58).
Evidence for tissue angiotensin-converting enzyme in explanted hearts of ischemic cardiomyopathy using targeted radiotracer technique.
Exposure to anthracyclines during childhood causes cardiac injury.
Fabry's disease: an example of cardiorenal syndrome type 5.
Fixing the "Broken Heart": Pharmacologic Implications.
Fosinopril Attenuates the Doxorubicin-induced Cardiomyopathy by Restoring the Function of Sarcoplasmic Reticulum.
Heart rate recovery--a potential marker of clinical outcomes in heart failure patients receiving beta-blocker therapy.
Hyperinsulinemia and insulin resistance in hypertension: differential effects of antihypertensive agents.
Identification and activation of autocrine renin-angiotensin system in adult ventricular myocytes.
Impact of angiotensin I converting enzyme insertion/deletion polymorphisms on dilated cardiomyopathy and hypertrophic cardiomyopathy risk.
Impact of interventricular lead distance and the decrease in septal-to-lateral delay on response to cardiac resynchronization therapy.
Implantable defibrillators and antiarrhythmic drugs in patients at risk for lethal arrhythmias.
Improved Cardiac Outcomes by Early Treatment with Angiotensin-Converting Enzyme Inhibitors in Becker Muscular Dystrophy.
Lack of association between insertion/deletion polymorphism of the angiotensin-converting enzyme gene and end-stage heart failure due to ischemic or idiopathic dilate cardiomyopathy in the Chinese.
Left ventricular function and response to enalapril in patients with duchenne muscular dystrophy during the second decade of life.
Long term survival and cardiopulmonary outcome in children with Hurler syndrome after haematopoietic stem cell transplantation.
Long-term outcomes and independent predictors of mortality in patients presenting to emergency departments with acute heart failure in Beijing: a multicenter cohort study with a 5-year follow-up.
Management of obesity cardiomyopathy.
MiRNA-30e mediated cardioprotection of ACE2 in rats with doxorubicin-induced heart failure through inhibiting cardiomyocytes autophagy.
Modulation of left ventricular iodine-125-MIBG accumulation in cardiomyopathic Syrian hamsters using the renin-angiotensin system.
Mortality in African-Americans Following Cardiac Resynchronization Therapy: A Single Center Experience.
Neuregulin-1/erbB-activation improves cardiac function and survival in models of ischemic, dilated, and viral cardiomyopathy.
Neurohormones and oxidative stress in nonischemic cardiomyopathy: relationship to survival and the effect of treatment with amlodipine.
Newer Therapies for Amyloid Cardiomyopathy.
Noncompaction cardiomyopathy and multiple coronary-cameral fistulae in an octogenarian.
Oxidative stress in patients with acute heart failure.
Peripartum cardiomyopathy in a previously asymptomatic carrier of Duchenne muscular dystrophy.
Peripartum cardiomyopathy: a review.
Pharmacogenetic Interactions between Angiotensin-Converting Enzyme Insertion/Deletion Polymorphism and Response to Cibenzoline in Patients with Hypertrophic Obstructive Cardiomyopathy.
Predictors and Clinical Impact of Late Ventricular Arrhythmias in Patients With Continuous-Flow Left Ventricular Assist Devices.
Predictors of Death in Adults With Duchenne Muscular Dystrophy-Associated Cardiomyopathy.
Predictors of response to cardiac resynchronization therapy in patients with chronic right ventricular pacing.
Pretreatment with angiotensin-converting enzyme inhibitor improves doxorubicin-induced cardiomyopathy via preservation of mitochondrial function.
Prevention of doxorubicin (adriamycin)-induced cardiomyopathy by simultaneous administration of angiotensin-converting enzyme inhibitor assessed by acoustic densitometry.
Reduced testosterone levels in males with lone atrial fibrillation.
Relations between deletion polymorphism of the angiotensin-converting enzyme gene and insulin resistance, glucose intolerance, hyperinsulinemia, and dyslipidemia.
Renin-angiotensin system gene polymorphisms as potential modifiers of hypertrophic and dilated cardiomyopathy phenotypes.
Response of symptomatic myocardial ischemia in ischemic cardiomyopathy to intensive vasodilator therapy.
Reverse remodeling in heart failure with intensification of vasodilator therapy.
Risk prediction for 30-day heart failure-specific readmission or death after discharge: Data from the Korean Acute Heart Failure (KorAHF) registry.
Safety of calcium antagonists in patients with congestive heart failure.
Strategies to prevent and treat cardiovascular risk in cancer patients.
Sudden Electrical Death.
The addition of pentoxifylline to conventional therapy improves outcome in patients with peripartum cardiomyopathy.
The effect of angiotensin-converting enzyme inhibitors on clinical outcomes in patients with ischemic cardiomyopathy and midrange ejection fraction: a post hoc subgroup analysis from the PEACE trial.
The Effective Use of Digoxin in a Patient with Metastatic Breast Cancer and Anthracycline-induced Cardiomyopathy.
The impact of medical interventions on admission characteristics in children with congenital heart disease and cardiomyopathy.
The SEISICAT study: a pilot study assessing efficacy and safety of spironolactone in cats with congestive heart failure secondary to cardiomyopathy.
Three cases of late-onset anthracycline-related cardiomyopathy due to chemotherapies for hematological malignancy.
Tissue angiotensin I-converting enzyme activity in aging hamsters with and without cardiomyopathy.
Tissue Doppler imaging for evaluation of myocardial function in patients with diabetes mellitus.
Treatment of experimental myocarditis via modulation of the renin-angiotensin system.
Unclassified cardiomyopathy in a geriatric cat.
Use of converting enzyme inhibitors in patients with asymptomatic left ventricular dysfunction.
Usefulness and Consequences of Cardiac Resynchronization Therapy in Dialysis-Dependent Patients With Heart Failure.
[Anthracycline-induced cardiomyopathy.]
[Expression of angiotensin converting enzyme and angiotensin II receptor in rabbits with hyperthyroid cardiomyopathy]
[Fabry's disease: an example of cardiorenal syndrome type 5].
[Heart Rate Variability in Chronic Heart Failure and Its Role in Prognosis of the Disease.]
[Ischemic cardiomyopathy: remodeling, hypertrophy, subendocardial risk. Can processes be controlled?]
[Myocarditis in the differential diagnosis of acute coronary syndrome]
[The association of risk of development of cardiomyopathies with polymorphic variants of genes of angiotensin converting enzyme, glutathione-S-transferase, interleukins 8 and 10].
[Treatment of cardiac insufficiency: does treatment depend on whether its cause is ischemic or idiopathic?]
[Treatment of ischemic myocardiopathy]
Cardiomyopathy, Alcoholic
Angiotensin-converting enzyme gene polymorphism is associated with vulnerability to alcoholic cardiomyopathy.
Valsartan inhibits RhoA-ROCK2-MYL pathway in rat model of alcoholic cardiomyopathy.
Cardiomyopathy, Dilated
A controlled study of the effects of carvedilol on clinical events, left ventricular function and proinflammatory cytokines levels in patients with dilated cardiomyopathy.
ACE I/D polymorphism in Indian patients with hypertrophic cardiomyopathy and dilated cardiomyopathy.
Acquired heart disease in children.
Adjunctive therapy with low-molecular-weight heparin in patients with chronic heart failure secondary to dilated cardiomyopathy: one-year follow-up results of the randomized trial.
Angiotensin converting enzyme inhibition restores cardiac and hormonal responses to volume overload in patients with dilated cardiomyopathy and mild heart failure.
Angiotensin deficiency in mice leads to dilated cardiomyopathy.
Angiotensin-converting enzyme 2 suppresses pathological hypertrophy, myocardial fibrosis, and cardiac dysfunction.
Angiotensin-converting enzyme DD genotype in patients with ischaemic or idiopathic dilated cardiomyopathy.
Angiotensin-converting enzyme inhibition and the progression of congestive cardiomyopathy. Effects on left ventricular and myocyte structure and function.
Angiotensin-converting enzyme inhibitor for epirubicin-induced dilated cardiomyopathy.
Angiotensin-converting enzyme inhibitors and beta-blockers in long-term treatment of dilated cardiomyopathy.
Angiotensin-converting enzyme inhibitors improve coronary flow reserve in dilated cardiomyopathy by a bradykinin-mediated, nitric oxide-dependent mechanism.
Angiotensin-converting enzyme polymorphism in patients with terminal renal failure.
Application of cine nuclear magnetic resonance imaging for sequential evaluation of response to angiotensin-converting enzyme inhibitor therapy in dilated cardiomyopathy.
Are Angiotensin-converting enzyme inhibitors and beta-blockers ineffective in children with dilated cardiomyopathy and heart failure?
Assessment of left ventricular diastolic function in dilated cardiomyopathy with cine magnetic resonance imaging: effect of an angiotensin converting enzyme inhibitor, benazepril.
Association between angiotensin converting enzyme (ACE) gene I/D polymorphism frequency and plasma ACE concentration in patients with idiopathic dilated cardiomyopathy.
Association of ACE I/D polymorphism in Tunisian patients with dilated cardiomyopathy.
Association of left ventricular systolic performance and cavity size with angiotensin-converting enzyme genotype in idiopathic dilated cardiomyopathy.
Atrial natriuretic peptide augments the variability of sympathetic nerve activity in human heart failure.
Beneficial effect of angiotensin-converting enzyme inhibitor on dilated cardiomyopathy induced by autoimmune mechanism against beta1-adrenoceptor.
Beneficial effects of metoprolol treatment in congestive heart failure. Reversal of sympathetic-induced alterations of immunologic function.
Beneficial effects of pentoxifylline in patients with idiopathic dilated cardiomyopathy treated with angiotensin-converting enzyme inhibitors and carvedilol: results of a randomized study.
Cardiac nitric oxide production due to angiotensin-converting enzyme inhibition decreases beta-adrenergic myocardial contractility in patients with dilated cardiomyopathy.
Cardiac remodelling in end stage heart failure: upregulation of matrix metalloproteinase (MMP) irrespective of the underlying disease, and evidence for a direct inhibitory effect of ACE inhibitors on MMP.
Cardiac sympathetic activity estimated by 123I-MIBG myocardial imaging in patients with dilated cardiomyopathy after beta-blocker or angiotensin-converting enzyme inhibitor therapy.
Cardioprotection for Duchenne's muscular dystrophy.
Cardiovascular diseases and molecular variants of the renin-angiotensin system components in Slovak population.
Carvedilol in children with cardiomyopathy: 3-year experience at a single institution.
Chronic effects of enalapril and amlodipine on cardiac remodeling in cardiomyopathic hamster hearts.
Comparative effects of angiotensin II receptor blockade (candesartan) with angiotensin-converting enzyme inhibitor (quinapril) in rats with dilated cardiomyopathy.
Current management of pediatric dilated cardiomyopathy.
Current treatment and management of dystrophinopathies.
DD genotype of the angiotensin-converting enzyme gene is a risk factor for left ventricular hypertrophy.
Diabetic Cardiomyopathy.
Dilated cardiomyopathy update: infectious-immune theory revisited.
Disappearance of left ventricular hypertrabeculation/noncompaction after biventricular pacing in a patient with polyneuropathy.
Does angiotensin-converting enzyme polymorphism influence the clinical manifestation and progression of heart failure in patients with dilated cardiomyopathy?
Doxorubicin-induced cardiomyopathy treated with carvedilol.
Effect of angiotensin-converting enzyme inhibitor (enalapril or imidapril) on ventilation during exercise in patients with chronic heart failure secondary to idiopathic dilated cardiomyopathy.
Effect of benazepril on heart rate turbulence in patients with dilated cardiomyopathy.
Effect of beta-blockade on regional left ventricular function in patients with dilated cardiomyopathy.
Effect of bilateral sympathectomy in a rat model of dilated cardiomyopathy induced by doxorubicin.
Effect of captopril on myocardial beta-adrenoceptor density and Gi alpha-proteins in patients with mild to moderate heart failure due to dilated cardiomyopathy.
Effect of Left Ventricular Reverse Remodeling on Long-Term Prognosis After Therapy With Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers and ? Blockers in Patients With Idiopathic Dilated Cardiomyopathy.
Effect of pimobendan on case fatality rate in doberman pinschers with congestive heart failure caused by dilated cardiomyopathy.
Effect of the addition of a beta-blocker on left ventricular remodeling and prognosis in patients with dilated cardiomyopathy treated with angiotensin-converting enzyme inhibitor.
Effect of the renin-angiotensin-aldosterone system on the cardiac interstitium in heart failure.
Effects of high-dose lisinopril-isosorbide dinitrate on severe mitral regurgitation and heart failure remodeling.
Effects of short- and long-term carvedilol administration on rest and exercise hemodynamic variables, exercise capacity and clinical conditions in patients with idiopathic dilated cardiomyopathy.
Effects of vasodilators on the coronary circulation in congestive heart failure.
Efficacy of benazepril hydrochloride to delay the progression of occult dilated cardiomyopathy in Doberman Pinschers.
Evidence that polymorphism of the angiotensin I converting enzyme gene may be related to idiopathic dilated cardiomyopathy in the Chinese population.
Heart failure in patients with preserved and deteriorated left ventricular ejection fraction.
Hemodynamic and clinical effects of oral levodopa in children with congestive heart failure.
Hemodynamic predictors of early intolerance and long-term effects of propranolol in dilated cardiomyopathy.
Impact of angiotensin I converting enzyme insertion/deletion polymorphisms on dilated cardiomyopathy and hypertrophic cardiomyopathy risk.
Insertion/Deletion polymorphism of Angiotensin converting enzyme gene in kawasaki disease.
Lack of association between insertion/deletion polymorphism of the angiotensin-converting enzyme gene and end-stage heart failure due to ischemic or idiopathic dilate cardiomyopathy in the Chinese.
Lack of association between the insertion/deletion polymorphism of the angiotensin-converting enzyme gene and idiopathic dilated cardiomyopathy.
Lack of association of polymorphisms of the angiotensin converting enzyme and angiotensinogen genes with nonfamilial hypertrophic or dilated cardiomyopathy.
Left Ventricular Unloading With an IABP in Patients Undergoing Ventricular Tachycardia Ablation With ECMO Support.
Lisinopril overdose and management with intravenous angiotensin II.
Long-term combined therapy with an angiotensin type I receptor blocker and an angiotensin converting enzyme inhibitor prolongs survival in dilated cardiomyopathy.
Long-term prognosis of dilated cardiomyopathy revisited: an improvement in survival over the past 20 years.
Long-term survival effect of metoprolol in dilated cardiomyopathy. The SPIC (Italian Multicentre Cardiomyopathy Study) Group.
Long-term survival of non-elderly patients with severe heart failure treated with angiotensin-converting enzyme inhibitors assessment of treatment with captopril and enalapril survival study (ACESS).
Metoprolol in dilated cardiomyopathy: is it possible to identify factors predictive of improvement? The Heart Muscle Disease Study Group.
More favourable haemodynamic effects from metoprolol than from captopril in patients with dilated cardiomyopathy.
Myocardial collagen matrix remodeling and congestive heart failure.
Pharmacological left ventricular reverse remodeling in elderly patients receiving optimal therapy for chronic heart failure.
Prediction of left ventricular reverse remodeling after therapy with angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers and ? blockers in patients with idiopathic dilated cardiomyopathy.
Prevalence, predictors, and prognosis of reversal of maladaptive remodeling with intensive medical therapy in idiopathic dilated cardiomyopathy.
Prolonged QRS duration and severity of mitral regurgitation are unfavorable prognostic markers of heart failure in patients with nonischemic dilated cardiomyopathy.
Quinapril inhibits progression of heart failure and fibrosis in rats with dilated cardiomyopathy after myocarditis.
Radionuclide monitoring of cardiac adaptations to volume loading in patients with dilated cardiomyopathy and mild heart failure. Effects of angiotensin-converting enzyme inhibition.
Recovery of iodine-123 metaiodobenzylguanidine uptake associated with left ventricular functional recovery in a patient with dilated cardiomyopathy. Endomyocardial histological findings before and after the improvement of uptake.
Relation of aldosterone "escape" despite angiotensin-converting enzyme inhibitor administration to impaired exercise capacity in chronic congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy.
Should Angiotensin-converting enzyme inhibitors be continued over the long term in patients whose left ventricular ejection fraction normalizes after an episode of acute myocarditis?
Sudden cardiac death in dilated cardiomyopathy -- therapeutic options.
The appropriate dose of angiotensin-converting-enzyme inhibitors or angiotensin receptor blockers in patients with dilated cardiomyopathy. The higher, the better?
The circulating renin-angiotensin system during treatment with metoprolol or captopril in patients with heart failure due to non-ischaemic dilated cardiomyopathy.
The effect of treatment with angiotensin-converting enzyme inhibitors on survival of pediatric patients with dilated cardiomyopathy.
The G-308A polymorphism of the TNF-alpha gene does not predict changes in cardiac function in response to medical therapy for idiopathic dilated cardiomyopathy.
The role of beta-blockers in the treatment of cardiomyopathy and ischaemic heart failure.
The Use of Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers Is Associated with the Recovered Ejection Fraction in Patients with Dilated Cardiomyopathy.
Treatment with angiotensin-converting-enzyme inhibitor for epirubicin-induced dilated cardiomyopathy.
Viral myocarditis and dilated cardiomyopathy: mechanisms, manifestations, and management.
[Angiotensin-converting enzyme inhibitor in the treatment of epirubicin-induced dilated cardiomyopathy]
[Angiotensin-converting enzyme inhibitor treatment of heart failure due to dilated cardiomyopathy]
[Beneficial effects of pentoxifylline in patients with idiopathic dilated cardiomyopathy treated with angiotensin-converting enzyme inhibitors and carvedilol. Results of a randomised study]
[Should Angiotensin-converting enzyme inhibitors be continued over the long term in patients whose left ventricular ejection fraction normalizes after an episode of acute myocarditis?]
Cardiomyopathy, Hypertrophic
A985G polymorphism of the endothelin-2 gene and atrial fibrillation in patients with hypertrophic cardiomyopathy.
ACE I/D polymorphism in Indian patients with hypertrophic cardiomyopathy and dilated cardiomyopathy.
Angiotensin-converting enzyme and angiotensinogen gene polymorphism in hypertrophic cardiomyopathy.
Angiotensin-converting enzyme and heart chymase gene polymorphisms in hypertrophic cardiomyopathy.
Angiotensin-converting enzyme gene insertion/deletion polymorphism and left ventricular hypertrophy in hemodialysis patients.
Angiotensin-converting enzyme gene polymorphism in Japanese patients with hypertrophic cardiomyopathy.
Angiotensin-converting enzyme polymorphism in hypertrophic cardiomyopathy and sudden cardiac death.
Angiotensin-I converting enzyme genotypes and left ventricular hypertrophy in patients with hypertrophic cardiomyopathy.
Association of angiotensin-converting enzyme activity and polymorphism with echocardiographic measures in familial and nonfamilial hypertrophic cardiomyopathy.
DD genotype of the angiotensin-converting enzyme gene is a risk factor for left ventricular hypertrophy.
Different pathophysiology of cardiac hypertrophy in hypertension and hypertrophic cardiomyopathy.
Effects of cardiac versus circulatory angiotensin-converting enzyme inhibition on left ventricular diastolic function and coronary blood flow in hypertrophic obstructive cardiomyopathy.
Gene-specific modifying effects of pro-LVH polymorphisms involving the renin-angiotensin-aldosterone system among 389 unrelated patients with hypertrophic cardiomyopathy.
Genetic polymorphism of angiotensin-converting enzyme and hypertrophic cardiomyopathy risk: A systematic review and meta-analysis.
Impact of angiotensin I converting enzyme insertion/deletion polymorphisms on dilated cardiomyopathy and hypertrophic cardiomyopathy risk.
Insertion/Deletion polymorphism of Angiotensin converting enzyme gene in kawasaki disease.
Pharmacogenetic Interactions between Angiotensin-Converting Enzyme Insertion/Deletion Polymorphism and Response to Cibenzoline in Patients with Hypertrophic Obstructive Cardiomyopathy.
Progression of left ventricular hypertrophy and the angiotensin-converting enzyme gene polymorphism in hypertrophic cardiomyopathy.
Relation between angiotensin-converting enzyme II genotype and atrial fibrillation in Japanese patients with hypertrophic cardiomyopathy.
Renin-angiotensin system: genes to bedside.
Successful heart failure therapy in mitochondrial disorder with noncompaction cardiomyopathy.
The beta 1 hyperselectivity in beta-blocker treatment.
The influence of Angiotensin converting enzyme and angiotensinogen gene polymorphisms on hypertrophic cardiomyopathy.
The relationship between angiotensin converting enzyme gene I/D polymorphism and QT dispersion in patients with hypertrophic cardiomyopathy.
[Polymorphism of angiotensin-converting enzyme and endothelial nitric oxide synthase genes in people with arterial hypertension, left ventricular hypertrophy, and hypertrophic cardiomyopathy]
[Polymorphism of the angiotensin-converting enzyme gene in cardiovascular pathology]
[The effect of polymorphisms of the angiotensin-converting enzyme and angiotensinogen genes on the phenotypic expression of Spanish patients with hypertrophic cardiomyopathy]
[The polymorphism of the angiotensin-converting enzyme gene in patients with hypertension, left ventricular hypertrophy and the development of a myocardial infarct at a young age. Preliminary report]
Cardiomyopathy, Hypertrophic, Familial
Familial hypertrophic cardiomyopathy. Insertion-deletion polymorphism of angiotensin-converting enzyme and angiotensin II receptor.
The influence of the angiotensin I converting enzyme genotype in familial hypertrophic cardiomyopathy varies with the disease gene mutation.
Cardiomyopathy, Restrictive
ACE I/D polymorphism in Indian patients with hypertrophic cardiomyopathy and dilated cardiomyopathy.
Cardiotoxicity
5-Fluorouracil induces arterial vasoconstrictions but does not increase angiotensin II levels.
Angiotensin converting enzyme inhibitors may be protective against cardiac complications following anthracycline chemotherapy.
Angiotensin-converting enzyme inhibition and angiotensin AT(1)-receptor antagonism equally improve doxorubicin-induced cardiotoxicity and nephrotoxicity.
Anthracycline-associated cardiotoxicity in survivors of childhood cancer.
Anthracycline-induced cardiotoxicity prevention with angiotensin-converting enzyme inhibitor ramipril in women with low-risk breast cancer: results of a prospective randomized study.
Assessment of cardiotoxicity with cardiac biomarkers in cancer patients.
Caffeic Acid Protects against Iron-Induced Cardiotoxicity by Suppressing Angiotensin-Converting Enzyme Activity and Modulating Lipid Spectrum, Gluconeogenesis and Nucleotide Hydrolyzing Enzyme Activities.
Can the epirubicin cardiotoxicity in cancer patients be prevented by angiotensin converting enzyme inhibitors?
Cardiac complications associated with hematopoietic stem-cell transplantation.
Cardiac Toxicity: Using Angiotensin-Converting Enzyme Inhibitors to Prevent Anthracycline-Induced Left Ventricular Dysfunction and Cardiomyopathy.
Cardio-oncology issues among pediatric cancer and stem cell transplant survivors.
Cardioprotective effects of zofenopril, a new angiotensin-converting enzyme inhibitor, on doxorubicin-induced cardiotoxicity in the rat.
Cardiotoxicity of Anthracyclines.
Cardiovascular disease in adult survivors of childhood cancer.
Cardiovascular Outcomes in Relation to Antihypertensive Medication Use in Women with and Without Cancer: Results from the Women's Health Initiative.
Design and baseline characteristics for the ACE Inhibitor After Anthracycline (AAA) study of cardiac dysfunction in long-term pediatric cancer survivors.
Diverging effects of enalapril or eplerenone in primary prevention against doxorubicin-induced cardiotoxicity.
Effects of angiotensin-1 converting enzyme inhibition on oxidative stress and bradykinin receptor expression during doxorubicin-induced cardiomyopathy in rats.
Effects of angiotensin-converting enzyme inhibitor on delayed-onset doxorubicin-induced cardiotoxicity.
Effects of Cardioprotective Tactics on the Myocardial Perfusion and Contractile Function of the Left Ventricular Myocardium in Cancer Patients with Evidence of Doxorubicin-Induced Cardiotoxicity.
Heart failure from cancer therapy: can we prevent it?
Intriguing relationship between antihypertensive therapy and cancer.
Letter by Hammoud et al regarding article "Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition".
Lisinopril or Coreg CR in reducing cardiotoxicity in women with breast cancer receiving trastuzumab: A rationale and design of a randomized clinical trial.
Mechanisms and management of doxorubicin cardiotoxicity.
Multidisciplinary Approach to Novel Therapies in Cardio-Oncology Research (MANTICORE 101-Breast): A Randomized Trial for the Prevention of Trastuzumab-Associated Cardiotoxicity.
Pharmacological interventions for preventing anthracycline-induced clinical and subclinical cardiotoxicity: A network meta-analysis of metastatic breast cancer.
Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition.
Prevention of Trastuzumab and Anthracycline-induced Cardiotoxicity Using Angiotensin-converting Enzyme Inhibitors or ?-blockers in Older Adults With Breast Cancer.
Protective Effects of ACEI/ARB on Left Ventricular Function in Anthracycline-Induced Chronic Cardiotoxicity: A Meta-Analysis of Randomized Controlled Trials.
Randomized Trial of Lisinopril Versus Carvedilol to Prevent Trastuzumab Cardiotoxicity in Patients With Breast Cancer.
Review: Role of biomarkers in cardioncology.
Risk of Cardiomyopathy in Breast Cancer: How Can We Attenuate the Risk of Heart Failure from Anthracyclines and Anti-HER2 Therapies?
Role of ACE inhibitors in anthracycline-induced cardiotoxicity: A randomized, double-blind, placebo-controlled trial.
Role of biomarkers in chemotherapy-induced cardiotoxicity.
Role of the renin-angiotensin-aldosterone system and the glutathione S-transferase Mu, Pi and Theta gene polymorphisms in cardiotoxicity after anthracycline chemotherapy for breast carcinoma.
The Preventive Role of Angiotensin Converting Enzyme Inhibitors/Angiotensin-II Receptor Blockers and ?-Adrenergic Blockers in Anthracycline- and Trastuzumab-Induced Cardiotoxicity.
The Protective Effects of Coenzyme Q10 and Lisinopril Against Doxorubicin-Induced Cardiotoxicity in Rats: A Stereological and Electrocardiogram Study.
Treatment with Beta-Blockers and ACE-Inhibitors in Breast Cancer Patients Receiving Adjuvant Trastuzumab-Based Therapy and Developing Mild Cardiac Toxicity: A Prospective Study.
Treatment-related cardiotoxicity in survivors of childhood cancer.
Troponins and brain natriuretic peptides for the prediction of cardiotoxicity in cancer patients: a meta-analysis.
Use of angiotensin-converting enzyme inhibitors in the prophylaxis of anthracycline or trastuzumab-related cardiac dysfunction: preclinical and clinical considerations.
Utilizing cardiac biomarkers to detect and prevent chemotherapy-induced cardiomyopathy.
[Cardiovascular toxicity of anti-angiogenic therapy.]
Cardiovascular Abnormalities
The effects of monotherapy or combined therapy with an angiotensin converting enzyme inhibitor following initial treatment with calcium channel blockers on residual cardiovascular abnormalities.
Cardiovascular Diseases
A possible Fourier transform infrared-based plasma fingerprint of angiotensin-converting enzyme inhibitor-induced reversal of endothelial dysfunction in diabetic mice.
A remarkable medical story: benefits of angiotensin-converting enzyme inhibitors in cardiac patients.
A review of the angiotensin-converting enzyme inhibitor, zofenopril, in the treatment of cardiovascular diseases.
A simple molecular assay for the C1166 variant of the angiotensin II type 1 receptor gene.
A variant in XPNPEP2 is associated with angioedema induced by angiotensin I-converting enzyme inhibitors.
A view from Europe.
A985G polymorphism of the endothelin-2 gene and atrial fibrillation in patients with hypertrophic cardiomyopathy.
Absence of an interaction between the angiotensin-converting enzyme insertion-deletion polymorphism and pravastatin on cardiovascular disease in high-risk hypertensive patients: the Genetics of Hypertension-Associated Treatment (GenHAT) study.
ACE inhibitors in cardiovascular disease. Which patient? Which drug? Which dose?
ACE Phenotyping as a Guide Toward Personalized Therapy With ACE Inhibitors.
ACE-DD genotype is associated with the occurrence of acute coronary syndrome in postmenopausal women.
ACE2 gene transfer attenuates hypertension-linked pathophysiological changes in the SHR.
Acute adverse reactions associated with angiotensin-converting enzyme inhibitors: genetic factors and therapeutic implications.
Acute changes in glomerular filtration rate with renin-angiotensin system (RAS) inhibition: clinical implications.
Administration of an angiotensin-converting enzyme inhibitor improves vascular function and urinary albumin excretion in low-risk essential hypertensive patients receiving anti-hypertensive treatment with calcium channel blockers. Organ-protecting effects independent of anti-hypertensive effect.
Aggressive treatment of atherosclerosis: the time is now.
Aliskiren therapy in hypertension and cardiovascular disease: a systematic review and a meta-analysis.
Aliskiren, the first approved renin inhibitor: Clinical application and safety in the treatment of hypertension.
Amiodarone for prevention of atrial fibrillation following esophagectomy.
An alternative fast and convenient genotyping method for the screening of angiotensin converting enzyme gene polymorphisms.
An angiotensin-converting enzyme gene polymorphism suggests a genetic distinction between ischaemic stroke and carotid stenosis.
Analysis of risk factors for occlusions of a synthetic femoropopliteal bypass graft.
ANGIOEDEMA AFTER ANGIOTENSIN-CONVERTING ENZYME INHIBITORS.
Angiotensin converting enzyme DD genotype is associated with development of rheumatic heart disease in Egyptian children.
Angiotensin converting enzyme gene insertion/deletion polymorphism and cardiovascular disease: therapeutic implications.
Angiotensin converting enzyme gene polymorphism and carotid atherosclerosis in a low-risk population.
Angiotensin converting enzyme gene, smoking and mortality in a population-based study.
Angiotensin converting enzyme in patients with sleep apnoea syndrome: plasma activity and gene polymorphisms.
Angiotensin converting enzyme inhibition and its impact on cardiovascular disease.
Angiotensin converting enzyme inhibition: changing the course of cardiovascular disease. Proceedings of an international symposium. 22-24 October 1993, Barcelona, Spain.
Angiotensin converting enzyme inhibitor-induced renal dysfunction: recommendations for prevention.
Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers: A Promising Medication for Chronic Obstructive Pulmonary Disease?
Angiotensin converting enzyme inhibitors: differences and advantages for first line therapy in hypertension.
Angiotensin I converting enzyme (ACE) gene polymorphism and essential hypertension in Japan. Ethnic difference of ACE genotype.
Angiotensin I converting enzyme gene: regulation, polymorphism and implications in cardiovascular diseases.
Angiotensin I converting enzyme polymorphism effects in patients with normal pressure hydrocephalus syndrome before and after surgery.
Angiotensin I-converting enzyme and plasminogen activator inhibitor-1 gene variants: risk of mortality and fatal cardiovascular disease in an elderly population-based cohort.
Angiotensin I-converting enzyme gene polymorphism and acute response to captopril in essential hypertension.
Angiotensin I-converting enzyme insertion/insertion genotype as a genetic risk factor for cardiovascular disease.
Angiotensin II AT2 subtype receptors: an emerging target for cardiovascular therapy.
Angiotensin II blockers in obstructive pulmonary disease: a randomised controlled trial.
Angiotensin II Receptor Blockers and Cancer Risk: A Meta-Analysis of Randomized Controlled Trials.
Angiotensin-(1-12): A Chymase-Mediated Cellular Angiotensin II Substrate.
Angiotensin-(1-7) attenuates the development of heart failure after myocardial infarction in rats.
Angiotensin-(1-7) is a modulator of the human renin-angiotensin system.
Angiotensin-converting enzyme (ACE) gene polymorphism and the erythrocyte sodium-lithium countertransporter (SLC) phenotype in hypertension.
Angiotensin-converting enzyme (ACE) insertion/deletion polymorphism and survival in a cohort of chronic hemodialysis patients.
Angiotensin-converting enzyme and cardiovascular disease risk.
Angiotensin-converting enzyme DD genotype and cardiovascular disease in heterozygous familial hypercholesterolemia.
Angiotensin-converting enzyme DD polymorphism is associated with poor coronary collateral circulation in patients with coronary artery disease.
Angiotensin-converting enzyme deletion allele is beneficial for the longevity of Europeans.
Angiotensin-converting enzyme gene and diabetes mellitus.
Angiotensin-Converting Enzyme Gene D/I Polymorphism in Relation to Endothelial Function and Endothelial-Released Factors in Chinese Women.
Angiotensin-converting enzyme gene deletion polymorphism determines an increase in frequency of migraine attacks in patients suffering from migraine without aura.
Angiotensin-converting enzyme gene insertion deletion (ACE I/D) polymorphism in Saudi children with congenital heart disease.
Angiotensin-converting enzyme gene insertion/deletion polymorphism and cardiovascular disease: identifying the guideposts for navigating the genetics landscape.
Angiotensin-converting enzyme gene insertion/deletion polymorphism and carotid artery wall thickness in patients with peripheral arterial occlusive disease.
Angiotensin-converting enzyme gene insertion/deletion polymorphism in Polish patients with myocardial infarction.
Angiotensin-converting enzyme gene mutations, blood pressures, and cardiovascular homeostasis.
Angiotensin-converting enzyme gene polymorphism and cardiovascular disease.
Angiotensin-converting enzyme gene polymorphism and cardiovascular endocrine system in coronary angiography patients.
Angiotensin-converting enzyme inhibition and novel cardiovascular risk biomarkers: results from the Trial of Angiotensin Converting Enzyme Inhibition and Novel Cardiovascular Risk Factors (TRAIN) study.
Angiotensin-converting enzyme inhibition by perindopril in the treatment of cardiovascular disease.
Angiotensin-converting enzyme inhibition in cardiovascular disease: evidence with perindopril.
Angiotensin-converting enzyme inhibition or angiotensin receptor blockade in hypertensive diabetics?
Angiotensin-converting enzyme inhibitor attenuates monocyte adhesion to vascular endothelium through modulation of intracellular zinc.
Angiotensin-Converting Enzyme Inhibitor Initiation and Dose Uptitration in Children With Cardiovascular Disease: A Retrospective Review of Standard Clinical Practice and a Prospective Randomized Clinical Trial.
Angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker treatment and haemodynamic factors are associated with increased cardiac mRNA expression of angiotensin-converting enzyme 2 in patients with cardiovascular disease.
Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers as therapeutic options in the treatment of renal cancer: A meta-analysis.
Angiotensin-converting enzyme inhibitors for the prevention and treatment of cardiovascular disease.
Angiotensin-Converting Enzyme Inhibitors in Hypertension: To Use or Not to Use?
Angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers and the risk of developing rheumatoid arthritis in antihypertensive drug users.
Angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, ?-blockers or both in incident end-stage renal disease patients without cardiovascular disease: a propensity-matched longitudinal cohort study.
Angiotensin-converting enzyme insertion/deletion polymorphism and prognosis of IgA nephropathy.
Angiotensin-converting enzyme polymorphism in patients with terminal renal failure.
Angiotensin-converting enzyme single nucleotide polymorphism is a genetic risk factor for cardiovascular disease: a cohort study of hypertensive patients.
Angiotensin-converting enzymes and drug discovery in cardiovascular diseases.
Angiotensine converting enzyme inhibitors In acute myocardial infarction--a review.
Anti-atherosclerotic properties of telmisartan in advanced atherosclerotic lesions in apolipoprotein E deficient mice.
Anti-inflammatory effects of different drugs/agents with antioxidant property on endothelial expression of adhesion molecules.
Antihypertensive Agents in Hemodialysis Patients: A Current Perspective.
Antihypertensive and renal protective effect of Shunaoxin pill combined with captopril on spontaneous hypertension rats.
Antihypertensive drug therapies and the risk of ischemic stroke.
Antihypertensive drugs metabolism: an update to pharmacokinetic profiles and computational approaches.
Antihypertensive medications and C-reactive protein in the multi-ethnic study of atherosclerosis.
Antihypertensive medications and risk of diabetes mellitus.
Antihypertensive treatment and homocysteine concentrations.
Antiplatelet therapy for atherothrombotic disease: an update for the primary care physician.
Aprotinin: a serine protease inhibitor with therapeutic actions: its interaction with ACE inhibitors.
Are reactive oxygen species important mediators of vascular dysfunction?
Are renin-angiotensin-aldosterone system blockers distinguishable based on cardiovascular and renal outcomes in nephropathy?
ARNI in cardiovascular disease - current evidence and future perspectives.
Assessment of the optimal daily dose of valsartan in patients with hypertension, heart failure, or both.
Assessment of the rs4340 ACE gene polymorphism in acute coronary syndrome in a Western Mexican population.
Association between angiotensin-converting-enzyme gene polymorphism and failure of renoprotective therapy.
Association between serum Na-Cl level and renal function decline in chronic kidney disease: results from the chronic kidney disease Japan cohort (CKD-JAC) study.
Association between the NOS3 (-786 T/C) and the ACE (I/D) DNA genotypes and early coronary artery disease.
Association of ACE I/D polymorphism with cardiovascular risk factors.
Association of angiotensin I converting enzyme (insertion/deletion) and angiotensin II type 1 receptor (A1166C) polymorphisms with breast cancer prognostic factors in iranian population.
Association of angiotensin I converting enzyme gene polymorphism with reflux nephropathy in children.
Association of arterial stiffness with the angiotensin-converting enzyme gene polymorphism in healthy individuals.
Association of CILP2 and ACE gene polymorphisms with cardiovascular risk factors in Slovak midlife women.
Association of essential hypertension in elderly Japanese with I/D polymorphism of the angiotensin-converting enzyme (ACE) gene.
Association of the insertion allele of the common ACE gene polymorphism with type 2 diabetes mellitus among Kuwaiti cardiovascular disease patients.
Atorvastatin completely inhibits VEGF-induced ACE upregulation in human endothelial cells.
Availability and affordability of cardiovascular disease medicines and their effect on use in high-income, middle-income, and low-income countries: an analysis of the PURE study data.
Benazepril affects integrin-linked kinase and smooth muscle ?-actin expression in diabetic rat glomerulus and cultured mesangial cells.
Benazepril hydrochloride protects against doxorubicin cardiotoxicity by regulating the PI3K/Akt pathway.
Blockade of the renin-angiotensin system.
Blockage of the Renin-Angiotensin System Attenuates Mortality but Not Vascular Calcification in Uremic Rats: Sevelamer Carbonate Prevents Vascular Calcification.
Blocking the tissue renin-angiotensin system: the future cornerstone of therapy.
Blood pressure and cardiovascular disease: what remains to be achieved?
Blood pressure behavior in the nursing home: implications for diagnosis and treatment of hypertension.
Blood pressure treatment levels and choice of antihypertensive agent in people with diabetes mellitus: an overview of systematic reviews.
Calcium antagonists and ACE inhibitors. Effect on endothelium and vascular smooth muscle.
Captopril alleviates hypertension-induced renal damage, inflammation, and NF-?B activation.
Captopril reduces cardiac inflammatory markers in spontaneously hypertensive rats by inactivation of NF-kB.
Captopril suppresses inflammation in endotoxin-induced uveitis in rats.
Cardiac risk factors and the use of cardioprotective medications in patients with chronic renal insufficiency.
Cardiomyopathy development protection after myocardial infarction in rats: Successful competition for major dihydropyridines' common metabolite against captopril.
Cardiovascular disease genetics: a long and winding road.
Cardiovascular disease prevention with a multidrug regimen in the developing world: a cost-effectiveness analysis.
Cardiovascular effects of I/D angiotensin-converting enzyme gene polymorphism in healthy subjects. Findings after follow-up of six years.
Cardiovascular outcomes in high-risk hypertensive patients stratified by baseline glomerular filtration rate.
Cardiovascular Risk and Risk Factor Management in Type 2 Diabetes Mellitus.
Carotid artery intima-media thickness and the renin-angiotensin system.
Carotid intima-media thickness and ACE-gene polymorphism in hemodialysis patients.
Carvedilol inhibits basal and stimulated ACE production in human endothelial cells.
Case study of patents related to captopril, Squibb's first blockbuster.
CD143 in the development of atherosclerosis.
Cell biology and genetics of angiotensin in cardiovascular disease.
Changes in drug treatment in the elderly between 1971 and 2000.
Changes in vascular distensibility during angiotensin-converting enzyme inhibition involve bradykinin type 2 receptors.
Characteristics of treated hypertension in incident hemodialysis and peritoneal dialysis patients.
Chronic treatment with the ACE inhibitor enalapril attenuates the development of frailty and differentially modifies pro-and anti-inflammatory cytokines in aging male and female C57BL/6 mice.
Cisplatin-induced renal toxicity in elderly people.
Classical and Counter-Regulatory Renin-Angiotensin System: Potential Key Roles in COVID-19 Pathophysiology.
Clinical impact of angiotensin I converting enzyme polymorphisms in subjects with resistant hypertension.
Combination inhibition of the renin-angiotensin system: is more better?
Combination of ACE inhibitors and calcium antagonists: a logical approach.
Combination therapy with an angiotensin-converting enzyme inhibitor and a calcium channel blocker.
Combined treatment with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers: a review of the current evidence.
Community Implementation and Translation of Kaiser Permanente's Cardiovascular Disease Risk-Reduction Strategy.
Comparative Effectiveness of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers in Terms of Major Cardiovascular Disease Outcomes in Elderly Patients: A Nationwide Population-Based Cohort Study.
Comparison of effects of enalapril and nitrendipine on cardiac sympathetic nervous system in essential hypertension.
Comparison of persistence rates with angiotensin-converting enzyme inhibitors used in secondary and primary prevention of cardiovascular disease.
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2017 EXECUTIVE SUMMARY.
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2018 EXECUTIVE SUMMARY.
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2019 EXECUTIVE SUMMARY.
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2020 EXECUTIVE SUMMARY.
Coronavirus Disease 2019 (COVID-19) and Cardiovascular Disease: A Viewpoint on the Potential Influence of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers on Onset and Severity of Severe Acute Respiratory Syndrome Coronavirus 2 Infection.
Coronavirus disease 2019 (COVID-19): angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers and cardiovascular disease.
Correlation between angiotensin-converting enzyme gene insertion/deletion polymorphism and kidney graft long-term outcome in pediatric recipients: a single-center analysis.
Cost Effectiveness of ACEIs/ARBs versus Amlodipine Monotherapies: A Single-Center Retrospective Chart Review.
Costs and effects of enalapril therapy in patients with symptomatic heart failure: an economic analysis of the Studies of Left Ventricular Dysfunction (SOLVD) Treatment Trial.
Cough and ACE Inhibitors: The Truth Beyond Placebo.
Could the pharmacological differences observed between angiotensin II antagonists and inhibitors of angiotensin converting enzyme be clinically beneficial?
COVID-19 and cardiac injury: clinical manifestations, biomarkers, mechanisms, diagnosis, treatment, and follow up.
COVID-19 and cardiovascular diseases.
Covid-19 and cardiovascular risk: Susceptibility to infection to SARS-CoV-2, severity and prognosis of Covid-19 and blockade of the renin-angiotensin-aldosterone system. An evidence-based viewpoint.
Deletion polymorphism in angiotensin converting enzyme gene associated with carotid wall thickening in a healthy male population.
Deletion polymorphism of angiotensin-converting enzyme gene is associated with postprandial hyperglycaemia in individuals undergoing general check-up.
Deletion polymorphism of the angiotensin I-converting enzyme gene is associated with serum ACE concentration and increased risk for CAD in the Japanese.
Development and validation of a clinical prediction rule for angiotensin-converting enzyme inhibitor-induced cough.
Diabetic nephropathy is associated with low-grade inflammation in Type 1 diabetic patients.
Dialysis modality is independently associated with circulating endothelial progenitor cells in end-stage renal diseases patients.
Differences in frequency of the deletion polymorphism of the angiotensin-converting enzyme gene in different ethnic groups.
Different angiotensin-converting enzyme inhibitors have similar clinical efficacy after myocardial infarction.
Dissecting the role of chymase in angiotensin II formation and heart and blood vessel diseases.
Distribution of different HLA antigens in Greek hypertensives according to the angiotensin-converting enzyme genotype.
Do thiazide diuretics confer specific protection against strokes?
Does angiotensin-converting enzyme gene polymorphism affect blood pressure? Findings after 6 years of follow-up in healthy subjects.
Does aspirin attenuate the effect of angiotensin-converting enzyme inhibitors in hypertension or heart failure?
Does Genetic Predisposition Contribute to the Exacerbation of COVID-19 Symptoms in Individuals with Comorbidities and Explain the Huge Mortality Disparity between the East and the West?
Downregulation of angiotensin-converting enzyme by tumor necrosis factor-alpha and interleukin-1beta in cultured human endothelial cells.
Drug use and low blood pressure in the elderly: a study of data from the kungsholmen project.
Effect of ACEI and ARB treatment on nitric oxide-dependent endothelial function.
Effect of captopril on serum lipid levels and cardiac mitochondrial oxygen consumption in experimentally-induced hypercholesterolemia in rabbits.
Effect of combinations of drugs on all cause mortality in patients with ischaemic heart disease: nested case-control analysis.
Effect of Different Classes of Antihypertensive Drugs on Endothelial Function and Inflammation.
Effect of direct renin inhibitor, aliskiren, on peripheral blood monocyte subsets and myocardial salvage in patients with primary acute myocardial infarction.
Effect of genotype on the angiotensin-converting enzyme mRNA level in human atria.
Effect of Pollypill on cardiovascular parameters: Systematic review and meta-analysis.
Effect of statin therapy on disease progression in pediatric ADPKD: Design and baseline characteristics of participants.
Effect of telmisartan on renal outcomes: a randomized trial.
Effect on the atherogenic marker plasminogen activator inhibitor type-1 of addition of the ACE inhibitor imidapril to angiotensin II type 1 receptor antagonist therapy in hypertensive patients with abnormal glucose metabolism: a prospective cohort study in primary care.
Effects of angiotensin converting enzyme inhibitor and angiotensin II receptor blocker on ventricular defibrillation threshold.
Effects of angiotensin receptor blockade (ARB) on mortality and cardiovascular outcomes in patients with long-term haemodialysis: a randomized controlled trial.
Effects of delapril on stroke, kidney dysfunction and cardiac hypertrophy in stroke-prone spontaneously hypertensive rats.
Effects of enalaprilat on venoconstriction to norepinephrine: role of prostaglandins.
Effects of natural peptides from food proteins on angiotensin converting enzyme activity and hypertension.
Effects of oestrogen-only and oestrogen-progestogen replacement therapy upon circulating angiotensin I-converting enzyme activity in postmenopausal women.
Effects of Recent Use of Renin-Angiotensin System Inhibitors on Mortality of Patients With Coronavirus Disease 2019.
Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138 769 individuals.
Elevated urinary albumin excretion is not linked to the angiotensin I-converting enzyme gene polymorphism in clinically healthy subjects.
Emerging approaches in the prevention of atherosclerotic cardiovascular diseases.
Endothelial cell damage and angiotensin-converting enzyme insertion/deletion genotype in elderly hypertensive patients.
Endothelial progenitor cell dysfunction in cardiovascular diseases: role of reactive oxygen species and inflammation.
Endothelial progenitor cells dysfunction and senescence: contribution to oxidative stress.
Endothelium-dependent responses and inhibition of angiotensin-converting enzyme.
Eplerenone, a new selective aldosterone blocker.
EVALUATING THE PRESCRIPTION OF ANGIOTENSIN CONVERTING ENZYME INHIBITORS OR RECEPTOR BLOCKERS IN PATIENTS WITH DIABETES IN JORDAN.
Evaluation of the effect of angiotensin converting enzyme inhibitors and angiotensin receptors blockers on aspirin antiplatelet effect.
Evaluation of the efficacy and safety of text messages targeting adherence to cardiovascular medications in secondary prevention: the txt2heart Colombia randomised controlled trial protocol.
Expert consensus document on angiotensin converting enzyme inhibitors in cardiovascular disease. The Task Force on ACE-inhibitors of the European Society of Cardiology.
Fast 5-hour determination of angiotensin-converting enzyme genotypes from blood by SDS-PAGE using PhastSystem.
Fine-Mapping Angiotensin-Converting Enzyme Gene: Separate QTLs Identified for Hypertension and for ACE Activity.
First orally active DRI Aliskiren--a new prospect in management of hypertension and beyond.
Fixed-Dose Combinations of Renin-Angiotensin System Inhibitors and Calcium Channel Blockers in the Treatment of Hypertension: A Comparison of Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors.
Flavonoids decrease the radiation-induced increase in the activity of the angiotensin-converting enzyme in rat aorta.
From pharmacogenomics to improved patient outcomes: angiotensin I-converting enzyme as an example.
Functional Foods and Nutraceuticals as Dietary Intervention in Chronic Diseases; Novel Perspectives for Health Promotion and Disease Prevention.
Gender differences in toxicokinetics, liver metabolism, and plasma esterase activity: observations from a chronic (27-week) toxicity study of enalapril/diltiazem combinations in rats.
Gene polymorphism of angiotensin II type 1 and type 2 receptors.
Genes of renin angiotensin system and coronary heart disease.
Genetic ACE I/D Polymorphism and Recurrence of Atrial Fibrillation After Catheter Ablation.
Genetic polymorphisms in the renin-angiotensin system: relevance for susceptibility to cardiovascular disease.
Genetic variation in angiotensin I-converting enzyme (ACE) and breast cancer risk: the multiethnic cohort.
Genetic variation of the angiotensin-converting enzyme gene: increased frequency of the insertion allele in Koreans.
Genetics of diabetic nephropathy.
Genome-wide scan for quantitative ACE activity in Taiwan young-onset hypertension study.
Getting advances in science to make a difference: Translation research for improving diabetes care.
Glyceryl trinitrate-induced angiotensin-converting enzyme (ACE) inhibition in healthy volunteers is dependent on ACE genotype.
Health Outcomes of Population-Based Pharmacy Outreach to Increase Statin Use for Prevention of Cardiovascular Disease in Patients with Diabetes.
Hemodynamic effects of anesthesia in patients chronically treated with angiotensin-converting enzyme inhibitors.
HOPE study impact on ACE inhibitors use.
Implementation of medication-related indicators of potentially preventable hospitalizations in a national chronic disease management program for older patients with multimorbidity.
Improvement of cardiac function by angiotensin converting enzyme inhibition. Sites of action.
Improvements in clinical outcomes with the use of angiotensin-converting enzyme inhibitors: cross-fertilization between clinical and basic investigation.
Improving patient outcomes by pooling resources (the Texas Heart Care Partnership experience).
In angiotensin-converting enzyme inhibitor-intolerant individuals, the angiotensin receptor blocker telmisartan does not reduce the incidence of major cardiovascular events in high-risk patients: lessons learned from the Telmisartan Randomized Assessment Study in ACE-Intolerant Subjects Wtih Cardiovascular Disease (TRANSCEND).
Income-related differences in the use of evidence-based therapies in older persons with diabetes mellitus in for-profit managed care.
Increased amount of the angiotensin-converting enzyme (ACE) mRNA originating from the ACE allele with deletion.
Increased cardiovascular risk in long-term hemodialysis patients carrying deletion allele of ACE gene polymorphism.
Increased expression of monocytic angiotensin-converting enzyme in dialysis patients with cardiovascular disease.
Induction of angiotensin I-converting enzyme transcription by a protein kinase C-dependent mechanism in human endothelial cells.
Inflammation and the metabolic syndrome: role of angiotensin II and oxidative stress.
Inflammation in atherosclerosis and psoriasis: common pathogenic mechanisms and the potential for an integrated treatment approach.
Influence of ACE I/D Polymorphism on Circulating Levels of Plasminogen Activator Inhibitor 1, D-Dimer, Ultrasensitive C-Reactive Protein and Transforming Growth Factor ?1 in Patients Undergoing Hemodialysis.
Influence of Angiotensin-converting enzyme polymorphism on neuropsychological subacute performance in moderate and severe traumatic brain injury.
Influence of cardiovascular risk factors on relation between angiotensin converting enzyme-gene polymorphism and blood pressure in arterial hypertension.
Influences of educational interventions and adverse news about calcium-channel blockers on first-line prescribing of antihypertensive drugs to elderly people in British Columbia.
Inhibition of the renin angiotensin system: implications for the endothelium.
Inhibition of the renin-angiotensin-aldosterone system prevents and cures atrial fibrillation: An overview of systematic reviews.
Inhibitors of the renin-angiotensin system: The potential role in the pathogenesis of COVID-19.
Insertion/deletion polymorphism of ACE gene in females with peripartum cardiomyopathy: A case-control study.
Insulin resistance and the endothelium.
Interaction between cyclooxygenase and the renin-angiotensin-aldosterone system: rationale and clinical relevance.
Interactions of angiotensin-converting enzyme, kinins and nitric oxide in circulation and the beneficial effects of ACE inhibitors in cardiovascular diseases.
International union of pharmacology. XXIII. The angiotensin II receptors.
Introduction.
Is angiotensin I-converting enzyme a "master" disease gene?
Is oxidative stress a therapeutic target in cardiovascular disease?
Kinins and cardiovascular diseases.
Lack of association between angiotensin converting enzyme gene insertion/deletion polymorphism and stroke.
Lack of association between insertion/deletion polymorphism of the angiotensin-converting enzyme gene and end-stage heart failure due to ischemic or idiopathic dilate cardiomyopathy in the Chinese.
Lack of association between renin-angiotensin system, gene polymorphisms, and wall thickness of the radial and carotid arteries.
Lactobacilli as multifaceted probiotics with poorly disclosed molecular mechanisms.
Left ventricular mass and volume with telmisartan, ramipril, or combination in patients with previous atherosclerotic events or with diabetes mellitus (from the ONgoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial [ONTARGET]).
Lessons learned from the ONTARGET and TRANSCEND trials.
Limitations of angiotensin inhibition.
Linkage and association analysis of angiotensin I-converting enzyme (ACE)-gene polymorphisms with ACE concentration and blood pressure.
Long-term adherence to evidence-based secondary prevention therapies in coronary artery disease.
Long-term angiotensin-converting enzyme inhibition with ramipril reduces thrombin generation in human hypertension.
Long-term clinical experience with zofenopril.
Losartan and other angiotensin II antagonists for nephropathy in type 2 diabetes mellitus: a review of the clinical trial evidence.
Main results and clinical interpretations from the TRANSCEND study.
Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Mechanisms by which angiotensin-converting enzyme inhibitors prevent diabetes and cardiovascular disease.
Mechanisms of ET-1-induced endothelial dysfunction.
Meta-Analysis of Randomized Trials on the Efficacy and Safety of Angiotensin-Converting Enzyme Inhibitors in Patients ?65 Years of Age.
Mineralocorticoid receptor antagonists and hypertension: is there a rationale?
Missed opportunities for the secondary prevention of cardiovascular disease in Canada.
Modification of cardiovascular risk in hemodialysis patients: an evidence-based review.
Molecular biology and genetics of the angiotensin-I-converting enzyme: potential implications in cardiovascular diseases.
Molecular genetics crying wolf? The case of the angiotensin-converting enzyme gene and cardiovascular disease.
Molecular imaging of high-risk atherosclerotic plaques: is it clinically translatable?
Molecular mechanism of the interactions between inhibitory tripeptides and angiotensin-converting enzyme.
Molecular variant of angiotensinogen gene is associated with coronary atherosclerosis.
Molecular variation at functional genes and the history of human populations--data on candidate genes for cardiovascular risk in the Mediterranean.
Mortality and Morbidity During and After Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial: Results by Sex.
Myocyte Specific Upregulation of ACE2 in Cardiovascular Disease: Implications for SARS-CoV-2 mediated myocarditis.
New dual inhibitors of neutral endopeptidase and angiotensin-converting enzyme: rational design, bioavailability, and pharmacological responses in experimental hypertension.
New fACEs to the renin-angiotensin system.
New Perspectives in the Renin-Angiotensin-Aldosterone System (RAAS) II: Albumin Suppresses Angiotensin Converting Enzyme (ACE) Activity in Human.
New Perspectives in the Renin-Angiotensin-Aldosterone System (RAAS) III: Endogenous Inhibition of Angiotensin Converting Enzyme (ACE) Provides Protection against Cardiovascular Diseases.
Next generation multifunctional angiotensin receptor blockers.
Nifedipine retard prevents hospitalization for angina pectoris better than angiotensin-converting enzyme inhibitors in hypertensive Japanese patients with previous myocardial infarction (JMIC-B substudy).
No HOPE without proof: do ARBs meet the standard for cardiovascular protection?
Noncompetitive inhibition of glycylsarcosine transport by quinapril in rabbit renal brush border membrane vesicles: effect on high-affinity peptide transporter.
Novel findings: Expression of angiotensin-converting enzyme and angiotensin-converting enzyme 2 in thoracic aortic dissection and aneurysm.
Novel ketomethylene inhibitors of angiotensin I-converting enzyme (ACE): inhibition and molecular modelling.
Novel mechanism of inhibition of human Angiotensin-I converting enzyme (ACE) by a highly specific phosphinic tripeptide.
Novel Therapeutic Approaches Targeting the Renin-Angiotensin System and Associated Peptides in Hypertension and Heart Failure.
Omapatrilat. Bristol-Myers Squibb.
Ongoing clinical outcome studies of calcium antagonists.
Ongoing trials involving angiotensin-converting enzyme inhibitors.
Overexpression of ACE in Myeloid Cells Increases Immune Effectiveness and Leads to a New Way of Considering Inflammation in Acute and Chronic Diseases.
Oxidative stress, AGE, and atherosclerosis.
Pathophysiologic and therapeutic importance of tissue ACE: a consensus report.
Patients with abdominal aortic aneurysm: are we missing the opportunity for cardiovascular risk reduction?
Pemphigus foliaceus: an adverse reaction to lisinopril.
Perindopril augments ecto-ATP diphosphohydrolase activity and enhances endothelial anti-platelet function in human umbilical vein endothelial cells.
Perindopril vs Enalapril in Patients with Systolic Heart Failure: Systematic Review and Metaanalysis.
Pharmacoeconomic analysis of angiotensin-converting enzyme inhibitors in type 2 diabetes: a Markov model.
Phorbol ester induction of angiotensin-converting enzyme transcription is mediated by Egr-1 and AP-1 in human endothelial cells via ERK1/2 pathway.
Pleiotropic effects of angiotensin-converting enzyme inhibitors in normotensive patients with coronary artery disease.
Point mutation in the stalk of angiotensin-converting enzyme causes a dramatic increase in serum angiotensin-converting enzyme but no cardiovascular disease.
Polymorphism in gene coding for ACE determines different development of myocardial fibrosis in rats.
Polymorphism modulates symptomatic response to antiarrhythmic drug therapy in patients with lone atrial fibrillation.
Polymorphism of angiotensin converting enzyme is associated with severe circulatory compromise in febrile neutropenic children with cancer.
Polymorphism of the angiotensin-converting enzyme (ACE) and angiotesinogen (AGT) genes and their associations with blood pressure and carotid artery intima media thickness among healthy Finnish young adults--the Cardiovascular Risk in Young Finns Study.
Polymorphism of the angiotensin-converting enzyme gene and cardiovascular disease.
Potential of RAS Inhibition to Improve Metabolic Bone Disorders.
Potential risk factors associated with progressive renal damage in childhood urological diseases: the role of angiotensin-converting enzyme gene polymorphism.
Predictors of self-reported noncompliance with antihypertensive drug treatment: A prospective cohort study.
Prescribing and deprescribing in chronic kidney disease.
Prevention of diabetes in hypertensive patients: results and implications from the VALUE trial.
Progression of cardiovascular damage: the role of renin-angiotensin system blockade.
Protective effects of angiotensin-converting enzyme inhibitors in high-risk African American men with coronary heart disease.
Protective effects of imidapril on He-Ne laser-induced thrombosis in cerebral blood vessels of stroke-prone spontaneously hypertensive rats.
Quantitative phenotype analysis for localization and identification of disease-related genes in a complex genetic background.
Ramipril in the treatment of vascular diseases.
Rate of Cough During Treatment With Angiotensin-Converting Enzyme Inhibitors: A Meta-Analysis of Randomized Placebo-Controlled Trials.
Rationale and design of the cardiac magnetic resonance imaging substudy of The ONTARGET Trial Programme.
Rationale and pharmacology of angiotensin II receptor antagonists: current status and future issues.
Rationale for ACE inhibition as an anti-ischaemic therapy.
Recent studies with eplerenone, a novel selective aldosterone receptor antagonist.
Redox status of patients before cardiac surgery.
Regression of albuminuria: latest evidence for a new approach.
Regression of left ventricular hypertrophy by lisinopril after renal transplantation: role of ACE gene polymorphism.
Regulation of cardiovascular remodeling by the counter-regulatory axis of the renin-angiotensin system.
Relationship between angiotensin-converting enzyme gene insertion/deletion polymorphism, angiographically defined coronary artery disease and myocardial infarction in patients with type 2 diabetes mellitus.
Relationship between circulating levels of angiotensin-converting enzyme 2-angiotensin-(1-7)-MAS axis and coronary heart disease.
Relationship between sleep disordered breathing and diabetic retinopathy: Analysis of 136 patients with diabetes.
Relationship between the angiotensin I-converting enzyme insertion/deletion (I/D) polymorphism and cardiovascular risk factors in healthy young Mexican women.
Relationship between the response to the angiotensin converting enzyme inhibitor imidapril and the angiotensin converting enzyme genotype.
Relationship of polymorphisms in the renin-angiotensin system and in E-selectin of patients with early severe coronary heart disease.
Renal considerations in angiotensin converting enzyme inhibitor therapy: a statement for healthcare professionals from the Council on the Kidney in Cardiovascular Disease and the Council for High Blood Pressure Research of the American Heart Association.
Renal outcomes with aliskiren in patients with type 2 diabetes: a prespecified secondary analysis of the ALTITUDE randomised controlled trial.
Renin inhibition.
Renin inhibition: a new modality for hypertension management.
Renin inhibitors: cardiovascular drugs of the future?
Renin-angiotensin system gene polymorphisms and left ventricular hypertrophy. The case against an association.
Renin-angiotensin system gene polymorphisms: potential mechanisms for their association with cardiovascular diseases.
Renin-Angiotensin System Inhibition in Cardiovascular Patients at the Time of COVID19: Much Ado for Nothing? A Statement of Activity from the Directors of the Board and the Scientific Directors of the Italian Society of Hypertension.
Replicated studies of two randomized trials of angiotensin-converting enzyme inhibitors: further empiric validation of the 'prior event rate ratio' to adjust for unmeasured confounding by indication.
Repurposing of drugs approved for cardiovascular diseases: Opportunity or mirage?
Risk of cardiovascular events after initiation of long-acting bronchodilators in patients with chronic obstructive lung disease: A population-based study.
Role of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors, angiotensin-converting enzyme inhibitors, cyclooxygenase-2 inhibitors, and aspirin in anti-inflammatory and immunomodulatory treatment of cardiovascular diseases.
Role of RAAS Inhibition in the Prevention of Cardiovascular Disease.
Role of thrombotic and fibrinolytic factors in acute coronary syndromes.
Serum angiotensin-I-converting enzyme activity in women with cardiological syndrome X: relation to blood pressure and lipid and carbohydrate metabolic risk markers for coronary heart disease.
Serum Levels of Adipocyte Fatty Acid-Binding Protein Are Associated with Rapid Renal Function Decline in Patients with Type 2 Diabetes Mellitus and Preserved Renal Function.
Severity and mortality of COVID 19 in patients with diabetes, hypertension and cardiovascular disease: a meta-analysis.
Sex Differences in Cardiovascular Medication Prescription in Primary Care: A Systematic Review and Meta-Analysis.
Signaling by the angiotensin-converting enzyme.
Socioeconomic aspects of ACE inhibition in the secondary prevention in cardiovascular diseases.
Species-specific splicing and expression of angiotensin converting enzyme.
Sphingosine-1-phosphate: A mediator of the ARB-MI paradox?
Stroke outcomes among participants randomized to chlorthalidone, amlodipine or lisinopril in ALLHAT.
Structural basis of Ac-SDKP hydrolysis by Angiotensin-I converting enzyme.
Sudden cardiac death in CKD patients.
Sulfhydryl angiotensin-converting enzyme inhibitor promotes endothelial cell survival through nitric-oxide synthase, fibroblast growth factor-2, and telomerase cross-talk.
SY 05-2 PROGRESSION OF HYPERTENSIVE HEART DISEASE: NEW THERAPEUTIC APPROACH.
Synergistic effect between apolipoprotein E and angiotensinogen gene polymorphisms in the risk for early myocardial infarction.
Targeting endothelial cell metabolism for cardio-protection from the toxicity of antitumor agents.
Targeting the Angiotensin II Type 1 Receptor in Cerebrovascular Diseases: Biased Signaling Raises New Hopes.
Telmisartan acts through the modulation of ACE-2/ANG 1-7/mas receptor in rats with dilated cardiomyopathy induced by experimental autoimmune myocarditis.
Telmisartan and cardioprotection.
Temporal patterns of antihypertensive medication use among elderly patients. The Cardiovascular Health Study.
The 2011 canadian hypertension education program recommendations for the management of hypertension: blood pressure measurement, diagnosis, assessment of risk, and therapy.
The AMP-Activated Protein Kinase Regulates Endothelial Cell Angiotensin-Converting Enzyme Expression via p53 and the Post-Transcriptional Regulation of microRNA-143/145.
The angiotensin converting enzyme gene in cardiovascular disease.
The angiotensin I-converting enzyme gene polymorphism: implication in hypertension and myocardial infarction.
The association between circulating angiotensin-converting enzyme and cardiovascular risk in the elderly: A cross-sectional study.
The association between the angiotensin I converting enzyme gene polymorphism and cardiovascular disease.
The beneficial effects of angiotensin-converting enzyme inhibitors on serum asymmetric dimethylarginine levels in the patients with cardiovascular disease.
The chymase-angiotensin system in humans: biochemistry, molecular biology and potential role in cardiovascular diseases.
The Combination of Lithium and ACE Inhibitors: Hazardous, Critical, Possible?
The DD-ACE genotype and cardiovascular disease.
The deletion genotype of the angiotensin I-converting enzyme is associated with an increased vascular reactivity in vivo and in vitro.
The deletion polymorphism of the angiotensin-converting enzyme gene is associated with acute aortic dissection.
The evolution of angiotensin blockade in the management of cardiovascular disease.
THE IMPACT OF CARDIOVASCULAR DRUGS ON GLYCEMIC CONTROL: A REVIEW.
The implications of a growing evidence base for drug use in elderly patients. Part 1. Statins for primary and secondary cardiovascular prevention.
The importance of the renin-angiotensin system in cardiovascular disease.
The link between angiotensin-converting enzyme genotype and pulmonary artery pressure in patients with COPD.
The Mediterranean Diet, its Components, and Cardiovascular Disease.
The molecular and cellular biology of heart failure.
The ONTARGET/TRANSCEND Trial Programme: baseline data.
The place of angiotensin-converting enzyme inhibition in the treatment of cardiovascular diseases.
The plasma and tissue kininogen-kallikrein-kinin system: role in the cardiovascular system.
The potential of stimulating nitric oxide formation in the treatment of hypertension.
The potential role of angiotensin converting enzyme and vasopeptidase inhibitors in the treatment of diabetic neuropathy.
The potential role of milk-derived peptides in cardiovascular disease.
The renin-angiotensin system and cardiovascular disease.
The Renin-Angiotensin System and Cardiovascular Disease.
The renin-angiotensin system and the long-term complications of diabetes: pathophysiological and therapeutic considerations.
The renin-angiotensin system blockers as adjunctive therapy for cancer: a meta-analysis of survival outcome.
The renin-angiotensin system in cardiovascular autonomic control: recent developments and clinical implications.
The risk of polymyalgia rheumatica in older adults with gout: a Medicare claims study.
The role of adiponectin in renal physiology and development of albuminuria.
The role of angiotensin II antagonism in type 2 diabetes mellitus: a review of renoprotection studies.
The role of angiotensin receptor blockers and/or angiotensin converting enzyme inhibitors in the prevention of atrial fibrillation in patients with cardiovascular diseases: meta-analysis of randomized controlled clinical trials.
The role of angiotensin receptor-neprilysin inhibitors in cardiovascular disease-existing evidence, knowledge gaps, and future directions.
The role of angiotensin-converting enzyme inhibitors in the therapy of cardiovascular disease: an overview.
The role of beta-cell dysfunction in the cardiometabolic syndrome.
The role of low-dose diuretics in essential hypertension.
The SARS-CoV-2 receptor, ACE-2, is expressed on many different cell types: implications for ACE-inhibitor- and angiotensin II receptor blocker-based cardiovascular therapies.
The structure of testis angiotensin-converting enzyme in complex with the C domain-specific inhibitor RXPA380.
The two fACEs of the tissue renin-angiotensin systems: implication in cardiovascular diseases.
The Use of ACE Inhibitor in Cardiovascular Disease.
The use of ACE inhibitors on diabetic patients without renal disease.
Therapeutic potential of quercetin as a cardiovascular agent.
Thiazide and loop diuretics.
Tissue ACE inhibitors for secondary prevention of cardiovascular disease in patients with preserved left ventricular function: a pooled meta-analysis of randomized placebo-controlled trials.
Tissue angiotensin-converting enzyme inhibitors for the prevention of cardiovascular disease in patients with diabetes mellitus without left ventricular systolic dysfunction or clinical evidence of heart failure: a pooled meta-analysis of randomized placebo-controlled clinical trials.
Treatment of isolated systolic hypertension in the elderly.
Turbina oblongata Protects Against Oxidative Cardiotoxicity by Suppressing Lipid Dysmetabolism and Modulating Cardiometabolic Activities Linked to Cardiac Dysfunctions.
Twenty years of progress in angiotensin converting enzyme 2 and its link to SARS-CoV-2 disease.
Two quantitative trait loci affect ACE activities in Mexican-Americans.
Update on the interaction between aspirin and angiotensin-converting enzyme inhibitors.
Use of calcium channel blockers and angiotensin-converting enzyme inhibitors after cardiac transplantation.
Use of Secondary Prevention Medications among Adults with Reduced Kidney Function.
Valsartan chronotherapy reverts the non-dipper pattern and improves blood pressure control through mediation of circadian rhythms of the renin-angiotensin system in spontaneous hypertension rats.
Variation at the Angiotensin-converting enzyme and endothelial nitric oxide synthase genes is associated with the risk of esophageal varices among patients with alcoholic cirrhosis.
Venom Immunotherapy in High-Risk Patients: The Advantage of the Rush Build-Up Protocol.
Voltage-programming-based capillary gel electrophoresis for the fast detection of angiotensin-converting enzyme insertion/deletion polymorphism with high sensitivity.
What is the impact of the ACE gene insertion/deletion (I/D) polymorphism on the clinical effectiveness and adverse events of ACE inhibitors?--Protocol of a systematic review.
What is the role of angiotensin-receptor blockade in cardiovascular protection?
Which drug should be used to treat patients with uncomplicated essential hypertension?
[ACE inhibitors--activators of kinin receptors].
[Anesthetic consequences of hemodynamic effects of angiotensin converting enzyme inhibitors]
[Angiotensin converting enzyme inhibitors and angiotensin receptor blockers use in patients with acute coronary syndrome]
[Angiotensin-converting enzyme inhibition and cardiovascular prevention: more than twenty years of clinical success]
[Association analysis of polymorphism in angiotensin-converting enzyme gene in ischemic stroke]
[AT1 angiotensin receptor inhibition as a new therapeutic possibility]
[Chinese expert consensus document on angiotensin converting enzyme inhibitors in cardiovascular diseases]
[Clinical study of the month. Which initial antihypertensive? Results from the ALLHAT trial]
[COVID-19 and its relationship with hypertension and cardiovascular disease].
[Deletion polymorphism of the angiotensin I-converting enzyme gene associates with increased risk for ischemic heart diseases in the Japanese]
[Drug-induced interstitial lung diseases].
[Ecogenetic aspects of acute side effects caused by angiotensin converting enzyme inhibitors]
[Effect of angiotensin-converting enzyme insertion-deletion polymorphism on progression of renal and cardiovascular diseases]
[Effect of anti-hypertensive therapy with irbesartan on the absolute cardiovascular risk]
[Effect of the location of previous atherosclerotic disease on prognosis in diabetic patients. The Barbanza Diabetes Study]
[Evaluation of angiotensin I converting enzyme gene polymorphism in patients with essential hypertension and coronary artery disease]
[Expert Consensus document on angiotensin converting enzyme inhibitors in cardiovascular disease]
[Glucocorticoid receptor mechanism of regulation of the activity of angiotensin-converting enzyme and new prospects in the treatment of cardiovascular diseases]
[Hemodynamic effects of captopril, an ACE inhibitor, in patients after aortocoronary bypass]
[Molecular genetics of cardiovascular diseases]
[Multifactorial aspect of acute side effects of angiotensin converting enzyme inhibitors]
[Network regulation of renin-angiotensin system on the cardiovascular diseases].
[Pathophysiological and clinical implications of AT(1)/AT(2) angiotensin II receptors in heart failure and coronary and renal failure]
[Polymorphism of the angiotensin I-converting enzyme gene in Moscovites with arterial hypertension and cardiovascular diseases]
[Polymorphism of the promotor region of the angiotensinogen gene and the gene for angiotensin I-converting enzyme in arterial hypertension and myocardial ischemia of the Kazakh ethnic groups]
[Prevention and treatment of ischemic heart disease in patients with diabetes mellitus]
[Prospective trends in the study of the therapeutic action of angiotensin-converting enzyme inhibitors in cardiovascular diseases]
[Renin-angiotensin system modulation: instructions for use]
[Synthesis of renin and angiotensin-converting enzyme in human heart]
[The clinical pharmacology of angiotensin II antagonists]
[The long way of angiotensin-converting enzyme inhibitors in the fight against cardiovascular diseases]
[The relationship between ACE I/D polymorphism and HDL cholesterol]
[Update cardiology 2006/2007]
[Use of aspirin in patients taking angiotensin converting enzyme inhibitors]
[Value of pleiotropic effects of angiotensin-converting enzyme inhibitors].
Carotid Artery Diseases
An interaction between systolic blood pressure and angiotensin-converting enzyme gene polymorphism on carotid atherosclerosis.
Angiotensin converting enzyme gene polymorphism and carotid atherosclerosis in a low-risk population.
Angiotensin-converting enzyme gene I/D polymorphism and carotid artery disease in renovascular hypertension.
Angiotensinogen and angiotensin converting enzyme genotypes and carotid atherosclerosis: the atherosclerosis risk in communities and the NHLBI family heart studies.
Anti-hypertensive treatment in peripheral artery disease.
Association between angiotensin converting enzyme gene polymorphism and carotid atherosclerosis.
Association of the ACE rs4646994 and rs4341 polymorphisms with the progression of carotid atherosclerosis in slovenian patients with type 2 diabetes mellitus.
Different effects of antihypertensive regimens based on fosinopril or hydrochlorothiazide with or without lipid lowering by pravastatin on progression of asymptomatic carotid atherosclerosis: principal results of PHYLLIS--a randomized double-blind trial.
Low potentiality of angiotensin-converting enzyme gene insertion/deletion polymorphism as a useful predictive marker for carotid atherogenesis in a large general population of a Japanese city: the Suita study.
Polymorphisms of apolipoprotein E and angiotensin-converting enzyme genes and carotid atherosclerosis in heavy drinkers.
Randomized, placebo-controlled trial of the angiotensin-converting enzyme inhibitor, ramipril, in patients with coronary or other occlusive arterial disease. PART-2 Collaborative Research Group. Prevention of Atherosclerosis with Ramipril.
Trials investigating the anti-atherosclerotic effects of antihypertensive drugs.
Carotid Artery Injuries
Neointima formation in injured hamster carotid artery is effectively prevented by the combination G4120 and quinapril.
Carotid Stenosis
An angiotensin-converting enzyme gene polymorphism suggests a genetic distinction between ischaemic stroke and carotid stenosis.
Angiotensin-converting enzyme gene deletion polymorphism. A new risk factor for lacunar stroke but not carotid atheroma.
Predictors of clinically significant postprocedural hypotension after carotid endarterectomy and carotid angioplasty with stenting.
Cataract
Association of angiotensin-converting enzyme,
Current treatment and management of dystrophinopathies.
Influence of selected angiotensin-converting enzyme inhibitors on alloxan-induced diabetic cataract in rabbits.
Therapeutic targets of renin-angiotensin system in ocular disorders.
Use of antihypertensive medications and topical beta-blockers and the long-term incidence of cataract and cataract surgery.
Celiac Disease
Angiotensin-converting enzyme activity in stools of healthy subjects and patients with celiac disease.
Cellulitis
Psoriasis: changing clinical patterns.
Central Nervous System Diseases
Activation of the Protective Arm of the Renin Angiotensin System in Demyelinating Disease.
Cerebral Amyloid Angiopathy
Angiotensin-converting enzyme (ACE) levels and activity in Alzheimer's disease, and relationship of perivascular ACE-1 to cerebral amyloid angiopathy.
Angiotensin-converting enzyme 2 is reduced in Alzheimer's disease in association with increasing amyloid-? and tau pathology.
Post-mortem assessment of hypoperfusion of cerebral cortex in Alzheimer's disease and vascular dementia.
Cerebral Hemorrhage
Angiotensin-converting enzyme (rs4646994) and ? ADDUCIN (rs4961) gene polymorphisms' study in primary spontaneous intracerebral hemorrhage.
Angiotensin-converting enzyme G2350A gene polymorphisms and hypertension among patients with intracerebral hemorrhage.
Angiotensin-converting enzyme inhibitors and pneumonia in elderly patients with intracerebral hemorrhage.
Angiotensin-converting enzyme insertion/deletion gene polymorphisms and risk of intracerebral hemorrhage: A meta-analysis of epidemiologic studies.
Angiotensin-converting enzyme polymorphisms and risk of spontaneous deep intracranial hemorrhage in Taiwan.
Angiotensin-converting enzyme tag single nucleotide polymorphisms in patients with intracerebral hemorrhage.
Association of angiotensin-converting enzyme insertion/deletion polymorphism (rs4646994) with the risk of primary intracerebral hemorrhage.
DD genotype of ACE gene is a risk factor for intracerebral hemorrhage.
Genetic Associations of Angiotensin-Converting Enzyme with Primary Intracerebral Hemorrhage: A Meta-analysis.
Orolingual Angioedema During or After Thrombolysis for Cerebral Ischemia.
Prior use of angiotensin-converting enzyme inhibitors does not affect outcome in patients with intracerebral hemorrhage.
Usage of Angiotensin-Converting Enzyme Inhibitor or Angiotensin II Receptor Blocker in Hypertension Intracerebral Hemorrhage.
Cerebral Infarction
Angiotensin converting enzyme gene polymorphism and traditional Sasang classification in Koreans with cerebral infarction.
Angiotensin-Converting Enzyme Gene Polymorphism and Plasminogen Activator Inhibitor 1 Levels in Subjects with Cerebral Infarction.
Effect of perindopril on cerebral vasomotor reactivity in patients with lacunar infarction.
Effects of bunazosin hydrochloride sustained-release formulation on cerebral circulation.
Inhibition of matrix metalloproteinase-9 activity by trandolapril after middle cerebral artery occlusion in rats.
Perindopril reduces blood pressure but not cerebral blood flow in patients with recent cerebral ischemic stroke.
Platelet angiotensin II in cerebrovascular accident and the effect of angiotensin-converting enzyme inhibitors.
Polymorphism of angiotensin-converting enzyme, angiotensinogen, and apolipoprotein E genes in Korean patients with cerebral infarction.
Polymorphism of the angiotensin-converting enzyme gene in patients with cerebral infarction in Koreans.
Resistin Level is Positively Correlated with Thrombotic Complications in Southern Chinese Metabolic Syndrome Patients.
Trandolapril reduces infarction area after middle cerebral artery occlusion in rats.
[A cross-sectional study on angiotensin-converting enzyme and angiotensin II type I receptor gene polymorphism and cerebral infarction]
[The relationship between angiotensin converting enzyme gene polymorphism and risk factors for cerebral infarct]
Cerebral Small Vessel Diseases
Angiotensin-converting enzyme in cerebrospinal fluid and risk of brain atrophy.
Association Between the Angiotensin-Converting Enzyme I/D Polymorphism and Risk of Cerebral Small Vessel Disease: A Meta-Analysis Based on 7186 Subjects.
Cerebrovascular Disorders
A perspective on telmisartan and cardiovascular risk.
A prospective study of frequency and characteristics of cough during ACE inhibitor treatment.
ACE genotype and cognitive decline in an African-Caribbean population.
Angiotensin I-converting enzyme gene (I/D) polymorphism in patients with migraine.
Angiotensin I-converting enzyme gene polymorphism in intracranial saccular aneurysm individuals.
Angiotensin-converting enzyme gene deletion polymorphism. A new risk factor for lacunar stroke but not carotid atheroma.
Angiotensin-converting enzyme insertion/deletion polymorphism and cerebrovascular disease.
Angiotensin-converting enzyme insertion/deletion polymorphism has no effect on the risk of atherosclerotic stroke or hypertension.
ASSOCIATIONS BETWEEN TRIGLYCERIDE/HIGH-DENSITY LIPOPROTEIN CHOLESTEROL RATIO AND MICRO- AND MACROANGIOPATHIES IN TYPE 2 DIABETES MELLITUS.
Atherosclerotic risk factors and renal function in the elderly: the role of hyperfibrinogenaemia and smoking. Results from the Italian Longitudinal Study on Ageing (ILSA).
Blood pressure lowering in patients with cerebrovascular disease: results of the PROGRESS (Perindopril Protection Against Recurrent Stroke Study) pilot phase.
Cerebrovascular disorders and genetic polymorphisms: mitochondrial DNA5178C is predominant in cerebrovascular disorders.
Clinical evidence of dose-dependent interaction between aspirin and angiotensin-converting enzyme inhibitors.
Complications of Cardiovascular Events in Patients Hospitalized with Influenza-Related Pneumonia.
Does Low Dose Angiotensin Converting Enzyme Inhibitor Prevent Pneumonia in Older People With Neurologic Dysphagia--A Randomized Placebo-Controlled Trial.
Drug therapy before coronary artery surgery: nitrates are independent predictors of mortality and beta-adrenergic blockers predict survival.
Evaluation of the Differences in the Effects of Antihypertensive Drugs on Blood Pressure Variability by 24-Hour Ambulatory Blood Pressure Monitoring in Chronic Cerebrovascular Disease.
Frequency of APOE, MTHFR and ACE polymorphisms in the Zambian population.
Genetic risk factors and ischaemic cerebrovascular disease: role of common variation of the genes encoding apolipoproteins and angiotensin-converting enzyme.
Influenza Vaccination Reduces Dementia Risk in Chronic Kidney Disease Patients: A Population-Based Cohort Study.
Lack of association between angiotensin I-converting enzyme gene deletion polymorphism and cerebrovascular disease in Taiwanese.
Managing the patient at risk for a second stroke.
Polymorphism of angiotensin converting enzyme, angiotensinogen, and apolipoprotein E genes in a Japanese population with cerebrovascular disease.
Polymorphism of the angiotensin-converting enzyme (ACE) gene in patients with thrombotic brain infarction.
Polymorphism of the angiotensin-converting enzyme gene in patients with cerebral infarction in Koreans.
Prevalence and Predictors of Statin Treatment Among Patients With Chronic Heart Failure at a Tertiary-Care Center in Thailand.
PROGRESS (Perindopril Protection Against Recurrent Stroke Study): regional characteristics of the study population at baseline. PROGRESS Management Committee.
The Risk of Acute Kidney Injury from Fluid Restriction and Hydroxyethyl Starch in Thoracic Surgery.
[Hypertension associated with cerebrovascular disease].
[Hypertension in the acute phase and in the secondary prevention of stroke]
Chagas Cardiomyopathy
Angiotensin-converting enzyme insertion/deletion gene polymorphism and progression of Chagas' cardiomyopathy.
Angiotensin-converting enzyme insertion/deletion gene polymorphism and progression of chagas' cardiomyopathy.
Chagas Disease
Angiotensin-Converting Enzyme ID Polymorphism in Patients with Heart Failure Secondary to Chagas Disease.
Beta blockers prevent correlation of plasma ACE2 activity with echocardiographic parameters in patients with idiopathic dilated cardiomyopathy.
Chagas' heart disease.
Treatment of chronic systolic heart failure secondary to Chagas heart disease in the current era of heart failure therapy.
Chalazion
Angiotensin-converting enzyme in sarcoid and chalazion granulomas of the conjunctiva.
Cholera
Love of Angiotensin-Converting Enzyme Inhibitors in the Time of Cholera.
Cholestasis
Hepatotoxicity effect of short-term Bradykinin potentiating factor in cholestatic rats.
Insertion-deletion polymorphism in the gene for angiotensin-converting enzyme is associated with obstetric cholestasis but not with preeclampsia.
The angiotensin-converting enzyme gene insertion-deletion polymorphism in a white British patient cohort with obstetric cholestasis.
Chondromalacia Patellae
Angiotensin converting enzyme in human synovium: increased stromal [(125)I]351A binding in rheumatoid arthritis.
Choroidal Neovascularization
An angiotensin-converting enzyme inhibitor modulates stromal-derived factor-1 through CD26/dipeptidyl peptidase IV to inhibit laser-induced choroidal neovascularization.
EFFECT OF SYSTEMIC BETA-BLOCKERS, ACE INHIBITORS, AND ANGIOTENSIN RECEPTOR BLOCKERS ON DEVELOPMENT OF CHOROIDAL NEOVASCULARIZATION IN PATIENTS WITH AGE-RELATED MACULAR DEGENERATION.
Suppression of choroidal neovascularization by inhibiting angiotensin-converting enzyme: minimal role of bradykinin.
Chronic Limb-Threatening Ischemia
Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers (ACEI/ARB) are Associated with Improved Limb Salvage after Infrapopliteal Interventions for Critical Limb Ischemia.
Angiotensin-converting enzyme inhibitor or angiotensin receptor blocker use is associated with reduced major adverse cardiovascular events among patients with critical limb ischemia.
Effectiveness of combined therapy with angiotensin-converting enzyme inhibitors and statins in reducing mortality in diabetic patients with critical limb ischemia: An observational study.
Improved survival with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in chronic limb-threatening ischemia.
Review of article: Effectiveness of combined therapy with angiotensin-converting enzyme inhibitors and statins in reducing mortality in diabetic patients with critical limb ischemia: an observational study by Ezio Faglia, Giacomo Clerici, Alessia Scatena et al (Diabetes Research and Clinical Practice 2014;103:292-297).
Chronic Periodontitis
Effect of antihypertensive therapy with angiotensin-converting enzyme inhibitors on chronic periodontitis: a case-control study.
Interactions of Lymphotoxin ? (TNF-?), Angiotensin-Converting Enzyme (ACE), and Endothelin-1 (ET-1) Gene Polymorphisms in Adult Periodontitis.
Interactions of lymphotoxin alpha (TNF-beta), angiotensin-converting enzyme (ACE), and endothelin-1 (ET-1) gene polymorphisms in adult periodontitis.
Renin-angiotensin gene polymorphisms in relation to severe chronic periodontitis.
Chronic Urticaria
An 82-year-old man with recurrent angioedema.
Association of insertion/deletion polymorphism of the angiotensin-converting enzyme gene with angio-oedema accompanying chronic urticaria but not chronic urticaria without angio-oedema or the autologous serum skin test response.
Chronic Urticaria and Recurrent Angioedema: Clues to the Mimics.
Cofactors and comorbidities in patients with aspirin/NSAID hypersensitivity.
Chylothorax
Chylothorax associated with tricuspid dysplasia and atrial septal defect in a bullmastiff.
Clostridium Infections
The Impact of angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers in patients with Clostridium difficile infection.
Coccidioidomycosis
Serum angiotensin-converting enzyme in leprosy and coccidioidomycosis.
Coinfection
Effects of Angiotensin Converting Enzyme Inhibitors on Liver Fibrosis in HIV and Hepatitis C Coinfection.
Electrolyte Imbalance at Admission Does Not Predict the Length of Stay or Mortality in Dengue-Infected Patients.
Exploring the causes of mild COVID-19 involvement in pediatric patients.
Colitis
Altered Expression of Angiotensinogen and Mediators of Angiogenesis in Ileal Crohn's Disease.
Beneficial anti-inflammatory effect of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker in the treatment of dextran sulfate sodium-induced colitis in mice.
Effect of Quercetin Monoglycosides on Oxidative Stress and Gut Microbiota Diversity in Mice with Dextran Sodium Sulphate-Induced Colitis.
Impact of Angiotensin II Signaling Blockade on Clinical Outcomes in Patients with Inflammatory Bowel Disease.
Orally administered angiotensin-converting enzyme-inhibitors captopril and isoleucine-proline-proline have distinct effects on local renin-angiotensin system and corticosterone synthesis in dextran sulfate sodium-induced colitis in mice.
Prevention of fibrosis in experimental colitis by captopril: the role of tgf-beta1.
Reduced severity of a mouse colitis model with angiotensin converting enzyme inhibition.
The effect of angiotensin-converting enzyme inhibitors on experimental colitis in rats.
The use of unlicensed bone marrow-derived platelet lysate-expanded mesenchymal stromal cells in colitis: a pre-clinical study.
Transanal delivery of angiotensin converting enzyme inhibitor prevents colonic fibrosis in a mouse colitis model: development of a unique mode of treatment.
Colitis, Ulcerative
Angiotensin-converting enzyme in Crohn's disease and ulcerative colitis.
Serum angiotensin converting enzyme activity in Crohn's disease and ulcerative colitis.
Serum angiotensin converting enzyme in Crohn's disease, ulcerative colitis and peptic ulceration.
Serum angiotensin I-converting enzyme is reduced in Crohn's disease and ulcerative colitis irrespective of genotype.
Serum angiotensin-I-converting enzyme and carboxypeptidase N in Crohn's disease and ulcerative colitis.
Ulcerative Colitis in a COVID-19 Patient: A Case Report.
Colonic Neoplasms
Angiotensin converting enzyme-independent, local angiotensin II-generation in human pancreatic ductal cancer tissues.
Bioactive, functional and edible film-forming properties of isolated hazelnut (Corylus avellana L.) meal proteins
Enhanced tumor localization of monoclonal antibody by treatment with kininase II inhibitor and angiotensin II.
Key-Protease Inhibition Regimens Promote Tumor Targeting of Neurotensin Radioligands.
Optimizing the Profile of [99mTc]Tc-NT(7-13) Tracers in Pancreatic Cancer Models by Means of Protease Inhibitors.
[Intrinsic angiotensin II-generating system in human pancreatic cancer tissues]
Colorectal Neoplasms
Angiotensin I-converting enzyme gene plays a crucial role in the pathology of carcinomas in colorectal cancer.
Angiotensin I-converting enzyme inhibitors/angiotensin II receptor blockers may reduce tumor recurrence in left-sided and early colorectal cancers.
Angiotensin-Converting Enzyme Gene Deletion Polymorphism is Associated with Lymph Node Metastasis in Colorectal Cancer Patients in a Chinese Population.
Angiotensin-converting enzyme inhibitor therapy and colorectal cancer risk.
Angiotensin-converting enzyme inhibitors/angiotensin receptor blockers therapy and colorectal cancer: a systematic review and meta-analysis.
Associations of angiotensin-converting enzyme inhibitor or angiotensin receptor blocker use with colorectal cancer risk in the Women's Health Initiative.
Cardiovascular medication use and risk for colorectal cancer.
Changes in the renin angiotensin system during the development of colorectal cancer liver metastases.
Cross-sectional associations between angiotensin-converting enzyme inhibitor use and cancer diagnosis in US adults.
Exposure to ACEI/ARB and ?-Blockers Is Associated with Improved Survival and Decreased Tumor Progression and Hospitalizations in Patients with Advanced Colon Cancer.
Long-term Use of Angiotensin Converting Enzyme Inhibitors Is Associated With Decreased Incidence of Advanced Adenomatous Colon Polyps.
No association with risk for colorectal cancer of the insertion/deletion polymorphism which affects levels of angiotensin-converting enzyme.
Peptides present in the non-digestible fraction of common beans (Phaseolus vulgaris L.) inhibit the angiotensin-I converting enzyme by interacting with its catalytic cavity independent of their antioxidant capacity.
Renin-angiotensin system gene polymorphisms and colorectal cancer risk: a meta-analysis.
Renin-angiotensin system inhibitor use and colorectal cancer risk and mortality: A dose-response meta analysis.
Renin-Angiotensin-Aldosterone System-Based Antihypertensive Agents and the Risk of Colorectal Cancer Among Medicare Beneficiaries.
Survivin and angiotensin-converting enzyme polymorphisms with risk of colorectal cancer: a systematic review and meta-analysis.
The gene polymorphism of the angiotensin I-converting enzyme correlates with tumor size and patient survival in colorectal cancer patients.
The Therapeutic Potential of Angiotensin-converting enzyme and angiotensin receptor inhibitors in the treatment of colorectal cancer: Rational Strategies and Recent Progress.
Coma
Long-term prognosis after out-of-hospital cardiac arrest with/without ST elevation myocardial infarction.
Common Cold
Cough provocation tests: their clinical value.
Communicable Diseases
Microfluidic chip-based method for genotyping microsatellites, VNTRs and insertion/deletion polymorphisms.
Severity of meningococcal disease in children and the angiotensin-converting enzyme insertion/deletion polymorphism.
The serum angiotensin converting enzyme and lysozyme levels in patients with ocular involvement of autoimmune and infectious diseases.
Uveitis: the collaborative diagnostic evaluation.
Complex Regional Pain Syndromes
A polymorphic locus in the intron 16 of the human angiotensin-converting enzyme (ACE) gene is not correlated with complex regional pain syndrome I (CRPS I).
Reduced serum protease activity in Complex Regional Pain Syndrome: The impact of angiotensin-converting enzyme and carboxypeptidases.
Confusion
Angiotensin-converting enzyme gene polymorphism. What to do about all the confusion.
Angiotensin-converting enzyme: confusion about activity units.
Genetics of intima-media thickness.
Histoplasmosis: a masquerader of sarcoidosis.
Relationship between ACE-inhibitors, ARBs and SARS-CoV-2 infection: where are we?
[Process in Citation].
Congenital Abnormalities
Angiotensin-converting enzyme inhibitors during the first trimester of pregnancy increase the incidence of fetal malformation, whereas calcium intake (1.0 to 2.0 g/day) prevents preeclampsia.
Are angiotensin-converting enzyme inhibitors and angiotensin receptor blockers safe in pregnancy: a report of ninety-one pregnancies.
Distention of the lateral intercellular spaces (LIS) in the proximal tubule cells of the non-stenosed kidney of the 2K-1C Goldblatt model of hypertension as evidence of pressure diuresis.
Increased rate of birth defects after first trimester use of angiotensin converting enzyme inhibitors - Treatment or hypertension related? An observational cohort study.
Risk Factors for Birth Defects.
[Epidemiologic, clinical, biological and therapeutic aspects of Gaucher disease]
Congenital Hypothyroidism
Angiotensin II (AII) and adrenal gland AII receptors in rats with congenital hypothyroidism.
Reduced serum angiotensin converting enzyme activity in children with congenital hypothyroidism.
Connective Tissue Diseases
Combined systolic and diastolic heart failure as the first presentation of mixed connective tissue disease.
Pulmonary capillary endothelial metabolic dysfunction: severity in pulmonary arterial hypertension related to connective tissue disease versus idiopathic pulmonary arterial hypertension.
[Renal involvement in connective tissue diseases]
Contracture
Salt-losing nephrogenic diabetes insipidus caused by fetal exposure to angiotensin receptor blocker.
Corneal Neovascularization
Localization of angiotensin converting enzyme in rabbit cornea and its role in controlling corneal angiogenesis in vivo.
Treatment of Acute Ocular Chemical Burns.
Coronary Aneurysm
Angiotensin Converting Enzyme and Angiotensin II Type 1 Receptor Polymorphisms in Patients with Coronary Aneurysms.
High incidence of angiotensin I converting enzyme genotype II in Kawasaki disease patients with coronary aneurysm.
Solitary focal coronary artery aneurysm in a middle aged male with atypical chest pain.
Coronary Artery Disease
A DNA variant at the angiotensin-converting enzyme gene locus associates with coronary artery disease in the Caerphilly Heart Study.
A meta-analysis on the association of genetic polymorphism of the angiotensin-converting enzyme and coronary artery disease in the chinese population.
A pharmacogenetic analysis of determinants of hypertension and blood pressure response to angiotensin-converting enzyme inhibitor therapy in patients with vascular disease and healthy individuals.
A polymorphism of angiotensinogen gene codon 174 and coronary artery disease in Japanese subjects.
A simplified approach to the management of non-ST-segment elevation acute coronary syndromes.
Abnormal indices of autonomic function are no longer predictors of poor outcome in diabetic patients without neuropathy but with coexisting coronary artery disease who receive optimal pharmacological therapy.
ACE (I/D) polymorphism and response to treatment in coronary artery disease: a comprehensive database and meta-analysis involving study quality evaluation.
ACE inhibition with perindopril and endothelial function. Results of a substudy of the EUROPA study: PERTINENT.
ACE inhibitors and statins acutely improve endothelial dysfunction of human coronary arterioles.
ACE-gene polymorphism is associated with the development of allograft vascular disease in heart transplant recipients.
Acute anti-ischemic effects of perindoprilat in men with coronary artery disease and their relation with left ventricular function.
Acute effects of captopril on the coronary circulation of patients with hypertension and angina.
Acute kidney injury can predict in-hospital and long-term mortality in elderly patients undergoing hip fracture surgery.
Advanced Strategies in the Diagnosis and Treatment of Patients with Coronary Artery Disease and Heart Failure: When heart failure causes ischemia and angiotensin converting enzyme inhibitor and betablockers helps in diuresis.
Age-related differences in the use of cardiac medications in patients with coronary artery disease.
Aldosterone blockade in patients with chronic heart failure.
Angiotensin converting enzyme DD genotype not associated with increased risk of coronary artery disease in the Iranian population.
Angiotensin converting enzyme gene deletion allele is independently and strongly associated with coronary atherosclerosis and myocardial infarction.
Angiotensin converting enzyme gene polymorphism and the course of angiographically defined coronary artery disease.
Angiotensin converting enzyme gene polymorphism and the risk and extent of ischemic heart disease among Turkish patients.
Angiotensin converting enzyme gene polymorphism in coronary artery disease: the Indian scenario.
Angiotensin converting enzyme gene polymorphism is associated with severity of coronary artery disease in men with high total cholesterol levels.
Angiotensin converting enzyme inhibition and coronary artery disease.
Angiotensin converting enzyme inhibition in chronic stable angina: effects on myocardial ischaemia and comparison with nifedipine.
Angiotensin converting enzyme insertion/deletion (I/D) (rs4646994) and Vegf polymorphism (+405G/C; rs2010963) in type II diabetic patients: Association with the risk of coronary artery disease.
Angiotensin converting enzyme insertion/deletion polymorphism in French Canadian subjects with premature coronary artery disease.
Angiotensin I-converting enzyme gene polymorphism in a low-risk European population for coronary artery disease.
Angiotensin I-converting enzyme gene polymorphism, coronary artery disease and myocardial infarction. An angiographically controlled study.
Angiotensin II receptor blockers versus angiotensin-converting enzyme inhibitors in patients with stable coronary artery disease: Prevalence, correlates, and prognostic impact (from the CORONOR study).
Angiotensin II type 1 receptor A1166C gene polymorphism. Absence of an association with the risk of coronary artery disease and myocardial infarction and of a synergistic effect with angiotensin-converting enzyme gene polymorphism on the risk of these diseases.
Angiotensin II type 1 receptor blockers do not promote coronary collateral circulation in patients with coronary artery disease.
Angiotensin II type I receptor blocker and endothelial function in humans: role of nitric oxide and oxidative stress.
Angiotensin- converting enzyme insertion/deletion polymorphism and its association with coronary artery disease in an Iranian population.
Angiotensin-1-converting enzyme (ACE) gene polymorphism, plasma ACE levels, and their association with the metabolic syndrome and electrocardiographic coronary artery disease in Pima Indians.
Angiotensin-converting enzyme (ACE) gene polymorphisms in patients characterised by coronary angiography.
Angiotensin-converting enzyme and angiotensin II receptor 1 polymorphisms: association with early coronary disease.
Angiotensin-converting enzyme and apolipoprotein B polymorphisms in coronary artery disease.
Angiotensin-converting enzyme and apolipoproteins genes polymorphism in coronary artery disease.
Angiotensin-converting enzyme and coronary haemodynamics in coronary artery disease.
Angiotensin-converting enzyme DD polymorphism is associated with poor coronary collateral circulation in patients with coronary artery disease.
Angiotensin-converting enzyme gene D-allele and the severity of coronary artery disease.
Angiotensin-converting enzyme gene polymorphism adds risk for the severity of coronary atherosclerosis in smokers.
Angiotensin-Converting Enzyme Gene Polymorphism and Plasminogen Activator Inhibitor 1 Levels in Subjects with Cerebral Infarction.
Angiotensin-converting enzyme gene polymorphism in coronary artery disease in north India.
Angiotensin-converting enzyme gene polymorphism in hypertensive individuals with parental history of stroke.
Angiotensin-converting enzyme gene polymorphism is not associated with coronary atherosclerosis and myocardial infarction in a sample of Italian patients.
Angiotensin-converting enzyme genotype in children and coronary events in their grandparents.
Angiotensin-converting enzyme in the human heart. Effect of the deletion/insertion polymorphism.
Angiotensin-converting enzyme inhibition and vascular remodeling in coronary artery disease.
Angiotensin-converting enzyme inhibition in patients with coronary artery disease and preserved left ventricular function Ischemia Management with Accupril post-bypass graft via inhibition of angiotensin-converting enzyme (IMAGINE) compared with the other major trials in coronary artery disease.
Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing ENdothelial Dysfunction) Study.
Angiotensin-converting enzyme inhibition with spirapril in patients with coronary artery disease.
Angiotensin-converting enzyme inhibitor promotes coronary collateral circulation in patients with coronary artery disease.
Angiotensin-converting enzyme inhibitor therapy for coronary artery disease and diabetes mellitus.
Angiotensin-converting enzyme inhibitors and coronary artery disease.
Angiotensin-converting enzyme inhibitors in coronary artery disease and preserved left ventricular systolic function: a systematic review and meta-analysis of randomized controlled trials.
Angiotensin-Converting Enzyme Inhibitors in Patients With Coronary Artery Disease and Absence of Heart Failure or Left Ventricular Systolic Dysfunction: An Overview of Long-term Randomized Controlled Trials.
Angiotensin-converting enzyme inhibitors in patients with coronary atherosclerosis.
Angiotensin-converting enzyme inhibitors.
Angiotensin-converting enzyme insertion/deletion gene polymorphic variant as a marker of coronary artery disease: a meta-analysis.
Angiotensin-converting enzyme insertion/deletion polymorphism has no effect on the risk of atherosclerotic stroke or hypertension.
Angiotensin-converting enzyme polymorphism and the risk of coronary heart disease in the Saudi male population.
Angiotensin-converting enzyme polymorphism in patients with terminal renal failure.
Angiotensin-converting-enzyme inhibition in stable coronary artery disease.
Angiotensin-I converting enzyme genotype DD is a risk factor for coronary artery disease.
Angiotensin-I-converting enzyme (ACE) insertion/deletion polymorphism in Mexican patients with coronary artery disease. Association with the disease but not with lipid levels.
Angiotensin-I-converting enzyme DD genotype is a risk factor of coronary artery disease.
Angiotensinogen and angiotensin-I converting enzyme gene polymorphisms and the risk of coronary artery disease in Chinese.
Anti-ischemic effects of angiotensin-converting enzyme inhibitors: a future therapeutic perspective.
Antioxidants and endothelial dysfunction in hyperlipidemia.
Apolipoprotein B and angiotensin-converting enzyme polymorphisms and aerobic interval training: randomized controlled trial in coronary artery disease patients.
Apolipoprotein B, apolipoprotein E, and angiotensin-converting enzyme polymorphisms in 2 Italian populations at different risk for coronary artery disease and comparison of allele frequencies among European populations.
Apolipoproteins B and E, and angiotensin I-converting enzyme (ACE) genetic polymorphisms in Italian women with coronary artery disease (CAD) and their relationships with plasma lipid and apolipoprotein levels.
Are Patients with Inflammatory Bowel Disease at Increased Risk of Coronary Artery Disease?
Aspirin and mortality in patients treated with angiotensin-converting enzyme inhibitors: a cohort study of 11,575 patients with coronary artery disease.
Association between angiotensin converting enzyme gene polymorphism and coronary artery disease in individuals of the South-Eastern Anatolian population.
Association between angiotensin-converting enzyme gene polymorphism and coronary artery disease.
Association between mortality and persistent use of beta blockers and angiotensin-converting enzyme inhibitors in patients with left ventricular systolic dysfunction and coronary artery disease.
Association of ACE gene polymorphisms with coronary artery disease in a northern area of Japan.
Association of angiotensin-converting enzyme gene insertion/deletion polymorphism with metabolic syndrome in Iranians with type 2 diabetes mellitus.
Association of angiotensin-converting enzyme polymorphism with coronary artery disease in Iranian patients with unipolar depression.
Association of angiotensin-converting enzyme, methylene tetrahydrofolate reductase and paraoxonase gene polymorphism and coronary artery disease in an Indian population.
Association of coronary artery disease with polymorphisms of angiotensin-converting enzyme and methylenetetrahydrofolate reductase gene.
Association of seven renin angiotensin system gene polymorphisms with restenosis in patients following coronary stenting.
ASSOCIATIONS BETWEEN TRIGLYCERIDE/HIGH-DENSITY LIPOPROTEIN CHOLESTEROL RATIO AND MICRO- AND MACROANGIOPATHIES IN TYPE 2 DIABETES MELLITUS.
Atorvastatin and quinapril inhibit blood coagulation in patients with coronary artery disease following 28 days of therapy.
¿Treatment of arterial hypertension in the diabetic .
Beneficial effects of a single dose of quinapril on left ventricular performance in chronic mitral regurgitation.
Blood pressure control and factors predicting control in a treatment-compliant male veteran population.
Blood pressure control in hypertensive patients in Irish primary care practices.
CAC score as a possible criterion for administration of angiotensin converting enzyme inhibitors and/or angiotensin receptor blockers: the MultiEthnic Study of Atherosclerosis.
Calcium antagonists in the treatment of hypertension in patients with ischaemic heart disease.
Candesartan-based therapy and risk of cancer in patients with systemic hypertension (Heart Institute of Japan Candesartan Randomized Trial for Evaluation in Coronary Artery Disease [HIJ-CREATE] substudy).
Cardio classics revisited: focus on the role of amlodipine.
Cardioprotection in the ESRD Population: How Do We Get There?
Cardioprotective effect of angiotensin-converting enzyme inhibitors in patients with coronary artery disease.
Carrier-state of D allele in ACE gene insertion/deletion polymorphism is associated with coronary artery disease, in contrast to the C677-->T transition in the MTHFR gene.
Case-control association study of polymorphisms in the angiotensinogen and angiotensin-converting enzyme genes and coronary artery disease and systemic artery hypertension in African-Brazilians and Caucasian-Brazilians.
Cholesterol end points predict outcome in patients with coronary disease: quality improvement metrics from the enhancing secondary prevention in coronary artery disease (ESP-CAD) trial.
Chronic kidney disease: tipping the scale to the benefit of angiotensin-converting enzyme inhibitors in patients with coronary artery disease.
Circadian activity of the endogenous fibrinolytic system in stable coronary artery disease: effects of beta-adrenoreceptor blockers and angiotensin-converting enzyme inhibitors.
Clinical assessment in ischaemic cardiomyopathy.
Clinical metric and medication persistency effects: evidence from a Medicaid care management program.
Clinical pharmacy specialist implementation of lisinopril therapy in patients with coronary artery disease and diabetes mellitus.
Combining salicylate and enalapril in patients with coronary artery disease and heart failure.
Comparative effects of AT1-antagonism and angiotensin-converting enzyme inhibition on markers of inflammation and platelet aggregation in patients with coronary artery disease.
Comparative Effects of Preoperative Angiotensin-converting Enzyme In-hibitor, Statin and Beta-blocker Treatment on Human Internal Mammary Artery Reactivity in Patients with Coronary Artery Disease: A Pilot Study.
Comparison of Frequency of Cardiovascular Events and Mortality in Patients With Heart Failure Using Versus Not Using Cocaine.
Comparison of hypertension prevalence and the use of renin-angiotensin-aldosterone system blockers in hospitalized patients with COVID-19 and non-COVID-19 viral pneumonia.
Comparison of mortality rates in statin users versus nonstatin users in a United States veteran population.
Comparison of nifedipine retard with angiotensin converting enzyme inhibitors in Japanese hypertensive patients with coronary artery disease: the Japan Multicenter Investigation for Cardiovascular Diseases-B (JMIC-B) randomized trial.
Complications of Cardiovascular Events in Patients Hospitalized with Influenza-Related Pneumonia.
Components of the metabolic syndrome, but not the metabolic syndrome per se, are associated with aortic distensibility.
Coronary artery disease and endothelial nitric oxide synthase and angiotensin-converting enzyme gene polymorphisms.
Coronary Artery Disease Is Under-diagnosed and Under-treated in Advanced Lung Disease.
Coronary artery disease screening, treatment, and follow-up.
Coronary atherosclerosis, low-density lipoproteins and markers of thrombosis, inflammation and endothelial dysfunction.
Counteraction of the vasodilator effects of enalapril by aspirin in severe heart failure.
COVID-19 and cardiac injury: clinical manifestations, biomarkers, mechanisms, diagnosis, treatment, and follow up.
Deletion polymorphism at the angiotensin-converting enzyme gene in Turkish patients with coronary artery disease.
Deletion polymorphism in the gene for angiotensin converting enzyme is associated with elevated fasting blood glucose levels.
Deletion polymorphism of the angiotensin I-converting enzyme gene is associated with increased plasma angiotensin-converting enzyme activity but not with increased risk for myocardial infarction and coronary artery disease.
Deletion/Deletion genotype of angiotensin-I converting enzyme gene is not associated with coronary artery disease in caucasians with type 2 diabetes.
Development of One-Step Tetra-primer ARMS-PCR for Simultaneous Detection of the Angiotensin Converting Enzyme (ACE) I/D and rs4343 Gene Polymorphisms and the Correlation with CAD Patients.
Differences in the effect of angiotensin-converting enzyme inhibitors on the rate of endothelial cell apoptosis: in vitro and in vivo studies.
Different impact of deletion polymorphism of gene on the risk of renal and coronary artery disease.
Discharge medication complexity and 30-day heart failure readmissions.
Discordance of anti-ischemic and hemodynamic effects of captopril in stable coronary artery disease.
Distinct Survival Benefits of Angiotensin-Converting Enzyme Inhibitors/Angiotensin II Receptor Blockers in Revascularized Coronary Artery Disease Patients According to History of Myocardial Infarction.
Do all patients with coronary artery disease benefit from angiotensin converting enzyme inhibitors?
Dose response of ACE inhibitors: implications of the SECURE trial.
Drug Insight: angiotensin-converting-enzyme inhibitors and atrial fibrillation-indications and contraindications.
Drug therapy before coronary artery surgery: nitrates are independent predictors of mortality and beta-adrenergic blockers predict survival.
Duration of evidence-based medical therapy and the hazard for atherothrombotic events following percutaneous coronary intervention.
Early sign of atherosclerosis in slow coronary flow and relationship with angiotensin-converting enzyme I/D polymorphism.
Effect of an educational program on the prevalence of use of antiplatelet drugs, beta blockers, angiotensin-converting enzyme inhibitors, lipid-lowering drugs, and calcium channel blockers prescribed during hospitalization and at hospital discharge in patients with coronary artery disease.
Effect of an ongoing educational program on the use of antiplatelet drugs, beta-blockers, angiotensin-converting enzyme inhibitors, and lipid-lowering drugs in patients with coronary artery disease seen in an academic cardiology clinic.
Effect of angiotensin converting enzyme inhibitor on plasma von Willebrand factor level in patients with coronary artery disease.
Effect of quinapril on in-stent restenosis and relation to plasma apoptosis signaling molecules.
Effective strategies for long-term statin use.
Effects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease.
Effects of aliskiren on the fibrinolytic system in patients with coronary artery disease receiving angiotensin-converting enzyme inhibitor or angiotensin II type 1 receptor blocker.
Effects of angiotensin-converting enzyme inhibition on exercise-induced angina and ST segment depression in patients with microvascular angina.
Effects of angiotensin-converting enzyme inhibition on transient ischemia: the Quinapril Anti-Ischemia and Symptoms of Angina Reduction (QUASAR) trial.
Effects of Angiotensin-Converting Enzyme Inhibitors and Beta Blockers on Clinical Outcomes in Patients With and Without Coronary Artery Obstructions at Angiography (from a Register-Based Cohort Study on Acute Coronary Syndromes).
Effects of Atorvastatin Dose and Concomitant Use of Angiotensin-Converting Enzyme Inhibitors on Renal Function Changes over Time in Patients with Stable Coronary Artery Disease: A Prospective Observational Study.
Effects of enalapril during continuous nitrate therapy: analysis of diameter of coronary arteries and platelet cyclic guanosine monophosphate.
Effects of quinapril on coronary blood flow in coronary artery disease patients with endothelial dysfunction. TREND Investigators. Trial on Reversing Endothelial Dysfunction.
Effects of valsartan, an angiotensin II receptor blocker, on coronary atherosclerosis in patients with acute myocardial infarction who receive an angiotensin-converting enzyme inhibitor.
Efficacy of Angiotensin-Converting Enzyme Inhibitors and Angiotensin-Receptor Blockers in Coronary Artery Disease without Heart Failure in the Modern Statin Era: a Meta-Analysis of Randomized-Controlled Trials.
Emerging concepts: angiotensin-converting enzyme inhibition in coronary artery disease.
Endothelin in cardiovascular control: the role of endothelin antagonists.
Endothelin-1 and vasopressin plasma levels are not associated with the insertion/deletion polymorphism of the human angiotensin I-converting enzyme gene in patients with coronary artery disease.
Enhanced expression of angiotensin-converting enzyme is associated with progression of coronary atherosclerosis in humans.
Enhancement of the efficacy of isosorbide dinitrate by captopril in stable angina pectoris.
Epidemiology and clinical characteristics of hospitalized elderly patients for heart failure with reduced, mid-range and preserved ejection fraction.
Epistatic interaction between variations in the angiotensin I converting enzyme and angiotensin II type 1 receptor genes in relation to extent of coronary atherosclerosis.
Erratum to: Efficacy of Angiotensin-Converting Enzyme Inhibitors and Angiotensin-Receptor Blockers in Coronary Artery Disease without Heart Failure in the Modern Statin Era: a Meta-Analysis of Randomized-Controlled Trials.
Evaluation of the effects of aspirin combined with angiotensin-converting enzyme inhibitors in patients with coronary artery disease.
Expression of Renin-Angiotensin System on Dendritic Cells of Patients with Coronary Artery Disease.
Factors influencing blood pressure response to trandolapril add-on therapy in patients taking verapamil SR (from the International Verapamil SR/Trandolapril [INVEST] Study).
Five polymorphisms in gene candidates for cardiovascular disease in Afro-Brazilian individuals.
Five-year follow-up of drug utilization for secondary prevention in coronary artery disease.
Gender specificity of a genetic variant of angiotensin-converting enzyme and risk of coronary artery disease.
Gene polymorphism but not catalytic activity of angiotensin I-converting enzyme is associated with coronary artery disease and myocardial infarction in low-risk patients.
Gene polymorphism of angiotensin II type 1 and type 2 receptors.
Gene-gene interaction of ACE I/D, endothelial nitric oxide synthase 4 a/b and ApoE does not affect coronary artery disease severity.
Genetic determinants of treatment benefit of the angiotensin-converting enzyme-inhibitor perindopril in patients with stable coronary artery disease.
Genetic influences of angiotensin-converting enzyme inhibitor response: an opportunity for personalizing therapy?
Genetic risk factors and ischaemic cerebrovascular disease: role of common variation of the genes encoding apolipoproteins and angiotensin-converting enzyme.
Genetic variation-optimized treatment benefit of angiotensin-converting enzyme inhibitors in patients with stable coronary artery disease: a 12-year follow-up study.
Genetic variations of Renin-angiontensin and Fibrinolytic systems and susceptibility to coronary artery disease: a population genetics perspective.
Genotype distribution of angiotensin-converting enzyme polymorphism in Australian healthy and coronary populations and relevance to myocardial infarction and coronary artery disease.
Haplotypes of the angiotensin-converting enzyme (ACE) gene are associated with coronary artery disease but not with restenosis after coronary stenting.
Has the controversy over the use of calcium channel blockers in coronary artery disease been resolved?
Heart Rate Variability Predicts Major Adverse Cardiovascular Events and Hospitalization in Maintenance Hemodialysis Patients.
High rate of renal recovery in survivors of COVID-19 associated acute renal failure requiring renal replacement therapy.
Impact of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers on Renal Function in Chronic Kidney Disease Patients Undergoing Coronary Angiography.
Impact of postprandial hypertriglyceridemia on vascular responses in patients with coronary artery disease: effects of ACE inhibitors and fibrates.
Impact of renin-angiotensin system inhibitors after revascularization of patients with left main coronary artery disease.
Impact of therapy with statins, beta-blockers and angiotensin-converting enzyme inhibitors on plasma myeloperoxidase in patients with coronary artery disease.
Improved treatment of coronary heart disease by implementation of a Cardiac Hospitalization Atherosclerosis Management Program (CHAMP).
Improvement in endothelial progenitor cells from peripheral blood by ramipril therapy in patients with stable coronary artery disease.
Improvement of myocardial blood flow to ischemic regions by angiotensin-converting enzyme inhibition with quinaprilat IV: a study using [15O] water dobutamine stress positron emission tomography.
Increased risk for ischaemic events is related to combined RAS polymorphism.
Increased Risk of Myocardial Infarction Associated With Angiotensin-Converting Enzyme Gene Polymorphism Is Age Dependent.
Incremental value of left ventricular shape parameters measured by gated SPECT MPI in predicting the super-response to CRT.
Individualised therapy of angiotensin converting enzyme (ACE) inhibitors in stable coronary artery disease: overview of the primary results of the PERindopril GENEtic association (PERGENE) study.
Individualized Angiotensin-Converting Enzyme (ACE)-Inhibitor Therapy in Stable Coronary Artery Disease Based on Clinical and Pharmacogenetic Determinants: The PERindopril GENEtic (PERGENE) Risk Model.
Inflammatory and Genetic Markers (APO B100 and Angiotensin-Converting Enzyme Gene) in the Coronary Artery Disease.
Influence of angiotensin converting enzyme inhibition on pump function and cardiac contractility in patients with chronic congestive heart failure.
Influence of Angiotensin-Converting-Enzyme Gene Polymorphism on Echocardiographic Data of Patients with Ischemic Heart Failure.
Influence of preventive therapy with quinapril on IL-6 level in patients with chronic stable angina.
Influence of propranolol, enalaprilat, verapamil, and caffeine on adenosine A(2A)-receptor-mediated coronary vasodilation.
Influence of smoking status on angiotensin-converting enzyme inhibition-related improvement in coronary endothelial function. TREND Investigators. Trial on Reversing Endothelial Dysfunction.
Inhibition of the renin-angiotensin system for lowering coronary artery disease risk.
Inhibitors of the renin angiotensin system: implications for the anaesthesiologist.
Insertion/deletion polymorphism of angiotensin-converting enzyme gene--risk factor for coronary artery disease in the Tuzla region population (Bosnia and Herzegovina).
Insertion/deletion polymorphism of the angiotensin converting enzyme gene in coronary artery disease in southern Turkey.
Insertion/deletion polymorphism of the angiotensin I-converting enzyme gene is associated with coronary artery plaque calcification as assessed by intravascular ultrasound.
Insight into ACE inhibition in the prevention of cardiac events in stable coronary artery disease: the EUROPA trial.
Interactions between angiotensin-I converting enzyme insertion/deletion polymorphism and response of plasma lipids and coronary atherosclerosis to treatment with fluvastatin: the lipoprotein and coronary atherosclerosis study.
Ischemic cardiovascular complications concurrent with administration of captopril. A clinical note.
Lack of association between the insertion/deletion polymorphism of the angiotensin-converting enzyme gene and vasospastic angina.
Lack of association of angiotensin converting enzyme gene polymorphism or serum enzyme activity with coronary artery disease in Japanese subjects.
Lack of association of angiotensin-converting enzyme (ACE). Gene insertion/deletion polymorphism with CAD in two Asian populations.
Lack of effect of nitrates on exercise tolerance in patients with mild to moderate heart failure caused by coronary disease already treated with captopril.
Left ventricular size, mass and function in relation to angiotensin-converting enzyme gene and angiotensin-II type 1 receptor gene polymorphisms in patients with coronary artery disease.
Length Polymorphisms in the Angiotensin I-Converting Enzyme Gene and the Serotonin-Transporter-Linked Polymorphic Region Constitute a Risk Haplotype for Depression in Patients with Coronary Artery Disease.
Lewis A. Conner Memorial Lecture. Mechanisms leading to myocardial infarction: insights from studies of vascular biology.
Long-term clinical experience with zofenopril.
Long-term effects of cholesterol lowering and angiotensin-converting enzyme inhibition on coronary atherosclerosis: The Simvastatin/Enalapril Coronary Atherosclerosis Trial (SCAT).
Long-term treatment with perindopril ameliorates dobutamine-induced myocardial ischemia in patients with coronary artery disease.
Lymphocyte-suppressing action of angiotensin-converting enzyme inhibitors in coronary artery disease patients with normal blood pressure.
Mechanism by which quinapril improves vascular function in coronary artery disease.
Mechanisms linking angiotensin II and atherogenesis.
Medical angioplasty - Hope and expectations: An optimistic overview.
Medical management of stable coronary artery disease.
Migraine and coronary artery disease: an open study on the genetic polymorphism of the 5, 10 methylenetetrahydrofolate (MTHFR) and angiotensin I-converting enzyme (ACE) genes.
Missed opportunities for the secondary prevention of cardiovascular disease in Canada.
Myocardial microvascular disease and major adverse cardiovascular events in patients with end-stage renal disease: rationale and design of the MICROCARD study.
New Areas of Interest: Is There a Role for Omega-3 Fatty Acid Supplementation in Patients With Diabetes and Cardiovascular Disease?
New considerations relating to class effect with angiotensin-converting enzyme inhibitors--the PEACE study.
Nifedipine retard prevents hospitalization for angina pectoris better than angiotensin-converting enzyme inhibitors in hypertensive Japanese patients with previous myocardial infarction (JMIC-B substudy).
Nifedipine retard was as effective as angiotensin converting enzyme inhibitors in preventing cardiac events in high-risk hypertensive patients with diabetes and coronary artery disease: the Japan Multicenter Investigation for Cardiovascular Diseases-B (JMIC-B) subgroup analysis.
Nutritional, metabolic, and genetic determinants of the progression of coronary heart disease. STARS Group.
On Target to Dual Block RASS?
Ongoing clinical trials of angiotensin-converting enzyme inhibitors for treatment of coronary artery disease in patients with preserved left ventricular function.
Opposing effects of ? blockers and angiotensin-converting enzyme inhibitors on development of new-onset diabetes mellitus in patients with stable coronary artery disease.
Ostial renal artery stent placement for atherosclerotic renal artery stenosis in patients with coronary artery disease.
Outcomes and risk prediction model for peripheral arterial disease in patients with stable coronary artery disease.
Performance assessment model for guideline-recommended pharmacotherapy in the secondary prevention of coronary artery disease and treatment of left ventricular dysfunction.
Perindopril alters vascular angiotensin-converting enzyme, AT(1) receptor, and nitric oxide synthase expression in patients with coronary heart disease.
Perindopril and ?-blocker for the prevention of cardiac events and mortality in stable coronary artery disease patients: A EUropean trial on Reduction Of cardiac events with Perindopril in stable coronary Artery disease (EUROPA) subanalysis.
Perindopril arginine: benefits of a new salt of the ACE inhibitor perindopril.
Perindopril: the reasonable choice in patients with coronary artery disease.
Peripheral arterial disease of the lower extremities.
Peripheral arterial disease versus other localizations of vascular disease: the ATTEST study.
PERTINENT--perindopril-thrombosis, inflammation, endothelial dysfunction and neurohormonal activation trial: a sub-study of the EUROPA study.
Pharmacogenetics of ACE inhibition in stable coronary artery disease: steps towards tailored drug therapy.
Pharmacogenomic considerations of the insertion/deletion gene polymorphism of the Angiotensin I-converting enzyme and coronary artery disease.
Pleiotropic effects of angiotensin-converting enzyme inhibitors in normotensive patients with coronary artery disease.
Polymorphism and synergism of angiotensin-converting enzyme (ACE) and plasminogen activator inhibitor-1 (PAI-1) genes in coronary artery disease.
Polymorphisms of renin-angiotensin system and natriuretic peptide receptor A genes in patients of Greek origin with a history of myocardial infarction.
Possible interaction between aspirin and ACE inhibitors: update on unresolved controversy.
Predictors of depressive symptoms post-acute coronary syndrome.
Predictors of heart failure in patients with stable coronary artery disease: a PEACE study.
Predisposition of Angiotensin-converting Enzyme Deletion/Deletion Genotype to Coronary Artery Disease with Type 2 Diabetes Mellitus in South India.
Presentation, surgical intervention, and long-term survival in patients with Marfan syndrome.
Prevalence of Appropriate Management of Diabetes Mellitus in an Academic General Medicine Clinic.
Prevalence of use of antiplatelet drugs, beta blockers, statins, and angiotensin-converting enzyme inhibitors or angiotensin receptor blockers in older patients with coronary artery disease in an academic nursing home.
Prevalence of use of cardiovascular drugs in 499 patients with suspected coronary artery disease at time of hospitalization for coronary angiography and in 357 patients with obstructive coronary artery disease documented by coronary angiography.
Preventing myocardial infarction and stroke with a simplified bundle of cardioprotective medications.
Prognostic significance of the Centers for Disease Control/American Heart Association high-sensitivity C-reactive protein cut points for cardiovascular and other outcomes in patients with stable coronary artery disease.
Prognostic value of B-Type natriuretic peptides in patients with stable coronary artery disease: the PEACE Trial.
Progression of left ventricular dysfunction secondary to coronary artery disease, sustained neurohormonal activation and effects of ibopamine therapy during long-term therapy with angiotensin-converting enzyme inhibitor.
Prospective evaluation of the effect of an angiotensin I converting enzyme gene polymorphism on the long term risk of major adverse cardiac events after percutaneous coronary intervention.
Proven strategies to reduce cardiovascular mortality in hemodialysis patients.
Quality of Care of the Initial Patient Cohort of the Diabetes Collaborative Registry(®).
Quantifying the interaction between angiotensin-converting enzyme inhibitors and aspirin: are we using the right method?
Quantitative coronary angiogram analysis: nifedipine retard versus angiotensin-converting enzyme inhibitors (JMIC-B side arm study).
Rationale and design features of a clinical trial examining the effects of cholesterol lowering and angiotensin-converting enzyme inhibition on coronary atherosclerosis: Simvastatin/Enalapril Coronary Atherosclerosis Trial (SCAT). SCAT Investigators.
Rationale and design of the Cardiac Hospitalization Atherosclerosis Management Program at the University of California Los Angeles.
Real-world use of ACEI/ARB in diabetic hypertensive patients before the initial diagnosis of obstructive coronary artery disease: patient characteristics and long-term follow-up outcome.
Redox status of patients before cardiac surgery.
Reduced testosterone levels in males with lone atrial fibrillation.
Reduction of exercise-induced myocardial ischemia during add-on treatment with the angiotensin-converting enzyme inhibitor enalapril in patients with normal left ventricular function and optimal beta blockade.
Relation between previous angiotensin-converting enzyme inhibitor use and in-hospital outcomes in acute coronary syndromes.
Relation between severity of coronary artery disease, left ventricular function and myocardial infarction, and influence of the ACE I/D gene polymorphism.
Relation between the deletion polymorphism of the angiotensin-converting enzyme gene and late luminal narrowing after coronary angioplasty.
Relationship between angiotensin-converting enzyme gene insertion/deletion polymorphism, angiographically defined coronary artery disease and myocardial infarction in patients with type 2 diabetes mellitus.
Relationship of the rs1799752 polymorphism of the angiotensin-converting enzyme gene and the rs699 polymorphism of the angiotensinogen gene to the process of in-stent restenosis in a population of Polish patients with stable coronary artery disease.
Renin Inhibition for Hypertension: Selecting the Right Role for a New Class of Drug.
Renin-angiotensin system antagonists and clinical outcomes in stable coronary artery disease without heart failure.
Renin-angiotensin system gene polymorphisms and coronary artery disease in Saudi patients with diabetes mellitus.
Renin-Angiotensin System Genes Polymorphisms and Long-Term Prognosis in Taiwanese Patients with Hypertension and Coronary Artery Disease.
Renin-angiotensin-system modulators and the incidence of atrial fibrillation following hospitalization for coronary artery disease.
Results of carotid endarterectomy in patients with contralateral internal carotid artery occlusion from the Mid-America Vascular Study Group and the Society for Vascular Surgery Vascular Quality Initiative.
Role of angiotensin-converting enzyme inhibition in reversal of endothelial dysfunction in coronary artery disease.
Role of Genetic Polymorphism of Angiotensin-Converting Enzyme, Plasminogen Activator Inhibitor-1 and Endothelial Nitric Oxide Synthase in the Prognosis of Coronary Artery Disease.
S-nitrosocaptopril. II. Effects on vascular reactivity.
Secondary prevention of CAD with ACE inhibitors: a struggle between life and death of the endothelium.
Severe Infrarenal Atheroma Load in Open Aortic Aneurysm Repair Is Not a Risk Factor for Postoperative Acute Kidney Injury.
Short-term prognostic effect of prior cerebrovascular and peripheral artery disease in patients with acute coronary syndrome: Can we do better?
Should angiotensin-converting enzyme inhibitors be used in all patients with coronary artery disease or restricted to those with a history of myocardial infarction or myocardial revascularization?
Stable Angina Pectoris.
Statin use is independently associated with smaller infarct volume in nonlacunar MCA territory stroke.
Successful reintroduction of previously failed ACE inhibitor therapy following stenting of atherosclerotic renovascular disease.
Survival Benefit of Statins in Hemodialysis Patients Awaiting Renal Transplantation.
Synergism between paraoxonase Arg 192 and the angiotensin converting enzyme D allele is associated with severity of coronary artery disease.
Tailored therapy of ACE inhibitors in stable coronary artery disease: pharmacogenetic profiling of treatment benefit.
The ACE-DD genotype is associated with endothelial dysfunction in postmenopausal women.
The angiotensin converting enzyme D allele is an independent risk factor for early onset coronary artery disease.
The angiotensin-converting enzyme gene insertion/deletion polymorphism and effects of quinapril and atorvastatin on haemostatic parameters in patients with coronary artery disease.
The cardioprotective effects of the angiotensin-converting enzyme inhibitor perindopril in patients with stable coronary artery disease are not modified by mild to moderate renal insufficiency: insights from the EUROPA trial.
The DD genotype of angiotensin converting enzyme polymorphism is a risk factor for coronary artery disease and coronary stent restenosis in Japanese patients.
The DD genotype of the angiotensin-converting enzyme gene is associated with increased mortality in idiopathic heart failure.
The effect of angiotensin converting enzyme inhibition of coronary blood flow and hemodynamics in patients without coronary artery disease.
The effect of angiotensin-converting enzyme inhibitors on plasma adipokine levels in normotensive patients with coronary artery disease.
The effect of perindopril on cardiovascular morbidity and mortality in patients with diabetes in the EUROPA study: results from the PERSUADE substudy.
The evaluation of angiotensin-converting enzyme (ACE) gene I/D and IL-4 gene intron 3 VNTR polymorphisms in coronary artery disease.
The history of inhibitors of angiotensin converting enzyme.
The I allele of the angiotensin converting enzyme I/D polymorphism confers protection against coronary artery disease.
The I/D polymorphism of angiotensin-converting enzyme gene but not the angiotensinogen gene is associated with insulin response to oral glucose in Japanese.
The impact of a multifaceted intervention to reduce potentially inappropriate prescribing among discharged older adults: a before-and-after study.
The PEACE study: limiting the role of angiotensin-converting enzyme inhibitors in stable coronary artery disease.
The platelet Pl(A2) and angiotensin-converting enzyme (ACE) D allele polymorphisms and the risk of recurrent events after acute myocardial infarction.
The rationale and design of the PERindopril GENEtic association study (PERGENE): a pharmacogenetic analysis of angiotensin-converting enzyme inhibitor therapy in patients with stable coronary artery disease.
The relationship between angiotensin converting enzyme gene polymorphism, coronary artery disease, and stent restenosis.
The Renin-Angiotensin-Aldosterone System: Approaches to Guide Angiotensin-Converting Enzyme Inhibition in Patients with Coronary Artery Disease.
The Role of Angiotensin Antagonism in Coronary Plaque Regression: Insights from the Glagovian Model.
The underutilization of cardiac medications of proven benefit, 1990 to 2002.
Tissue factor regulation and cytokine expression in monocyte-endothelial cell co-cultures: effects of a statin, an ACE-inhibitor and a low-molecular-weight heparin.
Traditional risk factors and angiotensin-converting enzyme insertion/deletion gene polymorphism in coronary artery disease.
Trandolapril. An update of its pharmacology and therapeutic use in cardiovascular disorders.
Treatment strategies for isolated systolic hypertension in elderly patients.
Treatment with triple combination of atorvastatin, perindopril, and amlodipine in patients with stable coronary artery disease: A subgroup analysis from the PAPA-CAD study.
Trends in cardiovascular risk profiles.
Triple Combination Therapy for Global Cardiovascular Risk: Atorvastatin, Perindopril, and Amlodipine.
Underutilization of aspirin, beta blockers, angiotensin-converting enzyme inhibitors, and lipid-lowering drugs and overutilization of calcium channel blockers in older persons with coronary artery disease in an academic nursing home.
Use of angiotensin-converting enzyme inhibitors in patients with diabetes and coronary artery disease.
Use of calcium channel blockers and angiotensin-converting enzyme inhibitors after cardiac transplantation.
Use of combination evidence-based medical therapy prior to acute myocardial infarction (from the National Registry of Myocardial Infarction-4).
Use of digoxin, diuretics, beta blockers, angiotensin-converting enzyme inhibitors, and calcium channel blockers in older patients in an academic hospital-based geriatrics practice.
Usefulness of acute delirium as a predictor of adverse outcomes in patients >65 years of age with acute decompensated heart failure.
Vascular effects of simvastatin combined with ramipril in hypercholesterolemic patients with coronary artery disease, compared with simvastatin alone: a randomized, double-blind, placebo-controlled, crossover study.
Verapamil and angiotensin-converting enzyme inhibitors in patients with coronary artery disease and reduced left ventricular ejection fraction.
Vulnerable disease may induce neointimal coverage after sirolimus-eluting stent implantation.
Warfarin use and the risk of valvular calcification.
[Analysis of gene complexes predisposing to coronary atherosclerosis]
[Angiotensin-Converting-Enzyme Inhibition in Stable Coronary Artery Disease. Results of the PEACE trial.]
[Anti-ischemic effect of angiotensin-converting enzyme inhibitor, but not vitamin C, in patients with coronary artery disease treated with beta-blockers and nitrates. Randomized, cross-over, double-blind comparison]
[Association between angiotensin-converting enzyme and endothelial nitric oxide synthase gene polymorphism and risk of coronary artery disease]
[Does quinapril improve coronary vasoconstriction in vasospastic angina?]
[Effect of angiotensin converting enzyme genotype on endothelial function in healthy subjects]
[Evaluation of angiotensin I converting enzyme gene polymorphism in patients with essential hypertension and coronary artery disease]
[Genetic aspects of atrial fibrillation in coronary artery disease patients].
[JMIC-B study and its sub-analyses: effect of nifedipine in Japanese hypertensive patients with coronary artery disease]
[Medical treatments in aortic stenosis: role of statins and angiotensin-converting enzyme inhibitors].
[Plaque progression and destabilization in human coronary arteries]
[Polymorphism of angiotensin converting enzyme in Han populations and its relevance to the severity of coronary atherosclerosis]
[Relation between coronary artery disease and polymorphism of angiotensin converting enzyme gene]
[Update cardiology 2006/2007]
Coronary Disease
1B.06: MASKED HYPERTENSION PREVALENCE AND ITS MARKERS IN ORGANIZED COHORT.
2010 guidelines of the Taiwan Society of Cardiology for the management of hypertension.
A deletion polymorphism in the angiotensin converting enzyme gene is not associated with coronary heart disease in an Austrian population.
A perspective on telmisartan and cardiovascular risk.
A systematic review of the effects of physician specialty on the treatment of coronary disease and heart failure in the United States.
Absence of an interaction between the angiotensin-converting enzyme insertion-deletion polymorphism and pravastatin on cardiovascular disease in high-risk hypertensive patients: the Genetics of Hypertension-Associated Treatment (GenHAT) study.
ACE inhibition with cilazapril improves myocardial perfusion to the ischemic regions during exercise: a pilot study.
ACE inhibitors versus diuretics: ALLHAT versus ANBP2.
Angiotensin converting enzyme (ACE) and non-ACE dependent angiotensin II generation in resistance arteries from patients with heart failure and coronary heart disease.
Angiotensin converting enzyme polymorphism is associated with severity of coronary heart disease and serum lipids (total cholesterol and triglycerides levels) in Japanese patients.
Angiotensin I converting enzyme gene polymorphism and coronary heart disease.
Angiotensin I converting enzyme gene polymorphism and insulin resistance in patients with hypertension.
Angiotensin I-Converting Enzyme Gene Polymorphism Enhances the Effect of Hypercholesterolemia on the Risk of Coronary Heart Disease in a General Japanese Population: The Hisayama Study.
Angiotensin-converting enzyme and angiotensin II receptor 1 polymorphism in coronary disease and malignant ventricular arrhythmias.
Angiotensin-converting enzyme and angiotensin II receptor 1 polymorphisms: association with early coronary disease.
Angiotensin-converting enzyme and p22(phox) polymorphisms and the risk of coronary heart disease in a low-risk Spanish population.
Angiotensin-converting enzyme gene deletion polymorphism determines an increase in frequency of migraine attacks in patients suffering from migraine without aura.
Angiotensin-converting enzyme gene polymorphism and carotid wall thickening in a community population.
Angiotensin-converting enzyme gene polymorphism and coronary heart disease in Turkish type 2 diabetic patients.
Angiotensin-converting enzyme gene polymorphism and premature coronary heart disease.
Angiotensin-converting enzyme gene polymorphism is associated with coronary heart disease in non-insulin-dependent diabetic patients evaluated for 9 years.
Angiotensin-converting enzyme genotype interacts with systolic blood pressure to determine coronary heart disease risk in healthy middle-aged men.
Angiotensin-converting enzyme genotypes in the high- and low-risk area for coronary heart disease in Finland.
Angiotensin-converting enzyme inhibitors and calcium channel blockers for coronary heart disease and stroke prevention.
Angiotensin-converting enzyme inhibitors and coronary heart disease prevention.
Angiotensin-converting enzyme inhibitors in coronary artery disease and preserved left ventricular systolic function: a systematic review and meta-analysis of randomized controlled trials.
Angiotensin-converting enzyme inhibitors, calcium blockers, estrogen and antioxidants in secondary prevention of coronary disease.
Angiotensin-converting enzyme polymorphism (I/D) and coronary heart disease in young adults.
Angiotensin-converting enzyme polymorphism and the risk of coronary heart disease in the Saudi male population.
Antiatherosclerotic activity of drugs in relation to nitric oxide function.
Antihypertensive Medication Use in Older Patients Transitioning from Chronic Kidney Disease to End-Stage Renal Disease on Dialysis.
Aspirin use and outcomes in a community-based cohort of 7352 patients discharged after first hospitalization for heart failure.
Association between elevated fibrosis markers and heart failure in the elderly: the cardiovascular health study.
Association of angiotensin converting enzyme and plasminogen activator inhibitor-1 promoter gene polymorphisms with features of the insulin resistance syndrome in patients with premature coronary heart disease.
Association of angiotensinogen M235T and A(-6)G gene polymorphisms with coronary heart disease with independence of essential hypertension: the PROCAGENE study. Prospective Cardiac Gene.
Association of polymorphisms in angiotensin-converting enzyme and type 1 angiotensin II receptor genes with coronary heart disease and the severity of coronary artery stenosis.
Associations between candidate loci angiotensin-converting enzyme and angiotensinogen with coronary heart disease and myocardial infarction: the NHLBI Family Heart Study.
Atherothrombosis and the Management of the Vulnerable Vascular Patient.
Back to thiazide-diuretics for hypertension: reflections after a decade of irrational prescribing.
Blood haemoglobin is an independent predictor of B-type natriuretic peptide (BNP).
Blood pressure treatment levels and choice of antihypertensive agent in people with diabetes mellitus: an overview of systematic reviews.
Cardioprotective medication use after renal transplantation.
Cardiovascular disease treatment among patients with severe mental illness: a data linkage study between primary and secondary care.
Cardiovascular diseases and molecular variants of the renin-angiotensin system components in Slovak population.
Cardiovascular outcomes and angiotensin converting enzyme inhibitors: beyond blood pressure control. Editorial to: "Secondary prevention of coronary disease with ACE inhibition--does blood pressure reduction with perindopril explain the benefits in EUROPA?" by Remme et al.
Cardiovascular outcomes in high-risk hypertensive patients stratified by baseline glomerular filtration rate.
Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: a multicenter analysis.
Carotid intima-media thickness and antihypertensive treatment: a meta-analysis of randomized controlled trials.
Clinical efficacies of antihypertensive drugs.
Comparative Effectiveness of Combination Therapy with Statins and Angiotensin-Converting Enzyme Inhibitors versus Angiotensin II Receptor Blockers in Patients with Coronary Heart Disease: A Nationwide Population-Based Cohort Study in Korea.
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2017 EXECUTIVE SUMMARY.
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2018 EXECUTIVE SUMMARY.
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2019 EXECUTIVE SUMMARY.
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2020 EXECUTIVE SUMMARY.
Contribution of deletion in angiotensin-converting enzyme but not A1166C angiotensin II type-1 receptor gene polymorphisms to clinical outcomes in atherothrombotic disease.
Coronary heart disease, hypertension, and angiotensinogen gene variants in Indian population.
Correlation between Sex and Prognosis of Acute Aortic Dissection in the Chinese Population.
Cost effectiveness of a smoking cessation program in patients admitted for coronary heart disease.
COVID-19 and cardiac injury: clinical manifestations, biomarkers, mechanisms, diagnosis, treatment, and follow up.
Covid-19 and cardiovascular risk: Susceptibility to infection to SARS-CoV-2, severity and prognosis of Covid-19 and blockade of the renin-angiotensin-aldosterone system. An evidence-based viewpoint.
Deletion polymorphism in angiotensin converting enzyme gene associated with carotid wall thickening in a healthy male population.
Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction.
Deletion polymorphism of the angiotensin I-converting enzyme gene in elderly patients with coronary heart disease.
Determinants of right ventricular remodeling following ST-segment elevation myocardial infarction.
Does aspirin attenuate the effect of angiotensin-converting enzyme inhibitors in hypertension or heart failure?
Doxazosin and congestive heart failure.
Drug benefit generosity and essential medication use among Medicare-eligible retirees.
Effect of infarct artery patency on prognosis after acute myocardial infarction. The Survival and Ventricular Enlargement Investigators.
Effect of lipid-lowering agents, angiotensin-converting enzyme inhibitors, and calcium antagonists on coronary disease risk.
Effect of statins and ACE inhibitors alone and in combination on clinical outcome in patients with coronary heart disease.
Effects of blood pressure-lowering on outcome incidence in hypertension: 5. Head-to-head comparisons of various classes of antihypertensive drugs - overview and meta-analyses.
Effects of losartan on low-density lipoprotein apheresis.
Effects of vasodilators on the coronary circulation in congestive heart failure.
Genetic polymorphisms in the renin-angiotensin system: relevance for susceptibility to cardiovascular disease.
Genetic polymorphisms of the renin-angiotensin system and complications of insulin-dependent diabetes mellitus.
Genetic variation in the renin-angiotensin system and athletic performance.
Genetic variation in the renin-angiotensin-aldosterone system is associated with cardiovascular risk factors and early mortality in established coronary heart disease.
Genotype combinations of plasminogen activator inhibitor-1 and angiotensin-converting enzyme genes and risk for early onset of coronary heart disease.
Global survey of current practice in management of hypertension as reported by societies affiliated with the international society of hypertension.
How should we manage heart failure developing in patients already treated with angiotensin-converting enzyme inhibitors and beta-blockers for hypertension, diabetes or coronary disease?
Impact of Medication Adherence on Mortality and Cardiovascular Morbidity: Protocol for a Population-Based Cohort Study.
Impact of renin-angiotensin system inhibitors after revascularization of patients with left main coronary artery disease.
Impacts of serum P-selectin on blood pressure control after PCI in patients with coronary heart disease complicated with hypertension.
Importance of HDL cholesterol levels and the total/ HDL cholesterol ratio as a risk factor for coronary heart disease in molecularly defined heterozygous familial hypercholesterolaemia.
Insertion/deletion polymorphism in the angiotensin-converting enzyme gene associated with macroangiopathy and blood pressure in patients with non-insulin-dependent diabetes mellitus.
Insertion/deletion polymorphism in the angiotensin-I-converting enzyme gene is associated with coronary heart disease in IDDM patients with diabetic nephropathy.
Insertion/deletion polymorphism of the angiotensin I-converting enzyme gene in patients with hypertension, non-insulin-dependent diabetes mellitus, and coronary heart disease in Taiwan.
Insertion/deletion polymorphism of the angiotensin-converting enzyme gene is strongly associated with coronary heart disease in non-insulin-dependent diabetes mellitus.
Intensity of Guideline-Directed Medical Therapy for Coronary Heart Disease and Ischemic Heart Failure Outcomes.
Interaction between angiotensin-converting enzyme inhibitors and aspirin: a review.
Interaction between apolipoprotein-E and angiotensin-converting enzyme genotype in Alzheimer's disease.
Interethnic differences in coronary heart disease mortality in 25 populations: association with the angiotensin-converting enzyme DD genotype frequency.
Lack of association between angiotensin-converting enzyme gene polymorphism and coronary heart disease in a Chinese population.
Long-term trandolapril treatment is associated with reduced aortic stiffness: the prevention of events with angiotensin-converting enzyme inhibition hemodynamic substudy.
Low use of statins and other coronary secondary prevention therapies in primary and secondary care in India.
Low-grade urinary albumin excretion in normotensive/non-diabetic obstructive sleep apnea patients.
Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Managing hypertension using combination therapy.
Medical angioplasty - Hope and expectations: An optimistic overview.
Meta-analysis of the association between the insertion/deletion polymorphism in ACE gene and coronary heart disease among the chinese population.
Microfluidic chip-based method for genotyping microsatellites, VNTRs and insertion/deletion polymorphisms.
Myocardial perfusion in type 2 diabetes with left ventricular hypertrophy: normalisation by acute angiotensin-converting enzyme inhibition.
Operational aspects of terminating the doxazosin arm of The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Participant recruitment in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Pathological interactions between the endothelin-1 and the angiotensin- converting enzyme among Tunisian coronary patients.
Perindopril alters vascular angiotensin-converting enzyme, AT(1) receptor, and nitric oxide synthase expression in patients with coronary heart disease.
Pharmacoinvasive management of acute coronary syndrome: incorporating the 2007 ACC/AHA guidelines: the CATH (cardiac catheterization and antithrombotic therapy in the hospital) Clinical Consensus Panel Report--III.
Pharmacological Implications of MMP-9 Inhibition by ACE Inhibitors.
Pharmacotherapy of hypertension in patients with diabetes mellitus.
Plasma concentrations of cystatin C in patients with coronary heart disease and risk for secondary cardiovascular events: more than simply a marker of glomerular filtration rate.
Polymorphisms of angiotensin converting enzyme and plasminogen activator inhibitor-1 genes in diabetes and macroangiopathy1.
Polymorphisms of the angiotensin-converting-enzyme gene in subjects who die from coronary heart disease.
Polymorphisms of the apolipoprotein and angiotensin converting enzyme genes in young North Karelian patients with coronary heart disease.
Potential prescribing omissions in patients with cardiovascular disease.
Prescription drug benefits and use of guideline recommended medications by elderly Medicare beneficiaries with diabetes mellitus.
Prognostic factors for adverse outcomes in patients with COVID-19: a field-wide systematic review and meta-analysis.
Prognostic value of B-Type natriuretic peptides in patients with stable coronary artery disease: the PEACE Trial.
Protective effects of angiotensin-converting enzyme inhibitors in high-risk African American men with coronary heart disease.
Rationale and design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). ALLHAT Research Group.
Rationale, design, methods and baseline demography of participants of the Anglo-Scandinavian Cardiac Outcomes Trial. ASCOT investigators.
Recent advances in the secondary prevention of coronary heart disease.
Redox status of patients before cardiac surgery.
Relation of genetic polymorphisms of apolipoprotein E, angiotensin converting enzyme, apolipoprotein B-100, and glycoprotein IIIa and early-onset coronary heart disease.
Relations between deletion polymorphism of the angiotensin-converting enzyme gene and insulin resistance, glucose intolerance, hyperinsulinemia, and dyslipidemia.
Relationship between circulating levels of angiotensin-converting enzyme 2-angiotensin-(1-7)-MAS axis and coronary heart disease.
Relationship of angiotensin converting enzyme (I/D) polymorphism (rs4646994) and coronary heart disease among a male Iraqi population with type 2 diabetes mellitus.
Renal function and effectiveness of angiotensin-converting enzyme inhibitor therapy in patients with chronic stable coronary disease in the Prevention of Events with ACE inhibition (PEACE) trial.
Renin-Angiotensin system modulators modestly reduce vascular risk in persons with prior stroke.
Residual risk for coronary heart disease events and mortality despite intensive medical management after myocardial infarction.
Role of angiotensin converting enzyme, paraoxonase 1 55, 192 gene polymorphisms in syndrome X and coronary heart disease.
Secondary prevention of coronary heart disease in the elderly.
Serum angiotensin-I-converting enzyme activity in women with cardiological syndrome X: relation to blood pressure and lipid and carbohydrate metabolic risk markers for coronary heart disease.
Should all patients with coronary disease receive angiotensin-converting-enzyme inhibitors?
Should angiotensin-converting enzyme-inhibitors be used to improve outcome in patients with coronary artery disease and 'preserved' left ventricular function?
Significance of angiotensin I-converting enzyme and angiotensin II type 1 receptor gene polymorphisms as risk factors for coronary heart disease.
Stroke Prevention: Not all Antihypertensive Drugs are Created Equal.
The angiotensin-converting enzyme gene and the angiotensin II type I receptor gene as candidate genes for microalbuminuria. A study in nondiabetic and non-insulin-dependent diabetic subjects.
The deletion polymorphism of the angiotensin I-converting enzyme gene is associated with target organ damage in essential hypertension.
The effect of angiotensin converting enzyme inhibition on myocardial function and blood pressure after coronary artery bypass surgery--a randomised study.
The insertion allele of the ACE gene I/D polymorphism. A candidate gene for insulin resistance?
The landscape after PEACE: do all ACE inhibitors act in an identical way?
The relation between obesity, abdominal fat deposit and the angiotensin-converting enzyme gene I/D polymorphism and its association with coronary heart disease.
The role of angiotensin-converting enzyme and apolipoprotein-E gene polymorphisms on lipid compositions in newborn infants with intrauterine growth restriction.
The use of inhibitors of angiotensin-converting enzyme and its relation to events in the postoperative period of CABG.
Time trends in high blood pressure control and the use of antihypertensive medications in older adults: the Cardiovascular Health Study.
Treatment and secondary prevention of ischemic coronary events in Croatia (TASPIC-CRO study).
Update on the management of hypertension: recent clinical trials and the JNC 7.
Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey.
Vitamin D deficiency and anemia is highly prevalent and dependent on the etiology of heart failure: A pilot study.
What is the optimal medical management of ischaemic heart failure?
What is the optimal medical management of ischemic heart failure?
Which drug should be used to treat patients with uncomplicated essential hypertension?
[A study of the influence of the guideline on the treatment of chronic congestive heart failure in the elderly.]
[Acute effects of the angiotensin converting enzyme inhibitor ramipril in patients with coronary heart disease]
[Angiotensin-converting enzyme inhibitors in angina pectoris]
[Apolipoprotein E and angiotensin-converting enzyme gene polymorphisms as risk factors of coronary disease]
[Clinical study of the month. The EUROPA study: cardiovascular protection with perindopril in patients with stable coronary heart disease]
[Clinical study of the month. Which initial antihypertensive? Results from the ALLHAT trial]
[D allele of the angiotensin converting enzyme gene is a putative risk factor of restenosis after coronary stenting in patients with coronary heart disease].
[Effect of an angiotensin-converting-enzyme inhibitor on the plasma concentration of cytokines and vasoactive molecules in patients with coronary heart disease and hypertension].
[Effect of losartan, lisinopril and their combination on hemodynamics and morphofunctional parameters of the heart in patients with chronic cardiac failure].
[Efficiancy Angiotensin -converting enzyme inhibitors for the clinical practice].
[Endothelial dysfunction and angiotensin-converting enzyme inhibitors in coronary disease]
[Gender-related differences in the efficacy of treatment of hypertensive and coronary heart diseases in aged and elderly patients by angiotensin II receptor blockers and angiotensin converting enzyme inhibitors].
[Hypertension and arteriopathy]
[Meta-analysis of association of deletion allele of angiotensin-converting enzyme gene with coronary heart disease in China]
[Nonocclusive acute mesenteric ischemia]
[Polymorphism of the angiotensin-converting enzyme gene in patients with coronary heart disease from Moscow population]
[Prevention of coronary heart disease and heart failure in the elderly]
[Relevant Research on ACE Gene Single Nucleotide Polymorphisms and Premature Coronary Heart Disease Patients with Blood Stasis Syndrome].
[Status on the use of anti-hypertensive drugs in the southwest areas of China].
[Study on relationship between the polymorphism of angiotensin converting enzyme gene and blood stasis syndrome in patients with coronary heart disease]
[The ability of captopril to enhance the anti-anginal effect of isosorbide dinitrate in patients with stable exercise-induced angina pectoris]
[The angiotensin-converting enzyme inhibitor in the treatment of angina pectoris]
[The insertion/deletion polymorphism of angiotensin I converting enzyme gene and coronary heart disease--discordant sib pair analysis and transmission/disequilibrium test]
[The involvement of the renin-angiotensin system gene polymorphisms in coronary heart disease]
[The polymorphism of the angiotensin I-converting enzyme gene and its association with ischemic cardiopathy]
[The relationship between angiotensin converting enzyme gene polymorphism and risk factors for coronary heart disease]
[The role of diabetes mellitus in cardiac disease in Spain. The CARDIOTENS Study 1999]
[Therapy of perindopril: organoprotection, not just the antihypertensive effect].
Coronary Occlusion
Beneficial effects of angiotensin-converting enzyme inhibitors during acute revascularization.
Effects of captopril on limiting infarct size in conscious dogs.
Functional infarct expansion, left ventricular dilation and isovolumic relaxation time after coronary occlusion: a two-dimensional echocardiographic study.
Hypertension and acute myocardial infarction: an overview.
Influence of angiotensin-converting enzyme inhibition on cardiac function in myocardial infarction.
Subcellular and molecular mechanisms of the effects of cardiac glycosides and angiotensin-converting enzyme inhibitors on contractile function and energy conversion in myocardial myofibrils under normal conditions and during acute cardiac insufficiency.
Coronary Restenosis
Angiotensin converting enzyme insertion or deletion polymorphism and coronary restenosis: meta-analysis of 16 studies.
Association of ACE insertion or deletion polymorphisms with the risk of coronary restenosis after percutaneous coronary intervention: A meta-analysis.
Effects of angiotensin converting enzyme inhibition on neointimal proliferation in a porcine coronary injury model.
Genetic Polymorphism of Angiotensin Converting Enzyme and Risk of Coronary Restenosis after Percutaneous Transluminal Coronary Angioplasties: Evidence from 33 Cohort Studies.
Influence of the angiotensin converting enzyme insertion or deletion genetic variant and coronary restenosis risk: evidence based on 11,193 subjects.
No association found between the insertion/deletion of a 287-bp alu repeat sequence within intron 16 of the angiotensin-I-converting enzyme (ACE) gene in Mexican patients and binary restenosis after coronary stenting.
[D/D genotype of the gene for angiotensin converting enzyme as a risk factor for post-stent coronary restenosis]
Coronary Stenosis
Angiotensin-converting enzyme gene polymorphism is associated with myocardial infarction but not with development of coronary stenosis.
Association of polymorphisms in angiotensin-converting enzyme and type 1 angiotensin II receptor genes with coronary heart disease and the severity of coronary artery stenosis.
Insertion/deletion polymorphism of the angiotensin-converting enzyme gene is strongly associated with coronary heart disease in non-insulin-dependent diabetes mellitus.
Left ventricular function after coronary artery reperfusion.
Myocardial microvascular disease and major adverse cardiovascular events in patients with end-stage renal disease: rationale and design of the MICROCARD study.
Coronary Thrombosis
Effects of captopril therapy on endogenous fibrinolysis in men with recent, uncomplicated myocardial infarction.
Effects of enalapril on tissue factor in patients with uncomplicated acute myocardial infarction.
Plasma kallikrein/kinin system: a revised hypothesis for its activation and its physiologic contributions.
Stimulation of plasminogen activator inhibitor in vivo by infusion of angiotensin II. Evidence of a potential interaction between the renin-angiotensin system and fibrinolytic function.
Coronavirus Infections
Autophagy as an emerging target for COVID-19: lessons from an old friend, chloroquine.
Combination of C21 and ARBs with rhACE2 as a therapeutic protocol: A new promising approach for treating ARDS in patients with coronavirus infection.
Coronavirus disease 2019 (COVID-19) and the renin-angiotensin system: A closer look at angiotensin-converting enzyme 2 (ACE2).
COVID-19 and cardiac injury: clinical manifestations, biomarkers, mechanisms, diagnosis, treatment, and follow up.
Current approaches for target-specific drug discovery using natural compounds against SARS-CoV-2 infection.
Protective role of ACE2 and its downregulation in SARS-CoV-2 infection leading to Macrophage Activation Syndrome: Therapeutic implications.
Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension.
Single-cell analysis of angiotensin-converting enzyme II expression in human kidneys and bladders reveals a potential route of 2019 novel coronavirus infection.
Cough
A Comparison of the Cough Profile of Fosinopril and Enalapril in Hypertensive Patients with a History of ACE Inhibitor-Associated Cough.
A crossover randomized comparative study of zofenopril and ramipril on cough reflex and airway inflammation in healthy volunteers.
A double-blind, long-term, comparative study on quality of life, safety, and efficacy during treatment with amlodipine or enalapril in mild or moderate hypertensive patients: a multicenter study.
A genome-wide association study identifies variants in KCNIP4 associated with ACE inhibitor-induced cough.
A high incidence of cough in Chinese subjects treated with angiotensin converting enzyme inhibitors.
A new class of antihypertensive therapy: angiotensin II receptor antagonists.
A profile of adverse effects of antihypertensive medicines in a tertiary care clinic in Nigeria.
ACE inhibitor- versus angiotensin II blocker-induced cough and angioedema.
ACE inhibitor-induced bronchial reactivity in patients with respiratory dysfunction.
ACE inhibitor-induced cough and bronchospasm. Incidence, mechanisms and management.
ACE inhibitors and chronotherapy.
ACE inhibitors and cough.
ACE inhibitors, angiotensin II antagonists and cough. The Losartan Cough Study Group.
ACEI-induced cough: A review of current evidence and its practical implications for optimal CV risk reduction.
Acid regurgitation associated with persistent cough after pulmonary resection: an observational study.
Acute ACE inhibition causes plasma extravasation in mice that is mediated by bradykinin and substance P.
Adjunctive therapies for community-acquired pneumonia: a systematic review.
Airway and cough responsiveness and exhaled nitric oxide in non-smoking patients with stable chronic heart failure.
Airway inflammation as an assessment of chronic nonproductive cough.
Airway responsiveness and cough induced by angiotensin converting enzyme inhibition.
An update on non-peptide angiotensin receptor antagonists and related RAAS modulators.
Angiotensin converting enzyme (ACE) inhibitor-induced cough and substance P.
Angiotensin converting enzyme inhibitor associated cough: a population-based case-control study.
Angiotensin converting enzyme inhibitor cough: lessons from heart-lung transplantation.
Angiotensin converting enzyme inhibitor induced cough in Nigerians.
Angiotensin converting enzyme inhibitor induced cough: experience in Siriraj Hospital.
Angiotensin converting enzyme inhibitors and cough--a north Indian study.
Angiotensin converting enzyme inhibitors and cough.
Angiotensin converting enzyme inhibitors and the allergist.
Angiotensin converting enzyme inhibitors are not associated with respiratory complications or mortality after noncardiac surgery.
Angiotensin II receptor antagonists in arterial hypertension.
Angiotensin II receptor antagonists in the treatment of hypertension.
Angiotensin II receptor blocker-associated angioedema: on the heels of ACE inhibitor angioedema.
Angiotensin II receptor inhibition. A new therapeutic principle.
Angiotensin II subtype 1-receptor antagonists in the treatment of diabetic nephropathy.
Angiotensin II-receptor antagonists: an overview.
Angiotensin-converting enzyme (ACE) gene insertion/deletion polymorphism and ACE inhibitor-related cough: a meta-analysis.
Angiotensin-converting enzyme and bradykinin gene polymorphisms and cough: A meta-analysis.
Angiotensin-converting enzyme and the cough reflex.
Angiotensin-converting enzyme gene insertion/deletion, not bradykinin B2 receptor -58T/C gene polymorphism, associated with angiotensin-converting enzyme inhibitor-related cough in Chinese female patients with non-insulin-dependent diabetes mellitus.
Angiotensin-converting enzyme inhibition, cough and the serum concentration of substance P.
Angiotensin-converting enzyme inhibition-emerging pulmonary issues relating to cough.
Angiotensin-converting enzyme inhibitor and danazol increase sensitivity of cough reflex in female guinea pigs.
Angiotensin-converting enzyme inhibitor associated cough: deceptive information from the Physicians' Desk Reference.
Angiotensin-converting enzyme inhibitor-induced cough.
Angiotensin-converting enzyme inhibitor-induced cough: ACCP evidence-based clinical practice guidelines.
Angiotensin-converting enzyme inhibitors and cough.
Angiotensin-converting enzyme inhibitors and cough. Prevalence in an outpatient medical clinic population.
Angiotensin-converting enzyme inhibitors and cough: a prospective evaluation in hypertension and in congestive heart failure.
Angiotensin-converting enzyme inhibitors and obstructive sleep apnea.
Angiotensin-converting enzyme inhibitors and their influence on inflammation, bronchial reactivity and cough. A research review.
Angiotensin-Converting Enzyme Inhibitors Induce Cough.
Angiotensin-Converting Enzyme Inhibitors, Asthma, and Cough: Relighting the Torch.
Angiotensin-converting enzyme-related cough among Chinese-Americans.
Angiotensin-I-converting enzyme gene polymorphism and susceptibility to cough.
Angiotensin-II receptor antagonists: a new class of antihypertensive agents.
Angiotensin-II receptor antagonists: their place in therapy.
Antagonizing the angiotensin II subtype 1 receptor: a focus on olmesartan medoxomil.
Antihypertensive drugs and airway function, with special reference to calcium channel blockade.
Antihypertensive efficacy and tolerability of once daily losartan potassium compared with captopril in patients with mild to moderate essential hypertension.
Antihypertensive therapy targeted to the needs of the patient: focus on the renin-angiotensin system; older and newer agents.
Antitussive effect of captopril, an angiotensin converting enzyme inhibitor, in the rat.
Approaching chronic cough.
Appropriate use of antitussives and protussives. A practical review.
Aprotinin suppresses ACE-inhibitor cough triggered by TAME-esterase.
Are physicians aware of the side effects of angiotensin-converting enzyme inhibitors?: a questionnaire survey in different medical categories.
Asian management of hypertension: Current status, home blood pressure, and specific concerns in Thailand.
Ask the doctor. I have had heart failure since my heart attack a year ago. My physician initially prescribed lisinopril, an angiotensin-converting enzyme (ACE) inhibitor. Unfortunately, I was one of the unlucky people who got a cough with this drug that was so annoying I had to stop taking it. Now my doctor wants me to try a newer drug called valsartan. Is it likely to help me?
Association between cough and angiotensin converting enzyme inhibitors versus angiotensin II antagonists: the design of a prospective, controlled study.
Association between genetic polymorphisms and angiotensin-converting enzyme inhibitor-induced cough: a systematic review and meta-analysis.
ATRA therapy restores normal renal function and renal reserve and prevents renal failure.
Attenuation of angiotensin converting enzyme inhibitor induced cough by iron supplementation: role of nitric oxide.
Augmentation of spontaneous cough by enalapril through up-regulation of bradykinin B1 receptors in guinea pigs.
Azilsartan: a newly approved angiotensin II receptor blocker.
Benefits of delapril in hypertensive patients along the cardiovascular continuum.
Biased Safety Reporting in Blinded Randomized Clinical Trials: Meta-Analysis of Angiotensin Receptor Blocker Trials.
Blockade of the renin-angiotensin system.
Bradykinin B(2) receptor gene polymorphism is associated with angiotensin-converting enzyme inhibitor-related cough.
Bradykinin-induced cough reflex markedly increases in patients with cough associated with captopril and enalapril.
Bronchial effects of alpha 2-adrenoceptor agonists and of other antihypertensive agents in asthma.
Bronchial hyperreactivity and cough due to angiotensin-converting enzyme inhibitors.
Bronchial hyperreactivity in patients who cough after receiving angiotensin converting enzyme inhibitors.
Bronchial hyperreactivity induced by angiotensin converting enzyme inhibitor.
Bronchospasm and cough as adverse reactions to the ACE inhibitors captopril, enalapril and lisinopril. A controlled retrospective cohort study.
Candesartan cilexetil in cardiovascular disease.
Candesartan cilexetil is not associated with cough in hypertensive patients with enalapril-induced cough. Multicentre Cough Study Group.
Candesartan Cilexetil is not Associated with Cough in Patients with Enalapril-induced Cough.
Candesartan cilexetil: an angiotensin II-receptor blocker.
Candesartan cilexetil: an update of its use in essential hypertension.
Captopril augments acetylcholine-induced bronchial smooth muscle contractions in vitro via kinin-dependent mechanisms.
Captopril-induced cough.
Cardiovascular events in hypertension trials of Angiotensin-converting enzyme inhibitors.
Changes in plasma bradykinin concentration and citric acid cough threshold at high altitude.
Changing etiological frequency of chronic cough in a tertiary hospital in Shanghai, China.
Characterization of cough associated with angiotensin-converting enzyme inhibitors.
Chronic cough caused by angiotensin converting enzyme inhibitors.
Chronic cough due to angiotensin-converting enzyme inhibitors.
Chronic Cough: An Update.
Clinical Factors and Rate of Cough During Angiotensin-Converting Enzyme Inhibitor Treatment.
Comparative study of effects of angiotensin II receptor antagonist, KD3-671, and angiotensin converting enzyme inhibitor, enalaprilat, on cough reflex in guinea pig.
Comparative study of the effects of three angiotensin converting enzyme inhibitors on the cough reflex.
Comparison between the effects of lisinopril and losartan on the cougn reflex in anesthetized and awake rabbits.
Comparison of Cause Distribution between Elderly and Non-Elderly Patients with Chronic Cough.
Comparison of Clinical Factors Between Patients With Angiotensin-Converting Enzyme Inhibitor-Induced Angioedema and Cough.
Comparison of diagnostic evaluations for cough among initiators of angiotensin converting enzyme inhibitors and angiotensin receptor blockers.
Comparison of the incidence of imidapril and enalapril induced cough.
Controversies in the evaluation and management of chronic cough.
Cough and ACE inhibitors.
Cough and angioedema from angiotensin-converting enzyme inhibitors: new insights into mechanisms and management.
Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. A review of the literature and pathophysiology.
Cough and angiotensin converting enzyme inhibition.
Cough and angiotensin converting enzyme inhibitors.
Cough and angiotensin II receptor antagonists: cause or confounding?
Cough and inhibition of the renin-angiotensin system.
Cough and wheeze caused by inhibitors of angiotensin-converting enzyme.
Cough associated with angiotensin converting enzyme inhibition.
Cough associated with angiotensin-converting enzyme inhibitors.
Cough caused by ACE inhibitors.
Cough in Pediatric Patients Receiving Angiotensin-Converting Enzyme Inhibitor Therapy or Angiotensin Receptor Blocker Therapy in Randomized Controlled Trials.
Cough induced activity of spirapril in rats.
Cough induced by angiotensin-converting-enzyme inhibitors.
Cough induced by angiotensin-converting-enzyme inhibitors: Airway responses to inhalation of methacholine in patients who have essential hypertension.
Cough induced by losartan with resolution after substitution with enalapril.
Cough induced by quinapril with resolution after changing to fosinopril.
Cough provocation tests: their clinical value.
Cough related to angiotensin-converting enzyme inhibition.
Cough requiring discontinuance of angiotensin-converting enzyme inhibitors in an urban inner-city population.
Cough with angiotensin converting enzyme inhibitors: how much of a problem?
Cough-challenge trial with a new angiotensin-converting enzyme inhibitor, imidapril.
Cough-induced activity of (-)-(2S, 3aR, 7aS)-1-[(S)-N-[(S)-1-ethoxycarbonyl-3- phenylpropyl]alanyl]hexahydro-2-indolinecarboxylic acid (trandolapril) in guinea pigs.
Cough: a worldwide problem.
Cromolyn for cough due to angiotensin-converting enzyme inhibitor therapy. Preliminary observations.
Current treatment and management of dystrophinopathies.
Days Needed for the Disappearance of a Cough Due to the Use of an Angiotensin-Converting Enzyme Inhibitor and Identification of Predisposing Factors Associated With Its Appearance in a Clinical Cohort of Hypertensive Patients.
Dechallenge and rechallenge method showed different incidences of cough among four ACE-Is.
Delay of diagnosis and empiric treatment of angiotensin-converting enzyme inhibitor-induced cough in office practice.
Deletion allele of the angiotensin-converting enzyme gene as a risk factor for pneumonia in elderly patients.
Demographic and Clinical Characteristics of Patients Presenting With Angiotensin-converting Enzyme Inhibitors Induced Cough.
Development and validation of a clinical prediction rule for angiotensin-converting enzyme inhibitor-induced cough.
Diagnosis and management of chronic persistent dry cough.
Difference in the incidence of cough induced by angiotensin converting enzyme inhibitors: a comparative study using imidapril hydrochloride and enalapril maleate.
Differences between zofenopril and ramipril, two ACE inhibitors, on cough induced by citric acid in guinea pigs: role of bradykinin and PGE2.
Differences in the mode of cough augmentation by four angiotensin-converting enzyme inhibitors in guinea-pigs.
Different effects of imidapril and enalapril on aminopeptidase P activity in the mouse trachea.
Discontinuation of Angiotensin Converting Enzyme Inhibitors due to Dry Cough: Incidence and Clinical Determinants.
Do Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers Decrease the Risk of Hospitalization Secondary to Community-Acquired Pneumonia? A Nested Case-Control Study.
Double-blind comparison of losartan, lisinopril and hydrochlorothiazide in hypertensive patients with a previous angiotensin converting enzyme inhibitor-associated cough.
Double-blind comparison of losartan, lisinopril, and metolazone in elderly hypertensive patients with previous angiotensin-converting enzyme inhibitor-induced cough.
Drug treatment of systolic and of diastolic heart failure in elderly persons.
Drug-induced bronchospasm.
Drug-induced chronic cough and the possible mechanism of action.
Drug-Induced Cough.
Drug-induced pulmonary disease.
Dyspnoea, asthma, and bronchospasm in relation to treatment with angiotensin converting enzyme inhibitors.
Effect of sulindac on angiotensin converting enzyme inhibitor-induced cough: randomised placebo-controlled double-blind cross-over study.
Effectiveness of amitriptyline versus cough suppressants in the treatment of chronic cough resulting from postviral vagal neuropathy.
Effects of angiotensin-converting enzyme inhibitors and sclerotherapy on portal hemodynamics in patients with portal hypertension.
Effects of glycopyrrolate on capsaicin-induced cough in normal volunteers treated with captopril.
Effects of modulators of the renin-angiotensin-aldosterone system on cough. Losartan Cough Study Group.
Effects of nifedipine and indomethacin on cough induced by angiotensin-converting enzyme inhibitors: a double-blind, randomized, cross-over study.
Effects of the angiotensin-converting enzyme inhibitor alacepril in dogs with mitral valve disease.
Effects of Zofenopril and Ramipril on Cough Reflex Responses in Anesthetized and Awake Rabbits.
Efficacy and Safety of Olmesartan in the Treatment of Mild-to-Moderate Essential Hypertension in Chinese Patients.
Enalapril and diltiazem co-administration and respiratory side effects of enalapril.
Epidemiology, pathophysiology, prognosis, and treatment of systolic and diastolic heart failure.
Evaluation and quality-of-life assessment of amlodipine and enalapril in patients with hypertension.
Evaluation of the patient with chronic cough.
Evidence-based Evaluation and Management of Chronic Cough.
Exploring the Relation between Glottal Closure and Plasma Substance P: A Study Protocol.
Factors influencing the spontaneous reporting of adverse drug reactions--the experience of the Slovak Republic.
Female gender as a determinant of cough threshold to inhaled capsaicin.
For potential resolution of cough associated with an angiotensin-converting enzyme inhibitor.
Foreign Body Granulomatous Reaction to Silica, Silicone, and Hyaluronic Acid in a Patient With Interferon-Induced Sarcoidosis.
From a prospective study of chronic cough: diagnostic and therapeutic aspects in older adults.
Genetic Association Between CD143 rs4340 Polymorphism and Pneumonia risk: A Meta Analysis.
Genetic variants associated with angiotensin-converting enzyme inhibitor-induced cough: a genome-wide association study in a Swedish population.
Ginkgo biloba Extract for Patients with Early Diabetic Nephropathy: A Systematic Review.
High prevalence of persistent cough with angiotensin converting enzyme inhibitors in Chinese.
Higher incidence of discontinuation of angiotensin converting enzyme inhibitors due to cough in black subjects.
Human ACE gene polymorphism and distilled water induced cough.
Hypertension in Asian/Pacific Island Americans.
Identification of genetic factors associated with susceptibility to angiotensin-converting enzyme inhibitors-induced cough.
If it is not cough, it must be dysgeusia: differing adverse effects of angiotensin-converting enzyme inhibitors in the same individual.
Implementation of a simple age-based strategy in the prevention of cardiovascular disease: the Polypill approach.
Incidence of discontinuation of angiotensin-converting enzyme inhibitors due to cough, in a primary healthcare centre in Singapore.
Increased cough reflex associated with angiotensin converting enzyme inhibitor cough.
Increased reporting of adverse reactions to ACE inhibitors associated with limitations to drug reimbursement for angiotensin-II receptor antagonists.
Indomethacin: Can It Counteract Bradykinin Effects in COVID-19 Patients?
Influence of ABO genotype and phenotype on angiotensin-converting enzyme plasma activity.
Inhalation of phosphoramidon, a neutral endopeptidase inhibitor, induces cough in awake guinea-pigs.
Inhaled sodium cromoglycate in angiotensin-converting enzyme inhibitor cough.
Inherent inaccuracies and potential utility of race/ethnicity labeling in the treatment of hypertension.
Inhibition of the renin-angiotensin system and cardio-renal protection: focus on losartan and angiotensin receptor blockade.
Interaction of noscapine with the bradykinin mediation of the cough response.
Intermediate but not low doses of aspirin can suppress angiotensin-converting enzyme inhibitor-induced cough.
Interventions to prevent pneumonia among older adults.
Introduction: The pharmacological profile of eprosartan--implications for cerebrovascular and cardiovascular risk reduction.
Laryngeal sensory neuropathy in patients with diabetes mellitus.
Levocloperastine in the treatment of chronic nonproductive cough: comparative efficacy versus standard antitussive agents.
Losartan treatment for hypertensive patients with hyperuricaemia in Chinese population: a meta-analysis.
Mechanism of cough with angiotensin-converting enzyme inhibition.
Methacholine inhalation challenge in patients with chronic cough induced by angiotensin-converting enzyme inhibitors.
Methylephedrine-induced heart failure in a habitual user of paediatric cough syrup: a case report.
Modulation of the renin-angiotensin-aldosterone system and cough.
Molecular studies of bronchial asthma, sarcoidosis and angiotensin converting enzyme inhibitor-induced cough.
Muscarinic blockade with oral hyoscine palliates angiotensin converting enzyme inhibitor induced cough.
New aspects on inflammatory reactions and cough following inhibiton of angiotensin converting enzyme.
New therapeutic agents for hypertension.
Noscapine suppresses angiotensin converting enzyme inhibitors-induced cough.
Novel Antitussive Effect of Suplatast Tosilate in Guinea Pigs.
Omeprazole-induced cough in a patient with gastroesophageal reflux disease.
Outbreak of acute renal failure in Panama in 2006: a case-control study.
Overcoming Cough and Angioedema: Advocating for the Use of ARBs Over ACE Inhibitors.
Pathophysiology and clinical presentations of cough.
Pathophysiology and therapy of chronic cough.
Peritoneal dialysis and cough: ACCP evidence-based clinical practice guidelines.
Pharmacogenetic predictors of angiotensin-converting enzyme inhibitor-induced cough: the role of ACE, ABO, and BDKRB2 genes.
Pharmacologic treatment of chronic pediatric hypertension.
Pharmacology of bradykinin evoked coughing in guinea pigs.
Pharmacotherapy in congestive heart failure: ACE inhibitors and anemia in congestive heart failure.
Pharmacotherapy of chronic cough in adults.
Pilot survey of the diagnosis and management of heart failure in primary care: a Singaporean perspective.
PNPT1 and PCGF3 variants associated with angiotensin-converting enzyme inhibitor-induced cough: a nested case-control genome-wide study.
Points: Angiotensin converting enzyme inhibition and cough.
Points: Cough and angiotensin converting enzyme inhibition.
Polymorphisms in the neurokinin-2 receptor gene are associated with angiotensin-converting enzyme inhibitor-induced cough.
Predictive values of the character, timing, and complications of chronic cough in diagnosing its cause.
Predictors of objective cough frequency in pulmonary sarcoidosis.
Prevalence of cough during angiotensin-converting enzyme inhibitor therapy.
Preventing aspiration pneumonia in older people: do we have the 'know-how'?
Preventive strategies for aspiration pneumonia in elderly disabled persons.
Pulmonary function and airway responsiveness during long-term therapy with captopril.
Putative mechanisms of cough after treatment with angiotensin converting enzyme inhibitors.
Racial difference in incidence of cough with angiotensin-converting enzyme inhibitors (a tale of two cities).
Ranolazine, ACE Inhibitors, and Angiotensin Receptor Blockers.
Rate of Cough During Treatment With Angiotensin-Converting Enzyme Inhibitors: A Meta-Analysis of Randomized Placebo-Controlled Trials.
Reduction of pneumonia risk by an angiotensin I-converting enzyme inhibitor in elderly Japanese inpatients according to insertion/deletion polymorphism of the angiotensin I-converting enzyme gene.
Reduction of risk of pneumonia associated with use of angiotensin I converting enzyme inhibitors in elderly inpatients.
Renin inhibitors.
Reproducibility of angiotensin converting enzyme inhibitor induced cough: a double-blind randomised study.
Response to "Clinical Factors and Rate of Cough During Angiotensin-Converting Enzyme Inhibitor Treatment".
Response to "Discontinuation of Angiotensin Converting Enzyme Inhibitors Due to Dry Cough: Incidence and Clinical Determinants".
Revised Korean Cough Guidelines, 2020: Recommendations and Summary statements.
Rhinorrhea, cough and fatigue in patients taking sitagliptin.
Role of angiotensin II AT1 receptor blockers in the treatment of arterial hypertension.
Role of losartan therapy in the management of diabetic hypertension.
Role of substance P in cough.
Rs495828 polymorphism of the ABO gene is a predictor of enalapril-induced cough in Chinese patients with essential hypertension.
Safety and tolerability of losartan compared with atenolol, felodipine and angiotensin converting enzyme inhibitors.
Safety and tolerability of losartan potassium, an angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipine ER, and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension.
Sarcoidosis: a journey through 50 years.
Sensitivity of the human cough reflex: effect of inflammatory mediators prostaglandin E2, bradykinin, and histamine.
Sex difference in the inhaled tartaric acid cough threshold in non-atopic healthy subjects.
Sex, drugs, and heart failure: a sex-sensitive review of the evidence base behind current heart failure clinical guidelines.
SLCO1B1 Variants and Angiotensin Converting Enzyme Inhibitor (Enalapril)-Induced Cough: a Pharmacogenetic Study.
Sodium cromoglycate prophylaxis for angiotensin-converting enzyme inhibitor cough.
Sodium cromoglycate: a remedy for ACE inhibitor-induced cough.
Spectrum of use for the angiotensin-receptor blocking drugs.
Spontaneous disappearance of cough induced by angiotensin-converting enzyme inhibitors (captopril or enalapril).
Stress urinary incontinence due to prescription medications: alpha-blockers and angiotensin converting enzyme inhibitors.
Studies on the magnitude and the mechanism of cough potentiation by angiotensin-converting enzyme inhibitors in guinea-pigs: involvement of bradykinin in the potentiation.
Substituted Benzimidazole Derivatives as Angiotensin II -AT1 Receptor Antagonist: A Review.
Systematic review and meta-analysis of ethnic differences in risks of adverse reactions to drugs used in cardiovascular medicine.
Ten Years of Chronic Cough in a 64-Year-Old Man With Multiple Pulmonary Nodules.
The ACE gene polymorphism and cough threshold for capsaicin after cilazapril usage.
The aetiology of chronic cough: a review of current theories for the otorhinolaryngologist.
The airway sensory hyperreactivity syndrome.
The combined cough frequency/severity scoring: a new approach to cough evaluation in clinical settings.
The effect of angiotensin converting enzyme inhibitors (ACE-I) and selective beta 1-antagonists on bronchial reactivity and the cough reflex in man.
The effect of sulindac on the abnormal cough reflex associated with dry cough.
The Effects of Antitussive Treatment of ACE Inhibitor-Induced Cough on Therapy Compliance: A Prescription Sequence Symmetry Analysis.
The impact of age and sex on the reporting of cough and angioedema with renin-angiotensin system inhibitors: a case/noncase study in VigiBase.
The incidence of cough during treatment with angiotensin converting enzyme inhibitors.
The influence of gender on cough reflex sensitivity.
The influence of inhaled furosemide on adverse effects of ACE-inhibitors in airways.
The Korean Cough Guideline: Recommendation and Summary Statement.
The pharmacologic treatment of uncomplicated arterial hypertension in patients with airway dysfunction.
The positive association of cough with angiotensin-converting enzyme inhibitors.
The potential economic impact of restricted access to angiotensin-receptor blockers.
The presence of underlying asthma should be investigated in patients diagnosed with ACE inhibitor induced cough.
The role of angiotensin receptor blockers in reducing the risk of cardiovascular disease.
The Role of Microaspiration in the Pathogenesis of Gastroesophageal Reflux-related Chronic Cough.
The role of the methacholine inhalation challenge in adult patients presenting with chronic cough.
The role of TRPA1 and TRPV4 channels in bronchoconstriction and plasma extravasation in airways of rats treated with captopril.
The Sexual Dimorphism of High Blood Pressure.
Theophylline in the inhibition of angiotensin-converting enzyme inhibitor-induced cough.
Therapeutic potential of angiotensin receptor blockers in hypertension.
Therapy Insight: treatment of gastroesophageal reflux in adults with chronic cough.
Three candidate genes and angiotensin-converting enzyme inhibitor-related cough: a pharmacogenetic analysis.
Thromboxane A2 synthetase inhibition suppresses cough induced by angiotensin converting enzyme inhibitors.
Thromboxane antagonism and cough induced by angiotensin-converting-enzyme inhibitor.
Tolerability and quality of life in ARB-treated patients.
Toxic effects of drugs used in the ICU. Nitroprusside, nitroglycerin, and angiotensin-converting enzyme inhibitors.
Toxicodynamic analysis of cough and inflammatory reactions by angiotensin-converting enzyme inhibitors in guinea pig.
Tracheopathia osteochondroplastica.
Treatment of angiotensin receptor blocker-induced Angioedema: A case series.
Treatment of chronic, refractory cough with baclofen.
Treatment of heart failure with decreased left ventricular ejection fraction.
Treatment of systemic hypertension in patients with pulmonary disease: COPD and asthma.
Treatment of systolic and diastolic heart failure in the elderly.
Unusual Complication of ACE Inhibitor-Induced Cough.
Update on the clinical pharmacology of candesartan cilexetil.
Use of baclofen to suppress cough induced by angiotensin-converting enzyme inhibitors.
Use of losartan in the treatment of hypertensive patients with a history of cough induced by angiotensin-converting enzyme inhibitors.
Usefulness of the Guidelines of the Spanish Society of Pulmonology and Thoracic Surgery (SEPAR) in Identifying the Causes of Chronic Cough.
Valsartan and the kidney: review of preclinical and clinical data.
Valsartan, a new angiotensin II receptor antagonist: a double-blind study comparing the incidence of cough with lisinopril and hydrochlorothiazide.
Valsartan: more than a decade of experience.
Visceral angioedema: an under-recognized complication of angiotensin-converting enzyme inhibitors.
What is a preferred angiotensin II receptor blocker-based combination therapy for blood pressure control in hypertensive patients with diabetic and non-diabetic renal impairment?
Zofenopril and incidence of cough: a review of published and unpublished data.
[A prospective study on the cough mechanism induced by angiotensin-converting enzyme inhibitors in patients with hypertension]
[A secondary effect of converting enzyme inhibitors: cough]
[Adverse effects of angiotensin II type 1 receptor blockers ]
[Analysis of the Cochrane Review: Angiotensin Converging Enzyme Inhibitors Versus Angiotensin Receptor Blockers for Primary Hypertension. Cochrane Database Syst Rev. 2014,8: CD009096].
[Angiotensin converting enzyme (ACE) inhibitor-induced cough in non-smoking hypertensive patients]
[Angiotensin converting enzyme inhibitor-induced cough: patterns and incidence. Consequences for continuation of therapy]
[Angiotensin II receptor blockers: current status and future prospects]
[AT1 angiotensin receptor inhibition as a new therapeutic possibility]
[Aural Stimulation with Capsaicin Ointment Improved the Swallowing Function in Patients with Dysphagia: Evaluation by the SMRC Scale].
[Berylliosis in Italy: a case of "sarcoidosis" under the threshold limit value]
[Bronchial hyperreactivity in cough associated with angiotensin converting enzyme inhibitors]
[Changes in the spectrum and frequency of causes for chronic cough: a retrospective analysis]
[Chronic cough]
[Cough and angiotensin converting enzyme inhibition]
[Cough and inhibitors of the angiotensin-converting enzyme]
[Cough as a side effect of angiotensin-converting enzyme inhibitors]
[Cough as an adverse effect during angiotensin-converting enzyme inhibitor therapy]
[Cough associated with angiotensin-converting enzyme inhibitors]
[Cough caused by angiotensin converting enzyme. Reflections on the data in computerized data banks of the French system of pharmacovigilance]
[Cough caused by angiotensin-converting enzyme inhibitors. A series of cases collected by spontaneous notification of adverse reactions]
[Cough during treatment with angiotensin-converting enzyme inhibitors is gender related]
[Cough induced by an inhibitor of the angiotensin-converting enzyme]
[Cough induced by angiotensin converting enzyme inhibitors: report of a case by lysinopril]
[Cough induced by inhibitors of angiotensin converting enzyme]
[Cough provoked by angiotensin-converting enzyme inhibitors. Effect of non-steroidal anti-inflammatory agents]
[Cough, bronchoconstriction and bronchial hyperreactivity in relation to treatment with angiotensin-converting enzyme]
[Cough: differential diagnosis and differentiated treatment].
[Cross-sensitivity between angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonist]
[Dry cough in the elderly patients treated with angiotensin converting enzyme inhibitor]
[Effect of captopril on pulmonary function]
[Effect of Rilmenidine(Tenaxum) on the activity of the autonomic nervous system in patients with hypertension and asthma]
[Etiological diagnosis and specific treatment of chronic cough in 106 patients]
[Isolated cough and bronchial asthma]
[No relation between angiotensin-converting enzyme (ACE) inhibitor-induced cough and ACE gene polymorphism, plasma bradykinin, substance P and ACE inhibitor concentration in Japanese patients]
[Novel approach to respiratory pharmacology--pharmacological basis of cough, sputum and airway clearance]
[Pneumopathy induced by pirindopril. A case report]
[Relationship between cough threshold to inhaled tartaric acid and sex, smoking and atopy in humans]
[Reporting of adverse drug reactions by primary care physicians]
[Resistance to ACE inhibitors. Myth or reality?]
[Study on candidate genes of benazepril related cough in Chinese hypertensives]
[The relationship between polymorphism of angiotensin converting enzyme gene and cough caused by angiotensin converting enzyme inhibitors]
COVID-19
A Comparison of Disease Severity and Outcomes in COVID-19 Cases Taking Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers Versus Other Antihypertensive Drugs.
A Comprehensive Literature Review on the Clinical Presentation, and Management of the Pandemic Coronavirus Disease 2019 (COVID-19).
A comprehensive review of imaging findings in COVID-19 - status in early 2021.
A consensus statement on the use of angiotensin receptor blockers and angiotensin converting enzyme inhibitors in relation to COVID-19 (corona virus disease 2019).
A mouse model of lethal respiratory dysfunction for SARS-CoV-2 infection.
A narrative review of the potential pharmacological influence and safety of ibuprofen on coronavirus disease 19 (COVID-19), ACE2, and the immune system: a dichotomy of expectation and reality.
A Patient Infected with SARS-CoV-2 Presenting with Complete Heart Block.
A Retrospective Study from 2 Centers in China on the Effects of Continued Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers in Patients with Hypertension and COVID-19.
A sugar-coated strategy to treat a rare neurologic disease provides a blueprint for a decoy glycan therapeutic and a potential vaccine for CoViD-19: An Editorial Highlight for "Selective inhibition of anti-MAG IgM autoantibody binding to myelin by an antigen specific glycopolymer"on page 486.
A systematic review and meta-analysis of the use of renin-angiotensin system drugs and COVID-19 clinical outcomes: What is the evidence so far?
A systematic review and meta-analysis to evaluate the clinical outcomes in COVID-19 patients on angiotensin-converting enzyme inhibitors or angiotensin receptor blockers.
Absence of SARS-CoV-2 in semen of a COVID-19 patient cohort.
ACE Gene I/D Polymorphism and Acute Pulmonary Embolism in COVID19 Pneumonia: A Potential Predisposing Role.
ACE Gene Variants Rise the Risk of Severe COVID-19 in Patients With Hypertension, Dyslipidemia or Diabetes: A Spanish Pilot Study.
ACE2 and SARS-CoV-2 Infection Risk: Insights From Patients With Two Rare Genetic Tubulopathies, Gitelman's and Bartter's Syndromes.
ACE2 as Drug Target of COVID-19 Virus Treatment, Simplified Updated Review.
ACE2 contributes to the maintenance of mouse epithelial barrier function.
ACE2 localizes to the respiratory cilia and is not increased by ACE inhibitors or ARBs.
ACEI/ARB use and risk of infection or severity or mortality of COVID-19: A systematic review and meta-analysis.
ACEIs, ARBs, ibuprofen originally linked to COVID-19: the other side of the mirror.
Acute Cardiac Injury in Coronavirus Disease 2019 and Other Viral Infections-A Systematic Review and Meta-Analysis.
Acute Kidney Injury in a Case Series of Patients with Confirmed COVID-19 (Coronavirus Disease 2019): Role of Angiotensin-Converting Enzyme 2 and Renin-Angiotensin System Blockade.
Adverse impact of renin-angiotensin system blockade on the clinical course in hospitalized patients with severe COVID-19: a retrospective cohort study.
Age-Related Differences in the Expression of Most Relevant Mediators of SARS-CoV-2 Infection in Human Respiratory and Gastrointestinal Tract.
Airborne Infections and Emergency Surgery: The COVID-19 Pandemic Perspective.
Analysis of the Spectrum of ACE2 Variation Suggests a Possible Influence of Rare and Common Variants on Susceptibility to COVID-19 and Severity of Outcome.
Angiotensin converting enzyme 2 at the interface between renin-angiotensin system inhibition and coronavirus disease 2019.
Angiotensin converting enzyme genotypes and mortality from COVID-19: An ecological study.
Angiotensin Converting Enzyme Inhibitor and Angiotensin II Receptor Blocker Use Among Outpatients Diagnosed With COVID-19.
Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers and Outcomes in patients with COVID-19: A Systematic Review and Meta-Analysis.
Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers and Mortality Among COVID-19 Patients: A Systematic Review and Meta-Analysis.
Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers and the Risk of SARS-CoV-2 Infection or Hospitalization With COVID-19 Disease: A Systematic Review and Meta-Analysis.
Angiotensin converting enzyme inhibitors and angiotensin receptor blockers improved the outcome of patients with severe COVID-19 and hypertension.
Angiotensin converting enzyme inhibitors do not increase the risk of poor outcomes in COVID-19 disease. A multi-centre observational study.
Angiotensin Converting Enzyme Inhibitors, A Risk Factor of Poor Outcome in Diabetic Patients with COVID-19 Infection.
Angiotensin converting enzyme: A review on expression profile and its association with human disorders with special focus on SARS-CoV-2 infection.
Angiotensin enzyme inhibitors and angiotensin receptor blockers as protective factors in COVID-19 mortality: a retrospective cohort study.
Angiotensin II Receptors - Impact for COVID-19 Severity.
Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors in COVID-19: Meta-analysis/Meta-regression Adjusted for Confounding Factors.
Angiotensin-Converting Enzyme (ACE) Inhibitors and Angiotensin Receptor Blockers (ARB) Are Protective Against ICU Admission and Mortality for Patients With COVID-19 Disease.
Angiotensin-Converting Enzyme 2 and Antihypertensives (Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors) in Coronavirus Disease 2019.
Angiotensin-Converting Enzyme as a new immunologic target for the new SARS-CoV-2.
Angiotensin-Converting Enzyme Gene Polymorphism and Severe Lung Injury in Patients with Coronavirus Disease 2019.
Angiotensin-converting enzyme II expression and its implication in the association between COVID-19 and allergic rhinitis.
Angiotensin-converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARBs) may be safe for COVID-19 patients.
Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers are not associated with severe COVID-19 infection in a multi-site UK acute hospital trust.
Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers: potential allies in the COVID-19 pandemic instead of a threat?
Angiotensin-converting enzyme inhibitors and angiotensin receptor blocker in coronavirus disease 2019: Safe and possibly beneficial.
Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Patients With Coronavirus Disease 2019: Friend or Foe?
Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may be harmful in patients with diabetes during COVID-19 pandemic.
Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers Withdrawal Is Associated with Higher Mortality in Hospitalized Patients with COVID-19.
Angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers and the risk of COVID-19 infection or severe disease: Systematic review and meta-analysis.
Angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers are not associated with increased risk of SARS-CoV-2 infection.
Angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers benefits outweigh the risks in COVID-19 hypertensive patients.
Angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers and prognosis of hypertensive patients hospitalised with COVID-19.
Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers Use and COVID-19 Infection Among 824 650 Patients With Hypertension From a US Integrated Healthcare System.
Angiotensin-Converting Enzyme Inhibitors Versus Angiotensin II Receptor Blockers: A Comparison of Outcomes in Patients With COVID-19.
Angiotensin-converting enzyme inhibitors, angiotensin II type 1 receptor blockers and risk of COVID 19: information from Bartter's and Gitelman's syndromes patients.
Angiotensin-Converting Enzyme Inhibitors, Angiotensin Receptor Blockers, and COVID-19: Demonstrating the Actionability of Real-World Evidence.
Angiotensin-converting enzyme-2 in SARS-CoV-2 infection: good or bad?
Angiotensin-Converting-Enzyme 2 and Renin-Angiotensin System Inhibitors in COVID-19: An Update.
Angiotensin-converting-enzyme inhibitors (ACE inhibitors) and angiotensin II receptor blocker (ARB) use in COVID-19 prevention or treatment: A paradox.
Angiotensin-converting-enzyme inhibitors and angiotensin II receptor blockers for COVID-19: A living systematic review of randomized clinical trials.
Angiotensin-II receptor blockers or angiotensin converting enzyme inhibitors for the treatment of hypertension amid COVID-19 pandemic.
Animal models of mechanisms of SARS-CoV-2 infection and COVID-19 pathology.
Antecedent Administration of Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Receptor Antagonists and Survival After Hospitalization for COVID-19 Syndrome.
Anti-Inflammatory Properties of Drugs Used to Control COVID-19 and their Effects on the Renin-Angiotensin System and Angiotensin-Converting Enzyme-2.
Antihypertensive drug treatment and susceptibility to SARS-CoV-2 infection in human PSC-derived cardiomyocytes and primary endothelial cells.
Antiviral Cyanometabolites-A Review.
Apelin-potential therapy for COVID-19?
Association between chronic ACE inhibitor exposure and decreased odds of severe disease in patients with COVID-19.
Association between renin-angiotensin-aldosterone system inhibitor treatment, neutrophil-lymphocyte ratio, D-Dimer and clinical severity of COVID-19 in hospitalized patients: a multicenter, observational study.
Association between renin-angiotensin-aldosterone system inhibitor use and COVID-19 hospitalization and death: a 1.4 million patient nationwide registry analysis.
Association Between Renin-Angiotensin-Aldosterone System Inhibitors and Clinical Outcomes in Patients With COVID-19: A Systematic Review and Meta-analysis.
Association of ACE2 receptor and ACEIs/ARBs with disease severity in COVID-19.
Association of ACEi/ARB Use and Clinical Outcomes of COVID-19 Patients With Hypertension.
Association of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers with risk of COVID-19, inflammation level, severity, and death in patients with COVID-19: A rapid systematic review and meta-analysis.
Association of Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use With COVID-19 Diagnosis and Mortality.
Association of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Blockers With Severity of COVID-19: A Multicenter, Prospective Study.
Association of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers with the Risk of Hospitalization and Death in Hypertensive Patients with Coronavirus Disease-19.
Association of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers With the Risk of Hospitalization and Death in Hypertensive Patients With COVID-19.
Association of angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers with risk of mortality, severity or SARS-CoV-2 test positivity in COVID-19 patients: meta-analysis.
Association of Antihypertensive Agents with the Risk of In-Hospital Death in Patients with Covid-19.
Association of in-hospital use of ACE-I/ARB and COVID-19 outcomes in African American population.
Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Mortality Among Patients With Hypertension Hospitalized With COVID-19.
Association of Renin-Angiotensin System Inhibitors With Severity or Risk of Death in Patients With Hypertension Hospitalized for Coronavirus Disease 2019 (COVID-19) Infection in Wuhan, China.
Association of Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Testing Positive for Coronavirus Disease 2019 (COVID-19).
Associations Between Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blocker Use, Gastrointestinal Symptoms, and Mortality Among Patients With COVID-19.
Autophagy as an emerging target for COVID-19: lessons from an old friend, chloroquine.
Baseline use of angiotensin-converting enzyme inhibitor/AT1 blocker and outcomes in hospitalized coronavirus disease 2019 African-American patients.
Biomolecular interactions with nanoparticles: applications for coronavirus disease 2019.
Biophysical analysis of SARS-CoV-2 transmission and theranostic development via N protein computational characterization.
Broadening COVID-19 Interventions to Drug Innovation: Neprilysin Pathway as a Friend, Foe, or Promising Molecular Target?
Cardiovascular drugs and COVID-19 clinical outcomes: A living systematic review and meta-analysis.
Cardiovascular risk and complications associated with COVID-19.
Cerebral Venous Sinus Thrombosis as an Unexpected Complication of COVID-19 Pneumonia.
Characteristics of Angiotensin I-converting enzyme 2, type II transmembrane serine protease 2 and 4 in tree shrew indicate it as a potential animal model for SARS-CoV-2 infection.
Classical and Counter-Regulatory Renin-Angiotensin System: Potential Key Roles in COVID-19 Pathophysiology.
Clinical and Genetic Characteristics of Covid-19 Patients from UK Biobank.
Clinical characteristics and fatal outcomes of hypertension in patients with severe COVID-19.
Clinical characteristics and outcomes of critically ill patients with COVID-19 in a tertiary community hospital in upstate New York.
Clinical Characterization of Patients With COVID-19 in Primary Care in Catalonia: Retrospective Observational Study.
Clinical outcome of renin-angiotensin-aldosterone system blockers in treatment of hypertensive patients with COVID-19: a systematic review and meta-analysis.
Clinical outcomes of COVID-19 following the use of angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers among patients with hypertension in Korea: a nationwide study.
Clinical, regional, and genetic characteristics of Covid-19 patients from UK Biobank.
Co-Expression of Mitochondrial Genes and ACE2 in Cornea Involved in COVID-19.
Cognitive impact of COVID-19: looking beyond the short term.
Combination of C21 and ARBs with rhACE2 as a therapeutic protocol: A new promising approach for treating ARDS in patients with coronavirus infection.
Commentary to Angiotensin-Converting-Enzyme 2 and Renin-Angiotensin System Inhibitors in COVID-19: An Update.
Comparison of renin-angiotensin-aldosterone system inhibitors with other antihypertensives in association with coronavirus disease-19 clinical outcomes.
Comparisons of Staphylococcus aureus infection and other outcomes between users of angiotensin-converting-enzyme inhibitors and angiotensin II receptor blockers: lessons for COVID-19 from a nationwide cohort study.
Compliance of Antihypertensive Medication and Risk of Coronavirus Disease 2019: a Cohort Study Using Big Data from the Korean National Health Insurance Service.
Continued In-Hospital Angiotensin-Converting Enzyme Inhibitor and Angiotensin II Receptor Blocker Use in Hypertensive COVID-19 Patients Is Associated With Positive Clinical Outcome.
Controversial Roles of the Renin Angiotensin System and Its Modulators During the COVID-19 Pandemic.
Coronavirus (SARS-CoV-2) in gastroenterology and its current epidemiological situation: An updated review until January 2021.
Coronavirus Disease 2019 (COVID-19) and Cardiovascular Disease: A Viewpoint on the Potential Influence of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers on Onset and Severity of Severe Acute Respiratory Syndrome Coronavirus 2 Infection.
Coronavirus disease 2019 (COVID-19): angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers and cardiovascular disease.
Coronavirus Disease 2019 (COVID-19): Do Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers Have a Biphasic Effect?
Coronavirus Disease 2019 in Children.
Coronavirus disease 2019: a comprehensive review and meta-analysis on cardiovascular biomarkers.
Coronavirus disease-19 and the gut-lung axis.
Coronaviruses and Integrin ?v?3: Does Thyroid Hormone Modify the Relationship?
Correction to: Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Mortality Among Patients With Hypertension Hospitalized With COVID-19.
Correlation between renin-angiotensin system and Severe Acute Respiratory Syndrome Coronavirus 2 infection: What do we know?
Correlation of Severity of COVID-19 Disease With Gastrointestinal Manifestations and Liver Injury - A North Brooklyn Community Hospital Experience: A Retrospective Cohort Study.
Could angiotensin-converting enzyme 1 I/D polymorphism be a modificator of COVID-19 response in different populations, diseases, and/or conditions?
Could Anti-Hypertensive Drug Therapy Affect the Clinical Prognosis of Hypertensive Patients With COVID-19 Infection? Data From Centers of Southern Italy.
COVID-19 and Angiotensin-Converting Enzyme Inhibitor/Angiotensin-Receptor Blocker Therapy.
COVID-19 and Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers: What Is the Evidence?
COVID-19 and cardiovascular diseases.
Covid-19 and cardiovascular risk: Susceptibility to infection to SARS-CoV-2, severity and prognosis of Covid-19 and blockade of the renin-angiotensin-aldosterone system. An evidence-based viewpoint.
COVID-19 and diabetes: Knowledge in progress.
COVID-19 and Kidney Disease: Molecular Determinants and Clinical Implications in Renal Cancer.
COVID-19 and Kidney Disease: Update on Epidemiology, Clinical Manifestations, Pathophysiology and Management.
COVID-19 and NSAIDS: A Narrative Review of Knowns and Unknowns.
COVID-19 and renin-angiotensin system modulators: what do we know so far?
Covid-19 and the angiotensin-converting enzyme (ACE2): Areas for research.
COVID-19 and the impact of arterial hypertension-An analysis of the international HOPE COVID-19 Registry (Italy-Spain-Germany).
COVID-19 and the role of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.
COVID-19 as a viral functional ACE2 deficiency disorder with ACE2 related multi-organ disease.
COVID-19 in adult patients with pre-existing chronic cardiac, respiratory and metabolic disease: a critical literature review with clinical recommendations.
COVID-19 In-Hospital Mortality and Use of Renin-Angiotensin System Blockers in Geriatrics Patients.
COVID-19 morbidity and mortality associated with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers use among 14,129 patients with hypertension from a US integrated healthcare system.
COVID-19 Pathogenesis: From Molecular Pathway to Vaccine Administration.
COVID-19: A review of therapeutics under investigation.
COVID-19: age, Interleukin-6, C-reactive protein, and lymphocytes as key clues from a multicentre retrospective study.
Cross talk between COVID-19 and breast cancer.
CT visual quantitative evaluation of hypertensive patients with coronavirus disease (COVID-19): Potential influence of angiotensin converting enzyme inhibitors / angiotensin receptor blockers on severity of lung involvement.
Diabetic Ketoacidosis in Coronavirus Disease Patients With Type 2 Diabetes Mellitus.
Different therapeutic associations of renin-angiotensin system inhibitors with coronavirus disease 2019 compared with usual pneumonia.
Dilated Cardiomyopathy Risk in Patients with Coronavirus Disease 2019: How to Identify and Characterise it Early?
Dipeptidylpeptidase-4 levels and DPP4 gene polymorphisms in patients with COVID-19. Association with disease and with severity.
Does Baseline Diuretics Use Affect Prognosis in Patients With COVID-19?
Does methotrexate influence COVID-19 infection? Case series and mechanistic data.
Does taking an angiotensin inhibitor increase the risk for COVID-19? - a systematic review and meta-analysis.
Double trouble: combined cardiovascular effects of particulate matter exposure and coronavirus disease 2019.
Down-Regulation of Colonic ACE2 Expression in Patients With Inflammatory Bowel Disease Responding to Anti-TNF Therapy: Implications for COVID-19.
Dual function of sialic acid in gastrointestinal SARS-CoV-2 infection.
Effect of Angiotensin Converting Enzyme Inhibitors/Angiotensin Receptor Blockers on COVID-19 outcome: A Record Based Observational Study in West Bengal.
Effect of Discontinuing vs Continuing Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on Days Alive and Out of the Hospital in Patients Admitted With COVID-19: A Randomized Clinical Trial.
Effect of ramipril on kidney, lung and heart ACE2 in a diabetic mice model.
Effect of Renin-Angiotensin-Aldosterone System Inhibitors in Patients with COVID-19: a Systematic Review and Meta-analysis of 28,872 Patients.
Effects of ACEI and ARB on COVID-19 patients: A meta-analysis.
Effects of angiotensin receptor blockers (ARBs) on in-hospital outcomes of patients with hypertension and confirmed or clinically suspected COVID-19.
Effects of angiotensin receptor blockers and angiotensin-converting enzyme inhibitors on COVID-19.
Effects of Recent Use of Renin-Angiotensin System Inhibitors on Mortality of Patients With Coronavirus Disease 2019.
Effects of renin-angiotensin-aldosterone system inhibitors on disease severity and mortality in patients with COVID-19: A meta-analysis.
Efficacy and safety of ACEI/ARB drugs in patients with COVID-19 combined with diabetes mellitus: A protocol for systematic review and meta-analysis of randomized controlled trials.
Efficacy of ACEIs/ARBs versus CCBs on the progression of COVID-19 patients with hypertension in Wuhan: A hospital-based retrospective cohort study.
Electronic Cigarette Aerosol Is Cytotoxic and Increases ACE2 Expression on Human Airway Epithelial Cells: Implications for SARS-CoV-2 (COVID-19).
Elucidating the Neuropathologic Mechanisms of SARS-CoV-2 Infection.
Epigallocatechin gallate and theaflavin gallate interaction in SARS-CoV-2 spike-protein central channel with reference to the hydroxychloroquine interaction: Bioinformatics and molecular docking study.
Epithelial response to IFN-? promotes SARS-CoV-2 infection.
Estimation of Renin-Angiotensin-Aldosterone-System (RAAS)-Inhibitor effect on COVID-19 outcome: A Meta-analysis.
Ethnic and age-specific acute lung injury/acute respiratory distress syndrome risk associated with angiotensin-converting enzyme insertion/deletion polymorphisms, implications for COVID-19: A meta-analysis.
Ethnic Prevalence of Angiotensin-Converting Enzyme Deletion (D) Polymorphism and COVID-19 Risk: Rationale for Use of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers.
Evaluating sources of bias in observational studies of angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker use during COVID-19: beyond confounding.
Evaluation of the Prognosis of COVID-19 Patients According to the Presence of Underlying Diseases and Drug Treatment.
Exploring the Mystery of Angiotensin-Converting Enzyme II (ACE2) in the Battle against SARS-CoV-2.
Facts and reflections on COVID-19 and anti-hypertensives drugs.
Flight hormones as therapeutic target for novel Coronavirus infectious disease.
From Other Journals: A Review of Recent Articles in Pediatric Cardiology.
Gastrointestinal Sequelae 3 and 6 Months After Hospitalization for Coronavirus Disease 2019.
Genetic and epigenetic control of ACE2 expression and its possible role in COVID-19.
Genetic and epigenetic factors associated with increased severity of Covid-19.
Genetic Polymorphisms in the Host and COVID-19 Infection.
Global interventions in hypertension: new and emerging concepts.
Herbal Medicine in Fighting Against COVID-19: New Battle with an Old Weapon.
Highlights from Studies in Cardiovascular Disease Prevention Presented at the Digital 2020 European Society of Cardiology Congress: Prevention Is Alive and Well.
Human Cathelicidin Inhibits SARS-CoV-2 Infection: Killing Two Birds with One Stone.
Human genetic basis of coronavirus disease 2019.
Human SARS CoV-2 spike protein mutations.
Hypertension and COVID-19: Ongoing Controversies.
Hypertension and related diseases in the era of COVID-19: a report from the Japanese Society of Hypertension Task Force on COVID-19.
Hypertension, medications, and risk of severe COVID-19: A Massachusetts community-based observational study.
Hypertension, renin-angiotensin-aldosterone-system-blocking agents, and COVID-19.
Hypertension, the renin-angiotensin system, and the risk of lower respiratory tract infections and lung injury: implications for COVID-19.
Hypothesis: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may increase the risk of severe COVID-19.
Hypoxia induces expression of angiotensin-converting enzyme II in alveolar epithelial cells: Implications for the pathogenesis of acute lung injury in COVID-19.
Immunomodulatory and anti-cytokine therapeutic potential of curcumin and its derivatives for treating COVID-19 - a computational modeling.
Immunomodulatory therapy for the management of severe COVID-19. Beyond the anti-viral therapy: A comprehensive review.
Impact of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers in Hypertensive Patients with COVID-19 (COVIDECA Study).
Impact of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on COVID-19 in a western population. CARDIOVID registry.
Impact of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on in-hospital mortality in COVID-19 patients: ?a systematic review and meta-analysis.
Impact of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers on the Inflammatory Response and Viral Clearance in COVID-19 Patients.
Impact of COVID-19 and other viruses on reproductive health.
Impact of I/D polymorphism of angiotensin-converting enzyme 1 (ACE1) gene on the severity of COVID-19 patients.
Impact of in-hospital discontinuation with angiotensin receptor blockers or converting enzyme inhibitors on mortality of COVID-19 patients: a retrospective cohort study.
Impact of renin-angiotensin system inhibitors use on mortality in severe COVID-19 patients with hypertension: a retrospective observational study.
Important Management Considerations In Patients With Pituitary Disorders During The Time Of The Covid-19 Pandemic.
In Silico Screening of Potential Chinese Herbal Medicine Against COVID-19 by Targeting SARS-CoV-2 3CLpro and Angiotensin Converting Enzyme II Using Molecular Docking.
Influence of angiotensin converting enzyme inhibitors/angiotensin receptor blockers on the risk of all-cause mortality and other clinical outcomes in patients with confirmed COVID-19: A systemic review and meta-analysis.
Inpatient Omission of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers Is Associated With Morbidity and Mortality in Coronavirus Disease 2019.
Insights into disparities observed with COVID-19.
Insights into the association of ACEIs/ARBs use and COVID-19 prognosis: a multistate modelling study of nationwide hospital surveillance data from Belgium.
Interaction effects between angiotensin-converting enzyme inhibitors or angiotensin receptor blockers and steroid or antiviral therapies in COVID-19: A population-based study.
Interplay of COVID-19 and cardiovascular diseases in Africa: an observational snapshot.
Is diet partly responsible for differences in COVID-19 death rates between and within countries?
Is the use of ACE inb/ARBs associated with higher in-hospital mortality in Covid-19 pneumonia patients?
Lack of association of antihypertensive drugs with the risk and severity of COVID-19: A meta-analysis.
Letter to the editor: The role of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in developing a COVID-19 comorbidity-based host risk score.
Letter to the editors in response to: Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may be harmful in patients with diabetes during COVID-19 pandemic (Cure et al.).
Long-Term ACE Inhibitor/ARB Use Is Associated with Severe Renal Dysfunction and Acute Kidney Injury in Patients with severe COVID-19: Results from a Referral Center Cohort in the North East of France.
Lower Serum Angiotensin-Converting Enzyme Level in Relation to Hyperinflammation and Impaired Antiviral Immune Response Contributes to Progression of COVID-19 Infection.
Male predisposition to severe COVID-19: Review of evidence and potential therapeutic prospects.
Marked Up-Regulation of ACE2 in Hearts of Patients With Obstructive Hypertrophic Cardiomyopathy: Implications for SARS-CoV-2-Mediated COVID-19.
Meta-analysis of the association between angiotensin pathway inhibitors and COVID-19 severity and mortality.
MicroRNAs Bioinformatics Analyses Identifying HDAC Pathway as a Putative Target for Existing Anti-COVID-19 Therapeutics.
Molecular Docking and Dynamics Simulation Revealed the Potential Inhibitory Activity of ACEIs Against SARS-CoV-2 Targeting the hACE2 Receptor.
More evidence is urgently needed to confirm the relation between angiotensin-converting enzyme inhibitors and COVID-19.
Mortality and Disease Severity Among COVID-19 Patients Receiving Renin-Angiotensin System Inhibitors: A Systematic Review and Meta-analysis.
Mortality and use of angiotensin-converting enzyme inhibitors in COVID 19 disease: a systematic review.
Mortality in Patients with COVID-19 on Renin Angiotensin System Inhibitor Long-Term Treatment: An Observational Study Showing that Things Are Not Always as They Seem.
Mortality, Severity, and Hospital Admission among COVID-19 Patients with ACEI/ARB Use: A Meta-Analysis Stratifying Countries Based on Response to the First Wave of the Pandemic.
Multi-organ damage by covid-19: congestive (cardio-pulmonary) heart failure, and blood-heart barrier leakage.
Myocyte Specific Upregulation of ACE2 in Cardiovascular Disease: Implications for SARS-CoV-2 mediated myocarditis.
Naringenin, a flavanone with antiviral and anti-inflammatory effects: A promising treatment strategy against COVID-19.
Nasal lavage containing Angiotensin-Converting Enzyme-2 agonist can prevent and reduce viral load in COVID-19.
Neither ACEIs nor ARBs are associated with respiratory distress or mortality in COVID-19 results of a prospective study on a hospital-based cohort.
Network pharmacology and RNA-sequencing reveal the molecular mechanism of Xuebijing injection on COVID-19-induced cardiac dysfunction.
Neuroinvasive potential of a primary respiratory pathogen SARS- CoV2: Summarizing the evidences.
Neurological diseases as mortality predictive factors for patients with COVID-19: a retrospective cohort study.
No association between use of angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers prior to hospital admission and clinical course of COVID-19 in the COvid MEdicaTion (COMET) study.
Obesity and COVID-19: the ominous duet affecting the renin-angiotensin system.
Oral angiotensin-converting enzyme inhibitors for treatment of delayed inflammatory reaction to dermal hyaluronic acid fillers following COVID-19 vaccination-a model for inhibition of angiotensin II-induced cutaneous inflammation.
Oroxylin A is a severe acute respiratory syndrome coronavirus 2-spiked pseudotyped virus blocker obtained from Radix Scutellariae using angiotensin-converting enzyme II/cell membrane chromatography.
Outcome of patients hospitalized for COVID-19 and exposure to angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers in France: results of the ACE-CoV study.
Outcome of patients hospitalized for Covid-19 and exposure to angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers in France: Results of the ACECoV study.
Outcomes Associated with the Use of Renin-Angiotensin-Aldosterone System Blockade in Hospitalized Patients with SARS-CoV-2 Infection.
Outcomes in Patients with COVID-19 Infection Taking ACEI/ARB.
Outcomes of COVID-19 Hospitalized Patients Previously Treated with Renin-Angiotensin System Inhibitors.
Outcomes of head and neck cancer management from two cancer centres in Southern and Northern Europe during the first wave of COVID-19.
Pan-Cancer Analysis of Genomic and Prognostic Characteristics Associated With Coronavirus Disease 2019 Regulators.
Pan-cancer analysis of RNA expression of ANGIOTENSIN-I-CONVERTING ENZYME 2 reveals high variability and possible impact on COVID-19 clinical outcomes.
Pandemic Perspective: Commonalities Between COVID-19 and Cardio-Oncology.
Peripheral blood microRNAs and the COVID-19 patient: methodological considerations, technical challenges and practice points.
Personalized prescription of ACEI/ARBs for hypertensive COVID-19 patients.
Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review.
Pharmacological perspective: glycyrrhizin may be an efficacious therapeutic agent for COVID-19.
Pharmacotherapy in COVID-19; A narrative review for emergency providers.
Positive association of angiotensin II receptor blockers, not angiotensin-converting enzyme inhibitors, with an increased vulnerability to SARS-CoV-2 infection in patients hospitalized for suspected COVID-19 pneumonia.
Possible molecular and paracrine involvement underlying the pathogenesis of COVID-19 cardiovascular complications.
Possible therapeutic interventions in COVID-19 induced ARDS by cotinine as an ACE-2 promoter and AT-1R blocker.
Potential benefits of dietary seaweeds as protection against COVID-19.
Predictors of severe or lethal COVID-19, including Angiotensin Converting Enzyme inhibitors and Angiotensin II Receptor Blockers, in a sample of infected Italian citizens.
Psoriasis and risk of the COVID-19: is there a role for angiotensin converting enzyme (ACE)?
Pulmonary adverse drug event data in hypertension with implications on COVID-19 morbidity.
RAAS, ACE2 and COVID-19; a mechanistic review.
RAMIC: Design of a randomized, double-blind, placebo-controlled trial to evaluate the efficacy of ramipril in patients with COVID-19.
Re: Association of Inpatient Use of Angiotensin-converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortality Among Patients with Hypertension Hospitalized with COVID-19.
Receptor for advanced glycation end-products axis and coronavirus disease 2019 in inflammatory bowel diseases: A dangerous liaison?
Relating angiotensin-converting enzyme inhibitors or angiotensin receptor blockers with incidence or mortality of COVID-19.
Relation of Statin Use Prior to Admission to Severity and Recovery Among COVID-19 Inpatients.
Relationship between angiotensin-converting enzyme inhibitors or angiotensin receptor blockers and COVID-19 incidence or severe disease.
Relative expression of proinflammatory molecules in COVID-19 patients who manifested disease severities.
Renin-Angiotensin System Blockade and Mortality in Patients With Hypertension and COVID-19 Infection.
Renin-Angiotensin System Blockers and Adverse Outcomes of Influenza and Pneumonia: A Danish Cohort Study.
Renin-angiotensin system blockers and severe acute respiratory syndrome coronavirus 2.
Renin-angiotensin system blockers and susceptibility to COVID-19: an international, open science, cohort analysis.
Renin-Angiotensin System Blockers and the Risk of COVID-19-Related Mortality in Patients with Kidney Failure.
Renin-Angiotensin System Inhibition in Cardiovascular Patients at the Time of COVID19: Much Ado for Nothing? A Statement of Activity from the Directors of the Board and the Scientific Directors of the Italian Society of Hypertension.
Renin-Angiotensin System Inhibitors and COVID-19: a Systematic Review and Meta-Analysis. Evidence for Significant Geographical Disparities.
Renin-angiotensin system inhibitors and susceptibility to COVID-19 in patients with hypertension: a propensity score-matched cohort study in primary care.
Renin-Angiotensin System Inhibitors in COVID-19: Current Concepts.
Renin-angiotensin system inhibitors in management of hypertension during the COVID-19 pandemic.
Renin-angiotensin system modulators and other risk factors in COVID-19 patients with hypertension: a Korean perspective.
Renin-angiotensin-aldosterone system and COVID-19 infection.
Renin-Angiotensin-Aldosterone System Blockers and the Risk of Covid-19.
Renin-Angiotensin-Aldosterone System Blockers Are Not Associated With Coronavirus Disease 2019 (COVID-19) Hospitalization: Study of 1,439 UK Biobank Cases.
Renin-Angiotensin-Aldosterone System Blockers Prior to Hospitalization and Their Association With Clinical Outcomes in Coronavirus Disease 2019 (COVID-19).
Renin-angiotensin-aldosterone system inhibitors and COVID-19 infection or hospitalization: a cohort study.
Renin-Angiotensin-Aldosterone System Inhibitors and COVID-19 Infection or Hospitalization: A Cohort Study.
Renin-Angiotensin-Aldosterone System Inhibitors and COVID-19: A Meta-Analysis and Systematic Review.
Renin-Angiotensin-Aldosterone System Inhibitors and Risk of Death in Patients Hospitalised with COVID-19: A Retrospective Italian Cohort Study of 43,000 Patients.
Renin-angiotensin-aldosterone system peptide profiles in patients with COVID-19.
Renin-angiotensin-system inhibition in the context of corona virus disease-19: experimental evidence, observational studies, and clinical implications.
Renin-angiotensin-system inhibitors and all-cause mortality in patients with COVID-19: a systematic review and meta-analysis of observational studies.
Response to the Comment 'Smoking and Angiotensin-converting Enzyme Inhibitor/Angiotensin Receptor Blocker Cessation to Limit Coronavirus Disease 2019.
Response to the letter to the editor entitled 'Angiotensin-II receptor blockers or angiotensin converting enzyme inhibitors for the treatment of hypertension amid COVID-19 pandemic'.
Retinal Microcirculation as a Correlate of a Systemic Capillary Impairment After Severe Acute Respiratory Syndrome Coronavirus 2 Infection.
Review of evidence on using ACEi and ARBs in patients with hypertension and COVID-19.
Review of Pharmacotherapy Trialed for Management of the Coronavirus Disease-19.
Risk Factors for Development of Acute Kidney Injury in COVID-19 Patients: A Retrospective Observational Cohort Study.
Risk factors of COVID-19 mortality: a systematic review of current literature and lessons from recent retracted articles.
Risk of severe COVID-19 in hypertensive patients treated with renin-angiotensin-aldosterone system inhibitors.
Risks and Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers on SARS-CoV-2 Infection in Adults: A Living Systematic Review.
Role of Oxidative Stress on SARS-CoV (SARS) and SARS-CoV-2 (COVID-19) Infection: A Review.
Role of the Backbenchers of the Renin-Angiotensin System ACE2 and AT2 Receptors in COVID-19: Lessons From SARS.
SARS-CoV-2 and ACE2: The biology and clinical data settling the ARB and ACEI controversy.
SARS-CoV-2 as an inflammatory cardiovascular disease: current knowledge and future challenges.
SARS-CoV-2 infection and smoking: What is the association? A brief review.
SARS-CoV-2 infection of human ACE2-transgenic mice causes severe lung inflammation and impaired function.
SARS-CoV-2 infections and COVID-19 mortalities strongly correlate with ACE1 I/D genotype.
SARS-CoV-2 Receptor Angiotensin I-Converting Enzyme Type 2 (ACE2) Is Expressed in Human Pancreatic ?-Cells and in the Human Pancreas Microvasculature.
SARS-CoV-2 Viral Entry Proteins in Hyperandrogenemic Female Mice: Implications for Women with PCOS and COVID-19.
Serum ACE activity and plasma ACE concentration in patients with SARS-CoV-2 infection.
Serum Renin Levels Increase With Age in Boys Resulting in Higher Renin Levels in Young Men Compared to Young Women, and Soluble Angiotensin-Converting Enzyme 2 Correlates With Renin and Body Mass Index.
Severity and mortality of COVID 19 in patients with diabetes, hypertension and cardiovascular disease: a meta-analysis.
Severity of COVID-19 infection in ACEI/ARB users in specialty hospitals: A retrospective cohort study.
Sex, Hormones, Immune Functions, and Susceptibility to Coronavirus Disease 2019 (COVID-19)-Related Morbidity.
Single-cell analysis of angiotensin-converting enzyme II expression in human kidneys and bladders reveals a potential route of 2019 novel coronavirus infection.
Smoking and Angiotensin-converting Enzyme Inhibitor/Angiotensin Receptor Blocker Cessation to Limit Coronavirus Disease 2019.
Smoking and COVID-19: Adding Fuel to the Flame.
Stress Decreases Host Viral Resistance and Increases Covid Susceptibility in Embryonic Stem Cells.
Stroke Care during the COVID-19 Pandemic: International Expert Panel Review.
Strong Correlation between the Case Fatality Rate of COVID-19 and the rs6598045 Single Nucleotide Polymorphism (SNP) of the Interferon-Induced Transmembrane Protein 3 (IFITM3) Gene at the Population-Level.
Studying the Effect of Taking Statins before Infection in the Severity Reduction of COVID-19 with Machine Learning.
Sympathetic activation: a potential link between comorbidities and COVID-19.
Systematic review of the role of renin-angiotensin system inhibitors in late studies on Covid-19: A new challenge overcome?
Targeting of renin-angiotensin system in COVID-19 patients affected by stroke: Emerging concerns about detrimental vs. benefit effect.
Targeting TMPRSS2 in SARS-CoV-2 Infection.
Testis and blood-testis barrier in Covid-19 infestation: role of angiotensin-converting enzyme 2 in male infertility.
The Angiotensin Converting Enzyme Deletion/Deletion Genotype Is a Risk Factor for Severe COVID-19: Implication and Utility for Patients Admitted to Emergency Department.
The angiotensin-converting enzyme 2 (ACE2) receptor in the prevention and treatment of COVID-19 are distinctly different paradigms.
The Association Between Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers and the Number of Covid-19 Confirmed Cases and Deaths in the United States: Geospatial Study.
The association of COVID-19 occurrence and severity with the use of angiotensin converting enzyme inhibitors or angiotensin-II receptor blockers in patients with hypertension.
The controversy of using angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in COVID-19 patients.
The dynamic association between COVID-19 and chronic disorders: An updated insight into prevalence, mechanisms and therapeutic modalities.
The effect of angiotensin-converting enzyme levels on COVID-19 susceptibility and severity: a Mendelian randomization study.
The Effect of Prior Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Treatment on Coronavirus Disease 2019 (COVID-19) Susceptibility and Outcome: A Systematic Review and Meta-analysis.
The effect of RAAS inhibitors on acute hypoxemic respiratory failure and in-hospital mortality in the hypertensive Covid-19 patients.
The Effects of ARBs, ACEis, and Statins on Clinical Outcomes of COVID-19 Infection Among Nursing Home Residents.
The Efficacy of the Mineralcorticoid Receptor Antagonist Canrenone in COVID-19 Patients.
The host's angiotensin-converting enzyme polymorphism may explain epidemiological findings in COVID-19 infections.
The Impact of the Renin-Angiotensin-Aldosterone System on Inflammation, Coagulation, and Atherothrombotic Complications, and to Aggravated COVID-19.
The influence of ACE inhibitors and ARBs on hospital length of stay and survival in people with COVID-19.
The Lung, the Heart, the Novel Coronavirus, and the Renin-Angiotensin System; The Need for Clinical Trials.
The outcomes of the postulated interaction between SARS-CoV-2 and the renin-angiotensin system on the clinician's attitudes toward hypertension treatment.
The Plasmatic Aldosterone and C-Reactive Protein Levels, and the Severity of Covid-19: The Dyhor-19 Study.
The Possible Relationship between the Abuse of Tobacco, Opioid, or Alcohol with COVID-19.
The potential role of serum angiotensin-converting enzyme in coronavirus disease 2019.
The renin-angiotensin-aldosterone system and its inhibitors in the context of the COVID-19 pandemic.
The use of renin angiotensin system inhibitor on mortality in patients with coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis.
The war against the SARS-CoV2 infection: Is it better to fight or mitigate it?
Theoretical Assessment of Therapeutic Effects of Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors on COVID-19.
Therapeutic targets of natural products for the management of cardiovascular symptoms of coronavirus disease 2019.
To Curb the Progression of Fatal COVID-19 Course-Dream or Reality.
To do or not to do: Angiotensin converting enzyme inhibitors/angiotensin receptor blocker in COVID-19 elderly patients.
Traditional Chinese medicine network pharmacology study on exploring the mechanism of Xuebijing Injection in the treatment of coronavirus disease 2019.
Treatment Options Available for COVID-19 and an Analysis on Possible Role of Combination of rhACE2, Angiotensin (1-7) and Angiotensin (1-9) as Effective Therapeutic Measure.
Treatment options for COVID-19: The reality and challenges.
Twenty years of progress in angiotensin converting enzyme 2 and its link to SARS-CoV-2 disease.
Ulcerative Colitis in a COVID-19 Patient: A Case Report.
Understanding COVID-19: A hypothesis regarding digit ratio (2D:4D), ACE I/D polymorphism, oxygen metabolism and national case fatality rates.
Update Alert 2: Risks and Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers on SARS-CoV-2 Infection in Adults.
Update Alert 3: Risks and Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers on SARS-CoV-2 Infection in Adults.
Update Alert 4: Risks and Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers on SARS-CoV-2 Infection in Adults.
Update Alert 5: Risks and Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers on SARS-CoV-2 Infection in Adults.
Update Alert 6: Risks and Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers on SARS-CoV-2 Infection in Adults.
Update Alert 7: Risks and Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers on SARS-CoV-2 Infection in Adults.
Update Alert 8: Risks and Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers on SARS-CoV-2 Infection in Adults.
Update Alert: Risks and Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers on SARS-CoV-2 Infection in Adults.
Use of angiotensin converting enzyme inhibitors and angiotensin receptor blockers associated with lower risk of COVID-19 in household contacts.
Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers During the COVID-19 Pandemic: A Modeling Analysis.
Use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in context of COVID-19 outbreak: a retrospective analysis.
Use of distinct anti-hypertensive drugs and risk for COVID-19 among hypertensive people: a population-based cohort study in Southern Catalonia, Spain.
Use of inhibitors of the renin-angiotensin system in hypertensive patients and COVID-19 severity: A systematic review and meta-analysis.
Use of RAAS inhibitors and risk of clinical deterioration in COVID-19: results from an Italian cohort of 133 hypertensives.
Wildland firefighter exposure to smoke and COVID-19: A new risk on the fire line.
[Air pollution: a determinant for COVID-19?]
[Cardiovascular implications of SARS-CoV-2 infection: A literature review].
[Effects of angiotensin converting enzyme inhibitor/angiotensin receptor blocker on clinical characteristics of coronavirus disease 2019 patients with hypertension].
[Hypertension, RAAS blockade and risk in COVID-19 patients].
[Impact of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on COVID-19 in a western population. CARDIOVID registry].
[Susceptibility of animal species to experimental SARS-CoV-2 (Coronaviridae: Coronavirinae: Betacoronavirus; Sarbecovirus) infection].
Cranial Nerve Diseases
A case of neurosarcoidosis presenting with multiple cranial neuropathies.
Craniocerebral Trauma
Analysis of risk factors for chronic subdural haematoma recurrence after burr hole surgery: Optimal management of patients on antiplatelet therapy.
Crohn Disease
Angiotensin-converting enzyme in Crohn's disease and ulcerative colitis.
Angiotensinogen and transforming growth factor beta1: novel genes in the pathogenesis of Crohn's disease.
Association of angiotensin-converting enzyme gene polymorphisms with Crohn's disease in a Chinese Han population.
Latent pulmonary involvement in Crohn's disease: biological, functional, bronchoalveolar lavage and scintigraphic studies.
Sarcoidosis presenting as granulomatous colitis.
Serum angiotensin converting enzyme activity in Crohn's disease and ulcerative colitis.
Serum angiotensin converting enzyme in Crohn's disease, ulcerative colitis and peptic ulceration.
Serum angiotensin converting enzyme in patients with Crohn's disease.
Serum angiotensin I-converting enzyme is reduced in Crohn's disease and ulcerative colitis irrespective of genotype.
Serum angiotensin-converting-enzyme in Crohn's disease.
Serum angiotensin-I-converting enzyme and carboxypeptidase N in Crohn's disease and ulcerative colitis.
The usefulness of angiotensin converting enzyme in the differential diagnosis of Crohn's disease and intestinal tuberculosis.
[Angiotensin-converting-enzyme (ACE) in Crohn's disease]
[Serum angiotensin-converting enzyme in Crohn's disease]
Cryoglobulinemia
Improvement of Central Nervous System Vasculitis in a Patient with Chronic Hepatitis C Virus Infection after Treatment with an Interferon-Free Regimen.
Renin-angiotensin system blockade is renoprotective in immune complex-mediated glomerulonephritis.
Cryptorchidism
Our experience with epoetins in treating renal anemia.
Cushing Syndrome
Cushing's syndrome due to primary adrenocortical nodular dysplasia, cardiac myxomas, and spotty pigmentation, complicated by sarcoidosis.
Polymorphisms in the angiotensin-converting enzyme gene are associated with unipolar depression, ACE activity and hypercortisolism.
Sarcoidosis following Cushing's syndrome: A report of two cases and review of the literature.
Cystic Fibrosis
A dictionary model for haplotyping, genotype calling, and association testing.
Angiotensin-converting enzyme insertion/deletion gene polymorphism in cystic fibrosis patients.
End-organ dysfunction in cystic fibrosis: association with angiotensin I converting enzyme and cytokine gene polymorphisms.
First study of angiotensin converting enzyme in cystic fibrosis Tunisian patients.
Genetic Polymorphisms in the Host and COVID-19 Infection.
Cystinuria
Association between vitamin D receptor gene polymorphisms and tubular citrate handling in calcium nephrolithiasis.
Cysts
ACE inhibitors, left ventricular mass and renal cyst growth in ADPKD.
Design and baseline characteristics of participants in the study of antihypertensive therapy in children and adolescents with autosomal dominant polycystic kidney disease (ADPKD).
Sex Differences in Kidney Stone Disease in Chinese Patients with Type 2 Diabetes Mellitus.
The intrarenal renin-angiotensin system in autosomal dominant polycystic kidney disease.
Cytomegalovirus Infections
[Chronic anemia in heart transplant patients: prevalence, predisposing factors and prognostic significance]
Dacryocystitis
Predictive Value of Serum Angiotensin-Converting Enzyme Titers in Sarcoid-Like Dacryoadenitis.
Death, Sudden, Cardiac
A view from Europe.
Angiotensin converting enzyme DD genotype is associated with acute coronary syndrome severity and sudden cardiac death in Taiwan: a case-control emergency room study.
Angiotensin-converting enzyme polymorphism in hypertrophic cardiomyopathy and sudden cardiac death.
Antiarrhythmic therapies for the prevention of sudden cardiac death.
Can angiotensin converting enzyme (ACE) inhibitors influence the risk of sudden cardiac death in patients with heart failure?
Carvedilol's antiarrhythmic properties: therapeutic implications in patients with left ventricular dysfunction.
Effect of angiotensin converting enzyme inhibition on sudden cardiac death in patients following acute myocardial infarction. A meta-analysis of randomized clinical trials.
Electrophysiologic and clinical effects of angiotensin-converting enzyme inhibitors in patients with prior myocardial infarction, nonsustained ventricular tachycardia, and depressed left ventricular function. MUSTT Investigators. Multicenter UnSustained Tachycardia Trial.
Genetic variation in angiotensin-converting enzyme-related pathways associated with sudden cardiac arrest risk.
Heart failure as a substrate and trigger for ventricular tachycardia.
Inhibition of c-Src tyrosine kinase prevents angiotensin II-mediated connexin-43 remodeling and sudden cardiac death.
Renin-angiotensin system: genes to bedside.
Role of angiotensin-converting enzyme insertion/deletion polymorphism in sudden cardiac arrest.
Sacubitril/Valsartan: potential treatment for paediatric heart failure.
Sudden cardiac arrest and sudden cardiac death on dialysis: Epidemiology, evaluation, treatment, and prevention.
The first cardioverter defibrillator implanted in Central Africa.
The role of the implantable cardioverter-defibrillator for prevention of sudden cardiac death.
Ventricular arrhythmias in heart failure.
Decompression Sickness
Angiotensin Converting Enzyme Inhibitor Has a Protective Effect on Decompression Sickness in Rats.
No changes in lung function after a saturation dive to 2.5 MPa with intermittent reduction in [Formula: see text] during decompression.
Deglutition Disorders
Angiotensin-converting enzyme inhibitors, angiotensin II receptor antagonists, and symptomless dysphagia.
Does Low Dose Angiotensin Converting Enzyme Inhibitor Prevent Pneumonia in Older People With Neurologic Dysphagia--A Randomized Placebo-Controlled Trial.
Intermittent Superior Vena Cava Syndrome Secondary to Malignant Pericardial Mesothelioma.
Nicergoline improves dysphagia by upregulating substance P in the elderly.
Relationship between polypharmacy, xerostomia, gustatory sensitivity, and swallowing complaints in the elderly: A multidisciplinary approach.
Risk Factors for Aspiration Pneumonia in Frail Older People: A Systematic Literature Review.
Dehydration
Angiotensin converting enzyme activity and nitric oxide level in serum patients with dehydration.
Blood pressure maintenance in awake dehydrated rats: renin, vasopressin, and sympathetic activity.
Changes in renal clearance of furosemide due to changes in renal blood flow and plasma albumin concentration.
Drug use and low blood pressure in the elderly: a study of data from the kungsholmen project.
False-positive result of a captopril-enhanced radionuclide renogram in a child secondary to dehydration.
Metformin Associated Lactic Acidosis in the Intensive Care Unit: A Rare Condition Mimicking Sepsis.
Serum angiotensin converting enzyme activity and plasma renin activity in experimental models of rats.
Use of an ACE inhibitor or angiotensin receptor blocker is a major risk factor for dehydration requiring readmission in the setting of a new ileostomy.
Vasopressin contributes to maintenance of arterial blood pressure in dehydrated baboons.
Water deprivation increases angiotensin-converting enzyme but not AT(1) receptor expression in brainstem and paraventricular nucleus of the hypothalamus of the rat.
[Angiotensin-converting enzyme activity in dehydrated rats]
[Effect of angiotensin II on vasopressin gene transcription in the hypothalamus of rats]
Delirium
Association between Use of Angiotensin-converting Enzyme Inhibitors or Angiotensin Receptor Blockers and Postoperative Delirium.
Associations among processes and outcomes of care for Medicare nursing home residents with acute heart failure.
Usefulness of acute delirium as a predictor of adverse outcomes in patients >65 years of age with acute decompensated heart failure.
Dementia
ACE2 and ACE: structure-based insights into mechanism, regulation and receptor recognition by SARS-CoV.
ACEI and ARB did not Reduce the Incidence of Dementia in Patients with Atrial Fibrillation: A Nationwide Cohort Study.
Analysis of alpha-1 antichymotrypsin, presenilin-1, angiotensin-converting enzyme, and methylenetetrahydrofolate reductase loci as candidates for dementia.
Angiotensin as a target for the treatment of Alzheimer's disease, anxiety and depression.
Angiotensin converting enzyme deletion allele in different kinds of dementia disorders.
Angiotensin II-inhibiting drugs have no effect on intraneuronal A? or oligomeric A? levels in a triple transgenic mouse model of Alzheimer's disease.
Angiotensin receptor blockers and risk of dementia: cohort study in UK Clinical Practice Research Datalink.
Angiotensin-Converting Enzyme and Progression of White Matter Lesions and Brain Atrophy - The SMART-MR Study.
Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers reduced dementia risk in patients with diabetes mellitus and hypertension.
Angiotensin-converting enzyme inhibitors and cognitive decline in older adults with hypertension: results from the Cardiovascular Health Study.
Angiotensin-converting enzyme, sleep-disordered breathing, and hypertension.
Antihypertensive drugs decrease risk of Alzheimer disease: Ginkgo Evaluation of Memory Study.
Antihypertensive Medication Classes and the Risk of Dementia: A Systematic Review and Network Meta-Analysis.
Apolipoprotein E, angiotensin-converting enzyme and alpha-1-antichymotrypsin genotypes are not associated with post-stroke dementia.
Are genetic factors important in the aetiology of leukoaraiosis? Results from a memory clinic population.
Associations of angiotensin targeting antihypertensive drugs with mortality and hospitalization in primary care patients with dementia.
Associations of Anti-Hypertensive Treatments with Alzheimer's Disease, Vascular Dementia, and Other Dementias.
Associations of cerebrovascular metabolism genotypes with neuropsychiatric symptoms and age at onset of Alzheimer's disease dementia.
Attenuating effect of lisinopril and telmisartan in intracerebroventricular streptozotocin induced experimental dementia of Alzheimer's disease type: possible involvement of PPAR-? agonistic property.
Brain-Penetrating Angiotensin-Converting Enzyme Inhibitors and Cognitive Change in Patients with Dementia due to Alzheimer's Disease.
Can Angiotensin-converting enzyme inhibitors prevent dementia in elderly patients with diabetes mellitus?
Cerebrospinal fluid levels of angiotensin-converting enzyme, acetylcholinesterase, and dopamine metabolites in dementia associated with Alzheimer's disease and Parkinson's disease: a correlative study.
Chronic idiopathic normocytic anaemia in older people: the risk factors and the role of age-associated renal impairment.
Cortical alterations of angiotensin converting enzyme, angiotensin II and AT1 receptor in Alzheimer's dementia.
Deletion/Insertion polymorphism of the Angiotensin-converting enzyme gene and white matter hyperintensities in dementia: a pilot study.
Differences in risk factors for dementia with neurodegenerative traits and for vascular dementia.
Distributions of ACE and APOE polymorphisms and their relations with dementia status in Korean centenarians.
Drug use and low blood pressure in the elderly: a study of data from the kungsholmen project.
Effect of dementia on the use of drugs for secondary prevention of ischemic heart disease.
Effects of antihypertensive drug treatment on the risk of dementia and cognitive impairment.
Effects of Centrally acting Angiotensin Converting Enzyme Inhibitors on Functional Decline in Patients with Alzheimer's Disease.
Genetic polymorphisms in the renin-angiotensin system and cognitive decline in Parkinson's disease.
Gout and dementia in the elderly: a cohort study of Medicare claims.
Influenza Vaccination Reduces Dementia Risk in Chronic Kidney Disease Patients: A Population-Based Cohort Study.
Involvement of angiotensin converting enzyme in cerebral hypoperfusion induced anterograde memory impairment and cholinergic dysfunction in rats.
Lack of association between angiotensin-converting enzyme and dementia of the Alzheimer's type in an elderly Arab population in Wadi Ara, Israel.
Left Ventricular global longitudinal strain predicts heart failure readmission in acute decompensated heart failure.
Management of hypertension in older patients.
No Association of Angiotensin I Converting Enzyme I/D Polymorphism with Domain-Specific Cognitive Function in Aged Men without Dementia.
Pharmacogenetic analyses of variations of measures of cardiovascular risk in Alzheimer's dementia.
Pharmacogenetic effects of angiotensin-converting enzyme inhibitors over age-related urea and creatinine variations in patients with dementia due to Alzheimer disease.
Pharmacogenetics of Angiotensin-Converting Enzyme Inhibitors in Patients with Alzheimer's Disease Dementia.
Possible Role of Vascular Risk Factors in Alzheimer's Disease and Vascular Dementia.
Poststroke dementia : clinical features and risk factors.
Prevention of dementia: lessons from SYST-EUR and PROGRESS.
Prognostic factors for adverse outcomes in patients with COVID-19: a field-wide systematic review and meta-analysis.
PROGRESS--perindopril protection against recurrent stroke study: status in July 1996. PROGRESS Management Committee.
Renin-angiotensin system blockade use and risks of cognitive decline and dementia: A meta-analysis.
Risk Factors for Aspiration Pneumonia in Frail Older People: A Systematic Literature Review.
Risk factors for falls in people with and without a diagnose of dementia living in residential care facilities: a prospective study.
Senile dementia and pharmacological drugs.
Serum markers of monocyte/macrophage activation in patients with Alzheimer's disease and other types of dementia.
Soluble adhesion molecules and angiotensin-converting enzyme in dementia.
The ACE Gene Is Associated with Late-Life Major Depression and Age at Dementia Onset in a Population-Based Cohort.
The ACE Insertion Deletion polymorphism relates to dementia by metabolic phenotype, APOEvarepsilon4, and age of dementia onset.
The angiotensin I converting enzyme gene as a susceptibility factor for dementia.
The Association between Hypertension and Dementia in the Elderly.
The effect of dementia on outcomes and process of care for Medicare beneficiaries admitted with acute myocardial infarction.
The Impact of Angiotensin-Converting Enzyme Gene on Behavioral and Psychological Symptoms of Dementia in Alzheimer's Disease.
The Implications of Angiotensin-Converting Enzymes and Their Modulators in Neurodegenerative Disorders: Current and Future Perspectives.
The Relationship Between the Use of Antihypertensive Drugs and the Incidence of Dementia in General Practices in Germany.
Tube feeding can be discontinued by taking dopamine agonists and angiotensin-converting enzyme inhibitors in the advanced stages of dementia.
Use of angiotensin receptor blockers and risk of dementia in a predominantly male population: prospective cohort analysis.
Use of Angiotensin-Converting Enzyme Inhibitors, Angiotensin Receptor Blockers, and Risk of Dementia in Heart Failure.
Usefulness of acute delirium as a predictor of adverse outcomes in patients >65 years of age with acute decompensated heart failure.
[Prevention and correction of cognitive disorders in arterial hypertension]
Dementia, Vascular
Angiotensin converting enzyme deletion allele in different kinds of dementia disorders.
Apolipoprotein E, angiotensin-converting enzyme and kallikrein gene polymorphisms and the risk of Alzheimer's disease and vascular dementia.
Association of ACE I/D gene polymorphism with vascular dementia: a meta-analysis.
Associations of Anti-Hypertensive Treatments with Alzheimer's Disease, Vascular Dementia, and Other Dementias.
DNA polymorphisms of apolipoprotein B and angiotensin I-converting enzyme genes and relationships with lipid levels in Italian patients with vascular dementia or Alzheimer's disease.
Genetic polymorphisms in older subjects with vascular or Alzheimer's dementia.
Sequence variants of ACE, AGT, AT1R, and PAI-1 as genetic risk factors for vascular dementia.
Demyelinating Diseases
Polymorphisms in the angiotensin I converting enzyme (ACE) gene are associated with multiple sclerosis risk and response to Interferon-? treatment.
Dengue
Losartan and enalapril decrease viral absorption and interleukin 1 beta production by macrophages in an experimental dengue virus infection.
Dent Disease
Phenotypic spectrum and antialbuminuric response to angiotensin converting enzyme inhibitor and angiotensin receptor blocker therapy in pediatric Dent disease.
Dermatitis
The renin-angiotensin system in lupus: physiology, genes and practice, in animals and humans.
Dermatitis, Allergic Contact
Association of angiotensin-converting enzyme gene insertion/deletion polymorphism with allergic contact dermatitis.
Modulation of cutaneous inflammation by angiotensin-converting enzyme.
Dermatitis, Contact
Modulation of cutaneous inflammation by angiotensin-converting enzyme.
Dermatitis, Exfoliative
Erythroderma secondary to gliclazide: a case report.
Dermatomyositis
Angiotensin-converting enzyme insertion/deletion gene polymorphism is associated with dermatomyositis.
Diabetes Complications
Altered cardiac bradykinin metabolism in experimental diabetes caused by the variations of angiotensin-converting enzyme and other peptidases.
Effects of manidipine and delapril in hypertensive patients with type 2 diabetes mellitus: the delapril and manidipine for nephroprotection in diabetes (DEMAND) randomized clinical trial.
Frequency of angiotensin-converting enzyme gene polymorphism in Turkish type 2 diabetic patients.
Genome-wide association study of angioedema induced by angiotensin-converting enzyme inhibitor and angiotensin receptor blocker treatment.
Impact of blood pressure control and angiotensin-converting enzyme inhibitor therapy on new-onset microalbuminuria in type 2 diabetes: a post hoc analysis of the BENEDICT trial.
In diabetes, treat hidden heart disease.
Increased serum angiotensin converting enzyme activity in type I insulin-dependent diabetes mellitus: its relation to metabolic control and diabetic complications.
Lack of both bradykinin B1 and B2 receptors enhances nephropathy, neuropathy, and bone mineral loss in Akita diabetic mice.
Measurable Urinary Albumin Predicts Cardiovascular Risk among Normoalbuminuric Patients with Type 2 Diabetes.
Methodological Comparisons of Heart Rate Variability Analysis in Patients With Type 2 Diabetes and Angiotensin Converting Enzyme Polymorphism.
Methylglyoxal stress, the glyoxalase system, and diabetic chronic kidney disease.
Microalbuminuria screening for patients having type 2 diabetes mellitus: who wants to participate?
Microfluidic chip-based method for genotyping microsatellites, VNTRs and insertion/deletion polymorphisms.
Preventing microalbuminuria in type 2 diabetes.
Role of endothelin in diabetic vascular complications.
Serum angiotensin-converting enzyme activity and active renin plasma concentrations in insulin-dependent diabetes mellitus.
The role of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists in the management of diabetic complications.
Treatment selection considerations for the hypertensive diabetic patient.
Vascular legacy beyond blood pressure control: benefits of perindopril/indapamide combination in hypertensive patients with diabetes.
[Relationship between I/D polymorphism of angiotensin I converting enzyme gene and microvascular complications in type 2 diabetic patients]
Diabetes Insipidus
Important Management Considerations In Patients With Pituitary Disorders During The Time Of The Covid-19 Pandemic.
Peripheral p-chloroamphetamine is an unsuitable probe for investigation of central serotoninergic control on renal renin secretion in the rat.
Selective increase of angiotensin-converting enzyme activity in discrete extrahypothalamic areas of Brattleboro rats.
Diabetes Insipidus, Neurogenic
Management of vasodilatory shock after cardiac surgery: identification of predisposing factors and use of a novel pressor agent.
Selective increase of angiotensin-converting enzyme activity in discrete extrahypothalamic areas of Brattleboro rats.
Diabetes Mellitus
2 year followup of patients with diabetes mellitus nephropathy showing albuminuria reversal following angiotensin converting enzyme inhibitors.
2012 Brazilian Society of Rheumatology Consensus on the management of comorbidities in patients with rheumatoid arthritis.
A controlled clinical trial of angiotensin-converting enzyme inhibition in type I diabetic nephropathy: study design and patient characteristics. The Collaborative Study Group.
A meta-analysis reporting effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients without heart failure.
A pharmacist's contribution within a patient-centered medical home.
A pilot study on the effect of telmisartan & ramipril on 24 h blood pressure profile & dipping pattern in type 1 diabetes patients with nephropathy.
A Pilot Trial on the Effect of Levothyroxine on Proteinuria in Patients With Advanced CKD.
A Prospective Noninterventional, Observational Study to Describe the Effectiveness and Safety of Trandolapril and Verapamil Single-Pill Combination in the Management of Patients with Hypertension and Type 2 Diabetes Mellitus: A Harvest TR Study.
A simplified approach to the management of non-ST-segment elevation acute coronary syndromes.
A study on the association between Angiotensin-I converting enzyme I/D dimorphism and type-2 diabetes mellitus.
Academic detailing to improve antihypertensive prescribing patterns.
ACE Inhibitor and ARB utilization and expenditures in the Medicaid fee-for-service program from 1991 to 2008.
ACE inhibitors improve nephrin expression in Zucker rats with glomerulosclerosis.
ACE-I and ARBs in early diabetic nephropathy.
Activity of angiotensin-converting enzyme and risk of severe hypoglycaemia in type 1 diabetes mellitus.
Acute effect of captopril administration on baroreflex sensitivity in patients with acute myocardial infarction.
Acute Increases in Serum Creatinine After Starting Angiotensin-Converting Enzyme Inhibitor-Based Therapy and Effects of its Continuation on Major Clinical Outcomes in Type 2 Diabetes Mellitus.
ADDRESSING HYPERTENSION IN THE PATIENT WITH TYPE 2 DIABETES MELLITUS: PATHOGENESIS, GOALS, AND THERAPEUTIC APPROACH.
Age-related differences in management of heart disease: a study of cardiac medication use in an older cohort. Pacemaker Selection in the Elderly (PASE) Investigators.
Aldosterone breakthrough during angiotensin II receptor blockade in hypertensive patients with diabetes mellitus.
Aminoglycoside-associated nephrotoxicity in the elderly.
An Assessment of the Concentration-Related Prognostic Value of Cardiac Troponin I Following Acute Coronary Syndrome.
Analysis of risk factors for chronic subdural haematoma recurrence after burr hole surgery: Optimal management of patients on antiplatelet therapy.
Anemia Evaluation and Erythropoietin Dose Requirement Among Hemodialysis Patients: a Multicenter Study.
Angioedema related to Angiotensin inhibitors.
Angiotensin blockade in type 2 diabetic renal disease.
Angiotensin converting enzyme (ACE) activity levels in insulin-independent diabetes mellitus and effect of ACE levels on diabetic patients with nephropathy.
Angiotensin converting enzyme gene I/D polymorphism in essential hypertension and nephroangiosclerosis.
Angiotensin converting enzyme gene polymorphism and glomerular filtration rate changes in type 2 diabetic patients.
Angiotensin converting enzyme gene polymorphism and renal artery resistance in patients with insulin dependent diabetes mellitus.
Angiotensin converting enzyme gene polymorphism in healthy Thais and patients with non-insulin dependent diabetes mellitus.
Angiotensin converting enzyme inhibition and arterial endothelial function in adults with Type 1 diabetes mellitus.
Angiotensin converting enzyme inhibitors for prevention of new-onset type 2 diabetes mellitus: A meta-analysis of 72,128 patients.
Angiotensin converting enzyme inhibitors may cause renal impairment in diabetes mellitus.
Angiotensin converting enzyme: history and relevance.
Angiotensin I converting enzyme and angiotensinogen gene polymorphisms related to 24-h blood pressure in paediatric type I diabetes mellitus.
Angiotensin I converting enzyme gene polymorphism and insulin resistance in patients with angina pectoris.
Angiotensin I converting enzyme gene polymorphism in non-insulin dependent diabetes mellitus.
Angiotensin I-converting enzyme gene polymorphisms: relationship to nephropathy in patients with non-insulin dependent diabetes mellitus.
Angiotensin I-converting enzyme: a pathogenetic role in diabetic renal damage?
Angiotensin II type I receptor blocker and endothelial function in humans: role of nitric oxide and oxidative stress.
Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors for the Treatment of Hypertensive Patients With Type 2 Diabetes Mellitus.
Angiotensin-converting enzyme (ACE) gene II genotype protects against the development of diabetic peripheral neuropathy in type 2 diabetes mellitus.
Angiotensin-converting enzyme activity is involved in the mechanism of increased endogenous nitric oxide synthase inhibitor in patients with type 2 diabetes mellitus.
Angiotensin-converting enzyme gene and diabetes mellitus.
Angiotensin-converting enzyme gene polymorphism and microvascular complications in Turkish type 2 diabetic patients.
Angiotensin-converting enzyme gene polymorphism as a potent risk factor for developing microalbuminuria in Japanese patients with type 2 diabetes mellitus: a 9-year follow-up study.
Angiotensin-converting enzyme gene polymorphism in non-insulin dependent diabetes mellitus and its relationship with diabetic nephropathy.
Angiotensin-Converting Enzyme Gene Polymorphism Influences Gastrointestinal Motility in Type 2 Diabetes Mellitus.
Angiotensin-converting enzyme genotype, albuminuria and plasma fibrinogen in type 2 diabetes mellitus.
Angiotensin-converting enzyme I/D polymorphism and diabetic peripheral neuropathy in type 2 diabetes mellitus: A meta-analysis.
Angiotensin-converting enzyme in diabetes mellitus dependence on metabolic aberration.
Angiotensin-converting enzyme inhibition curbs tyrosine nitration of mitochondrial proteins in the renal cortex during the early stage of diabetes mellitus in rats.
Angiotensin-converting enzyme inhibition does not correct early defects in renal and vascular permeability in diabetes mellitus.
Angiotensin-converting enzyme inhibitor therapy for coronary artery disease and diabetes mellitus.
Angiotensin-Converting Enzyme Inhibitor Use and Major Cardiovascular Outcomes in Type 2 Diabetes Mellitus Treated With the Dipeptidyl Peptidase 4 Inhibitor Alogliptin.
Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers effectively and directly potentiate superoxide scavenging by polymorphonuclear leukocytes from patients with type 2 diabetes mellitus.
Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers reduced dementia risk in patients with diabetes mellitus and hypertension.
Angiotensin-converting enzyme inhibitors and probucol suppress the time-dependent increase in urinary Type IV collagen excretion of Type II diabetes mellitus patients with early diabetic nephropathy.
Angiotensin-converting enzyme inhibitors and type 2 diabetic nephropathy: a meta-analysis.
Angiotensin-converting enzyme inhibitors in the treatment of hypertension: an update.
Angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers for prevention and treatment of nephropathy associated with type 2 diabetes mellitus.
Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes: a meta-analysis of randomized clinical trials.
Angiotensin-converting enzyme inhibitors versus angiotensin II receptor blockers in acute ST-segment elevation myocardial infarction patients with diabetes mellitus undergoing percutaneous coronary intervention.
Angiotensinogen gene T235 variant: a marker for the development of persistent microalbuminuria in children and adolescents with type 1 diabetes mellitus.
Angiotensinogen polymorphisms and post-transplantation diabetes mellitus in Korean renal transplant subjects.
Angiotensinogen t235 and Angiotensin-converting enzyme insertion/deletion polymorphisms associated with the development of posttransplantation diabetes mellitus in renal allograft recipients.
Anti-albuminuric efficacy of a combination of angiotensin converting enzyme inhibitor & angiotensin receptor blocker in type 1 DM with nephropathy.
Anti-hypertensive strategies in patients with MEtabolic parameters, DIabetes mellitus and/or NephropAthy (the M E D I N A study).
Anti-inflammatory action of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers and the prevention of diabetes mellitus in obese patients with hypertension.
Antihypertensive treatment efficacy in type II diabetes mellitus. Dissociation between casual and 24-hour ambulatory blood pressure. Spanish Multicenter Study Group.
Antihypertensives and the risk of serious hypoglycemia in older persons using insulin or sulfonylureas.
Antiproteinuric effects of combined antihypertensive therapies in patients with overt type 2 diabetic nephropathy.
Aortic atherosclerosis in diabetes mellitus is associated with an insertion/deletion polymorphism in the angiotensin I-converting enzyme gene. No relation between the polymorphism and aortic collagen content.
Arterial hypertension in diabetes mellitus: from theory to clinical practice.
Assessing the validity of national quality measures for coronary artery disease using an electronic health record.
Assessment of the optimal daily dose of valsartan in patients with hypertension, heart failure, or both.
Association analysis of genes in the renin-angiotensin system with subclinical cardiovascular disease in families with Type 2 diabetes mellitus: The Diabetes Heart Study.
Association between Angiotensin-Converting Enzyme- Insertion/Deletion Polymorphism and Diabetes Mellitus-2 in Saudi Population.
Association between plasma activities of semicarbazide-sensitive amine oxidase and angiotensin-converting enzyme in patients with type 1 diabetes mellitus.
Association between risk of type 2 diabetes mellitus and angiotensin-converting enzyme insertion/deletion gene polymorphisms in a Saudi Arabian population.
Association between serum Na-Cl level and renal function decline in chronic kidney disease: results from the chronic kidney disease Japan cohort (CKD-JAC) study.
Association between the ACE I/D gene polymorphism and T2DN susceptibility: The risk of T2DM developing into T2DN in the Asian population.
Association of ACE and MTHFR genetic polymorphisms with type 2 diabetes mellitus: Susceptibility and complications.
Association of ACE I/D gene polymorphism with T2DN susceptibility and the risk of T2DM developing into T2DN in a Caucasian population.
Association of angiotensin converting enzyme gene I/D polymorphism with type 2 diabetes mellitus.
Association of Angiotensin Converting Enzyme Insertion-Deletion Polymorphism with Hypertension in Emiratis with Type 2 Diabetes Mellitus and Its Interaction with Obesity Status.
Association of angiotensin-converting enzyme (ACE) and fatty acid binding protein 2 (FABP2) genes polymorphism with type 2 diabetes mellitus in Northern India.
Association of angiotensin-converting enzyme and angiotensin II type I receptor gene polymorphisms with extreme obesity in Polish individuals.
Association of angiotensin-converting enzyme gene insertion/deletion polymorphism with metabolic syndrome in Iranians with type 2 diabetes mellitus.
Association of Increased Serum ACE Activity with Logical Memory Ability in Type 2 Diabetic Patients with Mild Cognitive Impairment.
Association of insertion/deletion polymorphism of angiotensin-converting enzyme gene with essential hypertension and type 2 diabetes mellitus in Malaysian subjects.
Association of irisin concentrations with the presence of diabetic nephropathy and retinopathy.
Association of polymorphisms of angiotensin I converting enzyme 2 with retinopathy in type 2 diabetes mellitus among Chinese individuals.
Association of serum adiponectin with risk for cardiovascular events in patients with peripheral arterial disease.
Association of the ACE rs4646994 and rs4341 polymorphisms with the progression of carotid atherosclerosis in slovenian patients with type 2 diabetes mellitus.
Association of the insertion allele of the common ACE gene polymorphism with type 2 diabetes mellitus among Kuwaiti cardiovascular disease patients.
Associations between birth weight and antihypertensive medication in black and white medicaid recipients.
ASSOCIATIONS BETWEEN TRIGLYCERIDE/HIGH-DENSITY LIPOPROTEIN CHOLESTEROL RATIO AND MICRO- AND MACROANGIOPATHIES IN TYPE 2 DIABETES MELLITUS.
Atherosclerosis of carotid arteries and the ace insertion/deletion polymorphism in subjects with diabetes mellitus type 2.
Bayesian meta-analysis of tissue angiotensin-converting enzyme inhibitors for reduction of adverse cardiovascular events in patients with diabetes mellitus and preserved left ventricular function.
Beneficial effects of ramipril on myocardial diastolic function in patients with type 2 diabetes mellitus, normal LV systolic function and without coronary artery disease: a prospective study using tissue Doppler.
Beta-blockers have a beneficial effect upon endothelial function and microalbuminuria in African-American subjects with diabetes and hypertension.
Blockade of the renin-angiotensin system.
C-reactive protein and risk factors for peripheral vascular disease in subjects with Type 2 diabetes mellitus.
Captopril in patients with type II diabetes and renal insufficiency: systemic and renal hemodynamic alterations.
Cardiovascular effects of captopril and enalapril in obese Zucker rats.
Central retinal vein occlusion case-control study.
Chronic idiopathic normocytic anaemia in older people: the risk factors and the role of age-associated renal impairment.
Circulating apoptotic progenitor cells: a novel biomarker in patients with acute coronary syndromes.
Circulating CD40 and sCD40L Predict Changes in Renal Function in Subjects with Chronic Kidney Disease.
Cisplatin-induced renal toxicity in elderly people.
Clinical efficacy of traditional Chinese medicine on acute myocardial infarction-A prospective cohort study.
Clinical Implications of Recent Findings from the Antihypertensive and Lipid-Lowering Treatment To Prevent Heart Attack Trial (ALLHAT) and Other Studies of Hypertension.
Clinical outcomes of acute kidney injury developing outside the hospital in elderly.
Clinical pharmacy specialist implementation of lisinopril therapy in patients with coronary artery disease and diabetes mellitus.
Combination therapy with angiotensin-converting enzyme inhibitors and angiotensin receptor antagonists in the treatment of patients with type 2 diabetes mellitus.
Comparing the effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on renal function decline in diabetes.
Comparison of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in patients with diabetes mellitus and non-ST-segment elevation myocardial infarction who underwent successful percutaneous coronary intervention.
Comparison of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on cardiovascular outcomes in hypertensive patients with type 2 diabetes mellitus: A PRISMA-compliant systematic review and meta-analysis.
Comparison of Effects of ACEIs and ARBs on Albuminuria and Hyperkalemia in Indonesian Hypertensive Type 2 Diabetes Mellitus Patients.
Comparison of frequency of new-onset atrial fibrillation or flutter in patients on statins versus not on statins presenting with suspected acute coronary syndrome.
Comparison of mortality rates in statin users versus nonstatin users in a United States veteran population.
Conflicting and new risk factors for contrast induced nephropathy.
Conventional therapy and newer drug classes for cardiovascular protection in hypertension.
Coronary surgery in patients with preexisting chronic atrial fibrillation: early and midterm clinical outcome.
Daily sodium intake influences the relationship between angiotensin-converting enzyme gene insertion/deletion polymorphism and hypertension in older adults.
Dante Pazzanese risk score for non-st-segment elevation acute coronary syndrome.
DD genotype of angiotensin-converting enzyme in type 2 diabetes mellitus with renal disease in Mexican Mestizos.
Deletion polymorphism of the angiotensin converting enzyme gene is associated with an increase in left ventricular mass in men with type 2 diabetes mellitus.
Demographic analyses of the effects of carvedilol vs metoprolol on glycemic control and insulin sensitivity in patients with type 2 diabetes and hypertension in the Glycemic Effects in Diabetes Mellitus: Carvedilol-Metoprolol Comparison in Hypertensives (GEMINI) study.
Determining the appropriateness of selected surgical and medical management options in recurrent stroke prevention: A guideline for primary care physicians from the National Stroke Association work group on recurrent stroke prevention.
Diabetes medication persistence, different medications have different persistence rates.
Diabetes mellitus is associated with an increased risk of falls in elderly residents of a long-term care facility.
Diabetes mellitus, the renin-angiotensin system, and angiotensin-converting enzyme inhibition.
Diabetes, insulin, and development of acute lung injury.
Diabetics with hypertension not controlled with ACE inhibitors: alternate therapies.
Differential characteristics of acute heart failure in very elderly patients: the prospective RICA study.
Differential leukocyte counts and cardiovascular mortality in very old patients with acute myocardial infarction: a Chinese cohort study.
Direct evidence for intrarenal chymase-dependent angiotensin II formation on the diabetic renal microvasculature.
DPP-IV Inhibitor-Associated Angioedema in Patient With Known History of ACE Inhibitor Angioedema.
Drug treatment of hypertension in Sweden in relation to sex, age, and comorbidity.
Dual inhibition of neutral endopeptidase and angiotensin-converting enzyme in rats with hypertension and diabetes mellitus.
Effect of angiotensin blockade on the association between albuminuria and peripheral arterial disease in elderly taiwanese patients with type 2 diabetes mellitus.
Effect of angiotensin converting enzyme inhibitor or beta blocker on glomerular structural changes in young microalbuminuric patients with Type I (insulin-dependent) diabetes mellitus.
Effect of angiotensin converting enzyme inhibitors and angiotensin receptor blockers on hemoglobin levels.
Effect of Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor on Kidney Function and Blood Potassium Level in Indonesian Type 2 Diabetes Mellitus with Hypertension: A Three-Month Cohort Study.
Effect of angiotensin-converting enzyme inhibitor on serum asymmetric dimethylarginine and coronary circulation in patients with type 2 diabetes mellitus.
Effect of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on All-Cause Mortality, Cardiovascular Deaths, and Cardiovascular Events in Patients With Diabetes Mellitus: A Meta-analysis.
Effect of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor blockers on the rate of new-onset diabetes mellitus: a review and pooled analysis.
Effect of angiotensin-converting enzyme inhibitors on systemic inflammation and myocardial sympathetic innervation in normotensive patients with type 2 diabetes mellitus.
Effect of antihypertensive treatment with alacepril on insulin resistance in diabetic spontaneously hypertensive rats.
Effect of enalapril on diabetic nephropathy in OLETF rats: the role of an anti-oxidative action in its protective properties.
Effect of manidipine and delapril on insulin sensitivity in type 2 diabetic patients with essential hypertension.
Effect of Mineralocorticoid Receptor Antagonism and ACE Inhibition on Angiotensin Profiles in Diabetic Kidney Disease: An Exploratory Study.
Effect of moderate weight loss on health-related quality of life: an analysis of combined data from 4 randomized trials of sibutramine vs placebo.
Effect of quinapril on the albumin excretion rate in patients with mild to moderate essential hypertension. Multicenter Study Group.
Effect of quinapril or losartan alone and in combination on left ventricular systolic and diastolic functions in asymptomatic patients with diabetic autonomic neuropathy.
Effect of spironolactone therapy on albuminuria in patients with type 2 diabetes treated with angiotensin-converting enzyme inhibitors.
Effect of statin therapy on survival in patients with nonischemic dilated cardiomyopathy (from the Beta-blocker Evaluation of Survival Trial [BEST]).
Effect of statins on the development of renal dysfunction.
Effect of the renin-angiotensin system in the vascular disease of type II diabetes mellitus.
Effect of tranilast in early-stage diabetic nephropathy.
Effect on coronary flow velocity reserve in patients with type 2 diabetes mellitus: comparison between angiotensin-converting enzyme inhibitor and angiotensin II type 1 receptor antagonist.
Effect on the atherogenic marker plasminogen activator inhibitor type-1 of addition of the ACE inhibitor imidapril to angiotensin II type 1 receptor antagonist therapy in hypertensive patients with abnormal glucose metabolism: a prospective cohort study in primary care.
Effects of ACEI/ARB in hypertensive patients with type 2 diabetes mellitus: a meta-analysis of randomized controlled studies.
Effects of blood-pressure-lowering treatment on outcome incidence in hypertension: 10 - Should blood pressure management differ in hypertensive patients with and without diabetes mellitus? Overview and meta-analyses of randomized trials.
Effects of drospirenone/17-beta estradiol on blood pressure and potassium balance in hypertensive postmenopausal women.
Effects of long-term enalapril treatment on persistent microalbuminuria in normotensive type 2 diabetic patients: results of a 4-year, prospective, randomized study.
Effects of losartan in combination with or without exercise on insulin resistance in Otsuka Long-Evans Tokushima Fatty rats.
Effects of Losartan-based therapy on the incidence of end-stage renal disease and associated costs in type 2 diabetes mellitus: A retrospective cost-effectiveness analysis in the United Kingdom.
Effects of low-dose and early versus late perindopril treatment on the progression of severe diabetic nephropathy in (mREN-2)27 rats.
Effects of oral amino acid supplements on cardiac function and remodeling in patients with type 2 diabetes with mild-to-moderate left ventricular dysfunction.
Efficacy and safety of ACEI/ARB drugs in patients with COVID-19 combined with diabetes mellitus: A protocol for systematic review and meta-analysis of randomized controlled trials.
Efficacy of Administration of an Angiotensin Converting Enzyme Inhibitor for Two Years on Autonomic and Peripheral Neuropathy in Patients with Diabetes Mellitus.
Enalapril attenuates the renal hemodynamic effect of acetazolamide in patients with diabetes mellitus: possible implications for tubuloglomerular feedback.
Epidemiology and clinical characteristics of hospitalized elderly patients for heart failure with reduced, mid-range and preserved ejection fraction.
Erectile dysfunction in patients in a cardiac rehabilitation program.
Exposure to inhibitors of the renin-angiotensin system is a major independent risk factor for acute renal failure induced by sucrose-containing intravenous immunoglobulins: a case-control study.
Facility variation in utilization of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in patients with diabetes mellitus and chronic kidney disease.
Factors affecting heart rate as measured at home among treated hypertensive patients: the Japan home versus office blood pressure measurement evaluation (J-HOME) study.
Factors influencing arteriovenous fistula dysfunction in Japanese patients on chronic hemodialysis.
Fasting glucose levels and incident diabetes mellitus in older nondiabetic adults randomized to receive 3 different classes of antihypertensive treatment: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Frequency of angiotensin-converting enzyme gene polymorphism in Turkish type 2 diabetic patients.
Garlic Attenuates Plasma and Kidney ACE-1 and AngII Modulations in Early Streptozotocin-Induced Diabetic Rats: Renal Clearance and Blood Pressure Implications.
Gender differences in renal responses to hyperglycemia and angiotensin-converting enzyme inhibition in diabetes.
Genetic combination of angiotensin-converting enzyme with methylene tetrahydrofolate reductase polymorphisms and the risk of type 2 diabetes mellitus in Bahrain.
Genetic Predisposition for Development of Nephropathy in Type 2 Diabetes Mellitus.
Genetic variation in the renin-angiotensin system modifies the beneficial effects of ACE inhibitors on the risk of diabetes mellitus among hypertensives.
Genotypes and allele frequencies of angiotensin-converting enzyme (ACE) insertion/deletion polymorphism among Bahraini population with type 2 diabetes mellitus and related diseases.
Genotypic interactions of renin-angiotensin system genes with diabetes type 2 in a Tunisian population.
Glomerular hemodynamics and the renin-angiotensin system in patients with type 1 diabetes mellitus.
Guidelines adherence and hypertension control at a tertiary hospital in Malaysia.
Haemorheological disturbances in hypertensive type 2 diabetic patients--influence of antihypertensive therapy.
Heart failure in a multiethnic population in Kuala Lumpur, Malaysia.
Hyperkalemia in hospitalized patients.
Hyperkalemia: pathophysiology, risk factors and consequences.
Hyperuricemia treatment in acute heart failure patients does not improve their long-term prognosis: A propensity score matched analysis from the AHEAD registry.
Hypoglycemia associated with the administration of angiotensin-converting enzyme inhibitor in a patient with diabetes mellitus.
Impact of Angiotensin Converting Enzyme Inhibitor versus Angiotensin Receptor Blocker on Incidence of New-Onset Diabetes Mellitus in Asians.
Impact of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers on Renal Function in Chronic Kidney Disease Patients Undergoing Coronary Angiography.
Impact of diabetes, angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker use, and statin use on presentation and outcomes in patients with giant cell arteritis.
Impact of Empagliflozin on Blood Pressure in Patients With Type 2 Diabetes Mellitus and Hypertension by Background Antihypertensive Medication.
Impact of renin-angiotensin system polymorphisms on renal haemodynamic responsiveness to acute angiotensin-converting enzyme inhibition in type 2 diabetes mellitus.
Impact of the interval between coronary angiography and off-pump coronary bypass surgery on postoperative renal function.
Impaired vascular reactivity in African-American patients with type 2 diabetes mellitus and microalbuminuria or proteinuria despite angiotensin-converting enzyme inhibitor therapy.
Implications of nonsteroidal anti-inflammatory drug therapy.
Important Management Considerations In Patients With Pituitary Disorders During The Time Of The Covid-19 Pandemic.
Improvement in endothelial function by angiotensin converting enzyme inhibition in insulin-dependent diabetes mellitus.
Improvement in endothelial function by angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus.
In silico and in vitro analyses of the angiotensin-I converting enzyme inhibitory activity of hydrolysates generated from crude barley (Hordeum vulgare) protein concentrates.
In-hospital and short-term prognostic factors in acute pulmonary edema: clinical and morphological features.
Incidence of New Stroke or New Myocardial Infarction or Death at 39-Month Follow Up in Patients With Diabetes Mellitus, Hypertension, or Both Treated With and Without Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers.
Incidence, trends, and predictors of ischemic stroke 1 year after an acute myocardial infarction.
Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis.
Increased angiotensin-converting enzyme activities in diabetes mellitus: analysis of diabetes type, state of metabolic control and occurrence of diabetic vascular disease.
Increased serum angiotensin converting enzyme activity in diabetes mellitus is not a uniform finding.
Increasing the diagnostic yield of renal angiography for the diagnosis of atheromatous renovascular disease.
Inflammation, peritoneal transport, and response to erythropoietin in peritoneal dialysis patients.
Insertion/deletion polymorphism of angiotensin I converting enzyme gene and left ventricular hypertrophy in patients with type 2 diabetes mellitus.
Insulin sensitivity in hypertensive Type 2 diabetic patients after 1 and 19 days' treatment with trandolapril.
Interaction between angiotensin-converting enzyme genotype and glycaemic control influences lipoprotein levels in type 2 diabetes mellitus.
Joint effects of hypertension, smoking, dyslipidemia and obesity and angiotensin-converting enzyme DD genotype on albuminuria in Taiwanese patients with type 2 diabetes mellitus.
Long-term effects of the endothelin(A) receptor antagonist LU 135252 and the angiotensin-converting enzyme inhibitor trandolapril on diabetic angiopathy and nephropathy in a chronic type I diabetes mellitus rat model.
Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients.
Losartan and other angiotensin II antagonists for nephropathy in type 2 diabetes mellitus: a review of the clinical trial evidence.
Low-grade urinary albumin excretion in normotensive/non-diabetic obstructive sleep apnea patients.
Lowering blood pressure to prevent stroke recurrence: a systematic review of long-term randomized trials.
Management of blood glucose in type 2 diabetes mellitus.
Management of chronic stable angina pectoris.
Management of hypertension in older patients.
Management of hypertension in the patient with diabetes mellitus. Focus on the use of angiotensin-converting enzyme inhibitors.
Mesenteric vascular angiotensin-converting enzyme is increased in experimental diabetes mellitus.
Metabolic Acidosis, Hyperkalemia, and Renal Unresponsiveness to Aldosterone Syndrome: Response to Treatment with Low-Potassium Diet.
Metabolic Safety of Antihypertensive Drugs: Myth versus Reality.
Microalbuminuria in type 1 and type 2 diabetes mellitus: evidence with angiotensin converting enzyme inhibitors and angiotensin II receptor blockers for treating early and preventing clinical nephropathy.
Mineralocorticoid receptor blockade in addition to angiotensin converting enzyme inhibitor or angiotensin II receptor blocker treatment: an emerging paradigm in diabetic nephropathy: a systematic review.
Modern treatment of patients at risk: still a HOPE for ACE inhibitors?
New and emerging strategies for reducing cardiometabolic risk factors.
Night and day proteinuria in patients with sleep apnea.
No association between the angiotensin-converting-enzyme gene insertion/deletion polymorphism and the occurrence of macroangiopathy in patients with diabetes mellitus type 2.
Nonsteroidal antiinflammatory drugs and risk of gastrointestinal bleeding among patients on hemodialysis.
Opposing effects of ? blockers and angiotensin-converting enzyme inhibitors on development of new-onset diabetes mellitus in patients with stable coronary artery disease.
Optimal management of HIV- positive adults at risk for kidney disease in Nigeria (Renal Risk Reduction "R3" Trial): protocol and study design.
Optimization of heart failure with reduced ejection fraction prognosis-modifying drugs: A 2021 heart failure expert consensus paper.
Optimizing target-organ protection in patients with diabetes mellitus: angiotensin-converting enzyme inhibitors or angiotensin receptor blockers?
Outcome survey in unselected hypertensive patients with type 2 diabetes mellitus: effects of ACE inhibition.
Patient, hospital and country-level risk factors of all-cause mortality among patients with chronic heart failure: Prospective international cohort study.
Phosphodiesterase Type 5 Inhibition Reduces Albuminuria in Subjects with Overt Diabetic Nephropathy.
Plasma angiotensin II, renin activity and serum angiotensin-converting enzyme activity in non-insulin dependent diabetes mellitus patients with diabetic nephropathy.
Plasma concentrations of cystatin C in patients with coronary heart disease and risk for secondary cardiovascular events: more than simply a marker of glomerular filtration rate.
Plasma prorenin as an early marker of microvascular disease in patients with diabetes mellitus.
Pleiotropic effects of inhibitors of the RAAS in the diabetic population: above and beyond blood pressure lowering.
Polymorphism of angiotensin-converting enzyme (rs4340) and diabetic nephropathy in Caucasians with type 2 diabetes mellitus.
Polymorphism of the angiotensin I-converting enzyme gene in diabetic nephropathy in type II diabetic patients with proliferative retinopathy.
Potential role of angiotensin-converting enzyme inhibitors and statins on early podocyte damage in a model of type 2 diabetes mellitus, obesity, and mild hypertension.
Potentially inappropriate prescribing (IP) for elderly medical inpatients in Taiwan: A hospital-based study.
Predictors of acute kidney injury in geriatric patients undergoing total knee replacement surgery.
Predictors of infection-related rehospitalization in heart failure patients and its impact on long-term survival.
Predictors of patient survival in continuous ambulatory peritoneal dialysis: 10-year experience in 2 major centers in tehran.
Predisposition of Angiotensin-converting Enzyme Deletion/Deletion Genotype to Coronary Artery Disease with Type 2 Diabetes Mellitus in South India.
Prescribing angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in chronic kidney disease.
Preservation of renal function following partial or radical nephrectomy using 24-hour creatinine clearance.
Preventing microalbuminuria in type 2 diabetes.
Prevention of type 2 diabetes mellitus with angiotensin-converting-enzyme inhibitors.
Probucol in Albuminuric Type 2 Diabetes Mellitus Patients on Renin-Angiotensin System Blockade: A 16-Week, Randomized, Double-Blind, Placebo-Controlled Trial.
Prognostic significance of serum cholinesterase in patients with acute decompensated heart failure: a prospective comparative study with other nutritional indices.
Prognostic value of angiotensin-I converting enzyme I/D polymorphism for nephropathy in type 1 diabetes mellitus: a prospective study.
Prognostic Value of Changes in Galectin-3 Levels Over Time in Patients With Heart Failure: Data From CORONA and COACH.
Prognostic Value of Monocyte Count in Patients Hospitalized for Heart Failure With Reduced Ejection Fraction (from the EVEREST Trial).
Prospective validation of the dante pazzanese risk score in non-ST-segment elevation acute coronary syndrome.
Prostaglandins, angiotension II, and proteinuria.
Protection from the nephrotoxicity of contrast dye.
Protein kinase C beta isoenzymes in diabetic kidneys and their relation to nephroprotective actions of the ACE inhibitor lisinopril.
Proteinuria in systemic sclerosis: reversal by ACE inhibition.
Proteinuria versus albuminuria in 24-hour urine collection: prevalence and clinical outcome in non-hypoxemic adult patients with congenital heart disease.
Quality of Care of the Initial Patient Cohort of the Diabetes Collaborative Registry(®).
Ramipril modulates circadian gene expression in skeletal muscle.
Rates of Deintensification of Blood Pressure and Glycemic Medication Treatment Based on Levels of Control and Life Expectancy in Older Patients With Diabetes Mellitus.
Rationale for the use of a fixed-dose combination in the management of hypertension: efficacy and tolerability of lercanidipine/enalapril.
Reduction of microalbuminuria in type-2 diabetes mellitus with angiotensin-converting enzyme inhibitor alone and with cilnidipine.
Relation of systolic blood pressure to survival in both ischemic and nonischemic systolic heart failure.
Relationship between angiotensin-converting enzyme gene insertion/deletion polymorphism, angiographically defined coronary artery disease and myocardial infarction in patients with type 2 diabetes mellitus.
Relationship Between Medication Adherence and Distance to Dispensing Pharmacies and Prescribers Among an Urban Medicaid Population with Diabetes Mellitus.
Relationship between the ACE I/D gene polymorphism and T1DN susceptibility/risk of T1DM developing into T1DN in the Caucasian population.
Relationship of angiotensin converting enzyme (I/D) polymorphism (rs4646994) and coronary heart disease among a male Iraqi population with type 2 diabetes mellitus.
Relationship of angiotensin-converting enzyme gene polymorphism with nephropathy associated with Type 2 diabetes mellitus in Asian Indians.
Relationship of blood pressure to retinal vessel diameter in type 1 diabetes mellitus.
Relationship of the angiotensin-converting enzyme gene polymorphism to glucose intolerance, insulin resistance, and hypertension in NIDDM.
Renal hemodynamic effects of captopril and doxazosin during slight physical activity in hypertensive patients with type-1 diabetes mellitus.
Renal vascular responses to captopril and to candesartan in patients with type 1 diabetes mellitus.
Renoprotective action of angiotensin-converting enzyme inhibition in diabetes mellitus.
Replacement of angiotensin-converting enzyme inhibitors by angiotensin-II-receptor antagonists in hypertensive patients with type II diabetes mellitus: metabolic and hemodynamic consequences.
Risk factors associated with biochemically detected and hospitalised acute kidney injury in patients prescribed renin angiotensin system inhibitors.
Risk factors associated with the development of ischemic colitis.
Risk Factors for Aspiration Pneumonia in Frail Older People: A Systematic Literature Review.
Risk factors of vascular access failure in patients on hemodialysis.
Role of ACE and AGT gene polymorphisms in genetic susceptibility to diabetes mellitus type 2 in a Brazilian sample.
Role of angiotensin-converting enzyme inhibitors in early antihypertensive treatment in non-insulin dependent diabetes mellitus.
Scintigraphic evaluation of functional renal reserve using angiotensin-converting enzyme inhibition in patients with type II diabetes mellitus.
Serum angiotensin converting enzyme in diabetic patients.
Serum angiotensin-converting enzyme in diabetes mellitus: a negative report.
Serum angiotensin-converting enzyme: elevations in diabetes mellitus.
Should all patients with diabetes mellitus receive angiotensin-converting enzyme inhibitors?
Should all patients with type 1 diabetes mellitus and microalbuminuria receive angiotensin-converting enzyme inhibitors? A meta-analysis of individual patient data.
Should all Pima Indians with type 2 diabetes mellitus be prescribed routine angiotensin-converting enzyme inhibition therapy to prevent renal failure?
Skeletal muscle capillary responses to insulin are abnormal in late-stage diabetes and are restored by angiotensin-converting enzyme inhibition.
Slowing progression along the renal disease continuum.
Sodium bicarbonate versus normal saline for protection against contrast nephropathy.
Sodium-glucose cotransporter 2 inhibition in type 1 diabetes: simultaneous glucose lowering and renal protection?
Soluble adhesion molecules in end-stage renal disease: a predictor of outcome.
Studies to determine the basis for hyperkalemia in recipients of a renal transplant who are treated with cyclosporine.
Sudden Death After Hospitalization for Heart Failure With Reduced Ejection Fraction (from the EVEREST Trial).
Survival Benefit of Statins in Hemodialysis Patients Awaiting Renal Transplantation.
Swiss hypertension treatment programme with verapamil and/or enalapril in diabetic patients.
Temocapril, an angiotensin converting enzyme inhibitor, protects against diabetes-induced endothelial dysfunction.
The angiotensin-I converting enzyme gene I/D variation contributes to end-stage renal disease risk in Chinese patients with type 2 diabetes receiving hemodialysis.
The association of ACE gene polymorphism with diabetic kidney disease and renoprotective efficacy of valsartan.
The Association of Renin-Angiotensin-Aldosterone System Inhibitors With Outcomes Among a Predominantly Ethnic Minority Patient Population Hospitalized With COVID-19: The Bronx Experience.
The blood vessel, linchpin of diabetic lesions.
The Divergent Cardiovascular Effects of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Type 1 Receptor Blockers in Adult Patients With Type 2 Diabetes Mellitus.
The effect of antihypertensive agents on insulin sensitivity, lipids and haemostasis.
The effect of urapidil and ramipril on hyperglycemia in streptozotocin diabetic rats.
The efficacy and safety of SGLT2 inhibitors combined with ACEI/ARBs in the treatment of type 2 diabetes mellitus: A meta-analysis of randomized controlled studies.
THE IMPACT OF CARDIOVASCULAR DRUGS ON GLYCEMIC CONTROL: A REVIEW.
The kallikrein-kinin system, angiotensin converting enzyme inhibitors and insulin sensitivity.
The presence of allele D of angiotensin-converting enzyme polymorphism is associated with diabetic nephropathy in patients with less than 10 years duration of Type 2 diabetes.
The relation of angiotensin-converting enzyme to the pregnancy-induced hypertension-preeclampsia syndrome.
The relationship between of ACE I/D and the MTHFR C677T polymorphisms in the pathophysiology of type 2 diabetes mellitus in a population of Brazilian obese patients.
The renin angiotensin system in diabetes mellitus. A physiological and therapeutic study.
The renin-angiotensin-aldosterone system: a pivotal role in insulin sensitivity and glycemic control.
The Renin-Angiotensin-Aldosterone System: Approaches to Guide Angiotensin-Converting Enzyme Inhibition in Patients with Coronary Artery Disease.
The Risk of Acute Kidney Injury from Fluid Restriction and Hydroxyethyl Starch in Thoracic Surgery.
The risk of cancer in users of statins.
The role of angiotensin II antagonism in type 2 diabetes mellitus: a review of renoprotection studies.
The role of intraglomerular pressure in the initiation and progression of renal disease.
The role of the renin angiotensin hormonal system in the metabolic syndrome and type 2 diabetes.
The role of the renin-angiotensin system blocking in the management of atrial fibrillation.
The roles of angiotensin II and prostaglandins in the regulation of the glomerular filtration of albumin.
The use of ACE inhibitors on diabetic patients without renal disease.
The value of angiotensin-I-converting enzyme determinations in malignant and other diseases.
Tissue angiotensin-converting enzyme inhibitors for the prevention of cardiovascular disease in patients with diabetes mellitus without left ventricular systolic dysfunction or clinical evidence of heart failure: a pooled meta-analysis of randomized placebo-controlled clinical trials.
To RAS or not to RAS? The evidence for and cautions with renin-angiotensin system inhibition in patients with diabetic kidney disease.
Top 20 Research Studies of 2014 for Primary Care Physicians.
Trandolapril does not improve insulin sensitivity in patients with hypertension and type 2 diabetes: a double-blind, placebo-controlled crossover trial.
Treatment of acute coronary syndromes in patients with type 2 diabetes mellitus with beta-adrenoblockers and angiotensin-converting enzyme inhibitors: cardiohemodynamic effects and impact for prognosis.
Treatment of microalbuminuria in patients with type 2 diabetes mellitus.
Treatment selection considerations for the hypertensive diabetic patient.
Type 2 diabetes mellitus with hypertension at primary healthcare level in Malaysia: are they managed according to guidelines?
Upregulation of ACE2-ANG-(1-7)-Mas axis in jejunal enterocytes of type 1 diabetic rats: implications for glucose transport.
Urinary angiotensin-converting enzyme activity in type 2 diabetes mellitus: its relationship to diabetic nephropathy.
Use of angiotensin-converting enzyme inhibitors after coronary artery bypass grafting in patients with diabetes mellitus.
Usefulness and Consequences of Cardiac Resynchronization Therapy in Dialysis-Dependent Patients With Heart Failure.
Vascular hypertrophy and albumin permeability in a rat model combining hypertension and diabetes mellitus. Effects of calcium antagonism, angiotensin converting enzyme inhibition, and angiotensin II-AT1-receptor blockade.
Vascular protection in patients with diabetes admitted for vascular surgery in a canadian tertiary care hospital: pilot study.
Vasoplegic syndrome after cardiovascular surgery: A review of pathophysiology and outcome-oriented therapeutic management.
[Activity of converting enzyme angiotensin I to angiotensin II (ACE) in patients with diabetes type II]
[An IgA nephropathy case with highly reduced urinary protein concomitant with reduced obesity]
[Angiotensin converting enzyme gene and exercise-induced silent myocardial ischemia in type 2 diabetes mellitus]
[Angiotensin converting enzyme gene polymorphism in type 2 diabetes mellitus]
[Angiotensin-converting enzyme and diabetes mellitus]
[Association between insertion-deletion polymorphism of the angiotensin-converting enzyme gene and development of angiopathies in patients with non-insulin dependent diabetes mellitus from the Chuvash Republic]
[Association of insertion/deletion polymorphism in angiotensin-converting enzyme gene with hypertensive type 2 diabetes mellitus]
[Chronic anemia in heart transplant patients: prevalence, predisposing factors and prognostic significance]
[Chronopharmacological approaches to the therapeutic prophylaxis of chronic cardiac insufficiency in type I diabetes mellitus]
[Clinical study of the month. The HOPE study, a two-by-two factorial clinical trial with contrasted results]
[Correlation between polymorphism of angiotensin-converting enzyme gene and the lower extremity atherosclerosis in type 2 diabetes mellitus patients].
[Effect of angiotensin-converting enzyme inhibitors and angiotensin ii receptor blockers on all-cause mortality, cardiovascular deaths, and cardiovascular events in patients with diabetes mellitus. A meta-analysis].
[Effect of enalapril on endotheliun-dependent contractile reactions and oxygen cost of work of the smooth muscles in experimental diabetes mellitus]
[Effect of perindopril on the processes of subclinical inflammation in patients with arterial hypertension and type 2 diabetes mellitus].
[Effect of statin therapy on mortality in patients with non-ischemic dilated cardiomyopathy].
[Hyperkalemia - Pathophysiology, prognostic significance and treatment options].
[Hyperkalemia as a limiting factor in the use of drugs that block the Renin Angiotensin Aldosterone System (RAAS)].
[Hypertension and diabetes]
[I/D polymorphism of angiotensin I converting enzyme gene and arterial hypertension in patients with type 2 diabetes mellitus]
[J-MIND study: effect of nifedipine on renal function in Japanese hypertensive patients with diabetes mellitus]
[Long-term preventive effect and safety of amiodarone in patients with paroxysmal atrial fibrillation refractory to class I antiarrhythmic agents: analysis based on patient profiles]
[Malignant arrhythmias caused by hyperkalemia: a new area of drug-induced electrolyte abnormalities]
[Multicenter trial of olmesartan. Main results].
[Parameters of vasomotor function of endothelium and elasticity of arterial wall during therapy with angiotensin converting enzyme inhibitor ramiprilin patients with type 2 diabetes mellitus]
[Physician factors associated with the blood pressure control among hypertensive patients]
[Plasma N-terminal pro-B-type natriuretic peptide reference value in subjects without heart diseases]
[Polymorphism of the angiotensin I-converting enzyme gene in diabetic retinopathy patients and type 2 diabetes mellitus patients with myocardial infarction]
[Possible participation of angiotensin-converting enzyme and leukocyte elastase in the pathogenesis of insulin-independent diabetes mellitus]
[Prescribing of Non-Steroidal Anti-Inflammatory Drugs to Patients with Diabetes Mellitus in Portugal].
[Primary prevention of coronary heart disease : Evidence-based drug treatment].
[Relationship of angiotensin converting enzyme gene polymorphism with diabetic retinopathy].
[Risk factors for recurrent hospitalizations of patients with atrial fibrillation].
[Severe hypoglycemia secondary to angiotensin-converting-enzyme inhibitors in the absence of diabetes mellitus. Report of a case]
[Significance of kallikrein, angiotensin-converting enzyme, and proteolysis inhibitors in vascular complications in diabetes mellitus type 1 in children]
[Similar reduction in new cases of type 2 diabetes with angiotensin receptor blocker and ACE inhibitor: comparison of meta-analyses of prospective randomised trials]
[The polymorphic markers of ???? and APOE genes and the chromosomal region 3q21-q25 are associated with the development of diabetic nephropathy in type 1 diabetes mellitus].
[The practice guideline 'Stable angina pectoris' (second revision) from the Dutch College of General Practitioners; a response from the perspective of cardiology]
[The renin-angiotensin system in diabetic patients]
[Therapy of perindopril: organoprotection, not just the antihypertensive effect].
[Thiaside diuretics in combination with inhibitors of angiotensin-converting enzyme in patients with diabetes mellitus type 2 comorbid with arterial hypertension]
Diabetes Mellitus, Experimental
Angiotensin II-mediated renal injury.
Disparate effects of angiotensin converting enzyme inhibitor and calcium blocker treatment on the preservation of renal structure and function following subtotal nephrectomy or streptozotocin-induced diabetes in the rat.
Kinins or nitric oxide, or both, are involved in the antitrophic effects of angiotensin converting enzyme inhibitors on diabetes-associated mesenteric vascular hypertrophy in the rat.
Mesenteric vascular angiotensin-converting enzyme is increased in experimental diabetes mellitus.
The effect of urapidil and ramipril on hyperglycemia in streptozotocin diabetic rats.
[Adrenocortical and renin-angiotensin systems in dynamics of experimental diabetes].
[The metabolic effects of the angiotensin converting enzyme inhibitors in experimental diabetes mellitus]
Diabetes Mellitus, Type 1
A controlled clinical trial of angiotensin-converting enzyme inhibition in type I diabetic nephropathy: study design and patient characteristics. The Collaborative Study Group.
A pilot study on the effect of telmisartan & ramipril on 24 h blood pressure profile & dipping pattern in type 1 diabetes patients with nephropathy.
ACE genotype, phenotype and all-cause mortality in different cohorts of patients with type 1 diabetes.
ACE inhibitors and protection against kidney disease progression in patients with type 2 diabetes: what's the evidence.
ACE-I and ARBs in early diabetic nephropathy.
ACE-I/ARB treatment in type 1 diabetes patients with albuminuria is associated with lower odds of progression of coronary artery calcification.
Activity of angiotensin-converting enzyme and risk of severe hypoglycaemia in type 1 diabetes mellitus.
Adeno-Associated Virus Overexpression of Angiotensin-Converting Enzyme-2 Reverses Diabetic Retinopathy in Type 1 Diabetes in Mice.
Alterations in cortisol metabolism in insulin-dependent diabetes mellitus: relationship with metabolic control and estimated blood volume and effect of angiotensin-converting enzyme inhibition.
Angiotensin converting enzyme (ACE) insertion/deletion (I/D) polymorphism, and diabetic retinopathy in subjects with IDDM and NIDDM.
Angiotensin converting enzyme gene polymorphism and ACE inhibition in diabetic nephropathy.
Angiotensin converting enzyme inhibition and arterial endothelial function in adults with Type 1 diabetes mellitus.
Angiotensin converting enzyme inhibition and chronic cyclosporine-induced renal dysfunction in type 1 diabetes.
Angiotensin converting enzyme inhibitor therapy to decrease microalbuminuria in normotensive children with insulin-dependent diabetes mellitus.
Angiotensin-converting enzyme activity and cognitive impairment during hypoglycaemia in healthy humans.
Angiotensin-converting enzyme and angiotensin II receptor subtype 2 genotypes in type 1 diabetes and severe hypoglycaemia requiring emergency treatment: a case cohort study.
Angiotensin-converting enzyme gene polymorphism and lipid profiles in Kuwaiti children with type 1 diabetes.
Angiotensin-converting enzyme gene polymorphism: is there a link to nephropathy in patients with type 1 diabetes?
Angiotensin-converting enzyme inhibition by quinapril blocks the albuminuric effect of atrial natriuretic peptide in Type 1 diabetes and microalbuminuria.
Angiotensin-converting enzyme inhibition in diabetic nephropathy: ten years' experience.
Angiotensin-I-converting enzyme insertion/deletion polymorphism and high urinary albumin concentration in French Type 2 diabetes patients.
Angiotensinogen gene T235 variant: a marker for the development of persistent microalbuminuria in children and adolescents with type 1 diabetes mellitus.
Anti-albuminuric efficacy of a combination of angiotensin converting enzyme inhibitor & angiotensin receptor blocker in type 1 DM with nephropathy.
Antihypertensive treatment of patients with diabetes and hypertension.
Association between plasma activities of semicarbazide-sensitive amine oxidase and angiotensin-converting enzyme in patients with type 1 diabetes mellitus.
Association of ACE gene polymorphism and diabetic nephropathy? The Diabetic Nephropathy Study Group.
Association of angiotensin-converting enzyme DD genotype with 24-h blood pressure abnormalities in normoalbuminuric children and adolescents with Type 1 diabetes.
Association of angiotensin-converting enzyme gene polymorphism with lipid profiles in children and adolescents with insulin-dependent diabetes mellitus.
Blood glucose control determines the renal haemodynamic response to angiotensin converting enzyme inhibition in type 1 diabetes.
C-peptide and captopril are equally effective in lowering glomerular hyperfiltration in diabetic rats.
Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy.
Cost-effectiveness of screening and early treatment of nephropathy in patients with insulin-dependent diabetes mellitus.
Determinants of progression from microalbuminuria to proteinuria in patients who have type 1 diabetes and are treated with angiotensin-converting enzyme inhibitors.
Diabetic nephropathy and pregnancy: the effect of ACE inhibitors prior to pregnancy on fetomaternal outcome.
Diabetic nephropathy in children and adolescents: a critical review with particular reference to angiotensin-converting enzyme inhibitors.
Does renin-angiotensin system blockade have a role in preventing diabetic retinopathy? A clinical review.
Early loss of innervation of cornea epithelium in streptozotocin-induced type 1 diabetic rats: improvement with ilepatril treatment.
Effect of 5-year enalapril therapy on progression of microalbuminuria and glomerular structural changes in type 1 diabetic subjects.
Effect of angiotensin converting enzyme inhibitor on glomerular hyperfiltration in patients with type 1 diabetes.
Effect of angiotensin-converting enzyme (ACE) gene polymorphism on progression of renal disease and the influence of ACE inhibition in IDDM patients: findings from the EUCLID Randomized Controlled Trial. EURODIAB Controlled Trial of Lisinopril in IDDM.
Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria. European Microalbuminuria Captopril Study Group.
Effect of enalapril on endothelial function in young insulin-dependent diabetic patients: a randomized, double-blind study.
Effect of intensive blood pressure control on the course of type 1 diabetic nephropathy. Collaborative Study Group.
Effect of long-term therapy with captopril on proteinuria and renal function in patients with non-insulin-dependent diabetes and with non-diabetic renal diseases.
Effect of treatment of high fat fed/low dose streptozotocin-diabetic rats with Ilepatril on vascular and neural complications.
Effects of ACE inhibition and AT1-receptor blockade on haemodynamic responses to L-arginine in Type 1 diabetes.
Effects of angiotensin-converting enzyme inhibitor, captopril, on bone of mice with streptozotocin-induced type 1 diabetes.
End-stage renal disease: a southern epidemic.
Erythropoietin deficiency in hyporeninemia.
Evaluation of risk factors for the development of nephropathy in patients with IDDM: insertion/deletion angiotensin converting enzyme gene polymorphism, hypertension and metabolic control.
Examination of two genetic polymorphisms within the renin-angiotensin system: no evidence for an association with nephropathy in IDDM.
Gender differences in renal responses to hyperglycemia and angiotensin-converting enzyme inhibition in diabetes.
Genetic polymorphisms of the renin-angiotensin system and complications of insulin-dependent diabetes mellitus.
Genetic predisposition to diabetic nephropathy. Evidence for a role of the angiotensin I--converting enzyme gene.
Genetic variation and activity of the renin-angiotensin system and severe hypoglycemia in type 1 diabetes.
Glomerular size-selective dysfunction in NIDDM is not ameliorated by ACE inhibition or by calcium channel blockade.
Growth factors, cytokines, and renal fibrosis during the course of diabetic nephropathy.
High normo- or low microalbuminuria: basis for intervention in insulin-dependent diabetes mellitus.
High serum ACE activity predicts severe hypoglycaemia over time in patients with type 1 diabetes.
Hypoglycemia, S-ACE and ACE genotypes in a Danish nationwide population of children and adolescents with type 1 diabetes.
Improvement in endothelial function by angiotensin converting enzyme inhibition in insulin-dependent diabetes mellitus.
Increased serum angiotensin converting enzyme activity in type I insulin-dependent diabetes mellitus: its relation to metabolic control and diabetic complications.
Insertion/deletion polymorphism in the angiotensin-I-converting enzyme gene is associated with coronary heart disease in IDDM patients with diabetic nephropathy.
Lack of association between the insertion/deletion polymorphism of the angiotensin-converting-enzyme gene and diabetic nephropathy in IDDM patients.
Lack of effect of short-term treatment with Amlodipine and Lisinopril on retinal autoregulation in normotensive patients with type 1 diabetes and mild diabetic retinopathy.
Lack of effects of angiotensin-converting enzyme (ACE)-inhibitors on glucose metabolism in type 1 diabetes.
Lack of relationship between an insertion/deletion polymorphism in the angiotensin I-converting enzyme gene and diabetic nephropathy and proliferative retinopathy in IDDM patients.
Long-term comparison between perindopril and nifedipine in normotensive patients with type 1 diabetes and microalbuminuria.
Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus. A 7-year follow-up study.
Management of high-risk hypertensive patients with diabetes: potential role of angiotensin II receptor antagonists.
Microalbuminuria: a marker to increased renal and cardiovascular risk in diabetes mellitus.
Microalbuminuria: prognostic implications.
Microcirculation in hyperglycemic patients with IDDM without diabetic complications--effect of low-dose angiotensin-converting enzyme inhibition.
Microfluidic chip-based method for genotyping microsatellites, VNTRs and insertion/deletion polymorphisms.
No association of converting enzyme insertion/deletion polymorphism with immunoglobulin A glomerulonephritis.
Non-insulin-dependent diabetes mellitus, nephropathy, and the renin system.
Optimizing therapy in the diabetic patient with renal disease: antihypertensive treatment.
Prediction of severe hypoglycaemia by angiotensin-converting enzyme activity and genotype in type 1 diabetes.
Prescribing angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in chronic kidney disease.
Prognostic value of angiotensin-I converting enzyme I/D polymorphism for nephropathy in type 1 diabetes mellitus: a prospective study.
Recommendations for the management of special populations: renal disease in diabetes.
Relationship between markers of endothelial dysfunction, oxidant injury and tubular damage in patients with insulin-dependent diabetes mellitus.
Relationship between the ACE I/D gene polymorphism and T1DN susceptibility/risk of T1DM developing into T1DN in the Caucasian population.
Relationship of blood pressure to retinal vessel diameter in type 1 diabetes mellitus.
Relationships between angiotensin I converting enzyme gene polymorphism and renal complications in Korean IDDM patients.
Remission and regression of diabetic nephropathy.
Renal changes on hyperglycemia and angiotensin-converting enzyme in type 1 diabetes.
Role of the effect of inhibition of neutral endopeptidase on vascular and neural complications in streptozotocin-induced diabetic rats.
Serum angiotensin-converting enzyme activity and active renin plasma concentrations in insulin-dependent diabetes mellitus.
Serum angiotensin-converting enzyme and frequency of severe hypoglycaemia in Type 1 diabetes: does a relationship exist?
Serum angiotensin-converting enzyme levels in patients with recent-onset insulin-dependent diabetes after one year of low-dose cyclosporin therapy. IMDIAB Study Group.
Should all patients with type 1 diabetes mellitus and microalbuminuria receive angiotensin-converting enzyme inhibitors? A meta-analysis of individual patient data.
Should Angiotensin converting enzyme inhibitors be used in children with type 1 diabetes and microalbuminuria?
Single versus dual blockade of the renin-angiotensin system (angiotensin-converting enzyme inhibitors and/or angiotensin II receptor blockers) in diabetic nephropathy.
Slowing progression along the renal disease continuum.
Sodium-glucose cotransporter 2 inhibition in type 1 diabetes: simultaneous glucose lowering and renal protection?
The associations of apolipoprotein E and angiotensin-converting enzyme polymorphisms and cognitive function in Type 1 diabetes based on an 18-year follow-up of the DCCT cohort.
The beneficial effect of angiotensin-converting enzyme inhibition with captopril on diabetic nephropathy in normotensive IDDM patients with microalbuminuria. North American Microalbuminuria Study Group.
The DIabetic Retinopathy Candesartan Trials (DIRECT) Programme, rationale and study design.
The effect of an angiotensin converting enzyme inhibitor on skin microvascular hyperaemia in microalbuminuric insulin-dependent diabetes mellitus.
The Insertion/Deletion Polymorphism in the Angiotensin-converting Enzyme Gene and Hypoglycemia Awareness in Patients with Type 1 Diabetes.
The management of hypertension in diabetes: with special reference to diabetic kidney disease.
The RAAS in the pathogenesis and treatment of diabetic nephropathy.
The renin angiotensin system in diabetes mellitus. A physiological and therapeutic study.
The Renin-Angiotensin system and its blockade in diabetic renal and cardiovascular disease.
The role of angiotensin II receptor blockers in preventing the progression of renal disease in patients with type 2 diabetes.
The use of antihypertensive agents in prevention and treatment of diabetic nephropathy.
Time course of the antiproteinuric and renal haemodynamic responses to losartan in microalbuminuric IDDM.
Type 2 diabetes: RENAAL and IDNT--the emergence of new treatment options.
Upregulation of ACE2-ANG-(1-7)-Mas axis in jejunal enterocytes of type 1 diabetic rats: implications for glucose transport.
Urine RAS components in mice and people with type 1 diabetes and chronic kidney disease.
[Guidelines for diagnosis and therapy of diabetic nephropathy]
[Hypertension and diabetes]
[The polymorphic markers of ???? and APOE genes and the chromosomal region 3q21-q25 are associated with the development of diabetic nephropathy in type 1 diabetes mellitus].
[The role of angiotensin II AT1-receptor antagonists in renal and cardiac protection in type-2 diabetes mellitus]
Diabetes Mellitus, Type 2
"Anti-inflammatory" drugs and their effects on type 2 diabetes.
A Double-Blind, Randomized, Placebo-Controlled Clinical Trial on Benfotiamine Treatment in Patients with Diabetic Nephropathy.
A Prospective Noninterventional, Observational Study to Describe the Effectiveness and Safety of Trandolapril and Verapamil Single-Pill Combination in the Management of Patients with Hypertension and Type 2 Diabetes Mellitus: A Harvest TR Study.
ACE Gene Insertion/Deletion Polymorphism Among Patients with Type 2 Diabetes, and Its Relationship with Metabolic Syndrome at Sardjito Hospital Yogyakarta, Indonesia.
ACE inhibitors and protection against kidney disease progression in patients with type 2 diabetes: what's the evidence.
Acute Increases in Serum Creatinine After Starting Angiotensin-Converting Enzyme Inhibitor-Based Therapy and Effects of its Continuation on Major Clinical Outcomes in Type 2 Diabetes Mellitus.
ADDRESSING HYPERTENSION IN THE PATIENT WITH TYPE 2 DIABETES MELLITUS: PATHOGENESIS, GOALS, AND THERAPEUTIC APPROACH.
Albuminuria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT): a randomised, double-blind, placebo-controlled trial.
Altered activities of kininase II, an angiotensin converting enzyme, prekallikrein, and nitric oxide in Kuwaiti patients with type 2 diabetes.
An economic evaluation of atenolol vs. captopril in patients with Type 2 diabetes (UKPDS 54).
Angiotensin blockade in type 2 diabetes: what the new evidence tells us about renal and cardiac complications.
Angiotensin blockade in type 2 diabetic renal disease.
Angiotensin blockade prevents type 2 diabetes by formation of fat cells.
Angiotensin converting enzyme (ACE) insertion/deletion (I/D) polymorphism, and diabetic retinopathy in subjects with IDDM and NIDDM.
Angiotensin converting enzyme D allele is associated with an increased risk of type 2 diabetes: evidence from a meta-analysis.
Angiotensin Converting Enzyme Gene Insertion/Deletion Polymorphism Is Not Responsible for Antihypertensive Therapy Induced New Onset of Type 2 Diabetes in Essential Hypertension.
Angiotensin converting enzyme gene polymorphism and glomerular filtration rate changes in type 2 diabetic patients.
Angiotensin converting enzyme inhibitor or angiotensin II receptor blocker for the prevention of type 2 diabetes mellitus?
Angiotensin converting enzyme inhibitors for prevention of new-onset type 2 diabetes mellitus: A meta-analysis of 72,128 patients.
ANGIOTENSIN CONVERTING ENZYME INHIBITORS IMPROVE HEPATIC STEATOSIS BY MODULATING EXPRESSION OF TUMOR NECROSIS FACTOR-Alpha, INTERLEUKIN-6 AND ADIPONECTIN RECEPTOR-2 IN RATS WITH TYPE 2 DIABETES.
Angiotensin converting enzyme inhibitors or angiotensin receptor blockers in nephropathy from type 2 diabetes.
Angiotensin Converting Enzyme Inhibitors Reduce Albuminuria More Than Angiotensin Receptor Blockers in Patients with Type 2 Diabetes.
Angiotensin I-converting enzyme and angiotensinogen gene polymorphisms in non-insulin-dependent diabetes mellitus. Lack of relationship with diabetic nephropathy and retinopathy in a Caucasian Mediterranean population.
Angiotensin I-converting enzyme and chymase gene polymorphisms - relationship to left ventricular mass in type 2 diabetes patients.
Angiotensin I-converting enzyme gene polymorphism is associated with myocardial infarction, but not with retinopathy or nephropathy, in NIDDM.
Angiotensin inhibition stimulates PPARgamma and the release of visfatin.
Angiotensin receptor antagonist vs. angiotensin-converting enzyme inhibitor in Asian subjects with type 2 diabetes and albuminuria - a randomized crossover study.
Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors for the Treatment of Hypertensive Patients With Type 2 Diabetes Mellitus.
Angiotensin-converting enzyme (ACE) gene II genotype protects against the development of diabetic peripheral neuropathy in type 2 diabetes mellitus.
Angiotensin-converting enzyme (ACE) inhibition in type 2, diabetic patients-- interaction with ACE insertion/deletion polymorphism.
Angiotensin-converting enzyme activity is involved in the mechanism of increased endogenous nitric oxide synthase inhibitor in patients with type 2 diabetes mellitus.
Angiotensin-converting enzyme gene insertion/deletion, not bradykinin B2 receptor -58T/C gene polymorphism, associated with angiotensin-converting enzyme inhibitor-related cough in Chinese female patients with non-insulin-dependent diabetes mellitus.
Angiotensin-converting enzyme gene polymorphism and microvascular complications in Turkish type 2 diabetic patients.
Angiotensin-converting enzyme gene polymorphism as a potent risk factor for developing microalbuminuria in Japanese patients with type 2 diabetes mellitus: a 9-year follow-up study.
Angiotensin-Converting Enzyme Gene Polymorphism Influences Gastrointestinal Motility in Type 2 Diabetes Mellitus.
Angiotensin-converting enzyme gene polymorphism is associated with type 2 diabetes: a meta-analysis.
Angiotensin-converting enzyme genotype, albuminuria and plasma fibrinogen in type 2 diabetes mellitus.
Angiotensin-converting enzyme I/D polymorphism and diabetic peripheral neuropathy in type 2 diabetes mellitus: A meta-analysis.
Angiotensin-converting enzyme I/D polymorphism is not associated with type 2 diabetes in a Chinese population.
Angiotensin-Converting Enzyme Inhibition Delays Onset of Glucosuria With Regression of Renal Injuries in Genetic Rat Model of Non-Insulin-Dependent Diabetes Mellitus.
Angiotensin-converting enzyme inhibition with enalapril slows progressive intima-media thickening of the common carotid artery in patients with non-insulin-dependent diabetes mellitus.
Angiotensin-Converting Enzyme Inhibitor Use and Major Cardiovascular Outcomes in Type 2 Diabetes Mellitus Treated With the Dipeptidyl Peptidase 4 Inhibitor Alogliptin.
Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers effectively and directly potentiate superoxide scavenging by polymorphonuclear leukocytes from patients with type 2 diabetes mellitus.
Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers reduced dementia risk in patients with diabetes mellitus and hypertension.
Angiotensin-converting enzyme inhibitors and type 2 diabetic nephropathy: a meta-analysis.
Angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers for prevention and treatment of nephropathy associated with type 2 diabetes mellitus.
Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes: a meta-analysis of randomized clinical trials.
Angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers for end-stage renal disease/mortality in type 2 diabetes.
Angiotensin-Converting Enzyme Inhibitors vs. Angiotensin Receptor Blockers for the Treatment of Hypertension in Adults With Type 2 Diabetes: Why We Favour Angiotensin Receptor Blockers.
Angiotensin-converting enzyme insertion/deletion polymorphism and diabetic albuminuria in patients with NIDDM followed Up for 9 years.
Angiotensin-converting enzyme insertion/deletion polymorphism and polyneuropathy in type 2 diabetes without macroalbuminuria.
Angiotensin-converting enzyme insertion/deletion polymorphism and severe hypoglycemia complicating type 2 diabetes: the fremantle diabetes study.
Angiotensin-converting enzyme polymorphism and development of diabetic nephropathy in non-insulin-dependent diabetes mellitus.
Angiotensin-I-converting enzyme insertion/deletion polymorphism and high urinary albumin concentration in French Type 2 diabetes patients.
Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy.
Anti-albuminuric effects of spironolactone in patients with type 2 diabetic nephropathy: a multicenter, randomized clinical trial.
Antidiabetic mechanisms of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists: beyond the renin-angiotensin system.
Antihypertensive drug therapy and the risk of lower extremity amputations in pharmacologically treated type 2 diabetes patients.
Antihypertensive therapy in type 2 diabetes: implications of the appropriate blood pressure control in diabetes (ABCD) trial.
Antihypertensive therapy with Ca2+. Antagonist verapamil and/or ACE inhibitor enalapril in NIDDM patients.
Antihypertensive therapy with verapamil SR plus trandolapril versus atenolol plus chlorthalidone on glycemic control.
Antioxidant, Antidiabetic, and Antihypertensive Properties of Echinacea purpurea Flower Extract and Caffeic Acid Derivatives Using In Vitro Models.
Antiproteinuric effects of combined antihypertensive therapies in patients with overt type 2 diabetic nephropathy.
Are angiotensin-converting enzyme inhibitors the best treatment for hypertension in type 2 diabetes?
Arterial hypertension in diabetes mellitus: from theory to clinical practice.
Assessment of the optimal daily dose of valsartan in patients with hypertension, heart failure, or both.
Association analyses of the polymorphisms of angiotensin-converting enzyme and angiotensinogen genes with diabetic nephropathy in Japanese non-insulin-dependent diabetics.
Association analysis of genes in the renin-angiotensin system with subclinical cardiovascular disease in families with Type 2 diabetes mellitus: The Diabetes Heart Study.
Association between a polymorphism in the angiotensin-converting enzyme gene and microvascular complications in Japanese patients with NIDDM.
Association between Angiotensin-Converting Enzyme- Insertion/Deletion Polymorphism and Diabetes Mellitus-2 in Saudi Population.
Association between risk of type 2 diabetes mellitus and angiotensin-converting enzyme insertion/deletion gene polymorphisms in a Saudi Arabian population.
Association of ACE and MTHFR genetic polymorphisms with type 2 diabetes mellitus: Susceptibility and complications.
Association of ACE2 genetic variants with blood pressure, left ventricular mass, and cardiac function in caucasians with type 2 diabetes.
Association of angiotensin converting enzyme gene (I/D) polymorphism with hypertension and type 2 diabetes.
Association of angiotensin converting enzyme gene I/D polymorphism with type 2 diabetes mellitus.
Association of Angiotensin Converting Enzyme Insertion-Deletion Polymorphism with Hypertension in Emiratis with Type 2 Diabetes Mellitus and Its Interaction with Obesity Status.
Association of angiotensin-converting enzyme (ACE) and fatty acid binding protein 2 (FABP2) genes polymorphism with type 2 diabetes mellitus in Northern India.
Association of angiotensin-converting enzyme and angiotensin II type I receptor gene polymorphisms with extreme obesity in Polish individuals.
Association of angiotensin-converting enzyme gene insertion/deletion polymorphism with metabolic syndrome in Iranians with type 2 diabetes mellitus.
Association of Increased Serum ACE Activity with Logical Memory Ability in Type 2 Diabetic Patients with Mild Cognitive Impairment.
Association of insertion/deletion polymorphism of angiotensin-converting enzyme gene with essential hypertension and type 2 diabetes mellitus in Malaysian subjects.
Association of irisin concentrations with the presence of diabetic nephropathy and retinopathy.
Association of polymorphisms of angiotensin I converting enzyme 2 with retinopathy in type 2 diabetes mellitus among Chinese individuals.
Association of the ACE rs4646994 and rs4341 polymorphisms with the progression of carotid atherosclerosis in slovenian patients with type 2 diabetes mellitus.
Association of the insertion allele of the common ACE gene polymorphism with type 2 diabetes mellitus among Kuwaiti cardiovascular disease patients.
Association of the insertion/deletion polymorphism of the angiotensin-converting enzyme gene with type 2 diabetes in two ethnic groups of Jerba Island in Tunisia.
Associations Between Genetic Polymorphisms in the VEGFA, ACE, and SOD2 Genes and Susceptibility to Diabetic Nephropathy in the Han Chinese.
Autonomy of the renin system in type II diabetes mellitus: dietary sodium and renal hemodynamic responses to ACE inhibition.
Avosentan for overt diabetic nephropathy.
Beneficial effect of combination therapy using an angiotensin-converting enzyme inhibitor plus verapamil on circulating resistin levels in hypertensive patients with type 2 diabetes.
Beneficial effects of ramipril on myocardial diastolic function in patients with type 2 diabetes mellitus, normal LV systolic function and without coronary artery disease: a prospective study using tissue Doppler.
Beta-blockers have a beneficial effect upon endothelial function and microalbuminuria in African-American subjects with diabetes and hypertension.
Beyond ONTARGET: angiotensin-converting enzyme inhibition and angiotensin II receptor blockade in combination, a lesser evil in some?
Blood pressure lowering with fixed combination perindopril-indapamide: key findings from ADVANCE.
C-reactive protein and risk factors for peripheral vascular disease in subjects with Type 2 diabetes mellitus.
Can thiazolidinediones delay disease progression in type 2 diabetes?
Cardiovascular disease: much more aggressive in patients with type 2 diabetes.
Cardiovascular protective role of a low-dose antihypertensive combination in obese Zucker rats.
Care of adults with type 2 diabetes mellitus. A review of the evidence.
Cigarette smoking and increased urine albumin excretion are interrelated predictors of nephropathy progression in type 2 diabetes.
Cigarette smoking exacerbates and its cessation ameliorates renal injury in type 2 diabetes.
Circadian blood pressure variation in normotensive type 2 diabetes patients and angiotensin converting enzyme polymorphism.
Class benefits of AT(1) antagonists in Type 2 diabetes with nephropathy.
Clinical and biochemical characteristics of type 2 diabetic patients on continuous ambulatory peritoneal dialysis: relationships with insulin requirement.
Clinical Implications of Recent Findings from the Antihypertensive and Lipid-Lowering Treatment To Prevent Heart Attack Trial (ALLHAT) and Other Studies of Hypertension.
Combination of Angiotensin Converting Enzyme Insertion/Deletion (I/D) (rs4646994) and VEGF Polymorphism (+405G/C; rs2010963) Synergistically Associated With the Development, of Albuminuria in Iranian Patients With Type 2 Diabetes.
Combination of half doses of angiotensin type 1 receptor antagonist and angiotensin-converting enzyme inhibitor in diabetic nephropathy.
Combination therapy with angiotensin-converting enzyme inhibitors and angiotensin receptor antagonists in the treatment of patients with type 2 diabetes mellitus.
Comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on major adverse cardiac events in patients with newly diagnosed type 2 diabetes: a nationwide study.
Comparative effectiveness of angiotensin-converting-enzyme inhibitors and angiotensin II receptor blockers in patients with type 2 diabetes and retinopathy.
Comparative effectiveness of cardioprotective drugs in elderly individuals with type 2 diabetes.
Comparing the effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on renal function decline in diabetes.
Comparison of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on cardiovascular outcomes in hypertensive patients with type 2 diabetes mellitus: A PRISMA-compliant systematic review and meta-analysis.
Comparison of Effects of ACEIs and ARBs on Albuminuria and Hyperkalemia in Indonesian Hypertensive Type 2 Diabetes Mellitus Patients.
Comparison of effects of quinapril and metoprolol on glycaemic control, serum lipids, blood pressure, albuminuria and quality of life in non-insulin-dependent diabetes mellitus patients with hypertension. Swedish Quinapril Group.
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2017 EXECUTIVE SUMMARY.
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2018 EXECUTIVE SUMMARY.
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2019 EXECUTIVE SUMMARY.
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2020 EXECUTIVE SUMMARY.
Contemporary treatment strategies for Type 2 diabetes-related macrovascular disease.
Controlling hypertension in diabetes.
Cost effectiveness analysis of improved blood pressure control in hypertensive patients with type 2 diabetes: UKPDS 40. UK Prospective Diabetes Study Group.
Cost-effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in newly diagnosed type 2 diabetes in Germany.
DD genotype of angiotensin-converting enzyme in type 2 diabetes mellitus with renal disease in Mexican Mestizos.
Dehydrogenation of the indoline-containing drug 4-chloro-N-(2-methyl-1-indolinyl)-3-sulfamoylbenzamide (indapamide) by CYP3A4: correlation with in silico predictions.
Deletion polymorphism of the angiotensin converting enzyme gene is associated with an increase in left ventricular mass in men with type 2 diabetes mellitus.
Deletion/Deletion genotype of angiotensin-I converting enzyme gene is not associated with coronary artery disease in caucasians with type 2 diabetes.
Detection of the association between a deletion polymorphism in the gene encoding angiotensin I-converting enzyme and advanced diabetic retinopathy.
Diabetes: Renal benefits of lowering BP in the absence of hypertension.
Diabetic patients with essential hypertension treated with amlodipine: blood pressure and arterial stiffness effects of canagliflozin or perindopril.
Differential effects of beta-blockers on albuminuria in patients with type 2 diabetes.
Direct evidence for intrarenal chymase-dependent angiotensin II formation on the diabetic renal microvasculature.
Double-blind, placebo-controlled study of ramipril in diabetics with mild to moderate hypertension.
DPP-IV Inhibitor-Associated Angioedema in Patient With Known History of ACE Inhibitor Angioedema.
Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial.
Effect of ACE gene on diabetic nephropathy in NIDDM patients with insulin resistance.
Effect of angiotensin blockade on the association between albuminuria and peripheral arterial disease in elderly taiwanese patients with type 2 diabetes mellitus.
Effect of Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor on Kidney Function and Blood Potassium Level in Indonesian Type 2 Diabetes Mellitus with Hypertension: A Three-Month Cohort Study.
Effect of angiotensin-converting enzyme inhibitor on serum asymmetric dimethylarginine and coronary circulation in patients with type 2 diabetes mellitus.
Effect of angiotensin-converting enzyme inhibitors on systemic inflammation and myocardial sympathetic innervation in normotensive patients with type 2 diabetes mellitus.
Effect of enalapril on diabetic nephropathy in OLETF rats: the role of an anti-oxidative action in its protective properties.
Effect of fosinopril on cardiac and metabolic parameters in patients with NIDDM.
Effect of inhibition of angiotensin converting enzyme and/or neutral endopeptidase on vascular and neural complications in high fat fed/low dose streptozotocin-diabetic rats.
Effect of moderate weight loss on health-related quality of life: an analysis of combined data from 4 randomized trials of sibutramine vs placebo.
Effect of nifedipine, captopril and prazosin on secretory function of pancreatic beta-cells in hypertensive patients with type-2 (non-insulin-dependent) diabetes and in hypertensive non-diabetics.
Effect of PF-04634817, an Oral CCR2/5 Chemokine Receptor Antagonist, on Albuminuria in Adults with Overt Diabetic Nephropathy.
Effect of spironolactone therapy on albuminuria in patients with type 2 diabetes treated with angiotensin-converting enzyme inhibitors.
Effect of the sodium glucose co-transporter 2 inhibitor canagliflozin on plasma volume in patients with type 2 diabetes mellitus.
EFFECT OF THERMAL TREATMENT ON PHENOLIC COMPOUNDS AND FUNCTIONALITY LINKED TO TYPE 2 DIABETES AND HYPERTENSION MANAGEMENT OF PERUVIAN AND BRAZILIAN BEAN CULTIVARS (PHASEOLUS VULGARIS L.) USING IN VITRO METHODS
Effect of treatment with candesartan or enalapril on subcutaneous small artery structure in hypertensive patients with noninsulin-dependent diabetes mellitus.
Effect on coronary flow velocity reserve in patients with type 2 diabetes mellitus: comparison between angiotensin-converting enzyme inhibitor and angiotensin II type 1 receptor antagonist.
Effects of a long-term treatment with aliskiren or ramipril on structural alterations of subcutaneous small-resistance arteries of diabetic hypertensive patients.
Effects of ACEI/ARB in hypertensive patients with type 2 diabetes mellitus: a meta-analysis of randomized controlled studies.
Effects of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and their combination on microalbuminuria in normotensive patients with type 2 diabetes.
Effects of angiotensin-converting enzyme inhibitors, Ca2+ channel antagonists, and alpha-adrenergic blockers on glucose and lipid metabolism in NIDDM patients with hypertension.
Effects of candesartan cilexetil and enalapril on inflammatory markers of atherosclerosis in hypertensive patients with non-insulin-dependent diabetes mellitus.
Effects of dapagliflozin on urinary metabolites in people with type 2 diabetes.
Effects of drospirenone/17-beta estradiol on blood pressure and potassium balance in hypertensive postmenopausal women.
Effects of glibenclamide on blood pressure and cardiovascular responsiveness in non-insulin dependent diabetes mellitus.
Effects of long-term enalapril treatment on persistent micro-albuminuria in well-controlled hypertensive and normotensive NIDDM patients.
Effects of losartan in combination with or without exercise on insulin resistance in Otsuka Long-Evans Tokushima Fatty rats.
Effects of Losartan-based therapy on the incidence of end-stage renal disease and associated costs in type 2 diabetes mellitus: A retrospective cost-effectiveness analysis in the United Kingdom.
Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomised, double blind, placebo controlled trial (the DIABHYCAR study).
Effects of manidipine and delapril on glucose and lipid metabolism in hypertensive patients with non-insulin-dependent diabetes mellitus.
Effects of nitrendipine and enalapril on left ventricular mass in patients with non-insulin-dependent diabetes mellitus and hypertension.
Effects of oral amino acid supplements on cardiac function and remodeling in patients with type 2 diabetes with mild-to-moderate left ventricular dysfunction.
Effects of perindopril in hypertensive patients with or without type 2 diabetes mellitus, and with altered insulin sensitivity.
Effects of valsartan, benazepril and their combination in overt nephropathy of type 2 diabetes: A prospective, randomized, controlled trial.
Effects of verapamil added-on trandolapril therapy in hypertensive type 2 diabetes patients with microalbuminuria: the BENEDICT-B randomized trial.
Efficacy and safety of fixed combination of perindopril and indapamide in type 2 diabetes: results from ADVANCE in context of available evidence.
Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. UK Prospective Diabetes Study Group.
Emerging drug combinations to optimize renovascular protection and blood pressure goals.
Empagliflozin and Clinical Outcomes in Patients with Type 2 Diabetes, Established Cardiovascular Disease and Chronic Kidney Disease.
Endothelial cell autoantibodies in predicting declining renal function, end-stage renal disease, or death in adult type 2 diabetic nephropathy.
Equivalence of indapamide SR and enalapril on microalbuminuria reduction in hypertensive patients with type 2 diabetes: the NESTOR Study.
Evaluation of angiotensin-converting enzyme inhibitor use in patients with type 2 diabetes in a state managed care plan.
Evaluation of antihyperglycemia and antihypertension potential of native Peruvian fruits using in vitro models.
Evaluation of indigenous grains from the Peruvian Andean region for antidiabetes and antihypertension potential using in vitro methods.
Evaluation of the 24 h effects of the angiotensin II receptor blockers: means to improve cardiovascular outcomes?
Evidence of suboptimal management of cardiovascular risk in patients with type 2 diabetes mellitus and symptomatic atherosclerosis.
Evolving therapeutic strategies for retarding progression of diabetic nephropathy--an update for 2002.
Frequency of angiotensin-converting enzyme gene polymorphism in Turkish type 2 diabetic patients.
Genetic combination of angiotensin-converting enzyme with methylene tetrahydrofolate reductase polymorphisms and the risk of type 2 diabetes mellitus in Bahrain.
Genetic Predisposition for Development of Nephropathy in Type 2 Diabetes Mellitus.
Genotypes and allele frequencies of angiotensin-converting enzyme (ACE) insertion/deletion polymorphism among Bahraini population with type 2 diabetes mellitus and related diseases.
Genotypic interactions of renin-angiotensin system genes with diabetes type 2 in a Tunisian population.
Haemorheological disturbances in hypertensive type 2 diabetic patients--influence of antihypertensive therapy.
Health economic implications of irbesartan plus conventional antihypertensive medications versus conventional blood pressure control alone in patients with type 2 diabetes, hypertension, and renal disease in Switzerland.
Health economics studies assessing irbesartan use in patients with hypertension, type 2 diabetes, and microalbuminuria.
Hypertension in type 2 diabetes--targeting angiotensin.
Identification of angiotensin converting enzyme and dipeptidyl peptidase-IV inhibitory peptides derived from oilseed proteins using two integrated bioinformatic approaches.
Impact of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers on renal and mortality outcomes in people with Type 2 diabetes and proteinuria.
Impact of blood pressure control and angiotensin-converting enzyme inhibitor therapy on new-onset microalbuminuria in type 2 diabetes: a post hoc analysis of the BENEDICT trial.
Impact of Empagliflozin on Blood Pressure in Patients With Type 2 Diabetes Mellitus and Hypertension by Background Antihypertensive Medication.
Impact of renin-angiotensin system polymorphisms on renal haemodynamic responsiveness to acute angiotensin-converting enzyme inhibition in type 2 diabetes mellitus.
Impaired vascular reactivity in African-American patients with type 2 diabetes mellitus and microalbuminuria or proteinuria despite angiotensin-converting enzyme inhibitor therapy.
Improvement in endothelial function by angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus.
Improving cardiovascular health outcomes through the use of evidence-based medicine.
Improving the adverse cardiovascular prognosis of type 2 diabetes.
In half of hypertensive diabetics, co-administration of a calcium channel blocker and an angiotensin-converting enzyme inhibitor achieved a target blood pressure of <130/80 mmHg: the azelnidipine and temocapril in hypertensive patients with type 2 diabetes (ATTEST) study.
Increased 8-hydroxy-2'-deoxyguanosine in leukocyte DNA from patients with type 2 diabetes and microangiopathy.
Increased frequency of angiotensin-converting enzyme DD genotype in patients with type 2 diabetes in Taiwan.
Insertion/deletion plasminogen activator inhibitor 1 and insertion/deletion angiotensin-converting enzyme gene polymorphisms in diabetic retinopathy in type 2 diabetes.
Insertion/deletion polymorphism in the angiotensin-converting enzyme gene associated with macroangiopathy and blood pressure in patients with non-insulin-dependent diabetes mellitus.
Insertion/deletion polymorphism of angiotensin I converting enzyme gene and left ventricular hypertrophy in patients with type 2 diabetes mellitus.
Insertion/deletion polymorphism of the angiotensin I-converting enzyme gene in patients with hypertension, non-insulin-dependent diabetes mellitus, and coronary heart disease in Taiwan.
Insertion/deletion polymorphism of the angiotensin-converting enzyme gene is strongly associated with coronary heart disease in non-insulin-dependent diabetes mellitus.
Insulin sensitivity in hypertensive Type 2 diabetic patients after 1 and 19 days' treatment with trandolapril.
Interaction between angiotensin-converting enzyme genotype and glycaemic control influences lipoprotein levels in type 2 diabetes mellitus.
Joint effects of hypertension, smoking, dyslipidemia and obesity and angiotensin-converting enzyme DD genotype on albuminuria in Taiwanese patients with type 2 diabetes mellitus.
Kidney and hypertension.
Lack of association between angiotensin-converting enzyme gene polymorphism and peripheral vascular disease in type 2 diabetic patients in Taiwan.
Lack of association between the angiotensin-converting enzyme gene (I/D) polymorphism and diabetic nephropathy in Tunisian type 2 diabetic patients.
Lack of relationship between Alu repetitive elements in angiotensin converting enzyme and the severity of diabetic retinopathy.
Lessons from trials in hypertensive type 2 diabetic patients.
Long-term effect of a chicken-based diet versus enalapril on albuminuria in type 2 diabetic patients with microalbuminuria.
Long-term effects of the angiotensin converting enzyme inhibitor captopril on metabolic control in non-insulin-dependent diabetes mellitus.
Long-term renoprotection by perindopril or nifedipine in non-hypertensive patients with Type 2 diabetes and microalbuminuria.
Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus. A 7-year follow-up study.
Losartan and other angiotensin II antagonists for nephropathy in type 2 diabetes mellitus: a review of the clinical trial evidence.
Losartan, an angiotensin type 1 receptor antagonist, improves endothelial function in non-insulin-dependent diabetes.
Low-dose colchicine in type 2 diabetes with microalbuminuria: A double-blind randomized clinical trial.
Management of blood glucose in type 2 diabetes mellitus.
Management of cardiovascular risk in patients with type 2 diabetes mellitus as a component of the cardiometabolic syndrome.
Managing chronic kidney disease in type 2 diabetes in family practice.
Manidipine versus enalapril monotherapy in patients with hypertension and type 2 diabetes mellitus: a multicenter, randomized, double-blind, 24-week study.
Measurable Urinary Albumin Predicts Cardiovascular Risk among Normoalbuminuric Patients with Type 2 Diabetes.
Metabolic effects of ramipril treatment in hypertensive subjects with non-insulin-dependent diabetes mellitus.
Metabolic Safety of Antihypertensive Drugs: Myth versus Reality.
Methodological Comparisons of Heart Rate Variability Analysis in Patients With Type 2 Diabetes and Angiotensin Converting Enzyme Polymorphism.
Methylglyoxal and advanced glycation endproducts: new therapeutic horizons?
Microalbuminuria in type 1 and type 2 diabetes mellitus: evidence with angiotensin converting enzyme inhibitors and angiotensin II receptor blockers for treating early and preventing clinical nephropathy.
Microalbuminuria: a marker to increased renal and cardiovascular risk in diabetes mellitus.
Microfluidic chip-based method for genotyping microsatellites, VNTRs and insertion/deletion polymorphisms.
Mineralocorticoid receptor blockade in addition to angiotensin converting enzyme inhibitor or angiotensin II receptor blocker treatment: an emerging paradigm in diabetic nephropathy: a systematic review.
Myocardial perfusion in type 2 diabetes with left ventricular hypertrophy: normalisation by acute angiotensin-converting enzyme inhibition.
Nicardipine may impair glucose metabolism in hypertensive diabetic patients.
Nilvadipine attenuates mesangial expansion and glomerular hypertrophy in diabetic db/db mice, a model for type 2 diabetes.
Nodular glomerulosclerosis and renin angiotensin system in Chinese patients with type 2 diabetes.
Non-insulin-dependent diabetes mellitus, nephropathy, and the renin system.
Novel angiotensin II inhibitors in cardiovascular medicine.
Patients with Non-Insulin Depending Diabetes Mellitus and Metabolic Syndrome Are Suboptimal Treated in Swiss Primary Care.
Patients' need for more counseling on diet, exercise, and smoking cessation: results from the National Ambulatory Medical Care Survey.
Perindopril ameliorates glomerular and renal tubulointerstitial injury in the SHR/N-corpulent rat.
Peroxisome proliferator-activated receptor [gamma] agonist provides superior renal protection versus angiotensin-converting enzyme inhibition in a rat model of type 2 diabetes with obesity.
Pharmacoeconomic analysis of angiotensin-converting enzyme inhibitors in type 2 diabetes: a Markov model.
Phosphodiesterase Type 5 Inhibition Reduces Albuminuria in Subjects with Overt Diabetic Nephropathy.
Polymorphism in the angiotensin converting enzyme but not in the angiotensinogen gene is associated with hypertension and type 2 diabetes: the Skaraborg Hypertension and diabetes project.
Polymorphism of angiotensin-converting enzyme (rs4340) and diabetic nephropathy in Caucasians with type 2 diabetes mellitus.
Pomegranate juice: a heart-healthy fruit juice.
Potential of cranberry powder for management of hyperglycemia using in vitro models.
Potential role of angiotensin-converting enzyme inhibitors and statins on early podocyte damage in a model of type 2 diabetes mellitus, obesity, and mild hypertension.
Potentially inappropriate prescribing (IP) for elderly medical inpatients in Taiwan: A hospital-based study.
Predictors of the progression of diabetic nephropathy and the beneficial effect of angiotensin-converting enzyme inhibitors in NIDDM patients.
Predisposition of Angiotensin-converting Enzyme Deletion/Deletion Genotype to Coronary Artery Disease with Type 2 Diabetes Mellitus in South India.
Prescribing angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in chronic kidney disease.
Preventing diabetes in patients with hypertension: one more reason to block the renin-angiotensin system.
Preventing microalbuminuria in type 2 diabetes.
Prevention and treatment of diabetic nephropathy: the program for irbesartan mortality and morbidity evaluation.
Prevention and treatment of diabetic renal disease in type 2 diabetes: the BENEDICT study.
Prevention of diabetes in hypertensive patients: results and implications from the VALUE trial.
Prevention of hypertension and its complications: theoretical basis and guidelines for treatment.
Prevention of microalbuminuria using early intervention with renin-angiotensin system inhibitors in patients with type 2 diabetes: A systematic review.
Prevention of nephropathy in patients with type 2 diabetes mellitus.
Prevention of type 2 diabetes mellitus with angiotensin-converting-enzyme inhibitors.
Probucol in Albuminuric Type 2 Diabetes Mellitus Patients on Renin-Angiotensin System Blockade: A 16-Week, Randomized, Double-Blind, Placebo-Controlled Trial.
Protein kinase C beta inhibition: the promise for treatment of diabetic nephropathy.
Protein kinase C-beta inhibition for diabetic kidney disease.
Pulmonary diffusing capacity, serum angiotensin-converting enzyme activity and the angiotensin-converting enzyme gene in Japanese non-insulin-dependent diabetes mellitus patients.
Rationale and design of the ADVANCE study: a randomised trial of blood pressure lowering and intensive glucose control in high-risk individuals with type 2 diabetes mellitus. Action in Diabetes and Vascular Disease: PreterAx and DiamicroN Modified-Release Controlled Evaluation.
Rationale for the use of a fixed-dose combination in the management of hypertension: efficacy and tolerability of lercanidipine/enalapril.
Recommendations for the management of special populations: renal disease in diabetes.
Reduction of cardiovascular risk factors in subjects with type 2 diabetes by Pycnogenol supplementation.
Relationship between angiotensin-converting enzyme gene insertion/deletion polymorphism, angiographically defined coronary artery disease and myocardial infarction in patients with type 2 diabetes mellitus.
Relationship between genetic polymorphisms of angiotensin-converting enzyme and methylenetetrahydrofolate reductase as risk factors for type 2 diabetes in Tunisian patients.
Relationship between polymorphism in the angiotensinogen, angiotensin-converting enzyme or angiotensin II receptor and renal progression in Japanese NIDDM patients.
Relationship of angiotensin converting enzyme (I/D) polymorphism (rs4646994) and coronary heart disease among a male Iraqi population with type 2 diabetes mellitus.
Relationship of angiotensin-converting enzyme gene polymorphism with nephropathy associated with Type 2 diabetes mellitus in Asian Indians.
Relationship of the angiotensin-converting enzyme gene polymorphism to glucose intolerance, insulin resistance, and hypertension in NIDDM.
Renal damage in the SHR/N-cp type 2 diabetes model: comparison of an angiotensin-converting enzyme inhibitor and endothelin receptor blocker.
Renal function in noninsulin-dependent diabetes mellitus patients treated with angiotensin-converting enzyme inhibitors and calcium channel blockers.
Renal outcomes with aliskiren in patients with type 2 diabetes: a prespecified secondary analysis of the ALTITUDE randomised controlled trial.
Renin inhibition and microalbuminuria development: meaningful predictor of kidney disease progression.
Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part 2. Overview of physiological and biochemical mechanisms.
Renoprotective effect of N-type Ca channel blockade in diabetic nephropathy.
Response to the Letter to the Editor From Dr Kawada, "Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors for the Treatment of Hypertensive Patients With Type 2 Diabetes Mellitus".
Review: angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers prevent type 2 diabetes.
Revival of nifedipine, a dihydropyridine-based calcium blocker.
Risk constellations in patients with the metabolic syndrome: epidemiology, diagnosis, and treatment patterns.
Role of inflammatory pathways in the development and cardiovascular complications of type 2 diabetes.
Role of the renin-angiotensin system in the endocrine pancreas: implications for the development of diabetes.
Should all Pima Indians with type 2 diabetes mellitus be prescribed routine angiotensin-converting enzyme inhibition therapy to prevent renal failure?
Single versus dual blockade of the renin-angiotensin system (angiotensin-converting enzyme inhibitors and/or angiotensin II receptor blockers) in diabetic nephropathy.
Skeletal muscle capillary responses to insulin are abnormal in late-stage diabetes and are restored by angiotensin-converting enzyme inhibition.
Slowing progression along the renal disease continuum.
Strategies to prevent type 2 diabetes.
Telmisartan lowers albuminuria in type 2 diabetic patients treated with angiotensin enzyme inhibitors.
The albuminuria-lowering response to dapagliflozin is variable and reproducible among individual patients.
The angiotensin-converting enzyme DD genotype is associated with glomerulopathy lesions in type 2 diabetes.
The angiotensin-I converting enzyme gene I/D variation contributes to end-stage renal disease risk in Chinese patients with type 2 diabetes receiving hemodialysis.
The angiotensin-I converting enzyme I/D polymorphism is not associated with type 2 diabetes in individuals undergoing coronary angiography. (The Ludwigshafen Risk and Cardiovascular Health Study).
The association of ACE gene polymorphism with diabetic kidney disease and renoprotective efficacy of valsartan.
The cost-effectiveness of treating all patients with type 2 diabetes with angiotensin-converting enzyme inhibitors.
The D allele of the ACE I/D common gene variant is associated with Type 2 diabetes mellitus in Caucasian subjects.
The D allele of the angiotensin-converting enzyme insertion/ deletion (I/D) polymorphism is a risk factor for type 2 diabetes in a population-based Japanese sample.
The development of new-onset type 2 diabetes associated with choosing a calcium channel blocker compared to a diuretic or beta-blocker.
The DIabetic Retinopathy Candesartan Trials (DIRECT) Programme, rationale and study design.
The Divergent Cardiovascular Effects of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Type 1 Receptor Blockers in Adult Patients With Type 2 Diabetes Mellitus.
The effect of antihypertensive agents on insulin sensitivity, lipids and haemostasis.
The effect of CCR2 inhibitor CCX140-B on residual albuminuria in patients with type 2 diabetes and nephropathy: a randomised trial.
The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension.
The effects of the ACE gene insertion/deletion polymorphism on glucose tolerance and insulin secretion in elderly people are modified by birth weight.
The efficacy and safety of SGLT2 inhibitors combined with ACEI/ARBs in the treatment of type 2 diabetes mellitus: A meta-analysis of randomized controlled studies.
The impact of the Angiotensin-converting enzyme insertion/deletion polymorphism on severe hypoglycemia in type 2 diabetes.
The importance of blood pressure control in the patient with diabetes.
The insertion/deletion polymorphism of the angiotensin-converting enzyme gene is associated with progression, but not development, of albuminuria in Iranian patients with type 2 diabetes.
The kallikrein-kinin system, angiotensin converting enzyme inhibitors and insulin sensitivity.
The management of hypertension in diabetes: with special reference to diabetic kidney disease.
The presence of allele D of angiotensin-converting enzyme polymorphism is associated with diabetic nephropathy in patients with less than 10 years duration of Type 2 diabetes.
The relationship between ACE gene insertion/deletion polymorphism and diabetic retinopathy in Iranian patients with type 2 diabetes.
The relationship between angiotensin-converting enzyme insertion/deletion polymorphism and proliferative retinopathy in type 2 diabetes.
The relationship between of ACE I/D and the MTHFR C677T polymorphisms in the pathophysiology of type 2 diabetes mellitus in a population of Brazilian obese patients.
The relationship of ACE and CETP gene polymorphisms with cardiovascular disease in a cohort of Asian Indian patients with and those without type 2 diabetes.
The renin-angiotensin system and progression of renal disease: from hemodynamics to cell biology.
The renin-angiotensin-aldosterone system: a pivotal role in insulin sensitivity and glycemic control.
The role of angiotensin II antagonism in type 2 diabetes mellitus: a review of renoprotection studies.
The role of angiotensin II receptor blockers in preventing the progression of renal disease in patients with type 2 diabetes.
The use of antihypertensive agents in prevention and treatment of diabetic nephropathy.
Therapeutic approaches in the prevention of cardiovascular disease in metabolic syndrome and in patients with type 2 diabetes.
Trandolapril does not improve insulin sensitivity in patients with hypertension and type 2 diabetes: a double-blind, placebo-controlled crossover trial.
Treatment of acute coronary syndromes in patients with type 2 diabetes mellitus with beta-adrenoblockers and angiotensin-converting enzyme inhibitors: cardiohemodynamic effects and impact for prognosis.
Treatment of cardiovascular dysfunction associated with the metabolic syndrome and type 2 diabetes.
Treatment of hypertension in individuals with the cardiometabolic syndrome: role of an angiotensin II receptor blocker, telmisartan.
Treatment of microalbuminuria in patients with type 2 diabetes mellitus.
Trials that matter: the effect of a fixed-dose combination of an Angiotensin-converting enzyme inhibitor and a diuretic on the complications of type 2 diabetes.
Type 2 diabetes mellitus with hypertension at primary healthcare level in Malaysia: are they managed according to guidelines?
UK prospective diabetes study (UKPDS) 14: association of angiotensin-converting enzyme insertion/deletion polymorphism with myocardial infarction in NIDDM.
Urinary albumin excretion rate during angiotensin II infusion in microalbuminuric patients with insulin and non-insulin-dependent diabetes mellitus.
Urinary angiotensin-converting enzyme activity in type 2 diabetes mellitus: its relationship to diabetic nephropathy.
Urinary excretion of angiotensin-converting enzyme in NIDDM patients with nephropathy.
Use of medications to reduce cardiovascular risk among individuals with psychotic disorders and Type 2 diabetes.
Vasopeptidase inhibition attenuates proteinuria and podocyte injury in Zucker diabetic fatty rats.
Vildagliptin, a novel dipeptidyl peptidase IV inhibitor, has no pharmacokinetic interactions with the antihypertensive agents amlodipine, valsartan, and ramipril in healthy subjects.
What can be learned from the experience with the fixed low-dose combination of perindopril/indapamide in the treatment of hypertension?
[ADVANCE study: objectives, design and current status]
[Analysis of polymorphic variants of renin-angiotensin system genes in polymetabolic syndrome and non-insulin-dependent diabetes]
[Angiotensin converting enzyme (ACE) gene polymorphism in a diabetic cohort and diabetic nephropathy]
[Angiotensin converting enzyme gene and exercise-induced silent myocardial ischemia in type 2 diabetes mellitus]
[Angiotensin converting enzyme gene polymorphism in type 2 diabetes mellitus]
[Angiotensin-converting enzyme gene and the brachial artery endothelial dysfunction in type 2 diabetes without angiopathy]
[Association between ACE gene polymorphism and therapeutic responsiveness of ACEI in diabetic nephropathy]
[Association between insertion-deletion polymorphism of the angiotensin-converting enzyme gene and development of angiopathies in patients with non-insulin dependent diabetes mellitus from the Chuvash Republic]
[Association of insertion/deletion polymorphism in angiotensin-converting enzyme gene with hypertensive type 2 diabetes mellitus]
[Clinical study of the month. The CALM study assessing the combination of an angiotensin-converting enzyme inhibitor and an angiotensin II receptor antagonist in the treatment of diabetic nephropathy]
[Correlation between polymorphism of angiotensin-converting enzyme gene and the lower extremity atherosclerosis in type 2 diabetes mellitus patients].
[Effect of perindopril on the processes of subclinical inflammation in patients with arterial hypertension and type 2 diabetes mellitus].
[I/D polymorphism of angiotensin I converting enzyme gene and arterial hypertension in patients with type 2 diabetes mellitus]
[I/D polymorphism of angiotensin I converting enzyme gene and insulin resistance and some parameters of metabolic syndrome in patients with type 2 diabetes]
[Is PstI polymorphism of the angiotensin I converting enzyme gene associated with nephropathy development in non-insulin-dependent diabetes mellitus (preliminary study)]
[Metabolic effects of berlipril-5 in patients with non-insulin dependent diabetes mellitus and arterial hypertension]
[New therapeutic options in renal diseases--hypotensive therapy]
[Parameters of vasomotor function of endothelium and elasticity of arterial wall during therapy with angiotensin converting enzyme inhibitor ramiprilin patients with type 2 diabetes mellitus]
[Polymorphism of the angiotensin I-converting enzyme gene in diabetic retinopathy patients and type 2 diabetes mellitus patients with myocardial infarction]
[Possible participation of angiotensin-converting enzyme and leukocyte elastase in the pathogenesis of insulin-independent diabetes mellitus]
[Primary prevention of coronary heart disease : Evidence-based drug treatment].
[Relation of polymorphism of genes controlling endothelial function and blood pressure and the occurrence of vascular complications in type 2 diabetes]
[Relationship of angiotensin converting enzyme gene polymorphism with diabetic retinopathy].
[Similar reduction in new cases of type 2 diabetes with angiotensin receptor blocker and ACE inhibitor: comparison of meta-analyses of prospective randomised trials]
[The changes of serum angiotensin converting enzyme activity in Type 2 diabetes and its vascular complications]
[The role of angiotensin II AT1-receptor antagonists in renal and cardiac protection in type-2 diabetes mellitus]
[Use of angiotensin I converting enzyme inhibitors --essential progress in treatment of hypertension and late complications in patients with non-insulin-dependent diabetes mellitus]
Diabetes, Gestational
Angiotensin-converting enzyme gene insertion/deletion polymorphism studies in Asian Indian pregnant women biochemically identifies gestational diabetes mellitus.
Association of polymorphisms in angiotensin-converting enzyme gene with gestational diabetes mellitus in Indian women.
[Insertion-deletion polymorphism in the gene for angiotensin-converning enzyme (I/D ACE) in pregnant women with gestational diabetes]
Diabetic Angiopathies
Angiotensin converting enzyme inhibition reduces the expression of transforming growth factor-beta1 and type IV collagen in diabetic vasculopathy.
Appropriate Blood Pressure Control in NIDDM (ABCD) Trial.
Baseline characteristics of participants in the Appropriate Blood Pressure Control in Diabetes trial.
Changes of endothelin in streptozotocin-induced diabetic rats: effects of an angiotensin converting enzyme inhibitor, enalapril maleate.
Combination of Captopril with Gliclazide Decreases Vascular and Renal Complications and Improves Glycemic Control in Rats with Streptozotocin-induced Diabetes Mellitus.
Increased angiotensin-converting enzyme activities in diabetes mellitus: analysis of diabetes type, state of metabolic control and occurrence of diabetic vascular disease.
Levels of serum angiotensin-converting enzyme before and after forearm venous stasis in diabetic microangiopathy.
Long-term effects of the endothelin(A) receptor antagonist LU 135252 and the angiotensin-converting enzyme inhibitor trandolapril on diabetic angiopathy and nephropathy in a chronic type I diabetes mellitus rat model.
Meta-analysis of association of insertion/deletion polymorphism of angiotensin I-converting enzyme gene with diabetic nephropathy and retinopathy.
Diabetic Cardiomyopathies
Angiotensin-converting enzyme-2 overexpression improves left ventricular remodeling and function in a rat model of diabetic cardiomyopathy.
Azilsartan ameliorates diabetic cardiomyopathy in young db/db mice through the modulation of ACE-2/ANG 1-7/Mas receptor cascade.
Effects of Astragalus polysaccharides on chymase, angiotensin-converting enzyme and angiotensin II in diabetic cardiomyopathy in hamsters.
Streptozotocin-induced diabetic cardiomyopathy in rats: ameliorative effect of PIPERINE via Bcl2, Bax/Bcl2, and caspase-3 pathways.
Vasopeptidase inhibition has beneficial cardiac effects in spontaneously diabetic Goto-Kakizaki rats.
Diabetic Ketoacidosis
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2019 EXECUTIVE SUMMARY.
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2020 EXECUTIVE SUMMARY.
Diabetic Nephropathies
1995 update of the working group reports on chronic renal failure and renovascular hypertension. National High Blood Pressure Education Program Working Group.
A comparative study of the prevalence of hyperkalemia with the use of angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers.
A controlled clinical trial of angiotensin-converting enzyme inhibition in type I diabetic nephropathy: study design and patient characteristics. The Collaborative Study Group.
A cost-effectiveness analysis of Angiotensin-converting enzyme inhibitors and Angiotensin receptor blockers in diabetic nephropathy.
A double-blind trial of perindopril and nitrendipine in incipient diabetic nephropathy.
A population study of ethnic variations in the angiotensin-converting enzyme I/D polymorphism: relationships with gender, hypertension and impaired glucose metabolism.
A practical approach to achieving recommended blood pressure goals in diabetic patients.
A randomized, double-blind, placebo-controlled trial to evaluate the effect of enalapril in patients with clinical diabetic nephropathy.
A retrospective study of the effects of angiotensin receptor blockers and angiotensin converting enzyme inhibitors in diabetic nephropathy.
A Review of The Utility Values Used in Published Cost-Effectiveness Analyses of Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Therapy in Patients With Diabetic Nephropathy.
ACE gene polymorphism and progression of diabetic nephropathy in Korean type 2 diabetic patients: effect of ACE gene DD on the progression of diabetic nephropathy.
ACE gene polymorphism and serum ACE activity in Iranians type II diabetic patients with macroalbuminuria.
ACE genotype, phenotype and all-cause mortality in different cohorts of patients with type 1 diabetes.
ACE inhibition or angiotensin receptor blockade: which should we use in diabetic patients?
ACE inhibition preserves renal function better than beta-blockade in the treatment of essential hypertension.
ACE inhibitor-induced angioedema of the small intestine: a case report.
ACE inhibitors and angiotensin II antagonists in renal transplantation: an analysis of safety and efficacy.
ACE Variants Interact with the RAS Pathway to Confer Risk and Protection against Type 2 Diabetic Nephropathy.
ACE, PAI-1, decorin and Werner helicase genes are not associated with the development of renal disease in European patients with type 1 diabetes.
ACE-inhibitor use and the long-term risk of renal failure in diabetes.
Add-on anti-TGF-beta antibody to ACE inhibitor arrests progressive diabetic nephropathy in the rat.
Adding a statin to a combination of ACE inhibitor and ARB normalizes proteinuria in experimental diabetes, which translates into full renoprotection.
Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy.
Additive effect of ACE inhibition and angiotensin II receptor blockade in type I diabetic patients with diabetic nephropathy.
Aldosterone antagonists in monotherapy are protective against streptozotocin-induced diabetic nephropathy in rats.
Aldosterone breakthrough during angiotensin-converting enzyme inhibitor therapy.
An ACE inhibitor reduces bactericidal activity of human neutrophils in vitro and impairs mouse neutrophil activity in vivo.
An evidence-based review of ACE inhibitors in incipient diabetic nephropathy.
Angiotensin blockade and matrix synthesis by glomerular epithelial cells in high glucose: a further experimental insight into the pathophysiology of diabetic nephropathy.
Angiotensin converting enzyme (ACE) insertion/deletion (I/D) polymorphism, and diabetic retinopathy in subjects with IDDM and NIDDM.
Angiotensin converting enzyme gene polymorphism and ACE inhibition in diabetic nephropathy.
Angiotensin converting enzyme gene polymorphism and glomerular filtration rate changes in type 2 diabetic patients.
Angiotensin converting enzyme inhibition and calcium channel blockade in incipient diabetic nephropathy. The Melbourne Diabetic Nephropathy Study Group.
Angiotensin converting enzyme inhibition in diabetic nephropathy. The Collaborative Study Group.
Angiotensin converting enzyme inhibitor-induced renal dysfunction: recommendations for prevention.
Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney disease.
Angiotensin converting enzyme inhibitors and diabetic nephropathy.
Angiotensin converting enzyme inhibitors may cause renal impairment in diabetes mellitus.
Angiotensin I converting enzyme gene polymorphism and diabetic nephropathy in type II diabetes.
Angiotensin I-converting enzyme and angiotensinogen gene polymorphisms in non-insulin-dependent diabetes mellitus. Lack of relationship with diabetic nephropathy and retinopathy in a Caucasian Mediterranean population.
Angiotensin II and its receptors in the diabetic kidney.
Angiotensin II type 1-receptor mediated changes in heparan sulfate proteoglycans in human SV40 transformed podocytes.
Angiotensin II-receptor blockers: clinical relevance and therapeutic role.
Angiotensin inhibition or blockade for the treatment of patients with quiescent lupus nephritis and persistent proteinuria.
Angiotensin receptor blockers in diabetic nephropathy: renal and cardiovascular end points.
Angiotensin-(1-7) for diabetic kidney disease: better than an angiotensin-converting enzyme inhibitor alone?
Angiotensin-converting enzyme gene and diabetes mellitus.
Angiotensin-converting enzyme gene polymorphism in non-insulin dependent diabetes mellitus and its relationship with diabetic nephropathy.
Angiotensin-converting enzyme gene polymorphism: is there a link to nephropathy in patients with type 1 diabetes?
Angiotensin-converting enzyme genotype and renal allograft survival.
Angiotensin-converting enzyme genotype in blacks with diabetic nephropathy: effects on risk of diabetes and its complications.
Angiotensin-converting enzyme inhibition and diabetic nephropathy.
Angiotensin-converting enzyme inhibition in diabetic nephropathy.
Angiotensin-converting enzyme inhibition in diabetic nephropathy: it's all the RAGE.
Angiotensin-converting enzyme inhibition in diabetic nephropathy: ten years' experience.
Angiotensin-converting enzyme inhibition in type I diabetic nephropathy.
Angiotensin-converting enzyme inhibitors and angiotensin II receptor blocker in diabetic nephropathy.
Angiotensin-converting enzyme inhibitors and kidney protection: the AIPRI trial. The ACE Inhibition in Progressive Renal Insufficiency (AIPRI) Study Group.
Angiotensin-converting enzyme inhibitors and probucol suppress the time-dependent increase in urinary Type IV collagen excretion of Type II diabetes mellitus patients with early diabetic nephropathy.
Angiotensin-converting enzyme inhibitors and progression of diabetic nephropathy.
Angiotensin-converting enzyme inhibitors and type 2 diabetic nephropathy: a meta-analysis.
Angiotensin-converting enzyme inhibitors have adverse effects in anti-angiogenesis therapy for hepatocellular carcinoma.
Angiotensin-converting enzyme inhibitors in diabetes: effect on the kidney and on blood pressure.
Angiotensin-converting enzyme inhibitors in diabetic nephropathy.
Angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers for prevention and treatment of nephropathy associated with type 2 diabetes mellitus.
Angiotensin-converting enzyme inhibitors versus angiotensin II receptor blockers for renal outcomes and mortality in diabetic kidney disease.
Angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers for diabetic nephropathy: a retrospective comparison.
Angiotensin-converting enzyme inhibitors versus calcium antagonists in the progression of renal diseases.
Angiotensin-converting enzyme polymorphism and development of diabetic nephropathy in non-insulin-dependent diabetes mellitus.
Angiotensin-converting-enzyme insertion/deletion genotype and long-term renal allograft survival.
Angiotensin-I converting enzyme gene polymorphism in Turkish type 2 diabetic patients.
Angiotensin-I converting enzyme insertion/deletion polymorphism and its association with diabetic nephropathy: a meta-analysis of studies reported between 1994 and 2004 and comprising 14,727 subjects.
Anti-fibrosis therapy and diabetic nephropathy.
Anti-hypertensive agents inhibit in vivo the formation of advanced glycation end products and improve renal damage in a type 2 diabetic nephropathy rat model.
Anti-proteinuric effects of combination therapy with enalapril and losartan in patients with nephropathy due to type 2 diabetes.
Antihypertensive agents in patients with diabetes: trade-off between renal and cardiovascular protection.
Antihypertensive and cardioprotective effects after angiotensin-converting enzyme inhibition: role of kinins.
Antihypertensive therapy in renal disease and transplantation.
Antiproteinuric effects of mineralocorticoid receptor blockade in patients with chronic renal disease.
Approach to the treatment of diabetic nephropathy.
Arterial hypertension in diabetes mellitus: from theory to clinical practice.
Association analyses of the polymorphisms of angiotensin-converting enzyme and angiotensinogen genes with diabetic nephropathy in Japanese non-insulin-dependent diabetics.
Association between a polymorphism in the angiotensin-converting enzyme gene and microvascular complications in Japanese patients with NIDDM.
Association between angiotensin-converting enzyme gene polymorphisms and diabetic nephropathy: case-control, haplotype, and family-based study in three European populations.
Association between angiotensin-converting enzyme insertion/deletion gene polymorphism and end-stage renal disease in lebanese patients with diabetic nephropathy.
Association between genetic polymorphism of the angiotensin-converting enzyme and diabetic nephropathy: a meta-analysis comprising 26,580 subjects.
Association between serum Na-Cl level and renal function decline in chronic kidney disease: results from the chronic kidney disease Japan cohort (CKD-JAC) study.
Association between the ACE I/D gene polymorphism and T2DN susceptibility: The risk of T2DM developing into T2DN in the Asian population.
Association between the angiotensin-converting enzyme-insertion/deletion polymorphism and diabetic nephropathy: a methodologic appraisal and systematic review.
Association of ACE gene polymorphism and diabetic nephropathy? The Diabetic Nephropathy Study Group.
Association of ACE I/D gene polymorphism with T2DN susceptibility and the risk of T2DM developing into T2DN in a Caucasian population.
Association of angiotensin-converting enzyme gene insertion/deletion polymorphism with metabolic syndrome in Iranians with type 2 diabetes mellitus.
Association of angiotensin-converting enzyme insertion/deletion polymorphism with type 1 diabetic nephropathy: a meta-analysis.
Association of B? receptor polymorphisms and ACE activity with ACE inhibitor-induced angioedema in black and mixed-race South Africans.
Association of Diabetic Microvascular Complications and Parameters of Obstructive Sleep Apnea in Patients with Type 2 Diabetes.
Association of the angiotensinogen M235T and angiotensin-converting enzyme insertion/deletion gene polymorphisms in Turkish type 2 diabetic patients with and without nephropathy.
Associations between clinical characteristics and angiotensin-converting enzyme gene insertion/deletion polymorphism in Moroccan population with Type-2 diabetic nephropathy.
Associations Between Genetic Polymorphisms in the VEGFA, ACE, and SOD2 Genes and Susceptibility to Diabetic Nephropathy in the Han Chinese.
Avosentan reduces albumin excretion in diabetics with macroalbuminuria.
Beneficial effect of combination therapy with an angiotensin II receptor antagonist and angiotensin-converting enzyme inhibitor on overt proteinuria in a patient with type 1 diabetic nephropathy.
Beneficial effect of lisinopril plus telmisartan in patients with type 2 diabetes, microalbuminuria and hypertension.
Beneficial effects of angiotensin converting enzyme inhibition on renal function in patients with diabetic nephropathy.
Betablocker treatment in diabetes mellitus.
Blood pressure, angiotensin-converting enzyme (ACE) inhibitors, and the kidney.
Calcitriol regulates angiotensin-converting enzyme and angiotensin converting-enzyme 2 in diabetic kidney disease.
Captopril acutely lowers albuminuria in normotensive patients with diabetic nephropathy.
Captopril reverses high glucose-induced effects on LLC-PK1 cells partly by enhancing facilitative glucose transporter messenger RNA expressions.
Care of elderly patients with chronic kidney disease.
Changing the course of diabetic nephropathy: angiotensin-converting enzyme inhibition in type I diabetic renal disease.
Choosing Wisely: The Canadian Society of Nephrology's List of 5 Items Physicians and Patients Should Question.
Chronic endothelin receptor blockade prevents both early hyperfiltration and late overt diabetic nephropathy in the rat.
Cigarette smoking predicts faster progression of type 2 established diabetic nephropathy despite ACE inhibition.
Clinical and histological correlations of decline in renal function in diabetic patients with proteinuria.
Clinical evaluation of valsartan and metoprolol tartrate in treatment of diabetic nephropathy with positive ?1-adrenergic and anti-angiotensin II type 1 receptor antibody.
Clinical experience with angiotensin receptor blockers with particular reference to valsartan.
Clinical pharmacokinetics and selective pharmacodynamics of new angiotensin converting enzyme inhibitors: an update.
Combination ACE inhibitor and angiotensin II receptor antagonist therapy in diabetic nephropathy.
Combination antihypertensive therapy in the treatment of diabetic nephropathy.
Combination of Angiotensin Converting Enzyme Insertion/Deletion (I/D) (rs4646994) and VEGF Polymorphism (+405G/C; rs2010963) Synergistically Associated With the Development, of Albuminuria in Iranian Patients With Type 2 Diabetes.
Combination of half doses of angiotensin type 1 receptor antagonist and angiotensin-converting enzyme inhibitor in diabetic nephropathy.
Combination therapy with an ACE inhibitor and an angiotensin receptor blocker for diabetic nephropathy: a meta-analysis.
Combination therapy with an angiotensin-converting-enzyme inhibitor and an angiotensin II receptor antagonist ameliorates microinflammation and oxidative stress in patients with diabetic nephropathy.
Combination therapy with Chinese medicine and ACEI/ARB for the management of diabetic nephropathy: the promise in research fragments.
Combination use of angiotensin converting enzyme inhibitors and angiotensin receptor blockers in diabetic kidney disease.
Combinational effect of genes for the renin-angiotensin system in conferring susceptibility to diabetic nephropathy.
Combined inhibition of CCR2 and ACE provides added protection against progression of diabetic nephropathy in Nos3-deficient mice.
Comparative effects of captopril versus nifedipine on proteinuria and renal function of type 2 diabetic patients.
Comparing the Efficacy of Angiotensin Converting Enzyme Inhibitors with Calcium Channel Blockers on the Treatment of Diabetic Nephropathy: A Meta-Analysis.
Comparison between the angiotensin II receptor antagonist candesartan cilexetil and the angiotensin-converting enzyme inhibitor trandolapril in microalbuminuria of patients with early diabetic nephropathy.
Comparison of the effects of an angiotensin converting enzyme inhibitor and a calcium antagonist in hypertensive, macroproteinuric diabetic patients: a randomised double-blind study.
Contrasting effects of enalapril and metoprolol on proteinuria in diabetic nephropathy.
Cost-effectiveness of angiotensin-converting enzyme inhibitors for the prevention of diabetic nephropathy in The Netherlands--a Markov model.
Critical insights into the beneficial and protective actions of the kallikrein-kinin system.
CS-886, a new angiotensin II type 1 receptor antagonist, ameliorates glomerular anionic site loss and prevents progression of diabetic nephropathy in Otsuka Long-Evans Tokushima fatty rats.
DD genotype of angiotensin-converting enzyme in type 2 diabetes mellitus with renal disease in Mexican Mestizos.
Decreased glomerular and tubular expression of ACE2 in patients with type 2 diabetes and kidney disease.
Deletion insertion polymorphism of the angiotensin converting enzyme gene and progression of diabetic nephropathy.
Design of combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor for treatment of diabetic nephropathy (VA NEPHRON-D).
Determinants of heart rate variability in chronic hemodialysis patients.
Diabetic glomerulosclerosis can be the pathogenesis of refractory diabetic macular edema.
Diabetic nephropathy and antihypertensive treatment: what are the lessons from clinical trials?
Diabetic nephropathy and the insertion/deletion polymorphism of the angiotensin-converting enzyme gene.
Diabetic Nephropathy Following Posttransplant Diabetes Mellitus.
Diabetic nephropathy for the primary care provider: new understandings on early detection and treatment.
Diabetic nephropathy in children and adolescents: a critical review with particular reference to angiotensin-converting enzyme inhibitors.
Diabetic nephropathy in the rat: differing renal effects of an angiotensin converting enzyme inhibitor and a calcium inhibitor.
Diabetic Nephropathy Induced by Increased Ace Gene Dosage Is Associated with High Renal Levels of Angiotensin (1-7) and Bradykinin.
Diabetic nephropathy, percutaneous coronary interventions, and blockade of the renin-angiotensin system.
Diabetic nephropathy--prevention and treatment.
Diabetic nephropathy--the family physician's role.
Diabetic nephropathy.
Diabetic nephropathy: common questions.
Differential efficacy of perindopril and enalapril in experimental diabetic nephropathy.
Discovery of a potent angiotensin converting enzyme inhibitor via virtual screening.
Discrepancy between Intrarenal Messenger RNA and Protein Expression of ACE and ACE2 in Human Diabetic Nephropathy.
DNA polymorphisms in the ACE gene, serum ACE activity and the risk of nephropathy in insulin-dependent diabetes mellitus.
Drug of choice in the management of hypertension in diabetes and diabetic nephropathy: Angiotensin-converting enzyme inhibitors.
Dual blockade of the renin-angiotensin system in diabetic nephropathy.
Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy.
Dual blockade of the renin-angiotensin-aldosterone system is safe and effective in reducing albuminuria in Asian type 2 diabetic patients with nephropathy.
Early diabetic nephropathy. Emerging treatment options.
Economic evaluations of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in type 2 diabetic nephropathy: a systematic review.
Effect of ACE gene on diabetic nephropathy in NIDDM patients with insulin resistance.
Effect of angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade on streptozotocin-induced diabetic nephropathy.
Effect of camostat mesilate on heavy proteinuria in various nephropathies.
Effect of captopril on blood pressure and kidney function in normotensive insulin dependent diabetics with nephropathy.
Effect of captopril on heavy proteinuria in azotemic diabetics.
Effect of deletion polymorphism of angiotensin converting enzyme gene on progression of diabetic nephropathy during inhibition of angiotensin converting enzyme: observational follow up study.
Effect of deletion polymorphism of angiotensin converting enzyme gene on progression of diabetic nephropathy.
Effect of Dual Blockade of the Renin-Angiotensin System on the Progression of Type 2 Diabetic Nephropathy: A Randomized Trial.
Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial.
Effect of fosinopril on chemerin and VEGF expression in diabetic nephropathy rats.
Effect of indapamide SR on microalbuminuria--the NESTOR study (Natrilix SR versus Enalapril Study in Type 2 diabetic hypertensives with micrOalbuminuRia)--rationale and protocol for the main trial.
Effect of intensive blood pressure control on the course of type 1 diabetic nephropathy. Collaborative Study Group.
Effect of Omega-3 Fatty Acid on the Fatty Acid Content of the Erythrocyte Membrane and Proteinuria in Patients with Diabetic Nephropathy.
Effective Antihypertensive Strategies for High-Risk Patients With Diabetic Nephropathy.
Effects of ACE inhibition supplementary to beta blockers and diuretics in early diabetic nephropathy.
Effects of ACE Inhibitors and Angiotensin Receptor Blockers in Normotensive Patients with Diabetic Kidney Disease.
Effects of adding tripterygium glycosides to angiotensin-converting enzyme inhibitors or angiotensin receptor blockers on albuminuria in patients with diabetic nephropathy.
Effects of additive therapy with spironolactone on proteinuria in diabetic patients already on ACE inhibitor or ARB therapy: results of a randomized, placebo-controlled, double-blind, crossover trial.
Effects of an ACE inhibitor combined with a calcium channel blocker on progression of diabetic nephropathy.
Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy.
Effects of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists on mortality and renal outcomes in diabetic nephropathy: systematic review.
Effects of angiotensin converting enzyme inhibitors on the progression of diabetic nephropathy.
Effects of calcium channel blockers on proteinuria in patients with diabetic nephropathy.
Effects of candesartan on the proteinuria of chronic glomerulonephritis.
Effects of captopril on diabetic nephropathy in hypertensive women.
Effects of dehydroepiandrosterone and quinapril on nephropathy in obese Zucker rats.
Effects of dual blockade of renin-angiotensin system in type 2 diabetes mellitus patients with diabetic nephropathy.
Effects of dual blockade of the renin-angiotensin system on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy and hypertension in the ORIENT: a post-hoc analysis (ORIENT-Hypertension).
Effects of enalapril in insulin-dependent diabetic subjects with mild to moderate uncomplicated hypertension.
Effects of imidapril and captopril on streptozotocin-induced diabetic nephropathy in mice.
Effects of Losartan-based therapy on the incidence of end-stage renal disease and associated costs in type 2 diabetes mellitus: A retrospective cost-effectiveness analysis in the United Kingdom.
Effects of mineralocorticoid receptor antagonists on the progression of diabetic nephropathy.
Effects of monotherapy of temocapril or candesartan with dose increments or combination therapy with both drugs on the suppression of diabetic nephropathy.
Effects of nisoldipine and lisinopril on microvascular dysfunction in hypertensive Type I diabetes patients with nephropathy.
Effects of pentoxifylline on proteinuria and glucose control in patients with type 2 diabetes: a prospective randomized double-blind multicenter study.
Effects of renin-angiotensin system blockers on renal and cardiovascular outcomes in patients with diabetic nephropathy: a meta-analysis of randomized controlled trials.
Effects of renin-angiotensin system blockers on renal outcomes and all-cause mortality in patients with diabetic nephropathy: an updated meta-analysis.
Effects of short-term glycemic control, low protein diet and administration of enalapril on renal hemodynamics and protein permselectivity in type 2 diabetic patients with microalbuminuria.
Effects of the angiotensin II type 1 receptor antagonist candesartan, compared with angiotensin-converting enzyme inhibitors, on the urinary excretion of albumin and type IV collagen in patients with diabetic nephropathy.
Efficacy and safety of combining pentoxifylline with angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker in diabetic nephropathy: a meta-analysis.
Efficacy of captopril in postponing nephropathy in normotensive insulin dependent diabetic patients with microalbuminuria.
Egr1 Knockdown Combined with an ACE Inhibitor Ameliorates Diabetic Kidney Disease in Mice: Blockade of Compensatory Renin Increase.
Elevated circulating transforming growth factor beta-1 may explain poorer renal survival in type II diabetics with chronic hepatitis C.
Emerging drug combinations to optimize renovascular protection and blood pressure goals.
Emerging role of PPAR ligands in the management of diabetic nephropathy.
Emerging trends for prevention and treatment of diabetic nephropathy: blockade of the RAAS and BP control.
End-stage renal disease and adherence to angiotensin-converting enzyme inhibitors and angiotensin receptor blockers among patients with diabetes.
Endothelial nitric oxide synthase gene polymorphisms and renal responsiveness to RAS inhibition therapy in type 2 diabetic Asian Indians.
Endothelin in diabetic renal disease.
Evidence of apoptosis in human diabetic kidney.
Evolving strategies for renoprotection: diabetic nephropathy.
Evolving therapeutic strategies for retarding progression of diabetic nephropathy--an update for 2002.
Examination of two genetic polymorphisms within the renin-angiotensin system: no evidence for an association with nephropathy in IDDM.
Excess of DD homozygotes in haemodialysed patients with type II diabetes. The Diabetic Nephropathy Study Group.
From pharmacogenomics to improved patient outcomes: angiotensin I-converting enzyme as an example.
Genetic disposition and modifiable factors independently associated with anemia in patients with type 2 diabetes mellitus.
Genetic hypertension accelerates nephropathy in the streptozotocin diabetic rat.
Genetic Predisposition for Development of Nephropathy in Type 2 Diabetes Mellitus.
Genetic predisposition to diabetic nephropathy. Evidence for a role of the angiotensin I--converting enzyme gene.
Genetic Predisposition to Diabetic Nephropathy: Evidence for a Role of ACE (I/D) Gene Polymorphism in Type 2 Diabetic Population from Kutch Region.
Genetic variants of the renin-angiotensin system, diabetic nephropathy and hypertension.
Genetic variation in the Renin-Angiotensin system and progression of diabetic nephropathy.
Genetic variations associated with diabetic nephropathy and type II diabetes in a Japanese population.
Genetically increased angiotensin I-converting enzyme level and renal complications in the diabetic mouse.
High glucose instigates tubulointerstitial injury by stimulating hetero-dimerization of adiponectin and angiotensin II receptors.
High salt diet ameliorates effects of angiotensin converting enzyme inhibition in spontaneously hypertensive streptozotocin diabetic rats.
Identification of specific angiotensin-converting enzyme variants and haplotypes that confer risk and protection against type 2 diabetic nephropathy.
Ilepatril (AVE-7688), a vasopeptidase inhibitor for the treatment of hypertension.
Impaired vascular reactivity in African-American patients with type 2 diabetes mellitus and microalbuminuria or proteinuria despite angiotensin-converting enzyme inhibitor therapy.
Improving the Management of Chronic Kidney Disease in Uruguay: A National Renal Healthcare Program.
In memory of a legendary athlete: measured success in diabetic nephropathy.
In patients with chronic diabetic nephropathy, do angiotensin-converting enzyme inhibitors (ACEI) have greater renal protective effect as compared to angiotensin receptor blockers (ARB)?
Income-related differences in the use of evidence-based therapies in older persons with diabetes mellitus in for-profit managed care.
Increased frequency of angiotensin-converting enzyme DD genotype in patients with type 2 diabetes in Taiwan.
Inducible nitric oxide synthase (iNOS) expression is increased in lipopolysaccharide (LPS)-stimulated diabetic rat glomeruli: effect of ACE inhibitor and angiotensin II receptor blocker.
Influence of genetic variability at the ACE locus in intron 16 on Diabetic Nephropathy in T1DM patients.
Inhibition of IGF-I-induced Erk 1 and 2 activation and mitogenesis in mesangial cells by bradykinin.
Inhibition of MAPK-mediated ACE expression by compound C66 prevents STZ-induced diabetic nephropathy.
Inhibition of the renal renin-angiotensin system and renoprotection by pitavastatin in type1 diabetes.
Insertion/deletion polymorphism in the angiotensin-I-converting enzyme gene is associated with coronary heart disease in IDDM patients with diabetic nephropathy.
Integrated Treatment of Prostaglandin E1 and Angiotensin-Converting Enzyme Inhibitor in Diabetic Kidney Disease Rats: Possible Role of Antiapoptosis in Renal Tubular Epithelial Cells.
Interaction of MTHFR 1298C with ACE D Allele Augments the Risk of Diabetic Nephropathy in Western Iran.
Interrupting the renin-angiotensin system: the role of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists in the treatment of hypertension.
Involvement of angiotensin II in progression of renal injury in rats with genetic non-insulin-dependent diabetes mellitus (Wistar fatty rats).
Irbesartan in hypertensive non-diabetic advanced chronic kidney disease. Comparative study with ACEI.
Kidney involvement and disease in patients with diabetes.
Kinins are involved in the antiproteinuric effect of angiotensin-converting enzyme inhibition in experimental diabetic nephropathy.
Lack of association between the angiotensin-converting enzyme gene (I/D) polymorphism and diabetic nephropathy in Tunisian type 2 diabetic patients.
Lack of association between the insertion/deletion polymorphism of the angiotensin-converting-enzyme gene and diabetic nephropathy in IDDM patients.
Lack of relationship between an insertion/deletion polymorphism in the angiotensin I-converting enzyme gene and diabetic nephropathy and proliferative retinopathy in IDDM patients.
Lack of synergism between long-term poor glycaemic control and three gene polymorphisms of the renin angiotensin system on risk of developing diabetic nephropathy in type I diabetic patients.
Linkage analysis between loci in the renin-angiotensin axis and end-stage renal disease in African Americans.
Lisinopril-Induced Angioedema in a Patient with Plasma Prekallikrein Deficiency.
Long-term beneficial effect of ACE inhibition on diabetic nephropathy in normotensive type 1 diabetic patients.
Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients.
Losartan ameliorates progression of glomerular structural changes in diabetic KKAy mice.
Losartan and other angiotensin II antagonists for nephropathy in type 2 diabetes mellitus: a review of the clinical trial evidence.
Management of advanced chronic kidney disease in primary care - current data from Germany.
Management of diabetes complications in youth.
Management of hypertension in diabetes mellitus.
Management of Hypertension in Diabetic Nephropathy: How Low Should We Go?
Management of hypertension in patients with type 2 diabetes mellitus: guidelines based on current evidence.
Management of hypertension in the diabetic patient.
Mechanism of decreased albuminuria caused by angiotensin converting enzyme inhibitor in early diabetic nephropathy.
Mechanism of the progression of diabetic nephropathy to renal failure.
Meta-analysis of association of insertion/deletion polymorphism of angiotensin I-converting enzyme gene with diabetic nephropathy and retinopathy.
Meta-analysis: the efficacy and safety of combined treatment with ARB and ACEI on diabetic nephropathy.
Microalbuminuria in type 1 and type 2 diabetes mellitus: evidence with angiotensin converting enzyme inhibitors and angiotensin II receptor blockers for treating early and preventing clinical nephropathy.
Microfluidic chip-based method for genotyping microsatellites, VNTRs and insertion/deletion polymorphisms.
Mineralocorticoid receptor blockade in addition to angiotensin converting enzyme inhibitor or angiotensin II receptor blocker treatment: an emerging paradigm in diabetic nephropathy: a systematic review.
Modulation of angiotensin II-mediated signalling by heparan sulphate glycosaminoglycans.
Morphometric detection of incipient glomerular lesions in diabetic nephropathy in rats. Protective effects of ACE inhibition.
MTHFR C677T, A1298C and ACE I/D polymorphisms as risk factors for diabetic nephropathy among type 2 diabetic patients.
Nephroprotection in Zucker diabetic fatty rats by vasopeptidase inhibition is partly bradykinin B2 receptor dependent.
New treatment guidelines for a patient with diabetes and hypertension.
New trends in the treatment of diabetic nephropathy in children.
No association of converting enzyme insertion/deletion polymorphism with immunoglobulin A glomerulonephritis.
Novel therapies of diabetic nephropathy.
Nuclear hormone receptors as therapeutic targets.
Nuclear receptors in renal disease.
Options in antihypertensive drug therapy. Help in choosing from among the many agents.
Oral sulodexide reduces albuminuria in microalbuminuric and macroalbuminuric type 1 and type 2 diabetic patients: the Di.N.A.S. randomized trial.
Outcome survey in unselected hypertensive patients with type 2 diabetes mellitus: effects of ACE inhibition.
Over 11 years of stable renal function after remission of nephrotic-range proteinuria in type I diabetics treated with an ACE inhibitor.
Pancreas transplantation for the prevention of diabetic nephropathy.
Pathogenesis of diabetic nephropathy: focus on transforming growth factor-beta and connective tissue growth factor.
Perindopril attenuates tubular hypoxia and inflammation in an experimental model of diabetic nephropathy in transgenic Ren-2 rats.
Perindopril effects on ambulatory blood pressure: relation to sympathetic nervous activity in subjects with diabetic nephropathy.
Pharmacoeconomic challenges in the management of diabetic nephropathy.
Pharmacologic management of hypertension in patients with diabetes.
Pharmacological blockade of B2-kinin receptor reduces renal protective effect of angiotensin-converting enzyme inhibition in db/db mice model.
Physician knowledge and practice patterns relating to diabetic nephropathy.
Physiologic actions and molecular expression of the renin-angiotensin system in the diabetic rat.
Physiology of local renin-angiotensin systems.
Pioglitazone reduces urinary protein and urinary transforming growth factor-beta excretion in patients with type 2 diabetes and overt nephropathy.
Placebo-controlled trial of lisinopril in normotensive diabetic patients with incipient nephropathy.
Plasma angiotensin II, renin activity and serum angiotensin-converting enzyme activity in non-insulin dependent diabetes mellitus patients with diabetic nephropathy.
Polymorphism of angiotensin-converting enzyme (rs4340) and diabetic nephropathy in Caucasians with type 2 diabetes mellitus.
Polymorphism of the ACE Gene in dialysis patients: overexpression of DD genotype in type 2 diabetic end-stage renal failure patients.
Polymorphism of the angiotensin I-converting enzyme gene in diabetic nephropathy in type II diabetic patients with proliferative retinopathy.
Polymorphisms in the gene encoding angiotensin I converting enzyme 2 and diabetic nephropathy.
Potassium handling with dual renin-angiotensin system inhibition in diabetic nephropathy.
Preconception and pregnancy management of women with diabetic nephropathy on angiotensin converting enzyme inhibitors.
Predictors of the progression of diabetic nephropathy and the beneficial effect of angiotensin-converting enzyme inhibitors in NIDDM patients.
Prescribing omissions among elderly Brazilian patients at their hospital admission and discharge: cross-sectional study.
Preservation of kidney function with combined inhibition of NADPH oxidase and angiotensin-converting enzyme in diabetic nephropathy.
Prevalence of anemia in patients with type II diabetes and mild to moderate chronic kidney disease and the impact of anti-RAS medications.
Preventing diabetic nephropathy: an audit.
Preventing end stage renal disease in diabetic patients--genetic aspect (part I).
Preventing renal complications in type 2 diabetes: results of the diabetics exposed to telmisartan and enalapril trial.
Prevention and slowing down the progression of the diabetic nephropathy through antihypertensive therapy.
Prevention and treatment of diabetic nephropathy.
Prevention and treatment of diabetic nephropathy: role of angiotensin-converting enzyme inhibitors.
Prevention of diabetic nephropathy with enalapril in normotensive diabetics with microalbuminuria.
Progression of renal failure -- the role of hypertension.
Protection of kidney function and decrease in albuminuria by captopril in insulin dependent diabetics with nephropathy.
Protection of the cardiovascular system by imidapril, a versatile angiotensin-converting enzyme inhibitor.
Protective effects of a small dose of captopril on the reduction of glomerular basement membrane anionic sites in spontaneously hypertensive rats with streptozotocin-induced diabetes.
Proteinuria and the expression of the podocyte slit diaphragm protein, nephrin, in diabetic nephropathy: effects of angiotensin converting enzyme inhibition.
Proteinuria-lowering effect of heparin therapy in diabetic nephropathy without affecting the renin-angiotensin-aldosterone system.
Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia)
Rationale and design of diabetics exposed to telmisartan and enalapril (DETAIL) study.
Recent advance in the treatment of diabetic nephropathy: angiotensin I converting enzyme (ACE) inhibitors.
Reduced cortical renal GLUT1 expression induced by angiotensin-converting enzyme inhibition in diabetic spontaneously hypertensive rats.
Relations between eNOS Glu298Asp polymorphism and progression of diabetic nephropathy.
Relationship between angiotensin I converting enzyme gene polymorphism and diabetic nephropathy.
Relationship between polymorphism in the angiotensinogen, angiotensin-converting enzyme or angiotensin II receptor and renal progression in Japanese NIDDM patients.
Relationship between the ACE I/D gene polymorphism and T1DN susceptibility/risk of T1DM developing into T1DN in the Caucasian population.
Relationship of angiotensin I-converting enzyme (ACE) and bradykinin B2 receptor (BDKRB2) polymorphism with diabetic nephropathy.
Relative effects of angiotensin converting enzyme inhibitors and calcium antagonists in advanced diabetic nephropathy.
Renal accumulation and clearance of advanced glycation end-products in type 2 diabetic nephropathy: effect of angiotensin-converting enzyme and vasopeptidase inhibition.
Renal ACE immunohistochemical localization in NIDDM patients with nephropathy.
Renal angiotensin-converting enzyme localization in diabetic rats and the effect of low protein diet.
Renal autoregulation is normal in newly diagnosed, normotensive, NIDDM patients.
Renal changes on hyperglycemia and angiotensin-converting enzyme in type 1 diabetes.
Renal effects of converting enzyme inhibitors in hypertension and diabetes.
Renal GLUT1 reduction depends on angiotensin-converting enzyme inhibition in diabetic hypertensive rats.
Renal pro-inflammatory cytokine gene expression in diabetic nephropathy: effect of angiotensin-converting enzyme inhibition and pentoxifylline administration.
Renal protection in diabetes--an emerging role for calcium antagonists.
Renal protective effect of enalapril in diabetic nephropathy.
Renal Protective Effects of Combination of Diltiazem and ACEI/ARB on the Progression of Diabetic Nephropathy: Randomized Controlled Trial.
Renal scanning 99mTc diethylene-triamine pentaacetic acid glomerular filtration rate (GFR) determination compared with iothalamate clearance GFR in diabetics. The Collaborative Study Group for The study of Angiotensin-Converting Enzyme Inhibition in Diabetic Nephropathy.
Renal synthesis of urokinase type-plasminogen activator, its receptor, and plasminogen activator inhibitor-1 in diabetic nephropathy in rats: modulation by angiotensin-converting-enzyme inhibitor.
Renal therapeutics: patent highlights January to June 2003.
Renal tubular ACE-mediated tubular injury is the major contributor to microalbuminuria in early diabetic nephropathy.
Renin Inhibition for Hypertension: Selecting the Right Role for a New Class of Drug.
Renin Inhibition with Aliskiren: A Decade of Clinical Experience.
Renin-angiotensin system blockade at the level of the angiotensin converting enzyme or the angiotensin type-1 receptor: similarities and differences.
Renin-Angiotensin-Aldosterone System Gene Polymorphisms and Type 2 Diabetic Nephropathy in Asian Populations: An Updated Meta-analysis.
Renin-angiotensin-aldosterone system: fundamental aspects and clinical implications in renal and cardiovascular disorders.
Renoprotective effect of the addition of losartan to ongoing treatment with an angiotensin converting enzyme inhibitor in type-2 diabetic patients with nephropathy.
Resolution of early stage diabetic nephropathy in an obese diabetic patient after gastric bypass.
Response of fibroblast growth factor 23 to volume interventions in arterial hypertension and diabetic nephropathy.
Revival of nifedipine, a dihydropyridine-based calcium blocker.
Role of angiotensin converting enzyme and angiotensinogen gene polymorphisms in angiotensin converting enzyme inhibitor-mediated antiproteinuric action in type 2 diabetic nephropathy patients.
Role of angiotensin II in diabetic nephropathy.
Role of angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers in the prevention of progression of renal disease.
Role of glycaemic control in development of microalbuminuria in patients with insulin dependent diabetes.
Role of local and systemic angiotensin in diabetic renal disease.
Role of receptor for advanced glycation end-product (RAGE) and the JAK/STAT-signaling pathway in AGE-induced collagen production in NRK-49F cells.
Selection of the dose of angiotensin converting enzyme inhibitor for patients with diabetic nephropathy depends on the presence or absence of left ventricular hypertrophy.
Serum angiotensin converting enzyme activity in type 2 (non-insulin-dependent) diabetic patients with chronic glomerulonephritis.
Serum Sodium Profile of Congestive Heart Failure Patients and its Impact on Their Outcome at Discharge.
Short- and long-term treatment with angiotensin-converting enzyme inhibitors or calcium channel blockers for the prevention of diabetic nephropathy progression: A meta-analysis.
Short-term effect of angiotensin-converting enzyme inhibitor enalapril in incipient diabetic nephropathy.
Should all Pima Indians with type 2 diabetes mellitus be prescribed routine angiotensin-converting enzyme inhibition therapy to prevent renal failure?
Simultaneous inhibition of neprilysin and activation of ACE2 prevented diabetic cardiomyopathy.
Single versus dual blockade of the renin-angiotensin system (angiotensin-converting enzyme inhibitors and/or angiotensin II receptor blockers) in diabetic nephropathy.
Slowing the progression of kidney disease in patients with diabetes.
Soy ?-conglycinin retards progression of diabetic nephropathy via modulating the insulin sensitivity and angiotensin-converting enzyme activity in rats fed with high salt diet.
Spironolactone in type 2 diabetic nephropathy: Effects on proteinuria, blood pressure and renal function.
Study of ACEI versus ARB in managing hypertensive overt diabetic nephropathy: long-term analysis.
Study of the polymorphism of angiotensinogen, anigiotensin-converting enzyme and angiotensin receptor in type II diabetes with end-stage renal disease in Taiwan.
The association of ACE gene polymorphism with diabetic kidney disease and renoprotective efficacy of valsartan.
The beneficial effect of angiotensin-converting enzyme inhibition with captopril on diabetic nephropathy in normotensive IDDM patients with microalbuminuria. North American Microalbuminuria Study Group.
The comparative effects of perindopril and catechin on mesangial matrix and podocytes in the streptozotocin induced diabetic rats.
The cost-effectiveness of treating all patients with type 2 diabetes with angiotensin-converting enzyme inhibitors.
The current practice of using angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in diabetic hypertensive and non-hypertensive patients. Is there a room for vitamin D?
The DD genotype of the ACE gene polymorphism is associated with diabetic nephropathy in the type-1 diabetics.
The deletion polymorphism of the angiotensin-converting enzyme is associated with nephroangiosclerosis.
The DIAB-HYCAR Study.
The effect of 12 weeks carnosine supplementation on renal functional integrity and oxidative stress in pediatric patients with diabetic nephropathy: a randomized placebo-controlled trial.
The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy.
The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group.
The effect of beta-blockade and angiotensin converting enzyme inhibition on kidney function in diabetic nephropathy.
The Effect of Combined Treatment with the (Pro)Renin Receptor Blocker HRP and Quinapril in Type 1 Diabetic Rats.
The effects of angiotensin-converting enzyme inhibitors on the clinical and biochemical parameters in diabetic nephropathy.
The effects of perindopril and triple therapy in a normotensive model of diabetic nephropathy.
The emerging role of angiotensin-converting enzyme-2 in the kidney.
The frequency of factor V Leiden mutation, ACE gene polymorphism, serum ACE activity and response to ACE inhibitor and angiotensin II receptor antagonist drugs in Iranians type II diabetic patients with microalbuminuria.
The impact of angiotensin converting enzyme insertion/deletion gene polymorphism on diabetic kidney disease: A debatable issue.
The impact of angiotensin-converting enzyme inhibitors on managed care: economic, clinical, and humanistic outcomes.
The influence of the ACE ( I/D) polymorphism on systemic and renal vascular responses to angiotensins in normotensive, normoalbuminuric Type 1 diabetes mellitus.
The kallikrein-kinin system in diabetic nephropathy.
The molecular basis of increased glomerulosclerosis after blockade of the renin angiotensin system in growth hormone transgenic mice.
The presence of allele D of angiotensin-converting enzyme polymorphism is associated with diabetic nephropathy in patients with less than 10 years duration of Type 2 diabetes.
The renin angiotensin system in diabetes mellitus. A physiological and therapeutic study.
The renin-angiotensin system and diabetic nephropathy.
The renin-angiotensin system and the long-term complications of diabetes: pathophysiological and therapeutic considerations.
The renin-angiotensin-aldosterone system: cardiorenal effects and implications for renal and cardiovascular disease states.
The reno-protective effect of the dual blockade of the renin angiotensin system (RAS).
The role of aldosterone antagonism agents in diabetic kidney disease.
The role of angiotensin I-converting enzyme gene polymorphism in renal disease.
The role of angiotensin II antagonism in type 2 diabetes mellitus: a review of renoprotection studies.
The role of angiotensin II receptor blockers in preventing the progression of renal disease in patients with type 2 diabetes.
The role of the renal kallikrein-kinin system in diabetic nephropathy.
The study of the effect of intensity of blood pressure management on the progression of type 1 diabetic nephropathy: study design and baseline patient characteristics. Collaborative Study Group.
The use of antihypertensive agents in prevention and treatment of diabetic nephropathy.
The vasopeptidase inhibitor AVE7688 ameliorates Type 2 diabetic nephropathy.
Therapeutic approaches to slowing the progression of diabetic nephropathy - is less best?
Therapeutic interventions for nephropathy in type I diabetes mellitus.
Therapeutic modalities in diabetic nephropathy: standard and emerging approaches.
Therapeutic progress. III: Diabetic nephropathy.
To pay or not to pay? A decision and cost-utility analysis of angiotensin-converting-enzyme inhibitor therapy for diabetic nephropathy.
Transdermal delivery of Angiotensin Converting Enzyme inhibitors.
Treating hypertension in the patient with overt diabetic nephropathy.
Treatment of hypertension and microalbuminuria in children and adolescents with type 1 diabetes mellitus.
Treatment of metabolic syndrome.
Treatment of type 2 diabetic nephropathy by blockade of the renin-angiotensin system: a comparison of angiotensin-converting-enzyme inhibitors and angiotensin receptor antagonists.
Treatment selection considerations for the hypertensive diabetic patient.
Tumor necrosis factor-alpha gene expression in diabetic nephropathy: relationship with urinary albumin excretion and effect of angiotensin-converting enzyme inhibition.
Urinary angiotensin-converting enzyme activity in type 2 diabetes mellitus: its relationship to diabetic nephropathy.
Urinary messenger RNA expression of podocyte-associated molecules in patients with diabetic nephropathy treated by angiotensin-converting enzyme inhibitor and angiotensin receptor blocker.
Use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in clinical practice.
Use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in high-risk clinical and ethnic groups with diabetes.
Use of angiotensin-converting enzyme inhibitors in patients with diabetic nephropathy.
Use of Ophiocordyceps sinensis (syn. Cordyceps sinensis) combined with angiotensin-converting enzyme inhibitors (ACEI)/angiotensin receptor blockers (ARB) versus ACEI/ARB alone in the treatment of diabetic kidney disease: a meta-analysis.
Use of the serum creatinine to estimate glomerular filtration rate in health and early diabetic nephropathy. Collaborative Study Group of Angiotensin Converting Enzyme Inhibition in Diabetic Nephropathy.
Value of Angiotensin receptor blocker therapy in diabetes.
Vasoactive hormones and the diabetic kidney.
Weight loss for reduction of proteinuria in diabetic nephropathy: Comparison with angiotensin-converting enzyme inhibitor therapy.
When to initiate ACEI/ARB therapy in patients with type 1 and 2 diabetes.
Whether vitamin D3 is effective in reducing proteinuria in type 2 diabetic patients?
Why are physicians not prescribing diuretics more frequently in the management of hypertension?
Will the addition of pentoxifylline reduce proteinuria in patients with diabetic glomerulosclerosis refractory to maximal doses of both an angiotensin-converting enzyme inhibitor and an angiotensin receptor blocker?
[A case of an elderly type 2 diabetes who had severe diabetic nephropathy without retinopathy]
[Angiotensin converting enzyme (ACE) gene polymorphism in a diabetic cohort and diabetic nephropathy]
[Angiotensin converting enzyme gene polymorphism and type 2 diabetic nephropathy]
[Angiotensin converting enzyme inhibitors in renal diseases]
[Angiotensin converting enzyme inhibitors, angiotensin receptor blockers and combined therapy in microalbuminuric patients with one or more cardiovascular risk factors. Protocol of the Long-term Impact of RAS Inhibition on Cardiorenal Outcomes randomized trial (LIRICO).]
[Angiotensin-converting enyme insertion/deletion polymorphism and blood pressure regulation in type 2 diabetic patients].
[Angiotensin-converting enzyme inhibitors in the diagnosis and treatment of kidney diseases]
[Angiotensin-converting enzyme inhibitors in the treatment of diabetic nephropathy]
[Clinical study of the month. The CALM study assessing the combination of an angiotensin-converting enzyme inhibitor and an angiotensin II receptor antagonist in the treatment of diabetic nephropathy]
[Converting enzyme inhibitors in acute myocardial infarct and heart failure]
[Diabetic nephropathy with nephrotic syndrome--apropos of 2 cases. Advantages of combined conversion enzyme inhibitor and non-dihydropyridine calcium antagonist treatment]
[Does an association between angiotensin I converting enzyme gene polymorphism and the prevalence of diabetic nephropathy in patients with diabetes type II exist?]
[Effect of Chinese herbs for stasis removing and collaterals dredging upon angiotensin-converting enzyme 2-angiotensin-(1-7)-mas axis in the renal cortex of diabetic nephropathy rats].
[Effects of benazepril on apoptosis in the kidney of diabetic rats]
[Effects of cilazapril on the expression of vascular endothelial growth factor and intercellular adhesion molecule-1 in diabetic rat glomeruli]
[Gene loci and polymorphisms of angiotensin II receptor]
[Lack of effect of ACE inhibition on severe proteinuria in diabetic nephropathy--a 6-month-long study]
[Meta analysis of the efficacy and safety of combined treatment with ARB and ACEI on diabetic kidney disease].
[Nephropathy in non-insulin-dependent diabetics]
[Relationship between angiotensin 1 converting enzyme gene polymorphism and diabetic nephropathy]
[Relationship between serum angiotensin I-converting enzyme activity and diabetic nephropathy in patients with type II diabetes]
[Relationship of the I/D-polymorphism of the ACE gene and the T174M-polymorphism of the AGT gene to diabetic microangiopathies in children and adolescents].
[Sulodexide in the treatment of diabetic nephropathy]
[The antiproteinuric action of angiotensin-converting enzyme inhibitors in chronic glomerulonephritis and diabetic nephropathy]
[The effect of temocapril, an angiotensin-converting enzyme inhibitor with preferential biliary excretion, on experimental diabetic nephropathy]
[The polymorphic markers of ???? and APOE genes and the chromosomal region 3q21-q25 are associated with the development of diabetic nephropathy in type 1 diabetes mellitus].
[The procedure for using Renitec (an angiotensin-converting enzyme inhibitor) for the treatment and prevention of diabetic nephropathy]
[The relationship between genetic polymorphisms and disease, illustrated by the renin-angiotensin-aldosterone system and cardiovascular disease]
[The renin-angiotensin system and progression of kidney disease]
[The significance of candidate genes' polymorphism in the development of diabetic nephropathy]
[The significance of deletion polymorphism in the ACE gene for progression of diabetic nephropathies treated with ACE inhibitors]
[Treatment of renal hypertension]
[Use of angiotensin converting enzyme inhibitors in nephrology]
[Use of captopril in diabetics]
[Usefulness of angiotensin converting enzyme inhibitors in the treatment of diabetic nephropathy]
Diabetic Neuropathies
Can diabetic neuropathy be prevented by angiotensin-converting enzyme inhibitors?
Diabetic neuropathy after pancreas transplantation: determinants of recovery.
Effect of angiotensin-converting-enzyme (ACE) inhibitor trandolapril on human diabetic neuropathy: randomised double-blind controlled trial.
Effect of quinapril or losartan alone and in combination on left ventricular systolic and diastolic functions in asymptomatic patients with diabetic autonomic neuropathy.
Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group.
Proactive case management of high-risk patients with type 2 diabetes mellitus by a clinical pharmacist: a randomized controlled trial.
The Implications of Angiotensin-Converting Enzymes and Their Modulators in Neurodegenerative Disorders: Current and Future Perspectives.
The potential role of angiotensin converting enzyme and vasopeptidase inhibitors in the treatment of diabetic neuropathy.
[The genetic and biochemical mechanisms of the development of diabetic nephropathy in children].
Diabetic Retinopathy
Adeno-Associated Virus Overexpression of Angiotensin-Converting Enzyme-2 Reverses Diabetic Retinopathy in Type 1 Diabetes in Mice.
Angiotensin converting enzyme (ACE) insertion/deletion (I/D) polymorphism, and diabetic retinopathy in subjects with IDDM and NIDDM.
Angiotensin converting enzyme inhibiting therapy is associated with lower vitreous vascular endothelial growth factor concentrations in patients with proliferative diabetic retinopathy.
Angiotensin-converting enzyme activity and angiomodulatory effects of sera in patients with diabetic retinopathy.
Angiotensin-converting enzyme gene polymorphism is associated with proliferative diabetic retinopathy: a meta-analysis.
Angiotensin-converting enzyme gene polymorphism is correlated to diabetic retinopathy: a meta-analysis.
Angiotensin-converting enzyme gene variants interact with the renin-angiotensin system pathway to confer risk and protection against type 2 diabetic retinopathy.
Angiotensin-converting enzyme inhibition for the treatment of moderate to severe diabetic retinopathy in normotensive Type 2 diabetic patients. A pilot study.
Angiotensin-converting enzyme inhibitor therapy and diabetic retinopathy.
Association between angiotensin-converting enzyme gene polymorphism and diabetic retinopathy in the Chinese population.
Association between the Angiotensin-Converting Enzyme (ACE) Genetic Polymorphism and Diabetic Retinopathy-A Meta-Analysis Comprising 10,168 Subjects.
Association of angiotensin-converting enzyme gene 2350 G/A polymorphism with diabetic retinopathy in Chinese Han population.
ASSOCIATIONS BETWEEN TRIGLYCERIDE/HIGH-DENSITY LIPOPROTEIN CHOLESTEROL RATIO AND MICRO- AND MACROANGIOPATHIES IN TYPE 2 DIABETES MELLITUS.
Captopril inhibits capillary degeneration in the early stages of diabetic retinopathy.
Captopril inhibits glucose accumulation in retinal cells in diabetes.
Comparative effectiveness of angiotensin-converting-enzyme inhibitors and angiotensin II receptor blockers in patients with type 2 diabetes and retinopathy.
Correlation between angiotensin-converting enzyme, vascular endothelial growth factor, and matrix metalloproteinase-9 in the vitreous of eyes with diabetic retinopathy.
Detection of the association between a deletion polymorphism in the gene encoding angiotensin I-converting enzyme and advanced diabetic retinopathy.
Development of diabetic retinopathy after cataract surgery.
Diabetes and retinal vascular disorders: role of the reninangiotensin system.
Effect of systemic medications on onset and progression of diabetic retinopathy.
Effects of angiotensin-converting enzyme inhibitors and beta-adrenergic blockers on retinal vascular endothelial growth factor expression in rat diabetic retinopathy.
Effects of losartan on diabetic maculopathy in type 2 diabetic patients: a randomized, double-masked study.
Elevated serum levels of angiotensin-converting enzyme in patients with diabetic retinopathy.
High vitreous concentration of vascular endothelial growth factor in diabetic patients with proliferative retinopathy using statins.
Insertion/deletion plasminogen activator inhibitor 1 and insertion/deletion angiotensin-converting enzyme gene polymorphisms in diabetic retinopathy in type 2 diabetes.
Investigation of Ocular Neovascularization-Related Genes and Oxidative Stress in Diabetic Rat Eye Tissues After Resveratrol Treatment.
Is the presence of retinopathy of practical value in defining cases of diabetic nephropathy in genetic association studies? The experience with the ACE insertion/deletion polymorphism in 53 studies comprising 17,791 subjects.
Lack of relationship between Alu repetitive elements in angiotensin converting enzyme and the severity of diabetic retinopathy.
Plasma and aqueous humor angiotensin-converting enzyme levels in patients with diabetic retinopathy.
Preventing diabetic retinopathy through control of systemic factors.
Protective effect of perindopril on diabetic retinopathy is associated with decreased vascular endothelial growth factor-to-pigment epithelium-derived factor ratio: involvement of a mitochondria-reactive oxygen species pathway.
Pulsatile intermittent intravenous insulin therapy for attenuation of retinopathy and nephropathy in type 1 diabetes mellitus.
Renin-angiotensin system in proliferative diabetic retinopathy and its gene expression in cultured human müller cells.
Role of ACE and PAI-1 Polymorphisms in the Development and Progression of Diabetic Retinopathy.
Role of the angiotensin II type 1 receptor in the pathogenesis of diabetic retinopathy: effects of blood pressure control and beyond.
Serum 1,5-anhydroglucitol is associated with diabetic retinopathy in Type 2 diabetes.
Serum angiotensin converting enzyme in diabetic retinopathy.
The renin-angiotensin system and diabetic retinopathy.
The therapeutic effects of angiotensin-converting enzyme inhibitors in severe non-proliferative diabetic retinopathy.
Therapeutic targets of renin-angiotensin system in ocular disorders.
Update on the treatment of diabetic retinopathy.
[Activity of angiotensin-converting enzyme in the blood and tear of patients with diabetic retinopathy]
[Angiotensin converting enzyme gene polymorphism and type 2 diabetic retinopathy]
[Association between visual improvement after photocoagulation and the use of angiotensin converting enzyme inhibitors in diabetic macular oedema].
[Bradykinin and angiotensin-converting enzyme in serum of patients with diabetic retinopathy and the prognosis of diabetic macular edema development (pilot study)].
[Changes of retinal neurons and Muller glial cells in patients with type II diabetes in treatment of diabetic retinopathy with angiotensin-converting enzyme inhibitor].
[Genetic aspects of diabetic retinopathy]
[Polymorphism of the angiotensin I-converting enzyme gene in diabetic retinopathy patients and type 2 diabetes mellitus patients with myocardial infarction]
[Relationship of angiotensin converting enzyme gene polymorphism with diabetic retinopathy].
[The experimental study of captopril and valsartan on the preventing and treatment of diabetic retinopathy in diabetic mice]
[The relationship of angiotensin I-converting enzyme gene polymorphism with diabetic retinopathy and diabetes myocardial infarction]
Digestive System Neoplasms
Angiotensin-converting enzyme gene polymorphism and digestive system cancer risk: A meta-analysis based on 9656 subjects.
Lack of any association between insertion/deletion (I/D) polymorphisms in the angiotensin-converting enzyme gene and digestive system cancer risk: a meta-analysis.
Quantitative assessment of the association between the angiotensin-converting enzyme gene insertion/deletion polymorphism and digestive system cancer risk.
dipeptidyl-peptidase iv deficiency
Dipeptidyl peptidase IV deficiency increases susceptibility to angiotensin-converting enzyme inhibitor-induced peritracheal edema.
Dirofilariasis
An angiotensin converting enzyme inhibitor, benazepril can be transformed to an active metabolite, benazeprilat, by the liver of dogs with ascitic pulmonary heartworm disease.
Down Syndrome
Acute renal failure associated with use of angiotensin converting enzyme inhibitor--a report of two children with Down's syndrome.
Drug Hypersensitivity
Efficacy and safety of iron sucrose for iron deficiency in patients with dialysis-associated anemia: North American clinical trial.
Interstitial eosinophilic aggregates in diabetic nephropathy: allergy or not?
Drug-Related Side Effects and Adverse Reactions
A pharmacovigilance study of antihypertensive medicines at a South delhi hospital.
Acute Hypotensive Transfusion Reaction With Concomitant Use of Angiotensin-Converting Enzyme Inhibitors: A Case Report and Review of the Literature.
Adverse Drug Events during AKI and Its Recovery.
Adverse drug events in ambulatory care.
Adverse drug reaction monitoring with angiotensin converting enzyme inhibitors: A prospective, randomized, open-label, comparative study.
An evaluation of risk factors for adverse drug events associated with angiotensin-converting enzyme inhibitors.
Appropriate baseline laboratory testing following ACEI or ARB initiation by Medicare FFS beneficiaries.
Change in prescription pattern as a potential marker for adverse drug reactions of angiotensin converting enzyme inhibitors.
Comparison of Clinical Factors Between Patients With Angiotensin-Converting Enzyme Inhibitor-Induced Angioedema and Cough.
Detection and prevention of medication misadventures in general practice.
Dyspnoea, asthma, and bronchospasm in relation to treatment with angiotensin converting enzyme inhibitors.
Efficacy and safety of iron sucrose for iron deficiency in patients with dialysis-associated anemia: North American clinical trial.
Highlights of the 22nd French pharmacovigilance meeting.
Idiopathic non-histaminergic angio-oedema after routine extubation successfully treated with fresh frozen plasma.
Measuring Patients' Knowledge About Adverse Effects of Angiotensin-Converting Enzyme Inhibitors.
No substantial gender differences in suspected adverse reactions to ACE inhibitors and ARBs: results from spontaneous reporting system in Campania Region.
Pattern of Angiotensin-converting enzyme inhibitors induced adverse drug reactions in South Indian teaching hospital.
Reports of hypoglycaemia associated with the use of ACE inhibitors and other drugs: a case/non-case study in the French pharmacovigilance system database.
Severe hepatic encephalopathy in a patient with liver cirrhosis after administration of angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker combination therapy: a case report.
Sex, drugs, and heart failure: a sex-sensitive review of the evidence base behind current heart failure clinical guidelines.
Syncope caused by iatrogenic hyperkalemia.
The pharmacotherapy of cirrhosis: concerns and proposed investigations and solutions.
Wound healing, angiotensin-converting enzyme inhibition, and collagen-containing products: a case study.
Duodenal Ulcer
[Effect of the angiotensin converting enzyme inhibitor, perindopril, on heart rhythm variability and adrenoreactivity in patients with ischemic heart disease associated with duodenal ulcer]
Dysgerminoma
Elevated serum angiotensin converting enzyme levels in metastatic ovarian dysgerminoma.
Dysgeusia
Drug treatment of systolic and of diastolic heart failure in elderly persons.
Epidemiology, pathophysiology, prognosis, and treatment of systolic and diastolic heart failure.
If it is not cough, it must be dysgeusia: differing adverse effects of angiotensin-converting enzyme inhibitors in the same individual.
Mortality and other outcomes of patients with coronavirus disease pneumonia admitted to the emergency department: A prospective observational Brazilian study.
Treatment of systolic and diastolic heart failure in the elderly.
Dyskinesias
Potential protective role of ACE-inhibitors and AT1 receptor blockers against levodopa-induced dyskinesias: a retrospective case-control study.
Dyslipidemias
Angina Hospitalization Rates in Women With Signs and Symptoms of Ischemia But no Obstructive Coronary Artery Disease: A Report from the WISE (Women's Ischemia Syndrome Evaluation) Study.
Angiotensin-converting enzyme and apolipoprotein B polymorphisms in coronary artery disease.
Angiotensin-converting enzyme and apolipoproteins genes polymorphism in coronary artery disease.
Angiotensin-converting enzyme genotype and peripheral arterial disease in diabetic patients.
Anti-Amoxicillin Immunoglobulin E, Histamine-2 Receptor Antagonist Therapy and Mast Cell Activation Syndrome Are Risk Factors for Amoxicillin Anaphylaxis.
Association of angiotensin I converting enzyme, angiotensin II type 1 receptor and angiotensin I converting enzyme 2 gene polymorphisms with the dyslipidemia in type 2 diabetic patients of Chinese Han origin.
Blood pressure and low-density lipoprotein cholesterol control status in Chinese hypertensive dyslipidemia patients during lipid-lowering therapy.
Cardiovascular disease due to accelerated atherosclerosis in systemic vasculitides.
Chronic kidney disease management: comparison between renal transplant recipients and nontransplant patients with chronic kidney disease.
Comparison of clinical outcomes between angiotensin-converting-enzyme inhibitors and ARBs in patients with acute myocardial infarction with dyslipidemia after a successful stent implantation.
Contemporary treatment strategies for Type 2 diabetes-related macrovascular disease.
Effect of an ongoing educational program on the use of antiplatelet drugs, beta-blockers, angiotensin-converting enzyme inhibitors, and lipid-lowering drugs in patients with coronary artery disease seen in an academic cardiology clinic.
Effect of losartan and spironolactone on triglyceride-rich lipoproteins in diabetic nephropathy.
Effect of moderate weight loss on health-related quality of life: an analysis of combined data from 4 randomized trials of sibutramine vs placebo.
Incidence and Associated Risk Factors of Chemotherapy-Induced Cardiomyopathy in the African American and Afro-Caribbean Populations.
Influenza Vaccination Reduces Dementia Risk in Chronic Kidney Disease Patients: A Population-Based Cohort Study.
Interactions of captopril and verapamil on glucose tolerance and insulin action in an animal model of insulin resistance.
Interactions of exercise training and ACE inhibition on insulin action in obese Zucker rats.
Joint effects of hypertension, smoking, dyslipidemia and obesity and angiotensin-converting enzyme DD genotype on albuminuria in Taiwanese patients with type 2 diabetes mellitus.
Link between ACE I/D Gene Polymorphism and Dyslipidemia in Diabetic Nephropathy: A Case-control Study from Hyderabad, India.
Lipoprotein glomerulopathy treated with LDL-apheresis (Heparin-induced Extracorporeal Lipoprotein Precipitation system): a case report.
Management of blood glucose in type 2 diabetes mellitus.
Mechanism of differential effects of antihypertensive agents on serum lipids.
Neurological diseases as mortality predictive factors for patients with COVID-19: a retrospective cohort study.
NO-dependent endothelial dysfunction in type II diabetes is aggravated by dyslipidemia and hypertension, but can be restored by angiotensin-converting enzyme inhibition and weight loss.
Pharmacological Management of Glucose Dysregulation in Patients Treated with Second-Generation Antipsychotics.
Pharmacotherapy for the metabolic syndrome.
Predictors of in-hospital mortality in non-ST elevation acute coronary syndrome in Thai Acute Coronary Syndrome Registry (TACSR).
Prevalence and Predictors of Statin Treatment Among Patients With Chronic Heart Failure at a Tertiary-Care Center in Thailand.
Prevalence of symptomatic peripheral arterial disease, modifiable risk factors, and appropriate use of drugs in the treatment of peripheral arterial disease in older persons seen in a university general medicine clinic.
Prognostic significance of serum cholinesterase in patients with acute decompensated heart failure: a prospective comparative study with other nutritional indices.
Relations between deletion polymorphism of the angiotensin-converting enzyme gene and insulin resistance, glucose intolerance, hyperinsulinemia, and dyslipidemia.
Renal and metabolic disorders depend on the renin-angiotensin system in Lyon hypertensive rats associated with diabetes.
Risk factors associated with the development of ischemic colitis.
Sex differences in the antihypertensive treatment and risk of uncontrolled hypertension in 5308 hypertensive patients in the United Arab Emirates.
Treatment of heart failure in older persons. Dilemmas with coexisting conditions: diabetes mellitus, chronic obstructive pulmonary disease, and arthritis.
Warfarin Use and Prevalence of Coronary Artery Calcification Assessed by Multislice Computed Tomography.
Warfarin use and the risk of valvular calcification.
[Effects of hyper- and dyslipidemias on activity of angiotensin-converting enzyme (biochemical disturbances in metabolic syndrome)]
[Fixed combination atorvastatin-perindopril (Lipercosyl®) for substitution treatment of cardiovascular risk management].
[Plasminogen activator inhibitor-1 (PAI-1) 4G/5G and angiotensin converting enzyme (ACE) I/D gene polymorphisms and fibrinolytic activity in patients with essential hypertension and dyslipidemia]
[The influence of I/D polymorphism of the angiotensin I converting enzyme (ACE) gene and 4G/5G polymorphism of plasminogen activator inhibitor (PAI-1) gene promoter on the haemostatic system in patients with essential hypertension and dyslipidemia]
Dyspnea
ACE inhibitors in congestive heart failure.
Atypical reactions associated with use of angiotensin-converting enzyme inhibitors and apheresis.
Chylothorax associated with tricuspid dysplasia and atrial septal defect in a bullmastiff.
Circulating D dimer in patients with sarcoidosis.
Clinical Features and Outcomes Associated with Angioedema in the Emergency Department.
Intermittent Superior Vena Cava Syndrome Secondary to Malignant Pericardial Mesothelioma.
Low-density lipoprotein apheresis for prevention and regression of atherosclerosis: clinical results.
Prediction and primary prevention of major vascular complications in systemic sclerosis.
Recovery from complete atrioventricular block caused by idiopathic giant cell myocarditis after corticosteroid therapy.
Sarcoidosis: a journey through 50 years.
Talc granulomatosis: laboratory findings similar to sarcoidosis.
Type IV renal tubular acidosis presenting as dyspnea in two older patients taking angiotensin-converting enzyme inhibitors.
[Allergic emergencies].
Eclampsia
Evidence-based management for preeclampsia.
Hypertension-related gene polymorphisms in pre-eclampsia, eclampsia and gestational hypertension in Black South African women.
Eczema
Predictors of Basal Cell Carcinoma in High-Risk Patients in the VATTC (VA Topical Tretinoin Chemoprevention) Trial.
Embolism
Factors associated with renal impairment in Chinese patients with non-valvular AF and without an established renal disease: a cross-sectional study.
Embolism, Fat
Evidence for angiotensin mediation of the late histopathological effects of pulmonary fat embolism: Protection by losartan in a rat model.
Encephalitis
Angiotensin Converting Enzyme Inhibitors Ameliorate Brain Inflammation Associated with Microglial Activation: Possible Implications for Alzheimer's Disease.
Encephalomyelitis
Angiotensin-Converting Enzyme Gene Polymorphism in Patients with Multiple Sclerosis from Bosnia and Herzegovina.
Effects of Inhibitors of the Renin-Angiotensin System on the Efficacy of Interferon beta-1b: A post hoc Analysis of the BEYOND Study.
Effects of the angiotensin converting enzyme inhibitor captopril on experimental autoimmune encephalomyelitis.
Modulation of the kallikrein/kinin system by the angiotensin-converting enzyme inhibitor alleviates experimental autoimmune encephalomyelitis.
Encephalomyelitis, Autoimmune, Experimental
Angiotensin-Converting Enzyme Gene Polymorphism in Patients with Multiple Sclerosis from Bosnia and Herzegovina.
Effects of Inhibitors of the Renin-Angiotensin System on the Efficacy of Interferon beta-1b: A post hoc Analysis of the BEYOND Study.
Effects of the angiotensin converting enzyme inhibitor captopril on experimental autoimmune encephalomyelitis.
Modulation of the kallikrein/kinin system by the angiotensin-converting enzyme inhibitor alleviates experimental autoimmune encephalomyelitis.
Endocarditis
Carboxypeptidase activity common to viridans group streptococci cleaves angiotensin I to angiotensin II: an activity homologous to angiotensin-converting enzyme (ACE).
Endometrial Neoplasms
Angiotensin I-converting enzyme gene insertion/deletion polymorphism and endometrial human cancer in normotensive and hypertensive women.
Evaluation of the association between angiotensin converting enzyme insertion/deletion polymorphism and the risk of endometrial cancer in and characteristics of Polish women.
[Parameters of lipid metabolism and polymorphism of apolipoprotein aI and angiotensin-converting enzyme genes in patients with endometrial carcinoma]
Endometriosis
Angiotensin I-converting enzyme ACE 2350*G and ACE-240*T-related genotypes and alleles are associated with higher susceptibility to endometriosis.
Angiotensin I-converting enzyme insertion-related genotypes and allele are associated with higher susceptibility of endometriosis and leiomyoma.
Endometriosis and RAS System Gene Polymorphisms: The Association of ACE A2350G Polymorphism with Endometriosis in Polish Individuals.
Genetic polymorphisms and endometriosis: contribution of genes that regulate vascular function and tissue remodeling.
Genetic variations in vascular endothelial growth factor but not in angiotensin I-converting enzyme genes are associated with endometriosis in Estonian women.
Endomyocardial Fibrosis
[Angiotensin converting enzyme inhibitor enalapril in the treatment of endomyocardial fibrosis in patients with lymphogranulomatosis subjected to radio- and chemotherapy]
Endotoxemia
Alternative pathways for angiotensin II production as an important determinant of kidney damage in endotoxemia.
Enterocolitis, Necrotizing
Poor Weight Recovery Between Stage 1 Palliation and Hospital Discharge for Infants with Single Ventricle Physiology: An Analysis of the National Pediatric Cardiology Quality Improvement Collaborative Phase II Dataset.
Eosinophilia
Captopril, an angiotensin-converting enzyme inhibitor, induced pulmonary infiltration with eosinophilia.
Increased prevalence of eosinophilia in a hemodialysis population: Longitudinal and case control studies.
[Blood and tissue eosinophilia in patient with angioedema caused by inhibitor of angiotensin converting enzyme (ACE)--case report and a view of literature]
[Fasciitis with eosinophilia: a possible causal role of angiotensin converting enzyme inhibitor]
Epilepsy
Angiotensin I-converting enzyme gene (I/D) polymorphism in patients with migraine.
Angiotensin-converting enzyme gene deletion polymorphism determines an increase in frequency of migraine attacks in patients suffering from migraine without aura.
Association of the insertion/deletion polymorphism of the angiotensin I-converting enzyme gene in patients of migraine with aura.
Carbamazepine inhibits angiotensin I-converting enzyme, linking it to the pathogenesis of temporal lobe epilepsy.
Influenza Vaccination Reduces Dementia Risk in Chronic Kidney Disease Patients: A Population-Based Cohort Study.
The genetics of chronic headaches.
The levels of renin-angiotensin related components are modified in the hippocampus of rats submitted to pilocarpine model of epilepsy.
The Potential Therapeutic Capacity of Inhibiting the Brain Renin-Angiotensin System in the Treatment of Co-Morbid Conditions in Epilepsy.
Epilepsy, Temporal Lobe
Carbamazepine inhibits angiotensin I-converting enzyme, linking it to the pathogenesis of temporal lobe epilepsy.
Erectile Dysfunction
ACE gene I/D and NOS3 G894T polymorphisms and response to sildenafil in men with erectile dysfunction.
Angiotensin-Converting Enzyme Polymorphism and Erectile Dysfunction Complaints in the Brazilian Population.
Association between the insertion/deletion polymorphism of the angiotensin-converting enzyme gene and erectile dysfunction in patients with metabolic syndrome.
Determination of human angiotensin converting enzyme (ACE) gene polymorphisms in erectile dysfunction: frequency differences of ACE gene polymorphisms according to the method of analysis.
Effect of sildenafil citrate on blood pressure and heart rate in men with erectile dysfunction taking concomitant antihypertensive medication. Sildenafil Study Group.
Erectile dysfunction in patients in a cardiac rehabilitation program.
Evaluation and Management of Erectile Dysfunction in the Hypertensive Patient.
Gene-polymorphisms of angiotensin converting enzyme and endothelial nitric oxide synthase in patients with erectile dysfunction.
Glu298Asp endothelial nitric oxide synthase polymorphism is a risk factor for erectile dysfunction in the Mexican Mestizo population.
I/D genetic polymorphism of angiotensin-converting enzyme: pathogenesis evaluation for erectile dysfunction by gene ontology.
Long-term effect of inhibition of the angiotensin-converting enzyme (ACE) on cavernosal perfusion in men with atherosclerotic erectile dysfunction: a pilot study.
Moringa oleifera leaf and seed inclusive diets influenced the restoration of biochemicals associated with erectile dysfunction in the penile tissue of STZ-induced diabetic male rats treated with/without Acarbose drug.
Possible role of bradykinin and angiotensin II in the regulation of penile erection and detumescence.
Role of some vasoactive mediators in patients with erectile dysfunction: their relationship with angiotensin-converting enzyme and growth hormone.
Synergistic Effects of ACE Insertion/Deletion and GNB3 C825T Polymorphisms on the Efficacy of PDE-5 Inhibitor in Patients with Pulmonary Hypertension.
The insertion/deletion (I/D) polymorphism in the angiotensin-converting enzyme gene and erectile dysfunction risk: a meta-analysis.
Upregulation of the angiotensin-converting enzyme 2-angiotensin-(1-7)-Mas receptor axis by a combination of Yinyanghuo (Herba Epimedii Brevicornus) and Cheqianzi (Semen Plantaginis) improves erectile function in spontaneously hypertensive rats.
[The role of angiotensin-converting enzyme gene polymorphism in development of erectile dysfunction in patients with metabolic syndrome].
Erythema
Angiotensin-converting enzyme in newly detected sarcoidosis. With special reference to enzyme levels in patients with erythema nodosum.
Enalapril-associated erythema and vasculitis.
Systemic lupus erythematosus presenting as erythema annulare centrifugum.
Erythema Nodosum
Angiotensin-converting enzyme in newly detected sarcoidosis. With special reference to enzyme levels in patients with erythema nodosum.
Assessment of serum angiotensin-converting enzyme as a marker of activity in sarcoidosis: a study of 31 patients with erythema nodosum.
Characteristics of patients presenting with erythema nodosum and sarcoidosis.
Sarcoidosis and MIF gene polymorphism: a case-control study in an Irish population.
The level of angiotensin-converting enzyme as indicator of 2-year prognosis in untreated pulmonary sarcoidosis without erythema nodosum.
The relationship between disease duration and noninvasive pulmonary explorations in sarcoidosis with erythema nodosum.
[Modern criteria of sarcoidosis activity and approaches to glucocorticoid therapy]
Esophageal and Gastric Varices
Effect of enalapril treatment and sclerotherapy of esophageal varices on hepatic hemodynamics in portal hypertension.
Effects of angiotensin-converting enzyme inhibitors and sclerotherapy on portal hemodynamics in patients with portal hypertension.
Variation at the Angiotensin-converting enzyme and endothelial nitric oxide synthase genes is associated with the risk of esophageal varices among patients with alcoholic cirrhosis.
[Is it possible to predict a decrease in portal pressure after administration of ACE inhibitors?]
Esophageal Squamous Cell Carcinoma
Prognostic impact of renin-angiotensin system blockade in esophageal squamous cell carcinoma.
Essential Hypertension
-
A 24-week dose-titration study of the angiotensin-converting enzyme inhibitor imidapril in the treatment of mild-to-moderate essential hypertension in the elderly.
A common haplotype on methylenetetrahydrofolate reductase gene modifies the effect of angiotensin-converting enzyme inhibitor on blood pressure in essential hypertension patients--a family-based association study.
A comparative evaluation of therapeutic effects of once a day dose of losartan potassium versus enalapril maleate in mild to moderate essential hypertension.
A comparison of angiotensin-converting enzyme inhibitors, calcium antagonists, beta-blockers and diuretic agents on reactive hyperemia in patients with essential hypertension: a multicenter study.
A comparison of enalapril and metoprolol as initial therapy for mild to moderate hypertension.
A comparison of the antihypertensive effectiveness of a combination of moexipril or sustained-release verapamil with low-dose hydrochlorothiazide.
A deletion in the angiotensin converting enzyme (ACE) gene is common among African Americans with essential hypertension.
A discrepancy between the effects of a single oral dose of captopril on blood pressure, plasma renin activity, and serum angiotensin-converting enzyme levels.
A double blind comparison of the effects of amlodipine and enalapril on insulin sensitivity in hypertensive patients.
A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension.
A meta-analytical comparison of atenolol with angiotensin-converting enzyme inhibitors on arterial stiffness, peripheral blood pressure and heart rate in hypertensive patients.
A parallel study of enalapril and captopril and 1 year of experience with enalapril treatment in moderate-to-severe essential hypertension.
A postmarketing surveillance evaluation of quinapril in 3742 Canadian hypertensive patients: the ACCEPT Study. Accupril Canadian Clinical Evaluation and Patient Teaching.
A retrospective electronic chart review of blood pressure changes in elderly patients treated with amlodipine or an angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker.
A single-blind study of doxazosin in the treatment of essential hypertension when added to nonresponders to angiotensin-converting enzyme inhibitor therapy.
A study of the effects of delapril, a new angiotensin converting enzyme inhibitor, on the diurnal variation of arterial pressure in patients with essential hypertension using indirect and direct arterial pressure monitoring methods.
A survey of clinician attitudes and management practices in hypertension.
A systematic review and network meta-analysis of the comparative efficacy of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in hypertension.
A twelve-week, multicenter, randomized, double-blind, parallel-group, noninferiority trial of the antihypertensive efficacy and tolerability of imidapril and candesartan in adult patients with mild to moderate essential hypertension: the Iberian Multicenter Imidapril Study on Hypertension (IMISH).
Absence of linkage between the angiotensin converting enzyme locus and human essential hypertension.
ACE inhibitors: antihypertensive treatment and renal function.
Acute antihypertensive effect of angiotensin converting enzyme inhibition and calcium entry blockade.
Acute effect of captopril on serum lipid peroxides level in hypertensive patients.
Acute effects of angiotensin-converting enzyme inhibitor on erythrocyte sodium ion transport in essential hypertension.
Acute effects of the new oral angiotensin converting enzyme inhibitor 1-(D-3-acetylthio-2-methylpropanoyl)-L-prolyl-L-phenylalanine (Alacepril) in essential hypertension.
Adaptive and genetic alterations of the renin angiotensin system in cardiac hypertrophy and failure.
Additive effect of isradipine in combination with captopril in hypertensive patients.
Additive hypotensive effect of angiotensin-converting enzyme inhibition and angiotensin-receptor antagonism in essential hypertension.
Adverse effects of antihypertensive drug therapy on glucose intolerance.
Age- and gender-dependent association of the angiotensin-converting enzyme gene with essential hypertension in a Chinese population.
Airway and cough responsiveness and exhaled nitric oxide in non-smoking patients with stable chronic heart failure.
Albumin excretion rate and metabolic modifications in patients with essential hypertension. Effects of two angiotensin converting enzyme inhibitors.
Alcohol satiety, hypertension and the renin-angiotensin system.
Aldosterone blockers (mineralocorticoid receptor antagonism) and potassium-sparing diuretics.
Aliskiren.
alpha-adducin and angiotensin I-converting enzyme polymorphisms in essential hypertension.
An open multicenter study to assess the long-term efficacy, tolerance, and safety of the oral angiotensin converting enzyme inhibitor ramipril in patients with mild to moderate essential hypertension.
Angiotensin converting enzyme during acute and chronic enalapril therapy in essential hypertension.
Angiotensin converting enzyme gene I/D polymorphism in essential hypertension and nephroangiosclerosis.
Angiotensin Converting Enzyme Gene Insertion/Deletion Polymorphism Is Not Responsible for Antihypertensive Therapy Induced New Onset of Type 2 Diabetes in Essential Hypertension.
Angiotensin converting enzyme gene polymorphism (insertion/deletion) and hypertension in adult Asian Indians: a population-based study from Calcutta, India.
Angiotensin converting enzyme gene polymorphism and activity in Turkish patients with essential hypertension.
Angiotensin converting enzyme gene polymorphism in essential hypertension based on ambulatory blood pressure monitoring.
Angiotensin converting enzyme gene polymorphism is not related to essential hypertension in a Greek population.
Angiotensin converting enzyme inhibition and angiotensin II AT1-receptor blockade reduce the levels of asymmetrical N(G), N(G)-dimethylarginine in human essential hypertension.
Angiotensin converting enzyme inhibition and calcium channel blockade as primary antihypertensive therapy.
Angiotensin converting enzyme inhibition corrects Na+/H+ exchanger overactivity in essential hypertension.
Angiotensin converting enzyme inhibition reduces ACTH release due to hypoglycaemia.
Angiotensin converting enzyme inhibition, parasympathetic activity and exercise in essential hypertension.
Angiotensin converting enzyme inhibition, pulse wave velocity and ambulatory blood pressure measurements in essential hypertension.
Angiotensin I converting enzyme (ACE) gene polymorphism and essential hypertension in Japan. Ethnic difference of ACE genotype.
Angiotensin I converting enzyme activity in hypertension. Relationship to blood pressure, renin-sodium profiles, and antihypertensive therapy.
Angiotensin I-converting enzyme (ACE): estimation of DNA haplotypes in unrelated individuals using denaturing gradient gel blots.
Angiotensin I-converting enzyme and angiotensinogen gene interaction and prediction of essential hypertension.
Angiotensin I-converting enzyme gene polymorphism and acute response to captopril in essential hypertension.
Angiotensin I-converting enzyme gene polymorphism and salt sensitivity in essential hypertension.
Angiotensin II type 1 receptor blockade: a new development in cardiovascular pharmacology.
Angiotensin-converting enzyme (ACE) haplotypes and cyclosporine A (CsA) response: a model of the complex relationship between ACE quantitative trait locus and pathological phenotypes.
Angiotensin-converting enzyme activity in renal disorders: influence of disease pattern, hemodialysis and transplantation.
Angiotensin-converting enzyme and metals in untreated essential hypertension.
Angiotensin-converting enzyme gene 2350 G/A polymorphism and susceptibility to atrial fibrillation in Han Chinese patients with essential hypertension.
Angiotensin-converting enzyme gene 2350 G/A polymorphism is associated with left ventricular hypertrophy but not essential hypertension.
Angiotensin-converting enzyme gene insertion/deletion polymorphism frequency in normotensive children with a positive family history of essential hypertension.
Angiotensin-converting enzyme gene polymorphism and geometric patterns of hypertensive left ventricular hypertrophy.
Angiotensin-converting enzyme gene polymorphism and its association with essential hypertension in a Tibetan population.
Angiotensin-converting enzyme gene polymorphism in essential hypertensive patients in Japanese population.
Angiotensin-converting enzyme gene polymorphisms, blood pressure and pulse pressure in subjects with essential hypertension in a South Sulawesi Indonesian population.
Angiotensin-converting enzyme inhibition in patients with essential hypertension.
Angiotensin-converting enzyme inhibition, but not calcium antagonism, improves a response of the renal vasculature to L-arginine in patients with essential hypertension.
Angiotensin-converting enzyme inhibition, catecholamines and hemodynamics in essential hypertension.
Angiotensin-converting enzyme inhibitor versus calcium antagonist in the treatment of hypertension.
Angiotensin-converting enzyme inhibitors in essential hypertension.
Angiotensin-converting enzyme inhibitors in hypertension. A dozen years of experience.
Angiotensin-converting enzyme inhibitors in the treatment of mild to moderate essential hypertension.
Angiotensin-converting enzyme inhibitors reduce mortality compared to angiotensin receptor blockers: Systematic review and meta-analysis.
Angiotensin-converting enzyme inhibitory activity of Lactobacillus helveticus strains from traditional fermented dairy foods and antihypertensive effect of fermented milk of strain H9.
Angiotensin-converting enzyme polymorphism and essential hypertension.
Antihypertensive drugs and reversing of endothelial dysfunction in hypertension.
Antihypertensive effect of enalapril as first-step treatment of mild and moderate uncomplicated essential hypertension. Evaluation by two methods of blood pressure measurement.
Antihypertensive effect of the oral angiotensin I-converting enzyme inhibitor in long-term treatment of hypertensive patients.
Antihypertensive effectiveness of a very low fixed-dose combination of moexipril and hydrochlorothiazide.
Antihypertensive effects of fasidotril, a dual inhibitor of neprilysin and angiotensin-converting enzyme, in rats and humans.
Antihypertensive efficacy and safety of olmesartan medoxomil and ramipril in elderly mild to moderate essential hypertensive patients with or without metabolic syndrome: a pooled post hoc analysis of two comparative trials.
Antihypertensive efficacy and safety of perindopril in mild-to-moderate essential hypertension: results of a double-blind multicenter study versus atenolol.
Antihypertensive efficacy and tolerability of low-dose perindopril/indapamide combination compared with losartan in the treatment of essential hypertension.
Antihypertensive efficacy of telmisartan vs ramipril over the 24-h dosing period, including the critical early morning hours: a pooled analysis of the PRISMA I and II randomized trials.
Antihypertensive efficacy, tolerance, and safety of ramipril in young vs. old patients: a retrospective study.
Antihypertensive treatment using calcium antagonists in combination with captopril rather than diuretics.
Antihypertensive, enzymatic, and hormonal activity of cilazapril, a new angiotensin-converting enzyme inhibitor in patients with mild to moderate essential hypertension.
Antithrombotic effect of captopril and enalapril in young rats.
Aprocitentan (a Dual Endothelin-Receptor Antagonist) for Treatment-Resistant Hypertension.
Assessment of the acute arterial effects of converting enzyme inhibition in essential hypertension: a double-blind, comparative and crossover study.
Assessment of the efficacy, tolerance, and safety of ramipril in diabetic patients with mild-to-moderate hypertension: a retrospective analysis.
Association analysis of a polymorphism of the angiotensin converting enzyme gene with essential hypertension in the Japanese population.
Association between angiotensin converting enzyme gene polymorphism and essential hypertension: A systematic review and meta-analysis.
Association between polymorphism of the angiotensin I converting enzyme gene and hypertension in Turkish type II diabetic patients.
Association between the angiotensin-converting enzyme gene insertion/deletion polymorphism and essential hypertension in young Pakistani patients.
Association of a deletion polymorphism of the angiotensin-converting enzyme gene with left-ventricular hypertrophy in Japanese women with essential hypertension; multicenter study of 1,919 subjects.
Association of a polymorphism of the angiotensin I-converting enzyme gene with essential hypertension.
Association of ACE genotype and predominantly diastolic hypertension: a preliminary study.
Association of ACE, ACE2 and UTS2 polymorphisms with essential hypertension in Han and Dongxiang populations from north-western China.
Association of Angiotensin converting enzyme (insertion/deletion) gene polymorphism with essential hypertension in northern Indian subjects.
Association of angiotensin converting enzyme gene insertion/deletion polymorphism with essential hypertension in south Indian population.
Association of angiotensin-converting enzyme and angiotensin-converting enzyme-2 gene polymorphisms with essential hypertension in the population of Odisha, India.
Association of angiotensin-converting enzyme gene polymorphism with pulse pressure and its interaction with obesity status in Heilongjiang province.
Association of angiotensin-converting-enzyme gene polymorphism with the depressor response to mild exercise therapy in patients with mild to moderate essential hypertension.
Association of angiotensinogen gene M235T and angiotensin-converting enzyme gene I/D polymorphisms with essential hypertension in Han Chinese population: a meta-analysis.
Association of essential hypertension in elderly Japanese with I/D polymorphism of the angiotensin-converting enzyme (ACE) gene.
Association of insertion/deletion polymorphism of angiotensin-converting enzyme gene with essential hypertension and type 2 diabetes mellitus in Malaysian subjects.
Association of the angiotensin-converting enzyme (ACE) gene G2350A dimorphism with essential hypertension.
Association study of angiotensin converting enzyme gene polymorphism with elderly diabetic hypertension and lipids levels.
Associations of ACE Gene Insertion/Deletion Polymorphism, ACE Activity, and ACE mRNA Expression with Hypertension in a Chinese Population.
Atrial and brain natriuretic peptides: secretion during exercise in patients with essential hypertension and modulation by acute angiotensin-converting enzyme inhibition.
Beneficial effects of combination therapy with angiotensin II receptor blocker and angiotensin-converting enzyme inhibitor on vascular endothelial function.
Blood pressure effects of acute intravenous renin or oral angiotensin converting enzyme inhibition in essential hypertension.
Blood pressure response of nephrectomized subjects and patients with essential hypertension to ramipril: indirect evidence that inhibition of tissue angiotensin converting enzyme is important.
Blood pressure response to angiotensin converting enzyme inhibitor in essential hypertension: its relation to the renin status and natriuresis during acute sodium loading.
Brain natriuretic peptide as a marker for hypertensive left ventricular hypertrophy: changes during 1-year antihypertensive therapy with angiotensin-converting enzyme inhibitor.
Captopril and nifedipine in combination for moderate to severe essential hypertension.
Captopril attenuates reflex adrenergic response in essential hypertension.
Captopril, an orally active angiotensin I converting enzyme inhibitor in the treatment of renovascular and essential hypertension.
Captopril. An update of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure.
Cardiac effects of ACE inhibition.
Cardiovascular effects and regional blood flow distribution associated with angiotensin converting enzyme inhibition (captopril) in essential hypertension.
Central nervous system considerations in the use of beta-blockers, angiotensin-converting enzyme inhibitors, and thiazide diuretics in managing essential hypertension.
Changes in left ventricular mass during treatment with minoxidil and cilazapril in hypertensive patients with left ventricular hypertrophy.
Chronic effects of direct vasodilation (pinacidil), alpha-adrenergic blockade (prazosin) and angiotensin-converting enzyme inhibition (captopril) in systemic hypertension.
Chronotherapy With the Angiotensin-Converting Enzyme Inhibitor Ramipril in Essential Hypertension. Improved Blood Pressure Control With Bedtime Dosing.
Clinical effects of eplerenone, a selective aldosterone blocker, in Japanese patients with essential hypertension.
Clinical evaluation of the captopril screening test for primary aldosteronism.
Clinical implications of the molecular biology of the renin-angiotensin system.
Clinical pharmacodynamic studies with cilazapril and a combination of cilazapril and propranolol.
Clinical pharmacokinetics and efficacy of renin inhibitors.
Clinical pharmacokinetics and selective pharmacodynamics of new angiotensin converting enzyme inhibitors: an update.
Combination of an ACE Inhibitor and Indapamide Improves Blood Pressure Control, but Attenuates the Beneficial Effects of ACE Inhibition on Plasma Adiponectin in Patients With Essential Hypertension.
Combination of hydrochlorothiazide or benazepril with valsartan in hypertensive patients unresponsive to valsartan alone.
Combination therapy with an angiotensin converting enzyme inhibitor and an angiotensin-II receptor antagonist for refractory essential hypertension.
Combined enalapril and felodipine extended release (ER) for systemic hypertension. Enalapril-Felodipine ER Factorial Study Group.
Combined inhibition of neutral endopeptidase and angiotensin-converting enzyme by sampatrilat in essential hypertension.
Combined treatment of severe essential hypertension with the new angiotensin converting enzyme inhibitor ramipril.
Common genetic variations of the renin-angiotensin-aldosterone system and response to acute angiotensin I-converting enzyme inhibition in essential hypertension.
Comparative double-blind study of ramipril and captopril in mild to moderate essential hypertension.
Comparative efficacy of lisinopril and nifedipine retard in essential hypertension: a double-blind, placebo-controlled trial.
Comparative renal and cardiac effects of tertatolol and enalapril in essential hypertension.
Comparative trial of lisinopril and nifedipine in mild to severe essential hypertension.
Comparison of angiotensin II receptor antagonists.
Comparison of blood pressure and angiotensin responses to the renin inhibitor Ro 42-5892 and the angiotensin converting enzyme inhibitor enalapril in essential hypertension.
Comparison of captopril (SQ 14225) with hydrochlorothiazide in the treatment of essential hypertension.
Comparison of effects of angiotensin I-converting enzyme inhibition and beta-blockade for 2 years on function of small arteries from hypertensive patients.
Comparison of efficacy and side effects of combination therapy of angiotensin-converting enzyme inhibitor (benazepril) with calcium antagonist (either nifedipine or amlodipine) versus high-dose calcium antagonist monotherapy for systemic hypertension.
Comparison of enalapril and hydrochlorothiazide in mild hypertension and changes in plasma lipid concentrations during therapy.
Comparison of moexipril, a new ACE inhibitor, to verapamil-SR as add-on therapy to low dose hydrochlorothiazide in hypertensive patients.
Comparison of once-daily captopril or enalapril in mild essential hypertension.
Comparison of the angiotensin II antagonist losartan with the angiotensin converting enzyme inhibitor enalapril in patients with essential hypertension.
Conjugated Linoleic Acid Supplementation Enhances Antihypertensive Effect of Ramipril in Chinese Patients With Obesity-Related Hypertension.
Contrasting effect of antihypertensive treatment on the renal response to L-arginine.
Contrasting renal haemodynamic responses to the angiotensin converting enzyme inhibitor enalapril and the beta-adrenergic antagonist metoprolol in essential hypertension.
Contribution of angiotensin I converting enzyme gene polymorphism and angiotensinogen gene polymorphism to blood pressure regulation in essential hypertension.
Control of essential hypertension with captopril, an angiotensin converting enzyme inhibitor.
Correlation between angiotensin converting enzyme inhibition and the acute hypotensive response to MK 421 in essential hypertension.
Correlation of Angiotensin-converting enzyme gene polymorphism with effect of antihypertensive therapy by Angiotensin-converting enzyme inhibitor.
Correlation of renin angiotensin system (RAS) candidate gene polymorphisms with response to Ramipril in patients with essential hypertension.
Cost Effectiveness of ACEIs/ARBs versus Amlodipine Monotherapies: A Single-Center Retrospective Chart Review.
Cough induced by angiotensin-converting-enzyme inhibitors: Airway responses to inhalation of methacholine in patients who have essential hypertension.
Crossover comparison of the effects of enalapril and captopril on potassium homeostasis in patients with mild hypertension.
DD genotype of the angiotensin I-converting enzyme gene is a risk factor for early onset of essential hypertension in Japanese patients.
Deletion allele of angiotensin-converting enzyme gene increases risk of essential hypertension in Japanese men : the Suita Study.
Deletion polymorphism in the angiotensin-converting enzyme gene is not associated with hypertension in a Gulf Arab population.
Deletion polymorphism in the gene for angiotensin-converting enzyme is associated with essential hypertension in men born during the Pacific War.
Development of One-Step Tetra-primer ARMS-PCR for Simultaneous Detection of the Angiotensin Converting Enzyme (ACE) I/D and rs4343 Gene Polymorphisms and the Correlation with CAD Patients.
Diabetes mellitus, the renin-angiotensin system, and angiotensin-converting enzyme inhibition.
Dietary protein restriction in combination with angiotensin converting enzyme inhibitor improves insulin resistance in patients with chronic renal disease.
Dietary sodium, aldosterone, and left ventricular mass changes during long-term inhibition of the renin-angiotensin system.
Differences in response to the peptidyldipeptide hydrolase inhibitors SQ 20,881 and SQ 14,225 in normal-renin essential hypertension.
Different aortic reflection wave responses following long-term angiotensin-converting enzyme inhibition and beta-blocker in essential hypertension.
Differential effects of a long-acting angiotensin converting enzyme inhibitor (temocapril) and a long-acting calcium antagonist (amlodipine) on ventricular ectopic beats in older hypertensive patients.
Differentiation between renovascular and essential hypertension by means of changes in single kidney 99mTc-DTPA clearance induced by angiotensin-converting enzyme inhibition.
Disparate cardiac effects of afterload reduction in hypertension.
Disparate effects of ACE-inhibitors and calcium antagonists on left ventricular structure and function in essential hypertension.
Disparate structural effects on left and right ventricles by angiotensin-converting enzyme inhibitors and calcium antagonists in essential hypertension.
Does the combination of cilazapril and propranolol lower blood pressure at rest and during exercise more pronouncedly than either of the two components given alone?
Dopaminergic control of aldosterone secretion in hypertensive patients chronically treated with an angiotensin converting enzyme inhibitor.
Dose-finding study of cilazapril (Inhibace) in patients with uncomplicated essential hypertension.
Dose-response relation of the angiotensin converting enzyme inhibitor ramipril in mild to moderate essential hypertension.
Dose-response studies with benazepril in mild to moderate hypertension.
Double-blind comparison of captopril and enalapril in mild to moderate hypertension.
Double-blind crossover study of the interaction between perindopril and amlodipine on blood pressure and hormones related to fluid and electrolyte balance in patients with essential hypertension.
Economics of suboptimal drug use: cost-savings of using JNC-recommended medications for management of uncomplicated essential hypertension.
Effect of 24-week treatment with telmisartan on myocardial structure and function: relationship to insertion/deletion polymorphism of the angiotensin-converting enzyme gene.
Effect of a new angiotensin converting enzyme inhibitor, cilazapril, on circulating atrial natriuretic factor during exercise in patients with essential hypertension.
Effect of alacepril on blood pressure and neurohumoral factors at rest and during dynamic exercise in patients with essential hypertension.
Effect of amlodipine and lisinopril on microalbuminuria in patients with essential hypertension: A prospective study.
Effect of angiotensin converting enzyme inhibition on blood pressure, plasma renin activity and plasma aldosterone in essential hypertension.
Effect of angiotensin converting enzyme inhibition on cardiovascular regulation during reflex sympathetic activation in sodium-replete patients with essential hypertension.
Effect of angiotensin-converting enzyme inhibition on Na+/H(+)-exchange and Ca(2+)-efflux in human erythrocytes.
Effect of atenolol and ramipril on regression of left ventricular hypertrophy: comparative echocardiographic assessment.
Effect of benazepril on endothelial function in previously untreated hypertensive patients.The Working Group of Cardiology of the Academic Committee of Veszprém, Hungary.
Effect of captopril (SQ 14225) on blood pressure, plasma renin activity and angiotensin I converting enzyme activity.
Effect of captopril on plasma prolactin in patients with essential hypertension.
Effect of captopril on renal vascular tone in patients with essential hypertension.
Effect of captopril on serum angiotensin converting enzyme and blood pressure in hypertensive patients.
Effect of chronic ACE inhibition on glucose tolerance and insulin sensitivity in hypertensive type 2 diabetic patients.
Effect of chronic angiotensin converting enzyme inhibition on sympathetic nerve traffic and baroreflex control of the circulation in essential hypertension.
Effect of chronic inhibition of angiotensin converting enzyme on baroreceptor reflex in essential hypertension.
Effect of chronic treatment with enalapril on glucose tolerance and serum insulin in non-insulin-resistant Japanese patients with essential hypertension.
Effect of cis-unsaturated fatty acids, prostaglandins, and free radicals on angiotensin-converting enzyme activity in vitro.
Effect of converting enzyme inhibitor captopril on T cell functions in essential hypertension.
Effect of dietary sodium on angiotensin-converting enzyme (ACE) inhibition and the acute hypotensive effect of enalapril (MK-421) in essential hypertension.
Effect of irbesartan monotherapy compared with ACE inhibitors and calcium-channel blockers on patient compliance in essential hypertension patients: A multicenter, open-labeled, three-armed study.
Effect of irbesartan monotherapy compared with ACE inhibitors and calcium-channel blockers on patient compliance in essential hypertension patients: a multicenter, open-labeled, three-armed study.
Effect of long-term hormone replacement therapy on angiotensin-converting enzyme activity and bradykinin in postmenopausal women with essential hypertension and normotensive postmenopausal women.
Effect of manidipine and delapril on insulin sensitivity in type 2 diabetic patients with essential hypertension.
Effect of quinapril on the albumin excretion rate in patients with mild to moderate essential hypertension. Multicenter Study Group.
Effect of ramipril, a new angiotensin converting enzyme inhibitor, on diurnal variations of blood pressure in essential hypertension.
Effect of the angiotensin-converting enzyme inhibitor imidapril on reactive hyperemia in patients with essential hypertension: relationship between treatment periods and resistance artery endothelial function.
Effect of the angiotensin-converting enzyme inhibitor perindopril on haemostasis in essential hypertension.
Effects of ACE inhibition on renal haemodynamics in essential hypertension and hypertension associated with chronic renal failure.
Effects of amlodipine and fosinopril on heart rate variability and left ventricular mass in mild-to-moderate essential hypertension.
Effects of an angiotensin-converting enzyme inhibitor, alacepril, on cardiovascular and sympathetic nervous responses to mental stress in patients with essential hypertension.
Effects of angiotensin converting enzyme inhibitor and calcium antagonist on endothelial function in patients with essential hypertension.
Effects of angiotensin converting enzyme inhibitors on left ventricular hypertrophy.
Effects of angiotensin-converting enzyme inhibition on blood pressure and plasma renin activity in essential hypertension.
Effects of angiotensin-converting enzyme inhibition on left ventricular geometric patterns in patients with essential hypertension.
Effects of Angiotensin-Converting Enzyme Inhibition on Leptin and Adiponectin Levels in Essential Hypertension.
Effects of angiotensin-converting enzyme inhibition versus beta-adrenergic blockade on aortic stiffness in essential hypertension.
Effects of angiotensin-converting enzyme inhibitors on glucose and lipid metabolism in essential hypertension.
Effects of antihypertensive agents, alpha receptor blockers, beta blockers, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers and calcium channel blockers, on oxidative stress.
Effects of antihypertensive drugs on the circadian blood pressure profile.
Effects of antihypertensive treatment on vascular remodeling in essential hypertensive patients.
Effects of benazepril and hydrochlorothiazide, given alone and in low- and high-dose combinations, on blood pressure in patients with hypertension.
Effects of captopril and nitrendipine on the response to acute volume expansion in essential hypertension.
Effects of chronic angiotensin converting enzyme inhibition on glucose tolerance and insulin sensitivity in essential hypertension.
Effects of cilazapril on vascular structure and function in essential hypertension.
Effects of combination therapy with an angiotensin converting enzyme inhibitor and thiazide diuretic on insulin action in essential hypertension.
Effects of combined statin and ACE inhibitor therapy on endothelial function and blood pressure in essential hypertension - a randomised double-blind, placebo controlled crossover study.
Effects of Dexmedetomidine and ACE Genotype on Cardiovascular Response During the Decannulation Period of General Anesthesia in Patients With Essential Hypertension.
Effects of enalapril and hydrochlorothiazide on blood pressure, renin-angiotensin system, and atrial natriuretic factor in essential hypertension: a double blind factorial cross-over study.
Effects of enalapril on serum lipoproteins in mild essential hypertension.
Effects of enalapril, a new converting enzyme inhibitor, in hypertension.
Effects of fosenopril, a once-daily angiotensin-converting enzyme inhibitor, on resting and exercise-induced changes of blood pressure, hormonal variables, and plasma potassium in essential hypertension.
Effects of fosinopril on cardiac function in patients with hypertension. Radionuclide assessment of left ventricular systolic and diastolic performance.
Effects of hydrochlorothiazide on oxidative stress and pulse pressure in hypertensive patients with chronic stroke: the EMINENT study.
Effects of lisinopril and bisoprolol on lipoprotein metabolism in patients with mild-to-moderate essential hypertension.
Effects of lisinopril on stress-induced peak blood pressure and sodium excretion: a double-blind controlled study.
Effects of medium-term antihypertensive therapy on haemostatic parameters in patients with essential hypertension.
Effects of perindopril and hydrochlorothiazide on selected indices of oxidative stress in the blood of elderly patients with essential hypertension.
Effects of perindopril on glucose and lipid metabolism in patients with mild-to-moderate essential hypertension and glucose intolerance.
Effects of perindopril treatment on hemostatic function in patients with essential hypertension in relation to angiotensin converting enzyme (ACE) and plasminogen activator inhibitor-1 (PAI-1) gene polymorphisms.
Effects of quinapril hydrochloride in patients with essential hypertension and impaired renal function.
Effects of spironolactone and angiotensin-converting enzyme inhibitor on left ventricular hypertrophy in patients with essential hypertension.
Effects of the angiotensin converting enzyme inhibitor, benazepril, on the sino-aortic baroreceptor heart rate reflex.
Effects of the angiotensin converting enzyme inhibitor, captopril, in essential hypertension.
Effects of the angiotensin-converting enzyme (ACE) inhibitor perindopril on endothelial and platelet functions in essential hypertension.
Effects of the converting enzyme inhibitor quinapril (CI-906) on blood pressure, renin-angiotensin system, and prostanoids in essential hypertension.
Effects of the new angiotensin-converting enzyme inhibitor, ramipril, in patients with essential hypertension.
Effects of the new oral angiotensin converting enzyme inhibitor 2-[N-[(S)-1-ethoxycarbonyl-3-phenylpropyl]-L-alanyl]-(1S,3S,5S)-2- azabicyclo[3.3.0]octane-3-carboxylic acid (Hoe 498) in essential hypertension.
Effects of treatment with captopril on exercise tolerance and plasma catecholamines in elderly hypertensives.
Effects of valsartan and perindopril combination therapy on left ventricular hypertrophy and aortic arterial stiffness in patients with essential hypertension.
Effects of various doses of captopril on plasma aldosterone concentrations in patients with essential hypertension.
Effects of verapamil and trandolapril in the treatment of hypertension. Trandolapril Study Group.
Effects on insulin action of adding low-dose thiazide to Angiotensin-converting enzyme inhibitor in essential hypertension.
Efficacy and safety of a new angiotensin-converting enzyme inhibitor, ramipril, vs. enalapril in essential hypertension: a multicenter trial.
Efficacy and safety of cilazapril, a new angiotensin-converting enzyme inhibitor.
Efficacy and safety of lisinopril in older patients with essential hypertension.
Efficacy and Safety of Quinapril 40mg Once Daily as Monotherapy for Patients with Poorly Controlled Hypertension : The EUREKA Study.
Efficacy and tolerability of cilazapril in patients with essential hypertension.
Efficacy and tolerability of the fixed lercanidipine-enalapril combination in the treatment of patients with essential hypertension.
Elevated angiotensin-I-converting enzyme (ACE) in patients with essential hypertension.
Enalapril improves systemic and renal hemodynamics and allows regression of left ventricular mass in essential hypertension.
Enalapril in essential hypertension: a comparative study with propranolol. Enalapril in Hypertension Study Group (UK).
Enalaprilat: an intravenous substitute for oral enalapril therapy. Humoral and pharmacokinetic effects.
Essential hypertension: effect of an oral inhibitor of angiotensin-converting enzyme.
Evaluation of amlodipine, lisinopril, and a combination in the treatment of essential hypertension.
Evaluation of cilazapril versus captopril in patients with mild to moderate essential hypertension.
Evaluation of the efficacy and tolerability of the combination delapril plus indapamide in the treatment of mild to moderate essential hypertension: a randomised, multicentre, controlled study.
Evidence for benefits of perindopril in hypertension and its complications.
Evidence for involvement of the type 1 angiotensin II receptor locus in essential hypertension.
Expression of angiotensin-converting enzyme gene in whole blood in patients with essential hypertension.
Fixed combination of perindopril and indapamide at low dose improves endothelial function in essential hypertensive patients after acute administration.
Fixed combination verapamil SR/trandolapril.
Fixed low-dose combination of an angiotensin converting enzyme inhibitor and a calcium channel blocker drug in the treatment of essential hypertension.
Fixed-dose combination of zofenopril plus hydrochlorothiazide vs. irbesartan plus hydrochlorothiazide in hypertensive patients with established metabolic syndrome uncontrolled by previous monotherapy. The ZAMES study (Zofenopril in Advanced MEtabolic Syndrome).
Fosenopril, an angiotensin-converting enzyme inhibitor, and propranolol: comparative effects at rest and exercise on blood pressure, hormonal variables, and plasma potassium in essential hypertension.
Fosinopril versus enalapril in the treatment of hypertension: a double-blind study in 195 patients.
Gene polymorphisms of the renin-angiotensin system in essential hypertension.
Genetic analysis of essential hypertension in Japanese populations.
Genetic polymorphisms and endothelial dysfunction in patients with essential hypertension: a cross-sectional case-control study.
Genetic variants of the renin-angiotensin system and ambulatory blood pressure in essential hypertension.
Genome-wide response to antihypertensive medication using home blood pressure measurements: a pilot study nested within the HOMED-BP study.
Glucose tolerance and insulin secretion in essential hypertension after treatment with an angiotensin converting enzyme inhibitor.
GNB3 gene C825T and ACE gene I/D polymorphisms in essential hypertension in a Kazakh genetic isolate.
Haemodynamic and clinical effects of long-term treatment of essential hypertension with captopril.
Hemodynamic and renal function in essential hypertension during treatment with enalapril.
Hemodynamic effects of angiotensin-converting enzyme inhibitors in essential hypertension: a review.
Hemodynamic effects of quinapril, a novel angiotensin-converting enzyme inhibitor.
High dose enalapril impairs the response to erythropoietin treatment in haemodialysis patients.
High serum level of procollagen type III amino-terminal peptide contributes to the efficacy of spironolactone and angiotensin-converting enzyme inhibitor therapy on left ventricular hypertrophy in essential hypertensive patients.
Higher small arterial elasticity in hypertensive patients treated with angiotensin II receptor blockers.
Humoral and blood pressure effects of the angiotensin converting enzyme inhibitor ramipril in essential hypertension.
Humoral and hemodynamic effects of increasing doses of captopril in patients with essential hypertension.
Hypertension as a low-grade systemic inflammatory condition that has its origins in the perinatal period.
Hypotensive effects and influence on serum lipids of SQ29,852, a new angiotensin converting enzyme inhibitor, in patients with essential hypertension: a comparison with atenolol.
Imidapril hydrochloride in essential hypertension: a double-blind comparative study using enalapril maleate as a control.
Immediate and short-term cardiovascular effects of fosinopril, a new angiotensin-converting enzyme inhibitor, in patients with essential hypertension.
Immediate regional blood flow distribution following angiotensin converting enzyme inhibition in patients with essential hypertension.
Impact of angiotensin converting enzyme inhibition on the haemodynamic profile during laboratory stress tests.
Impact of obesity and nitric oxide synthase gene G894T polymorphism on essential hypertension.
Impaired renal haemodynamic response to amino acid infusion in essential hypertension during angiotensin converting enzyme inhibitor treatment.
Increased glomerular filtration rate after converting-enzyme inhibition in essential hypertension.
Influence of age on blood pressure response to enalapril.
Influence of the angiotensin converting enzyme I/D gene polymorphisms on left ventricular diastolic filling in patients with essential hypertension.
Influence of the I/D polymorphism of the angiotensin-converting enzyme gene on the outcome of microalbuminuria in essential hypertension.
Inhibitors of the renin-angiotensin system. Clinical pharmacology studies on kinetics, dynamics and concentration-effect relationships.
Inhibitory effect of captopril on cell degeneration and growth.
Insulin sensitivity, glucose effectiveness, and beta-cell function in obese males with essential hypertension: investigation of the effects of treatment with a calcium channel blocker (diltiazem) or an angiotensin-converting enzyme inhibitor (quinapril).
Insulin-like growth factor-1 and cardiac mass in essential hypertension: comparative effects of captopril, lisinopril and quinapril.
Interaction and relationship between angiotensin converting enzyme gene and environmental factors predisposing to essential hypertension in Mongolian population of China.
Interaction of ACE and CYP11B2 Genes on Blood Pressure Response to Hydrochlorothiazide in Han Chinese Hypertensive Patients.
Intron-2 conversion polymorphism of the aldosterone synthase gene and the antihypertensive response to angiotensin-converting enzyme inhibitors.
Investigation of major genetic polymorphisms in the Renin-Angiotensin-aldosterone system in subjects with young-onset hypertension selected by a targeted-screening system at university.
Involvement of (pro)renin receptor in the glomerular filtration barrier.
Is microalbuminuria a marker of early intrarenal vascular dysfunction in essential hypertension?
Lack of association between the I/D polymorphism of the angiotensin-converting enzyme gene and essential hypertension in a Belgian population.
Lack of association of the angiotensin converting enzyme polymorphism with essential hypertension in a Chinese population.
Left ventricular (LV) geometry and dipping state are determinants of LV mass reduction with angiotensin-converting enzyme inhibitor antihypertensive treatment.
Left Ventricular Diastolic Function in Nigerian Patients with Essential Hypertension: A Retrospective Study to Compare Angiotensin Converting Enzyme Inhibitors, Calcium Channel Blockade or Their Combination.
Left ventricular systolic function after marked reduction of ventricular hypertrophy induced by 5 years' enalapril treatment.
Linkage analysis between loci in the renin-angiotensin axis and end-stage renal disease in African Americans.
Lisinopril decreases plasma free testosterone in male hypertensive patients and increases sex hormone binding globulin in female hypertensive patients.
Lisinopril in essential hypertension: a six month comparative study with nifedipine.
Lisinopril in the treatment of hypertension: a Canadian postmarketing surveillance study.
Lisinopril is neutral to insulin sensitivity and serum lipoproteins in essential hypertensive patients.
Lisinopril versus lisinopril plus hydrochlorothiazide in essential hypertension.
Lisinopril versus slow release nifedipine in patients with essential hypertension: a multicentre study.
Lisinopril. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure.
Long-term and strict blood pressure lowering by imidapril reverses left ventricular hypertrophy in patients with essential hypertension: an evaluation using a novel indicator of burden on the left ventricle.
Long-term angiotensin-converting enzyme inhibition with ramipril reduces thrombin generation in human hypertension.
Long-term effect of antihypertensive therapy with calcium antagonist or angiotensin converting enzyme inhibitor on serum nitrite/nitrate levels in human essential hypertension.
Long-term effects of angiotensin-converting enzyme inhibitors and calcium antagonists on the right and left ventricles in essential hypertension.
Long-term effects of captopril (SQ14 225) on blood-pressure and hormone levels in essential hypertension.
Long-term efficacy of angiotensin-converting-enzyme inhibition with captopril in mild-to-moderate essential hypertension.
Long-term hemodynamic effects at rest and during exercise of newer antihypertensive agents and salt restriction in essential hypertension: review of epanolol, doxazosin, amlodipine, felodipine, diltiazem, lisinopril, dilevalol, carvedilol, and ketanserin.
Long-term renal preservation in essential hypertension. Angiotensin converting enzyme inhibition is superior to beta-blockade.
Long-term treatment with enalapril or losartan does not show antiproliferative effects in peripheral blood mononuclear cells.
Long-term treatment with imidapril but not with nifedipine enhances plasma NOx concentration in patients with essential hypertension.
Manidipine versus enalapril monotherapy in patients with hypertension and type 2 diabetes mellitus: a multicenter, randomized, double-blind, 24-week study.
Memory function--effects of different antihypertensive drugs.
Metabolic effects of long-term angiotensin-converting enzyme inhibition with fosinopril in patients with essential hypertension: relationship to angiotensin-converting enzyme inhibition.
Metabolic neutrality of perindopril: focus on insulin sensitivity in overweight patients with essential hypertension.
Metabolism and production of angiotensin I in different vascular beds in subjects with hypertension.
Microalbuminuria in patients with essential hypertension. Effects of an angiotensin converting enzyme inhibitor and of a calcium channel blocker.
Moderate sodium restriction with angiotensin converting enzyme inhibitor in essential hypertension.
Moderate sodium restriction with angiotensin converting enzyme inhibitor in essential hypertension: a double blind study.
Moderate sodium restriction, angiotensin converting enzyme inhibition, and thiazide diuretic in the management of essential hypertension.
Moexipril in the treatment of mild to moderate essential hypertension: comparison with sustained-release verapamil.
Myocardial perfusion during long-term angiotensin-converting enzyme inhibition or beta-blockade in patients with essential hypertension.
Nephron heterogeneity: clue to the pathogenesis of essential hypertension and effectiveness of angiotensin-converting enzyme inhibitor treatment.
Neurogenic essential hypertension revisited: the case for increased clinical and research attention.
Neutral endopeptidase versus angiotensin converting enzyme inhibition in essential hypertension.
No correlation of polymorphism of angiotensin-converting enzyme genes with left ventricular hypertrophy in essential hypertension.
Non-modulating essential hypertension: renal hemodynamic effects of long-term angiotensin converting enzyme inhibition.
Once-daily lisinopril compared with twice-daily captopril in the treatment of mild to moderate hypertension: assessment of office and ambulatory blood pressures.
Orally active angiotensin-converting enzyme inhibitor (SO 14,225) as a treatment for essential hypertension.
Oxygen free radical scavenger system intermediates in essential hypertensive patients before and immediately after sublingual captopril administration.
Perindopril. A review of its pharmacokinetics and clinical pharmacology.
Pharmacokinetics and acute effect on the renin-angiotensin system of delapril in patients with chronic renal failure.
Pharmacokinetics and depressor effect of delapril in patients with essential hypertension.
Pharmacokinetics of single and consecutive doses of cilazapril and its depressor effects in patients with essential hypertension.
Pilot study of the effects of the angiotensin-converting enzyme inhibitor CI-906 on patients with essential hypertension.
Pituitary - adrenocortical function in patients during treatment with the angiotensin-converting enzyme inhibitor captopril.
Placebo-controlled comparison of the efficacy and tolerability of once-daily moxonidine and enalapril in mild to moderate essential hypertension.
Plasma levels of nitric oxide and related vasoactive factors following long-term treatment with angiotensin-converting enzyme inhibitor in patients with essential hypertension.
Pleiotropic AT1 receptor signaling pathways mediating physiological and pathogenic actions of angiotensin II.
Polymorphisms of angiotensin-converting enzyme and angiotensin II receptor type 1 genes in essential hypertension in a Polish population.
Polymorphisms of renin-angiotensin system in essential hypertension in Chinese Tibetans.
Potential future developments in the field of antihypertensive drugs.
Potentiation of the antihypertensive effect of enalapril by randomized addition of different doses of hydrochlorothiazide.
Practitioner's Trial on the Efficacy of Antihypertensive Treatment in the Elderly Hypertension (The PATE-Hypertension Study) in Japan.
Preliminary experiences with HOE 498, a novel long-acting converting enzyme inhibitor, in hypertensive patients.
Randomly allocated study of the effects of standard therapy versus ACE inhibition on micro-albuminuria in essential hypertension.
Rationale for ACE inhibition in the elderly: treatment of arterial hypertension with enalapril.
Regression of left ventricular hypertrophy in previously untreated essential hypertension: different effects of enalapril and hydrochlorothiazide.
Regulation of glomerular filtration in essential hypertension: role of abnormal Na+ transport and atrial natriuretic peptide.
Relationship between blood pressure and blood levels of angiotensin I converting enzyme inhibitor (SQ 14,225).
Relationship between the angiotensin converting enzyme gene polymorphism and the effects of enalapril on left ventricular hypertrophy and impaired diastolic filling in essential hypertension: M-mode and pulsed Doppler echocardiographic studies.
Relationship of bradykinin B2 receptor gene polymorphism with essential hypertension and left ventricular hypertrophy.
Relative long-term effects of spironolactone in conjunction with an angiotensin-converting enzyme inhibitor on left ventricular mass and diastolic function in patients with essential hypertension.
Renal artery stenosis: a disease worth pursuing.
Renal effects of nifedipine and captopril in patients with essential hypertension and reduced renal reserve.
Renal endothelial dysfunction and hypertension.
Renal haemodynamics in hypertension: effects of antihypertensive drugs.
Renal protection in essential hypertension: how do angiotensin-converting enzyme inhibitors compare with calcium antagonists?
Renal protective effect of long term antihypertensive therapy with enalapril.
Renal response to angiotensin-converting enzyme inhibition.
Renin and angiotensin-converting enzyme genotypes in patients with essential hypertension and left ventricular hypertrophy.
Renin Inhibition with Aliskiren: A Decade of Clinical Experience.
Renin inhibitors.
Renin-angiotensin gene polymorphism in children with uremia and essential hypertension.
Renin-angiotensin system is involved in the mechanism of increased serum asymmetric dimethylarginine in essential hypertension.
Renin-angiotensin-aldosterone system loci and multilocus interactions in young-onset essential hypertension.
Response to mental and physical stress before and during adrenoreceptor blocker and angiotensin-converting enzyme inhibitor treatment in essential hypertension.
Reversal of cardiac and large artery structural abnormalities induced by long-term antihypertensive treatment with trandolapril.
Role of kallikrein-kinin system in the hypotensive mechanisms of converting enzyme inhibitors in essential hypertension.
Role of vascular wall renin: intracellular and extracellular mechanism.
Roles of renal and vascular renin in spontaneous hypertension and switching of the mechanism upon nephrectomy. Lack of hypotensive effects of inhibition of renin, converting enzyme, and angiotensin II receptor blocker after bilateral nephrectomy.
Selective alpha-blockade versus angiotensin-converting enzyme inhibition as initial antihypertensive therapy. Effects on circulating lipoproteins.
Short-term effects of rilmenidine on left ventricular hypertrophy and systolic and diastolic function in patients with essential hypertension: comparison with an angiotensin converting enzyme inhibitor and a calcium antagonist.
Significance of kallikrein-kinin and renin-angiotensin systems in the hypotensive mechanism of angiotensin-I converting enzyme inhibitors in essential hypertensives.
Single nucleotide polymorphisms of the angiotensin-converting enzyme (ACE) gene are associated with essential hypertension and increased ACE enzyme levels in Mexican individuals.
Some metabolic aspects of essential hypertension and its treatment.
Spironolactone and altizide versus converting enzyme inhibitor (enalapril).
Stimulation of aldosterone secretion by metoclopramide is not affected by chronic converting enzyme inhibition.
Studies on the antihypertensive effect of single doses of the angiotensin converting enzyme inhibitor ramipril (HOE 498) in man.
Submaximal endurance exercise performance during enalapril treatment in patients with essential hypertension.
Sulfhydryl angiotensin-converting enzyme inhibition induces sustained reduction of systemic oxidative stress and improves the nitric oxide pathway in patients with essential hypertension.
Synergism between alpha 1-blockade and angiotensin converting enzyme inhibition in essential hypertension.
Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for treating essential hypertension.
Systemic and renal effects of a new angiotensin converting enzyme inhibitor, benazepril, in essential hypertension.
Systemic and renal effects of enalapril and its effects on cardiac mass.
T-lymphocyte and plasma angiotensin-converting enzyme activity during enalapril and losartan administration in humans.
The 2000 Canadian recommendations for the management of hypertension: Part one--therapy.
The ACE I/D polymorphism in US adults: limited evidence of association with hypertension-related traits and sex-specific effects by race/ethnicity.
The angiotensin converting enzyme gene insertion/deletion (I/D) polymorphism and essential hypertension in the Chinese population: a meta-analysis including 21058 participants.
The angiotensin converting enzyme inhibitor enalapril and its effects on renal function.
The beneficial effects of angiotensin receptor blockers and angiotensin converting enzyme inhibitors on atrial electrical remodeling in patients with essential hypertension.
The C677T polymorphism of the methylenetetrahydrofolate reductase gene is associated with the level of decrease on diastolic blood pressure in essential hypertension patients treated by angiotensin-converting enzyme inhibitor.
The choice of first-line therapy: rationale for low-dose combinations of an angiotensin converting enzyme inhibitor and a diuretic.
The deletion polymorphism of the angiotensin I-converting enzyme gene is associated with target organ damage in essential hypertension.
The effect of antihypertensive drugs on in vivo platelet activity in essential hypertension.
The effect of fosinopril sodium on cerebral blood flow in moderate essential hypertension.
The effect of long-term treatment by the angiotensin I-converting enzyme inhibitor enalapril on renal function and left ventricular hypertrophy in severe essential hypertension.
The effect of ramipril, a new angiotensin-converting enzyme inhibitor on cortical nephron flow and effective renal plasma flow in patients with essential hypertension.
The effects of benazepril, a new angiotensin-converting enzyme inhibitor, in mild to moderate essential hypertension: a multicenter study.
The effects of long-term treatment on left ventricular hypertrophy in patients with essential hypertension: relation to changes in neurohumoral factors.
The Efficacy of Perindopril/Amlodipine in Reaching Blood Pressure Targets: Results of the CONTROL Study.
The hypotensive action of captopril and enalapril is not prostacyclin dependent.
The influence of one-year treatment by angiotensin converting enzyme inhibitor on baroreflex sensitivity and flow-mediated vasodilation of the brachial artery in essential hypertension--comparison with calcium channel blockers.
The initial hemodynamic response to newer antihypertensive agents at rest and during exercise: review of visacor, doxazosin, nisoldipine, tiapamil, perindoprilat, pinacidil, dilevalol, and carvedilol.
The measurement of intrarenal plasma flow distribution in essential hypertension. The effect of angiotensin-converting enzyme inhibition.
The pharmacodynamics and dose-response relationships of the angiotensin converting enzyme inhibitor, cilazapril, in essential hypertension.
The pharmacokinetics and angiotensin converting enzyme inhibition dynamics of cilazapril in essential hypertension.
The relationship between blood pressure and left ventricular mass in essential hypertension is observed only in the presence of the angiotensin-converting enzyme gene deletion allele.
The relationship of angiotensin-converting enzyme gene to essential hypertension and drug treatment in Chongqing.
The renin angiotensin system: importance in physiology and pathology.
The role of plasma angiotensin I converting enzyme in regulation of renin-angiotensin system activity in patients with essential hypertension.
The safety and efficacy of quinapril in the treatment of mild to moderate essential hypertension.
The smoothness index, but not the trough-to-peak ratio predicts changes in carotid artery wall thickness during antihypertensive treatment.
Time course of the effects of temocapril on cardiovascular structure and function in patients with essential hypertension.
Tissue availability of insulin-like growth factor I is inversely related to insulin resistance in essential hypertension: effects of angiotensin converting enzyme inhibition.
Toward the biochemical assessment of myocardial fibrosis in hypertensive patients.
Trandolapril in patients with essential hypertension: effects on vascular and cardiac structural changes.
Trandolapril. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in essential hypertension.
Transforming growth factor-beta1 is associated with kidney damage in patients with essential hypertension: renoprotective effect of ACE inhibitor and/or angiotensin II receptor blocker.
Treatment for one year with perindopril: effect on cardiac mass and arterial compliance in essential hypertension.
Treatment of essential arterial hypertension with enalapril does not result in normalization of endothelial dysfunction of the conduit arteries.
Treatment of Hypertension in Coarctation of the Aorta.
Treatment of hypertension with enalapril and hydrochlorothiazide or enalapril and atenolol: contrasts in hypotensive interactions.
Updates on the treatment of essential hypertension: a summary of AHRQ's comparative effectiveness review of angiotensin- converting enzyme inhibitors, angiotensin II receptor blockers, and direct renin inhibitors.
Upregulation of the angiotensin-converting enzyme 2-angiotensin-(1-7)-Mas receptor axis by a combination of Yinyanghuo (Herba Epimedii Brevicornus) and Cheqianzi (Semen Plantaginis) improves erectile function in spontaneously hypertensive rats.
Urinary albumin excretion and atherosclerosis in essential hypertension.
Urinary angiotensin II: a marker of renal tissue activity?
Urinary excretions of kininase I and kininase II activities in essential hypertension. A sensitive and simple method for its kinin-destroying capacity.
Use of angiotensin II receptor blockers alone and in combination with other drugs: a large clinical experience trial.
Usefulness of moexipril and hydrochlorothiazide in moderately severe essential hypertension.
Vagal cardiac activity in essential hypertension: the effects of metoprolol and ramipril.
Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy, tolerability and safety compared to an angiotensin-converting enzyme inhibitor, lisinopril.
Valsartan, a new angiotensin II antagonist; blood pressure reduction in essential hypertension compared with an angiotensin converting enzyme inhibitor, enalapril.
Vasodilators, antihypertensive therapy and the kidney.
Zinc, angiotensin I-converting enzyme and hypertension.
[A decrease in left ventricular hypertrophy and the dynamics of the parameters of circadian BP monitoring under the influence of ramipril in patients with essential arterial hypertension]
[A new principle in long-term treatment of essential hypertension: angiotensin-converting enzyme inhibition (author's transl)]
[Activity of angiotensin-converting enzyme in serum and its association with left ventricular mass and blood pressure level in patients with essential hypertension]
[Acute inhibition of angiotensin-converting enzyme by captopril. Hemodynamic and biochemical aspects in normotension and essential hypertension]
[Angiotensin converting enzyme inhibitors and vascular remodelling in arterial hypertension]
[Angiotensin-converting enzyme inhibitors as neutralizers of hydroxyl radical]
[Antihypertensive effectiveness and tolerance of cicletanine. Results obtained with bitherapy]
[Antihypertensive mechanism of oral angiotensin I converting enzyme inhibitor (captopril) in renin-independent essential hypertension]
[Approaches to the treatment of hypertension]
[Are newer antihypertensive agents better than the older ones? Results of trials (CAPPP, STOP-2, NORDIL, INSIGHT and ALLHAT) with newer antihypertensive agents]
[Association between angiotensin converting enzyme gene, chymase gene and regression of left ventricular hypertrophy in patients treated with angiotensin converting enzyme inhibitors.]
[Association of angiotensin I converting enzyme 2 gene polymorphism with essential hypertension in Chinese]
[Association of angiotensin I-converting enzyme gene polymorphism with ACE and PAI-1 levels in Guangdong Chinese Han patients with essential hypertension]
[Beneficial effects of statins and angiotensin converting enzyme inhibitors on aggregability of red blood cells in hypertensive patients]
[Blood concentration and urinary excretion of captopril (SQ 14,255), angiotensin converting enzyme activity and R-A-A system after administration of captopril--in patients with chronic renal failure compared with essential hypertension]
[Changes in humoral pressor and depressor factors in essential hypertension during lisinopril therapy]
[Chronic effects of spironolactone in conjunction with an angiotensin-converting enzyme inhibitor enalapril on circulating procollagen marker P III NP and vascular resistance in patients with essential hypertension]
[Circadian rhythm of autonomic heart activity in patients with primary essential hypertension treated with angiotensin converting enzyme inhibitor]
[Clinical significance of serum angiotensin I-converting enzyme in essential hypertension]
[Comparison of preventive effect of "new" and "old" antihypertensive agents]
[Comparison of treatment effects with an angiotensin converting enzyme inhibitor--lisinopril and a calcium blocker--nifedipine retard on urinary albumin excretion in patients with non-complicated essential hypertension]
[Control of hyperinsulinemia in essential hypertension using the angiotensin-converting enzyme inhibitor, lisinopril]
[Conversion of inactive renin to active renin following acute angiotensin converting enzyme inhibition in essential hypertension and renovascular hypertension]
[Deletion polymorphism in the angiotensin converting enzyme gene associated with essential hypertension in Hans Chinese population]
[Effect of captopril in essential hypertension (author's transl)]
[Effect of ramipril on the glucose/insulin coefficient and the ventricular mass index in patients with light to moderate arterial hypertension]
[Effects of 3 different angiotensin converting enzyme inhibitors, MK 421, SQ 14225 and SA 446 on renal function and blood pressure in patients with essential hypertension]
[Effects of angiotensin converting enzyme inhibitor (captopril) on erythrocyte sodium ion transport systems in patients with essential hypertension]
[Effects of angiotensin converting enzyme inhibitor captopril on blood pressure in "juvenile" essential hypertension]
[Effects of angiotensin I converting enzyme inhibitor (captopril) on blood pressure, pulse rate, plasma renin activity, and plasma aldosterone concentration in patients with essential hypertension and normal subjects]
[Effects of angiotensin-converting enzyme gene and environment interaction on essential hypertension in the Han nationality].
[Effects of calcium antagonist, angiotensin-converting enzyme inhibitors and beta-blocker on hemodynamic and sympathetic nerve responses to exercise in essential hypertension]
[Effects of converting enzyme inhibition by enalapril on renal hemodynamics in essential arterial hypertension]
[Efficacy of monotherapy with 15 antihypertensive agents in treating essential hypertension assessed by 24-hour ambulatory blood pressure monitoring]
[Efficiancy Angiotensin -converting enzyme inhibitors for the clinical practice].
[Endothelial function and i/d polymorphism of Angiotensin converting enzyme gene in patients with essential hypertension.]
[Estimation of urinary excretion rate of guanidinoacetic acid in essential hypertension]
[Evaluation of angiotensin I converting enzyme gene polymorphism in patients with essential hypertension and coronary artery disease]
[High doses of aspirin reduce natriuresis in hypertensive patients treated with enalapril]
[Humoral mechanisms in the pathogenesis of arterial hypertension with emphasis on the renin-angiotensin-aldosterone system and natriuretic substances]
[Hypertension from the nephrologist's point of view]
[Membrane transport of cations in erythrocytes during treatment of essential hypertension with angiotensin-converting enzyme inhibitors]
[Pharmacological correction of hyperactivity of Renin-Angiotensin-aldosteron system.]
[Plasminogen activator inhibitor-1 (PAI-1) 4G/5G and angiotensin converting enzyme (ACE) I/D gene polymorphisms and fibrinolytic activity in patients with essential hypertension and dyslipidemia]
[Polymorphic markers I/D and G7831A of angiotensin-I-converting enzyme gene and left ventricular hypertrophy in patients with essential hypertension]
[Prospective study of the effects of an angiotensin converting enzyme inhibitor and a beta blockader on the structure and function of resistant arteries in mild essential hypertension]
[Relationship between angiotensin converting enzyme gene polymorphism and essential hypertension in children].
[Risk factors relating to coronary artery disease in the elderly]
[Specifics of distribution of polymorphic markers of the renin-angiotensin-system genes, relation to ventricular hypertrophy in patients with essential hypertension of Uzbek nationality]
[Stiffness of the Arterial Wall and Central Hemodynamics During Long-Term Combination Antihypertensive Therapy].
[The acute effects of the new angiotensin I-converting enzyme inhibitor, enalapril maleate, on blood pressure, plasma renin, aldosterone and kinins in hypertensive patients]
[The antihypertensive activity of benazepril in the long-term treatment of hypertension patients and its effect on adrenal cortical function]
[The behavior of serum angiotensin-converting enzyme in normotensive subjects, in subjects with essential hypertension and in subjects with primary hyperaldosteronism on the orthostatic test]
[The comparison of the effect of enalapril and indapamine on the peripheral blood pressure and central blood pressure through pulse wave analysis]
[The correlation between serum angiotensin I-converting enzyme activity and the renin-angiotensin-aldosterone system in hypertensive patients (author's transl)]
[The distribution of angiotensin converting enzyme gene I/D polymorphism and its relationship with essential hypertension]
[The effect of alacepril on insulin sensitivity in patients with essential hypertension]
[The effect of alterations of the renin-angiotensin system and the sympathetic nervous system on plasma bradykinin concentration in patients with essential hypertension]
[The effect of cilazapril on left ventricular function and myocardial perfusion in patients with essential hypertension (hypertensive disease) stage II]
[The hemostasis parameters and ACE gene polymorphism in patients with essential hypertension treated with perindopril]
[The influence of I/D polymorphism of the angiotensin I converting enzyme (ACE) gene and 4G/5G polymorphism of plasminogen activator inhibitor (PAI-1) gene promoter on the haemostatic system in patients with essential hypertension and dyslipidemia]
[The polymorphism of the angiotensin-converting enzyme gene in patients with hypertension, left ventricular hypertrophy and the development of a myocardial infarct at a young age. Preliminary report]
[The regression of the structural-functional changes in the hypertrophic left ventricle during the long-term correction of the arterial pressure with Inhibace (cilazapril)]
[The relationship between polymorphism of angiotensin converting enzyme gene and cough caused by angiotensin converting enzyme inhibitors]
[The relationship of polymorphism of angiotensinogen and angiotensin converting enzyme with essential hypertension]
[The significance of the kallikrein-kinin system in the pathogenesis of essential hypertension]
[The therapy of complicated forms of essential hypertension with the ACE inhibitor perindopril]
[Usefulness of converting enzyme inhibitors in the diagnosis of arterial hypertension]
[Volume of the extracellular liquid and renal function during short-term administration of angiotensin converting enzyme inhibitors in essential hypertension]
Exanthema
Anaphylactoid reaction to recombinant tissue plasminogen activator.
Angioedema and photosensitive rash induced by valsartan.
Drug treatment of systolic and of diastolic heart failure in elderly persons.
Drug-induced hypersensitivity syndrome with superficial granulomatous dermatitis--a novel finding.
Epidemiology, pathophysiology, prognosis, and treatment of systolic and diastolic heart failure.
Lack of cross sensitivity between captopril and enalapril.
Prolonged generalized pruritus associated with selective elevation of IgA as the presenting symptoms of sarcoidosis.
Sarcoid-related uveitis occurring during etanercept therapy.
Severe cutaneous reactions to captopril and enalapril; histological study and comparison with early mycosis fungoides.
Toxicodynamic analysis of inflammatory reactions by an angiotensin converting enzyme inhibitor (lisinopril) in guinea-pig skin.
Treatment of systolic and diastolic heart failure in the elderly.
[Cross-sensitivity between angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonist]
[Cutaneous lesions during hot-tub hypersensitivity pneumonitis: Pseudomonas folliculitis ?]
Eye Diseases
Difficult therapeutic decisions in the management of diabetic retinopathy.
Fabry Disease
Antiproteinuric therapy and fabry nephropathy: sustained reduction of proteinuria in patients receiving enzyme replacement therapy with agalsidase-beta.
Facial Paralysis
Heerfordt's Syndrome Presenting with Recurrent Facial Nerve Palsy: Case report and 10-year literature review.
Reversible facial paralysis in sarcoidosis. Confirmation by serum angiotensin-converting enzyme assay.
[A case of pulmonary sarcoidosis mimicking relapse of pulmonary tuberculosis]
Familial Mediterranean Fever
Familial Mediterranean fever. Another cause of raised serum angiotensin converting enzyme; another abortive attempt at masquerading as sarcoidosis.
Lack of association between familial Mediterranean fever and angiotensin converting enzyme gene polymorphism.
Familial Primary Pulmonary Hypertension
Angiotensin converting enzyme expression in primary pulmonary hypertension.
Angiotensin-converting enzyme DD genotype in patients with primary pulmonary hypertension: increased frequency and association with preserved haemodynamics.
Drug treatment of primary pulmonary hypertension.
Effects of captopril (SQ 14,225) in a patient with primary pulmonary hypertension.
Lack of association between angiotensin converting enzyme (ACE) genotype, serum ACE activity, and haemodynamics in patients with primary pulmonary hypertension.
[Long-term treatments for systemic sclerosis: what are the perspectives?]
[Therapeutic management of systemic sclerosis]
[Treatment of scleroderma]
Farmer's Lung
Angiotensin-converting enzyme in farmer's lung.
Fasciitis
[Fasciitis with eosinophilia: a possible causal role of angiotensin converting enzyme inhibitor]
Fasciitis, Plantar
Top 20 Research Studies of 2014 for Primary Care Physicians.
Fatigue Syndrome, Chronic
[Chronic fatigue syndrome and angiotensin-converting enzyme]
Fatty Liver
Angiotensin-converting enzyme in diseases of the liver.
[The effects of renin-angiotensin system blockade on the liver steatosis in rats on long-term high-fat diet]
Fatty Liver, Alcoholic
Angiotensin-converting enzyme activity in experimental alcoholic fatty liver of the rat.
Febrile Neutropenia
Gene polymorphisms and febrile neutropenia in acute leukemia--no association with IL-4, CCR-5, IL-1RA, but the MBL-2, ACE, and TLR-4 are associated with the disease in Turkish patients: a preliminary study.
Fecal Impaction
Clinical Evaluation of the Safety, Efficacy and Tolerability of Lanthanum Carbonate in the Management of Hyperphosphatemia in Patients with End-Stage Renal Disease.
Fetal Death
Reversible oligohydramnios in a pregnancy with angiotensin-converting enzyme inhibitor exposure.
[Captopril use in pregnancy and its effects on the fetus and the newborn: case report]
Fetal Diseases
Is there an embryopathy associated with first-trimester exposure to angiotensin-converting enzyme inhibitors and angiotensin receptor antagonists? A critical review of the evidence.
Fetal Growth Retardation
Congenital renal tubular dysplasia and skull ossification defects similar to teratogenic effects of angiotensin converting enzyme (ACE) inhibitors.
Evaluation of the renin-angiotensin-aldosterone system in pregnancy complicated by preeclampsia with and without intrauterine growth retardation.
Maternal deletion allele of angiotensin-converting enzyme gene is associated with fetal growth restriction.
Polymorphisms of the angiotensin converting enzyme gene in relation to intrauterine growth restriction.
The influence of mode of delivery and ACE genotype on serum angiotensin converting enzyme (ACE) activity in the mother and infant at term.
The role of angiotensin-converting enzyme and apolipoprotein-E gene polymorphisms on lipid compositions in newborn infants with intrauterine growth restriction.
[Fetopathy associated with exposure to angiotensin converting enzyme inhibitors]
Fetal Hypoxia
Neonatal hemochromatosis, renal tubular dysgenesis, and hypocalvaria in a neonate.
Fibromyalgia
Angiotensin converting enzyme and methylenetetrahydrofolate reductase gene variations in fibromyalgia syndrome.
Common genetic risk factors for psychiatric and simatic disorders.
Fibrosarcoma
Isolation and identification of fresh tumor-derived endothelial cells from a murine RIF-1 fibrosarcoma.
Focal Nodular Hyperplasia
Angiotensin I-converting enzyme (CD143) is down-regulated in focal nodular hyperplasia of the liver.
[Expression of CD143 and its significance in focal nodular hyperplasia of liver]
Food Hypersensitivity
Advances in allergic skin disease, anaphylaxis, and hypersensitivity reactions to foods, drugs, and insects in 2008.
Foot Diseases
Getting advances in science to make a difference: Translation research for improving diabetes care.
Foot Ulcer
The differential effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers with respect to foot ulcer and limb amputation in those with diabetes.
Friedreich Ataxia
A dictionary model for haplotyping, genotype calling, and association testing.
Gallbladder Neoplasms
Angiotensin I-Converting Enzyme Insertion/Deletion Polymorphism and Increased Risk of Gall Bladder Cancer in Women.
Gallstones
Mirtazapine-Induced Pancreatitis-A Case Report.
Gastritis
Mast cell chymase expression in Helicobacter pylori-associated gastritis.
Oral burning symptoms and burning mouth syndrome-significance of different variables in 150 patients.
Gastritis, Atrophic
Lack of association between gene polymorphisms of Angiotensin converting enzyme, Nod-like receptor 1, Toll-like receptor 4, FAS/FASL and the presence of Helicobacter pylori-induced premalignant gastric lesions and gastric cancer in Caucasians.
Gastroenteritis
Enalapril-induced eosinophilic gastroenteritis.
Gastroesophageal Reflux
Airway inflammation as an assessment of chronic nonproductive cough.
Anatomical diagnostic protocol in evaluating chronic cough with specific reference to gastroesophageal reflux disease.
Chronic cough and a normal chest X-ray - a simple systematic approach to exclude common causes before referral to secondary care: a retrospective cohort study.
Chronic cough with a history of excessive sputum production. The spectrum and frequency of causes, key components of the diagnostic evaluation, and outcome of specific therapy.
Chronic Cough: An Update.
Cough: a worldwide problem.
From a prospective study of chronic cough: diagnostic and therapeutic aspects in older adults.
Omeprazole-induced cough in a patient with gastroesophageal reflux disease.
Pathophysiology and therapy of chronic cough.
Peritoneal dialysis and cough: ACCP evidence-based clinical practice guidelines.
Pharmacotherapy of chronic cough in adults.
Ten Years of Chronic Cough in a 64-Year-Old Man With Multiple Pulmonary Nodules.
The aetiology of chronic cough: a review of current theories for the otorhinolaryngologist.
The airway sensory hyperreactivity syndrome.
The role of the methacholine inhalation challenge in adult patients presenting with chronic cough.
Therapy Insight: treatment of gastroesophageal reflux in adults with chronic cough.
Treating systemic sclerosis in 2001.
Usefulness of the Guidelines of the Spanish Society of Pulmonology and Thoracic Surgery (SEPAR) in Identifying the Causes of Chronic Cough.
[Cough: differential diagnosis and differentiated treatment].
[Etiological diagnosis and specific treatment of chronic cough in 106 patients]
Gastrointestinal Hemorrhage
[Adverse drug reaction surveillance in pediatric and adult patients in an emergency room]
Gaucher Disease
ACE phenotyping in Gaucher disease.
Biomarkers in Serbian patients with Gaucher disease.
Correlation of surrogate markers of Gaucher disease. Implications for long-term follow up of enzyme replacement therapy.
Elevated angiotensin-converting enzyme in type 1 and 2 Gaucher's disease, and elevated serum lysozyme in type 1; association of hepatic fibrosis with long-spacing collagen fibrils in type 2.
Elevated serum and spleen angiotensin converting enzyme and serum lysozyme in Gaucher's disease.
Elevation of serum angiotensin-converting enzyme in Gaucher's disease.
Histiocytosis X. VI. Angiotensin-converting enzyme activity.
Immunofluorescent detection of angiotensin-converting enzyme (ACE) in Gaucher cells.
Marked elevation of serum angiotension-converting enzyme and hepatic fibrosis containing long-spacing collagen fibrils in type 2 acute neuronopathic Gaucher's disease.
Normal acid-phosphatase and angiotensin converting enzyme activities in serum of a patient with Gaucher's disease.
Novel ACE mutations mimicking sarcoidosis by increasing blood ACE levels.
Sensitive fluorimetric assay for serum angiotensin-converting enzyme with the natural substrate angiotensin I.
Serum angiotensin-converting enzyme in leprosy and coccidioidomycosis.
[Epidemiologic, clinical, biological and therapeutic aspects of Gaucher disease]
Genetic Diseases, Inborn
Impact of ACE I/D gene polymorphism on congenital renal malformations.
Thoracic aortic aneurysm and dissection.
Germinoma
Angiotensin I-converting enzyme in a suprasellar germinoma.
Angiotensin-I-converting enzyme in germinomas.
Giant Cell Arteritis
Impact of diabetes, angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker use, and statin use on presentation and outcomes in patients with giant cell arteritis.
Polymyalgia rheumatica and giant cell arteritis--rational diagnosis and treatment predicated and disordered prostaglandin metabolism.
Serum Angiotensin-converting enzyme (SACE) in temporal arteritis.
Treatment with angiotensin II receptor blockers is associated with prolonged relapse-free survival, lower relapse rate, and corticosteroid-sparing effect in patients with giant cell arteritis.
[Angiotensin-converting enzyme in patients with temporal arteritis]
Gingival Overgrowth
Influence of Different Antihypertensive Drugs on Gingival Overgrowth: A Cross-Sectional Study in A Turkish Population.
Glaucoma
Autonomic Dysfunction and Blood Pressure in Glaucoma Patients: The Lifelines Cohort Study.
Central retinal vein occlusion case-control study.
Chymase and angiotensin converting enzyme activities in a hamster model of glaucoma filtering surgery.
Disruption of 24-Hour Rhythm in Intraocular Pressure Correlates with Retinal Ganglion Cell Loss in Glaucoma.
Effect of selected antihypertensives, antidiabetics, statins and diuretics on adjunctive medical treatment of glaucoma: a population based study.
Oculohypotensive effect of angiotensin-converting enzyme inhibitors in acute and chronic models of glaucoma.
Potential role for angiotensin-converting enzyme inhibitors in the treatment of glaucoma.
Prevention of visual field defect progression with angiotensin-converting enzyme inhibitor in eyes with normal-tension glaucoma.
Therapeutic targets of renin-angiotensin system in ocular disorders.
[Bilateral recurrent blurred vision associated with halos around sources of light and headache].
Glaucoma, Open-Angle
Angiotensin-converting enzyme insertion-deletion polymorphism in primary open-angle glaucoma.
Use of an angiotensin converting enzyme inhibitor in ocular hypertension and primary open-angle glaucoma.
[Bilateral recurrent blurred vision associated with halos around sources of light and headache].
[Study of kini-kallikrein and renin--angiotensin systems in patients with primary open angle glaucoma]
Glioblastoma
Endothelin-converting enzyme-1 inhibition and growth of human glioblastoma cells.
Matrix metalloproteinase-2 and -9 in glioblastoma: a trio of old drugs-captopril, disulfiram and nelfinavir-are inhibitors with potential as adjunctive treatments in glioblastoma.
Regulation of aminopeptidase A in human brain tumor vasculature: evidence for a role of transforming growth factor-beta.
Renin and angiotensinogen expression and functions in growth and apoptosis of human glioblastoma.
Glioma
Angiotensin-converting enzyme insertion/deletion gene polymorphisms and the risk of glioma in an Algerian population.
Angiotensin-converting enzyme insertion/deletion gene polymorphisms is associated with risk of glioma in a Chinese population.
Evidence for thiol-dependent metallo-endopeptidase involved in degradation of luteinizing hormone-releasing hormone in glioma cells.
Sex differences exist in brain renin-angiotensin system-regulating aminopeptidase activities in transplacental ethyl-nitrosourea-induced gliomas.
The genetic polymorphisms of angiotensin converting enzyme insertion/deletion and glioma susceptibility: A meta-analysis.
The renin-angiotensin system in hybrid NG108-15 cells. Renin gene is from mouse neuroblastoma, angiotensinogen and angiotensin-converting enzyme genes are of rat glioma origin.
Globus Sensation
Laryngeal sensory neuropathy in patients with diabetes mellitus.
Glomerulonephritis
ACE inhibitors and angiotensin II antagonists in renal transplantation: an analysis of safety and efficacy.
ACEI/ATRA therapy decreases proteinuria by improving glomerular permselectivity in IgA nephritis.
Additive antiproteinuric effect of combined ACE inhibition and angiotensin II receptor blockade.
Angiotensin I-converting enzyme genotype significantly affects progression of IgA glomerulonephritis in an italian population.
Angiotensin-converting enzyme inhibition and the combination of a beta blocker and a diuretic are equally effective in lowering proteinuria in patients with glomerulonephritis.
Angiotensin-converting enzyme inhibition but not angiotensin II receptor blockade regulates matrix metalloproteinase activity in patients with glomerulonephritis.
Angiotensin-converting enzyme inhibition but not beta-adrenergic blockade limits transforming growth factor-beta overexpression in acute normotensive anti-thy1 glomerulonephritis.
Angiotensin-converting enzyme inhibition in experimental in-situ immune complex glomerulonephritis: influence on renal function, proteinuria, and morphology.
Antiproteinuric response to dual blockade of the renin-angiotensin system in primary glomerulonephritis: meta-analysis and metaregression.
Association of aldosterone synthase (CYP11B2) gene -344T/C polymorphism with the risk of primary chronic glomerulonephritis in the Polish population.
Blocking angiotensin II ameliorates proteinuria and glomerular lesions in progressive mesangioproliferative glomerulonephritis.
Canine glomerulonephritis: new thoughts on proteinuria and treatment.
Captopril ameliorates the posturally induced fall in creatinine clearance in patients with chronic glomerulonephritis.
Combination therapy with lamivudine and angiotensin-converting enzyme inhibitor/angiotensin receptor blocker for hepatitis B virus-associated glomerulonephritis with mild to moderate proteinuria: a clinical review of 38 cases.
Comparison of higher dose of losartan treatment with losartan plus carvedilol and losartan plus ramipril in patients with glomerulonephritis and proteinuria.
Effect of the angiotensin converting enzyme inhibitor, captopril, on proteinuria in chronic glomerular disease.
Enalapril influence on blood pressure and echocardiographic parameters in children with acute postinfectious glomerulonephritis.
Expression and activation of STAT3 in chronic proliferative immune complex glomerulonephritis and the effect of fosinopril.
Gene-polymorphisms of angiotensin converting enzyme and endothelial nitric oxide synthase in patients with primary glomerulonephritis.
Glomerulonephritis after recombinant hepatitis B vaccine.
In hereditary nephritis angiotensin-converting enzyme inhibition decreases proteinuria and may slow the rate of progression.
Increased urinary excretion of angiotensin converting enzyme in patients with renal diseases.
Indomethacin blunts the orthostatic increase in plasma aldosterone in glomerulonephritis.
Long-term effect of imidapril hydrochloride compared with dilazep hydrochloride administration on blood pressure and renal function in patients with chronic glomerulonephritis.
Lyme nephritis.
Nature and Mediators of Parietal Epithelial Cell Activation in Glomerulonephritides of Human and Rat.
Passive Heymann nephritis: evidence that angiotensin-converting enzyme inhibition reduces proteinuria and retards renal structural injury.
Patient with diffuse mesangial and endocapillary proliferative glomerulonephritis with hypocomplementemia and elevated anti-streptolysin O treated with prednisolone, angiotensin-converting enzyme inhibitor, and angiotensin II receptor antagonist.
Possible new role for angiotensin-converting enzyme inhibitors in treating glomerulonephritis.
Primary glomerulonephritis: an update on renal survival and determinants of progression.
Reduction of proteinuria and changes of renal function in patients with glomerulonephritis and mild renal insufficiency. Short- versus long-acting angiotensin-converting enzyme inhibitors.
Reduction of proteinuria; combined effects of receptor blockade and low dose angiotensin-converting enzyme inhibition.
Renin gene expression in human kidney biopsies from patients with glomerulonephritis or graft rejection.
Renoprotective effect of the addition of losartan to ongoing treatment with an angiotensin converting enzyme inhibitor in type-2 diabetic patients with nephropathy.
Serum angiotensin converting enzyme activity in type 2 (non-insulin-dependent) diabetic patients with chronic glomerulonephritis.
Short-term treatment with captopril in hypertension due to acute glomerulonephritis.
Therapeutic advantage of angiotensin converting enzyme inhibitors in chronic glomerulonephritis.
Treatments of hemodynamic maladjustment and oxidative stress prevent renal disease progression in chronically severe glomerulonephritides.
Urinary glycosaminoglycans, sialic acid and lysosomal enzymes increase in nonalbuminuric diabetic patients.
[Acute pharmacological block of the renin-angiotensin system and the recovery of intrarenal hemodynamics in patients with chronic glomerulonephritis]
[Additive antiproteinuric effect of angiotensin II receptor antagonist and angiotensin-converting enzyme inhibitor in patients with chronic glomerulonephritis]
[Arterial hypertension in glomerulonephritis]
[Effect of irbesartan in proteinuric non-diabetic renal disease]
[Effect of the angiotensin-converting enzyme inhibitor ramipril on proteinuria, blood pressure and kidney function in histologically confirmed glomerulonephritis with nephrotic syndrome]
[Etiologic aspects of acute renal insufficiency in the adult]
[I/D relationship between polymorphism of ACE gene and progression of chronic glomerulonephritis]
[Influence of angiotensin-converting enzyme gene polymorphism on the anti-proteinuria efficacy of angiotensin-converting enzyme inhibitor in Han nationality of southern Sichuan province in China]
[Polymorphism studies of angiotensin converting enzyme gene in chronic glomerulonephritis]
[The antiproteinuric action of angiotensin-converting enzyme inhibitors in chronic glomerulonephritis and diabetic nephropathy]
[The effect of angiotensin-converting enzyme inhibitors on left ventricular hypertrophy in patients with chronic glomerulonephritis and pronounced kidney failure]
[The effect of angiotensin-converting enzyme inhibitors on proteinuria in chronic glomerulonephritis]
[The role of polymorphic markers of vasoactive hormones genes in clinical characteristics of chronic glomerulonephritis]
[The use of angiotensin-converting enzyme inhibitors and the function of the renin-angiotensin-aldosterone system in chronic glomerulonephritis (a review of the literature and the author's own data)]
[The use of angiotensin-converting enzyme inhibitors in patients with chronic glomerulonephritis]
Glomerulonephritis, IGA
A clinicopathological study of IgA nephropathy in renal transplant recipients: beneficial effect of angiotensin-converting enzyme inhibitor.
A meta-analysis of the association between angiotensin-converting enzyme insertion/deletion gene polymorphism and end-stage renal disease risk in IgA nephropathy patients.
A Randomized, Controlled Trial of Rituximab in IgA Nephropathy with Proteinuria and Renal Dysfunction.
A-20C angiotensinogen gene polymorphism and proteinuria in childhood IgA nephropathy.
ACE gene polymorphism and disease progression of IgA nephropathy in Asians in Singapore.
ACE gene polymorphism and IgA nephropathy: an ethnically homogeneous study and a meta-analysis.
ACE gene polymorphism in childhood IgA nephropathy: association with clinicopathologic findings.
Aldosterone breakthrough during therapy with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in proteinuric patients with immunoglobulin A nephropathy.
Angiotensin converting enzyme gene insertion/deletion polymorphism in idiopathic nephrotic syndrome in Kuwaiti Arab children.
Angiotensin converting enzyme gene polymorphism in renal transplant patients with IgA nephropathy: relationship with graft function and prevalence of hypertension.
Angiotensin converting enzyme gene polymorphism: potential silencer motif and impact on progression in IgA nephropathy.
Angiotensin converting enzyme inhibition delays the progression of chronic renal failure in hypertensive patients with immunoglobulin A nephropathy.
Angiotensin converting enzyme inhibition improves glomerular size-selectivity in IgA nephropathy.
Angiotensin I-converting enzyme genotype significantly affects progression of IgA glomerulonephritis in an italian population.
Angiotensin-converting enzyme gene polymorphism is correlated to the progression of disease in patients with IgA nephropathy: a meta-analysis.
Angiotensin-converting enzyme genotype and outcome in pediatric IgA nephropathy.
Angiotensin-converting enzyme genotype and renal allograft survival.
Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for IgA nephropathy.
Angiotensin-converting enzyme inhibitors in young patients with IgA nephropathy: effects against deterioration of renal function. A Biomedicine and Health Research Concerted Action.
Angiotensin-converting enzyme insertion/deletion polymorphism and prognosis of IgA nephropathy.
Angiotensin-converting-enzyme inhibitors slow renal decline in IgA nephropathy, independent of tubulointerstitial fibrosis at presentation.
Angiotensin-converting-enzyme insertion/deletion genotype and long-term renal allograft survival.
Angiotensinogen gene variation and renoprotective efficacy of renin-angiotensin system blockade in IgA nephropathy.
Antiproteinuric effect of olmesartan in patients with IgA nephropathy.
Association between ACE polymorphism and risk of IgA nephropathy: A meta-analysis.
Association of a uteroglobin polymorphism with rate of progression in patients with IgA nephropathy.
Association of angiotensin I-converting enzyme gene insertion/deletion polymorphism and IgA nephropathy: a meta-analysis.
Association of angiotensin-converting enzyme gene insertion/deletion polymorphism with the clinico-pathological manifestations in immunoglobulin A nephropathy patients.
Association of angiotensin-converting enzyme gene polymorphism and renal pathology in Japanese children with IgA nephropathy.
Association of angiotensinogen gene T235 variant with progression of immunoglobin A nephropathy in Caucasian patients.
Blood pressure reduction associated with preservation of renal function in hypertensive patients with IgA nephropathy: a 3-year follow-up.
Combination therapy of prednisone and ACE inhibitor versus ACE-inhibitor therapy alone in patients with IgA nephropathy: a randomized controlled trial.
Combined therapy of enalapril and losartan attenuates histologic progression in immunoglobulin A nephropathy.
Comparison of antiproteinuric effects of two different combination therapies in children with IgA nephropathy.
Correlation analysis of angiotensin-converting enzyme, angiotensinogen, and endothelial nitric oxide synthase gene polymorphisms and the progression of immunoglobulin A nephropathy/membranous nephropathy.
Deterioration rate in hypertensive IgA nephropathy: comparison of a converting enzyme inhibitor and beta-blocking agents.
Dual renin-angiotensin system blockade plus oral methylprednisone for the treatment of proteinuria in IgA nephropathy.
Effect of angiotensin-converting enzyme and calcium channel inhibition on progression of IgA nephropathy.
Effects of angiotensin-converting enzyme inhibitor, angiotensin II receptor antagonist and calcium antagonist on urinary podocytes in patients with IgA nephropathy.
Effects of cyclosporin A therapy combined with steroids and angiotensin converting enzyme inhibitors on childhood IgA nephropathy.
Effects of lisinopril administration on blood bcl-2 concentrations in patients with immunoglobulin A nephropathy.
Efficacy and safety of angiotensin-converting enzyme inhibitors/angiotensin receptor blocker therapy for IgA nephropathy: A meta-analysis of randomized controlled trials.
Efficacy and Safety of Renin-Angiotensin Aldosterone System Inhibitor in Patients with IgA Nephropathy: A Meta-Analysis of Randomized Controlled Trials.
Fractional urinary excretion of IgG is the most powerful predictor of renoprotection by ACE inhibitors in IgA nephropathy.
Genetic polymorphisms of the renin-angiotensin-aldosterone system in Chinese patients with end-stage renal disease secondary to IgA nephropathy.
IgA glomerulonephritis: beyond angiotensin-converting enzyme inhibitors.
IgA nephropathy and Henoch-Schönlein purpura nephritis.
IgA nephropathy: an update.
IgACE: a placebo-controlled, randomized trial of angiotensin-converting enzyme inhibitors in children and young people with IgA nephropathy and moderate proteinuria.
Immunoglobulin A nephropathy and chronic kidney disease.
Improved renal survival in Japanese children with IgA nephropathy.
Influence of genetic polymorphisms of the renin-angiotensin system on IgA nephropathy.
Insertion/deletion angiotensin converting enzyme gene polymorphism affects the microvascular structure of the kidney in patients with nondiabetic renal disease.
Interaction between ACE and ADD1 gene polymorphisms in the progression of IgA nephropathy in Japanese patients.
Interdependent effect of angiotensin-converting enzyme and platelet-activating factor acetylhydrolase gene polymorphisms on the progression of immunoglobulin A nephropathy.
Long-term beneficial effects of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker therapy for patients with advanced immunoglobulin A nephropathy and impaired renal function.
Long-term benefits of angiotensin-converting enzyme inhibitor therapy in patients with severe immunoglobulin a nephropathy: a comparison to patients receiving treatment with other antihypertensive agents and to patients receiving no therapy.
Long-term effects of calcium antagonists and angiotensin-converting enzyme inhibitors in patients with chronic renal failure of IgA nephropathy.
Long-term renal prognosis of IgA nephropathy with therapeutic trend shifts.
Loss of renal function following bone marrow transplantation: an analysis of angiotensin converting enzyme D/I polymorphism and other clinical risk factors.
Low-dose sirolimus combined with angiotensin-converting enzyme inhibitor and statin stabilizes renal function and reduces glomerular proliferation in poor prognosis IgA nephropathy.
One-year angiotensin-converting enzyme inhibition plus mycophenolate mofetil immunosuppression in the course of early IgA nephropathy: a multicenter, randomised, controlled study.
Plasma oxidative stress level of IgA nephropathy in children and the effect of early intervention with angiotensin-converting enzyme inhibitors.
Polymorphism of angiotensin converting enzyme, angiotensinogen, and angiotensin II type 1 receptor genes and end-stage renal failure in IgA nephropathy: IGARAS--a study of 274 Men.
Polymorphism of renin-angiotensin system genes in IgA nephropathy.
Polymorphism of the ACE gene in Henoch-Schönlein purpura nephritis.
Polymorphism of the angiotensin converting enzyme gene and clinical aspects of IgA nephropathy.
Polymorphisms in angiotensin-converting enzyme gene and severity of renal disease in Henoch-Schoenlein patients. Italian Group of Renal Immunopathology.
Polymorphisms in angiotensin-converting-enzyme gene and progression of IgA nephropathy.
Polymorphisms of renin-angiotensin system genes in childhood IgA nephropathy.
Renin-angiotensin system gene polymorphisms: its impact on IgAN and its progression to end-stage renal failure among Chinese in Singapore.
Reply to Yang et al. Treatment with low-dose angiotensin-converting enzyme inhibitor (ACEI) plus angiotensin receptor blocker (ARB) in pediatric patients with IgA nephropathy.
Role of the deletion of polymorphism of the angiotensin converting enzyme gene in the progression and therapeutic responsiveness of IgA nephropathy.
Supportive Management of IgA Nephropathy With Renin-Angiotensin Blockade, the AIIMS Primary IgA Nephropathy Cohort (APPROACH) Study.
Supportive Versus Immunosuppressive Therapy of Progressive IgA nephropathy (STOP) IgAN trial: rationale and study protocol.
The DD genotype of the ACE gene polymorphism is associated with progression of diabetic nephropathy to end stage renal failure in IDDM.
The deletion polymorphism of the angiotensin-converting enzyme is associated with nephroangiosclerosis.
The effects of angiotensin-converting enzyme gene polymorphism on the progression of immunoglobulin A nephropathy in Malaysian patients.
The role of angiotensin I-converting enzyme gene polymorphism in renal disease.
Treatment of early immunoglobulin A nephropathy by angiotensin-converting enzyme inhibitor.
Treatment of IgA nephropathy with ACE inhibitors: a randomized and controlled trial.
Treatment of IgA nephropathy with angiotensin converting enzyme inhibitors: design of a prospective randomized multicenter trial.
Treatment with low-dose angiotensin-converting enzyme inhibitor (ACEI) plus angiotensin II receptor blocker (ARB) in pediatric patients with IgA nephropathy.
Urinary proteome in a snapshot: normal urine and glomerulonephritis.
Urine protein profile of IgA nephropathy patients may predict the response to ACE-inhibitor therapy.
Valsartan combined with clopidogrel and/or leflunomide for the treatment of progressive immunoglobulin A nephropathy.
Value of urinary excretion of microalbumin in predicting glomerular lesions in children with isolated microscopic hematuria.
[Multicentered, randomized, controlled clinical trial on patients with IgA nephropathy of Qi-yin deficiency syndrome type]
[Successful treatment of combination therapy using an angiotensin-converting enzyme inhibitor and an angiotensin II receptor blocker in a patient with IgA nephropathy]
[The effects of angiotensin-converting enzyme inhibitor on IgA nephropathy and the influencing factors]
Glomerulonephritis, Membranoproliferative
Effects of angiotensin converting enzyme inhibitor on renal function in patients of membranoproliferative glomerulonephritis with mild to moderate renal insufficiency.
Renin-angiotensin system blockade is renoprotective in immune complex-mediated glomerulonephritis.
Glomerulonephritis, Membranous
Angiotensin-converting enzyme inhibition prevents glomerular-tubule disconnection and atrophy in passive Heymann nephritis, an effect not observed with a calcium antagonist.
Angiotensin-converting enzyme inhibition prevents loss of glomerular hydraulic permeability in passive heymann nephritis.
Antiproteinuric effect of angiotensin-converting enzyme inhibition and C5b-9 urinary excretion in membranous glomerulonephritis.
Comparison of the influence of angiotensin-converting enzyme inhibitor lisinopril and angiotensin II receptor antagonist losartan in patients with idiopathic membranous nephropathy and nephrotic syndrome.
Effect of dietary protein and enalapril on proximal tubular delivery and absorption of albumin in nephrotic rats.
Effect of dietary protein intake and angiotensin converting enzyme inhibition in Heymann nephritis.
Low-dose angiotensin-converting-enzyme inhibitor captopril to reduce proteinuria in adult idiopathic membranous nephropathy: a prospective study of long-term treatment.
Management of glomerular diseases of primary and secondary origin.
Membranous glomerulonephritis induced in the pig by antibody to angiotensin-converting enzyme: considerations on its relevance to the pathogenesis of human idiopathic membranous glomerulonephritis.
Membranous glomerulopathy and treatment with Acthar®: a case study.
Passive Heymann nephritis: evidence that angiotensin-converting enzyme inhibition reduces proteinuria and retards renal structural injury.
Prostaglandins, angiotension II, and proteinuria.
Renoprotective effect of contemporary blocking of angiotensin II and endothelin-1 in rats with membranous nephropathy.
Spironolactone Plus Full-Dose ACE Inhibition in Patients with Idiopathic Membranous Nephropathy and Nephrotic Syndrome: Does It Really Work?
Successful effect of triple blockade of renin-angiotensin-aldosterone system on massive proteinuria in a patient with chronic kidney disease.
Successful therapeutic use of rituximab in refractory membranous glomerulonephritis.
The effects of enalapril on urinary protein excretion in patients with idiopathic membranous nephropathy.
The renoprotective properties of angiotensin-converting enzyme inhibitors in a chronic model of membranous nephropathy are solely due to the inhibition of angiotensin II: evidence based on comparative studies with a receptor antagonist.
Treatment of idiopathic membranous nephropathy with the herb Astragalus membranaceus.
Glomerulosclerosis, Focal Segmental
ACE-inhibition increases podocyte number in experimental glomerular disease independent of proliferation.
Angiotensin antagonists and steroids in the treatment of focal segmental glomerulosclerosis.
Angiotensin converting enzyme gene polymorphism in Indian children with steroid sensitive nephrotic syndrome.
Angiotensin converting enzyme inhibition prevents development of collapsing focal segmental glomerulosclerosis in Thy-1.1 transgenic mice.
Angiotensin-converting enzyme gene polymophism in adult primary focal segmental glomerulosclerosis.
Angiotensin-converting enzyme gene polymorphism and the progression rate of focal segmental glomerulosclerosis in Iranian children.
Angiotensin-converting enzyme gene polymorphism in patients with minimal-change nephrotic syndrome and focal segmental glomerulosclerosis.
Cyanotic congenital heart disease associated with glomerulomegaly and focal segmental glomerulosclerosis: remission of nephrotic syndrome with angiotensin converting enzyme inhibitor.
Early, but not late therapy with a vasopressin V1a-antagonist ameliorates the development of renal damage after 5/6 nephrectomy.
Effect of proteinuria reduction on prevention of focal glomerulosclerosis by angiotensin-converting enzyme inhibition is modifiable.
Effects of the genetic polymorphisms of the renin-angiotensin system on focal segmental glomerulosclerosis.
Focal segmental glomerulosclerosis in African Americans: effects of steroids and angiotensin converting enzyme inhibitors.
Renal protective effects of angiotensin-converting enzyme inhibition.
Significance of ACE genotypes and medical treatments in childhood focal glomerulosclerosis.
The association between angiotensin-converting enzyme insertion/deletion gene variant and risk of focal segmental glomerulosclerosis: a systematic review and meta-analysis.
The role of kidney biopsy in diagnosis of preeclampsia in kidney transplant patients.
Use of angiotensin converting enzyme inhibitors for the treatment of focal segmental glomerulosclerosis.
Glucose Intolerance
Adverse effects of antihypertensive drug therapy on glucose intolerance.
Can thiazolidinediones delay disease progression in type 2 diabetes?
Cardiovascular kinin-generating capability in hypertensive fructose-fed rats.
Effect of cilazapril therapy on glucose and lipid metabolism in patients with hypertension.
Effect of ramipril and of rosiglitazone on carotid intima-media thickness in people with impaired glucose tolerance or impaired fasting glucose: STARR (STudy of Atherosclerosis with Ramipril and Rosiglitazone).
Effects of perindopril on glucose and lipid metabolism in patients with mild-to-moderate essential hypertension and glucose intolerance.
Increase in nitric oxide and reductions in blood pressure, protein kinase C beta II and oxidative stress by L-carnitine: a study in the fructose-fed hypertensive rat.
Insulin resistance in essential hypertensive patients with impaired glucose tolerance.
Interactions of exercise training and ACE inhibition on insulin action in obese Zucker rats.
Relations between deletion polymorphism of the angiotensin-converting enzyme gene and insulin resistance, glucose intolerance, hyperinsulinemia, and dyslipidemia.
Relationship of the angiotensin-converting enzyme gene polymorphism to glucose intolerance, insulin resistance, and hypertension in NIDDM.
The effect of angiotensin-converting enzyme inhibition using captopril on energy balance and glucose homeostasis.
Thiazide and loop diuretics.
Treatment of diabetic vasculopathy with rosiglitazone and ramipril: Hype or hope?
Treatment of insulin resistance in uremia.
Why are physicians not prescribing diuretics more frequently in the management of hypertension?
[The role of angiotensin-converting enzyme gene I/D polymorphism in development of metabolic disorders in patients with cardiovascular pathology]
glycogen phosphorylase deficiency
Phenotype modulators in myophosphorylase deficiency.
Glycogen Storage Disease
Progression of Renal Damage in Glycogen Storage Disease Type I Is Associated to Hyperlipidemia: A Multicenter Prospective Italian Study.
Glycogen Storage Disease Type I
Progression of Renal Damage in Glycogen Storage Disease Type I Is Associated to Hyperlipidemia: A Multicenter Prospective Italian Study.
Glycogen Storage Disease Type II
The angiotensin-converting enzyme insertion/deletion polymorphism modifies the clinical outcome in patients with Pompe disease.
The influence of a polymorphism in the gene encoding angiotensin converting enzyme (ACE) on treatment outcomes in late-onset Pompe patients receiving alglucosidase alfa.
Glycogen Storage Disease Type V
Phenotype modulators in myophosphorylase deficiency.
Randomized, placebo-controlled, double-blind pilot trial of ramipril in McArdle's disease.
The I allele of the ACE gene is associated with improved exercise capacity in women with McArdle disease.
Variable presentation of the clinical phenotype of McArdle's disease in a kindred harbouring a novel compound genotype in the muscle glycogen phosphorylase gene.
Glycogen Storage Disease Type VI
Sarcoidosis with acute recurrent polyarthritis and hypercalcemia.
Glycosuria
Angiotensin-converting enzyme inhibitors and glycosuria.
Glycosuria, Renal
Angiotensin-converting enzyme inhibitors and glycosuria.
Goiter, Nodular
Comparison of serum angiotensin-converting enzyme in Graves' disease, toxic nodular goiter, and other thyroid conditions.
Gonadoblastoma
Gonadoblastoma: evidence for a stepwise progression to dysgerminoma in a dysgenetic ovary.
Gout
Evidence for the presence of dipeptidyl carboxypeptidase and its inhibitors in inflammatory synovial fluids.
Gout and dementia in the elderly: a cohort study of Medicare claims.
Journal scan.
Six-minute walk distance predicts 30-day readmission in hospitalized heart failure patients.
The risk of polymyalgia rheumatica in older adults with gout: a Medicare claims study.
The role of kinin B1 receptor and the effect of angiotensin I-converting enzyme inhibition on acute gout attacks in rodents.
Granuloma
A case of neurosarcoidosis with necrotizing granuloma expressing angiotensin-converting enzyme.
A case of renal sarcoidosis showing central necrosis and abnormal expression of angiotensin converting enzyme in the granuloma.
A case of sarcoidosis associated with bronchial asthma.
A case of sarcoidosis with severe acute renal failure requiring dialysis.
A comparison of foreign body and hypersensitivity granuloma formation in the mouse: kinetic development, anergy, angiotensin converting enzyme levels, and response to captopril therapy.
A curious case of growth failure and hypercalcemia: Answers.
A curious case of growth failure and hypercalcemia: Questions.
A patient with hepatic granuloma formation and angiotensin-converting enzyme production by granuloma cells during clinical relapse of hepatitis A.
A patient with sarcoidosis presenting with acute renal failure: implication for granulomatous interstitial nephritis and hypercalcemia.
Alteration of granuloma angiotensin I-converting enzyme activity by regulatory T lymphocytes in murine schistosomiasis.
Amounts of angiotensin-converting enzyme mRNA reflect the burden of granulomas in granulomatous lung disease.
An improved noninfectious murine skin model of organized granulomatous inflammation.
An in vitro model for the induction of angiotensin-converting enzyme in sarcoidosis: possible parallels to the immune response.
Angiotensin converting enzyme concentrations in rabbits with talc-induced pulmonary granulomas.
Angiotensin II augmentation of tyrosine kinase activity in human adherent mononuclear cells.
Angiotensin-converting Enzyme as a Predictor of Extrathoracic Involvement of Sarcoidosis.
Angiotensin-converting enzyme in macrophages and Freund's adjuvant granuloma.
Angiotensin-converting enzyme in sarcoid and chalazion granulomas of the conjunctiva.
ApoE-deficient mice on cholate-containing high-fat diet reveal a pathology similar to lung sarcoidosis.
Association of peripheral multifocal choroiditis with sarcoidosis: a study of thirty-seven patients.
Captopril enhances in vitro human lymphocyte thymidine incorporation.
Cardiac Sarcoidosis Presenting as Acute Progressive Heart Failure with Abdominal Lymphadenopathy.
Characteristics of monocyte angiotensin-converting enzyme (ACE) induction by dexamethasone.
Characteristics of patients presenting with erythema nodosum and sarcoidosis.
Childhood Sarcoidosis Presenting as Recurrent Facial Palsy.
Choroidal granuloma in sarcoidosis.
Coexistent sarcoidosis and lymphangioleiomyomatosis in a patient with cystic lung disease.
Comparison of the T lymphocyte-dependent induction of angiotensin-converting enzyme and leucine aminopeptidase in cultured human monocytes.
Corticosteroid-resistant bulbar neurosarcoidosis responsive to intravenous immunoglobulin.
Effect of SQ 14225, an inhibitor of angiotensin I-converting enzyme, on the granulomatous response to Schistosoma mansoni eggs in mice.
Effects of granuloma modulation induced by regulatory-T-lymphocyte activity on angiotensin II/III production by granuloma macrophages in murine schistosomiasis mansoni.
Endoscopic diagnosis of sarcoidosis in a patient presenting with bilateral exophthalmos and pansinusitis.
Enhanced granuloma angiotensin I converting enzyme activity associated with modulation in murine schistosomiasis.
Gamma-delta T cells in sarcoidosis. Correlation with clinical features.
Heerfordt syndrome: a cause of facial paralysis.
HFE Hemochromatosis and Hepatic Sarcoid.
Histoplasmosis: a masquerader of sarcoidosis.
Immunofluorescent localization of angiotensin converting enzyme in epithelioid and giant cells of sarcoidosis granulomas.
Immunohistologic diagnosis of sarcoidosis. Detection of angiotensin-converting enzyme in sarcoid granulomas.
In vitro angiotensin-converting enzyme and interleukin-1 production by epithelioid cells isolated from induced rabbit lung granuloma.
Induction of granuloma-dependent angiotensin-converting enzyme and eosinophil chemotactic factor in the skin of athymic nude mice.
La crosse virus encephalitis preceding neurosarcoidosis diagnosed by brain biopsy.
Localization of angiotensin converting enzyme (ACE) in granulomas of sarcoidosis cutaneous lesions.
Lysozyme and angiotensin converting enzyme levels in experimental mycobacterial granulomas.
Markedly elevated angiotensin converting enzyme in lymph nodes containing non-necrotizing granulomas in sarcoidosis.
Mediastinal Seminoma with an Elevated Level of Serum Angiotensin-converting Enzyme.
Melkersson-Rosenthal syndrome: elevations in serum angiotensin converting enzyme and results of treatment with methotrexate.
Ocular sarcoidosis misdiagnosed as primary intraocular lymphoma.
Optic Nerve Head Granuloma, Retinal Vasculitis and Elevated Levels of Angiotensin-converting Enzyme: Dilemma of Forme Fruste Ocular Sarcoidosis.
Pathogenesis of sarcoidosis: an hypothetical model.
Possible role of the hormonal form of vitamin D3 in the granuloma-associated angiotensin-converting enzyme activity.
Primary presentation of sarcoidosis with profound bilateral sensorineural hearing loss.
Primary Sjögren's syndrome complicated by sarcoidosis.
Production of angiotensin I converting enzyme by liver granuloma macrophages of Schistosoma mansoni infected mice.
Prolonged generalized pruritus associated with selective elevation of IgA as the presenting symptoms of sarcoidosis.
Prolonged Uhthoff phenomenon in sarcoidosis.
Recurrence of sarcoidosis following interferon alpha therapy for chronic hepatitis C.
Reversible esophageal motility disorder in a patient with sarcoidosis.
Sarcoidosis detected due to tattoo swellings in an Indian female.
Sarcoidosis in a patient with systemic sclerosis and primary biliary cirrhosis.
Sarcoidosis Presenting Addison's Disease.
Schistosoma mansoni: angiotensin converting enzyme activity in mice under the influence of praziquantel and/or captopril.
Sequential development of angiotensin receptors and angiotensin I converting enzyme during angiogenesis in the rat subcutaneous sponge granuloma.
Serum angiotensin I-converting enzyme level in patients with cutaneous sarcoidal granulomas.
Serum angiotensin-converting enzyme (SACE) activity as an indicator of total body granuloma load and prognosis in sarcoidosis.
Serum angiotensin-converting-enzyme in Crohn's disease.
Serum angiotensin-converting-enzyme in rabbits with and without pulmonary granulomatosis. Granulomatosis induced with complete-Freund's-adjuvant or BCG.
Severe refractory sarcoidosis in a 64-year-old man with persistent leucopenia.
Sinonasal sarcoidosis: review and report of fifteen cases.
Skin as a marker of internal disease: a case of sarcoidosis.
Studies of heterogeneity of angiotensin-converting enzyme and acid phosphatase in granulomatous lesions of skin.
Talc granulomatosis: laboratory findings similar to sarcoidosis.
The significance of angiotensin I converting enzyme in granulomatous inflammation. Functions of ACE in granulomas.
Widespread foreign-body granulomas and elevated serum angiotensin-converting enzyme.
X-linked chronic granulomatous disease (CGD) caused by an intra-exonic splice mutation (CYBB exon 3, c.262G->A) is mimicking juvenile sarcoidosis.
[A case of pulmonary sarcoidosis complicated with bronchial asthma that proved eosinophilic invasion].
[A case of sarcoidosis presenting with high fever and rash progressing to acute respiratory failure]
[A study of epithelioid cell granulomas in transbronchial lung biopsy specimens of sarcoidosis patients--correlation between granulomas and clinical activity or chest X-ray lesions]
[Angiotensin I-converting enzyme (ACE) for sarcoidosis diagnosis]
[Angiotensin I-converting enzyme in cerebrospinal fluid and neurosarcoidosis]
[Branch retinal vein occlusion and sarcoidosis in a child: A case report.]
[Direct effect of angiotensin converting enzyme (ACE) on experimental granuloma formation in the rabbit lung]
[Immunohistochemical localization of angiotensin converting enzyme in epithelioid sarcoidosis granulomas]
[Localization and chronologic changes of angiotensin-converting enzyme in experimental pulmonary granulomas by the substrate film technique. Comparison with serum ACE activity and tissue ACE activity]
[Localization of angiotensin converting enzyme (ACE) in granulomas of sarcoidosis of the skin]
[Localization of angiotensin-converting enzyme and its activity in sarcoid granuloma by the substrate film technic]
[Localization of tissue angiotensin-converting enzyme activity in rabbit lung--comparison between normal lung and the lung with granulomas induced by Freund's complete adjuvant]
[Mediastino-pulmonary localizations of sarcoidosis]
[Neurosarcoidosis presenting with severe hyposmia and polyradiculopathy].
[Pulmonary infiltrates in a 19 year old patient with dysuria and hypercalcemia]
[Sarcoid granuloma simulating amelanotic melanoma of the iris: a case report]
[Sarcoidosis with hypercalcemia and increased 1 alpha, 25-dihydroxyvitamin D in lung tissue]
[Weight loss, joint pain and abdominal lymphadenopathy as signs of sarcoidosis, but also of Whipple's disease]
Granuloma Annulare
Serum angiotensin-converting enzyme in granuloma annulare.
Granulomatosis with Polyangiitis
Gene polymorphisms of immunoregulatory cytokines and angiotensin-converting enzyme in Wegener's granulomatosis.
Sinonasal sarcoidosis: review and report of fifteen cases.
The investigation of nasal septal perforations and ulcers.
Granulomatous Disease, Chronic
Serum angiotensin-converting enzyme activity in chronic granulomatous disease.
Graves Disease
Angiotensin-converting enzyme and anorexia nervosa.
Changes of serum angiotensin-converting enzyme activity during treatment of patients with Graves' disease.
Comparison of serum angiotensin-converting enzyme in Graves' disease, toxic nodular goiter, and other thyroid conditions.
Thyroid hormones affect serum angiotensin I converting enzyme levels.
[Changes in serum levels of angiotensin converting enzyme in Basedow's disease]
Gynecomastia
Gynecomastia and hypertension.
Hallucinations
Doctor, there's a fly in my soup! Angiotensin-converting enzyme inhibitors, endogenous opioids and visual hallucinations.
Hallucinations as an adverse effect of angiotensin converting enzyme inhibition.
Highlights of the 22nd French pharmacovigilance meeting.
The Protean Neuropsychiatric and Vestibuloauditory Manifestations of Neurosarcoidosis.
Visual hallucinations related to angiotensin-converting enzyme inhibitor use: case reports and review.
Hamartoma
The personalised medicine. A paradigm of evidence-based medicine.
Head and Neck Neoplasms
Angiotensin-converting enzyme inhibitors predict acute kidney injury during chemoradiation for head and neck cancer.
Survival impact of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists in head and neck cancer.
Headache Disorders, Primary
Headaches precipitated by cough, prolonged exercise or sexual activity: a prospective etiological and clinical study.
Headache Disorders, Secondary
Cortical response to somatosensory stimulation in medication overuse headache patients is influenced by angiotensin converting enzyme (ACE) I/D genetic polymorphism.
Healthcare-Associated Pneumonia
Genetic Association Between CD143 rs4340 Polymorphism and Pneumonia risk: A Meta Analysis.
Hearing Loss
The Protean Neuropsychiatric and Vestibuloauditory Manifestations of Neurosarcoidosis.
Heart Arrest
Angiotensin II: a new therapeutic option for vasodilatory shock.
Angiotensin-converting enzyme inhibitor - An innocuous factor behind cardiac arrest following induction of anesthesia.
Angiotensin-converting enzyme inhibitor and cardiac arrest following induction of anesthesia.
Captopril improves postresuscitation hemodynamics protective against pulmonary embolism by activating the ACE2/Ang-(1-7)/Mas axis.
Effects of angiotensin-I and ischemia on functional recovery in isolated hearts.
Effects of long-term vasodilator therapy in patients with carotid sinus hypersensitivity.
Intraoperative cardiac arrest: was it the ACE inhibitor?
Pre-hospital cardiac arrest in acute coronary syndromes: insights from the global registry of acute coronary events and the canadian registry of acute coronary events.
Preventable sudden death in patients receiving angiotensin converting enzyme inhibitors and loop/potassium sparing diuretic combinations.
Risk factors for pacemaker implantation following aortic valve replacement: a single centre experience.
The potential mechanisms of reduced incidence of ventricular fibrillation as the presenting rhythm in sudden cardiac arrest.
Heart Block
A Patient Infected with SARS-CoV-2 Presenting with Complete Heart Block.
Syncope caused by iatrogenic hyperkalemia.
Heart Defects, Congenital
Angiotensin converting enzyme activity in children with congenital heart disease.
Angiotensin Converting Enzyme Inhibitor (ACEI)-Induced Acute Renal Failure in Premature Newborns with Congenital Heart Disease.
Angiotensin converting enzyme inhibitor improves nephrotic syndrome associated with cyanotic congenital heart disease.
Angiotensin-converting enzyme gene insertion deletion (ACE I/D) polymorphism in Saudi children with congenital heart disease.
Angiotensin-converting enzyme inhibition alters the inflammatory and fibrinolytic response to cardiopulmonary bypass in children.
Angiotensin-converting enzyme inhibitors in adults with cyanotic congenital heart disease.
Angiotensin-converting enzyme insertion/deletion (ACE I/D) gene polymorphism in Egyptian children with congenital heart disease.
Applying standard therapies to new targets: the use of ACE inhibitors and B-blockers for heart failure in adults with congenital heart disease.
Cyanotic congenital heart disease associated with glomerulomegaly and focal segmental glomerulosclerosis: remission of nephrotic syndrome with angiotensin converting enzyme inhibitor.
Nephropathy of cyanotic congenital heart disease: clinical characteristics and effectiveness of an angiotensin-converting enzyme inhibitor.
Thrombomodulin and angiotensin-converting enzyme activity during pediatric open heart operations.
Treatment of chronic heart failure in the 21st century: A new era of biomedical engineering has come.
[Angiotensin converting enzyme activity in atrial and cubital venous blood]
[Association study between the angiotensin converting enzyme gene insertion/deletion polymorphism and Qinghai Han Chinese with congenital heart disease].
Heart Diseases
A DNA variant at the angiotensin-converting enzyme gene locus associates with coronary artery disease in the Caerphilly Heart Study.
A Liquid Chromatography-Tandem Mass Spectrometry Method for Evaluation of Two Brands of Enalapril 20?mg Tablets in Healthy Human Volunteers.
A new myocardial conversion of angiotensin I.
A prospective, double-blind, randomized controlled trial of the angiotensin-converting enzyme inhibitor Ramipril In Aortic Stenosis (RIAS trial).
ACE gene polymorphism in Turkish children with nephrotic syndrome.
ACE-inhibitors and defence reflexes of the airways.
Acetaminophen-Induced Changes in Systemic Blood Pressure in Critically Ill Patients: Results of a Multicenter Cohort Study.
Advanced hypertensive heart disease in spontaneously hypertensive rats. Lisinopril-mediated regression of myocardial fibrosis.
AL Amyloidosis.
Aldosterone breakthrough during angiotensin-converting enzyme inhibitor therapy.
An overview of the influence of ACE inhibitors on fetal-placental circulation and perinatal development.
Angiotensin converting enzyme (ACE) gene expression in the human left ventricle: effect of ACE gene insertion/deletion polymorphism and left ventricular function.
Angiotensin converting enzyme (ACE) insertion/deletion (I/D) polymorphism, and diabetic retinopathy in subjects with IDDM and NIDDM.
Angiotensin converting enzyme and angiotensin II type 1-receptor gene polymorphisms and risk of ischaemic heart disease.
Angiotensin converting enzyme inhibition modulates cardiac fibroblast growth.
Angiotensin converting enzyme inhibitors and ischaemic heart disease.
Angiotensin II type 1 receptor A1166C gene polymorphism. Absence of an association with the risk of coronary artery disease and myocardial infarction and of a synergistic effect with angiotensin-converting enzyme gene polymorphism on the risk of these diseases.
Angiotensin-converting enzyme activity and inhibition in dogs with cardiac disease and an angiotensin-converting enzyme polymorphism.
Angiotensin-converting enzyme and angiotensinogen gene polymorphisms and heart rate variability in twins.
Angiotensin-converting enzyme and heart chymase gene polymorphisms in hypertrophic cardiomyopathy.
Angiotensin-converting enzyme gene insertion/deletion polymorphism in Egyptian patients with myocardial infarction.
Angiotensin-converting enzyme gene polymorphism and cardiovascular disease.
Angiotensin-converting enzyme gene polymorphism is not associated with coronary atherosclerosis and myocardial infarction in a sample of Italian patients.
Angiotensin-converting enzyme inhibitor nephrotoxicity in neonates with cardiac disease.
Angiotensin-converting enzyme inhibitors are associated with the need for increased recombinant human erythropoietin maintenance doses in hemodialysis patients. Risks of Cardiac Disease in Dialysis Patients Study Group.
Angiotensin-converting enzyme inhibitors as cardioprotective agents.
Angiotensin-converting enzyme inhibitors in acute myocardial infarction: a clinical approach.
Angiotensin-converting enzyme inhibitors slow recovery from anemia following cardiac surgery.
Angiotensinogen Met235Thr polymorphism, angiotensin-converting enzyme inhibitor therapy, and the risk of nonfatal stroke or myocardial infarction in hypertensive patients.
Anti-adrenergic effects of angiotensin converting enzyme inhibitors.
Anti-arrhythmic drug therapy for atrial fibrillation: current anti-arrhythmic drugs, investigational agents, and innovative approaches.
Antihypertensive drug therapy in Saskatchewan: patterns of use and determinants in hypertension.
Aortic atherosclerosis in diabetes mellitus is associated with an insertion/deletion polymorphism in the angiotensin I-converting enzyme gene. No relation between the polymorphism and aortic collagen content.
Asphyxia due to angiotensin converting enzyme (ACE) inhibitor mediated angioedema of the tongue during the treatment of hypertensive heart disease.
Assessment of risk factors for mortality in patients with cardiovascular disease and a history of treatment for malignancy.
Association between angiotensin-converting enzyme insertion/deletion polymorphisms and the risk of heart disease: an updated meta-analysis.
Asymptomatic cardiac involvement in Thai systemic sclerosis: prevalence and clinical correlations with non-cardiac manifestations (preliminary report).
AT1 receptors: coronary flow and flow reserve.
B2-kinin receptor plays a key role in B1-, angiotensin converting enzyme inhibitor-, and vascular endothelial growth factor-stimulated in vitro angiogenesis in the hypoxic mouse heart.
Captopril ameliorates myocarditis in acute experimental Chagas disease.
Cardiac complications of systemic sclerosis.
Cardioprotective effect of angiotensin-converting enzyme inhibitors in patients with coronary artery disease.
Cardioreparative effects of lisinopril in rats with genetic hypertension and left ventricular hypertrophy.
Characteristics and prognosis of patients with acute heart failure without troponin determination: The EAHFE-TROPICA3 study.
Chronic dual inhibition of angiotensin-converting enzyme and neutral endopeptidase during the development of left ventricular dysfunction in dogs.
Chronic oral therapy with enalapril in normal ponies.
Combination therapy with Renin-Angiotensin-aldosterone receptor blockers for hypertension: how far have we come?
Comparison of the effects of imidapril and enalapril in a prospective, multicentric randomized trial in dogs with naturally acquired heart failure.
Differences in mean and variability of heart rate and ambulatory rate-pressure product when valsartan or carvedilol is added to lisinopril.
Differential response to resistance training in CHF according to ACE genotype.
Effect of angiotensin-converting enzyme inhibitors on non-diseased myocardium of experimental animals: potential clinical implications.
Effect of combinations of drugs on all cause mortality in patients with ischaemic heart disease: nested case-control analysis.
Effect of the renin-angiotensin-aldosterone system on the cardiac interstitium in heart failure.
Effects of angiotensin-converting enzyme inhibitors on tissue renin-angiotensin systems.
Effects of enalapril, tempol, and eplerenone on salt-induced hypertension in dahl salt-sensitive rats.
Effects of growth hormone following chronic angiotensin-converting enzyme inhibition in chronic heart failure: their relation to infarct size.
Effects of the ACE inhibitor quinapril on echocardiographic variables in horses with mitral valve insufficiency.
Eplerenone: selective aldosterone antagonism in management of cardiovascular and renal disease.
Evaluation of benazepril in cats with heart disease in a prospective, randomized, blinded, placebo-controlled clinical trial.
Functional polymorphisms in ACE and CYP11B2 genes and atrial fibrillation in patients with hypertensive heart disease.
Geriatric heart diseases in dogs.
Gout and dementia in the elderly: a cohort study of Medicare claims.
Haemodynamic and myocardial metabolic effects of captopril in chronic heart failure.
Improvement of coronary flow reserve after long-term therapy with enalapril.
Influence of angiotensin converting enzyme inhibition on relation of atrial natriuretic peptide concentration to atrial pressure in heart failure.
Influence of Angiotensin-converting Enzyme Insertion/Deletion Gene Polymorphism in Progression of Chagas Heart Disease.
Inhibition of RNA synthesis by bradykinin involves both the B1 and B2 receptor subtypes.
Left bundle-branch block is associated with increased 1-year sudden and total mortality rate in 5517 outpatients with congestive heart failure: a report from the Italian network on congestive heart failure.
Lisinopril-mediated regression of myocardial fibrosis in patients with hypertensive heart disease.
Local renin-angiotensin systems in the genitourinary tract.
Management of a case of peripartum cardiomyopathy.
Management of hypertension in patients with cardiac disease: use of renin-angiotensin blocking agents.
Managing heart failure in a specialist clinic.
Meta-analysis of association of insertion/deletion polymorphism of angiotensin I-converting enzyme gene with diabetic nephropathy and retinopathy.
Methodological Comparisons of Heart Rate Variability Analysis in Patients With Type 2 Diabetes and Angiotensin Converting Enzyme Polymorphism.
Myocardial collagen matrix remodeling and congestive heart failure.
Nerve growth factor and neuropeptides circulating levels in systemic sclerosis (scleroderma).
Neutrophil hypersegmentation in children receiving angiotensin converting enzyme inhibitors.
New antiarrhythmic drugs for atrial fibrillation: Focus on dronedarone and vernakalant.
Outcomes for patients with COVID-19 admitted to Australian intensive care units during the first four months of the pandemic.
Primary systemic amyloidosis and high levels of Angiotensin-converting enzyme: two case reports.
Prospectives for angiotensin converting enzyme inhibition in heart diseases.
Regression of cardiac hypertrophy: experimental and clinical results.
Retrospective evaluation of a dose-dependent effect of angiotensin-converting enzyme inhibitors on long-term outcome in dogs with cardiac disease.
Role of bradykinin and eNOS in the anti-ischaemic effect of trandolapril.
Role of bradykinin and tachykinins in the potentiation by enalapril of coughing induced by citric acid in pigs.
Role of the cardiac renin-angiotensin system in human heart failure.
Safety of Enalapril in Infants: Data from the Pediatric Heart Network Infant Single Ventricle Trial.
Should aspirin be used with angiotensin-converting enzyme inhibitors in patients with chronic heart failure?
Spironolactone in severe heart failure: enhances efficacy of diuretic + ACE inhibitor combinations.
Statins and polyunsaturated fatty acids for treatment of atrial fibrillation.
Synthesis and evaluation of a series of 99mTc(CO)3+ lisinopril complexes for in vivo imaging of angiotensin-converting enzyme expression.
The Association of Renin-Angiotensin-Aldosterone System Inhibitors With Outcomes Among a Predominantly Ethnic Minority Patient Population Hospitalized With COVID-19: The Bronx Experience.
The DD-ACE genotype and cardiovascular disease.
The effects of initial drug choice and comorbidity on antihypertensive therapy compliance: results from a population-based study in the elderly.
Therapeutic management of elderly hypertensives with concomitant ischaemic heart disease.
Transient recurrent ascites.
Treatment of dystrophin cardiomyopathies.
Treatment of hypertensive heart disease with ACE inhibitors.
Upstream therapies for management of atrial fibrillation: review of clinical evidence and implications for European Society of Cardiology guidelines. Part II: secondary prevention.
What can be expected for the management of heart failure in the near future?
[Role of antihypertensive drugs in the treatment of migraine].
[Serum potassium levels and long-term mortality in the elderly with hypertension].
[The role of diabetes mellitus in cardiac disease in Spain. The CARDIOTENS Study 1999]
[The role of DNA polymorphism in the renin-angiotensin system and the pathogenesis of cardiovascular diseases]
Heart Failure
"Triple therapy" of heart failure with angiotensin-converting enzyme inhibitor, beta-blocker, and aldosterone antagonist may triple survival time: shouldn't we tell patients?
A 13-year review of lisinopril ingestions in children less than 6 years of age.
A 3-month double-blind cross-over study of the effect of benazepril and hydrochlorothiazide on functional class in symptomatic mild heart failure.
A Bayesian nonparametric causal inference model for synthesizing randomized clinical trial and real-world evidence.
A clinical approach to the management of a patient with suspected renovascular disease who presents with leg ischemia.
A comparative study of the first dose hypotensive effects of captopril and perindopril in patients with heart failure.
A comparative study of the prevalence of hyperkalemia with the use of angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers.
A comparison of intervention with losartan or captopril in acute myocardial infarction.
A comparison of the effects of captopril and flosequinan in patients with severe heart failure.
A cooperative multicenter study of captopril in congestive heart failure: hemodynamic effects and long-term response.
A coronary artery fistula having connection between 2 coronary arteries and the left ventricle: A case report.
A critical evaluation of the NICE guidelines for post-myocardial infarction prophylaxis. National Institute for Clinical Excellence.
A Database Cohort Study to Assess the Risk of Angioedema Among Patients with Heart Failure Initiating Angiotensin-Converting Enzyme Inhibitors in the USA.
A double-blind comparison of lisinopril with captopril in patients with symptomatic congestive heart failure.
A mechanistic investigation of ACE inhibitor dose effects on aerobic exercise capacity in heart failure patients.
A meta-analysis reporting effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients without heart failure.
A metabolomics study of Qiliqiangxin in a rat model of heart failure: a reverse pharmacology approach.
A Modern History RAAS Inhibition and Beta Blockade for Heart Failure to Underscore the Non-equivalency of ACEIs and ARBs.
A multi-center, double-blind, randomized, parallel group study to evaluate the effects of two different doses of losartan on morbidity and mortality in Chinese patients with symptomatic heart failure intolerant of angiotensin converting enzyme inhibitor treatment.
A multicenter study of the safety and efficacy of benazepril hydrochloride, a long-acting angiotensin-converting enzyme inhibitor, in patients with chronic congestive heart failure.
A multicenter, randomized, double-blind, placebo-controlled trial of pimobendan, a new cardiotonic and vasodilator agent, in patients with severe congestive heart failure.
A multicentre, double-blind, placebo-controlled trial of quinapril in mild, chronic heart failure.
A multivariate model for predicting mortality in patients with heart failure and systolic dysfunction.
A national survey of heart failure in French hospitals. The Myocardiopathy and Heart Failure Working Group of the French Society of Cardiology, the National College of General Hospital Cardiologists and the French Geriatrics Society.
A new angiotensin-converting enzyme inhibitor: treatment of hypertension and congestive heart failure. Proceedings of an international symposium on enalapril, sponsored by Merck Sharp & Dohme International, São Paulo, Brazil, November 10, 1984.
A new myocardial conversion of angiotensin I.
A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9.
A Novel Design of Combining ACE Inhibitor Captopril with Angiotensin Receptor blocker Losartan Using Homo Coupling Via PEG Diacid Linker.
A Novel Intelligent Two-Way Communication System for Remote Heart Failure Medication Uptitration (the CardioCoach Study): Randomized Controlled Feasibility Trial.
A Novel Therapeutic Approach in the Treatment of Pulmonary Arterial Hypertension: Allium ursinum Liophylisate Alleviates Symptoms Comparably to Sildenafil.
A per-protocol initiation of sacubitril/valsartan in an advanced heart failure disease management programme in the Middle East Gulf Region.
A perspective on telmisartan and cardiovascular risk.
A pharmacokinetic study of cilazapril in patients with congestive heart failure.
A physician targeted intervention improves prescribing in chronic heart failure in general medical units.
A prognostic index to predict long-term mortality in patients with mild to moderate chronic heart failure stabilised on angiotensin converting enzyme inhibitors.
A propensity score analysis of the impact of angiotensin-converting enzyme inhibitors on long-term survival of older adults with heart failure and perceived contraindications.
A propensity-matched study of the comparative effectiveness of angiotensin receptor blockers versus angiotensin-converting enzyme inhibitors in heart failure patients age ? 65 years.
A propensity-matched study of the effects of chronic diuretic therapy on mortality and hospitalization in older adults with heart failure.
A prospective study of frequency and characteristics of cough during ACE inhibitor treatment.
A prospective, double-blind, randomized controlled trial of the angiotensin-converting enzyme inhibitor Ramipril In Aortic Stenosis (RIAS trial).
A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: The Flolan International Randomized Survival Trial (FIRST).
A randomized trial of ecadotril versus placebo in patients with mild to moderate heart failure: the U.S. ecadotril pilot safety study.
A Rapid Access Heart Failure Clinic provides a prompt diagnosis and appropriate management of new heart failure presenting in the community.
A review of heart failure treatment.
A review of Perindopril in the reduction of cardiovascular events.
A review of the current evidence for the use of angiotensin-receptor blockers in chronic heart failure.
A review of the role of statins in heart failure treatment.
A risk score to predict the absence of left ventricular reverse remodeling: Implications for the timing of ICD implantation in primary prevention.
A simple bedside test of 1-minute heart rate variability during deep breathing as a prognostic index after myocardial infarction.
A Single-Center, Open-Label, Randomized, Parallel-Group Study Assessing the Differences Between an Angiotensin II Receptor Antagonist and an Angiotensin-Converting Enzyme Inhibitor in Hypertensive Patients with Congestive Heart Failure: The Research for Efficacy of Angiotensin II Receptor Antagonist in Hypertensive Patients with Congestive Heart Failure Study.
A story of two ACEs.
A Study of Prescribing Valsartan in Out-patient Clinics at the Royal Hospital, Muscat, Oman.
A study of the efficacy and safety of irbesartan in combination with conventional therapy, including ACE inhibitors, in heart failure. Irbesartan Heart Failure Group.
A study of the sequential treatment of acute heart failure with sacubitril/valsartan by recombinant human brain natriuretic peptide: A randomized controlled trial.
A survey of current use of angiotensin-converting-enzyme inhibitors by Scottish physicians in the treatment of chronic cardiac failure.
A survey of the dose of ACE inhibitors prescribed by general physicians for patients with heart failure.
A systematic review and network meta-analysis of the comparative efficacy of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in hypertension.
A systematic review of the effects of physician specialty on the treatment of coronary disease and heart failure in the United States.
A Systematic Review on the Efficacy of Amlodipine in the Treatment of Patients With Hypertension With Concomitant Diabetes Mellitus and/or Renal Dysfunction, When Compared With Other Classes of Antihypertensive Medication.
A ten-year follow-up of a 109-year-old woman with myocardial infarction.
A three year clinical review of the impact of angiotensin converting enzyme inhibitors on the intra hospital mortality of congestive heart failure in Nigerians.
Abnormalities of hemorheological, endothelial, and platelet function in patients with chronic heart failure in sinus rhythm: effects of angiotensin-converting enzyme inhibitor and beta-blocker therapy.
Academic detailing to improve antihypertensive prescribing patterns.
ACE gene insertion/deletion polymorphism has a mild influence on the acute development of left ventricular dysfunction in patients with ST elevation myocardial infarction treated with primary PCI.
ACE inhibition improves cardiac NE uptake and attenuates sympathetic nerve terminal abnormalities in heart failure.
ACE inhibition in the 1990s.
ACE inhibitor and angiotensin II type 1 receptor blocker differently regulate ventricular fibrosis in hypertensive diastolic heart failure.
ACE Inhibitor and ARB utilization and expenditures in the Medicaid fee-for-service program from 1991 to 2008.
ACE inhibitor co-therapy in patients with heart failure: rationale for the Randomized Aldactone Evaluation Study (RALES).
ACE Inhibitor Delapril Prevents Ca(2+)-Dependent Blunting of IK1 and Ventricular Arrhythmia in Ischemic Heart Disease.
ACE inhibitor use and mortality reduction: do controlled trial results equal clinical practice?
ACE inhibitor-induced angioedema of the small intestine: a case report.
ACE inhibitors and angiotensin II antagonists in renal transplantation: an analysis of safety and efficacy.
ACE inhibitors and ARBs: Managing potassium and renal function.
ACE inhibitors and chronotherapy.
ACE inhibitors and mineralocorticoid receptor blockade in patients with congestive heart failure.
ACE inhibitors and statins acutely improve endothelial dysfunction of human coronary arterioles.
ACE inhibitors and their influence on inflammation, bronchial reactivity and cough.
ACE inhibitors before or after heart failure?
ACE inhibitors in congestive heart failure.
ACE inhibitors in early stages of heart failure.
ACE inhibitors in heart failure: an update.
ACE inhibitors in non-ischaemic heart failure: results from the MEGA trials.
ACE inhibitors vs ARBs: is one class better for heart failure.
ACE inhibitors: review of four new agents.
ACE-inhibition and angiotensin II receptor blockers in chronic heart failure: pathophysiological consideration of the unresolved battle.
ACE-Inhibition Benefit on Lung Function in Heart Failure is Modulated by ACE Insertion/Deletion Polymorphism.
ACE-inhibitors in coronary artery disease?
ACEi/ARB for systolic heart failure: Closing the quality gap with a sustainable intervention at an academic medical center.
Activation of matrix metalloproteinases precedes left ventricular remodeling in hypertensive heart failure rats: its inhibition as a primary effect of Angiotensin-converting enzyme inhibitor.
Activation of the renin-angiotensin system in dogs with asymptomatic and symptomatic dilated cardiomyopathy.
Activation of vascular tissue angiotensin-converting enzyme (ACE) in heart failure. Effects of ACE inhibitors.
Actual state of "triple therapy" for heart failure patients in eight regions of Japan: An analysis of a nationwide medical claims database.
Acute administration of angiotensin converting enzyme inhibitors in thrombolysed myocardial infarction patients is associated with a decreased incidence of heart failure, but an increased re-infarction risk.
Acute administration of captopril lowers the natriuretic and diuretic response to a loop diuretic in patients with chronic cardiac failure.
Acute administration of diclofenac, but possibly not long term low dose aspirin, causes detrimental renal effects in heart failure patients treated with ACE-inhibitors.
Acute and chronic effects of ramipril and captopril in congestive heart failure.
Acute and chronic hemodynamic effects of enalapril (MK-421) in congestive heart failure.
Acute and chronic in vivo inhibition of angiotensin-converting enzyme by perindopril in the endothelium and adventitia of large arteries and organs of the rabbit.
Acute and long-term effects of enalapril on the cardiovascular response to exercise and exercise tolerance in patients with congestive heart failure.
Acute and long-term hemodynamic effects of pimobendan (UD-CG 115 BS) in comparison with captopril.
Acute and long-term response to enalapril in congestive failure.
Acute and short-term effects of the nonpeptide endothelin-1 receptor antagonist bosentan in humans.
Acute declines in estimated glomerular filtration rate on enalapril and mortality and cardiovascular outcomes in patients with heart failure with reduced ejection fraction.
Acute effect of captopril administration on baroreflex sensitivity in patients with acute myocardial infarction.
Acute effects of Angiotensin Converting Enzyme Inhibition versus Angiotensin II Receptor Blockade on Cardiac Sympathetic Activity in Patients with Heart Failure.
Acute effects of the ACE inhibitor lisinopril on cardiac electrophysiological parameters of isolated guinea pig hearts.
Acute effects of the new angiotensin converting enzyme inhibitor ramipril on hemodynamics and carotid sinus baroreflex activity in congestive heart failure.
Acute heart failure with and without acute coronary syndrome: clinical correlates and prognostic impact (From the HEARTS registry).
Acute hemodynamic and hormonal effects of lisinopril (MK-521) in congestive heart failure.
Acute hemodynamic and hormonal effects of MK-521 in congestive heart failure.
Acute Hemodynamic and Hormonal Effects of Mk-521 in Congestive Heart Failure.
Acute hemodynamic effects and preload-dependent cardiovascular profile of the partial phosphodiesterase inhibitor nanterinone in patients with mild to moderate heart failure.
Acute Myocarditis in Children: An Overview of Treatment and Recent Patents.
Acute myocarditis in children: current concepts and management.
Acute natriuretic effect of fasidotrilat, a mixed inhibitor of neutral endopeptidase and angiotensin I-converting enzyme, in rats with heart failure.
Acute pulmonary pressure change after transition to sacubitril/valsartan in patients with heart failure reduced ejection fraction.
Acute renal effects of captopril in patients with congestive heart failure.
Acute renal failure after the use of angiotensin-converting-enzyme inhibitors in patients without renal artery stenosis.
Acute renal failure with ACE inhibition in aortic coarctation.
Acute tubular necrosis due to captopril.
Addition of angiotensin II receptor antagonist to an ACE inhibitor in heart failure improves cardiovascular function by a bradykinin-mediated mechanism.
Addition of angiotensin II receptor blockade to maximal angiotensin-converting enzyme inhibition improves exercise capacity in patients with severe congestive heart failure.
Addition of Angiotensin-Converting Enzyme Inhibitors to Beta-Blockers Does Not Have a Distinct Effect on Hispanics Compared With African Americans and Whites With Heart Failure and Reduced Ejection Fraction.
Addition of angiotensin-converting enzyme inhibitors to beta-blockers has a distinct effect on hispanics compared with african americans and whites with heart failure and reduced ejection fraction: a propensity score-matching study.
Addition of candesartan to angiotensin converting enzyme inhibitor therapy in patients with chronic heart failure does not reduce levels of oxidative stress.
Addition of Losartan to angiotensin-converting enzyme inhibitors improves insulin resistance in patients with chronic heart failure treated without ?-blockers.
Addition of spironolactone to an angiotensin-converting enzyme inhibitor decreases lung congestion and edema in Dahl hypertensive rats.
Addition of spironolactone to angiotensin-converting enzyme inhibition in heart failure improves endothelial vasomotor dysfunction: role of vascular superoxide anion formation and endothelial nitric oxide synthase expression.
Addition of valsartan to an angiotensin-converting enzyme inhibitor improves cardiac sympathetic nerve activity and left ventricular function in patients with congestive heart failure.
Additional effects of endothelin receptor blockade and angiotensin converting enzyme inhibition in rats with chronic heart failure.
Additive beneficial effects of the combination of a calcium channel blocker and an angiotensin blocker on a hypertensive rat-heart failure model.
Adenylyl cyclase type 5 disruption prolongs longevity and protects the heart against stress.
ADEPT: Addition of the AT1 receptor antagonist eprosartan to ACE inhibitor therapy in chronic heart failure trial: hemodynamic and neurohormonal effects.
Adherence and optimization of angiotensin converting enzyme inhibitor/angiotensin II receptors blockers and beta-blockers in patients hospitalized for acute heart failure.
Adherence to angiotensin-converting enzyme inhibitor therapy for heart failure.
Adherence to angiotensin-converting-enzyme inhibitors and illness beliefs in older heart failure patients.
Adherence to guidelines is a predictor of outcome in chronic heart failure: the MAHLER survey.
Adherence to prescribed medications in patients with heart failure - insights from liquid chromatography-tandem mass spectrometry-based urine analysis.
Adherence to the evidence-based heart failure drug treatment: Are there sex-specific differences among new users?
Adjunctive therapy with low-molecular-weight heparin in patients with chronic heart failure secondary to dilated cardiomyopathy: one-year follow-up results of the randomized trial.
Administration of angiotensin-converting enzyme inhibitors and ?-blockers during adjuvant trastuzumab chemotherapy for nonmetastatic breast cancer: marker of risk or cardioprotection in the real world?
Advanced Strategies in the Diagnosis and Treatment of Patients with Coronary Artery Disease and Heart Failure: When heart failure causes ischemia and angiotensin converting enzyme inhibitor and betablockers helps in diuresis.
Advances in angiotensin converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs).
African-American Heart Failure Trial (A-HeFT): rationale, design, and methodology.
Afterload reduction therapy in patients following intraatrial baffle operation for transposition of the great arteries.
Age and sex do not bias the use of angiotensin-converting enzyme inhibitors in acute myocardial infarction and congestive heart failure.
Age-related short-term effect of ramipril on N-terminal pro-brain natriuretic peptide and markers of hemostasis in patients after acute myocardial infarction.
Age-related underutilization of angiotensin-converting enzyme inhibitors in older hospitalized heart failure patients.
Airway and cough responsiveness and exhaled nitric oxide in non-smoking patients with stable chronic heart failure.
AL Amyloidosis.
Aldosterone antagonism in addition to angiotensin-converting enzyme inhibitors in heart failure.
Aldosterone antagonists in congestive heart failure.
Aldosterone blockade over and above ACE-inhibitors in patients with coronary artery disease but without heart failure.
Aldosterone blockade reduces vascular collagen turnover, improves heart rate variability and reduces early morning rise in heart rate in heart failure patients.
Aldosterone blockers (mineralocorticoid receptor antagonism) and potassium-sparing diuretics.
Aldosterone breakthrough does not alter central hemodynamics.
Aldosterone breakthrough during angiotensin-converting enzyme inhibitor therapy.
Aldosterone escape during ACE inhibitor therapy in chronic heart failure.
Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in chronic heart failure.
Aldosterone receptor antagonists for heart failure: current status, future indications.
Aldosterone receptor blockade in the management of heart failure.
Aldosterone Receptor Blockers in the Treatment of Heart Failure.
Aldosterone, a new appreciation of its role in heart failure.
Aldosterone: cardiovascular assault.
Aldosterone: effects on the kidney and cardiovascular system.
Aliskiren, Enalapril, or Aliskiren and Enalapril in Heart Failure.
ALLHAT: still providing correct answers after 7 years.
Altered vascular function in early stages of heart failure in hamsters.
Alternative pathways for angiotensin II generation in the cardiovascular system.
Amiodarone for prevention of atrial fibrillation following esophagectomy.
Amlodipine monotherapy, angiotensin-converting enzyme inhibition, and combination therapy with pacing-induced heart failure.
An ACE inhibitor reduces bactericidal activity of human neutrophils in vitro and impairs mouse neutrophil activity in vivo.
An approach to heart failure and diabetes mellitus.
An Assessment of the Concentration-Related Prognostic Value of Cardiac Troponin I Following Acute Coronary Syndrome.
An Economic Evaluation of Valsartan for Post-MI Patients in the UK Who Are Not Suitable for Treatment with ACE Inhibitors.
An interactive workshop: An effective means of integrating the Canadian Cardiovascular Society clinical practice guidelines on congestive heart failure into Canadian family physicians' practice.
Analysis of medication use patterns:apparent overuse of antibiotics and underuse of prescription drugs for asthma, depression, and CHF.
Analysis of Renal Artery Stenosis in Patients with Heart Failure: A RASHEF Study.
Anemia in heart failure--a concise review.
Angioedema in heart failure patients treated with sacubitril/valsartan (LCZ696) or enalapril in the PARADIGM-HF study.
Angioedema induced by angiotensin-converting enzyme inhibitors.
Angioedema secondary to angiotensin-converting enzyme inhibitors.
Angiotensin AT1 receptor inhibition, angiotensin-converting enzyme inhibition, and combination therapy with developing heart failure: cellular mechanisms of action.
Angiotensin blockade or aldosterone blockade as the third neuroendocrine-blocking drug in mild but symptomatic heart failure patients.
Angiotensin converting enzyme (ACE) and non-ACE dependent angiotensin II generation in resistance arteries from patients with heart failure and coronary heart disease.
Angiotensin converting enzyme (ACE) inhibitors and heart failure. The consequences of underprescribing.
Angiotensin converting enzyme (ACE) inhibitors and renal function. A review of the current status.
Angiotensin converting enzyme (ACE) inhibitors in the treatment of heart failure in general practice in north Cumbria.
Angiotensin converting enzyme 2-Angiotensin 1-7/1-9 system: novel promising targets for heart failure treatment.
Angiotensin converting enzyme DD genotype not associated with increased risk of coronary artery disease in the Iranian population.
Angiotensin converting enzyme inhibition and cerebral circulation--a review.
Angiotensin converting enzyme inhibition and hospitalisation rates for heart failure in the Netherlands, 1980 to 1999: the end of an epidemic?
Angiotensin converting enzyme inhibition and sympathetic activity in healthy subjects.
Angiotensin converting enzyme inhibition and ventricular remodeling in heart failure.
Angiotensin converting enzyme inhibition at rest and during exercise in congestive heart failure.
Angiotensin converting enzyme inhibition improves baroreflex-induced noradrenaline spillover responses in rabbits with heart failure.
Angiotensin converting enzyme inhibition improves cerebrovascular control during exercise in male rats with heart failure.
Angiotensin converting enzyme inhibition in asymptomatic left ventricular systolic dysfunction and early heart failure.
Angiotensin converting enzyme inhibition in heart failure.
Angiotensin converting enzyme inhibition in heart failure: clinical trials and clinical practice.
Angiotensin converting enzyme inhibition in patients with congestive heart failure.
Angiotensin converting enzyme inhibition in the management of congestive heart failure.
Angiotensin converting enzyme inhibition restores cardiac and hormonal responses to volume overload in patients with dilated cardiomyopathy and mild heart failure.
Angiotensin converting enzyme inhibition, AT1 receptor inhibition, and combination therapy with pacing induced heart failure: effects on left ventricular performance and regional blood flow patterns.
Angiotensin converting enzyme inhibition. Systemic and regional hemodynamics in rats and humans.
Angiotensin converting enzyme inhibition. Unique and effective therapy for hypertension and congestive heart failure.
Angiotensin converting enzyme inhibition: pharmacologic management to minimize postinfarction heart failure.
Angiotensin converting enzyme inhibitor induced cough: experience in Siriraj Hospital.
Angiotensin converting enzyme inhibitor therapy.
Angiotensin converting enzyme inhibitor use in congestive heart failure. Florida Medical Quality Assurance, Inc.
Angiotensin converting enzyme inhibitor-induced renal dysfunction: recommendations for prevention.
Angiotensin converting enzyme inhibitors and angiotensin receptor blockers in acute heart failure: invasive hemodynamic parameters and clinical outcomes.
Angiotensin converting enzyme inhibitors and beta-blockers in African Americans with heart failure.
Angiotensin converting enzyme inhibitors and delayed onset, recurrent angioedema of the head and neck.
Angiotensin converting enzyme inhibitors and magnesium conservation in patients with congestive cardiac failure.
Angiotensin converting enzyme inhibitors and the allergist.
Angiotensin converting enzyme inhibitors attenuated the expression of g-protein coupled receptor kinases in heart failure patients.
Angiotensin converting enzyme inhibitors for heart failure with reduced ejection fraction or left ventricular dysfunction: A complementary network meta-analyses.
Angiotensin converting enzyme inhibitors in congestive heart failure. Overview in comparison of captopril and enalapril.
Angiotensin converting enzyme inhibitors in heart failure: how good are they?
Angiotensin converting enzyme inhibitors in perspective: an update.
Angiotensin converting enzyme inhibitors suppress production of tumor necrosis factor-alpha in vitro and in vivo.
Angiotensin converting enzyme inhibitors versus digoxin for the treatment of congestive heart failure.
Angiotensin converting enzyme inhibitors.
Angiotensin converting enzyme inhibitors: comparative structure, pharmacokinetics, and pharmacodynamics.
Angiotensin converting enzyme insertion/deletion polymorphism and the risk of heart failure in hypertensive subjects.
Angiotensin converting enzyme: history and relevance.
Angiotensin deficiency in mice leads to dilated cardiomyopathy.
Angiotensin I converting enzyme inhibitors and cardiac remodeling.
Angiotensin II and angiotensin 1-7: which is their role in atrial fibrillation?
Angiotensin II contributes to arterial compliance in congestive heart failure.
Angiotensin II levels, hemodynamics, and sympathoadrenal function after low-dose captopril in heart failure.
Angiotensin II reactivation and aldosterone escape phenomena in renin-angiotensin-aldosterone system blockade: is oral renin inhibition the solution?
Angiotensin II receptor antagonism in ovine heart failure: acute hemodynamic, hormonal, and renal effects.
Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
Angiotensin II receptor antagonists in heart failure: rationale and design of the evaluation of losartan in the elderly (ELITE) trial.
Angiotensin II receptor blockade after myocardial infarction in rats: effects on hemodynamics, myocardial DNA synthesis, and interstitial collagen content.
Angiotensin II receptor blockers in congestive heart failure.
Angiotensin II receptor blockers in older patients.
Angiotensin II Type 1 receptor antagonists in chronic heart failure.
Angiotensin II type 1 receptor blockade: a new development in cardiovascular pharmacology.
Angiotensin II type 1 receptor gene polymorphisms in patients with cardiac hypertrophy.
Angiotensin II type-1 receptor antagonist as well as angiotensin converying enzyme inhibitor attenuates the development of heart failure in aortocaval fistula rats.
Angiotensin II-forming pathways in normal and failing human hearts.
Angiotensin II-receptor blockade further reduces afterload safely in patients maximally treated with angiotensin-converting enzyme inhibitors for heart failure.
Angiotensin II-receptor blockers: clinical relevance and therapeutic role.
Angiotensin in cardiac surgery: efficacy in patients on angiotensin converting enzyme inhibitors.
Angiotensin inhibition and atrial natriuretic peptide release after acute volume expansion in rats with aortocaval shunt.
Angiotensin inhibition in severe heart failure: acute central and limb hemodynamic effects of captopril with observations on sustained oral therapy.
Angiotensin receptor blockade with candesartan in heart failure: findings from the Candesartan in Heart failure - Assessment of Reduction in Mortality and morbidity (CHARM) programme.
Angiotensin receptor blocker therapy for heart failure patients: is combination treatment a feasible prospect?
Angiotensin receptor blockers in congestive heart failure: evidence, concerns, and controversies.
Angiotensin receptor blockers in heart failure after the ELITE II trial.
Angiotensin receptor blockers in hypertension. New insights from Japan.
Angiotensin receptor blockers: therapeutic targets and cardiovascular protection.
Angiotensin receptor neprilysin inhibition provides superior cardioprotection compared to angiotensin converting enzyme inhibition after experimental myocardial infarction.
Angiotensin Receptor-Neprilysin Inhibition.
Angiotensin receptor-neprilysin inhibitors: A new paradigm in heart failure with reduced ejection fraction.
Angiotensin receptors: physiology and pharmacology.
Angiotensin system inhibitors and outcome of sunitinib treatment in patients with metastatic renal cell carcinoma: A retrospective examination.
Angiotensin-converting enzyme (ACE) inhibitor prescription affects non-small-cell lung cancer (NSCLC) patients response to PD-1/PD-L1 immune checkpoint blockers.
Angiotensin-converting enzyme (ACE) inhibitors and angio-oedema.
Angiotensin-converting enzyme and matrix metalloproteinase inhibition with developing heart failure: comparative effects on left ventricular function and geometry.
Angiotensin-converting enzyme gene deletion polymorphism modulation of onset of symptoms and survival rate of patients with heart failure.
Angiotensin-converting enzyme gene expression in skeletal muscle in patients with chronic heart failure.
Angiotensin-converting enzyme gene polymorphism and cardiovascular disease.
Angiotensin-converting enzyme gene polymorphism influences degree of left ventricular hypertrophy and its regression in patients undergoing operation for aortic stenosis.
Angiotensin-converting enzyme genetic polymorphism: its impact on cardiac remodeling.
Angiotensin-converting enzyme genotype is not associated with exercise capacity or the training effect of cardiac rehabilitation in patients after acute myocardial infarction.
Angiotensin-converting enzyme genotype modulates pulmonary function and exercise capacity in treated patients with congestive stable heart failure.
Angiotensin-Converting Enzyme ID Polymorphism in Patients with Heart Failure Secondary to Chagas Disease.
Angiotensin-converting enzyme inhibition alters the inflammatory and fibrinolytic response to cardiopulmonary bypass in children.
Angiotensin-converting enzyme inhibition and endothelin antagonism for endothelial dysfunction in heart failure: mono-or combination therapy.
Angiotensin-converting enzyme inhibition and physical training in heart failure.
Angiotensin-converting enzyme inhibition and radial artery compliance in patients with congestive heart failure.
Angiotensin-converting enzyme inhibition as antiatherosclerotic therapy: no answer yet. QUIET Investigators. QUinapril Ischemic Event Trial.
Angiotensin-converting enzyme inhibition facilitates alveolar-capillary gas transfer and improves ventilation-perfusion coupling in patients with left ventricular dysfunction.
Angiotensin-converting enzyme inhibition for congestive heart failure: achievements and potential.
Angiotensin-converting enzyme inhibition improves cardiac fatty acid metabolism in patients with congestive heart failure.
Angiotensin-converting enzyme inhibition in congestive heart failure: benefit and perspective.
Angiotensin-converting enzyme inhibition in congestive heart failure: the concept.
Angiotensin-converting enzyme inhibition in infarct-induced heart failure in rats: bradykinin versus angiotensin II.
Angiotensin-converting enzyme inhibition in mild to moderate congestive heart failure: an evolving approach.
Angiotensin-converting enzyme inhibition prolongs survival and modifies the transition to heart failure in rats with pressure overload hypertrophy due to ascending aortic stenosis.
Angiotensin-converting enzyme inhibition reduces oxidative stress and protects dopaminergic neurons in a 6-hydroxydopamine rat model of Parkinsonism.
Angiotensin-converting enzyme inhibition restores hepatocyte growth factor production in patients with congestive heart failure.
Angiotensin-converting enzyme inhibition restores the diffusing capacity for carbon monoxide in patients with chronic heart failure by improving the molecular diffusion across the alveolar capillary membrane.
Angiotensin-converting enzyme inhibition therapy in heart failure: practical guidelines.
Angiotensin-converting enzyme inhibition to enhance vascular health--clinical and research models.
Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing ENdothelial Dysfunction) Study.
Angiotensin-converting enzyme inhibition with spirapril in patients with coronary artery disease.
Angiotensin-converting enzyme inhibition, autonomic activity, and hemodynamics in patients with heart failure who perform isometric exercise.
Angiotensin-converting enzyme inhibition, the sympathetic nervous system, and congestive heart failure. The Australian Zestril (Lisinopril) Study Group.
Angiotensin-converting enzyme inhibitor and spironolactone combination therapy. New objectives in congestive heart failure treatment.
Angiotensin-converting enzyme inhibitor as a risk factor for the development of anemia, and the impact of incident anemia on mortality in patients with left ventricular dysfunction.
Angiotensin-converting enzyme inhibitor compliance and dosing among patients with heart failure.
Angiotensin-converting enzyme inhibitor dosages in elderly patients with heart failure.
Angiotensin-converting enzyme inhibitor dosing in heart failure: what is optimal?
Angiotensin-converting enzyme inhibitor improves force and Ca2 +--frequency relationships in myocytes from rats with heart failure.
Angiotensin-converting enzyme inhibitor or angiotensin receptor blocker adherence in patients with primary versus secondary diagnosis of heart failure.
Angiotensin-converting enzyme inhibitor therapy affects left ventricular mass in patients with ejection fraction > 40% after acute myocardial infarction.
Angiotensin-converting enzyme inhibitor therapy improves respiratory muscle strength in patients with heart failure.
Angiotensin-converting enzyme inhibitor therapy in patients with heart failure enrolled in a managed care organization: effect on costs and probability of hospitalization.
Angiotensin-converting enzyme inhibitor therapy prevents upregulation of endothelin-converting enzyme-1 in failing human myocardium.
Angiotensin-converting enzyme inhibitor use in elderly patients hospitalized with heart failure and left ventricular systolic dysfunction.
Angiotensin-converting enzyme inhibitor use in older patients with heart failure and renal dysfunction.
Angiotensin-Converting Enzyme Inhibitor-Induced Gastrointestinal Angioedema: The First Danish Case Report.
Angiotensin-converting enzyme inhibitors (ACE) in congestive heart failure.
Angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists in the treatment of heart failure caused by left ventricular systolic dysfunction.
Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers: what we know and current controversies.
Angiotensin-converting enzyme inhibitors and angiotensin II type I receptor blockers in the management of congestive heart failure patients: what have we learned from recent clinical trials?
Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with congestive heart failure and chronic kidney disease.
Angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers in chronic heart failure.
Angiotensin-Converting Enzyme Inhibitors and Contrast-Associated Acute Kidney Injury After Coronary Angiography and Intervention.
Angiotensin-converting enzyme inhibitors and cough: a prospective evaluation in hypertension and in congestive heart failure.
Angiotensin-converting enzyme inhibitors and cytokines in heart failure: dose and effect?
Angiotensin-converting enzyme inhibitors and end-organ damage in heart failure.
Angiotensin-converting enzyme inhibitors and insulin sensitivity: metabolic effects in hypertension, diabetes, and heart failure.
Angiotensin-converting enzyme inhibitors and outcome among patients with heart failure and renal insufficiency: need for a prospective study.
Angiotensin-converting Enzyme Inhibitors and Outcomes in Heart Failure and Preserved Ejection Fraction.
Angiotensin-converting enzyme inhibitors and receptor blockers in heart failure and chronic kidney disease - Demystifying controversies.
Angiotensin-converting enzyme inhibitors and renal function in heart failure.
Angiotensin-converting enzyme inhibitors and survival in women and men with heart failure.
Angiotensin-converting enzyme inhibitors and their influence on inflammation, bronchial reactivity and cough. A research review.
Angiotensin-converting enzyme inhibitors for elderly patients with congestive heart failure.
Angiotensin-converting enzyme inhibitors in concomitant heart failure and depression.
Angiotensin-converting enzyme inhibitors in congestive heart failure.
Angiotensin-converting enzyme inhibitors in heart failure.
Angiotensin-converting enzyme inhibitors in heart failure: a role after myocardial infarction.
Angiotensin-converting enzyme inhibitors in heart failure: blood pressure changes after the first dose.
Angiotensin-converting enzyme inhibitors in heart failure: new strategies justified by recent clinical trials.
Angiotensin-converting enzyme inhibitors in heart failure: physicians' prescribing behavior.
Angiotensin-converting enzyme inhibitors in heart failure: target dose prescription in elderly patients.
Angiotensin-converting enzyme inhibitors in hypertension and congestive heart failure.
Angiotensin-converting enzyme inhibitors in hypertension: a review.
Angiotensin-converting enzyme inhibitors in left ventricular dysfunction.
Angiotensin-Converting Enzyme Inhibitors in Patients With Coronary Artery Disease and Absence of Heart Failure or Left Ventricular Systolic Dysfunction: An Overview of Long-term Randomized Controlled Trials.
Angiotensin-converting enzyme inhibitors in preventing remodeling and development of heart failure after acute myocardial infarction: results of the German multicenter study of the effects of captopril on cardiopulmonary exercise parameters (ECCE).
Angiotensin-converting enzyme inhibitors in the clinical setting of chronic congestive heart failure.
Angiotensin-converting enzyme inhibitors in the treatment of clinical heart failure.
Angiotensin-converting enzyme inhibitors in the treatment of hypertension: an update.
Angiotensin-Converting Enzyme Inhibitors Induce Cough.
Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers in Patients Without Heart Failure? Insights From 254,301 Patients From Randomized Trials.
Angiotensin-converting enzyme inhibitors or beta-blockers in heart failure: does it matter who goes first?
Angiotensin-Converting Enzyme Inhibitors Prescription Is Associated With Longer Survival Among Patients Hospitalized for Congestive Heart Failure Who Have Preserved Systolic Function: A Long-Term Follow-Up Study.
Angiotensin-Converting Enzyme Inhibitors Versus Angiotensin II Receptor Blockers in Acute Coronary Syndrome and Preserved Ventricular Ejection Fraction.
Angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers in hypertensive patients with myocardial infarction or heart failure: a systematic review and meta-analysis.
Angiotensin-converting enzyme inhibitors, angiotensin-II-receptor antagonists and angiotensin-receptor blocker/neprilysin inhibitor utilization in heart failure patients: Sub-analysis of a nation-wide population-based study in the Czech Republic.
Angiotensin-converting enzyme inhibitors, angiotensin-receptor blockers, or both in chronic heart failure.
Angiotensin-converting enzyme inhibitors, left ventricular dysfunction, and early heart failure.
Angiotensin-converting enzyme inhibitors--when to use?
Angiotensin-converting enzyme inhibitors: a new mechanism of action.
Angiotensin-converting enzyme inhibitors: congestive heart failure and beyond.
Angiotensin-converting-enzyme gene polymorphism and heart failure: a case-control study.
Angiotensin-converting-enzyme inhibition in heart failure or after myocardial infarction.
Angiotensin-converting-enzyme inhibition in stable coronary artery disease.
Angiotensin-converting-enzyme inhibitors and treatment of heart failure.
Angiotensin-converting-enzyme inhibitors in hemodynamic congestion: a meta-analysis of early studies.
Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials.
Angiotensin-converting-enzyme inhibitors in the management of cardiac failure: are we ignoring the evidence?
Angiotensin-converting-enzyme inhibitors in treatment of heart failure.
Angiotensin-receptor blockers in heart failure: evidence from the CHARM trial.
Anion Gap Was Associated with Inhospital Mortality and Adverse Clinical Outcomes of Coronary Care Unit Patients.
ANP infusion in the treatment of heart failure and comparison with ACE inhibition.
Anthracycline-induced cardiomyopathy.
Anti-adrenergic effects of angiotensin converting enzyme inhibitors.
Anti-inflammatory agents and renal function.
Anti-oxidative properties of beta-blockers and angiotensin-converting enzyme inhibitors in congestive heart failure.
Antiarrhythmic effect of converting enzyme inhibitors in congestive heart failure.
Antihypertensive Agents in Hemodialysis Patients: A Current Perspective.
Antihypertensive and cardioprotective effects after angiotensin-converting enzyme inhibition: role of kinins.
Antihypertensive and natriuretic effects of CGS 30440, a dual inhibitor of angiotensin-converting enzyme and neutral endopeptidase 24.11.
Antihypertensive treatment with ACE inhibitors or beta-blockers and risk of incident atrial fibrillation in a general hypertensive population.
Antithrombotic effect of captopril and enalapril in young rats.
Antithrombotic therapy for congestive heart failure.
Apoptosis, Bcl-2, and proliferating cell nuclear antigen in the failing human heart: observations made after implantation of left ventricular assist device.
Application of cine nuclear magnetic resonance imaging for sequential evaluation of response to angiotensin-converting enzyme inhibitor therapy in dilated cardiomyopathy.
Applying standard therapies to new targets: the use of ACE inhibitors and B-blockers for heart failure in adults with congenital heart disease.
Architecture of the left ventricle: insights for optimal surgical ventricular restoration.
Are angiotensin II receptor blockers more efficacious than placebo in heart failure? Implications of ELITE-2. Evaluation of Losartan In The Elderly.
Are angiotensin-converting enzyme inhibitors indicated for the routine treatment of elderly heart failure patients?
Are angiotensin-converting enzyme inhibitors or angiotensin 2 receptor antagonists effective in heart failure with preserved ejection fraction?
Are patients in heart failure trials representative of primary care populations? A systematic review.
Aristolochic Acid induces heart failure in zebrafish embryos that is mediated by inflammation.
ARNI in cardiovascular disease - current evidence and future perspectives.
Arrhythmias and mortality in congestive heart failure.
Arrhythmias and their treatment in patients with heart failure.
Arrhythmias, electrolytes, and ACE inhibitor therapy in the elderly.
Ask the doctor. I have had heart failure since my heart attack a year ago. My physician initially prescribed lisinopril, an angiotensin-converting enzyme (ACE) inhibitor. Unfortunately, I was one of the unlucky people who got a cough with this drug that was so annoying I had to stop taking it. Now my doctor wants me to try a newer drug called valsartan. Is it likely to help me?
Aspects of gene polymorphisms in cardiovascular disease: the renin-angiotensin system.
Aspects of the Use of Angiotensin-Converting Enzyme Inhibitors and Calcium Antagonists in Treatment of Heart Failure in the Older Patient.
Aspirin alters arterial function in patients with chronic heart failure treated with ACE inhibitors: a dose-mediated deleterious effect.
Aspirin does not adversely affect survival in patients with stable congestive heart failure treated with Angiotensin-converting enzyme inhibitors.
Aspirin Does Not Increase Heart Failure Events in Heart Failure Patients: From the WARCEF Trial.
Aspirin impairs reverse myocardial remodeling in patients with heart failure treated with beta-blockers.
Aspirin inhibits the acute arterial and venous vasodilator response to captopril in patients with chronic heart failure.
Aspirin use and outcomes in a community-based cohort of 7352 patients discharged after first hospitalization for heart failure.
Aspirin worsens exercise performance and pulmonary gas exchange in patients with heart failure who are taking angiotensin-converting enzyme inhibitors.
Aspirin-angiotensin-converting enzyme inhibitor coadministration and mortality in patients with heart failure: a dose-related adverse effect of aspirin.
Assessing Guideline-Directed Medication Therapy for Heart Failure in End-Stage Renal Disease.
Assessing the treatment of congestive heart failure: diuretics, vasodilators, and angiotensin-converting enzyme inhibitors.
Assessing the treatment of congestive heart failure: inotropic agents and calcium channel blockers.
Assessment of drug therapy management and the prevalence of heart failure in a managed care population with hypertension.
Assessment of left ventricular systolic function by echocardiography.
Assessment of perindopril's efficacy on arterial distensibility in mild to moderate hypertension.
Assessment of the optimal daily dose of valsartan in patients with hypertension, heart failure, or both.
Association between mortality and persistent use of beta blockers and angiotensin-converting enzyme inhibitors in patients with left ventricular systolic dysfunction and coronary artery disease.
Association between performance measures and clinical outcomes for patients hospitalized with heart failure.
Association of angiotensin-converting enzyme I/D polymorphism with heart failure: a meta-analysis.
Association of B? receptor polymorphisms and ACE activity with ACE inhibitor-induced angioedema in black and mixed-race South Africans.
Association of left ventricular systolic performance and cavity size with angiotensin-converting enzyme genotype in idiopathic dilated cardiomyopathy.
Association of the angiotensin-converting enzyme gene polymorphism with chronic heart failure in Chinese Han patients.
Associations between birth weight and antihypertensive medication in black and white medicaid recipients.
Associations of serum potassium levels with mortality in chronic heart failure patients.
AT1 receptor blockade for the prevention of cardiovascular events after myocardial infarction.
AT1-receptor blockade in experimental myocardial ischemia/reperfusion.
Atherosclerotic Renal Artery Stenosis.
Atherosclerotic renal artery stenosis: surgery, percutaneous transluminal angioplasty, or medical therapy?
Atrial fibrillation in heart failure: prognostic significance and management.
Atrial fibrosis and the mechanisms of atrial fibrillation.
Atrial natriuretic peptide levels in congestive heart failure in man before and during converting enzyme inhibition.
Attenuation of angiotensin II-mediated coronary vasoconstriction and vasodilatory action of angiotensin-converting enzyme inhibitor in pacing-induced heart failure in dogs.
Attenuation of heart failure due to coronary stenosis by ACE inhibitor and angiotensin receptor blocker.
Attenuation of Human Lysozyme Amyloid Fibrillation by ACE Inhibitor Captopril: A Combined Spectroscopy, Microscopy, Cytotoxicity, and Docking Study.
Attenuation of the pressor response to intravenous furosemide by angiotensin converting enzyme inhibition in congestive heart failure.
Augmented short- and long-term hemodynamic and hormonal effects of an angiotensin receptor blocker added to angiotensin converting enzyme inhibitor therapy in patients with heart failure. Vasodilator Heart Failure Trial (V-HeFT) Study Group.
Automating Quality Measures for Heart Failure Using Natural Language Processing: A Descriptive Study in the Department of Veterans Affairs.
Autonomic tone as a cardiovascular risk factor: the dangers of chronic fight or flight.
Availability, cost and affordability of essential cardiovascular disease medicines in the south west region of Cameroon: Preliminary findings from the Cameroon science for disease study.
Balance between angiotensin converting enzyme and angiotensin converting enzyme 2 in patients with chronic heart failure.
Baseline demographics of the Valsartan Heart Failure Trial. Val-HeFT Investigators.
Benazepril inhibited the NF-?B and TGF-? networking on LV hypertrophy in rats.
Beneficial effect of ACE inhibitor in congestive heart failure.
Beneficial effect of perindopril, an angiotensin-converting enzyme inhibitor, on left ventricular performance and noradrenaline myocardial content during cardiac failure development in the rat.
Beneficial effect of replacing of angiotensin-converting enzyme inhibitor with angiotensin II antagonist for heart failure patients.
Beneficial effects of angiotensin-converting enzyme inhibition on sarcoplasmic reticulum function in the failing heart of the Dahl rat.
Beneficial effects of beta-blockers and angiotensin-converting enzyme inhibitors in Duchenne muscular dystrophy.
Beneficial effects of carvedilol on angiotensin-converting enzyme activity and renin plasma levels in patients with chronic heart failure.
Beneficial effects of combination therapy with angiotensin II receptor blocker and angiotensin-converting enzyme inhibitor on vascular endothelial function.
Beneficial effects of growth hormone and insulin-like growth factor-1 in experimental heart failure in rats treated with chronic ACE inhibition.
Beneficial effects of sampatrilat, a novel vasopeptidase inhibitor, on cardiac remodeling and function of rats with chronic heart failure following left coronary artery ligation.
Beneficial Effects of Statin Therapy on Survival in Hypertensive Patients With Acute Myocardial Infarction: Data From the RICO Survey.
Beneficial effects of trandolapril on experimentally induced congestive heart failure in rats.
Beneficial hemodynamic and renal effects of intravenous enalaprilat following coronary artery bypass surgery complicated by left ventricular dysfunction.
Beneficial renal and hemodynamic effects of omapatrilat in mild and severe heart failure.
Benefits and adverse effects of ACE inhibitors in patients with heart failure with reduced ejection fraction: a systematic review and meta-analysis.
Benefits and pitfalls of cardiovascular medication in seniors.
Benefits and Risks of Continuing Angiotensin-Converting Enzyme Inhibitors, Angiotensin II Receptor Antagonists, and Mineralocorticoid Receptor Antagonists during Hospitalizations for Acute Heart Failure.
Benefits of prolonged angiotensin-converting enzyme inhibition in congestive heart failure.
Benefits of the RAS blockade: clinical evidence before the ONTARGET study.
Beta blockade in congestive heart failure: persistent adverse haemodynamic effects during chronic treatment with subsequent doses.
Beta blocker and angiotensin-converting enzyme inhibitor therapy is associated with decreased Th1/Th2 cytokine ratios and inflammatory cytokine production in patients with chronic heart failure.
Beta blockers in systolic heart failure.
Beta blockers or angiotensin-converting-enzyme inhibitor/angiotensin receptor blocker: what should be first?
Beta-adrenergic blocking agents in heart failure: benefits of vasodilating and non-vasodilating agents according to patients' characteristics: a meta-analysis of clinical trials.
Beta-adrenergic blocking drugs in severe heart failure.
Beta-adrenergic receptor blockade and the angiotensin-converting enzyme deletion polymorphism in patients with chronic heart failure.
Beta-blocker therapy and severe heart failure: myth or reality?
Beta-blocker therapy for heart failure.
Beta-blocker therapy for heart failure: the standard of care.
Beta-blocker therapy for patients with ventricular heart failure and reduced systolic function.
beta-Blocker therapy in heart failure.
beta-Blocker therapy in heart failure: scientific review.
Beta-blocker treatment before angiotensin-converting enzyme inhibitor therapy in newly diagnosed heart failure.
Beta-blocker treatment in heart failure.
Beta-blockers and angiotensin-converting enzyme inhibitors/receptor blockers prescriptions after hospital discharge for heart failure are associated with decreased mortality in Alberta, Canada.
Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction.
Beta-blockers for congestive heart failure: what is the current consensus?
Beta-blockers in heart failure--a cardioprotective therapy?
Beta-blockers in heart failure: promising or proved?
Beta-blockers in left ventricular systolic dysfunction--from evidence to practice.
beta-blockers, angiotensin II, and ACE inhibitors in patients with heart failure.
Beta-blockers, angiotensin-converting enzyme inhibitors, and calcium antagonists in treatment of elderly patients with acute myocardial infarction.
Beta-blockers: the new standard of therapy for mild heart failure.
Beyond remodeling: a new paradigm for angiotensin-converting enzyme inhibitors following myocardial infarction.
Bioactive Signaling in Next-Generation Pharmacotherapies for Heart Failure: A Review.
Bioanalytical Assessment of Plasma Concentrations of Angiotensin-Converting Enzyme II Inhibitors and Angiotensin Receptor Blockers: A Pilot Study Among Patients Hospitalized With Acute Heart Failure.
Bioequivalence study of two formulations of enalapril, at a single oral dose of 20 mg (tablets): A randomized, two-way, open-label, crossover study in healthy volunteers.
Biomarker-Guided Versus Guideline-Based Treatment of Patients With Heart Failure: Results From BIOSTAT-CHF.
Biomarkers of activation of renin-angiotensin-aldosterone system in heart failure: how useful, how feasible?
Bisoprolol in chronic heart failure.
Biventricular pacing improves quality of life and exercise tolerance in patients with heart failure and intraventricular conduction delay.
Biventricular pacing in congestive heart failure: a boost toward finer living.
Biventricular thrombi in dilated cardiomyopathy in a patient with human immunodeficiency virus infection: a case report.
Blockade of Renin-Angiotensin-Aldosterone System in Elderly Patients with Heart Failure and Chronic Kidney Disease: Results of a Single-Center, Observational Cohort Study.
Blockade of the renin-angiotensin system in heart failure in conscious dogs.
Blockade of the renin-angiotensin system.
Blood pressure response to the first dose of angiotensin-converting enzyme inhibitors in congestive heart failure.
Bolus versus continuous low dose of enalaprilat in congestive heart failure with acute refractory decompensation.
Bradykinin contributes to the systemic hemodynamic effects of chronic angiotensin-converting enzyme inhibition in patients with heart failure.
Bradykinin contributes to the vasodilator effects of chronic angiotensin-converting enzyme inhibition in patients with heart failure.
Bradykinin improves left ventricular diastolic function under long-term angiotensin-converting enzyme inhibition in heart failure.
Bradykinin pathway is involved in acute hemodynamic effects of enalaprilat in dogs with heart failure.
Bradykinin-evoked sensitization of airway sensory nerves: a mechanism for ACE-inhibitor cough.
Brain angiotensin-converting enzyme activity and autonomic regulation in heart failure.
Brain natriuretic peptide and optimal management of heart failure.
Brief review: Angiotensin converting enzyme inhibitors and angioedema: anesthetic implications: [Revue sommaire sur les implications anesthesiques de l'oedeme de Quincke et des inhibiteurs de l'enzyme de conversion de l'angiotensine].
Broken Heart Syndrome, Neurogenic Stunned Myocardium and Stroke.
CAC score as a possible criterion for administration of angiotensin converting enzyme inhibitors and/or angiotensin receptor blockers: the MultiEthnic Study of Atherosclerosis.
Calcium channel blockers in treatment of hypertension.
Can angiotensin-converting enzyme inhibitors reverse atherosclerosis?
Can further benefit be achieved by adding flosequinan to patients with congestive heart failure who remain symptomatic on diuretic, digoxin, and an angiotensin converting enzyme inhibitor? Results of the flosequinan-ACE inhibitor trial (FACET).
Can pharmacological therapy influence the mortality of chronic congestive heart failure?
Can treatment with angiotensin-converting enzyme inhibitors in elderly patients with moderate to severe chronic heart failure be improved by a nurse-monitored structured care program? A randomized controlled trial.
Candesartan cilexetil in the treatment of chronic heart failure.
Candesartan for the management of heart failure: more than an alternative.
Candesartan in Heart Failure - Assessment of Reduction in Mortality and Morbidity (CHARM) Study Programme.
Candoxatril improves exercise capacity in patients with chronic heart failure receiving angiotensin converting enzyme inhibition.
Canine idiopathic dilated cardiomyopathy. Part II: pathophysiology and therapy.
Captopril and angiotensin II receptor antagonist therapy in a pacing model of heart failure.
Captopril and spironolactone therapy for refractory congestive heart failure.
Captopril attenuates TAC-induced heart failure via inhibiting Wnt3a/?-catenin and Jak2/Stat3 pathways.
Captopril does not acutely modulate plasma endothelin-1 concentration in human congestive heart failure.
Captopril enhances intracellular calcium handling and beta-adrenergic responsiveness of myocardium from rats with postinfarction failure.
Captopril enhances renal responsiveness to ANF in dogs with compensated high-output heart failure.
Captopril in congestive heart failure: improved left ventricular function with decreased metabolic cost.
Captopril in heart failure: a double-blind study of the effects on renal function.
Captopril in refractory heart failure: clinical and hemodynamic observations.
Captopril in the treatment of congestive heart failure.
Captopril increases skin microvascular blood flow secondary to bradykinin, nitric oxide, and prostaglandins.
Captopril inhibits angiogenesis and slows the growth of experimental tumors in rats.
Captopril pharmacokinetics and the acute hemodynamic and hormonal response in patients with severe chronic congestive heart failure.
Captopril treatment improves the sarcoplasmic reticular Ca(2+) transport in heart failure due to myocardial infarction.
Captopril treatment of chronic heart failure in the very old.
Captopril-associated "pseudocholangitis'. A case report and review of the literature.
Captopril. A review of its pharmacology and therapeutic efficacy after myocardial infarction and in ischaemic heart disease.
Captopril. An update of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure.
Cardiac 123 I-MIBG imaging and clinical variables in risk stratification in patients with heart failure treated with beta blockers.
Cardiac and Noncardiac Disease Burden and Treatment Effect of Sacubitril/Valsartan: Insights From a Combined PARAGON-HF and PARADIGM-HF Analysis.
Cardiac and renal distribution of ACE and ACE-2 in rats with heart failure.
Cardiac angiotensin converting enzyme and endothelin receptor in rats with chronic myocardial infarction.
Cardiac angiotensin II formation: the angiotensin-I converting enzyme and human chymase.
Cardiac event rates after acute myocardial infarction in patients treated with verapamil and trandolapril versus trandolapril alone. Danish Verapamil Infarction Trial (DAVIT) Study Group.
Cardiac magnetic resonance imaging in sunitinib malate-related cardiomyopathy: no late gadolinium enhancement.
Cardiac metaiodobenzylguanidine activity can predict the long-term efficacy of angiotensin-converting enzyme inhibitors and/or beta-adrenoceptor blockers in patients with heart failure.
Cardiac remodelling in end stage heart failure: upregulation of matrix metalloproteinase (MMP) irrespective of the underlying disease, and evidence for a direct inhibitory effect of ACE inhibitors on MMP.
Cardiac Toxicity: Using Angiotensin-Converting Enzyme Inhibitors to Prevent Anthracycline-Induced Left Ventricular Dysfunction and Cardiomyopathy.
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Cardiomyopathy in children.
Cardioprotection and ACE inhibitors.
Cardioprotection by aldosterone receptor antagonism in heart failure. Part I. The role of aldosterone in heart failure.
Cardioprotection in the clinical setting-lessons from J-WIND studies.
Cardioprotection in the ESRD Population: How Do We Get There?
Cardioprotective effect of angiotensin II receptor antagonists.
Cardioprotective effects mediated by angiotensin II type 1 receptor blockade and enhancing angiotensin 1-7 in experimental heart failure in angiotensin-converting enzyme 2-null mice.
Cardioprotective effects of quinapril after myocardial infarction in hypertensive rats.
Cardiotoxic consequences of anthracycline-containing therapy in patients with breast cancer.
Cardiovascular ACE2 receptor expression in patients undergoing heart transplantation.
Cardiovascular disease treatment among patients with severe mental illness: a data linkage study between primary and secondary care.
Cardiovascular drug therapy in the elderly: benefits and challenges.
Cardiovascular effects of the novel dual inhibitor of neutral endopeptidase and angiotensin-converting enzyme BMS-182657 in experimental hypertension and heart failure.
Cardiovascular impact of exercise and drug therapy in older hypertensives with coronary heart disease: PREHACOR study.
Cardiovascular outcomes in high-risk patients without heart failure treated with ARBs: a systematic review and meta-analysis.
Cardiovascular protection with ace inhibitors--more HOPE for EUROPA?
CART and logistic regression analyses of risk factors for first dose hypotension by an ACE-inhibitor.
Carvedilol in the treatment of chronic heart failure.
Carvedilol: the new role of beta blockers in congestive heart failure.
Case study: enhancing effective and efficient congestive heart failure management at Columbus Regional Hospital.
Catecholamine levels and treatment in chronic heart failure.
Causes and impact on survival of underuse of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in heart failure.
Cellular mechanisms of captopril-induced matrix remodeling in Syrian hamster cardiomyopathy.
Challenging the dogma of high target doses in the treatment of heart failure: is more always better?
Changes in ?-adrenoceptors in heart failure due to myocardial infarction are attenuated by blockade of renin-angiotensin system.
Changes in beta-adrenoceptors in heart failure due to myocardial infarction are attenuated by blockade of renin-angiotensin system.
Changes in pulmonary hemodynamics predict benefits in exercise capacity after ACE inhibition in patients with mild to moderate congestive heart failure.
Changes of chymase, angiotensin converting enzyme and angiotensin II type 1 receptor expressions in the hamster heart during the development of heart failure.
Changing ideas in the treatment of heart failure--an overview.
Changing patterns of investigation and treatment of cardiac failure in hospital.
Characteristics and prognosis of patients with acute heart failure without troponin determination: The EAHFE-TROPICA3 study.
Characteristics of early sacubitril/valsartan patients and considerations for studies in electronic health record data.
Characteristics of patients hospitalized with acute decompensated heart failure who are referred for hospice care.
Characteristics, treatments and 1-year prognosis of hospitalized and ambulatory heart failure patients with chronic obstructive pulmonary disease in the European Society of Cardiology Heart Failure Long-Term Registry.
Characterization, Biomedical and Agricultural applications of Protease Inhibitors: A review.
CHART: Congestive cardiac failure in hospitals, an Australian review of treatment.
Chemotherapy-Induced Cardiotoxicity.
Choice of drug treatment for elderly hypertensive patients.
Choosing Wisely: The Canadian Society of Nephrology's List of 5 Items Physicians and Patients Should Question.
Chronic ACE inhibition by quinapril modulates central vasopressinergic system.
Chronic angiotensin-converting-enzyme inhibition improves cardiac output and fluid balance during heart failure.
Chronic captopril and losartan (DuP 753) administration in rats with high-output heart failure.
Chronic therapy for congestive heart failure with benazepril HCl, a new angiotensin converting enzyme inhibitor.
Chronotropic dose response of atropine in Nigerians with congestive heart failure: assessment of ethnic variation and reversibility of parasympathetic dysfunction.
Cilazapril treatment in a cohort of seven patients with congestive heart failure: a seven-year follow-up study.
Circadian variation in blood pressure and heart rate in nonhypertensive congestive heart failure.
Circulatory basis for the use of angiotensin converting enzyme inhibitors in hypertension and cardiac failure.
Clinical analysis of sampatrilat, a combined renal endopeptidase and angiotensin-converting enzyme inhibitor I: assay in plasma of human volunteers by atmospheric-pressure ionisation mass-spectrometry following derivatisation with BF3-methanol.
Clinical analysis of sampatrilat, a combined renal endopeptidase and angiotensin-converting enzyme inhibitor II: assay in the plasma and urine of human volunteers by dissociation enhanced lanthanide fluorescence immunoassay (DELFIA).
Clinical and autonomic effects of ibopamine as adjunct to angiotensin-converting enzyme inhibitors in chronic heart failure.
Clinical and neurohormonal effects of nicardipine hydrochloride in patients with severe chronic heart failure receiving angiotensin-converting enzyme inhibitor therapy.
Clinical and neurohumoral differences between spirapril and captopril in mild to moderate chronic congestive heart failure.
Clinical and neurohumoral response of patients with severe congestive heart failure treated with two different captopril dosages.
Clinical and pharmacologic management of chronic heart failure associated with left ventricular systolic dysfunction.
Clinical benefit of angiotensin-converting enzyme inhibitors in chronic heart failure.
Clinical Characteristics and Outcomes of Patients With Heart Failure With Reduced Ejection Fraction and Chronic Obstructive Pulmonary Disease: Insights From PARADIGM-HF.
Clinical consequences of angiotensin-converting enzyme inhibitor withdrawal in chronic heart failure: a double-blind, placebo-controlled study of quinapril. The Quinapril Heart Failure Trial Investigators.
Clinical Effectiveness of Hydralazine-Isosorbide Dinitrate Therapy in Patients With Heart Failure and Reduced Ejection Fraction: Findings From the Get With The Guidelines-Heart Failure Registry.
Clinical Effectiveness of Sacubitril/Valsartan Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction.
Clinical efficacies of antihypertensive drugs.
Clinical epidemiology of heart failure: public and private health burden.
Clinical experience in protecting the failing heart.
Clinical experience with angiotensin receptor blockers with particular reference to valsartan.
Clinical experience with lisinopril in congestive heart failure. Focus on the older patient.
Clinical factors associated with hyperkalemia in patients with congestive heart failure.
Clinical findings and survival time in dogs with advanced heart failure.
Clinical heart failure trials and the design rationale of Studies of Left Ventricular Dysfunction (SOLVD).
Clinical impacts of additive use of olmesartan in hypertensive patients with chronic heart failure: the supplemental benefit of an angiotensin receptor blocker in hypertensive patients with stable heart failure using olmesartan (SUPPORT) trial.
Clinical implications of alpha 1 adrenergic blockade and angiotensin converting enzyme inhibition 'cross talk' in heart failure in Nigerians.
Clinical implications of an accurate problem list on heart failure treatment.
Clinical inertia in the treatment of heart failure: a major issue to tackle.
Clinical investigations of statins in heart failure: ventricular function and anti-remodeling.
Clinical metric and medication persistency effects: evidence from a Medicaid care management program.
Clinical outcomes of acute kidney injury developing outside the hospital in elderly.
Clinical overview of antihypertensive classes--clinically relevant differences: myths or facts? Based on a presentation by Alan H. Gradman, MD.
Clinical pharmacokinetics and efficacy of renin inhibitors.
Clinical pharmacokinetics and selective pharmacodynamics of new angiotensin converting enzyme inhibitors: an update.
Clinical pharmacokinetics of the angiotensin converting enzyme inhibitors. A review.
Clinical pharmacology of quinapril in healthy volunteers and in patients with hypertension and congestive heart failure.
Clinical potential: angiotensin converting enzyme inhibitor or angiotensin II antagonist?
Clinical practice guidelines for heart failure.
Clinical predictors of worsening heart failure during withdrawal from digoxin therapy.
Clinical relevance of apoptosis in early and late post-infarction left ventricular remodeling.
Clinical response to angiotensin-converting enzyme inhibition in cardiac failure.
Clinical studies on beta blockers and heart failure preceding the MERIT-HF Trial. Metoprolol CR/XL Randomized Intervention Trial in Heart Failure.
Clinical trials evaluating angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in the setting of acute myocardial infarction.
Clinical trials of angiotensin receptor blockers in heart failure: what do we know and what will we learn?
Clinical trials of beta-blockers in heart failure: a class review.
Clinical utility of angiotensin converting enzyme inhibitors in hypertension.
Clinical, demographic and functional characteristics associated with pharmacotherapy for heart failure in older home care clients: a retrospective, population-level, cross-sectional study.
Clopidogrel is associated with a lesser increase in NT-proBNP when compared to aspirin in patients with ischemic heart failure.
Cold temperature impairs maximal exercise performance in patients with heart failure: attenuation by acute ACE inhibitor therapy.
Combination Angiotensin Converting Enzyme and Direct Renin Inhibition in Heart Failure following Experimental Myocardial Infarction.
Combination inhibition of the renin-angiotensin system: is more better?
Combination neurohormonal blockade with ACE inhibitors, angiotensin II antagonists and beta-blockers in patients with congestive heart failure: design of the Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) Pilot Study.
Combination of Hydralazine and Isosorbide-Dinitrate in the Treatment of Patients with Heart Failure with Reduced Ejection Fraction.
Combination of site of infarct, unrecognized glucose intolerance, and reinfarction after acute myocardial infarction in normotensive subjects is determinant of the development of subsequent systemic hypertension: a pilot study.
Combination pharmacologic therapies for heart failure: what next after angiotensin-converting enzyme inhibitors and beta-blockers?
Combination pharmacotherapies for cardiac reverse remodeling in heart failure patients with reduced ejection fraction: A systematic review and network meta-analysis of randomized clinical trials.
Combined angiotensin II AT1-receptor blockade and angiotensin I-converting enzyme inhibition on survival and cardiac remodeling in chronic heart failure in rats.
Combined Angiotensin Receptor Antagonism and Neprilysin Inhibition.
Combined angiotensin-converting enzyme inhibition and adrenomedullin in an ovine model of heart failure.
Combined aspirin/ACE inhibitor treatment for CHF.
Combined effects of angiotensin converting enzyme inhibition and angiotensin II receptor antagonism in conscious pigs with congestive heart failure.
Combined effects of low-dose oral spironolactone and captopril therapy in a rat model of spontaneous hypertension and heart failure.
Combined inhibition of neutral endopeptidase and angiotensin converting enzyme in cardiomyopathic hamsters with compensated heart failure.
Combined neutral endopeptidase and angiotensin-converting enzyme inhibition in heart failure: role of natriuretic peptides and angiotensin II.
Combined selective angiotensin II AT1-receptor blockade and angiotensin I-converting enzyme inhibition on coronary flow reserve in postischemic heart failure in rats.
Combined sympathetic suppression and angiotensin-converting enzyme inhibition in congestive heart failure.
Combined systolic and diastolic heart failure as the first presentation of mixed connective tissue disease.
Combined therapy with an angiotensin II receptor blocker and an angiotensin-converting enzyme inhibitor in heart failure.
Combined therapy with captopril and potassium supplementation. A potential for hyperkalemia.
Combined treatment with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers: a review of the current evidence.
Combined treatment with losartan and an ACE inhibitor in mild to moderate heart failure: results of a double-blind, randomized, placebo-controlled trial
Combining aspirin with angiotensin converting enzyme inhibitors in heart failure: how safe is it?
Combining salicylate and enalapril in patients with coronary artery disease and heart failure.
Comment--the REMATCH trial: Long-term use of a left ventricular assist device for end-stage heart failure.
Common misconceptions that arise in the first-year medical physiology curriculum concerning heart failure.
Community pharmacist outreach program directed at physicians treating congestive heart failure.
Comparative associations between angiotensin converting enzyme inhibitors, angiotensin receptor blockers and their combination, and outcomes in patients with heart failure and reduced ejection fraction.
Comparative effect of aspirin and clopidogrel on arterial function in CHF.
Comparative effectiveness of different angiotensin-converting enzyme inhibitors on the risk of hospitalization in patients with heart failure.
Comparative effectiveness of enalapril, lisinopril and ramipril in the treatment of patients with chronic heart failure. A propensity score matched cohort study.
Comparative effects of a vasopeptidase inhibitor vs. an angiotensin converting enzyme inhibitor on cardiomyocyte apoptosis in rats with heart failure.
Comparative effects of angiotensin II receptor blockade (candesartan) with angiotensin-converting enzyme inhibitor (quinapril) in rats with dilated cardiomyopathy.
Comparative effects of losartan and enalapril on exercise capacity and clinical status in patients with heart failure. The Losartan Pilot Exercise Study Investigators.
Comparative effects of losartan, captopril, and enalapril on murine acute myocarditis due to encephalomyocarditis virus.
Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group.
Comparative effects of perindopril with enalapril in rats with dilated cardiomyopathy.
Comparative effects of quinapril with enalapril in rats with heart failure.
Comparative haemodynamic responses to the first dose of short- and long-acting ACE inhibitors in patients with congestive heart failure.
Comparative study on the short-term effects of angiotensin converting enzyme inhibitors (Lopirin, SQUIBB and Tensiomin), and dihydralazine in chronic cardiac failure.
Comparative systemic and renal effects of dopamine and angiotensin-converting enzyme inhibition with enalaprilat in patients with heart failure.
Comparing angiotensin-converting enzyme inhibitor trial results in patients with acute myocardial infarction.
Comparison between angiotensin receptor antagonism and converting enzyme inhibition in heart failure. Differential acute effects according to the renin-angiotensin system activation.
Comparison of 12-month kinetics of serum markers of fibrosis between treatment with angiotensin receptor neprilysin inhibitor (ARNI) and angiotensin converting enzyme inhibitor (ACE-I) in patients with heart failure with reduced ejection fraction.
Comparison of angiotensin-converting enzyme inhibitor alone and in combination with irbesartan for the treatment of heart failure.
Comparison of angiotensin-converting enzyme inhibitors in the treatment of congestive heart failure.
Comparison of captopril and enalapril in patients with severe chronic heart failure.
Comparison of captopril with enalapril in the treatment of heart failure: influence on hemodynamics and measures of renal function.
Comparison of cardioprotective effects of mibefradil and ramipril in stroke-prone spontaneously hypertensive rats.
Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial.
Comparison of changes in respiratory function and exercise oxygen uptake with losartan versus enalapril in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy.
Comparison of effects on peak oxygen consumption, quality of life, and neurohormones of felodipine and enalapril in patients with congestive heart failure.
Comparison of high- versus low-tissue affinity ACE-inhibitor treatment on circulating aldosterone levels in patients with chronic heart failure.
Comparison of lisinopril versus placebo for congestive heart failure.
Comparison of losartan and captopril on heart failure-related outcomes and symptoms from the losartan heart failure survival study (ELITE II).
Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE).
Comparison of the angiotensin II type 1-receptor antagonist YM358 and the angiotensin-converting enzyme inhibitor enalapril in rats with cardiac volume overload.
Comparison of the effect of renin inhibition and angiotensin-converting enzyme inhibition in ovine heart failure.
Comparison of the effects of cilazapril and captopril versus placebo on exercise testing in chronic heart failure patients: a double-blind, randomized, multicenter trial. The Cilazapril-Captopril Multicenter Group.
Comparison of the effects of losartan and enalapril on clinical status and exercise performance in patients with moderate or severe chronic heart failure.
Comparison of the Efficacy and Safety of Different ACE Inhibitors in Patients With Chronic Heart Failure: A PRISMA-Compliant Network Meta-Analysis.
Comparison of three methods of glomerular filtration rate measurement with and without captopril pretreatment in groups of patients with left ventricular dysfunction.
Comparison of treatment initiation with bisoprolol vs. enalapril in chronic heart failure patients: rationale and design of CIBIS-III.
Comparison of type 1 angiotensin II receptor blockers and angiotensin converting enzyme inhibitors in the treatment of hypertension.
Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial.
Compliance with and dosing of angiotensin-converting-enzyme inhibitors before and after hospitalization.
Complications of Cardiovascular Events in Patients Hospitalized with Influenza-Related Pneumonia.
Composite outcomes: weighting component events according to severity assisted interpretation but reduced statistical power.
Comprehensive comparative effectiveness and safety of first-line antihypertensive drug classes: a systematic, multinational, large-scale analysis.
Comprehensive treatment of heart failure: state-of-the-art medical therapy.
Computerized Electronic Order Set: Use and Outcomes for Heart Failure Following Hospitalization.
Concurrent alpha 1 adrenergic blockade and angiotensin converting enzyme inhibition in the treatment of congestive heart failure.
Concurrent neutral endopeptidase and ACE inhibition in experimental heart failure: renal and hormonal effects.
Congestive cardiac failure following laxative withdrawal.
Congestive heart failure and Alzheimer's disease.
Congestive heart failure and atrial fibrillation: rhythm versus rate control.
Congestive heart failure clinical outcomes study in a private community medical group.
Congestive heart failure. New frontiers.
Congestive heart failure: guidelines for the primary care physician.
Congestive heart failure: new therapeutic strategies.
Containment of heart failure hospitalizations and cost by angiotensin-converting enzyme inhibitor dosage optimization.
Contemporary management of patients with left ventricular systolic dysfunction. Results from the Study of Patients Intolerant of Converting Enzyme Inhibitors (SPICE) Registry.
Continuation of Angiotensin Converting Enzyme Inhibitors in Acute Heart Failure.
Contractility and stiffness of noninfarcted myocardium after coronary ligation in rats. Effects of chronic angiotensin converting enzyme inhibition.
Contrasting peripheral short-term and long-term effects of converting enzyme inhibition in patients with congestive heart failure. A double-blind, placebo-controlled trial.
Control by circulating factors of mitochondrial function and transcription cascade in heart failure: a role for endothelin-1 and angiotensin II.
Controversies in heart failure. Are beneficial effects of angiotensin-converting enzyme inhibitors attenuated by aspirin in patients with heart failure?
Controversies in the use of beta blockers in heart failure.
Converting enzyme inhibition after experimental myocardial infarction in rats: comparative study between spirapril and zofenopril.
Converting enzyme inhibition and heart failure.
Converting enzyme inhibition improves congestion and survival in hypertensive rats with high-output heart failure.
Converting enzyme inhibition: search for additional mechanisms of action.
Coronary hemodynamic effects of angiotensin inhibition by captopril and teprotide in patients with congestive heart failure.
Coronary surgery in patients with preexisting chronic atrial fibrillation: early and midterm clinical outcome.
Coronary vasodilatation and improved myocardial lactate metabolism after angiotensin converting enzyme inhibition with cilazapril in patients with congestive heart failure.
Correlation between fibronectin and cardiothoracic ratio in heart failure treated with angiotensin converting enzyme inhibitors.
Cost Effectiveness of the Angiotensin Receptor Neprilysin Inhibitor Sacubitril/Valsartan for Patients with Chronic Heart Failure and Reduced Ejection Fraction in the Netherlands: A Country Adaptation Analysis Under the Former and Current Dutch Pharmacoeconomic Guidelines.
Cost of Heart Failure in Patients Receiving beta-Blockers and Angiotensin-Converting Enzyme Inhibitors.
Cost-effective management of heart failure.
Cost-effectiveness analysis in clinical practice: the case of heart failure.
Cost-Effectiveness of Sacubitril-Valsartan in Patients With Heart Failure With Reduced Ejection Fraction.
Cost-effectiveness of sacubitril/valsartan in chronic heart-failure patients with reduced ejection fraction.
Cost-Effectiveness of Switching Patients With Heart Failure and Reduced Ejection Fraction to Sacubitril/Valsartan: The Australian Perspective.
Costs and effectiveness of angiotensin converting enzyme inhibition in patients with congestive heart failure.
Costs and effects of enalapril therapy in patients with symptomatic heart failure: an economic analysis of the Studies of Left Ventricular Dysfunction (SOLVD) Treatment Trial.
Cough and angioedema from angiotensin-converting enzyme inhibitors: new insights into mechanisms and management.
Cough caused by cilazapril.
Counteraction of the vasodilator effects of enalapril by aspirin in severe heart failure.
COVID-19 and cardiac injury: clinical manifestations, biomarkers, mechanisms, diagnosis, treatment, and follow up.
Covid-19 and cardiovascular risk: Susceptibility to infection to SARS-CoV-2, severity and prognosis of Covid-19 and blockade of the renin-angiotensin-aldosterone system. An evidence-based viewpoint.
Critical assessment of ACE inhibitors. Part 2.
Cross-sectional study of heart failure therapy with angiotensin converting enzyme inhibitors and digoxin.
Current and emerging drug targets in heart failure treatment.
Current and future uses of candesartan in the treatment of heart failure.
Current challenges in the management of heart failure.
Current concepts in secondary prevention after acute myocardial infarction.
Current concepts in the management of heart failure.
Current guidelines in the pharmacological management of chronic heart failure.
Current indications for ACE inhibitors and HOPE for the future.
Current limitations in treatment of heart failure: new avenues and treatment options.
Current perspectives on beta-receptor antagonists in the treatment of symptomatic ventricular dysfunction.
Current Pharmacologic Management of Pediatric Heart Failure in Congenital Heart Disease.
Current recommendations for the treatment of hypertension: are they still valid?
Current status of safety and efficacy of calcium channel blockers in cardiovascular diseases: a critical analysis based on 100 studies.
Current Strategies to Achieve Further Cardiac and Renal Protection through Enhanced Renin-Angiotensin-Aldosterone System Inhibition.
Current treatment of heart failure with reduction of left ventricular ejection fraction.
Current trends and future perspectives for heart failure treatment leveraging cGMP modifiers and the practical effector PKG.
Cyclooxygenase inhibition causes marked impairment of renal function in elderly subjects treated with diuretics and ACE-inhibitors.
Cytokines and heart failure.
Czech and Slovak spirapril intervention study (CASSIS). A randomized, placebo and active-controlled, double-blind multicentre trial in patients with congestive heart failure.
Death and hospitalization in heart failure patients receiving carvedilol vs. metoprolol tartrate.
Decline in ACEI/ARB Prescribing as Heart Failure Core Metrics Improve During Computer-Based Clinical Decision Support.
Declining Risk of Sudden Death in Heart Failure.
DEFEAT - Heart Failure: a guide to management of geriatric heart failure by generalist physicians.
DEFibrillators In Non-Ischemic Cardiomyopathy Treatment Evaluation (DEFINITE).
Defibrillators in nonischemic cardiomyopathy treatment evaluation.
Defining quality at Catholic Healthcare West.
Delayed onset of angioedema with angiotensin-converting enzyme inhibitors: case report and review of the literature.
Design and analysis of the HYPREN-trial: safety of enalapril and prazosin in the initial treatment phase of patients with congestive heart failure.
Design of a multicentre randomized controlled trial to assess the safety and efficacy of dose titration by specialized nurses in patients with heart failure. ETIFIC study protocol.
Design of the Beta-Blocker Evaluation Survival Trial (BEST). The BEST Steering Committee.
Design of the heart failure endpoint evaluation of AII-antagonist losartan (HEAAL) study in patients intolerant to ACE-inhibitor.
Designing a Comprehensive Strategy to Improve One Core Measure: Discharge of Patients With Myocardial Infarction or Heart Failure on ACE Inhibitors/ARBs.
Determinants and prognostic information provided by pulse pressure in patients with coronary artery disease undergoing revascularization. The Balloon Angioplasty Revascularization Investigation (BARI).
Determinants of angiotensin-converting enzyme inhibitor prescription in severe heart failure with left ventricular systolic dysfunction: the EPICAL study.
Determinants of failure to prescribe target doses of angiotensin-converting enzyme inhibitors for heart failure.
Determinants of mortality in elderly patients with heart failure: the role of angiotensin-converting enzyme inhibitors.
Determinants of the initial effects of captopril on blood pressure, glomerular filtration rate, and natriuresis in mild-to-moderate chronic congestive heart failure secondary to coronary artery disease.
Development of circulatory-renal limitations to angiotensin-converting enzyme inhibitors identifies patients with severe heart failure and early mortality.
Development of heart failure following isoproterenol administration in the rat: role of the renin-angiotensin system.
Development of press-coated, floating-pulsatile drug delivery of lisinopril.
Diabetes, Heart Failure and Beyond: Elucidating the Cardioprotective Mechanisms of Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors.
Diagnosis and management of viral myocarditis.
Diagnosis of patients with chronic heart failure in primary care: usefulness of history, examination, and investigations.
Dietary sodium restriction specifically potentiates left ventricular ACE inhibition by zofenopril, and is associated with attenuated hypertrophic response in rats with myocardial infarction.
Difference in mortality between patients treated with captopril or enalapril in the Xamoterol in Severe Heart Failure Study.
Differences between zofenopril and ramipril, two ACE inhibitors, on cough induced by citric acid in guinea pigs: role of bradykinin and PGE2.
Differences in first dose response to angiotensin converting enzyme inhibition in congestive heart failure: a placebo controlled study.
Differences in generalist and specialist physicians' knowledge and use of angiotensin-converting enzyme inhibitors for congestive heart failure.
Different ventricular remodelling and autonomic modulation after long-term beta-blocker treatment in hypertensive, ischaemic and idiopathic dilated cardiomyopathy.
Differential actions of vasopeptidase inhibition versus angiotensin-converting enzyme inhibition on diuretic therapy in experimental congestive heart failure.
Differential effects of captopril and enalapril on tissue renin-angiotensin systems in experimental heart failure.
Differential Effects of Prevention and Reversal Treatment with Lisinopril on Left Ventricular Remodelling in a Rat Model of Heart Failure.
Differential expression of angiotensin-converting enzyme and chymase in dogs with chronic mitral regurgitation.
Differential therapy of hypertensive heart disease.
Differing clinical courses and outcomes in two siblings with Barth syndrome and left ventricular noncompaction.
Differing early blood pressure and renin-angiotensin system responses to the first dose of angiotensin-converting enzyme inhibitors in congestive heart failure.
Digoxin and angiotensin converting enzyme inhibitors in chronic heart failure.
Digoxin Discontinuation and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction.
Digoxin in heart failure and cardiac arrhythmias.
Digoxin in heart failure: implications of recent trials.
Digoxin or angiotensin converting enzyme inhibitors for congestive heart failure in geriatric patients. Which is the preferred treatment?
Digoxin therapy in the elderly: pharmacokinetic considerations in nursing.
Digoxin use and digoxin toxicity in the post-DIG trial era.
Digoxin, converting-enzyme inhibition (quinapril), and the combination in patients with congestive heart failure functional class II and sinus rhythm.
Dilated cardiomyopathy update: infectious-immune theory revisited.
Dilated Cardiomyopathy.
Dilated cardiomyopathy.
Direct renin inhibition in addition to or as an alternative to angiotensin converting enzyme inhibition in patients with chronic systolic heart failure: rationale and design of the Aliskiren Trial to Minimize OutcomeS in Patients with HEart failuRE (ATMOSPHERE) study.
Directly Measured Adherence to Treatment in Chronic Heart Failure: LEVEL-CHF Registry.
Disappearance of left ventricular hypertrabeculation/noncompaction after biventricular pacing in a patient with polyneuropathy.
Discharge use of angiotensin receptor blockers provides comparable effects with angiotensin-converting enzyme inhibitors on outcomes in patients hospitalized for heart failure.
Discontinuation of angiotensin-converting enzyme inhibitors or beta-blockers and the impact on heart failure hospitalization rates.
Discontinuation/Dose Reduction of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers during Acute Decompensated Heart Failure in African-American Patients with Reduced Left-Ventricular Ejection Fraction.
Discordance of anti-ischemic and hemodynamic effects of captopril in stable coronary artery disease.
Discovery of remikiren as the first orally active renin inhibitor.
Discrepancy between plasma and lung angiotensin-converting enzyme activity in experimental congestive heart failure. A novel aspect of endothelium dysfunction.
Disparate results of ACE inhibitor dosage on exercise capacity in heart failure: a reappraisal of vasodilator therapy and study design.
Disparities in health care are driven by where minority patients seek care: examination of the hospital quality alliance measures.
Dissociation between ACE activity and autonomic response to ACE inhibition in patients with heart failure.
Dissociation between improvement in left ventricular performance and functional class in patients with chronic heart failure.
Diuretic therapy in congestive heart failure.
Diuretics - a panacea for acute heart failure? Different formulations, doses, and combinations.
Diuretics potentiate angiotensin converting enzyme inhibitor-induced acute renal failure.
Diverse effects of AT1 receptor antagonists on normal blood pressure and regulatory system.
Do all patients with coronary artery disease benefit from angiotensin converting enzyme inhibitors?
Do angiotensin-converting enzyme inhibitors prolong life in patients with heart failure treated in clinical practice?
Do evidence-based treatments provide incremental benefits to patients with congestive heart failure already receiving angiotensin-converting enzyme inhibitors? A secondary analysis of one-year outcomes from the Assessment of Treatment with Lisinopril and Survival (ATLAS) study.
Do Renin-Angiotensin Blockers Affect Renal Function and Cardiac Outcomes in Patients Undergoing Partial Nephrectomy?
Dobutamine as bridge to angiotensin-converting enzyme inhibitor-nitrate therapy in endstage heart failure.
Does angiotensin-converting enzyme inhibition improve the energetic status of cardiac and skeletal muscles in heart failure induced by aortic stenosis in rats?
Does angiotensin-converting enzyme polymorphism influence the clinical manifestation and progression of heart failure in patients with dilated cardiomyopathy?
Does angiotensin-converting-enzyme inhibitor therapy improve cognitive function in heart failure patients?
Does aspirin attenuate the beneficial effects of angiotensin-converting enzyme inhibition in heart failure?
Does aspirin attenuate the effect of angiotensin-converting enzyme inhibitors in hypertension or heart failure?
Does aspirin interfere with the therapeutic efficacy of angiotensin-converting enzyme inhibitors in hypertension or congestive heart failure?
Does aspirin use adversely influence intermediate-term postdischarge outcomes for hospitalized patients who are treated with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers? Findings from Organized Program to Facilitate Life-Saving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF).
Does the duration of action of angiotensin converting enzyme inhibitors affect their safety and adverse effects?
Does the target dose of neurohormonal blockade matter for outcome in Systolic heart failure in octogenarians?
Dose of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers and Outcomes in Heart Failure: A Meta-Analysis.
Dose response of ACE inhibitors: implications of the SECURE trial.
Dose-dependent inhibition of angiotensin converting enzyme by enalapril in cats.
Dose-finding study of imidapril, a novel angiotensin converting enzyme inhibitor, in patients with stable chronic heart failure.
Dose-ranging study of isosorbide-5-mononitrate in chronic congestive heart failure treated with diuretics and angiotensin-converting enzyme inhibitor.
Dose-related beneficial long-term hemodynamic and clinical efficacy of irbesartan in heart failure.
Dose-response of chronic beta-blocker treatment in heart failure from either idiopathic dilated or ischemic cardiomyopathy. Bucindolol Investigators.
Dosing of losartan in men versus women with heart failure with reduced ejection fraction: the HEAAL trial.
Double-blind comparison of captopril alone against frusemide plus amiloride in mild heart failure.
Double-blind, placebo-controlled study of the long-term efficacy of carvedilol in patients with severe chronic heart failure.
Double-blind, placebo-controlled study to evaluate the effect of organic nitrates in patients with chronic heart failure treated with angiotensin-converting enzyme inhibition.
Doxorubicin-induced cardiomyopathy treated with carvedilol.
Drug and drug-device therapy in heart failure patients in the post-COMET and SCD-HeFT era.
Drug benefit generosity and essential medication use among Medicare-eligible retirees.
Drug class effects: definitions and practical applications.
Drug Insight: angiotensin-converting-enzyme inhibitors and atrial fibrillation-indications and contraindications.
Drug therapy for chronic heart failure due to left ventricular systolic dysfunction: a review. III. Angiotensin-converting enzyme inhibitors.
Drug therapy for patients with systolic heart failure after the PARADIGM-HF trial: in need of a new paradigm of LCZ696 implementation in clinical practice.
Drug therapy of chronic heart failure in the elderly: the current state of clinical-trial evidence.
Drug treatment of hypertension in Sweden in relation to sex, age, and comorbidity.
Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF).
Dual blockade of aldosterone and angiotensin II additively suppresses TGF-beta and NADPH oxidase in the hypertensive kidney.
Dual blockade of the renin-angiotensin-aldosterone system: beyond the ACE inhibitor and angiotensin-II receptor blocker combination.
Dual blockade versus single blockade of the renin-angiotensin system in the light of ONTARGET.
Dual ECE/NEP inhibition on cardiac and neurohumoral function during the transition from hypertrophy to heart failure in rats.
Dual inhibition of ACE and NEP provides greater cardioprotection in mice with heart failure.
Dyspnoea, asthma, and bronchospasm in relation to treatment with angiotensin converting enzyme inhibitors.
Early and chronic captopril or Losartan therapy reduces infarct size and avoids congestive heart failure after myocardial infarction in rats.
Early initiation of beta blockade in heart failure: issues and evidence.
Early insights into the characteristics and evolution of clinical parameters in a cohort of patients prescribed sacubitril/valsartan in Germany.
Early intervention in heart failure.
Early or late ACE inhibition after myocardial infarction.
Early versus delayed angiotensin-converting enzyme inhibition in experimental chronic heart failure. Effects on survival, hemodynamics, and cardiovascular remodeling.
Economic evaluation of the randomized aldactone evaluation study (RALES): treatment of patients with severe heart failure.
Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Angiotensin-converting enzyme inhibitors in the management of congestive heart failure: a pharmaceutical industry perspective.
ED 01-1 ARE ARBS COMPARABLE TO ACEIS IN PATIENTS WITH MYOCARDIAL INFARCTION?
Effect of a do-not-resuscitate order on the quality of care in acute heart failure patients: a single-center cohort study.
Effect of acute and chronic zofenopril administration on cardiac gene expression.
Effect of acute angiotensin converting enzyme inhibition on left ventricular filling in patients with congestive heart failure. Relation to right ventricular volumes.
Effect of adherence to evidence-based therapy after acute myocardial infarction on all-cause mortality.
Effect of amlodipine on mode of death among patients with advanced heart failure in the PRAISE trial. Prospective Randomized Amlodipine Survival Evaluation.
Effect of angiotensin converting enzyme inhibition on plasma endothelin in congestive heart failure.
Effect of angiotensin converting enzyme inhibition on renal function in the treatment of heart failure.
Effect of angiotensin converting enzyme inhibitor on the calcium transients and calcium handling proteins in ventricular myocytes from rats with heart failure.
Effect of angiotensin converting enzyme inhibitors and angiotensin receptor blockers on hemoglobin levels.
Effect of angiotensin receptor blockers and angiotensin converting enzyme?2 on plasma equilibrium angiotensin peptide concentrations in dogs with heart disease.
Effect of angiotensin-converting enzyme blockade, alone or combined with blockade of soluble epoxide hydrolase, on the course of congestive heart failure and occurrence of renal dysfunction in Ren-2 transgenic hypertensive rats with aorto-caval fistula.
Effect of angiotensin-converting enzyme inhibition on plasma brain natriuretic peptide levels in patients with heart failure.
Effect of angiotensin-converting enzyme inhibition on protein kinase C and SR proteins in heart failure.
Effect of angiotensin-converting enzyme inhibition on sympathetic tone in patients with mild to moderate heart failure.
Effect of angiotensin-converting enzyme inhibitor (enalapril or imidapril) on ventilation during exercise in patients with chronic heart failure secondary to idiopathic dilated cardiomyopathy.
Effect of angiotensin-converting enzyme inhibitor dosing interval on functional parameters in patients with chronic heart failure.
Effect of angiotensin-converting enzyme inhibitor therapy on 30-day outcome in patient > or = 65 years of age with chronic congestive heart failure.
Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on cardiovascular events in patients with heart failure: a meta-analysis of randomized controlled trials.
Effect of angiotensin-converting enzyme inhibitors in left ventricular dysfunction: results of the studies of left ventricular dysfunction in the context of other similar trials.
Effect of angiotensin-converting enzyme inhibitors on endothelium-dependent peripheral vasodilation in patients with chronic heart failure.
Effect of Angiotensin-Converting Enzyme Inhibitors on Physical Function in Elderly Subjects: A Systematic Review and Meta-Analysis.
Effect of angiotensin-converting enzyme inhibitors on response to erythropoietin therapy in chronic dialysis patients.
Effect of angiotensin-converting enzyme inhibitors on the peripheral circulation in heart failure.
Effect of angiotensin-converting enzyme inhibitors, beta blockers, statins, and aspirin on C-reactive protein levels in outpatients with heart failure.
Effect of angiotensin-converting enzyme or vasopeptidase inhibition on ventricular size and function in patients with heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE) echocardiographic study.
Effect of benazepril on survival and cardiac events in dogs with asymptomatic mitral valve disease: a retrospective study of 141 cases.
Effect of beta blockers alone, of angiotensin-converting enzyme inhibitors alone, and of beta blockers plus angiotensin-converting enzyme inhibitors on new coronary events and on congestive heart failure in older persons with healed myocardial infarcts and asymptomatic left ventricular systolic dysfunction.
Effect of beta-blocker on left ventricular function and natriuretic peptides in patients with chronic heart failure treated with angiotensin-converting enzyme inhibitor.
Effect of captopril on cardiac parasympathetic activity in chronic cardiac failure secondary to coronary artery disease.
Effect of captopril on renal function in patients with congestive heart failure.
Effect of captopril therapy on lymphocyte potassium and magnesium concentrations in patients with congestive heart failure.
Effect of captopril, an angiotensin-converting enzyme inhibitor, in patients with angina pectoris and heart failure.
Effect of certain angiotensin-converting enzyme inhibitors on mortality in heart failure: A multiple-propensity analysis.
Effect of chronic Angiotensin converting enzyme inhibitor therapy on myocardial injury in patients undergoing percutaneous coronary interventions.
Effect of chronic angiotensin II type I receptor antagonism and angiotensin converting enzyme inhibition on plasma fibrinolytic variables in patients with heart failure.
Effect of chronic angiotensin-converting enzyme inhibition on endothelial function in patients with chronic heart failure.
Effect of cilazapril on exercise tolerance in congestive heart failure.
Effect of combination angiotensin-converting enzyme and angiotensin receptor blocker therapy on heart failure mortality and morbidity.
Effect of combinations of drugs on all cause mortality in patients with ischaemic heart disease: nested case-control analysis.
Effect of combined aspirin and angiotensin-converting enzyme inhibitor therapy versus angiotensin-converting enzyme inhibitor therapy alone on readmission rates in heart failure.
Effect of comorbidities on outcomes and angiotensin converting enzyme inhibitor effects in patients with predominantly left ventricular dysfunction and heart failure.
Effect of converting-enzyme inhibition on renal response to ANF in rats with experimental heart failure.
Effect of different angiotensin-converting-enzyme inhibitors on mortality among elderly patients with congestive heart failure.
Effect of direct renin inhibitor on left ventricular remodeling in patients with primary acute myocardial infarction.
Effect of direct vasodilation with hydralazine versus angiotensin-converting enzyme inhibition with captopril on mortality in advanced heart failure: the Hy-C trial.
Effect of drug therapy for heart failure on quality of life.
Effect of drug therapy on survival in chronic congestive heart failure.
Effect of enalapril in dogs with pacing-induced heart failure.
Effect of enalapril initiated early after acute myocardial infarction on heart failure parameters, with reference to clinical class and echocardiographic determinants. CONSENSUS II Multi-Echo Study Group.
Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators.
Effect of heart failure program on cardiovascular drug utilization and dosage in patients with chronic heart failure.
Effect of high- versus low-dose angiotensin converting enzyme inhibition on cytokine levels in chronic heart failure.
Effect of intense angiotensin II suppression on the diuretic response to furosemide during chronic ACE inhibition.
Effect of L-2286, a poly(ADP-ribose)polymerase inhibitor and enalapril on myocardial remodeling and heart failure.
Effect of lipid-lowering agents, angiotensin-converting enzyme inhibitors, and calcium antagonists on coronary disease risk.
Effect of long-term angiotensin-converting enzyme inhibition on vascular function in patients with chronic congestive heart failure.
Effect of long-term angiotensin-converting enzyme inhibitor therapy on arterial oxygen saturation in patients with mild to moderate heart failure.
Effect of long-term treatment with trandolapril on Hsp72 and Hsp73 induction of the failing heart following myocardial infarction.
Effect of low dose aspirin on cardiorenal function and acute hemodynamic response to enalaprilat in a canine model of severe heart failure.
Effect of oral captopril on premature ventricular complexes in patients with preserved left ventricular systolic function: a randomized clinical trial.
Effect of organic anion-transporting polypeptide 1B1 (OATP1B1) polymorphism on the single- and multiple-dose pharmacokinetics of enalapril in healthy Chinese adult men.
Effect of perindopril in pacing-induced canine models of acute and chronic heart failure.
Effect of perindopril on physical function in elderly people with functional impairment: a randomized controlled trial.
Effect of perindopril on platelet nitric oxide resistance in patients with chronic heart failure secondary to ischemic left ventricular dysfunction.
Effect of pimobendan in patients with chronic heart failure.
Effect of pimobendan on exercise capacity in patients with heart failure: main results from the Pimobendan in Congestive Heart Failure (PICO) trial.
Effect of Prescribing Patterns of Renin-Angiotensin System Blockers and Beta-Blockers on Prognosis of Heart Failure.
Effect of prophylactic betablocker or ACE inhibitor on cardiac dysfunction & heart failure during anthracycline chemotherapy ± trastuzumab.
Effect of propranolol versus no propranolol on total mortality plus nonfatal myocardial infarction in older patients with prior myocardial infarction, congestive heart failure, and left ventricular ejection fraction > or = 40% treated with diuretics plus angiotensin-converting enzyme inhibitors.
Effect of ramipril on heart rate variability in digitalis-treated patients with chronic heart failure.
Effect of ramipril on postrevascularization prevalence of angina and quality of life.
Effect of renin-angiotensin-aldosterone system inhibitors on all-cause mortality and major cardiovascular events in patients with diabetes: A meta-analysis focusing on the number needed to treat and minimal clinical effect.
Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial.
Effect of sildenafil on pulmonary hypertension associated with left heart failure.
Effect of statins, angiotensin-converting enzyme inhibitors, and beta blockers on survival in patients >or=65 years of age with heart failure and preserved left ventricular systolic function.
Effect of telmisartan on renal outcomes: a randomized trial.
Effect of the addition of a beta-blocker on left ventricular remodeling and prognosis in patients with dilated cardiomyopathy treated with angiotensin-converting enzyme inhibitor.
Effect of the angiotensin-converting enzyme inhibitor alacepril on ventricular function and beta-adrenoceptor number in rabbits with aortic regurgitation.
Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients.
Effect of the insertion/deletion polymorphism of the angiotensin-converting enzyme gene on response to angiotensin-converting enzyme inhibitors in patients with heart failure.
Effect of the renin-angiotensin system on limb circulation and metabolism during exercise in patients with heart failure.
Effect of the renin-angiotensin-aldosterone system on the cardiac interstitium in heart failure.
Effect of therapeutic interchange on medication reconciliation during hospitalization and upon discharge in a geriatric population.
Effect of timed semirecumbency and furosemide dosing on urinary sodium excretion in patients with compensated heart failure.
Effect of valsartan added to background ACE inhibitor therapy in patients with heart failure: results from Val-HeFT.
Effect of valsartan on quality of life when added to usual therapy for heart failure: results from the Valsartan Heart Failure Trial.
Effect of vasodilator therapy on mortality in chronic congestive heart failure.
Effect on survival and hospitalization of initiating treatment for chronic heart failure with bisoprolol followed by enalapril, as compared with the opposite sequence: results of the randomized Cardiac Insufficiency Bisoprolol Study (CIBIS) III.
Effect on the myocardial energy metabolism of angiotensin-converting enzyme inhibition in chronic heart failure.
Effectiveness and Factors Determining the Success of Management Programs for Patients With Heart Failure: A Systematic Review and Meta-analysis.
Effectiveness of hydralazine/isosorbide dinitrate in racial/ethnic subgroups with heart failure.
Effectiveness of repeat enhanced external counterpulsation for refractory angina in patients failing to complete an initial course of therapy.
Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study [RALES]).
Effects of 12 weeks of ramipril treatment on the quality of life in patients with moderate congestive heart failure: results of a placebo-controlled trial. Ramipril Study Group.
Effects of a DA2/alpha2 agonist and a beta1-blocker in combination with an ACE inhibitor on adrenergic activity and left ventricular remodeling in an experimental model of left ventricular dysfunction after coronary artery occlusion.
Effects of a new angiotensin converting enzyme inhibitor, enalapril, in acute and chronic left ventricular failure in dogs.
Effects of a new angiotensin-converting enzyme inhibitor, alacepril, on changes in neurohormonal factors and arterial baroreflex sensitivity in patients with congestive heart failure.
Effects of ACE gene insertion/deletion polymorphism on response to spironolactone in patients with chronic heart failure.
Effects of ACE inhibition and beta-receptor blockade on energy metabolism in rats postmyocardial infarction.
Effects of ACE inhibitor and AT1 blocker on dystrophin-related proteins and calpain in failing heart.
Effects of ACE inhibitor therapy on quality of life in patients with heart failure.
Effects of ACE inhibitor, AT1 antagonist, and combined treatment in mice with heart failure.
Effects of ACE inhibitors on heart failure in The Netherlands: a pharmacoeconomic model.
Effects of ACE inhibitors on skeletal muscle.
Effects of acetylsalicylic acid on peripheral hemodynamics in patients with chronic heart failure treated with angiotensin-converting enzyme inhibitors.
Effects of acute angiotensin converting enzyme inhibition on renal blood flow in patients with stable congestive heart failure.
Effects of acute angiotensin II type 1 receptor antagonism and angiotensin converting enzyme inhibition on plasma fibrinolytic parameters in patients with heart failure.
Effects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease.
Effects of AGTR1 A1166C gene polymorphism in patients with heart failure treated with candesartan.
Effects of alatriopril, a mixed inhibitor of atriopeptidase and angiotensin I-converting enzyme, on cardiac hypertrophy and hormonal responses in rats with myocardial infarction. Comparison with captopril.
Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators.
Effects of angiotensin converting enzyme inhibitors on remodeling in clinical trials.
Effects of angiotensin II (AT1) receptor blockade on cardiac vagal control in heart failure.
Effects of angiotensin II type 1 receptor blockade and angiotensin-converting enzyme inhibition on cardiac beta-adrenergic signal transduction.
Effects of angiotensin receptor blocker at discharge in patients with heart failure with reduced ejection fraction: Korean Acute Heart Failure (KorAHF) registry.
Effects of angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade on beta-adrenoceptor signaling in heart failure produced by myocardial Infarction in rabbits: reversal of altered expression of beta-adrenoceptor kinase and G i alpha.
Effects of angiotensin-converting enzyme inhibition on changes in left ventricular myocardial creatine kinase system after myocardial infarction: their relation to ventricular remodeling and function.
Effects of angiotensin-converting enzyme inhibition on the development of the atrial fibrillation substrate in dogs with ventricular tachypacing-induced congestive heart failure.
Effects of angiotensin-converting enzyme inhibitor or angiotensin receptor blocker therapy after hospital discharge on subsequent rehospitalization for acute myocardial infarction and heart failure.
Effects of angiotensin-converting enzyme inhibitor plus irbesartan on maximal and submaximal exercise capacity and neurohumoral activation in patients with congestive heart failure.
Effects of angiotensin-converting enzyme inhibitor therapy on presence of late potentials detected using signal-averaged electrocardiography in patients with congestive heart failure.
Effects of angiotensin-converting enzyme inhibitors (ACE i) on zinc metabolism in patients with heart failure.
Effects of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in patients with chronic kidney disease.
Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure. Role of kinins and angiotensin II type 2 receptors.
Effects of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers on Angiotensin-Converting Enzyme 2 Levels: A Comprehensive Analysis Based on Animal Studies.
Effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on cardiovascular events in patients with diabetes and overt nephropathy: a meta-analysis of randomised controlled trials.
Effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on left ventricular mass index and ejection fraction in hemodialysis patients: A meta-analysis with trial sequential analysis of randomized controlled trials.
Effects of Angiotensin-Converting Enzyme Inhibitors and Angiotensin-Receptor Blockers in Heart Failure With Chronic Kidney Disease?- Propensity Score Matching Analysis.
Effects of angiotensin-converting enzyme inhibitors and digoxin on health outcomes of very old patients with heart failure. SAGE Study Group. Systematic Assessment of Geriatric drug use via Epidemiology.
Effects of angiotensin-converting enzyme inhibitors on tissue renin-angiotensin systems.
Effects of angiotensin-converting-enzyme inhibitor therapy on the regulation of the plasma and cardiac tissue renin-angiotensin system in heart transplant patients.
Effects of aspirin and clopidogrel on plasma brain natriuretic peptide in patients with heart failure receiving ACE inhibitors.
Effects of aspirin on angiotensin-converting enzyme inhibition and left ventricular dilation one year after acute myocardial infarction.
Effects of AT1 receptor antagonist therapy in patients with severe heart failure pretreated with angiotensin-converting enzyme inhibitors.
Effects of blood pressure-lowering on outcome incidence in hypertension: 5. Head-to-head comparisons of various classes of antihypertensive drugs - overview and meta-analyses.
Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial.
Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial.
Effects of candesartan on the proteinuria of chronic glomerulonephritis.
Effects of captopril in acute and chronic heart failure. Correlations with plasma levels of noradrenaline, renin, and aldosterone.
Effects of captopril on ischemia and dysfunction of the left ventricle after myocardial infarction.
Effects of carvedilol on right ventricular ejection fraction and cytokines levels in patients with systolic heart failure.
Effects of chronic heart failure on the responsiveness to angiotensin I and to angiotensin converting enzyme inhibition with cilazapril in rats.
Effects of cilazapril on ventricular arrhythmia in patients with congestive heart failure.
Effects of coadministration of aspirin or clopidogrel on exercise testing in patients with heart failure receiving angiotensin-converting enzyme inhibitors.
Effects of combined candesartan and ACE inhibitors on BNP, markers of inflammation and oxidative stress, and glucose regulation in patients with symptomatic heart failure.
Effects of combined inhibition of the Na+-H+ exchanger and angiotensin-converting enzyme in rats with congestive heart failure after myocardial infarction.
Effects of combined renin-angiotensin-aldosterone system inhibitor and beta-blocker treatment on outcomes in heart failure with reduced ejection fraction: insights from BIOSTAT-CHF and ASIAN-HF registries.
Effects of enalapril in heart failure: a double blind study of effects on exercise performance, renal function, hormones, and metabolic state.
Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group.
Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS).
Effects of enalapril on myocardial noradrenaline overflow during exercise in patients with chronic heart failure.
Effects of enalapril on vasoactive intestinal peptide metabolism and tissue levels.
Effects of enalapril, a new angiotensin-converting enzyme inhibitor, in a controlled trial in heart failure.
Effects of enalapril, candesartan or both on neurohumoral activation and LV volumes and function in patients with heart failure not treated with a beta-blocker.
Effects of fosinopril on exercise tolerance and clinical deterioration in patients with chronic congestive heart failure not taking digitalis. Fosinopril Heart Failure Study Group.
Effects of growth hormone following chronic angiotensin-converting enzyme inhibition in chronic heart failure: their relation to infarct size.
Effects of high thoracic epidural sympathetic blockade for the treatment of severe chronic heart failure due to dilated cardiomyopathy.
Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial.
Effects of imidapril and TA-606 on rat dilated cardiomyopathy after myocarditis.
Effects of imidapril on endothelin-1 and ACE gene expression in failing hearts of salt-sensitive hypertensive rats.
Effects of imidapril on NOS expression and myocardial remodelling in failing heart of Dahl salt-sensitive hypertensive rats.
Effects of Increased Dose of Diuretics on Symptoms, Weight, 6-Minute Walk Distance, and Echocardiographic Measurements of Left Ventricular Systolic and Diastolic Function in 51 Patients With Symptomatic Heart Failure Caused by Reduced Left Ventricular Ejection Fraction Treated With Beta Blockers and Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers.
Effects of increasing maintenance dose of digoxin on left ventricular function and neurohormones in patients with chronic heart failure treated with diuretics and angiotensin-converting enzyme inhibitors.
Effects of lacidipine on peak oxygen consumption, neurohormones and invasive haemodynamics in patients with mild to moderate chronic heart failure.
Effects of lisinopril, a new angiotensin converting enzyme inhibitor in a cryo-injury model of chronic left ventricular failure.
Effects of Long- and Intermediate-Acting Dihydropyridine Calcium Channel Blockers in Hypertension: A Systematic Review and Meta-Analysis of 18 Prospective, Randomized, Actively Controlled Trials.
Effects of long-term angiotensin II AT1 receptor blockade on survival, hemodynamics and cardiac remodeling in chronic heart failure in rats.
Effects of long-term monotherapy with enalapril, metoprolol, and digoxin on the progression of left ventricular dysfunction and dilation in dogs with reduced ejection fraction.
Effects of long-term therapy with ACE inhibitors, captopril, enalapril and trandolapril, on myocardial energy metabolism in rats with heart failure following myocardial infarction.
Effects of long-term treatment with pimobendan on neurohumoral factors in patients with non-ischemic chronic moderate heart failure.
Effects of long-term treatment with trandolapril on augmented vasoconstriction in rats with chronic heart failure.
Effects of losartan and captopril on left ventricular volumes in elderly patients with heart failure: results of the ELITE ventricular function substudy.
Effects of losartan versus captopril on mortality in patients with symptomatic heart failure: rationale, design, and baseline characteristics of patients in the Losartan Heart Failure Survival Study--ELITE II.
Effects of myocardial infarction and captopril therapy on anxiety-related behaviors in the rat.
Effects of neurohormonal antagonism on symptoms and quality-of-life in heart failure.
Effects of neutral endopeptidase inhibition and combined angiotensin converting enzyme and neutral endopeptidase inhibition on angiotensin and bradykinin peptides in rats.
Effects of omapatrilat on hemodynamics and safety in patients with heart failure.
Effects of omapatrilat on systemic arterial function in patients with chronic heart failure.
Effects of once-daily benazepril therapy on exercise tolerance and manifestations of chronic congestive heart failure. The Benazepril Heart Failure Study Group.
Effects of pentoxifylline on cytokine profiles and left ventricular performance in patients with decompensated congestive heart failure secondary to idiopathic dilated cardiomyopathy.
Effects of perindopril on aldosterone production in the failing human heart.
Effects of perindopril on cardiac sympathetic nerve activity in patients with congestive heart failure: comparison with enalapril.
Effects of ramipril on renal function during progressive overpacing-induced heart failure in dogs.
Effects of renin inhibition compared to angiotensin converting enzyme inhibition in conscious dogs with pacing-induced heart failure.
Effects of Sacubitril/Valsartan in the PARADIGM-HF Trial (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) According to Background Therapy.
Effects of spirapril and captopril on regional blood flow in chronic congestive heart failure: a comparison between a short- and a long-acting angiotensin-converting enzyme inhibitor.
Effects of spironolactone and eprosartan on cardiac remodeling and angiotensin-converting enzyme isoforms in rats with experimental heart failure.
Effects of spironolactone on endothelial function, vascular angiotensin converting enzyme activity, and other prognostic markers in patients with mild heart failure already taking optimal treatment.
Effects of spironolactone on exercise capacity and neurohormonal factors in patients with heart failure treated with loop diuretics and angiotensin-converting enzyme inhibitor.
Effects of subchronic treatment with trandolapril and enalapril on cardiovascular morphologic alterations in the aged spontaneously hypertensive rat with heart failure.
Effects of telmisartan added to Angiotensin-converting enzyme inhibitors on mortality and morbidity in hemodialysis patients with chronic heart failure a double-blind, placebo-controlled trial.
Effects of the 1994 Canadian Cardiovascular Society clinical practice guidelines for congestive heart failure.
Effects of the ACE inhibitor quinapril on echocardiographic variables in horses with mitral valve insufficiency.
Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dilatation in patients with asymptomatic systolic dysfunction. SOLVD (Studies of Left Ventricular Dysfunction) Investigators.
Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dysfunction in patients with heart failure. SOLVD Investigators.
Effects of the angiotensin-converting enzyme inhibitor alacepril on exercise capacity and neurohormonal factors in patients with mild-to-moderate heart failure.
Effects of the angiotensin-converting enzyme inhibitor enalapril on sympathetic neuronal function and beta-adrenergic desensitization in heart failure after myocardial infarction in rats.
Effects of the early administration of zofenopril on onset and progression of congestive heart failure in patients with anterior wall acute myocardial infarction. The SMILE Study Investigators. Survival of Myocardial Infarction Long-term Evaluation.
Effects of the replacement of the angiotensin converting enzyme inhibitor enalapril by the angiotensin II receptor blocker telmisartan in patients with congestive heart failure. The replacement of angiotensin converting enzyme inhibition (REPLACE) investigators.
Effects of Tolvaptan With or Without the Pre-Administration of Renin-Angiotensin System Blockers in Hospitalized Patients With Acute Decompensated Heart Failure.
Effects of torasemide on left ventricular function and neurohumoral factors in patients with chronic heart failure.
Effects of trandolapril on cardiac angiotensin I converting enzyme activity in rats with chronic heart failure following myocardial infarction.
Effects of two different enalapril dosages on clinical, haemodynamic and neurohumoral response of patients with severe congestive heart failure.
Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors.
Efficacy and acceptability of perindopril in mild to moderate chronic congestive heart failure.
Efficacy and safety of Angiotensin-converting enzyme inhibitors in patients with left ventricular systolic dysfunction and hyponatremia.
Efficacy and safety of calcium channel blockers in heart failure: focus on recent trials with second-generation dihydropyridines.
Efficacy and safety of LCZ696 (sacubitril-valsartan) according to age: insights from PARADIGM-HF.
Efficacy and safety of sacubitril-valsartan in heart failure: a meta-analysis of randomized controlled trials.
Efficacy of adding ramipril (VAsotop) to the combination of furosemide (Lasix) and pimobendan (VEtmedin) in dogs with mitral valve degeneration: The VALVE trial.
Efficacy of aldosterone receptor antagonism in heart failure: potential mechanisms.
Efficacy of Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor-Neprilysin Inhibitors in the Treatment of Chronic Heart Failure: A Review of Landmark Trials.
Efficacy of angiotensin-converting enzyme inhibition in reducing progression from asymptomatic left ventricular dysfunction to symptomatic heart failure in black and white patients.
Efficacy of Angiotensin-Converting Enzyme Inhibitors and Angiotensin-Receptor Blockers in Coronary Artery Disease without Heart Failure in the Modern Statin Era: a Meta-Analysis of Randomized-Controlled Trials.
Efficacy of Calcium Channel Blockers Versus Other Classes of Antihypertensive Medication in the Treatment of Hypertensive Patients With Previous Stroke and/or Coronary Artery Disease: A Systematic Review and Meta-Analysis.
Efficacy of enalapril for prevention of congestive heart failure in dogs with myxomatous valve disease and asymptomatic mitral regurgitation.
Efficacy of Long-term Selenium Supplementation in the Treatment of Chronic Keshan Disease with Congestive Heart Failure.
Efficacy of oral angiotensin-converting enzyme inhibition with captopril therapy in severe chronic normotensive congestive heart failure.
Efficacy Of Zofenopril Alone Or In Combination With Hydrochlorothiazide In Patients With Kidney Dysfunction.
Elevated plasma aldosterone levels despite complete inhibition of the vascular angiotensin-converting enzyme in chronic heart failure.
Elevated plasma renin activity predicts adverse outcome in chronic heart failure, independently of pharmacologic therapy: data from the Valsartan Heart Failure Trial (Val-HeFT).
Elevated potassium levels in patients with chronic kidney disease: occurrence, risk factors and clinical outcomes-a Danish population-based cohort study.
Elimination of early rehospitalization in a randomized, controlled trial of multidisciplinary care in a high-risk, elderly heart failure population: the potential contributions of specialist care, clinical stability and optimal angiotensin-converting enzyme inhibitor dose at discharge.
Emerging concepts: angiotensin-converting enzyme inhibition in coronary artery disease.
Emerging drugs for acute and chronic heart failure: current and future developments.
Emerging role of pharmacogenomics in heart failure.
Enalapril (MK-421), a new angiotensin-converting enzyme inhibitor. Acute and chronic effects in heart failure.
Enalapril and Acute Kidney Injury in a Hypertensive Premature Newborn - Should It Be Used or Not?
Enalapril Associated with Furosemide Induced Acute Kidney Injury in an Infant with Heart Failure. A Case Report, a Revision of the Literature and a Pharmacovigilance Database Analysis.
Enalapril does not enhance exercise capacity in patients after Fontan procedure.
Enalapril effects on atrial remodeling and atrial fibrillation in experimental congestive heart failure.
Enalapril for congestive heart failure.
Enalapril improves heart failure induced by monocrotaline without reducing pulmonary hypertension in rats: roles of preserved myocardial creatine kinase and lactate dehydrogenase isoenzymes.
Enalapril in chronic heart failure, a double-blind placebo-controlled study.
Enalapril in heart failure.
Enalapril in infants with single ventricle: results of a multicenter randomized trial.
Enalapril induced severe hyponatremia and altered sensorium in a child.
Enalapril reduces QTc dispersion in mild congestive heart failure secondary to coronary artery disease.
Enalapril reduces the catecholamine response to exercise in patients with heart failure.
Enalapril suppresses ventricular remodeling more effectively than losartan in patients with acute myocardial infarction.
Enalapril: a long-acting angiotensin-converting enzyme inhibitor.
Enalapril: a new angiotensin converting enzyme inhibitor.
Enalapril: a new angiotensin-converting enzyme inhibitor in chronic heart failure: acute and chronic hemodynamic evaluations.
Enalaprilat augments arterial and cardiopulmonary baroreflex control of sympathetic nerve activity in patients with heart failure.
Enalaprilat restores sensitivity of baroreflex control of renal and total noradrenaline spillover in heart failure rabbit.
Enalaprilat, a new parenteral angiotensin-converting enzyme inhibitor: rapid changes in systemic and coronary hemodynamics and humoral profile in chronic heart failure.
End of life care in advanced heart failure.
End-of-life care in heart failure.
Endocrine mechanisms in congestive cardiac failure. Renin, aldosterone and atrial natriuretic hormone.
Endogenous Bradykinin Suppresses Myocardial Fibrosis through the Cardiac-generated Endothelin System Under Chronic Angiotensin-converting Enzyme Inhibition in Heart Failure.
Endogenous Cardiotonics: Search And Problems.
Endothelial dysfunction in heart failure.
Endothelin antagonism with bosentan: a review of potential applications.
Endothelin in cardiovascular control: the role of endothelin antagonists.
Enhanced cardiac angiotensinogen gene expression and angiotensin converting enzyme activity in tachypacing-induced heart failure in rats.
Enhancing quality of heart failure care in managed Medicare and Medicaid in North Carolina: results of the North Carolina Achieving Cardiac Excellence (NC ACE) Project.
Epidemiology of myocardial infarction in France: therapeutic and prognostic implications of heart failure during the acute phase.
Epidemiology, associated factors, and prognostic outcomes of renal artery stenosis in chronic heart failure assessed by magnetic resonance angiography.
Epidemiology, pathophysiology, prognosis, and treatment of systolic and diastolic heart failure in elderly patients.
Eplerenone in the treatment of chronic heart failure.
Eplerenone: new drug. Recent myocardial infarction with heart failure: a spironolactone me too.
Erratum to: Efficacy of Angiotensin-Converting Enzyme Inhibitors and Angiotensin-Receptor Blockers in Coronary Artery Disease without Heart Failure in the Modern Statin Era: a Meta-Analysis of Randomized-Controlled Trials.
Estimated 5-Year Number Needed to Treat to Prevent Cardiovascular Death or Heart Failure Hospitalization With Angiotensin Receptor-Neprilysin Inhibition vs Standard Therapy for Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of Data From the PARADIGM-HF Trial.
Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials.
Estimation of angiotensin-converting enzyme inhibitors protein binding degree using chromatographic hydrophobicity data.
Evaluating the use of angiotensin-converting enzyme inhibitors for older nursing home residents with chronic heart failure.
Evaluation of angiotensin-converting enzyme inhibitor in congestive heart failure.
Evaluation of echocardiography in the management of elderly patients with heart failure.
Evaluation of guideline-based cardiovascular medications and their respective doses in heart failure patients in Oman.
Evaluation of impurities level of perindopril tert-butylamine in tablets.
Evaluation of Patients with Heart Failure To Determine Eligibility for Treatment with Sacubitril/Valsartan: Insights from a Veterans Administration Healthcare System.
Evaluation of renal function in elderly heart failure patients on ACE inhibitors.
Evaluation of some pharmaceutical formulations of lisinopril through dissolution testing.
Evaluation of the 24 h effects of the angiotensin II receptor blockers: means to improve cardiovascular outcomes?
Evaluation of the effects of aspirin combined with angiotensin-converting enzyme inhibitors in patients with coronary artery disease.
Evaluation of the use of evidence-based angiotensin-converting enzyme inhibitor criteria for the treatment of congestive heart failure: opportunities for pharmacists to improve patient outcomes.
Even low-dose aspirin inhibits arachidonic acid-induced vasodilation in heart failure.
Evidence against a major role for angiotensin converting enzyme-related carboxypeptidase (ACE2) in angiotensin peptide metabolism in the human coronary circulation.
Evidence for cardioprotective, renoprotective, and vasculoprotective effects of vasopeptidase inhibitors in disease.
Evidence of inadequate investigation and treatment of patients with heart failure.
Evolution of angiotensin-converting enzyme inhibition in hypertension, heart failure, and vascular protection.
Evolution of the atrial fibrillation substrate in experimental congestive heart failure: angiotensin-dependent and -independent pathways.
Evolving rationale for angiotensin-converting enzyme inhibition in chronic heart failure.
Exacerbation of atherosclerosis by hypertension. Potential mechanisms and clinical implications.
Exfoliative dermatitis from captopril.
Expanding Role of Mineralocorticoid Receptor Antagonists in the Treatment of Heart Failure.
Expanding role of mineralocorticoid receptor antagonists in the treatment of heart failure.
Expanding role of pharmacogenomics in the management of cardiovascular disorders.
Experience with beta-blocker therapy in patients with advanced heart failure evaluated for HTx.
Experimental and clinical evidence that angiotensin II is an independent risk factor for cardiovascular disease.
Expert Comment: Is Medication Titration in Heart Failure too Complex?
Expression of ACE mRNA in the human atrial myocardium is not dependent on left ventricular function, ACE inhibitor therapy, or the ACE I/D genotype.
Expression of renin-angiotensin system components in the heart, kidneys, and lungs of rats with experimental heart failure.
Extended-release metoprolol succinate in chronic heart failure.
Extensive induction of important mediators of fibrosis and dystrophic calcification in desmin-deficient cardiomyopathy.
Eye on the elderly. Hypertension care: striking the proper balance.
Factors Associated With Noncompletion During the Run-In Period Before Randomization and Influence on the Estimated Benefit of LCZ696 in the PARADIGM-HF Trial.
Factors associated with renal impairment in Chinese patients with non-valvular AF and without an established renal disease: a cross-sectional study.
Factors determining angiotensin-converting enzyme inhibitor underutilization in heart failure in a community setting.
Factors influencing recovery of left ventricular structure in patients with chronic heart failure.
Failure of aldosterone suppression despite angiotensin-converting enzyme (ACE) inhibitor administration in chronic heart failure is associated with ACE DD genotype.
Failure of captopril to prevent nitrate tolerance in congestive heart failure secondary to coronary artery disease.
Failure of evidence-based medicine in the treatment of hypertension in older patients.
Failure to practice evidence-based medicine: why do physicians not treat patients with heart failure with angiotensin-converting enzyme inhibitors?
Felodipine improves left ventricular emptying in patients with chronic heart failure: V-HeFT III echocardiographic substudy of multicenter reproducibility and detecting functional change.
Fibrosis of atria and great vessels in response to angiotensin II or aldosterone infusion.
First dose hypotension with enalapril and prazosin in congestive heart failure.
First-dose effects of enalapril 2.5 mg and captopril 6.25 mg in patients with heart failure: a double-blind, randomized, multicenter study. The Enalapril-Captopril Investigators.
First-dose hypotension after angiotensin-converting enzyme (ACE) inhibitors in chronic heart failure: a comparison of enalapril and perindopril. Slovak Investigator Group.
First-dose response to angiotensin-converting enzyme inhibition in congestive cardiac failure: a Malaysian experience.
Flosequinan in chronic heart failure: how is exercise capacity improved?
Fluid matters in choosing antihypertensive therapy: a hypothesis that the data speak volumes.
Follow-up of three patients with a large in-frame deletion of exons 45-55 in the Duchenne muscular dystrophy (DMD) gene.
Follow-up study of patients randomly allocated ramipril or placebo for heart failure after acute myocardial infarction: AIRE Extension (AIREX) Study. Acute Infarction Ramipril Efficacy.
Fosinopril decreases levels of soluble vascular cell adhesion molecule-1 in borderline hypertensive type II diabetic patients with microalbuminuria.
Fosinopril H(2)-receptor antagonists interaction studies by derivative spectroscopy.
Foundations of Pharmacotherapy for Heart Failure With Reduced Ejection Fraction: Evidence Meets Practice, Part I.
Foundations of Pharmacotherapy for Heart Failure With Reduced Ejection Fraction: Evidence Meets Practice, Part II.
Frequency of compound genotypes associated with beta-blocker efficacy in congestive heart failure.
Frequency of ST-segment elevation myocardial infarction, non-ST-segment myocardial infarction, and unstable angina: results from a Southwest Chinese Registry.
From ACE Inhibitors/ARBs to ARNIs in Coronary Artery Disease and Heart Failure (Part 2/5).
From digoxin to angiotensin-converting enzyme inhibitors: issues in pharmacotherapy for congestive heart failure.
From evidence to rationale: cardiovascular protection by angiotensin II receptor blockers compared with angiotensin-converting enzyme inhibitors.
From hypertension to heart failure.
From kinetics to dynamics: are there differences between ACE inhibitors?
From Other Journals: A Review of Recent Articles in Pediatric Cardiology.
From the HOPE to the ONTARGET and the TRANSCEND studies: challenges in improving prognosis.
Frontiers in congestive heart failure: comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure.
Frontiers in congestive heart failure: Rationale for the use of combination angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker therapy in heart failure.
Functional and biochemical analysis of angiotensin II-forming pathways in the human heart.
Functional single-cell hybridoma screening using droplet-based microfluidics.
Fundamental role of angiotensin-converting enzyme inhibitors in the management of congestive heart failure.
Further experience with long-term captopril therapy in severe refractory congestive heart failure.
Further studies on the effect of intracellular angiotensins on heart cell communication: on the role of endogenous angiotensin II.
Gender differences in treatment of heart failure and acute myocardial infarction: a question of quality or epidemiology?
Gene expression profile revealed different effects of angiotensin II receptor blockade and angiotensin-converting enzyme inhibitor on heart failure.
Gene polymorphism of angiotensin II type 1 and type 2 receptors.
Gene polymorphism of angiotensin-converting enzyme and angiotensin II type 1 receptor in patients with congestive heart failure.
Gene polymorphisms and thyroid function in patients with heart failure.
Genetic aspects of heart failure.
Genetic determinants of drug response in heart failure.
Genetic influences of angiotensin-converting enzyme inhibitor response: an opportunity for personalizing therapy?
Genetic polymorphism, medical therapy and sequential cardiac function in patients with heart failure.
Genetic tailoring of pharmacotherapy in heart failure: optimize the old, while we wait for something new.
Genome-wide association study of angioedema induced by angiotensin-converting enzyme inhibitor and angiotensin receptor blocker treatment.
Genotype-phenotype associations between chymase and angiotensin-converting enzyme gene polymorphisms in chronic systolic heart failure patients.
Geographical Variations in Patients with Heart Failure and Preserved Ejection Fraction: A Sub-Group Analysis of the APOLLON Registry
Global and regional hemodynamic effects of ramipril in congestive heart failure.
Goals and guidelines for treating hypertension in a patient with heart failure.
Growth hormone therapy in heart failure: a novel therapy worthy of further consideration?
Growth hormone therapy in heart failure: where are we now?
Guideline-directed medical therapy in real-world heart failure patients with low blood pressure and renal dysfunction.
Haemodynamic effects of aliskiren in decompensated severe heart failure.
Haemodynamic effects of enalaprilat and preload in acute severe heart failure complicating myocardial infarction.
Health care improvement and cost reduction opportunities in hypertensive Medicaid beneficiaries.
Health outcomes associated with calcium antagonists compared with other first-line antihypertensive therapies: a meta-analysis of randomised controlled trials.
Heart and renal failure in renovascular hypertension caused by giant cell arteritis--case report.
Heart failure and angiotensin converting enzyme inhibition: problems and perspectives.
Heart failure and angiotensin-converting enzyme inhibitors. Is there a need for specialty care?
Heart failure and angiotensin-converting enzyme inhibitors: towards evidence-based health care.
Heart failure and first dose hypotension after angiotensin converting enzyme inhibitors.
Heart failure and non-ST-segment elevation myocardial infarction: a review for a widespread situation.
Heart failure between 1986 and 1994: temporal trends in drug-prescribing practices, hospital readmissions, and survival at an academic medical center.
Heart failure complicating acute myocardial infarction.
Heart failure development in rats with ascending aortic constriction and angiotensin-converting enzyme inhibition.
Heart Failure Due to Reduced Ejection Fraction: Medical Management.
Heart failure in 2001: a prophecy.
Heart failure in African Americans.
Heart failure in primary care: qualitative study of current management and perceived obstacles to evidence-based diagnosis and management by general practitioners.
Heart failure in women.
Heart Failure Medications Detection and Prescription Status Classification in Clinical Narrative Documents.
Heart failure mortality among older Medicare beneficiaries: association with left ventricular function evaluation and angiotensin-converting enzyme inhibitor use.
Heart failure patients receiving ACEIs/ARBs were less likely to be hospitalized or to use emergency care in the following year.
Heart failure resolved? An interactive debate. Practical challenges.
Heart failure therapy in children.
Heart failure treatment with angiotensin-converting enzyme inhibitors in hospitalized Medicare patients in 10 large states. The Large State Peer Review Organization Consortium.
Heart failure treatment: the state of Austrian clinical practice--the Cor survey. Cor Survey Study Group.
Heart failure, renal function, and angiotensin converting enzyme inhibitors.
Heart failure, ventricular remodelling and the renin-angiotensin system: insights from recently completed clinical trials.
Heart failure--implications of the true size of the problem.
Heart failure--the options for therapy.
Heart failure-potential new targets for therapy.
Heart failure.
Heart failure. The pacing therapy.
Heart failure: an update on pathophysiology.
Heart failure: future treatment approaches.
Heart failure: highlights from new consensus guidelines.
Heart failure: New data do not SUPPORT triple RAAS blockade.
Heart rate turbulence to guide treatment for prevention of sudden death.
Hemodynamic effects of anesthesia in patients with ischemic heart failure chronically treated with angiotensin-converting enzyme inhibitors.
Hemodynamic effects of angiotensin-converting enzyme inhibitors in essential hypertension: a review.
Hemodynamic effects of captopril in patients with severe chronic heart failure.
Hemodynamic effects of captropril in chronic heart failure: efficacy of low-dose treatment and comparison with prazosin.
Hemodynamic effects of inhibitors of the renin-angiotensin system.
Hemodynamic effects of renin inhibition by enalkiren in chronic congestive heart failure.
Hemodynamic response to intravenous enalaprilat in patients with severe congestive heart failure and mitral regurgitation.
Hemodynamic, hormonal, and pharmacokinetic aspects of treatment with lisinopril in congestive heart failure.
High dose enalapril impairs the response to erythropoietin treatment in haemodialysis patients.
High dose lisinopril in heart failure: economic considerations.
High flow and high dose neosynephrine are effective to maintain perfusion pressure for the patient with preoperative angiotensin converting enzyme inhibitor during cardiopulmonary bypass.
High or low dose of angiotensin-converting enzyme inhibitor in patients with left ventricular dysfunction?
High output heart failure.
High prevalence of microalbuminuria in chronic heart failure patients.
High prevalence of persistent cough with angiotensin converting enzyme inhibitors in Chinese.
High- versus low-dose ACE inhibition in chronic heart failure: a double-blind, placebo-controlled study of imidapril.
High- versus low-dose angiotensin converting enzyme inhibitor therapy in the treatment of heart failure: an economic analysis of the Assessment of Treatment with Lisinopril and Survival (ATLAS) trial.
High-dose 17beta-estradiol treatment prevents development of heart failure post-myocardial infarction in the rat.
High-dose versus low-dose angiotensin converting enzyme inhibitors in heart failure: systematic review and meta-analysis.
Higher doses of loop diuretics limit uptitration of angiotensin-converting enzyme inhibitors in patients with heart failure and reduced ejection fraction.
Higher versus lower doses of ACE inhibitors, angiotensin-2 receptor blockers and beta-blockers in heart failure with reduced ejection fraction: Systematic review and meta-analysis.
Hit-to-lead optimization and discovery of a potent, and orally bioavailable G protein coupled receptor kinase 2 (GRK2) inhibitor.
Hormonal and cardiorenal responses to acute saline loading in mild congestive heart failure--the effect of angiotensin converting enzyme inhibition.
Hormonal and renal differences between low dose and high dose angiotensin converting enzyme inhibitor treatment in patients with chronic heart failure.
How long should angiotensin-converting enzyme inhibitors be given to patients following myocardial infarction: implications of the HOPE trial.
How should we manage heart failure developing in patients already treated with angiotensin-converting enzyme inhibitors and beta-blockers for hypertension, diabetes or coronary disease?
How to best assess quality of drug treatment in patients with heart failure.
How to use diuretics in heart failure.
Human Tissue Angiotensin Converting Enzyme (ACE) Activity Is Regulated by Genetic Polymorphisms, Posttranslational Modifications, Endogenous Inhibitors and Secretion in the Serum, Lungs and Heart.
Hyperkalaemia in congestive heart failure patients using ACE inhibitors and spironolactone.
Hyperkalaemia in people with diabetes: occurrence, risk factors and outcomes in a Danish population-based cohort study.
Hyperkalemia in patients with heart failure: incidence, prevalence, and management.
Hypertension and diastolic heart failure.
Hypertension and vascular disease in the 1990s.
Hypertension Canada's 2018 Guidelines for Diagnosis, Risk Assessment, Prevention, and Treatment of Hypertension in Adults and Children.
Hypertension in elderly--an overview.
Hypertension in the elderly.
Hypertension: Which drugs to choose for patients with cardiovascular disease.
Hyponatremia after initiation of angiotensin-converting enzyme inhibitor in a geriatric patient with chronic heart failure: A case of mineralocorticoid-responsive hyponatremia of the elderly.
Hyponatremia due to enalapril in an elderly patient. A case report.
Hyponatremic Coma after Bowel Preparation.
Ibopamine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in congestive heart failure.
Identification of inappropriate prescribing in geriatrics at a Veterans Affairs hospital using STOPP/START screening tools.
Identifying optimal doses of heart failure medications in men compared with women: a prospective, observational, cohort study.
Idiopathic Giant Cell Myocarditis.
Imagine how many lives you save: angiotensin-converting enzyme inhibition for atherosclerotic vascular disease in the present era of risk reduction.
Imaging left ventricular remodeling: targeting the neurohumoral axis.
Imaging Review of Angiotensin-Converting Enzyme Inhibitor-Induced Angioedema of the Head and Neck.
Imidapril in heart failure.
Imidaprilat inhibits matrix metalloproteinase-2 activity in human cardiac fibroblasts induced by interleukin-1beta via NO-dependent pathway.
Immediate and sustained hemodynamic and clinical improvement in chronic heart failure by an oral angiotensin-converting enzyme inhibitor.
Impact of ALLHAT on the role of angiotensin-converting enzyme inhibitors in the primary prevention of heart failure.
Impact of angiotensin converting enzyme inhibitors/angiotensin receptors blockers on mortality in acute heart failure patients with left ventricular systolic dysfunction in the Middle East: Observations from the Gulf Acute Heart Failure Registry (Gulf CARE).
Impact of angiotensin-converting enzyme gene polymorphism on neurohormonal responses to high- versus low-dose enalapril in advanced heart failure.
Impact of angiotensin-converting enzyme inhibitor underdosing on rehospitalization rates in congestive heart failure.
Impact of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers on Renal Function in Type 1 Cardiorenal Syndrome.
Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers on Acute Kidney Injury in Emergency Medical Admissions.
Impact of chronic kidney disease and anemia on hospitalization expense in patients with left ventricular dysfunction.
Impact of converting enzyme inhibition on progression of chronic heart failure: results of the Munich Mild Heart Failure Trial.
Impact of COPD on the mortality and treatment of patients hospitalized with acute decompensated heart failure: the Worcester Heart Failure Study.
Impact of ethnicity and race on response to Angiotensin-converting enzyme inhibitors in heart failure.
Impact of genetic polymorphisms on heart failure prognosis.
Impact of Green Tea Catechin Ingestion on the Pharmacokinetics of Lisinopril in Healthy Volunteers.
Impact of Individual Patient Profiles on Adherence to Guideline Directed Medical Therapy in Heart Failure With Reduced Ejection Fraction: VCOR-HF Study.
Impact of inhibition of angiotensin-converting enzyme on urinary excretion of proteins in chronic heart failure.
Impact of initiating carvedilol before angiotensin-converting enzyme inhibitor therapy on cardiac function in newly diagnosed heart failure.
Impact of opinion leader-endorsed evidence summaries on the quality of prescribing for patients with cardiovascular disease: a randomized controlled trial.
Impact of Patient and Model of Care Factors on Titration and Tolerability of Sacubitril/Valsartan: An Early Australian Real-World Experience.
Impact of renin-angiotensin system inhibitors continuation versus discontinuation on outcome after major surgery: protocol of a multicenter randomized, controlled trial (STOP-or-NOT trial).
Impact of Sacubitril-Valsartan on Markers of Glomerular Function.
Impact of Sacubitril/Valsartan on Patient Outcomes in Heart Failure: Evidence to Date.
Impact of sex-specific target dose in chronic heart failure patients with reduced ejection fraction.
Impact of the interval between coronary angiography and off-pump coronary bypass surgery on postoperative renal function.
Impaired bradykinin response to ischaemia and exercise in patients with mild congestive heart failure during angiotensin-converting enzyme treatment. Relationships with endothelial function, coagulation and inflammation.
Implantable cardioverter-defibrillator therapy in clinical practice.
Implications of CIBIS III: a commentary.
Implications of heart failure drug trials: COMET, CHARM, EPHESUS.
Implications of recent hypertension trials for the generalist physician: whom do we treat, and how?
Importance of angiotensin-converting enzyme inhibitors in myocardial infarction and congestive heart failure: implications for clinical practice.
Importance of long-acting angiotensin-converting enzyme inhibitors for congestive heart failure.
Improvement of endothelial function by chronic angiotensin-converting enzyme inhibition in heart failure : role of nitric oxide, prostanoids, oxidant stress, and bradykinin.
Improvement of exercise capacity of rats with chronic heart failure by long-term treatment with trandolapril.
Improvement of the outcome in patients with infantile dilated cardiomyopathy over three decades - The usefulness of long-term gradually medical supportive care.
Improvement of vagal tone by ACE inhibition: a mechanism of cardioprotection in patients with mild-to-moderate heart failure.
Improving ACE inhibitor use in patients hospitalized with systolic heart failure: a cluster randomized controlled trial of clinical practice guideline development and use.
Improving outcomes in chronic heart failure.
Improving outcomes in post-acute myocardial infarction heart failure: incorporation of aldosterone blockade into combination therapy to optimize neurohormonal blockade.
Improving patient care: some unresolved issues in heart failure.
Improving patient outcomes by pooling resources (the Texas Heart Care Partnership experience).
Improving prognosis in hypertension: exploring the benefits of angiotensin II type 1 receptor blockade.
Improving Prognosis in Hypertension: Exploring the Benefits of Angiotensin II Type 1 Receptor Blockade.
Improving survival for patients with advanced heart failure: a study of 737 consecutive patients.
Improving the managed care of hypertension with angiotensin II antagonists.
Incidence and predictors of development of acute renal failure related to treatment of congestive heart failure with ACE inhibitors.
Incidence and risk factors of asymptomatic first-dose hypotension with angiotensin-converting enzyme inhibitors in chronic heart failure due to systolic dysfunction.
Incidence of and risk factors for severe acute kidney injury in children with heart failure treated with renin-angiotensin system inhibitors.
Incidence, predictors and clinical management of hyperkalaemia in new users of mineralocorticoid receptor antagonists.
Incidence, Predictors, and Outcomes Associated With Hypotensive Episodes Among Heart Failure Patients Receiving Sacubitril/Valsartan or Enalapril: The PARADIGM-HF Trial (Prospective Comparison of Angiotensin Receptor Neprilysin Inhibitor With Angiotensin-Converting Enzyme Inhibitor to Determine Impact on Global Mortality and Morbidity in Heart Failure).
Incidence, time of occurrence and response to heart failure therapy in patients with anthracycline cardiotoxicity.
Incidence, trends, and predictors of ischemic stroke 1 year after an acute myocardial infarction.
Increase in vasoactive intestinal polypeptides (VIP) by the angiotensin converting enzyme (ACE) inhibitor lisinopril in congestive heart failure. Relation to haemodynamic and hormonal changes.
Increased alveolar/capillary membrane resistance to gas transfer in patients with chronic heart failure.
Increased bradykinin levels accompany the hemodynamic response to acute inhibition of angiotensin-converting enzyme in dogs with heart failure.
Increased cardiac angiotensin-converting enzyme in rats with chronic heart failure.
Increased cardiomyocyte apoptosis during the transition to heart failure in the spontaneously hypertensive rat.
Increased expression of the renin-angiotensin system and mast cell density but not of angiotensin-converting enzyme II in late stages of human heart failure.
Increased frequency and severity of angio-oedema related to long-term therapy with angiotensin-converting enzyme inhibitor in two patients.
Increased IGF1 levels in relation to heart failure and cardiovascular mortality in an elderly population: impact of ACE inhibitors.
Increased plasma level of substance P in patients with severe congestive heart failure treated with ACE inhibitors.
Increased risk of contrast-induced acute kidney injury in patients with pulmonary thromboembolism.
Increased survival after long-term treatment with mibefradil, a selective T-channel calcium antagonist, in heart failure.
Increased survival in rats with congestive heart failure treated with enalapril.
Increased susceptibility to SARS-CoV-2 infection in patients with reduced left ventricular ejection fraction.
Increases in the myocardial concentration of vasoactive intestinal peptide may explain the positive inotropic effect of angiotensin converting enzyme inhibitors.
Increasing plasma potassium with amiloride shortens the QT interval and reduces ventricular extrasystoles but does not change endothelial function or heart rate variability in chronic heart failure.
Incremental cost-effectiveness of guideline-directed medical therapies for heart failure.
Incremental value of myocardial viability for prediction of long-term prognosis in surgically revascularized patients with left ventricular dysfunction.
Indications for immediate angiotensin-converting enzyme inhibition in patients with acute myocardial infarction.
Indicators for preventable drug related morbidity: application in primary care.
Individualized treatment effects with censored data via fully nonparametric Bayesian accelerated failure time models.
Induction of cardiac fibrosis by aldosterone.
Infarct-related heart failure: the choice of ACE inhibitor does not matter.
Influence of ACE Inhibition on Fluid Metabolism in Chronic Heart Failure and Its Pathophysiologic Relevance.
Influence of age on neurohormonal activation and prognosis in patients with chronic heart failure.
Influence of angiotensin converting enzyme inhibition on exercise performance and clinical symptoms in chronic heart failure: a multicentre, double-blind, placebo-controlled trial.
Influence of angiotensin converting enzyme inhibition on pump function and cardiac contractility in patients with chronic congestive heart failure.
Influence of angiotensin converting enzyme inhibition on relation of atrial natriuretic peptide concentration to atrial pressure in heart failure.
Influence of Angiotensin-Converting-Enzyme Gene Polymorphism on Echocardiographic Data of Patients with Ischemic Heart Failure.
Influence of carvedilol on hospitalizations in heart failure: incidence, resource utilization and costs. U.S. Carvedilol Heart Failure Study Group.
Influence of comorbidities and medication use on tilt table test outcome in elderly patients.
Influence of gene polymorphisms of the renin-angiotensin system on clinical outcome in heart failure among the Chinese.
Influence of long-term treatment of imidapril on mortality, cardiac function, and gene expression in congestive heart failure due to myocardial infarction.
Influence of order and type of drug (bisoprolol vs. enalapril) on outcome and adverse events in patients with chronic heart failure: a post hoc analysis of the CIBIS-III trial.
Influence of severity of heart failure on the efficacy of angiotensin-converting enzyme inhibition.
Inhibiting the renin-angiotensin system in myocardial infarction and heart failure: lessons from SAVE, VALIANT and CHARM, and other clinical trials.
Inhibiting the renin-angiotensin system: why and in which patients.
Inhibition of angiotensin converting enzyme with enalapril maleate in infants with congestive heart failure.
Inhibition of angiotensin-converting enzyme and phosphodiesterase type 5 improves endothelial function in heart failure.
Inhibition of angiotensin-converting enzyme in congestive heart failure.
Inhibition of both angiotensin-converting enzyme and neutral endopeptidase by S21402 (RB105) in rats with experimental myocardial infarction.
Inhibition of matrix metalloproteinase activity by ACE inhibitors prevents left ventricular remodeling in a rat model of heart failure.
Inhibition of progression of heart failure and expression of TGF-beta 1 mRNA in rats with heart failure by the ACE inhibitor quinapril.
Inhibition of renin-angiotensin system and advanced glycation end products formation: a promising therapeutic approach targeting on cardiovascular diseases.
Inhibition of the renin-angiotensin system for lowering coronary artery disease risk.
Inhibition of the renin-angiotensin system in the treatment of heart failure: why, when, and where.
Inhibition of the renin-angiotensin-aldosterone system in heart failure: new insights from basic clinical research.
Inhibition of the renin-angiotensin-aldosterone system: is there room for dual blockade in the cardiorenal continuum?
Inhibitors of the angiotensin I converting enzyme as antihypertensive drugs.
Inhibitors of the renin-angiotensin system.
Initiating angiotensin converting enzyme inhibitors in mild to moderate heart failure in general practice: randomised, placebo controlled trial.
Initiation, Continuation, or Withdrawal of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers and Outcomes in Patients Hospitalized With Heart Failure With Reduced Ejection Fraction.
Innovations in the pharmacologic management of heart failure.
Innovative drug treatments for viral and autoimmune myocarditis.
Insight into ACE inhibition in the prevention of cardiac events in stable coronary artery disease: the EUROPA trial.
Insights into implementation of sacubitril/valsartan into clinical practice.
Integrating traditional and emerging treatment options in heart failure.
Interaction between angiotensin-converting enzyme inhibitors and aspirin: a review.
Interaction between aspirin and angiotensin-converting enzyme inhibitors: should they be used together in older adults with heart failure?
Interaction between neutral endopeptidase and angiotensin converting enzyme inhibition in rats with myocardial infarction: effects on cardiac hypertrophy and angiotensin and bradykinin peptide levels.
Interaction of angiotensin-converting enzyme inhibition and aspirin in congestive heart failure: long controversy finally resolved?
Interaction of implantable defibrillator therapy with angiotensin-converting enzyme deletion/insertion polymorphism.
Interaction of papaverine with the enalapril-induced cough in guinea pig.
Interactions between cytokines and neurohormonal systems in the failing heart.
Interrupting the adaptive changes in congestive heart failure.
Interrupting the renin-angiotensin system: the role of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists in the treatment of hypertension.
Interruptive Versus Noninterruptive Clinical Decision Support: Usability Study.
Intracoronary blockade of angiotensin-converting enzyme in humans: interaction with cardiac sympathetic neurotransmission?
Intractable heart failure despite angiotensin-converting enzyme inhibitors, digoxin, and diuretics: long-term effectiveness of add-on therapy with pimobendan.
Intraoperative administration of the intravenous angiotensin-converting enzyme inhibitor, enalaprilat, in a patient with congestive heart failure.
Intrarenal determinants of sodium retention in mild heart failure: effects of angiotensin-converting enzyme inhibition.
Introduction of angiotensin-converting enzyme inhibitors induces a fall in hemoglobin levels in elderly patients hospitalized with heart failure: a cohort study.
Introduction of sacubitril/valsartan in primary care follow-up of heart failure: a prospective observational study (THESEUS).
Inverse relation between aldosterone and venous capacitance in chronically treated congestive heart failure.
Involvement of the TRPV1 receptor in plasma extravasation in airways of rats treated with an angiotensin-converting enzyme inhibitor.
Is addition of prazosin beneficial in chronic heart failure refractory to angiotensin converting enzyme inhibition?
Is angiotensin II a growth factor masquerading as a vasopressor?
Is growth hormone deficiency contributing to heart failure in patients with beta-thalassemia major?
Is optimal angiotensin-converting enzyme inhibitor dosing neglected in elderly patients with heart failure?
Is the optimal dose of angiotensin-converting enzyme inhibitors in patients with congestive heart failure definitely established?
Is the prognosis of heart failure improving?
Is there a role for adjuvant therapy in patients being treated with epoetin?
Is there a role for renin profiling in selecting chronic heart failure patients for ACE inhibitor treatment?
Is there an embryopathy associated with first-trimester exposure to angiotensin-converting enzyme inhibitors and angiotensin receptor antagonists? A critical review of the evidence.
Is there an internal cardiac renin-angiotensin system?
Is there any difference between angiotensin converting enzyme inhibitors and angiotensin receptor blockers for heart failure?
Is too much neurohormonal blockade harmful?
Ischemic and nonischemic heart failure do not require different treatment strategies.
Ischemic heart failure.
Ischemic versus non-ischemic heart failure: should the etiology be determined?
Isolation of a cDNA encoding the vascular type-1 angiotensin II receptor.
Isosorbide dinitrate-hydralazine improves outcomes in African Americans with heart failure.
Isosorbide dinitrate/hydralazine: its role in the treatment of heart failure.
Issues concerning the use of angiotensin-converting enzyme inhibitors in the treatment of heart failure and myocardial infarction.
Issues in the perioperative management of the elderly patient with cardiovascular disease.
Ivabradine for chronic heart failure?
Junctional Bradycardia as Early Sign of Digoxin Toxicity in a Premature Infant with Congestive Heart Failure due to a Left to Right Shunt.
Just the beginning: novel functions for angiotensin-converting enzymes.
KATP channel opening does not contribute significantly to the vasodilatory effect of SH-group-containing ACE inhibitors.
Kidney Function, ACE-Inhibitor/Angiotensin Receptor Blocker Use, and Survival Following Hospitalization for Heart Failure: A Cohort Study.
Kinin B1 receptor blockade and ACE inhibition attenuate cardiac postinfarction remodeling and heart failure in rats.
Kinin-mediated coronary nitric oxide production contributes to the therapeutic action of angiotensin-converting enzyme and neutral endopeptidase inhibitors and amlodipine in the treatment in heart failure.
L-arginine fails to prevent ventricular remodeling and heart failure in the spontaneously hypertensive rat.
Lack of association between ACE and bradykinin B2 receptor gene polymorphisms and ACE inhibitor-induced coughing in hypertensive Koreans.
Lack of association between insertion/deletion polymorphism of the angiotensin-converting enzyme gene and end-stage heart failure due to ischemic or idiopathic dilate cardiomyopathy in the Chinese.
Lack of correlation of hypotensive effects with prevention of cardiac hypertrophy by perindopril after ligation of rat coronary artery.
Lack of cross sensitivity between captopril and enalapril.
Lack of deleterious interaction between angiotensin receptor blockers and beta-blockers in the treatment of patients with heart failure.
Lack of effect of nitrates on exercise tolerance in patients with mild to moderate heart failure caused by coronary disease already treated with captopril.
Lack of long-term ventricular arrhythmia reduction by enalapril in heart failure. SOLVD Investigators.
Late onset angiotensin-converting enzyme induced angioedema: case report and review of the literature.
LC-MS/MS assay for quantitation of enalapril and enalaprilat in plasma for bioequivalence study in Indian subjects.
Left ventricular atrioventricular plane displacement: an echocardiographic technique for rapid assessment of prognosis in heart failure.
Left ventricular dilatation after myocardial infarction: ACE inhibitors, beta-blockers, or both?
Left ventricular filling after long-term angiotensin converting enzyme inhibition in congestive heart failure.
Left ventricular hypertrophy and angiotensin II receptor blocking agents.
Left ventricular performance after intravenous infusion of captopril in patients with congestive heart failure.
Left ventricular systolic dysfunction and nonischemic cardiomyopathy.
Lessons from animal experiments in myocarditis.
Lessons learned from the national heart failure project: a center for medicare and medicaid services initiative to improve the care of medicare beneficiaries with heart failure.
Letter regarding article by Masoudi et al, "national patterns of use and effectiveness of angiotensin-converting enzyme inhibitors in older patients with heart failure and left ventricular systolic dysfunction".
Levels of vasopressin in children undergoing cardiopulmonary bypass.
Life-saving or life-prolonging? Interpreting trial data and survival curves for patients with congestive heart failure.
Life-threatening angioedema.
Life-Threatening Complications Associated with the Tyrosine Kinase Inhibitor Sunitinib Malate.
Life-threatening hyperkalemia associated with captopril administration.
Limitations of current medical therapies for the treatment of heart failure.
Lisinopril and captopril in the treatment of heart failure in older patients. Comparison of a long- and short-acting angiotensin-converting enzyme inhibitor.
Lisinopril in the treatment of congestive heart failure in elderly patients: comparison versus captopril.
Lisinopril lowers cardiac adrenergic drive and increases beta-receptor density in the failing human heart.
Lisinopril versus placebo in the treatment of heart failure: the Lisinopril Heart Failure Study Group.
Lisinopril-Induced Alopecia: A Case Report.
Lisinopril-Induced Angioedema in a Patient with Plasma Prekallikrein Deficiency.
Long-acting angiotensin-converting enzyme inhibition: once-daily lisinopril versus twice-daily captopril in mild-to-moderate heart failure.
Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group.
Long-term adherence to evidence-based secondary prevention therapies in coronary artery disease.
Long-term angiotensin-converting enzyme and angiotensin I--receptor inhibition in pacing-induced heart failure: effects on myocardial interstitial bradykinin levels.
Long-term captopril therapy for chronic congestive heart failure.
Long-term captopril treatment improves diastolic filling more than systolic performance in rats with large myocardial infarction.
Long-term changes of renal function in relation to ace inhibitor/angiotensin receptor blocker dosing in patients with heart failure and chronic kidney disease.
Long-term combined therapy with losartan and an angiotensin-converting enzyme inhibitor improves functional capacity in patients with left ventricular dysfunction.
Long-term effect of efonidipine therapy on plasma aldosterone and left ventricular mass index in patients with essential hypertension.
Long-term effects of a once-a-day versus twice-a-day regimen of enalapril for congestive heart failure.
Long-term effects of clinical outcome with low and high dose in the Captopril in Heart Insufficient Patients Study (CHIPS).
Long-term effects of darusentan on left-ventricular remodelling and clinical outcomes in the EndothelinA Receptor Antagonist Trial in Heart Failure (EARTH): randomised, double-blind, placebo-controlled trial.
Long-Term Effects of Flosequinan on the Morbidity and Mortality of Patients With Severe Chronic Heart Failure: Primary Results of the PROFILE Trial After 24 Years.
Long-term effects of patiromer for hyperkalaemia treatment in patients with mild heart failure and diabetic nephropathy on angiotensin-converting enzymes/angiotensin receptor blockers: results from AMETHYST-DN.
Long-term effects of the angiotensin-converting enzyme inhibitor enalapril on chronic heart failure. Examination by 123I-MIBG imaging.
Long-term follow-up evaluation of renal function in patients treated with peritoneal dialysis after cardiac surgery for correction of congenital anomalies.
Long-term follow-up in peripartum cardiomyopathy patients with contemporary treatment: low mortality, high cardiac recovery, but significant cardiovascular co-morbidities.
Long-term follow-up of acute renal failure caused by angiotensin converting enzyme inhibitors.
Long-term impact of secondary preventive treatments in patients with stable angina.
Long-term neprilysin inhibition - implications for ARNIs.
Long-term outcomes of non-ischemic dilated cardiomyopathy patients with left ventricular ejection fraction ?19% on medical therapy.
Long-term prognosis of patients presenting to the emergency room with decompensated congestive heart failure.
Long-term survival and hemodynamics after endothelin-a receptor antagonism and angiotensin-converting enzyme inhibition in rats with chronic heart failure: monotherapy versus combination therapy.
Long-term survival effect of metoprolol in dilated cardiomyopathy. The SPIC (Italian Multicentre Cardiomyopathy Study) Group.
Long-term survival of non-elderly patients with severe heart failure treated with angiotensin-converting enzyme inhibitors assessment of treatment with captopril and enalapril survival study (ACESS).
Long-Term Survival of Routine Implantable Cardioverter/Defibrillator Recipients Appears to be Significantly Impaired with Concomitant Diuretics and Improved with Aldosterone Antagonists.
Long-term treatment with angiotensin I-converting enzyme inhibitors attenuates the loss of cardiac beta-adrenoceptor responses in rats with chronic heart failure.
Long-term treatment with trandolapril opposes cardiac remodeling and prolongs survival after myocardial infarction in rats.
Long-term trends of angiotensin-converting enzyme inhibitor and angiotensin-receptor blocker use after heart failure hospitalization in community-dwelling seniors.
Losartan but not enalaprilat acutely reduces reperfusion ventricular tachyarrhythmias in hypertrophied rat hearts after low-flow ischaemia.
Losartan: a selective angiotensin II type 1 (AT1) receptor antagonist for the treatment of heart failure.
Low body mass index is a risk factor for hyperkalaemia associated with angiotensin converting enzyme inhibitors and angiotensin II receptor blockers treatments.
Low doses vs. high doses of the angiotensin converting-enzyme inhibitor lisinopril in chronic heart failure: a cost-effectiveness analysis based on the Assessment of Treatment with Lisinopril and Survival (ATLAS) study. The ATLAS Study Group.
Low-dose aspirin does not interfere with the blood pressure-lowering effects of antihypertensive therapy.
Low-grade urinary albumin excretion in normotensive/non-diabetic obstructive sleep apnea patients.
Lower Hospitalization and Healthcare Costs With Sacubitril/Valsartan Versus Angiotensin-Converting Enzyme Inhibitor or Angiotensin-Receptor Blocker in a Retrospective Analysis of Patients With Heart Failure.
Lower than conventional doses of captopril in the initiation of converting enzyme inhibition in patients with severe congestive heart failure.
Management of a case of peripartum cardiomyopathy.
Management of arrhythmias in heart failure. What a practicing physician should know in the current times.
Management of heart failure in primary care after implementation of the National Service Framework for Coronary Heart Disease: a cross-sectional study.
Management of Heart Failure Patient with CKD.
Management of heart failure: evidence versus practice. Does current prescribing provide optimal treatment for heart failure patients?
Management of hypertension in children with cardiovascular disease and heart failure.
Management of hypertension in older patients.
Management of obesity cardiomyopathy.
Management of older persons after myocardial infarction.
Management of the older person with ventricular arrhythmias.
Managing congestive heart failure in a general hospital in Malaysia. Are we keeping pace with evidence?
Managing high-risk patients with acute coronary syndromes: the Prospective Registry of Acute Ischaemic Syndromes in the UK (PRAIS-UK).
Managing hypertension using combination therapy.
Managing the patient with diabetes mellitus and heart failure: issues and considerations.
Managing therapeutic competition in patients with heart failure, lower urinary tract symptoms and incontinence.
Marked bradykinin-induced tissue plasminogen activator release in patients with heart failure maintained on long-term angiotensin-converting enzyme inhibitor therapy.
Marked difference between angiotensin-converting enzyme and neutral endopeptidase inhibition in vivo by a dual inhibitor of both enzymes.
Matrix metallopropteinases in heart failure.
Maximally recommended doses of angiotensin-converting enzyme (ACE) inhibitors do not completely prevent ACE-mediated formation of angiotensin II in chronic heart failure.
Maximizing benefits of therapies in acute myocardial infarction.
Maximizing management of patients with decompensated heart failure.
Measuring equity: an index of health care disparities.
Mechanism of action of angiotensin-converting enzyme (ACE) inhibitors in hypertension and heart failure. Role of plasma versus tissue ACE.
Mechanism of action of angiotensin-receptor blocking agents.
Mechanism of captopril toxicity to a human mammary ductal carcinoma cell line in the presence of copper.
Mechanisms and management of heart failure in active rheumatic carditis.
Mechanisms in heart failure and the role of angiotensin-converting enzyme inhibition.
Mechanistic and clinical rationales for using beta-blockers in heart failure.
Mediators of chronic heart failure: how drugs work.
Medical therapy doses at hospital discharge in patients with existing and de novo heart failure.
Medical treatment of end-stage heart failure.
Medication nonadherence: Part II--A pilot study in patients with congestive heart failure.
Medication undertreatment in assisted living settings.
Medication-related hospital admissions in aged care residents.
Mercaptoacyl dipeptides as orally active dual inhibitors of angiotensin-converting enzyme and neutral endopeptidase.
Meta-analyses of mortality and morbidity effects of an angiotensin receptor blocker in patients with chronic heart failure already receiving an ACE inhibitor (alone or with a beta-blocker).
Meta-analysis of combined therapy with angiotensin receptor antagonists versus ACE inhibitors alone in patients with heart failure.
Meta-Analysis of effectiveness or lack thereof of angiotensin-converting enzyme inhibitors for prevention of heart failure in patients with systemic hypertension.
Meta-analysis of morbidity and mortality in five exercise capacity trials evaluating ramipril in chronic congestive cardiac failure.
Meta-analysis: angiotensin-receptor blockers in chronic heart failure and high-risk acute myocardial infarction.
Meta-analysis: inhibition of renin-angiotensin system prevents new-onset atrial fibrillation.
Metabolic Modulation and Cellular Therapy of Cardiac Dysfunction and Failure.
Metabolic Modulation: A New Therapeutic Target in Treatment of Heart Failure.
Methylephedrine-induced heart failure in a habitual user of paediatric cough syrup: a case report.
Mibefradil: a selective T-type calcium antagonist.
MMP/TIMP expression in spontaneously hypertensive heart failure rats: the effect of ACE- and MMP-inhibition.
Modern treatment of patients at risk: still a HOPE for ACE inhibitors?
Modification of sarcolemmal Na+-K+-ATPase and Na+/Ca2+ exchanger expression in heart failure by blockade of renin-angiotensin system.
Modifier genes and heart failure.
Modulation of left ventricular iodine-125-MIBG accumulation in cardiomyopathic Syrian hamsters using the renin-angiotensin system.
Modulation of Vascular ACE by Oxidative Stress in Young Syrian Cardiomyopathic Hamsters: Therapeutic Implications.
Moexipril and left ventricular hypertrophy.
Molecular and cellular mechanisms of myocardial failure.
Molecular imaging of human ACE-1 expression in transgenic rats.
Molecular signaling of G-protein-coupled receptor in chronic heart failure and associated complications.
Mortality and morbidity of non-systolic heart failure treated with angiotensin-converting enzyme inhibitors A propensity-adjusted case-control study.
Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials.
Mortality matters.
Multidisciplinary Approach to Novel Therapies in Cardio-Oncology Research (MANTICORE 101-Breast): A Randomized Trial for the Prevention of Trastuzumab-Associated Cardiotoxicity.
Multidisciplinary outpatient congestive heart failure clinic: impact on hospital admissions and emergency room visits.
Multiple renin-angiotensin-aldosterone-blocking agents in heart failure: how much is too much?
Muscle energy metabolism in severe chronic congestive heart failure--effect of treatment with enalapril.
Muscle water and electrolytes in severe chronic congestive heart failure before and after treatment with enalapril.
Myocardial angiotensin II receptor expression and ischemia-reperfusion injury.
Myocardial bradykinin following acute angiotensin-converting enzyme inhibition, AT1 receptor blockade, or combined inhibition in congestive heart failure.
Myocardial collagen matrix remodeling and congestive heart failure.
Myocarditis.
Na(+)-H(+) exchanger inhibitor prevents early death in hereditary cardiomyopathy.
Nanoparticle-Mediated Delivery of Pitavastatin to Monocytes/Macrophages Inhibits Left Ventricular Remodeling After Acute Myocardial Infarction by Inhibiting Monocyte-Mediated Inflammation.
Nasal nitric oxide concentration is decreased in heart failure patients receiving nitrates.
National patterns of angiotensin-converting enzyme inhibitor use in congestive heart failure.
National patterns of use and effectiveness of angiotensin-converting enzyme inhibitors in older patients with heart failure and left ventricular systolic dysfunction.
Neprilysin Inhibition as a PARADIGM Shift in Heart Failure Therapy.
Neprilysin Inhibitors in Cardiovascular Disease.
Neuroendocrine changes in acute myocardial infarction.
Neuroendocrine changes in chronic cardiac failure.
Neuroendocrine manifestations of congestive heart failure.
Neurohormonal activation and congestive heart failure: today's experience with ACE inhibitors and rationale for their use.
Neurohormonal activation in patients with acute myocardial infarction or chronic congestive heart failure. With special reference to treatment with angiotensin converting enzyme inhibitors.
Neurohormonal activation, the renal dopaminergic system and sodium handling in patients with severe heart failure under vasodilator therapy.
Neurohormonal antagonism in heart failure; beneficial effects of vasopressin V(1a) and V(2) receptor blockade and ACE inhibition.
Neurohormonal control of heart failure.
Neurohormonal mechanisms and the role of angiotensin-converting enzyme (ACE) inhibitors in heart failure.
Neurohormonal modulation in heart failure: ACE inhibition and beyond.
Neurohormonal modulation: The new paradigm of pharmacological treatment of heart failure.
Neurohormonal reactivation in heart failure patients on chronic ACE inhibitor therapy: a longitudinal study.
Neurohormonal Therapy for Congestive Heart Failure.
Neurohumoral activation and progression of heart failure: hypothetical and clinical considerations.
Neurohumoral and hemodynamic effects of the selective endothelin antagonist darusentan in advanced chronic heart failure.
Neurohumoral effects of aliskiren in patients with symptomatic heart failure receiving a mineralocorticoid receptor antagonist: the Aliskiren Observation of Heart Failure Treatment study.
Neutral endopeptidase inhibition augments vascular actions of bradykinin in patients treated with angiotensin-converting enzyme inhibition.
Neutral endopeptidase inhibitors and endothelin antagonists.
New alpha-thiol dipeptide dual inhibitors of angiotensin-I converting enzyme and neutral endopeptidase EC 3.4.24.11.
New angiotensin converting enzyme inhibitors. Their role in the management of hypertension.
New approaches to managing congestive heart failure.
New classes of antihypertensive drugs and new findings with established agents.
New competition in the realm of renin-angiotensin axis inhibition; the angiotensin II receptor antagonists in congestive heart failure.
New considerations relating to class effect with angiotensin-converting enzyme inhibitors--the PEACE study.
New directions in the treatment of heart failure: some paradoxical observations.
New drugs in the treatment of heart failure.
New information on the role of beta-blockers in cardiac therapy.
New medications for heart failure.
New Perspectives in the Renin-Angiotensin-Aldosterone System (RAAS) II: Albumin Suppresses Angiotensin Converting Enzyme (ACE) Activity in Human.
New pharmacological treatments for heart failure with reduced ejection fraction (HFrEF): A Bayesian network meta-analysis.
New pharmacotherapy for heart failure with reduced ejection fraction.
New strategies for treatment of heart failure with aldosterone antagonists and the risk of hyperkalaemia.
New therapeutic agents for the management of congestive heart failure.
New thiol inhibitors of neutral endopeptidase EC 3.4.24.11: synthesis and enzyme active-site recognition.
New trends in the use of angiotensin converting enzyme inhibitors in chronic heart failure.
Nitrate Therapy for Heart Failure: Benefits and Strategies to Overcome Tolerance.
Nitrate tolerance. How to prevent it or minimize its effect.
Nitrates versus angiotensin-converting enzyme inhibitors for congestive heart failure.
No sex-related pharmacokinetic and pharmacodynamic differences of captopril.
Non-adherence with ACE inhibitor treatment is common in heart failure and can be detected by routine serum ACE activity assays.
Nonadherence with ACE inhibitors is common and can be detected in clinical practice by routine serum ACE activity.
Nonadherence with angiotensin-converting enzyme inhibitor therapy: a comparison of different ways of measuring it in patients with chronic heart failure.
Noninferiority of heart failure nurse titration versus heart failure cardiologist titration. ETIFIC multicenter randomized trial.
Nonpharmacologic therapy improves functional and emotional status in congestive heart failure.
Nonsteroidal antiinflammatory drugs and risk of gastrointestinal bleeding among patients on hemodialysis.
North of England evidence based development project: guideline for angiotensin converting enzyme inhibitors in primary care management of adults with symptomatic heart failure.
Novel angiotensin II inhibitors in cardiovascular medicine.
NSAIDs and heart failure.
Nurse Practitioner Practice Patterns for Management of Heart Failure in Long-Term Care Facilities.
Nurse-coordinated collaborative disease management improves the quality of guideline-recommended heart failure therapy, patient-reported outcomes, and left ventricular remodelling.
Nurse-led titration of angiotensin converting enzyme inhibitors, beta-adrenergic blocking agents, and angiotensin receptor blockers for people with heart failure with reduced ejection fraction.
Nurse-Led Titration of Angiotensin-Converting Enzyme Inhibitors, ?-Adrenergic Blocking Agents, and Angiotensin Receptor Blockers in Patients With Heart Failure With Reduced Ejection Fraction.
Nutrition and heart failure: impact of drug therapies and management strategies.
Of fads, fashion, surrogate endpoints and dual RAS blockade.
Olmesartan medoxomil: a clinical review.
Omapatrilat. Bristol-Myers Squibb.
Omapatrilat: a unique new agent for the treatment of cardiovascular disease.
Omapatrilat: penetration across the blood-brain barrier and effects on ischaemic stroke in rats.
On Target to Dual Block RASS?
One-year clinical and echocardiographic follow-up of patients with congestive cardiomyopathy treated with captopril compared to placebo.
Ongoing clinical outcome studies of calcium antagonists.
Ongoing clinical trials of angiotensin-converting enzyme inhibitors for treatment of coronary artery disease in patients with preserved left ventricular function.
Ongoing trials of angiotensin-converting enzyme inhibition: what they can tell us.
Optimal dosing of angiotensin-converting enzyme inhibitors in patients with chronic heart failure: a cross-sectional study in Palestine.
Optimal recognition of neutral endopeptidase and angiotensin-converting enzyme active sites by mercaptoacyldipeptides as a means to design potent dual inhibitors.
Optimising drug management of individuals with cryptogenic hypertension.
Optimized determination of angiotensin I-converting enzyme activity with hippuryl-L-histidyl-L-leucine as substrate.
Optimizing dose selection with modeling and simulation: application to the vasopeptidase inhibitor M100240.
Optimizing therapeutic strategies to achieve renal and cardiovascular risk reduction in diabetic patients with angiotensin receptor blockers.
Optimizing treatment and outcomes in acute heart failure: beyond initial triage.
Options in antihypertensive drug therapy. Help in choosing from among the many agents.
Oral captopril versus placebo among 14,962 patients with suspected acute myocardial infarction: a multicenter, randomized, double-blind, placebo controlled clinical trial. Chinese Cardiac Study (CCS-1) Collaborative Group.
Outcomes of a Pharmacist-Managed Heart Failure Medication Titration Assistance Clinic.
Outcomes with Angiotensin-converting Enzyme Inhibitors vs Other Antihypertensive Agents in Hypertensive Blacks.
Outpatient treatment of systolic heart failure.
Outpatient utilization of angiotensin-converting enzyme inhibitors among heart failure patients after hospital discharge.
Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials.
Overview of the relationship between ischemia and congestive heart failure.
Overview: the role of angiotensin-converting enzyme inhibitors in cardiovascular therapy.
Pathophysiologic and pharmacologic rationales for clinical management of chronic heart failure with beta-blocking agents.
Pathophysiologic role of the renin-angiotensin-aldosterone and sympathetic nervous systems in heart failure.
Pathophysiological aspects of the renin-angiotensin-aldosterone system in acute myocardial infarction.
Pathophysiology and clinical aspects of hypertensive hypertrophy.
Pathophysiology of cardiac hypertrophy and heart failure: signaling pathways and novel therapeutic targets.
Pathophysiology of congestive heart failure. Role of angiotensin-converting enzyme inhibitors.
Pathophysiology of edema in congestive heart failure.
Pathophysiology of fluid retention in heart failure.
Pathophysiology of sodium and water retention in heart failure.
Pathways for bradykinin formation and inflammatory disease.
Patients with mild heart failure worsen during withdrawal from digoxin therapy.
Patterns of ACE inhibitor use in elderly medicaid patients with heart failure.
Patterns of angiotensin-converting enzyme inhibitor prescriptions, educational interventions, and outcomes among hospitalized patients with heart failure.
Patterns of angiotensin-converting enzyme inhibitor use in congestive heart failure in two community hospitals.
Patterns of pharmacologic treatment of congestive heart failure in elderly nursing home residents and related issues: a review of the literature.
Patterns of physician use of angiotensin converting enzyme inhibitors in the inpatient treatment of congestive heart failure.
Pediatric Cardiac Intensive Care Society 2014 Consensus Statement: Pharmacotherapies in Cardiac Critical Care Chronic Heart Failure.
Peptides as targets for antihypertensive drug development.
Perceived barriers for treatment of chronic heart failure in general practice; are they affecting performance?
Perceived risk profile and treatment optimization in heart failure: an analysis from BIOlogy Study to TAilored Treatment in chronic heart failure.
Performance assessment model for guideline-recommended pharmacotherapy in the secondary prevention of coronary artery disease and treatment of left ventricular dysfunction.
Perindopril arginine: benefits of a new salt of the ACE inhibitor perindopril.
Perindopril reduces blood pressure but not cerebral blood flow in patients with recent cerebral ischemic stroke.
Perindopril safety and tolerance in at-risk patients.
Perindopril treatment for congestive heart failure.
Peripartum cardiomyopathy.
Peripartum cardiomyopathy: analysis of clinical outcome, left ventricular function, plasma levels of cytokines and Fas/APO-1.
Peripheral haemodynamic effects of inhibition of prostaglandin synthesis in congestive heart failure and interactions with captopril.
Persistent formation of angiotensin II despite treatment with maximally recommended doses of angiotensin converting enzyme inhibitors in patients with chronic heart failure.
Pharmacodynamic and pharmacokinetic profiles of sacubitril/valsartan (LCZ696) in patients with heart failure and reduced ejection fraction.
Pharmacodynamic effects of C-domain-specific ACE inhibitors on the renin-angiotensin system in myocardial infarcted rats.
Pharmacodynamic Impact of Carboxylesterase 1 Gene Variants in Patients with Congestive Heart Failure Treated with Angiotensin-Converting Enzyme Inhibitors.
Pharmacoeconomics of angiotensin converting enzyme inhibitors in heart failure.
Pharmacogenetic interactions between angiotensin-converting enzyme inhibitor therapy and the angiotensin-converting enzyme deletion polymorphism in patients with congestive heart failure.
Pharmacogenetic interactions between beta-blocker therapy and the angiotensin-converting enzyme deletion polymorphism in patients with congestive heart failure.
Pharmacogenetic Risk Stratification in Angiotensin-Converting Enzyme Inhibitor-Treated Patients with Congestive Heart Failure: A Retrospective Cohort Study.
Pharmacogenetics in heart failure: genomic markers of endothelial and neurohumoral function.
Pharmacogenetics of heart failure: evidence, opportunities, and challenges for cardiovascular pharmacogenomics.
Pharmacogenomics of heart failure.
Pharmacokinetic and dynamic interactions of the angiotensin-converting enzyme inhibitor imidapril with hydrochlorothiazide, bisoprolol and nilvadipine.
Pharmacokinetic drug interactions with ACE inhibitors.
Pharmacokinetic optimisation of angiotensin converting enzyme (ACE) inhibitor therapy.
Pharmacokinetic-pharmacodynamic model for perindoprilat regional haemodynamic effects in healthy volunteers and in congestive heart failure patients.
Pharmacokinetic-pharmacodynamic model relating spiraprilat plasma concentrations to systemic and regional hemodynamic effects in congestive heart failure.
Pharmacokinetics of captopril in healthy subjects and in patients with cardiovascular diseases.
Pharmacologic advances in long-term heart failure management.
Pharmacologic blockade of the renin-angiotensin system: vascular benefits beyond commonly understood pharmacologic actions.
Pharmacologic management of heart failure among older adults by office-based physicians in the United States.
Pharmacologic treatment of congestive heart failure.
Pharmacological interventions for heart failure in people with chronic kidney disease.
Pharmacological management of chronic heart failure
Pharmacological Management of Heart Failure: A Century of Expert Opinions in Cecil Textbook of Medicine.
Pharmacological profile of the new inotropic agent AT-11.
Pharmacological treatment and prevention of heart failure in the diabetic patient.
Pharmacological Treatment of Heart Failure with Preserved Ejection Fraction.
Pharmacology of angiotensin-converting enzyme inhibitors as a guide to their use in congestive heart failure.
Pharmacology of enalapril in children: a review.
Pharmacology of losartan, an angiotensin II receptor antagonist, in animal models of hypertension.
Pharmacology of valsartan, an angiotensin II receptor antagonist.
Pharmacotherapeutic management of paediatric heart failure and ACE-I use patterns: a European survey.
Pharmacotherapy for chronic heart failure.
Pharmacotherapy for heart failure in patients with renal insufficiency.
Pharmacotherapy for heart failure with left ventricular dysfunction: beyond angiotensin-converting enzyme inhibitors and beta-blockers.
Pharmacotherapy in congestive heart failure: Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in congestive heart failure: do they differ in their renal effects in man?
Pharmacotherapy in congestive heart failure: Hyperkalemia in congestive heart failure.
Pharmacotherapy of heart failure with normal ejection fraction (HFNEF) - a systematic review.
Pharmacy-based interdisciplinary intervention for patients with chronic heart failure: results of the PHARM-CHF randomized controlled trial.
Physical working capacity after acute myocardial infarction in patients with low ejection fraction and effect of captopril.
Physician, organisational and patient characteristics explaining the use of angiotensin converting enzyme inhibitors in heart failure treatment: a multilevel study.
Physiology of local renin-angiotensin systems.
Pilot study of combined blockade of the renin-angiotensin system in essential hypertensive patients.
Pilot survey of the diagnosis and management of heart failure in primary care: a Singaporean perspective.
Placebo controlled trial of felodipine in patients with mild to moderate heart failure. UK Study Group.
Placebo-controlled comparison of candoxatril, an orally active neutral endopeptidase inhibitor, and captopril in patients with chronic heart failure.
Placebo-controlled study of lisinopril in congestive heart failure: a multicentre study.
Plasma endothelin in congestive heart failure: effect of the ACE inhibitor, fosinopril.
Plasma levels of enalaprilat in chronic therapy of heart failure: relationship to adverse events.
Plasma renin activity has a complex prognostic role in patients with acute coronary syndromes.
Plasma renin activity in infants with congenital heart disease.
Polypharmacy (or polytherapy) in the treatment of heart failure.
Possible therapeutic targets in cardiac myocyte apoptosis.
Post-myocardial infarction left ventricular pseudoaneurysm diagnosed incidentally by echocardiography.
Postmyocardial infarction patients: experience from the SAVE trial.
Postponement of Death by Pharmacological Heart Failure Treatment: A Meta-Analysis of Randomized Clinical Trials.
Posture determines the nature of the interaction between angiotensin converting enzyme inhibitors and loop diuretics in patients with chronic cardiac failure.
Potassium homeostasis and Renin-Angiotensin-aldosterone system inhibitors.
Potential beneficial as well as detrimental effects of chronic treatment with lisinopril and (or) spironolactone on isolated hearts following low-flow ischemia in normal and infarcted rats.
Potential prescribing omissions in patients with cardiovascular disease.
Potential Uses of Sacubitril/Valsartan: Need for Data on Efficacy and Safety.
Potentially inappropriate prescribing (IP) for elderly medical inpatients in Taiwan: A hospital-based study.
Practical aspects of using beta-adrenergic blockade in systolic heart failure.
PREAMI: Perindopril and Remodelling in Elderly with Acute Myocardial Infarction: study rationale and design.
Prediction on admission of in-hospital mortality in patients older than 70 years with acute myocardial infarction.
Predictive models for adverse clinical outcomes in Chinese patients with atrial fibrillation undergoing percutaneous coronary intervention with stenting.
Predictors and Clinical Impact of Late Ventricular Arrhythmias in Patients With Continuous-Flow Left Ventricular Assist Devices.
Predictors of Acute Kidney Injury Following Surgical Valve Replacement.
Predictors of Death in Adults With Duchenne Muscular Dystrophy-Associated Cardiomyopathy.
Predictors of decreased renal function in patients with heart failure during angiotensin-converting enzyme inhibitor therapy: results from the studies of left ventricular dysfunction (SOLVD)
Predictors of left ventricular remodelling in patients with dilated cardiomyopathy - a cardiovascular magnetic resonance study.
Prescribing and emergency admissions for heart failure in greater Glasgow.
Prescribing of ACE inhibitors for cardiovascular disorders in general practice.
Prescribing patterns of evidence-based heart failure pharmacotherapy and outcomes in the ASIAN-HF registry: a cohort study.
Prescriptions of recommended heart failure medications can be correlated with patient and physician characteristics.
Present and future pharmacotherapy for heart failure.
Pretreatment with angiotensin-converting enzyme inhibitor improves doxorubicin-induced cardiomyopathy via preservation of mitochondrial function.
Prevalence of anemia and effects on mortality in patients with heart failure.
Preventable sudden death in patients receiving angiotensin converting enzyme inhibitors and loop/potassium sparing diuretic combinations.
Preventing recurrent events long term after coronary artery bypass graft: suboptimal use of medications in a population study.
Prevention and Reversal of LV Remodeling with Neurohormonal Inhibitors.
Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis.
Prevention of cancer therapy-related heart failure: is it really possible? A population-based study.
Prevention of endothelial dysfunction in small and large arteries in a model of chronic heart failure. Effect of angiotensin converting enzyme inhibition.
Prevention of Heart Failure in Patients in the Heart Outcomes Prevention Evaluation (HOPE) Study.
Prevention of heart failure.
Prevention of heart failure: effective strategies to combat the growing epidemic.
Preventive effects of angiotensin-converting enzyme inhibitors on nitrate tolerance during continuous transdermal application of nitroglycerin in patients with chronic heart failure.
Primary and secondary prevention of myocardial infarction and strokes: an update of randomly allocated, controlled trials.
Profile of sacubitril/valsartan in the treatment of heart failure: patient selection and perspectives.
Prognosis and mechanism of death in treated heart failure: data from the placebo arm of Val-HeFT.
Prognostic impact of carboxylesterase 1 gene variants in patients with congestive heart failure treated with angiotensin-converting enzyme inhibitors.
Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting-enzyme inhibitors: an observational study.
Prognostic significance of nonsustained ventricular tachycardia in patients receiving cardiac resynchronization therapy for primary prevention: Analysis of the Japan cardiac device treatment registry database.
Prognostic significance of serum cholinesterase in patients with acute decompensated heart failure: a prospective comparative study with other nutritional indices.
Prognostic significance of systolic blood pressure changes during dobutamine-atropine stress technetium-99m sestamibi perfusion scintigraphy in patients with chest pain and known or suspected coronary artery disease.
Prognostic value of neurohumoral activation in patients with an acute myocardial infarction: effect of captopril.
Prognostic value of peripheral blood inflammatory cell subsets in patients with acute coronary syndrome undergoing percutaneous coronary intervention.
Prognostic value of the QRS duration in patients with heart failure: a subgroup analysis from 24 centers of Val-HeFT.
Progress in angiotensin-converting enzyme inhibition in heart failure: rationale, mechanisms, and clinical responses.
Progress in the development of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.
Progression of left ventricular dysfunction secondary to coronary artery disease, sustained neurohormonal activation and effects of ibopamine therapy during long-term therapy with angiotensin-converting enzyme inhibitor.
Proinflammatory cytokines, soluble Fas receptor, nitric oxide and angiotensin converting enzyme in congestive heart failure.
Prolonging action of imidapril on the lifespan expectancy of cardiomyopathic hamsters.
Prophylactic pacemaker use to allow beta-blocker therapy in patients with chronic heart failure with bradycardia.
Prospective evaluation comparing the effects of enalapril and losartan in left ventricular remodeling after acute myocardial infarction.
Protection of the cardiovascular system by imidapril, a versatile angiotensin-converting enzyme inhibitor.
Protection: risk ratio of antihypertensive drug treatment in the elderly.
Protective effect of ACE- and kininase-inhibitor on the onset of cardiomyopathy.
Protective effect of captopril against clozapine-induced myocarditis in rats: Role of oxidative stress, proinflammatory cytokines and DNA damage.
Protective effects of angiotensin-converting enzyme inhibitors in high-risk African American men with coronary heart disease.
Proteinuria, Chronic Kidney Disease, and the Effect of an Angiotensin Receptor Blocker in Addition to an Angiotensin-Converting Enzyme Inhibitor in Patients With Moderate to Severe Heart Failure.
Quality and outcomes of heart failure care in older adults: role of multidisciplinary disease-management programs.
Quality of congestive heart failure treatment at a Canadian teaching hospital.
Quality of heart failure care in managed Medicare and Medicaid patients in North Carolina.
Quality of life among 5,025 patients with left ventricular dysfunction randomized between placebo and enalapril: the Studies of Left Ventricular Dysfunction. The SOLVD Investigators.
Quality of life in chronic heart failure: cilazapril and captopril versus placebo. Cilazapril-Captopril Multicentre Group.
Quality of life in older patients with congestive heart failure. Effects of ACE inhibitors.
Quality of life with ACE inhibitors in chronic heart failure.
Quality of medical care delivered to Medicare beneficiaries: A profile at state and national levels.
Quality of Physician Adherence to Guideline Recommendations for Life-saving Treatment in Heart Failure: an International Survey.
Quality of US primary care delivered by resident and staff physicians.
Quantifying the interaction between angiotensin-converting enzyme inhibitors and aspirin: are we using the right method?
Quantitative two-dimensional echocardiographic measurements are major predictors of adverse cardiovascular events after acute myocardial infarction. The protective effects of captopril.
Quinapril in chronic heart failure.
Quinaprilat increases total body vascular compliance in rats with myocardial infarction.
RAAS Inhibition/Blockade in patients with Cardiovascular disease : Implications of recent large scale randomized trials for clinical practice.
Race and association of angiotensin converting enzyme/angiotensin receptor blocker exposure with outcome in heart failure.
Race and the response to adrenergic blockade with carvedilol in patients with chronic heart failure.
Racial differences in patients' potassium concentrations during spironolactone therapy for heart failure.
Racial response to angiotensin-converting enzyme therapy in systolic heart failure.
Radial, carotid and aortic distensibility in congestive heart failure: effects of high-dose angiotensin-converting enzyme inhibitor or low-dose association with angiotensin type 1 receptor blockade.
Radionuclide monitoring of cardiac adaptations to volume loading in patients with dilated cardiomyopathy and mild heart failure. Effects of angiotensin-converting enzyme inhibition.
Ramipril and captopril in patients with heart failure: effects on hemodynamics and vasoconstrictor systems.
Randomised comparison of losartan vs. captopril on quality of life in elderly patients with symptomatic heart failure: the losartan heart failure ELITE quality of life substudy.
Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE)
Randomized trial of candesartan cilexetil in the treatment of patients with congestive heart failure and a history of intolerance to angiotensin-converting enzyme inhibitors.
Rational drug correction of systemic inflammatory response syndrome in severe experimental heart failure.
Rationale and design of a trial of angiotensin-converting enzyme inhibition in infants with single ventricle.
Rationale and design of the third vasodilator-heart failure trial (V-HeFT III): felodipine as adjunctive therapy to enalapril and loop diuretics with or without digoxin in chronic congestive heart failure. V-HeFT III investigators.
Rationale and design of the Valsartan Heart Failure Trial: a large multinational trial to assess the effects of valsartan, an angiotensin-receptor blocker, on morbidity and mortality in chronic congestive heart failure.
Rationale for the use of combination angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker therapy in heart failure.
Rationale for the use of combination angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker therapy in heart failure.
Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials.
Readmissions and the quality of care in patients hospitalized with heart failure.
Reappraisal of beta-blocker therapy in the acute and chronic post-myocardial infarction period.
Reasons for underuse of angiotensin-converting enzyme inhibitors in patients with heart failure and left ventricular dysfunction.
Reassessing guidelines for heart failure.
Recent Advances in Angiotensin-Converting Enzyme Inhibition in the Treatment of Hypertension and Heart Failure. Symposium proceedings. Barcelona, Spain, August 30, 1992.
Recent advances in cardiovascular risk reduction: implications of ONTARGET.
Recent developments in the design of angiotensin-converting enzyme inhibitors.
Recognition and Management of Hypertension in Older Persons: Focus on African Americans.
Recruitment strategies in the studies of left ventricular dysfunction (SOLVD): strategies for screening and enrollment in two concurrent but separate trials. The SOLVD Investigators.
Recurrent Takotsubo Cardiomyopathy: Getting to the Root of the Problem.
Redistribution of regional blood flow following angiotensin-converting enzyme inhibition. Comparison of normal subjects and patients with heart failure.
Reduced costs with bisoprolol treatment for heart failure: an economic analysis of the second Cardiac Insufficiency Bisoprolol Study (CIBIS-II).
Reduced ejection fraction heart failure - new data from multicenter studies and national registries regarding general and elderly populations: hopes and disappointments.
Reduced lymphocyte stimulatory guanine nucleotide regulatory protein and beta-adrenergic receptors in congestive heart failure and reversal with angiotensin converting enzyme inhibitor therapy.
Reduced mortality and morbidity with the use of angiotensin-converting enzyme inhibitors in patients with left ventricular dysfunction and congestive heart failure.
Reduction of Mean Arterial Pressure and Proteinuria by the Effect of ACEIs (Lisinopril) in Kurdish Hypertensive Patients in Hawler City.
Refocus on diuretics in the treatment of heart failure.
Regional and systemic metabolic effects of angiotensin-converting enzyme inhibition during exercise in patients with severe heart failure.
Regression of left ventricular hypertrophy in hemodialysis patients is possible.
Regression of left ventricular remodeling in chronic heart failure: Comparative and combined effects of captopril and carvedilol.
Regulation of aldosterone secretion in patients with chronic congestive heart failure by endothelins.
Regulation of beta-adrenoceptors in a rat model of cardiac failure: effect of perindopril.
Relation between serum sodium levels and prognosis in outpatients with chronic heart failure: neutral effect of treatment with beta-blockers and angiotensin-converting enzyme inhibitors: data from the Italian network on congestive heart failure (IN-CHF database).
Relation between use of angiotensin-converting enzyme inhibitors and muscle strength and physical function in older women: an observational study.
Relation of aldosterone "escape" despite angiotensin-converting enzyme inhibitor administration to impaired exercise capacity in chronic congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy.
Relation of dosing of the renin-angiotensin system inhibitors after cardiac resynchronization therapy to long-term prognosis.
Relation of functional improvement in congestive heart failure after quinapril therapy to peripheral limitation.
Relation of pathophysiologic mechanisms to outcome in heart failure.
Relationship between blood pressure levels and adherence to medication in patients with chronic heart failure: How come?
Relationship between decrease in afterload and beneficial effects of ACE inhibitors in experimental cardiac hypertrophy and congestive heart failure.
Relationship of dose of background angiotensin-converting enzyme inhibitor to the benefits of candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial.
Relationship of microalbuminuria with the diabetic foot ulcers in type II diabetes.
Relationships Between Race, Bleeding, and Mortality in Coronary Reperfusion.
Relative Bioavailability of Enalapril Administered as Orodispersible Minitablets in Healthy Adults.
Relative efficacy of angiotensin converting enzyme inhibitors on mortality of patients with congestive heart failure: implications of randomized trials and role of the aetiology (ischaemic or non-ischaemic) of heart failure.
Renal and electrolyte complications of congestive heart failure and effects of therapy with angiotensin-converting enzyme inhibitors.
Renal antifibrotic effect of N-acetyl-seryl-aspartyl-lysyl-proline in diabetic rats.
Renal effects of angiotensin converting enzyme inhibitors in heart failure: a clinician's guide to minimizing azotemia and diuretic-induced electrolyte imbalances.
Renal effects of angiotensin-converting enzyme inhibition in cardiac failure.
Renal effects of angiotensin-converting enzyme inhibition in congestive heart failure.
Renal effects of L-DOPA in heart failure.
Renal effects of nonselective NSAIDs and coxibs.
Renal functional alterations induced by angiotensin-converting enzyme inhibitors in heart failure.
Renal hemodynamic consequences of angiotensin-converting enzyme inhibition in congestive heart failure.
Renal hemodynamic control by endothelin and nitric oxide under angiotensin II blockade in man.
Renal hemodynamic effects of nonhypotensive doses of angiotensin-converting enzyme inhibitors in hypertension and heart failure rats.
Renal insufficiency due to angiotensin-converting enzyme inhibitors.
Renal morphology and function in dogs after treatment with the angiotensin-converting enzyme inhibitor quinapril.
Renal protection in chronic heart failure: focus on sacubitril/valsartan.
Renal reserve is normal in patients with dilative cardiomyopathy waiting for heart transplantation.
Renal safety and efficacy of angiotensin receptor-neprilysin inhibitor: A meta-analysis of randomized controlled trials.
Renin and angiotensin responses to posture and exercise in elderly patients with heart failure.
Renin angiotensin aldosterone and adrenergic modulation in chronic heart failure: contemporary concepts.
Renin Inhibition for Hypertension: Selecting the Right Role for a New Class of Drug.
Renin Inhibition with Aliskiren: A Decade of Clinical Experience.
Renin inhibition: a new approach to cardiovascular therapy.
Renin inhibitors in chronic heart failure: the Aliskiren Observation of Heart Failure Treatment study in context.
Renin inhibitors.
Renin inhibitors: discovery and development. An overview and perspective.
Renin inhibitors: specific modulators of the renin-angiotensin system.
Renin-angiotensin blockade in heart failure with preserved ejection fraction: a systematic review and meta-analysis.
Renin-Angiotensin Inhibition and Outcomes in Nursing Home Residents With Heart Failure.
Renin-angiotensin system and cancer: epidemiology, cell signaling, genetics and epigenetics.
Renin-angiotensin system antagonists and clinical outcomes in stable coronary artery disease without heart failure.
Renin-Angiotensin System Blockade after Acute Kidney Injury (AKI) and Risk of Recurrent AKI.
Renin-Angiotensin System Blockade and Risk of Heart Failure After Myocardial Infarction Based on Left Ventricular Ejection Fraction: A Retrospective Cohort Study.
Renin-angiotensin system blockade at the level of the angiotensin converting enzyme or the angiotensin type-1 receptor: similarities and differences.
Renin-Angiotensin System Blockade Improves Cardiac Indices in Acromegaly Patients.
Renin-Angiotensin System Inhibition and Lower 30-Day All-Cause Readmission in Medicare Beneficiaries with Heart Failure.
Renin-angiotensin system inhibition in COVID-19 patients.
Renin-angiotensin system inhibition on noradrenergic nerve terminal function in pacing-induced heart failure.
Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part 2. Overview of physiological and biochemical mechanisms.
Renin-angiotensin system modulation: the weight of evidence.
Renin-Angiotensin-Aldosterone Signaling Inhibitors-Losartan, Enalapril, and Cardosten-Prevent Infarction-induced Heart Failure Development in Rats.
Renin-angiotensin-aldosterone system inhibitors improve membrane stability and change gene-expression profiles in dystrophic skeletal muscles.
Renin-Angiotensin-Aldosterone System Optimization for Acute Decompensated Heart Failure Patients (ROAD-HF): Rationale and Design.
Renin-angiotensin-aldosterone system: fundamental aspects and clinical implications in renal and cardiovascular disorders.
Replicated studies of two randomized trials of angiotensin-converting enzyme inhibitors: further empiric validation of the 'prior event rate ratio' to adjust for unmeasured confounding by indication.
Repression of angiotensin II and potentiation of bradykinin contribute to the synergistic effects of dual metalloprotease inhibition in heart failure.
Resource utilization implications of treatment were able to be assessed from appropriately reported clinical trial data.
Response of large and small vessels to alpha and beta adrenoceptor stimulation in heart failure: effect of angiotensin converting enzyme inhibition.
Response to sorafenib after sunitinib-induced acute heart failure in a patient with metastatic renal cell carcinoma: case report and review of the literature.
Responses of plasma concentrations of A type natriuretic peptide and B type natriuretic peptide to alacepril, an angiotensin-converting enzyme inhibitor, in patients with congestive heart failure.
Responses of plasma concentrations of A type natriuretic peptide and B type natriuretic to alacepril, an angiotensin-converting enzyme inhibitor, in patients with congestive heart failure.
Results of therapy with carvedilol, a beta-blocker vasodilator with antioxidant properties, in hypertensive patients.
Rethinking the renin-angiotensin system and its role in cardiovascular regulation.
Revealing the synergistic mechanism of Shenfu Decoction for anti-heart failure through network pharmacology strategy.
Reversal of peripheral microvascular dysfunction during long-term treatment with the angiotensin-converting enzyme inhibitor fosinopril in congestive heart failure.
Reverse remodeling in heart failure with intensification of vasodilator therapy.
Reversible renal failure after combined treatment with enalapril and frusemide in a patient with congestive heart failure.
Review: Novel roles of nuclear angiotensin receptors and signaling mechanisms.
Right ventricular dysplasia in an asymptomatic young man: an uncommon case with biventricular involvement and no known family history.
Risk factors associated with biochemically detected and hospitalised acute kidney injury in patients prescribed renin angiotensin system inhibitors.
Risk factors associated with the development of ischemic colitis.
Risk factors for appropriate cardioverter-defibrillator shocks, inappropriate cardioverter-defibrillator shocks, and time to mortality in 549 patients with heart failure.
Risk Factors for the Development of Postoperative Acute Kidney Injury in Patients Undergoing Joint Replacement Surgery: A Meta-Analysis.
Risk of cardiovascular events after initiation of long-acting bronchodilators in patients with chronic obstructive lung disease: A population-based study.
Risk of lung cancer and renin-angiotensin blockade: a concise review.
Risk of morbidity from renovascular disease in elderly patients with congestive cardiac failure.
Risk-benefit assessment of angiotensin II receptor antagonists.
Risks and benefits of the treatment of heart failure. Current status.
Role and optimal dosing of angiotensin-converting enzyme inhibitors in heart failure.
Role of a selective aldosterone blocker in mice with chronic heart failure.
Role of angiotensin converting enzyme inhibitors in patients with left ventricular dysfunction and congestive heart failure.
Role of angiotensin II in the evolution of diastolic heart failure.
Role of angiotensin receptor blockers in diabetes: implications of recent clinical trials.
Role of Angiotensin receptor blockers in the prevention and treatment of arrhythmias.
Role of angiotensin-converting enzyme inhibition in reversal of endothelial dysfunction in coronary artery disease.
Role of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in the management of atrial fibrillation.
Role of angiotensin-converting enzyme inhibitors in congestive heart failure.
Role of angiotensin-converting enzyme inhibitors in preventing or reducing end-organ damage in hypertension.
Role of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and aldosterone antagonists in the prevention of atrial and ventricular arrhythmias.
Role of bradykinin-NO pathway in prevention of cardiac hypertrophy by ACE inhibitor in rat cardiomyocytes.
Role of converting enzyme inhibitors in the treatment of heart failure.
Role of G-protein-coupled receptor kinase 2 in the heart--do regulatory mechanisms open novel therapeutic perspectives?
Role of kinins in chronic heart failure and in the therapeutic effect of ACE inhibitors in kininogen-deficient rats.
Role of nitrates for the therapy of coronary artery disease patients in the years beyond 2000.
Role of race in the pharmacotherapy of heart failure.
Role of Rho kinase and oxidative stress in cardiac fibrosis induced by aldosterone and salt in angiotensin type 1a receptor knockout mice.
Role of spectral measures of heart rate variability as markers of disease progression in patients with chronic congestive heart failure not treated with angiotensin-converting enzyme inhibitors.
Role of the angiotensin II receptor blocker valsartan in heart failure.
Role of the cardiac renin-angiotensin system in human heart failure.
Role of valsartan and other angiotensin receptor blocking agents in the management of cardiovascular disease.
Roles of renin-angiotensin and endothelin systems in development of diastolic heart failure in hypertensive hearts.
S-nitrosocaptopril. II. Effects on vascular reactivity.
Sacubitril-valsartan improves conduit vessel function and functional capacity and reduces inflammation in heart failure with reduced ejection fraction.
Sacubitril/valsartan for the management of heart failure: A perspective viewpoint on current evidence.
Sacubitril/Valsartan in Advanced Heart Failure With Reduced Ejection Fraction: Rationale and Design of the LIFE Trial.
Sacubitril/Valsartan in Asian Patients with Heart Failure with Reduced Ejection Fraction.
Sacubitril/valsartan: A novel angiotensin receptor-neprilysin inhibitor.
Sacubitril/Valsartan: A Review in Chronic Heart Failure with Reduced Ejection Fraction.
Sacubitril/valsartan: from a large clinical trial to clinical practice.
Sacubitril/Valsartan: Neprilysin Inhibition 5 Years After PARADIGM-HF.
Sacubitril/Valsartan: potential treatment for paediatric heart failure.
Sacubitril/Valsartan: The Newest Addition to the Toolbox for Guideline Directed Medical Therapy of Heart Failure.
Safety and costs of initiating angiotensin converting enzyme inhibitors for heart failure in primary care: analysis of individual patient data from studies of left ventricular dysfunction.
Safety and efficacy of enalapril in multivalvular heart disease with significant mitral stenosis--SCOPE-MS.
Safety and efficacy of epoprostenol in patients with severe congestive heart failure. Epoprostenol Multicenter Research Group.
Safety and efficacy of valsartan versus enalapril in heart failure patients.
Safety and Prognostic Impact of Early Treatment with Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers in Patients with Acute Heart Failure.
Safety and tolerability of angiotensin-converting enzyme inhibitor versus the combination of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker in patients with left ventricular dysfunction: a systematic review and meta-analysis of randomized controlled trials.
Safety of calcium antagonists in patients with congestive heart failure.
Safety of concomitant potassium-sparing diuretics in angiotensin-converting enzyme inhibitor therapy in severe congestive heart failure. Xamoterol in Severe Heart Failure Study Group.
Scar and pulmonary expression and shedding of ACE in rat myocardial infarction.
Screening for drug related dyspepsia: an analysis of prescription symmetry.
Secondary prevention in coronary heart disease: baseline survey of provision in general practice.
Secondary prevention of CAD with ACE inhibitors: a struggle between life and death of the endothelium.
Selections from current literature: treatment of congestive heart failure with angiotensin converting enzyme inhibitors.
Selective and time related activation of the cardiac renin-angiotensin system after experimental heart failure: relation to ventricular function and morphology.
Separation methods for captopril in pharmaceuticals and biological fluids.
Sequential big endothelin plasma levels in heart transplant recipients during bridging therapy and after successful heart transplantation.
Serial echocardiographic-Doppler assessment of left ventricular geometry and function in rats with pressure-overload hypertrophy. Chronic angiotensin-converting enzyme inhibition attenuates the transition to heart failure.
Severe migratory Angioedema due to ACE inhibitors use.
Severe preeclampsia, pulmonary edema, and peripartum cardiomyopathy in a primigravida patient.
Severity of heart failure and dosage of angiotensin converting enzyme inhibitors.
Sex differences in the effectiveness of angiotensin receptor blockers and angiotensin converting enzyme inhibitors in patients with congestive heart failure--a population study.
Sex differences in the effectiveness of angiotensin receptor blockers and angiotensin converting enzyme inhibitors in patients with congestive heart failure.
Sex-linked differences in the mortality in Ren-2 transgenic hypertensive rats with aorto-caval fistula: effects of treatment with angiotensin converting enzyme alone and combined with inhibitor of soluble epoxide hydrolase.
Sex-Related Characteristics, Quality of Care, and Short-Term Mortality Rates in Patient With Chronic Heart Failure.
Sex-related differences in the use and adverse effects of angiotensin-converting enzyme inhibitors in heart failure: the study of patients intolerant of converting enzyme inhibitors registry.
Short- and long-acting angiotensin-converting enzyme inhibitors: a randomized trial of lisinopril versus captopril in the treatment of congestive heart failure. The Multicenter Lisinopril-Captopril Congestive Heart Failure Study Group.
Short-term effects of angiotensin receptor blockers on blood pressure control, and plasma inflammatory and fibrinolytic parameters in patients taking angiotensin-converting enzyme inhibitors.
Short-term prognosis of normalising serum potassium following an episode of hypokalaemia in patients with chronic heart failure.
Should angiotensin receptor blockers be added to angiotensin-converting enzyme inhibitors in the treatment of heart failure?
Should Angiotensin Receptor Neprilysin Inhibitors Replace Angiotensin-converting Enzyme Inhibitors in Heart Failure With a Reduced Ejection Fraction?
Should Angiotensin-converting enzyme inhibitors be continued over the long term in patients whose left ventricular ejection fraction normalizes after an episode of acute myocarditis?
Should angiotensin-converting enzyme-inhibitors be used to improve outcome in patients with coronary artery disease and 'preserved' left ventricular function?
Should beta blockers be used in the treatment of hypertension in the elderly?
Sickness Behavior in Community-Dwelling Elderly Associations With Impaired Cardiac Function and Inflammation.
Side effects of using nitrates to treat heart failure and the acute coronary syndromes, unstable angina and acute myocardial infarction.
Similar clinical benefits from below-target and target dose enalapril in patients with heart failure in the SOLVD Treatment trial.
Simultaneous angiotensin converting enzyme inhibition moderates ventricular dysfunction caused by doxorubicin.
Simultaneous ultraperformance liquid chromatography/tandem mass spectrometry determination of four antihypertensive drugs in human plasma using hydrophilic-lipophilic balanced reversed phase sorbents sample preparation protocol.
Skeletal muscle blood flow, metabolism and morphology in chronic congestive heart failure and effects of short- and long-term angiotensin-converting enzyme inhibition.
Skeletal muscle depressed calcium and phosphofructokinase in chronic heart failure are upregulated by captopril--a double-blind, placebo-controlled study.
Skeletal muscle RAS and exercise performance.
Socioeconomic aspects of ACE inhibition in the secondary prevention in cardiovascular diseases.
Soluble angiotensin-converting enzyme levels in heart failure or acute coronary syndrome: revisiting its modulation and prognosis value.
Special clinical considerations of beta-blocker treatment.
Special considerations for carvedilol use in heart failure.
Specific phosphodiesterase inhibition and maximal and submaximal exercise performance in patients with congestive heart failure.
Spectrophotometric determination of enalapril through ternary complex formation.
Spironolactone in congestive heart failure refractory to high-dose loop diuretic and low-dose angiotensin-converting enzyme inhibitor.
Spironolactone in congestive heart failure.
Spironolactone in severe heart failure: enhances efficacy of diuretic + ACE inhibitor combinations.
Spironolactone use and renal toxicity: population based longitudinal analysis.
Spotlight on valsartan-sacubitril fixed-dose combination for heart failure: the evidence to date.
Starting treatment with angiotensin converting enzyme inhibitors in heart failure: how, where, and how much?
Strategic actions of angiotensin-converting enzyme inhibitors in treatment of congestive heart failure.
Strategies for the treatment of acute heart failure in children.
Strategies to improve the use of evidence-based heart failure therapies: OPTIMIZE-HF.
Studies of Left Ventricular Dysfunction (SOLVD) Registry: rationale, design, methods and description of baseline characteristics.
Studies on the magnitude and the mechanism of cough potentiation by angiotensin-converting enzyme inhibitors in guinea-pigs: involvement of bradykinin in the potentiation.
Studies with an automated kinetic assay for plasma angiotensin-converting enzyme activity and its potentiation by zinc ion.
Sublingual administration of captopril versus nitroglycerin in patients with severe congestive heart failure.
Successful heart failure therapy in mitochondrial disorder with noncompaction cardiomyopathy.
Successful management of severe congestive cardiac failure with enalapril.
Successful treatment of hyponatremia with angiotensin-converting enzyme inhibitors in patients with congestive heart failure.
Successful treatment of severe hypertension with the combination of angiotensin converting enzyme inhibitor and angiotensin II receptor blocker.
Sudden cardiac death in dilated cardiomyopathy -- therapeutic options.
Sudden death in dilated cardiomyopathy.
Sudden death in heart failure patients: effects of optimized medical therapy.
Summary of AHRQ's comparative effectiveness review of angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers added to standard medical therapy for treating stable ischemic heart disease.
Summary of randomized trials of angiotensin converting enzyme inhibitors.
Superior cardiovascular effect of aerobic interval training versus moderate continuous training in heart failure patients: a randomized study.
Superiority of "triple" drug therapy in heart failure: insights from the PROVED and RADIANCE trials. Prospective Randomized Study of Ventricular Function and Efficacy of Digoxin. Randomized Assessment of Digoxin and Inhibitors of Angiotensin-Converting Enzyme.
Supportive treatment improves survival in multivisceral cholesterol crystal embolism.
Surgical ventricular remodeling: should we STICH or not?
Survival after myocardial infarction in rats: captopril versus losartan.
Survival and echocardiographic data in dogs with congestive heart failure caused by mitral valve disease and treated by multiple drugs: a retrospective study of 21 cases.
Survival and prognosis: investigation of Crataegus extract WS 1442 in congestive heart failure (SPICE)--rationale, study design and study protocol.
Survival benefits of angiotensin-converting enzyme inhibitors in older heart failure patients with perceived contraindications.
Survival in congestive heart failure: have we made a difference?
Survival of rats with experimental chronic heart failure depending on pharmacodynamic and pharmacokinetic parameters of angiotensin-converting enzyme inhibitors and beta-adrenoceptor blockers.
Surviving heart failure: Robert L. Frye lecture.
Sustainable biocatalytic synthesis of L-homophenylalanine as pharmaceutical drug precursor.
Sustained augmentation of parasympathetic tone with angiotensin-converting enzyme inhibition in patients with congestive heart failure.
Sustained beneficial effects of enalapril in Africans with congestive heart failure.
Sustained haemodynamic and clinical effects of captopril in long-term treatment of severe chronic congestive heart failure.
Sustained haemodynamic effects of enalapril in left ventricular failure.
Sustained hemodynamic response to flosequinan in patients with heart failure receiving angiotensin-converting enzyme inhibitors.
Sustained improvement in cardiac function with persistent amyloid deposition in a patient with multiple myeloma-associated cardiac amyloidosis treated with bortezomib.
Sustained inhibition of angiotensin I-converting enzyme (ACE) expression and long-term antihypertensive action by virally mediated delivery of ACE antisense cDNA.
Sympathetic activation in heart failure and its treatment with beta-blockade.
Sympathetic control of circulation in hypertension and congestive heart failure.
Symposium on angiotensin-converting enzyme inhibition in cardiac failure. Oslo, 23 October 1985. Proceedings.
Symptomatic recovery and pharmacological management in a clinical cohort with peripartum cardiomyopathy.
Syndrome of Inappropriate Secretion of Antidiuretic Hormone Associated With Angiotensin-Converting Enzyme Inhibitor Administration.
Synthesis and evaluation of a series of 99mTc(CO)3+ lisinopril complexes for in vivo imaging of angiotensin-converting enzyme expression.
Systemic and coronary haemodynamics and pharmacodynamics of enalapril and enalaprilat in congestive heart failure.
Systemic and regional hemodynamic effects of perindopril in congestive heart failure.
Systemic and renal effects of atrial natriuretic peptide in patients with heart failure treated with angiotensin-converting enzyme inhibitor or in acute saline solution loading.
Systemic hemodynamics, renal function and hormonal levels during inhibition of neutral endopeptidase 3.4.24.11 and angiotensin-converting enzyme in conscious dogs with pacing-induced heart failure.
Systemic vascular resistance during brief withdrawal of angiotensin converting enzyme inhibition in heart failure.
Systemic, pulmonary, brachial, renal and hepato-splanchnic hemodynamic effects of spirapril in severe congestive heart failure.
Systolic versus diastolic heart failure in community practice: clinical features, outcomes, and the use of angiotensin-converting enzyme inhibitors.
Tailoring therapy for ischemic cardiomyopathy: is Laplace's law enough?
Targeting endothelial cell metabolism for cardio-protection from the toxicity of antitumor agents.
Targeting Endothelial Function to Treat Heart Failure with Preserved Ejection Fraction: The Promise of Exercise Training.
Telmisartan, ramipril, or both in high-risk Chinese patients: analysis of ONTARGET China data.
Telmisartan, ramipril, or both in patients at high risk for vascular events.
Temporal patterns in the medical treatment of congestive heart failure with angiotensin-converting enzyme inhibitors in older adults, 1989 through 1995.
Temporal trends in antihypertensive drug prescriptions in Canada before and after introduction of the Canadian Hypertension Education Program.
The ACE2-Ang (1-7)-Mas receptor axis attenuates cardiac remodeling and fibrosis in post-myocardial infarction.
The activated immune system and the renin-angiotensin-aldosterone system in congestive heart failure.
The acute and chronic effects of losartan in heart failure.
The acute haemodynamic effects of quinapril, a new non-sulfhydryl angiotensin converting enzyme inhibitor, in patients with severe congestive cardiac failure.
The acute hemodynamic, hormonal, and pharmacokinetic properties of oral spirapril in patients with moderate to severe heart failure.
The addition of angiotensin receptor blockers to angiotensin-converting enzyme inhibitors--what has time told us?
The advantages of angiotensin II antagonism.
The African American Heart Failure Trial: a clinical trial update.
The ageing spontaneously hypertensive rat as a model of the transition from stable compensated hypertrophy to heart failure.
The AHCPR clinical practice guideline for heart failure revisited.
The Aliskiren Trial to Minimize OutcomeS in Patients with HEart failure trial (ATMOSPHERE): revised statistical analysis plan and baseline characteristics.
The Angiotensin-converting Enzyme Inhibition Post Revascularization Study (APRES).
The angiotensin-converting enzyme inhibitor and aspirin interaction in congestive heart failure: fear or reality?
The anti-ischemic potential of angiotensin-converting enzyme inhibition: insights from the heart outcomes prevention evaluation trial.
The antiarrhythmic effect of the ACE inhibitor captopril in patients with congestive heart failure largely is due to its potassium sparing effects.
The antiarrhythmic potential of angiotensin II antagonism: experience with losartan.
The antiatherogenic potential of blocking the renin-angiotensin system.
The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Heart Failure Validation Study: diagnosis and prognosis.
The appropriate dose of angiotensin-converting-enzyme inhibitors or angiotensin receptor blockers in patients with dilated cardiomyopathy. The higher, the better?
The association between neurohormonal therapy and mortality in older adults with heart failure with reduced ejection fraction.
The Association Between Serum Calcium Levels and Short-Term Mortality in Patients with Chronic Heart Failure.
The barriers to effective management of heart failure in general practice.
The beta-adrenergic receptor-adenylate cyclase complex as a target for therapeutic intervention in heart failure.
The brain is a possible target for an angiotensin-converting enzyme inhibitor in the treatment of chronic heart failure.
The cardiovascular effects of eplerenone, a selective aldosterone-receptor antagonist.
The Carvedilol and ACE-Inhibitor Remodelling Mild Heart Failure EvaluatioN trial (CARMEN)--rationale and design.
The CHARM program: study design leads to findings of clinical and public health importance.
The circulating renin-angiotensin system during treatment with metoprolol or captopril in patients with heart failure due to non-ischaemic dilated cardiomyopathy.
The clinical implications of aldosterone escape in congestive heart failure.
The clinical pharmacology of angiotensin converting enzyme inhibitors in chronic heart failure.
The clinical use of angiotensin converting enzyme inhibitors in hypertension and cardiac failure.
The clinical, cardiac, renal, arterial and neurohormonal effects of omapatrilat, a vasopeptidase inhibitor, in patients with chronic heart failure.
The comparative efficacy and safety of the angiotensin receptor blockers in the management of hypertension and other cardiovascular diseases.
The concept of cardioreparation: Part 2. Medical implications of cardioreparation.
The contributions of sympathetic tone and the renin-angiotensin system to severe chronic congestive heart failure: response to specific inhibitors (prazosin and captopril).
The cost-effective way forward for the management of the patient with heart failure.
The current status of angiotensin converting enzyme inhibitors in the management of patients with chronic heart failure.
The data monitoring experience in the Candesartan in Heart Failure Assessment of Reduction in Mortality and morbidity (CHARM) program.
The DD genotype of the angiotensin-converting enzyme gene is associated with increased mortality in idiopathic heart failure.
The design and properties of N-carboxyalkyldipeptide inhibitors of angiotensin-converting enzyme.
The design of the Mortality Assessment in Congestive Heart Failure Trial (MACH-1, mibefradil).
The Diuretic Potential of Sacubitril/Valsartan: A Tale of 2 Patients.
The diversified pharmacology of angiotensin II-receptor blockade.
The effect of amlodipine and the combination of amlodipine and enalapril on the renin-angiotensin-aldosterone system in the dog.
The Effect of Anemia on Mortality in Indigent Patients With Mild-to-Moderate Chronic Heart Failure.
The effect of benazepril on survival times and clinical signs of dogs with congestive heart failure: Results of a multicenter, prospective, randomized, double-blinded, placebo-controlled, long-term clinical trial.
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
The effect of chronic treatment with trandolapril on cyclic AMP-and cyclic GMP-dependent relaxations in aortic segments of rats with chronic heart failure.
The effect of digoxin on the quality of life in patients with heart failure.
The effect of high dose losartan on erythropoietin resistance in patients undergoing haemodialysis.
The effect of referral for cardiac rehabilitation on survival following acute myocardial infarction: a comparison survival in two cohorts collected in 1995 and 2003.
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
The effect of the angiotensin converting enzyme inhibitor, enalapril, on exercise tolerance and abnormalities of limb blood flow and respiratory function in patients with severe heart failure.
The effect of treatment on survival in congestive heart failure.
The effects of ACE inhibition on progression of atherosclerosis.
The effects of ACE inhibitors on exercise capacity in the treatment of congestive heart failure.
The effects of frusemide and angiotensin-converting enzyme inhibitors and their combination on cardiac and renal haemodynamics in heart failure.
The Effects of LCZ696 in Patients With Hypertension Compared With Angiotensin Receptor Blockers: A Meta-Analysis of Randomized Controlled Trials.
The effects of long-term beta-blockade on the ventilatory responses to exercise in chronic heart failure.
The effects of medication supply on hospitalizations and health-care costs in patients with chronic heart failure.
The effects of sacubitril/valsartan on coronary outcomes in PARADIGM-HF.
The efficacy and safety of chronic oral administration of xamoterol to patients with severe heart failure treated with ACE inhibitors.
The emerging role of ACE inhibitors in the treatment of cardiovascular disease.
The endothelin-aldosterone axis and cardiovascular diseases.
The endothelium and the renin-angiotensin system.
The European trial on reduction of cardiac events with perindopril in stable coronary artery disease (EUROPA).
The evolving role of angiotensin-converting enzyme inhibition in heart failure: expanding the protective envelope.
The history of inhibitors of angiotensin converting enzyme.
The impact of angiotensin-converting enzyme inhibitor therapy on the extracellular collagen matrix during left ventricular assist device support in patients with end-stage heart failure.
The impact of angiotensin-converting enzyme inhibitors on managed care: economic, clinical, and humanistic outcomes.
The impact of beta-receptor blocker addition to high-dose angiotensin-converting enzyme inhibitor-nitrate therapy in heart failure.
The impact of discontinuation of sacubitril-valsartan and shifting to angiotensin-converting enzyme inhibitor or angiotensin receptor blocker in patients with heart failure with reduced ejection fraction.
The impact of race on response to RAAS inhibition.
The implications of a growing evidence base for drug use in elderly patients Part 2. ACE inhibitors and angiotensin receptor blockers in heart failure and high cardiovascular risk patients.
The importance of beta blockers in the treatment of heart failure.
The Influence of Cardiovascular Medications on Iron Metabolism in Patients with Heart Failure.
The influence of dose of angiotensin I-converting enzyme inhibitor on systolic blood pressure variability in heart failure: a substudy of the Assessment of Treatment with Lisinopril and Survival in heart failure (ATLAS) trial.
The influence of posture on the response to loop diuretics in patients with chronic cardiac failure is reduced by angiotensin converting enzyme inhibition.
The kidney in congestive heart failure: renal adverse event rate of treatment.
The management of the diabetic patient with prior cardiovascular events.
The management of ventricular arrhythmias in older patients after CAST.
The multifacetted role of angiotensin converting enzyme inhibitors in congestive heart failure.
The Optimal Haemoglobin Target in Dialysis Patients May Be Determined by Its Contrasting Effects on Arterial Stiffness and Pressure Pulsatility.
The Path to an Angiotensin Receptor Antagonist-Neprilysin Inhibitor in the Treatment of Heart Failure.
The pharmacokinetics of captopril in infants with congestive heart failure.
The pharmacokinetics of lisinopril in hospitalized patients with congestive heart failure.
The physician-hospital team: a successful approach to improving care in a large academic medical center.
The Positive Effects of Exercise in Chemotherapy-Related Cardiomyopathy.
The potential role of calcium antagonists in the management of congestive heart failure: initial experience with lacidipine.
The Preventive Role of Angiotensin Converting Enzyme Inhibitors/Angiotensin-II Receptor Blockers and ?-Adrenergic Blockers in Anthracycline- and Trastuzumab-Induced Cardiotoxicity.
The push, the pull and the periphery.
The rational use of beta-adrenoceptor blockers in the treatment of heart failure. The changing face of an old therapy.
The rationale and design of the PERindopril GENEtic association study (PERGENE): a pharmacogenetic analysis of angiotensin-converting enzyme inhibitor therapy in patients with stable coronary artery disease.
The relationship of the erythrocyte sedimentation rate to inflammatory cytokines and survival in patients with chronic heart failure treated with angiotensin-converting enzyme inhibitors.
The renal and cardiovascular effects of natriuretic peptides.
The renin-angiotensin system as a risk factor and therapeutic target for cardiovascular and renal disease.
The renin-angiotensin system in essential hypertension: associations with cardiovascular risk.
The renin-angiotensin system in heart failure.
The renin-angiotensin-aldosterone system and catecholamines in chronic congestive heart failure. Effect of angiotensin I converting enzyme inhibitor SQ 14225 (Captopril).
The renin-angiotensin-aldosterone system and myocardial collagen matrix remodelling in congestive heart failure.
The renin-angiotensin-aldosterone system: a pivotal role in insulin sensitivity and glycemic control.
The Renin-Angiotensin-Aldosterone System: Approaches to Guide Angiotensin-Converting Enzyme Inhibition in Patients with Coronary Artery Disease.
The role and regulation of cardiac angiotensin-converting enzyme for noninvasive molecular imaging in heart failure.
The role of angiotensin receptor blockers in the management of chronic heart failure.
The role of angiotensin receptor-neprilysin inhibitors in cardiovascular disease-existing evidence, knowledge gaps, and future directions.
The role of angiotensin-converting enzyme polymorphism in congestive heart failure.
The role of beta-blockers in the treatment of cardiomyopathy and ischaemic heart failure.
The role of BNP testing in heart failure.
The role of coronary endothelial function testing in patients suspected for angina pectoris.
The Role of Digoxin in the Treatment of Chronic Congestive Heart Failure.
The role of existing and newer calcium channel blockers in the treatment of hypertension.
The role of genetic variants in angiotensin I converting enzyme, angiotensinogen and the angiotensin II type-1 receptor in the pathophysiology of heart muscle disease.
The role of inflammation in the pathogenesis of heart failure.
The role of organic nitrates in the treatment of heart failure.
The role of the renin-angiotensin system blocking in the management of atrial fibrillation.
The role of the renin-angiotensin-aldosterone system in heart failure.
The role of the renin-angiotensin-aldosterone system in the management of heart failure.
The safety and tolerability of quinapril.
The safety of ACE inhibitors for the treatment of hypertension and congestive heart failure.
The safety of spironolactone treatment in patients with heart failure.
The safety profile of quinapril: is there a difference among ACE inhibitors?
The SEISICAT study: a pilot study assessing efficacy and safety of spironolactone in cats with congestive heart failure secondary to cardiomyopathy.
The serum angiotensin-converting enzyme 2 and angiotensin-(1-7) concentrations after optimal therapy for acute decompensated heart failure with reduced ejection fraction.
The sudden demise of dual renin-angiotensin system blockade or the soft science of the surrogate end point.
The treatment of heart failure: the role of neurohumoral activation.
The two fACEs of the tissue renin-angiotensin systems: implication in cardiovascular diseases.
The underutilization of cardiac medications of proven benefit, 1990 to 2002.
The use of angiotensin-converting enzyme inhibitors and other drugs with cardiovascular effects by non-demented and demented elderly with a clinical diagnosis of heart failure. A population-based study of the very old.
The use of angiotensin-converting enzyme inhibitors in congestive heart failure.
The use of angiotensin-converting enzyme inhibitors in heart failure.
The use of angiotensin-converting enzyme inhibitors in patients undergoing coronary artery bypass graft surgery.
The use of angiotensin-converting enzyme inhibitors in the treatment and prevention of congestive heart failure.
The use of angiotensin-converting enzyme inhibitors in the treatment of heart failure in hospital practice.
The Use of Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers Is Associated with the Recovered Ejection Fraction in Patients with Dilated Cardiomyopathy.
The use of guideline recommended beta-blocker therapy in primary prevention implantable cardioverter defibrillator patients: insight from Danish nationwide registers.
The use of metoprolol CR/XL in the treatment of patients with diabetes and chronic heart failure.
The use of microcalorimetry and HPLC for the determination of degradation kinetics and thermodynamic parameters of Perindopril Erbumine in aqueous solutions.
The value of angiotensin converting enzyme inhibitors for the treatment of patients with left ventricular dysfunction, heart failure or after acute myocardial infarction.
The Warfarin and Antiplatelet Therapy in Heart Failure trial (WATCH): rationale, design, and baseline patient characteristics.
Theoretical basis for the use of angiotensin II antagonists in the treatment of heart failure.
Therapeutic achievements of phosphodiesterase inhibitors and the future.
Therapeutic efficacy of a combination of a beta1-adrenoreceptor (AR) blocker and beta2-AR agonist in a rat model of postmyocardial infarction dilated heart failure exceeds that of a beta1-AR blocker plus angiotensin-converting enzyme inhibitor.
Therapeutic implications of escape from angiotensin-converting enzyme inhibition in patients with chronic heart failure.
Therapeutic interventions to reduce rates of hospitalization and death in patients with heart failure: new clinical evidence.
Therapeutic investigations of novel indoxyl-based indolines: A drug target validation and Structure-Activity Relationship of angiotensin-converting enzyme inhibitors with cardiovascular regulation and thrombolytic potential.
Thiazide and loop diuretics.
Thirty Years of Evidence on the Efficacy of Drug Treatments for Chronic Heart Failure With Reduced Ejection Fraction: A Network Meta-Analysis.
Time and technology will tell: the pathophysiologic basis of neurohormonal modulation in heart failure.
Tissue angiotensin II system in the human heart.
Tissue angiotensin-converting enzyme inhibitors for the prevention of cardiovascular disease in patients with diabetes mellitus without left ventricular systolic dysfunction or clinical evidence of heart failure: a pooled meta-analysis of randomized placebo-controlled clinical trials.
Tissue expression of components of the renin-angiotensin system in experimental post-infarction heart failure in rats: effects of heart failure and angiotensin-converting enzyme inhibitor treatment.
Tissue-specific activation of cardiac angiotensin converting enzyme in experimental heart failure.
Titration of vasodilator therapy in chronic heart failure according to plasma brain natriuretic peptide concentration: randomized comparison of the hemodynamic and neuroendocrine effects of tailored versus empirical therapy.
TNF and congestive heart failure: therapeutic possibilities.
Tolerability of enalapril in congestive heart failure.
Tolerability of extended duration intravenous milrinone in patients hospitalized for advanced heart failure and the usefulness of uptitration of oral angiotensin-converting enzyme inhibitors.
Tolerance to ACE inhibitors after cardiac surgery.
Toleration of high doses of angiotensin-converting enzyme inhibitors in patients with chronic heart failure: results from the ATLAS trial. The Assessment of Treatment with Lisinopril and Survival.
Towards 2001: will ACE inhibitors have a role in atherosclerosis treatment?
Towards the better treatment of heart failure.
Trandolapril. An update of its pharmacology and therapeutic use in cardiovascular disorders.
Trandolapril: a newer angiotensin-converting enzyme inhibitor.
Transcriptional changes associated with recovery from heart failure in the SHR.
Transdermal delivery of Angiotensin Converting Enzyme inhibitors.
Translation of clinical trial results into practice.
Treating patients with severe heart failure.
Treating the Patient with Kidney Failure to Reduce Cardiovascular Disease Risk.
Treatment Effectiveness in Heart Failure with Comorbidity: Lung Disease and Kidney Disease.
Treatment of chronic congestive heart failure with captopril, an oral inhibitor of angiotensin-converting enzyme.
Treatment of chronic heart failure in long-term care facilities: implications of recent heart failure guidelines recommendations.
Treatment of chronic systolic heart failure secondary to Chagas heart disease in the current era of heart failure therapy.
Treatment of congestive heart failure a neuroendocrine disorder.
Treatment of congestive heart failure. II. Vasodilators and angiotensin-converting enzyme inhibitors.
Treatment of early heart failure: an ACEI or a beta-blocker first?
Treatment of heart failure in older persons. Dilemmas with coexisting conditions: diabetes mellitus, chronic obstructive pulmonary disease, and arthritis.
Treatment of Heart Failure in Real-World Clinical Practice: Findings From the REFLECT-HF Registry in Patients With NYHA Class II Symptoms and a Reduced Ejection Fraction.
Treatment of heart failure with fosinopril: an angiotensin converting enzyme inhibitor with a dual and compensatory route of excretion.
Treatment of high-risk African American patients: left ventricular dysfunction, heart failure, renal disease, and postmyocardial infarction.
Treatment of Hyperkalemia in Heart Failure.
Treatment of hypertension in patients with comorbidities: results from the study of hypertensive prescribing practices (SHyPP).
Treatment of Hypertension in Patients with Coronary Artery Disease. A Case-Based Summary of the 2015 AHA/ACC/ASH Scientific Statement.
Treatment of severe heart failure: quantity or quality of life? A trial of enoximone. Enoximone Investigators.
Treatment of systemic hypertension in patients with pulmonary disease: COPD and asthma.
Treatment of systolic heart failure in the elderly: an evidence-based review.
Treatment of the elderly post-myocardial infarction patient.
Treatment of ventricular arrhythmias in older adults.
Treatment optimization of angiotensin converting enzyme inhibitors and associated factors in Ayder Comprehensive Specialized Hospital: a cross-sectional study.
Treatment strategies for isolated systolic hypertension in elderly patients.
Treatment with angiotensin converting enzyme inhibitors, angiotensin-II-antagonists and beta-blockers in an unselected group of patients with chronic heart failure.
Treatment with Optimal Dose Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers Has a Positive Effect on Long-Term Survival in Older Individuals (Aged >70 Years) and Octogenarians with Systolic Heart Failure.
Treatment with renin-angiotensin system inhibitors and prognosis of heart failure with preserved ejection fraction: A propensity-matched study in the community.
Treatment with verapamil and trandolapril in patients with congestive heart failure and myocardial infarction. The Danish Verapamil Infarction Trial (DAVIT Study Group).
Trends and inequities in beta-blocker prescribing for heart failure.
Trends in Kidney Function Outcomes Following RAAS Inhibition in Patients With Heart Failure With Reduced Ejection Fraction.
Trends of congestive heart failure epidemiology: contrast with clinical trial results.
Twice-daily administration of a long-acting angiotensin-converting enzyme inhibitor has greater effects on neurohumoral factors than a once-daily regimen in patients with chronic congestive heart failure.
Type 2 diabetes mellitus and heart failure.
Type 2 diabetes--the pharmacotherapy of glycaemic control and risk factor modification.
Ultrasonic tissue characterization of end-stage dilated cardiomyopathy.
Under pressure: future prospects in hypertension management. Interview by Laura Dormer.
Understanding the early mortality benefit observed in the PARADIGM-HF trial: considerations for the management of heart failure with sacubitril/valsartan.
Undertreatment of congestive heart failure in an Australian setting.
Underuse of standard care and outcome of patients with acute myocardial infarction and chronic renal insufficiency.
Underutilization and clinical benefits of angiotensin-converting enzyme inhibitors in patients with asymptomatic left ventricular dysfunction.
Underutilization of angiotensin converting enzyme inhibitors among heart failure patients.
Underutilization of angiotensin-converting enzyme inhibitors in older patients with Q-wave anterior myocardial infarction in an academic hospital-based geriatrics practice.
Unequal effects of renin-angiotensin system inhibitors in acute cardiac dysfunction induced by isoproterenol.
Up-titrating angiotensin-converting enzyme inhibitors in heart failure: evidence and challenges.
Update of recent clinical trials in heart failure and myocardial infarction.
Update on digoxin therapy in congestive heart failure.
Update on the drug treatment of hypertension in patients with cardiovascular disease.
Update on the management of hypertension: recent clinical trials and the JNC 7.
Update on the medical treatment of stable angina.
Update on therapy for heart failure.
Urocortin 2 combined with angiotensin-converting enzyme inhibition in experimental heart failure.
Use and Interpretation of Propensity Scores in Aging Research: A Guide for Clinical Researchers.
Use of a clinical audit to promote the quality use of medicines to rural and remote general practitioners.
Use of ACE Inhibitors for Secondary Prevention.
Use of angiotensin-converting enzyme inhibitor therapy and dose-related outcomes in older adults with new heart failure in the community.
Use of angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker therapy to reduce cardiovascular events in high-risk patients: Part 1.
Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers During the COVID-19 Pandemic: A Modeling Analysis.
Use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in clinical practice.
Use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with congestive heart failure: an observational study of treatment rates and clinical outcome.
Use of angiotensin-converting enzyme inhibitors and variations in cognitive performance among patients with heart failure.
Use of angiotensin-converting enzyme inhibitors in elderly people with heart failure: prevalence and outcomes.
Use of angiotensin-converting enzyme inhibitors in heart failure and renal insufficiency.
Use of angiotensin-converting enzyme inhibitors in heart failure with preserved left ventricular systolic function.
Use of angiotensin-converting enzyme inhibitors in patients with heart failure and renal insufficiency: how concerned should we be by the rise in serum creatinine?
Use of Angiotensin-Converting Enzyme Inhibitors, Angiotensin Receptor Blockers, and Risk of Dementia in Heart Failure.
Use of aspirin in conjunction with angiotensin-converting enzyme inhibitors does not worsen long-term survival in heart failure.
Use of converting enzyme inhibitors in patients with asymptomatic left ventricular dysfunction.
Use of Heart Failure Medical Therapies Among Patients With Left Ventricular Assist Devices: Insights From INTERMACS.
Use of medications to reduce cardiovascular risk among individuals with psychotic disorders and Type 2 diabetes.
Use of noninvasive hemodynamics to aid decision making in the initiation and titration of neurohormonal agents.
Use of quinapril in the elderly patient.
Use of Sacubitril/valsartan in patients with cardio toxicity and heart failure due to chemotherapy.
Use of spironolactone in heart failure patients receiving angiotensin-converting enzyme inhibitors and beta-blockers.
Use of valsartan for the treatment of heart-failure patients not receiving ACE inhibitors: a budget impact analysis.
Usefulness of (123)I-BMIPP with myocardial imaging for evaluation of the efficacy of drug therapy in patients with chronic heart failure.
Usefulness of C-reactive protein as an independent predictor of death in patients with ischemic cardiomyopathy.
Usefulness of patch tests for diagnosing selective allergy to captopril.
Using cardiac biomarkers and treating cardiotoxicity in cancer.
Utilization and Dose Optimization of Angiotensin-Converting Enzyme Inhibitors among Heart Failure Patients in Southwest Ethiopia.
Utilization and dosing of angiotensin-converting enzyme inhibitors for heart failure. Effect of physician specialty and patient characteristics.
VALIANT (VALsartan In Acute myocardial iNfarcTion) trial.
Validity of cardiovascular prescriptions to the guidelines in the elderly according to the STOPP and START method.
Valsartan benefits left ventricular structure and function in heart failure: Val-HeFT echocardiographic study.
VALsartan In Acute myocardial iNfarcTion (VALIANT) trial: baseline characteristics in context.
Valsartan in chronic heart failure.
Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both.
Valsartan: the past, present and future.
Value of digoxin in heart failure and sinus rhythm: new features of an old drug?
Variation in captopril formulations in pharmacies across Canada.
Variation in use and dosing escalation of renin angiotensin system, mineralocorticoid receptor antagonist, angiotensin receptor neprilysin inhibitor and beta-blocker therapies in heart failure and reduced ejection fraction: Association of comorbidities.
Various approaches to blockade of the renin-angiotensin system: persistent renin response.
Vascular and myocardial protective effects of converting enzyme inhibition in experimental heart failure.
Vascular B1 kinin receptors in patients with congestive heart failure.
Vascular renin-angiotensin-system, endothelial function and atherosclerosis?
Vasodilation by urapidil in the treatment of chronic congestive heart failure in addition to angiotensin-converting enzyme inhibitors is not beneficial: results of a placebo-controlled, double-blind study.
Vasodilator therapy for acute heart failure: haemodynamic comparison of hydralazine/isosorbide, alpha-adrenoceptor blockade, and angiotensin-converting enzyme inhibition.
Vasodilator therapy for congestive heart failure. Lessons from mortality trials.
Vasodilator therapy in chronic congestive heart failure.
Vasodilator therapy of severe congestive heart failure: the special importance of angiotensin-converting enzyme inhibition with captopril.
Vasodilators for heart failure--useful or useless?
Vasopeptidase inhibition with omapatrilat in chronic heart failure: acute and long-term hemodynamic and neurohumoral effects.
Vasopeptidase inhibitors: will they have a role in clinical practice?
Vasoplegic syndrome after cardiovascular surgery: A review of pathophysiology and outcome-oriented therapeutic management.
Ventricular arrhythmias in heart failure.
Ventricular remodeling after myocardial infarction. Experimental and clinical studies.
Ventricular remodeling following myocardial infarction.
Ventricular remodeling in heart failure.
Ventricular remodeling.
Ventricular unloading and improvement in left ventricular function after angiotensin converting enzyme inhibition with enalapril in patients with chronic congestive heart failure.
Verapamil and angiotensin-converting enzyme inhibitors in patients with coronary artery disease and reduced left ventricular ejection fraction.
Viral myocarditis and dilated cardiomyopathy: mechanisms, manifestations, and management.
Viral Myocarditis.
Was the Enalapril Dose Too Low in the PARADIGM-HF Trial?
Weight loss, muscle strength, and angiotensin-converting enzyme inhibitors in older adults with congestive heart failure or hypertension.
What can we learn from Europe?
What does ATLAS really tell us about "high" dose angiotensin-converting enzyme inhibition in heart failure?
What is the ideal study design for evaluation of treatment for heart failure? Insights from trials assessing the effect of ACE inhibitors on exercise capacity.
What is the optimal angiotensin-converting enzyme inhibitor dose in heart failure?
What is the optimal medical management of ischaemic heart failure?
What is the role of angiotensin-converting enzyme inhibitors in congestive heart failure and after myocardial infarction?
When and how to use angiotensin-converting enzyme inhibition in congestive heart failure.
When Conventional Heart Failure Therapy is not Enough: Angiotensin Receptor Blocker, Direct Renin Inhibitor, or Aldosterone Antagonist?
Which drug should be used to treat patients with uncomplicated essential hypertension?
Who should be treated with angiotensin-converting enzyme inhibitors after myocardial infarction?
Why are angiotensin converting enzyme inhibitors underutilised in the treatment of heart failure by general practitioners?
Why are physicians not prescribing diuretics more frequently in the management of hypertension?
Why do patients die after myocardial infarction?
Why renin inhibitors?
Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors.
Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors. RADIANCE Study.
Within-patient comparison of effects of different dosages of enalapril on functional capacity and neurohormone levels in patients with chronic heart failure.
WORSENING RENAL FUNCTION IN ACUTE DECOMPENSATED HEART FAILURE: A BAD SIGN, OR MAYBE NOT?
Wound healing: captopril, an angiogenesis inhibitor, and Staphylococcus aureus peptidoglycan.
Xamoterol in severe heart failure. The Xamoterol in Severe Heart Failure Study Group.
[A case of severe heart failure complicating chronic hemodialysis in which angiotensin converting enzyme inhibitor was markedly effective]
[ACE inhibitor or ATII receptor blocker in heart failure and myocardial infarction?]
[ACE-inhibitors in the treatment of chronic heart failure: pathophysiologic principles of protective effects]
[Acetylsalicylic acid antagonism vs ACE inhibitor in congestive heart failure as shown by a diminished respiratory and exercise capacity]
[Acute and chronic heart failure].
[Addition of beta blockers in chronic heart failure]
[Adherence to guidelines in CHF therapy in Germany]
[Ambulatory management of patients after myocardial infarction]
[Analysis of the mitochondrial function and ultrastructure in healthy albino mice treated with heart failure medications]
[Angioedema and angiotensin converting enzyme inhibitors: a report of 19 cases]
[Angioneurotic edema in relation to therapeutic use of angiotensin-converting enzyme inhibitor]
[Angiotensin converting enzyme inhibitors in acute period of myocardial infarction: the place of zofenopril]
[Angiotensin converting enzyme inhibitors in arterial hypertension and cardiac failure. The question of the dose]
[Angiotensin converting enzyme inhibitors in the treatment of heart failure]
[Angiotensin I-converting enzyme inhibitors in the treatment of congestive heart failure]
[Angiotensin II antagonists: new therapeutic perspectives]
[Angiotensin II AT1 receptor antagonists: clinical development and future perspectives]
[Angiotensin II receptor blocker add-on therapy for low cardiac output in decompensated heart failure]
[Angiotensin-converting enzyme inhibition and cardiovascular prevention: more than twenty years of clinical success]
[Angiotensin-converting enzyme inhibition--new methods in the treatment of arterial hypertension and heart failure]
[Angiotensin-converting enzyme inhibition: a pathophysiologically based concept for the therapy of hypertension and heart failure]
[Angiotensin-converting enzyme inhibitor in heart failure]
[Angiotensin-converting enzyme inhibitor treatment of heart failure due to dilated cardiomyopathy]
[Angiotensin-converting enzyme inhibitors :from vasoactive drugs to cardiovascular prevention tools]
[Angiotensin-converting enzyme inhibitors as first choice drugs in chronic congestive heart failure]
[Angiotensin-converting enzyme inhibitors as neutralizers of hydroxyl radical]
[Angiotensin-converting enzyme inhibitors in congestive heart failure: clinical practice guidelines]
[Angiotensin-converting enzyme inhibitors in heart failure]
[Angiotensin-converting enzyme inhibitors in the treatment of heart failure: toward a change in the natural history of the disease]
[Angiotensin-converting enzyme inhibitors: recent therapeutic aspect]
[Angiotensin-converting enzyme, quinapril, in treating chronic cardiac failure]
[Anthracycline-induced cardiomyopathy.]
[Anti-aldosterone therapy in severe heart failure]
[Anti-ischemic and infarction-reducing effects of angiotensin-converting enzyme inhibitors]
[Antihypertensive drugs in diabetic's hypertension]
[Arterial hypertension and systolic left ventricular dysfunction: therapeutic approach]
[Arterial hypotension in myocardial revascularization surgery: influence of angiotensin-converting enzyme inhibitors.]
[Assessment of medical management of heart failure at National Hospital Blaise COMPAORE].
[Assessment of the efficacy of bisoprolol administration by cardiopulmonary exercise testing in patients with heart failure]
[Association between serum cardiac troponin I and myocardial remodeling in patients with chronic heart failure]
[Association of atherosclerosis and cardiac cell dysfunction]
[Association of polymorphic markers I/D of gene ACE and A1166C of gene AT2R1 with ischemic chronic heart failure in the Russian and Tatar populations of Bashkortostan Republic]
[Beta-blockers and new drugs for cardiac failure]
[Calcium antagonists and treatment of chronic heart failure]
[Can pharmacotherapy in heart failure affect mortality?]
[Captopril in the treatment of heart failure]
[Captopril in the treatment of patients with congestive heart failure. Its bicycle ergometry evaluation]
[Captopril inhibits angiotensin converting enzyme. New principles for therapy in hypertension and heart failure]
[Captopril versus digoxin in the treatment of mild to moderately severe heart failure]
[Captopril-induced toxic hepatitis]
[Cardiac insufficiency: what treatment? what dose? For which patients? Converting enzyme inhibitors and diuretics]
[Cardiac involvement in dystrophinopathies].
[Cardiovascular agents in the elderly: main rules to optimize their use]
[Cardiovascular pharmacology (IX). Angiotensin-converting enzyme inhibitors in hypertension and heart failure]
[Change of circadian pattern of arterial pressure in patients with congestive heart failure treated with perindopril, an inhibitor of angiotensin-converting enzyme (ACE)]
[Changes in lipid spectrum in rats with chronic heart failure of different severity on the background of angiotensin-converting enzyme inhibitors and beta-adrenoblockers].
[Changes in Parameters of Coagulation System After Treatment of Chronic Heart Failure with ?-Adrenoblockers, Angiotensin-Converting Enzyme Inhibitors, Calcium Antagonists, Diuretics, Anticoagulants, Antiagregants, Cardiac Glycosides, and Physical Exercise].
[Characteristics of the patients with heart disease in a health area of A Coruña province. Barbanza 2000 study]
[Chemotherapy and cardiotoxicity]
[Chronic anemia in heart transplant patients: prevalence, predisposing factors and prognostic significance]
[Chronic heart failure]
[Clinical and hemodynamic effects of nisoldipine and captopril in heart failure: a double-blind comparative study of long and short-term effects]
[Clinical findings with inhibitors of the renin-angiotensin system]
[Clinical pharmacology of angiotensin II antagonists]
[Clinical sequelae of tissue angiotensin converting enzyme inhibition: practicability of use in ischemic heart disease]
[Clinical study of the month. The EUROPA study: cardiovascular protection with perindopril in patients with stable coronary heart disease]
[Clinical, haemodynamic and biochemical effects of angiotensin-converting enzyme inhibition in chronic refractory cardiac failure (author's transl)]
[Clinical, hemodynamic and neurohumoral effects of long-term therapy of patients with severe chronic heart failure with beta-adrenoblocker bisoprolol]
[Comparison between the effects of angiotensin-converting enzyme inhibitors and angiotensin II antagonists]
[Congestive heart insufficiency. Prophylactic aspects]
[Contemporary approaches to diagnosis and management of chronic heart failure (summary of the American College of Cardiology/American Heart Association Guidelines)]
[Conversion enzyme inhibitors against the progression of renal and vascular diseases: yes but again]
[Converting enzyme inhibitors and acute renal insufficiency--precautions to be taken]
[Converting enzyme inhibitors and aims of the objectives of the treatment of cardiac failure]
[Converting enzyme inhibitors and cardiac insufficiency: current findings and perspectives]
[Converting enzyme inhibitors in acute myocardial infarct and heart failure]
[Correlations between plasma concentrations of atrial natriuretic factor and right ventricular function in patients with severe cardiac failure]
[Digitalis and beta-blockers: what treatment, what dose and for which patient?]
[Digitalis, diuretic and vasodilator treatment of cardiac failure]
[Digoxin and angiotensin-converting enzyme inhibitors in the treatment of chronic congestive heart failure]
[Do cytokines have any value in the patients with chronic blood circulation insufficiency?]
[Double-blind clinical and echocardiographic study of oral enoximone versus placebo in severe cardiac insufficiency]
[Drug prospects in the treatment of heart insufficiency]
[Drug therapy of cardiac insufficiency: status 1995]
[Dry cough in the elderly patients treated with angiotensin converting enzyme inhibitor]
[Effect of aldosterone antagonism in heart failure: pharmacotherapeutic options]
[Effect of angiotensin converting enzyme inhibitor lisinopril on sympathetic heart rate response during exercise in the early phase of acute myocardial infarction]
[Effect of angiotensin-converting enzyme inhibitors in congestive heart failure]
[Effect of angiotensin-converting enzyme inhibitors, beta-adrenoblockers, and their combinations on survival and plasma catecholamine levels in rats with chronic heart failure with induced exacerbations].
[Effect of beta-Blocker Bisoprolol on Function of Hibernating Myocardium in Patients With Chronic Heart Failure of Ischemic Etiology]
[Effect of captopril on glutathione level in the liver and paracetamol-induced liver damage in rats]
[Effect of enalapril on restrictive type diastolic filling disorder in severe congestive heart failure]
[Effect of the polymorphism of the angiotensin-converting enzyme gene on the drug treatment in patients with chronic heart failure]
[Effect of the polymorphism of the angiotensin-converting enzyme gene on the plasma angiotensin II levels and the risk of chronic heart failure]
[Effects of angiotensin converting enzyme inhibitor on short time prognosis in patients with chronic heart failure combined with paroxysmal atrial fibrillation.]
[Effects of angiotensin converting enzyme inhibitor with different doses on plasma brain natriuretic peptide and norepinephrine in patients with chronic heart failure]
[Effects of angiotensin-converting enzyme inhibitors and cosaar on quality of life of patients with pulmonary tuberculosis and chronic heart failure]
[Effects of angiotensin-converting enzyme inhibitors in heart failure]
[Effects of long term therapy with angiotensin converting enzyme inhibitor quinapril, antagonist of receptors to angiotensin II valsartan, and combination of quinapril and valsartan in patients with moderate chronic heart failure. Main results of the SADKO-CHF study]
[Efficacy of angiotensin II receptor antagonists as a novel drug for the treatment of chronic heart failure--in comparison with ACE inhibitors]
[Efficiancy Angiotensin -converting enzyme inhibitors for the clinical practice].
[Endothelial dysfunction in cardial failure: potential mechanisms]
[Enzyme converting inhibitors. Current knowledge and perspectives]
[Epidemiology and treatment of chronic heart failure; use of bisoprolol].
[Evidence-based management of right heart failure: a systematic review of an empiric field]
[From basic research to clinical results. The OVERTURE, ENABLE, and RENEWAL studies]
[From bench to bedside: new insights into the treatment of heart failure].
[Functional acute kidney failure]
[Growth stimulating properties of angiotensin II on the heart: consequences for therapy of heart failure]
[Guideline 'Chronic heart failure']
[Guidelines for the therapy of heart failure: importance of the treatment individualization]
[Heart failure in advanced age]
[History of the renin-angiotensin system: great men, a great finding].
[How and to what extent has beta-blocker treatment been established for chronic heart failure?]
[How to handle cardiovascular treatments during general anesthesia?]
[Hyperkalemia - Pathophysiology, prognostic significance and treatment options].
[Hyperkalemia as a limiting factor in the use of drugs that block the Renin Angiotensin Aldosterone System (RAAS)].
[Hypotension followed the first dose of angiotensin-converting enzyme inhibitor in patients with heart failure (a multicenter clinical trial)]
[I/D angiotensin-converting enzyme gene polymorphism: structural changes in the myocardium and predictive value in chronic heart failure].
[Idiopathic Dilated Cardiomyopathy-an Appraisal in 2005.]
[Influence of medical treatments on the functional status in patients with chronic cardiac insufficiency]
[Interaction between antiplatelet agents and angiotensin-converting enzyme inhibitors]
[Interaction of angiotensin converting enzyme inhibitors with nonsteroidal antiinflammatory drugs]
[Is it necessary to discontinue captopril before heart surgery?]
[Is triple combination of different neurohormonal modulators recommended for treatment of mild-to-moderate congestive heart failure patients? (Results of Sadko-CHF study)]
[Isolated non-compaction of left ventricle in childhood: clinical experience with 5 cases]
[JMIC-B study and its sub-analyses: effect of nifedipine in Japanese hypertensive patients with coronary artery disease]
[Late drug-induced hyperkalemia in a patient with congestive heart failure]
[Levosimendan: a new option in the pharmacologic management of cardiac insufficiency]
[Life threatening drug-induced hyperkaliemia--case report]
[Long-term treatment of chronic heart failure by an inhibitor of angiotensin converting enzyme]
[Malignant arrhythmias caused by hyperkalemia: a new area of drug-induced electrolyte abnormalities]
[Management of atherosclerotic renal artery stenoses]
[Management of cardiac failure: a guilty one easy to target!].
[Management of heart failure by French general practitioners in 2003]
[Management of heart failure: a challenge for healthcare systems].
[Medical treatments in aortic stenosis: role of statins and angiotensin-converting enzyme inhibitors].
[Mineralocorticoid receptor antagonists and therapeutic strategies of cardiovascular damage].
[Modern therapy of cardiac insufficiency]
[Modification of hemodynamics by angiotensin converting enzyme inhibitors in heart failure]
[Moexipril and cardiovascular diseases in women: is there a reason for optimism?]
[Myocarditis in a cachectic female, nonsteroidal anti-inflammatory drugs abuser, in a course of progressive systemic sclerosis]
[New knowledge on the subject of therapy in cardiac decompensation in the light of large trials]
[New pharmacologic therapies for chronic heart failure].
[Nitrate derivatives and cardiac insufficiency]
[No advantage of the combination of ACE-inhibition and angiotensin receptor blockade in patients with high cardiovascular risk]
[Optimal treatment of chronic heart failure--with particular emphasis on angiotensin-converting enzyme (ACE) inhibitors]
[Peroxisome proliferator-activated receptors-alpha (PPAR-alpha) and chronic heart failure: is there a reason to discuss the metabolic strategy of treatment?].
[Pharmacogenomic control of angiotensin converting enzyme gene I/D polymorphism predominant risk factor of development of chronic heart failure and target of enalapril treatment].
[Pharmacological correction of hyperactivity of Renin-Angiotensin-aldosteron system.]
[Pharmacological therapy of heart failure with reduced ejection fraction].
[Pharmacotherapy of chronic heart failure in clinical practice]
[Physical activity and sports in heart failure due to myocarditis and dilated cardiomyopathy]
[Physical training in chronic heart failure: pathophysiology and clinical evolution].
[Physiopathologic bases for the use of angiotensin converting enzyme inhibitors in congestive heart failure]
[Physiopathological basis of the treatment of heart failure]
[Polymorphism of the ACE gene, structural-functional state of the left ventricle in patients with post-infarction cardiac failure and effects of the ACE-inhibitor Perindopril]
[Positive inotropic agents]
[Postpartum dyspnea, edema and fever]
[Practical difficulties in drug prescription in chronic cardiac insufficiency]
[Practice guidelines of the Spanish Society of Cardiology. Cardiac and heart-lung transplants]
[Preliminary exploration on effect of yiqi wenyang huoxue lishui treatment on neuroendocrine system in patients with congestive heart failure]
[Prevention and treatment of congestive heart failure in diabetic patients]
[Prevention and treatment of ischemic heart disease in patients with diabetes mellitus]
[Prevention with angiotensin-converting enzyme (ACE) inhibitors]
[Progress in treatment of chronic heart failure in Western medicine and treatment strategies in traditional Chinese medicine]
[Protective effects of perindopril in an experimental model of cardiomyopathy]
[Rational therapy of heart failure]
[Rationale, characteristics and study design of PREAMI (Perindopril and Remodelling in the Elderly with Acute Myocardial Infraction)]
[Recent aspects of cardiologic therapy in advanced age]
[Recommendations for the treatment of heart failure : What's new?].
[Regional blood flow in congestive cardiac failure and inhibition of angiotensin converting enzyme]
[Renal function after administration of angiotensin-converting enzyme inhibitors]
[Renal side effects of angiotensin converting enzyme inhibitors]
[Renin-angiotensin system and its role in cardiovascular physiopathology and therapy]
[Resistance to ACE inhibitors. Myth or reality?]
[Respiratory and renal functions and blood electrolytic composition in patients with pulmonary tuberculosis in the treatment of heart failure]
[Revascularization of atherosclerotic stenosis of the renal artery. Indications and results]
[Review of randomized trials of angiotensin receptor blockers in the treatment of patients with congestive heart failure]
[Risk factors for recurrent hospitalizations of patients with atrial fibrillation].
[Role of angiotensin-converting enzyme inhibitors in the treatment of heart failure in the 21st century]
[Role of digitalis derivatives in the treatment of cardiac insufficiency with sinusal rhythm]
[Sacubitril/valsartan, a new and effective treatment for heart failure with reduced ejection fraction].
[Serum potassium levels and long-term mortality in the elderly with hypertension].
[Should Angiotensin-converting enzyme inhibitors be continued over the long term in patients whose left ventricular ejection fraction normalizes after an episode of acute myocarditis?]
[Should cardiac insufficiency be first treated by angiotensin converting enzyme inhibitors?]
[Significance of neuroendocrine parameters in heart failure]
[Similar reduction in new cases of type 2 diabetes with angiotensin receptor blocker and ACE inhibitor: comparison of meta-analyses of prospective randomised trials]
[Spironolactone: renaissance of anti-aldosterone therapy in heart failure?]
[Study of the month. The RALES study (randomized aldactone evaluation study]
[Sudden death and chronic cardiac insufficiency]
[Symptoms of primary endocardial fibroelastosis in a young adult]
[Temporal trends in pharmacological therapy in the IN-CHF registry from 1995 to 2005]
[Terminal heart failure; therapeutic strategies. Drug therapy in cases of absence of possibility of heart transplantation: dobutamine therapy, aspects of compassion?]
[The angiotensin-converting enzyme inhibitor perindopril in the treatment of congestive heart failure]
[The clinical efficacy of the first Russian angiotensin-converting enzyme inhibitor methiopril in patients with heart failure]
[The clinical pharmacology of angiotensin II antagonists]
[The effects of nitric oxide and endothelia levels on plasma in patients with chronic heart failure]
[The efficacy of treatment with the angiotensin-converting enzyme inhibitor ramipril in patients with congestive heart failure of rheumatic etiology]
[The influence of 3-month treatment with molsidomine on structure, function and some neurohormonal parameters in patients with chronic heart failure treated with digoxin, diuretic and angiotensin converting enzyme inhibitors]
[The main aspects of symptomatic therapy of chronic heart failure]
[The problem of sudden death in heart failure]
[The process of drug development. The "case" of spironolactone]
[The renin-angiotensin system in cardiovascular diseases]
[The role of angiotensin converting enzyme inhibition for therapy of patients with hypertension and heart failure]
[The role of diabetes mellitus in cardiac disease in Spain. The CARDIOTENS Study 1999]
[The significance of converting enzyme inhibitor angiotensin I to angiotensin II in treatment of patients with coronary disease]
[The treatment of heart decompensation using angiotensin converting enzyme inhibitors. Pharmaco-economic aspects]
[The use of angiotensin converting enzyme inhibitors in patients after myocardial infarction]
[The use of beta blockers in heart failure: clinical studies]
[The value of ACE inhibitors in heart failure (mechanism of action)]
[Therapy of chronic heart failure with angiotensin-converting enzyme inhibitors]
[Therapy of heart failure with angiotensin converting enzyme inhibitors. Effects on renal function]
[Therapy of perindopril: organoprotection, not just the antihypertensive effect].
[Treatment after myocardial infarction]
[Treatment of cardiac failure with angiotensin-converting enzyme inhibitors and diuretics]
[Treatment of cardiac failure with enalapril]
[Treatment of chronic congestive heart failure using angiotensin converting enzyme inhibitors]
[Treatment of chronic heart failure: current views]
[Treatment of heart failure based on large-scale clinical trials: renin-angiotensin system antagonists and beta-blockers]
[Treatment of heart failure with angiotensin converting enzyme inhibitors]
[Treatment of ischemic myocardiopathy]
[Treatment of life-threatening arrhythmias in patients with chronic heart failure]
[Treatment of low cardiac output following extracorporeal circulation with captopril]
[Treatment of mitral valve insufficiency in dogs with the ACE inhibitor enalapril. A clinical progress study]
[Triple/quadruple therapy in heart failure: integrating scientific evidence with clinical reasoning]
[Update cardiology 2006/2007]
[Use of angiotensin II receptor blockaders in heart failure]
[Use of angiotensin type II receptor blockers as a potential strategy for chronic heart failure]
[Use of angiotensin-converting enzyme inhibitors in patients with congestive heart failure. Same efficacy? Same costs?]
[Use of beta-blockers in the treatment of chronic heart failure]
[Usefulness of angiotensin converting enzyme inhibitors in chronic heart failure]
[Usefulness of exercise tests in the evaluation of the effects of treatment in chronic cardiac insufficiency]
[Value of pleiotropic effects of angiotensin-converting enzyme inhibitors].
[Value of vasodilator treatment in beginning cardiac insufficiency]
[Vasodilator hormonal agents in chronic heart failure: effect of angiotensin-converting enzyme inhibitors]
[Volume of the extracellular liquid and renal function during short-term administration of angiotensin converting enzyme inhibitors in essential hypertension]
[What have we learned about inhibitors of the renin-angiotensin system?]
[What have we learned from converting enzyme inhibitors on renin-angiotensin system?]
[When and how to use angiotensin-converting enzyme inhibitors in heart failure]
Heart Failure, Diastolic
Demonstrating the pharmacogenetic effects of angiotensin-converting enzyme inhibitors on long-term prognosis of diastolic heart failure.
Diagnosis and management of diastolic dysfunction and heart failure.
Effectiveness of digoxin in reducing one-year mortality in chronic heart failure in the Digitalis Investigation Group trial.
Effects of digoxin on morbidity and mortality in diastolic heart failure: the ancillary digitalis investigation group trial.
Epidemiology of stroke in chronic heart failure patients with normal sinus rhythm: Findings from the DIG stroke sub-study.
Management of left ventricular diastolic heart failure: is it only blood pressure control?
Mechanisms and management of heart failure due to diastolic dysfunction.
Mechanisms, diagnosis, and treatment of diastolic heart failure.
Pathways involved in the transition from hypertension to hypertrophy to heart failure. Treatment strategies.
Prognostic impact of angiotensin-converting enzyme inhibitor therapy in diastolic heart failure.
Systolic versus diastolic heart failure in community practice: clinical features, outcomes, and the use of angiotensin-converting enzyme inhibitors.
Treatment of diastolic dysfunction in hypertension.
Heart Failure, Systolic
A new class of drugs for systolic heart failure: The PARADIGM-HF study.
A propensity score analysis of the impact of angiotensin-converting enzyme inhibitors on long-term survival of older adults with heart failure and perceived contraindications.
ACE inhibitor and angiotensin II type 1 receptor blocker differently regulate ventricular fibrosis in hypertensive diastolic heart failure.
Aldosterone and aldosterone receptor antagonists in patients with chronic heart failure.
Angiotensin-converting enzyme inhibitor use in elderly patients hospitalized with heart failure and left ventricular systolic dysfunction.
Angiotensin-converting enzyme inhibitors, beta-blockers, and mortality in systolic heart failure.
Antihypertensive Medication Use in Older Patients Transitioning from Chronic Kidney Disease to End-Stage Renal Disease on Dialysis.
Association of Fibroblast Growth Factor-23 Levels and Angiotensin-Converting Enzyme Inhibition in Chronic Systolic Heart Failure.
Beta-blocker, angiotensin-converting enzyme inhibitor/angiotensin receptor blocker, nitrate-hydralazine, diuretics, aldosterone antagonist, ivabradine, devices and digoxin (BANDAID(2) ): an evidence-based mnemonic for the treatment of systolic heart failure.
Carvedilol reduces aldosterone release in systolic heart failure.
Chronic heart failure: developments and perspectives.
Clinical factors associated with early readmission among acutely decompensated heart failure patients.
Combination treatment with a calcium channel blocker and an angiotensin blocker in a rat systolic heart failure model with hypertension.
Comparative Effectiveness of Sacubitril-Valsartan Versus ACE/ARB Therapy in Heart Failure With Reduced Ejection Fraction.
Direct renin inhibition in addition to or as an alternative to angiotensin converting enzyme inhibition in patients with chronic systolic heart failure: rationale and design of the Aliskiren Trial to Minimize OutcomeS in Patients with HEart failuRE (ATMOSPHERE) study.
Drug therapy for patients with systolic heart failure after the PARADIGM-HF trial: in need of a new paradigm of LCZ696 implementation in clinical practice.
Drug therapy of chronic heart failure in the elderly: the current state of clinical-trial evidence.
Drug treatment for chronic systolic heart failure.
Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF).
Effect of Angiotensin-Converting Enzyme Inhibitors and Receptor Blockers on Appropriate Implantable Cardiac Defibrillator Shock in Patients With Severe Systolic Heart Failure (from the GRADE Multicenter Study).
Effects of angiotensin-converting enzyme inhibitors in systolic heart failure patients with chronic kidney disease: a propensity score analysis.
Effects of enalapril in systolic heart failure patients with and without chronic kidney disease: Insights from the SOLVD Treatment trial.
Evaluation of heart failure management in a Military Hospital.
Exploring the potential synergistic action of spironolactone on nitric oxide-enhancing therapy: insights from the African-American Heart Failure Trial.
Genotype-phenotype associations between chymase and angiotensin-converting enzyme gene polymorphisms in chronic systolic heart failure patients.
Heart failure in older people: causes, diagnosis and treatment.
High-versus low-dose ACE inhibitor therapy in chronic heart failure.
Influence of gene polymorphisms of the renin-angiotensin system on clinical outcome in heart failure among the Chinese.
LCZ696 (angiotensin-neprilysin inhibition): the new kid on the heart failure block?
Losartan improves heart rate variability and heart rate turbulence in heart failure due to ischemic cardiomyopathy.
Management of hypertension in patients with cardiac disease: use of renin-angiotensin blocking agents.
Medical management of mild-to-moderate heart failure before the advent of beta blockers.
Narrative review: pharmacotherapy for chronic heart failure: evidence from recent clinical trials.
Perindopril vs Enalapril in Patients with Systolic Heart Failure: Systematic Review and Metaanalysis.
Prognostic impact of angiotensin-converting enzyme inhibitor therapy in diastolic heart failure.
Racial response to angiotensin-converting enzyme therapy in systolic heart failure.
Rationale and design of a randomized trial to assess the effects of beta-blocker in diastolic heart failure; Japanese Diastolic Heart Failure Study (J-DHF).
Real-World Prevalence of Adverse Events After Initiating Sacubitril/Valsartan Compared With Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers in Systolic Heart Failure.
Renal Outcomes in Patients with Systolic Heart Failure Treated With Sacubitril-Valsartan or Angiotensin Converting Enzyme Inhibitor/Angiotensin Receptor Blocker.
Renin-Angiotensin Inhibition in Systolic Heart Failure and Chronic Kidney Disease.
Role of race in the pharmacotherapy of heart failure.
Treatment with Optimal Dose Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers Has a Positive Effect on Long-Term Survival in Older Individuals (Aged >70 Years) and Octogenarians with Systolic Heart Failure.
Use of beta-blockers in older adults with chronic heart failure.
Use of different types of angiotensin converting enzyme inhibitors and mortality in systolic heart failure.
[Is there evidence to treat heart failure based on race or ethnicity?]
Heart Rupture
Cardiac rupture complicating myocardial infarction.
Changes in hospital mortality rates in 425 patients with acute ST-elevation myocardial infarction and cardiac rupture over a 30-year period.
Ventricular free wall rupture in acute myocardial infarction.
Heart Septal Defects, Atrial
Analysis of Angiotensin Converting Enzyme, Endothelial Nitric Oxide Synthase & Serotonin Gene Polymorphisms among Atrial Septal Defect Subjects with and without Pulmonary Arterial Hypertension.
Heart Septal Defects, Ventricular
[Oral enalapril in patients with symptomatic ventricular septal defects]
Heart Valve Diseases
Effect of angiotensin-converting enzyme inhibitors on phenylephrine responsiveness in patients with valvular heart disease.
Hemangioma
Angiotensin-converting Enzyme Inhibitors: Can it be a Potential Treatment of Infantile Hemangioma.
Expression of Cathepsins B, D, and G in Infantile Hemangioma.
Hemangioma, Cavernous, Central Nervous System
Angiotensin-converting enzyme insertion/deletion gene polymorphism in patients with familial multiple cerebral cavernous malformations.
Hematologic Neoplasms
Role of ACE inhibitors in anthracycline-induced cardiotoxicity: A randomized, double-blind, placebo-controlled trial.
Hematoma, Subdural, Chronic
Angiotensin converting enzyme inhibition for arterial hypertension reduces the risk of recurrence in patients with chronic subdural hematoma possibly by an antiangiogenic mechanism.
Preoperative angiotensin converting enzyme inhibitor usage in patients with chronic subdural hematoma: Associations with initial presentation and clinical outcome.
The Role of Angiotensin-Converting Enzyme Inhibitors in Patients with Chronic Subdural Hematoma: A Scandinavian Population-Based Multicenter Study.
Hematuria
A single-center study of C1q nephropathy in children.
Drugs controlling proteinuria of patients with Alport syndrome.
Immunoadsorption: a new strategy to induce remission in membranous lupus nephritis.
Loin pain-hematuria syndrome associated with thin glomerular basement membrane disease and hemorrhage into renal tubules.
Spironolactone with ACE inhibitor is effective in gross hematuria caused by nephroptosis.
Tonsillectomy and steroid pulse therapy significantly impact on clinical remission in patients with IgA nephropathy.
Wiskott-Aldrich syndrome with IgA nephropathy: a case report and literature review.
Hemochromatosis
Potential thrombophilic mutations/polymorphisms in patients with no flow-limiting stenosis after myocardial infarction.
Hemoglobinopathies
Erythropoiesis-stimulating agent hyporesponsiveness in end-stage renal disease patients.
Hemolytic-Uremic Syndrome
Additive antiproteinuric effect of enalapril and losartan in children with hemolytic uremic syndrome.
[Etiologic aspects of acute renal insufficiency in the adult]
Hemoptysis
Tracheopathia osteochondroplastica.
Hemorrhagic Stroke
Association between Angiotensin Converting Enzyme Insertion/Deletion gene polymorphism with the risk of Hemorrhagic Stroke: A systematic review and Meta-Analysis of 53 studies.
COVID-19 Associated Ischemic Stroke and Hemorrhagic Stroke: Incidence, Potential Pathological Mechanism, and Management.
Neuroprotective mechanisms of the ACE2-angiotensin-(1-7)-Mas axis in stroke.
Secondary prevention treatment after acute stroke in older South Asian, Chinese and other Canadians: a retrospective data analysis.
Hepatic Encephalopathy
Severe hepatic encephalopathy in a patient with liver cirrhosis after administration of angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker combination therapy: a case report.
Hepatitis
A patient with hepatic granuloma formation and angiotensin-converting enzyme production by granuloma cells during clinical relapse of hepatitis A.
Angiotensin converting enzyme inhibitor toxicity causing interstitial pneumonitis and cholestatic hepatitis.
Changes of serum angiotensin I converting enzyme in patients with viral hepatitis and liver cirrhosis.
Drug-induced hypersensitivity syndrome with superficial granulomatous dermatitis--a novel finding.
Hepatotoxicity effect of short-term Bradykinin potentiating factor in cholestatic rats.
Preparation and antagonistic effect of ACE inhibitory peptide from cashew.
Sarcoidosis presenting as multiple subcutaneous nodules.
Serum activity of angiotensin converting enzyme (ACE) is not affected by hepatitis B viral infection.
The angiotensin-converting enzyme inhibitor captopril rescues mice from endotoxin-induced lethal hepatitis.
[Variations in serum kininase II activity in acute jaundice]
Hepatitis A
A patient with hepatic granuloma formation and angiotensin-converting enzyme production by granuloma cells during clinical relapse of hepatitis A.
Hepatitis B
Atrophic and Annular Scarring Alopecia of the Scalp as a Finding in Underlying Systemic Sarcoidosis.
Combination therapy with lamivudine and angiotensin-converting enzyme inhibitor/angiotensin receptor blocker for hepatitis B virus-associated glomerulonephritis with mild to moderate proteinuria: a clinical review of 38 cases.
Development of an electronic health record-based chronic kidney disease registry to promote population health management.
Effects of gender, Helicobacter pylori and hepatitis B virus serology status on cardiovascular and renal complications in Chinese type 2 diabetic patients with overt nephropathy.
Serum activity of angiotensin converting enzyme (ACE) is not affected by hepatitis B viral infection.
Hepatitis B, Chronic
Decrease of serum Angiotensin converting enzyme levels upon telbivudine treatment for chronic hepatitis B virus infection and negative correlations between the enzyme levels and estimated glumerular filtration rates.
Is Serum Angiotensin-Converting Enzyme Level Useful For Determining Necroinflammatory Activity In Chronic Hepatitis B Infection?
Reply to Dr Onal: the importance of serum angiotensin-converting enzyme level in chronic hepatitis B.
Serum angiotensin-converting enzyme level as a marker of fibrosis in patients with chronic hepatitis B.
Serum angiotensin-converting enzyme level as a marker of severity in HBeAg-negative chronic Hepatitis B Virus infection.
Serum angiotensin-converting enzyme level for evaluating significant fibrosis in chronic hepatitis B.
Hepatitis C
Are the current chronic allograft nephropathy grading systems sufficient to predict renal allograft survival?
Effects of Angiotensin Converting Enzyme Inhibitors on Liver Fibrosis in HIV and Hepatitis C Coinfection.
Glomerular damage as a predictor of renal allograft loss.
Increased Time Exposure to Tenofovir Is Associated with a Greater Decrease in Estimated Glomerular Filtration Rate in HIV Patients with Kidney Function of Less than 60 ml/min/1.73 m.
Lichen planus.
Sex-related influence of angiotensin-converting enzyme polymorphisms on fibrosis progression due to recurrent hepatitis C after liver transplantation.
The clinical epidemiology and course of the spectrum of renal diseases associated with HIV infection.
[Study of various factors that could have an impact on the treatment with erythropoietin of hemodialysis anemia]
Hepatitis C, Chronic
Effect of Antiviral Therapy on Serum Activity of Angiotensin Converting Enzyme in Patients with Chronic Hepatitis C.
Influence of angiotensin-converting enzyme I/D gene polymorphism on clinical and histological correlates of chronic hepatitis C.
Interferon augments the anti-fibrotic activity of an angiotensin-converting enzyme inhibitor in patients with refractory chronic hepatitis C.
Possible role of angiotensin-converting enzyme polymorphism on progression of hepatic fibrosis in chronic hepatitis C virus infection.
Hepatitis, Autoimmune
Angiotensin-converting enzyme for noninvasive assessment of liver fibrosis in autoimmune hepatitis.
Hepatitis, Chronic
Is serum angiotensin converting enzyme level a useful non-invasive marker for liver fibrosis in patients with chronic hepatitis C?
Hepatomegaly
Enzyme replacement therapy for Gaucher disease.
Sarcoidosis: a journey through 50 years.
Hepatorenal Syndrome
Captopril in the hepatorenal syndrome.
[Correlative study between angiotensin-converting enzyme gene polymorphism and hepatorenal syndrome.]
Hereditary Angioedema Type III
Angioedema.
Recurrent episodes of skin angioedema and severe attacks of abdominal pain induced by oral contraceptives or hormone replacement therapy.
Hereditary Angioedema Types I and II
Recurrent episodes of skin angioedema and severe attacks of abdominal pain induced by oral contraceptives or hormone replacement therapy.
Hereditary Complement Deficiency Diseases
Angioedema: A Life-threatening Complication of Tissue Plasminogen Activator.
Hernias, Diaphragmatic, Congenital
Angiotensin-converting enzyme activity is increased in lungs of rats with pulmonary hypoplasia and congenital diaphragmatic hernia.
Antenatal glucocorticoid therapy suppresses angiotensin-converting enzyme activity in rats with nitrofen-induced congenital diaphragmatic hernia.
Herpes Simplex
Brassicasterol with Dual Anti-Infective Properties against HSV-1 and Mycobacterium tuberculosis, and Cardiovascular Protective Effect: Nonclinical In Vitro and In Silico Assessments.
The effect of captopril on the expression of MMP-9 and the prognosis of neurological function in herpes simplex encephalitis mice.
Herpes Zoster
Long-term effects of captopril on the morphology of normal rat adrenal zona glomerulosa. A morphometric study.
Hirsutism
The Sexual Dimorphism of High Blood Pressure.
Histiocytic Sarcoma
Angiotensin converting enzyme and malignant histiocytosis.
Angiotensin converting enzyme: a tumour marker in malignant histiocytosis.
Histiocytosis
Angiotensin-converting enzyme, transforming growth factor beta(1), and interleukin 11 in the osteolytic lesions of Langerhans cell histiocytosis.
Case report: Langerhans cell histiocytosis associated with elevation of angiotensin-converting enzyme levels.
Histiocytosis, Langerhans-Cell
Angiotensin-converting enzyme, transforming growth factor beta(1), and interleukin 11 in the osteolytic lesions of Langerhans cell histiocytosis.
Case report: Langerhans cell histiocytosis associated with elevation of angiotensin-converting enzyme levels.
Histiocytosis X. VI. Angiotensin-converting enzyme activity.
Histoplasmosis
Elevated serum angiotensin-converting enzyme (SACE) activity in acute pulmonary histoplasmosis.
Histoplasmosis With Tenosynovitis of the Hand and Hypercalcemia Mimicking Sarcoidosis.
Histoplasmosis: a masquerader of sarcoidosis.
Serum angiotensin converting enzyme activity in patients with histoplasmosis.
HIV Infections
Adverse Drug Reaction Reporting in Africa and a Comparison of Individual Case Safety Report Characteristics Between Africa and the Rest of the World: Analyses of Spontaneous Reports in VigiBase(®).
Angiotensin converting enzyme inhibitor and HMG-CoA reductase inhibitor as adjunct treatment for persons with HIV infection: a feasibility randomized trial.
Captopril and renal survival in patients with human immunodeficiency virus nephropathy.
Clinical factors associated with early readmission among acutely decompensated heart failure patients.
[Serum angiotensin-converting enzyme (SACE) in HIV infection]
Hodgkin Disease
Angiotensin-converting enzyme expression of the lymphoma-associated macrophages in the lymph nodes of Hodgkin's disease.
Angiotensin-converting enzyme in untreated Hodgkin's disease.
Low-grade B-cell lymphoma and concomitant extensive sarcoidlike granulomas: a case report and review of the literature.
Serum angiotensin-converting enzyme in malignant lymphomas, leukaemia and multiple myeloma.
Serum angiotensin-I-converting enzyme and lysozyme levels in untreated and unsplenectomized patients with Hodgkin's disease.
Serum angiotensin-I-converting enzyme in Hodgkin's disease.
[Case report: A case of Hodgkin lymphoma required a differential diagnosis from sarcoidosis due to elevated serum level of angiotensin converting enzyme (ACE)].
[Elevation of serum angiotensin converting enzyme levels in Hodgkin's lymphoma]
Huntington Disease
Angiotensin converting enzyme in kainic acid--injected striata.
Angiotensin-converting enzyme in substantia nigra: reduction of activity in Huntington's disease and after intrastriatal kainic acid in rats.
Huntington's chorea: selective depletion of activity of angiotensin coverting enzyme in the corpus striatum.
Huntington's disease: deterioration in clinical state during treatment with angiotensin converting enzyme inhibitor.
The Implications of Angiotensin-Converting Enzymes and Their Modulators in Neurodegenerative Disorders: Current and Future Perspectives.
Hydrocephalus
Angiotensin converting enzyme inhibition, CBF autoregulation, and ICP in patients with normal-pressure hydrocephalus.
Angiotensin I converting enzyme polymorphism effects in patients with normal pressure hydrocephalus syndrome before and after surgery.
Facial nerve enhancement on gadolinium-DTPA in a case with neurosarcoidosis.
Systemic sarcoidosis: a case with a focal hydrocephalus and elevated lysozyme and angiotensin-converting enzyme in the cerebrospinal fluid.
Hydrocephalus, Normal Pressure
Angiotensin I converting enzyme polymorphism effects in patients with normal pressure hydrocephalus syndrome before and after surgery.
Hydronephrosis
Angiotensin converting enzyme inhibition worsens the excretory phase of diuretic renography for obstructive hydronephrosis.
Effects of angiotensin converting enzyme inhibition on glomerular number, juxtaglomerular cell activity and renin content in experimental unilateral hydronephrosis.
Hydronephrosis alters cardiac ACE2 and Mas receptor expression in mice.
Hyperaldosteronism
Acute effects of captopril on systemic and renal hemodynamics and on renal function in cirrhotic patients with ascites.
Aldosterone antagonism: an emerging strategy for effective blood pressure lowering.
Angiotensin I converting enzyme activity in hypertension. Relationship to blood pressure, renin-sodium profiles, and antihypertensive therapy.
Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in hypertension due to primary aldosteronism: a case for exclusion.
Arrhythmias, electrolytes, and ACE inhibitor therapy in the elderly.
Clinical evaluation of the captopril screening test for primary aldosteronism.
Efficacy of low-dose spironolactone in subjects with resistant hypertension.
Endocrine mechanisms in congestive cardiac failure. Renin, aldosterone and atrial natriuretic hormone.
Genetic basis of familial dyslipidemia and hypertension: 15-year results from Utah.
Hyperaldosteronism in the sodium-depleted rat: mechanism of aldosterone stimulation by peritoneal dialysis with glucose solution.
Influence of antihypertensive drugs in the subtype diagnosis of primary aldosteronism by adrenal venous sampling.
Mineralocorticoid Receptor Antagonists Decrease the Rates of Positive Screening for Primary Aldosteronism.
Mineralocorticoid Receptor-Associated Hypertension and Its Organ Damage: Clinical Relevance for Resistant Hypertension.
Myocardial fibrosis and the concepts of cardioprotection and cardioreparation.
Pathologic hypertrophy with fibrosis: the structural basis for myocardial failure.
Reversal of diuretic-induced secondary hyperaldosteronism and hypokalemia by enalapril (MK-421): a new angiotensin-converting enzyme inhibitor.
The importance of lost minerals in heart failure.
The therapeutic effect of a new angiotensin-converting enzyme inhibitor, enalapril maleate, in idiopathic hyperaldosteronism.
Treatment of hypertension with angiotensin converting enzyme inhibitors.
[Adrenal ACE and type II glucocorticoid receptors in primary hyperaldosteronism]
[Detection of primary aldosteronism using the captopril test]
[Influence of angiotensin on the secretion of aldosterone in idiopathic hyperaldosteronism]
[Sarcoidosis in childhood. Presentation of a case in a very young child]
[The activity of renin-angiotensin-aldosterone system (RAA) and possibilities of application angiotensin converting enzyme inhibitors (ACE I) in selected diseases of endocrine glands]
[The acute effects of the new angiotensin I-converting enzyme inhibitor, enalapril maleate, on blood pressure, plasma renin, aldosterone and kinins in hypertensive patients]
[The behavior of serum angiotensin-converting enzyme in normotensive subjects, in subjects with essential hypertension and in subjects with primary hyperaldosteronism on the orthostatic test]
[The correlation between serum angiotensin I-converting enzyme activity and the renin-angiotensin-aldosterone system in hypertensive patients (author's transl)]
Hyperalgesia
Inhibition of angiotensin converting enzyme induces mechanical allodynia through increasing substance P expression in mice.
Involvement of 5-hydroxytryptamine and bradykinin in the hyperalgesia induced in rats by collagenase from Clostridium histolyticum.
Substance P and capsaicin-induced mechanical hyperalgesia in the rat knee joint; the involvement of bradykinin B1 and B2 receptors.
Hyperandrogenism
Effect of hypertension therapy with the angiotensin-converting enzyme inhibitor lisinopril on hyperandrogenism in women with polycystic ovary syndrome.
Hypercalcemia
A case of renal sarcoidosis: a special reference to calcium metabolism as a diagnostic and the therapeutic implications.
A case of scrotal sarcoidosis that mimicked tuberculosis.
A patient with sarcoidosis associated with recurrent urolithiasis and tubular injury caused by calcium deposition.
A rarer association of eosinophilic fasciitis.
Active crohn disease and hypercalcemia treated with infliximab: case report and literature review.
Bartonella henselae Infection: An Uncommon Mimicker of Autoimmune Disease.
Calcitriol-Mediated Hypercalcemia: Causes and Course in 101 Patients.
Development of Hypercalcemia in a Patient Receiving Peginterferon alfa-2a Therapy for Polycythemia Vera.
Granulomatous Lithiasic Cholecystitis in Sarcoidosis.
Granulomatous Tubulointerstitial Nephritis in a Kidney Transplant Recipient: Case Report and Review of the Literature.
Histoplasmosis With Tenosynovitis of the Hand and Hypercalcemia Mimicking Sarcoidosis.
Hypercalcemia associated with an elevated 1,25 dihydroxy vitamin D3 level and an elevated angiotensin-converting enzyme level in a patient without evidence of sarcoidosis or malignancy.
Hypercalcemia due to excess 1,25-dihydroxyvitamin D in Crohn's disease.
Hypercalcemia of sarcoidosis treated with cellulose sodium phosphate.
Hypertension in a patient with hypercalcemia: captopril and verapamil.
Influence of Gender on Epidemiology and Clinical Manifestations of Sarcoidosis: A Population-Based Retrospective Cohort Study 1976-2013.
Non-Hodgkin's lymphoma associated with hypercalcemia and increased activity of serum angiotensin-converting enzyme.
Orosomucoid and haptoglobin types in patients with sarcoidosis.
Progressive weakness with respiratory failure in a patient with sarcoidosis.
Pure extra-thoracic sarcoidosis: about 24 cases.
Sarcoidosis.
Sarcoidosis: a primary care review.
Serum angiotensin-converting enzyme activity. Its use in the evaluation and management of hypercalcemia associated with sarcoidosis.
Sphenoid sinus brown tumor, hypercalcemia, and blindness: an unusual presentation of primary hyperparathyroidism.
Systemic elastolytic granulomatosis with cutaneous, ocular, lymph nodal, and intestinal involvement. Spectrum of annular elastolytic giant cell granuloma and sarcoidosis.
The predictive value of serum angiotensin-converting enzyme activity in the differential diagnosis of hypercalcemia.
[A patient with type ZZ alpha 1-antitrypsin deficiency and hypercalcemia caused by sarcoidosis]
[Angiotensin-converting enzyme and 1,25-dihydroxyvitamin D3 in hypercalcemia of unknown origin]
[Lymphoma B associated with hypercalcemia and increase in angiotensin converting enzyme]
[Pulmonary infiltrates in a 19 year old patient with dysuria and hypercalcemia]
Hypercholesterolemia
Alligator pepper/Grain of Paradise (Aframomum melegueta) modulates Angiotensin-I converting enzyme activity, lipid profile and oxidative imbalances in a rat model of hypercholesterolemia.
Angiotensin I-Converting Enzyme Gene Polymorphism Enhances the Effect of Hypercholesterolemia on the Risk of Coronary Heart Disease in a General Japanese Population: The Hisayama Study.
Angiotensin-converting enzyme inhibition attenuates hypercholesterolemia and glomerular injury in hyperlipidemic Imai rats.
Anion Gap Was Associated with Inhospital Mortality and Adverse Clinical Outcomes of Coronary Care Unit Patients.
Anti-CD20 monoclonal antibody (rituximab) for the treatment of recurrent idiopathic membranous nephropathy in a renal transplant patient.
Beneficial Effects of Statin Therapy on Survival in Hypertensive Patients With Acute Myocardial Infarction: Data From the RICO Survey.
Cardiovascular Risk and Risk Factor Management in Type 2 Diabetes Mellitus.
Cardiovascular risk factors, angiotensin-converting enzyme gene I/D polymorphism, and left ventricular mass in systemic hypertension.
Contraceptive Methods and Informed Consent among Women Receiving Medications with Potential for Adverse Fetal Effects: A Washington, Wyoming, Alaska, Montana, Idaho (WWAMI) Region Study.
Diverse effects of increasing lisinopril doses on lipid abnormalities in chronic nephropathies.
Effect of long-term treatment with enalapril in streptozotocin diabetic and DOCA hypertensive rats.
Factors associated with aspirin resistance in patients premedicated with aspirin and clopidogrel for endovascular neurosurgery.
Homocysteine levels in hypertensive patients with a history of cardiac or cerebral atherothrombotic events.
Incomplete inhibition of thromboxane biosynthesis by acetylsalicylic acid: determinants and effect on cardiovascular risk.
Modification of the coronary artery disease risk associated with the presence of traditional risk factors by insertion/deletion polymorphism of the ACE gene.
Pathophysiology of experimental nephrotic syndrome induced by puromycin aminonucleoside in rats. I. The role of proteinuria, hypoproteinemia, and renin-angiotensin-aldosterone system on sodium retention.
Phenolic compounds from sandpaper (ficus exasperata) leaf inhibits angiotensin 1 converting enzyme in high cholesterol diet fed rats.
Predicting Readmission or Death After Acute ST-Elevation Myocardial Infarction.
Prognostic Value of Monocyte Count in Patients Hospitalized for Heart Failure With Reduced Ejection Fraction (from the EVEREST Trial).
Renin-angiotensin system polymorphisms and coronary events in familial hypercholesterolemia.
The effect of angiotensin-converting enzyme inhibition on inflammatory and angiogenic factors in hypercholesterolemia.
The influence of angiotensin converting enzyme inhibitors on lipid peroxidation in sera and aorta of rabbits in diet-induced hypercholesterolemia.
The use of lipid-lowering therapy for secondary prevention in patients undergoing percutaneous coronary intervention.
Vascular effects of systemic hypertension.
Vasomotor responses in cyclosporin A-treated rats after chronic angiotensin blockade.
Vasoprotection and antihypertensive therapy.
[Angiotensin converting enzyme and Alzheimer's disease].
[Beneficial effects of statins and angiotensin converting enzyme inhibitors on aggregability of red blood cells in hypertensive patients]
[Primary prevention of coronary heart disease : Evidence-based drug treatment].
[The influence of angiotensin-converting enzyme inhibitors on collagen content of the aorta wall in experimental hypercholesterolemia]
[Treatment of essential arterial hypertension with hypercholesterolemia. Effects of an alpha-adrenergic blocker and an inhibitor of the angiotensin converting enzyme]
Hyperemia
A comparison of angiotensin-converting enzyme inhibitors, calcium antagonists, beta-blockers and diuretic agents on reactive hyperemia in patients with essential hypertension: a multicenter study.
Angiotensin I-converting enzyme inhibitor improves reactive hyperemia in elderly hypertensives with arteriosclerosis obliterans.
Converting enzyme inhibitor improves forearm reactive hyperemia in essential hypertension.
Effect of the angiotensin-converting enzyme inhibitor imidapril on reactive hyperemia in patients with essential hypertension: relationship between treatment periods and resistance artery endothelial function.
Estrogen replacement therapy in postmenopausal women augments reactive hyperemia in the forearm by reducing angiotensin converting enzyme activity.
Severity of hypertension affects improved resistance artery endothelial function by angiotensin-converting enzyme inhibition.
[Diastolic cardiac failure: therapeutic modalities]
[Effect of endogenous metabolites on autoregulation and dilational reserve of coronary vessels]
Hypergammaglobulinemia
A case of sarcoidosis which relapsed twice after successive parturitions.
The renin-angiotensin system in lupus: physiology, genes and practice, in animals and humans.
The varied clinical and laboratory manifestations of type II Gaucher's disease.
[A case of sarcoidosis associated with Sjögren's syndrome]
[Kaposi's disease in AIDS: 31 cases]
Hyperglycemia
An update on 'progression promoters' in renal diseases.
Angiogenesis and diabetes: different responses to pro-angiogenic factors in the chorioallantoic membrane assay.
Angiotensin blockade and matrix synthesis by glomerular epithelial cells in high glucose: a further experimental insight into the pathophysiology of diabetic nephropathy.
Angiotensin-converting enzyme inhibitors reduce oxidative stress intensity in hyperglicemic conditions in rats independently from bradykinin receptor inhibitors.
Association Between Ethnicity and Postoperative Hyperglycemia in a Southeast Asian Population Undergoing Cardiac Surgery.
Cardiovascular autonomic neuropathy: diagnosis and management.
Cardiovascular disease in chronic kidney disease.
Des-aspartate-angiotensin I exerts hypoglycemic action via glucose transporter-4 translocation in type 2 diabetic KKAy mice and GK rats.
Diabetes, insulin, and development of acute lung injury.
Effect of angiotensin II antagonist eprosartan on hyperglycemia-induced activation of intrarenal renin-angiotensin system in healthy humans.
Evaluation of antihyperglycemia and antihypertension potential of native Peruvian fruits using in vitro models.
Evaluation of antiproliferative, anti-type 2 diabetes, and antihypertension potentials of ellagitannins from strawberries (Fragaria ×?ananassa Duch.) using in vitro models.
Evaluation of Bacillus subtilis SPB1 biosurfactant effects on hyperglycemia, angiotensin I-converting enzyme (ACE) activity and kidney function in rats fed on high-fat-high-fructose diet.
EVALUATION OF RED CURRANTS (RIBES RUBRUM L.), BLACK CURRANTS (RIBES NIGRUM L.), RED AND GREEN GOOSEBERRIES (RIBES UVA-CRISPA) FOR POTENTIAL MANAGEMENT OF TYPE 2 DIABETES AND HYPERTENSION USING IN VITRO MODELS
Fosinopril Prevents the Development of Tactile Allodynia in a Streptozotocin-Induced Diabetic Rat Model.
Functionality of bioactive compounds in Brazilian strawberry (Fragaria x ananassa Duch.) cultivars: evaluation of hyperglycemia and hypertension potential using in vitro models.
Gender differences in renal responses to hyperglycemia and angiotensin-converting enzyme inhibition in diabetes.
Genetic markers of increased susceptibility to diabetic nephropathy.
Glucose specifically regulates TRPC6 expression in the podocyte in an AngII-dependent manner.
HEALTH-RELATED FUNCTIONALITY OF PHENOLIC-ENRICHED PEA SPROUTS IN RELATION TO DIABETES AND HYPERTENSION MANAGEMENT
Potential of cranberry powder for management of hyperglycemia using in vitro models.
Renal changes on hyperglycemia and angiotensin-converting enzyme in type 1 diabetes.
Targeting the upregulation of reactive oxygen species subsequent to hyperglycemia prevents type 1 diabetic cardiomyopathy in mice.
The effect of urapidil and ramipril on hyperglycemia in streptozotocin diabetic rats.
The renin-angiotensin system: a target of and contributor to dyslipidemias, altered glucose homeostasis, and hypertension of the metabolic syndrome.
Twenty years after ACEIs and ARBs: emerging treatment strategies for diabetic nephropathy.
[Considerations on the treatment of incipient diabetic nephropathy (lst of 2 parts)]
[The impact of diabetes mellitus on the mortality of acute coronary syndromes]
Hyperhomocysteinemia
Angiotensin-converting enzyme DD genotype, angiotensin type 1 receptor CC genotype, and hyperhomocysteinemia increase first-trimester fetal-loss susceptibility.
Impairment of cerebrovascular reactivity by methionine-induced hyperhomocysteinemia and amelioration by quinapril treatment.
Methylenetetrahydrofolate reductase gene mutation and hyperhomocysteinemia as a risk factor for coronary heart disease in the Indian population.
Thrombosis and occlusion of vascular access in hemodialyzed patients.
Hyperinsulinism
Hyperinsulinemia as a risk factor for restenosis after coronary balloon angioplasty.
Inhibition of the renin-angiotensin system ameliorates genetically determined hyperinsulinemia.
Interactions of captopril and verapamil on glucose tolerance and insulin action in an animal model of insulin resistance.
Relations between deletion polymorphism of the angiotensin-converting enzyme gene and insulin resistance, glucose intolerance, hyperinsulinemia, and dyslipidemia.
Treatment of insulin resistance in uremia.
[Control of hyperinsulinemia in essential hypertension using the angiotensin-converting enzyme inhibitor, lisinopril]
[Effect of ramipril on the glucose/insulin coefficient and the ventricular mass index in patients with light to moderate arterial hypertension]
[The role of angiotensin-converting enzyme gene I/D polymorphism in development of metabolic disorders in patients with cardiovascular pathology]
Hyperkalemia
A comparative study of the prevalence of hyperkalemia with the use of angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers.
A Quick Reference on Hyperkalemia.
A Whole Food Plant-Based Diet With a Novel Potassium-Binding Resin in a Patient With Advanced Chronic Kidney Disease.
ACP Journal Club. Review: Aliskiren plus ACEIs or ARBs increases hyperkalemia more than aliskiren, ACEIs, or ARBs alone.
Acute and Chronic Cardiovascular Effects of Hyperkalemia: New Insights Into Prevention and Clinical Management.
Acute poststreptococcal glomerulonephritis: the most common acute glomerulonephritis.
Adequate intake of potassium does not cause hyperkalemia in hypertensive individuals taking medications that antagonize the renin angiotensin aldosterone system.
Advances in understanding the role of angiotensin-regulated proteins in kidney diseases.
Aldosterone blockers (mineralocorticoid receptor antagonism) and potassium-sparing diuretics.
Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
Angiotensin-converting enzyme inhibitors.
Antihypertensive Medication Use in Older Patients Transitioning from Chronic Kidney Disease to End-Stage Renal Disease on Dialysis.
Antihypertensive Medications and the Prevalence of Hyperkalemia in a Large Health System.
Cardiovascular risk in patients with mild renal insufficiency: implications for the use of ACE inhibitors.
Clinical factors associated with hyperkalemia in patients with congestive heart failure.
Combination use of medicines from two classes of renin-angiotensin system blocking agents: risk of hyperkalemia, hypotension, and impaired renal function.
Effect of Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers on Serum Potassium Levels and Renal Function in Ambulatory Outpatients: Risk Factors Analysis.
Effect of standard-dose trimethoprim/sulfamethoxazole on the serum potassium concentration in elderly men.
Effect of the SGLT2 Inhibitor Dapagliflozin on Potassium Levels in Patients with Type 2 Diabetes Mellitus: A Pooled Analysis.
Effectiveness of the selective aldosterone blocker, eplerenone, in patients with resistant hypertension.
Effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on cardiovascular events in patients with diabetes and overt nephropathy: a meta-analysis of randomised controlled trials.
Efficacy and Safety of Dual Blockade of the Renin-Angiotensin-Aldosterone System in Diabetic Kidney Disease: A Meta-Analysis.
Endocrine crises. Hyperkalemia.
Eplerenone: a new selective aldosterone receptor antagonist.
Estimation of glomerular filtration rate to prevent life-threatening hyperkalemia due to combined therapy with spironolactone and angiotensin-converting enzyme inhibition or angiotensin receptor blockade.
Hyperkalemia After Initiating Renin-Angiotensin System Blockade: The Stockholm Creatinine Measurements (SCREAM) Project.
Hyperkalemia and renal function during monotherapy and dual Renin-Angiotensin blockade in the community setting.
Hyperkalemia and Treatment With RAAS Inhibitors During Acute Heart Failure Hospitalizations and Their Association With Mortality.
Hyperkalemia Associated with Angiotensin Converting Enzyme Inhibitor or Angiotensin Receptor Blockers in Chronic Kidney Disease.
Hyperkalemia Associated with Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers.
Hyperkalemia Develops in Some Thyroidectomized Patients Undergoing Thyroid Hormone Withdrawal in Preparation for Radioactive Iodine Ablation for Thyroid Carcinoma.
Hyperkalemia due to hyporeninemic hypoaldosteronism with liver cirrhosis and hypertension.
Hyperkalemia in ambulant postcardiac surgery patients during combined therapy with angiotensin-converting enzyme inhibitor, spironolactone, and diet rich in potassium: A report of two cases and review of literature.
Hyperkalemia in azotemic patients during angiotensin-converting enzyme inhibition and aldosterone reduction with captopril.
Hyperkalemia in hospitalized patients.
Hyperkalemia in outpatients using angiotensin-converting enzyme inhibitors. How much should we worry?
Hyperkalemia induced failure of atrial and ventricular pacemaker capture.
Hyperkalemia of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers in hemodialysis: a meta-analysis.
Hyperkalemia with concomitant watery diarrhea: an unusual association.
Hyperkalemia: pathophysiology, risk factors and consequences.
Hypertension after kidney transplant.
Hypertension, Living Kidney Donors, and Transplantation: Where Are We Today?
Hypokalemia and anesthetic implications.
Impact of Renin-Angiotensin Aldosterone System Inhibition on Serum Potassium Levels among Peritoneal Dialysis Patients.
Implications of nonsteroidal anti-inflammatory drug therapy.
Inadequate aldosterone response to hyperkalemia during angiotensin converting enzyme inhibition in chronic renal failure.
Incidence and predictors of development of acute renal failure related to treatment of congestive heart failure with ACE inhibitors.
Incidence and predictors of hyperkalemia in patients with heart failure: an analysis of the CHARM Program.
Incidence of hyperkalemia in high risk patients during treatment with an angiotensin converting enzyme inhibitor (Lisinopril) versus an angiotensin II receptor blocker (Losartan).
Increased colonic K+ excretion through inhibition of the H,K-ATPase type 2 helps reduce plasma K+ level in a murine model of nephronic reduction.
Influence of combined angiotensin-converting enzyme inhibitors and spironolactone on serum K+, Mg 2+, and Na+ concentrations in small dogs with degenerative mitral valve disease.
Intravenous infusion of haptoglobin for the prevention of adverse clinical outcome in Sickle Cell Disease.
Laboratory monitoring of patients treated with antihypertensive drugs and newly exposed to non steroidal anti-inflammatory drugs: a cohort study.
Life-threatening hyperkalemia during combined therapy with angiotensin-converting enzyme inhibitors and spironolactone.
Life-threatening hyperkalemia during combined therapy with angiotensin-converting enzyme inhibitors and spironolactone: an analysis of 25 cases.
Life-threatening hyperkalemia in a patient with normal renal function.
Low renin hypertension in the next millennium.
Low-dose aldosterone blockade as a new treatment paradigm for controlling resistant hypertension.
Management of hypertension in diabetes mellitus.
Mechanisms of impaired potassium handling with dual renin-angiotensin-aldosterone blockade in chronic kidney disease.
Mineralocorticoid receptor blockade in chronic kidney disease.
Mineralocorticoid Receptor Blockade in Chronic Kidney Disease.
No Increase in Adverse Events During Aliskiren Use Among Ontario Patients Receiving Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers.
Nonsteroidal anti-inflammatory drug use and risk of acute kidney injury and hyperkalemia in older adults: a population-based study.
Onset of Hyperkalemia following the Administration of Angiotensin-Converting Enzyme Inhibitor or Angiotensin II Receptor Blocker.
Optimally managing hyperkalemia in patients with cardiorenal syndrome.
Pharmacologic therapies for chronic and acute decompensated heart failure: specific insights on cardiorenal syndromes.
Pharmacological and non pharmacological strategies in the management of coronary artery disease and chronic kidney disease.
Pharmacotherapy in congestive heart failure: ACE inhibitors and anemia in congestive heart failure.
Pharmacotherapy in congestive heart failure: Hyperkalemia in congestive heart failure.
Physicians make different decisions from nephrologists at serum creatinine 2.0 mg/dl.
Prediction and management of hyperkalemia across the spectrum of chronic kidney disease.
Predictors of the development of hyperkalemia in patients using angiotensin-converting enzyme inhibitors.
Prevalence of hyperkalemia in adult patients taking spironolactone and angiotensin converting enzyme inhibitors or angiotensin receptor blockers.
Prevalence of Hyperkalemia in Diabetic and Non-Diabetic Patients with Chronic Kidney Disease: A Nested Case-Control Study.
Quantification of the risk and predictors of hyperkalemia in patients with left ventricular dysfunction: a retrospective analysis of the Studies of Left Ventricular Dysfunction (SOLVD) trials.
Rapid life-threatening hyperkalemia after addition of amiloride HCl/hydrochlorothiazide to angiotensin-converting enzyme inhibitor therapy.
Renal Considerations in Geriatric Patients With Heart Disease.
Renin-angiotensin system blockade and the risk of hyperkalemia in chronic hemodialysis patients.
Reversible impairment of renal function associated with enalapril in a diabetic patient.
Risk of hyperkalemia in nondiabetic patients with chronic kidney disease receiving antihypertensive therapy.
Risk of hyperkalemia in patients with moderate chronic kidney disease initiating angiotensin converting enzyme inhibitors or angiotensin receptor blockers: a randomized study.
Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes.
Serum potassium, cardiovascular risk, and effects of an ACE inhibitor: results of the HOPE study.
Severe hyperkalemia during very-low-calorie diets and angiotensin converting enzyme use.
Short-term changes of serum potassium concentration induced by physical exercise in patient with arterial hypertension treated with angiotensin-converting enzyme inhibitor alone or in combination with statin.
Studies to determine the basis for hyperkalemia in recipients of a renal transplant who are treated with cyclosporine.
Syncope caused by hyperkalemia during use of a combined therapy with the angiotensin-converting enzyme inhibitor and spironolactone.
Syncope caused by iatrogenic hyperkalemia.
Syncope caused by nonsteroidal anti-inflammatory drugs and angiotensin-converting enzyme inhibitors.
The effects of angiotensin converting enzyme inhibitors on potassium homeostasis in dialysis patients with and without residual renal function.
The frequency of hyperkalemia and its significance in chronic kidney disease.
The Role of Finerenone in the Management of Diabetic Nephropathy.
The sudden demise of dual renin-angiotensin system blockade or the soft science of the surrogate end point.
Tissue renin angiotensin systems: theoretical implications for the development of hyperkalemia using angiotensin-converting enzyme inhibitors.
Treatment of Hyperkalemia in Heart Failure.
Trimethoprim-induced hyperkalemia: An analysis of reported cases.
Trimethoprim-sulfamethoxazole-induced hyperkalemia in patients receiving inhibitors of the renin-angiotensin system: a population-based study.
[Drug-related hyperkalemia resulted from spironolactone and angiotensin converting enzyme inhibitors therapy]
[Hyperkalemia - Pathophysiology, prognostic significance and treatment options].
[Ineffective atrial pacing and cardiac arrest in a 80-year old woman with hyperkalemia]
[Life threatening drug-induced hyperkaliemia--case report]
[Prospective observational study of angiotensin converting enzyme inhibitors-induced hyperkalemia in hospitalized patients with chronic renal failure].
[Risk for hyperkalemia during long-term treatment with angiotensin-converting enzyme inhibitors in insulin-dependent type 2 diabetics in relation to the glomerular filtration rate]
[Seniors and cardiovascular medications].
[Severe hyperkalemia associated to the use of losartan and spironolactone: Case report.]
[Treatment of heart failure with angiotensin converting enzyme inhibitors]
Hyperlipidemias
A randomized, controlled trial of steroids and cyclophosphamide in adults with nephrotic syndrome caused by idiopathic membranous nephropathy.
A review of the role of statins in heart failure treatment.
A simplified approach to the management of non-ST-segment elevation acute coronary syndromes.
Achieving maximal renal protection in nondiabetic chronic renal disease.
Acute kidney injury after gastric bypass surgery.
Aldosterone receptor blockade inhibits degenerative processes in the early stage of calcific aortic stenosis.
Cardiovascular disease in chronic kidney disease.
Carotid endarterectomy remains the standard of care, even in high-risk surgical patients.
Circulating apoptotic progenitor cells: a novel biomarker in patients with acute coronary syndromes.
Contribution of systemic blood pressure to myocardial remodeling in uremic rats.
Delayed kidney injury following coronary angiography.
Drug benefit generosity and essential medication use among Medicare-eligible retirees.
Dyspnea With Unilateral Pulmonary Ground Glass Opacities and Cavitary Lesions.
Effect of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) on Conduction System Disease.
Effects of receipt of chronic statin therapy before the onset of acute myocardial infarction: a retrospective study in patients undergoing primary percutaneous coronary intervention.
Evaluation and treatment of chronic renal failure.
Evolving strategies for renoprotection: non-diabetic chronic renal disease.
Genotype combinations of plasminogen activator inhibitor-1 and angiotensin-converting enzyme genes and risk for early onset of coronary heart disease.
Hemostatic dysfunction associated with endocrine disorders as a major risk factor and cause of human morbidity and mortality: a comprehensive meta-review.
How cost-effective are new preventive strategies for cardiovascular disease?
Hyperlipidemia is secondary to proteinuria and is completely normalized by angiotensin-converting enzyme inhibition in hypertensive fawn-hooded rats.
Improvement of lipid abnormalities associated with proteinuria using fosinopril, an angiotensin-converting enzyme inhibitor.
Long-term protection of obese Zucker rat kidneys from fibrosis and renal failure with an angiotensin-converting enzyme inhibitor/diuretic combination.
Losartan in patients with renal insufficiency.
National Trends in Statin Medication Prescribing in Patients With a History of Stroke or Transient Ischemic Attack.
Nutritional management of the child with mild to moderate chronic renal failure.
Patients' need for more counseling on diet, exercise, and smoking cessation: results from the National Ambulatory Medical Care Survey.
Preventing cardiovascular disease in women.
Proteinuria, hyperlipidemia, and the kidney.
Psoriasis risk in patients with type 2 diabetes in German primary care practices.
Sex differences in environmental and genetic factors for hypertension.
Statin use is independently associated with smaller infarct volume in nonlacunar MCA territory stroke.
The environmental and genetic evidence for the association of hyperlipidemia and hypertension.
The influencing factors for clopidogrel-mediated platelet inhibition are assay-dependent.
The management of cardiac disease in chronic uremia.
The management of idiopathic nephrotic syndrome in children.
The potential use of angiotensin-converting enzyme inhibitors in patients with hyperlipidemia.
Understanding lupus nephritis: diagnosis, management, and treatment options.
Use of medications to reduce cardiovascular risk among individuals with psychotic disorders and Type 2 diabetes.
Why are physicians not prescribing diuretics more frequently in the management of hypertension?
[An IgA nephropathy case with highly reduced urinary protein concomitant with reduced obesity]
[Comparative characteristic of angiotensin-converting enzyme inhibitor--captopril and the angiotensin II receptor blokers--losartan action on the oxidative metabolism in experimental hyperlipidemia in rabbits]
[Long-term preventive effect and safety of amiodarone in patients with paroxysmal atrial fibrillation refractory to class I antiarrhythmic agents: analysis based on patient profiles]
[Revascularization of occluded renal arteries. A case]
Hyperlipoproteinemia Type I
Genetic basis of familial dyslipidemia and hypertension: 15-year results from Utah.
Hyperlipoproteinemia Type II
Angiotensin-converting enzyme DD genotype and cardiovascular disease in heterozygous familial hypercholesterolemia.
Association of angiotensin converting enzyme gene insertion/deletion polymorphism and familial hypercholesterolemia in the Saudi population.
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2019 EXECUTIVE SUMMARY.
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2020 EXECUTIVE SUMMARY.
Hyperparathyroidism
Association between vitamin D receptor gene polymorphisms and tubular citrate handling in calcium nephrolithiasis.
Erythropoiesis-stimulating agent hyporesponsiveness in end-stage renal disease patients.
Erythropoiesis-stimulating agent hyporesponsiveness.
Meeting the challenges of a new millennium: optimizing the use of recombinant human erythropoietin.
[Pravovirus B19 infection--the cause of severe anaemia after renal transplantation]
[The activity of renin-angiotensin-aldosterone system (RAA) and possibilities of application angiotensin converting enzyme inhibitors (ACE I) in selected diseases of endocrine glands]
Hyperparathyroidism, Primary
Angiotensin-Converting Enzyme Inhibition and Parathyroid Hormone Secretion.
Coexisting Primary Hyperparathyroidism and Sarcoidosis Cause Increased Angiotensin-Converting Enzyme and Decreased Parathyroid Hormone and Phosphate Levels.
Hyperparathyroidism, Secondary
Effectiveness of multidisciplinary care for chronic kidney disease in Taiwan: a 3-year prospective cohort study.
Factors Related to Erythropoietin Hyporesponsiveness in Peritoneal Dialysis Patients with Anemia.
Regression of left ventricular hypertrophy in hemodialysis patients is possible.
The importance of lost minerals in heart failure.
Use of renin-angiotensin system inhibitors is associated with reduction of fracture risk in hemodialysis patients.
Hypersensitivity
A comparison of foreign body and hypersensitivity granuloma formation in the mouse: kinetic development, anergy, angiotensin converting enzyme levels, and response to captopril therapy.
A Forgotten Cause of Allergy at ER That Is Still Difficult to Diagnose and Treat at Poor Resource Setting: Angioedema after Using Angiotensin Converting Enzyme Inhibitors for 4 Years.
Acquired angioedema induced by angiotensin-converting enzyme inhibitors - experience of a hospital-based allergy center.
Advances in allergic skin disease, anaphylaxis, and hypersensitivity reactions to foods, drugs, and insects in 2008.
Allergy immunotherapy for inhalant allergens: Strategies to minimize adverse reactions.
Angiotensin-converting enzyme inhibitors and angioedema.
Antihypertensive medication use is associated with increased organ system involvement and hospitalization in emergency department patients with anaphylaxis.
Cofactors and comorbidities in patients with aspirin/NSAID hypersensitivity.
Des-Arg9-bradykinin metabolism in patients who presented hypersensitivity reactions during hemodialysis: role of serum ACE and aminopeptidase P.
Dialyzer reactions in a patient switching from peritoneal dialysis to hemodialysis.
Drug Allergies Documented in Electronic Health Records of a Large Healthcare System.
Effect of an ACE inhibitor on allergic reaction to a bee sting.
Effect of enalapril on allergen-induced cutaneous hypersensitivity reaction.
Effectiveness of amitriptyline versus cough suppressants in the treatment of chronic cough resulting from postviral vagal neuropathy.
Eosinophilic myocarditis in patients awaiting heart transplantation.
Hepatotoxicity associated with angiotensin-converting enzyme inhibitors.
Hypersensitivity reactions in patients receiving hemodialysis.
Increased sensitivity to bradykinin in pregnant rats.
Induction of granuloma-dependent angiotensin-converting enzyme and eosinophil chemotactic factor in the skin of athymic nude mice.
Insect sting allergy: new guidelines from the European and USA consensus groups: algorithms and recommendations.
Kinin-dependent hypersensitivity reactions in hemodialysis: metabolic and genetic factors.
Laryngeal sensory neuropathy in patients with diabetes mellitus.
Nonallergic Hypersensitivity to Nonsteroidal Antiinflammatory Drugs, Angiotensin-Converting Enzyme Inhibitors, Radiocontrast Media, Local Anesthetics, Volume Substitutes and Medications used in General Anesthesia.
Pollen count and presentation of Angiotensin-converting enzyme inhibitor-associated angioedema.
Predictors of severe systemic anaphylactic reactions in patients with Hymenoptera venom allergy: importance of baseline serum tryptase-a study of the European Academy of Allergology and Clinical Immunology Interest Group on Insect Venom Hypersensitivity.
Prominent features of allergic angioedema on oral mucosa.
Risk of severe anaphylaxis for patients with Hymenoptera venom allergy: Are angiotensin-receptor blockers comparable to angiotensin-converting enzyme (ACE) inhibitors?
Safety of Angiotensin-converting enzyme inhibitors in patients with insect venom allergies.
Severe Angioedema Associated With Angiotensin-Converting Enzyme Inhibitor Therapy in Two Patients With Pollen-Food Allergy Syndrome.
Studies of heterogeneity of angiotensin-converting enzyme and acid phosphatase in granulomatous lesions of skin.
The effect of electronegativity and angiotensin-converting enzyme inhibition on the kinin-forming capacity of polyacrylonitrile dialysis membranes.
The Microbiota and Health Promoting Characteristics of the Fermented Beverage Kefir.
The PRICE clinic for low-income elderly: a managed care model for implementing pharmacist-directed services.
The role of fiberoptic nasopharyngoscopy in the management of the acute airway in angioneurotic edema.
The therapeutic effect of a new angiotensin-converting enzyme inhibitor, enalapril maleate, in idiopathic hyperaldosteronism.
When Nothing Else Works: Fresh Frozen Plasma in the Treatment of Progressive, Refractory Angiotensin-Converting Enzyme Inhibitor-Induced Angioedema.
[Hypersensitivity reaction and Chinese heparin]
Hypersensitivity, Delayed
Serum angiotensin-converting enzyme and delayed hypersensitivity in pulmonary tuberculosis.
Hypersensitivity, Immediate
IgE receptor-mediated mast-cell renin release.
Hypersplenism
Erythropoiesis-stimulating agent hyporesponsiveness in end-stage renal disease patients.
Erythropoiesis-stimulating agent hyporesponsiveness.
Hypertension
1-trifluoromethoxyphenyl-3-(1-propionylpiperidin-4-yl) urea (TPPU), a soluble epoxide hydrolase inhibitor, lowers L-NAME-induced hypertension through suppression of angiotensin-converting enzyme in rats.
1995 update of the working group reports on chronic renal failure and renovascular hypertension. National High Blood Pressure Education Program Working Group.
2009 Canadian Hypertension Education Program recommendations: the scientific summary--an annual update.
2010 guidelines of the Taiwan Society of Cardiology for the management of hypertension.
2012 Brazilian Society of Rheumatology Consensus on the management of comorbidities in patients with rheumatoid arthritis.
2A.04: WHETHER ACE INHIBITOR/ARB COMBINED WITH CCB IS SUPERIOR TO OTHER COMBINATIONS? A META-ANALYSIS IN 20,669 HYPERTENSIVES.
35 MHz quartz crystal microbalance and surface plasmon resonance studies on the binding of angiotensin converting enzyme with lisinopril.
4B.04: COST-UTILITY OF ANGIOTENSIN-CONVERTING ENZYME INHIBITOR COMPARED TO THIAZIDE DIURETIC -BASED TREATMENT FOR HYPERTENSION IN ELDERLY AUSTRALIANS CONSIDERING DIABETES AS COMORBIDITY.
4B.10: 24 HOUR URINE FREE CORTISOL TO CORTISONE RATIO IS A NOVEL BIOMARKER FOR INCREASED LEFT VENTRICULAR MASS IN DIABETIC HYPERTENSIVES.
90-kDa N-domain angiotensin I-converting enzyme (ACE): possible marker for hypertension in a renal transplant model.
?-blocker use in patients after percutaneous coronary interventions: One size fits all? Worse outcomes in patients without myocardial infarction or heart failure.
?-Lipoic acid reduces neurogenic hypertension by blunting oxidative stress-mediated increase in ADAM17.
A 13-year review of lisinopril ingestions in children less than 6 years of age.
A case management of hypertension in the elderly in sub-Sahara Africa: lessons from Granny.
A Case of Life-Threatening Angioedema Occurred During Prolonged Angiotensin-Converting Enzyme Inhibitor Treatment.
A case of losartan induced angioedema.
A case of malignant hypertension and scleroderma after cosmetic surgery.
A Case of Nephrotic Syndrome Associated with Buerger's Disease.
A Case of Secondary Hypertension due to Giant Hydatid Cyst.
A central role for protein kinase C overactivity in diabetic glomerulosclerosis: implications for prevention with antioxidants, fish oil, and ACE inhibitors.
A clinical approach to the management of a patient with suspected renovascular disease who presents with leg ischemia.
A clinical dose of angiotensin-converting enzyme (ACE) inhibitor and heterozygous ACE deletion exacerbate Alzheimer's disease pathology in mice.
A clinical prediction rule for renal artery stenosis.
A Combination of Candesartan Cilexetil/hydrochlorothiazide (HCTZ), 8/12.5 mg, has a Similar Antihypertensive Efficacy and is Better Tolerated than Lisinopril/HCTZ, 10/12.5 mg.
A common variant of the ABO gene protects against hypertension in a Spanish population.
A comparative study of endralazine and captopril in essential hypertension: effect on renin levels, pulmonary function studies and lipid profile.
A comparative study of the prevalence of hyperkalemia with the use of angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers.
A comparison of outcomes with angiotensin-converting enzyme inhibitors and diuretics for hypertension in the elderly.
A comparison of outcomes with angiotensin-converting--enzyme inhibitors and diuretics for hypertension in the elderly.
A comparison of the effect of angiotensin converting enzyme inhibition and angiotensin II receptor antagonism on the structural changes associated with hypertension in rat small arteries.
A comparison of the tolerability of the direct renin inhibitor aliskiren and lisinopril in patients with severe hypertension.
A computational framework to identify patients with poor adherence to blood pressure lowering medication.
A critical appraisal of the guidelines from France, the UK, Europe and the USA for the management of hypertension in adults.
A cross-sectional study on factors associated with hypertension and genetic polymorphisms of renin-angiotensin-aldosterone system in Chinese hui pilgrims to hajj.
A decade of angiotensin-converting enzyme (ACE) inhibition.
A dedicated investigation unit improves management of syncopal attacks (Syncope Study of Unselected Population in Malmo--SYSTEMA I).
A diuretic is more effective than a beta-blocker in hypertensive patients not controlled on amlodipine and lisinopril.
A double blind comparison of perindopril and atenolol in essential hypertension.
A double-blind evaluation of captopril in elderly hypertensives.
A European Renal Best Practice (ERBP) position statement on the Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guideline for the Management of Blood Pressure in Non-dialysis-dependent Chronic Kidney Disease: an endorsement with some caveats for real-life application.
A fermented milk high in bioactive peptides has a blood pressure-lowering effect in hypertensive subjects.
A fluorescence-based protocol for quantifying angiotensin-converting enzyme activity.
A Liquid Chromatography-Tandem Mass Spectrometry Method for Evaluation of Two Brands of Enalapril 20?mg Tablets in Healthy Human Volunteers.
A Longitudinal Cohort Study of Aspirin Use and Progression of Emphysema-like Lung Characteristics on CT Imaging: The MESA Lung Study.
A multicenter comparison of adverse reaction profiles of isradipine and enalapril at equipotent doses in patients with essential hypertension.
A narrative review on the interaction between genes and the treatment of hypertension and breast cancer.
A new angiotensin-converting enzyme inhibitor: treatment of hypertension and congestive heart failure. Proceedings of an international symposium on enalapril, sponsored by Merck Sharp & Dohme International, São Paulo, Brazil, November 10, 1984.
A new myocardial conversion of angiotensin I.
A new syndrome: angiotensin-converting enzyme dysfunction syndrome: differential diagnosis and pathogenesis--case reports.
A new trial of the efficacy, tolerability, and safety of angiotensin-converting enzyme inhibition in mild systemic hypertension with concomitant diseases and therapies. Perindopril Therapeutic Safety Study Group (PUTS).
A nonpeptide, piperidine renin inhibitor provides renal and cardiac protection in double-transgenic mice expressing human renin and angiotensinogen genes.
A pharmacist's contribution within a patient-centered medical home.
A pharmacogenetic analysis of determinants of hypertension and blood pressure response to angiotensin-converting enzyme inhibitor therapy in patients with vascular disease and healthy individuals.
A phase II trial of the effect of perindopril on hand-foot skin reaction (HFSR) incidence and severity in patients receiving regorafenib for refractory mCRC.
A population study of ethnic variations in the angiotensin-converting enzyme I/D polymorphism: relationships with gender, hypertension and impaired glucose metabolism.
A Practical Approach to Hypertension Management in Diabetes.
A pragmatic approach to the use of angiotensin-converting enzyme inhibitors in acute myocardial infarction.
A program encouraging early defibrillation results in improved in-hospital resuscitation efficacy.
A prospective comparison of four study designs used in assessing safety and effectiveness of drug therapy in hypertension management.
A Prospective Noninterventional, Observational Study to Describe the Effectiveness and Safety of Trandolapril and Verapamil Single-Pill Combination in the Management of Patients with Hypertension and Type 2 Diabetes Mellitus: A Harvest TR Study.
A Quantitative Systems Physiology Model of Renal Function and Blood Pressure Regulation: Application in Salt-Sensitive Hypertension.
A randomised controlled trial of potential for pharmacologic prevention of new-onset albuminuria, hypertension and diabetes in a remote Aboriginal Australian community, 2008-2013.
A randomized comparison of the effect of four antihypertensive monotherapies on the subjective quality of life in previously untreated asymptomatic patients: field trial in general practice. The OCAPI Study Group. Optimiser le Choix d'un Anti-hypertenseur de Première Intention.
A randomized, controlled trial of steroids and cyclophosphamide in adults with nephrotic syndrome caused by idiopathic membranous nephropathy.
A randomized, double-blind, placebo-controlled study to determine the effects of valsartan on exercise time in patients with symptomatic heart failure with preserved ejection fraction.
A rash decision. The hazards of the wrongful use of adrenaline.
A Retrospective Study from 2 Centers in China on the Effects of Continued Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers in Patients with Hypertension and COVID-19.
A review of Perindopril in the reduction of cardiovascular events.
A Review of Potential Marine-Derived Hypotensive and Anti-Obesity Peptides.
A review on prescribing patterns of antihypertensive drugs.
A simplified approach to the management of non-ST-segment elevation acute coronary syndromes.
A single nucleotide polymorphism in the carboxylesterase gene is associated with the responsiveness to imidapril medication and the promoter activity.
A single-blind, randomized, cross-over study of angiotensin-converting enzyme inhibitor and triamterene and hydrochlorothiazide in the treatment of mild to moderate hypertension in the elderly.
A story of two ACEs.
A study of 24-hour ambulatory blood pressure monitoring in cases of intermittent acute porphyria with hypertension: special reference to safety and efficacy of angiotensin-converting enzyme inhibitor (enalapril) therapy.
A Study of Prescribing Valsartan in Out-patient Clinics at the Royal Hospital, Muscat, Oman.
A symposium: systemic hypertension: contribution of trandolapril, a new angiotensin-converting enzyme inhibitor, toward patient protection. Introduction.
A systematic review and network meta-analysis of the comparative efficacy of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in hypertension.
A systematic review on randomized control trials on rennin angiotensin aldosterone system inhibitors role in managing hypertension among hemodialysis patients.
Abnormalities in hypothalamic and neurohypophysial vasopressin content are not a consequence of hypertension in the spontaneously hypertensive rat.
Absence of association between the angiotensin-converting enzyme gene polymorphism and borderline hypertension in men of St Petersburg, Russia.
Absence of detectable regression of human hypertensive left ventricular hypertrophy following drug treatment for 1 year.
ACE and ADD1 gene in extra and intracranial atherosclerosis in ischaemic stroke.
ACE gene and physical activity, blood pressure, and hypertension: a population study in Finland.
ACE Gene Variant Causing High Blood Pressure May Be Associated With Medication-related Jaw Osteonecrosis.
ACE I/D and eNOS E298D gene polymorphisms in Saudi subjects with hypertension.
ACE I/D and MMP-7 A-181G variants and the risk of end stage renal disease.
ACE inhibition and cardiovascular mortality and morbidity in essential hypertension: the end of the search or a need for further investigations?
ACE inhibition and the vascular intima in hypertension.
ACE inhibition delays development of terminal renal failure in the presence of severe albuminuria.
ACE inhibition in chronic renal failure and in the treatment of diabetic nephropathy: focus on spirapril.
Ace inhibition in renal disease: risks and benefits.
ACE inhibition in the 1990s.
ACE Inhibitor and ARB utilization and expenditures in the Medicaid fee-for-service program from 1991 to 2008.
ACE inhibitor-induced angioedema of the small intestine: a case report.
ACE inhibitor-induced angioedema: a case report and review of current management.
ACE inhibitors and angiotensin II antagonists in renal transplantation: an analysis of safety and efficacy.
ACE inhibitors and ARBs: Managing potassium and renal function.
ACE inhibitors and chronotherapy.
ACE inhibitors and strategies for managing hypertension.
ACE inhibitors and survival of hemodialysis patients.
ACE inhibitors and their influence on inflammation, bronchial reactivity and cough.
ACE Inhibitors as First-Line Treatment Agents: A Comparative Study of Trandolapril and Enalapril on Casual and Ambulatory Blood Pressures.
ACE inhibitors as initial therapy for hypertension.
ACE inhibitors in elderly patients with hypertension. Special considerations.
ACE inhibitors in hypertension: a European viewpoint.
ACE inhibitors in renal disease.
ACE inhibitors in the elderly.
ACE inhibitors in the treatment of hypertension in the older patient.
ACE inhibitors, left ventricular mass and renal cyst growth in ADPKD.
ACE inhibitors. A safe option for hypertension and congestive heart failure.
ACE inhibitors. Differential use in elderly patients with hypertension.
ACE inhibitors: over two decades of use.
ACE inhibitors: review of four new agents.
ACE-I Inhibitory Activity from Phaseolus lunatus and Phaseolus vulgaris Peptide Fractions Obtained by Ultrafiltration.
ACE-inhibitors and defence reflexes of the airways.
ACE-inhibitors in coronary artery disease?
ACE-inhibitors in the treatment of elderly hypertensives.
ACE-Triggered Hypertension Incites Stroke: Genetic, Molecular, and Therapeutic Aspects.
ACE2-Ang-(1-7)-Mas Axis in Brain: A Potential Target for Prevention and Treatment of Ischemic Stroke.
Achieving maximal renal protection in nondiabetic chronic renal disease.
Acquired Brachial Cutaneous Dyschromatosis in a Middle Aged Male.
Acquired brachial cutaneous dyschromatosis.
Acquired brachial cutaneous dyschromatosis: a common pigmentary disorder of the arm in middle-aged women.
Active-site directed peptide l-Phe-d-His-l-Leu inhibits angiotensin converting enzyme activity and dexamethasone-induced hypertension in rats.
Activity and bioavailability of food protein-derived angiotensin-I-converting enzyme-inhibitory peptides.
Activity of angiotensin-converting enzyme in hereditary stress-induced arterial hypertension.
Activity Prediction and Molecular Mechanism of Bovine Blood Derived Angiotensin I-Converting Enzyme Inhibitory Peptides.
Acute and chronic effects of the angiotensin-converting enzyme inhibitor captopril in severe hypertension.
Acute and chronic in vivo inhibition of angiotensin-converting enzyme by perindopril in the endothelium and adventitia of large arteries and organs of the rabbit.
Acute and long-term effects of ACE inhibition on renal haemodynamics in glomerular and interstitial nephropathies.
Acute effect of captopril administration on baroreflex sensitivity in patients with acute myocardial infarction.
Acute effect of captopril on serum lipid peroxides level in hypertensive patients.
Acute effects of angiotensin-converting enzyme inhibition on coronary vasomotion in hypertensive patients.
Acute effects of captopril on the coronary circulation of patients with hypertension and angina.
Acute hypertension after nitric oxide synthase inhibition is mediated primarily by increased endothelin vasoconstriction.
Acute Kidney Injury in COVID-19 Patients: An Inner City Hospital Experience and Policy Implications.
Acute liver failure due to enalapril.
Acute phosphate nephropathy following oral sodium phosphate bowel purgative: an underrecognized cause of chronic renal failure.
Acute phosphate nephropathy.
Acute poststreptococcal glomerulonephritis: the most common acute glomerulonephritis.
Acute renal failure after the use of angiotensin-converting-enzyme inhibitors in patients without renal artery stenosis.
Acute tubular necrosis in kidney transplant patients treated with enalapril.
Adding thiazide to a rennin-angiotensin blocker regimen to improve left ventricular relaxation in diabetes and nondiabetes patients with hypertension.
Additive effects of diltiazem and lisinopril in the treatment of elderly patients with mild-to-moderate hypertension.
ADDRESSING HYPERTENSION IN THE PATIENT WITH TYPE 2 DIABETES MELLITUS: PATHOGENESIS, GOALS, AND THERAPEUTIC APPROACH.
Adenine/cytosine1166 polymorphism of the angiotensin II type 1 receptor gene and the antihypertensive response to angiotensin-converting enzyme inhibitors.
Adherence to oral antihypertensive medications, are all medications equal?
Adherence to Oral Medications for Hypertension and Diabetes in Veterans with Comorbid Airflow Limitation.
Administration of bovine casein-derived peptide prevents cognitive decline in Alzheimer disease model mice.
Advanced Approaches Based on Expression of Different Genes and Biomarkers for the Diagnosis and Treatment of Renal Disorders.
Advanced glycation end products activate a chymase-dependent angiotensin II-generating pathway in diabetic complications.
Advances in angiotensin converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs).
Advances in antihypertensive combination therapy: benefits of low-dose thiazide diuretics in conjunction with omapatrilat, a vasopeptidase inhibitor.
Advances in noninvasive screening for renovascular disease.
Adverse effects of angiotensin-converting enzyme inhibitors in antihypertensive therapy with focus on quinapril.
Age and the pharmacodynamics of angiotensin converting enzyme inhibitors enalapril and enalaprilat.
Age-dependent hypertension in Mpv17-deficient mice, a transgenic model of glomerulosclerosis and inner ear disease.
Age-Related Dysfunctions: Evidence and Relationship with Some Risk Factors and Protective Drugs.
Age-related increase in sensitivity for ischemic ATP breakdown in hypertrophic hearts of SHR normalized by enalapril.
Aggregation behavior of fosinopril sodium--a new angiotensin-converting enzyme inhibitor.
Aggressive blood pressure reduction and renin-angiotensin system blockade in chronic kidney disease: time for re-evaluation?
Albumin transport characteristics of rat aorta in early phase of hypertension.
Albuminuria among Alaska Natives - Findings from the Genetics of Coronary Artery Disease in Alaska Natives (GOCADAN) Study.
Aldosterone blockers (mineralocorticoid receptor antagonism) and potassium-sparing diuretics.
Aldosterone breakthrough during angiotensin II receptor blockade in hypertensive patients with diabetes mellitus.
Aldosterone escape with diuretic or angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker combination therapy in patients with mild to moderate hypertension.
Aldosterone plays a pivotal role in the pathogenesis of thrombotic microangiopathy in SHRSP.
Aldosterone synthase inhibitors in hypertension: current status and future possibilities.
Aldosterone: Role in Edematous Disorders, Hypertension, Chronic Renal Failure, and Metabolic Syndrome.
Aliskiren - an alternative to angiotensin-converting enzyme inhibitors or angiotensin receptor blockers in the therapy of arterial hypertension.
Aliskiren add-on therapy effectively reduces proteinuria in chronic kidney disease: An open-label prospective trial.
Aliskiren in the management of hypertension.
Aliskiren therapy in hypertension and cardiovascular disease: a systematic review and a meta-analysis.
Aliskiren, the first direct renin inhibitor for treatment of hypertension: The path of its development.
Aliskiren, the first renin inhibitor for treating hypertension: reactive renin secretion may limit its effectiveness.
Aliskiren, the future of renin-angiotensin system blockade?
Aliskiren: a new inhibitor of renin-angiotensin aldosterone system activity.
Aliskiren: a renin inhibitor offering a new approach for the treatment of hypertension.
Allergic reaction related to ramipril use: a case report.
ALLHAT in perspective: implications to clinical practice and clinical trials.
ALLHAT says diuretics are better; ANBP2 says ACEs are better--can we resolve the differences?
alpha-adducin and angiotensin I-converting enzyme polymorphisms in essential hypertension.
alpha-Adducin and angiotensin-converting enzyme polymorphisms in hypertension: evidence for a joint influence on albuminuria.
alpha-Adducin Gly460Trp polymorphism, left ventricular mass and plasma renin activity.
Alpha-adrenergic and angiotensin II pressor sensitivity in hypertensive patients treated with an angiotensin-converting enzyme inhibitor.
Alport syndrome: its effects on the glomerular filtration barrier and implications for future treatment.
Alterations in circulatory and renal angiotensin-converting enzyme and angiotensin-converting enzyme 2 in fetal programmed hypertension.
Alternative pathways for angiotensin II generation in the cardiovascular system.
Alternative pharmacologic approaches to the initial management of hypertension.
Ambulatory systolic blood pressure is related to the deletion allele of the angiotensin I converting enzyme gene in young normotensives with parental history of hypertension.
Amlodipine and angiotensin-converting enzyme inhibitor combination versus amlodipine monotherapy in hypertension: a meta-analysis of randomized controlled trials.
Amlodipine besylate/olmesartan medoximil fixed combination for the treatment of hypertension.
An ACE inhibitor reduces bactericidal activity of human neutrophils in vitro and impairs mouse neutrophil activity in vivo.
An ACE inhibitor reduces Th2 cytokines and TGF-beta1 and TGF-beta2 isoforms in murine lupus nephritis.
An effective approach for treating elderly patients with isolated systolic hypertension: results of an Italian multicenter study with fosinopril.
An open-label, noncomparative, multicenter study of ramipril in the treatment of patients with mild-to-moderate hypertension.
An open-label, randomized, controlled, 4-week comparative clinical trial of barnidipine hydrochloride, a calcium-channel blocker, and benazepril, an angiotensin-converting enzyme inhibitor, in Chinese patients with renal parenchymal hypertension.
An overview of angiotensin-converting enzyme inhibitors in the treatment of hypertension.
An overview of the influence of ACE inhibitors on fetal-placental circulation and perinatal development.
An Unexpected Case of Lisinopril-Associated Severe Hyponatremia.
An update of irbesartan and renin-angiotensin system blockade in diabetic nephropathy.
Analysis from the EMPA-REG OUTCOME® trial indicates empagliflozin may assist in preventing the progression of chronic kidney disease in patients with type 2 diabetes irrespective of medications that alter intrarenal hemodynamics.
Analysis of Angiotensin Converting Enzyme, Endothelial Nitric Oxide Synthase & Serotonin Gene Polymorphisms among Atrial Septal Defect Subjects with and without Pulmonary Arterial Hypertension.
Analysis of candidate genes and hypertension in African American adults.
Analysis of Family- and Population-Based Samples Using Multiple Linkage Disequilibrium Mapping.
Analysis of insertion/deletion polymorphisms of the angiotensin converting enzyme gene in Malaysian end-stage renal disease patients.
Analysis of risk factors for chronic subdural haematoma recurrence after burr hole surgery: Optimal management of patients on antiplatelet therapy.
Anemia and angiotensin-converting enzyme inhibition in renal transplant recipients.
Anesthetic Management of the Hypertensive Patient: Part I.
Anesthetic Management of the Hypertensive Patient: Part II.
Angina Hospitalization Rates in Women With Signs and Symptoms of Ischemia But no Obstructive Coronary Artery Disease: A Report from the WISE (Women's Ischemia Syndrome Evaluation) Study.
Angioedema as a complication in periodontal surgery: report of a case.
Angioedema induced by angiotensin-converting enzyme inhibitors.
Angioedema related to Angiotensin inhibitors.
Angioedema secondary to angiotensin-converting enzyme inhibitors.
Angioedema: 5 years' experience, with a review of the disorder's presentation and treatment.
Angioneurotic edema, agranulocytosis, and fatal septicemia following captopril therapy.
Angiotenin Converting Enzyme Inhibitor Treatment of Hypertension in Infancy and Childhood.
Angiotensin and adrenoceptors in the hemodynamic response to aortic cross-clamping.
Angiotensin and angiotensin converting enzyme tissue levels in two-kidney, one clip hypertensive rats.
Angiotensin and bradykinin peptides in the TGR(mRen-2)27 rat.
Angiotensin blockade reverses hypertension during long-term nitric oxide synthase inhibition.
Angiotensin blocking drugs and the heart beyond 2000.
Angiotensin Converting Enzyme (ACE) Inhibitor Extends Caenorhabditis elegans Life Span.
Angiotensin converting enzyme (ACE) inhibitors and renal function. A review of the current status.
Angiotensin converting enzyme (ACE) inhibitors in experimental hypertension: influence on heart and arteries.
Angiotensin converting enzyme (ACE) inhibitors versus angiotensin receptor blockers for primary hypertension.
Angiotensin converting enzyme 1 in the median preoptic nucleus contributes to chronic intermittent hypoxia hypertension.
Angiotensin converting enzyme 2 and angiotensin (1-7) axis in pulmonary arterial hypertension.
Angiotensin Converting Enzyme 2 antagonizes Ang II-induced pressor response and NADPH oxidase activation in WKY rats and in SHR model.
Angiotensin Converting Enzyme 90 kDa isoform: Biomarker for diagnosis of preeclampsia?
Angiotensin converting enzyme and genetic hypertension: cloning of rat cDNAs and characterization of the enzyme.
Angiotensin converting enzyme gene deletion allele is independently and strongly associated with coronary atherosclerosis and myocardial infarction.
Angiotensin converting enzyme gene insertion/deletion polymorphism, angiotensinogen gene polymorphisms, family history of hypertension, and childhood blood pressure.
Angiotensin converting enzyme gene polymorphism (insertion/deletion) and hypertension in adult Asian Indians: a population-based study from Calcutta, India.
Angiotensin converting enzyme gene polymorphism and hypertension: no ace yet in the pack of cards.
Angiotensin Converting Enzyme Gene Polymorphism and its Association with Hypertension in South Indian Population.
Angiotensin converting enzyme gene polymorphism in renal transplant patients with IgA nephropathy: relationship with graft function and prevalence of hypertension.
Angiotensin converting enzyme gene polymorphism: potential silencer motif and impact on progression in IgA nephropathy.
Angiotensin converting enzyme genetic polymorphism is not associated with hypertension in a cross-sectional sample of a Japanese population: the Shibata Study.
Angiotensin converting enzyme genotype influences the response to the angiotensin II receptor antagonist losartan in patients with hypertension.
Angiotensin converting enzyme inhibition and cerebral circulation--a review.
Angiotensin converting enzyme inhibition and dihydropyridine calcium channel blockade in the treatment of left ventricular hypertrophy in arterial hypertension.
Angiotensin converting enzyme inhibition and vascular hypertrophy in hypertension.
Angiotensin converting enzyme inhibition does not prevent development of ACTH-induced hypertension in sheep.
Angiotensin converting enzyme inhibition for arterial hypertension reduces the risk of recurrence in patients with chronic subdural hematoma possibly by an antiangiogenic mechanism.
Angiotensin converting enzyme inhibition in hypertension.
Angiotensin converting enzyme inhibition prevents trophic and hypertensive effects of an antagonist of adenosine receptors.
Angiotensin converting enzyme inhibition reveals an important role for the renin system in the control of normal and high blood pressure in man.
Angiotensin converting enzyme inhibition, pulse wave velocity and ambulatory blood pressure measurements in essential hypertension.
Angiotensin converting enzyme inhibition. Unique and effective therapy for hypertension and congestive heart failure.
Angiotensin converting enzyme inhibitor induced cough: experience in Siriraj Hospital.
Angiotensin converting enzyme inhibitor potentiates the hypoglycaemic effect of NG-nitro-L-arginine methyl ester (L-NAME) in rats.
Angiotensin converting enzyme inhibitor therapy.
Angiotensin converting enzyme inhibitor treatment of hypertension in infancy and childhood.
Angiotensin converting enzyme inhibitor-induced renal dysfunction: recommendations for prevention.
Angiotensin converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) and lactation: an update.
Angiotensin converting enzyme inhibitors and angiotensin II receptor blockers: evidence for and against the combination in the treatment of hypertension and proteinuria.
Angiotensin converting enzyme inhibitors and angiotensin receptor blockers improved the outcome of patients with severe COVID-19 and hypertension.
Angiotensin converting enzyme inhibitors and angiotensin receptor blockers in hypertension.
Angiotensin converting enzyme inhibitors and angiotensin receptor blockers in the treatment of hypertension: should they be used together?
Angiotensin converting enzyme inhibitors and cognitive and functional decline in patients with Alzheimer's disease: an observational study.
Angiotensin converting enzyme inhibitors and delayed onset, recurrent angioedema of the head and neck.
Angiotensin converting enzyme inhibitors and diuretics in hypertension.
Angiotensin converting enzyme inhibitors and moderate hypertension.
Angiotensin converting enzyme inhibitors and progressive renal insufficiency. Current experience and future directions.
Angiotensin converting enzyme inhibitors and renal function.
Angiotensin converting enzyme inhibitors and the allergist.
Angiotensin converting enzyme inhibitors and the progress of antihypertensive therapy.
Angiotensin converting enzyme inhibitors and vascular protection in hypertension.
Angiotensin converting enzyme inhibitors as initial monotherapy in severe hypertension. Quinapril and captopril.
Angiotensin converting enzyme inhibitors do not increase the risk of poor outcomes in COVID-19 disease. A multi-centre observational study.
Angiotensin converting enzyme inhibitors enhance the antihypertensive efficacy of diuretics and blunt or prevent adverse metabolic effects.
Angiotensin converting enzyme inhibitors for hypertension and heart failure?
Angiotensin converting enzyme inhibitors in hypertension: potential problems.
Angiotensin converting enzyme inhibitors in modern treatment of hypertension.
Angiotensin converting enzyme inhibitors in perspective: an update.
Angiotensin converting enzyme inhibitors in pregnancy.
Angiotensin converting enzyme inhibitors in the treatment of hypertension.
Angiotensin converting enzyme inhibitors in the treatment of hypertension: efficacy, metabolic effects and side effects.
Angiotensin converting enzyme inhibitors reduce alcohol consumption: some possible mechanisms and important conditions for its therapeutic use.
Angiotensin converting enzyme inhibitors use in the first trimester of pregnancy.
Angiotensin converting enzyme inhibitors v. angiotensin receptor blockers in the management of hypertension: a funder's perspective.
Angiotensin converting enzyme inhibitors versus calcium antagonists in the treatment of diabetic hypertensive patients.
Angiotensin converting enzyme inhibitors, regional vascular hemodynamics, and the development and prevention of experimental genetic hypertension.
Angiotensin converting enzyme inhibitors: are they preferred first-line therapy?
Angiotensin converting enzyme inhibitors: differences and advantages for first line therapy in hypertension.
Angiotensin converting enzyme inhibitory peptides from a lactotripeptide-enriched milk beverage are absorbed intact into the circulation.
Angiotensin converting enzyme insertion/deletion polymorphism does not influence postcardiac transplantation hypertension onset or progression.
Angiotensin converting enzyme insertion/deletion polymorphism is associated with increased adiposity and blood pressure in obese children and adolescents.
Angiotensin Converting Enzyme insertion/deletion polymorphism: A potential connection with hypertension in childhood obesity.
Angiotensin converting enzyme: history and relevance.
Angiotensin gene polymorphism as a determinant of posttransplantation renal dysfunction and hypertension.
Angiotensin I converting enzyme activity in hypertension. Relationship to blood pressure, renin-sodium profiles, and antihypertensive therapy.
Angiotensin I converting enzyme activity in portal vein studied in normotensive rats and in models of primary and secondary hypertension.
Angiotensin I converting enzyme gene polymorphism and insulin resistance in patients with hypertension.
Angiotensin I converting enzyme gene polymorphism in Chinese patients with hypertension.
Angiotensin I-converting enzyme antisense gene therapy causes permanent antihypertensive effects in the SHR.
Angiotensin I-converting enzyme antisense prevents altered renal vascular reactivity, but not high blood pressure, in spontaneously hypertensive rats.
Angiotensin I-converting enzyme gene polymorphism in a Serbian population: a gender-specific association with hypertension.
Angiotensin I-converting enzyme genotypes and angiotensin II receptors. Response to therapy.
Angiotensin I-converting enzyme inhibitory peptides derived from bovine casein and identified by MALDI-TOF-MS/MS.
Angiotensin I-converting enzyme inhibitory peptides produced from tuna cooking juice hydrolysate by continuous enzymatic membrane reactor.
Angiotensin II reactivation and aldosterone escape phenomena in renin-angiotensin-aldosterone system blockade: is oral renin inhibition the solution?
Angiotensin II receptor blockade or deletion of vascular endothelial ACE does not prevent vascular dysfunction and remodeling in 20-HETE-dependent hypertension.
Angiotensin II receptor blockers in older patients.
Angiotensin II receptor type 1-mediated vascular oxidative stress and proinflammatory gene expression in aldosterone-induced hypertension: the possible role of local renin-angiotensin system.
Angiotensin II type 1 receptor antagonist and angiotensin-converting enzyme inhibitor altered the activation of Cu/Zn-containing superoxide dismutase in the heart of stroke-prone spontaneously hypertensive rats.
Angiotensin II type 1 receptor antagonist, losartan, causes regression of left ventricular hypertrophy in end-stage renal disease.
Angiotensin II type 1 receptor blockade: a novel therapeutic concept.
Angiotensin II Type 1 Receptor Blockade: a Novel Therapeutic Concept.
Angiotensin II type I receptor blocker and endothelial function in humans: role of nitric oxide and oxidative stress.
Angiotensin II up-regulates angiotensin I-converting enzyme (ACE), but down-regulates ACE2 via the AT1-ERK/p38 MAP kinase pathway.
Angiotensin II, angiotensin-converting enzyme inhibitors, and blood vessel structure.
Angiotensin II-receptor antagonists: an overview.
Angiotensin II-receptor blockers: clinical relevance and therapeutic role.
Angiotensin in cardiac surgery: efficacy in patients on angiotensin converting enzyme inhibitors.
Angiotensin inhibitors for hypertension.
Angiotensin receptor blockers (ARB) outperform angiotensin-converting enzyme (ACE) inhibitors on ischemic stroke prevention in patients with hypertension and diabetes - A real-world population study in Taiwan.
Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors: Challenges in Comparative Effectiveness Using Medicare Data.
Angiotensin receptor blockers for management of hypertension.
Angiotensin receptor blockers in chronic renal disease: the promise of a bright clinical future.
Angiotensin Receptor Blockers Versus Angiotensin Converting Enzyme Inhibitors for the Treatment of Arterial Hypertension and the Role of Olmesartan.
Angiotensin receptors: physiology and pharmacology.
Angiotensin system inhibitors and outcome of sunitinib treatment in patients with metastatic renal cell carcinoma: A retrospective examination.
Angiotensin-converting enzyme (ACE) gene insertion/deletion polymorphism is not a risk factor for hypertension in SLE nephritis.
Angiotensin-converting enzyme (ACE) gene polymorphism and the erythrocyte sodium-lithium countertransporter (SLC) phenotype in hypertension.
Angiotensin-converting enzyme (ACE) gene polymorphisms, serum ACE activity and blood pressure in a Spanish-Mediterranean population.
Angiotensin-converting enzyme (ACE) inhibitor prescription affects non-small-cell lung cancer (NSCLC) patients response to PD-1/PD-L1 immune checkpoint blockers.
Angiotensin-converting enzyme (ACE) inhibitors and angio-oedema.
Angiotensin-converting enzyme (ACE) inhibitory potential of standardized Mucuna pruriens seed extract.
Angiotensin-converting enzyme 2 suppresses pathological hypertrophy, myocardial fibrosis, and cardiac dysfunction.
Angiotensin-converting enzyme 2: the first decade.
Angiotensin-converting enzyme activity of the brain and the aorta in experimental hypertensive rats.
Angiotensin-Converting Enzyme and Adducin-1 Polymorphisms in Women With Preeclampsia and Gestational Hypertension.
Angiotensin-converting enzyme and Angiotensin-converting enzyme 2 are involved in sinoaortic denervation-induced cardiovascular hypertrophy in rats.
Angiotensin-converting enzyme and angiotensinogen gene polymorphisms are non-randomly distributed in oral contraceptive-induced hypertension.
Angiotensin-converting enzyme as a potential target for treatment of Alzheimer's disease: inhibition or activation?
Angiotensin-converting enzyme D/I gene polymorphism and age-related changes in pulse pressure in subjects with hypertension.
Angiotensin-converting enzyme deletion polymorphism is associated with hypertension in a Sikh population.
Angiotensin-converting enzyme G2350A gene polymorphisms and hypertension among patients with intracerebral hemorrhage.
Angiotensin-converting enzyme gene and retinal arteriolar narrowing: The Funagata Study.
Angiotensin-converting enzyme gene I/D polymorphism increases the susceptibility to hypertension and additive diseases: A study on North Indian patients.
Angiotensin-converting enzyme gene insertion/deletion polymorphism and hypertension disease.
Angiotensin-converting enzyme gene insertion/deletion polymorphism and left ventricular hypertrophy in hemodialysis patients.
Angiotensin-converting enzyme gene insertion/deletion, not bradykinin B2 receptor -58T/C gene polymorphism, associated with angiotensin-converting enzyme inhibitor-related cough in Chinese female patients with non-insulin-dependent diabetes mellitus.
Angiotensin-converting enzyme gene polymorphism in hypertensive rural population of Haryana, India.
Angiotensin-converting enzyme gene polymorphism in north Indian population with obstructive sleep apnea.
Angiotensin-converting enzyme gene polymorphism in systemic hypertension.
Angiotensin-converting enzyme gene polymorphism, carotid intima-media thickness, and left ventricular mass index in adolescent hypertension.
Angiotensin-converting enzyme gene polymorphisms and hypertension in occupational noise exposure in Egypt.
Angiotensin-converting enzyme gene polymorphisms and obesity: an examination of three black populations.
Angiotensin-converting enzyme I/D polymorphism and hypertension: the Ohasama study.
Angiotensin-converting enzyme in human skeletal muscle. A simple in vitro assay of activity in needle biopsy specimens.
Angiotensin-converting enzyme inhibiting ability of ethanol extracts, steviol glycosides and protein hydrolysates from stevia leaves.
Angiotensin-converting enzyme inhibition and vascular structure in hypertension.
Angiotensin-converting enzyme inhibition as first-line treatment for hypertension.
Angiotensin-converting enzyme inhibition attenuates arterial constrictor responses in experimental hypertension.
Angiotensin-converting enzyme inhibition improves cardiac function. Role of bradykinin.
Angiotensin-converting enzyme inhibition in congestive heart failure: benefit and perspective.
Angiotensin-converting enzyme inhibition in hypertensive patients is associated with a reduction in the occurrence of atrial fibrillation.
Angiotensin-converting enzyme inhibition in mild hypertension with concomitant diseases and therapies: an efficacy, safety, and compatibility study of novel design, the Perindopril Therapeutic Safety Study.
Angiotensin-converting enzyme inhibition in renal and hypertensive disorders.
Angiotensin-converting enzyme inhibition in renal disease; contrasting effects on renal function in renal artery stenosis and progressive renal injury.
Angiotensin-converting enzyme inhibition in the prevention and treatment of chronic renal damage in the hypertensive fawn-hooded rat.
Angiotensin-converting enzyme inhibition reduces oxidative stress and protects dopaminergic neurons in a 6-hydroxydopamine rat model of Parkinsonism.
Angiotensin-converting enzyme inhibition to enhance vascular health--clinical and research models.
Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing ENdothelial Dysfunction) Study.
Angiotensin-converting enzyme inhibition with spirapril in patients with coronary artery disease.
Angiotensin-converting enzyme inhibition, cell growth, and left ventricular hypertrophy in hypertension.
Angiotensin-converting enzyme inhibition-emerging pulmonary issues relating to cough.
Angiotensin-converting enzyme inhibitor (SQ 20881) in the diagnosis of renovascular hypertension.
Angiotensin-converting enzyme inhibitor activity of peptides derived from Kacang goat skin collagen through thermolysin hydrolysis.
Angiotensin-converting enzyme inhibitor cilazapril prevents chronic morphologic vasospasm in rat.
Angiotensin-converting enzyme inhibitor fetopathy.
Angiotensin-converting enzyme inhibitor preserves p21 and endothelial nitric oxide synthase expression in monocrotaline-induced pulmonary arterial hypertension in rats.
Angiotensin-Converting Enzyme Inhibitor Protects Against Cisplatin Nephrotoxicity by Modulating Kinin B1 Receptor Expression and Aminopeptidase P Activity in Mice.
Angiotensin-converting enzyme inhibitor versus calcium antagonist in the treatment of hypertension.
Angiotensin-Converting Enzyme Inhibitor-Induced Gastrointestinal Angioedema: The First Danish Case Report.
Angiotensin-converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARBs) may be safe for COVID-19 patients.
Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers are not associated with severe COVID-19 infection in a multi-site UK acute hospital trust.
Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers reduced dementia risk in patients with diabetes mellitus and hypertension.
Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers used for the treatment of hypertension appear to be safe in the early posttransplant period.
Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers: is there a difference in response and any advantage to using them together in the treatment of hypertension?
Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for hypertension: are they equivalent?
Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in African-American patients with hypertension.
Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in combination: theory and practice.
Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in hypertension due to primary aldosteronism: a case for exclusion.
Angiotensin-converting enzyme inhibitors and cognitive decline in older adults with hypertension: results from the Cardiovascular Health Study.
Angiotensin-Converting Enzyme Inhibitors and Contrast-Associated Acute Kidney Injury After Coronary Angiography and Intervention.
Angiotensin-converting enzyme inhibitors and cough: a prospective evaluation in hypertension and in congestive heart failure.
Angiotensin-converting enzyme inhibitors and glycosuria.
Angiotensin-converting enzyme inhibitors and insulin sensitivity: metabolic effects in hypertension, diabetes, and heart failure.
Angiotensin-converting enzyme inhibitors and stroke risk: benefit beyond blood pressure reduction?
Angiotensin-converting enzyme inhibitors and their influence on inflammation, bronchial reactivity and cough. A research review.
Angiotensin-converting enzyme inhibitors for bevacizumab-induced hypertension.
Angiotensin-converting enzyme inhibitors for systemic hypertension in young and elderly patients.
Angiotensin-converting enzyme inhibitors implicated in oral mucosal lichenoid reactions.
Angiotensin-converting enzyme inhibitors in hypertension and congestive heart failure.
Angiotensin-converting enzyme inhibitors in hypertension. A dozen years of experience.
Angiotensin-converting enzyme inhibitors in hypertension: a review.
Angiotensin-Converting Enzyme Inhibitors in Hypertension: To Use or Not to Use?
Angiotensin-converting enzyme inhibitors in the treatment of hypertension.
Angiotensin-converting enzyme inhibitors in the treatment of hypertension: an update.
Angiotensin-converting enzyme inhibitors in the treatment of mild arterial hypertension.
Angiotensin-Converting Enzyme Inhibitors Induce Cough.
Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers Use and COVID-19 Infection Among 824 650 Patients With Hypertension From a US Integrated Healthcare System.
Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin-angiotensin-aldosterone system inhibitors involving 158 998 patients.
Angiotensin-converting enzyme inhibitors side effects--physiologic and non-physiologic considerations.
Angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers in the treatment of hypertension: Adding more fuel for the fire?
Angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers. A mini-symposium held at the British Hypertension Society Meeting, September 2005.
Angiotensin-Converting Enzyme Inhibitors vs. Angiotensin Receptor Blockers for the Treatment of Hypertension in Adults With Type 2 Diabetes: Why We Favour Angiotensin Receptor Blockers.
Angiotensin-converting enzyme inhibitors.
Angiotensin-converting enzyme inhibitors: a new mechanism of action.
Angiotensin-converting enzyme inhibitors: are they all alike?
Angiotensin-converting enzyme inhibitors: congestive heart failure and beyond.
Angiotensin-converting enzyme inhibitors: pathogenic and therapeutic implications for arterial hypertension.
Angiotensin-converting enzyme insertion/deletion polymorphism has no effect on the risk of atherosclerotic stroke or hypertension.
Angiotensin-converting enzyme labeled with [3H]captopril. Tissue localizations and changes in different models of hypertension in the rat.
Angiotensin-converting enzyme polymorphism in patients with terminal renal failure.
Angiotensin-converting enzyme, sleep-disordered breathing, and hypertension.
Angiotensin-Converting-Enzyme 2 and Renin-Angiotensin System Inhibitors in COVID-19: An Update.
Angiotensin-converting-enzyme inhibitors and diuretics for hypertension.
Angiotensin-converting-enzyme inhibitors in the treatment of hypertension.
Angiotensin-I converting enzyme (ACE) gene polymorphism and the erythrocyte sodium-lithium countertransport in hypertension.
Angiotensin-I Converting Enzyme (ACE) Inhibitory and Anti-Hypertensive Effect of Protein Hydrolysate from Actinopyga lecanora (Sea Cucumber) in Rats.
Angiotensin-I converting enzyme inhibitory peptide derived from the shiitake mushroom (Lentinula edodes).
Angiotensin-I-Converting Enzyme (ACE)-Inhibitory Peptides from Plants.
Angiotensin-II receptor antagonists: their place in therapy.
Angiotensin-II receptor blockers or angiotensin converting enzyme inhibitors for the treatment of hypertension amid COVID-19 pandemic.
Angiotensin-II-receptors: new targets for antihypertensive therapy.
Angiotensinase and vasopressinase activities in hypothalamus, plasma, and kidney after inhibition of angiotensin-converting enzyme: basis for a new working hypothesis.
Angiotensinogen and angiotensin-converting enzyme genotypes, and day and night blood pressures in elderly Japanese hypertensives.
Angiotensinogen gene haplotype and hypertension: interaction with ACE gene I allele.
Angiotensinogen gene polymorphism predicts hypertension, and iridological constitutional classification enhances the risk for hypertension in Koreans.
Angiotensinogen Met235Thr polymorphism, angiotensin-converting enzyme inhibitor therapy, and the risk of nonfatal stroke or myocardial infarction in hypertensive patients.
Anthology of the renin-angiotensin system: a one hundred reference approach to angiotensin II antagonists.
Anti-diabetic and anti-hypertensive potential of sprouted and solid-state bioprocessed soybean.
Anti-inflammatory action of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers and the prevention of diabetes mellitus in obese patients with hypertension.
Anti-inflammatory Effects of ?-3 Polyunsaturated Fatty Acids and Soluble Epoxide Hydrolase Inhibitors in Angiotensin-II-Dependent Hypertension.
Anti-ischemic effects of angiotensin- converting enzyme inhibition in hypertension.
Anti-ischemic effects of cilazapril in patients with both hypertension and angina pectoris. Preliminary report of a pilot study.
Antidiabetic and Other Therapies Used in Subjects with Diabetes and Chronic Kidney Disease in a Hospital-Based Clinic Population in Greece.
Antifibrotic effect of Ac-SDKP and angiotensin-converting enzyme inhibition in hypertension.
Antihypertensive action of a novel orally active angiotensin converting enzyme inhibitor altiopril calcium (MC-838) in several hypertensive models of rats: comparison with captopril.
Antihypertensive action of angiotensin-I converting enzyme inhibitors in the kidney.
Antihypertensive activity of Rosa rugosa Thunb. flowers: angiotensin I converting enzyme inhibitor.
Antihypertensive agents acting on the renin angiotensin system and the risk of sepsis.
Antihypertensive agents in patients with diabetes: trade-off between renal and cardiovascular protection.
Antihypertensive agents prevent nephrosclerosis and left ventricular hypertrophy induced in rats by prolonged inhibition of nitric oxide synthesis.
Antihypertensive and antiproteinuric efficacy of ramipril in children with chronic renal failure.
Antihypertensive and cardioprotective effects after angiotensin-converting enzyme inhibition: role of kinins.
Antihypertensive and natriuretic effects of CGS 30440, a dual inhibitor of angiotensin-converting enzyme and neutral endopeptidase 24.11.
Antihypertensive and renal protective effect of Shunaoxin pill combined with captopril on spontaneous hypertension rats.
Antihypertensive drugs and fatal myocardial infarction in persons with uncomplicated hypertension.
Antihypertensive Drugs and the Risk of Cancer: A Nationwide Cohort Study.
Antihypertensive drugs use over a 5-year period among children and adolescents in Beijing, China: An observational study.
Antihypertensive effect of spirapril and felodipine during repeated administration to spontaneously hypertensive rats.
Antihypertensive effect of the oral angiotensin I-converting enzyme inhibitor in long-term treatment of hypertensive patients.
Antihypertensive effect of zofenopril plus hydrochlorothiazide versus zofenopril monotherapy in patients with essential hypertension according to their cardiovascular risk level: A post hoc analysis.
Antihypertensive effects of fasidotril, a dual inhibitor of neprilysin and angiotensin-converting enzyme, in rats and humans.
Antihypertensive efficacy and acceptability of perindopril in elderly hypertensive patients.
Antihypertensive efficacy of lisinopril. Ambulatory blood pressure monitoring.
Antihypertensive efficacy of zofenopril compared with atenolol in patients with mild to moderate hypertension.
Antihypertensive medication changes and blood pressure goal achievement in a managed care population.
Antihypertensive monotherapy with nisoldipine CC is superior to enalapril in black patients with severe hypertension.
Antihypertensive peptides from curd.
Antihypertensive Potential of Plant Foods: Research Progress and Prospect of Plant-Derived Angiotensin-Converting Enzyme Inhibition Compounds.
Antihypertensive prescribing patterns and hypertension control in females of childbearing age.
Antihypertensive properties of a new long-acting angiotensin converting enzyme inhibitor in renin-dependent and independent hypertensive models.
Antihypertensive properties of flavonoid-rich apple peel extract.
Antihypertensive therapy and coronary prevention.
Antihypertensive therapy and the progression of renal disease.
Antihypertensive therapy in patients with metabolic syndrome.
Antihypertensive therapy prevents endothelial dysfunction in chronic nitric oxide deficiency. Effect of verapamil and trandolapril.
Antihypertensive therapy with verapamil SR plus trandolapril versus atenolol plus chlorthalidone on glycemic control.
Antihypertensive therapy: newer concepts and agents.
Antihypertensive treatment decreases arterial stiffness at night but not during the day. Results from the Hypertension in the Very Elderly Trial.
Antihypertensive treatment efficacy in type II diabetes mellitus. Dissociation between casual and 24-hour ambulatory blood pressure. Spanish Multicenter Study Group.
Antihypertensive treatment in postmenopausal women: results from a prospective, randomized, double-blind, controlled study comparing an ACE inhibitor (moexipril) with a diuretic (hydrochlorothiazide).
Antihypertensive treatment with ACE inhibitors or beta-blockers and risk of incident atrial fibrillation in a general hypertensive population.
Antioxidant activity of peptide-based angiotensin converting enzyme inhibitors.
Antioxidant status in hypertension and effects of angiotensin converting enzyme inhibition.
Antiproteinuric effects of combined antihypertensive therapies in patients with overt type 2 diabetic nephropathy.
Antisense Inhibition of Angiotensinogen With IONIS-AGT-LRx: Results of Phase 1 and Phase 2 Studies.
APOL1 associations with nephropathy, atherosclerosis, and all-cause mortality in African Americans with type 2 diabetes.
Apoptosis in vasculature of spontaneously hypertensive rats: effect of an angiotensin converting enzyme inhibitor and a calcium channel antagonist.
ARB-Based Combination Therapy for the Clinical Management of Hypertension and Hypertension-Related Comorbidities: A Spotlight on Their Use in COVID-19 Patients.
ARBs and target organ protection. Exploring benefits beyond their antihypertensive effects.
Are angiotensin-converting enzyme inhibitors the best treatment for hypertension in type 2 diabetes?
Are beta-blockers efficacious as first-line therapy for hypertension in the elderly?
Are there pleiotropic effects of antihypertensive medications or is it all about the blood pressure in the patient with diabetes and hypertension?
Arrhythmias, electrolytes, and ACE inhibitor therapy in the elderly.
Arterial function in mineralocorticoid-NaCl hypertension: influence of angiotensin-converting enzyme inhibition.
Arterial hemodynamics in human hypertension. Effects of angiotensin converting enzyme inhibition.
Arterial hypertension and sleep apnoea: effect of the angiotensin-converting enzyme (ACE) inhibitor cilazapril on continuously measured blood pressure during sleep and wakefulness.
Arterial hypertension treated with angiotensin converting enzyme inhibitors and glucocorticoids are independent risk factors associated with decreased glomerular filtration rate in systemic sclerosis.
Arterial Hypertension.
Arterial stents in the management of neurofibromatosis and renovascular hypertension in a pediatric patient: case report of a new treatment modality.
Arterial structure in hypertension and the effects of angiotensin converting enzyme inhibition.
Asian management of hypertension: Current status, home blood pressure, and specific concerns in China.
Aspirin use in older patients with heart failure and coronary artery disease: national prescription patterns and relationship with outcomes.
Assay of angiotensin I-converting enzyme-inhibiting activity based on the detection of 3-hydroxybutyric acid.
Assessment of angiotensin-converting enzyme inhibitor/angiotensin receptor blocker on the split renal function in the patients with primary hypertension.
Assessment of arterial ventricular coupling changes in patients under therapy with various antihypertensive agents by a non-invasive echocardiographic method.
Assessment of drug therapy management and the prevalence of heart failure in a managed care population with hypertension.
Assessment of quality of life in a double-blind, randomized clinical trial of imidapril and captopril for hypertensive Chinese in Taiwan.
Assessment of structure and function in progressive renal disease.
Assessment of the association between blood pressure control and health care resource use.
Assessment of the optimal daily dose of valsartan in patients with hypertension, heart failure, or both.
Association among ACE, ESR1 polymorphisms and preeclampsia in Brazilian pregnant women.
Association between angiotensin converting enzyme G2350A polymorphism and hypertension risk: a meta-analysis.
Association between angiotensin I-converting enzyme gene polymorphism and hypertension in selected individuals of the Bangladeshi population.
Association Between Angiotensin-Converting Enzyme Insertion/Deletion Genetic Polymorphism and Hypertension in a Sample of Lebanese Patients.
Association between angiotensinogen, angiotensin II receptor genes, and blood pressure response to an angiotensin-converting enzyme inhibitor.
Association between antihypertensive agent use and hospital admissions in a managed care population.
Association between elevated fibrosis markers and heart failure in the elderly: the cardiovascular health study.
Association between gene polymorphisms of the components of the renin-angiotensin-aldosteron system, graft function, and the prevalence of hypertension, anemia, and erythrocytosis after kidney transplantation.
Association between polymorphism of the angiotensin I converting enzyme gene and hypertension in Turkish type II diabetic patients.
Association between scleroderma, renal cell carcinoma and membranous nephropathy.
Association between the angiotensin-converting enzyme gene insertion/deletion polymorphism and essential hypertension in young Pakistani patients.
Association of a polymorphism at the 5'-region of the angiotensin II type 1 receptor with hypertension.
Association of ACE2 genetic variants with blood pressure, left ventricular mass, and cardiac function in caucasians with type 2 diabetes.
Association of angiotensin converting enzyme (ACE) gene polymorphism with hypertension in a Bangladeshi population.
Association of Angiotensin converting enzyme (insertion/deletion) gene polymorphism with essential hypertension in northern Indian subjects.
Association of angiotensin converting enzyme DD genotype with hypertension in diabetes.
Association of angiotensin converting enzyme gene (I/D) polymorphism with hypertension and type 2 diabetes.
Association of Angiotensin converting enzyme gene insertion / deletion polymorphism with risk of ischemic heart disease in a population of smokers in southern India.
Association of Angiotensin Converting Enzyme Insertion-Deletion Polymorphism with Hypertension in Emiratis with Type 2 Diabetes Mellitus and Its Interaction with Obesity Status.
Association of angiotensin-converting enzyme G2350A gene polymorphisms with hypertension among patients with intracerebral haemorrhage.
Association of angiotensin-converting enzyme gene insertion/deletion polymorphism with metabolic syndrome in Iranians with type 2 diabetes mellitus.
Association of angiotensin-converting enzyme inhibitor therapy initiation with a reduction in hemoglobin levels in patients without renal failure.
Association of angiotensinogen gene T235 variant with increased risk of coronary heart disease.
Association of B? receptor polymorphisms and ACE activity with ACE inhibitor-induced angioedema in black and mixed-race South Africans.
Association of DD genotype of angiotensin-converting enzyme gene (I/D) polymorphism with hypertension among a North Indian population.
Association of Diabetic Microvascular Complications and Parameters of Obstructive Sleep Apnea in Patients with Type 2 Diabetes.
Association of elevated glycosylated hemoglobin A1c with hyperfiltration in a middle-aged and elderly Chinese population with prediabetes or newly diagnosed diabetes: a cross-sectional study.
Association of Fenofibrate and Diabetic Retinopathy in Type 2 Diabetic Patients: A Population-Based Retrospective Cohort Study in Taiwan.
Association of high-altitude systemic hypertension with the deletion allele-of the angiotensin-converting enzyme (ACE) gene.
Association of hypertension genotypes and decline in renal function after kidney transplantation.
Association of Hypertension with All-Cause Mortality among Hospitalized Patients with COVID-19.
Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Mortality Among Patients With Hypertension Hospitalized With COVID-19.
Association of insertion/deletion polymorphism of angiotensin-converting enzyme gene among Malay male hypertensive subjects in response to ACE inhibitors.
Association of insertion/deletion polymorphism of angiotensin-converting enzyme gene with essential hypertension and type 2 diabetes mellitus in Malaysian subjects.
Association of Metformin Use With End-Stage Renal Disease in Patients With Type 2 Diabetes Mellitus: A Nationwide Cohort Study Under the Pay-for-Performance Program.
Association of peripheral and central arterial wave reflections with the CYP11B2 -344C allele and sodium excretion.
Association of polymorphisms of the renin-angiotensin system and bradykinin B2 receptor with ACE-inhibitor-related cough.
Association of Race/Ethnicity-Specific Changes in Antihypertensive Medication Classes Initiated Among Medicare Beneficiaries With the Eighth Joint National Committee Panel Member Report.
Association of renin-angiotensin system and natriuretic peptide receptor A gene polymorphisms with hypertension in a Hellenic population.
Association of Renin-Angiotensin System Inhibitors With Severity or Risk of Death in Patients With Hypertension Hospitalized for Coronavirus Disease 2019 (COVID-19) Infection in Wuhan, China.
Association of serum adiponectin with risk for cardiovascular events in patients with peripheral arterial disease.
Association of the angiotensin-converting enzyme (ACE) gene G2350A dimorphism with essential hypertension.
Association of the Optic Disc Structure With the Use of Antihypertensive Medications: The Thessaloniki Eye Study.
Association of Urine Dipstick Proteinuria and Postoperative Renal Function Following Robotic Partial Nephrectomy.
Association studies between the angiotensin-converting enzyme insertion/deletion polymorphism and hypertension: still interesting?
Association study of angiotensin converting enzyme gene polymorphism with elderly diabetic hypertension and lipids levels.
Associations between retinal microvascular abnormalities and declining renal function in the elderly population: the Cardiovascular Health Study.
Associations of ACE I/D, AGT M235T gene polymorphisms with pregnancy induced hypertension in Chinese population: a meta-analysis.
Associations of candidate loci angiotensinogen and angiotensin-converting enzyme with severe hypertension: The NHLBI Family Heart Study.
Associations of the angiotensinogen gene (M235T, T174M) and the angiotensin I-converting enzyme gene (I/D) with blood pressure in Japanese workers.
AT1 receptors: coronary flow and flow reserve.
Atherosclerotic Renal Artery Stenosis.
Atherosclerotic renal artery stenosis: surgery, percutaneous transluminal angioplasty, or medical therapy?
Attenuation of genetic hypertension after short-term vasopressin V1A receptor antagonism.
Attenuation of Human Lysozyme Amyloid Fibrillation by ACE Inhibitor Captopril: A Combined Spectroscopy, Microscopy, Cytotoxicity, and Docking Study.
Atypical fatigue.
Augmentation of myocardial blood flow in hypertensive heart disease by angiotensin antagonists: a comparison of lisinopril and losartan.
Australian comparative outcome trial of angiotensin-converting enzyme inhibitor- and diuretic-based treatment of hypertension in the elderly (ANBP2): objectives and protocol. Management Committee on behalf of the High Blood Pressure Research Council of Australia.
Autonomic tone as a cardiovascular risk factor: the dangers of chronic fight or flight.
Azilsartan: Novel Angiotensin Receptor Blocker.
B2-kinin receptor plays a key role in B1-, angiotensin converting enzyme inhibitor-, and vascular endothelial growth factor-stimulated in vitro angiogenesis in the hypoxic mouse heart.
Background and design of the new U.S. trial on diet and drug treatment of "mild" hypertension (TOMHS).
Bad gut feeling: ACE inhibitor induced intestinal angioedema.
Benazepril inhibited the NF-?B and TGF-? networking on LV hypertrophy in rats.
Beneficial effect of lisinopril plus telmisartan in patients with type 2 diabetes, microalbuminuria and hypertension.
Beneficial effects of angiotensin converting enzyme inhibition on renal function in patients with diabetic nephropathy.
Beneficial effects of angiotensin-converting enzyme inhibitor on renal function and glucose homeostasis in diabetics with hypertension.
Benefits of angiotensin converting enzyme inhibition and angiotensin II receptor antagonists in hypertension.
Benefits of delapril in hypertensive patients along the cardiovascular continuum.
Benefits of the RAS blockade: clinical evidence before the ONTARGET study.
Best strategies for hypertension management in type 2 diabetes and obesity.
Beta-adrenergic receptor antagonist antihypertensive medications impair arousal-induced modulation of working memory in elderly humans.
beta-Blocker use following myocardial infarction: low prevalence of evidence-based dosing.
Beta-blockers vs. angiotensin-converting enzyme inhibitors in hypertension: effects on left ventricular hypertrophy.
Better blood pressure control: how to combine drugs.
Beyond ONTARGET: angiotensin-converting enzyme inhibition and angiotensin II receptor blockade in combination, a lesser evil in some?
Beyond remodeling: a new paradigm for angiotensin-converting enzyme inhibitors following myocardial infarction.
Beyond the sphygmomanometric numbers: hypertension as a syndrome.
Binding of ACE-inhibitors to in vitro and patient-derived amyloid-? fibril models.
Bioavailability of angiotensin I converting enzyme inhibitory peptides.
Bioequivalence of enalapril oral solution for treatment of pediatric hypertension and enalapril tablets.
Biosensors for the enantioselective analysis of S-enalapril and S-ramipril.
Biotechnological production of the angiotensin-converting enzyme inhibitory dipeptide isoleucine-tryptophan.
Blockade of angiotensin-converting enzyme or tumor necrosis factor-? reverses maternal high-fat diet-induced sensitization of angiotensin II hypertension in male rat offspring.
Blockade of apoptosis by ACE inhibitors and angiotensin receptor antagonists.
Blockade of the renin-angiotensin system.
Blood Leukocyte Count on Admission Predicts Cardiovascular Events in Patients with Acute Non-ST Elevation Myocardial Infarction.
Blood pressure and adverse events during continuous flow left ventricular assist device support.
Blood pressure and NaCl-sensitive hypertension are influenced by angiotensin-converting enzyme gene expression in transgenic mice.
Blood pressure and proteinuria after cessation of a brief renin-angiotensin system blockade in young and adult Lyon hypertensive rats.
Blood pressure control and response rates with zofenopril compared with amlodipine in hypertensive patients.
Blood pressure control in hypertensive patients in Irish primary care practices.
Blood pressure control, risk factors and cardiovascular prognosis in patients with diabetes: 30 years of progress.
Blood Pressure Effects of Combined ?-Blocker and Angiotensin-Converting Enzyme Inhibitor Therapy Compared With the Individual Agents: A Placebo-Controlled Study With Nebivolol and Lisinopril.
Blood pressure in relation to three candidate genes in a Chinese population.
Blood pressure is normal, but is the heart?
Blood pressure lowering efficacy of angiotensin converting enzyme (ACE) inhibitors for primary hypertension.
Blood pressure lowering efficacy of renin inhibitors for primary hypertension: a Cochrane systematic review.
Blood pressure management in patients with type 2 diabetes mellitus.
Blood pressure responses to enalapril in rats with one- and two-kidney DOC-NaCl hypertension.
Blood Pressure-Lowering Effects of Alacalase-Hydrolyzed Camellia Seed Hull In Vitro and in Spontaneous Hypertensive Rats.
Bovine casein hydrolysate (c12 Peptide) reduces blood pressure in prehypertensive subjects.
Bradykinin and inhibition of angiotensin-converting enzyme in hypertension.
Bradykinin and matrix metalloproteinases are involved the structural alterations of rat small resistance arteries with inhibition of ACE and NEP.
Bradykinin-evoked sensitization of airway sensory nerves: a mechanism for ACE-inhibitor cough.
Bradykinin-potentiating peptides: Beyond captopril.
Brazilian multicenter study on efficacy and tolerability of trandolapril in mild-to-moderate essential arterial hypertension. EMBATHE substudy with ambulatory blood pressure monitoring.
Brief review: Angiotensin converting enzyme inhibitors and angioedema: anesthetic implications: [Revue sommaire sur les implications anesthesiques de l'oedeme de Quincke et des inhibiteurs de l'enzyme de conversion de l'angiotensine].
Brief treatment of SHR with an ace inhibitor fails to cause long-term normotension but markedly increases mortality.
Bronchial hyperreactivity and cough due to angiotensin-converting enzyme inhibitors.
Burning Mouth Syndrome Induced by Angiotensin-Converting Enzyme Inhibitors.
C1 Esterase Inhibitor for Ace-Inhibitor Angioedema: A Case Series and Literature Review.
C1q nephropathy in a 2-year-old boy presenting with steroid resistant nephrotic syndrome.
Calcium antagonists and the diabetic patient: a response to recent controversies.
Calcium antagonists and the second drug for hypertensive therapy.
Calcium antagonists in the treatment of hypertension in patients with ischaemic heart disease.
Calcium channel blockade in combination with angiotensin-converting enzyme inhibition or angiotensin II (AT(1)-receptor) antagonism in hypertensive diabetics and patients with renal disease and hypertension.
Calcium channel blockers and renal protection: insights from the latest clinical trials.
Calcium channel blockers or angiotensin-converting enzyme inhibitors for de novo hypertension after liver transplant: and the winner is …?
Calcium channel blockers, angiotensin receptor blockers, and angiotensin-converting enzyme inhibitors: effectiveness in combination with diuretics or beta-blockers for treating hypertension.
Calcium-channel blockade (nitrendipine) in combination with ACE inhibition (captopril) in the treatment of mild to moderate hypertension.
Callypyrones from marine Callyspongiidae sponge Callyspongia diffusa: antihypertensive bis-?-pyrone polypropionates attenuate angiotensin-converting enzyme.
Can progression of renal disease be prevented?
Candesartan cilexetil is not associated with cough in hypertensive patients with enalapril-induced cough. Multicentre Cough Study Group.
Captopril alleviates hypertension-induced renal damage, inflammation, and NF-?B activation.
Captopril attenuates hypertension and renal injury induced by the vascular endothelial growth factor inhibitor sorafenib.
Captopril attenuates TAC-induced heart failure via inhibiting Wnt3a/?-catenin and Jak2/Stat3 pathways.
Captopril in essential hypertension; contrasting effects of adding hydrochlorothiazide or propranolol.
Captopril in primary hypertension. Effects related to the renin-angiotensin-aldosterone and kallikrein-kinin systems.
Captopril in severe preeclampsia.
Captopril in treatment-resistant essential and renal hypertension.
Captopril increases skin microvascular blood flow secondary to bradykinin, nitric oxide, and prostaglandins.
Captopril inhibits angiogenesis and slows the growth of experimental tumors in rats.
Captopril inhibits the proliferation of hematopoietic stem and progenitor cells in murine long-term bone marrow cultures.
Captopril normalises systolic blood pressure in rats with hypertension induced by fetal exposure to maternal low protein diets.
Captopril overdose resulting in hypotension.
Captopril prevents chronic hypertension produced by infusion of endothelin-1 in rats.
Captopril prevents NO-deficient hypertension and left ventricular hypertrophy without affecting nitric oxide synthase activity in rats.
Captopril reduces cardiac inflammatory markers in spontaneously hypertensive rats by inactivation of NF-kB.
Captopril renal scintigraphy in renovascular hypertension.
Captopril renography in two kidney and one kidney Goldblatt hypertension in dogs.
Captopril treatment of hypertension and renal failure in systemic lupus erythematosus.
Captopril withdrawal after chronic therapy.
Captopril, an angiotensin-converting enzyme inhibitor, induced pulmonary infiltration with eosinophilia.
Captopril, an orally active converting enzyme inhibitor, in the treatment of primary hypertension. A controlled long-term study with reference to initial plasma renin activity.
Captopril-associated "pseudocholangitis'. A case report and review of the literature.
Captopril-associated cholestatic jaundice.
Captopril-induced proteinuria in hypertensive psoriatic patients.
Captopril. A review of its pharmacology and therapeutic efficacy after myocardial infarction and in ischaemic heart disease.
Captopril. An update of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure.
Captopril. Long-term treatment of hypertension in a preterm infant and in older children.
Captopril: a new treatment for rheumatoid arthritis?
Captopril: clinical pharmacology and benefit-to-risk ratio in hypertension and congestive heart failure.
Carbohydrate metabolism in hypertension: influence of treatment.
Cardiac angiotensin converting enzyme overproduction indicates interstitial activation in renovascular hypertension.
Cardiac angiotensin II formation: the angiotensin-I converting enzyme and human chymase.
Cardiac Arrest during Total Hip Arthroplasty in a Patient on an Angiotensin Receptor Antagonist.
Cardiac benefits of ACE inhibitors and calcium antagonists alone and in combination.
Cardiac hypertrophy and remodeling in relation to ACE and angiotensinogen genes genotypes in Chinese dialysis patients.
Cardiac mitogen-activated protein kinase activities are chronically increased in stroke-prone hypertensive rats.
Cardiac structure and function in a mouse model of uraemia without hypertension.
Cardiac syndrome X. Diagnosis, pathogenesis and management.
Cardioprotection and ACE inhibitors.
Cardioprotection by aldosterone receptor antagonism in heart failure. Part I. The role of aldosterone in heart failure.
Cardioprotective effects of an angiotensin-converting-enzyme inhibitor, imidapril, and Ca2+ channel antagonist, amlodipine, in spontaneously hypertensive rats at established stage of hypertension.
Cardioprotective properties of bradykinin: role of the B(2) receptor.
Cardioreparative effects of lisinopril in rats with genetic hypertension and left ventricular hypertrophy.
Cardiovascular and cerebrovascular outcomes in elderly hypertensive patients treated with either ARB or ACEI.
Cardiovascular and renal surrogate markers in the clinical management of hypertension.
Cardiovascular Benefits of Angiotensin-Converting Enzyme Inhibition Plus Calcium Channel Blockade in Patients Achieving Tight Blood Pressure Control and With Resistant Hypertension.
Cardiovascular disease due to accelerated atherosclerosis in systemic vasculitides.
Cardiovascular disease in chronic kidney disease.
Cardiovascular disease management in people with diabetes outside North America and Western Europe in 2006 and 2015.
Cardiovascular drugs that increase the risk of new-onset diabetes.
Cardiovascular effects of captopril and enalapril in obese Zucker rats.
Cardiovascular effects of the novel dual inhibitor of neutral endopeptidase and angiotensin-converting enzyme BMS-182657 in experimental hypertension and heart failure.
Cardiovascular events in hypertension trials of Angiotensin-converting enzyme inhibitors.
Cardiovascular outcomes in high-risk hypertensive patients stratified by baseline glomerular filtration rate.
Cardiovascular protection with ace inhibitors--more HOPE for EUROPA?
Cardiovascular protective role of a low-dose antihypertensive combination in obese Zucker rats.
Cardiovascular regulation during angiotensin converting enzyme inhibition with captopril in diabetes-associated hypertension.
Cardiovascular risk factors, angiotensin-converting enzyme gene I/D polymorphism, and left ventricular mass in systemic hypertension.
Cardiovascular risk reduction in hypertension: angiotensin-converting enzyme inhibitors, angiotensin receptor blockers. Where are we up to?
Cardiovascular risk reduction with Renin-Angiotensin aldosterone system blockade.
Cardiovascular risk reduction: the role of antihypertensive treatment.
Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: a multicenter analysis.
Carotid and femoral intima-media thickness in relation to three candidate genes in a Caucasian population.
Carotid artery intima-media thickness and the renin-angiotensin system.
Carotid thickening, cardiac hypertrophy, and angiotensin converting enzyme gene polymorphism in patients with hypertension.
Case study of patents related to captopril, Squibb's first blockbuster.
Case-control association study of polymorphisms in the angiotensinogen and angiotensin-converting enzyme genes and coronary artery disease and systemic artery hypertension in African-Brazilians and Caucasian-Brazilians.
Catecholamine-resistant hypotension following induction for spinal exploration.
Cellular and functional aspects of the renal kallikrein system in health and disease.
Central retinal vein occlusion case-control study.
Change in cough reflex after treatment with enalapril and ramipril.
Changes in endothelium-derived hyperpolarizing factor in hypertension and ageing: response to chronic treatment with renin-angiotensin system inhibitors.
Changes in left ventricular geometry during antihypertensive treatment.
Characteristics of Patients with Hypertension at a Nicaraguan Clinic.
Characterization of angiotensin-converting enzyme inhibitory activity of fermented milk produced by Lactobacillus helveticus.
Characterization, Biomedical and Agricultural applications of Protease Inhibitors: A review.
Chickpea (Cicer arietinum L.) Lectin Exhibit Inhibition of ACE-I, ?-amylase and ?-glucosidase Activity.
Childhood sporadic pheochromocytoma: clinical profile and outcome in 19 patients.
Chimeric renin-angiotensin system demonstrates sustained increase in blood pressure of transgenic mice carrying both human renin and human angiotensinogen genes.
Choosing Wisely: The Canadian Society of Nephrology's List of 5 Items Physicians and Patients Should Question.
Chromosome 17q23: a locus for cardiovascular disease.
Chronic ACE inhibition by quinapril modulates central vasopressinergic system.
Chronic angiotensin-converting enzyme inhibition may improve sodium excretion in cardiac transplant hypertension.
Chronic central administration of enalaprilat lowers blood pressure in stroke-prone spontaneously hypertensive rats.
Chronic effects of angiotensin-converting enzyme inhibition on kinin receptor binding sites in the rat spinal cord.
Chronic effects of direct vasodilation (pinacidil), alpha-adrenergic blockade (prazosin) and angiotensin-converting enzyme inhibition (captopril) in systemic hypertension.
Chronic hypertension and altered baroreflex responses in transgenic mice containing the human renin and human angiotensinogen genes.
Chronic infusion of enalaprilat into hypothalamic paraventricular nucleus attenuates angiotensin II-induced hypertension and cardiac hypertrophy by restoring neurotransmitters and cytokines.
Chronic kidney disease management: comparison between renal transplant recipients and nontransplant patients with chronic kidney disease.
Chronic kidney disease screening and renoprotection in type 2 diabetes.
Chronic renal insufficiency in a boy with cystic renal lymphangiectasia: morphological findings and long-term follow-up.
Chronic thrombotic microangiopathy associated with antineoplastic therapy with minimal hematologic effects.
Chronic Use of ?-Blockers and the Risk of Parkinson's Disease.
Chymase-like angiotensin II-generating activity in end-stage human autosomal dominant polycystic kidney disease.
Cilazapril prevents the development of cardiac hypertrophy and the decrease of coronary vascular reserve in spontaneously hypertensive rats.
Cilazapril: a new non-thiol-containing angiotensin-converting enzyme inhibitor. Worldwide clinical experience in hypertension.
Circadian variation in blood pressure and heart rate in nonhypertensive congestive heart failure.
Circadian variation of blood pressure in patients with diabetic nephropathy.
Circulating activities of angiotensin-converting enzyme, its homolog, angiotensin-converting enzyme 2, and neprilysin in a family study.
Circulating amylin in human essential hypertension: heritability and early increase in individuals at genetic risk.
Circulating angiotensin converting enzyme levels are increased in concentric, but not eccentric, left ventricular hypertrophy in elderly men.
Circulating apoptotic progenitor cells: a novel biomarker in patients with acute coronary syndromes.
Circulating endothelial progenitor cells and age-related white matter changes.
Circulatory basis for the use of angiotensin converting enzyme inhibitors in hypertension and cardiac failure.
Classical and Counter-Regulatory Renin-Angiotensin System: Potential Key Roles in COVID-19 Pathophysiology.
Clinical analysis of sampatrilat, a combined renal endopeptidase and angiotensin-converting enzyme inhibitor I: assay in plasma of human volunteers by atmospheric-pressure ionisation mass-spectrometry following derivatisation with BF3-methanol.
Clinical analysis of sampatrilat, a combined renal endopeptidase and angiotensin-converting enzyme inhibitor II: assay in the plasma and urine of human volunteers by dissociation enhanced lanthanide fluorescence immunoassay (DELFIA).
Clinical and economic implications of therapeutic switching of angiotensin receptor blockers to angiotensin-converting enzyme inhibitors: a population-based study.
Clinical and genetic correlates of aldosterone-to-renin ratio and relations to blood pressure in a community sample.
Clinical and Molecular Features of Thiazide-Induced Hyponatremia.
Clinical approach to the inflammatory etiology of cardiovascular diseases.
Clinical characteristics and fatal outcomes of hypertension in patients with severe COVID-19.
Clinical evaluation of the captopril screening test for primary aldosteronism.
Clinical evidence of dose-dependent interaction between aspirin and angiotensin-converting enzyme inhibitors.
Clinical experience and rationale for angiotensin-converting enzyme inhibition with lisinopril as the initial treatment for hypertension in older patients.
Clinical experience with converting-enzyme inhibitors in hypertension.
Clinical experience with labetalol and enalapril in combination in patients with severe essential and renovascular hypertension.
Clinical impact of angiotensin I converting enzyme polymorphisms in subjects with resistant hypertension.
Clinical implications of aldosterone blockade.
Clinical inquiries. Which combination drug therapies are most effective for hypertension?
Clinical management of early progressive renal failure.
Clinical outcome of renin-angiotensin-aldosterone system blockers in treatment of hypertensive patients with COVID-19: a systematic review and meta-analysis.
Clinical outcomes of acute kidney injury developing outside the hospital in elderly.
Clinical outcomes of COVID-19 following the use of angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers among patients with hypertension in Korea: a nationwide study.
Clinical pharmacokinetics of angiotensin converting enzyme (ACE) inhibitors in renal failure.
Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension.
Clinical pharmacokinetics of the angiotensin converting enzyme inhibitors. A review.
Clinical pharmacokinetics of vasodilators. Part II.
Clinical pharmacology of quinapril in healthy volunteers and in patients with hypertension and congestive heart failure.
Clinical potential: angiotensin converting enzyme inhibitor or angiotensin II antagonist?
Clinical reasoning: a 51-year-old man with cervical pain and progressively deteriorating gait.
Clinical utility of angiotensin converting enzyme inhibitors in hypertension.
Clinical utility of long-term enalapril/diltiazem ER in stage 3-4 essential hypertension. Long-term Use of Enalapril/Diltiazem ER in Stage 3-4 Hypertension Group.
Clinical utility of valsartan in treatment of children and adolescents with high blood pressure.
Clofibrate, a Peroxisome Proliferator-Activated Receptor-Alpha (PPAR?) Agonist, and Its Molecular Mechanisms of Action against Sodium Fluoride-Induced Toxicity.
Cocaine, HIV, and their cardiovascular effects: is there a role for ACE-inhibitor therapy?
Collaborative optimization and molecular docking exploration of novel ACE-inhibitory peptides from bovine milk by complex proteases hydrolysis.
Combating Combination of Hypertension and Diabetes in Different Rat Models.
Combination ACE inhibitor and angiotensin receptor blocker therapy - future considerations.
Combination ACE inhibitors and angiotensin II receptor blockers for hypertension.
Combination ACEI and ARB therapy: additional benefit in renoprotection?
Combination angiotensin-converting enzyme inhibitor and angiotensin receptor blocker therapy: its role in clinical practice.
Combination antihypertensive therapy in the treatment of diabetic nephropathy.
Combination drug therapy in hypertension: a rational approach for the pharmacist.
Combination inhibition of the renin-angiotensin system: is more better?
Combination of a calcium antagonist, verapamil, with an angiotensin converting enzyme inhibitor, trandolapril, in experimental myocardial ischemia and reperfusion: antiarrhythmic and hemodynamic effects of chronic oral pretreatment.
Combination of site of infarct, unrecognized glucose intolerance, and reinfarction after acute myocardial infarction in normotensive subjects is determinant of the development of subsequent systemic hypertension: a pilot study.
Combination therapy of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in chronic kidney disease.
Combination therapy with lercanidipine and enalapril in the management of the hypertensive patient: an update of the evidence.
Combinative effect of sardine peptides and quercetin alleviates hypertension through inhibition of angiotensin I converting enzyme activity and inflammation.
Combinatorial inhibition of Angiotensin converting enzyme, Neutral endopeptidase and Aminopeptidase N by N-methylated peptides alleviates blood pressure and fibrosis in rat model of dexamethasone-induced hypertension.
Combined oral contraceptive-induced hypertension is accompanied by endothelial dysfunction and upregulated intrarenal angiotensin II type 1 receptor gene expression.
Combined therapy with benazepril and amlodipine in the treatment of hypertension inadequately controlled by an ACE inhibitor alone.
Combined therapy with captopril and potassium supplementation. A potential for hyperkalemia.
Combined treatment with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers: a review of the current evidence.
Combining RAAS and calcium channel blockade: ACCOMPLISH in perspective.
Comorbidity of hypertension and diabetes: the fosinopril versus amlodipine cardiovascular events trial (FACET)
Comparative dosage of angiotensin-converting enzyme inhibitors in the treatment of hypertension.
Comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on major adverse cardiac events in patients with newly diagnosed type 2 diabetes: a nationwide study.
Comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for hypertension on clinical end points: a cohort study.
Comparative effectiveness of angiotensin-converting enzyme inhibitors versus beta-blockers as second-line therapy for hypertension.
Comparative effectiveness of antihypertensive drugs in nondiabetic patients with hypertension: A population-based study.
Comparative effectiveness of renin-angiotensin system inhibitors in hypertension.
Comparative effects of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on pulmonary function in hypertensive patients.
Comparative effects of enalapril, enalaprilic acid and captopril in blocking angiotensin I-induced pressor and dipsogenic responses in spontaneously hypertensive rats.
Comparative effects of telmisartan in the treatment of hypertension.
Comparative efficacy and safety of aliskiren, an oral direct renin inhibitor, and ramipril in hypertension: a 6-month, randomized, double-blind trial.
Comparative efficacy and safety of enalapril and sustained-release nifedipine in patients with mild to moderate hypertension. The Enalapril vs Nifedipine French Study Group.
Comparative pharmacokinetic and clinical profiles of angiotensin-converting enzyme inhibitors and calcium antagonists in systemic hypertension.
Comparative properties of angiotensin-converting enzyme inhibitors: relations with inhibition of tissue angiotensin-converting enzyme and potential clinical implications.
Comparing angiotensin-converting enzyme inhibitor trial results in patients with acute myocardial infarction.
Comparing Outcomes Between Thiazide Diuretics and Other First-line Antihypertensive Drugs in Long-term Nursing Home Residents.
Comparison between chronic converting enzyme inhibition and AT1 blockade in mRen2 transgenic rats.
Comparison of amlodipine and quinapril on ambulatory blood pressure and platelet function in hypertension.
Comparison of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in the primary prevention of myocardial infarction in hypertensive patients.
Comparison of angiotensin-converting enzyme inhibitors and calcium antagonists in the treatment of mild to moderate systemic hypertension, according to baseline ambulatory blood pressure level.
Comparison of antihypertensive effects of an angiotensin-converting enzyme inhibitor, a calcium antagonist and a diuretic in patients with hypertension not controlled by angiotensin receptor blocker monotherapy.
Comparison of captopril with propranolol in the treatment of mild and moderate essential hypertension.
Comparison of effect of endothelin antagonism and angiotensin-converting enzyme inhibition on blood pressure and vascular structure in spontaneously hypertensive rats treated with N omega-nitro-L-arginine methyl ester. Correlation with topography of vascular endothelin-1 gene expression.
Comparison of effects of ACE inhibition with calcium channel blockade on renal disease in a model combining genetic hypertension and diabetes.
Comparison of effects of low dose of spironolactone and a thiazide diuretic in patients with hypertension treated with an angiotensin-converting enzyme inhibitor or an angiotensin type 1 receptor blocker.
Comparison of effects of quinapril and metoprolol on glycaemic control, serum lipids, blood pressure, albuminuria and quality of life in non-insulin-dependent diabetes mellitus patients with hypertension. Swedish Quinapril Group.
Comparison of efficacy and side effects of combination therapy of angiotensin-converting enzyme inhibitor (benazepril) with calcium antagonist (either nifedipine or amlodipine) versus high-dose calcium antagonist monotherapy for systemic hypertension.
Comparison of enalapril and atenolol in mild to moderate hypertension.
Comparison of enalapril and valsartan in cyclosporine A-induced hypertension and nephrotoxicity in spontaneously hypertensive rats on high-sodium diet.
Comparison of fosinopril and hydrochlorothiazide in patients with mild to moderate hypertension.
Comparison of Frequency of Cardiovascular Events and Mortality in Patients With Heart Failure Using Versus Not Using Cocaine.
Comparison of health costs associated with treatment of hypertension with a calcium channel blocker and angiotensin-converting enzyme inhibitor in the United States and Japan.
Comparison of hypertension prevalence and the use of renin-angiotensin-aldosterone system blockers in hospitalized patients with COVID-19 and non-COVID-19 viral pneumonia.
Comparison of irbesartan with captopril effects on cardiac hypertrophy and gene expression in heart failure-prone male SHHF/Mcc-fa(cp) rats.
Comparison of mortality rates in statin users versus nonstatin users in a United States veteran population.
Comparison of response rates to the angiotensin-converting enzyme inhibitor ramipril in mild-to-moderate hypertension in a double-blind, parallel-group study and an open single-blind study.
Comparison of the combination of enalapril and a very low dose of hydrochlorothiazide with atenolol in patients with mild-to-moderate hypertension. Scandinavian Study Group.
Comparison of the effects of an ACE inhibitor and alphabeta blocker on the progression of renal failure with left ventricular hypertrophy: preliminary report.
Comparison of the effects of an angiotensin converting enzyme inhibitor and a calcium channel blocker on blood pressure and respiratory function in patients with hypertension and asthma.
Comparison of the effects of angiotensin receptor antagonist, angiotensin converting enzyme inhibitor, and their combination on regression of left ventricular hypertrophy of diabetes type 2 patients on recent onset hemodialysis therapy.
Comparison of the effects of indapamide and captopril on the development of spontaneous hypertension.
Comparison of the efficacy and tolerability of an angiotensin converting enzyme inhibitor (lisinopril) versus a calcium channel antagonist (diltiazem SR) in the treatment of moderate to severe hypertension.
Comparison of the time course of action of captopril on angiotensin-converting enzyme with the time course of its antihypertensive effect.
Comparison of type 1 angiotensin II receptor blockers and angiotensin converting enzyme inhibitors in the treatment of hypertension.
Comparison of valsartan 160 mg with lisinopril 20 mg, given as monotherapy or in combination with a diuretic, for the treatment of hypertension: the Blood Pressure Reduction and Tolerability of Valsartan in Comparison with Lisinopril (PREVAIL) study.
Compliance changes in physiological and pathological states.
Complications of Cardiovascular Events in Patients Hospitalized with Influenza-Related Pneumonia.
Components of the metabolic syndrome, but not the metabolic syndrome per se, are associated with aortic distensibility.
Comprehensive comparative effectiveness and safety of first-line antihypertensive drug classes: a systematic, multinational, large-scale analysis.
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2017 EXECUTIVE SUMMARY.
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2018 EXECUTIVE SUMMARY.
Considerations on the use of antihypertensive blockers of the renin-angiotensin system in adults and children in the face of the COVID-19 pandemic.
Constancy of serum angiotensin-converting enzyme activity in normal and complicated pregnancy.
Contraceptive Methods and Informed Consent among Women Receiving Medications with Potential for Adverse Fetal Effects: A Washington, Wyoming, Alaska, Montana, Idaho (WWAMI) Region Study.
Contrasting renal effects of chronic administrations of enalapril and losartan on one-kidney, one clip hypertensive rats.
Contribution by bradykinin to the natriuretic response to the angiotensin converting enzyme inhibitor ramiprilat in spontaneously hypertensive rats.
Contribution of bradykinin to the cardioprotective action of angiotensin converting enzyme inhibition in hypertension and after myocardial infarction.
Contribution of captopril thiol group to the prevention of spontaneous hypertension.
Contribution of Four Polymorphisms in Renin-Angiotensin-Aldosterone-Related Genes to Hypertension in a Thai Population.
Contribution of plasma matrix metalloproteinases to development of left ventricular hypertrophy and diastolic dysfunction in hypertensive subjects.
Control of Edema in Hypertensive Subjects Treated With Calcium Antagonist (Nifedipine) or Angiotensin-Converting Enzyme Inhibitors With Pycnogenol.
Control of hypertension with the angiotensin converting enzyme inhibitor captopril reduces glomerular proteinuria.
Controlling hypertension in patients with diabetes.
Conventional therapy and newer drug classes for cardiovascular protection in hypertension.
Converting enzyme inhibition in chronic renal failure.
Converting enzyme inhibition with an orally active compound in hypertensive man.
Converting enzyme inhibition with captopril in patients with primary hyperaldosteronism.
Converting enzyme inhibition: search for additional mechanisms of action.
Converting enzyme inhibitors in the treatment of elderly hypertensives.
Converting-enzyme inhibitor enalapril (MK421) in treatment of hypertension with renal artery stenosis.
Coronary artery disease screening, treatment, and follow-up.
Coronary heart disease, hypertension, and angiotensinogen gene variants in Indian population.
Coronary surgery in patients with preexisting chronic atrial fibrillation: early and midterm clinical outcome.
Correction of carotid augmentation index for heart rate in elderly essential hypertensives. ANBP2 Investigators. Australian Comparative Outcome Trial of Angiotensin-Converting Enzyme Inhibitor- and Diuretic-Based Treatment of Hypertension in the Elderly.
Correction of remodeling and function of small arteries in human hypertension by cilazapril, an angiotensin I-converting enzyme inhibitor.
Correction to: Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Mortality Among Patients With Hypertension Hospitalized With COVID-19.
Correlates of arterial stiffness in an ageing population: Role of asymmetric dimethylarginine.
Correlation between Sex and Prognosis of Acute Aortic Dissection in the Chinese Population.
Cost analysis of different pharmacological treatment strategies in elderly hypertensives.
Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes.
Cost-minimization and the number needed to treat in uncomplicated hypertension.
Cost-utility of Angiotensin-converting enzyme inhibitor-based treatment compared with thiazide diuretic-based treatment for hypertension in elderly australians considering diabetes as comorbidity.
Cough and ACE inhibitors.
Cough and angioedema from angiotensin-converting enzyme inhibitors: new insights into mechanisms and management.
Cough and inhibition of the renin-angiotensin system.
Cough associated with the use of captopril.
Cough caused by cilazapril.
Cough requiring discontinuance of angiotensin-converting enzyme inhibitors in an urban inner-city population.
Cough-challenge trial with a new angiotensin-converting enzyme inhibitor, imidapril.
Could Anti-Hypertensive Drug Therapy Affect the Clinical Prognosis of Hypertensive Patients With COVID-19 Infection? Data From Centers of Southern Italy.
Covid-19 and cardiovascular risk: Susceptibility to infection to SARS-CoV-2, severity and prognosis of Covid-19 and blockade of the renin-angiotensin-aldosterone system. An evidence-based viewpoint.
COVID-19 and Older Adults: What We Know.
COVID-19 and the impact of arterial hypertension-An analysis of the international HOPE COVID-19 Registry (Italy-Spain-Germany).
COVID-19 in Patients with Hypertension.
COVID-19 morbidity and mortality associated with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers use among 14,129 patients with hypertension from a US integrated healthcare system.
Critical assessment of ACE inhibitors. Part 2.
Critical insights into the beneficial and protective actions of the kallikrein-kinin system.
Cross-over study comparing effects of treatment with an angiotensin converting enzyme inhibitor and an angiotensin II type 1 receptor antagonist on cardiovascular changes in hypertension.
Crossover design for the dose determination of an angiotensin converting enzyme inhibitor in hypertension.
Crystal structure of a peptidyl-dipeptidase K-26-DCP from Actinomycete in complex with its natural inhibitor.
CT visual quantitative evaluation of hypertensive patients with coronavirus disease (COVID-19): Potential influence of angiotensin converting enzyme inhibitors / angiotensin receptor blockers on severity of lung involvement.
Curable hypertension.
Current focus on cardiovascular function with angiotensin converting enzyme inhibitors in hypertension.
Current position of calcium antagonists in hypertension.
Current possibilities of ACE inhibitor and ARB combination in arterial hypertension and its complications.
Current problems in hypertension and nephrology.
Current recommendations for the treatment of hypertension: are they still valid?
Current role of beta-blockers in the treatment of hypertension.
Current status of renin-aldosterone angiotensin system-targeting anti-hypertensive drugs as therapeutic options for Alzheimer's disease.
Current status of safety and efficacy of calcium channel blockers in cardiovascular diseases: a critical analysis based on 100 studies.
Current Strategies to Achieve Further Cardiac and Renal Protection through Enhanced Renin-Angiotensin-Aldosterone System Inhibition.
Current treatment and management of dystrophinopathies.
Current Treatment Options for the Metabolic Syndrome.
Cyclosporin-induced hypertension in marmosets: a new model of hypertension sensitive to angiotensin-converting enzyme inhibition.
Daily oral sodium bicarbonate preserves glomerular filtration rate by slowing its decline in early hypertensive nephropathy.
Daily sodium intake influences the relationship between angiotensin-converting enzyme gene insertion/deletion polymorphism and hypertension in older adults.
Decreased expression of Kv4.2 and novel Kv4.3 K+ channel subunit mRNAs in ventricles of renovascular hypertensive rats.
Decreased survival in diabetic patients with heart failure due to systolic dysfunction.
Deficiency of COX-1 causes natriuresis and enhanced sensitivity to ACE inhibition.
Delapril slows the progression of atherosclerosis and maintains endothelial function in cholesterol-fed rabbits.
Delayed kidney injury following coronary angiography.
Delayed onset of angioedema with angiotensin-converting enzyme inhibitors: case report and review of the literature.
Deletion polymorphism at the angiotensin-converting enzyme gene in Turkish patients with coronary artery disease.
Deletion polymorphism in the alpha2B-adrenergic receptor gene is associated with flow-mediated dilatation of the brachial artery.
Deletion polymorphism in the angiotensin-converting enzyme gene is not associated with hypertension in a Gulf Arab population.
Deletion polymorphism of the angiotensin I-converting enzyme gene is associated with serum ACE concentration and increased risk for CAD in the Japanese.
Deletion polymorphism of the angiotensin-converting enzyme gene is independently associated with left ventricular mass and geometric remodeling in systemic hypertension.
Demographic and Clinical Characteristics of Patients Presenting With Angiotensin-converting Enzyme Inhibitors Induced Cough.
Design and baseline characteristics of participants in the African American Study of Kidney Disease and Hypertension (AASK) Pilot Study.
Design and evaluation of a new formulation of enalapril maleate tablet.
Deterioration of renal function in hypertensive patients with scleroderma despite blood pressure normalization with captopril.
Deterioration rate in hypertensive IgA nephropathy: comparison of a converting enzyme inhibitor and beta-blocking agents.
Determinants of progression of coronary artery calcification in type 2 diabetes role of glycemic control and inflammatory/vascular calcification markers.
Determination of bezafibrate, methotrexate, cyclophosphamide, orlistat and enalapril in waste and surface waters using on-line solid-phase extraction liquid chromatography coupled to polarity-switching electrospray tandem mass spectrometry.
Determination of captopril in biological samples by high-performance liquid chromatography with ThioGlo 3 derivatization.
Determination of renin, angiotensin converting enzyme and angiotensin II levels in human placenta, chorion and amnion from women with pregnancy induced hypertension.
Development and Characterization of Orally Disintegrating Tablets Containing a Captopril-Cyclodextrin Complex.
Development of hypertension and effects of benazepril hydrochloride in a canine remnant kidney model of chronic renal failure.
Development of non-peptide ACE inhibitors as novel and potent cardiovascular therapeutics: An in silico modelling approach.
Development of press-coated, floating-pulsatile drug delivery of lisinopril.
Developments in renal pharmacogenomics and applications in chronic kidney disease.
Dexamethasone induced alterations in the levels of proteases involved in blood pressure homeostasis and blood coagulation in rats.
Diabetes and CVD risk during angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker treatment in hypertension: a study of 15,990 patients.
Diabetes mellitus and hypertension: key risk factors for kidney disease.
Diabetes mellitus is associated with an increased risk of falls in elderly residents of a long-term care facility.
Diabetes update: long-term treatment of adults.
Diabetic nephropathy in children with type 1 diabetes mellitus in Bahrain.
Diabetic nephropathy: common questions.
Diabetic patients with essential hypertension treated with amlodipine: blood pressure and arterial stiffness effects of canagliflozin or perindopril.
Diabetics with hypertension not controlled with ACE inhibitors: alternate therapies.
Diastolic heart failure: challenges of diagnosis and treatment.
Dietary n-3 polyunsaturated fatty acids affect the development of renovascular hypertension in rats.
Difference in the incidence of cough induced by angiotensin converting enzyme inhibitors: a comparative study using imidapril hydrochloride and enalapril maleate.
Differences between zofenopril and ramipril, two ACE inhibitors, on cough induced by citric acid in guinea pigs: role of bradykinin and PGE2.
Differences in mean and variability of heart rate and ambulatory rate-pressure product when valsartan or carvedilol is added to lisinopril.
Differences in the Clinical Effects of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers: A Critical Review of the Evidence.
Differences in the effects of angiotensin converting enzyme inhibitors with or without a thiol group in chronic renal failure in rats.
Different Angiotensin-Converting Enzyme Inhibitors and the Associations With Overall and Cause-Specific Mortalities in Patients With Hypertension.
Different aortic reflection wave responses following long-term angiotensin-converting enzyme inhibition and beta-blocker in essential hypertension.
Different effects of antihypertensive regimens based on fosinopril or hydrochlorothiazide with or without lipid lowering by pravastatin on progression of asymptomatic carotid atherosclerosis: principal results of PHYLLIS--a randomized double-blind trial.
Different pathophysiology of cardiac hypertrophy in hypertension and hypertrophic cardiomyopathy.
Differential effects of angiotensin converting enzyme inhibition and diuretic therapy on reductions in ambulatory blood pressure, left ventricular mass, and vascular hypertrophy.
Differential effects of beta-blockers on albuminuria in patients with type 2 diabetes.
Differential effects of diuresis and beta-adrenoreceptor blockade during angiotensin-converting enzyme inhibition in patients with severe hypertension.
Differential leukocyte counts and cardiovascular mortality in very old patients with acute myocardial infarction: a Chinese cohort study.
Differential modulation of baroreceptor sensitivity by long-term antihypertensive treatment.
Differential regulation of brain angiotensin II in genetically hypertensive and normotensive rats after nephrectomy.
Differential regulation of vascular angiotensin I-converting enzyme in hypertension.
Differentiated response of the sympathetic nervous system to angiotensin-converting enzyme inhibition in hypertension.
Differentiation between renovascular and essential hypertension by means of changes in single kidney 99mTc-DTPA clearance induced by angiotensin-converting enzyme inhibition.
Differing effects of antihypertensive drugs on the incidence of diabetes mellitus among patients with hypertensive kidney disease.
Differing mechanisms of action of angiotensin-converting enzyme inhibition in black and white hypertensive patients. The Trandolapril Multicenter Study Group.
Digit preferences observed in the measurement of blood pressure: repercussions on the success criteria in current treatment of hypertension.
Dihydroquercetin Does Not Affect Age-Dependent Increase in Blood Pressure and Angiotensin-Converting Enzyme Activity in the Aorta of Hypertensive Rats.
Dipeptidyl peptidase-4 (DPP-4) inhibitor and mortality in coronavirus disease 2019 (COVID-19) - A systematic review, meta-analysis, and meta-regression.
Discoordinate re-expression of cardiac fetal genes in N(omega)-nitro-L-arginine methyl ester (L-NAME) hypertension.
Discordance of anti-ischemic and hemodynamic effects of captopril in stable coronary artery disease.
Discordant nephron function. A pathogenic factor in hypertension and its vascular complications of stroke and heart attack.
Discovery of a potent angiotensin converting enzyme inhibitor via virtual screening.
Discovery of new angiotensin converting enzyme (ACE) inhibitors from medicinal plants to treat hypertension using an in vitro assay.
Discovery of remikiren as the first orally active renin inhibitor.
Discrepancy between plasma angiotensin converting enzyme activity and in vivo extent of angiotensin I conversion in hypertensive rats.
Discrepant Regulation of QT (QTc) Interval Duration by Calcium Channel Blockade and Angiotensin Converting Enzyme Inhibition in Experimental Hypertension.
Disease progression and the application of evidence-based treatment guidelines diagnose it early: a case for screening and appropriate management.
Disparate cardiovascular response to stress tests during isradipine and fosinopril therapy.
Dissecting the contradictory findings of angiotensin converting enzyme genetic polymorphism with blood pressure and hypertension.
Distribution of prolyl oligopeptidase in human peripheral tissues and body fluids.
Diuretic and enhanced sodium restriction results in improved antiproteinuric response to RAS blocking agents.
Diuretic response to acute hypertension is blunted during angiotensin II clamp.
Diuretics potentiate angiotensin converting enzyme inhibitor-induced acute renal failure.
Diuretics, Ca-Antagonists, and Angiotensin-Converting Enzyme Inhibitors Affect Zinc Status in Hypertensive Patients on Monotherapy: A Randomized Trial.
Diuretics: a review and update.
Diurnal blood pressure in patients with mild-to-moderate hypertension treated with once-daily benazepril hydrochloride.
Do angiotensin converting enzyme inhibitors represent a progress in hypertension care in diabetes mellitus?
Do angiotensin-converting enzyme (ACE) inhibitors enhance the effect of exercise rehabilitation in patients with hypertension and ACE DD and DI genotypes?
Docking Studies of Methylthiomorpholin Phenols (LQM300 Series) with Angiotensin-Converting Enzyme (ACE).
Does angiotensin-II protect against strokes?
Does aspirin attenuate the effect of angiotensin-converting enzyme inhibitors in hypertension or heart failure?
Does aspirin interfere with the therapeutic efficacy of angiotensin-converting enzyme inhibitors in hypertension or congestive heart failure?
Does blood pressure reduction necessarily compromise cardiac function or renal hemodynamics? Effects of the angiotensin-converting enzyme inhibitor quinapril.
Does combined therapy of Ca-channel blocker and angiotensin converting enzyme inhibitor exceed monotherapy in renal protection against hypertensive injury in rats?
Does Genetic Predisposition Contribute to the Exacerbation of COVID-19 Symptoms in Individuals with Comorbidities and Explain the Huge Mortality Disparity between the East and the West?
Does the duration of action of angiotensin converting enzyme inhibitors affect their safety and adverse effects?
Does vitamin D modulate asymmetric dimethylarginine and C-reactive protein concentrations?
Dopamine and the kidney: a role in hypertension?
Dosage considerations with perindopril for systemic hypertension.
Dose optimization study of arterial changes associated with angiotensin converting enzyme inhibition in hypertension.
Doxazosin. An update of its clinical pharmacology and therapeutic applications in hypertension and benign prostatic hyperplasia.
DPP-IV Inhibitor-Associated Angioedema in Patient With Known History of ACE Inhibitor Angioedema.
Drug class effects: definitions and practical applications.
Drug Insight: angiotensin-converting-enzyme inhibitors and atrial fibrillation-indications and contraindications.
Drug of choice in the management of hypertension in diabetes and diabetic nephropathy: Angiotensin-converting enzyme inhibitors.
Drug therapy before coronary artery surgery: nitrates are independent predictors of mortality and beta-adrenergic blockers predict survival.
Drug therapy for hypertension in hemodialysis patients.
Drug therapy for prevention of cardiovascular disease--should surrogate measures be abandoned?
Drug treatment of hypertension in older persons in an academic hospital-based geriatrics practice.
Drug-drug interactions of angiotensin converting enzyme inhibitors mediated by metabolizing enzymes and transporters.
Drug-induced subacute cutaneous lupus erythematosus: a paradigm for bedside-to-bench patient-oriented translational clinical investigation.
Drugs affecting the renin-angiotensin system and survival from cancer: a population based study of breast, colorectal and prostate cancer patient cohorts.
Dual ACE and NEP inhibitor MDL-100,240 prevents and regresses severe angiotensin II-dependent hypertension partially through bradykinin type 2 receptor.
Dual Blockade of the Renin-angiotensin-aldosterone System in Type 2 Diabetic Kidney Disease.
Dual deficiency of angiotensin-converting enzyme-2 and Mas receptor enhances angiotensin II-induced hypertension and hypertensive nephropathy.
Dual effects of RAS blockade on blood pressure and podocyte function.
Dual inhibition of ACE and NEP provides greater cardioprotection in mice with heart failure.
Dual inhibition of angiotensin-converting enzyme and neutral endopeptidase by the orally active inhibitor mixanpril: a potential therapeutic approach in hypertension.
Dual inhibition of angiotensin-converting enzyme and neutral endopeptidase in rats with hypertension.
Dual inhibition of neutral endopeptidase and angiotensin-converting enzyme in rats with hypertension and diabetes mellitus.
Dual RAS Blockade Normalizes Angiotensin-Converting Enzyme-2 Expression, Prevents Hypertension and Tubular Apoptosis in Akita Angiotensinogen-Transgenic Mice.
Duplex ultrasound and renin ratio predict treatment failure after revascularization for renal artery stenosis.
Duration of angiotensin-converting enzyme inhibition: implications for tolerability.
Dyspnea With Unilateral Pulmonary Ground Glass Opacities and Cavitary Lesions.
Dyspnoea, asthma, and bronchospasm in relation to treatment with angiotensin converting enzyme inhibitors.
Early administration of angiotensin-converting enzyme inhibitor captopril, prevents the development of hypertension programmed by intrauterine exposure to a maternal low-protein diet in the rat.
Early recognition and treatment of glucose abnormalities to prevent type 2 diabetes mellitus and coronary heart disease.
Early renal denervation prevents development of hypertension in growth-restricted offspring.
Ectopic Fat Storage, Insulin Resistance, and Hypertension.
Editorial on hemoglobin A1c, blood pressure, and low-density lipoprotein cholesterol goals in diabetics.
Effect of 12-hour infusions of saralasin or captopril on blood pressure in hypertensive conscious rats. Relationship to plasma renin, duration of hypertension, and effect of unclipping.
Effect of a milk drink supplemented with whey peptides on blood pressure in patients with mild hypertension.
Effect of ACE inhibitors and angiotensin II receptor antagonists in a mouse model of colorectal cancer liver metastases.
Effect of ACE insertion/deletion and 12 other polymorphisms on clinical outcomes and response to treatment in the LIFE study.
Effect of ACE polymorphisms on the association between noise and hypertension in a Pakistani population.
Effect of allopurinol on blood pressure and aortic compliance in hypertensive patients.
Effect of amiloride, or amiloride plus hydrochlorothiazide, versus hydrochlorothiazide on glucose tolerance and blood pressure (PATHWAY-3): a parallel-group, double-blind randomised phase 4 trial.
Effect of Amlodipine in Stroke and Myocardial infarction: A Systematic Review and Meta-analysis.
Effect of an excess intake of casein hydrolysate containing val-pro-pro and ile-pro-pro in subjects with normal blood pressure, high-normal blood pressure, or mild hypertension.
Effect of an intravenous angiotensin-converting enzyme inhibitor on the electrophysiologic features of normal and hypertrophied feline ventricles.
Effect of angiotensin converting enzyme inhibition after acute myocardial infarction in patients with arterial hypertension. TRACE Study Group, Trandolapril Cardiac Event.
Effect of angiotensin converting enzyme inhibitor (lisinopril) on insulin sensitivity and sodium transport in mild hypertension.
Effect of angiotensin converting enzyme inhibitors and angiotensin receptor blockers on hemoglobin levels.
Effect of angiotensin II type I receptor A1166C polymorphism on benazepril action in hypertensive patients: a family-based association test study.
Effect of Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor on Kidney Function and Blood Potassium Level in Indonesian Type 2 Diabetes Mellitus with Hypertension: A Three-Month Cohort Study.
Effect of angiotensin-converting enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPP) randomized trial. The Captopril Prevention Project (CAPP) Study Group.
Effect of angiotensin-converting enzyme inhibitors on arterial stiffness in hypertension: systematic review and meta-analysis.
Effect of angiotensin-converting enzyme inhibitors on fructose induced hypertension and hyperinsulinaemia in rats.
Effect of angiotensin-converting enzyme inhibitors on response to erythropoietin therapy in chronic dialysis patients.
Effect of angiotensin-converting enzyme insertion/deletion genotype on collagen type I synthesis and degradation in patients with atrial fibrillation and arterial hypertension.
Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial.
Effect of antihypertensive treatment with alacepril on insulin resistance in diabetic spontaneously hypertensive rats.
Effect of antihypertensive treatments on insulin signalling in lympho-monocytes of essential hypertensive patients: A pilot study.
Effect of benazepril monotherapy in subjects with hypertension associated with renal dysfunction.
Effect of beta blockade (carvedilol or metoprolol) on activation of the renin-angiotensin-aldosterone system and natriuretic peptides in chronic heart failure.
Effect of captopril (SQ 14225) on blood pressure, plasma renin activity and angiotensin I converting enzyme activity.
Effect of captopril and enalapril on endothelial function in hypertensive patients.
Effect of captopril on 99mTc-diethylenetriaminepentaacetic acid renograms in two-kidney, one clip hypertension.
Effect of captopril on infantile haemangiomas: A retrospective case series.
Effect of central administration of MK-422 (the diacid form of enalapril) on the development of hypertension in the spontaneously hypertensive rat.
Effect of Chronic Blockade of the Kallikrein-Kinin System on the Development of Hypertension in Rats.
Effect of chronic treatment with losartan on streptozotocin induced diabetic nephropathy.
Effect of cilazapril and indomethacin on endothelial dysfunction in the aortas of spontaneously hypertensive rats.
Effect of cilazapril therapy on glucose and lipid metabolism in patients with hypertension.
Effect of combining extended-release carvedilol and lisinopril in hypertension: results of the COSMOS study.
Effect of delapril on the vascular angiotensin II release in isolated hind legs of the spontaneously hypertensive rat: evidence for potential relevance of vascular angiotensin II to the maintenance of hypertension.
Effect of Different Classes of Antihypertensive Drugs on Endothelial Function and Inflammation.
Effect of Different Proteases on the Degree of Hydrolysis and Angiotensin I-Converting Enzyme-Inhibitory Activity in Goat and Cow Milk.
Effect of dual angiotensin converting enzyme/neutral endopeptidase inhibition, angiotensin converting enzyme inhibition, or AT1 antagonism on coronary microvasculature in spontaneously hypertensive rats.
Effect of dual compared to no or single renin-angiotensin system blockade on risk of renal replacement therapy or death in predialysis patients: PREPARE-2 study.
Effect of enalapril in subjects with hypertension associated with moderate to severe renal dysfunction.
Effect of enalapril on aortic smooth muscle cell polyploidy in the spontaneously hypertensive rat.
Effect of enalapril on erythrocytosis in hypertensive patients with renal disease.
Effect of enalapril on renin, angiotensin converting enzyme activity, aldosterone and prostaglandins in patients with hypertension.
Effect of enalaprilat on postoperative hypertension after surgical repair of coarctation of the aorta.
Effect of estrogen and angiotensin-converting enzyme inhibitor on vascular remodeling in ovariectomized spontaneously hypertensive rats.
Effect of experimentally-induced hypertension on angiotensin converting enzyme activity in the aortic endothelium and smooth muscle cum adventitia of the Sprague Dawley rat.
Effect of fosinopril on cardiac and metabolic parameters in patients with NIDDM.
Effect of Functional Bread Rich in Potassium, ?-Aminobutyric Acid and Angiotensin-Converting Enzyme Inhibitors on Blood Pressure, Glucose Metabolism and Endothelial Function: A Double-blind Randomized Crossover Clinical Trial.
Effect of hypertension on angiotensin-(1-7) levels in rats with different angiotensin-I converting enzyme polymorphism.
Effect of hypertension therapy with the angiotensin-converting enzyme inhibitor lisinopril on hyperandrogenism in women with polycystic ovary syndrome.
Effect of imidapril in dipper and nondipper hypertensive patients: comparison between morning and evening administration.
Effect of immunisation against angiotensin II with CYT006-AngQb on ambulatory blood pressure: a double-blind, randomised, placebo-controlled phase IIa study.
Effect of incubation time, inoculum size, temperature, pasteurization time, goat milk powder and whey powder on ACE inhibitory activity in fermented milk by L. plantarum LP69.
Effect of initial drug choice on persistence with antihypertensive therapy: the importance of actual practice data.
Effect of intraoperative angiotensin-converting enzyme inhibition by quinaprilat on hypertension after coronary artery surgery.
Effect of intravenous enalaprilat in moderate and severe systemic hypertension.
Effect of Jatropha curcas peptide fractions on the angiotensin I-converting enzyme inhibitory activity.
Effect of long-term treatment with enalapril in streptozotocin diabetic and DOCA hypertensive rats.
Effect of losartan on nocturnal blood pressure in patients with stroke: comparison with angiotensin converting enzyme inhibitor.
Effect of moderate weight loss on health-related quality of life: an analysis of combined data from 4 randomized trials of sibutramine vs placebo.
Effect of organic anion-transporting polypeptide 1B1 (OATP1B1) polymorphism on the single- and multiple-dose pharmacokinetics of enalapril in healthy Chinese adult men.
Effect of pentoxifylline on GFR decline in CKD: a pilot, double-blind, randomized, placebo-controlled trial.
Effect of perindopril on renal medullary hemodynamics in genetically hypertensive rats.
Effect of perindopril on the immune arterial wall remodeling in the rat model of arterial graft rejection.
Effect of prolonged administration of a urinary kinase inhibitor, ebelactone B on the development of deoxycorticosterone acetate-salt hypertension in rats.
Effect of quinapril and triamterene/hydrochlorothiazide on cardiac and vascular end-organ damage in isolated systolic hypertension.
Effect of quinapril therapy on blood pressure and serotonin change in patients with mild to moderate hypertension.
Effect of rate and rhythm control on left ventricular function and cardiac dimensions in patients with persistent atrial fibrillation: results from the RAte Control versus Electrical Cardioversion for Persistent Atrial Fibrillation (RACE) study.
Effect of Renin-Angiotensin-Aldosterone System Blockade on Long-Term Outcomes in Postacute Kidney Injury Patients With Hypertension.
Effect of sodium intake on brain angiotensin-converting enzyme activity in spontaneously hypertensive rat.
Effect of spironolactone and captopril on nitric oxide and S-nitrosothiol formation in kidney of L-NAME-treated rats.
Effect of statin therapy on survival in patients with nonischemic dilated cardiomyopathy (from the Beta-blocker Evaluation of Survival Trial [BEST]).
Effect of statins on the development of renal dysfunction.
Effect of statins on the mortality of patients with ischaemic heart disease: population based cohort study with nested case-control analysis.
Effect of the ACE inhibitor ceronapril on cerebral blood flow in hypertensive patients.
Effect of the metabolic syndrome and hyperuricemia on outcome in patients with coronary artery disease (from the Bezafibrate Infarction Prevention Study).
EFFECT OF THERMAL TREATMENT ON PHENOLIC COMPOUNDS AND FUNCTIONALITY LINKED TO TYPE 2 DIABETES AND HYPERTENSION MANAGEMENT OF PERUVIAN AND BRAZILIAN BEAN CULTIVARS (PHASEOLUS VULGARIS L.) USING IN VITRO METHODS
Effect of treatment with candesartan or enalapril on subcutaneous small artery structure in hypertensive patients with noninsulin-dependent diabetes mellitus.
Effect of varying chain length between P(1) and P(1') position of tripeptidomimics on activity of angiotensin-converting enzyme inhibitors.
Effect on the development of ankle edema of adding delapril to manidipine in patients with mild to moderate essential hypertension: a three-way crossover study.
Effective treatment of hypertension by recombinant Lactobacillus plantarum expressing angiotensin converting enzyme inhibitory peptide.
Effective use of captopril in postoperative paradoxical hypertension of coarctation of the aorta.
Effects of a fixed-dose ACE inhibitor-diuretic combination on ambulatory blood pressure and arterial properties in isolated systolic hypertension.
Effects of a novel ACE inhibitor, 3-(3-thienyl)-l-alanyl-ornithyl-proline, on endothelial vasodilation and hepatotoxicity in l-NAME-induced hypertensive rats.
Effects of ACE inhibition and beta-blockade on plasminogen activator inhibitor-1 and transforming growth factor-beta1 in carotid glomus and autonomic ganglia in hypertensive rats.
Effects of ACE inhibition on proximal tubule sodium transport.
Effects of ACE inhibition versus non-ACE inhibitor antihypertensive treatment on myocardial fibrosis in patients with arterial hypertension. Retrospective analysis of 120 patients with left ventricular endomyocardial biopsies.
Effects of acute and chronic angiotensin-converting enzyme inhibition on large arteries in human hypertension.
Effects of acute exercise on angiotensin I-converting enzyme (ACE) activity in horses.
Effects of add-on nebivolol on blood pressure and glucose parameters in hypertensive patients with prediabetes.
Effects of an ACE inhibitor and a calcium channel blocker on cardiovascular autonomic nervous system and carotid distensibility in patients with mild to moderate hypertension.
Effects of an angiotensin converting enzyme inhibitor on psychosocial hypertension in mice.
Effects of an angiotensin-converting enzyme inhibitor and a beta-blocker on cerebral arteriolar dilatation in hypertensive rats.
Effects of angiotensin converting enzyme and angiotensin II receptor inhibition on impaired fibrinolysis in systemic hypertension.
Effects of angiotensin converting enzyme gene polymorphism on hypertension in Africa: A meta-analysis and systematic review.
Effects of angiotensin converting enzyme inhibition on endothelial vasodilator function in primary human hypertension.
Effects of angiotensin converting enzyme inhibitor and angiotensin II analogue on hypertension. Study of hypertension with two different blockers of the renin-angiotensin-aldosterone system.
Effects of angiotensin converting enzyme inhibitor and angiotensin II receptor blocker on ventricular defibrillation threshold.
Effects of angiotensin converting enzyme inhibitors and of hydralazine on endothelial function in hypertensive rats.
Effects of angiotensin converting enzyme inhibitors on thrombotic mediators: potential clinical implications.
Effects of angiotensin II receptor blockade-based therapy with losartan on left ventricular hypertrophy and geometry in previously treated hypertensive patients.
Effects of angiotensin II type 1 receptor antagonist on smooth muscle cell phenotype in intramyocardial arteries from spontaneously hypertensive rats.
Effects of angiotensin II type 1 receptor blockade and angiotensin-converting enzyme inhibition on cardiac beta-adrenergic signal transduction.
Effects of Angiotensin-Converting Enzyme Inhibition and Alpha 1-Adrenergic Receptor Blockade on Inflammation and Hemostasis in Human Hypertension.
Effects of angiotensin-converting enzyme inhibition on left ventricular geometric patterns in patients with essential hypertension.
Effects of angiotensin-converting enzyme inhibition on plasma aldosterone concentration, plasma renin activity, and blood pressure in spontaneously hypertensive cats with chronic renal disease.
Effects of angiotensin-converting enzyme inhibitor and angiotensin type 1 receptor antagonist in deoxycorticosterone acetate-salt hypertensive mice lacking Ren-2 gene.
Effects of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in patients with chronic kidney disease.
Effects of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers on Angiotensin-Converting Enzyme 2 Levels: A Comprehensive Analysis Based on Animal Studies.
Effects of angiotensin-converting enzyme inhibitors on cerebral vascular structure in chronic hypertension.
Effects of angiotensin-converting enzyme inhibitors on tissue renin-angiotensin systems.
Effects of angiotensin-converting enzyme inhibitors, Ca2+ channel antagonists, and alpha-adrenergic blockers on glucose and lipid metabolism in NIDDM patients with hypertension.
Effects of angiotensin-converting-enzyme inhibitors in combination with diuretics on blood pressure and renal injury in nitricoxide-deficiency-induced hypertension in rats.
Effects of antihypertensive drugs on renal function and atrial natriuretic polypeptide in spontaneously hypertensive rats with renal ablation.
Effects of antihypertensive therapy on kidney function in diabetic patients.
Effects of antihypertensive therapy on mechanics of cerebral arterioles in rats.
Effects of aspirin on angiotensin-converting enzyme inhibition and left ventricular dilation one year after acute myocardial infarction.
Effects of atenolol, perindopril and verapamil on haemodynamic and vascular function in Marfan syndrome - a randomised, double-blind, crossover trial.
Effects of benazepril on functional activity of endothelial progenitor cells from hypertension patients.
Effects of benazepril, an angiotensin-converting enzyme inhibitor, combined with CGS 35066, a selective endothelin-converting enzyme inhibitor, on arterial blood pressure in normotensive and spontaneously hypertensive rats.
Effects of calcium channel blockers comparing to angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with hypertension and chronic kidney disease stage 3 to 5 and dialysis: A systematic review and meta-analysis.
Effects of candesartan on the proteinuria of chronic glomerulonephritis.
Effects of Captopril and Losartan on Cardiac Stereology in Rats with Renovascular Hypertension.
Effects of captopril on neurosecretion and vascular responsiveness in hypertension.
Effects of chronic ACE inhibition on cardiac hypertrophy and coronary vascular reserve in spontaneously hypertensive rats with developed hypertension.
Effects of chronic blockade of angiotensin II receptor on the maintenance of hypertension and vascular changes in spontaneously hypertensive rats.
Effects of chronic cilazapril treatment on cardiovascular control: a spectral analytical approach.
Effects of chronic hypertension and left ventricular hypertrophy on the extent of infarct expansion in rats.
Effects of chronic inhibition of ACE and AT1 receptors on glomerular injury in dahl salt-sensitive rats.
Effects of cilazapril on hypertension, sleep, and apnea.
Effects of combination of cyclosporine with losartan or enalapril on kidney function in uremic rats.
Effects of cyclooxygenase inhibition on endothelial function in hypertensive patients treated with angiotensin-converting enzyme inhibitors.
Effects of dopamine receptor antagonist antipsychotic therapy on blood pressure.
Effects of dual blockade of the renin-angiotensin system on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy and hypertension in the ORIENT: a post-hoc analysis (ORIENT-Hypertension).
Effects of enalapril on the cardiovascular response to treadmill exercise in patients with mild to moderate systemic hypertension.
Effects of enalapril, tempol, and eplerenone on salt-induced hypertension in dahl salt-sensitive rats.
Effects of enalaprilat on hemodynamics and ventricular activation duration in hypertensive patients with left ventricular hypertrophy: clinical evidence of improved excitation-contraction coupling with angiotensin converting enzyme inhibition in human hypertension.
Effects of eprosartan versus hydrochlorothiazide on markers of vascular oxidation and inflammation and blood pressure (renin-angiotensin system antagonists, oxidation, and inflammation).
Effects of Hypertension and Anti-Hypertensive Treatment on Amyloid-? (A?) Plaque Load and A?-Synthesizing and A?-Degrading Enzymes in Frontal Cortex.
Effects of lisinopril and hydrochlorothiazide on platelet function and blood rheology in essential hypertension: a randomly allocated double-blind study.
Effects of losartan in combination with or without exercise on insulin resistance in Otsuka Long-Evans Tokushima Fatty rats.
Effects of low-dose combination therapy with an angiotensin-converting enzyme inhibitor and a diuretic on flow-mediated vasodilation in hypertensive patients: a 6-month, single-center study.
Effects of maternal undernutrition on renal angiotensin II and chymase in hypertensive offspring.
Effects of natural peptides from food proteins on angiotensin converting enzyme activity and hypertension.
Effects of neutral endopeptidase inhibition and combined angiotensin converting enzyme and neutral endopeptidase inhibition on angiotensin and bradykinin peptides in rats.
Effects of nifedipine GITS 20 mg or enalapril 20 mg on blood pressure and inflammatory markers in patients with mild-moderate hypertension.
Effects of nitrendipine and enalapril on left ventricular mass in patients with non-insulin-dependent diabetes mellitus and hypertension.
Effects of non-steroidal anti-inflammatory drugs on hypertension control using angiotensin converting enzyme inhibitors and thiazide diuretics.
Effects of omapatrilat on blood pressure and renal injury in L-NAME and L-NAME plus DOCA-treated rats.
Effects of omapatrilat on hemodynamics and safety in patients with heart failure.
Effects of once-daily angiotensin-converting enzyme inhibition and calcium channel blockade-based antihypertensive treatment regimens on left ventricular hypertrophy and diastolic filling in hypertension: the prospective randomized enalapril study evaluating regression of ventricular enlargement (preserve) trial.
Effects of perindopril on hypertension and stroke prevention in experimental animals.
Effects of perindopril on serum lipids in hypertensive patients with hyperlipidemia.
Effects of raloxifene therapy on plasma renin and aldosterone levels and blood pressure in postmenopausal women.
Effects of ramipril on left ventricular mass and function in cardiovascular patients with controlled blood pressure and with preserved left ventricular ejection fraction: a substudy of the Heart Outcomes Prevention Evaluation (HOPE) Trial.
Effects of renin-angiotensin system blockade and dietary salt intake on left ventricular hypertrophy in Dahl salt-sensitive rats.
Effects of Renin-Angiotensin-Aldosterone Inhibitors on Early Outcomes of Hypertensive COVID-19 Patients: A Randomized Triple-Blind Clinical Trial.
Effects of SA7060, a novel dual inhibitor of neutral endopeptidase and angiotensin-converting enzyme, on deoxycorticosterone acetate-salt-induced hypertension in rats.
Effects of the administration of an angiotensin-converting enzyme inhibitor during the acute phase of myocardial infarction in patients with arterial hypertension. SMILE Study Investigators. Survival of Myocardial Infarction Long-term Evaluation.
Effects of the angiotensin converting enzyme inhibitor enalapril compared with diuretic therapy in elderly hypertensive patients.
Effects of the angiotensin converting enzyme inhibitor, lisinopril, on normal and diabetic rats.
Effects of the angiotensin I converting enzyme inhibitor perindopril on cerebral blood flow in awake hypertensive rats.
Effects of the angiotensin II receptor antagonist losartan on 24-hour blood pressure profiles of primary and secondary hypertensive rats.
Effects of the AT1 receptor antagonist on adhesion molecule expression in leukocytes and brain microvessels of stroke-prone spontaneously hypertensive rats.
Effects of the blockade of the renin-angiotensin system in cyclosporin-induced hypertension.
Effects of the new oral angiotensin converting enzyme inhibitor MK-421 in human hypertension.
Effects of the oral angiotensin-converting enzyme inhibitor MK-421 in human hypertension.
Effects of trandolapril on vascular morphology and function during the established phase of systemic hypertension in the spontaneously hypertensive rat.
Effects of treatment strategy on endothelial function.
Effects of tryptophan-containing peptides on angiotensin-converting enzyme activity and vessel tone ex vivo and in vivo.
Effects of two structurally different angiotensin-converting enzyme inhibitors, captopril and quinapril (CI-906), in rats with one-kidney deoxycorticosterone-salt hypertension.
Effects of variations in sodium intake on the acute vasodepressor response to kininase II inhibition in rats with mild two-kidney, one-clip hypertension.
Efficacy and safety of cilazapril in hypertensive patients with moderate to severe renal impairment.
Efficacy and safety of delapril/indapamide compared to different ACE-inhibitor/hydrochlorothiazide combinations: a meta-analysis.
Efficacy and safety of eprosartan in severe hypertension. Eprosartan Multinational Study Group.
Efficacy and Safety of Firibastat, A First-in-Class Brain Aminopeptidase A Inhibitor, in Hypertensive Overweight Patients of Multiple Ethnic Origins.
Efficacy and safety of fosinopril/hydrochlorothiazide combinations on ambulatory blood pressure profiles in hypertension. Fosinopril/Hydrochlorothiazide Investigators.
Efficacy and Safety of Incremental Dosing of a New Single-Pill Formulation of Perindopril and Amlodipine in the Management of Hypertension.
Efficacy and safety of lercanidipine versus hydrochlorothiazide as add-on to enalapril in diabetic populations with uncontrolled hypertension.
Efficacy and Safety of Quinapril 40mg Once Daily as Monotherapy for Patients with Poorly Controlled Hypertension : The EUREKA Study.
Efficacy and safety of quinapril in the elderly hypertensive patient.
Efficacy and safety of sacubitril-valsartan in heart failure: a meta-analysis of randomized controlled trials.
Efficacy and safety of the selective aldosterone blocker eplerenone in Japanese patients with hypertension: a randomized, double-blind, placebo-controlled, dose-ranging study.
Efficacy and safety of valsartan, an angiotensin II receptor antagonist, in hypertension after renal transplantation: a randomized multicenter study.
Efficacy and Safety Profile of Aliskiren: Practical Implications for Clinicians.
Efficacy and tolerability of moexipril and nitrendipine in postmenopausal women with hypertension. MADAM study group. Moexipril as Antihypertensive Drug After Menopause.
Efficacy and tolerability of tasosartan, a novel angiotensin II receptor blocker: results from a 10-week, double-blind, placebo-controlled, dose-titration study. Tasosartan Investigators Group.
Efficacy and tolerability of trandolapril in mild to moderate hypertension--a double blind comparative clinical trial with enalapril in Indian population.
Efficacy of ACEIs/ARBs versus CCBs on the progression of COVID-19 patients with hypertension in Wuhan: A hospital-based retrospective cohort study.
Efficacy of an oral angiotensin-converting enzyme inhibitor (captopril) in severe hypertension.
Efficacy of antihypertensive therapy in decreasing renal and cardiovascular complications in diabetes mellitus.
Efficacy of atenolol as a single antihypertensive agent in hyperthyroid cats.
Efficacy of candesartan cilexetil as add-on therapy in hypertensive patients uncontrolled on background therapy: a clinical experience trial. ACTION Study Investigators.
Efficacy of cilazapril compared with hydrochlorothiazide in the treatment of mild-to-moderate essential hypertension. Multicentre Study Group.
Efficacy of combination therapy with angiotensin-converting enzyme inhibitor and calcium channel blocker in hypertension.
Efficacy of low-dose spironolactone in subjects with resistant hypertension.
Efficacy of once-daily lisinopril monotherapy in systemic hypertension.
Efficacy of Traditional Chinese Medicine in patients with acute myocardial infarction suffering from diabetes mellitus.
Efficacy, tolerance and hormonal effects of a new oral angiotensin converting enzyme inhibitor, ramipril (HOE 498), in mild to moderate primary hypertension.
Eighth European meeting on hypertension.
Electronic health record components and the quality of care.
Elevated lipoprotein(a) levels predict cardiovascular disease in type 2 diabetes mellitus: a 10-year prospective cohort study.
Elevated vascular angiotensin converting enzyme in chronic two-kidney, one clip hypertension in the dog.
Elevated vascular angiotensin converting enzyme mediates increased neointima formation after balloon injury in spontaneously hypertensive rats.
Emergency Room Treatment of Hypertensive Crises.
Emerging concepts: angiotensin-converting enzyme inhibition in coronary artery disease.
Emerging drug combinations to optimize renovascular protection and blood pressure goals.
Enalapril and Acute Kidney Injury in a Hypertensive Premature Newborn - Should It Be Used or Not?
Enalapril attenuates endothelin-1-induced hypertension via increased kinin survival.
Enalapril improves glucose tolerance in two rat models: a new hypertensive diabetic strain and a fructose-induced hyperinsulinaemic rat.
Enalapril in essential hypertension.
Enalapril induced severe hyponatremia and altered sensorium in a child.
Enalapril: a long-acting angiotensin-converting enzyme inhibitor.
Enalapril: a new angiotensin converting enzyme inhibitor.
Enalaprilat in hypertensive emergencies.
End-organ protection in hypertension by the novel and selective Rho-kinase inhibitor, SAR407899.
End-stage renal disease: a southern epidemic.
Endothelial dysfunction and subendothelial monocyte macrophages in hypertension. Effect of angiotensin converting enzyme inhibition.
Endothelial factors and microvascular hypertensive disease.
Endothelial function in spontaneously hypertensive rats: influence of quinapril treatment.
Endothelin and active renin levels in essential hypertension and hypertension with renal artery stenosis before and after percutaneous transluminal renal angioplasty.
Endothelin in cardiovascular control: the role of endothelin antagonists.
Endothelin-1 and nitric oxide in patients on chronic hemodialysis.
Endothelin-1 attenuates bradykinin-induced hypotension in rats.
Endothelin-receptor antagonists: current and future perspectives.
Enhancement by diuretics of the antihypertensive action of long-term angiotensin converting enzyme blockade.
Epidemiologic review of the calcium channel blocker drugs. An up-to-date perspective on the proposed hazards.
Epigenetic modification of the renin-angiotensin system in the fetal programming of hypertension.
Epigenetics and arterial hypertension: the challenge of emerging evidence.
Eplerenone: a selective aldosterone blocker.
Eprosartan provides safe and effective long-term maintenance of blood pressure control in patients with mild to moderate essential hypertension.
Equivalence of indapamide SR and enalapril on microalbuminuria reduction in hypertensive patients with type 2 diabetes: the NESTOR Study.
Erectile dysfunction in patients in a cardiac rehabilitation program.
Erythropoietin upregulates angiotensin receptors in cultured rat vascular smooth muscle cells.
Essential hypertension and chronic viral hepatitis.
Essential oil of Zygophyllum album inhibits key-digestive enzymes related to diabetes and hypertension and attenuates symptoms of diarrhea in alloxan-induced diabetic rats.
Estimation of angiotensin-converting enzyme inhibitors protein binding degree using chromatographic hydrophobicity data.
Ethnic variations in the pharmacological and nonpharmacological treatment of hypertension: biopsychosocial perspective.
EUROASPIRE III. Management of cardiovascular risk factors in asymptomatic high-risk patients in general practice: cross-sectional survey in 12 European countries.
Evaluation and Management of Erectile Dysfunction in the Hypertensive Patient.
Evaluation and treatment of chronic renal failure.
Evaluation of antihyperglycemia and antihypertension potential of native Peruvian fruits using in vitro models.
Evaluation of antiproliferative, anti-type 2 diabetes, and antihypertension potentials of ellagitannins from strawberries (Fragaria ×?ananassa Duch.) using in vitro models.
Evaluation of impurities level of perindopril tert-butylamine in tablets.
EVALUATION OF PEPPER (CAPSICUM ANNUUM) FOR MANAGEMENT OF DIABETES AND HYPERTENSION
Evaluation of PepT1 transport of food-derived antihypertensive peptides, Ile-Pro-Pro and Leu-Lys-Pro using in vitro, ex vivo and in vivo transport models.
Evaluation of recent fixed-dose combination therapies in the management of hypertension.
EVALUATION OF RED CURRANTS (RIBES RUBRUM L.), BLACK CURRANTS (RIBES NIGRUM L.), RED AND GREEN GOOSEBERRIES (RIBES UVA-CRISPA) FOR POTENTIAL MANAGEMENT OF TYPE 2 DIABETES AND HYPERTENSION USING IN VITRO MODELS
Evaluation of risk factors for the development of nephropathy in patients with IDDM: insertion/deletion angiotensin converting enzyme gene polymorphism, hypertension and metabolic control.
Evaluation of some pharmaceutical formulations of lisinopril through dissolution testing.
Evaluation of the antihypertensive effect of lisinopril compared with nifedipine in patients with mild to severe essential hypertension.
Evaluation of the effects of inhibition of angiotensin converting enzyme with enalapril in dogs with induced chronic renal insufficiency.
Evaluation of the Losartan in Hemodialysis (ELHE) Study.
Evaluation of the safety and efficacy of telmisartan and enalapril, with the potential addition of frusemide, in moderate-renal failure patients with mild-to-moderate hypertension.
Evaluation of the total cost of treating elderly hypertensive patients with ACE inhibitors: a comparison of older and newer agents.
Evidence for a captopril-sensitive angiotensin converting enzyme in the hindquarter vasculature of SHR and WKY.
Evidence for a sodium-induced activation of central neurogenic mechanisms in one-kidney, one-clip renal hypertensive rats.
Evidence for an association between haptoglobin and MnSOD (Val9Ala) gene polymorphisms in essential hypertension based on a Brazilian case-control study.
Evidence for association and genetic linkage of the angiotensin-converting enzyme locus with hypertension and blood pressure in men but not women in the Framingham Heart Study.
Evidence for cardioprotective, renoprotective, and vasculoprotective effects of vasopeptidase inhibitors in disease.
Evidence for pericyte origin of TSC-associated renal angiomyolipomas and implications for angiotensin receptor inhibition therapy.
Evidence-based management for preeclampsia.
Evolution of angiotensin-converting enzyme inhibition in hypertension, heart failure, and vascular protection.
Evolution of angiotensin-converting enzyme inhibitors.
Evolving rationale for angiotensin-converting enzyme inhibition in chronic heart failure.
Evolving role of aldosterone blockers alone and in combination with angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers in hypertension management: a review of mechanistic and clinical data.
Evolving strategies for renoprotection: non-diabetic chronic renal disease.
Exaggerated blood pressure response during the exercise treadmill test as a risk factor for hypertension.
Exfoliative dermatitis from captopril.
Existing treatment strategies: does noncompliance make a difference?
Expanding role of pharmacogenomics in the management of cardiovascular disorders.
Experimental evidence for effects of ramipril on cardiac and vascular hypertrophy beyond blood pressure reduction.
Exposure to inhibitors of the renin-angiotensin system is a major independent risk factor for acute renal failure induced by sucrose-containing intravenous immunoglobulins: a case-control study.
Expression and response to Angiotensin-converting enzyme inhibition of matrix metalloproteinases 2 and 9 in renal glomerular damage in young transgenic rats with Renin-dependent hypertension.
Extract of Plantago asiatica L. Seeds Ameliorates Hypertension in Spontaneously Hypertensive Rats by Inhibition of Angiotensin Converting Enzyme.
Facilitation of noradrenergic transmission by angiotensin in hypertensive rats.
Factors associated with aspirin resistance in patients premedicated with aspirin and clopidogrel for endovascular neurosurgery.
Factors associated with chronic renal failure in HIV-infected ambulatory patients.
Factors associated with uncontrolled hypertension in an affluent, elderly population.
Factors contributing to the hospitalization of patients with congestive heart failure.
Factors determining the response to angiotensin-converting enzyme inhibitors in hypertension.
False-positive result of a captopril-enhanced radionuclide renogram in a child secondary to dehydration.
Fatal outcome of late-onset angiotensin-converting enzyme inhibitor induced angioedema: A case report.
Fatal Renal Failure in a Spinal Cord Injury Patient with Vesicoureteric Reflux Who Underwent Repeated Ureteric Reimplantations Unsuccessfully: Treatment Should Focus on Abolition of High Intravesical Pressures rather than Surgical Correction of Reflux.
Feasibility study of the early detection and treatment of renal disease by mass screening.
Fetal and neonatal effects of treatment with angiotensin-converting enzyme inhibitors in pregnancy.
Fetopathy associated with exposure to angiotensin converting enzyme inhibitors and angiotensin receptor antagonists.
Fibroblast Growth Factor-23, Heart Failure Risk, and Renin-Angiotensin-Aldosterone-System Blockade in Hypertension: The Multi-Ethnic Study of Atherosclerosis.
Filtration fraction.noninvasive measurement with Tc-99m DTPA and changes induced by angiotensin-converting enzyme inhibition in hypertension.
Fine-Mapping Angiotensin-Converting Enzyme Gene: Separate QTLs Identified for Hypertension and for ACE Activity.
First orally active DRI Aliskiren--a new prospect in management of hypertension and beyond.
First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension.
Five polymorphisms in gene candidates for cardiovascular disease in Afro-Brazilian individuals.
Fixed low-dose combination of an angiotensin converting enzyme inhibitor and a calcium channel blocker drug in the treatment of essential hypertension.
Fixed-combination therapies in hypertension management: focus on enalapril/lercanidipine.
Fixed-dose combination of perindopril with indapamide in spontaneously hypertensive rats: haemodynamic, biological and structural effects.
Fixed-dose combination therapy with trandolapril and verapamil SR is effective in primary hypertension. Trandolapril Study Group.
Fixed-Dose Combinations of Renin-Angiotensin System Inhibitors and Calcium Channel Blockers in the Treatment of Hypertension: A Comparison of Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors.
Flank pain and hematuria is not always a kidney stone.
Flavonoid-Rich Extract of Actinidia macrosperma (A Wild Kiwifruit) Inhibits Angiotensin-Converting Enzyme In Vitro.
Food protein-derived renin-inhibitory peptides: in vitro and in vivo properties.
Fosinopril H(2)-receptor antagonists interaction studies by derivative spectroscopy.
Fosinopril reduces ADP-induced platelet aggregation in hypertensive patients.
Fosinopril: an overview.
Frequencies of variants of candidate genes in different age groups of hypertensives.
Frequency of a deletion polymorphism in the gene for angiotensin converting enzyme is increased in African-Americans with hypertension.
From evidence to rationale: cardiovascular protection by angiotensin II receptor blockers compared with angiotensin-converting enzyme inhibitors.
From kinetics to dynamics: are there differences between ACE inhibitors?
Functional and biochemical analysis of angiotensin II-forming pathways in the human heart.
Functional cross-talk between the cyclic AMP and Jak/STAT signaling pathways in vascular smooth muscle cells.
Functional single-cell hybridoma screening using droplet-based microfluidics.
Functionality of bioactive compounds in Brazilian strawberry (Fragaria x ananassa Duch.) cultivars: evaluation of hyperglycemia and hypertension potential using in vitro models.
Gender differences in antihypertensive drug treatment: results from the Swedish Primary Care Cardiovascular Database (SPCCD).
Gene polymorphism of angiotensin II type 1 and type 2 receptors.
Gene therapy for hypertension: sense and antisense strategies.
Gene-environment interaction in hypertension, stroke and atherosclerosis in experimental models and supportive findings from a world-wide cross-sectional epidemiological survey: a WHO-cardiac study.
General considerations in selecting antihypertensive agents in patients with type II diabetes mellitus and hypertension.
Genetic approaches to common diseases.
Genetic basis of familial dyslipidemia and hypertension: 15-year results from Utah.
Genetic determination of human essential hypertension.
Genetic factors in hypertension. Angiotensin-converting enzyme polymorphism.
Genetic influences of angiotensin-converting enzyme inhibitor response: an opportunity for personalizing therapy?
Genetic linkage of the ACE gene to plasma angiotensin-converting enzyme activity but not to blood pressure. A quantitative trait locus confers identical complex phenotypes in human and rat hypertension.
Genetic polymorphisms in the renin-angiotensin system: relevance for susceptibility to cardiovascular disease.
Genetic polymorphisms of the renin-angiotensin system and complications of insulin-dependent diabetes mellitus.
Genetic variants of the renin-angiotensin system and ambulatory blood pressure in essential hypertension.
Genetic variation in the renin-angiotensin system and abdominal adiposity in men: the Olivetti Prospective Heart Study.
Genetics of hypertension. Therapeutic implications.
Genome-wide association study of angioedema induced by angiotensin-converting enzyme inhibitor and angiotensin receptor blocker treatment.
Genotype combinations of plasminogen activator inhibitor-1 and angiotensin-converting enzyme genes and risk for early onset of coronary heart disease.
GenTAC registry report: Gender differences among individuals with genetically triggered thoracic aortic aneurysm and dissection.
Glomerular filtration rate in early experimental diabetes.
Glomerular hypertension in the progression of chronic renal failure: role of low protein diet and angiotensin converting enzyme inhibitors.
Goals and guidelines for treating hypertension in a patient with heart failure.
Gonadal effects on plasma ACE activity in mice.
Green asparagus (Asparagus officinalis) prevented hypertension by an inhibitory effect on angiotensin-converting enzyme activity in the kidney of spontaneously hypertensive rats.
Guidelines adherence and hypertension control at a tertiary hospital in Malaysia.
Guidelines on the care of diabetic nephropathy, retinopathy and foot disease.
Haemodynamic and endocrine effects of deliberate hypotension with magnesium sulphate for cerebral-aneurysm surgery.
Haemodynamic effects of ACE inhibitors.
Haemodynamic effects of atenolol, labetalol, pindolol and captopril: a comparison in hypertensive patients with special reference to changes in limb blood flow, heart rate and left ventricular function.
Health economic implications of irbesartan plus conventional antihypertensive medications versus conventional blood pressure control alone in patients with type 2 diabetes, hypertension, and renal disease in Switzerland.
Health economics studies assessing irbesartan use in patients with hypertension, type 2 diabetes, and microalbuminuria.
Health outcomes and economic consequences of using angiotensin-converting enzyme inhibitors in comparison with angiotensin receptor blockers in the treatment of arterial hypertension in the contemporary Polish setting.
HEALTH-RELATED FUNCTIONALITY OF PHENOLIC-ENRICHED PEA SPROUTS IN RELATION TO DIABETES AND HYPERTENSION MANAGEMENT
Heart Angiotensin-Converting Enzyme and Angiotensin-Converting Enzyme 2 Gene Expression Associated With Male Sex and Salt-Sensitive Hypertension in the Dahl Rat.
Heart rate variability and left ventricular dilatation early after myocardial infarction.
Hemodialysis-resistant hypertension: control with an orally active inhibitor of angiotensin-converting enzyme.
Hemodynamic and endocrine changes associated with captopril in diuretic-resistant hypertensive patients.
Hemodynamic and morphological effects of quinapril during genetic hypertension development.
Hemodynamic effects of angiotensin-converting enzyme inhibitors in essential hypertension: a review.
Hemodynamic effects of inhibitors of the renin-angiotensin system.
Hemodynamic effects of new angiotensin converting enzyme inhibitors during continuous angiotensin I infusion on conscious dogs.
Hepatic morphological alterations, glycogen content and cytochrome P450 activities in rats treated chronically with N(omega)-nitro-L-arginine methyl ester (L-NAME).
High blood pressure-lowering and vasoprotective effects of milk products in experimental hypertension.
High calcium diet, different antihypertensive agents, and cytosolic free Ca2+ in spontaneously hypertensive rats.
High flow and high dose neosynephrine are effective to maintain perfusion pressure for the patient with preoperative angiotensin converting enzyme inhibitor during cardiopulmonary bypass.
High prevalence of persistent cough with angiotensin converting enzyme inhibitors in Chinese.
High sodium intake strengthens the association of ACE I/D polymorphism with blood pressure in a community.
High-performance liquid chromatography of the drug fosenopril.
High-pressure improves enzymatic proteolysis and the release of peptides with angiotensin I converting enzyme inhibitory and antioxidant activities from lentil proteins.
High-resolution crystal structures of Drosophila melanogaster angiotensin-converting enzyme in complex with novel inhibitors and antihypertensive drugs.
Highly positive intraoperative fluid balance during cardiac surgery is associated with adverse outcome.
How are hypertensive children evaluated and managed? A survey of North American pediatric nephrologists.
How cost-effective are new preventive strategies for cardiovascular disease?
How ineffective hypertension control in subjects treated with angiotensin-converting enzyme inhibitors is related to polymorphisms in the renin-angiotensin-aldosterone system.
How should we manage heart failure developing in patients already treated with angiotensin-converting enzyme inhibitors and beta-blockers for hypertension, diabetes or coronary disease?
How To Assess a Claudication and When To Intervene.
How to treat hypertension in blacks: review of the evidence.
HPLC preparation of fish waste hydrolysate fractions. Effect on guinea pig ileum and ACE activity.
Human Tissue Angiotensin Converting Enzyme (ACE) Activity Is Regulated by Genetic Polymorphisms, Posttranslational Modifications, Endogenous Inhibitors and Secretion in the Serum, Lungs and Heart.
Hyperinsulinemia, insulin resistance, and hypertension.
Hypertension after Kidney Transplantation: Clinical Significance and Therapeutical Aspects.
Hypertension and ace gene insertion/deletion polymorphism in pediatric renal transplant patients.
Hypertension and acute myocardial infarction: an overview.
Hypertension and atrial fibrillation: epidemiology, pathophysiology and therapeutic implications.
Hypertension and cardiovascular remodelling in rats exposed to continuous light: protection by ACE-inhibition and melatonin.
Hypertension and coronary artery disease: a summary of the american heart association scientific statement.
Hypertension and diabetes. Clinical problems.
Hypertension and heart failure with preserved ejection fraction: position paper by the European Society of Hypertension.
Hypertension and kidneys: unraveling complex molecular mechanisms underlying hypertensive renal damage.
Hypertension and lipids: lipid factors in the hypertension syndrome.
Hypertension and non-insulin-dependent diabetes. A comparison between an angiotensin-converting enzyme inhibitor and a calcium antagonist.
Hypertension and outcomes research. From clinical trials to clinical epidemiology.
Hypertension and related diseases in the era of COVID-19: a report from the Japanese Society of Hypertension Task Force on COVID-19.
Hypertension and single nucleotide polymorphisms.
Hypertension and the kidney: determinants of the response to antihypertensive therapy and their implications.
Hypertension and the kidneys--inter-relationship and therapeutic approach.
Hypertension as a risk factor syndrome: therapeutic implications.
Hypertension awareness, treatment, and control in adults with CKD: results from the Chronic Renal Insufficiency Cohort (CRIC) Study.
Hypertension due to antiangiogenic cancer therapy with vascular endothelial growth factor inhibitors: understanding and managing a new syndrome.
Hypertension due to blockade of adenosine receptors.
Hypertension exacerbates predisposition to neurodegeneration and memory impairment in the presence of a neuroinflammatory stimulus: Protection by angiotensin converting enzyme inhibition.
Hypertension following orthopaedic surgery in children.
Hypertension in a patient with hypercalcemia: captopril and verapamil.
Hypertension in autosomal dominant polycystic kidney disease.
Hypertension in childhood.
Hypertension in children and adolescents--1986.
Hypertension in children: approach to management.
Hypertension in CKD: Core Curriculum 2019.
Hypertension in hypophosphatemic rickets--role of secondary hyperparathyroidism.
Hypertension in neonates causes and treatments.
Hypertension in patients with chronic kidney disease.
Hypertension in patients with type 2 diabetes mellitus: Targets and management.
Hypertension in the 1990s: a new disease.
Hypertension in the elderly with a special focus on treatment with angiotensin-converting enzyme inhibitors and calcium antagonists.
Hypertension in the very elderly: Brief review of management.
Hypertension management in outpatient visits by diabetic patients.
Hypertension mega-trials with cardiovascular end points: effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.
Hypertension subtypes and angiotensin converting enzyme (ACE) gene polymorphism in Indian population.
Hypertension treatment and the prevention of coronary heart disease in the elderly.
Hypertension Update: Resistant Hypertension.
Hypertension, anti-hypertensive therapy and neoplasia.
Hypertension, medications, and risk of severe COVID-19: A Massachusetts community-based observational study.
Hypertension, the renin-angiotensin system, and the risk of lower respiratory tract infections and lung injury: implications for COVID-19.
Hypertension, thermotolerance, and the "African gene": an hypothesis.
Hypertension.
Hypertension: are beta-blockers and diuretics appropriate first-line therapies?
Hypertension: endothelial dysfunction, the prothrombotic state and antithrombotic therapy.
Hypertensive mechanisms and converting enzyme inhibitors.
Hypertensive nephrosclerosis: update.
Hyponatremia due to enalapril in an elderly patient. A case report.
Hypotension following the initiation of tizanidine in a patient treated with an angiotensin converting enzyme inhibitor for chronic hypertension.
I/D polymorphism of the angiotensin-converting enzyme gene does not predict isolated systolic or systolic-diastolic hypertension in the elderly.
Identification and characterization of novel angiotensin-converting enzyme inhibitors obtained from goat milk.
Identification and in silico characterization of a novel peptide inhibitor of angiotensin converting enzyme from pigeon pea (Cajanus cajan).
Identification and Inhibitory Mechanism of Angiotensin I-Converting Enzyme Inhibitory Peptides Derived from Bovine Hemoglobin.
Identification of angiotensin converting enzyme and dipeptidyl peptidase-IV inhibitory peptides derived from oilseed proteins using two integrated bioinformatic approaches.
Identification of Hypotensive Biofunctional Compounds of Coriandrum sativum and Evaluation of Their Angiotensin-Converting Enzyme (ACE) Inhibition Potential.
Identification of novel dipeptidyl peptidase-IV and angiotensin-I-converting enzyme inhibitory peptides from meat proteins using in silico analysis.
Identification of risk factors of severe hypersensitivity reactions in general anaesthesia.
IgA nephropathy in kidney allograft recipients-therapeutic perspective.
Ilepatril (AVE-7688), a vasopeptidase inhibitor for the treatment of hypertension.
Imagine how many lives you save: angiotensin-converting enzyme inhibition for atherosclerotic vascular disease in the present era of risk reduction.
Imaging Review of Angiotensin-Converting Enzyme Inhibitor-Induced Angioedema of the Head and Neck.
Imbalance between Angiotensin II - Angiotensin (1-7) system is associated with vascular endothelial dysfunction and inflammation in type 2 diabetes with newly diagnosed hypertension.
Impact of anemia after renal transplantation on patient and graft survival and on rate of acute rejection.
Impact of angiotensin II on the kidney: does an angiotensin II receptor blocker make sense?
Impact of angiotensin-converting enzyme gene polymorphism on proteinuria and arterial hypertension.
Impact of Empagliflozin on Blood Pressure in Patients With Type 2 Diabetes Mellitus and Hypertension by Background Antihypertensive Medication.
Impact of Green Tea Catechin Ingestion on the Pharmacokinetics of Lisinopril in Healthy Volunteers.
Impact of hypertension and renin-angiotensin system inhibitors in aortic stenosis.
Impact of interactions between risk alleles on clinical endpoints in hypertension.
Impact of Nephron Number Dosing on Cardiorenal Damage and Effects of ACE Inhibition.
Impact of renin-angiotensin system inhibitors continuation versus discontinuation on outcome after major surgery: protocol of a multicenter randomized, controlled trial (STOP-or-NOT trial).
Impact of the interval between coronary angiography and off-pump coronary bypass surgery on postoperative renal function.
Impacts of center and clinical factors in antihypertensive medication use after kidney transplantation.
Impacts of serum P-selectin on blood pressure control after PCI in patients with coronary heart disease complicated with hypertension.
Impaired baroreflex sensitivity and responses to angiotensin converting enzyme inhibitor in salt-induced hypertension and its prevention by dietary calcium supplement in Sprague-Dawley rats.
Implication of endogenous prostaglandin system in the antihypertensive effect of captopril, SQ 14225, in low renin hypertension.
Importance of infarct size versus other variables for clinical outcomes after PPCI in STEMI patients.
Improved insulin action and glycemic control after long-term angiotensin-converting enzyme inhibition in subjects with arterial hypertension and type II diabetes.
Improvement in metabolic risk factors for coronary heart disease associated with cilazapril treatment.
Improvement of coronary flow reserve after long-term therapy with enalapril.
Improving compliance and increasing control of hypertension: needs of special hypertensive populations.
Improving the Management of Chronic Kidney Disease in Uruguay: A National Renal Healthcare Program.
In search of genes causing spontaneous hypertension.
In Silico Analysis of ACE Inhibitory Peptides from Chloroplast Proteins of Red Alga Grateloupia asiatica.
In silico and in vitro analyses of the angiotensin-I converting enzyme inhibitory activity of hydrolysates generated from crude barley (Hordeum vulgare) protein concentrates.
In silico identification of angiotensin-1 converting enzyme inhibitors using text mining and virtual screening.
In Silico identification of angiotensin-converting enzyme inhibitory peptides from MRJP1.
In Silico Investigations of Chemical Constituents of Clerodendrum colebrookianum in the Anti-Hypertensive Drug Targets: ROCK, ACE, and PDE5.
In vitro antidiabetic and inhibitory potential of turmeric (Curcuma longa L) rhizome against cellular and LDL oxidation and angiotensin converting enzyme.
In vitro renin-angiotensin system inhibition and in vivo antihypertensive activity of peptide fractions from lima bean (Phaseolus lunatus L.).
In vivo angiotensin I-converting enzyme inhibition by long-term intake of antihypertensive lactoferrin hydrolysate in spontaneously hypertensive rats
In vivo effect of ACE inhibiting in mealworms on ovarian composition and ecdysteroid amounts.
In vivo pharmacology of an angiotensin AT1 receptor antagonist with balanced affinity for AT2 receptors.
Inadequate aldosterone response to hyperkalemia during angiotensin converting enzyme inhibition in chronic renal failure.
Incidence and Associated Risk Factors of Chemotherapy-Induced Cardiomyopathy in the African American and Afro-Caribbean Populations.
Incidence and Risk Factors of Dry Eye in a Spanish Adult Population: 11-Year Follow-Up From the Salnés Eye Study.
Incidence of and risk factors for severe acute kidney injury in children with heart failure treated with renin-angiotensin system inhibitors.
Incidence of appropriate cardioverter-defibrillator shocks and mortality in patients with heart failure treated with combined cardiac resynchronization plus implantable cardioverter-defibrillator therapy versus implantable cardioverter-defibrillator therapy.
Incidence of new coronary events in older persons with prior myocardial infarction and systemic hypertension treated with beta blockers, angiotensin-converting enzyme inhibitors, diuretics, calcium antagonists, and alpha blockers.
Incidence of New Stroke or New Myocardial Infarction or Death at 39-Month Follow Up in Patients With Diabetes Mellitus, Hypertension, or Both Treated With and Without Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers.
Incipient Albuminuria in Persons with Newly Diagnosed Type 2 Diabetes Mellitus: A 5-Year Retrospective Cohort Study.
Increase of angiotensin converting enzyme gene expression in the hypertensive aorta.
Increase of angiotensin-converting enzyme activity and peripheral sympathetic dysfunction could contribute to hypertension development in streptozotocin-induced diabetic rats.
Increased angiotensin II-induced hypertension and inflammatory cytokines in mice lacking angiotensin-converting enzyme N domain activity.
Increased apoptosis in the heart of genetic hypertension, associated with increased fibroblasts.
Increased colonic K+ excretion through inhibition of the H,K-ATPase type 2 helps reduce plasma K+ level in a murine model of nephronic reduction.
Increased efficacy and tolerability with losartan plus hydrochlorothiazide in patients with uncontrolled hypertension and therapy-related symptoms receiving two monotherapies.
Increased frequency and severity of angio-oedema related to long-term therapy with angiotensin-converting enzyme inhibitor in two patients.
Increased frequency of the DI genotype of the Angiotensin-I Converting Enzyme (ACE) and association of the II genotype with Insulin Resistance in Polycystic Ovary Syndrome.
Increased rate of birth defects after first trimester use of angiotensin converting enzyme inhibitors - Treatment or hypertension related? An observational cohort study.
Increased renovascular response to angiotensin II in persons genetically predisposed to arterial hypertension disappears after chronic angiotensin-converting enzyme inhibition.
Increased systolic blood pressure in adult rats induced by fetal exposure to maternal low protein diets.
Increased Time Exposure to Tenofovir Is Associated with a Greater Decrease in Estimated Glomerular Filtration Rate in HIV Patients with Kidney Function of Less than 60 ml/min/1.73 m.
Increased vascular formation of angiotensin II in one-kidney, one clip hypertension.
Increasing the diagnostic yield of renal angiography for the diagnosis of atheromatous renovascular disease.
Indicators for preventable drug related morbidity: application in primary care.
Indomethacin inhibits the antihypertensive effect of captopril, SQ 14225, in low renin hypertension.
Induction of insulin resistance by beta-blockade but not ACE-inhibition: long-term treatment with atenolol or trandolapril.
Influence of a history of arterial hypertension and pretreatment blood pressure on the effect of angiotensin converting enzyme inhibition after acute myocardial infarction. Trandolapril Cardiac Evaluation Study.
Influence of ABO genotype and phenotype on angiotensin-converting enzyme plasma activity.
Influence of angiotensin-converting enzyme inhibition on reversibility of alterations in arterial wall and cognitive performance associated with early hypertension: A follow-up study.
Influence of cardiovascular risk factors on relation between angiotensin converting enzyme-gene polymorphism and blood pressure in arterial hypertension.
Influence of comorbidities and medication use on tilt table test outcome in elderly patients.
Influence of enalapril on established pressure-overload cardiac hypertrophy in low and normal renin states in female rats.
Influence of food on the clinical effect of angiotensin I converting enzyme inhibitor (SQ 14,225).
Influence of Patient Race on Physician Prescribing Decisions: A Randomized On-Line Experiment.
INFLUENCE OF POLYMORPHISM OF GENES INVOLVED IN ARTERIAL HYPERTENSION: ANGIOTENSIN I CONVERTING ENZYME (ACE); ANGIOTENSINOGEN (AGT); AT1 RECEPTOR OF ANGIOTENSIN II (AT1-R); AND ENDOTHELIAL CONSTITUTIVE NO SYNTHASE (ecNOS); ON LONG TERM RESULTS AFTER RENAL TRANSPLANTATION.
Influence of pressure overload and ACE inhibitor therapy on constitutive protein mRNA expression in the spontaneously hypertensive rat.
Influence of selected angiotensin-converting enzyme inhibitors on alloxan-induced diabetic cataract in rabbits.
Influence of the angiotensin converting enzyme inhibitor cilazapril, the beta-blocker propranolol and their combination on haemodynamics in hypertension.
Influenza Vaccination Reduces Dementia Risk in Chronic Kidney Disease Patients: A Population-Based Cohort Study.
Inhibition effect of nicotinamide (vitamin B3) and reduced glutathione (GSH) peptide on angiotensin-converting enzyme activity purified from sheep kidney.
Inhibition of angiotensin-converting enzyme in renal-transplant recipients with hypertension.
Inhibition of Human Liver Carboxylesterase (hCE1) by Organophosphate Ester Flame Retardants and Plasticizers: Implications for Pharmacotherapy.
Inhibition of renin-angiotensin system and advanced glycation end products formation: a promising therapeutic approach targeting on cardiovascular diseases.
Inhibition of Renin-Angiotensin system: implications for diabetes control and prevention.
Inhibition of the renin angiotensin system: implications for the endothelium.
Inhibition of the renin-angiotensin system ameliorates genetically determined hyperinsulinemia.
Inhibition of the renin-angiotensin system and chronic kidney disease.
Inhibition of the renin-angiotensin system prevents re-hospitalization of heart failure patients with preserved ejection fraction.
Inhibition of tissue angiotensin converting enzyme activity prevents malignant hypertension in TGR(mREN2)27.
Inhibitors of angiotensin I converting enzyme for treating hypertension.
Inhibitors of angiotensin-converting enzyme for treatment of hypertension.
Inhibitors of the angiotensin I converting enzyme as antihypertensive drugs.
Inhibitors of the renin angiotensin system: implications for the anaesthesiologist.
Inhibitors of the renin-angiotensin system.
Inhibitory actions of captopril on norepinephrine release from adrenergic nerve endings in spontaneously hypertensive rats.
Inhibitory Activities of Polyphenolic Extracts of Bangladeshi Vegetables against ?-Amylase, ?-Glucosidase, Pancreatic Lipase, Renin, and Angiotensin-Converting Enzyme.
Inhibitory influences of xanthine oxidase inhibitor and angiotensin I-converting enzyme inhibitor on multinucleated giant cell formation from monocytes by downregulation of adhesion molecules and purinergic receptors.
Initial angiotensin-converting enzyme inhibitor/calcium channel blocker combination therapy achieves superior blood pressure control compared with calcium channel blocker monotherapy in patients with stage 2 hypertension.
Initial therapy for uncomplicated hypertension: insights from the alphabetic maze of recent studies.
Innappropriate renin secretion unmasked by captopril (SQ 14 225) in hypertension of chronic renal failure.
Insertion/deletion polymorphism in the angiotensin-converting enzyme gene associated with macroangiopathy and blood pressure in patients with non-insulin-dependent diabetes mellitus.
Insertion/deletion polymorphism of the angiotensin I-converting enzyme gene in patients with hypertension, non-insulin-dependent diabetes mellitus, and coronary heart disease in Taiwan.
Insertion/deletion polymorphism of the angiotensin-converting enzyme gene and hypertension.
Insertion/deletion polymorphism of the angiotensin-converting enzyme gene and preeclampsia in Japanese patients.
Insertion/deletion polymorphism of the angiotensin-converting enzyme gene and the risk of hypertension among residents of two cities, South-South Nigeria.
Insulin resistance and sympathetic overactivity in women.
Insulin resistance in adipocytes from spontaneously hypertensive rats: effect of long-term treatment with enalapril and losartan.
Insulin resistance in hypertension: a focused review.
Insulin resistance, diabetes, hypertension, and renin-angiotensin system inhibition: reducing risk for cardiovascular disease.
Insulin-dependent diabetes mellitus as long term complication of haemolytic-uraemic syndrome.
Intensive management of type II diabetes.
Interacting cogs in the machinery of the renin angiotensin system.
Interaction between ACE and ADD1 gene polymorphisms in the progression of IgA nephropathy in Japanese patients.
Interaction between neutral endopeptidase and angiotensin converting enzyme inhibition in rats with myocardial infarction: effects on cardiac hypertrophy and angiotensin and bradykinin peptide levels.
Interaction between the angiotensin-converting enzyme gene insertion/deletion polymorphism and obstructive sleep apnoea as a mechanism for hypertension.
Interaction of angiotensin I-converting enzyme insertion-deletion polymorphism and daily salt intake influences hypertension in Japanese men.
Interaction of papaverine with the enalapril-induced cough in guinea pig.
Interactions between angiotensin-converting enzyme-2 polymorphisms and high salt intake increase the risk of hypertension in the Chinese Wa population.
Interactions between oestrogen and the renin angiotensin system - potential mechanisms for gender differences in Alzheimer's disease.
Interactions of the DASH Diet with the Renin-Angiotensin-Aldosterone System.
Interactive Effect of Ethnicity and ACE Insertion/Deletion Polymorphism on Vascular Reactivity.
Interleukin-10 serum levels and systemic endothelial vasoreactivity in patients with coronary artery disease.
Intermittent Superior Vena Cava Syndrome Secondary to Malignant Pericardial Mesothelioma.
Interplay of various factors in glucose-induced hyperkalemia during captopril treatment.
Interrupting the renin-angiotensin system: the role of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists in the treatment of hypertension.
Intra-arterial infusion of Tc-99m MAA: a case of highly selective targeting of liver metastases and shunting.
Intrarenal angiotensin and bradykinin peptide levels in the remnant kidney model of renal insufficiency.
Intrarenal Angiotensin-converting enzyme induces hypertension in response to Angiotensin I infusion.
Intratubular Renin-Angiotensin System in Hypertension.
Introduction to a structural basis for renal and vascular complications in diabetes and hypertension.
Investigation and management of hypertension in children. A personal perspective.
Investigation of circulatory and tissue ACE activity during development of lead-induced hypertension.
Investigation of local ACE activity and structural alterations during development of L-NAME-induced hypertension.
Involvement of the TRPV1 receptor in plasma extravasation in airways of rats treated with an angiotensin-converting enzyme inhibitor.
Iontophoretically enhanced transdermal delivery of an ACE inhibitor in induced hypertensive rabbits: preliminary report.
Irbesartan reduces creatinine clearance in type 1 diabetic children with renal hyperfunction: a randomized, double-blind, placebo-controlled trial.
Is amiloride a promising cardiovascular medication to persist in the COVID-19 crisis?
Is hypertension an inflammatory process?
Is inhibition of the renin-angiotensin system a new treatment option for Alzheimer's disease?
Is magnetic resonance angiography useful in renovascular disease?
Is the association between ACE genes and blood pressure mediated by postnatal growth during the first 3years?
Is there a place for combining angiotensin-converting enzyme inhibitors and angiotensin-receptor antagonists in the treatment of hypertension, renal disease or congestive heart failure?
Is there a role for adjuvant therapy in patients being treated with epoetin?
Is there an association between angiotensin-converting enzyme gene polymorphism and functional activation of monocytes and macrophage in young patients with essential hypertension?
Is there an embryopathy associated with first-trimester exposure to angiotensin-converting enzyme inhibitors and angiotensin receptor antagonists? A critical review of the evidence.
Is there any role of renin-angiotensin system inhibitors in modulating inflammatory bowel disease outcome?
Ischemic renal disease: an emerging cause of chronic renal failure and end-stage renal disease.
Isolated perioperative hypertension: clinical implications & contemporary treatment strategies.
Isolated unilateral tongue oedema: the adverse effect of Angiotensin converting enzyme inhibitors.
Isolation of a cDNA encoding the vascular type-1 angiotensin II receptor.
Isolation, purification and the anti-hypertensive effect of a novel angiotensin I-converting enzyme (ACE) inhibitory peptide from Ruditapes philippinarum fermented with Bacillus natto.
Isotopic scan for diagnosis of renal disease.
Issues in the perioperative management of the elderly patient with cardiovascular disease.
Issues with antihypertensive therapy: safety perspectives.
Joint effects of hypertension, smoking, dyslipidemia and obesity and angiotensin-converting enzyme DD genotype on albuminuria in Taiwanese patients with type 2 diabetes mellitus.
Joseph Rudinger memorial lecture: Unexpected functions of angiotensin converting enzyme, beyond its enzymatic activity.
Just the beginning: novel functions for angiotensin-converting enzymes.
KATP channel opening does not contribute significantly to the vasodilatory effect of SH-group-containing ACE inhibitors.
Kinetics of cardiac and vascular remodeling by spontaneously hypertensive rats after discontinuation of long-term captopril treatment.
Kinin-mediated antihypertensive effect of captopril in deoxycorticosterone acetate-salt hypertension.
Lack of an association between the angiotensin-converting enzyme insertion/deletion polymorphism and intracranial aneurysms in a Caucasian population in the United States.
Lack of association between ACE and bradykinin B2 receptor gene polymorphisms and ACE inhibitor-induced coughing in hypertensive Koreans.
Lack of association between renin-angiotensin system (RAS) polymorphisms and hypertension in Tunisian type 2 diabetics.
Lack of correlation between Mbo I restriction fragment length polymorphism of renin gene and essential hypertension in Japanese.
Lack of cross sensitivity between captopril and enalapril.
Lack of sex-specific effects on the association between angiotensin-converting enzyme gene polymorphism and hypertension in Japanese.
Lactobacilli as multifaceted probiotics with poorly disclosed molecular mechanisms.
Lactotripeptides intake and blood pressure management: a meta-analysis of randomised controlled clinical trials.
Laparoscopic bilateral nephrectomy for renin-mediated hypertension.
Large therapeutic studies in elderly patients with hypertension.
Late onset angiotensin-converting enzyme induced angioedema: case report and review of the literature.
Latin American Consensus on the management of hypertension in the patient with diabetes and the metabolic syndrome.
LC-MS/MS assay for quantitation of enalapril and enalaprilat in plasma for bioequivalence study in Indian subjects.
LCZ696: the next step in improving RAS inhibition?
Lead-induced hypertension: role of oxidative stress.
Left ventricular hypertrophy and angiotensin II receptor blocking agents.
Left ventricular hypertrophy predicts the decline of glomerular filtration rate in patients with type 2 diabetes mellitus.
Left ventricular hypertrophy was infrequent in patients starting dialysis after undergoing a strict blood pressure control in the pre-dialytic period.
Left ventricular mass in relation to genetic variation in angiotensin II receptors, renin system genes, and sodium excretion.
Lercanidipine/enalapril combination in the management of obesity-related hypertension.
Lessons from the African-American Study of Kidney Disease andHypertension: An Update.
Levels of plasma angiotensin-(1-7) in patients with hypertension who have the angiotensin-I-converting enzyme deletion/deletion genotype.
Life-threatening hyperkalemia associated with captopril administration.
Life-threatening hyperkalemia in a patient with normal renal function.
Lifelong inorganic arsenic compounds consumption affected blood pressure in rats.
Linkage analysis between loci in the renin-angiotensin axis and end-stage renal disease in African Americans.
Lipoprotein glomerulopathy treated with LDL-apheresis (Heparin-induced Extracorporeal Lipoprotein Precipitation system): a case report.
Lisinopril in elderly patients with hypertension.
Lisinopril in hypertension associated with renal impairment.
Lisinopril in hypertensive patients with renal function impairment.
Lisinopril versus hydrochlorothiazide in obese hypertensive patients: a multicenter placebo-controlled trial. Treatment in Obese Patients With Hypertension (TROPHY) Study Group.
Lisinopril-Induced Angioedema in a Patient with Plasma Prekallikrein Deficiency.
Lisinopril-induced angioedema of the lip.
Lisinopril: a new angiotensin-converting enzyme inhibitor.
Liver involvement in early autosomal-dominant polycystic kidney disease.
Lizinopril in the Treatment of Arterial Hypertension.
Long term reduction of microalbuminuria after 1 year of angiotensin converting enzyme inhibition by perindopril in hypertensive insulin-treated diabetic patients.
Long-range safety and protective benefits of angiotensin-converting enzyme inhibitors for hypertension. Do we need more clinical trials?
Long-term and strict blood pressure lowering by imidapril reverses left ventricular hypertrophy in patients with essential hypertension: an evaluation using a novel indicator of burden on the left ventricle.
Long-term angiotensin-converting enzyme inhibition with ramipril reduces thrombin generation in human hypertension.
Long-term benefits of angiotensin-converting enzyme inhibitor therapy in patients with severe immunoglobulin a nephropathy: a comparison to patients receiving treatment with other antihypertensive agents and to patients receiving no therapy.
Long-term captopril treatment in moderate to severe hypertension.
Long-term comparison between captopril and nifedipine in the progression of renal insufficiency.
Long-term effect of efonidipine therapy on plasma aldosterone and left ventricular mass index in patients with essential hypertension.
Long-term effects of angiotensin-converting enzyme inhibition on the arterial wall of adult spontaneously hypertensive rats.
Long-term effects of enalapril and nicardipine on urinary albumin excretion in patients with chronic renal insufficiency: a 1-year follow-up.
Long-term efficacy and safety of moexipril in the treatment of hypertension.
Long-term evaluation of combined antihypertensive therapy with lisinopril and a thiazide diuretic in patients with essential hypertension.
Long-term follow-up of acute renal failure caused by angiotensin converting enzyme inhibitors.
Long-term inhibition of nitric oxide synthesis increases arterial thrombogenecity in rat carotid artery.
Long-term intake of egg white hydrolysate attenuates the development of hypertension in spontaneously hypertensive rats.
Long-term organ protection by doxazosin and/or quinapril as antihypertensive therapy.
Long-term persistence with statin treatment in a not-for-profit health maintenance organization: a population-based retrospective cohort study in Israel.
Long-term preservation of renal function in hypertensive heart transplant recipients treated with enalapril and a diuretic.
Long-term renal effects of enalapril therapy in patients with renal insufficiency.
Long-term safety and efficacy of moexipril alone and in combination with hydrochlorothiazide in elderly patients with hypertension.
Long-term treatment of hypertension in man by an orally active angiotensin-converting enzyme inhibitor.
Long-term treatment with sulfhydryl angiotensin-converting enzyme inhibition reduces carotid intima-media thickening and improves the nitric oxide/oxidative stress pathways in newly diagnosed patients with mild to moderate primary hypertension.
Long-term use of angiotensin-converting enzyme inhibitors protects against bone loss in African-American elderly men.
Longitudinal change in left ventricular hypertrophy in the elderly on antihypertensive therapy.
Longitudinal changes of insulin sensitivity in essential hypertension: influence of blood pressure control and familial predisposition to hypertension.
Losartan attenuates chronic cigarette smoke exposure-induced pulmonary arterial hypertension in rats: possible involvement of angiotensin-converting enzyme-2.
Losartan in patients with renal insufficiency.
Losartan prevents salt-induced hypertension in reduced renal mass rats.
Lovastatin but not enalapril reduces glomerular injury in Dahl salt-sensitive rats.
Low body mass index is a risk factor for hyperkalaemia associated with angiotensin converting enzyme inhibitors and angiotensin II receptor blockers treatments.
Low-dose combination therapy: the rationalization for an ACE inhibitor and a calcium channel blocker in higher risk patients.
Low-dose, short-acting, angiotensin-converting enzyme inhibitors as rescue therapy in pregnancy.
Low-grade urinary albumin excretion in normotensive/non-diabetic obstructive sleep apnea patients.
Lowering of blood pressure improves endothelial dysfunction by increase of nitric oxide production in hypertensive rats.
Lupus nephritis: treatment issues.
Lys(173)Arg and -344T/C variants of CYP11B2 in Japanese patients with low-renin hypertension.
Macro- and Microelement Status in Animal and Human Hypertension: the Role of the ACE Gene I/D Polymorphism.
Magnetic resonance imaging left ventricular mass reduction with fixed-dose Angiotensin-converting enzyme inhibitor-based regimens in patients with high-risk hypertension.
Main objectives and new aspects of combination treatment of hypertension.
Management issues in the metabolic syndrome.
Management of abdominal aortic aneurysms.
Management of blood glucose in type 2 diabetes mellitus.
Management of blood pressure and heart rate in patients with diabetes mellitus.
Management of diabetes complications in youth.
Management of diabetic hypertensives.
Management of diastolic heart failure.
Management of hypertension in 2017: targets and therapies.
Management of Hypertension in CAKUT: Protective Factor for CKD.
Management of hypertension in elderly diabetic patients.
Management of hypertension in older patients.
Management of hypertension in the diabetic patient.
Management of hypertension in the patient with diabetes mellitus. Focus on the use of angiotensin-converting enzyme inhibitors.
Management of hypertension. What is the role of beta blockers?
Management of hypertension: the advent of a new angiotensin II receptor antagonist.
Management of hypertension: the role of combination therapy.
Management of IgA nephropathy: evidence-based recommendations.
Management of patients with resistant hypertension: current treatment options.
Management of persistent lingual angioedema: a team approach.
Management of severe hypertension in childhood Takayasu's arteritis.
Management of the elderly person after myocardial infarction.
Management of type 2 diabetes mellitus: is it in accordance with the guidelines?
Managing chronic kidney disease in type 2 diabetes in family practice.
Managing Henoch-Schonlein purpura in children with fish oil and ACE inhibitor therapy.
Managing hypertension in family practice: a nationwide collaborative study of the use of four antihypertensives in the treatment of mild-to-moderate hypertension. A report from CEN. Clinical Experience Network.
Managing hypertension using combination therapy.
Managing Hypertension Using Combination Therapy.
Managing the hypertensive patient with ischemic heart disease.
Marine Organisms as Potential Sources of Bioactive Peptides that Inhibit the Activity of Angiotensin I-Converting Enzyme: A Review.
Marked difference between angiotensin-converting enzyme and neutral endopeptidase inhibition in vivo by a dual inhibitor of both enzymes.
Maternal Gestational Hypertension-Induced Sensitization of Angiotensin II Hypertension Is Reversed by Renal Denervation or Angiotensin-Converting Enzyme Inhibition in Rat Offspring.
Matrix metalloproteinase-2 and -9 in glioblastoma: a trio of old drugs-captopril, disulfiram and nelfinavir-are inhibitors with potential as adjunctive treatments in glioblastoma.
Maurício Rocha e Silva MD: snake venom, bradykinin and the rise of autopharmacology.
Mechanical function and histological structure of the arterial wall. The response to antihypertensive treatment.
Mechanism of action of angiotensin converting enzyme inhibitors on endothelial function in hypertension.
Mechanism of action of angiotensin-converting enzyme (ACE) inhibitors in hypertension and heart failure. Role of plasma versus tissue ACE.
Mechanism of captopril toxicity to a human mammary ductal carcinoma cell line in the presence of copper.
Mechanisms and consequences of arterial hypertension after renal transplantation.
Mechanisms by which angiotensin-converting enzyme inhibitors prevent diabetes and cardiovascular disease.
Mechanisms of target organ damage caused by hypertension: therapeutic potential.
Mechanistic and Clinical Aspects of Renin-Angiotensin-Aldosterone System (RAAS) Blockade in the Prevention of Diabetes and Cardiovascular Disease.
Medical management of the diabetic patient with coronary artery disease.
Medical management of vesicoureteral reflux--quiz within the article. Don't overlook placebos.
Meeting the challenge to improve the treatment of hypertension in blacks.
Mercaptoacyl dipeptides as orally active dual inhibitors of angiotensin-converting enzyme and neutral endopeptidase.
Mesangioproliferative glomerulonephritis with extracapillary crescents - unexpected fatal complication in a 17-year-old patient with implanted left ventricular assist device.
Meta-Analysis of effectiveness or lack thereof of angiotensin-converting enzyme inhibitors for prevention of heart failure in patients with systemic hypertension.
Metabolic disturbances and antihypertensive therapy.
Metabolic effects of low dose angiotensin converting enzyme inhibitor in dietary obesity in the rat.
Metabolic effects of the combination of furosemide and captopril in rat.
Metabolic engineering of Saccharomyces cerevisiae producing nicotianamine: potential for industrial biosynthesis of a novel antihypertensive substrate.
Metformin and Risk of Hypertension in Taiwanese Patients With Type 2 Diabetes Mellitus.
Methodological Comparisons of Heart Rate Variability Analysis in Patients With Type 2 Diabetes and Angiotensin Converting Enzyme Polymorphism.
Metoprolol Increases Uric Acid and Risk of Gout in African Americans With Chronic Kidney Disease Attributed to Hypertension.
Microalbuminuria and essential hypertension: renal and cardiovascular implications.
Microalbuminuria in essential hypertension. Reduction by different antihypertensive drugs.
Microalbuminuria in Thai essential hypertensive patients.
Microfluidic chip-based method for genotyping microsatellites, VNTRs and insertion/deletion polymorphisms.
Microvascular effects of cocaine; interaction with nitrendipine and enalaprilat.
Mild hypertension protects the elderly from cognitive impairment: a 7-year retrospective cohort study.
Mineralocorticoid receptor antagonists and hypertension: is there a rationale?
Mineralocorticoid Receptor-Associated Hypertension and Its Organ Damage: Clinical Relevance for Resistant Hypertension.
Mitochondrial Disease (MELAS Syndrome) Discovered at the Start of Pregnancy in a Patient with Advanced CKD: A Clinical and Ethical Challenge.
Moderate sodium restriction, angiotensin converting enzyme inhibition, and thiazide diuretic in the management of essential hypertension.
Modulation of acute transient exercise-induced hypertension after oral administration of four angiotensin-converting enzyme inhibitors in normotensive horses.
Modulation of genetic hypertension by short-term AVP V1A or V2 receptor antagonism in young SHR.
Modulation of pain perception by ramipril and losartan in human volunteers.
Modulation of protein kinase C in aorta of spontaneously hypertensive rats with enalapril treatment.
Molecular aspects of blood pressure regulation.
Molecular biology of angiotensin II biosynthesis and receptors.
Molecular dynamics investigation on the interaction of human angiotensin-converting enzyme with tetrapeptide inhibitors.
Molecular genetics of human hypertension.
Molecular interactions, bioavailability, and cellular mechanisms of angiotensin-converting enzyme inhibitory peptides.
Molecular mechanism of the interactions between inhibitory tripeptides and angiotensin-converting enzyme.
Monotherapy of hypertension with angiotensin-converting enzyme inhibitors.
Mortality and morbidity during and after the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.
Mortality in patients with hypertension on angiotensin-I converting enzyme (ACE)-inhibitor treatment is influenced by the ACE insertion/deletion polymorphism.
Multiple Polymorphisms in the renin- angiotensin-aldosterone system (ACE, CYP11B2, AGTR1) and their contribution to hypertension in African Americans and Latinos in the multiethnic cohort.
Myocardial and vascular effects of perindopril, a new converting enzyme inhibitor, during hypertension development in spontaneously hypertensive rats.
Myocyte Specific Upregulation of ACE2 in Cardiovascular Disease: Implications for SARS-CoV-2 mediated myocarditis.
N-domain angiotensin I-converting enzyme with 80 kDa as a possible genetic marker of hypertension.
N-domain isoform of Angiotensin I converting enzyme as a marker of hypertension: populational study.
Neglected nephropathy.
Neonatal renal failure: a complication of maternal antihypertensive therapy.
Nephron heterogeneity: clue to the pathogenesis of essential hypertension and effectiveness of angiotensin-converting enzyme inhibitor treatment.
Neurological diseases as mortality predictive factors for patients with COVID-19: a retrospective cohort study.
New alpha-thiol dipeptide dual inhibitors of angiotensin-I converting enzyme and neutral endopeptidase EC 3.4.24.11.
New angiotensin converting enzyme inhibitors. Their role in the management of hypertension.
New dual inhibitors of neutral endopeptidase and angiotensin-converting enzyme: rational design, bioavailability, and pharmacological responses in experimental hypertension.
New Evidence Supporting the Use of Mineralocorticoid Receptor Blockers in Drug-Resistant Hypertension.
New formulation of an old drug in hypertension treatment: the sustained release of captopril from cyclodextrin nanoparticles.
New Perspectives in the Renin-Angiotensin-Aldosterone System (RAAS) II: Albumin Suppresses Angiotensin Converting Enzyme (ACE) Activity in Human.
New potentially antihypertensive peptides liberated in milk during fermentation with selected lactic acid bacteria and kombucha cultures.
New Quantitative Structure-Activity Relationship Model for Angiotensin-Converting Enzyme Inhibitory Dipeptides Based on Integrated Descriptors.
New therapeutic strategies for systemic sclerosis--a critical analysis of the literature.
New thiol inhibitors of neutral endopeptidase EC 3.4.24.11: synthesis and enzyme active-site recognition.
New-user persistence with antihypertensives and prescription drug cost-sharing.
Newer antihypertensive agents.
Newly manufactured Marukome MK-34-1 miso with angiotensin-converting enzyme inhibitory activity and its antihypertensive effects in genetic hypertensive rat models.
Next generation multifunctional angiotensin receptor blockers.
Nisoldipine CC: efficacy and tolerability in hypertension and ischemic heart disease.
Nitric oxide release from kidneys of hypertensive rats treated with imidapril.
No influence of antihypertensive agents on plasma free metanephrines.
No sex-related pharmacokinetic and pharmacodynamic differences of captopril.
NO-dependent endothelial dysfunction in type II diabetes is aggravated by dyslipidemia and hypertension, but can be restored by angiotensin-converting enzyme inhibition and weight loss.
Nonatherosclerotic Vascular Abnormalities Associated with Chronic Kidney Disease.
Noncompetitive inhibition of glycylsarcosine transport by quinapril in rabbit renal brush border membrane vesicles: effect on high-affinity peptide transporter.
Nonlipid primary and secondary prevention strategies for coronary heart disease.
Nonsteroidal antiinflammatory drugs and risk of gastrointestinal bleeding among patients on hemodialysis.
Not all proteinuria is created equal.
Novel angiotensin I-converting enzyme inhibitory peptides derived from an edible mushroom, Pleurotus cystidiosus O.K. Miller identified by LC-MS/MS.
Novel angiotensin I-converting enzyme inhibitory peptides derived from soya milk.
Novel Angiotensin-Converting Enzyme Inhibitory Peptides Derived from Oncorhynchus mykiss Nebulin: Virtual Screening and In Silico Molecular Docking Study.
Novel antihypertensive action of rutin is mediated via inhibition of angiotensin converting enzyme/mineralocorticoid receptor/angiotensin 2 type 1 receptor (ATR1) signaling pathways in uninephrectomized hypertensive rats.
Novel approaches to improving endothelium-dependent nitric oxide-mediated vasodilatation.
Novel ketomethylene inhibitors of angiotensin I-converting enzyme (ACE): inhibition and molecular modelling.
Novel mechanism of inhibition of human Angiotensin-I converting enzyme (ACE) by a highly specific phosphinic tripeptide.
Novel peptidomimics as angiotensin-converting enzyme inhibitors: a combinatorial approach.
Novel renin inhibitors containing the amino acid statine.
Novel Therapeutic Approaches Targeting the Renin-Angiotensin System and Associated Peptides in Hypertension and Heart Failure.
Now or never: optimal antihypertensive therapy in the elderly.
Nrf2 Deficiency Upregulates Intrarenal Angiotensin-Converting Enzyme-2 and Angiotensin 1-7 Receptor Expression and Attenuates Hypertension and Nephropathy in Diabetic Mice.
Obesity-associated hypertension: hypothesized link between etiology and selection of therapy.
Observations with captopril (Tensiomin) treatment in hypertensive patients (one-year period).
Ocular and orbital blood flow in patients with essential hypertension treated with trandolapril.
Of fads, fashion, surrogate endpoints and dual RAS blockade.
Office management after myocardial infarction.
Olmesartan medoxomil: a clinical review.
Olmesartan vs ramipril in the treatment of hypertension and associated clinical conditions in the elderly: a reanalysis of two large double-blind, randomized studies at the light of the most recent blood pressure targets recommended by guidelines.
Omapatrilat. Bristol-Myers Squibb.
Omapatrilat: penetration across the blood-brain barrier and effects on ischaemic stroke in rats.
On arterial physiology, pathophysiology of vascular compliance, and cardiovascular disease.
Once daily perindopril versus slow release diltiazem in the treatment of mild to moderate essential hypertension. Canadian Study Group on Perindopril.
One-year effectiveness and safety of open-label losartan/hydrochlorothiazide combination therapy in Japanese patients with hypertension uncontrolled with ARBs or ACE inhibitors.
Ongoing clinical outcome studies of calcium antagonists.
Opportunities for targeting the Angiotensin-converting enzyme 2/angiotensin-(1-7)/mas receptor pathway in hypertension.
Optimal medical management of peripheral arterial disease.
Optimal recognition of neutral endopeptidase and angiotensin-converting enzyme active sites by mercaptoacyldipeptides as a means to design potent dual inhibitors.
Optimising diuretic therapy in elderly patients with hypertension.
Optimization of Culture Condition for ACEI and GABA Production by Lactic Acid Bacteria.
Optimization of Nutrient Composition for Producing ACE Inhibitory Peptides from Goat Milk Fermented by Lactobacillus bulgaricus LB6.
Optimized determination of angiotensin I-converting enzyme activity with hippuryl-L-histidyl-L-leucine as substrate.
Optimizing blood pressure control in the obese patient.
Optimizing dose selection with modeling and simulation: application to the vasopeptidase inhibitor M100240.
Options in antihypertensive drug therapy. Help in choosing from among the many agents.
Oral angiotensin-converting enzyme inhibitor in long-term treatment of hypertensive patients.
Oral bullous eruption after taking lisinopril--case report and literature review.
Ostial renal artery stent placement for atherosclerotic renal artery stenosis in patients with coronary artery disease.
Our ACE in the HOLE: Justifying the Use of Angiotensin-converting Enzyme Inhibitors as Adjuvants to Standard Chemotherapy.
Outbreak of acute renal failure in Panama in 2006: a case-control study.
Outcome of patients with multiple myeloma and hypertension treated with angiotensin-I-converting enzyme inhibitors during high-dose chemotherapy.
Outcome survey in unselected hypertensive patients with type 2 diabetes mellitus: effects of ACE inhibition.
Outcomes for patients with COVID-19 admitted to Australian intensive care units during the first four months of the pandemic.
Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril.
Outcomes with Angiotensin-converting Enzyme Inhibitors vs Other Antihypertensive Agents in Hypertensive Blacks.
Overexpression of Bax protein and enhanced apoptosis in the left ventricle of spontaneously hypertensive rats: effects of AT1 blockade with losartan.
Overexpression of catalase prevents hypertension and tubulointerstitial fibrosis and normalization of renal angiotensin-converting enzyme-2 expression in Akita mice.
Overview: the role of angiotensin-converting enzyme inhibitors in cardiovascular therapy.
Oxalate nephropathy with a granulomatous lesion due to excessive intake of peanuts.
Oxidative stress, AGE, and atherosclerosis.
Oxidative stress-associated hypertension in surgically induced brain injury patients: effects of ?-blocker and angiotensin-converting enzyme inhibitor.
Oxygen free radical scavenger system intermediates in essential hypertensive patients before and immediately after sublingual captopril administration.
Page kidney: A rare but surgically treatable cause of hypertension.
Parkia speciosa empty pod prevents hypertension and cardiac damage in rats given N(G)-nitro-l-arginine methyl ester.
Participation of the renin system in treatment-resistant hypertension as measured by acute blockade of the angiotensin converting enzyme.
Pathogenesis of diabetic glomerulopathy: hemodynamic considerations.
Pathogenesis of lead-induced hypertension: role of oxidative stress.
Pathogenetic role of vascular angiotensin-converting enzyme in the spontaneously hypertensive rat.
Pathophysiology and management of angiotensin-converting enzyme inhibitor-associated refractory hypotension during the perioperative period.
Pathophysiology and therapeutic possibilities of calcitonin gene-related peptide in hypertension.
Pathways for bradykinin formation and inflammatory disease.
Patient adherence with amlodipine, lisinopril, or valsartan therapy in a usual-care setting.
Patient Awareness, Prevalence, and Risk Factors of Chronic Kidney Disease among Diabetes Mellitus and Hypertensive Patients at Jimma University Medical Center, Ethiopia.
Patient compliance and angiotensin converting enzyme inhibitors in hypertension.
Patients With Newly Diagnosed Hypertension Treated With the Renin Angiotensin Receptor Blocker Azilsartan Medoxomil vs Angiotensin-Converting Enzyme Inhibitors: The Prospective EARLY Registry.
Patients' need for more counseling on diet, exercise, and smoking cessation: results from the National Ambulatory Medical Care Survey.
Pattern of hospitalizations for angioedema in New York between 1990 and 2003.
Pattern of prescription of anti-hypertensive medications in a tertiary health care facility in Abuja, Nigeria.
Patterns of renal function in hypertension due to unilateral renal artery occlusion.
Pentoxifylline treatment enhances antihypertensive activity of captopril through hemorheological improvement in spontaneously hypertensive rats during development of arterial hypertension.
Peptide metabolism and the control of body fluid homeostasis.
Peptides as targets for antihypertensive drug development.
Perinatal DDT Exposure Induces Hypertension and Cardiac Hypertrophy in Adult Mice.
Perindopril + indapamide: new preparation. Simple trick.
Perindopril ameliorates glomerular and renal tubulointerstitial injury in the SHR/N-corpulent rat.
Perindopril arginine: benefits of a new salt of the ACE inhibitor perindopril.
Perindopril as monotherapy in hypertension: a multicenter comparison of two dosing regimens. The Perindopril Study Group.
Perindopril Attenuates Lipopolysaccharide-Induced Amyloidogenesis and Memory Impairment by Suppression of Oxidative Stress and RAGE Activation.
Perindopril reduces blood pressure but not cerebral blood flow in patients with recent cerebral ischemic stroke.
Perindopril safety and tolerance in at-risk patients.
Perindopril vs Enalapril in Patients with Systolic Heart Failure: Systematic Review and Metaanalysis.
Perioperative angiotensin-converting enzyme inhibitors or angiotensin II type 1 receptor blockers for preventing mortality and morbidity in adults.
Perioperative Quality Initiative consensus statement on postoperative blood pressure, risk and outcomes for elective surgery.
Peripheral haemodynamics and angiotensin converting enzyme inhibition. Satellite symposium of the twelfth scientific meeting of the International Society of Hypertension. 21 May 1988, Kyoto, Japan.
Permeation Studies Of Captopril Transdermal Films Through Human Cadaver Skin.
Persistence with treatment in newly treated middle-aged patients with essential hypertension.
Persistent effects on blood pressure and renal function of perindopril alone or combined with losartan in Lyon hypertensive rats.
Pharmacodynamic effects of C-domain-specific ACE inhibitors on the renin-angiotensin system in myocardial infarcted rats.
Pharmacoeconomic Evaluation of Hypothetical Over-the-counter Angiotensin-converting Enzyme (ACE) Inhibitors for the Prevention of Stroke in Patients with Grade I Hypertension.
Pharmacoepidemiology of antihypertensive drugs in primary care setting of Bahrain between 1998 and 2000.
Pharmacogenetics of antihypertensive treatment.
Pharmacokinetic and dynamic interactions of the angiotensin-converting enzyme inhibitor imidapril with hydrochlorothiazide, bisoprolol and nilvadipine.
Pharmacokinetic assessment of an oral enalapril suspension for use in children.
Pharmacokinetic optimisation of angiotensin converting enzyme (ACE) inhibitor therapy.
Pharmacokinetics and drug-drug interaction between enalapril, enalaprilat and felodipine extended release (ER) in healthy subjects.
Pharmacokinetics and pharmacodynamics of aliskiren, an oral direct renin inhibitor.
Pharmacokinetics and pharmacodynamics of trandolapril after repeated administration of 2 mg to young and elderly patients with mild-to-moderate hypertension.
Pharmacokinetics of captopril in healthy subjects and in patients with cardiovascular diseases.
Pharmacokinetics, Pharmacodynamics, and Safety of Lisinopril in Pediatric Kidney Transplant Patients: Implications for Starting Dose Selection.
Pharmacologic blockade of the renin-angiotensin system: vascular benefits beyond commonly understood pharmacologic actions.
Pharmacologic management of feline hyperthyroidism.
Pharmacologic management of hypertension in patients with diabetes.
Pharmacologic management of hypertension. New guidelines based on latest studies.
Pharmacological Implications of MMP-9 Inhibition by ACE Inhibitors.
Pharmacological Management of Glucose Dysregulation in Patients Treated with Second-Generation Antipsychotics.
Pharmacological management of hypertension.
Pharmacological modulation of cardiac fibroblast function.
Pharmacological prevention of atherothrombotic events in patients with peripheral arterial disease.
Pharmacological properties of angiotensin II antagonists: examining all the therapeutic implications.
Pharmacological Treatment of Arterial Hypertension in Children and Adolescents: A Network Meta-Analysis.
Pharmacology and drug interaction effects of the phosphodiesterase 5 inhibitors: focus on alpha-blocker interactions.
Pharmacology of antihypertensive drugs.
Pharmacology of enalapril in children: a review.
Pharmacology of losartan, an angiotensin II receptor antagonist, in animal models of hypertension.
Pharmacotherapeutic approaches to the prevention of Alzheimer's disease.
Pharmacotherapy and analysis of gaseous mediators in hypertensive patients.
Pharmacotherapy for the metabolic syndrome.
Phenolic compounds, antioxidant activity and in vitro inhibitory potential against key enzymes relevant for hyperglycemia and hypertension of commonly used medicinal plants, herbs and spices in Latin America.
Physical exercise improves cardiac autonomic modulation in hypertensive patients independently of angiotensin-converting enzyme inhibitor treatment.
Physician conformity and patient adherence to ACE inhibitors and ARBs in patients with diabetes, with and without renal disease and hypertension, in a medicaid managed care organization.
Physiologic evidence of renoprotection by antihypertensive therapy.
Physiologically based pharmacokinetic modelling of lisinopril in children: A case story of angiotensin converting enzyme inhibitors.
Physiology of local renin-angiotensin systems.
Pinacidil: history, basic pharmacology, and therapeutic implications.
Pitfalls and Limitations of Radionuclide Renal Imaging in Adults.
PL 03-3 THE FUTURE DEVELOPMENT OF DRUG THERAPY FOR HYPERTENSION.
Placebo Effect and Efficacy of Nebivolol in Patients with Hypertension not Controlled with Lisinopril or Losartan: A Phase IV, Randomized, Placebo-Controlled Trial.
Placental insufficiency results in temporal alterations in the renin angiotensin system in male hypertensive growth restricted offspring.
Plasma Angiotensin-converting Enzyme Levels in Patients With Keloids and/or Hypertension.
Plasma digoxin immunoreactivity and arterial potassium relaxation after quinapril therapy in hypertensive rats.
Plasma markers of endothelial cells and platelet activation following handgrip in normals and hypertensive patients.
Plasma visfatin/nicotinamide phosphoribosyltransferase levels in hypertensive elderly - results from the PolSenior substudy.
Plasminogen activator inhibitor-1 and angiotensin I converting enzyme gene polymorphism in patients with hypertension.
Platelet hyperactivity in hypertensive older patients is controlled by lowering blood pressure.
Platelet-to-Lymphocyte Ratio Predicts Contrast-Induced Acute Kidney Injury in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.
Pleiotropic effects of inhibitors of the RAAS in the diabetic population: above and beyond blood pressure lowering.
Pleiotropic effects of type 2 diabetes management strategies on renal risk factors.
Polymorphism in the angiotensin converting enzyme but not in the angiotensinogen gene is associated with hypertension and type 2 diabetes: the Skaraborg Hypertension and diabetes project.
Polymorphism insertion/deletion of the ACE gene and ambulatory blood pressure circadian variability in essential hypertension.
Polymorphism of the angiotensin converting enzyme gene and blood pressure in a Japanese general population (the Shigaraki Study).
Polymorphism of the angiotensin I converting enzyme gene in essential hypertensive patients.
Polymorphism of the angiotensin I converting enzyme gene is apparently not related to high blood pressure: Dutch Hypertension and Offspring Study.
Polymorphisms in the gene encoding angiotensin I converting enzyme 2 and diabetic nephropathy.
Polymorphisms of angiotensin-converting enzyme and angiotensin II receptor type 1 genes in essential hypertension in a Polish population.
Polymorphisms of EDNRB, ATG, and ACE genes in salt-sensitive hypertension.
Population-based case-control study of renin-angiotensin system genes polymorphisms and hypertension among Hispanics.
Position Paper of the Department of Hypertension of the Brazilian Society of Nephrology: Use of renin-angiotensin system blockers during the course of Covid-19 infection.
Positive Association between Tinnitus and Arterial Hypertension.
Positive association of CYP11B2 gene polymorphism with genetic predisposition to essential hypertension.
Possible role of bradykinin and angiotensin II in the regulation of penile erection and detumescence.
Possible role of vascular angiotensin converting enzyme in the genesis of hypertension.
Possible Role of Vascular Risk Factors in Alzheimer's Disease and Vascular Dementia.
Post-thrombolysis intracerebral hemorrhage: data from the Spanish Register ARIAM.
Postoperative hypotension associated with enalapril.
Potassium homeostasis and Renin-Angiotensin-aldosterone system inhibitors.
Potential angiotensin converting enzyme (ACE) inhibitors from Iranian traditional plants described by Avicenna's Canon of Medicine.
Potential cardioprotective effect of mibefradil in the long-term treatment of hypertension.
Potential cognitive decline linked to angiotensin-converting enzyme gene but not hypertension: Evidence from cognitive event-related potentials.
Potential Contribution of Carotid Body-Induced Sympathetic and Renin-Angiotensin System Overflow to Pulmonary Hypertension in Intermittent Hypoxia.
Potential indications for angiotensin-converting enzyme inhibitors in atherosclerotic vascular disease.
Potential of cranberry powder for management of hyperglycemia using in vitro models.
Potential of Ginkgo biloba L. leaves in the management of hyperglycemia and hypertension using in vitro models.
Potential renoprotective effects of the angiotensin receptor blocker eprosartan: a review of preliminary renal studies.
Potential role for angiotensin-converting enzyme inhibitors in the treatment of glaucoma.
Potential role of angiotensin-converting enzyme inhibitors and statins on early podocyte damage in a model of type 2 diabetes mellitus, obesity, and mild hypertension.
Potentials and limitations of angiotensin converting enzyme inhibition in the treatment of hypertension.
Practical Approach to Detection and Management of Chronic Kidney Disease for the Primary Care Clinician.
Practice patterns in transitioning patients from chronic kidney disease to dialysis: a survey of United States nephrologists.
Prazosin versus captopril as initial therapy. Effect on hypertension and lipid levels.
Prediabetes is associated with glomerular hyperfiltration in a European Mediterranean cohort study.
Predictive Modeling of Angiotensin I-Converting Enzyme Inhibitory Peptides Using Various Machine Learning Approaches.
Predictors and prognostic implications of major adverse cardiovascular events after renal transplant: 10 years outcomes in 321 patients.
Predictors of Acute Kidney Injury Following Surgical Valve Replacement.
Predictors of distant metastasis and mortality in patients with stage II colorectal cancer.
Predictors of postoperative acute kidney injury in patients undergoing hip fracture surgery: A systematic review and meta-analysis.
Predictors of Recurrent Ischemic Stroke in Obese Patients With Type 2 Diabetes Mellitus: A Population-based Study.
Predictors of self-reported noncompliance with antihypertensive drug treatment: A prospective cohort study.
Prehypertension exercise training attenuates hypertension and cardiac hypertrophy accompanied by temporal changes in the levels of angiotensin II and angiotensin (1-7).
Preliminary study about the relationship between estimated training status and RAS polymorphisms on blood pressure and ACE activity in the elderly.
Present aspects and future developments with ACE inhibitors.
Presentation, surgical intervention, and long-term survival in patients with Marfan syndrome.
Preservation of renal function following partial or radical nephrectomy using 24-hour creatinine clearance.
Prevalence and determinants of microalbuminurea among type 2 diabetes mellitus patients, Baghdad, Iraq, 2013.
Prevalence and management of hypertension in type 1 diabetes mellitus in Europe: the EURODIAB IDDM Complications Study.
Prevalence of angiotensin converting enzyme (ACE) gene insertion/deletion polymorphism in South Indian population with hypertension and chronic kidney disease.
Prevalence of Periapical Abscesses in Patients with Hypertension: A Cross-sectional Study of a Large Hospital Population.
Prevalence of the fibrinogen beta-chain, angiotensin-converting enzyme and plasminogen activator inhibitor-1 polymorphisms in Costa Rican young adults with thrombotic disease.
Prevalence, predictors and prognosis of ventricular reverse remodeling in idiopathic dilated cardiomyopathy.
Preventing cardiovascular disease in women.
Preventing microalbuminuria in type 2 diabetes.
Preventing recurrent events long term after coronary artery bypass graft: suboptimal use of medications in a population study.
Preventing renal complications in type 2 diabetes: results of the diabetics exposed to telmisartan and enalapril trial.
Prevention and reversal by enalapril of target organ damage in angiotensin II hypertension.
Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis.
Prevention of diabetes in hypertensive patients: results and implications from the VALUE trial.
Prevention of genetic hypertension by early treatment of spontaneously hypertensive rats with the angiotensin converting enzyme inhibitor captopril.
Prevention of heart failure: effective strategies to combat the growing epidemic.
Prevention of nephrosclerosis and cardiac hypertrophy by captopril treatment of spontaneously hypertensive rats.
Prevention of salt induced hypertension and fibrosis by angiotensin converting enzyme inhibitors in Dahl S rats.
Prevention of structural changes in the heart in hypertension by angiotensin converting enzyme inhibition.
Primary prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with end-stage renal disease undergoing dialysis.
Primary renal renin secretion responding to angiotensin converting enzyme inhibition.
Production of Angiotensin I Converting Enzyme Inhibitory (ACE-I) Peptides during Milk Fermentation and Their Role in Reducing Hypertension.
Production of Bio-Functional Protein through Revalorization of Apricot Kernel Cake.
Profiling of the renal kinome: a novel tool to identify protein kinases involved in angiotensin II-dependent hypertensive renal damage.
Prognostic significance of blood pressure in the very old. Implications for the treatment decision.
Prognostic significance of serum cholinesterase in patients with acute decompensated heart failure: a prospective comparative study with other nutritional indices.
Prognostic significance of the dobutamine echocardiography test in idiopathic dilated cardiomyopathy.
Prognostic value of cardiac troponin T elevation is independent of renal function and clinical findings in heart failure patients.
Progress in the development of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.
Prolylcarboxypeptidase gene, chronic hypertension, and risk of preeclampsia.
Prophylactic effect of imidapril on stroke in stroke-prone spontaneously hypertensive rats.
Prorenin/renin receptor, signals, and therapeutic efficacy of receptor blocker in end-organ damage.
Prospective studies of diagnosis and intervention: the Dutch experience.
Proteases as drug targets.
Protection of the cardiovascular system by imidapril, a versatile angiotensin-converting enzyme inhibitor.
Protective effect of captopril against clozapine-induced myocarditis in rats: Role of oxidative stress, proinflammatory cytokines and DNA damage.
Protective effects of angiotensin-converting enzyme inhibitors in high-risk African American men with coronary heart disease.
Protective effects of enalapril in streptozotocin-induced diabetic rat: studies of DNA damage, apoptosis and expression of CCN2 in the heart, kidney and liver.
Protective effects of imidapril on He-Ne laser-induced thrombosis in cerebral blood vessels of stroke-prone spontaneously hypertensive rats.
Protein remodelling of the heart in NO-deficient hypertension: the effect of captopril.
Proteinuria versus albuminuria in 24-hour urine collection: prevalence and clinical outcome in non-hypoxemic adult patients with congenital heart disease.
Provider factors influencing prescriptions of recommended antihypertensive medications among patients with diabetes and hypertension?.
Public health, cardiovascular disease and molecular biology.
Pulse pressure as a risk factor for peripheral vascular disease in type 2 diabetic patients.
Pulse pressure is a predictor of vascular endothelial function in middle-aged subjects with no apparent heart disease.
Pulses' germination and fermentation: Two bioprocessing against hypertension by releasing ACE inhibitory peptides.
Purification and characterization of a novel angiotensin-I converting enzyme (ACE) inhibitory peptide derived from enzymatic hydrolysate of grass carp protein.
QRS duration is associated with atrial fibrillation in patients with left ventricular dysfunction.
Quality of diabetes care among cancer survivors with diabetes.
Quality of life among hypertensive patients with a diuretic background who are taking atenolol and enalapril.
Quantifying sociodemographic and income disparities in medical therapy and lifestyle among symptomatic patients with suspected coronary artery disease: a cross-sectional study in North America.
Quantitation of quinapril in human plasma by matrix-assisted laser desorption ionization time-of-flight mass spectrometry with quinolone matrix additives.
Quantitative phenotype analysis for localization and identification of disease-related genes in a complex genetic background.
Quantitative trait loci for blood pressure exist near the IGF-1, the Liddle syndrome, the angiotensin II-receptor gene and the renin loci in man.
Quinapril versus enalapril in the treatment of mild-to-moderate essential hypertension.
Quinapril, an angiotensin converting enzyme inhibitor, prevents cardiac hypertrophy during episodic hypertension.
RAAS inhibition and mortality in hypertension.
RAAS Inhibition/Blockade in patients with Cardiovascular disease : Implications of recent large scale randomized trials for clinical practice.
Racial differences in blood pressure response to angiotensin-converting enzyme inhibitors in children: a meta-analysis.
Racial differences in endothelial function in postmenopausal women.
Radioligands for the angiotensin II subtype 1 (AT1) receptor.
Ramipril and felodipine: a comparison of the efficacy and safety of monotherapy versus combination therapy.
Ramipril therapy improves arterial dilation in experimental hypertension.
Ramipril-associated cholestasis in the setting of recurrent drug-induced liver injury.
Ramipril-induced liver injury: case report and review of the literature.
Ramiprilat enhances endothelial autacoid formation by inhibiting breakdown of endothelium-derived bradykinin.
Randomized clinical stroke trials in 2004.
Rapid improvement of acute pulmonary edema with angiotensin converting enzyme inhibitor under hemodialysis in a patient with renovascular disease.
RAS-Mediated Adaptive Mechanisms in Cardiovascular Tissues: Confounding Factors of RAS Blockade Therapy and Alternative Approaches.
Rat models of cardiometabolic diseases: baseline clinical chemistries, and rationale for their use in examining air pollution health effects.
Rationale and design of diabetics exposed to telmisartan and enalapril (DETAIL) study.
Rationale and design of HOMED-BP Study: hypertension objective treatment based on measurement by electrical devices of blood pressure study.
Rationale and pharmacology of angiotensin II receptor antagonists: current status and future issues.
Rationale for triple fixed-dose combination therapy with an angiotensin II receptor blocker, a calcium channel blocker, and a thiazide diuretic.
Re: Association of Inpatient Use of Angiotensin-converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortality Among Patients with Hypertension Hospitalized with COVID-19.
Receipt of Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers among Medicare Beneficiaries with Diabetes and Hypertension.
Recent Advances in Angiotensin-Converting Enzyme Inhibition in the Treatment of Hypertension and Heart Failure. Symposium proceedings. Barcelona, Spain, August 30, 1992.
Recent developments in the design of angiotensin-converting enzyme inhibitors.
Recent Updates on the Proximal Tubule Renin-Angiotensin System in Angiotensin II-Dependent Hypertension.
Receptors for angiotensins I and II: their relevance to renal haemodynamics, blood pressure control and hind-limb blood flow.
Reciprocal interactions of obstructive sleep apnea and hypertension associated with ACE I/D polymorphism in males.
Reciprocal regulation of angiotensin converting enzyme and neutral endopeptidase in rats with experimental hypertension.
Recognition and management of angiotensin converting enzyme inhibitor fetopathy.
Recovery of renal function in patients with accelerated malignant nephrosclerosis on maintenance dialysis with management of blood pressure by captopril.
Recruitment of African Americans with chronic renal insufficiency into a multicenter clinical trial: the african american study of kidney disease and hypertension.
Red ginger-extract nanoemulsion modulates high blood pressure in rats by regulating angiotensin-converting enzyme production.
Redefining beta-blocker use in hypertension: selecting the right beta-blocker and the right patient.
Reduced expression of angiotensin I-converting enzyme in Caveolin-1 knockout mouse lungs.
Reduced testosterone levels in males with lone atrial fibrillation.
Reduction in arterial stiffness with angiotensin II antagonist is comparable with and additive to ACE inhibition.
Reduction of cardiovascular risk factors in subjects with type 2 diabetes by Pycnogenol supplementation.
Reduction of left ventricular mass by lisinopril and nifedipine in hypertensive renal transplant recipients: a prospective randomized double-blind study.
Reduction of Mean Arterial Pressure and Proteinuria by the Effect of ACEIs (Lisinopril) in Kurdish Hypertensive Patients in Hawler City.
Regression of left ventricular hypertrophy and prevention of left ventricular dysfunction by captopril in the spontaneously hypertensive rat.
Regression of left ventricular hypertrophy in hemodialysis patients is possible.
Regression of left ventricular hypertrophy: do antihypertensive classes differ?
Regression of Left Ventricular Mass by Antihypertensive Treatment. A Meta-Analysis of Randomized Comparative Studies.
Regulation of angiotensin-converting enzyme production by nicotine in human endothelial cells.
Regulation of sodium excretion in human hypertension: long-term effects of calcium antagonist and angiotensin converting enzyme inhibitor.
Regulatory role of brain angiotensins in the control of physiological and behavioral responses.
Relation between the angiotensin-converting enzyme insertion/deletion polymorphism and blood pressure in Japanese male subjects.
Relation of albuminuria to angiographically determined coronary arterial narrowing in patients with and without type 2 diabetes mellitus and stable or suspected coronary artery disease.
Relation of C-reactive protein to long-term risk of recurrence of atrial fibrillation after electrical cardioversion.
Relation of coronary atherosclerosis determined by electron beam computed tomography and plasma levels of n-terminal pro-brain natriuretic peptide in a multiethnic population-based sample (the Dallas Heart Study).
Relationship between decrease in afterload and beneficial effects of ACE inhibitors in experimental cardiac hypertrophy and congestive heart failure.
Relationship between left ventricular mass and the ACE D/I polymorphism varies according to sodium intake.
Relationship between low Ankle-Brachial Index and rapid renal function decline in patients with atrial fibrillation: a prospective multicentre cohort study.
Relationship between proteinuria and progressive renal disease.
Relationship between sleep disordered breathing and diabetic retinopathy: Analysis of 136 patients with diabetes.
Relationship of angiotensin converting enzyme gene polymorphism and hypertension in Yogyakarta, Indonesia.
Relationship of renin-angiotensin system polymorphisms with ambulatory and central blood pressure in patients with hypertension.
Relationship of the angiotensin-converting enzyme gene polymorphism to glucose intolerance, insulin resistance, and hypertension in NIDDM.
Reliability of ACE inhibitor-enhanced 99Tcm-DTPA gamma camera renography in the detection of renovascular hypertension.
Remodeling of resistance arteries in human hypertension: effects of cilazapril, an angiotensin-I-converting enzyme inhibitor.
Remodelling of the vascular system in response to hypertension and drug therapy.
Renal ACE2 expression and activity is unaltered during established hypertension in adult SHRSP and TGR(mREN2)27.
Renal angiotensin II receptor regulation and renin-angiotensin system inhibition in one-kidney, one clip hypertensive rats.
Renal angiotensin II receptor regulation in two-kidney, one clip hypertensive rats: effect of ACE inhibition.
Renal Angiotensin-Converting Enzyme Is Essential for the Hypertension Induced by Nitric Oxide Synthesis Inhibition.
Renal antifibrotic effect of N-acetyl-seryl-aspartyl-lysyl-proline in diabetic rats.
Renal artery stenosis presenting as preeclampsia.
Renal artery stenosis: a disease worth pursuing.
Renal considerations in angiotensin converting enzyme inhibitor therapy: a statement for healthcare professionals from the Council on the Kidney in Cardiovascular Disease and the Council for High Blood Pressure Research of the American Heart Association.
Renal Considerations in Geriatric Patients With Heart Disease.
Renal disease in obesity: the need for greater attention.
Renal effect of anti-hypertensive drugs depends on sodium diet in the excision remnant kidney model.
Renal effects of angiotensin converting enzyme inhibitors in hypertension.
Renal effects of antihypertensive drugs.
Renal function in meningomyelocele: risk factors, chronic renal failure, renal replacement therapy and transplantation.
Renal function in relation to three candidate genes.
Renal hemodynamic control by endothelin and nitric oxide under angiotensin II blockade in man.
Renal hemodynamic effects of nonhypotensive doses of angiotensin-converting enzyme inhibitors in hypertension and heart failure rats.
Renal insufficiency due to angiotensin-converting enzyme inhibitors.
Renal involvement in autoimmune connective tissue diseases.
Renal morphology and function in dogs after treatment with the angiotensin-converting enzyme inhibitor quinapril.
Renal outcome and vascular morbidity in systemic lupus erythematosus (SLE): lack of association with the angiotensin-converting enzyme gene polymorphism.
Renal protective effect of long term antihypertensive therapy with enalapril.
Renal response to blood pressure elevation in normal and glomerulonephritic rats.
Renal transplantation unveils Conn's syndrome: a case report.
Renal vascular effects of antihypertensive therapy in uninephrectomized SHR.
Renal volume, renin-angiotensin-aldosterone system, hypertension, and left ventricular hypertrophy in patients with autosomal dominant polycystic kidney disease.
Renin Angiotensin Aldosterone System Blockade: Little to No Rationale for ACE Inhibitor and ARB Combinations.
Renin Inhibition for Hypertension: Selecting the Right Role for a New Class of Drug.
Renin inhibition: a new approach to cardiovascular therapy.
Renin inhibition: immunological procedures and renin inhibitor peptides.
Renin inhibitors as possible antihypertensive agents.
Renin inhibitors in hypertension.
Renin inhibitors versus angiotensin converting enzyme (ACE) inhibitors for primary hypertension.
Renin inhibitors.
Renin inhibitors: discovery and development. An overview and perspective.
Renin inhibitors: specific modulators of the renin-angiotensin system.
Renin-angiotensin system and cancer: epidemiology, cell signaling, genetics and epigenetics.
Renin-Angiotensin System Blockade and Mortality in Patients With Hypertension and COVID-19 Infection.
Renin-angiotensin system blockade at the level of the angiotensin converting enzyme or the angiotensin type-1 receptor: similarities and differences.
Renin-Angiotensin System Genes Polymorphisms and Long-Term Prognosis in Taiwanese Patients with Hypertension and Coronary Artery Disease.
Renin-Angiotensin System Inhibition in Cardiovascular Patients at the Time of COVID19: Much Ado for Nothing? A Statement of Activity from the Directors of the Board and the Scientific Directors of the Italian Society of Hypertension.
Renin-angiotensin system inhibition in COVID-19 patients.
Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part 2. Overview of physiological and biochemical mechanisms.
Renin-angiotensin system inhibitors and susceptibility to COVID-19 in patients with hypertension: a propensity score-matched cohort study in primary care.
Renin-angiotensin system polymorphisms and risk of hypertension: influence of environmental factors.
Renin-Angiotensin-aldosterone system in autosomal dominant polycystic kidney disease.
Renin-angiotensin-aldosterone system: fundamental aspects and clinical implications in renal and cardiovascular disorders.
Renin-dependent renal parenchymatous hypertension detected by angiotensin-converting enzyme inhibitor renography.
Renin-induced hypertension in Wilms tumor patients.
Renoprotective Effect of the Combination of Renin-angiotensin System Inhibitor and Calcium Channel Blocker in Patients with Hypertension and Chronic Kidney Disease.
Renoprotective effects of antihypertensive drugs.
Renoprotective effects of soy protein hydrolysates in N(omega)-nitro-L-arginine methyl ester hydrochloride-induced hypertensive rats.
Renovascular hypertension in children: current concepts in evaluation and treatment.
Renovascular hypertension in pediatric patients: update on diagnosis and management.
Renovascular hypertension: treatment with the oral angiotensin-converting enzyme inhibitor enalapril.
Repeated massive tongue swelling due to the combined use of estramustine phosphate and angiotensin-converting enzyme inhibitor.
Reporting of the estimated glomerular filtration rate was associated with increased use of angiotensin-converting enzyme inhibitors and angiotensin-II receptor blockers in CKD.
Research Progress on Pulmonary Arterial Hypertension and the Role of the Angiotensin Converting Enzyme 2-Angiotensin-(1-7)-Mas Axis in Pulmonary Arterial Hypertension.
Resistant Hypertension in Pregnancy: How to Manage?
Resistant Hypertension Management: Comparison of the 2017 American and 2018 European High Blood Pressure Guidelines.
Response by Cohen et al to Letter Regarding Article, "Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Mortality Among Patients With Hypertension Hospitalized With COVID-19".
Response by Zhang et al to Letter Regarding Article, "Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Mortality Among Patients With Hypertension Hospitalized With COVID-19".
Response of fibroblast growth factor 23 to volume interventions in arterial hypertension and diabetic nephropathy.
Response to the letter to the editor entitled 'Angiotensin-II receptor blockers or angiotensin converting enzyme inhibitors for the treatment of hypertension amid COVID-19 pandemic'.
Restoration of flow-dependent coronary dilation by ACE inhibition improves papaverine-induced maximal coronary blood flow in hypertensive patients: demonstration that large epicardial coronary arteries are more than conductance vessels.
Rethinking the renin-angiotensin system and its role in cardiovascular regulation.
Retrospective longitudinal cohort study comparing the effects of angiotensin-converting enzyme inhibitors and long-acting calcium channel blockers on total and cardiovascular mortality in patients with hypertension.
Reversal of diastolic dysfunction in borderline hypertension by long-term medical treatment. Longitudinal evaluation by pulsed Doppler echocardiography.
Reversal of early metabolic dysfunction in hypertensive rat left-ventricular myocytes by angiotensin-converting enzyme inhibition.
Reversible acute renal failure as an atypical presentation of ischemic nephropathy.
Reversible oligohydramnios in a pregnancy with angiotensin-converting enzyme inhibitor exposure.
Reversible renal failure associated with angiotensin-converting enzyme inhibitors in polycystic kidney disease.
Reversible renal failure due to the use of captopril in a renal allograft recipient treated with cyclosporin.
Review: Novel roles of nuclear angiotensin receptors and signaling mechanisms.
Risk factor-induced cardiovascular remodeling and the effects of angiotensin-converting enzyme inhibitors.
Risk factors associated with the development of ischemic colitis.
Risk factors for acute kidney injury in patients with acute myocardial infarction.
Risk factors for appropriate cardioverter-defibrillator shocks, inappropriate cardioverter-defibrillator shocks, and time to mortality in 549 patients with heart failure.
Risk factors for developing acute kidney injury in older people with diabetes and community-acquired pneumonia: a population-based UK cohort study.
Risk factors for developing hyponatremia in thyroid cancer patients undergoing radioactive iodine therapy.
Risk factors for the delayed viral clearance in COVID-19 patients.
Risk of cardiovascular events after initiation of long-acting bronchodilators in patients with chronic obstructive lung disease: A population-based study.
Risk of hyperkalemia in nondiabetic patients with chronic kidney disease receiving antihypertensive therapy.
Risk of impaired renal function after colonoscopy: a cohort study in patients receiving either oral sodium phosphate or polyethylene glycol.
Risk of lung cancer and renin-angiotensin blockade: a concise review.
Risk of Osteoporotic Fractures with Angiotensin II Receptor Blockers Versus Angiotensin Converting-Enzyme Inhibitors in Hypertensive Community-Dwelling Elderly.
Risk of Renal Cell Carcinoma Associated with Calcium Channel Blockers: A Nationwide Observational Study Focusing on Confounding by Indication.
Risk prediction for 30-day heart failure-specific readmission or death after discharge: Data from the Korean Acute Heart Failure (KorAHF) registry.
Risk reduction following regression of cardiac hypertrophy.
Risk-benefit assessment of angiotensin II receptor antagonists.
Risks and benefits of early treatment of acute myocardial infarction with an angiotensin-converting enzyme inhibitor in patients with a history of arterial hypertension: analysis of the GISSI-3 database.
Role of aliskiren in blood pressure control and renoprotection.
Role of angiotensin converting enzyme inhibitors and angiotensin receptor blockers in hypertension of chronic kidney disease and renoprotection. Study results.
Role of angiotensin II in blood pressure regulation and in the pathophysiology of cardiovascular disorders.
Role of angiotensin II in cerebrovascular and renal damage in deoxycorticosterone acetate-salt hypertensive rats.
Role of angiotensin II in hyperinsulinemia-induced hypertension in rats.
Role of Angiotensin receptor blockers in the prevention and treatment of arrhythmias.
Role of angiotensin-converting enzyme inhibition in reversal of endothelial dysfunction in coronary artery disease.
Role of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in the management of atrial fibrillation.
Role of angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers in the prevention of progression of renal disease.
Role of angiotensin-converting enzyme inhibitors in preventing or reducing end-organ damage in hypertension.
Role of angiotensin-converting-enzyme inhibitors in the treatment of hypertension.
Role of bradykinin and tachykinins in the potentiation by enalapril of coughing induced by citric acid in pigs.
Role of bradykinin in hypertension and the antihypertensive effect of angiotensin-converting enzyme inhibitors.
Role of brain and peripheral angiotensin II in hypertension and altered arterial baroreflex programmed during fetal life in rat.
Role of calcium on excitation-contraction coupling in cardiac and vascular smooth muscle.
Role of chymase in blood pressure control, plasma and tissue angiotensin II, renal Haemodynamics, and excretion in spontaneously hypertensive rats.
Role of endogenous angiotensin II and prostaglandins in the antihypertensive mechanism of angiotensin converting enzyme inhibitor in hypertension.
Role of kinins in the acute antihypertensive effect of enalapril in hypertensive rats.
Role of N-acetyl-seryl-aspartyl-lysyl-proline in the antifibrotic and anti-inflammatory effects of the angiotensin-converting enzyme inhibitor captopril in hypertension.
Role of neutral endopeptidase and angiotensin-converting enzyme in deoxycorticosterone acetate-salt hypertension.
Role of the angiotensin II type 1 receptor in the pathogenesis of diabetic retinopathy: effects of blood pressure control and beyond.
Role of the kidney in primary hypertension: a renal transplantation study in rats.
Role of valsartan and other angiotensin receptor blocking agents in the management of cardiovascular disease.
Role of valsartan, amlodipine and hydrochlorothiazide fixed combination in blood pressure control: an update.
Role of vascular angiotensin converting enzyme in hypertension.
Role of vascular wall renin: intracellular and extracellular mechanism.
Roles of Dietary Bioactive Peptides in Redox Balance and Metabolic Disorders.
Roles of renal and vascular renin in spontaneous hypertension and switching of the mechanism upon nephrectomy. Lack of hypotensive effects of inhibition of renin, converting enzyme, and angiotensin II receptor blocker after bilateral nephrectomy.
Roles of vascular angiotensin converting enzyme and chymase in two-kidney, one clip hypertensive hamsters.
Rosiglitazone, a Ligand to PPAR?, Improves Blood Pressure and Vascular Function through Renin-Angiotensin System Regulation.
S-nitrosocaptopril. II. Effects on vascular reactivity.
Safety and efficacy of chronic therapy with captopril in hypertensive patients: an update.
Safety and efficacy of eprosartan, a new angiotensin II receptor blocker.
Safety and tolerability of losartan potassium, an angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipine ER, and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension.
Safety issues during antihypertensive treatment with angiotensin converting enzyme inhibitors.
Safety of the newer antihypertensive agents in children.
Safety profile of perindopril.
Safety profiles of the angiotensin-converting enzyme inhibitors.
Salt sensitivity of hypertension and responses to angiotensin converting enzyme inhibition with benazepril.
Salt, the renin-angiotensin-aldosterone system and resistant hypertension.
Saluretics and converting-enzyme blockade in the treatment of resistant hypertension.
Sampatrilat Shire.
Scleroderma renal crisis in progressive systemic sclerosis: a case report.
Scleroderma with crescentic glomerulonephritis: a case report.
Scleroderma--clinical and pathological advances.
Screening and treatment of diabetic nephropathy by primary care physicians.
Screening for primary aldosteronism in a primary care unit.
Screening of Egyptian obese children and adolescents for insertion/deletion (I/D) polymorphism in angiotensin-converting enzyme gene.
Screening of Zulu medicinal plants for angiotensin converting enzyme (ACE) inhibitors.
Secondary Hypertension: Discovering the Underlying Cause.
Secondary prevention of CAD with ACE inhibitors: a struggle between life and death of the endothelium.
Secondary prevention of coronary heart disease in elderly patients.
Secretory dysfunction of vascular endothelium limits the effect of angiotensin converting enzyme inhibitor quinapril on aggregation of erythrocytes in experimental hypertension.
Secular Trends in Prescription Patterns of Single-Pill Combinations of an Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Plus a Thiazide Diuretic for Hypertensive Patients in Taiwan.
Separation methods for captopril in pharmaceuticals and biological fluids.
Serial micropuncture analysis of glomerular function in two rat models of glomerular sclerosis.
Serum 1,5-anhydroglucitol is associated with diabetic retinopathy in Type 2 diabetes.
Serum albumin may prevent hypertension by inhibiting angiotensin converting enzyme.
Serum angiotensin converting enzyme activity and the capacity to develop hypertention-associated arterial disease. Studies during the induction phase of one-kidney perinephritis hypertension in rabbits.
Serum angiotensin converting enzyme activity in normal adults and patients with different types of hypertension.
Serum angiotensin converting enzyme and the obstructive sleep apnea hypopnea syndrome.
Severe central sleep apnea is associated with atrial fibrillation in patients with left ventricular systolic dysfunction.
Severe migratory Angioedema due to ACE inhibitors use.
Severe paradoxical hypertension with angiotensin-converting enzyme inhibitors: an unusual feature of renal artery stenosis.
Severity and mortality of COVID 19 in patients with diabetes, hypertension and cardiovascular disease: a meta-analysis.
Severity of hypertension affects improved resistance artery endothelial function by angiotensin-converting enzyme inhibition.
Sex differences in antihypertensive drug use: determinants of the choice of medication for hypertension.
Sex differences in environmental and genetic factors for hypertension.
Sexual function, satisfaction, and association of erectile dysfunction with cardiovascular disease and risk factors in cardiovascular high-risk patients: substudy of the ONgoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNT Study in ACE-INtolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND).
Shedding the load of hypertension: the proteolytic processing of angiotensin-converting enzyme.
Short Course of Eculizumab May Be Effective in Dialysis-Dependent Transplantation-Associated Thrombotic Microangiopathy After Hematopoietic Stem Cell Transplantation: A Case Report.
Short-term changes of serum potassium concentration induced by physical exercise in patient with arterial hypertension treated with angiotensin-converting enzyme inhibitor alone or in combination with statin.
Short-term effects of blood pressure control and antihypertensive drug regimen on glomerular filtration rate: the African-American Study of Kidney Disease and Hypertension Pilot Study.
Short-term treatment with captopril in hypertension due to acute glomerulonephritis.
Should ACE inhibitors and ARBs be used in combination in children?
Should an angiotensin-converting enzyme inhibitor be standard therapy for patients with atherosclerotic disease?
Should hypertension be treated with angiotensin-converting-enzyme inhibitors, calcium-channel blockers or diuretics?
Sibutramine is safe and effective for weight loss in obese patients whose hypertension is well controlled with angiotensin-converting enzyme inhibitors.
Sick vessel syndrome. Recovery of atherosclerotic and hypertensive vessels.
Significant target organs for hypertension and cardiac hypertrophy by angiotensin-converting enzyme inhibitors.
Similar renoprotection after renin-angiotensin-dependent and -independent antihypertensive therapy in 5/6-nephrectomized Ren-2 transgenic rats: are there blood pressure-independents effects?
Simple Reason for Hypoglycemia: ACE Inhibitor-induced Severe Recurrent Hypoglycemia in a Nondiabetic Patient.
Simultaneous bilateral renal artery reconstruction and intraoperative renal protection. A case report.
Skeletal muscle angiotensin-converting enzyme and its relationship to blood pressure in primary hypertension and healthy elderly men.
Slow developing pressor effect of angiotensin II and vascular structure.
Slowing the progression of kidney disease in patients with diabetes.
Small but powerful: Short peptide hormones and their role in autoimmune inflammation.
Smart damping modulation of carotid wall energetics in human hypertension: effects of angiotensin-converting enzyme inhibition.
Smoking-dependent effects of the angiotensin-converting enzyme gene insertion/deletion polymorphism on blood pressure.
SNP-by-fitness and SNP-by-BMI interactions from seven candidate genes and incident hypertension after 20 years of follow-up: the CARDIA Fitness Study.
Sodium-Glucose Linked Cotransporter-2 Inhibition Does Not Attenuate Disease Progression in the Rat Remnant Kidney Model of Chronic Kidney Disease.
Somatic gene therapy for hypertension.
South african hypertension guideline 2011.
Soy protein hydrolysate ameliorates cardiovascular remodeling in rats with L-NAME-induced hypertension.
Spectrophotometric determination of enalapril through ternary complex formation.
Speed and duration of dose titration with the angiotensin converting enzyme inhibitor quinapril: relationship with efficacy in patients with moderate hypertension.
Spirapril. A preliminary review of its pharmacology and therapeutic efficacy in the treatment of hypertension.
Spironolactone Use and Improved Outcomes in Patients With Heart Failure With Preserved Ejection Fraction With Resistant Hypertension.
Spirulina maxima Decreases Endothelial Damage and Oxidative Stress Indicators in Patients with Systemic Arterial Hypertension: Results from Exploratory Controlled Clinical Trial.
Spontaneous Hinge-Bending Motions of Angiotensin I Converting Enzyme: Role in Activation and Inhibition.
Statin therapy in patients with chronic kidney disease undergoing percutaneous coronary intervention (from the Evaluation of Drug Eluting Stents and Ischemic Events Registry).
Statin Use and Aneurysm Risk in Patients With Bicuspid Aortic Valve Disease.
Statins and blood pressure regulation.
Statins and risk for new-onset diabetes mellitus: A real-world cohort study using a clinical research database.
Stress response and antihypertensive treatment.
Stress-Induced Sensitization of Angiotensin II Hypertension Is Reversed by Blockade of Angiotensin-Converting Enzyme or Tumor Necrosis Factor-?.
Structural and molecular bases of angiotensin-converting enzyme inhibition by bovine casein-derived peptides: an in silico molecular dynamics approach.
Structural Basis of Metallo-?-Lactamase Inhibition by Captopril Stereoisomers.
Structural determinants for binding, activation, and functional selectivity of the angiotensin AT1 receptor.
Structure of human ACE gives new insights into inhibitor binding and design.
Structure-based pharmacophore design and virtual screening for novel Angiotensin converting enzyme 2 inhibitors.
Studies on the magnitude and the mechanism of cough potentiation by angiotensin-converting enzyme inhibitors in guinea-pigs: involvement of bradykinin in the potentiation.
Studies with an automated kinetic assay for plasma angiotensin-converting enzyme activity and its potentiation by zinc ion.
Study design of HOMED-BP: hypertension objective treatment based on measurement by electrical devices of blood pressure.
Study of correlation between elevation of blood pressure and tissue ACE activity during development of hypertension in 1K1C rats.
Study on the effectiveness of enalapril as a monotherapy in mild to moderate hypertension.
Substituted Benzimidazole Derivatives as Angiotensin II -AT1 Receptor Antagonist: A Review.
Substrate dependence of angiotensin I-converting enzyme inhibition: captopril displays a partial selectivity for inhibition of N-acetyl-seryl-aspartyl-lysyl-proline hydrolysis compared with that of angiotensin I.
Successful acute and long-term treatment of renin-induced hypertension in two infants with captopril.
Successful treatment of severe hypertension with the combination of angiotensin converting enzyme inhibitor and angiotensin II receptor blocker.
Suits you? A qualitative study exploring preferences regarding the tailoring of consumer medicines information.
Sunitinib Malate, a Receptor Tyrosine Kinase Inhibitor, Is Effective in the Treatment of Restrictive Heart Failure due to Heart Metastases from Renal Cell Carcinoma.
Superior effect of an angiotensin-converting enzyme inhibitor over a diuretic for reducing aortic systolic pressure.
Suppression of aldosterone synthesis and secretion by ca(2+) channel antagonists.
Suppression of vascular transforming growth factor-beta1 and extracellular matrix gene expressions by cilazapril and nifedipine in hypertensive rats.
Suppressive Effects of Imidapril on TH1- and TH2-Related Chemokines in Monocytes.
Supratherapeutic doses of angiotensin receptor blockers to decrease proteinuria in patients with chronic kidney disease.
Surface plasmon resonance analysis of the binding mechanism of pharmacological and peptidic inhibitors to human somatic angiotensin I-converting enzyme.
Survival Benefit of Statins in Hemodialysis Patients Awaiting Renal Transplantation.
Sustainable biocatalytic synthesis of L-homophenylalanine as pharmaceutical drug precursor.
Sustained inhibition of angiotensin I-converting enzyme (ACE) expression and long-term antihypertensive action by virally mediated delivery of ACE antisense cDNA.
SY 05-2 PROGRESSION OF HYPERTENSIVE HEART DISEASE: NEW THERAPEUTIC APPROACH.
Sympathetic nervous system function in renal hypertension.
Sympathetic overactivity as a cause of hypertension in chronic renal failure.
Symposium on Angiotensin Converting Enzyme Inhibition. Report of a meeting held in conjunction with the Third annual meeting of the High Blood Pressure Research Council of Australia, Melbourne, December, 1981.
Symposium: Systemic Hypertension: Contribution of Trandolapril, a New Angiotensin-Converting Enzyme Inhibitor, Toward Patient Protection. 14th scientific meeting of the International Society of Hypertension. Madrid, Spain, June 13, 1992.
Syncope caused by nonsteroidal anti-inflammatory drugs and angiotensin-converting enzyme inhibitors.
Syndrome of inappropriate secretion of antidiuretic hormone associated with angiotensin-converting enzyme inhibitor therapy in the perioperative period.
Syndrome X.
Synergistic attenuation of myocardial fibrosis in spontaneously hypertensive rats by joint treatment with benazepril and candesartan.
Synergistic expression of angiotensin-converting enzyme (ACE) and ACE2 in human renal tissue and confounding effects of hypertension on the ACE to ACE2 ratio.
Synthesis and Characterization of Compounds Related to Lisinopril.
Systematic review of combined angiotensin-converting enzyme inhibition and angiotensin receptor blockade in hypertension.
Systemic and localized scleroderma.
Systemic hypertension in postmenopausal women: a clinical approach.
Tamsulosin treatment of 19,365 patients with lower urinary tract symptoms: does co-morbidity alter tolerability?
Targeting inflammation in metabolic syndrome.
Targeting the renin-angiotensin system for the reduction of cardiovascular outcomes in hypertension: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.
Technology for the production and utilization of food protein-derived anti-hypertensive peptides: a review.
Telmisartan in the treatment of hypertension.
Temporal patterns of antihypertensive medication use among elderly patients. The Cardiovascular Health Study.
Temporal relationships of treatment with angiotensin converting enzyme inhibitors on the hypertension and cardiac hypertrophy in spontaneously hypertensive rats.
The 2005 Canadian Hypertension Education Program recommendations for the management of hypertension: part II - therapy.
The 2006 Canadian Hypertension Education Program recommendations for the management of hypertension: Part II - Therapy.
The 2007 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2 - therapy.
The 2008 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2 - therapy.
The 2011 canadian hypertension education program recommendations for the management of hypertension: blood pressure measurement, diagnosis, assessment of risk, and therapy.
The 6-min walk test: a quick measure of functional status in elderly adults.
The absence of intrarenal ACE protects against hypertension.
The ACE gene I/D polymorphism does not affect the susceptibility to or prognosis of PBC.
The ACE I/D polymorphism is associated with nitric oxide metabolite and blood pressure levels in healthy Mexican men.
The ACE inhibitors enalapril and captopril modulate cytokine responses in Balb/c and C57Bl/6 normal mice and increase CD4(+)CD103(+)CD25(negative) splenic T cell numbers.
The advantages of angiotensin II antagonism.
The advantages of combination therapy on hypertension: development of immediate release perindopril-indapamide tablet and assessment of bioequivalence studies.
The African American Study of Kidney Disease and Hypertension (AASK) trial: what more have we learned?
The angiotensin I converting enzyme gene and predisposition to high blood pressure.
The angiotensin I-converting enzyme gene polymorphism: implication in hypertension and myocardial infarction.
The angiotensin II receptor antagonist losartan: a new advance in the treatment of hypertension.
The Angiotensin II Type 1(AT1) Receptor and Cardiac Hypertrophy: Did We Have It Wrong All Along?
The angiotensin receptor blocker, Losartan, inhibits mammary tumor development and progression to invasive carcinoma.
The angiotensin-converting enzyme 2 (ACE2) receptor in the prevention and treatment of COVID-19 are distinctly different paradigms.
The angiotensin-converting enzyme gene family: genomics and pharmacology.
The angiotensin-converting enzyme inhibitor, perindopril, prevents cardiac hypertrophy in low-renin hypertensive rats.
The angiotensin-converting enzyme insertion/deletion polymorphism is associated with phagocytic NADPH oxidase-dependent superoxide generation: potential implication in hypertension.
The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Heart Failure Validation Study: diagnosis and prognosis.
The antihypertensive effect of acute intracerebroventricular administration of captopril in Dahl salt-sensitive rats.
The antihypertensive effect of peptides: a novel alternative to drugs?
The antihypertensive efficacy and tolerability of a low dose combination of ramipril and felodipine ER in mild to moderate essential hypertension.
The Antihypertensive, Antimicrobial and Anticancer peptides from Arthrospira with therapeutic potential: A minireview.
The application of the Plackett-Burman design in investigating ACE inhibitory peptide-producing conditions and media for Lactobacillus bulgaricus LB6.
The association between previous statin use and development of atrial fibrillation in patients presenting with acute coronary syndrome.
The association between the insertion/deletion polymorphism of the angiotensin converting enzyme gene and hypertension, as well as environmental, biochemical and anthropometric factors.
The association of angiotensin converting enzyme (ACE) polymorphisms with sleep apnea and hypertension.
The association of COVID-19 occurrence and severity with the use of angiotensin converting enzyme inhibitors or angiotensin-II receptor blockers in patients with hypertension.
The association of hypertension with renin-angiotensin system gene polymorphisms in the Lebanese population.
The Association of Renin-Angiotensin-Aldosterone System Inhibitors With Outcomes Among a Predominantly Ethnic Minority Patient Population Hospitalized With COVID-19: The Bronx Experience.
The association of vitamin D deficiency and insufficiency with diabetic nephropathy: implications for health disparities.
The Avoid Stroke as Soon as Possible (ASAP) general practice stroke audit.
The benefits of angiotensin II receptor blockers in patients with renal insufficiency or failure.
The benefits of renin-angiotensin blockade in renal transplant recipients with biopsy-proven allograft nephropathy.
The blood vessel, linchpin of diabetic lesions.
The Captopril Prevention Project: a prospective intervention trial of angiotensin converting enzyme inhibition in the treatment of hypertension. The CAPPP Group.
The captopril test: an aid to investigation of hypertension.
The cardiac renin-angiotensin-aldosterone system and hypertensive cardiac hypertrophy.
The clinical use of angiotensin converting enzyme inhibitors in hypertension and cardiac failure.
The combination of verapamil and captopril in the treatment of essential hypertension.
The concept of cardioreparation: Part 2. Medical implications of cardioreparation.
The contribution of systemic hypertension to progression of chronic renal failure in the rat remnant kidney: effect of treatment with an angiotensin converting enzyme inhibitor or a calcium inhibitor.
The cost of new drugs in the treatment of hypertension--the Australian experience.
The D allele of the angiotensin-converting enzyme gene contributes towards blood LDL-cholesterol levels and the presence of hypertension.
The design and properties of N-carboxyalkyldipeptide inhibitors of angiotensin-converting enzyme.
The diabetogenic potential of thiazide-type diuretic and beta-blocker combinations in patients with hypertension.
The differences between ACE inhibitor-treated and calcium channel blocker-treated hypertensive patients.
The effect and mechanism of forsinopril on ventricular hypertrophy of SHR and left ventricular pressure overloading rat.
The effect duration of candesartan cilexetil once daily, in comparison with enalapril once daily, in patients with mild to moderate hypertension.
The effect of amlodipine and the combination of amlodipine and enalapril on the renin-angiotensin-aldosterone system in the dog.
The effect of angiotensin converting enzyme inhibition on effective renal plasma flow in patients with diffuse renal parenchymal diseases and hypertension.
The effect of antihypertensive therapy on the course of renal failure.
The effect of beta-blockade and angiotensin converting enzyme inhibition on kidney function in diabetic nephropathy.
The effect of captopril on severe renin-dependent hypertension of uraemics on regular dialysis treatment.
The effect of chronic angiotensin converting enzyme inhibition on circulating prolactin in systemic hypertension.
The effect of high dose losartan on erythropoietin resistance in patients undergoing haemodialysis.
The effect of hydrochlorothiazide on the enhanced coughing associated with treatment with enalapril.
The effect of indapamide versus hydrochlorothiazide on ventricular and arterial function in patients with hypertension and diabetes: results of a randomized trial.
The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension.
The effect of renin-angiotensin system blockers on spinal cord dysfunction and imaging features of spinal cord compression in patients with symptomatic cervical spondylosis.
The effect of the year angiotensin-converting enzyme inhibitors (ACE I) intake on circadian heart rate variability in patients with primary hypertension.
The effect of treatment based on a diuretic (indapamide) +/- ACE inhibitor (perindopril) on fractures in the Hypertension in the Very Elderly Trial (HYVET).
The effects of ACE inhibition on progression of atherosclerosis.
The effects of ACE inhibitors on exercise capacity in the treatment of congestive heart failure.
The effects of alpha 1-adrenoceptor blockade and angiotensin converting enzyme inhibition on central and brachial blood pressure and vascular reactivity: the doxazosin-ramipril study.
The effects of angiotensin II signaling blockade on platelet activity in subjects with hypertension.
The effects of antihypertensive medications on the physiological response to maximal exercise testing.
The effects of calcium channel blockers on nephropathy and pigment epithelium-derived factor in the treatment of hypertensive patients with type 2 diabetes mellitus.
The effects of genes implicated in cardiovascular disease on blood pressure response to treatment among treatment-naive hypertensive African Americans in the GenHAT study.
The effects of ramipril on glucose tolerance, insulin secretion, and insulin sensitivity in patients with hypertension.
The effects of two types of renin-angiotensin system inhibitors on the hypertension induced by new pressor protein associated with beta-factor XIIa in rats.
The efficacy of aliskiren, a direct renin inhibitor, in the treatment of hypertension.
The emerging role of ACE inhibitors in the treatment of cardiovascular disease.
The emerging role of angiotensin-converting enzyme-2 in the kidney.
The environmental and genetic evidence for the association of hyperlipidemia and hypertension.
The EPR effect for macromolecular drug delivery to solid tumors: Improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo.
The EUROPA trial: design, baseline demography and status of the substudies.
The European trial on reduction of cardiac events with perindopril in stable coronary artery disease (EUROPA).
The evolution of angiotensin blockade in the management of cardiovascular disease.
The Evolution of Renin-Angiotensin Blockade: Angiotensin-Converting Enzyme Inhibitors as the Starting Point.
The exercise-induced rise in atrial natriuretic factor is reduced by chronic angiotensin converting enzyme inhibition in patients with primary hypertension.
The expanding role of angiotensin converting enzyme inhibitors in the management of hypertension.
The French multicentre study of ramipril in ambulatory patients with mild-to-moderate hypertension.
The genetic basis of essential hypertension.
The genetics of hypertension.
The growth factor midkine regulates the renin-angiotensin system in mice.
The higher exercise intensity and the presence of allele I of ACE gene elicit a higher post-exercise blood pressure reduction and nitric oxide release in elderly women: an experimental study.
The history of inhibitors of angiotensin converting enzyme.
The impact of ACE inhibition on all-cause and cardiovascular mortality in contemporary hypertension trials: a review.
The impact of angiotensin converting enzyme inhibitors on the arterial wall.
The impact of angiotensin-converting enzyme inhibitors on managed care: economic, clinical, and humanistic outcomes.
The impact of angiotensin-converting-enzyme inhibitors versus angiotensin receptor blockers on 3-year clinical outcomes in patients with acute myocardial infarction without hypertension.
The Impact of Antihypertensive Medications on Bone Mineral Density and Fracture Risk.
The Impact of Lipoic Acid on Endothelial Function and Proteinuria in Quinapril-Treated Diabetic Patients With Stage I Hypertension: Results From the QUALITY Study.
The impact of renin-angiotensin system polymorphisms on physiological and pathophysiological processes in humans.
The impact of the 'Better Care Better Value' prescribing policy on the utilisation of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for treating hypertension in the UK primary care setting: longitudinal quasi-experimental design.
The impact of the Canadian Hypertension Education Program on antihypertensive prescribing trends.
The Impact of the Renin-Angiotensin-Aldosterone System on Inflammation, Coagulation, and Atherothrombotic Complications, and to Aggravated COVID-19.
The importance of left ventricular hypertrophy in human hypertension.
The influence of long-term ACE inhibitor treatment on circulatory responses to stress in human hypertension.
The Influence of Microneedles on the Percutaneous Penetration of Selected Antihypertensive Agents: Diltiazem Hydrochloride and Perindopril Erbumine.
The influence of national guidelines on antihypertensive prescribing patterns.
The influencing factors for clopidogrel-mediated platelet inhibition are assay-dependent.
The integration of medical management with recovery.
The interaction between the endocannabinoid system and the renin angiotensin system and its potential implication for COVID-19 infection.
The Interaction of Apolipoprotein E and Angiotensin I-Converting Enzyme Dna Polymorphisms with Hypertension on Early Ischemic Stroke Risk.
The intrarenal generation of angiotensin II is required for experimental hypertension.
The kallikrein-kinin system, angiotensin converting enzyme inhibitors and insulin sensitivity.
The less familiar side of heart failure: symptomatic diastolic dysfunction.
The management of acute myocardial infarction.
The natural history of renal artery stenosis: who should be evaluated for suspected ischemic nephropathy?
The necessity and effectiveness of mineralocorticoid receptor antagonist in the treatment of diabetic nephropathy.
The need for evidence in hypertension management: historical perspective.
The Ontario printed educational message (OPEM) trial to narrow the evidence-practice gap with respect to prescribing practices of general and family physicians: a cluster randomized controlled trial, targeting the care of individuals with diabetes and hypertension in Ontario, Canada.
The outcome of STOP-Hypertension-2 in relation to the 1999 WHO/ISH hypertension guidelines.
The Outcome of STOP-Hypertension-2 in Relation to the 1999 WHO/ISH Hypertension Guidelines.
The PHARAO study: prevention of hypertension with the angiotensin-converting enzyme inhibitor ramipril in patients with high-normal blood pressure: a prospective, randomized, controlled prevention trial of the German Hypertension League.
The pharmacological basis for the combination of calcium channel antagonists and angiotensin converting enzyme inhibitors in the treatment of hypertension.
The potential of cod hydrolyzate to inhibit blood pressure in spontaneously hypertensive rats.
The potential of stimulating nitric oxide formation in the treatment of hypertension.
The potential role of antisense oligodeoxynucleotide therapy for cardiovascular disease.
The practical aspects of combination therapy with angiotensin receptor blockers and angiotensin-converting enzyme inhibitors.
The prescription of best medical therapy following infrainguinal bypass grafting in Australia and New Zealand: a multicentre Australasian audit.
The problem of hypertension in the elderly.
The Problem of Hypertension in the Elderly.
The Prognostic Value of High-Sensitive Troponin I in Stable Coronary Artery Disease Depends on Age and Other Clinical Variables.
The rationale and design of the AASK cohort study.
The rationale and design of the PERindopril GENEtic association study (PERGENE): a pharmacogenetic analysis of angiotensin-converting enzyme inhibitor therapy in patients with stable coronary artery disease.
The relation of angiotensin-converting enzyme to the pregnancy-induced hypertension-preeclampsia syndrome.
The relationship between apoptosis and spontaneous hypertension.
The release of the substrate for xanthine oxidase in hypertensive patients was suppressed by angiotensin converting enzyme inhibitors and alpha1-blockers.
The renal antifibrotic effects of angiotensin-converting enzyme inhibition involve bradykinin B2 receptor activation in angiotensin II-dependent hypertension.
The renal antihypertensive effect of angiotensin I converting enzyme inhibitors.
The renin-angiotensin system and its receptors.
The renin-angiotensin system and ramipril, a new converting enzyme inhibitor.
The renin-angiotensin system and vascular hypertrophy.
The renin-angiotensin system in cardiovascular autonomic control: recent developments and clinical implications.
The renin-angiotensin system in essential hypertension: associations with cardiovascular risk.
The renin-angiotensin system: a possible contributor to migraine pathogenesis and prophylaxis.
The Renin-Angiotensin-Aldosterone System: Approaches to Guide Angiotensin-Converting Enzyme Inhibition in Patients with Coronary Artery Disease.
The renin-angiotensin-aldosterone system: cardiorenal effects and implications for renal and cardiovascular disease states.
The response to the first dose of an angiotensin converting enzyme inhibitor in uncomplicated hypertension--a placebo controlled study utilising ambulatory blood pressure recording.
The retrospective analysis of 343 Czech patients with IgA nephropathy--one centre experience.
The Risk of Hypertension after Preoperative Discontinuation of Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Antagonists in Ambulatory and Same-Day Admission Patients.
The role of angiotensin II receptor antagonists in the management of diabetes.
The role of angiotensin II receptor blockers in preventing the progression of renal disease in patients with type 2 diabetes.
The role of angiotensin-converting enzyme inhibitors in the treatment of hypertension.
The role of genetic variants in angiotensin I converting enzyme, angiotensinogen and the angiotensin II type-1 receptor in the pathophysiology of heart muscle disease.
The role of percutaneous revascularization for renal artery stenosis.
The role of renin inhibition in treating the hypertensive patient with diabetes: a summary of preclinical and clinical evidence.
The role of the renin-angiotensin system blocking in the management of atrial fibrillation.
The safety and acceptability of perindopril.
The safety and tolerability of quinapril.
The safety of ACE inhibitors for the treatment of hypertension and congestive heart failure.
The safety of angiotensin-converting enzyme (ACE) inhibitors in moderate hypertension.
The safety profile of quinapril: is there a difference among ACE inhibitors?
The SARS-CoV-2 receptor, ACE-2, is expressed on many different cell types: implications for ACE-inhibitor- and angiotensin II receptor blocker-based cardiovascular therapies.
The serum protease network - one key to understand Complex Regional Pain Syndrome pathophysiology.
The structure of testis angiotensin-converting enzyme in complex with the C domain-specific inhibitor RXPA380.
The treatment of idiopathic membranous nephropathy.
The treatment of mild hypertension study. A randomized, placebo-controlled trial of a nutritional-hygienic regimen along with various drug monotherapies. The Treatment of Mild Hypertension Research Group.
The two fACEs of the tissue renin-angiotensin systems: implication in cardiovascular diseases.
The use of angiotensin converting enzyme inhibitors in elderly patients with hypertension.
The use of angiotensin-converting enzyme inhibitor in the diagnosis and treatment of hypertension.
The use of benazepril in hypertensive patients age 55 and over.
The use of calcium antagonists in the treatment of hypertensive persons with kidney disease.
The use of captopril to control hypertension in post-transplant renal artery stenosis.
The use of microcalorimetry and HPLC for the determination of degradation kinetics and thermodynamic parameters of Perindopril Erbumine in aqueous solutions.
The use of the angiotensin-converting enzyme (ACE) inhibitor enalapril in the treatment of mild to moderate hypertension in the elderly.
The vascular biology of hypertension and atherosclerosis and intervention with calcium antagonists and angiotensin-converting enzyme inhibitors.
The vascular tissue angiotensin I-converting enzyme activity and aortic elastin content in stroke-prone spontaneously hypertensive rats fed fish diet.
Therapeutic advantage of angiotensin-converting enzyme inhibitors in patients with proteinuric chronic kidney disease.
Therapeutic approach of patients with IgA nephropathy.
Therapeutic assessment of urapidil or angiotensin-converting enzyme inhibition in systemic hypertension.
Therapeutic controversies in hypertension management: angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor blockers for diabetic nephropathy? A case for ACE inhibitors.
Therapeutic controversies in hypertension management: angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor blockers in diabetic nephropathy? ACE inhibitors.
Therapeutic experience with cilazapril.
Therapeutic implications of hypertension-induced glomerular injury. Comparison of enalapril and a combination of hydralazine, reserpine, and hydrochlorothiazide in an experimental model.
Therapeutic implications of recent megatrials in hypertension: in favor of new drugs.
Therapeutic investigations of novel indoxyl-based indolines: A drug target validation and Structure-Activity Relationship of angiotensin-converting enzyme inhibitors with cardiovascular regulation and thrombolytic potential.
Therapeutic perspective: starting an angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker in a diabetic patient.
Therapeutic potential of quercetin as a cardiovascular agent.
Therapeutic role of angiotensin II receptor blockers in the treatment of heart failure.
Thiazide and loop diuretics.
Thiazide diuretics: first-line therapy for hypertension.
Thiazide-like/calcium channel blocker agents: a major combination for hypertension management.
Thinking intelligently about therapy of atherosclerosis.
Three-Year Safety and Effectiveness of Fixed-Dose Losartan/Hydrochlorothiazide Combination Therapy in Japanese Patients with Hypertension under Clinical Setting (PALM-1 Extension Study).
Thrombosis and occlusion of vascular access in hemodialyzed patients.
Tissue angiotensin II generating system by angiotensin-converting enzyme and chymase.
Tissue angiotensin II system in the human heart.
Tissue-specific upregulation of Angiotensin-converting enzyme 1 in spontaneously hypertensive rats through histone code modifications.
Tolerance and safety of perindopril.
Total arterial compliance in ambulatory hypertension during selective beta1-adrenergic receptor blockade and angiotensin-converting enzyme inhibition.
Towards 2001: will ACE inhibitors have a role in atherosclerosis treatment?
Toxicodynamic analysis of cough and inflammatory reactions by angiotensin-converting enzyme inhibitors in guinea pig.
Toxicodynamic analysis of inflammatory reactions by an angiotensin converting enzyme inhibitor (lisinopril) in guinea-pig skin.
Traditional first-line therapy. Overview of medical benefits and side effects.
Trandolapril does not improve insulin sensitivity in patients with hypertension and type 2 diabetes: a double-blind, placebo-controlled crossover trial.
Trandolapril in hypertension: overview of a new angiotensin-converting enzyme inhibitor.
Trandolapril restores circadian blood pressure variation in normoalbuminuric normotensive Type 1 diabetic patients.
Trandolapril. An update of its pharmacology and therapeutic use in cardiovascular disorders.
Trandolapril: a newer angiotensin-converting enzyme inhibitor.
Transcatheter closure of atrial septal communication: Impact on quality of life in mid-term follow-up.
Transdermal delivery of Angiotensin Converting Enzyme inhibitors.
Transdermal delivery of angiotensin II receptor blockers (ARBs), angiotensin-converting enzyme inhibitors (ACEIs) and others for management of hypertension.
Transforming growth factor-beta1 and tumor growth factor-beta-inducible gene-H3 in nonrenal transplant cyclosporine nephropathy.
Transient anuria following administration of angiotensin I-converting enzyme inhibitor (SQ 14225) in a patient with renal artery stenosis of the solitary kidney successfully treated with renal autotransplantation.
Transient Exposure of Enalapril Normalizes Prenatal Programming of Hypertension and Urinary Angiotensinogen Excretion.
Translating data on antihypertensive drugs into clinical practice.
Transplant Coronary Vasculopathy.
Treating anesthesia-induced hypotension by angiotensin II in patients chronically treated with angiotensin-converting enzyme inhibitors.
Treating hypertension and prehypertension in older people: when, whom and how.
Treating hypertension in the diabetic patient: therapeutic goals and the role of calcium channel blockers.
Treatment after myocardial infarction.
Treatment and control of hypertension as preventive therapy.
Treatment at discharge after myocardial infarction in 2,102 patients. The PRIMA study. Prise en charge de l'Infarctus du Myocarde Aigu.
Treatment modalities for hypertensive patients with intracranial pathology: options and risks.
Treatment of diabetic patients with hypertension.
Treatment of diabetic sensory polyneuropathy.
Treatment of diastolic dysfunction in hypertension.
Treatment of drug-resistant hypertension with minoxidil or angiotensin-converting enzyme inhibitor: blood pressure, renin, aldosterone, and electrolyte responses.
Treatment of essential hypertension does not normalize capillary rarefaction.
Treatment of experimental myocarditis via modulation of the renin-angiotensin system.
Treatment of heart failure in older persons. Dilemmas with coexisting conditions: diabetes mellitus, chronic obstructive pulmonary disease, and arthritis.
Treatment of Heart Failure with Abnormal Left Ventricular Systolic Function in Older Adults.
Treatment of heart failure with normal ejection fraction.
Treatment of hypertension and renal injury induced by the angiogenesis inhibitor sunitinib: preclinical study.
Treatment of hypertension in black patients with angiotensin-converting enzyme inhibitors.
Treatment of Hypertension in Coarctation of the Aorta.
Treatment of hypertension in individuals with the cardiometabolic syndrome: role of an angiotensin II receptor blocker, telmisartan.
Treatment of hypertension in type 2 diabetes mellitus: blood pressure goals, choice of agents, and setting priorities in diabetes care.
Treatment of hypertension with an angiotensin II-receptor antagonist compared with an angiotensin-converting enzyme inhibitor: a review of clinical studies of telmisartan and enalapril.
Treatment of hypertension with angiotensin converting enzyme inhibitors.
Treatment of hypertension: the place of angiotensin-converting enzyme inhibitors in the nineties.
Treatment of metabolic syndrome.
Treatment of neonatal renovascular hypertension with intravenous enalapril.
Treatment of patients with severe hypertension by inhibition of angiotensin-converting enzyme.
Treatment of pediatric hypertension.
Treatment of severe hypertension in a 14-year-old child: Successful blood pressure control with additive administration of captopril, an angiotensin-converting enzyme inhibitor, in a patient with bilateral renovascular hypertension.
Treatment of stable angina.
Treatment options for hypertension in high-risk patients.
Treatment strategies to minimize or prevent chronic allograft dysfunction in pediatric renal transplant recipients: an overview.
Trend in the clinical profile of type 2 diabetes in India - Study from a diabetes care centre in South India.
Trends in Angiotensin-Converting Enzyme Inhibitor and Angiotensin II Receptor Blocker Use among Those with Impaired Kidney Function in the United States.
Trends in pharmacologic management of hypertension in the United States.
Trends in Quality of Care for Patients with CKD in the United States.
Trials investigating the anti-atherosclerotic effects of antihypertensive drugs.
Triple Vasopeptidase Inhibition of Angiotensinconverting Enzyme/Neutral Endopeptidase/Endothelinconverting Enzyme Activities on the Hemodynamic Profile of Chronically Instrumented Unrestrained Conscious Spontaneously Hypertensive Rats.
Trough:peak ratio of the blood pressure response to angiotensin converting enzyme inhibitors.
Twenty years after ACEIs and ARBs: emerging treatment strategies for diabetic nephropathy.
Two Novel Bioactive Peptides from Antarctic Krill with Dual Angiotensin Converting Enzyme and Dipeptidyl Peptidase IV Inhibitory Activities.
Type 2 diabetes mellitus with hypertension at primary healthcare level in Malaysia: are they managed according to guidelines?
Type 2 diabetes--the pharmacotherapy of glycaemic control and risk factor modification.
Uncoupled cardiac nitric oxide synthase mediates diastolic dysfunction.
Under pressure: future prospects in hypertension management. Interview by Laura Dormer.
Understanding structure-based dynamic interactions of antihypertensive peptides extracted from food sources.
Understanding the genetic basis for adverse drug effects: the calcineurin inhibitors.
Understanding the role of ACE-2 receptor in pathogenesis of COVID-19 disease: a potential approach for therapeutic intervention.
Underuse of ACE inhibitors and angiotensin II receptor blockers among patients with diabetic nephropathy in Taiwan.
Underuse of ACE inhibitors and angiotensin II receptor blockers in elderly patients with diabetes.
Unexplained systemic hypertension after closure of ductus arteriosus.
University discoveries and intellectual property rights: from Bothrops jararaca bradykinin potentiating peptides to angiotensin converting enzyme inhibitors.
University of Miami Division of Clinical Pharmacology Therapeutic Rounds: ischemic renal disease.
University of Miami Division of Clinical Pharmacology Therapeutic Rounds: managing hypertension in patients with kidney disease-implications for preservation of renal function.
Unsolved problems in treating hypertension: rationale for new approaches.
Update of treatment of heart failure with reduction of left ventricular ejection fraction.
Update on the drug treatment of hypertension in patients with cardiovascular disease.
Updated Report on Comparative Effectiveness of ACE inhibitors, ARBs, and Direct Renin Inhibitors for Patients with Essential Hypertension: Much More Data, Little New Information.
Upregulation of Brain Renin Angiotensin System by 27-Hydroxycholesterol in Alzheimer's Disease.
Urinary proteome in a snapshot: normal urine and glomerulonephritis.
Urocortin 2 in patients with hypertension treated with angiotensin converting enzyme inhibitors or angiotensin receptor blockers.
Usage of Angiotensin-Converting Enzyme Inhibitor or Angiotensin II Receptor Blocker in Hypertension Intracerebral Hemorrhage.
Use of angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker therapy to reduce cardiovascular events in high-risk patients: Part 1.
Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers During the COVID-19 Pandemic: A Modeling Analysis.
Use of antihypertensive drug therapy in older persons in an academic nursing home.
Use of centrally acting sympatholytic agents in the management of hypertension.
Use of digoxin, diuretics, beta blockers, angiotensin-converting enzyme inhibitors, and calcium channel blockers in older patients in an academic hospital-based geriatrics practice.
Use of direct renin inhibitor in an HIV positive subject.
Use of lipid-lowering drugs and blood pressure control in patients with arterial hypertension.
Use of medications to reduce cardiovascular risk among individuals with psychotic disorders and Type 2 diabetes.
Use of quinapril in the elderly patient.
Use of the factorial design and quadratic response surface models to evaluate the fosinopril and hydrochlorothiazide combination therapy in hypertension.
Usefulness of patch tests for diagnosing selective allergy to captopril.
Usefulness of satisfactory control of low-density lipoprotein cholesterol to predict left ventricular remodeling after a first ST-elevation myocardial infarction successfully reperfused.
Using ACE inhibitors appropriately.
Using angiotensin converting enzyme inhibitors in African-American hypertensives: a new approach to treating hypertension and preventing target-organ damage.
Using Mendelian randomization study to assess the renal effects of antihypertensive drugs.
Valsartan and the kidney: review of preclinical and clinical data.
Valsartan chronotherapy reverts the non-dipper pattern and improves blood pressure control through mediation of circadian rhythms of the renin-angiotensin system in spontaneous hypertension rats.
Valsartan versus lisinopril or extended-release metoprolol in preventing cardiovascular and renal events in patients with hypertension.
Valsartan: new preparation. Just a second-line antihypertensive drug.
Variability in Atherosclerotic Disease Progression within the Infrainguinal Arterial Circulation is Dependent on Both Patient and Anatomical Factors.
Variation at the angiotensin-converting enzyme gene and angiotensinogen gene loci in relation to blood pressure.
Various approaches to blockade of the renin-angiotensin system: persistent renin response.
Vascular conversion of angiotensin I in stroke-prone spontaneously hypertensive and Wistar-Kyoto rats.
Vascular effects of egg white-derived peptides in resistance arteries from rats. Structure-activity relationships
Vascular effects of egg white-derived peptides in resistance arteries from rats. Structure-activity relationships.
Vascular effects of perindopril: from experimental to clinical investigation.
Vascular hypertrophy and albumin permeability in a rat model combining hypertension and diabetes mellitus. Effects of calcium antagonism, angiotensin converting enzyme inhibition, and angiotensin II-AT1-receptor blockade.
Vascular hypertrophy in hypertension: role of the renin-angiotensin system.
Vascular renin-angiotensin system and vascular protection.
Vascular renin-angiotensin system in hypertension. New insights into the mechanism of action of angiotensin converting enzyme inhibitors.
Vascular renin-angiotensin system in two-kidney, one clip hypertensive rats.
Vascular smooth muscle polyploidy and cardiac hypertrophy in genetic hypertension.
Vascular surgery and arterial hypertension.
Vascular wall thickness in hypertension: the Perindopril Regression of Vascular Thickening European Community Trial: PROTECT.
Vasculoprotective and cardioprotective mechanisms of angiotensin-converting enzyme inhibition: the homeostatic balance between angiotensin II and nitric oxide.
Vasoactive peptides and hypertension: role of angiotensin converting enzyme.
Vasodilators and inhibitors of angiotensin converting enzyme in resistant hypertension.
Vasomotor responses in cyclosporin A-treated rats after chronic angiotensin blockade.
Vasopeptidase inhibition for blood pressure control: emerging experience.
Vasopeptidase inhibition normalizes blood pressure and restores endothelial function in renovascular hypertension.
Vasopeptidase inhibition reverses myocardial vasoactive intestinal peptide depletion and decreases fibrosis in salt sensitive hypertension.
Vasopeptidase inhibition: effective blood pressure control for vascular protection.
Vasopeptidase inhibitors: will they have a role in clinical practice?
Vesico-ureteric reflux: occurrence and long-term risks.
Voltage-programming-based capillary gel electrophoresis for the fast detection of angiotensin-converting enzyme insertion/deletion polymorphism with high sensitivity.
Volume of white matter hyperintensities in healthy adults: Contribution of age, vascular risk factors, and inflammation-related genetic variants.
Waist circumference and the metabolic syndrome predict the development of elevated albuminuria in non-diabetic subjects: the DESIR Study.
Warfarin Use and Prevalence of Coronary Artery Calcification Assessed by Multislice Computed Tomography.
Warfarin use and the risk of valvular calcification.
Weight loss, muscle strength, and angiotensin-converting enzyme inhibitors in older adults with congestive heart failure or hypertension.
What differentiates primary care physicians who predominantly prescribe diuretics for treating mild to moderate hypertension from those who do not? A comparative qualitative study.
What do we actually know about the relationship between arterial hypertension and atrial fibrillation?
What every doctor needs to know about chronic kidney disease.
What have we learned from clinical trials on prevention?
What is the impact of PRIME on real-life diabetic nephropathy?
What to treat? The structural basis for renal and vascular complications and hypertension, and the role of angiotensin converting enzyme inhibition. Symposium, 26th meeting of the European Association for the Study of Diabetes. Dublin, Ireland, 10 September 1991.
When antihypertensive monotherapy fails: fixed-dose combination therapy.
Whether vitamin D3 is effective in reducing proteinuria in type 2 diabetic patients?
Which drug should be used to treat patients with uncomplicated essential hypertension?
Which is more important for the efficiency of hypertension treatment: hypertension stage, type of drug or therapeutic compliance?
Who should be treated with angiotensin-converting enzyme inhibitors after myocardial infarction?
Why angiotensin converting enzyme inhibitors and angiotensin II receptor blockers are not prescribed in the management of hypertension among hemodialysis patients in India.
Why are physicians not prescribing diuretics more frequently in the management of hypertension?
Why blockade of the renin-angiotensin system reduces the incidence of new-onset diabetes.
Why is blood pressure so hard to control in patients with type 2 diabetes?
Why lowering blood pressure is not enough: the hypertension syndrome and the clinical context of cardiovascular risk reduction.
Why patients with diabetes, hypertension and/or proteinuria are not on angiotensin converting enzyme inhibitors.
Why renin inhibitors?
Why use angiotensin converting enzyme inhibitors to lower blood pressure?
Winged bean [Psophorcarpus tetragonolobus (L.) DC] seeds as an underutilised plant source of bifunctional proteolysate and biopeptides.
Wound healing: captopril, an angiogenesis inhibitor, and Staphylococcus aureus peptidoglycan.
YIA 03-04 EPIGENETIC CHANGES AFTER ACUTE TREATMENT WITH ACUTE ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACEi).
Young SHR express increased type 1 angiotensin II receptors in renal proximal tubule.
Zinc, angiotensin I-converting enzyme and hypertension.
Zofenopril exerts a cardiovascular protective effect on rats infused with angiotensin II beyond angiotensin-converting enzyme inhibition.
Zonal distribution and regulation of adrenal renin in a transgenic model of hypertension in the rat.
[A case of an elderly type 2 diabetes who had severe diabetic nephropathy without retinopathy]
[A case of angioedema with dysarthria mimicking transient ischemic attack].
[A case of renal failure due to primary cholesterol atheroembolism]
[A case with juvenile rheumatoid arthritis who developed cerebral vasculitis and venovascular hypertension]
[A prospective study on the cough mechanism induced by angiotensin-converting enzyme inhibitors in patients with hypertension]
[Absence of an association of the D allele of the ACE gene with arterial pressure in mild-moderate essential arterial hypertension]
[ACE inhibitor or ATII receptor blocker in heart failure and myocardial infarction?]
[ACE inhibitor therapy of hemodialyzed patients]
[Activation of bradykinin formation cascade on receiving autologous blood transfusion through a white cell-reduction filter in a patient treated with an ACE inhibitor]
[Activity of angiotensin-converting enzyme in serum and its association with left ventricular mass and blood pressure level in patients with essential hypertension]
[Activity of serum angiotensin converting enzyme in pregnancy-induced hypertension]
[Acute and reversible interstitial granulomatous nephropathy after treatment with captopril]
[Acute inhibition of angiotensin-converting enzyme by captopril. Hemodynamic and biochemical aspects in normotension and essential hypertension]
[Acute pharmacological block of the renin-angiotensin system and the recovery of intrarenal hemodynamics in patients with chronic glomerulonephritis]
[Acute renal insufficiency following inhibition of the angiotensin conversion enzyme by various agents]
[Acute renal insufficiency secondary to the use of angiotensin converting enzyme inhibitors in 2 patients without renal artery stenosis]
[Advantages of long-term controlled stepwise therapy of arterial hypertension with the use of angiotensin converting enzyme inhibitor spirapril]
[Adverse effects of new biological therapies for non-small-cell bronchial cancer.]
[Ambulatory continuous 24-hour blood pressure monitoring in the diagnosis and therapy of arterial hypertension and modification by the antihypertensive agents enalapril, metoprolol, mepindolol and nitrendipine]
[An attempt to use enalapril in arterial hypertension in patients with juvenile obesity]
[Analysis of the Cochrane Review: Angiotensin Converging Enzyme Inhibitors Versus Angiotensin Receptor Blockers for Primary Hypertension. Cochrane Database Syst Rev. 2014,8: CD009096].
[Angioedema and angiotensin converting enzyme inhibitors: a report of 19 cases]
[Angioedema caused by angiotensin-converting enzyme inhibitors]
[Angioedema due to medication treatment]
[Angioneurotic edema in relation to therapeutic use of angiotensin-converting enzyme inhibitor]
[Angiotensin converting enzyme and Alzheimer's disease].
[Angiotensin converting enzyme inhibitor moexipril in the treatment of arterial hypertension. Possibilities of moexipril in the treatment of postmenopausal women]
[Angiotensin converting enzyme inhibitors and vascular remodelling in arterial hypertension]
[Angiotensin converting enzyme inhibitors for hypertension]
[Angiotensin converting enzyme inhibitors in arterial hypertension and cardiac failure. The question of the dose]
[Angiotensin converting enzyme inhibitors in arterial hypertension]
[Angiotensin converting enzyme inhibitors in the treatment of arterial hypertension]
[Angiotensin converting enzyme inhibitors increase insulin sensitivity in offspring of families with hypertension even after active interventions. Results of a clamp study]
[Angiotensin converting enzyme inhibitors. Increasing importance in the treatment of hypertension]
[Angiotensin converting enzyme inhibitors: drug of first or second choice in hypertension in advanced age]
[Angiotensin I converting enzyme inhibitor in the treatment of hypertension and myocardial insufficiency]
[Angiotensin II AT1 receptor antagonists: clinical development and future perspectives]
[Angiotensin-converting enzyme activity of the aorta in experimental hypertensive rats]
[Angiotensin-converting enzyme inhibition and cardiovascular prevention: more than twenty years of clinical success]
[Angiotensin-converting enzyme inhibition--new methods in the treatment of arterial hypertension and heart failure]
[Angiotensin-converting enzyme inhibition: a pathophysiologically based concept for the therapy of hypertension and heart failure]
[Angiotensin-converting enzyme inhibition: direct and indirect mechanisms]
[Angiotensin-converting enzyme inhibitors and/or angiotensin II receptors antagonists in the treatment of arterial hypertension]
[Angiotensin-converting enzyme inhibitors in the diagnosis and treatment of kidney diseases]
[Angiotensin-converting enzyme inhibitors in the treatment of arterial hypertension]
[Angiotensin-converting enzyme inhibitors in the treatment of hypertension in Air Force personnel]
[Angiotensin-converting enzyme inhibitors in the treatment of hypertension. Part 2. Emphasis on cilazapril]
[Angiotensin-converting enzyme inhibitors in treatment of hypertension. Part 1. Emphasis on cilazapril]
[Angiotensin-converting enzyme inhibitors. Familiar drugs--new indications]
[Angiotensin-converting enzyme inhibitors: effects on renal physiology and applications in hypertension and renal disease]
[Angiotensin-converting enzyme inhibitors: recent therapeutic aspect]
[Angiotensin-converting-enzyme inhibition in arterial hypertension]
[Angiotensinogen and angiotensin-I converting enzyme gene variations in Chinese pregnancy induced hypertension]
[Antihypertensive drugs in 2010: old and new agents].
[Antihypertensive drugs prescribed to patients before their first consultation in a hypertension unit: comparison between 2001 and 2006]
[Antihypertensive effect of repeated oral administration of MK-0521 in 2-kidney Goldblatt hypertensive dogs]
[Antihypertensive pharmacotherapy of patients in primary care with either a statutory or private health insurance]
[Antihypertensive therapy for refractory morning hypertension in patients on peritoneal dialysis]
[Approach to peripheral arterial disease in the elderly].
[Are angiotensin-converting enzyme inhibitors the treatment of choice for arterial hypertension in patients with arteritis?]
[Arterial hypertension in glomerulonephritis]
[Arterial hypertension in periarteritis nodosa. 37 case reports]
[Arterial hypertension in the elderly. Experience at a hospital service]
[Arterial hypertension, renal function and angiotensin-converting enzyme inhibition]
[Arterial hypotension in myocardial revascularization surgery: influence of angiotensin-converting enzyme inhibitors.]
[Arterial pressure after transplantation]
[Assessment of effects of angiotensin converting enzyme inhibitor perindopril on function of endothelium of arterial vessels in patients with ischemic heart disease and hypertension]
[Assessment of the effect of angiotensin converting enzyme inhibitor moexipril on the functional state of vascular wall in patients with I - III degree arterial hypertension]
[Association between visual improvement after photocoagulation and the use of angiotensin converting enzyme inhibitors in diabetic macular oedema].
[Association of alpha-adducin and angiotensin converting enzyme gene polymorphisms with salt-sensitive hypertension and early renal injury]
[AT1 angiotensin receptor inhibition as a new therapeutic possibility]
[Atherosclerosis regression and plaque stabilization: comparison of therapeutic targets].
[Beta-blockers and arterial hypertension]
[Blockers of renin-angiotensin-aldosterone system in the treatment of arterial hypertension: classics versus the modern].
[Blood pressure control and diabetic retinopathy]
[Brain angiotensin-converting enzyme activity in experimental hypertension in the rats]
[Calcium channel blockers and angiotensin converting enzyme inhibitors in the treatment of high blood pressure]
[Calcium entry blockers and angiotensin converting enzyme antagonists in the treatment of high blood pressure]
[Captopril and other angiotensin converting enzyme inhibitors in the treatment of hypertension]
[Captopril inhibits angiotensin converting enzyme. New principles for therapy in hypertension and heart failure]
[Captopril use in pregnancy and its effects on the fetus and the newborn: case report]
[Captopril-induced toxic hepatitis]
[Cardiovascular complications in patients with chronic renal insufficiency and chronic kidney failure]
[Cardiovascular pharmacology (IX). Angiotensin-converting enzyme inhibitors in hypertension and heart failure]
[Cardiovascular risk in polycystic kidney disease].
[Changes in humoral pressor and depressor factors in essential hypertension during lisinopril therapy]
[Characteristics of hemodynamics and metabolism and structural polymorphisms of angiotensin converting enzyme and angiotensin II type I receptors genes in women of childbearing]
[Choice of an Optimal Blocker of the Renin-Angiotensin-Aldosterone System in Patients With Concomitant Arterial Hypertension and Chronic Obstructive Pulmonary Disease].
[Chronic treatment of hypertension by an inhibitor of angiotensin converting enzyme]
[Clinical aspects of use of angiotensin-converting enzyme inhibitors in patients with arterial hypertension]
[Clinical effectiveness of and tolerance to ramipril in the treatment of essential arterial hypertension phase 1 and 2. Results of a multicenter study]
[Clinical Efficacy of Combination Therapy With Trimetazidine and Angiotensin Converting Enzyme Inhibitors in Patients With Hypertension and Ischemic Heart Disease Associated With Type II Diabetes]
[Clinical evaluation of tonsillectomy with modified high-dose intravenous methylprednisolone therapy in patients with IgA nephropathy]
[Clinical pharmacology of angiotensin II antagonists]
[Clinical sequelae of tissue angiotensin converting enzyme inhibition: practicability of use in ischemic heart disease]
[Clinical significance of serum angiotensin I-converting enzyme in essential hypertension]
[Clinical study of serum angiotensin converting enzyme in hypertension]
[Clinical study of the month. The CALM study assessing the combination of an angiotensin-converting enzyme inhibitor and an angiotensin II receptor antagonist in the treatment of diabetic nephropathy]
[Clinico-economical efficacy of angiotensin converting enzyme inhibitors in patients with arterial hypertension and ischemic heart disease]
[Clinico-genetic aspects of the hypotensive response and regression of left ventricular hypertrophy in arterial hypertension patients]
[Combination therapy of arterial hypertension combined with liver pathology. The place of angiotensin converting enzyme inhibitors]
[Combined captopril and labetalol treatment of malignant arterial hypertension (author's transl)]
[Comparative assessment of a calcium antagonist with controlled release of nifedipine and enalapril in arterial hypertension in subjects older than 60 years]
[Comparative assessment of antihypertensive effects of angiotensin-converting enzyme inhibitors ramipril and captopril in patients with hypertension in ambulatory settings]
[Comparative assessment of efficacy of hypotensive drugs from various groups and angiotensin converting enzyme inhibitors in patients with hypothyroidism and hypertension]
[Comparative eficacy of antihypertensive therapy in patients with arterial hypertension and various sensitivity to salt].
[Comparison between the effects of angiotensin-converting enzyme inhibitors and angiotensin II antagonists]
[Comparison of angiotensin receptor antagonists and angiotensin converting enzyme inhibitors in arterial hypertension]
[Comparison of the cardiac, renal and endocrine effects of converting enzyme inhibition with those of a classical triple therapy in experimental renal hypertension]
[Comparison of the efficacy of captopril and enalapril in single doses in the treatment of arterial hypertension. Evaluation by means of non-invasive ambulatory monitoring]
[Compliance with the 2002 consensus document of the Spanish Society of Nephrology for the control of diabetic nephropathy in Catalonia (ECCODIAB).]
[Conversion enzyme inhibitors against the progression of renal and vascular diseases: yes but again]
[Converting enzyme inhibitors and acute renal insufficiency--precautions to be taken]
[Converting enzyme inhibitors in acute myocardial infarct and heart failure]
[Converting enzyme inhibitors in the diagnosis of secondary arterial hypertension --focus on the captopril test]
[Converting enzyme inhibitors in the treatment of arterial hypertension]
[Converting enzyme inhibitors or AT1 receptor blockers]
[Cross-sensitivity between angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonist]
[Current status of blood pressure control in patients with coronary heart disease].
[Current treatment regimen in essential arterial hypertension]
[Daily blood pressure profiles and endothelial functions during long-term treatment of arterial hypertension with angiotensin-converting enzyme inhibitors]
[Deletion polymorphism of the angiotensin I-converting enzyme gene associates with increased risk for ischemic heart diseases in the Japanese]
[Detection of primary aldosteronism using the captopril test]
[Diagnostic and therapeutic criteria of arterial hypertension in childhood]
[Diuretics as a problem-Pharmacokinetics, pharmacodynamics, use in edema or hypertension].
[Do generic drugs help control expenditure on hypertension? Apropos of a case]
[Dry cough in the elderly patients treated with angiotensin converting enzyme inhibitor]
[Dynamics of left ventricular longitudinal function in patients with arterial hypertension during therapy with angiotensin converting enzyme inhibitor moexipril]
[Early detection and control of risk factors in diabetic nephropathy]
[Early prevention of experimental left ventricular hypertrophy in experimental hypertension and angiotensin II levels]
[Effect of an angiotensin-converting-enzyme inhibitor on the plasma concentration of cytokines and vasoactive molecules in patients with coronary heart disease and hypertension].
[Effect of angiotensin converting enzyme inhibitor on arterial wall thickening in coarctation hypertension]
[Effect of anti-hypertensive therapy with irbesartan on the absolute cardiovascular risk]
[Effect of captopril on glutathione level in the liver and paracetamol-induced liver damage in rats]
[Effect of Chinese herbal therapy on T-lymphocytes of IgA nephropathy patients: a clinical observation].
[Effect of enalapril, lisinopril, and amlodipine on the course of chronic gastrititis in patients with arterial hypertension]
[Effect of fosinopril on some parameters of endothelial function in patients with metabolic syndrome]
[Effect of inhibition of angiotensin converting enzyme on hypertension following kidney transplantation]
[Effect of low calcium diet on blood pressure and pressure natriuresis response in rats: role of the renin-angiotensin system]
[Effect of perindopril on the processes of subclinical inflammation in patients with arterial hypertension and type 2 diabetes mellitus].
[Effect of statin therapy on mortality in patients with non-ischemic dilated cardiomyopathy].
[Effectiveness and tolerance of benazepril versus captopril in patients with hypertension]
[Effects of angiotensin converting enzyme inhibitor/angiotensin receptor blocker on clinical characteristics of coronavirus disease 2019 patients with hypertension].
[Effects of angiotensin-converting enzyme inhibitors in hypertension]
[Effects of clinical medicine on salt sensitivity hypertension: a systematic review and meta-analysis].
[Effects of perindopril on hypertension, serum angiotensin-I-converting enzyme activity and urine level of N-acetyl-beta-D-glucosaminidase]
[Efficacy of angiotensin-converting enzyme inhibitors in the therapy of arterial hypertension in the aged]
[Elevation of compliance and motivation to antihypertensive therapy in patients with arterial hypertension by way of educational programs and rational use of angiotensin converting enzyme perindopril. Results of the PRISMA study].
[Enzyme converting inhibitors. Current knowledge and perspectives]
[Establishment and validation of a new predictive equation with multiple risk factors for the development of cardiorenal syndrome type 1 in patients with acute myocardial infarction].
[Estimation of urinary excretion rate of guanidinoacetic acid in essential hypertension]
[Evaluation and control of hypertensive diabetics seen in Primary Care centres in Spain. BRAND II study.]
[Evaluation of efficacy and safety of hypertension treatment with original angiotensin-converting enzyme inhibitors: the comparison of original and generic formulations].
[Evaluation of influence of long-term therapy with angiotensin converting enzyme inhibitor lisinopril on morphofunctional parameters of the left ventricle peripheral artery endothelium disfunction, and painless myocardial ischemia in premenopausal women with hypertension]
[Evaluation of orthostatic hypotension frequency and associated factors in type 2 diabetics].
[Evaluation of ten years of pharmacovigilance of antihypertensive drugs in the Toulouse University Regional Hospital Center (1981-1990)]
[Evaluation of the effectivenes of treatment of patients with renal arterial hypertension with carvedilol]
[Evaluation of the efficacy and tolerance of the new delayed-action angiotensin-converting enzyme inhibitor cilazapril in patients with hypertension (preliminary report)]
[Evaluation of the tolerance and effectiveness of Diltiazem LP 300 mg in hypertensive patients with chronic renal insufficiency]
[Fixed dose combination perindopril-indapamide-amlodipine (Triplixam) for the treatment of arterial hypertension].
[Gender-related differences in the efficacy of treatment of hypertensive and coronary heart diseases in aged and elderly patients by angiotensin II receptor blockers and angiotensin converting enzyme inhibitors].
[Gene loci and polymorphisms of angiotensin II receptor]
[Genes in rennin-angiotensin system]
[Genetic polymorphisms of the renin-angiotensin system]
[Growth stimulating properties of angiotensin II on the heart: consequences for therapy of heart failure]
[Have angiotensin-converting enzyme inhibitors improved therapy of hypertension?]
[Heart failure with preserved ejection fraction (diastolic heart failure)].
[Hemolytic-uremic syndrome in children. Review of nine cases]
[History of the renin-angiotensin system: great men, a great finding].
[How and when to search for a renal artery atheromatous stenosis in diabetic patients?]
[How to handle cardiovascular treatments during general anesthesia?]
[Human essential hypertension and genetic hypertension in rats: the Lyon model]
[Hypertension and gene polymorphisms]
[Hypertension combined with atherosclerotic lesions in carotid arteries: should angiotensin converting enzyme inhibitors be prescribed?]
[Hypertension in old age]
[Hypertension in patients with polycystic kidney disease -? incidence, pathogenesis, prognosis, therapy].
[Hypertension management in practice, 1986]
[Hypertension treatment 1985: significance of calcium antagonists and angiotensin-converting enzyme inhibitors]
[Hypertension, rehabilitation medicine and laboratory medicine--my 38-year academic career in Tohoku University and Hirosaki University].
[Hypertensive patients' adherence, motivation, and awareness during fixed-dose perindopril A and amlodipine combination treatment (results of the CONSTANTA trial)].
[Hypotensive, organoprotective, and metabolic effects of Angiotensin converting enzyme inhibitor moexipril in women with postmenopausal syndrome]
[Hypoxic eosinophilic pneumonia in two patients treated with ACE inhibitors]
[I/D polymorphism of angiotensin I converting enzyme gene and arterial hypertension in patients with type 2 diabetes mellitus]
[Impact of angiotensin-converting enzyme, angiotensinogen, endothelial NO synthase, and bradykinin receptor B2 gene polymorphisms on myocardium in patients with hypertension and in athletes]
[Improvement in diastolic function in hypertensive patients with left ventricular hypertrophy with inhibitors of the angiotensin converting enzyme]
[Individualising antihypertensive therapy in patients with diabetes. A guideline by the Austrian Diabetes Association (Update 2019)].
[Inhibitors of angiotensin-converting enzyme in the treatment of arterial hypertension]
[Insertion/deletion polymorphism of the gene encoding for angiotensin-converting enzyme and microalbuminuria in essential arterial hypertension]
[Interaction between antiplatelet agents and angiotensin-converting enzyme inhibitors]
[Interaction of angiotensin converting enzyme inhibitors with nonsteroidal antiinflammatory drugs]
[Left Ventricular Hypertrophy in Hypertension. Part III. Reversibility of Left Ventricular Hypertrophy During Treatment With Antihypertensive Drugs]
[Level of endothelial vasodilatation and activity of angiotensin converting enzyme as criterion of efficacy of therapy in patients with mild and moderate hypertension]
[Lizinopril in the Treatment of Arterial Hypertension].
[Long-term decrease of microalbuminuria after one year of treatment with perindopril in hypertensive diabetic patients]
[Long-term monotherapy with prestarium, anap and lomir in patients with mild and moderate arterial hypertension: clinical efficacy, hemodynamics and morphofunctional parameters of heart]
[Long-term preventive effect and safety of amiodarone in patients with paroxysmal atrial fibrillation refractory to class I antiarrhythmic agents: analysis based on patient profiles]
[Management of atherosclerotic renal artery stenoses]
[Mechanisms of hypertension in patients with terminal kidney failure on programmed hemodialysis]
[Medical and social implications of sexual dysfunction and safety of antihypertensive therapy in hypertensive patients].
[Medical treatments in aortic stenosis: role of statins and angiotensin-converting enzyme inhibitors].
[Membrane transport of cations in erythrocytes during treatment of essential hypertension with angiotensin-converting enzyme inhibitors]
[Modes of intensive therapy for arterial hypertension in children with terminal chronic kidney failure]
[Monotherapy with the ACE-inhibitor ramipril or the calcium antagonist nitrendipine in essential hypertension]
[Multicenter prospective survey of prognosis of hypertensive elderly outpatient under antihypertensive treatment--morbidity and mortality of cardiovascular diseases and cancer]
[Nephroprotection by inhibition of the renin-angiotensin system--wish or reality?]
[Network regulation of renin-angiotensin system on the cardiovascular diseases].
[Neurohumoral mechanisms regulating renal blood circulation in patients with hypertension undergoing captopril block of angiotensin-converting enzyme]
[New techniques and laboratory examinations in the detection and evaluation of hypertension]
[Non SLE connective tissue diseases: general aspects and kidney]
[OP.LB.02.09] WHAT ANGIOTENSIN CONVERTING ENZYME GENOTYPE AND HIGH BLOOD PRESSURE HAVE IN COMMON IN PORTUGUESE CENTENARIANS?
[Optimization of treatment in hypertensive patients in real clinical practice: Role of a fixed-dose perindopril A and amlodipine combination (Results of the Russian observational CONSTANTA trial].
[Orolingual angioedema as complication after rt-PA in stroke patient treated with ACE inhibitor]
[Pathophysiological and clinical implications of AT(1) and AT(2) angiotensin II receptors in essential hypertension]
[Peptide inhibitors of the renin-angiotensin system. 2. Polymer-bound tri-, penta- and nonapeptide inhibitors of angiotensin converting enzyme]
[Pharmacokinetic and pharmacodynamic characteristics of antihypertensive drugs in the treatment of hypertensive patients with chronic diseases of the liver].
[Pharmacological correction of hyperactivity of Renin-Angiotensin-aldosteron system.]
[Pharmacotherapy with fixed low-dose combination of perindopril and the indapamide for arterial hypertension].
[Physiologically active peptides and the regulation of arterial pressure in normal and pathological states]
[Plasma N-terminal pro-B-type natriuretic peptide reference value in subjects without heart diseases]
[Polymorphism of angiotensin-converting enzyme and endothelial nitric oxide synthase genes in people with arterial hypertension, left ventricular hypertrophy, and hypertrophic cardiomyopathy]
[Polymorphism of gene angiotensin converting enzyme in pregnancy induced hypertension]
[Polymorphism of the angiotensin I-converting enzyme gene in Moscovites with arterial hypertension and cardiovascular diseases]
[Polymorphism of the angiotensin-converting enzyme gene in cardiovascular pathology]
[Polymorphism of the promotor region of the angiotensinogen gene and the gene for angiotensin I-converting enzyme in arterial hypertension and myocardial ischemia of the Kazakh ethnic groups]
[Polymorphisms of angiotensin converting enzyme and angiotensin II type 1 receptors genes and the state of regional hemodynamics in borderline arterial hypertension in young men]
[Post-transplant nephropathy and arterial hypertension]
[Predictors of successful renal artery revascularization in atherosclerotic renovascular disease]
[Prevention with angiotensin-converting enzyme (ACE) inhibitors]
[Preventive effect of captopril on the development of genetic hypertension in SHR rats (author's transl)]
[Preventive strategy for atrial fibrillation in arterial hypertension]
[Primary prevention of coronary heart disease : Evidence-based drug treatment].
[Prospective observational study of angiotensin converting enzyme inhibitors-induced hyperkalemia in hospitalized patients with chronic renal failure].
[Psychotropic effects of angiotensin-converting enzyme inhibitors: what are the arguments?]
[Pulse pressure in the therapeutic management of hypertension?]
[Ramipril effects on 24 hour profile of blood pressure in patients with mild and moderate hypertension]
[Regional changes in the activity of the angiotensin-converting enzyme in the brain of rats with developing hereditarily induced hypertension]
[Regression of left ventricular hypertrophy in essential arterial hypertension]
[Relationship of I/D polymorphism of angiotensin converting enzyme gene with hypertension in Xinjiang Kazakh isolated group]
[Relationships between polymorphisms of angiotensin-converting enzyme and methylenetetrahydrofolate reductase genes and genetic susceptibility to pregnancy induced hypertension]
[Remission of left ventricular hypertrophy of hypertensive origin. Experimental data]
[Renal function after administration of angiotensin-converting enzyme inhibitors]
[Renal involvement in connective tissue diseases]
[Renal side effects of angiotensin converting enzyme inhibitors]
[Renin-angiotensin system and its role in cardiovascular physiopathology and therapy]
[Renovascular hypertension: diagnostic and therapeutic strategy]
[Resistance to ACE inhibitors. Myth or reality?]
[Results of a 5-year study with captopril in patients with severe therapy-resistant hypertension]
[Revascularization of atherosclerotic stenosis of the renal artery. Indications and results]
[Revascularization of occluded renal arteries. A case]
[Risk factors for mortality in abdominal aortic surgery]
[Risk factors for recurrent hospitalizations of patients with atrial fibrillation].
[Role of angiotensin converting enzyme inhibitors in the therapy of hypertension]
[Role of structural polymorphism of the angiotensin-converting enzyme gene in the development of myocardial infarction]
[Russian study of efficacy and safety of an angiotensin converting enzyme inhibitor quinapril in patients with hypertension]
[Serum angiotensin converting enzyme activity in patients with untreated essential arterial hypertension]
[Severe pancytopenia in old age after 12-month ACE inhibitor therapy]
[Side effects in 28 patients treated with angiotensin converting enzyme (ACE) inhibitor in arterial hypertension in general practice]
[Significance of angiotensin converting enzyme (ACE) in coronary circulation]
[Significance of inhibitors of conversion enzymes in elderly subjects. The example of perindopril]
[Similar reduction in new cases of type 2 diabetes with angiotensin receptor blocker and ACE inhibitor: comparison of meta-analyses of prospective randomised trials]
[Slowing the progression of chronic renal insufficiency with captopril in rats with spontaneous arterial hypertension and adriamycin nephropathy]
[Special features of clinical effects of an angiotensin converting enzyme inhibitor lisinopril in patients with arterial hypertension]
[Stratification of patients with hypertension and selection of antihypertensive therapy]
[Study on a deletion polymorphism of the angiotensin converting enzyme gene in pregnancy induced hypertension]
[Study on the polymorphism of angiotensin converting enzyme genes and serum angiotensin II level in patients with obstructive sleep apnea hypopnea syndrome accompanied hypertension]
[Study on the relation between the angiotensin converting enzyme gene and pregnancy induced hypertension]
[Synthesis of renin and angiotensin-converting enzyme in human heart]
[The acute effects of the new angiotensin I-converting enzyme inhibitor, enalapril maleate, on blood pressure, plasma renin, aldosterone and kinins in hypertensive patients]
[The antihypertensive activity of benazepril in the long-term treatment of hypertension patients and its effect on adrenal cortical function]
[The association between angiotensin I converting enzyme gene polymorphism and Chinese late onset Alzheimer disease]
[The clinical pharmacology of angiotensin II antagonists]
[The correlation between serum angiotensin I-converting enzyme activity and the renin-angiotensin-aldosterone system in hypertensive patients (author's transl)]
[The effect of angiotensin-converting enzyme inhibitors on left ventricular hypertrophy in patients with arterial hypertension]
[The effect of captopril on the arterial pressure, structural resistance and vascular reactivity of the kidney in rats with nephrogenic hypertension]
[The effect of ramipril on metabolic, renal and cardiac function in hypertension and type II diabetes mellitus]
[The effect of the angiotensin-converting enzyme inhibitor Capoten on the volume-regulation indices of patients with stage-II hypertension]
[The effect of the angiotensinogen M235T and the angiotensin-converting enzyme I/D polymorphisms on arterial hypertension and other cardiovascular risk factors]
[The effect of the new angiotensin-converting enzyme inhibitor moexipril on the circadian rhythms of arterial pressure in hypertension patients]
[The effect of trandolapril, in monotherapy and associated with verapamil, on arterial pressure, albuminuria, and metabolic control in hypertensive patients with type 2 diabetes and albuminuria]
[The FORTISSIMO program: advantages of fixed full dose combination of perindopril arginine and indapamide in the treatment of poorly controlled arterial hypertension].
[The influence of combined therapy with calcium antagonist and angiotensin-converting enzyme inhibitor on the circadian profile of arterial pressure in patients with arterial hypertension in the Far North].
[The place of enalapril in the management of hypertension]
[The polymorphism of the angiotensin-converting enzyme gene in patients with hypertension, left ventricular hypertrophy and the development of a myocardial infarct at a young age. Preliminary report]
[The radionuclide diagnosis of vasorenal hypertension using an angiotensin-converting enzyme inhibitor]
[The relationship between angiotensin converting enzyme gene polymorphism and hypertensive kidney lesion and PAI-1 in hypertension patients]
[The relationship between genetic polymorphisms and disease, illustrated by the renin-angiotensin-aldosterone system and cardiovascular disease]
[The role of angiotensin converting enzyme inhibition for therapy of patients with hypertension and heart failure]
[The role of DNA polymorphism in the renin-angiotensin system and the pathogenesis of cardiovascular diseases]
[The side effects of angiotensin-converting enzyme inhibitors in the treatment of arterial hypertension]
[The significance of converting enzyme inhibitor angiotensin I to angiotensin II in treatment of patients with coronary disease]
[The use of angiotensin converting enzyme inhibitors in practice]
[The value of angiotensin-converting enzyme inhibitors in the treatment of hypertension]
[Therapeutic options for treatment of cardiometabolic risk]
[Therapy of perindopril: organoprotection, not just the antihypertensive effect].
[Thiaside diuretics in combination with inhibitors of angiotensin-converting enzyme in patients with diabetes mellitus type 2 comorbid with arterial hypertension]
[Tissue renin-angiotensin system. Physiology and physiopathological value of their inhibition by ramipril]
[Tolerance and safety of the use of perindopril]
[Tolerance to Triatec in monotherapy and in combination with Lasilix in a French multicenter study]
[Treatment of arterial hypertension in diabetics. Contribution of converting enzyme inhibitors]
[Treatment of arterial hypertension in the aged subject with a converting enzyme inhibitor: enalapril]
[Treatment of essential arterial hypertension of moderate severity with an orally active inhibitor of the angiotensin converting enzyme (Captopril)]
[Treatment of essential arterial hypertension with hypercholesterolemia. Effects of an alpha-adrenergic blocker and an inhibitor of the angiotensin converting enzyme]
[Treatment of hypertension in diabetes: threshold of intervention and therapeutic options]
[Treatment of hypertension in diabetics with trandolapril, an angiotensin converting enzyme inhibitor--a multicenter study]
[Treatment of hypertension in postmenopausal women]
[Treatment of hypertension using angiotensin-converting enzyme inhibitors]
[Treatment of severe arterial hypertension with captopril (SQ 14.225) (author's transl)]
[Treatment of systemic sclerosis].
[Update cardiology 2006/2007]
[Use of angiotensin converting enzyme inhibitor captopril and peripheral vasodilator minoxidil in the treatment of patients with stable and malignant arterial hypertension]
[Use of angiotensin converting enzyme inhibitors in nephrology]
[Use of angiotensin I converting enzyme inhibitors --essential progress in treatment of hypertension and late complications in patients with non-insulin-dependent diabetes mellitus]
[Use of angiotensin-converting enzyme inhibitors in arterial hypertension (according to the proceedings of XVI-XXII congresses of European Cardiologic Society)]
[Use of captopril in diabetics]
[Use of enalapril, an angiotensin-converting enzyme inhibitor, in pulmonary artery hypertension]
[Usefulness of angiotensin converting enzyme inhibitors in the diagnosis of renovascular hypertension. II. Comparison of the effect of angiotensin converting enzyme inhibition on reno-scintigraphic curves with DTPA in patients with essential and renovascular hypertension]
[Usefulness of angiotensin converting enzyme inhibitors in the diagnosis of renovascular hypertension. III. Evaluation of the validity of the captopril test and the reno-scintigraphic captopril test in the diagnosis of renovascular hypertension according to accepted criteria]
[Usefulness of converting enzyme inhibitors in diagnosis of renovascular hypertension. I. Comparison of the effect of angiotensin converting enzyme inhibition on blood pressure and plasma renin activity in patients with primary hypertension and renovascular hypertension]
[Value of pleiotropic effects of angiotensin-converting enzyme inhibitors].
[Views on the use of calcium channel blockers in the treatment of heart ischemia and hypertension]
[Volume of the extracellular liquid and renal function during short-term administration of angiotensin converting enzyme inhibitors in essential hypertension]
[What do large clinical trials learn us about cardiovascular and renal prevention in patients with type 2 diabetes mellitus and hypertension?]
[What have we learned about inhibitors of the renin-angiotensin system?]
[What have we learned from converting enzyme inhibitors on renin-angiotensin system?]
[What is new about stroke prevention?]
Hypertension, Malignant
Acute and chronic treatment of severe and malignant hypertension with the oral angiotensin-converting enzyme inhibitor captopril.
Advances in noninvasive screening for renovascular disease.
Angiotensin converting enzyme inhibition and renal insufficiency in patients with bilateral renovascular disease.
Angiotensin-converting enzyme gene I/D polymorphism in malignant hypertension.
Angiotensin-converting enzyme i/d polymorphism in patients with malignant hypertension.
Antihypertensive effect of the oral angiotensin I-converting enzyme inhibitor in long-term treatment of hypertensive patients.
Blood pressure, angiotensin-converting enzyme (ACE) inhibitors, and the kidney.
Enalaprilat, an intravenous angiotensin-converting enzyme inhibitor, in hypertensive crises.
Inhibition of tissue angiotensin converting enzyme activity prevents malignant hypertension in TGR(mREN2)27.
Intrarenal alterations of the angiotensin-converting enzyme type 2/angiotensin 1-7 complex of the renin-angiotensin system do not alter the course of malignant hypertension in Cyp1a1-Ren-2 transgenic rats.
Refractory hypertension in childhood--efficacy of captopril therapy.
Response of arterial blood pressure, plasma renin activity and plasma aldosterone concentration to long-term administration of captopril in patients with severe, treatment-resistant malignant hypertension.
Thrombotic microangiopathy due to malignant hypertension following corticosteroid therapy for microscopic polyangitis.
Treatment of malignant hypertension with an angiotensin converting enzyme inhibitor.
Usefulness of orally active angiotensin I converting enzyme inhibitor (SQ 14,225) in the treatment of malignant hypertension.
[Antihypertensive effect of an oral angiotensin I-converting enzyme inhibitor in two cases with malignant hypertension (author's transl)]
[Effects of angiotensin converting enzyme inhibitor SQ 14,225 on the blood pressure, renin-angiotensin-aldosterone system and renal function in patients with malignant hypertension (author's transl)]
[Use of angiotensin converting enzyme inhibitors in nephrology]
Hypertension, Portal
A1166C angiotensin II type 1 receptor gene polymorphism may predict hemodynamic response to losartan in patients with cirrhosis and portal hypertension.
Cirrhotic portal hypertension: From pathophysiology to novel therapeutics.
Effect of enalapril treatment and sclerotherapy of esophageal varices on hepatic hemodynamics in portal hypertension.
Effects of angiotensin-converting enzyme inhibitors and sclerotherapy on portal hemodynamics in patients with portal hypertension.
HFE Hemochromatosis and Hepatic Sarcoid.
Severe hepatic encephalopathy in a patient with liver cirrhosis after administration of angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker combination therapy: a case report.
[Correction of portal hypertension and renal dysfunction with help of nebivolol and lizinopril in patients with hepatic cirrhosis]
[Is it possible to predict a decrease in portal pressure after administration of ACE inhibitors?]
Hypertension, Pregnancy-Induced
Angiotensin-converting enzyme activity in hypertensive subjects after magnesium sulfate therapy.
Angiotensin-Converting Enzyme and Adducin-1 Polymorphisms in Women With Preeclampsia and Gestational Hypertension.
Association of angiotensin-converting enzyme gene polymorphism with pregnancy-induced hypertension.
Associations of ACE I/D, AGT M235T gene polymorphisms with pregnancy induced hypertension in Chinese population: a meta-analysis.
Constancy of serum angiotensin-converting enzyme activity in normal and complicated pregnancy.
Correlation of ACE gene deletion/insertion polymorphism and risk of pregnancy-induced hypertension: a meta-analysis based on 10,236 subjects.
Determination of renin, angiotensin converting enzyme and angiotensin II levels in human placenta, chorion and amnion from women with pregnancy induced hypertension.
Effect of angiotensin-converting enzyme gene polymorphism on pregnancy outcome, enzyme activity, and zinc concentration.
Enalapril: pharmacokinetic/dynamic inferences for comparative developmental toxicity. A review.
Hypertension-related gene polymorphisms in pre-eclampsia, eclampsia and gestational hypertension in Black South African women.
Maternal and fetal angiotensin-converting enzyme gene insertion/deletion polymorphism not associated with pregnancy-induced hypertension in Chinese women.
Renin-angiotensin-aldosterone system in pregnancy-induced hypertension.
Serum angiotensin-converting enzyme activity in pregnancy-induced hypertension.
The relation of angiotensin-converting enzyme to the pregnancy-induced hypertension-preeclampsia syndrome.
[Activity of serum angiotensin converting enzyme in pregnancy-induced hypertension]
[Angiotensinogen and angiotensin-I converting enzyme gene variations in Chinese pregnancy induced hypertension]
[Meta analysis of correlation of angiotensin-converting enzyme gene deletion/insertion polymorphism and risk of pregnancy-induced hypertension in Chinese women].
[Polymorphism of gene angiotensin converting enzyme in pregnancy induced hypertension]
[Relationships between polymorphisms of angiotensin-converting enzyme and methylenetetrahydrofolate reductase genes and genetic susceptibility to pregnancy induced hypertension]
[Study on a deletion polymorphism of the angiotensin converting enzyme gene in pregnancy induced hypertension]
[Study on the relation between the angiotensin converting enzyme gene and pregnancy induced hypertension]
Hypertension, Pulmonary
ACE gene polymorphism is associated with COPD and COPD with pulmonary hypertension: a meta-analysis.
ACE I allele and eNOS G allele crosstalk may have a role in chronic obstructive pulmonary disease.
Acute effects of nifedipine administration in pulmonary haemodynamics and oxygen delivery during exercise in patients with chronic obstructive pulmonary disease: implication of the angiotensin-converting enzyme gene polymorphisms.
Alveolar hemorrhage and pulmonary hypertension in systemic sclerosis: a continuum of scleroderma renal crisis?
Angiotensin converting enzyme activity and evolution of pulmonary vascular disease in rats with monocrotaline pulmonary hypertension.
Angiotensin converting enzyme expression is increased in small pulmonary arteries of rats with hypoxia-induced pulmonary hypertension.
Angiotensin converting enzyme inhibitors and pulmonary hypertension.
Angiotensin-converting enzyme activity is increased in lungs of rats with pulmonary hypoplasia and congenital diaphragmatic hernia.
Angiotensin-converting enzyme gene polymorphisms and prognosis in chronic thromboembolic pulmonary hypertension.
Angiotensin-converting enzyme inhibitors, angiotensin II receptors antagonists, beta-blockers and ivabradine as supportive therapy in pulmonary hypertension: Drug safety and tolerability.
Antenatal glucocorticoid therapy suppresses angiotensin-converting enzyme activity in rats with nitrofen-induced congenital diaphragmatic hernia.
Association between the angiotensin-converting enzyme gene polymorphisms and tissue oxygenation during exercise in patients with COPD.
Associations between endothelial nitric oxide synthase A/B, angiotensin converting enzyme I/D and serotonin transporter L/S gene polymorphisms with pulmonary hypertension in COPD patients.
Brain renin-angiotensin system in broiler chickens with cold-induced pulmonary hypertension.
Cardiac renin-angiotensin system (gene expression) and plasma angiotensin II in chickens with T3-induced pulmonary hypertension.
Characterization of high-altitude pulmonary hypertension in the Kyrgyz: association with angiotensin-converting enzyme genotype.
Deletion polymorphisms in the angiotensin converting enzyme gene are associated with pulmonary hypertension evoked by exercise challenge in patients with chronic obstructive pulmonary disease.
Developmental regulation of angiotensin converting enzyme and angiotensin type 1 receptor in the rat pulmonary circulation.
Effect of chronic hypoxia on angiotensin-induced pulmonary vasoconstriction and converting enzyme activity in the rat.
Effect of prolonged inhibition of angiotensin converting enzyme by captopril on some hemodynamic parameters of pulmonary circulation in patients with secondary pulmonary hypertension.
Effects of captopril administration on pulmonary haemodynamics and tissue oxygenation during exercise in ACE gene subtypes in patients with COPD: a preliminary study.
Effects of captopril on hemodynamics and blood gases in chronic obstructive lung disease with pulmonary hypertension.
Effects of SQ 14.225, an orally active inhibitor of angiotensin-converting enzyme, on hypoxic pulmonary hypertension and right ventricular hypertrophy in rats.
Enalapril protects mice from pulmonary hypertension by inhibiting TNF-mediated activation of NF-kappaB and AP-1.
Expression of pulmonary vascular angiotensin-converting enzyme in primary and secondary plexiform pulmonary hypertension.
Gene polymorphisms of endothelial nitric oxide synthase enzyme associated with pulmonary hypertension in patients with COPD.
Genetic polymorphisms of angiotensin system genes in congenital diaphragmatic hernia associated with persistent pulmonary hypertension.
Importance of angiotensin-converting enzyme in pulmonary hypertension.
Increased serum angiotensin I-converting enzyme activity in patients with mixed connective tissue disease and pulmonary hypertension.
Influence of oxygen administration on pulmonary haemodynamics and tissue oxygenation during exercise in COPD patients with different ACE genotypes.
Inhibition of tissue angiotensin-converting enzyme with quinapril reduces hypoxic pulmonary hypertension and pulmonary vascular remodeling.
Intrapulmonary activation of the angiotensin-converting enzyme type 2/angiotensin 1-7/G-protein-coupled Mas receptor axis attenuates pulmonary hypertension in Ren-2 transgenic rats exposed to chronic hypoxia.
Intravenous cyclophosphamide pulse therapy for the treatment of lung disease associated with scleroderma.
Intravenous Delivery of Lung-Targeted Nanofibers for Pulmonary Hypertension in Mice.
Local Renin-Angiotensin II Systems, Angiotensin-Converting Enzyme and its Homologue ACE2: Their Potential Role in the Pathogenesis of Chronic Obstructive Pulmonary Diseases, Pulmonary Hypertension and Acute Respiratory Distress Syndrome.
Low serum albumin: A significant predictor of reduced survival in patients with chronic heart failure.
Lung angiotensin converting enzyme activity in chronically hypoxic rats.
Lung angiotensin converting enzyme activity in monocrotaline pulmonary hypertension.
Lung angiotensin converting enzyme activity in rats with pulmonary hypertension.
Lung angiotensin receptor binding characteristics during the development of monocrotaline-induced pulmonary hypertension.
Monocrotaline-induced cardiopulmonary injury in rats: modification by the nonthiol ACE inhibitors CGS13945 and CGS16617.
Polymorphisms of renin-angiotensin system genes with high-altitude pulmonary edema in Japanese subjects.
Pulmonary angiotensin-converting enzyme (ACE) binding and inhibition in humans. A positron emission tomography study.
Pulmonary artery remodeling differs in hypoxia- and monocrotaline-induced pulmonary hypertension.
Reduction in hypertension-induced protein synthesis in the rat pulmonary trunk after treatment with teprotide (SQ 20881).
rhACE2 Therapy Modifies Bleomycin-Induced Pulmonary Hypertension via Rescue of Vascular Remodeling.
Right ventricular angiotensin converting enzyme activity and expression is increased during hypoxic pulmonary hypertension.
Risk factors for pacemaker implantation following aortic valve replacement: a single centre experience.
Role of angiotensin-converting enzyme and angiotensin II in development of hypoxic pulmonary hypertension.
Role of angiotensin-converting enzyme gene polymorphism in persistent pulmonary hypertension of the newborn.
Role of HIF-1alpha in the regulation ACE and ACE2 expression in hypoxic human pulmonary artery smooth muscle cells.
S-nitrosocaptopril: acute in-vivo pulmonary vasodepressor effects in pulmonary hypertensive rats.
Successful pregnancy with scleroderma renal disease and pulmonary hypertension in a patient using angiotensin converting enzyme inhibitors.
The angiotensin-converting enzyme 2/angiogenesis-(1-7)/Mas axis confers cardiopulmonary protection against lung fibrosis and pulmonary hypertension.
The beneficial effects of angiotensin-converting enzyme II (ACE2) activator in pulmonary hypertension secondary to left ventricular dysfunction.
The inhibition of angiotensin converting enzyme attenuates the effects of chronic hypoxia on pulmonary blood vessels in the rat.
Thrombomodulin and angiotensin-converting enzyme activity during pediatric open heart operations.
Treatment of systemic sclerosis.
[A case of MCTD with pulmonary hypertension showing elevated serum angiotensin I-converting enzyme activity]
[Comparative studies between the effects of captopril and nitrendipine on the hemodynamics and angiotensin converting enzyme of pigs with acute hypoxic pulmonary hypertension]
[Effect of captopril on pulmonary arterial hypertension in congestive heart failure associated with chronic obstructive bronchopneumopathy]
[Effect of captopril on pulmonary vascular remodeling induced by left-to-right shunt in rats]
[Effect of captopril on the activities of angiotensin II and angiotensin converting enzyme during hypoxia induced pulmonary hypertension]
[Effects of captopril on hemodynamics, gas exchange and exercise capacity in patients with pulmonary hypertension secondary to chronic obstructive pulmonary disease]
[Expression of angiotensin I converting enzyme in pulmonary hypertension]
[Lack of additional action of oxygen on pulmonary artery pressure at the peak of verapamil or captopril action in pulmonary hypertension secondary to mitral stenosis]
[Plasma renin activity, angiotensin II, angiotensin converting enzyme, thromboxane A2 and prostacyclin I2 levels in pigs with severe hypoxia and hypercapnea and acidosis shock]
[Precapillary pulmonary hypertension: effect of Captopril]
[Role of pulmonary arterial angiotensin converting enzyme in development of hypoxic pulmonary hypertension]
[Successful treatment for pulmonary hypertension with angiotensin 1 converting enzyme inhibitor in a patient with mixed connective tissue disease]
[The changes in the angiotensin-converting enzyme in patients with obliterative pulmonary hypertension]
[The changes in the levels of angiotensins and angiotensin converting enzyme and effects of captopril in patients with hypoxic pulmonary hypertension]
[Treatments of progressive systemic sclerosis]
Hypertension, Renal
Cerebrovascular changes in chronic hypertension. Protective effects of enalapril in rats.
Changes in plasma ACE activity during the development and reversal of one-kidney, one clip hypertension in rats.
Differential effects of captopril and nicardipine on baroreflex control of sympathetic nerve activity and heart rate in renal hypertension.
Effect of the angiotensin-converting enzyme inhibitor, captopril, on development of renal hypertension in rats.
Effects of changes in sodium balance and of experimental renal hypertension on plasma angiotensin I converting enzyme activity of rabbits.
Effects of treatment with angiotensin-converting enzyme inhibitor (ACEI) or angiotensin II receptor antagonist (AIIRA) on renal function and glomerular injury in subtotal nephrectomized rats.
Pressor sensitivity to angiotensin I and angiotensin II during the development of experimental renal hypertension in the rat.
Ramipril in the treatment of hypertension and proteinuria in children with chronic kidney diseases.
Role of angiotensin converting enzyme inhibitors in essential and renal hypertension. Effects of captopril and enalapril on renin-angiotensin-aldosterone, renal function and hemodynamics, salt and water excretion, and body fluid composition.
The inhibition of angiotensin converting enzyme in chronic renal hypertension by a synthetic peptide.
Vascular angiotensin converting enzyme in the development of renal hypertension.
[Captopril and enalapril in the treatment of renal hypertension]
[Hypertension and chronic renal insufficiency--chronic kidney failure]
[Reversible panmyelopathy following captopril treatment]
Hypertension, Renovascular
A discrepancy between the effects of a single oral dose of captopril on blood pressure, plasma renin activity, and serum angiotensin-converting enzyme levels.
A screening test for renovascular hypertension by means of orally active angiotensin I converting enzyme inhibitor, captopril (SQ 14225).
Abnormal captopril renogram with a technetium-99m-labeled hippuran analog.
Abnormal glomerular and tubular function during angiotensin converting enzyme inhibition in renovascular hypertension evaluated by the lithium clearance method.
Ace gene dosage influences the development of renovascular hypertension.
ACE inhibition is superior to angiotensin receptor blockade for renography in renal artery stenosis.
ACE inhibition scintigraphy in the management of hypertension in children.
Activity of angiotensin-converting enzyme after treatment with L-arginine in renovascular hypertension.
Acute renal thrombosis induced by angiotensin-converting enzyme inhibitors in patients with renovascular hypertension.
Advances in noninvasive screening for renovascular disease.
Adverse effect of the calcium channel blocker nitrendipine on nephrosclerosis in rats with renovascular hypertension.
Angiotensin converting enzyme inhibition improves diagnostic procedures for renovascular hypertension in dogs.
Angiotensin converting enzyme inhibition in renovascular hypertension: failure of the stenotic kidney.
Angiotensin converting enzyme inhibition in renovascular hypertension: frequency of reversible renal failure.
Angiotensin converting enzyme inhibitors.
Angiotensin I converting enzyme activity in hypertension. Relationship to blood pressure, renin-sodium profiles, and antihypertensive therapy.
Angiotensin-converting enzyme gene I/D polymorphism and carotid artery disease in renovascular hypertension.
Angiotensin-converting enzyme inhibition in renovascular hypertension: the narrowing gap between functional renal failure and progressive renal atrophy.
Angiotensin-converting enzyme inhibition-induced changes in hippurate renography and renal function in renovascular hypertension.
Angiotensin-converting enzyme inhibitor (SQ 20881) in the diagnosis of renovascular hypertension.
Angiotensin-converting enzyme inhibitor induced angioedema of the head and neck.
Angiotensin-converting enzyme inhibitor renography in the diagnosis of renovascular hypertension. Studies before and after angioplasty.
Angiotensin-converting enzyme inhibitor-enhanced phase-contrast MR imaging to measure renal artery velocity waveforms in patients with suspected renovascular hypertension.
Angiotensin-converting enzyme inhibitor-induced renal failure: causes, consequences, and diagnostic uses.
Antihypertensive and hormonal effects of lisinopril, a new angiotensin converting enzyme (ACE) inhibitor in patients with renovascular hypertension.
Antihypertensive effect of the oral angiotensin I-converting enzyme inhibitor in long-term treatment of hypertensive patients.
Beneficial Effects of the Angiotensin-Converting Enzyme 2 Activator Dize in Renovascular Hypertension.
Bioequivalence study of two formulations of enalapril, at a single oral dose of 20 mg (tablets): A randomized, two-way, open-label, crossover study in healthy volunteers.
Captopril renal scintigraphy in renovascular hypertension.
Captopril renography and the relevance of abnormal but bilateral identical curves in the diagnosis of renal artery stenosis.
Cardiac angiotensin converting enzyme overproduction indicates interstitial activation in renovascular hypertension.
Cardioprotective action of perindopril versus candesartan in renovascular hypertensive rats.
Characterization of neurohormonal changes following the production of the benign and malignant phases of two-kidney, two-clip Goldblatt hypertension.
Chronic angiotensin converting enzyme inhibition in the two-kidney, one clip hypertensive rat.
Clinical evaluation of the captopril screening test for primary aldosteronism.
Comparative effects of captopril and nifedipine on split renal function in renovascular hypertension.
Comparison of two noninvasive screening tests for renovascular hypertension.
Contrasting acute effects of captopril and nifedipine on renal function in renovascular hypertension.
Diagnosis of unilateral renovascular hypertension: comparative effect of intravenous enalaprilat and oral captopril.
Diagnostic uses of angiotensin-converting enzyme inhibitors in renovascular hypertension.
Differential renal function during angiotensin converting enzyme inhibition in renovascular hypertension.
Direct radio-immunoassay of renin substrate: effect of converting enzyme inhibition.
Effect of angiotensin converting enzyme inhibition in renovascular hypertension.
Effect of captopril and hydrochlorothiazide on glomerular haemodynamics and histological damage in Goldblatt hypertension with partial renal ablation.
Effects of 4 weeks of treatment with trandolapril on renal hypertension and cardiac and vascular hypertrophy in the rat.
Effects of angiotensin-converting enzyme inhibition and calcium channel blockade on cardiac apoptosis in rats with 2K1C (two-kidney/one-clip) renovascular hypertension.
Effects of enalapril maleate (MK-421) on renovascular hypertension.
Effects of enalapril maleate on plasma level of inactive renin in renovascular hypertension.
Effects of Ro 40-5967, a new calcium antagonist, and enalapril on cardiac remodeling in renal hypertensive rats.
Effects of the angiotensin converting enzyme inhibitors captopril, rentiapril, and alacepril in patients with essential and renovascular hypertension.
Enalapril and Lisinopril in Renovascular Hypertension Antihypertensne and Hormonal Effects of Two New Angio-Tensin-Converting-Enzyme (ACE) Inhibitors.
Enalapril and lisinopril in renovascular hypertension--antihypertensive and hormonal effects of two new angiotensin-converting-enzyme (ACE) inhibitors. A preliminary report.
Enalapril in the treatment of renovascular hypertension.
Enhancement of screening tests for renovascular hypertension by angiotensin-converting enzyme inhibition.
Epidemiology and clinical presentation.
European Captopril Radionuclide Test Multicenter Study. Preliminary results. Inspective renographic analysis. The European Captopril Radionuclide Test Multicenter Study Group.
Factors affecting the aldosterone/renin ratio.
Functional testing: ACEI renography.
Functional testing: renin studies.
Furosemide-131I-hippuran renography after angiotensin-converting enzyme inhibition for the diagnosis of renovascular hypertension.
Gd-DOTA tubular transit asymmetry induced by angiotensin-converting enzyme inhibitor in experimental renovascular hypertension.
Genetic risk of atherosclerotic renal artery disease: the candidate gene approach in a renal angiography cohort.
Hematocrit-lowering effect following inactivation of renin-angiotensin system with angiotensin converting enzyme inhibitors and angiotensin receptor blockers.
High-performance liquid chromatographic-radioimmunoassay method for the measurement of angiotensin II peptides in human plasma.
Hypertension in elderly patients. The special concerns in this growing population.
Hyponatremic-hypertensive syndrome associated with renovascular hypertension: a case report.
Impairment of the angiotensin-converting enzyme 2-angiotensin-(1-7)-Mas axis contributes to the acceleration of two-kidney, one-clip Goldblatt hypertension.
In vivo visualization of subendocardial arteriolar response in renovascular hypertensive hearts.
Increased angiotensin-converting enzyme activity of aorta in two-kidney, one-clip Goldblatt hypertension in rats.
Inhibition of left ventricular fibrosis by tranilast in rats with renovascular hypertension.
Inhibition of the slow pressor effect of angiotensin II contributes to the antihypertensive effect of angiotensin-converting enzyme inhibitors in renovascular hypertension.
Intrarenal kallikrein-kinin activity in acute renovascular hypertension in dogs.
Intravenous cyclophosphamide pulse therapy for the treatment of lung disease associated with scleroderma.
Ischemic nephropathy: noninvasive testing.
Ischemic renal disease: an emerging cause of chronic renal failure and end-stage renal disease.
Isotopic scan for diagnosis of renal disease.
Lack of effect of percutaneous transluminal renal angioplasty on nocturnal hypotension in renovascular hypertensive patients.
Long-term effects of converting enzyme inhibitors on split renal function in renovascular hypertension.
Myocardial collagen matrix remodelling in arterial hypertension.
Normal-appearing captopril MAG-3 renal scintigraphy in hemodynamically significant renal artery stenosis. A case report.
Pharmacologic nephrectomy with chronic angiotensin converting enzyme inhibitor treatment in renovascular hypertension in the rat.
Preventive effect of chronic converting enzyme inhibition on aortic stiffening induced by renovascular hypertension in conscious dogs.
Regulation of renal hemodynamics and glomerular filtration in patients with renovascular hypertension during converting enzyme inhibition with captopril.
Regulation of the structural remodelling of the myocardium: from hypertrophy to heart failure.
Reliability of ACE inhibitor-enhanced 99Tcm-DTPA gamma camera renography in the detection of renovascular hypertension.
Remodeling of the rat right and left ventricles in experimental hypertension.
Renal artery stenosis in patients with aortic dissection: increased prevalence.
Renal artery stenosis: a disease worth pursuing.
Renal studies in nuclear medicine.
Renin-angiotensin system and myocardial collagen matrix remodeling in hypertensive heart disease: in vivo and in vitro studies on collagen matrix regulation.
Renographic diagnosis of renovascular hypertension with angiotensin converting enzyme inhibition and furosemide.
Renovascular hypertension: an update.
Renovascular hypertension: nuclear medicine techniques.
Renovascular hypertension: treatment with the oral angiotensin-converting enzyme inhibitor enalapril.
Reversal of renovascular hypertension by antibodies specific for angiotensin-converting enzyme.
Secondary Hypertension: Discovering the Underlying Cause.
Serum angiotensin converting enzyme activity and plasma renin activity in experimental models of rats.
Study of correlation between elevation of blood pressure and tissue ACE activity during development of hypertension in 1K1C rats.
The cardiac structure-function relationship and the renin-angiotensin-aldosterone system in hypertension and heart failure.
The effect of non-antihypertensive doses of angiotensin converting enzyme inhibitor on myocardial necrosis and hypertrophy in young rats with renovascular hypertension.
The investigation of renovascular hypertension in children: the accuracy of radio-isotopes in detecting renovascular disease.
The kallikrein-kinin system in blood pressure homeostasis.
Total and split renal function in patients with renovascular hypertension: effects of angiotensin-converting enzyme inhibition.
Treatment of severe hypertension in a 14-year-old child: Successful blood pressure control with additive administration of captopril, an angiotensin-converting enzyme inhibitor, in a patient with bilateral renovascular hypertension.
University of Miami Division of Clinical Pharmacology Therapeutic Rounds: ischemic renal disease.
Use of angiotensin-converting-enzyme inhibitors for diagnosing renovascular hypertension.
Value of the Filtration Fraction Assessed by Dynamic 99mTc-Diethylenetriaminepentaacetic Acid Renal Scintigraphy After Angiotensin-Converting Enzyme Inhibition for the Diagnosis of Renovascular Hypertension.
[A case of bilateral renovascular hypertension controlled by angiotensin converting enzyme inhibitor (captopril) after arterioplasty for predominantly stenotic side (author's transl)]
[Angiotensin-converting enzyme activity of the aorta in experimental hypertensive rats]
[Angiotensin-converting enzyme inhibitor renography. Physiopathological, diagnostic and therapeutic aspects in renal artery stenosis]
[Angiotensin-converting enzyme inhibitors in the diagnosis and treatment of kidney diseases]
[Captopril renography in the diagnosis of renovascular hypertension]
[Cardiac structure-function relationship and the renin-angiotensin-aldosterone system in hypertensive heart disease]
[Conversion of inactive renin to active renin following acute angiotensin converting enzyme inhibition in essential hypertension and renovascular hypertension]
[Effect of an oral angiotensin I-converting enzyme inhibitor on blood pressure and renin-angiotensin-aldosterone system before and after nephrectomy in two cases with acute renovascular hypertension]
[Effects of angiotensin I converting enzyme inhibitor on renal function and serum potassium in renal and renovascular hypertension]
[Hypertension from the nephrologist's point of view]
[Induction of blood plasma carboxycathepsin (angiotensin I-converting enzyme) in normo- and hypertensive rats in response to a single administration of captopril]
[Inhibition of the angiotensin I converting enzyme with SQ-14225 (captopril) in the medical treatment of severe renovascular hypertension]
[New aspects of nuclear medicine diagnosis of kidney function: improved potential by pharmacologic intervention and quantitative analytic procedures]
[Renovascular hypertension. Radionuclide renography for detection and prediction of clinical response to revascularization]
[Renovascular hypertension]
[Surgical treatment of renovascular hypertension with special reference to the indications for reconstructive surgery]
[Synthesis of angiotensin-converting enzyme inhibitors and its application to experimental hypertensive rat for understanding the pathogenesis of renovascular hypertension (author's transl)]
[The acute effects of the new angiotensin I-converting enzyme inhibitor, enalapril maleate, on blood pressure, plasma renin, aldosterone and kinins in hypertensive patients]
[The correlation between serum angiotensin I-converting enzyme activity and the renin-angiotensin-aldosterone system in hypertensive patients (author's transl)]
[Usefulness of angiotensin converting enzyme inhibitors in the diagnosis of renovascular hypertension. II. Comparison of the effect of angiotensin converting enzyme inhibition on reno-scintigraphic curves with DTPA in patients with essential and renovascular hypertension]
[Usefulness of angiotensin converting enzyme inhibitors in the diagnosis of renovascular hypertension. III. Evaluation of the validity of the captopril test and the reno-scintigraphic captopril test in the diagnosis of renovascular hypertension according to accepted criteria]
[Usefulness of converting enzyme inhibitors in diagnosis of renovascular hypertension. I. Comparison of the effect of angiotensin converting enzyme inhibition on blood pressure and plasma renin activity in patients with primary hypertension and renovascular hypertension]
[Worldwide experience with enalapril]
Hypertensive Retinopathy
The relationship between hypertensive retinopathy and Angiotensin converting enzyme gene polymorphism.
Hyperthyroidism
Angiotensin-converting enzyme and anorexia nervosa.
Changes of serum angiotensin-I-converting enzyme in patients with thyroid disorders.
Cilazapril prevents cardiac hypertrophy and postischemic myocardial dysfunction in hyperthyroid rats.
Effect of thyroid hormone on uncoupling protein-3 mRNA expression in rat heart and skeletal muscle.
Effect of thyroid hormones on plasma protein concentrations in man.
Effects of variations in thyroid hormone serum concentrations on serum ACE-activity.
Efficacy of atenolol as a single antihypertensive agent in hyperthyroid cats.
Elevated serum angiotensin-converting enzyme in hyperthyroidism.
Elevation of serum angiotensin-converting enzyme activity in patients with hyperthyroidism.
Increased levels of serum angiotensin-converting enzyme activity in hyperthyroidism.
Reduced testosterone levels in males with lone atrial fibrillation.
Serum angiotensin-converting enzyme and plasma atrial natriuretic peptide levels in hyperthyroid and hypothyroid rabbits.
Serum angiotensin-converting enzyme in severe nonthyroidal illnesses associated with low serum thyroxine concentration.
Serum angiotensin-converting enzyme. Alterations in hyperthyroidism, hypothyroidism, and subacute thyroiditis.
Thyroid hormone resistance in a large kindred: physiologic, biochemical, pharmacologic, and neuropsychologic studies.
Tissue-specific modulation of angiotensin-converting enzyme (ACE) in hyperthyroidism.
Triiodothyronine increases serum angiotensin converting enzyme.
Why is plasma angiotensin-converting enzyme activity elevated in hyperthyroidism?
[Activity of angiotensin-converting enzyme in women with hyperthyroidism accompanying Graves-Basedow disease]
[Behavior of serum angiotensin converting enzyme in hyperthyroidism correlated to that of TSH]
[Expression of angiotensin converting enzyme and angiotensin II receptor in rabbits with hyperthyroid cardiomyopathy]
[Renin-angiotensin-aldosterone system in thyroid disorders]
[Responses of plasma bradykinin and the renin angiotensin axis to angiotensin II in hyperthyroid patients]
[Serum activity of angiotensin-converting enzyme and osteocalcin levels in hyperthyroidism]
[Serum angiotensin I converting enzyme activity in patients with hyperthyroidism and hypothyroidism: relation to renin and aldosterone]
[The activity of renin-angiotensin-aldosterone system (RAA) and possibilities of application angiotensin converting enzyme inhibitors (ACE I) in selected diseases of endocrine glands]
Hypertriglyceridemia
Diverse effects of increasing lisinopril doses on lipid abnormalities in chronic nephropathies.
Effect of long-term treatment with enalapril in streptozotocin diabetic and DOCA hypertensive rats.
Impact of postprandial hypertriglyceridemia on vascular responses in patients with coronary artery disease: effects of ACE inhibitors and fibrates.
Pathophysiology of experimental nephrotic syndrome induced by puromycin aminonucleoside in rats. I. The role of proteinuria, hypoproteinemia, and renin-angiotensin-aldosterone system on sodium retention.
Hypertrophy, Left Ventricular
A specific B2-bradykinin receptor antagonist HOE 140 abolishes the antihypertrophic effect of ramipril.
Absence of association or genetic linkage between the angiotensin-converting-enzyme gene and left ventricular mass.
ACE and AGTR1 polymorphisms and left ventricular hypertrophy in endurance athletes.
ACE and angiotensinogen gene genotypes and left ventricular mass in athletes.
ACE I/D polymorphism and cardiac adaptations in adolescent athletes.
ACE inhibition reduces left ventricular mass independent of pressure without affecting coronary flow and flow reserve in spontaneously hypertensive rats.
ACE inhibitor ramipril is more effective than the beta-blocker atenolol in reducing left ventricular mass in hypertension. Results of the RACE (ramipril cardioprotective evaluation) study on behalf of the RACE study group.
Adaptive and genetic alterations of the renin angiotensin system in cardiac hypertrophy and failure.
Aerobic Exercise Training-Induced Left Ventricular Hypertrophy Involves Regulatory MicroRNAs, Decreased Angiotensin-Converting Enzyme-Angiotensin II, and Synergistic Regulation of Angiotensin-Converting Enzyme 2-Angiotensin (1-7).
Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in essential hypertensive patients with left ventricular hypertrophy.
Analysis of gene-environment interactions by "stressing-the-genotype" studies: the angiotensin converting enzyme and exercise-induced left ventricular hypertrophy as an example.
Angiotensin converting enzyme gene I/D polymorphism in essential hypertension and nephroangiosclerosis.
Angiotensin converting enzyme gene polymorphism: potential silencer motif and impact on progression in IgA nephropathy.
Angiotensin converting enzyme inhibition and dihydropyridine calcium channel blockade in the treatment of left ventricular hypertrophy in arterial hypertension.
Angiotensin converting enzyme inhibition for cardiac hypertrophy in patients with end-stage renal disease: what is the evidence?
Angiotensin converting enzyme inhibition prevents polyploidization of cardiomyocytes in spontaneously hypertensive rats with left ventricular hypertrophy.
Angiotensin converting enzyme inhibitors, left ventricular hypertrophy and fibrosis.
Angiotensin I converting enzyme gene polymorphism and exercise trainability in elderly women: an electrocardiological approach.
Angiotensin II receptor blockers in older patients.
Angiotensin II-induced cardiomyocyte hypertrophy and cardiac fibrosis in stroke-prone spontaneously hypertensive rats.
Angiotensin-converting enzyme and angiotensinogen genes in patterns of left ventricular hypertrophy and in diastolic dysfunction.
Angiotensin-converting enzyme deletion polymorphism is associated with hypertension in a Sikh population.
Angiotensin-converting enzyme gene 2350 G/A polymorphism is associated with left ventricular hypertrophy but not essential hypertension.
Angiotensin-converting enzyme gene deletion allele increases the risk of left ventricular hypertrophy: evidence from a meta-analysis.
Angiotensin-converting enzyme gene insertion/deletion polymorphism and left ventricular hypertrophy in hemodialysis patients.
Angiotensin-converting enzyme gene polymorphism and geometric patterns of hypertensive left ventricular hypertrophy.
Angiotensin-converting enzyme gene polymorphism and reversibility of uremic left ventricular hypertrophy following long-term antihypertensive therapy.
Angiotensin-converting enzyme gene polymorphism influences degree of left ventricular hypertrophy and its regression in patients undergoing operation for aortic stenosis.
Angiotensin-converting enzyme I/D gene polymorphisms and effects of left ventricular hypertrophy in Turkish myocardial infarction patients.
Angiotensin-converting enzyme I/D polymorphism and arterial wall thickness in a general population. The Vobarno Study.
Angiotensin-converting enzyme in the human heart. Effect of the deletion/insertion polymorphism.
Angiotensin-converting enzyme inhibition improves cardiac function. Role of bradykinin.
Angiotensin-converting enzyme inhibition, cell growth, and left ventricular hypertrophy in hypertension.
Angiotensin-converting enzyme inhibitors and effects on left ventricular hypertrophy.
Angiotensin-converting enzyme inhibitors increase anti-fibrotic biomarkers in African Americans with left ventricular hypertrophy.
Angiotensin-converting enzyme insertion/deletion polymorphism, 24-h blood pressure profile and left ventricular hypertrophy in hypertensive individuals: a cross-sectional study.
Angiotensin-converting enzyme polymorphism in patients with terminal renal failure.
Angiotensin-I converting enzyme genotypes and left ventricular hypertrophy in patients with hypertrophic cardiomyopathy.
Antihypertensive agents prevent nephrosclerosis and left ventricular hypertrophy induced in rats by prolonged inhibition of nitric oxide synthesis.
Antihypertensive and cardioprotective effects after angiotensin-converting enzyme inhibition: role of kinins.
Antihypertensive therapy and coronary prevention.
Antihypertensive treatment modulates the association between the D/I ACE gene polymorphism and left ventricular hypertrophy: a meta-analysis.
Association between a deletion polymorphism of the angiotensin-converting-enzyme gene and left ventricular hypertrophy.
Association between angiotensin-converting enzyme gene polymorphisms and regression of left ventricular hypertrophy in patients treated with angiotensin-converting enzyme inhibitors.
Association of ACE polymorphisms with left ventricular hypertrophy.
Association of angiotensin converting enzyme gene polymorphisms with left ventricular hypertrophy.
Beta-blockers vs. angiotensin-converting enzyme inhibitors in hypertension: effects on left ventricular hypertrophy.
Blockade of the renin-angiotensin system in cardiac pressure-overload hypertrophy in rats.
Both a calcium antagonist and ACE inhibitor reverse hypertrophy in hypertension but a calcium antagonist also depresses contractility.
Bradykinin blocks angiotensin II-induced hypertrophy in the presence of endothelial cells.
Brain natriuretic peptide as a marker for hypertensive left ventricular hypertrophy: changes during 1-year antihypertensive therapy with angiotensin-converting enzyme inhibitor.
Cardiac and vascular remodelling: effect of antihypertensive agents.
Cardiac effects of combination therapy in hypertension.
Cardiac effects of combination therapy.
Cardiac hypertrophy and remodeling in relation to ACE and angiotensinogen genes genotypes in Chinese dialysis patients.
Cardiac weight in hypertension induced by nitric oxide synthase blockade.
Cardioprotective effect of angiotensin II receptor antagonists.
Cardioreparation with lisinopril in the management of hypertension and heart failure.
Cardioreparative effects of lisinopril in rats with genetic hypertension and left ventricular hypertrophy.
Cardiovascular activities of the bradykinin system.
Cardiovascular structural changes and calcium antagonist therapy in patients with hypertension.
Changes in plasma cardiac natriuretic peptides concentrations during 1 year treatment with angiotensin-converting enzyme inhibitor in elderly hypertensive patients with left ventricular hypertrophy.
Circulating angiotensin converting enzyme levels are increased in concentric, but not eccentric, left ventricular hypertrophy in elderly men.
Comparable effects of angiotensin II and converting enzyme blockade on hemodynamics and cardiac hypertrophy in spontaneously hypertensive rats.
Comparative effects of candesartan and enalapril on left ventricular hypertrophy in patients with essential hypertension: the candesartan assessment in the treatment of cardiac hypertrophy (CATCH) study.
Comparison of spirapril, isradipine, or combination in hypertensive patients with left ventricular hypertrophy: effects on LVH regression and arrhythmogenic propensity.
Comparison of the effects of an ACE inhibitor and alphabeta blocker on the progression of renal failure with left ventricular hypertrophy: preliminary report.
Comparison of the effects of angiotensin receptor antagonist, angiotensin converting enzyme inhibitor, and their combination on regression of left ventricular hypertrophy of diabetes type 2 patients on recent onset hemodialysis therapy.
Comparison of the effects of indapamide and captopril on the development of spontaneous hypertension.
Coronary reserve in experimental myocardial hypertrophy.
Correlation of left ventricular hypertrophy and its regression by lisinopril with salt-induced hypertension.
Creating a combination antihypertensive regimen: what does the research show?
DD genotype of the angiotensin-converting enzyme gene is a risk factor for left ventricular hypertrophy.
Deletion Polymorphism of Angiotensin Converting Enzyme Gene is Associated with Left Ventricular Hypertrophy in Uighur Hypertension-Obstructive Sleep Apnea Hypopnea Syndrome (OSAHS) Patients.
Deletion polymorphism of angiotensin-converting enzyme gene and left ventricular hypertrophy in southern Italian patients.
Diastolic Dysfunction.
Diastolic properties in canine hypertensive left ventricular hypertrophy: effects of angiotensin converting enzyme inhibition and angiotensin II type-1 receptor blockade.
Distribution and functional significance of cardiac angiotensin converting enzyme in hypertrophied rat hearts.
Does a reduction in left ventricular hypertrophy reduce cardiovascular morbidity and mortality?
Does the kinin system mediate in cardiovascular abnormalities? An overview.
Drug therapy for hypertension in hemodialysis patients.
Dual ECE/NEP inhibition on cardiac and neurohumoral function during the transition from hypertrophy to heart failure in rats.
Effect of ACE insertion/deletion and 12 other polymorphisms on clinical outcomes and response to treatment in the LIFE study.
Effect of angiotensin converting enzyme inhibition on pressure-induced left ventricular hypertrophy in rats.
Effect of chronic captopril treatment on circulating and tissue renin-angiotensin system in SHR rats.
Effect of combination of valsartan with benazepril on blood pressure and left ventricular hypertrophy in SHR.
Effect of early onset angiotensin converting enzyme inhibition on myocardial capillaries.
Effect of indapamide on left ventricular hypertrophy in hypertension: a meta-analysis.
Effect of ramipril on left ventricular mass in normotensive hemodialysis patients.
Effects of a long-term treatment with alacepril on left ventricular hypertrophy and function in patients with essential hypertension.
Effects of angiotensin converting enzyme inhibitors on left ventricular hypertrophy.
Effects of angiotensin-converting enzyme inhibition and angiotensin II AT1 receptor antagonism on cardiac parameters in left ventricular hypertrophy.
Effects of angiotensin-converting enzyme inhibitor and angiotensin type 1 receptor antagonist in deoxycorticosterone acetate-salt hypertensive mice lacking Ren-2 gene.
Effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on left ventricular mass index and ejection fraction in hemodialysis patients: A meta-analysis with trial sequential analysis of randomized controlled trials.
Effects of antihypertensive treatment on cardiac hypertrophy and cardiac function in elderly hypertensive patients.
Effects of antihypertensive treatment on ultrasound measures of myocardial fibrosis in hypertensive patients with left ventricular hypertrophy: results of a randomized trial comparing the angiotensin receptor antagonist, candesartan and the angiotensin-converting enzyme inhibitor, enalapril.
Effects of chronic hypertension and left ventricular hypertrophy on the extent of infarct expansion in rats.
Effects of enalaprilat on hemodynamics and ventricular activation duration in hypertensive patients with left ventricular hypertrophy: clinical evidence of improved excitation-contraction coupling with angiotensin converting enzyme inhibition in human hypertension.
Effects of long-term antihypertensive treatment with lisinopril on resistance arteries in hypertensive patients with left ventricular hypertrophy.
Effects of once-daily angiotensin-converting enzyme inhibition and calcium channel blockade-based antihypertensive treatment regimens on left ventricular hypertrophy and diastolic filling in hypertension: the prospective randomized enalapril study evaluating regression of ventricular enlargement (preserve) trial.
Effects of renal sympathetic denervation and angiotensin-converting enzyme inhibitor on left ventricular hypertrophy : Comparison in spontaneously hypertensive rats.
Effects of renin-angiotensin system blockade and dietary salt intake on left ventricular hypertrophy in Dahl salt-sensitive rats.
Effects of spironolactone and angiotensin-converting enzyme inhibitor on left ventricular hypertrophy in patients with essential hypertension.
Effects of telmisartan, ramipril, and their combination on left ventricular hypertrophy in individuals at high vascular risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial and the Telmisartan Randomized Assessment Study in ACE Intolerant Subjects With Cardiovascular Disease.
Evaluation of the 24 h effects of the angiotensin II receptor blockers: means to improve cardiovascular outcomes?
Experimental evidence for effects of ramipril on cardiac and vascular hypertrophy beyond blood pressure reduction.
FOSIDIAL: a randomised placebo controlled trial of the effects of fosinopril on cardiovascular morbidity and mortality in haemodialysis patients. Study design and patients' baseline characteristics.
Functional activity and expression of the myocardial postreceptor adenylyl cyclase system in pressure overload hypertrophy in rat.
Gene polymorphism of angiotensin II type 1 and type 2 receptors.
Gene polymorphisms predisposing to cardiac hypertrophy in patients with cardiac syndrome X.
Genetic aspects of heart failure.
Genetic polymorphisms in the renin-angiotensin system: relevance for susceptibility to cardiovascular disease.
Genetic variants of proteins from the renin angiotensin system are associated with pressure load cardiac hypertrophy.
Genetics of hypertension. Therapeutic implications.
Goals of antihypertensive therapy.
High serum level of procollagen type III amino-terminal peptide contributes to the efficacy of spironolactone and angiotensin-converting enzyme inhibitor therapy on left ventricular hypertrophy in essential hypertensive patients.
Hypertension and the bradykinin system.
Hypertension in the 1990s: a new disease.
Hypertensive heart disease--significance of left ventricular hypertrophy.
Improving prognosis in hypertension: exploring the benefits of angiotensin II type 1 receptor blockade.
Improving Prognosis in Hypertension: Exploring the Benefits of Angiotensin II Type 1 Receptor Blockade.
Incidence of New Stroke or New Myocardial Infarction or Death at 39-Month Follow Up in Patients With Diabetes Mellitus, Hypertension, or Both Treated With and Without Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers.
Increased rat cardiac angiotensin converting enzyme activity and mRNA expression in pressure overload left ventricular hypertrophy. Effects on coronary resistance, contractility, and relaxation.
Inhibition of left ventricular hypertrophy and expression of proto-oncogenes c-myc other than c-fos in myocardium by early captopril treatment in SHR rats.
Inhibitory effect of the angiotensin converting enzyme inhibitors captopril and enalapril on the conversion of procollagen to collagen.
Insertion/deletion polymorphism of angiotensin I converting enzyme gene and left ventricular hypertrophy in patients with type 2 diabetes mellitus.
Insertion/deletion polymorphism of the angiotensin-converting enzyme predicts left ventricular hypertrophy after renal transplantation.
Insulin-like growth factor-1 and cardiac mass in essential hypertension: comparative effects of captopril, lisinopril and quinapril.
Intracardiac angiotensin-converting enzyme inhibition improves diastolic function in patients with left ventricular hypertrophy due to aortic stenosis.
Intracoronary angiotensin-converting enzyme inhibition improves diastolic function in patients with hypertensive left ventricular hypertrophy.
Is there a role for echocardiography in intracerebral haemorrhage?
Isoproterenol and angiotensin I-converting enzyme in lung, left ventricle, and plasma during myocardial hypertrophy and fibrosis.
Kidney Disease Progression in Autosomal Recessive Polycystic Kidney Disease.
Lack of association between ACE gene polymorphism and left ventricular hypertrophy in essential hypertension.
Left and right coronary circulation in left ventricular hypertrophy: effects of angiotensin converting enzyme inhibition.
Left ventricular hypertrophy among black hypertensive patients: focusing on the efficacy of angiotensin converting enzyme inhibitors.
Left ventricular hypertrophy and angiotensin-converting enzyme gene polymorphism in renal allograft recipients.
Left ventricular hypertrophy and performance: therapeutic options among the angiotensin-converting enzyme inhibitors.
Left ventricular hypertrophy, blood pressure and ACE genotype in untreated hypertension.
Left ventricular hypertrophy: major risk factor in patients with hypertension: update and practical clinical applications.
Localized Antileptin Therapy Prevents Aortic Root Dilatation and Preserves Left Ventricular Systolic Function in a Murine Model of Marfan Syndrome.
Long-term and strict blood pressure lowering by imidapril reverses left ventricular hypertrophy in patients with essential hypertension: an evaluation using a novel indicator of burden on the left ventricle.
Long-term angiotensin II type 1 receptor blockade with fonsartan doubles lifespan of hypertensive rats.
Longitudinal change in left ventricular hypertrophy in the elderly on antihypertensive therapy.
Losartan reduces left ventricular hypertrophy proportionally to blood pressure reduction in hypertensives, but does not affect diastolic cardiac function.
Management of diastolic heart failure.
Mechanism of angiotensin II type 1 receptor blocker action in the regression of left ventricular hypertrophy.
Mechanisms responsible for sustained hypotension after captopril treatment.
Modulation of left ventricular hypertrophy by dietary salt and inhibition of angiotensin converting enzyme.
Molecular variant of angiotensinogen gene is associated with coronary atherosclerosis.
Myocardial perfusion in type 2 diabetes with left ventricular hypertrophy: normalisation by acute angiotensin-converting enzyme inhibition.
Naringenin inhibits NG-nitro-L-arginine methyl ester-induced hypertensive left ventricular hypertrophy by decreasing angiotensin-converting enzyme 1 expression.
New concepts regarding events that lead to myocardial infarction.
No correlation of polymorphism of angiotensin-converting enzyme genes with left ventricular hypertrophy in essential hypertension.
No effect of angiotensin-converting enzyme gene polymorphism on disease progression and left ventricular hypertrophy in autosomal dominant polycystic kidney disease.
Pharmacogenetic Interactions between Angiotensin-Converting Enzyme Insertion/Deletion Polymorphism and Response to Cibenzoline in Patients with Hypertrophic Obstructive Cardiomyopathy.
Physical function is weakly associated with angiotensin-converting enzyme gene I/D polymorphism in elderly Japanese subjects.
Prevalence of Appropriate Management of Diabetes Mellitus in an Academic General Medicine Clinic.
Primary diastolic heart failure.
Progression of left ventricular hypertrophy and the angiotensin-converting enzyme gene polymorphism in hypertrophic cardiomyopathy.
Prospects for cardioreparation.
Protective effects of angiotensin-converting enzyme inhibitors in high-risk African American men with coronary heart disease.
QT dispersion and left ventricular hypertrophy in athletes: relationship with angiotensin-converting enzyme I/D polymorphism.
Quinapril decreases myocardial accumulation of extracellular matrix components in spontaneously hypertensive rats.
Reciprocal regulation of pulmonary and cardiac angiotensin-converting enzyme in rats with severe left ventricular hypertrophy.
Reduction in cardiac conduction velocity delay by angiotensin converting enzyme inhibition in hypertensive patients with left ventricular hypertrophy. Detection by signal averaged electrocardiography.
Reduction in left ventricular hypertrophy in hypertensive patients treated with enalapril, losartan or the combination of enalapril and losartan.
Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril.
Regression of left ventricular hypertrophy by angiotensin converting enzyme inhibitor in reduced renal mass hypertensive rats.
Regression of left ventricular hypertrophy in hemodialysis patients is possible.
Regression of left ventricular hypertrophy under ramipril treatment investigated by nuclear magnetic resonance imaging.
Regression of left ventricular hypertrophy with moexipril, an angiotensin-converting enzyme inhibitor, in hypertensive patients.
Regression of left ventricular hypertrophy: do antihypertensive classes differ?
Regression of media-to-lumen ratio of human subcutaneous arteries and left ventricular hypertrophy during treatment with an angiotensin-converting enzyme inhibitor-based regimen in hypertensive patients.
Regression of the Left Ventricular Hypertrophy in Patients with Essential Hypertension on Standard Drug Therapy.
Relationship between ACE gene polymorphism and ischemic chronic heart failure in Turkish population.
Relationship between the angiotensin converting enzyme gene polymorphism and the effects of enalapril on left ventricular hypertrophy and impaired diastolic filling in essential hypertension: M-mode and pulsed Doppler echocardiographic studies.
Relative long-term effects of spironolactone in conjunction with an angiotensin-converting enzyme inhibitor on left ventricular mass and diastolic function in patients with essential hypertension.
Remodeling of myocardium and arteries by chronic angiotensin converting enzyme inhibition in hypertensive patients.
Renin and angiotensin-converting enzyme genotypes in patients with essential hypertension and left ventricular hypertrophy.
Reversal of cardiac and large artery structural abnormalities induced by long-term antihypertensive treatment with trandolapril.
Reversal of left ventricular hypertrophy with angiotensin converting enzyme inhibition in hypertensive patients with autosomal dominant polycystic kidney disease.
Risk reduction following regression of cardiac hypertrophy.
Role of angiotensin II in blood pressure regulation and in the pathophysiology of cardiovascular disorders.
Role of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in the management of atrial fibrillation.
Role of bradykinin in the reduction of left ventricular hypertrophy induced by angiotensin-converting enzyme inhibitors in spontaneously hypertensive rats.
Role of kinins and nitric oxide in the antihypertrophic effect of ramipril.
Role of tissue kallikrein-kininogen-kinin pathways in the cardiovascular system.
Selection of the dose of angiotensin converting enzyme inhibitor for patients with diabetic nephropathy depends on the presence or absence of left ventricular hypertrophy.
Short-term effects of rilmenidine on left ventricular hypertrophy and systolic and diastolic function in patients with essential hypertension: comparison with an angiotensin converting enzyme inhibitor and a calcium antagonist.
Should all patients at high cardiovascular risk receive renin-angiotensin system blockers?
Sodium valproate, a histone deacetylase inhibitor, but not captopril, prevents right ventricular hypertrophy in rats.
Studies to Elucidate the Mechanism of Cardio Protective and Hypotensive Activities of Anogeissus acuminata (Roxb. ex DC.) in Rodents.
Substrate metabolism, hormone interaction, and angiotensin-converting enzyme inhibitors in left ventricular hypertrophy.
Synergistic effect of angiotensin-converting enzyme and angiotensinogen gene on cardiac hypertrophy.
The DD genotype of the angiotensin-converting enzyme gene is associated with increased mortality in idiopathic heart failure.
The DD genotype of the angiotensin-converting enzyme gene occurs in very low frequency in Australian Aboriginals.
The deletion polymorphism of the angiotensin I-converting enzyme gene is associated with target organ damage in essential hypertension.
The effect and mechanism of forsinopril on ventricular hypertrophy of SHR and left ventricular pressure overloading rat.
The effect of long-term treatment by the angiotensin I-converting enzyme inhibitor enalapril on renal function and left ventricular hypertrophy in severe essential hypertension.
The effects of simultaneous hyperlipemia-hyperglycemia on the resistance arteries, myocardium and kidney glomeruli.
The efficacy of valsartan in essential hypertension and its effects on left ventricular hypertrophy.
The Gene Polymorphism of Angiotensin-Converting Enzyme Intron Deletion and Angiotensin-Converting Enzyme G2350A in Patients With Left Ventricular Hypertrophy: A Meta-analysis.
The kinin system in hypertensive pathophysiology.
The prevalence of supraventricular arrhythmias with regard to the type and degree of left ventricular hypertrophy in patients with hypertensive heart disease.
The role of genetic variants in angiotensin I converting enzyme, angiotensinogen and the angiotensin II type-1 receptor in the pathophysiology of heart muscle disease.
Time course of complete normalization of left ventricular hypertrophy during long-term antihypertensive therapy with angiotensin converting enzyme inhibitors.
Trandolapril in patients with essential hypertension: effects on vascular and cardiac structural changes.
Transforming growth factor beta 1 and extracellular matrix gene expression in isoprenaline induced cardiac hypertrophy: effects of inhibition of the renin-angiotensin system.
Treatment of metabolic syndrome.
Upregulation of ligand, receptor system, and amidating activity of adrenomedullin in left ventricular hypertrophy of severely hypertensive rats: effects of angiotensin-converting enzyme inhibitors and diuretic.
Use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in clinical practice.
Use of nuclear magnetic resonance imaging to show regression of hypertrophy with ramipril treatment.
Use of quinapril in the elderly patient.
Usefulness of the I/D angiotensin-converting enzyme genotype for detecting the risk of left ventricular hypertrophy in pharmacologically treated hypertensive men.
Variants of renin-angiotensin system genes and echocardiographic left ventricular mass.
Vascular and cardiac protection by ramipril in spontaneously hypertensive rats: prevention versus regression study.
Vascular structure in the forearm and calf after 6 months of angiotensin converting enzyme inhibition in elderly hypertensive subjects with left ventricular hypertrophy.
Visit-to-Visit Blood Pressure Variability Is a Strong Predictor of Cardiovascular Events in Hemodialysis: Insights From FOSIDIAL.
Will angiotensin converting enzyme genotype, receptor mutation identification, and other miracles of molecular biology permit reduction of NNT?
Zi Shen Huo Luo Formula Enhances the Therapeutic Effects of Angiotensin-Converting Enzyme Inhibitors on Hypertensive Left Ventricular Hypertrophy by Interfering With Aldosterone Breakthrough and Affecting Caveolin-1/Mineralocorticoid Receptor Colocalization and Downstream Extracellular Signal-Regulated Kinase Signaling.
[A decrease in left ventricular hypertrophy and the dynamics of the parameters of circadian BP monitoring under the influence of ramipril in patients with essential arterial hypertension]
[Activity of angiotensin-converting enzyme in serum and its association with left ventricular mass and blood pressure level in patients with essential hypertension]
[Angiotensin converting enzyme and left ventricular hypertrophy in uremic patients: correlation and therapeutic options]
[Angiotensin converting enzyme, NO-synthase, and endothelin-1 genes and left ventricular hypertrophy in natives of Yakutia with hypertensive disease]
[Association between angiotensin converting enzyme gene, chymase gene and regression of left ventricular hypertrophy in patients treated with angiotensin converting enzyme inhibitors.]
[Atorvastatin induced increase in homologous angiotensin i converting enzyme (ACE2) mRNA is associated to decreased fibrosis and decreased left ventricular hypertrophy in a rat model of diabetic cardiomyopathy].
[Changes in the expression of alpha- and beta-myosin heavy chain gene during the development of renal hypertension in rats]
[Comparative analysis of the combined treatment efficacy of the Chernobyl accident clean-up workers with essential hypertension].
[Effect of a non-antihypertensive dose of ramipril on the plasma and tissue renin-angiotensin system in 27 TGR (mRen2) rats.]
[Effects of perindopril on left ventricular hypertrophy, coronary reserve and mechanical properties of the papillary muscle of the rat with renovascular arterial hypertension]
[Effects of the prolonged inhibition of the angiotensin-converting enzyme on the morphological and functional characteristics of left ventricular hypertrophy in rats with persistent pressure overload]
[Gene loci and polymorphisms of angiotensin II receptor]
[Hereditary factors and left ventricular hypertrophy]
[I/D gene polymorphism of the angiotensin-converting enzyme and left ventricular hypertrophy. Response to converting enzyme inhibitors]
[Impact of antihypertensive treatment on target organs]
[Improvement in diastolic function in hypertensive patients with left ventricular hypertrophy with inhibitors of the angiotensin converting enzyme]
[Influence of insertion-deletion polymorphism of the angiotensin converting enzyme gene on left ventricular hypertrophy in patients with aortic stenosis--differences in men and women]
[Left Ventricular Hypertrophy in Hypertension. Part III. Reversibility of Left Ventricular Hypertrophy During Treatment With Antihypertensive Drugs]
[Left ventricular hypertrophy in spontaneously hypertensive rats: effect of angiotensin converting enzyme inhibitors on morphologic ultrastructure]
[Losartan and the LIFE-study. Antihypertensive treatment with AT1-receptor antagonist]
[Mechanism of inhibition in left ventricular hypertrophy by captopril treatment in spontaneously hypertensive rats]
[Multicenter trial of olmesartan. Main results].
[Polymorphic markers I/D and G7831A of angiotensin-I-converting enzyme gene and left ventricular hypertrophy in patients with essential hypertension]
[Polymorphism of angiotensin-converting enzyme and endothelial nitric oxide synthase genes in people with arterial hypertension, left ventricular hypertrophy, and hypertrophic cardiomyopathy]
[Polymorphism of the ACE gene and left ventricular morphology and function in patients with borderline, mild and moderate hypertension]
[Regression of left ventricular hypertrophy in essential arterial hypertension]
[Relationship between genotype of angiotensin converting enzyme gene and left ventricular hypertrophy in Chinese hypertensives]
[Role of the cardiac renin-angiotensin system in hypertensive heart disease]
[The effect of angiotensin-converting enzyme inhibitors on left ventricular hypertrophy in patients with arterial hypertension]
[The effect of angiotensin-converting enzyme inhibitors on left ventricular hypertrophy in patients with chronic glomerulonephritis and pronounced kidney failure]
[The polymorphism of the angiotensin-converting enzyme gene in patients with hypertension, left ventricular hypertrophy and the development of a myocardial infarct at a young age. Preliminary report]
[Value of pleiotropic effects of angiotensin-converting enzyme inhibitors].
Hypertrophy, Right Ventricular
Angiotensin converting enzyme activity and evolution of pulmonary vascular disease in rats with monocrotaline pulmonary hypertension.
Contrasting effects of an angiotensin converting enzyme inhibitor and a calcium antagonist on calcium transients in isolated rat cardiac myocytes.
Different effects of an angiotensin converting enzyme inhibitor and a calcium antagonist on protein metabolism in rats with right ventricular hypertrophy.
Effect of losartan on right ventricular hypertrophy and cardiac angiotensin I-converting enzyme activity in pulmonary hypertensive rats.
Effect of monocrotaline ingestion on the distribution of protein and angiotensin converting enzyme activity in the rat lung.
Effects of SQ 14.225, an orally active inhibitor of angiotensin-converting enzyme, on hypoxic pulmonary hypertension and right ventricular hypertrophy in rats.
Pulmonary artery remodeling differs in hypoxia- and monocrotaline-induced pulmonary hypertension.
Right ventricular angiotensin converting enzyme activity and expression is increased during hypoxic pulmonary hypertension.
Simvastatin causes endothelial cell apoptosis and attenuates severe pulmonary hypertension.
The DD genotype of the angiotensin converting enzyme gene is negatively associated with right ventricular hypertrophy in male patients with chronic obstructive pulmonary disease.
Time course sequences of angiotensin converting enzyme and chymase-like activities during development of right ventricular hypertrophy induced by pulmonary artery constriction in dogs.
Vascular injury after whole thoracic x-ray irradiation in the rat.
Hyperventilation
Effect of angiotensin converting enzyme inhibition on airway conductance during hypocapnic hyperventilation in normal subjects.
Hypoalbuminemia
A randomized, controlled trial of steroids and cyclophosphamide in adults with nephrotic syndrome caused by idiopathic membranous nephropathy.
Diverse effects of increasing lisinopril doses on lipid abnormalities in chronic nephropathies.
Nephrotic proteinuria without hypoalbuminemia: clinical characteristics and response to angiotensin-converting enzyme inhibition.
Regression of left ventricular hypertrophy in hemodialysis patients is possible.
Hypoaldosteronism
Hyperkalemia due to hyporeninemic hypoaldosteronism with liver cirrhosis and hypertension.
Membranous nephropathy with renal salt wasting: role of neurohumoral factors in sodium retention.
Metabolic Acidosis, Hyperkalemia, and Renal Unresponsiveness to Aldosterone Syndrome: Response to Treatment with Low-Potassium Diet.
Reversible hyperkalemia during antihypertensive therapy in a hypertensive diabetic patient with latent hypoaldosteronism and mild renal failure.
Type IV renal tubular acidosis presenting as dyspnea in two older patients taking angiotensin-converting enzyme inhibitors.
[Hyperreninemic hypoaldosteronism syndrome induced by plasma exchange]
[Risk for hyperkalemia during long-term treatment with angiotensin-converting enzyme inhibitors in insulin-dependent type 2 diabetics in relation to the glomerular filtration rate]
Hypoglycemia
Angiotensin-Converting Enzyme Inhibitors Used Concomitantly with Insulin Secretagogues and the Risk of Serious Hypoglycemia.
Angiotensin-converting enzyme insertion/deletion polymorphism and severe hypoglycemia complicating type 2 diabetes: the fremantle diabetes study.
Association between antihypertensive drug use and hypoglycemia: a case-control study of diabetic users of insulin or sulfonylureas.
Effect of angiotensin-converting enzyme inhibition on pituitary hormone responses to insulin-induced hypoglycemia in humans.
Genetic variation and activity of the renin-angiotensin system and severe hypoglycemia in type 1 diabetes.
Hypoglycemia associated with the administration of angiotensin-converting enzyme inhibitor in a diabetic hemodialysis patient.
Hypoglycemia associated with the administration of angiotensin-converting enzyme inhibitor in a patient with diabetes mellitus.
Hypoglycemia in patients with type 2 diabetes treated with oral antihyperglycemic agents detected by continuous glucose monitoring: a multi-center prospective observational study in Croatia.
Hypoglycemia induced by angiotensin-converting enzyme inhibitors in patients with non-insulin-dependent diabetes receiving sulfonylurea therapy.
Hypoglycemia, S-ACE and ACE genotypes in a Danish nationwide population of children and adolescents with type 1 diabetes.
Prolonged sulfonylurea-induced hypoglycemia in diabetic patients with end-stage renal disease.
Proximal Predictors of Long-Term Discontinuance with Noninsulin Antihyperglycemic Agents.
Serum ACE predicts severe hypoglycemia in children and adolescents with type 1 diabetes.
The impact of the Angiotensin-converting enzyme insertion/deletion polymorphism on severe hypoglycemia in type 2 diabetes.
The Insertion/Deletion Polymorphism in the Angiotensin-converting Enzyme Gene and Hypoglycemia Awareness in Patients with Type 1 Diabetes.
[Adverse drug reaction surveillance in pediatric and adult patients in an emergency room]
[Hypoglycemia associated with angiotensin-converting enzyme inhibitors]
[Hypoglycemia caused by interference between an angiotensin-converting enzyme inhibitor and a hypoglycemic sulfonamide]
[Severe hypoglycemia secondary to angiotensin-converting-enzyme inhibitors in the absence of diabetes mellitus. Report of a case]
Hypokalemia
A case of aldosterone producing adenoma associated with high PRA after long-term angiotensin converting enzyme inhibitor treatment.
Arrhythmias, electrolytes, and ACE inhibitor therapy in the elderly.
Evaluations of hospitalizations associated with thiazide-associated hyponatremia.
Hyponatremic-hypertensive syndrome associated with renovascular hypertension: a case report.
Mineralocorticoid hypertension.
Renal effects of angiotensin-converting enzyme inhibition in cardiac failure.
Renal transplantation unveils Conn's syndrome: a case report.
Reversal of diuretic-induced secondary hyperaldosteronism and hypokalemia by enalapril (MK-421): a new angiotensin-converting enzyme inhibitor.
Severe polyuria and polydipsia in hyponatremic-hypertensive syndrome associated with Wilms tumor.
The role of laboratory testing in the diagnosis of renovascular hypertension.
Thiazide and loop diuretics.
Treatment of hypertension with angiotensin converting enzyme inhibitors.
[Case of hypokalemia similar to Bartter's syndrome, suggesting deficiency of angiotensin converting enzyme]
[Expert consensus for the diagnosis and treatment of patients with Gitelman syndrome].
Hyponatremia
ACE inhibitors in congestive heart failure.
Acute hyponatremic encephalopathy after a cerebrovascular accident.
Angiotensin-converting enzyme inhibitor-induced syndrome of inappropriate secretion of antidiuretic hormone: case report and review of the literature.
Associations Between Antihypertensive Medications and Severe Hyponatremia: A Swedish Population-Based Case-Control Study.
Efficacy and safety of Angiotensin-converting enzyme inhibitors in patients with left ventricular systolic dysfunction and hyponatremia.
Epidemiology, Symptoms, and Treatment Characteristics of Hyponatremic Psychiatric Inpatients.
Hyponatremia after initiation of angiotensin-converting enzyme inhibitor in a geriatric patient with chronic heart failure: A case of mineralocorticoid-responsive hyponatremia of the elderly.
Hyponatremia Secondary to Lisinopril in a Veteran Patient.
Hyponatremia-Inducing Drugs.
Hyponatremic-hypertensive syndrome associated with renovascular hypertension: a case report.
Influence of combined angiotensin-converting enzyme inhibitors and spironolactone on serum K+, Mg 2+, and Na+ concentrations in small dogs with degenerative mitral valve disease.
Low Serum Sodium as a Poor Prognostic Indicator for Mortality in Congestive Heart Failure Patients.
Oleuropein Protects Against Cerebral Ischemia Injury in Rats: Molecular Docking, Biochemical and Histological Findings.
Relation between serum sodium levels and prognosis in outpatients with chronic heart failure: neutral effect of treatment with beta-blockers and angiotensin-converting enzyme inhibitors: data from the Italian network on congestive heart failure (IN-CHF database).
Risk factors for developing hyponatremia in thyroid cancer patients undergoing radioactive iodine therapy.
Serum Sodium Profile of Congestive Heart Failure Patients and its Impact on Their Outcome at Discharge.
Successful treatment of hyponatremia with angiotensin-converting enzyme inhibitors in patients with congestive heart failure.
The prognosis of heart failure patients: Does sodium level play a significant role?
Hypoplastic Left Heart Syndrome
A word on netting of angiotensin-converting enzyme inhibitor therapy in hypoplastic left heart syndrome following stage-I.
Angiotensin converting enzyme inhibitors and interstage failure in infants with hypoplastic left heart syndrome.
Angiotensin-Converting Enzyme Inhibitor Prescription for Patients With Single Ventricle Physiology Enrolled in the NPC-QIC Registry.
Hypoproteinemia
Pathophysiology of experimental nephrotic syndrome induced by puromycin aminonucleoside in rats. I. The role of proteinuria, hypoproteinemia, and renin-angiotensin-aldosterone system on sodium retention.
Hypotension
A double-blind randomized trial: prophylactic vasopressin reduces hypotension after cardiopulmonary bypass.
A role for the extracellular matrix component hyaluronan in kidney dysfunction during ACE-inhibitor fetopathy.
Acetaminophen-Induced Changes in Systemic Blood Pressure in Critically Ill Patients: Results of a Multicenter Cohort Study.
Acute Bradykinin Receptor Blockade During Hemorrhagic Shock in Mice Prevents the Worsening Hypotensive Effect of Angiotensin-Converting Enzyme Inhibitor.
Acute hypotensive transfusion reaction during liver transplantation in a patient on angiotensin converting enzyme inhibitors from low aminopeptidase P activity.
Acute kidney injury after gastric bypass surgery.
Aminophylline reversal of antihypertensive agent toxicity.
An examination of chronic angiotensin-converting enzyme inhibition in the rat.
An inhibitor of angiotensin converting enzyme (enalapril) augments endotoxin-induced hypotension in the pig.
An unusual cause of abdominal pain and hypotension: angioedema of the bowel.
Analysis of adrenoceptor blockade and hypotension elicited by urapidil and prazosin in conscious rat.
Anaphylactoid reaction to recombinant tissue plasminogen activator.
Angiotensin axis blockade, acute kidney injury, and perioperative morbidity in patients undergoing colorectal surgery: A retrospective cohort study.
Angiotensin axis blockade, hypotension, and acute kidney injury in elective major orthopedic surgery.
Angiotensin converting enzyme activity in strains of normo- and hypertensive rats.
Angiotensin converting enzyme inhibitors in the clinic: first-dose hypotension.
Angiotensin II levels, hemodynamics, and sympathoadrenal function after low-dose captopril in heart failure.
Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
Angiotensin system inhibitors in a general surgical population.
Angiotensin-converting enzyme inhibitors increase vasoconstrictor requirements after cardiopulmonary bypass.
Angiotensin-converting enzyme inhibitors predispose to hypotension refractory to norepinephrine but responsive to methylene blue.
Angiotensin-converting enzyme inhibitors.
Arginine vasopressin as a rescue vasopressor agent in the operating room.
Arterial Stiffness Predicts General Anesthesia-Induced Vasopressor-Resistant Hypotension in Patients Taking Angiotensin-Converting Enzyme Inhibitors.
Association Trends Between Antihypertensive Drug Therapies and Diastolic Hypotension in Emirati Patients with Type 2 Diabetes: A Single-Center Retrospective Longitudinal Study.
Associations among processes and outcomes of care for Medicare nursing home residents with acute heart failure.
Atypical reactions associated with use of angiotensin-converting enzyme inhibitors and apheresis.
Auto-intoxication with flecainide and quinapril: ECG-changes, symptoms and treatment.
Beta-blockers, angiotensin-converting enzyme inhibitors, and calcium antagonists in treatment of elderly patients with acute myocardial infarction.
Beta-blockers, calcium channel blockers, angiotensin converting enzyme inhibitors and angiotensin receptor blockers: should they be stopped or not before ambulatory anaesthesia?
Blood pressure reduction in hypertensive-diabetic rats by the somatostatin analog MK-678.
Candesartan cilexetil on regular hemodialysis: inability to reduce excessive thirst, but good tolerance and efficacy in hypertensive patients.
Cardiovascular homeostasis in hypotension associated with initial stages of severe acute pancreatitis.
Changes in plasma aldosterone levels and renin activity after bilateral superior cervical ganglionectomy in two strains of rats.
Chronic angiotensin-converting enzyme inhibitor or angiotensin receptor blocker therapy combined with diuretic therapy is associated with increased episodes of hypotension in noncardiac surgery.
Clinical effects of early angiotensin-converting enzyme inhibitor treatment for acute myocardial infarction are similar in the presence and absence of aspirin: systematic overview of individual data from 96,712 randomized patients. Angiotensin-converting Enzyme Inhibitor Myocardial Infarction Collaborative Group.
Cognitive Impairment in CKD: Pathophysiology, Management, and Prevention.
Combination use of medicines from two classes of renin-angiotensin system blocking agents: risk of hyperkalemia, hypotension, and impaired renal function.
Combined blockade of renin-angiotensin-aldosterone system reduced all-cause but not cardiovascular mortality in dialysis patients: A mediation analysis and systematic review.
Comparative Efficacy and Safety of BP-Lowering Pharmacotherapy in Patients Undergoing Maintenance Dialysis: A Network Meta-Analysis of Randomized, Controlled Trials.
Comparison of the effect of imidaprilat and ramiprilat on broncho-constriction and hypotension induced by bradykinin in guinea pigs.
Consequences of continuing renin angiotensin aldosterone system antagonists in the preoperative period: a systematic review and meta-analysis.
Continuation of angiotensin converting enzyme inhibitors on the day of surgery is not associated with increased risk of hypotension upon induction of general anesthesia in elective non-cardiac surgeries.
Continuation of Angiotensin-Converting Enzyme Inhibitors on the Day of Surgery Is Not Associated With Increased Risk of Hypotension Upon Induction of General Anesthesia in Elective Noncardiac Surgeries.
Continuous infusion of calcium gluconate in 5% albumin is safe and prevents most hypocalcemic reactions during therapeutic plasma exchange.
Design and analysis of the HYPREN-trial: safety of enalapril and prazosin in the initial treatment phase of patients with congestive heart failure.
Determinants of the initial effects of captopril on blood pressure, glomerular filtration rate, and natriuresis in mild-to-moderate chronic congestive heart failure secondary to coronary artery disease.
Development of hypotension in patients newly diagnosed with heart failure in UK general practice: retrospective cohort and nested case-control analyses.
Drug use and low blood pressure in the elderly: a study of data from the kungsholmen project.
Effect of angiotensin-converting enzyme inhibition on renal norepinephrine spillover rate and baroreflex responses in conscious rabbits.
Effect of angiotensin-converting enzyme inhibitors on phenylephrine responsiveness in patients with valvular heart disease.
Effect of gender and left ventricular dysfunction on the incidence of hypotension induced by dobutamine stress echocardiography.
Effect of omitting regular ACE inhibitor medication before cardiac surgery on haemodynamic variables and vasoactive drug requirements.
Effect of preoperative angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker use on hemodynamic variables in pediatric patients undergoing cardiopulmonary bypass.
Effects of an alpha-2 adrenoceptor agonist on angiotensin converting enzyme inhibitor-induced hypotension and potentiated allergen-evoked inflammatory skin responses.
Effects of converting enzyme inhibitor (SQ 20881) on changes in blood pressure and plasma aldosterone induced by angiotensin I or acute hemorrhage in rabbits.
Effects of hypotension and fluid depletion on central angiotensin-induced thirst and salt appetite.
Effects of long-acting angiotensin-converting enzyme inhibitor, imidapril, on the lower limit of cerebral blood flow autoregulation in hypertensive rats.
Effects of losartan on blood pressure and humoral factors in a patient who suffered from anaphylactoid reactions when treated with ACE inhibitors during LDL apheresis.
Effects of orally administered enalapril on blood pressure and hemodynamic response to vasopressors during isoflurane anesthesia in healthy dogs.
Efficacy and safety of Angiotensin-converting enzyme inhibitors in patients with left ventricular systolic dysfunction and hyponatremia.
Efficacy and Safety of Dual Blockade of the Renin-Angiotensin-Aldosterone System in Diabetic Kidney Disease: A Meta-Analysis.
Emerging low-density lipoprotein (LDL) therapies: Management of severely elevated LDL cholesterol--the role of LDL-apheresis.
Enhanced tumor localization of monoclonal antibody by treatment with kininase II inhibitor and angiotensin II.
False-positive result of a captopril-enhanced radionuclide renogram in a child secondary to dehydration.
Fetopathy associated with exposure to angiotensin converting enzyme inhibitors and angiotensin receptor antagonists.
First dose hypotension after angiotensin converting enzyme inhibitor captopril and angiotensin II blocker losartan in patients with acute myocardial infarction.
First dose hypotension with enalapril and prazosin in congestive heart failure.
First-dose hypotension after angiotensin-converting enzyme (ACE) inhibitors in chronic heart failure: a comparison of enalapril and perindopril. Slovak Investigator Group.
Frequency of Intraoperative Hypotension After the Induction of Anesthesia in Hypertensive Patients with Preoperative Angiotensin-converting Enzyme Inhibitors.
Global and regional hemodynamic effects of ramipril in congestive heart failure.
Haemodynamic and endocrine effects of deliberate hypotension with magnesium sulphate for cerebral-aneurysm surgery.
Heart failure and first dose hypotension after angiotensin converting enzyme inhibitors.
Heart failure complicating acute myocardial infarction.
Hemodynamic Collapse Following Therapeutic Plasma Exchange in a Patient Receiving an Angiotensin Receptor Blocker.
Hemodynamic effect of propofol in enalapril-treated hypertensive patients during induction of general anesthesia.
Hemodynamic effects of angiotensin inhibitors in elderly hypertensives undergoing total knee arthroplasty under regional anesthesia.
Hemopressin: a novel bioactive peptide derived from the alpha1-chain of hemoglobin.
Hypocalcemic toxicity and atypical reactions in therapeutic plasma exchange.
Hypotension as the Etiology for Angiotensin-Converting Enzyme (ACE) Inhibitor-Associated Acute Kidney Injury in Pediatric Patients.
Hypotension following the initiation of tizanidine in a patient treated with an angiotensin converting enzyme inhibitor for chronic hypertension.
Hypotension induced by inhibition of angiotensin-converting enzyme in pentobarbital-anesthetized dogs.
Hypotension induced by interleukin-3 in patients on angiotensin-converting enzyme inhibitors.
Hypotensive effect of human factor XII active fragment in conscious normotensive rats: role of bradykinin.
Hypotensive effect of the methanolic extract of Mimusops elengi in normotensive rats.
Hypotensive mechanism of the extracts and artemetin isolated from Achillea millefolium L. (Asteraceae) in rats.
Incidence and risk factors of asymptomatic first-dose hypotension with angiotensin-converting enzyme inhibitors in chronic heart failure due to systolic dysfunction.
Incidence, Predictors, and Outcomes Associated With Hypotensive Episodes Among Heart Failure Patients Receiving Sacubitril/Valsartan or Enalapril: The PARADIGM-HF Trial (Prospective Comparison of Angiotensin Receptor Neprilysin Inhibitor With Angiotensin-Converting Enzyme Inhibitor to Determine Impact on Global Mortality and Morbidity in Heart Failure).
Influence of angiotensin-converting enzyme inhibitors on hypotension after anesthetic induction: is the preoperative discontinuation of this drug necessary?
Influence of chronic angiotensin-converting enzyme inhibition on anesthetic induction.
Influence of converting enzyme inhibition on isoflurane-induced hypotension for cerebral aneurysm surgery.
Influence of inhibition of angiotensin I converting enzyme with SQ-14225 on the arterial blood pressure of mongrel dogs.
Inhibition of angiotensin-converting enzyme modulates the autoregulation of regional cerebral blood flow in hypertensive rats.
Insignificant response of the fetal placental circulation to arterial hypotension in sheep.
Intraoperative cardiac arrest: was it the ACE inhibitor?
Ivabradine in Cancer Treatment-Related Left Ventricular Dysfunction.
Lack of contribution of circulatory kinin elevated by captopril to induce hypotension in normotensive and hypertensive rats.
Lack of effect of percutaneous transluminal renal angioplasty on nocturnal hypotension in renovascular hypertensive patients.
Letter: Hypotension during administration of angiotensin converting enzyme inhibitor SQ 20,881.
Liver involvement in early autosomal-dominant polycystic kidney disease.
Low-Dose Vasopressin and Analogues to Treat Intraoperative Refractory Hypotension in Patients Prescribed Angiotensin-Converting Enzyme Inhibitors Undergoing General Anesthesia: A Systematic Review.
Maintenance of normal blood pressure and renal functions are independent effects of angiotensin-converting enzyme.
Management of Heart Failure in the Emergency Department Setting: An Evidence-Based Review of the Literature.
Mice lacking angiotensin-converting enzyme have low blood pressure, renal pathology, and reduced male fertility.
More hypotension in patients taking antihypertensives preoperatively during shoulder surgery in the beach chair position.
Neurotensins and their therapeutic potential: research field study.
New proline-rich oligopeptides from the venom of African adders: Insights into the hypotensive effect of the venoms.
Overall cardiovascular profile of sildenafil citrate.
Pathophysiology and management of angiotensin-converting enzyme inhibitor-associated refractory hypotension during the perioperative period.
Perioperative hypotension following plasma volume expansion with albumin in an angiotensin-converting enzyme inhibited infant.
Perioperative management of patients treated with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers: a quality improvement audit.
Physiological non-equivalence of the two isoforms of angiotensin-converting enzyme.
Plasma constituents other than low-density lipoprotein adsorbed by dextran-sulfate column.
Poisoning in the elderly. Epidemiological, clinical and management considerations.
Postoperative fatal intestinal necrosis after enalapril treatment in a patient with rheumatoid arthritis.
Postoperative hypotension associated with enalapril.
Pre-anesthetic ultrasonographic assessment of the internal jugular vein for prediction of hypotension during the induction of general anesthesia.
Predictors of clinically significant postprocedural hypotension after carotid endarterectomy and carotid angioplasty with stenting.
Profound hypotension in a tetraplegic patient following angiotensin-converting enzyme inhibitor lisinopril. Case report.
Propofol increases vascular relaxation in aging rats chronically treated with the Angiotensin-converting enzyme inhibitor captopril.
Ranolazine, ACE Inhibitors, and Angiotensin Receptor Blockers.
Rapid onset of haemodynamic effects after angiotensin converting enzyme-inhibitor overdose: implications for initial patient triage.
Refractory hypotension during general anesthesia despite preoperative discontinuation of an angiotensin receptor blocker.
Refractory Hypotension During General Anesthesia Despite Withholding Telmisartan.
Refractory hypotension in a patient chronically treated with a long acting angiotensin-converting enzyme inhibitor.
Refractory intraoperative hypotension with elevated serum tryptase.
Remission of nephrotic syndrome in type 1 diabetes: long-term follow-up of patients in the Captopril Study.
Renal and electrolyte complications of congestive heart failure and effects of therapy with angiotensin-converting enzyme inhibitors.
Renin-angiotensin-aldosterone-system inhibition is safe in the preoperative period surrounding carotid endarterectomy.
Role of renal nerves in sodium depletion-induced salt appetite.
Role of the kallikrein-kinin system in the renal effects of angiotensin-converting enzyme inhibition in anaesthetized dogs.
Sacubitril/Valsartan: A Novel Cardiovascular Combination Agent.
Safety profiles of the angiotensin-converting enzyme inhibitors.
Salt-losing nephrogenic diabetes insipidus caused by fetal exposure to angiotensin receptor blocker.
Severe hypotension associated with angiotensin-converting enzyme inhibition in anaesthesia.
Should increasing the dose or adding an AT1 receptor blocker follow a relatively low dose of ACE inhibitor initiated in acute myocardial infarction?
Side effects of using nitrates to treat heart failure and the acute coronary syndromes, unstable angina and acute myocardial infarction.
Spironolactone alleviates late cardiac remodeling after left ventricular restoration surgery.
Spironolactone and altizide used in combination with enalapril: twenty-four-hour ambulatory recording of blood pressure.
Spironolactone in congestive heart failure refractory to high-dose loop diuretic and low-dose angiotensin-converting enzyme inhibitor.
The effect of angiotensin converting enzyme inhibition on myocardial function and blood pressure after coronary artery bypass surgery--a randomised study.
The effect of angiotensin-converting enzyme inhibitor on hemodynamic instability in patients undergoing cardiopulmonary bypass: results of a dose-comparison study.
The Effect of Sacubitril-Valsartan in Heart Failure Patients With Mid-Range and Preserved Ejection Fraction: A Meta-Analysis.
The Risk of Hypertension after Preoperative Discontinuation of Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Antagonists in Ambulatory and Same-Day Admission Patients.
The role of nitric oxide, adrenergic activation and kinin-degradation in blood pressure homeostasis following an acute kinin-induced hypotension.
The sudden demise of dual renin-angiotensin system blockade or the soft science of the surrogate end point.
Tissue levels, tissue angiotensin converting enzyme inhibition and antihypertensive effect of the novel antihypertensive agent alacepril in renal hypertensive rats.
Toxic effects of drugs used in the ICU. Nitroprusside, nitroglycerin, and angiotensin-converting enzyme inhibitors.
Treating anesthesia-induced hypotension by angiotensin II in patients chronically treated with angiotensin-converting enzyme inhibitors.
Washed RBCs prevent recurrent acute hypotensive transfusion reactions.
Why are angiotensin converting enzyme inhibitors underutilised in the treatment of heart failure by general practitioners?
Withholding versus Continuing Angiotensin-converting Enzyme Inhibitors or Angiotensin II Receptor Blockers before Noncardiac Surgery: An Analysis of the Vascular events In noncardiac Surgery patIents cOhort evaluatioN Prospective Cohort.
[Aggression to the immature kidney]
[ANALYSIS OF THE ASSOCIATIONS BETWEEN ANGIOTENSIN-CONVERTING ENZYME GENE POLYMORPHISM AND ARTERIAL HYPOTENSION IN PREMATURE INFANTS WITH EARLY ONSET BACTERIAL INFECTIONS].
[Angiotensin converting enzyme activity in parts of the brain, hypophysis and adrenal gland of rabbits one hour after posthemorrhagic hypotension]
[Angiotensin converting enzyme activity in the blood of dogs with posthemorrhagic hypotension]
[Angiotensin converting enzyme inhibitors in controlled hypotension during spinal surgery]
[Angiotensin-converting enzyme inhibitors and pregnancy. Apropos of 2 cases]
[Arterial hypotension in myocardial revascularization surgery: influence of angiotensin-converting enzyme inhibitors.]
[Captopril use in pregnancy and its effects on the fetus and the newborn: case report]
[Cardiac failure and nitrates]
[Cellular immunity in patients with psoriasis]
[Hypotension followed the first dose of angiotensin-converting enzyme inhibitor in patients with heart failure (a multicenter clinical trial)]
[Kidney insufficiency and persistent hypotension following compromise of the renin-angiotensin system in a fetus and a young infant]
[Non-steroidal anti-inflammatory agent and angiotensin converting enzyme inhibitor: a dangerous combination during postoperative period]
[Perioperative blood pressure management : What is the optimal pressure?]
[Perioperative Management of Medications Used for Comorbidities: Preface and Comments].
[Pseudo-Bartter's syndrome induced by surreptitious ingestion of furosemide to lose weight: a case report and possible pathophysiology]
[Refractory hypotension sustained during general anesthesia due to chronic treatment with angiotensin-converting enzyme inhibitors]
[Refractory shock after converting enzyme inhibitor administration. Usefulness of angiotensin II]
[Severe hypotension during spinal anesthesia induced by angiotensin-converting enzyme inhibitors.]
[Severe hypotension during spinal anesthesia induced by angiotensin-converting enzyme inhibitors]
Hypotension, Orthostatic
Blood pressure behavior in the nursing home: implications for diagnosis and treatment of hypertension.
Current therapeutic strategies in cardiac amyloidosis.
Orthostatic hypotension in genetically related hypertensive and normotensive individuals.
Polymorphisms of genes encoding components of the sympathetic nervous system but not the renin-angiotensin system as risk factors for orthostatic hypotension.
The antihypertensive effect of the angiotensin II receptor antagonist DuP 753 may not be due solely to angiotensin II receptor antagonism.
[Drug induced orthostatic hypotension]
Hypothyroidism
Age-related decrease in serum angiotensin converting enzyme activity: the role of thyroidal status and food intake.
Angiotensin-converting enzyme activity. A potential marker of tissue hypothyroidism in critical illness.
Angiotensin-converting enzyme and anorexia nervosa.
Elevated serum angiotensin-converting enzyme in hyperthyroidism.
Elevation of serum angiotensin-converting enzyme activity in patients with hyperthyroidism.
Serum angiotensin-converting enzyme. Alterations in hyperthyroidism, hypothyroidism, and subacute thyroiditis.
[Activity of angiotensin converting enzyme in women with hypothyroidism]
[Comparative assessment of efficacy of hypotensive drugs from various groups and angiotensin converting enzyme inhibitors in patients with hypothyroidism and hypertension]
[Renin-angiotensin-aldosterone system in thyroid disorders]
[Serum angiotensin I converting enzyme activity in patients with hyperthyroidism and hypothyroidism: relation to renin and aldosterone]
[The activity of renin-angiotensin-aldosterone system (RAA) and possibilities of application angiotensin converting enzyme inhibitors (ACE I) in selected diseases of endocrine glands]
Idiopathic Pulmonary Fibrosis
Angiotensin-converting enzyme (ACE) gene polymorphisms are associated with idiopathic pulmonary fibrosis.
Impact of angiotensin-converting enzyme inhibitors and statins on survival in idiopathic pulmonary fibrosis.
The role of the methacholine inhalation challenge in adult patients presenting with chronic cough.
[Association of genetic polymorphisms of angiotensin converting enzyme and matrix metallo proteinase-1 with idiopathic pulmonary fibrosis].
IgA Vasculitis
Henoch-Schoenlein purpura and angiotensin-converting enzyme inhibitors.
Ileus
Clinical Evaluation of the Safety, Efficacy and Tolerability of Lanthanum Carbonate in the Management of Hyperphosphatemia in Patients with End-Stage Renal Disease.
Immunoglobulin Light-chain Amyloidosis
Primary systemic amyloidosis and high levels of Angiotensin-converting enzyme: two case reports.
Infarction, Middle Cerebral Artery
Inhibition of matrix metalloproteinase-9 activity by trandolapril after middle cerebral artery occlusion in rats.
Infections
A mouse model of lethal respiratory dysfunction for SARS-CoV-2 infection.
A Patient Infected with SARS-CoV-2 Presenting with Complete Heart Block.
A targetable, injectable adenoviral vector for selective gene delivery to pulmonary endothelium in vivo.
A ten-year follow-up of a 109-year-old woman with myocardial infarction.
Accuracy of retinal changes in predicting microalbuminuria among elderly hypertensive patients: a cross-sectional study from a teaching hospital in South India.
ACE I/D polymorphism in Czech first-wave SARS-CoV-2-positive survivors.
ACE/ACE2 balance might be instrumental to explain the certain comorbidities leading to severe COVID-19 cases.
ACEI/ARB use and risk of infection or severity or mortality of COVID-19: A systematic review and meta-analysis.
ACEIs, ARBs, ibuprofen originally linked to COVID-19: the other side of the mirror.
Acute kidney injury and infections in patients taking antihypertensive drugs: a self-controlled case series analysis.
Air-liquid interphase culture confers SARS-CoV-2 susceptibility to A549 alveolar epithelial cells.
Anaemia after renal transplantation.
Anaesthetic Approach for Patient with Hereditary Angioedema.
Angioedema without urticaria: a large clinical survey.
Angiotensin Converting Enzyme Inhibitors, A Risk Factor of Poor Outcome in Diabetic Patients with COVID-19 Infection.
Angiotensin II is a new component involved in splenic T lymphocyte responses during Plasmodium berghei ANKA infection.
Angiotensin II receptor blocker or angiotensin-converting enzyme inhibitor use and COVID-19-related outcomes among US Veterans.
Angiotensin-Converting Enzyme 2 and Antihypertensives (Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors) in Coronavirus Disease 2019.
Angiotensin-converting enzyme 2 inhibits lung injury induced by respiratory syncytial virus.
Angiotensin-Converting Enzyme Inhibitor Treatment and the Development of Urinary Tract Infections: A Prescription Sequence Symmetry Analysis.
Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers are not associated with severe COVID-19 infection in a multi-site UK acute hospital trust.
Angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers and the risk of COVID-19 infection or severe disease: Systematic review and meta-analysis.
Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers Use and COVID-19 Infection Among 824 650 Patients With Hypertension From a US Integrated Healthcare System.
Angiotensin-converting enzyme limits inflammation elicited by Trypanosoma cruzi cysteine proteases: a peripheral mechanism regulating adaptive immunity via the innate kinin pathway.
Angiotensin-converting-enzyme activity in serum from calves infected continuously or with a single dose of Dictyocaulus viviparus infective larvae.
Anti-SARS-CoV Spike Antibodies Trigger Infection of Human Immune Cell via a pH- and Cysteine Protease-Independent Fc{gamma}R Pathway.
Antimicrobial Peptides: A New Hope in Biomedical and Pharmaceutical Fields.
Association between vitamin D receptor gene polymorphisms and tubular citrate handling in calcium nephrolithiasis.
Association of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers With the Risk of Hospitalization and Death in Hypertensive Patients With COVID-19.
Cardiovascular drugs and COVID-19 clinical outcomes: A living systematic review and meta-analysis.
Causes and therapy of microinflammation in renal failure.
Clinical outcomes of acute kidney injury developing outside the hospital in elderly.
Comparisons of Staphylococcus aureus infection and other outcomes between users of angiotensin-converting-enzyme inhibitors and angiotensin II receptor blockers: lessons for COVID-19 from a nationwide cohort study.
Controversies in the evaluation and management of chronic cough.
Coronavirus Disease 2019 (COVID-19) and Cardiovascular Disease: A Viewpoint on the Potential Influence of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers on Onset and Severity of Severe Acute Respiratory Syndrome Coronavirus 2 Infection.
Could Anti-Hypertensive Drug Therapy Affect the Clinical Prognosis of Hypertensive Patients With COVID-19 Infection? Data From Centers of Southern Italy.
COVID-19 and Cardiovascular Disease.
COVID-19 and renin-angiotensin system modulators: what do we know so far?
Differential expression of angiotensin-converting enzyme-2 in human paranasal sinus mucosa in patients with chronic rhinosinusitis.
Diversity of ACE2 and its interaction with SARS-CoV-2 receptor binding domain.
Do Changes in ACE-2 Expression Affect SARS-CoV-2 Virulence and Related Complications: A Closer Look into Membrane-Bound and Soluble Forms.
Do outpatient statins and ACEIs/ARBs have synergistic effects in reducing the risk of pneumonia? A population-based case-control study.
Effectiveness of amitriptyline versus cough suppressants in the treatment of chronic cough resulting from postviral vagal neuropathy.
Effects of ACEI and ARB on COVID-19 patients: A meta-analysis.
Effects of pentoxifylline on the urinary protein excretion profile of type 2 diabetic patients with microproteinuria: A double-blind, placebo-controlled randomized trial.
Electronic Cigarette Aerosol Is Cytotoxic and Increases ACE2 Expression on Human Airway Epithelial Cells: Implications for SARS-CoV-2 (COVID-19).
Endothelial cells: target for the HIV1 virus?
Engineered ACE2 receptor traps potently neutralize SARS-CoV-2.
Enhanced activity of liposomal polymyxin B against Pseudomonas aeruginosa in a rat model of lung infection.
Exploring the Mystery of Angiotensin-Converting Enzyme II (ACE2) in the Battle against SARS-CoV-2.
Expression of ACE2, Soluble ACE2, Angiotensin I, Angiotensin II and Angiotensin-(1-7) Is Modulated in COVID-19 Patients.
Factors influencing pleural effusion after Fontan operation: an analysis with 95 patients.
Factors Related to Erythropoietin Hyporesponsiveness in Peritoneal Dialysis Patients with Anemia.
FDA-approved thiol-reacting drugs that potentially bind into the SARS-CoV-2 main protease, essential for viral replication.
Flight hormones as therapeutic target for novel Coronavirus infectious disease.
Gastrointestinal manifestations of coronavirus disease 2019.
Hereditary angioedema: classification, pathogenesis, and diagnosis.
Higher pharyngeal epithelial gene expression of angiotensin-converting Enzyme-2 in patients with upper respiratory infection.
Highlights from Studies in Cardiovascular Disease Prevention Presented at the Digital 2020 European Society of Cardiology Congress: Prevention Is Alive and Well.
Highlights of the 22nd French pharmacovigilance meeting.
Histoplasmosis With Tenosynovitis of the Hand and Hypercalcemia Mimicking Sarcoidosis.
Human cardiosphere-derived stromal cells exposed to SARS-CoV-2 evolve into hyper-inflammatory/pro-fibrotic phenotype and produce infective viral particles depending on the levels of ACE2 receptor expression.
Human coronavirus NL63 employs the severe acute respiratory syndrome coronavirus receptor for cellular entry.
Human SARS CoV-2 spike protein mutations.
Hyperreninemic hypoaldosteronism in the critically ill: a new entity.
Hypertension prevalence in human coronavirus disease: the role of ACE system in infection spread and severity.
Impact of anemia after renal transplantation on patient and graft survival and on rate of acute rejection.
Impact of COVID-19 and other viruses on reproductive health.
Impact of statins and angiotensin-converting enzyme inhibitors on mortality of subjects hospitalised with pneumonia.
Impairment of granulomatous inflammatory response to Histoplasma capsulatum by inhibitors of angiotensin-converting enzyme.
Improvement of Central Nervous System Vasculitis in a Patient with Chronic Hepatitis C Virus Infection after Treatment with an Interferon-Free Regimen.
Increased urine angiotensin I converting enzyme activity in patients with upper urinary tract infection.
Induction of granuloma-dependent angiotensin-converting enzyme and eosinophil chemotactic factor in the skin of athymic nude mice.
Inhibition of Angiotensin Converting Enzyme Impairs Anti-staphylococcal Immune Function in a Preclinical Model of Implant Infection.
Is Serum Angiotensin-Converting Enzyme Level Useful For Determining Necroinflammatory Activity In Chronic Hepatitis B Infection?
Is Spironolactone the Preferred Renin-Angiotensin-Aldosterone Inhibitor for Protection Against COVID-19?
Kawasaki-like disease in children with COVID-19: A hypothesis.
Low-grade urinary albumin excretion in normotensive/non-diabetic obstructive sleep apnea patients.
Lower Serum Angiotensin-Converting Enzyme Level in Relation to Hyperinflammation and Impaired Antiviral Immune Response Contributes to Progression of COVID-19 Infection.
Management of hypertension in COVID-19.
Meeting the challenges of a new millennium: optimizing the use of recombinant human erythropoietin.
Meta-analysis of the association between angiotensin pathway inhibitors and COVID-19 severity and mortality.
Microalbuminuria: associations with height and sex in non-diabetic subjects.
Molecular Insights into Human Transmembrane Protease Serine-2 (TMPS2) Inhibitors against SARS-CoV2: Homology Modelling, Molecular Dynamics, and Docking Studies.
Myocyte Specific Upregulation of ACE2 in Cardiovascular Disease: Implications for SARS-CoV-2 mediated myocarditis.
Neuroretinitis as a manifestation of Lyme disease in South India: a case report.
Non-antibiotic treatment for bacterial infections: how to validate chance findings.
Origin and genomic characteristics of SARS-CoV-2 and its interaction with angiotensin converting enzyme type 2 receptors, focusing on the gastrointestinal tract.
Patients taking angiotensin-converting enzyme inhibitors/angiotensin II type I receptor blockers: higher risks of severe acute respiratory syndrome coronavirus 2 infection but milder clinical manifestations?
Peritoneal dialysis: misperceptions and reality.
Pharmacological Modulators of Autophagy as a Potential Strategy for the Treatment of COVID-19.
Physical exercise effects on the brain during COVID-19 pandemic: links between mental and cardiovascular health.
Polymorphisms of the angiotensin converting enzyme and angiotensin II type 1 receptor genes and renal scarring in non-uropathic children with recurrent urinary tract infection.
Population-Based Study of Statins, ARBs, and ACE inhibitors on Pneumonia-Related Outcomes.
Potential of CRISPR/Cas13 System in Treatment and Diagnosis of COVID-19.
Production of angiotensin I converting enzyme by liver granuloma macrophages of Schistosoma mansoni infected mice.
Psoriasis risk in patients with type 2 diabetes in German primary care practices.
Psoriasis: changing clinical patterns.
Quality of US outpatient care: temporal changes and racial/ethnic disparities.
RAAS, ACE2 and COVID-19; a mechanistic review.
Reduced hemoglobin after heart transplantation is no independent risk factor for survival but is associated closely with impaired renal function.
Regulation Mechanism for the Binding between the SARS-CoV-2 Spike Protein and Host Angiotensin-Converting Enzyme II.
Relationship between ACE-inhibitors, ARBs and SARS-CoV-2 infection: where are we?
Relationship between angiotensin-converting enzyme inhibitors or angiotensin receptor blockers and COVID-19 incidence or severe disease.
Relationship of microalbuminuria with the diabetic foot ulcers in type II diabetes.
Renin-Angiotensin System Blockade and Mortality in Patients With Hypertension and COVID-19 Infection.
Renin-angiotensin system blockers and severe acute respiratory syndrome coronavirus 2.
Renin-angiotensin system blockers and susceptibility to COVID-19: a multinational open science cohort study.
Renin-angiotensin-aldosterone system inhibitors and COVID-19 infection or hospitalization: a cohort study.
Renin-Angiotensin-Aldosterone System Inhibitors and COVID-19 Infection or Hospitalization: A Cohort Study.
Renin-Angiotensin-Aldosterone System Inhibitors and COVID-19: A Meta-Analysis and Systematic Review.
Retinal Microcirculation as a Correlate of a Systemic Capillary Impairment After Severe Acute Respiratory Syndrome Coronavirus 2 Infection.
Risk factors for persistent pleural effusions after the extracardiac Fontan procedure.
Role of Oxidative Stress on SARS-CoV (SARS) and SARS-CoV-2 (COVID-19) Infection: A Review.
Role of renin-angiotensin system in gastric oncogenesis.
SARS-CoV-2 as an inflammatory cardiovascular disease: current knowledge and future challenges.
Serum angiotensin-converting enzyme level as a marker of fibrosis in patients with chronic hepatitis B.
Severe acute respiratory syndrome coronavirus 2 infection, angiotensin-converting enzyme 2 and treatment with angiotensin-converting enzyme inhibitors or angiotensin II type 1 receptor blockers.
Severe acute respiratory syndrome coronavirus infection causes neuronal death in the absence of encephalitis in mice transgenic for human ACE2.
Stress Decreases Host Viral Resistance and Increases Covid Susceptibility in Embryonic Stem Cells.
Stroke increases the expression of ACE2, the SARS-CoV-2 binding receptor, in murine lungs.
Systematic review: cystic fibrosis in the SARS-CoV-2/COVID-19 pandemic.
Systemic arterio-venous thrombosis in COVID-19: A pictorial review.
Targeting the GRP78-Dependant SARS-CoV-2 Cell Entry by Peptides and Small Molecules.
Testis and blood-testis barrier in Covid-19 infestation: role of angiotensin-converting enzyme 2 in male infertility.
The angiotensin-converting enzyme 2 (ACE2) receptor in the prevention and treatment of COVID-19 are distinctly different paradigms.
The effect of captopril on the expression of MMP-9 and the prognosis of neurological function in herpes simplex encephalitis mice.
The host's angiotensin-converting enzyme polymorphism may explain epidemiological findings in COVID-19 infections.
The Impact of angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers in patients with Clostridium difficile infection.
The impact of host's genetic susceptibility on Helicobacter pylori infection in children.
The impact of prior outpatient ACE inhibitor use on 30-day mortality for patients hospitalized with community-acquired pneumonia.
The management of idiopathic nephrotic syndrome in children.
The outcomes of the postulated interaction between SARS-CoV-2 and the renin-angiotensin system on the clinician's attitudes toward hypertension treatment.
The Possible Relationship between the Abuse of Tobacco, Opioid, or Alcohol with COVID-19.
Towards Neuro-CoViD-19.
Treatment and clinical outcomes of elderly idiopathic membranous nephropathy: A multicenter cohort study in Korea.
Trimethoprim-induced hyperkalemia: An analysis of reported cases.
Two hits to the renin-angiotensin system may play a key role in severe COVID-19.
Unexpected tumor reduction in metastatic colorectal cancer patients during SARS-Cov-2 infection.
US of renal insufficiency in neonates.
Usefulness of the Guidelines of the Spanish Society of Pulmonology and Thoracic Surgery (SEPAR) in Identifying the Causes of Chronic Cough.
[ACE gene polymorphism and renal scarring in children with urinary tract infection and vesicoureteric reflux: preliminary results]
[High dose of enzyme replacement therapy was successful for the pulmonary involvement in a case of type 2 Gaucher disease].
[Role of age, comorbidity and renin- angiotensin-aldosterone system in COVID-19. Effects of ACE inhibitors and angiotensin receptor blockers].
[Susceptibility of animal species to experimental SARS-CoV-2 (Coronaviridae: Coronavirinae: Betacoronavirus; Sarbecovirus) infection].
Inferior Wall Myocardial Infarction
Effects of enalapril on ventricular volumes and neurohumoral status after inferior wall myocardial infarction.
Infertility
Combinations of fibrinolytic gene polymorphisms (plasminogen activator inhibitor type 1 4G/5G, factor XIII Val34Leu and angiotensin-converting enzyme I/D) in women with idiopathic infertility.
Somatic angiotensin converting enzyme in varicocele.
Infertility, Male
Angiotensin-converting enzymes play a dominant role in fertility.
Effect of captopril on semen quality.
Lack of association between polymorphisms in the testis-specific angiotensin converting enzyme gene and male infertility in an Asian population.
Maintenance of normal blood pressure and renal functions are independent effects of angiotensin-converting enzyme.
Physiological non-equivalence of the two isoforms of angiotensin-converting enzyme.
Relationship between human seminal kallikrein-kinin system and spermatogenesis.
Inflammatory Bowel Diseases
Angiotensin-converting enzyme in Crohn's disease and ulcerative colitis.
Angiotensin-converting enzyme insertion/deletion gene polymorphism in inflammatory bowel diseases.
Are Patients with Inflammatory Bowel Disease at Increased Risk of Coronary Artery Disease?
Gene expression profiling of the mouse gut: Effect of intestinal flora on intestinal health.
Is there any role of renin-angiotensin system inhibitors in modulating inflammatory bowel disease outcome?
Serum angiotensin converting enzyme activity in Crohn's disease and ulcerative colitis.
Ulcerative Colitis in a COVID-19 Patient: A Case Report.
Influenza, Human
Acute Cardiac Injury in Coronavirus Disease 2019 and Other Viral Infections-A Systematic Review and Meta-Analysis.
Effect of a patient panel-support tool on care delivery.
Extracellular processing of peptide antigens that bind class I major histocompatibility molecules.
Getting advances in science to make a difference: Translation research for improving diabetes care.
Implementation of a CKD checklist for primary care providers.
Mortality Risk Factors among Hospitalized COVID-19 Patients in a Major Referral Center in Iran.
Insulin Resistance
A comparison between enalapril and captopril on insulin sensitivity in normotensive healthy volunteers.
A comparison of the hypotensive and hypoglycaemic actions of an angiotensin converting enzyme inhibitor, an AT1a antagonist and troglitazone.
A double blind comparison of the effects of amlodipine and enalapril on insulin sensitivity in hypertensive patients.
A long-term comparison between enalapril and captopril on insulin sensitivity in normotensive non-insulin dependent diabetic volunteers.
A meta-analysis of the effects of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers on insulin sensitivity in hypertensive patients without diabetes.
ACE gene polymorphism and insulin action in older subjects and healthy centenarians.
ACE inhibition but not angiotensin II antagonism reduces plasma fibrinogen and insulin resistance in overweight hypertensive patients.
Acute effect of the dual angiotensin-converting enzyme and neutral endopeptidase 24-11 inhibitor mixanpril on insulin sensitivity in obese Zucker rat.
Addition of Losartan to angiotensin-converting enzyme inhibitors improves insulin resistance in patients with chronic heart failure treated without ?-blockers.
Angiotensin converting enzyme inhibition lowers body weight and improves glucose tolerance in C57BL/6J mice maintained on a high fat diet.
Angiotensin converting enzyme inhibitors and modulation of skeletal muscle insulin resistance.
Angiotensin converting enzyme inhibitors suppress production of tumor necrosis factor-alpha in vitro and in vivo.
Angiotensin I converting enzyme gene polymorphism and insulin resistance in patients with angina pectoris.
Angiotensin I converting enzyme gene polymorphism and insulin resistance in patients with hypertension.
Angiotensin I-converting enzyme gene polymorphism modulates the consequences of in utero growth retardation on plasma insulin in young adults.
Angiotensin mediates forearm glucose uptake by hemodynamic rather than direct effects.
Angiotensin-(1-7) contributes to insulin-sensitizing effects of angiotensin-converting enzyme inhibition in obese mice.
Angiotensin-converting enzyme gene polymorphism and risk of insulin resistance in PCOS.
Angiotensin-converting enzyme gene polymorphism in overweight and obese Turkish patients with insulin resistance.
Angiotensin-converting enzyme inhibition reverses diet-induced obesity, insulin resistance and inflammation in C57BL/6J mice.
Angiotensin-converting enzyme inhibitor increases insulin-induced pp185 phosphorylation in liver and muscle of obese rats.
Angiotensin-converting enzyme inhibitors and insulin sensitivity: metabolic effects in hypertension, diabetes, and heart failure.
Angiotensin-converting enzyme inhibitors versus angiotensin II receptor blockers on insulin sensitivity in hypertensive patients: A meta-analysis of randomized controlled trials.
Angiotensinogen polymorphisms and post-transplantation diabetes mellitus in Korean renal transplant subjects.
Antidiabetic mechanisms of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists: beyond the renin-angiotensin system.
Antihypertensive agents, insulin sensitivity, and new-onset diabetes.
Antihypertensive therapy and insulin sensitivity: do we have to redefine the role of beta-blocking agents?
Antihypertensive therapy. Current issues and challenges.
Antihypertensive treatment in insulin resistant patients.
Association of angiotensin converting enzyme and plasminogen activator inhibitor-1 promoter gene polymorphisms with features of the insulin resistance syndrome in patients with premature coronary heart disease.
Association of irisin concentrations with the presence of diabetic nephropathy and retinopathy.
Beneficial effects of losartan or telmisartan on the local hepatic renin-angiotensin system to counter obesity in an experimental model.
Bradykinin may not be involved in improvement of insulin resistance by angiotensin converting enzyme inhibitor.
Cardiovascular effects of captopril and enalapril in obese Zucker rats.
Chronic renin inhibition with aliskiren improves glucose tolerance, insulin sensitivity, and skeletal muscle glucose transport activity in obese Zucker rats.
Cilostazol, a phosphodiesterase inhibitor, improves insulin sensitivity in the Otsuka Long-Evans Tokushima Fatty Rat, a model of spontaneous NIDDM.
Combination therapy of exercise and angiotensin-converting enzyme inhibitor markedly improves insulin sensitivities in hypertensive patients with insulin resistance.
Comparative effects of N-acetyl-L-cysteine and ramipril on arterial hypertension, insulin resistance, and oxidative stress in chronically glucose-fed rats.
Comparison of effects of captopril used either alone or in combination with a thiazide diuretic on insulin action in hypertensive Type 2 diabetic patients: a double-blind crossover study.
Considerations in the treatment of insulin resistance and related disorders with a new sympatholytic agent.
Controlled study of the effect of angiotensin converting enzyme inhibition versus calcium-entry blockade on insulin sensitivity in overweight hypertensive patients: Trandolapril Italian Study (TRIS).
Deletion polymorphism of angiotensin-converting enzyme gene is associated with postprandial hyperglycaemia in individuals undergoing general check-up.
Determination of insulin sensitivity: methodological considerations.
Dietary protein restriction in combination with angiotensin converting enzyme inhibitor improves insulin resistance in patients with chronic renal disease.
Differential effect of chronic treatment with two beta-blocking agents on insulin sensitivity: the carvedilol-metoprolol study.
Differential effects of ACE-inhibition and angiotensin II antagonism on fibrinolysis and insulin sensitivity in hypertensive postmenopausal women.
Direct renin inhibitor prevents and ameliorates insulin resistance, aortic endothelial dysfunction and vascular remodeling in fructose-fed hypertensive rats.
Effect of angiotensin converting enzyme inhibitor (lisinopril) on insulin sensitivity and sodium transport in mild hypertension.
Effect of angiotensin-converting enzyme inhibition on endothelial function and insulin sensitivity in hypertensive patients.
Effect of antihypertensive treatment with alacepril on insulin resistance in diabetic spontaneously hypertensive rats.
Effect of chronic ACE inhibition on glucose tolerance and insulin sensitivity in hypertensive type 2 diabetic patients.
Effect of chronic treatment with enalapril on glucose tolerance and serum insulin in non-insulin-resistant Japanese patients with essential hypertension.
Effect of imidapril, an angiotensin-converting enzyme inhibitor, on fructose-induced insulin resistance in rats.
Effect of manidipine and delapril on insulin sensitivity in type 2 diabetic patients with essential hypertension.
Effect of Renin-Angiotensin system inhibition on cardiovascular events in older hypertensive patients with metabolic syndrome.
Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial.
Effect on insulin sensitivity of angiotensin converting enzyme inhibitors with or without a sulphydryl group: bradykinin may improve insulin resistance in dogs and humans.
Effects of angiotensin II on insulin sensitivity: a placebo-controlled study.
Effects of angiotensin receptor antagonist and angiotensin converting enzyme inhibitor on insulin sensitivity in fructose-fed hypertensive rats and essential hypertensives.
Effects of antihypertensive treatment on insulin sensitivity with special reference to ACE inhibitors.
Effects of benazepril on insulin resistance and glucose tolerance in uremia.
Effects of chronic angiotensin converting enzyme inhibition on glucose tolerance and insulin sensitivity in essential hypertension.
Effects of dual angiotensin-converting enzyme and neutral endopeptidase 24-11 chronic inhibition by mixanpril on insulin sensitivity in lean and obese Zucker rats.
Effects of hormone replacement therapy on left ventricular hypertrophy and growth-promoting factors in hypertensive postmenopausal women.
Effects of imidapril, an angiotensin-converting enzyme inhibitor, on insulin sensitivity and responsiveness in streptozotocin-induced diabetic rats.
Effects of losartan in combination with or without exercise on insulin resistance in Otsuka Long-Evans Tokushima Fatty rats.
Effects of perindopril in hypertensive patients with or without type 2 diabetes mellitus, and with altered insulin sensitivity.
Effects of perindopril on insulin sensitivity and plasma lipid profile in hypertensive non-insulin-dependent diabetic patients.
Effects of quinapril and losartan on insulin sensitivity in genetic hypertensive rats with different metabolic abnormalities.
Effects of the angiotensin converting enzyme inhibitor temocapril on insulin sensitivity and its effects on renal sodium handling and the pressor system in essential hypertensive patients.
Evidence for a direct effect of captopril on early steps of insulin action in BC3H-1 myocytes.
Exercise-induced changes in insulin action are associated with ACE gene polymorphisms in older adults.
Four week administration of an ACE inhibitor and a cardioselective beta-blocker in healthy volunteers: no influence on insulin sensitivity.
Genotypes of renin-angiotensin system and plasma adiponectin concentration in kidney transplant patients.
Glucose intolerance in spontaneously hypertensive and Wistar-Kyoto rats: enhanced gene expression and synthesis of skeletal muscle glucose transporter 4.
Hyperinsulinemia, insulin resistance, and the treatment of hypertension.
Hypertension and insulin disorders.
Hypertension and insulin resistance.
Hypertension in patients with diabetes mellitus.
Hypoglycaemia associated with use of inhibitors of angiotensin converting enzyme.
Imidapril, an angiotensin-converting enzyme inhibitor, improves insulin sensitivity by enhancing signal transduction via insulin receptor substrate proteins and improving vascular resistance in the Zucker fatty rat.
Impact of the renin-angiotensin system on lipid and carbohydrate metabolism.
Improved early-phase insulin response after candesartan treatment in hypertensive patients with impaired glucose tolerance.
Improved insulin action and glycemic control after long-term angiotensin-converting enzyme inhibition in subjects with arterial hypertension and type II diabetes.
Increased frequency of the DI genotype of the Angiotensin-I Converting Enzyme (ACE) and association of the II genotype with Insulin Resistance in Polycystic Ovary Syndrome.
Induction of Type 2 Diabetes Mellitus with Antihypertensive Therapy: Is There Any Role of Alpha Adducin, ACE, and IRS-1 Gene?
Influence of nebivolol and enalapril on metabolic parameters and arterial stiffness in hypertensive type 2 diabetic patients.
Influence of the PPAR-gamma2 Pro12Ala and ACE I/D polymorphisms on insulin sensitivity and training effects in healthy offspring of type 2 diabetic subjects.
Influence of West African Ethnicity and Gender on Beta-Cell Function and Insulin Sensitivity in Essential Hypertensives Treated with Hydrochlorothiazide and Hydrochlorothiazide-lisinopril Combination.
Inhibition of Renin-Angiotensin system: implications for diabetes control and prevention.
Insertion/Deletion Polymorphism on ACE Gene is Associated with Endothelial Dysfunction in Young Patients with Hypertension.
Insulin and the renin-angiotensin-aldosterone system: influence of ACE inhibition.
Insulin resistance and angiotensin converting enzyme polymorphism in Japanese hypertensive subjects.
Insulin resistance and diabetes in the context of treatment of hypertension.
Insulin resistance and essential hypertension: pathophysiologic and therapeutic implications.
Insulin resistance and hypertension.
Insulin resistance and sympathetic overactivity in women.
Insulin resistance as an intermediary endpoint.
Insulin resistance in adipocytes from spontaneously hypertensive rats: effect of long-term treatment with enalapril and losartan.
Insulin resistance in hypertension: a focused review.
Insulin sensitivity and endothelial function in hypertension: a comparison of temocapril and candesartan.
Insulin sensitivity in a long-term crossover trial with celiprolol and other antihypertensive agents.
Insulin sensitivity in hypertensive Type 2 diabetic patients after 1 and 19 days' treatment with trandolapril.
Insulin sensitivity in newly detected hypertensive patients: influence of captopril and other antihypertensive agents on insulin sensitivity and related biological parameters.
Insulin sensitivity in normotensive subjects during angiotensin converting enzyme inhibition with fosinopril.
Insulin sensitivity, glucose effectiveness, and beta-cell function in obese males with essential hypertension: investigation of the effects of treatment with a calcium channel blocker (diltiazem) or an angiotensin-converting enzyme inhibitor (quinapril).
Interactions of captopril and verapamil on glucose tolerance and insulin action in an animal model of insulin resistance.
Interactions of exercise training and ACE inhibition on insulin action in obese Zucker rats.
Introduction to a structural basis for renal and vascular complications in diabetes and hypertension.
Is captopril-induced improvement of insulin sensitivity mediated via endothelin?
Is hypertension an insulin-resistant state? Metabolic changes associated with hypertension and antihypertensive therapy.
Is there relationship between the A1166C polymorphism of the angiotensin II receptor AT1 and plasma renin activity, insulin resistance and reduction of blood pressure after angiotensin-converting enzyme inhibitor therapy?
Kinins contribute to the improvement of insulin sensitivity during treatment with angiotensin converting enzyme inhibitor.
Lack of impact of angiotensin-converting enzyme gene polymorphism and salt intake on insulin resistance and limb blood flow.
Lemon Extract Reduces Angiotensin Converting Enzyme (ACE) Expression and Activity and Increases Insulin Sensitivity and Lipolysis in Mouse Adipocytes.
Lisinopril is neutral to insulin sensitivity and serum lipoproteins in essential hypertensive patients.
Long-term protection of obese Zucker rat kidneys from fibrosis and renal failure with an angiotensin-converting enzyme inhibitor/diuretic combination.
Longdan Xiegan Tang attenuates liver injury and hepatic insulin resistance by regulating the angiotensin-converting enzyme 2/Ang (1-7)/Mas axis-mediated anti-inflammatory pathway in rats.
Management of Arterial Hypertension in Obese Patients.
Mechanism of differential effects of antihypertensive agents on serum lipids.
Metabolic effects of long-term angiotensin-converting enzyme inhibition with fosinopril in patients with essential hypertension: relationship to angiotensin-converting enzyme inhibition.
Metabolic manifestations of low-dose diuretics.
Metabolic neutrality of perindopril: focus on insulin sensitivity in overweight patients with essential hypertension.
Metabolic Safety of Antihypertensive Drugs: Myth versus Reality.
Metabolic syndrome and chronic kidney disease.
Milk-derived peptide Val-Pro-Pro (VPP) inhibits obesity-induced adipose inflammation via an angiotensin-converting enzyme (ACE) dependent cascade.
Modulation of metabolic control by angiotensin converting enzyme (ACE) inhibition.
New concepts regarding events that lead to myocardial infarction.
New evidence for the fetal insulin hypothesis: fetal angiotensinogen M235T polymorphism is associated with birth weight and elevated fetal total glycated hemoglobin at birth.
New risk factors for coronary heart disease in Asia.
Obesity, essential hypertension and renin-angiotensin system.
Oxidative phenotype induced by aerobic physical training prevents the obesity-linked insulin resistance without changes in gastrocnemius muscle ACE2-Angiotensin(1-7)-Mas axis.
Pharmacogenetics of Angiotensin-Converting Enzyme Inhibitors in Patients with Alzheimer's Disease Dementia.
Polymorphisms in the Renin-Angiotensin System and Outcome of Very-Low-Birthweight Infants.
Quantitative characterization of insulin-glucose response in Watanabe heritable hyperlipidemic and cholesterol-fed rabbits and the effect of cilazapril.
Ramipril increases the protein level of skeletal muscle IRS-1 and alters protein tyrosine phosphatase activity in spontaneously hypertensive rats.
Rats with low brain angiotensinogen do not exhibit insulin resistance during early aging.
Relations between deletion polymorphism of the angiotensin-converting enzyme gene and insulin resistance, glucose intolerance, hyperinsulinemia, and dyslipidemia.
Relationship between angiotensin-converting enzyme gene insertion or deletion polymorphism and insulin sensitivity in healthy newborns.
Relationship between angiotensin-converting enzyme gene polymorphism and insulin resistance in never-treated hypertensive patients.
Relationship of the angiotensin-converting enzyme gene polymorphism to glucose intolerance, insulin resistance, and hypertension in NIDDM.
Renin-angiotensin-system blockade in the prevention of diabetes.
Requirements for antihypertensive therapy in diabetic patients: metabolic aspects.
Salutary effects of attenuation of angiotensin II on coronary perivascular fibrosis associated with insulin resistance and obesity.
Soy ?-conglycinin retards progression of diabetic nephropathy via modulating the insulin sensitivity and angiotensin-converting enzyme activity in rats fed with high salt diet.
Syndrome X: a consequence of intra-uterine malnutrition?
Telmisartan improves insulin resistance in high renin nonmodulating salt-sensitive hypertensives.
The alterations in insulin sensitivity during angiotensin converting enzyme inhibitor treatment are related to changes in the calcium/magnesium balance.
The coronary artery disease paradox: the role of hyperinsulinemia and insulin resistance and implications for therapy.
The effects of an angiotensin-converting enzyme inhibitor and an angiotensin II receptor antagonist on insulin resistance in fructose-fed rats.
The effects of ramipril on glucose tolerance, insulin secretion, and insulin sensitivity in patients with hypertension.
The effects of the renin-angiotensin-aldosterone system gene polymorphisms on insulin resistance in hypertensive families.
The efficacy of angiotensin converting enzyme inhibitors versus angiotensin II receptor blockers on insulin resistance in hypertensive patients: A protocol for a systematic review and meta-analysis.
The I/D polymorphism of angiotensin-converting enzyme gene but not the angiotensinogen gene is associated with insulin response to oral glucose in Japanese.
The insertion allele at the angiotensin I-converting enzyme gene locus is associated with insulin resistance.
The kallikrein-kinin system, angiotensin converting enzyme inhibitors and insulin sensitivity.
The link between insulin resistance and hypertension. Effects of antihypertensive and antihyperlipidaemic drugs on insulin sensitivity.
The mechanisms of insulin sensitivity improving effects of angiotensin converting enzyme inhibitor.
The mechanisms of the improvement of insulin sensitivity by angiotensin converting enzyme inhibitor.
The renin-angiotensin system: a target of and contributor to dyslipidemias, altered glucose homeostasis, and hypertension of the metabolic syndrome.
The renin-angiotensin-aldosterone system: a pivotal role in insulin sensitivity and glycemic control.
The role of angiotensin II and its receptors in regulation of adipose tissue metabolism and cellularity.
The role of angiotensin-converting enzyme and apolipoprotein-E gene polymorphisms on lipid compositions in newborn infants with intrauterine growth restriction.
The role of the renin-angiotensin system in insulin sensitivity in normotensive subjects.
The tissue renin-angiotensin system and intracellular signalling.
The use of ACE inhibitors on diabetic patients without renal disease.
Tissue availability of insulin-like growth factor I is inversely related to insulin resistance in essential hypertension: effects of angiotensin converting enzyme inhibition.
Toxic effects of drugs used in the ICU. Nitroprusside, nitroglycerin, and angiotensin-converting enzyme inhibitors.
Trandolapril does not improve insulin sensitivity in patients with hypertension and type 2 diabetes: a double-blind, placebo-controlled crossover trial.
Treatment of arterial hypertension in obese patients.
Treatment of insulin resistance in uremia.
[Angiotensin converting enzyme inhibitors increase insulin sensitivity in offspring of families with hypertension even after active interventions. Results of a clamp study]
[Diabetes mellitus].
[I/D polymorphism of angiotensin I converting enzyme gene and insulin resistance and some parameters of metabolic syndrome in patients with type 2 diabetes]
[Influence of angiotensin converting enzyme gene insertion/deletion polymorphism and beta3-adrenergic receptor gene Trp64Arg polymorphism on fetal growth and neonatal insulin sensitivity]
[Left ventricular hypertrophy--an important, often unrecognized risk factor]
[Prevention of type II diabetes by inhibiting the renin-angiotensin system]
[RAAS and insulin resistance].
[The effect of alacepril on insulin sensitivity in patients with essential hypertension]
[The effect of treatment with enalapril versus losartan on levels of insulin resistance in patients with essential hypertension]
[Therapeutic options for metabolic syndrome in obese patients]
[Use of captopril in diabetics]
Intellectual Disability
DPP-IV Inhibitor-Associated Angioedema in Patient With Known History of ACE Inhibitor Angioedema.
Intermittent Claudication
Angiotensin converting enzyme inhibitors and angiotensin receptor blockers have no effect on the outcomes of endovascular revascularization in tibial arterial occlusive disease.
Angiotensin-converting enzyme inhibitors for intermittent claudication associated with peripheral arterial disease.
Meta-analysis of angiotensin converting enzyme inhibitors effect on walking ability and ankle brachial pressure index in patients with intermittent claudication.
Randomized clinical trial of angiotensin-converting enzyme inhibitor, ramipril, in patients with intermittent claudication.
The influence of chronic treatment with betablockade and angiotensin converting enzyme inhibition on the peripheral blood flow in hypertensive patients with and without concomitant intermittent claudication. A comparative cross-over trial.
[Management of patients with intermittent claudication]
Intracranial Aneurysm
Angiotensin-converting enzyme insertion/deletion gene polymorphism and risk of intracranial aneurysm in a Chinese population.
Association between angiotensin-converting enzyme insertion/deletion polymorphisms and intracranial aneurysm susceptibility: A meta-analysis.
Common Variants of the ACE Gene and Aneurysmal Subarachnoid Hemorrhage in a Danish Population: A Case-control Study.
Intraoperative cardiac arrest: was it the ACE inhibitor?
Lack of an association between the angiotensin-converting enzyme insertion/deletion polymorphism and intracranial aneurysms in a Caucasian population in the United States.
The ACE I allele is associated with increased risk for ruptured intracranial aneurysms.
The angiotensin converting enzyme insertion/deletion polymorphism and intracranial aneurysm: a meta-analysis of case-control studies.
[The role of angiotensin-converting enzyme and apolipoprotein E in the development of intracranial aneurysms.]
Intracranial Arteriosclerosis
Association between deletion polymorphism of the angiotensin-converting enzyme gene and cerebral atherosclerosis.
Intracranial Hemorrhages
Analysis of Renal Artery Stenosis in Patients with Heart Failure: A RASHEF Study.
Angiotensin-converting enzyme polymorphisms and risk of spontaneous deep intracranial hemorrhage in Taiwan.
Genetic association of angiotensin-converting enzyme I/D polymorphism with intracranial hemorrhage: an updated meta-analysis of 39 case-control studies.
Intracranial Hypertension
Treatment modalities for hypertensive patients with intracranial pathology: options and risks.
Iridocyclitis
A comparison of Blau's syndrome and sarcoidosis.
Cushing's syndrome due to primary adrenocortical nodular dysplasia, cardiac myxomas, and spotty pigmentation, complicated by sarcoidosis.
Role of MRI in diagnosis of childhood sarcoidosis with fever of unknown origin.
Iron Deficiencies
Anemia and diabetic nephropathy.
Factor deficiency in the anemia of renal transplant patients with grade III-IV chronic kidney disease: baseline results of the ARES Study.
[Etiology and clinical management of anemia in heart failure. GESAIC study.]
[Heart failure and iron deficiency].
[Pravovirus B19 infection--the cause of severe anaemia after renal transplantation]
[Recommendations for the treatment of heart failure : What's new?].
Ischemic Attack, Transient
Antihypertensive and lipid lowering treatment in stroke prevention: current state and future.
Cognitive function and the emotional state of stroke patients on antihypertensive therapy.
Factors associated with renal impairment in Chinese patients with non-valvular AF and without an established renal disease: a cross-sectional study.
Fibrin Clot Permeability as a Predictor of Stroke and Bleeding in Anticoagulated Patients With Atrial Fibrillation.
Obesity and intracranial in-stent thrombosis.
Resource utilization implications of treatment were able to be assessed from appropriately reported clinical trial data.
Ischemic Stroke
A calcium channel or angiotensin converting enzyme inhibitor/angiotensin receptor blocker regime to reduced blood pressure variability in acute ischaemic stroke (CAARBS): A feasibility trial.
A Novel Approach to the Treatment of Orolingual Angioedema After Tissue Plasminogen Activator Administration.
ACE and ADD1 gene in extra and intracranial atherosclerosis in ischaemic stroke.
ACE I/D polymorphism in different etiologies of ischemic stroke.
ACE-II genotype and I allele predicts ischemic stroke among males in south India.
ACE2-Ang-(1-7)-Mas Axis in Brain: A Potential Target for Prevention and Treatment of Ischemic Stroke.
Advantages of lipid-lowering therapy in cerebral ischemia: role of HMG-CoA reductase inhibitors.
An angiotensin-converting enzyme gene polymorphism suggests a genetic distinction between ischaemic stroke and carotid stenosis.
Analysis of Renal Artery Stenosis in Patients with Heart Failure: A RASHEF Study.
Angioedema associated with thrombolysis for ischemic stroke: analysis of a case-control study.
Angiotensin converting enzyme (I/D) gene polymorphism contributes to ischemic stroke risk in Caucasian individuals: A meta-analysis based on 22 case-control studies.
Angiotensin converting enzyme polymorphism and ischemic stroke.
Angiotensin receptor blockers (ARB) outperform angiotensin-converting enzyme (ACE) inhibitors on ischemic stroke prevention in patients with hypertension and diabetes - A real-world population study in Taiwan.
Angiotensin-converting enzyme inhibitor use is associated with reduced plasma concentration of C-reactive protein in patients with first-ever ischemic stroke.
Angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers and the risk of major adverse cardiac events in patients with diabetes and prior stroke: a nationwide study.
Angiotensin-converting enzyme insertion/deletion polymorphism and the risk of ischemic stroke in a South Indian population.
Angiotensin-converting enzyme insertion/deletion polymorphism contributes to ischemic stroke risk: a meta-analysis of 50 case-control studies.
Antihypertensive drug therapies and the risk of ischemic stroke.
Antihypertensive medications for risk reduction of first and recurrent ischemic stroke.
Association between angiotensin converting enzyme gene insertion/deletion polymorphism and ischemic stroke in north Indian population: a case-control study and meta-analysis.
Association between the ACE I/D polymorphism and risk of ischemic stroke: an updated meta-analysis of 47,026 subjects from 105 case-control studies.
Association of AGT M235T and ACE I/D polymorphisms with the risk of ischemic stroke: Meta-analysis in Han Chinese population.
Association of Angiotensin converting enzyme gene insertion / deletion polymorphism with risk of ischemic heart disease in a population of smokers in southern India.
Audit report and systematic review of orolingual angioedema in post-acute stroke thrombolysis.
Biochemical basis of angioedema associated with recombinant tissue plasminogen activator treatment: an in vitro experimental approach.
Clinical Relevance of MTHFR, eNOS, ACE, and ApoE Gene Polymorphisms and Serum Vitamin Profile among Malay Patients with Ischemic Stroke.
Coexistence of angiotensin II Type-1 receptor A1166C and angiotensin-converting enzyme D/D polymorphism suggests susceptibility for small-vessel-associated ischemic stroke.
Contribution of angiotensin-converting enzyme and angiotensin II to ischemic stroke: their role in the formation of stable and unstable carotid atherosclerotic plaques.
DD genotype of ACE gene is a risk factor for intracerebral hemorrhage.
Deletion polymorphism in the angiotensin-converting enzyme gene in patients with a history of ischemic stroke.
Determining the appropriateness of selected surgical and medical management options in recurrent stroke prevention: A guideline for primary care physicians from the National Stroke Association work group on recurrent stroke prevention.
Effect of pre-stroke use of ACE inhibitors on ischemic stroke severity.
Effect of prestroke use of Angiotensin-converting enzyme inhibitors alone versus combination with antiplatelets and statin on ischemic stroke outcome.
Effects of Angiotensin-Converting Enzyme Inhibition on Circulating Endothelial Progenitor Cells in Patients with Acute Ischemic Stroke.
Endothelial nitric oxide synthase gene interactions and the risk of ischaemic stroke.
Epidemiology, Pathophysiology, and Treatment of Hypertension in Ischaemic Stroke Patients.
Evaluation of the angiotensin-converting enzyme insertion/deletion polymorphism and the risk of ischaemic stroke.
Evaluation of the interactions of common genetic mutations in stroke subtypes.
Evaluation of the interactions of common genetic mutations in stroke.
Evaluation of the modifying effects of unfavourable genotypes on classical clinical risk factors for ischaemic stroke.
Gender association of the angiotensin-converting enzyme gene with ischaemic stroke.
Gene polymorphism of angiotensin II type 1 and type 2 receptors.
Gene polymorphisms of angiotensin-converting enzyme and angiotensinogen and risk of idiopathic ischemic stroke.
Gene-gene and gene-environment interplay represent specific susceptibility for different types of ischaemic stroke and leukoaraiosis.
Genetics of ischaemic stroke among persons of non-European descent: a meta-analysis of eight genes involving approximately 32,500 individuals.
Global peak left atrial longitudinal strain assessed by transthoracic echocardiography is a good predictor of left atrial appendage thrombus in patients in sinus rhythm with heart failure and very low ejection fraction - an observational study.
Impact of angiotensin-converting enzyme inhibitors administration prior to acute ischemic stroke onset on in-hospital mortality.
Impact of the Additive Effect of Angiotensin-Converting Enzyme Inhibitors and?/or Statins with Antiplatelet Medication on Mortality After Acute Ischaemic Stroke.
Influence of on-going treatment with angiotensin-converting enzyme inhibitor or angiotensin receptor blocker on the outcome of patients treated with intravenous rt-PA for ischemic stroke.
Interaction of angiotensin-converting enzyme and apolipoprotein E gene polymorphisms in ischemic stroke involving large-vessel disease.
Involvement of angiotensin-(1-7) in the neuroprotection of captopril against focal cerebral ischemia.
Ischemic stroke and the gene for angiotensin-converting enzyme in Japanese hypertensives.
Lack of an association between angiotensin-converting enzyme gene insertion/deletion polymorphism and ischaemic stroke.
Meta-analysis of genetic studies from journals published in China of ischemic stroke in the Han Chinese population.
Meta-analysis of genetic studies in ischemic stroke: thirty-two genes involving approximately 18,000 cases and 58,000 controls.
Orolingual angioedema after alteplase therapy of acute ischaemic stroke: incidence and risk of prior angiotensin-converting enzyme inhibitor use.
Peripheral arterial disease versus other localizations of vascular disease: the ATTEST study.
Polymorphisms of ACE-1 and MTHFR genes and genetic susceptibility of ischemic strok.
Polymorphisms of MTHFR, eNOS, ACE, AGT, ApoE, PON1, PDE4D, and Ischemic Stroke: Meta-Analysis.
Post-myocardial infarction left ventricular pseudoaneurysm diagnosed incidentally by echocardiography.
Predictive models for adverse clinical outcomes in Chinese patients with atrial fibrillation undergoing percutaneous coronary intervention with stenting.
Prevalence of Appropriate Management of Diabetes Mellitus in an Academic General Medicine Clinic.
Prevalence of Thrombophilic Mutations and ACE ID Polymorphism in Turkish Ischemic Stroke Patients.
Randomised controlled trial of a Calcium Channel or Angiotensin Converting Enzyme Inhibitor/Angiotensin Receptor Blocker Regime to Reduce Blood Pressure Variability following Ischaemic Stroke (CAARBS): a protocol for a feasibility study.
Risk of cardiovascular events after initiation of long-acting bronchodilators in patients with chronic obstructive lung disease: A population-based study.
Stroke prevention therapy beyond antithrombotics: unifying mechanisms in ischemic stroke pathogenesis and implications for therapy: an invited review.
The D allele of the angiotensin-converting enzyme (ACE) insertion/deletion (I/D) polymorphism is associated with worse functional outcome of ischaemic stroke.
The expression of angiotensin-converting enzyme 2-angiotensin-(1-7)-Mas receptor axis are upregulated after acute cerebral ischemic stroke in rats.
The Interaction of Apolipoprotein E and Angiotensin I-Converting Enzyme Dna Polymorphisms with Hypertension on Early Ischemic Stroke Risk.
Tissue Plasminogen Activator-Induced Angioedema Involving a Posterior Cerebral Artery Infarct: A Case Presentation.
Treatment with angiotensin-converting enzyme inhibitors is associated with a reduction in short-term mortality in older patients with acute ischemic stroke.
Up-regulation of angiotensin-converting enzyme in response to acute ischemic stroke via ERK/NF-?B pathway in spontaneously hypertensive rats.
Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers for Geriatric Ischemic Stroke Patients: Are the Rates Right?
[Association analysis of polymorphism in angiotensin-converting enzyme gene in ischemic stroke]
[Association between angiotensin-converting enzyme and polymorphisms of N5, N10-methylenetetrahydrofolic acid reductase gene in patients with ischemic stroke]
[Relationship between angiotensin converting enzyme gene and ischemic stroke]
[The role of polymorphic variants of renin-angiotensin system genes in the development of ischemic stroke in Moscow population]
Keloid
CASE REPORT Total Management of a Severe Case of Systemic Keloids Associated With High Blood Pressure (Hypertension): Clinical Symptoms of Keloids May Be Aggravated by Hypertension.
Expression of Components of the Renin-Angiotensin System by the Embryonic Stem Cell-Like Population within Keloid Lesions.
Keloids: Current and emerging therapies.
Plasma Angiotensin-converting Enzyme Levels in Patients With Keloids and/or Hypertension.
Review on novel targets and therapies for Keloids.
Wound healing, angiotensin-converting enzyme inhibition, and collagen-containing products: a case study.
Keratosis, Actinic
ACE and ACE2 expression in normal and malignant skin lesions.
Predictors of Basal Cell Carcinoma in High-Risk Patients in the VATTC (VA Topical Tretinoin Chemoprevention) Trial.
Ketosis
Angiotensin-converting enzyme in diabetes mellitus dependence on metabolic aberration.
COVID-19-Induced Diabetic Ketoacidosis in an Adult with Latent Autoimmune Diabetes.
Metformin Associated Lactic Acidosis in the Intensive Care Unit: A Rare Condition Mimicking Sepsis.
Kidney Calculi
Astaxanthin modulates osteopontin and transforming growth factor ?1 expression levels in a rat model of nephrolithiasis: a comparison with citrate administration.
Kidney Diseases
Abelmoschus manihot - a traditional Chinese medicine versus losartan potassium for treating IgA nephropathy: study protocol for a randomized controlled trial.
ACE inhibition reduces glomerulosclerosis and regenerates glomerular tissue in a model of progressive renal disease.
ACE Inhibitor and ARB utilization and expenditures in the Medicaid fee-for-service program from 1991 to 2008.
Acute Kidney Injury after Heart Valve Surgery in Elderly Patients: any Risk Factors to Modify?
Albuminuria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT): a randomised, double-blind, placebo-controlled trial.
Aldosterone blockade in chronic kidney disease: can it improve outcome?
Angiotensin I-Converting Enzyme Inhibitors Block Protein Kinase C{epsilon} by Activating Bradykinin B1 Receptors in Human Endothelial Cells.
Angiotensin II as a renal growth factor.
Angiotensin system inhibitors and outcome of sunitinib treatment in patients with metastatic renal cell carcinoma: A retrospective examination.
Angiotensin-converting enzyme in non-neoplastic kidney diseases.
Angiotensin-converting enzyme inhibitor for slowing progression of diabetic and nondiabetic kidney disease.
Angiotensin-converting enzyme inhibitors in patients with Alport syndrome: can all patients benefit?
Antiproteinuric therapy and fabry nephropathy: sustained reduction of proteinuria in patients receiving enzyme replacement therapy with agalsidase-beta.
Are two better than one? Angiotensin-converting enzyme inhibitors plus angiotensin receptor blockers for reducing blood pressure and proteinuria in kidney disease.
Association between obesity and urinary albumin-creatinine ratio in the middle-aged and elderly population of Southern and Northern China: a cross-sectional study.
Blood pressure control and nephroprotection in diabetes.
Blood pressure, antihypertensive therapy and risk for renal injury in African-Americans.
Calcium antagonists: effects on cardio-renal risk in hypertensive patients.
Calcium channel blockers and renal protection: insights from the latest clinical trials.
Change in proteinuria after adding aldosterone blockers to ACE inhibitors or angiotensin receptor blockers in CKD: a systematic review.
Combination therapy with an angiotensin-converting enzyme inhibitor and a vitamin D analog suppresses the progression of renal insufficiency in uremic rats.
Combination therapy with Renin-Angiotensin-aldosterone receptor blockers for hypertension: how far have we come?
Combined angiotensin inhibition for the treatment of diabetic nephropathy.
Continuation of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in the Face of Kidney Disease Progression-Safe and Possibly Life Saving.
Correlation between angiotensin-converting enzyme gene insertion/deletion polymorphism and kidney graft long-term outcome in pediatric recipients: a single-center analysis.
Decline in glomerular filtration rate during pre-dialysis phase and survival on chronic renal replacement therapy.
Diabetes mellitus and hypertension: key risk factors for kidney disease.
Diagnosis of Alport syndrome-search for proteomic biomarkers in body fluids.
Differential effects of angiotensin II and transforming growth factor beta on the production of heparan sulfate proteoglycan by mesangial cells in vitro.
Differing effects of antihypertensive drugs on the incidence of diabetes mellitus among patients with hypertensive kidney disease.
Dual blockade of the renin-angiotensin-aldosterone system with high-dose angiotensin-converting enzyme inhibitor for nephroprotection: An open, controlled, randomized study.
Dual blockade of the renin-angiotensin-aldosterone system with high-dose angiotensin-converting enzyme inhibitor for nephroprotection: an open, controlled, randomized study.
Effect of angiotensin converting enzyme gene I/D polymorphism in South Indian children with nephrotic syndrome.
Effects of angiotensin II receptor blockers on diabetic nephropathy.
Effects of AT1 and AT2 receptor blockade on angiotensin II induced apoptosis of human renal proximal tubular epithelial cells.
Effects of combination treatment with losartan and trandolapril on office and ambulatory blood pressures in non-diabetic renal disease: a COOPERATE-ABP substudy.
Efficacy Of Zofenopril Alone Or In Combination With Hydrochlorothiazide In Patients With Kidney Dysfunction.
Emerging insights in the first-step use of antihypertensive combination therapy.
Empagliflozin and Clinical Outcomes in Patients with Type 2 Diabetes, Established Cardiovascular Disease and Chronic Kidney Disease.
Evaluation of fixed dose combination (FDC) of telmisartan+ramipril usage in patients with micro-albuminuria and persistent hypertension: A TRIUMPH study.
Hydrolyzed proteins from herring and salmon rest raw material contain peptide motifs with angiotensin-I converting enzyme inhibitors and resulted in lower urine concentrations of protein, cystatin C and glucose when fed to obese Zucker fa/fa rats.
Hypertensive nephrosclerosis: update.
Identification of genetic factors associated with susceptibility to angiotensin-converting enzyme inhibitors-induced cough.
Impact of chronic kidney disease and anemia on hospitalization expense in patients with left ventricular dysfunction.
In-hospital and short-term prognostic factors in acute pulmonary edema: clinical and morphological features.
Lessons from the African-American Study of Kidney Disease andHypertension: An Update.
Meeting the challenge to improve the treatment of hypertension in blacks.
Meta-regression detected associations between heterogeneous treatment effects and study-level, but not patient-level, factors.
Metoprolol Increases Uric Acid and Risk of Gout in African Americans With Chronic Kidney Disease Attributed to Hypertension.
Mitigation of Radiation Injuries via Suppression of the Renin-Angiotensin System: Emphasis on Radiation Nephropathy.
Obesity and chronic kidney disease: prevalence, mechanism, and management.
Podocyturia: A Clue for the Rational Use of Amiloride in Alport Renal Disease.
Polymorphisms in the gene encoding angiotensin I converting enzyme 2 and diabetic nephropathy.
Potential protective effects of telmisartan on renal function deterioration.
Prevalence and predictors of epoetin hyporesponsiveness in chronic kidney disease patients.
Progression risk, urinary protein excretion, and treatment effects of angiotensin-converting enzyme inhibitors in nondiabetic kidney disease.
Prospective Cohort Study of Renin-Angiotensin System Blocker Usage after Hospitalized Acute Kidney Injury.
Proteinuria in systemic sclerosis: reversal by ACE inhibition.
Proteinuria reduction: mandatory consideration or option when selecting an antihypertensive agent?
Proteinuria: Increased angiotensin-receptor blocking is not the first option.
Protocol of the Long-term Impact of RAS Inhibition on Cardiorenal Outcomes (LIRICO) randomized trial.
Rat models of cardiometabolic diseases: baseline clinical chemistries, and rationale for their use in examining air pollution health effects.
Rationale and design of a study to evaluate management of proteinuria in patients at high risk for vascular events: the IMPROVE trial.
Rationale for Combining a Direct Renin Inhibitor with other Renin- Angiotensin System Blockers. Focus on Aliskiren and Combinations.
Recruitment of African Americans with chronic renal insufficiency into a multicenter clinical trial: the african american study of kidney disease and hypertension.
Renal effects of nonselective NSAIDs and coxibs.
Renin-angiotensin system blockade in biopsy-proven allograft nephropathy.
Risk Factors for the Development of Postoperative Acute Kidney Injury in Patients Undergoing Joint Replacement Surgery: A Meta-Analysis.
Risk of hyperkalemia in nondiabetic patients with chronic kidney disease receiving antihypertensive therapy.
Role of angiotensin converting enzyme inhibitors and angiotensin receptor blockers in hypertension of chronic kidney disease and renoprotection. Study results.
Short-term effects of blood pressure control and antihypertensive drug regimen on glomerular filtration rate: the African-American Study of Kidney Disease and Hypertension Pilot Study.
Single versus dual blockade of the renin-angiotensin system (angiotensin-converting enzyme inhibitors and/or angiotensin II receptor blockers) in diabetic nephropathy.
Small but powerful: Short peptide hormones and their role in autoimmune inflammation.
Steroid- and immunosuppressant-based protocol of Henoch-Schönlein purpura nephritis without angiotensin inhibitors in the acute phase: case series with correlation to histology.
Study design and methods for a clinical trial of an oral carbonaceous adsorbent used to prevent the progression of chronic kidney disease (CAP-KD).
Summaries for patients. Using a type of blood pressure medicine, angiotensin-converting enzyme inhibitors, to prevent worsening of kidney disease unrelated to diabetes.
The 2011 canadian hypertension education program recommendations for the management of hypertension: blood pressure measurement, diagnosis, assessment of risk, and therapy.
The African American Study of Kidney Disease and Hypertension (AASK) trial: what more have we learned?
The African American Study of Kidney Disease: do these results indicate that 140/90 mm hg is good enough?
The benefits of renin-angiotensin blockade in renal transplant recipients with biopsy-proven allograft nephropathy.
The differential effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers with respect to foot ulcer and limb amputation in those with diabetes.
The Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers on Clinical Outcomes of Acute Kidney Disease Patients: A Systematic Review and Meta-Analysis.
The impact of atherosclerotic renovascular disease on diabetic renal failure.
The impact of stopping inhibitors of the renin-angiotensin system in patients with advanced chronic kidney disease.
The use of calcium antagonists in the treatment of hypertensive persons with kidney disease.
The vasoprotective axes of the renin-angiotensin system: Physiological relevance and therapeutic implications in cardiovascular, hypertensive and kidney diseases.
To RAS or not to RAS? The evidence for and cautions with renin-angiotensin system inhibition in patients with diabetic kidney disease.
Treatment of severe Henoch-Schönlein and immunoglobulin A nephritis. A single center experience.
Treatment of systemic sclerosis.
Urinary angiotensin-I-converting enzyme activity as a marker of tubulo-interstitial involvement in kidney diseases.
US of renal insufficiency in neonates.
Use of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers and Acute Kidney Disease after an Episode of AKI: A Multicenter Prospective Cohort Study.
Use of Ophiocordyceps sinensis (syn. Cordyceps sinensis) combined with angiotensin-converting enzyme inhibitors (ACEI)/angiotensin receptor blockers (ARB) versus ACEI/ARB alone in the treatment of diabetic kidney disease: a meta-analysis.
[Angiotensin converting enzyme 2 and its emerging role in the regulation of the renin angiotensin system]
[Angiotensin-converting enzyme inhibitors in the diagnosis and treatment of kidney diseases]
[Arterial hypertension in glomerulonephritis]
[Modest risk of phosphate nephropathy by bowel cleansing.]
[Polymorphism of the angiotensin converting enzyme gene (ACE) and kidney diseases]
[Renin inhibition and the kidney]
[Renoprotective effects of antihypertensives]
[The use of angiotensin-converting enzyme inhibitors in chronic diffuse kidney diseases]
[Uses of angiotensin converting enzyme inhibitor in kidney diseases]
Kidney Diseases, Cystic
Angiotensin converting enzyme inhibitor limits pulse wave velocity and aortic calcification in a rat model of cystic renal disease.
Bi-allelic mutations in renin-angiotensin system genes, associated with renal tubular dysgenesis, can also present as a progressive chronic kidney disease.
[Study of various factors that could have an impact on the treatment with erythropoietin of hemodialysis anemia]
Kidney Failure, Chronic
A case of renal sarcoidosis showing central necrosis and abnormal expression of angiotensin converting enzyme in the granuloma.
A COL4A5 mutation with glomerular disease and signs of chronic thrombotic microangiopathy.
A comparison between angiotensin converting enzyme inhibitors and angiotensin receptor blockers on end stage renal disease and major adverse cardiovascular events in diabetic patients: a population-based dynamic cohort study in Taiwan.
A cost-effectiveness analysis of Angiotensin-converting enzyme inhibitors and Angiotensin receptor blockers in diabetic nephropathy.
A meta-analysis of the association between angiotensin-converting enzyme insertion/deletion gene polymorphism and end-stage renal disease risk in IgA nephropathy patients.
A meta-analysis of the relationship between ACE I/D gene polymorphism and end-stage renal disease in patients with diabetic nephropathy.
A practical approach to achieving recommended blood pressure goals in diabetic patients.
A review of clinical characteristics and genetic backgrounds in Alport syndrome.
ACE gene insertion/deletion polymorphism in childhood idiopathic nephrotic syndrome.
ACE gene polymorphism and disease progression of IgA nephropathy in Asians in Singapore.
ACE gene polymorphism in childhood IgA nephropathy: association with clinicopathologic findings.
ACE gene polymorphism, left ventricular geometry, and mortality in diabetic patients with end-stage renal disease.
ACE I/D and MMP-7 A-181G variants and the risk of end stage renal disease.
ACE inhibition is effective and renoprotective in hypertensive nephrosclerosis: the African American Study of Kidney Disease and Hypertension (AASK) trial.
ACE Inhibitor Benefit to Kidney and Cardiovascular Outcomes for Patients with Non-Dialysis Chronic Kidney Disease Stages 3-5: A Network Meta-Analysis of Randomised Clinical Trials.
ACE inhibitor versus beta-blocker for the treatment of hypertension in renal allograft recipients.
ACE inhibitors and survival of hemodialysis patients.
ACE inhibitors do not induce recombinant human erythropoietin resistance in hemodialysis patients.
ACE-inhibitor use and the long-term risk of renal failure in diabetes.
Activity of the renin-angiotensin-aldosterone (RAA) and secretion of the atrial natriuretic peptide (ANP) in patients with chronic renal failure.
Albuminuria is Not an Appropriate Therapeutic Target in Patients with CKD: The Con View.
An angiotensin converting enzyme haplotype predicts survival in patients with end stage renal disease.
Anaemia due to ACE inhibitors and losartan in patients with renal failure.
Anaemia in chronic obstructive pulmonary disease. Does it really matter?
Analysis of insertion/deletion polymorphisms of the angiotensin converting enzyme gene in Malaysian end-stage renal disease patients.
Angiotensin converting enzyme inhibition and protein restriction in progression of experimental chronic renal failure.
Angiotensin converting enzyme inhibition delays the progression of chronic renal failure in hypertensive patients with immunoglobulin A nephropathy.
Angiotensin converting enzyme inhibition for cardiac hypertrophy in patients with end-stage renal disease: what is the evidence?
Angiotensin converting enzyme inhibition increases ADMA concentration in patients on maintenance hemodialysis--a randomized cross-over study.
Angiotensin converting enzyme inhibitor and chronic renal failure.
Angiotensin converting enzyme inhibitors and progression of chronic renal failure.
Angiotensin converting enzyme inhibitors impair recombinant human erythropoietin induced erythropoiesis in patients with chronic renal failure.
Angiotensin converting enzyme inhibitors in normotensive diabetic patients with microalbuminuria.
Angiotensin converting enzyme inhibitors, calcium channel blockers, and their combination in the treatment of glomerular disease.
Angiotensin I-converting enzyme gene insertion/deletion and angiotensinogen M235T polymorphisms: risk of chronic renal failure. End-Stage Renal Disease Study Group.
Angiotensin II and the endothelium: diverse signals and effects.
Angiotensin II receptor antagonists and treatment of hypertension and renal disease.
Angiotensin II receptor blockade and renal protection.
Angiotensin-converting enzyme inhibition and renal protection in nondiabetic patients: the data of the meta-analyses.
Angiotensin-converting enzyme inhibition in the prevention and treatment of chronic renal damage in the hypertensive fawn-hooded rat.
Angiotensin-converting enzyme inhibitor therapy for non-diabetic progressive renal disease.
Angiotensin-converting enzyme inhibitor therapy in chronic hemodialysis patients: any evidence of erythropoietin resistance?
Angiotensin-converting enzyme inhibitor withdrawal and ACE gene polymorphism.
Angiotensin-converting enzyme inhibitors and cardiovascular outcomes in patients on maintenance hemodialysis.
Angiotensin-converting enzyme inhibitors but not angiotensin II AT 1 receptor antagonists affect erythropoiesis in patients with anemia of end-stage renal disease.
Angiotensin-converting enzyme inhibitors in chronic renal failure.
Angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers for end-stage renal disease/mortality in type 2 diabetes.
Angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, ?-blockers or both in incident end-stage renal disease patients without cardiovascular disease: a propensity-matched longitudinal cohort study.
Angiotensin-converting enzyme inhibitors: therapeutic implications in the management of chronic renal failure.
Angiotensin-converting enzyme polymorphism gene and evolution of nephropathy to end-stage renal disease.
Angiotensin-converting enzyme polymorphism in patients with terminal renal failure.
Antihypertensive and antiproteinuric efficacy of ramipril in children with chronic renal failure.
Antihypertensive effect of the oral angiotensin I-converting enzyme inhibitor in long-term treatment of hypertensive patients.
Antihypertensive effects and arterial haemodynamic alterations during angiotensin converting enzyme inhibition.
Antihypertensive Medication Use in Older Patients Transitioning from Chronic Kidney Disease to End-Stage Renal Disease on Dialysis.
Aspirin, beta-blocker, and angiotensin-converting enzyme inhibitor therapy in patients with end-stage renal disease and an acute myocardial infarction.
Association between angiotensin-converting enzyme insertion/deletion gene polymorphism and end-stage renal disease in lebanese patients with diabetic nephropathy.
Association between angiotensin-converting enzyme insertion/deletion gene polymorphism and end-stage renal disease susceptibility.
Association between the A1166C polymorphism of the angiotensin II receptor type 1 and progression of chronic renal insufficiency.
Association between the rate of low-birth weight newborns and the incidence of end-stage renal disease in 47 prefectures in Japan.
Association of angiotensin-converting enzyme and endothelial Nitric Oxide synthase gene polymorphisms with vascular disease in ESRD patients in a Chinese population.
Autonomy of the renin system in type II diabetes mellitus: dietary sodium and renal hemodynamic responses to ACE inhibition.
Benazepril inhibited the NF-?B and TGF-? networking on LV hypertrophy in rats.
Bi-allelic mutations in renin-angiotensin system genes, associated with renal tubular dysgenesis, can also present as a progressive chronic kidney disease.
Blocking angiotensin II ameliorates proteinuria and glomerular lesions in progressive mesangioproliferative glomerulonephritis.
Blood Pressure Goals and Treatment in Pregnant Patients With Chronic Kidney Disease.
Blood pressure treatment levels and choice of antihypertensive agent in people with diabetes mellitus: an overview of systematic reviews.
Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial.
Calcium antagonists and renal failure progression.
Can ACE Inhibitors and Angiotensin Receptor Blockers Be Detrimental in CKD Patients?
Captopril renal scintigraphy in patients with hypertension and chronic renal failure.
Captopril to mitigate chronic renal failure after hematopoietic stem cell transplantation: a randomized controlled trial.
Cardiac hypertrophy, aortic compliance, peripheral resistance, and wave reflection in end-stage renal disease. Comparative effects of ACE inhibition and calcium channel blockade.
Cardiovascular outcomes in high-risk hypertensive patients stratified by baseline glomerular filtration rate.
Causes and consequences of increased sympathetic activity in renal disease.
Chronic angiotensin-converting enzyme inhibition and angiotensin II antagonism in rats with chronic renal failure.
Chronic proteinuric nephropathies. II. Outcomes and response to treatment in a prospective cohort of 352 patients: differences between women and men in relation to the ACE gene polymorphism. Gruppo Italiano di Studi Epidemologici in Nefrologia (Gisen)
Chronic proteinuric nephropathies: outcomes and response to treatment in a prospective cohort of 352 patients with different patterns of renal injury.
Circulating monocyte subpopulations with high expression of angiotensin-converting enzyme predict mortality in patients with end-stage renal disease.
Clinical effects of rheum and captopril on preventing progression of chronic renal failure.
Coadministration of losartan and enalapril exerts additive antiproteinuric effect in IgA nephropathy.
Combination therapy with an angiotensin-converting enzyme (ACE) inhibitor and a calcium antagonist: beyond the renoprotective effects of ACE inhibitor monotherapy in a spontaneous hypertensive rat with renal ablation.
Combination therapy with angiotensin-converting enzyme inhibitor and oral adsorbent of uremic toxins can delay the appearance of glomerular sclerosis and interstitial fibrosis in established renal failure.
Combined treatment with angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers to prevent end-stage kidney disease in patients who do not have diabetes.
Comparative efficacy and safety of blood pressure-lowering agents in adults with diabetes and kidney disease: a network meta-analysis.
Comparisons of Three Main Treatments on Renoprotective Effects in Diabetes Mellitus.
Congestive heart failure in patients with chronic kidney disease and on dialysis.
Converting enzyme inhibition in chronic renal failure.
Delayed onset of posterior reversible encephalopathy syndrome in a case of scleroderma renal crisis with maintenance hemodialysis: Case report and literature review.
Diabetic renal disease: microalbuminuria, implications and intervention.
Diagnosis and therapy of coronary artery disease in renal failure, end-stage renal disease, and renal transplant populations.
Differences in the effects of angiotensin converting enzyme inhibitors with or without a thiol group in chronic renal failure in rats.
Does angiotensin blockade influence graft outcome in renal transplant recipients with IgA nephropathy?
Drug therapy for hypertension in hemodialysis patients.
Dual blockade of the renin-angiotensin system with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in chronic kidney disease.
Dual blockade of the renin-angiotensin system: the ultimate treatment for renal protection?
Dual renin-angiotensin system blockade for nephroprotection.
Effect of candesartan cilexetil (TCV-116) in rats with chronic renal failure.
Effect of enalapril on haemoglobin and serum erythropoietin in patients with chronic nephropathy.
Effect of genetic variation on therapy with angiotensin converting enzyme inhibitors or angiotensin receptor blockers in dialysis patients.
Effect of Renin-Angiotensin-Aldosterone System Blockade on Long-Term Outcomes in Postacute Kidney Injury Patients With Hypertension.
Effects of adding Rheum officinale to angiotensin-converting enzyme inhibitors or angiotensin receptor blockers on renal function in patients with chronic renal failure: A meta-analysis of randomized controlled trials?.
Effects of an angiotensin-converting enzyme inhibitor on residual renal function in patients receiving peritoneal dialysis. A randomized, controlled study.
Effects of angiotensin converting enzyme inhibitors on the progression of renal failure and proteinuria in humans.
Effects of angiotensin II and of angiotensin converting enzyme inhibition in chronic renal failure.
Effects of angiotensin-converting-enzyme inhibitors on progression to end-stage renal failure in chronic vascular rejection.
Effects of antihypertensive drugs on renal function and atrial natriuretic polypeptide in spontaneously hypertensive rats with renal ablation.
Effects of Losartan-based therapy on the incidence of end-stage renal disease and associated costs in type 2 diabetes mellitus: A retrospective cost-effectiveness analysis in the United Kingdom.
Effects of nitrendipine and cilazapril on renal hemodynamics and albuminuria in hypertensive patients with chronic renal failure.
Effects of soy protein hydrolysate on blood pressure and angiotensin-converting enzyme activity in rats with chronic renal failure.
Efficacy of captopril on posttransplant erythrocytosis. Long-term follow-up.
Emerging therapeutic strategies in diabetic nephropathy.
Enalaprilat inhibits hydrogen peroxide production by murine mesangial cells exposed to high glucose concentrations.
End-stage renal disease and adherence to angiotensin-converting enzyme inhibitors and angiotensin receptor blockers among patients with diabetes.
End-stage renal disease patients using angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may reduce the risk of mortality: a Taiwanese Nationwide cohort study.
Experimental and clinical evidence that angiotensin II is an independent risk factor for cardiovascular disease.
Feasibility study of the early detection and treatment of renal disease by mass screening.
Fixed low-dose perindopril-indapamide combination in hypertensive patients with chronic renal failure.
Gene expression profiling in the remnant kidney model of wild type and kinin B1 and B2 receptor knockout mice.
Gene polymorphism of angiotensin II type 1 and type 2 receptors.
Genetic polymorphisms of the renin-angiotensin system in end-stage renal disease.
Glomerular hypertension in the progression of chronic renal failure: role of low protein diet and angiotensin converting enzyme inhibitors.
GSTM1 Gene, Diet, and Kidney Disease: Implication for Precision Medicine?: Recent Advances in Hypertension.
Haematological Indicators of Response to Erythropoietin Therapy in Chronic Renal Failure Patients on Haemodialysis: Impact of Angiotensin-Converting Enzyme rs4343 Gene Polymorphism.
Haplotype analysis of NAD(P)H oxidase p22 phox polymorphisms in end-stage renal disease.
Heart rate variability (HRV) in kidney failure: measurement and consequences of reduced HRV.
Hemodialysis-resistant hypertension: control with an orally active inhibitor of angiotensin-converting enzyme.
Highly positive intraoperative fluid balance during cardiac surgery is associated with adverse outcome.
HIV-associated nephropathy: an urban epidemic.
HIV-associated renal disorders: recent insights into pathogenesis and treatment.
Hypertensive rebound after angiotensin converting enzyme inhibitor withdrawal in diabetic patients with chronic renal failure.
Impact of ACE I/D gene polymorphism on congenital renal malformations.
Impact of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers on renal and mortality outcomes in people with Type 2 diabetes and proteinuria.
Impact of interaction of cigarette smoking with angiotensin-converting enzyme polymorphisms on end-stage renal disease risk in a Han Chinese population.
Impact of the angiotensin II receptor antagonist, losartan, on myocardial fibrosis in patients with end-stage renal disease: assessment by ultrasonic integrated backscatter and biochemical markers.
Improved preservation of residual renal function in chronic hemodialysis patients using polysulfone dialyzers.
Improvement in Mortality and End-Stage Renal Disease in Patients With Type 2 Diabetes After Acute Kidney Injury Who Are Prescribed Dipeptidyl Peptidase-4 Inhibitors.
Improving the Management of Chronic Kidney Disease in Uruguay: A National Renal Healthcare Program.
Inadequate aldosterone response to hyperkalemia during angiotensin converting enzyme inhibition in chronic renal failure.
Inadequate treatment of congestive heart failure in dialysis patients.
Increased serum angiotensin-converting enzyme in end-stage renal disease.
Influence of Angiotensin Converting Enzyme I/D Polymorphism on Hemodynamic and Antioxidant Response to Long-Term Intradialytic Resistance Training in Patients With Chronic Kidney Disease: A Randomized Controlled Trial.
Influence of angiotensin converting enzyme inhibitor treatment on cardiac autonomic modulation in patients receiving haemodialysis.
Inhibition of Angiotensin-Converting Enzyme Ameliorates Renal Fibrosis by Mitigating DPP-4 Level and Restoring Antifibrotic MicroRNAs.
Initial effect of enalapril on kidney function in patients with moderate to severe chronic nephropathy.
Innappropriate renin secretion unmasked by captopril (SQ 14 225) in hypertension of chronic renal failure.
Insufficient therapeutic management of hypertensive patients with renal failure in France.
Interpreting treatment effects from clinical trials in the context of real-world risk information: end-stage renal disease prevention in older adults.
Is population-wide diuretic use directly associated with the incidence of end-stage renal disease in the United States? A hypothesis.
Kinin and angiotensin II receptor antagonists in rats with chronic renal failure: chronic effects on cardio- and renoprotection of angiotensin converting enzyme inhibitors.
Lisinopril pharmacokinetics in chronic renal failure.
Long-term effects of calcium antagonists and angiotensin-converting enzyme inhibitors in patients with chronic renal failure of IgA nephropathy.
Long-term protection of obese Zucker rat kidneys from fibrosis and renal failure with an angiotensin-converting enzyme inhibitor/diuretic combination.
Long-term renoprotective effect of combination therapy with prostaglandin E1 and angiotensin-converting enzyme inhibitor in patients with chronic renal failure.
Low prekallikrein and high angiotensin-converting enzyme activity in patients with chronic renal failure on haemodialysis.
Low renin-angiotensin system activity gene polymorphism and dysplasia associated with posterior urethral valves.
Low-protein diets and angiotensin-converting enzyme inhibition in progressive renal failure.
Lower progression rate of end-stage renal disease in patients with peripheral arterial disease using statins or Angiotensin-converting enzyme inhibitors.
Management of hypertension in renal disease.
Maps of end-stage renal disease and amounts of angiotensin-converting enzyme inhibitors prescribed in Japan.
Mechanism of progression of renal disease: current hemodynamic concepts.
Mechanisms and treatment of CKD.
Microalbuminuria: a marker to increased renal and cardiovascular risk in diabetes mellitus.
Mineral Metabolites, Angiotensin II Inhibition and Outcomes in Advanced Chronic Kidney Disease.
Mitigation of Late Renal and Pulmonary Injury After Hematopoietic Stem Cell Transplantation.
Mortality benefit of angiotensin-converting enzyme inhibitors after cardiac events in patients with end-stage renal disease.
Myocardial microvascular disease and major adverse cardiovascular events in patients with end-stage renal disease: rationale and design of the MICROCARD study.
OACE inhibition does not interfere with acute extrarenal or renal potassium disposal in chronic renal failure.
Optimizing therapeutic strategies to achieve renal and cardiovascular risk reduction in diabetic patients with angiotensin receptor blockers.
Pharmacoeconomic challenges in the management of diabetic nephropathy.
Pharmacokinetics and acute effect on the renin-angiotensin system of delapril in patients with chronic renal failure.
Pharmacokinetics and pharmacodynamics of trandolapril after repeated administration of 2 mg to patients with chronic renal failure and healthy control subjects.
Pharmacokinetics of imidapril and its active metabolite imidaprilat following single dose and during steady state in patients with chronic renal failure.
Pharmacokinetics of quinapril and its active metabolite quinaprilat during continuous ambulatory peritoneal dialysis.
Polymorphism of angiotensin converting enzyme, angiotensinogen, and angiotensin II type 1 receptor genes and end-stage renal failure in IgA nephropathy: IGARAS--a study of 274 Men.
Polymorphism of the angiotensin-converting enzyme gene in end-stage renal failure patients.
Predictive value of 99Tcm-DTPA captopril scintigraphy in patients with a solitary kidney and reduced kidney function.
Predictors of the development of hyperkalemia in patients using angiotensin-converting enzyme inhibitors.
Predictors of the progression of diabetic nephropathy and the beneficial effect of angiotensin-converting enzyme inhibitors in NIDDM patients.
Prescription patterns of pharmacological agents for left ventricular systolic dysfunction among hemodialysis patients.
Preserving the diabetic kidney.
Prevalence and Management of Diabetic Nephropathy in Western Countries.
Primary prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with end-stage renal disease undergoing dialysis.
Prognosis of scleroderma renal crisis: a long-term observational study.
Prognostic role of serum ACE activity on outcome of type 2 diabetic patients on chronic ambulatory peritoneal dialysis.
Progressive loss of renal function is an age-dependent heritable trait in type 1 autosomal dominant polycystic kidney disease.
Proposal for mapping renal failure in Japan and its application for strategy to arrest endstage renal disease.
Protective effects of CGS 30440, a combined angiotensin-converting enzyme inhibitor and neutral endopeptidase inhibitor, in a model of chronic renal failure.
RAAS inhibition and the course of Alport syndrome.
Ramipril versus placebo in kidney transplant patients with proteinuria: a multicentre, double-blind, randomised controlled trial.
Randomised controlled trial of enalapril and beta blockers in non-diabetic chronic renal failure.
Randomized, double-blind, placebo-controlled trial to evaluate efficacy of ketodiet in predialytic chronic renal failure.
Reduction of sympathetic hyperactivity by enalapril in patients with chronic renal failure.
Regulation of blood pressure in chronic renal failure: determinants of hypertension and dialysis-related hypotension.
Renal artery stenosis: a common, treatable cause of renal failure?
Renal damage in the SHR/N-cp type 2 diabetes model: comparison of an angiotensin-converting enzyme inhibitor and endothelin receptor blocker.
Renin-angiotensin gene polymorphism in children with uremia and essential hypertension.
Renin-angiotensin system polymorphisms in Taiwanese primary vesicoureteral reflux.
Renin-Angiotensin system polymorphisms: a risk factor for progression to end-stage renal disease in vesicoureteral reflux patients.
Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria.
Risk factors for vasoplegia after coronary artery bypass and valve surgery.
Role of angiotensin II in the development of nephropathy and podocytopathy of diabetes.
Role of kinins in the renoprotective effect of angiotensin-converting enzyme inhibitors in experimental chronic renal failure.
Role of the alpha-adducin genotype on renal disease progression.
Role of the intrarenal renin-angiotensin-aldosterone system in chronic kidney disease.
Safety of the combination of valsartan and benazepril in patients with chronic renal disease. European Group for the Investigation of Valsartan in Chronic Renal Disease.
Scleroderma renal crisis: a pathology perspective.
Serum angiotensin converting enzyme (S-ACE) activity in patients with chronic renal failure on regular hemodialysis.
Serum angiotensin converting enzyme activity in patients with chronic renal failure on long term hemodialysis.
Serum angiotensin-converting enzyme levels in patients with chronic renal failure.
Short-term effect of captopril on renal haemodynamics in chronic renal failure.
Sodium intake, ACE inhibition, and progression to ESRD.
Sodium-glucose cotransporter-2 inhibitors and non-steroidal mineralocorticoid receptor antagonists: Ushering in a new era of nephroprotection beyond renin-angiotensin system blockade.
Study of the polymorphism of angiotensinogen, anigiotensin-converting enzyme and angiotensin receptor in type II diabetes with end-stage renal disease in Taiwan.
The 2014 international workshop on alport syndrome.
The angiotensin II type 2 receptor in renal disease.
The angiotensin-I converting enzyme gene I/D variation contributes to end-stage renal disease risk in Chinese patients with type 2 diabetes receiving hemodialysis.
The contribution of systemic hypertension to progression of chronic renal failure in the rat remnant kidney: effect of treatment with an angiotensin converting enzyme inhibitor or a calcium inhibitor.
The effect of antihypertensive therapy on the course of renal failure.
The effectiveness and safety of angiotensin-converting enzyme inhibition or receptor blockade in vascular diseases in patients with hemodialysis.
The evolving science of apolipoprotein-L1 and kidney disease.
The pharmacokinetics and pharmacodynamics of angiotensin-receptor blockers in end-stage renal disease.
The pharmacokinetics of perindopril and its effects on serum angiotensin converting enzyme activity in hypertensive patients with chronic renal failure.
The position of the polycystic kidney disease 1 (PKD1) gene mutation correlates with the severity of renal disease.
The Prevalence and Management of Diabetic Nephropathy in Asia.
The RAAS in the pathogenesis and treatment of diabetic nephropathy.
The rationale for early management of chronic renal insufficiency.
The renin-angiotensin system and progression of renal disease: from hemodynamics to cell biology.
The renoprotective effect of angiotensin-converting enzyme inhibitors in experimental chronic renal failure is not dependent on enhanced kinin activity.
The role of kidney biopsy in diagnosis of preeclampsia in kidney transplant patients.
The Safe Introduction of Angiotensin-converting Enzyme Inhibitor in Renal Allograft Recipients.
Therapeutic interventions for nephropathy in type I diabetes mellitus.
To pay or not to pay? A decision and cost-utility analysis of angiotensin-converting-enzyme inhibitor therapy for diabetic nephropathy.
Transient anuria following administration of angiotensin I-converting enzyme inhibitor (SQ 14225) in a patient with renal artery stenosis of the solitary kidney successfully treated with renal autotransplantation.
Treatment of hypertension with lisinopril in end-stage renal failure.
Treatment of type 2 diabetic nephropathy by blockade of the renin-angiotensin system: a comparison of angiotensin-converting-enzyme inhibitors and angiotensin receptor antagonists.
Underuse of American College of Cardiology/American Heart Association Guidelines in hemodialysis patients.
Use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in high-risk clinical and ethnic groups with diabetes.
WITHDRAWN: Angiotensin converting enzyme inhibitors in normotensive diabetic patients with microalbuminuria.
[Association analysis of angiotensin-converting enzyme gene polymorphism with end-stage renal disease]
[Blood concentration and urinary excretion of captopril (SQ 14,255), angiotensin converting enzyme activity and R-A-A system after administration of captopril--in patients with chronic renal failure compared with essential hypertension]
[Effects of CS-866, an angiotensin II receptor antagonist, in 5/6 nephrectomized spontaneously hypertensive rats]
[Evaluation of the tolerance and effectiveness of Diltiazem LP 300 mg in hypertensive patients with chronic renal insufficiency]
[Kidney insufficiency and persistent hypotension following compromise of the renin-angiotensin system in a fetus and a young infant]
[Progressive renal failure. Why blood pressure must now be monitored]
[Prospective observational study of angiotensin converting enzyme inhibitors-induced hyperkalemia in hospitalized patients with chronic renal failure].
[Renal crisis in scleroderma]
[Renal function during treatment of chronic renal failure with angiotensin converting enzyme inhibitors]
[Renal Involvement in Connective Tissue Diseases].
[Serum angiotensin converting enzyme activity in patients with untreated essential arterial hypertension]
[The acute effects of the new angiotensin I-converting enzyme inhibitor, enalapril maleate, on blood pressure, plasma renin, aldosterone and kinins in hypertensive patients]
[The correlation between serum angiotensin I-converting enzyme activity and the renin-angiotensin-aldosterone system in hypertensive patients (author's transl)]
[The effect of a low-protein diet and certain pharmaceutical agents on the course of ablation nephropathy in rats]
[The effect of angiotensin-converting enzyme inhibitors on left ventricular hypertrophy in patients with chronic glomerulonephritis and pronounced kidney failure]
[The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure]
[The effect of the angiotensin-converting enzyme inhibitor enalapril on the rates of progression of chronic kidney failure in patients with different degrees of functional kidney disorders]
[The effects of ACE inhibitor treatment and ACE gene polymorphism on erythropoiesis in chronic hemodialysis patients]
[The role of angiotensin I converting enzyme (ACE) Pst 1 polymorphism in the development of chronic renal failure]
[Use of angiotensin converting enzyme inhibitors in nephrology]
[Variations in blood aldosterone, plasma renin activity and plasma levels of converting enzyme during bicarbonate dialysis in chronic kidney failure]
Kidney Neoplasms
Analysis of the insertion/deletion polymorphism of the human angiotensin converting enzyme (ACE) gene in patients with renal cancer.
Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers as therapeutic options in the treatment of renal cancer: A meta-analysis.
Antihypertensive medications are associated with the risk of kidney and bladder cancer: a systematic review and meta-analysis.
Calcium channel blockers and the risk of cancer.
Medication use and kidney cancer survival: A population-based study.
Kounis Syndrome
Kounis syndrome due to angiotensin converting enzyme inhibitor.
Laryngeal Edema
Angioedema Related to Angiotensin-Converting Enzyme Inhibitors: Attack Severity, Treatment, and Hospital Admission in a Prospective Multicenter Study.
Evidence and evidence gaps of medical treatment of non-tumorous diseases of the head and neck.
[Strong and Deficient Evidence in Drug-Treated, Non-Tumorous Diseases in ENT].
Laryngeal Neoplasms
Up-Regulation of Angiotensin-Converting Enzyme (ACE) Enhances Cell Proliferation and Predicts Poor Prognosis in Laryngeal Cancer.
Laryngopharyngeal Reflux
Differential diagnosis of chronic cough.
Effectiveness of amitriptyline versus cough suppressants in the treatment of chronic cough resulting from postviral vagal neuropathy.
Laryngeal sensory neuropathy in patients with diabetes mellitus.
The aetiology of chronic cough: a review of current theories for the otorhinolaryngologist.
Latent Tuberculosis
The serum angiotensin converting enzyme and lysozyme levels in patients with ocular involvement of autoimmune and infectious diseases.
Leiomyoma
Angiotensin I-converting enzyme insertion-related genotypes and allele are associated with higher susceptibility of endometriosis and leiomyoma.
Angiotensin-Converting Enzyme Inhibitors Reduce Uterine Fibroid Incidence in Hypertensive Women.
Leishmaniasis
Possible cardioprotective effect of angiotensin-converting enzyme inhibitors during treatment of American tegumentary leishmaniasis with meglumine antimoniate.
Leprosy
Serum angiotensin-converting enzyme in leprosy and coccidioidomycosis.
Serum angiotensin-converting enzyme in leprosy.
[Angiotensin converting enzyme in the blood serum of patients with tuberculosis and leprosy]
Leprosy, Lepromatous
[Increase of the serum activity of angiotensin converting enzyme in lepromatous leprosy]
Lethargy
Central nervous system considerations in the use of beta-blockers, angiotensin-converting enzyme inhibitors, and thiazide diuretics in managing essential hypertension.
Evaluation of survival rate and prognostic indicators for surgical treatment of left-to-right patent ductus arteriosus in dogs: 52 cases (1995-2003).
Thiazide and loop diuretics.
Leukemia
A Novel UDP-Glycosyltransferase of Rhodiola crenulata Converts Tyrosol to Specifically Produce Icariside D2.
Circulating and local bone marrow renin-angiotensin system in leukemic hematopoiesis: preliminary evidences.
Early Post-Therapy Prescription Drug Usage among Childhood and Adolescent Cancer Survivors.
Gene polymorphisms and febrile neutropenia in acute leukemia--no association with IL-4, CCR-5, IL-1RA, but the MBL-2, ACE, and TLR-4 are associated with the disease in Turkish patients: a preliminary study.
Metabolic engineering Escherichia coli for efficient production of icariside D2.
Paternal fenvalerate exposure influences reproductive functions in the offspring.
Tuna muscle peptide, PTHIKWGD, inhibits leukocyte-mediated injury and leukocyte adhesion to cultured endothelial cells.
Leukemia, Myeloid
Inhibition of proliferation on some neoplastic cell lines-act of carvedilol and captopril.
Leukemia, Myeloid, Acute
Angiotensin-converting enzyme (CD143) is abundantly expressed by dendritic cells and discriminates human monocyte-derived dendritic cells from acute myeloid leukemia-derived dendritic cells.
The effect of calcium channel blockers on the outcome of acute myeloid leukemia.
Leukocytosis
Bartonella henselae Infection: An Uncommon Mimicker of Autoimmune Disease.
Clinical features of spinal cord sarcoidosis: analysis of 17 neurosarcoidosis patients.
Discriminating long myelitis of neuromyelitis optica from sarcoidosis.
Micturitional disturbance in a patient with neurosarcoidosis.
Sarcoidosis of the anterior visual pathway: 24 new cases.
Leukopenia
Ulcerative sarcoidosis successfully treated with apligraf.
Leukostasis
Dialyzer reactions in a patient switching from peritoneal dialysis to hemodialysis.
Lichen Planus
A Case of Lichen Planus Masquerading as Guttate Psoriasis.
Lichen planus.
Mucosal (oral and vulval) lichen planus in women: are angiotensin-converting enzyme inhibitors protective, and beta-blockers and non-steroidal anti-inflammatory drugs associated with the condition?
Ramipril-associated lichen planus pemphigoides.
Serum and tissue angiotensin converting enzyme in patients with lichen planus.
Lichen Planus, Oral
Prevalence of oral lichen planus in patients with diabetes mellitus.
Liddle Syndrome
Pseudoaldosteronism due to the concurrent use of two herbal medicines containing glycyrrhizin: interaction of glycyrrhizin with angiotensin-converting enzyme inhibitor.
Quantitative trait loci for blood pressure exist near the IGF-1, the Liddle syndrome, the angiotensin II-receptor gene and the renin loci in man.
Linear IgA Bullous Dermatosis
Linear IgA dermatosis induced by a new angiotensin-converting enzyme inhibitor.
lipoprotein lipase deficiency
Genetic basis of familial dyslipidemia and hypertension: 15-year results from Utah.
Liver Cirrhosis
Analysis of risk factors for chronic subdural haematoma recurrence after burr hole surgery: Optimal management of patients on antiplatelet therapy.
Angiotensin converting enzyme (ACE) gene expression in experimentally induced liver cirrhosis in rats.
Angiotensin-converting enzyme for noninvasive assessment of liver fibrosis in autoimmune hepatitis.
Angiotensin-converting enzyme gene polymorphism (insertion/deletion) and liver fibrosis in Turkish patients from the western Black Sea region, Turkey.
Angiotensin-converting enzyme inhibition in cirrhotic patients--pharmacokinetics of ramipril.
Angiotensin-converting-enzyme 2 inhibits liver fibrosis in mice.
Angiotensin-I-converting enzyme inhibitors may be an alternative anti-angiogenic strategy in the treatment of liver fibrosis and hepatocellular carcinoma. Possible role of vascular endothelial growth factor.
Angiotensin-II type 1 receptor interaction is a major regulator for liver fibrosis development in rats.
Blockade of renin-angiotensin system in antifibrotic therapy.
Changes of serum angiotensin I converting enzyme in patients with viral hepatitis and liver cirrhosis.
Combination of branched-chain amino acid and angiotensin-converting enzyme inhibitor improves liver fibrosis progression in patients with cirrhosis.
Combination of interferon-beta and angiotensin-converting enzyme inhibitor, perindopril, attenuates the murine liver fibrosis development.
Combined treatment of vitamin K2 and angiotensin-converting enzyme inhibitor ameliorates hepatic dysplastic nodule in a patient with liver cirrhosis.
Correlation of endothelin-1 concentration and angiotensin-converting enzyme activity with the staging of liver fibrosis.
Effect of losartan on early liver fibrosis development in a rat model of nonalcoholic steatohepatitis.
Effect of medications after cardiac surgery on long-term outcomes in patients with cirrhosis.
Effects of Angiotensin Converting Enzyme Inhibitors on Liver Fibrosis in HIV and Hepatitis C Coinfection.
Impact of inhibitors of the Renin-Angiotensin-aldosterone system on liver fibrosis and portal hypertension.
Is serum angiotensin converting enzyme level a useful non-invasive marker for liver fibrosis in patients with chronic hepatitis C?
Lack of efficacy of mTOR inhibitors and ACE pathway inhibitors as antifibrotic agents in evolving and established fibrosis in Mdr2(-/-) mice.
Pharmacokinetics and haemodynamic effects of a single oral dose of the novel ACE inhibitor spirapril in patients with chronic liver disease.
Pharmacokinetics of enalapril and lisinopril in subjects with normal and impaired hepatic function.
Possible Involvement of Angiogenesis in Chronic Liver Disease: Interaction among Renin-Angiotensin-Aldosterone System, Insulin Resistance and Oxidative Stress.
Preventative and therapeutic effects of perindopril on hepatic fibrosis induced by bile duct ligation in rats.
Renal Effects of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Patients with Liver Cirrhosis: A Nationwide Cohort Study.
Renin-angiotensin system inhibitors as therapeutic alternatives in the treatment of chronic liver diseases.
Serum angiotensin I-converting enzyme levels and the therapeutic effects of octreotide in esophageal variceal hemorrhage.
Serum angiotensin-converting enzyme in patients with hepatic cirrhosis and ascites in the recumbent and orthostatic positions.
Serum angiotensin-converting enzyme level for evaluating significant fibrosis in chronic hepatitis B.
Serum levels of angiotensin converting enzyme as a biomarker of liver fibrosis.
Severe hepatic encephalopathy in a patient with liver cirrhosis after administration of angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker combination therapy: a case report.
Targeting AngII/AT1R signaling pathway by Perindopril inhibits ongoing liver fibrosis in rat.
The ACE gene I/D polymorphism does not affect the susceptibility to or prognosis of PBC.
The circadian rhythm of serum angiotensin-converting enzyme is disrupted in ascitic liver cirrhosis.
[Clinical value of the estimation of plasma converting enzyme activity]
[Combination therapy of arterial hypertension combined with liver pathology. The place of angiotensin converting enzyme inhibitors]
[Effects of hypoxia on the production of angiotensin converting enzyme in decompensated liver cirrhosis]
[Effects of perindopril and valsartan on the expression of TGF beta 1 and TGF beta receptor II mRNA, Smad3 and Smad7 in experimental hepatic fibrotic rats]
[Is there any connection between angiotensin converting enzyme activity and liver cirrhosis of alcoholic genesis?]
[Pharmacokinetic and pharmacodynamic characteristics of antihypertensive drugs in the treatment of hypertensive patients with chronic diseases of the liver].
[RAAS inhibitors as therapeutic alternatives in the treatment of chronic liver diseases]
[Role of the renin-angiotensin-aldosterone system in ascitic hepatic cirrhosis. Effects of inhibition of angiotensin I converting enzyme]
[The usefulness of serum angiotensin-converting enzyme for distinguishing liver cirrhosis from other histological forms of alcoholic hepatopathy]
Liver Cirrhosis, Alcoholic
Elevation of serum angiotensin-converting enzyme level. Occurrence in alcoholic liver disease.
Single-dose and steady-state pharmacokinetics of fosinopril and fosinoprilat in patients with hepatic impairment.
Variation at the Angiotensin-converting enzyme and endothelial nitric oxide synthase genes is associated with the risk of esophageal varices among patients with alcoholic cirrhosis.
Liver Cirrhosis, Biliary
Moexipril for Treatment of Primary Biliary Cirrhosis in Patients with an Incomplete Response to Ursodeoxycholic Acid.
The ACE gene I/D polymorphism does not affect the susceptibility to or prognosis of PBC.
Liver Diseases
Activity of serum angiotensin-converting enzyme as a tumour marker of hepatocellular carcinoma.
Acute hypotensive transfusion reaction during liver transplantation in a patient on angiotensin converting enzyme inhibitors from low aminopeptidase P activity.
Alkaline phosphatase is independently associated with renal function in normoalbuminuric type 1 diabetic patients.
Angiotensin 1-7, an alternative metabolite of the renin-angiotensin system, is upregulated in human liver disease and has antifibrotic activity in the bile duct ligated rat.
Angiotensin converting enzyme inhibitors and angiotensin II antagonists as therapy in chronic liver disease.
Attenuation of hepatic fibrosis through captopril and enalapril in the livers of bile duct ligated rats.
Diagnostic significance of serum angiotensin-converting enzyme activity in biochemical tests with special reference of chronic liver diseases.
Effect of captopril on renin and blood pressure in cirrhosis.
Elevation of serum angiotensin-converting enzyme level. Occurrence in alcoholic liver disease.
Genetic modifiers of liver disease in cystic fibrosis.
HbA1c negatively correlates with LCAT activity in type 2 diabetes.
Mild but prolonged elevation of serum angiotensin converting enzyme (ACE) activity in alcoholics.
Pharmacokinetics and haemodynamic effects of a single oral dose of the novel ACE inhibitor spirapril in patients with chronic liver disease.
Prognostic factors for adverse outcomes in patients with COVID-19: a field-wide systematic review and meta-analysis.
Renal effects of nonselective NSAIDs and coxibs.
Role of Renin-Angiotensin-converting Enzyme Level and ACE Gene Polymorphism in Patients with Nonalcoholic Fatty Liver Disease.
Safety of drugs commonly used to treat hypertension, dyslipidemia, and type 2 diabetes (the metabolic syndrome): part 1.
Serum angiotensin converting enzyme activity in evaluation of patients with liver disease.
Statins and Angiotensin-Converting Enzyme Inhibitors are Associated with Reduced Mortality and Morbidity in Chronic Liver Disease.
Telmisartan, an AT1 receptor blocker and a PPAR gamma activator, alleviates liver fibrosis induced experimentally by Schistosoma mansoni infection.
The ACE gene I/D polymorphism does not affect the susceptibility to or prognosis of PBC.
[Serum angiotensin converting enzyme (ACE) activity in various liver diseases and its diagnostic value]
Liver Diseases, Alcoholic
Elevation of serum angiotensin-converting enzyme level. Occurrence in alcoholic liver disease.
Serum angiotensin converting enzyme and C4 protein of complement as a combined diagnostic index in alcoholic liver disease.
Serum angiotensin-converting enzyme in severe nonthyroidal illnesses associated with low serum thyroxine concentration.
Statins and Angiotensin-Converting Enzyme Inhibitors are Associated with Reduced Mortality and Morbidity in Chronic Liver Disease.
Liver Failure
Angiotensin II: a new therapeutic option for vasodilatory shock.
Liver Neoplasms
Angiotensin converting enzyme inhibitors and hepatocellular carcinoma incidence in the General Practice Research Database.
Does Angiotensin-Converting Enzyme Inhibitor and ?-Blocker Use Reduce the Risk of Primary Liver Cancer? A Case-Control Study Using the UK Clinical Practice Research Datalink.
Effects of angiotensin II type 2 receptor overexpression on the growth of hepatocellular carcinoma cells in vitro and in vivo.
Novel Bacillus Milk-Clotting Enzyme Produces Diverse Functional Peptides in Semihard Cheese.
Lung Diseases
A comprehensive review of imaging findings in COVID-19 - status in early 2021.
Alternative Roles of STAT3 and MAPK Signaling Pathways in the MMPs Activation and Progression of Lung Injury Induced by Cigarette Smoke Exposure in ACE2 Knockout Mice.
Amounts of angiotensin-converting enzyme mRNA reflect the burden of granulomas in granulomatous lung disease.
Angiotensin II is mitogenic for human lung fibroblasts via activation of the type 1 receptor.
Angiotensin-converting enzyme activity in serum and bronchoalveolar lavage fluid after damage to the alveolo-capillary barrier in the human lung.
Angiotensin-converting enzyme in sarcoidosis and other pulmonary diseases: a comparison of two methods of determination.
Anion Gap Was Associated with Inhospital Mortality and Adverse Clinical Outcomes of Coronary Care Unit Patients.
Chronic obstructive pulmonary disease: an update of treatment related to frequently associated comorbidities.
Determinants of Utility Based on the EuroQol Five-Dimensional Questionnaire in Patients with Chronic Heart Failure and Their Change Over Time: Results from the Swedish Heart Failure Registry.
Development and characterization of a rapid-onset rodent inhalation model of asbestosis for disease prevention.
Diagnostic value of serum angiotensin converting enzyme activity in lung diseases.
Direct radioimmunoassay of angiotensin-converting enzyme in sera from patients with pulmonary diseases.
Drug therapy before coronary artery surgery: nitrates are independent predictors of mortality and beta-adrenergic blockers predict survival.
Effects of preoperative statin treatment on the incidence of postoperative atrial fibrillation in patients undergoing coronary artery bypass grafting.
Effects on cytokines and histology by treatment with the ACE inhibitor captopril and the antioxidant retinoic acid in the monocrotaline model of experimentally induced lung fibrosis.
Follow-up on angiotensin-converting enzyme in serum of patients with sarcoidosis.
Genetic associations of surfactant protein D and angiotensin-converting enzyme with lung disease in preterm neonates.
Genetic factors in lung disease. Part II: Lung cancer and angiotensin converting enzyme gene.
Heart failure with preserved ejection fraction has a better long-term prognosis than heart failure with reduced ejection fraction in old patients in a 5-year follow-up retrospective study.
Kininase II in bronchoalveolar lavage fluid and serum of patients with pulmonary disorders.
Meta-Analysis of Risks for Short-Term Readmission in Patients With Heart Failure.
Nerve growth factor and neuropeptides circulating levels in systemic sclerosis (scleroderma).
Nicotine Downregulates the Compensatory Angiotensin-Converting Enzyme 2/Angiotensin Type 2 Receptor of the Renin-Angiotensin System.
Predictors of mortality after discharge in patients hospitalized with heart failure: an analysis from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF).
QRS duration is associated with atrial fibrillation in patients with left ventricular dysfunction.
Renal and pulmonary effects of angiotensin converting enzyme inhibition in chronic hypoxic lung disease.
Risk Factors for Aspiration Pneumonia in Frail Older People: A Systematic Literature Review.
Role of serum angiotensin converting enzyme in sarcoidosis.
Serum angiotensin converting enzyme activity in pulmonary diseases: correlation with lung function parameters.
Serum angiotensin converting enzyme in pulmonary disease.
Serum angiotensin-converting enzyme in sarcoidosis.
Structure-based pharmacophore design and virtual screening for novel Angiotensin converting enzyme 2 inhibitors.
The D/I Polymorphism in the Angiotensin-Converting Enzyme Gene and Chronic Obstructive Pulmonary Disease Risk: A Meta-Analysis.
The value of serial serum angiotensin converting enzyme determinations in hospitalized patients with lung disease.
Treatment Effectiveness in Heart Failure with Comorbidity: Lung Disease and Kidney Disease.
[Angiotensin converting enzyem (ACE) - a blood chemistry parameter in the diagnosis of sarcoidosis]
[Angiotensin converting enzyme (ACE) a bloodtest for diagnosis of sarcoidosis (author's transl)]
[Angiotensin converting enzyme in lung diseases]
[Angiotensin I converting enzyme and carboxypeptidase B-like enzymes in sarcoidosis and other lung diseases]
[Assay of angiotensin converting enzyme (ACE) in thoracic forms of sarcoidosis and other pulmonary diseases]
[Clinical significance of bronchoalveolar lavage, Ga scintigraphy and serum angiotensin converting enzyme activity in granulomatous lung disease]
[Determination of angiotensin-converting enzyme activity in internal diseases]
[Determination of serum angiotensin converting enzyme activity in normal children and in children with pulmonary disease]
[Direct radioimmunoassay of angiotensin-converting enzyme in serum and bronchoalveolar lavage fluid from patients with pulmonary diseases]
[Measurement of angiotensin-converting enzyme in lung diseases]
[Serum angiotensin converting enzyme in the diagnosis of sarcoidosis and other lung diseases]
[Serum angiotensin I-converting enzyme activity in various pulmonary diseases (author's transl)]
[The examinations for diffuse lung diseases]
[Variations in plasma angiotensin-converting enzyme and renin in sarcoidosis]
Lung Diseases, Interstitial
Angiogenic activity of sera from interstitial lung disease patients in relation to Angiotensin-converting enzyme activity.
Angiotensin converting enzyme inhibitor toxicity causing interstitial pneumonitis and cholestatic hepatitis.
Bronchoalveolar lavage fluid angiotensin-converting enzyme in interstitial lung diseases.
Childhood Sarcoidosis Presenting as Recurrent Facial Palsy.
Drug-induced pulmonary disease.
Elevated serum levels of lysozyme in desquamative interstitial pneumonia.
Gallium scans and serum angiotensin converting enzyme levels in talc granulomatosis and lymphocytic interstitial pneumonitis.
Highlights of the 22nd French pharmacovigilance meeting.
Increased D allele frequency of the angiotensin-converting enzyme gene in pulmonary fibrosis.
Revised Korean Cough Guidelines, 2020: Recommendations and Summary statements.
Scleroderma renal crisis during intravenous cyclophosphamide pulse therapy for complicated interstitial lung disease was successfully treated with angiotensin converting enzyme inhibitor and plasma exchange.
Serum angiotensin converting enzyme in the diagnosis of pulmonary sarcoidosis.
Serum angiotensin-converting enzyme activity, concentration, and specific activity in granulomatous interstitial lung disease, tuberculosis, and COPD.
The Korean Cough Guideline: Recommendation and Summary Statement.
The pulmonary renin-angiotensin system.
[Angiotensin converting enzyme, lysozyme and circulating immune complexes in the serum of patients with sarcoidosis and other interstitial lung diseases]
[Cutaneous lesions during hot-tub hypersensitivity pneumonitis: Pseudomonas folliculitis ?]
Lung Diseases, Obstructive
[Change in activity of angiotensin-converting enzyme in pneumonia and chronic obstructive lung diseases]
[Changes in angiotensin-converting enzyme activity in pneumonia and chronic obstructive lung diseases]
Lung Injury
Age-Dependent Changes in the Pulmonary Renin-Angiotensin System Are Associated With Severity of Lung Injury in a Model of Acute Lung Injury in Rats.
Angiotensin converting enzyme 2 abrogates bleomycin-induced lung injury.
Angiotensin II and the fibroproliferative response to acute lung injury.
Angiotensin II receptor antagonists in the treatment and prevention of radiation nephropathy.
Angiotensin-converting enzyme 2 inhibits lung injury induced by respiratory syncytial virus.
Angiotensin-converting enzyme activity: a novel way of assessing pulmonary changes during total knee arthroplasty.
Angiotensin-converting enzyme and its clinical significance--a review.
Angiotensin-converting enzyme and lung injury.
Angiotensin-Converting Enzyme Gene Polymorphism and Severe Lung Injury in Patients with Coronavirus Disease 2019.
Angiotensin-converting enzyme genetic variation and lung injury: are we genetically predisposed to develop acute respiratory distress syndrome?
Angiotensin-converting enzyme inhibition attenuates lipopolysaccharide-induced lung injury by regulating the balance between Angiotensin-converting enzyme and Angiotensin-converting enzyme 2 and inhibiting mitogen-activated protein kinase activation.
Angiotensin-converting enzyme N-terminal inactivation alleviates bleomycin-induced lung injury.
Biochemical and histological alterations in rats after acute nitrogen dioxide intoxication.
Bleomycin-Induced Neonatal Lung Injury Requires the Autocrine Pulmonary Angiotensin System.
Captopril reduces lung inflammation and accelerated senescence in response to thoracic radiation in mice.
Contribution of angiotensin II in hepatic ischemia /reperfusion induced lung injury: Acute versus chronic usage of captopril.
Control of radiation-induced pneumopathy and lung fibrosis by angiotensin-converting enzyme inhibitors and an angiotensin II type 1 receptor blocker.
Curcumin protects bleomycin-induced lung injury in rats.
Decreased Risk of Radiation Pneumonitis With Coincident Concurrent Use of Angiotensin-converting Enzyme Inhibitors in Patients Receiving Lung Stereotactic Body Radiation Therapy.
Decreased Risk of Radiation Pneumonitis with Incidental Concurrent Use of Angiotensin-Converting Enzyme Inhibitors and Thoracic Radiation Therapy.
Diabetes and COVID-19: evidence, current status and unanswered research questions.
Do angiotensin-converting enzyme inhibitors reduce the risk of symptomatic radiation pneumonitis in patients with non-small cell lung cancer after definitive radiation therapy? Analysis of a single-institution database.
Early detection of oxygen-induced lung injury in conscious rabbits. Reduced in vivo activity of angiotensin converting enzyme and removal of 5-hydroxytryptamine.
Early markers of lung injury.
Effect of a fibrin-derived vasoactive peptide on pulmonary angiotensin converting enzyme activity and on pressure responses to bradykinin.
Effectiveness of liposomal-N-acetylcysteine against LPS-induced lung injuries in rodents.
Effects of an angiotensin-converting enzyme inhibitor on the inflammatory response in in vivo and in vitro models.
Effects of intratracheal captopril on severely meconium-injured piglet lungs.
Enhanced activity of liposomal polymyxin B against Pseudomonas aeruginosa in a rat model of lung infection.
Hyperoxic lung injury in mice: a possible protective role for prostacyclin.
Identification of potent human neutralizing antibodies against SARS-CoV-2 implications for development of therapeutics and prophylactics.
Lavage angiotensin-converting enzyme as a marker of lung injury.
Lung injury in rabbits induced by intravenous administration of heterologous polyclonal antibodies to angiotensin converting enzyme (kininase II).
Lung injury induced by antibody fragments to angiotensin-converting enzyme.
Monocrotaline-induced cardiopulmonary damage in rats: amelioration by the angiotensin-converting enzyme inhibitor CL242817.
Plasma fibronectin and angiotensin-converting enzyme: markers of primary pulmonary injury in burn patients.
Pre-ischaemic conditioning of the pulmonary endothelium by immunotargeting of catalase via angiotensin-converting-enzyme antibodies.
Prophylaxis against lipopolysaccharide-induced acute lung injury by alpha-tocopherol liposomes.
Prophylaxis against lipopolysaccharide-induced lung injuries by liposome-entrapped dexamethasone in rats.
Pros and cons for use of statins in people with coronavirus disease-19 (COVID-19).
Pseudomonas aeruginosa-induced lung injury: role of oxidative stress.
Pulmonary midkine inhibition ameliorates sepsis induced lung injury.
Radiation injury in rat lung. II. Angiotensin-converting enzyme activity.
Resolution of impaired pulmonary function and pulmonary hypertension after phorbol ester administration in rabbits.
Role of angiotensin-converting enzyme (ACE) and ACE2 in a rat model of smoke inhalation induced acute respiratory distress syndrome.
Role of the membrane attack complex of complement in lung injury mediated by antibodies to endothelium.
The angiotensin-converting enzyme 2/angiotensin (1-7)/mas axis protects against pyroptosis in LPS-induced lung injury by inhibiting NLRP3 activation.
The pulmonary renin-angiotensin system.
The role of angiotensin-converting enzyme inhibition in endotoxin-induced lung injury in rats.
[A preliminary approach to pathological and biochemical changes of the lungs injured by domestic pingyangmycinum]
[Angiotensin converting enzyme (ACE) in scalded rats and protective effect of chloroquine (CQ) in lung injury]
[ARDS and leukotoxin]
[Medical prevention and treatment of radiation-induced pulmonary complications].
Lung Neoplasms
Angiotensin converting enzyme inhibitors and incidence of lung cancer in a population based cohort of common data model in Korea.
Angiotensin converting enzyme inhibitors and lung cancer.
Angiotensin converting enzyme inhibitors and risk of lung cancer: A systematic review and meta-analysis.
Angiotensin converting enzyme inhibitors and risk of lung cancer: population based cohort study.
Angiotensin-converting enzyme (ACE) inhibitor prescription affects non-small-cell lung cancer (NSCLC) patients response to PD-1/PD-L1 immune checkpoint blockers.
Angiotensin-Converting Enzyme and Aldosterone Serum Levels as Prognostic and Predictive Biomarkers for Cediranib in NCIC Clinical Trials Group Study BR.24.
Angiotensin-converting enzyme and its association with outcome in lung cancer.
Angiotensin-converting enzyme gene polymorphism is associated with anemia in non small-cell lung cancer.
Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers might be associated with lung adenocarcinoma risk: a nationwide population-based nested case-control study.
Angiotensin-converting Enzyme Inhibitors Decrease the Incidence of Radiation-induced Pneumonitis Among Lung Cancer Patients: A Systematic Review and Meta-analysis.
Angiotensin-converting enzyme insertion/deletion gene polymorphism and lung cancer risk: A meta-analysis.
Angiotensin-Converting Enzyme Insertion/Deletion Gene Polymorphism in Lung Cancer Patients.
Association between Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers and Lung Cancer.
Association between Angiotensin-Converting Enzyme Inhibitors and Lung Cancer-A Nationwide, Population-Based, Propensity Score-Matched Cohort Study.
Association of angiotensin converting enzyme gene insertion/deletion polymorphism with lung cancer in Turkey.
Association of Angiotensin-Converting Enzyme Insertion/Deletion Gene Polymorphism With Lung Cancer Susceptibility.
Can angiotensin-converting enzyme inhibitors protect against symptomatic radiation pneumonitis?
Comparison Between Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers for Incidence of Lung Cancer: A Retrospective Study.
Comparison of diagnostic evaluations for cough among initiators of angiotensin converting enzyme inhibitors and angiotensin receptor blockers.
Diagnostic value of serum angiotensin converting enzyme activity in lung diseases.
Distinct effects of asthma and COPD comorbidity on disease expression and outcome in patients with COVID-19.
Do angiotensin-converting enzyme inhibitors reduce the risk of symptomatic radiation pneumonitis in patients with non-small cell lung cancer after definitive radiation therapy? Analysis of a single-institution database.
Evaluation of TReatment With Angiotensin Converting Enzyme Inhibitors and the Risk of Lung Cancer: ERACER-An Observational Cohort Study.
Gene polymorphisms of endothelial nitric oxide synthase and angiotensin-converting enzyme in patients with lung cancer.
Genetic factors in lung disease. Part II: Lung cancer and angiotensin converting enzyme gene.
Genetic variations in TGF?1, tPA, and ACE and radiation-induced thoracic toxicities in patients with non-small-cell lung cancer.
Impact of angiotensin I converting enzyme inhibitors and angiotensin II type 1 receptor blockers on survival in patients with advanced non-small-cell lung cancer undergoing first-line platinum-based chemotherapy.
Interaction of tobacco smoking and chewing with Angiotensin converting enzyme (insertion/deletion) gene polymorphisms and risk of lung cancer in a high risk area from northeast India.
Kinetic parameters of serum and lung tissue angiotensin-converting enzyme in patients with lung cancer.
Kininase II in bronchoalveolar lavage fluid and serum of patients with pulmonary disorders.
Lack of association between ACE insertion/deletion polymorphism and lung cancer: A meta-analysis.
Long-term use of angiotensin receptor blockers and the risk of cancer.
Lung Cancer Adverse Events Reports for Angiotensin-Converting Enzyme Inhibitors: Data Mining of the FDA Adverse Event Reporting System Database.
Lung cancer in the older population:Interactive effects of angiotensin converting enzyme gene polymorphism (rs 4340 ID) and tobacco addiction in risk assessment.
Modest Association of Long-Term ACE Inhibitor Treatment With Lung Cancer: The Promise and Pitfalls of Epidemiological Drug-Safety Analyses.
Renin-Angiotensin system blockers may prolong survival of metastatic non-small cell lung cancer patients receiving erlotinib.
Retrospective clinical study of renin-angiotensin system blockers in lung cancer patients with hypertension.
Revised Korean Cough Guidelines, 2020: Recommendations and Summary statements.
Serum angiotensin converting enzyme activity in pulmonary diseases: correlation with lung function parameters.
Serum zinc and angiotensin-converting enzyme levels in patients with lung cancer.
Small Cell Lung Cancer with Sarcoidosis in Spontaneous Remission: A Case Report.
The angiotensin receptor blocker, Losartan, inhibits mammary tumor development and progression to invasive carcinoma.
The Angiotensin-Converting Enzyme Inhibitory State Promotes the Transformation of Non-Small Cell Lung Cancer Blood Supply Pattern Toward Vasculogenic Mimicry Formation.
The Korean Cough Guideline: Recommendation and Summary Statement.
The relationship between three well-characterized polymorphisms of the angiotensin converting enzyme gene and lung cancer risk: a case-control study and a meta-analysis.
The value of angiotensin-I-converting enzyme determinations in malignant and other diseases.
Tumor growth-inhibitory effect of an angiotensin-converting enzyme inhibitor (captopril) in a lung cancer xenograft model analyzed using 18F-FDG-PET/CT.
Use of ACE (Angiotensin-Converting Enzyme) Inhibitors and Risk of Lung Cancer: A Nationwide Nested Case-Control Study.
Utility of the ACE Inhibitor Captopril in Mitigating Radiation-associated Pulmonary Toxicity in Lung Cancer: Results From NRG Oncology RTOG 0123.
[Activity of angiotensin I converting enzyme in serum and bronchoalveolar lavage fluid of patients with sarcoidosis and lung neoplasms]
[An observation of change in serum angiotensin-converting enzyme activity in patients with lung cancer.]
[Analysis of the relationship between polymorphism of angiotensin-converting enzyme gene and lung cancer.]
[Angiotensin converting enzyme as a diagnostic aid in newly diagnosed sarcoidosis compared with pulmonary cancer and tuberculosis]
[Changes in serum angiotensin converting enzyme activity in patients with lung cancer]
[Determination of angiotensin-converting enzyme activity in internal diseases]
[Serum angiotensin-converting enzyme and lysozyme activities as markers of host immunoreactive cells in lung cancer]
Lupus Erythematosus, Cutaneous
Subacute cutaneous lupus erythematosus in the course of rheumatoid arthritis: a relationship with TNF-? antagonists and rituximab therapy?
Lupus Erythematosus, Systemic
Angiotensin I converting enzyme gene polymorphisms in systemic lupus erythematosus: decreased prevalence of DD genotype in African American patients.
Angiotensin II type 1 receptor gene polymorphism and serum angiotensin-converting enzyme level in Egyptian children with systemic lupus erythematosus.
Angiotensin II type 2 receptor gene polymorphisms and serum angiotensin-converting enzyme level in Egyptian children with systemic lupus erythematosus.
Angiotensin-converting enzyme (ACE) serum levels and gene polymorphism in Egyptian patients with systemic lupus erythematosus.
Angiotensin-converting enzyme (insertion/deletion) and endothelial nitric oxide synthase polymorphisms in patients with systemic lupus erythematosus.
Angiotensin-converting enzyme gene I/D dimorphism does not play a major role in the susceptibility of Malaysian systemic lupus erythematosus patients.
Angiotensin-Converting Enzyme Gene I/D Polymorphism Is Associated With Systemic Lupus Erythematosus Susceptibility: An Updated Meta-Analysis and Trial Sequential Analysis.
Angiotensin-converting enzyme gene polymorphism in Kuwaiti patients with systemic lupus erythematosus.
Angiotensin-converting enzyme gene polymorphism in Thai patients with systemic lupus erythematosus.
Angiotensin-converting enzyme insertion/deletion gene polymorphism in Egyptian children with systemic lupus erythematosus: a possible relation to proliferative nephritis.
Angiotensin-converting enzyme insertion/deletion polymorphism and systemic lupus erythematosus: a metaanalysis.
Antiproteinuric effect of angiotensin-converting enzyme inhibitors and an angiotensin II receptor blocker in patients with lupus nephritis.
Association between systemic lupus erythematosus and insertion/deletion polymorphism of the angiotensin converting enzyme (ACE) gene.
Association between the angiotensin-converting enzyme gene insertion/deletion polymorphism and susceptibility to systemic lupus erythematosus in an Indian population.
Association between the angiotensin-converting enzyme insertion/deletion polymorphism and susceptibility to systemic lupus erythematosus: a meta-analysis.
Association of ACE gene polymorphism with genetic susceptibility to systemic lupus erythematosus in a Chinese population: a family-based association study.
Association of an insertion polymorphism of angiotensin-converting enzyme gene with the activity of systemic lupus erythematosus.
Association of angiotensin-converting enzyme gene dimorphisms with severity of lupus disease.
Association of angiotensin-converting enzyme insertion/deletion polymorphism with susceptibility to systemic lupus erythematosus: a meta-analysis.
Association of angiotensin-converting enzyme polymorphisms with systemic lupus erythematosus and nephritis: analysis of 644 SLE families.
Association of the genetic polymorphisms of the ACE gene and the eNOS gene with lupus nephropathy in northern Chinese population.
Captopril-associated granulocytopenia in hypertension after renal transplantation.
Differential effects of captopril and enalapril, two angiotensin converting enzyme inhibitors, on immune reactivity in experimental lupus disease.
Distribution of Human Leukocyte Antigen alleles in Systemic Lupus Erythematosus patients with Angiotensin Converting Enzyme Insertion/Deletion Polymorphism.
E/E' ratio is more sensitive than E/A ratio for detection of left ventricular diastolic dysfunction in systemic lupus erythematosus.
Linkage analysis of angiotensin-converting enzyme (ACE) insertion/deletion polymorphism and systemic lupus erythematosus.
Night and day proteinuria in patients with sleep apnea.
Relationship Between Angiotensin-converting Enzyme Insertion/Deletion Gene Polymorphism and Systemic Lupus Erythematosus/Lupus Nephritis: A Systematic Review and Metaanalysis.
Renal outcome and vascular morbidity in systemic lupus erythematosus (SLE): lack of association with the angiotensin-converting enzyme gene polymorphism.
Systemic lupus erythematosus presenting as erythema annulare centrifugum.
[Renal involvement in connective tissue diseases]
Lupus Nephritis
Angiotensin inhibition or blockade for the treatment of patients with quiescent lupus nephritis and persistent proteinuria.
Angiotensin-converting enzyme gene polymorphism in Kuwaiti patients with systemic lupus erythematosus.
Angiotensin-converting enzyme gene polymorphism in Thai patients with systemic lupus erythematosus.
Angiotensin-converting enzyme insertion/deletion polymorphism and systemic lupus erythematosus: a metaanalysis.
Antiproteinuric effect of angiotensin-converting enzyme inhibitors and an angiotensin II receptor blocker in patients with lupus nephritis.
Association between the angiotensin-converting enzyme insertion/deletion polymorphism and susceptibility to systemic lupus erythematosus: a meta-analysis.
Association of an insertion polymorphism of angiotensin-converting enzyme gene with the activity of lupus nephritis.
Association of angiotensin-converting enzyme polymorphisms with systemic lupus erythematosus and nephritis: analysis of 644 SLE families.
Captopril treatment of hypertension and renal failure in systemic lupus erythematosus.
Does renin-angiotensin system blockade protect lupus nephritis patients from atherosclerotic cardiovascular events? A case-control study.
Effect of combining ACE inhibitor and statin in lupus-prone mice.
Exploring new territory: considering the future.
Insertion/deletion polymorphism of the angiotensin-converting enzyme gene in lupus nephritis among Mexicans.
Kinin system in lupus nephritis.
The renoprotective potential of pentoxifylline in chronic kidney disease.
[Angiotensin-converting enzyme gene polymorphism and the clinical pathological features and progression in lupus nephritis]
[Hemodynamic mechanisms of lupus nephritis progression]
Lyme Disease
Cutaneous Rosai-Dorfman disease: a case report.
Lymphadenitis
Acute reversible dysphagia and dysphonia as initial manifestations of sarcoidosis.
Lymphadenopathy
"Crack" cocaine-induced syndrome mimicking sarcoidosis.
A case of sarcoid reaction associated with papillary thyroid carcinoma.
A case of sarcoidosis which relapsed twice after successive parturitions.
A patient with sarcoidosis presenting with acute renal failure: implication for granulomatous interstitial nephritis and hypercalcemia.
A Rare Presentation of Sarcoidosis as a Pancreatic Head Mass.
A trout fisherman with hypercalcaemia and skin lesions.
Acute reversible dysphagia and dysphonia as initial manifestations of sarcoidosis.
Adverse effect of chronic tonsillitis on clinical course of sarcoidosis.
Choroidal nonperfusion on optical coherence tomography angiography in a case of unilateral posterior segment ocular sarcoidosis misdiagnosed as MEWDS.
Corticosteroid-resistant bulbar neurosarcoidosis responsive to intravenous immunoglobulin.
Course of chronic hilar sarcoidosis in relation to markers of granulomatous activity.
Cushing's syndrome due to primary adrenocortical nodular dysplasia, cardiac myxomas, and spotty pigmentation, complicated by sarcoidosis.
Diffuse placoid choroidopathy in a patient with common variable immunodeficiency.
Discriminating long myelitis of neuromyelitis optica from sarcoidosis.
Elevated serum angiotensin converting enzyme levels in metastatic ovarian dysgerminoma.
Evaluation of characteristic ocular signs and systemic investigations in ocular sarcoidosis patients.
FUO due to sarcoidosis-lymphoma syndrome.
Hypercalcemia-induced acute kidney injury in a Caucasian female due to radiographically silent systemic sarcoidosis.
International criteria for the diagnosis of ocular sarcoidosis: results of the first International Workshop On Ocular Sarcoidosis (IWOS).
Intramedullary cervical spinal cord sarcoidosis.
Isolated sarcoidosis of the lacrimal sac without systemic manifestations.
Juvenile sarcoidosis presenting as Crohn's disease.
Long-term use of corticosteroid eye drops delays the spontaneous remission of pulmonary sarcoidosis.
Löfgren Syndrome with Hypercalcemia and Neuroendocrinological Involvement: A Case Report.
Neurosarcoidosis with spinal root pain as the first symptom.
Noninvasive testing of asymptomatic bilateral hilar adenopathy.
Orbital sarcoidosis presenting as diffuse swelling of the lower eyelid.
Pembrolizumab-induced Sarcoid-like Reactions during Treatment of Metastatic Melanoma.
Primary presentation of sarcoidosis with profound bilateral sensorineural hearing loss.
Prolonged Uhthoff phenomenon in sarcoidosis.
Retrograde radiographic development in pulmonary sarcoidosis.
Role of MRI in diagnosis of childhood sarcoidosis with fever of unknown origin.
Sarcoid Uveitis: A Look Beyond The Eyes.
Sarcoidosis following Cushing's syndrome: A report of two cases and review of the literature.
Sarcoidosis of the breast.
Sarcoidosis of the tongue.
Sarcoidosis Presenting Addison's Disease.
Sarcoidosis presenting as multiple subcutaneous nodules.
Sarcoidosis: a journey through 50 years.
Subcutaneous sarcoidosis of the upper and lower extremities: A case report and review of the literature.
Systemic elastolytic granulomatosis with cutaneous, ocular, lymph nodal, and intestinal involvement. Spectrum of annular elastolytic giant cell granuloma and sarcoidosis.
X-linked chronic granulomatous disease (CGD) caused by an intra-exonic splice mutation (CYBB exon 3, c.262G->A) is mimicking juvenile sarcoidosis.
[A case of relapsing sarcoidosis with pleurisy 14 years after spontaneous remission]
[A clinical study on 8 cases of sarcoidosis with a cervical mass as a symptom].
[Bilateral recurrent blurred vision associated with halos around sources of light and headache].
[Branch retinal vein occlusion and sarcoidosis in a child: A case report.]
[Case of sarcoidosis with squamous cell carcinoma which originated from solitary bronchial papilloma].
[Conjunctival biopsy: a useful procedure for the diagnosis of sarcoidosis.]
[Endoscope-assisted biopsy for the diagnosis of neurosarcoidosis]
[Neurosarcoidosis presenting with severe hyposmia and polyradiculopathy].
[The diagnosis of sarcoidosis based on ocular manifestations]
[Unilateral papillitis as the presenting symptom of neurosarcoidosis]
Lymphangioleiomyomatosis
Angiotensin-converting enzyme inhibitors may affect pulmonary function in lymphangioleiomyomatosis.
Lymphatic Metastasis
Angiotensin-Converting Enzyme Gene Deletion Polymorphism is Associated with Lymph Node Metastasis in Colorectal Cancer Patients in a Chinese Population.
Expression of the Local Angiotensin II System in Gastric Cancer May Facilitate Lymphatic Invasion and Nodal Spread.
Polymorphism of angiotensin I-converting enzyme gene is related to oral cancer and lymph node metastasis in male betel quid chewers.
The ACE gene polymorphism is associated with the incidence of gastric cancer among H. pylori seropositive subjects with atrophic gastritis.
The ectopeptidases CD10, CD13, CD26, and CD143 are upregulated in gastric cancer.
The number of lymph node metastases in gastric cancer correlates with the angiotensin I-converting enzyme gene insertion/deletion polymorphism.
Lymphocytosis
Association of peripheral multifocal choroiditis with sarcoidosis: a study of thirty-seven patients.
Characteristics of patients presenting with erythema nodosum and sarcoidosis.
Diagnosis of cutaneous sarcoidosis; clinical and the prognostic significance of skin lesions.
Lack of correlation between serum angiotensin-converting enzyme activity and bronchoalveolar lymphocytosis in lung sarcoidosis.
Pulmonary sarcoidosis: role of CT in the evaluation of disease activity and functional impairment and in prognosis assessment.
Urinary neopterin in pulmonary sarcoidosis. Relationship to clinical and biologic assessment of the disease.
Value of s-ACE, BAL lymphocytosis, and CD4+/CD8+ and CD103+CD4+/CD4+ T-cell ratios in diagnosis of sarcoidosis.
[Bilateral scleritis and extra-ocular inflammation in a patient with undiagnosed chronic lymphatic leukaemia].
[Branch retinal vein occlusion and sarcoidosis in a child: A case report.]
[Clinical and paraclinical of mediastinal-pulmonary sarcoidosis]
Lymphoma
Early Post-Therapy Prescription Drug Usage among Childhood and Adolescent Cancer Survivors.
Elevated serum angiotensin I converting enzyme in sarcoidosis.
Orbital lymphoma with concomitant sarcoid-like granulomas.
Relevance of Brain MRI in Patients with Uveitis: Retrospective Cohort on 402 Patients.
Serum angiotensin-converting enzyme in malignant lymphomas, leukaemia and multiple myeloma.
The value of angiotensin-I-converting enzyme determinations in malignant and other diseases.
[A case of so-called Lennert's lymphoma, suspected of sarcoidosis due to uveitis occurring first and elevation of serum angiotensin-converting enzyme (ACE)]
[Lymphoma B associated with hypercalcemia and increase in angiotensin converting enzyme]
[Malignant lymphoma and sarcoidosis. Changes in the serum levels of angiotensin-converting enzyme]
Lymphoma, B-Cell
Streptozotocin-induced diabetic cardiomyopathy in rats: ameliorative effect of PIPERINE via Bcl2, Bax/Bcl2, and caspase-3 pathways.
Lymphoma, Non-Hodgkin
Low-grade B-cell lymphoma and concomitant extensive sarcoidlike granulomas: a case report and review of the literature.
Non-Hodgkin's lymphoma associated with hypercalcemia and increased activity of serum angiotensin-converting enzyme.
Serum angiotensin-converting enzyme in malignant lymphomas, leukaemia and multiple myeloma.
Lymphoma, T-Cell, Cutaneous
Association of variants in angiotensin-converting enzyme and endothelin-1 genes with phototherapy in cutaneous T-cell lymphoma.
Lymphopenia
Pure extra-thoracic sarcoidosis: about 24 cases.
Relevance of diagnostic investigations in patients with uveitis: Retrospective cohort study on 300 patients.
Lymphoproliferative Disorders
Angioedema, lymphoproliferative disorder and angiotensin-converting enzyme inhibitors: masking of diagnosis by corticosteroids.
Co-occurrence between C1 esterase inhibitor deficiency and autoimmune disease: a systematic literature review.
Macroglossia
Angiotensin-converting Enzyme (ACE) Inhibitor Induced Macroglossia.
Episodic macroglossia as the sole manifestation of angiotensin-converting enzyme inhibitor-induced angioedema.
Macroglossia secondary to lisinopril-induced acute angioedema.
Macrophage Activation Syndrome
SARS-CoV-2 as an inflammatory cardiovascular disease: current knowledge and future challenges.
Macular Degeneration
Angiotensin-converting enzyme inhibitors (ACEIs) and age-related maculopathy (ARM): cross-sectional findings from the Blue Mountains Eye Study.
Effect of Statins, Metformin, Angiotensin-Converting Enzyme Inhibitors, and Angiotensin II Receptor Blockers on Age-Related Macular Degeneration.
EFFECT OF SYSTEMIC BETA-BLOCKERS, ACE INHIBITORS, AND ANGIOTENSIN RECEPTOR BLOCKERS ON DEVELOPMENT OF CHOROIDAL NEOVASCULARIZATION IN PATIENTS WITH AGE-RELATED MACULAR DEGENERATION.
The Relationship Between Angiotensin Converting Enzyme Insertion/deletion Polymorphism and Age-related Macular Degeneration.
Therapeutic targets of renin-angiotensin system in ocular disorders.
Use of statins and angiotensin converting enzyme inhibitors (ACE-Is) and the risk of age-related macular degeneration: nested case-control study.
Macular Edema
A randomized, masked, cross-over trial of lisinopril for inflammatory macular edema.
Development of diabetic retinopathy after cataract surgery.
Quantitative measurement of retinal thickness in patients with diabetic macular edema is useful for evaluation of therapeutic agents.
[Bradykinin and angiotensin-converting enzyme in serum of patients with diabetic retinopathy and the prognosis of diabetic macular edema development (pilot study)].
[The effect of intravitreally administered angiogenesis inhibitor on the concentration of angiotensin-converting enzyme in the blood serum and lacrimal fluid in patients with diabetic macular edema].
Malaria
Ace-1 duplication in Anopheles gambiae: a challenge for malaria control.
An ace-1 gene duplication resorbs the fitness cost associated with resistance in Anopheles gambiae, the main malaria mosquito.
Contemporary evolution of resistance at the major insecticide target site gene Ace-1 by mutation and copy number variation in the malaria mosquito Anopheles gambiae.
CYP6 P450 Enzymes and ACE-1 Duplication Produce Extreme and Multiple Insecticide Resistance in the Malaria Mosquito Anopheles gambiae.
Detection of G119S ace-1 (R) mutation in field-collected Anopheles gambiae mosquitoes using allele-specific loop-mediated isothermal amplification (AS-LAMP) method.
Detection of kdr and ace-1 mutations in wild populations of Anopheles arabiensis and An. melas in a residual malaria transmission area of Senegal.
Human Angiotensin-Converting Enzyme may be under malaria selection pressure: a need to explore.
Mapping insecticide resistance in Anopheles gambiae (s.l.) from Côte d'Ivoire.
Novel mutations on the ace-1 gene of the malaria vector Anopheles albimanus provide evidence for balancing selection in an area of high insecticide resistance in Peru.
Phenotypic effects of concomitant insensitive acetylcholinesterase ( ace-1 R ) and knockdown resistance ( kdr R ) in Anopheles gambiae : a hindrance for insecticide resistance management for malaria vector control.
The ace-1 Locus Is Amplified in All Resistant Anopheles gambiae Mosquitoes: Fitness Consequences of Homogeneous and Heterogeneous Duplications.
Malaria, Cerebral
Gene polymorphisms in angiotensin I converting enzyme (ACE I/D) and angiotensin II converting enzyme (ACE2 C-->T) protect against cerebral malaria in Indian adults.
Malnutrition
Anaemia in chronic obstructive pulmonary disease: an insight into its prevalence and pathophysiology.
Anemia Evaluation and Erythropoietin Dose Requirement Among Hemodialysis Patients: a Multicenter Study.
Angiotensin-converting enzyme gene insertion/deletion polymorphism in nutritional disorders in children.
Antihypertensive treatment in early postnatal life modulates prenatal dietary influences upon blood pressure in the rat.
Factors Related to Erythropoietin Hyporesponsiveness in Peritoneal Dialysis Patients with Anemia.
Risk Factors for Aspiration Pneumonia in Frail Older People: A Systematic Literature Review.
Thrombosis and occlusion of vascular access in hemodialyzed patients.
Mania
Exploring the evidence implicating the renin- angiotensin system (RAS) in the physiopathology of mood disorders.
Marfan Syndrome
?-Blockers and angiotensin converting enzyme inhibitors: comparison of effects on aortic growth in pediatric patients with Marfan syndrome.
A role for plasma transforming growth factor-beta and matrix metalloproteinases in aortic aneurysm surveillance in Marfan syndrome?
A systematic review of the pharmacological management of aortic root dilation in Marfan syndrome.
The personalised medicine. A paradigm of evidence-based medicine.
Thoracic aortic aneurysm and dissection.
Masked Hypertension
2010 guidelines of the Taiwan Society of Cardiology for the management of hypertension.
Mastocytosis
Clinical Practice Guidelines for Diagnosis and Management of Hypersensitivity Reactions to Contrast Media.
Melanoma
Inhibition of proliferation on some neoplastic cell lines-act of carvedilol and captopril.
Melanoma and Non-Melanoma Skin Cancer Associated with Angiotensin-Converting-Enzyme Inhibitors, Angiotensin-Receptor Blockers and Thiazides: A Matched Cohort Study.
Melanoma incidence and exposure to angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.
Mice with Enhanced Macrophage Angiotensin-Converting Enzyme Are Resistant to Melanoma.
Mice with enhanced macrophage angiotensin-converting enzyme are resistant to melanoma.
Overexpression of the C-domain of angiotensin-converting enzyme reduces melanoma growth by stimulating M1 macrophage polarization.
The role of microparticles in chronic obstructive pulmonary disease.
Melanoma, Experimental
Development of Dendritic Cell-Based Immunotherapy Targeting Tumor Blood Vessels in a Mouse Model of Lung Metastasis.
MELAS Syndrome
Detection of kdr and ace-1 mutations in wild populations of Anopheles arabiensis and An. melas in a residual malaria transmission area of Senegal.
Melkersson-Rosenthal Syndrome
Melkersson-Rosenthal syndrome.
Melkersson-Rosenthal syndrome: elevations in serum angiotensin converting enzyme and results of treatment with methotrexate.
Memory Disorders
A Comparative Study on the Memory-Enhancing Actions of Oral Renin-Angiotensin System Altering Drugs in Scopolamine-Treated Mice.
Meningioma
Sarcoid masquerading as optic nerve sheath meningioma.
Meningitis, Aseptic
[Endoscope-assisted biopsy for the diagnosis of neurosarcoidosis]
Meningococcal Infections
Severity of meningococcal disease in children and the angiotensin-converting enzyme insertion/deletion polymorphism.
Mesenteric Ischemia
[Nonocclusive acute mesenteric ischemia]
Metabolic Diseases
RAS-Mediated Adaptive Mechanisms in Cardiovascular Tissues: Confounding Factors of RAS Blockade Therapy and Alternative Approaches.
Metabolic Syndrome
2012 Brazilian Society of Rheumatology Consensus on the management of comorbidities in patients with rheumatoid arthritis.
A randomized study of the beneficial effects of aldosterone antagonism on LV function, structure, and fibrosis markers in metabolic syndrome.
Accuracy of retinal changes in predicting microalbuminuria among elderly hypertensive patients: a cross-sectional study from a teaching hospital in South India.
ACE Gene Insertion/Deletion Polymorphism Among Patients with Type 2 Diabetes, and Its Relationship with Metabolic Syndrome at Sardjito Hospital Yogyakarta, Indonesia.
ACE inhibitor and angiotensin type I receptor antagonist in combination reduce renal damage in obese Zucker rats.
ACE insertion/deletion polymorphism and its relationships to the components of metabolic syndrome in elderly Slovaks.
ALLHAT: still providing correct answers after 7 years.
An update on 'progression promoters' in renal diseases.
Anaesthetic considerations with the metabolic syndrome.
Angiotensin-(1-7) contributes to insulin-sensitizing effects of angiotensin-converting enzyme inhibition in obese mice.
Angiotensin-Converting Enzyme Gene Insertion/Deletion Polymorphism with Metabolic Syndrome in Turkish Patients.
Antihypertensive therapy in patients with metabolic syndrome.
Antimicrobial Peptides: A New Hope in Biomedical and Pharmaceutical Fields.
Aronia melanocarpa Elliot reduces the activity of angiotensin i-converting enzyme-in vitro and ex vivo studies.
Association between the insertion/deletion polymorphism of the angiotensin-converting enzyme gene and erectile dysfunction in patients with metabolic syndrome.
Association of angiotensin-converting enzyme gene insertion/deletion polymorphism with metabolic syndrome in Iranians with type 2 diabetes mellitus.
Association of angiotensin-converting enzyme I/D and ?-actinin-3 R577X genotypes with metabolic syndrome risk factors in Korean children.
Can aspirin resistance be clinically predicted in stroke patients?
Components of the metabolic syndrome, but not the metabolic syndrome per se, are associated with aortic distensibility.
Conflicting and new risk factors for contrast induced nephropathy.
Current Treatment Options for the Metabolic Syndrome.
Dipeptidyl peptidase IV inhibition alters the hemodynamic response to angiotensin-converting enzyme inhibition in humans with the metabolic syndrome.
Effect of a combined nutraceutical containing Orthosiphon stamineus effect on blood pressure and metabolic syndrome components in hypertensive dyslipidaemic patients: a randomized clinical trial.
Effect of amiloride, or amiloride plus hydrochlorothiazide, versus hydrochlorothiazide on glucose tolerance and blood pressure (PATHWAY-3): a parallel-group, double-blind randomised phase 4 trial.
Effect of angiotensin converting enzyme gene I/D polymorphism in patients with metabolic syndrome in North Indian population.
Effect of angiotensin converting enzyme inhibitors on periprocedural myocardial infarction in patients with metabolic syndrome.
Effects of angiotensin-converting enzyme inhibitor therapy on levels of inflammatory markers in response to exercise-induced stress: studies in the metabolic syndrome.
Fixed-dose combination of zofenopril plus hydrochlorothiazide vs. irbesartan plus hydrochlorothiazide in hypertensive patients with established metabolic syndrome uncontrolled by previous monotherapy. The ZAMES study (Zofenopril in Advanced MEtabolic Syndrome).
Identification of novel dipeptidyl peptidase-IV and angiotensin-I-converting enzyme inhibitory peptides from meat proteins using in silico analysis.
Inhibition of the renin-angiotensin system ameliorates genetically determined hyperinsulinemia.
Insulin resistance and sympathetic overactivity in women.
Interaction of genetic risk factors confers increased risk for metabolic syndrome: the role of peroxisome proliferator-activated receptor ?.
Management issues in the metabolic syndrome.
Mechanisms by which angiotensin-converting enzyme inhibitors prevent diabetes and cardiovascular disease.
Metabolic syndrome and risk of stroke.
Microalbuminuria in Thai essential hypertensive patients.
Neutral endopeptidase inhibitor versus angiotensin converting enzyme inhibitor in a rat model of the metabolic syndrome.
Nutraceutical management of metabolic syndrome as a palliative and a therapeutic to coronavirus disease (COVID) crisis.
Potentially inappropriate prescribing (IP) for elderly medical inpatients in Taiwan: A hospital-based study.
Reduced cardiac expression of plasminogen activator inhibitor 1 and transforming growth factor beta1 in obese Zucker rats by perindopril.
Role of ACE inhibitors in treating hypertensive diabetic patients.
Serum Uric Acid for Risk Stratification of Patients with Coronary Artery Disease.
The renin-angiotensin system: a target of and contributor to dyslipidemias, altered glucose homeostasis, and hypertension of the metabolic syndrome.
The role of beta-cell dysfunction in the cardiometabolic syndrome.
The role of the renin angiotensin hormonal system in the metabolic syndrome and type 2 diabetes.
The top 12 advances in vascular medicine.
Therapeutic approaches in the prevention of cardiovascular disease in metabolic syndrome and in patients with type 2 diabetes.
Thiazide and loop diuretics.
Treatment of cardiovascular dysfunction associated with the metabolic syndrome and type 2 diabetes.
Treatment of metabolic syndrome.
Treatment of Obese Adolescents: The Influence of Periodization Models and ACE Genotype.
Vascular and neural dysfunctions in obese Zucker rats: effect of AVE7688.
[Comparative efficacy and safety of contemporary Angiotensin converting enzyme inhibitors moexipril and spirapril in women with postmenopausal metabolic syndrome]
[CURRENT ISSUES IN THE CHOICE OF ANTIHYPERTENSIVE THERAPY IN PATIENTS WITH METABOLIC SYNDROME AND RELATED NON-ALCOHOLIC FATTY LIVER DISEASE].
[Current status of the therapeutic effects of angiotensin converting enzyme inhibitors on metabolic syndrome]
[Effect of fosinopril on some parameters of endothelial function in patients with metabolic syndrome]
[Hypotensive, organoprotective, and metabolic effects of Angiotensin converting enzyme inhibitor moexipril in women with postmenopausal syndrome]
[I/D polymorphism of angiotensin I converting enzyme gene and insulin resistance and some parameters of metabolic syndrome in patients with type 2 diabetes]
[Metabolic syndrome in patients with hypertension]
[Renin-angiotensin system in mesenteric adipose tissues in rats with metabolic syndrome]
[Role of angiotensin-converting enzyme gene polymorphism in the development of metabolic syndrome]
[The role of angiotensin-converting enzyme gene polymorphism in development of erectile dysfunction in patients with metabolic syndrome].
[Therapeutic options for treatment of cardiometabolic risk]
Microvascular Angina
Angiotensin-converting enzyme inhibitors and 3-hydroxy-3-methylglutaryl coenzyme A reductase in cardiac Syndrome X: role of superoxide dismutase activity.
Effects of angiotensin-converting enzyme inhibition on exercise-induced angina and ST segment depression in patients with microvascular angina.
Improvement of coronary flow reserve after long-term therapy with enalapril.
Treatment of the hypertensive patient with microvascular angina.
Migraine Disorders
ACE and ARB Agents in the Prophylactic Therapy of Migraine-How Effective Are They?
Angiotensin I-converting enzyme gene (I/D) polymorphism in patients with migraine.
Angiotensin II receptor antagonists against migraine in pregnancy: fatal outcome.
Angiotensin- converting enzyme gene insertion/deletion polymorphism in migraine patients.
Angiotensin-converting enzyme gene deletion polymorphism determines an increase in frequency of migraine attacks in patients suffering from migraine without aura.
Angiotensin-converting enzyme gene rs4343 polymorphism increases susceptibility to migraine.
Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for the prevention of migraines.
Are angiotensin-converting enzyme (ACE) inhibitors effective in preventing migraine in nonhypertensive patients?
Association between angiotensin-converting enzyme insertion/deletion polymorphism and migraine: a meta-analysis.
Association of the insertion/deletion polymorphism of the angiotensin I-converting enzyme gene in patients of migraine with aura.
Chronopathology for angiotensin converting enzyme circadian rhythm in migraine.
Combined effects of ACE and MMP-3 polymorphisms on migraine development.
Common genetic risk factors for psychiatric and simatic disorders.
Efficacy of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in the Preventative Treatment of Episodic Migraine in Adults.
Efficacy of Enalapril in Migraine Prophylaxis: A Randomized, Double-blind, Placebo-controlled Trial.
Endothelial Nitric Oxide Synthase and Angiotensin Converting Enzyme Gene Polymorphisms in Migraine Patients.
Genetic variants of angiotensin converting enzyme and methylenetetrahydrofolate reductase may act in combination to increase migraine susceptibility.
Headache and arterial hypertension.
Homozygous deletion genotype of angiotensin converting enzyme confers protection against migraine in man.
Involvement of the renin-angiotensin system in migraine.
Migraine and coronary artery disease: an open study on the genetic polymorphism of the 5, 10 methylenetetrahydrofolate (MTHFR) and angiotensin I-converting enzyme (ACE) genes.
MTHFR and ACE Polymorphisms Do Not Increase Susceptibility to Migraine Neither Alone Nor in Combination.
Other Preventive Anti-Migraine Treatments: ACE Inhibitors, ARBs, Calcium Channel Blockers, Serotonin Antagonists, and NMDA Receptor Antagonists.
Preventive Oral Treatment of Episodic Migraine: An Overview.
Prophylactic treatment of migraine with angiotensin converting enzyme inhibitor (lisinopril): randomised, placebo controlled, crossover study.
Reduction in the therapeutic intensity of abortive migraine drug use during ACE inhibition therapy--a pilot study.
Regulatory role of bradykinin in the coronary and cerebral circulations and in systemic hemodynamics.
Renin angiotensin system: A novel target for migraine prophylaxis.
Renin-angiotensin system in pain: existing in a double life?
Renin-angiotensin-aldosterone system and migraine: a systematic review of human studies.
The evolving management of migraine.
The genetics of chronic headaches.
The renin-angiotensin system: a possible contributor to migraine pathogenesis and prophylaxis.
[Genetic analysis of migraine headache: a review]
[Role of antihypertensive drugs in the treatment of migraine].
Migraine with Aura
Angiotensin I-converting enzyme gene (I/D) polymorphism in patients with migraine.
Association of the insertion/deletion polymorphism of the angiotensin I-converting enzyme gene in patients of migraine with aura.
The genetics of chronic headaches.
Migraine without Aura
Angiotensin-converting enzyme gene deletion polymorphism determines an increase in frequency of migraine attacks in patients suffering from migraine without aura.
The genetics of chronic headaches.
MINOCA
Comparative effect of angiotensin converting enzyme inhibitor versus angiotensin ii type i receptor blocker in acute myocardial infarction with non-obstructive coronary arteries; from the Korea Acute Myocardial Infarction Registry - National Institute of Health.
Prevalence, Clinical Factors, and Outcomes Associated With Myocardial Infarction With Nonobstructive Coronary Artery.
Variability of discharge medical therapy for secondary prevention among patients with myocardial infarction with non-obstructive coronary arteries (MINOCA) in the United States.
Mitochondrial Diseases
Successful heart failure therapy in mitochondrial disorder with noncompaction cardiomyopathy.
Mitral Valve Insufficiency
A Multiparametric Clinical and Echocardiographic Score to Risk Stratify Patients with Chronic Systolic Heart Failure: Derivation and Testing.
ACE inhibitors in HF restore canine pulmonary endothelial function and ANG II vasoconstriction.
Angiotensin-converting enzyme inhibitors in pediatric patients with mitral valve regurgitation-case-control study and review of the literature.
Association of left ventricular strain with 30-day mortality and readmission in patients with heart failure.
Atrial natriuretic peptide levels in rheumatic mitral regurgitation and response to angiotensin-converting enzyme inhibitors.
Beneficial effects of a single dose of quinapril on left ventricular performance in chronic mitral regurgitation.
Clinical trials in heart valve disease.
Determinants of prolonged hospitalization in patients who underwent trans-femoral transcatheter aortic valve implantation.
Differential effects of the angiotensin-converting enzyme inhibitor lisinopril versus the beta-adrenergic receptor blocker atenolol on hemodynamics and left ventricular contractile function in experimental mitral regurgitation.
Differential expression of angiotensin-converting enzyme and chymase in dogs with chronic mitral regurgitation.
Effect of angiotensin-converting enzyme inhibitor therapy in mitral regurgitation with normal left ventricular function.
Effect of enalapril therapy on left ventricular mass and volumes in asymptomatic chronic, severe mitral regurgitation secondary to mitral valve prolapse.
Effect of pimobendan on echocardiographic values in dogs with asymptomatic mitral valve disease.
Effective regurgitant orifice area of rheumatic mitral insufficiency: response to angiotensin converting enzyme inhibitor treatment.
Effects of angiotensin-converting enzyme inhibition on mitral regurgitation severity, left ventricular size, and functional capacity.
Effects of high-dose lisinopril-isosorbide dinitrate on severe mitral regurgitation and heart failure remodeling.
Effects of the ACE inhibitor quinapril on echocardiographic variables in horses with mitral valve insufficiency.
Efficacy of enalapril for prevention of congestive heart failure in dogs with myxomatous valve disease and asymptomatic mitral regurgitation.
Efficacy of monotherapy with benazepril, an angiotensin converting enzyme inhibitor, in dogs with naturally acquired chronic mitral insufficiency.
Geriatric heart diseases in dogs.
Hemodynamic effects of a single oral dose of enalapril among children with asymptomatic chronic mitral regurgitation.
Impact of chronic lisinopril therapy on left atrial volume versus dimension in chronic organic mitral regurgitation.
Increased ACE and chymase-like activity in cardiac tissue of dogs with chronic mitral regurgitation.
Lessons learned from a pediatric clinical trial: the Pediatric Heart Network angiotensin-converting enzyme inhibition in mitral regurgitation study.
Long-term effect of angiotensin-converting enzyme inhibitor in volume overloaded heart during growth: a controlled pilot study.
Mitral regurgitation in chronic heart failure: more questions than answers?
Modulation of the tissue reninangiotensin-aldosterone system in dogs with chronic mild regurgitation through the mitral valve.
Neurohormonal and circulatory effects of short-term treatment with enalapril and quinapril in dogs with asymptomatic mitral regurgitation.
Outcomes for children with cardiomyopathy awaiting transplantation.
Predictors of Acute Kidney Injury Following Surgical Valve Replacement.
Quinapril therapy in patients with chronic mitral regurgitation.
Role of echocardiography in assessing the mechanism and effect of ramipril on functional mitral regurgitation in dilated cardiomyopathy.
Selective induction of the creatine kinase-B gene in chronic volume overload hypertrophy is not affected by ACE-inhibitor therapy.
Six month pilot study of captopril for mildly symptomatic, severe isolated mitral and isolated aortic regurgitation.
Survival and echocardiographic data in dogs with congestive heart failure caused by mitral valve disease and treated by multiple drugs: a retrospective study of 21 cases.
The Effect of Angiotensin-Converting Enzyme Inhibitors of Left Atrial Pressure in Dogs with Mitral Valve Regurgitation.
Vasoactive drugs in chronic regurgitant lesions of the mitral and aortic valves.
Volume-overload cardiac hypertrophy is unaffected by ACE inhibitor treatment in dogs.
[Long-term treatment with quinapril in chronic aortic and mitral insufficiency]
Mitral Valve Prolapse
AGT and ACE genes influence classic mitral valve prolapse predisposition in Marfan patients.
Association between angiotensin I-converting enzyme gene insertion/deletion polymorphism and mitral valve prolapse syndrome.
Effect of enalapril therapy on left ventricular mass and volumes in asymptomatic chronic, severe mitral regurgitation secondary to mitral valve prolapse.
Mitral Valve Stenosis
Therapeutic Controversies in the Medical Management of Valvular Heart Disease.
Mixed Connective Tissue Disease
Combined systolic and diastolic heart failure as the first presentation of mixed connective tissue disease.
Increased serum angiotensin I-converting enzyme activity in patients with mixed connective tissue disease and pulmonary hypertension.
Scleroderma Renal Crisis in a Case of Mixed Connective Tissue Disease Treated Successfully with Angiotensin-Converting Enzyme Inhibitors.
Scleroderma renal crisis in a newly diagnosed mixed connective tissue disease resulting in dialysis-dependent chronic kidney disease despite angiotensin-converting enzyme inhibition.
[A case of MCTD with pulmonary hypertension showing elevated serum angiotensin I-converting enzyme activity]
[Successful treatment for pulmonary hypertension with angiotensin 1 converting enzyme inhibitor in a patient with mixed connective tissue disease]
Motor Neuron Disease
Angiotensin-converting enzyme inhibitors and motor neuron disease: An unconfirmed association.
Mouth Neoplasms
Association of angiotensin-converting enzyme gene insertion/deletion polymorphism with increased risk for oral cancer.
Lack of association between angiotensin-converting enzyme inhibitors and angiotensin receptor blockers and pain improvement in patients with oral cancer.
Polymorphism of angiotensin I-converting enzyme gene is related to oral cancer and lymph node metastasis in male betel quid chewers.
Movement Disorders
Sleep-related movement disorder symptoms in SHR are attenuated by physical exercise and an angiotensin-converting enzyme inhibitor.
Mucocutaneous Lymph Node Syndrome
Angiotensin-converting enzyme insertion/deletion polymorphism and susceptibility to Kawasaki disease: a meta-analysis.
Are Angiotensin Converting Enzyme and von Willebrand factor circulating levels useful surrogate parameters to monitor disease activity in Kawasaki disease?
Effect of angiotensin-converting enzyme inhibitor on matrix metalloproteinase-9 activity in patients with Kawasaki disease.
High incidence of angiotensin I converting enzyme genotype II in Kawasaki disease patients with coronary aneurysm.
Insertion/Deletion polymorphism of Angiotensin converting enzyme gene in kawasaki disease.
Nerve growth factor circulating levels are increased in Kawasaki disease: correlation with disease activity and reduced angiotensin converting enzyme levels.
Possible synergic effect of angiotensin-I converting enzyme gene insertion/deletion polymorphism and angiotensin-II type-1 receptor 1166A/C gene polymorphism on ischemic heart disease in patients with Kawasaki disease.
Multicystic Dysplastic Kidney
US of renal insufficiency in neonates.
Multifocal Choroiditis
Relevance of diagnostic investigations in patients with uveitis: Retrospective cohort study on 300 patients.
Multiple Endocrine Neoplasia Type 2a
[The effect of angiotensin-converting enzyme inhibitors on proteinuria in chronic glomerulonephritis]
Multiple Endocrine Neoplasia Type 2b
[The effect of intracoronary infused captopril on luminal width in coronary stenosis]
Multiple Myeloma
Conflicting and new risk factors for contrast induced nephropathy.
Elevated serum angiotensin converting enzyme levels as a reflection of bone marrow renin-angiotensin system activation in multiple myeloma.
Hypercalcemia as a rare presentation of angioimmunoblastic T cell lymphoma: a case report.
Löfgren Syndrome with Hypercalcemia and Neuroendocrinological Involvement: A Case Report.
Outcome of patients with multiple myeloma and hypertension treated with angiotensin-I-converting enzyme inhibitors during high-dose chemotherapy.
Serum angiotensin-converting enzyme in malignant lymphomas, leukaemia and multiple myeloma.
Multiple Sclerosis
Activation of the Protective Arm of the Renin Angiotensin System in Demyelinating Disease.
Age-adjusted CSF ?2-microglobulin and lactate are increased and ACE is decreased in patients with multiple sclerosis, but only lactate correlates with clinical disease duration and severity.
Angiotensin-converting enzyme (ACE) and ACE2 levels in the cerebrospinal fluid of patients with multiple sclerosis.
Angiotensin-Converting Enzyme Gene Polymorphism in Patients with Multiple Sclerosis from Bosnia and Herzegovina.
Angiotensin-converting enzyme I/D gene polymorphism and risk of multiple sclerosis.
Angiotensin-converting enzyme insertion/deletion gene polymorphism and interferon-? treatment response in multiple sclerosis patients: a preliminary report.
Angiotensin-converting enzyme insertion/deletion gene polymorphism in multiple sclerosis: a meta-analysis.
Development of therapies for autoimmune disease at Stanford: a tale of multiple shots and one goal.
Effect of angiotensin?II type?2 receptor on stroke, cognitive impairment and neurodegenerative diseases.
Polymorphisms in the angiotensin I converting enzyme (ACE) gene are associated with multiple sclerosis risk and response to Interferon-? treatment.
Relevance of Brain MRI in Patients with Uveitis: Retrospective Cohort on 402 Patients.
Renin-angiotensin system gene polymorphisms as risk factors for multiple sclerosis.
Serum angiotensin-converting enzyme in multiple sclerosis.
The lack of association between angiotensin-converting enzyme gene insertion/deletion polymorphism and nicotine dependence in multiple sclerosis.
Two frequent polymorphisms of angiotensinogen and their association with multiple sclerosis progression rate.
[A suspicious case of central neurosarcoidosis, manifesting as a progressive gait disturbance with a lesion in the central gray matter of the midbrain, accompanying an elevated level of angiotensin converting enzyme in the cerebrospinal fluid]
Multiple Sclerosis, Chronic Progressive
Development of therapies for autoimmune disease at Stanford: a tale of multiple shots and one goal.
Multiple System Atrophy
Angiotensin converting enzyme inhibition lowers blood pressure in patients with primary autonomic failure independently of plasma renin levels and sympathetic nervous activity.
Muscular Diseases
A case of sarcoidosis developing as sarcoid myopathy concomitant with systemic sclerosis and review of the literature.
ACE-2/Ang1-7/Mas cascade mediates ACE inhibitor, captopril, protective effects in estrogen-deficient osteoporotic rats.
Familial myopathy with elevated serum angiotensin-converting enzyme, creatine kinase and lactate dehydrogenase isoenzyme 5.
[A case of Weber-Christian disease with elevated angiotensin-converting enzyme (ACE) activity and myopathy]
Muscular Dystrophies
Beta-blocker therapy for cardiac dysfunction in patients with muscular dystrophy.
Cardioprotection for Duchenne's muscular dystrophy.
Intramuscular renin-angiotensin system is activated in human muscular dystrophy.
Na(+)-H(+) exchanger inhibitor prevents early death in hereditary cardiomyopathy.
Muscular Dystrophy, Duchenne
A randomized, double-blind trial of lisinopril and losartan for the treatment of cardiomyopathy in duchenne muscular dystrophy.
Abnormality of the myocardial sympathetic nervous system in a patient with Becker muscular dystrophy detected with iodine-123 metaiodobenzylguanidine scintigraphy.
Angiotensin-converting enzyme inhibitors and beta-blockers in cardiac asymptomatic patients with Duchenne muscular dystrophy.
Angiotensin-converting-enzyme inhibitors versus steroids as first-line drug treatment in Duchenne muscular dystrophy.
Association between prophylactic angiotensin-converting enzyme inhibitors and overall survival in Duchenne muscular dystrophy-analysis of registry data.
Beneficial effects of beta-blockers and angiotensin-converting enzyme inhibitors in Duchenne muscular dystrophy.
Consensus Statement on the Management of Duchenne Muscular Dystrophy in Saudi Arabia During the Coronavirus Disease 2019 Pandemic.
Effects of angiotensin-converting enzyme inhibitors and/or beta blockers on the cardiomyopathy in Duchenne muscular dystrophy.
Effects of steroids and angiotensin converting enzyme inhibition on circumferential strain in boys with Duchenne muscular dystrophy: a cross-sectional and longitudinal study utilizing cardiovascular magnetic resonance.
Gene expression effects of glucocorticoid and mineralocorticoid receptor agonists and antagonists on normal human skeletal muscle.
Improved Cardiac Outcomes by Early Treatment with Angiotensin-Converting Enzyme Inhibitors in Becker Muscular Dystrophy.
Intramuscular renin-angiotensin system is activated in human muscular dystrophy.
Left ventricular function and response to enalapril in patients with duchenne muscular dystrophy during the second decade of life.
Management of Cardiac Involvement in NeuroMuscular Diseases: Review.
Mineralocorticoid Receptor Antagonists in Muscular Dystrophy Mice During Aging and Exercise.
Progressive left ventricular dysfunction and myocardial fibrosis in Duchenne and Becker muscular dystrophy: a longitudinal cardiovascular magnetic resonance study.
Recovery of Systolic Dysfunction in Duchenne Muscular Dystrophy due to the Point Mutation c.4213C>T.
Similar efficacy from specific and non-specific mineralocorticoid receptor antagonist treatment of muscular dystrophy mice.
The Angiotensin Converting Enzyme Inhibitor Lisinopril Improves Muscle Histopathology but not Contractile Function in a Mouse Model of Duchenne Muscular Dystrophy.
[Cardiac involvement in dystrophinopathies].
Mycosis Fungoides
A quinine-induced drug reaction of photosensitive distribution with histological features mimicking mycosis fungoides.
Myocardial Infarction
A 13-year review of lisinopril ingestions in children less than 6 years of age.
A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group.
A Comparison between Imidapril and Ramipril on Attenuation of Ventricular Remodeling after Myocardial Infarction.
A comparison between statin with ACE inhibitor or ARB therapy in STEMI patients who underwent successful PCI with drug-eluting stents.
A comparison of intervention with losartan or captopril in acute myocardial infarction.
A local kallikrein-kinin system is present in rat hearts.
A meta-analysis of the association of the deletion allele of the angiotensin-converting enzyme gene with myocardial infarction.
A meta-analysis reporting effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients without heart failure.
A mouse model of heart failure exhibiting pulmonary edema and pleural effusion: Useful for testing new drugs.
A Natural p300-Specific Histone Acetyltransferase Inhibitor, Curcumin, in Addition to Angiotensin-Converting Enzyme Inhibitor, Exerts Beneficial Effects on Left Ventricular Systolic Function After Myocardial Infarction in Rats.
A pharmacoeconomic model to aid in the allocation of ambulatory clinical pharmacy services.
A pragmatic approach to the use of angiotensin-converting enzyme inhibitors in acute myocardial infarction.
A prospective evaluation of an angiotensin-converting-enzyme gene polymorphism and the risk of ischemic heart disease.
A prospective study of frequency and characteristics of cough during ACE inhibitor treatment.
A role of angiotensin-converting enzyme gene polymorphism in left ventricular remodeling after myocardial infarction.
A Systematic Review on the Efficacy of Amlodipine in the Treatment of Patients With Hypertension With Concomitant Diabetes Mellitus and/or Renal Dysfunction, When Compared With Other Classes of Antihypertensive Medication.
A systematic review: effect of angiotensin converting enzyme inhibition on left ventricular volumes and ejection fraction in patients with a myocardial infarction and in patients with left ventricular dysfunction.
ACE gene polymorphism: ischemic heart disease and longevity in 10,150 individuals. A case-referent and retrospective cohort study based on the Copenhagen City Heart Study.
ACE Inhibition Modulates Myeloid Hematopoiesis after Acute Myocardial Infarction and Reduces Cardiac and Vascular Inflammation in Ischemic Heart Failure.
ACE inhibition with perindopril and endothelial function. Results of a substudy of the EUROPA study: PERTINENT.
ACE Inhibitor and ARB utilization and expenditures in the Medicaid fee-for-service program from 1991 to 2008.
ACE Inhibitor Delapril Prevents Ca(2+)-Dependent Blunting of IK1 and Ventricular Arrhythmia in Ischemic Heart Disease.
ACE inhibitors and mineralocorticoid receptor blockade in patients with congestive heart failure.
ACE inhibitors in acute myocardial infarction.
ACE inhibitors increase type III collagen synthesis: a potential explanation for reduction in acute vascular events by ACE inhibitors.
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.
ACE inhibitors versus diuretics: ALLHAT versus ANBP2.
ACE inhibitors: myocardial infarction and congestive heart failure.
ACE/DD genotype is associated with hemostasis balance disturbances reflecting hypercoagulability and endothelial dysfunction in patients with untreated hypertension.
Activation of angiotensin-converting enzyme expression in infarct zone following myocardial infarction.
Acute administration of angiotensin converting enzyme inhibitors in thrombolysed myocardial infarction patients is associated with a decreased incidence of heart failure, but an increased re-infarction risk.
Acute intervention with captopril during thrombolysis in patients with first anterior myocardial infarction. Results from the Captopril and Thrombolysis Study (CATS).
Acute myocardial infarction in young adults: prognostic role of angiotensin-converting enzyme, angiotensin II type I receptor, apolipoprotein E, endothelial constitutive nitric oxide synthase, and glycoprotein IIIa genetic polymorphisms at medium-term follow-up.
Adaptive and genetic alterations of the renin angiotensin system in cardiac hypertrophy and failure.
Adding angiotensin II type 1 receptor blockade to angiotensin-converting enzyme inhibition limits myocyte remodeling after myocardial infarction.
Additive beneficial effects of beta-blockers to angiotensin-converting enzyme inhibitors in the Survival and Ventricular Enlargement (SAVE) Study. SAVE Investigators.
Additive beneficial effects of two inhibitors of vasoconstrictor mediators in acute myocardial ischemia.
Additive improvement of left ventricular remodeling and neurohormonal activation by aldosterone receptor blockade with eplerenone and ACE inhibition in rats with myocardial infarction.
Adherence to evidence-based therapies after discharge for acute coronary syndromes: an ongoing prospective, observational study.
Adherence Tradeoff to Multiple Preventive Therapies and All-Cause Mortality After Acute Myocardial Infarction.
Adjunctive therapies in the treatment of acute coronary syndromes.
Adjunctive therapy in the management of patients with acute myocardial infarction.
Advances in angiotensin converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs).
Age and sex do not bias the use of angiotensin-converting enzyme inhibitors in acute myocardial infarction and congestive heart failure.
Age-related short-term effect of ramipril on N-terminal pro-brain natriuretic peptide and markers of hemostasis in patients after acute myocardial infarction.
Aldosterone inhibition limits collagen synthesis and progressive left ventricular enlargement after anterior myocardial infarction.
ALLHAT says diuretics are better; ANBP2 says ACEs are better--can we resolve the differences?
American Heart Association scientific sessions.
Amlodipine Ameliorates Ischemia-Induced Neovascularization in Diabetic Rats through Endothelial Progenitor Cell Mobilization.
An angiotensin II receptor antagonist attenuates left ventricular dilatation after myocardial infarction in the hypertensive rat.
An angiotensin-converting enzyme gene variant is associated with acute myocardial infarction in women but not in men.
An application of conditional logistic regression and multifactor dimensionality reduction for detecting gene-gene interactions on risk of myocardial infarction: the importance of model validation.
Analysis of Renal Artery Stenosis in Patients with Heart Failure: A RASHEF Study.
Analysis of the postulated interaction between the angiotensin II sub-type 1 receptor gene A1166C polymorphism and the insertion/deletion polymorphism of the angiotensin converting enzyme gene on risk of myocardial infarction.
Angiotensin converting enzyme and angiotensin II type 1-receptor gene polymorphisms and risk of ischaemic heart disease.
Angiotensin converting enzyme and myofibroblasts during tissue repair in the rat heart.
Angiotensin converting enzyme as a genetic risk factor for coronary artery spasm. Implication in the pathogenesis of myocardial infarction.
Angiotensin converting enzyme DD genotype affects the changes of plasma plasminogen activator inhibitor-1 activity after primary percutaneous transluminal coronary angioplasty in acute myocardial infarction patients.
Angiotensin converting enzyme expression in the inflammation zone of human myocardial infarction and rat model of skin injury.
Angiotensin converting enzyme gene deletion allele is independently and strongly associated with coronary atherosclerosis and myocardial infarction.
Angiotensin converting enzyme gene polymorphism and carotid atherosclerosis in a low-risk population.
Angiotensin converting enzyme gene polymorphism and myocardial infarction a large association and linkage study.
Angiotensin converting enzyme gene polymorphism and the risk and extent of ischemic heart disease among Turkish patients.
Angiotensin converting enzyme gene polymorphism in coronary artery disease: the Indian scenario.
Angiotensin converting enzyme gene polymorphism: potential silencer motif and impact on progression in IgA nephropathy.
Angiotensin converting enzyme inhibition and ventricular remodeling in heart failure.
Angiotensin converting enzyme inhibition therapy following myocardial infarction. Rationale for clinical trials.
Angiotensin converting enzyme inhibitor prevents left ventricular remodelling after myocardial infarction in angiotensin II type 1 receptor knockout mice.
Angiotensin converting enzyme inhibitors in acute myocardial infarction.
Angiotensin converting enzyme inhibitors in angina and myocardial infarction. What role will they play in the 1990s?
Angiotensin converting enzyme inhibitors in perspective: an update.
Angiotensin converting enzyme polymorphism is associated with severity of coronary heart disease and serum lipids (total cholesterol and triglycerides levels) in Japanese patients.
Angiotensin I converting enzyme gene polymorphism and coronary heart disease.
Angiotensin I converting enzyme, angiotensin II type 1 receptor and angiotensinogen polymorphisms and early myocardial infarction in Turkish population.
Angiotensin I-converting enzyme gene polymorphism in a low-risk European population for coronary artery disease.
Angiotensin I-converting enzyme gene polymorphism is associated with myocardial infarction, but not with retinopathy or nephropathy, in NIDDM.
Angiotensin I-converting enzyme gene polymorphism, coronary artery disease and myocardial infarction. An angiographically controlled study.
Angiotensin II activates Stat5 through Jak2 kinase in cardiac myocytes.
Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
Angiotensin II receptor blockade after myocardial infarction in rats: effects on hemodynamics, myocardial DNA synthesis, and interstitial collagen content.
Angiotensin II receptor blockers and myocardial infarction: deeds and misdeeds.
Angiotensin II receptor blockers in older patients.
Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells. A potential link between the renin-angiotensin system and thrombosis.
Angiotensin II signalling pathways in cardiac fibroblasts: conventional versus novel mechanisms in mediating cardiac growth and function.
Angiotensin II type 1 receptor A1166C gene polymorphism. Absence of an association with the risk of coronary artery disease and myocardial infarction and of a synergistic effect with angiotensin-converting enzyme gene polymorphism on the risk of these diseases.
Angiotensin II type 1 receptor blockade does not enhance apoptotic cell death during ischemia and reperfusion in humans in vivo.
Angiotensin II type 1 receptor blockade: a new development in cardiovascular pharmacology.
Angiotensin II type-I receptor and ACE polymorphisms and risk of myocardial infarction in men and women.
Angiotensin receptor blockade and angiotensin-converting-enzyme inhibition limit adverse remodeling of infarct zone collagens and global diastolic dysfunction during healing after reperfused ST-elevation myocardial infarction.
Angiotensin Receptor Blockers as an Alternative to Angiotensin-Converting Enzyme Inhibitors in Patients with Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention.
Angiotensin receptor blockers in acute myocardial infarction.
Angiotensin receptor blockers in hypertension. New insights from Japan.
Angiotensin receptor blockers versus ACE inhibitors: prevention of death and myocardial infarction in high-risk populations.
Angiotensin receptor neprilysin inhibition provides superior cardioprotection compared to angiotensin converting enzyme inhibition after experimental myocardial infarction.
Angiotensin-(1-7) inhibits growth of cardiac myocytes through activation of the mas receptor.
Angiotensin-(1-9) regulates cardiac hypertrophy in vivo and in vitro.
Angiotensin-1-converting enzyme (ACE) gene polymorphism, plasma ACE levels, and their association with the metabolic syndrome and electrocardiographic coronary artery disease in Pima Indians.
Angiotensin-converting enzyme (ACE) gene polymorphisms in patients characterised by coronary angiography.
Angiotensin-converting enzyme (ACE) inhibitor therapy after myocardial infarction in relation to left ventricular function.
Angiotensin-converting enzyme (ACE) inhibitors and angio-oedema.
Angiotensin-converting enzyme and angiotensin II receptor 1 polymorphism in coronary disease and malignant ventricular arrhythmias.
Angiotensin-converting enzyme and apolipoprotein E genotypes and restenosis after coronary angioplasty.
Angiotensin-converting enzyme and lipoprotein(a) as risk factors for myocardial infarction.
Angiotensin-converting enzyme and myocardial fibrosis in the rat receiving angiotensin II or aldosterone.
Angiotensin-converting enzyme and p22(phox) polymorphisms and the risk of coronary heart disease in a low-risk Spanish population.
Angiotensin-converting enzyme DD genotype in patients with ischaemic or idiopathic dilated cardiomyopathy.
Angiotensin-converting enzyme deletion polymorphism is associated with hypertension in a Sikh population.
Angiotensin-converting enzyme expression in human carotid artery atherosclerosis.
Angiotensin-converting enzyme gene deletion polymorphism. A new risk factor for lacunar stroke but not carotid atheroma.
Angiotensin-converting enzyme gene insertion/deletion polymorphism in Egyptian patients with myocardial infarction.
Angiotensin-converting enzyme gene insertion/deletion polymorphism in Polish patients with myocardial infarction.
Angiotensin-converting enzyme gene polymorphism adds risk for the severity of coronary atherosclerosis in smokers.
Angiotensin-converting enzyme gene polymorphism and cardiovascular disease.
Angiotensin-converting enzyme gene polymorphism and premature coronary heart disease.
Angiotensin-converting enzyme gene polymorphism and risk of myocardial infarction in Colombia.
Angiotensin-converting enzyme gene polymorphism in a cohort of coronary angiography patients.
Angiotensin-converting enzyme gene polymorphism interacts with left ventricular ejection fraction and brain natriuretic peptide levels to predict mortality after myocardial infarction.
Angiotensin-converting enzyme gene polymorphism is associated with myocardial infarction but not with development of coronary stenosis.
Angiotensin-converting enzyme gene polymorphism is not associated with coronary atherosclerosis and myocardial infarction in a sample of Italian patients.
Angiotensin-converting enzyme gene variant and its levels: risk factors for myocardial infarction in a South Indian population.
Angiotensin-converting enzyme genotype is not associated with endothelial dysfunction in subjects without other coronary risk factors.
Angiotensin-converting enzyme genotype is not associated with exercise capacity or the training effect of cardiac rehabilitation in patients after acute myocardial infarction.
Angiotensin-converting enzyme genotypes and risk for myocardial infarction in women.
Angiotensin-converting enzyme genotypes in the high- and low-risk area for coronary heart disease in Finland.
Angiotensin-converting enzyme I/D gene polymorphisms and effects of left ventricular hypertrophy in Turkish myocardial infarction patients.
Angiotensin-converting enzyme in acute myocardial infarction and angina pectoris.
Angiotensin-converting enzyme in the human heart. Effect of the deletion/insertion polymorphism.
Angiotensin-converting enzyme inhibition after acute myocardial infarction with special reference to the Fourth International Study of Infarct Survival (ISIS-4).
Angiotensin-converting enzyme inhibition after experimental myocardial infarct: role of the kinin B1 and B2 receptors.
Angiotensin-converting enzyme inhibition after myocardial infarction: the Trandolapril Cardiac Evaluation Study.
Angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade prevent cardiac remodeling in pigs after myocardial infarction: role of tissue angiotensin II.
Angiotensin-converting enzyme inhibition and beta-adrenoceptor blockade regress established ventricular remodeling in a canine model of discrete myocardial damage.
Angiotensin-converting enzyme inhibition and salt in experimental myocardial infarction.
Angiotensin-converting enzyme inhibition and ventricular remodeling after myocardial infarction.
Angiotensin-converting enzyme inhibition during thrombolytic therapy in acute myocardial infarction: the Captopril and Thrombolysis Study (CATS).
Angiotensin-converting enzyme inhibition in infarct-induced heart failure in rats: bradykinin versus angiotensin II.
Angiotensin-converting enzyme inhibition in myocardial infarction--Part 1: Clinical data.
Angiotensin-converting enzyme inhibition in myocardial infarction--Part 2: Clinical issues and controversies.
Angiotensin-converting enzyme inhibition preserves endothelium-dependent coronary microvascular responses during short-term ischemia-reperfusion.
Angiotensin-converting enzyme inhibition prevents myocardial infarction-induced increase in renal cortical cGMP and cAMP phosphodiesterase activities.
Angiotensin-Converting Enzyme Inhibition Prevents the Release of Monocytes From Their Splenic Reservoir in Mice With Myocardial Infarction.
Angiotensin-converting enzyme inhibition produces electrophysiologic but not antiarrhythmic effects in the intact heart.
Angiotensin-converting enzyme inhibition reduces monocyte chemoattractant protein-1 and tissue factor levels in patients with myocardial infarction.
Angiotensin-converting enzyme inhibition with perindopril in patients with prior myocardial infarction and/or revascularization: a subgroup analysis of the EUROPA trial.
Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing ENdothelial Dysfunction) Study.
Angiotensin-converting enzyme inhibitor helps prevent late remodeling after left ventricular aneurysm repair in rats.
Angiotensin-converting enzyme inhibitor prevents skeletal muscle fibrosis in diabetic mice.
Angiotensin-converting enzyme inhibitor therapy affects left ventricular mass in patients with ejection fraction > 40% after acute myocardial infarction.
Angiotensin-converting enzyme inhibitor therapy affects myocardial fatty acid metabolism after acute myocardial infarction.
Angiotensin-converting enzyme inhibitor trandolapril does not affect C-reactive protein levels in myocardial infarction patients.
Angiotensin-converting enzyme inhibitor treatment after myocardial infarction. A selective approach for maximum benefit.
Angiotensin-converting enzyme inhibitor treatment early after myocardial infarction attenuates acute cardiac and neuroinflammation without effect on chronic neuroinflammation.
Angiotensin-converting enzyme inhibitor use in survivors of acute myocardial infarction.
Angiotensin-converting enzyme inhibitors after acute myocardial infarction.
Angiotensin-converting enzyme inhibitors after myocardial infarction: indications and timing.
Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers Are Associated With Improved Outcome but Do Not Prevent New-Onset Atrial Fibrillation After Acute Myocardial Infarction.
Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Myocardial Infarction Patients With Renal Dysfunction.
Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Myocardial Infarction.
Angiotensin-converting enzyme inhibitors and calcium antagonists after acute myocardial infarction.
Angiotensin-converting enzyme inhibitors and coronary heart disease prevention.
Angiotensin-converting enzyme inhibitors and left ventricular remodeling: implications for nurses.
Angiotensin-converting enzyme inhibitors and myocardial infarction: a class effect?
Angiotensin-converting enzyme inhibitors downregulate tissue factor synthesis in monocytes.
Angiotensin-converting enzyme inhibitors in acute myocardial infarction: a clinical approach.
Angiotensin-converting enzyme inhibitors in heart failure: a role after myocardial infarction.
Angiotensin-converting enzyme inhibitors in left ventricular dysfunction.
Angiotensin-Converting Enzyme Inhibitors in Patients With Coronary Artery Disease and Absence of Heart Failure or Left Ventricular Systolic Dysfunction: An Overview of Long-term Randomized Controlled Trials.
Angiotensin-converting enzyme inhibitors in preventing remodeling and development of heart failure after acute myocardial infarction: results of the German multicenter study of the effects of captopril on cardiopulmonary exercise parameters (ECCE).
Angiotensin-Converting Enzyme Inhibitors Induce Cough.
Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers are beneficial in normotensive atherosclerotic patients: a collaborative meta-analysis of randomized trials.
Angiotensin-converting enzyme inhibitors reduce mortality compared to angiotensin receptor blockers: Systematic review and meta-analysis.
Angiotensin-converting enzyme inhibitors versus angiotensin II receptor blockers in acute ST-segment elevation myocardial infarction patients with diabetes mellitus undergoing percutaneous coronary intervention.
Angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers in hypertensive patients with myocardial infarction or heart failure: a systematic review and meta-analysis.
Angiotensin-converting enzyme inhibitors, inhibition of brain and peripheral angiotensin-converting enzymes, and left ventricular dysfunction in rats after myocardial infarction.
Angiotensin-converting enzyme inhibitors.
Angiotensin-converting enzyme insertion/deletion gene polymorphism in a Tunisian healthy and acute myocardial infarction population.
Angiotensin-converting enzyme insertion/deletion polymorphism and risk of myocardial infarction in an updated meta-analysis based on 34993 participants.
Angiotensin-converting enzyme insertion/deletion polymorphism has no effect on the risk of atherosclerotic stroke or hypertension.
Angiotensin-converting-enzyme inhibition in heart failure or after myocardial infarction.
Angiotensin-converting-enzyme inhibition in stable coronary artery disease.
Angiotensin-converting-enzyme inhibitor prevents skeletal muscle fibrosis in myocardial infarction mice.
Angiotensinogen and angiotensin-I converting enzyme gene polymorphisms and the risk of coronary artery disease in Chinese.
Angiotensinogen Met235Thr polymorphism, angiotensin-converting enzyme inhibitor therapy, and the risk of nonfatal stroke or myocardial infarction in hypertensive patients.
Antagonism of the renin-angiotensin-aldosterone system and collagen metabolism in cardiac fibroblasts.
Antiarrhythmic therapies for the prevention of sudden cardiac death.
Antihypertensive drugs and fatal myocardial infarction in persons with uncomplicated hypertension.
Apolipoprotein B, apolipoprotein E, and angiotensin-converting enzyme polymorphisms in 2 Italian populations at different risk for coronary artery disease and comparison of allele frequencies among European populations.
Appropriate blood pressure control in hypertensive and normotensive type 2 diabetes mellitus: a summary of the ABCD trial.
Are we inhibited? Renal insufficiency should not preclude the use of ACE inhibitors for patients with myocardial infarction and depressed left ventricular function.
Ask the doctor. I have had heart failure since my heart attack a year ago. My physician initially prescribed lisinopril, an angiotensin-converting enzyme (ACE) inhibitor. Unfortunately, I was one of the unlucky people who got a cough with this drug that was so annoying I had to stop taking it. Now my doctor wants me to try a newer drug called valsartan. Is it likely to help me?
Aspirin and angiotensin-converting enzyme inhibitors among elderly survivors of hospitalization for an acute myocardial infarction.
Aspirin and angiotensin-converting enzyme inhibitors are safe when taken together after acute myocardial infarction in patients with left ventricular dysfunction.
Aspirin does not influence the effect of angiotensin-converting enzyme inhibition on left ventricular ejection fraction 3 months after acute myocardial infarction.
Aspirin does not interact with ACE inhibitors when both are given early after acute myocardial infarction: results of the GISSI-3 Trial.
Aspirin, beta-blocker, and angiotensin-converting enzyme inhibitor therapy in patients with end-stage renal disease and an acute myocardial infarction.
Assessing the validity of national quality measures for coronary artery disease using an electronic health record.
Association between angiotensin I-converting enzyme genotypes, extracranial artery stenosis, and stroke.
Association between angiotensin-converting enzyme gene polymorphism and coronary artery disease.
Association of 3 Different Antihypertensive Medications With Hip and Pelvic Fracture Risk in Older Adults: Secondary Analysis of a Randomized Clinical Trial.
Association of angiotensin converting enzyme and plasminogen activator inhibitor-1 promoter gene polymorphisms with features of the insulin resistance syndrome in patients with premature coronary heart disease.
Association of Angiotensin converting enzyme gene insertion / deletion polymorphism with risk of ischemic heart disease in a population of smokers in southern India.
Association of angiotensin I-converting enzyme gene polymorphism with myocardial ischemia and patency of infarct-related artery in patients with acute myocardial infarction.
Association of Angiotensin-Converting Enzyme Gene 2350 G>A Polymorphism With Myocardial Infarction in a Chinese Population.
Association of angiotensinogen gene T235 variant with increased risk of coronary heart disease.
Association of essential hypertension in elderly Japanese with I/D polymorphism of the angiotensin-converting enzyme (ACE) gene.
Association of polymorphisms of zinc metalloproteinases with clinical response to stem cell therapy.
Association of renin-angiotensin system genes polymorphisms and risk of premature ST elevation myocardial infarction in young Mexican population.
Association of serum adiponectin with risk for cardiovascular events in patients with peripheral arterial disease.
Association study of the angiotensin-converting enzyme (ACE) gene G2350A dimorphism with myocardial infarction.
Associations between candidate loci angiotensin-converting enzyme and angiotensinogen with coronary heart disease and myocardial infarction: the NHLBI Family Heart Study.
Associations of ACE I/D polymorphism with the levels of ACE, kallikrein, angiotensin II and interleukin-6 in STEMI patients.
Attenuation of left ventricular dysfunction by an ACE inhibitor after myocardial infarction in a kininogen-deficient rat model.
Balancing benefit against risk in the choice of therapy for coronary artery disease. Lesson from prospective, randomized, clinical trials of percutaneous coronary intervention and coronary artery bypass graft surgery.
Beneficial effects of angiotensin-converting enzyme inhibitor and nitrate association on left ventricular remodeling in patients with large acute myocardial infarction: the Delapril Remodeling after Acute Myocardial Infarction (DRAMI) trial.
Beneficial effects of captopril on prognosis in patients with acute myocardial infarction. Shanghai Secondary Prevention of Acute Myocardial Infarction Study Group.
Beneficial effects of combination of ACE inhibitor and angiotensin II type 1 receptor blocker on cardiac remodeling in rat myocardial infarction.
Beneficial effects of long-term treatment with enalapril on cardiac function and heart rate variability in patients with old myocardial infarction.
Beneficial effects of therapy on the progression of structural remodeling during healing after reperfused and nonreperfused myocardial infarction: different effects on different parameters.
Benefits of early administration of Sacubitril/Valsartan in patients with ST-elevation myocardial infarction after primary percutaneous coronary intervention.
Beta blocker use in the treatment of community hospital patients discharged after myocardial infarction.
Beta-blockade improves adjacent regional sympathetic innervation during postinfarction remodeling.
Beta-blockers and renin-angiotensin system inhibitors in acute myocardial infarction managed with inhospital coronary revascularization.
Beta-blockers, angiotensin-converting enzyme inhibitors, and calcium antagonists in treatment of elderly patients with acute myocardial infarction.
Beyond remodeling: a new paradigm for angiotensin-converting enzyme inhibitors following myocardial infarction.
Blockade of the renin-angiotensin system.
Blood haemoglobin is an independent predictor of B-type natriuretic peptide (BNP).
Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren.
Blood pressure reduction and cardiovascular prevention: an update including the 2003-2004 secondary prevention trials.
Blood pressure reduction and clinical outcomes with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers: protocol for a systematic review and meta-regression analysis.
Blood pressure response to the first dose of angiotensin-converting enzyme inhibitors in congestive heart failure.
Blood-pressure reduction and cardiovascular risk in HOPE study.
Bone marrow mesenchymal stem cell transplantation combined with perindopril treatment attenuates infarction remodelling in a rat model of acute myocardial infarction.
Bone marrow stromal cell transplantation combined with angiotensin-converting enzyme inhibitor treatment in rat with acute myocardial infarction and the role of insulin-like growth factor-1.
Bradykinin metabolism in rat hearts with left-ventricular hypertrophy following myocardial infarction.
Calcium antagonists in the treatment of hypertension in patients with ischaemic heart disease.
Calcium channel blockers and cardiovascular outcomes: a meta-analysis of 175,634 patients.
Calcium channel blockers and renal protection: insights from the latest clinical trials.
Captopril adjuvant therapy to beta-blockers and nitrates improves post-myocardial infarction left ventricular performance.
Captopril administration reduces thrombus formation and surface expression of platelet glycoprotein IIb/IIa in early postmyocardial infarction stage.
Captopril in cardioplegia and reperfusion: protective effects on the ischemic heart.
Captopril modifies the response of infarcted rat hearts to isoprenaline stimulation.
Captopril reduced plasminogen activator inhibitor activity in patients with acute myocardial infarction.
Cardiac angiotensin converting enzyme and endothelin receptor in rats with chronic myocardial infarction.
Cardiac angiotensin-converting enzyme activity in myocardial infarction.
Cardiac contractility and conduction: a comparison of antihypertensives.
Cardiac event rates after acute myocardial infarction in patients treated with verapamil and trandolapril versus trandolapril alone. Danish Verapamil Infarction Trial (DAVIT) Study Group.
Cardiac protection by long-term treatment with captopril in patients with acute myocardial infarction.
Cardiac rehabilitation and secondary prevention.
Cardiopreventive effect of ethanolic extract of Date Palm Pollen against isoproterenol induced myocardial infarction in rats through the inhibition of the angiotensin-converting enzyme.
Cardioprotection in the clinical setting-lessons from J-WIND studies.
Cardioprotection in the ESRD Population: How Do We Get There?
Cardioprotective effects of benazepril, an angiotensin-converting enzyme inhibitor, in an ischaemia-reperfusion model of myocardial infarction in rats.
Cardioprotective effects of quinapril after myocardial infarction in hypertensive rats.
Cardioprotective role of zofenopril in hypertensive patients with acute myocardial infarction: a pooled individual data analysis of the SMILE studies.
Cardiovascular diseases and molecular variants of the renin-angiotensin system components in Slovak population.
Cardiovascular protection with ace inhibitors--more HOPE for EUROPA?
Cardiovascular risk factors in people with different genotypes in the insertion/deletion (I/D) polymorphism at the locus for angiotensin I-converting enzyme (ACE).
Carotid artery intimal-medial thickness: indicator of atherosclerotic burden and response to risk factor modification.
Carotid thickening, cardiac hypertrophy, and angiotensin converting enzyme gene polymorphism in patients with hypertension.
Carvedilol's antiarrhythmic properties: therapeutic implications in patients with left ventricular dysfunction.
Causes of death in patients with acute myocardial infarction treated with angiotensin-converting enzyme inhibitors: findings from the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto (GISSI)-3 trial.
Cellular distribution of angiotensin-converting enzyme after myocardial infarction.
Changes in ?-adrenoceptors in heart failure due to myocardial infarction are attenuated by blockade of renin-angiotensin system.
Changes in beta-adrenoceptors in heart failure due to myocardial infarction are attenuated by blockade of renin-angiotensin system.
Changes in cardiac angiotensin converting enzyme after myocardial infarction and hypertrophy in rats.
Changes in Hsp60 level of the failing heart following acute myocardial infarction and the effect of long-term treatment with trandolapril.
Changes in left ventricular mass and volumes in patients receiving angiotensin-converting enzyme inhibitor therapy for left ventricular dysfunction after Q-wave myocardial infarction.
Changes in ventricular size and function in patients treated with valsartan, captopril, or both after myocardial infarction.
Changes of expressions of VEGF, bFGF, and angiogenesis, and effect of benazepril, bFGF on angiogenesis in acute myocardial infarction model of the rabbits.
Changes of Matrix Metalloproteinase-9 Level Is Associated With Left Ventricular Remodeling Following Acute Myocardial Infarction Among Patients Treated With Trandolapril, Valsartan or Both.
Chronic angiotensin II receptor blockade induces cardioprotection during ischemia by increased PKC-epsilon expression in the mouse heart.
Chronic effects of ACE-inhibition (quinapril) and angiotensin-II-type-1 receptor blockade (losartan) on atrial natriuretic peptide in brain nuclei of rats with experimental myocardial infarction.
Chronic effects of early started angiotensin converting enzyme inhibition and angiotensin AT1-receptor subtype blockade in rats with myocardial infarction: role of bradykinin.
Chronic kidney disease, cardiovascular risk, and response to angiotensin-converting enzyme inhibition after myocardial infarction: the Survival And Ventricular Enlargement (SAVE) study.
Class effect of angiotensin-converting enzyme inhibitors on prevention of myocardial infarction.
Clinical and biochemical predictors affect the choice and the short-term outcomes of different thrombolytic agents in acute myocardial infarction.
Clinical aspects of ACE inhibition in patients with acute myocardial infarction.
Clinical assessment of indication for ACE-inhibitor treatment early after acute myocardial infarction.
Clinical background to the use of ACE inhibitor therapy after myocardial infarction.
Clinical benefit of angiotensin converting enzyme inhibition after acute myocardial infarction: myocardial reperfusion revisited.
Clinical characteristics and outcomes of critically ill patients with COVID-19 in a tertiary community hospital in upstate New York.
Clinical effects of early angiotensin-converting enzyme inhibitor treatment for acute myocardial infarction are similar in the presence and absence of aspirin: systematic overview of individual data from 96,712 randomized patients. Angiotensin-converting Enzyme Inhibitor Myocardial Infarction Collaborative Group.
Clinical events in high-risk hypertensive patients randomly assigned to calcium channel blocker versus angiotensin-converting enzyme inhibitor in the antihypertensive and lipid-lowering treatment to prevent heart attack trial.
Clinical experience in protecting the failing heart.
Clinical implications for the Acute Infarction Ramipril Efficacy extension (AIREX) Study.
Clinical Implications of Recent Findings from the Antihypertensive and Lipid-Lowering Treatment To Prevent Heart Attack Trial (ALLHAT) and Other Studies of Hypertension.
Clinical Inquiries: Which drugs should post-MI patients routinely receive?
Clinical outcome of patients treated with spinal cord stimulation for therapeutically refractory angina pectoris. The Working Group on Neurocardiology.
Clinical pharmacokinetics and selective pharmacodynamics of new angiotensin converting enzyme inhibitors: an update.
Clinical presentation, management, and in-hospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function: a report from the Acute Decompensated Heart Failure National Registry (ADHERE) Database.
Clinical trials evaluating angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in the setting of acute myocardial infarction.
Clopidogrel bioactivation and risk of bleeding in patients cotreated with angiotensin-converting enzyme inhibitors after myocardial infarction: a proof-of-concept study.
Coenzyme Q10 Modulates Remodeling Possibly by Decreasing Angiotensin-Converting Enzyme in Patients with Acute Coronary Syndrome.
Combination Angiotensin Converting Enzyme and Direct Renin Inhibition in Heart Failure following Experimental Myocardial Infarction.
Combination therapy with angiotensin converting enzyme inhibition and AT1 receptor inhibitor on ventricular remodeling after myocardial infarction in rats.
Combined angiotensin converting enzyme inhibition and angiotensin AT(1) receptor blockade up-regulates myocardial AT(2) receptors in remodeled myocardium post-infarction.
Combined secondary prevention after hospitalization for myocardial infarction in France: Analysis from a large administrative database.
Common polymorphisms and cardiovascular factors in patients with myocardial infarction of Costa Rica.
Community Implementation and Translation of Kaiser Permanente's Cardiovascular Disease Risk-Reduction Strategy.
Comparative effect of angiotensin converting enzyme inhibitor versus angiotensin ii type i receptor blocker in acute myocardial infarction with non-obstructive coronary arteries; from the Korea Acute Myocardial Infarction Registry - National Institute of Health.
Comparative Effectiveness of Angiotensin II Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors in Older Nursing Home Residents After Myocardial Infarction: A Retrospective Cohort Study.
Comparative Effectiveness of Angiotensin II Receptor Blockers Versus Angiotensin-Converting Enzyme Inhibitors Following Contemporary Treatments in Patients with Acute Myocardial Infarction: Results from the Korean Working Group in Myocardial Infarction (KorMI) Registry.
Comparative effectiveness of cardioprotective drugs in elderly individuals with type 2 diabetes.
Comparative effects of a novel angiotensin-converting enzyme inhibitor versus captopril on plasma angiotensins after myocardial infarction.
Comparative effects of angiotensin converting enzyme inhibition (perindopril) or diuretic therapy on cardiac hypertrophy and sympathetic activity following myocardial infarction in rats.
Comparative effects of chronic angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade on cardiac remodeling after myocardial infarction in the rat.
Comparing angiotensin-converting enzyme inhibitor trial results in patients with acute myocardial infarction.
Comparison between angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on the risk of myocardial infarction, stroke and death: a meta-analysis.
Comparison Between Beta-Blockers with Angiotensin-Converting Enzyme Inhibitors and Beta-Blockers with Angiotensin II Type I Receptor Blockers in ST-Segment Elevation Myocardial Infarction After Successful Percutaneous Coronary Intervention with Drug-Eluting Stents.
Comparison of 5-year survival after acute myocardial infarction using angiotensin-converting enzyme inhibitor versus angiotensin II receptor blocker.
Comparison of angiotensin converting enzyme and renin inhibition in rats following myocardial infarction.
Comparison of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in patients with diabetes mellitus and non-ST-segment elevation myocardial infarction who underwent successful percutaneous coronary intervention.
Comparison of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in the primary prevention of myocardial infarction in hypertensive patients.
Comparison of baseline data, initial course, and management: losartan versus captopril following acute myocardial infarction (The OPTIMAAL Trial). OPTIMAAL Trial Steering Committee and Investigators. Optimal Trial in Myocardial Infarction with the Angiotensin II Antagonist Losartan.
Comparison of cardioprotective effects of mibefradil and ramipril in stroke-prone spontaneously hypertensive rats.
Comparison of Cardiovascular Events Among Users of Different Classes of Antihypertension Medications: A Systematic Review and Network Meta-analysis.
Comparison of clinical outcomes between angiotensin-converting-enzyme inhibitors and ARBs in patients with acute myocardial infarction with dyslipidemia after a successful stent implantation.
Comparison of effectiveness of angiotensin-converting enzyme inhibitors after acute myocardial infarction in diabetic versus nondiabetic patients.
Comparison of perindopril versus captopril for treatment of acute myocardial infarction.
Comparison of the effects of an angiotensin-converting enzyme inhibitor and a vasopeptidase inhibitor after myocardial infarction in the rat.
Composite outcomes: weighting component events according to severity assisted interpretation but reduced statistical power.
Comprehensive comparative effectiveness and safety of first-line antihypertensive drug classes: a systematic, multinational, large-scale analysis.
Congestive Heart Failure With Apparently Preserved Left Ventricular Systolic Function: A 10-Year Observational Study.
Congestive heart failure. New frontiers.
Connective tissue growth factor and cardiac fibrosis after myocardial infarction.
Contemporary management of acute myocardial infarction.
Contemporary trends in evidence-based treatment for acute myocardial infarction.
Contribution of bradykinin to the cardioprotective action of angiotensin converting enzyme inhibition in hypertension and after myocardial infarction.
Contribution of cardiac renin-angiotensin system to ventricular remodelling in myocardial-infarcted rats.
Control by circulating factors of mitochondrial function and transcription cascade in heart failure: a role for endothelin-1 and angiotensin II.
Converting enzyme inhibition after experimental myocardial infarction in rats: comparative study between spirapril and zofenopril.
Coronary surgery in patients with preexisting chronic atrial fibrillation: early and midterm clinical outcome.
Correlation of flow mediated dilation with inflammatory markers in patients with impaired cardiac function. Beneficial effects of inhibition of ACE.
Cost-effectiveness analysis of early lisinopril use in patients with acute myocardial infarction. Results from GISSI-3 trial.
Cost-effectiveness of providing full drug coverage to increase medication adherence in post-myocardial infarction Medicare beneficiaries.
Cost-minimization and the number needed to treat in uncomplicated hypertension.
COVID-19 and cardiac injury: clinical manifestations, biomarkers, mechanisms, diagnosis, treatment, and follow up.
Current indications for ACE inhibitors and HOPE for the future.
Current recommendations for the treatment of hypertension: are they still valid?
D allele of the angiotensin-converting enzyme gene is a risk factor for secondary cardiac events after myocardial infarction.
DD angiotensin-converting enzyme gene polymorphism is associated with endothelial dysfunction in normal humans.
DD genotype of the angiotensin-converting enzyme gene is a risk factor for left ventricular hypertrophy.
Decrease in plasma cyclophilin A concentration at 1 month after myocardial infarction predicts better left ventricular performance and synchronicity at 6 months: a pilot study in patients with ST elevation myocardial infarction.
Delayed onset of angioedema with angiotensin-converting enzyme inhibitors: case report and review of the literature.
Deletion polymorphism in angiotensin-converting enzyme gene associated with parental history of myocardial infarction.
Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction.
Deletion polymorphism of the angiotensin converting enzyme gene is associated with an increase in left ventricular mass in men with type 2 diabetes mellitus.
Deletion polymorphism of the angiotensin I-converting enzyme gene is associated with increased plasma angiotensin-converting enzyme activity but not with increased risk for myocardial infarction and coronary artery disease.
Deletion polymorphism of the angiotensin-converting enzyme gene is independently associated with left ventricular mass and geometric remodeling in systemic hypertension.
Deletion-type allele of the angiotensin-converting enzyme gene is associated with progressive ventricular dilation after anterior myocardial infarction. Captopril and Thrombolysis Study Investigators.
Designing a Comprehensive Strategy to Improve One Core Measure: Discharge of Patients With Myocardial Infarction or Heart Failure on ACE Inhibitors/ARBs.
Determinants of appropriate use of angiotensin-converting enzyme inhibitors after acute myocardial infarction in persons > or = 65 years of age.
Determinants of interindividual variation of renin and prorenin concentrations: evidence for a sexual dimorphism of (pro)renin levels in humans.
Development and prevention of skeletal muscle structural alterations after experimental myocardial infarction.
Development of press-coated, floating-pulsatile drug delivery of lisinopril.
Diagnosing left ventricular dysfunction after myocardial infarction: the Dundee algorithm.
Dietary sodium restriction specifically potentiates left ventricular ACE inhibition by zofenopril, and is associated with attenuated hypertrophic response in rats with myocardial infarction.
Differences in the expression of the renin angiotensin system and the kallikrein-kinin system during the course of myocardial infarction in male and female Wistar rats.
Different angiotensin-converting enzyme inhibitors have similar clinical efficacy after myocardial infarction.
Different frequencies of angiotensin-converting enzyme genotypes in older hypertensive individuals.
Differential effects of long-term renin-angiotensin system blockade on limitation of infarct size in cholesterol-fed rabbits.
Diminished cardioprotective response to inhibition of angiotensin-converting enzyme and angiotensin II type 1 receptor in B(2) kinin receptor gene knockout mice.
Discovery of a potent angiotensin converting enzyme inhibitor via virtual screening.
Disparities in health care are driven by where minority patients seek care: examination of the hospital quality alliance measures.
Distinct Survival Benefits of Angiotensin-Converting Enzyme Inhibitors/Angiotensin II Receptor Blockers in Revascularized Coronary Artery Disease Patients According to History of Myocardial Infarction.
Divergent effects of angiotensin-converting enzyme inhibition and angiotensin II-receptor antagonism on myocardial cellular proliferation and collagen deposition after myocardial infarction in rats.
Divergent effects of losartan and metoprolol on cardiac remodeling, C-kit+ cells, proliferation and apoptosis in the left ventricle after myocardial infarction.
Do angiotensin converting enzyme inhibitors limit myocardial infarct size?
Do angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers have similar effects in the improvement of left ventricular dysfunction after myocardial infarction in Japanese?
Do radionuclide and echocardiographic techniques give a universal cut off value for left ventricular ejection fraction that can be used to select patients for treatment with ACE inhibitors after myocardial infarction?
Do the investigative sites that take part in a positive clinical trial translate that evidence into practice?
Does aspirin attenuate the effect of angiotensin-converting enzyme inhibitors in hypertension or heart failure?
Does long-term angiotensin converting enzyme inhibition affect the concentration of tissue-type plasminogen activator-plasminogen activator inhibitor-1 in the blood of patients with a previous myocardial infarction.
Double-blind comparison between zofenopril and lisinopril in patients with acute myocardial infarction: results of the Survival of Myocardial Infarction Long-term Evaluation-2 (SMILE-2) study.
Drug differences between ACE inhibitors in experimental settings and clinical practice.
Drug prescriptions after acute myocardial infarction: dosage, compliance, and persistence.
Drug therapy before coronary artery surgery: nitrates are independent predictors of mortality and beta-adrenergic blockers predict survival.
Dual renin angiotensin system blockade in patients with acute myocardial infarction and preserved left ventricular systolic function.
Early administration of ramipril in acute myocardial infarction: neurohormonal and hemodynamic effects and tolerability.
Early and late angiotensin-converting enzyme inhibition after myocardial infarction: an overview of randomized clinical trials.
Early and late angiotensin-converting enzyme inhibition in acute myocardial infarction.
Early angiotensin converting enzyme inhibitor therapy after experimental myocardial infarction prevents left ventricular dilation by reducing infarct expansion: a possible mechanism of clinical benefits.
Early angiotensin converting enzyme inhibitor therapy enhances the benefits of late coronary artery reperfusion on infarct expansion.
Early intervention with angiotensin-converting enzyme inhibitors during thrombolytic therapy in acute myocardial infarction: rationale and design of captopril and thrombolysis study. CATS investigators group.
Early neurohormonal effects of trandolapril in patients with left ventricular dysfunction and a recent acute myocardial infarction: a double-blind, randomized, placebo-controlled multicentre study.
Early prevention of left ventricular dysfunction after myocardial infarction with angiotensin-converting-enzyme inhibition.
Early treatment of acute myocardial infarction with angiotensin-converting enzyme inhibition: safety considerations. SMILE pilot study working party.
Early treatment with low-dose enalapril after acute myocardial infarction: an equilibrium radionuclide angiographic study. Enalapril despues del Infarto (EDI) Trial Investigators.
Early use of ACE inhibitors in the treatment of acute myocardial infarction in the United States: experience from the National Registry of Myocardial Infarction 2. National Registry of Myocardial Infarction 2 participants.
Early versus delayed angiotensin-converting enzyme inhibition therapy in acute myocardial infarction. The healing and early afterload reducing therapy trial.
ED 01-1 ARE ARBS COMPARABLE TO ACEIS IN PATIENTS WITH MYOCARDIAL INFARCTION?
Effect of ACE inhibitor trandolapril on life expectancy of patients with reduced left-ventricular function after acute myocardial infarction. TRACE Study Group. Trandolapril Cardiac Evaluation.
Effect of activation and inhibition of the renin-angiotensin system on plasma PAI-1.
Effect of angiotensin converting enzyme inhibition after acute myocardial infarction in patients with arterial hypertension. TRACE Study Group, Trandolapril Cardiac Event.
Effect of angiotensin converting enzyme inhibition on myocardial phosphoinositide metabolism visualised with 1-[1-11C]-butyryl-2-palmitoyl-rac-glycerol in myocardial infarction in the rat.
Effect of angiotensin converting enzyme inhibition on sudden cardiac death in patients following acute myocardial infarction. A meta-analysis of randomized clinical trials.
Effect of angiotensin converting enzyme inhibitors on periprocedural myocardial infarction in patients with metabolic syndrome.
Effect of angiotensin-converting enzyme gene polymorphism on left ventricular remodeling after anteroseptal infarction.
Effect of angiotensin-converting enzyme inhibition on infarct collagen deposition and remodelling during healing after transmural canine myocardial infarction.
Effect of Angiotensin-converting enzyme inhibition on one-year mortality and frequency of repeat acute myocardial infarction in patients with acute myocardial infarction.
Effect of angiotensin-converting enzyme inhibitor on cardiopulmonary baroreflex sensitivity in patients with acute myocardial infarction.
Effect of angiotensin-converting enzyme inhibitor on collagenolytic enzyme activity in patients with acute myocardial infarction.
Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on cardiovascular events in patients with heart failure: a meta-analysis of randomized controlled trials.
Effect of angiotensin-converting enzyme inhibitors on the power spectrum of heart rate variability in post-myocardial infarction patients.
Effect of angiotensin-converting enzyme inhibitors on ventricular remodeling and survival following myocardial infarction.
Effect of apolipoprotein E alleles and angiotensin-converting enzyme insertion/deletion polymorphisms on lipid and lipoprotein markers in middle-aged men and in patients with stable angina pectoris or healed myocardial infarction.
Effect of aspirin and ifetroban on skeletal muscle blood flow in patients with congestive heart failure treated with Enalapril. Ifetroban Study Group.
Effect of beta blockers alone, of angiotensin-converting enzyme inhibitors alone, and of beta blockers plus angiotensin-converting enzyme inhibitors on new coronary events and on congestive heart failure in older persons with healed myocardial infarcts and asymptomatic left ventricular systolic dysfunction.
Effect of captopril and enalapril on left ventricular geometry, function and collagen during healing after anterior and inferior myocardial infarction in a dog model.
Effect of captopril on post-infarction remodelling visualized by light sheet microscopy and echocardiography.
Effect of carvedilol in comparison with metoprolol on myocardial collagen postinfarction.
Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial.
Effect of chronic Angiotensin converting enzyme inhibitor therapy on myocardial injury in patients undergoing percutaneous coronary interventions.
Effect of cilazapril on regional left ventricular wall thickness and chamber dimension following acute myocardial infarction: in vivo assessment using MRI.
Effect of Combined Beta-Blocker and Angiotensin-Converting Enzyme Inhibitor Treatment on 1-Year Survival After Acute Myocardial Infarction: Findings of the PRIAMHO-II Registry.
Effect of direct renin inhibitor on left ventricular remodeling in patients with primary acute myocardial infarction.
Effect of drugs used in different type of myocardial infarction (STEMI or (NTEMI) on mortality.
Effect of early captopril treatment on blood adrenaline levels in acute myocardial infarction (the substudy of ISIS-4). International Study of Infarct Survival-4.
Effect of early enalapril therapy on left ventricular function and structure in acute myocardial infarction.
Effect of enalapril initiated early after acute myocardial infarction on heart failure parameters, with reference to clinical class and echocardiographic determinants. CONSENSUS II Multi-Echo Study Group.
Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions.
Effect of long-term therapy with fasidotril, a mixed inhibitor of neprilysin and angiotensin-converting enzyme (ACE), on survival of rats after myocardial infarction.
Effect of long-term treatment with trandolapril on Hsp72 and Hsp73 induction of the failing heart following myocardial infarction.
Effect of propranolol versus no propranolol on total mortality plus nonfatal myocardial infarction in older patients with prior myocardial infarction, congestive heart failure, and left ventricular ejection fraction > or = 40% treated with diuretics plus angiotensin-converting enzyme inhibitors.
Effect of ramipril on postrevascularization prevalence of angina and quality of life.
Effect of renin-angiotensin system inhibitors on long-term survival in patients treated with beta blockers and antiplatelet agents after acute myocardial infarction (from the MONICA/KORA Myocardial Infarction Registry).
Effect of renin-angiotensin-aldosterone system inhibitors on all-cause mortality and major cardiovascular events in patients with diabetes: A meta-analysis focusing on the number needed to treat and minimal clinical effect.
Effect of single and dual renin-angiotensin blockade on stroke in patients with and without diabetes in VALIANT.
Effect of the angiotensin-converting enzyme inhibitor trandolapril on mortality and morbidity in diabetic patients with left ventricular dysfunction after acute myocardial infarction. Trace Study Group.
Effect of the metabolic syndrome and hyperuricemia on outcome in patients with coronary artery disease (from the Bezafibrate Infarction Prevention Study).
Effect of the renin-angiotensin-aldosterone system on the cardiac interstitium in heart failure.
Effect of vasopeptidase inhibitor omapatrilat on cardiomyocyte apoptosis and ventricular remodeling in rat myocardial infarction.
Effect of very early angiotensin-converting enzyme inhibition on left ventricular dilation after myocardial infarction in patients receiving thrombolysis: results of a meta-analysis of 845 patients. FAMIS, CAPTIN and CATS Investigators.
Effects of a new angiotensin-converting enzyme inhibitor (idrapril) in rats with left ventricular dysfunction after myocardial infarction.
Effects of ACE inhibition on endothelial progenitor cell mobilization and prognosis after acute myocardial infarction in type 2 diabetic patients.
Effects of ACE inhibitors on mortality when started in the early phase of myocardial infarction: evidence from the larger randomized controlled trials.
Effects of acute angiotensin II type 1 receptor antagonism and angiotensin converting enzyme inhibition on plasma fibrinolytic parameters in patients with heart failure.
Effects of age on the quality of care provided to older patients with acute myocardial infarction.
Effects of alatriopril, a mixed inhibitor of atriopeptidase and angiotensin I-converting enzyme, on cardiac hypertrophy and hormonal responses in rats with myocardial infarction. Comparison with captopril.
Effects of amlodipine versus enalapril on left ventricular remodelling after reperfused anterior myocardial canine infarction.
Effects of angiotensin converting enzyme inhibition on cardiac innervation and ventricular arrhythmias after myocardial infarction.
Effects of angiotensin II receptor blockade versus angiotensin-converting-enzyme inhibition on ventricular remodelling following myocardial infarction in the mouse.
Effects of angiotensin II receptor blockers on serum levels of epoxyeicosatrienoic acids and dihydroxyeicosatrienoic acids in patients admitted to a cardiovascular center.
Effects of angiotensin-converting enzyme inhibition and angiotensin II AT1 receptor antagonism on cardiac parameters in left ventricular hypertrophy.
Effects of angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade on beta-adrenoceptor signaling in heart failure produced by myocardial Infarction in rabbits: reversal of altered expression of beta-adrenoceptor kinase and G i alpha.
Effects of angiotensin-converting enzyme inhibition and bradykinin peptides in rats with myocardial infarction.
Effects of angiotensin-converting enzyme inhibition on angiotensin and bradykinin peptides in rats with myocardial infarction.
Effects of angiotensin-converting enzyme inhibition on changes in left ventricular myocardial creatine kinase system after myocardial infarction: their relation to ventricular remodeling and function.
Effects of angiotensin-converting enzyme inhibition with perindopril on left ventricular remodeling and clinical outcome: results of the randomized Perindopril and Remodeling in Elderly with Acute Myocardial Infarction (PREAMI) Study.
Effects of angiotensin-converting enzyme inhibitor on plasma B-type natriuretic peptide levels in patients with acute myocardial infarction.
Effects of angiotensin-converting enzyme inhibitor or angiotensin receptor blocker therapy after hospital discharge on subsequent rehospitalization for acute myocardial infarction and heart failure.
Effects of angiotensin-converting enzyme inhibitor therapy on QT dispersion post acute myocardial infarction.
Effects of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers on Prothrombotic Processes and Myocardial Infarction Risk.
Effects of aspirin on angiotensin-converting enzyme inhibition and left ventricular dilation one year after acute myocardial infarction.
Effects of bradykinin on inducible sustained ventricular tachycardia two weeks after myocardial infarction in pigs.
Effects of candesartan and cilazapril on rats with myocardial infarction assessed by echocardiography.
Effects of canrenoate plus angiotensin-converting enzyme inhibitors versus angiotensin-converting enzyme inhibitors alone on systolic and diastolic function in patients with acute anterior myocardial infarction.
Effects of captopril and omapatrilat on early post-myocardial infarction survival and cardiac hemodynamics in rats: interaction with cardiac cytokine expression.
Effects of captopril on ischemia and dysfunction of the left ventricle after myocardial infarction.
Effects of captopril therapy on endogenous fibrinolysis in men with recent, uncomplicated myocardial infarction.
Effects of combination of angiotensin-converting enzyme inhibitor and angiotensin receptor antagonist on inflammatory cellular infiltration and myocardial interstitial fibrosis after acute myocardial infarction.
Effects of combined inhibition of the Na+-H+ exchanger and angiotensin-converting enzyme in rats with congestive heart failure after myocardial infarction.
Effects of converting enzyme inhibition on baroreflex sensitivity in patients with myocardial infarction.
Effects of early and late administration of angiotensin-converting enzyme inhibitors on mortality after myocardial infarction.
Effects of early angiotensin-converting enzyme inhibition in a pig model of myocardial ischemia and reperfusion.
Effects of early angiotensin-converting enzyme inhibition in patients with non-ST-elevation acute anterior myocardial infarction.
Effects of early angiotensin-converting enzyme inhibition on cardiac gene expression after acute myocardial infarction.
Effects of early enalapril treatment on global and regional wall motion in acute myocardial infarction. CONSENSUS II Multi Echo Study Group.
Effects of early treatment with captopril and metoprolol singly or together on six-month mortality and morbidity after acute myocardial infarction. Results of the RIMA (Rimodellamento Infarto Miocardico Acuto) study. The RIMA researchers.
Effects of enalapril and losartan in left ventricular remodeling after acute myocardial infarction: a possible mechanism of prevention of cardiac events by angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in high-risk myocardial infarction.
Effects of enalapril on T and B cell function in rats after myocardial infarction.
Effects of enalapril on ventricular volumes and neurohumoral status after inferior wall myocardial infarction.
Effects of growth hormone following chronic angiotensin-converting enzyme inhibition in chronic heart failure: their relation to infarct size.
Effects of imidapril therapy on endogenous fibrinolysis in patients with recent myocardial infarction.
Effects of lisinopril on experimental ischemia in rats. Influence of infarct size.
Effects of Long- and Intermediate-Acting Dihydropyridine Calcium Channel Blockers in Hypertension: A Systematic Review and Meta-Analysis of 18 Prospective, Randomized, Actively Controlled Trials.
Effects of long-term treatment with trandolapril on sarcoplasmic reticulum function of cardiac muscle in rats with chronic heart failure following myocardial infarction.
Effects of losartan and captopril on left ventricular systolic and diastolic function after acute myocardial infarction: results of the Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan (OPTIMAAL) echocardiographic substudy.
Effects of metoprolol and ramipril on action potentials after myocardial infarction in rats.
Effects of myocardial infarction and captopril therapy on anxiety-related behaviors in the rat.
Effects of nisoldipine and/or enalapril on left ventricular function and exercise capacity in patients with recent anterior myocardial infarction and mild cardiac dysfunction.
Effects of purified herbal extract of Salvia miltiorrhiza on ischemic rat myocardium after acute myocardial infarction.
Effects of ramipril on cardiac gene transcription levels of angiotensin II receptors after myocardial infarction.
Effects of reviparin, a low-molecular-weight heparin, on mortality, reinfarction, and strokes in patients with acute myocardial infarction presenting with ST-segment elevation.
Effects of sildenafil in combination with angiotensin-converting enzyme inhibitor on limiting infarct expansion in a porcine model of acute myocardial infarction.
Effects of stimulation frequency on calcium transients in noninfarcted myocardium: modulation by chronic captopril treatment.
Effects of the administration of an angiotensin-converting enzyme inhibitor during the acute phase of myocardial infarction in patients with arterial hypertension. SMILE Study Investigators. Survival of Myocardial Infarction Long-term Evaluation.
Effects of the angiotensin-converting enzyme inhibitor enalapril on sympathetic neuronal function and beta-adrenergic desensitization in heart failure after myocardial infarction in rats.
Effects of trandolapril on cardiac angiotensin I converting enzyme activity in rats with chronic heart failure following myocardial infarction.
Effects of valsartan, an angiotensin II receptor blocker, on coronary atherosclerosis in patients with acute myocardial infarction who receive an angiotensin-converting enzyme inhibitor.
Efficacy and safety of Angiotensin-converting enzyme inhibitors in patients with left ventricular systolic dysfunction and hyponatremia.
Efficacy and safety of early initiation of Sacubitril/Valsartan in patients after acute myocardial infarction: A meta-analysis.
Efficacy of aldosterone receptor antagonism in heart failure: potential mechanisms.
Efficacy of angiotensin-converting enzyme inhibition and AT1 receptor blockade on cardiac pump performance after myocardial infarction in rats.
Efficacy Of Zofenopril Alone Or In Combination With Hydrochlorothiazide In Patients With Kidney Dysfunction.
Efficacy of Zofenopril Compared With Placebo and Other Angiotensin-converting Enzyme Inhibitors in Patients With Acute Myocardial Infarction and Previous Cardiovascular Risk Factors: A Pooled Individual Data Analysis of 4 Randomized, Double-blind, Controlled, Prospective Studies.
Efficacy of zofenopril in combination with amlodipine in patients with acute myocardial infarction: a pooled individual patient data analysis of four randomized, double-blind, controlled, prospective studies.
Efficacy of zofenopril in combination with thiazide diuretics in patients with acute myocardial infarction: a pooled individual data analysis of four randomized, double-blind, controlled, prospective studies.
Electrocardiographic Changes and Mortality Due to Myocardial Infarction in Rats With or Without Imidapril Treatment.
Electrophysiologic and clinical effects of angiotensin-converting enzyme inhibitors in patients with prior myocardial infarction, nonsustained ventricular tachycardia, and depressed left ventricular function. MUSTT Investigators. Multicenter UnSustained Tachycardia Trial.
Electrophysiologic effects of quinaprilat in dogs during acute myocardial ischemia and following reperfusion.
Electrophysiological changes of angiotensin-converting enzyme inhibition after myocardial infarction.
Eliminating out-of-pocket drug costs may improve outcomes after myocardial infarction--but at what cost to Medicare?
Elite athletes and the gene for angiotensin-converting enzyme.
Enalapril attenuates downregulation of Angiotensin-converting enzyme 2 in the late phase of ventricular dysfunction in myocardial infarcted rat.
Enalapril increases ischemia-induced endothelial progenitor cell mobilization through manipulation of the CD26 system.
Enalapril therapy and cardiac remodelling in sickle cell disease patients.
Endothelin-converting enzyme and angiotensin-converting enzyme in failing hearts of rats with myocardial infarction.
Enhanced cardioprotective effects mediated by plasmid containing the short-hairpin RNA of angiotensin converting enzyme with a biodegradable hydrogel after myocardial infarction.
Enhanced expression of angiotensin-converting enzyme is associated with progression of coronary atherosclerosis in humans.
Enhanced predictability of myocardial infarction in Japanese by combined genotype analysis.
Eplerenone in the treatment of chronic heart failure.
Estimation of contribution of changes in coronary care to improving survival, event rates, and coronary heart disease mortality across the WHO MONICA Project populations.
EUROPA: has anything new been learned with angiotensin-converting enzyme inhibitors?
Evaluation of some pharmaceutical formulations of lisinopril through dissolution testing.
Evidence of a partial escape of renin-angiotensin-aldosterone blockade in patients with acute myocardial infarction treated with ACE inhibitors.
Evidence-based management of coronary artery disease in the elderly--current perspectives.
Evidence-based pharmacotherapy after myocardial infarction in France: adherence-associated factors and relationship with 30-month mortality and rehospitalization.
Exacerbation of atherosclerosis by hypertension. Potential mechanisms and clinical implications.
EXP3174, the AII antagonist human metabolite of losartan, but not losartan nor the angiotensin-converting enzyme inhibitor captopril, prevents the development of lethal ischemic ventricular arrhythmias in a canine model of recent myocardial infarction.
Exploration of pharmacological interventions to prevent isoproterenol-induced myocardial infarction in experimental models.
Expression of angiotensin-converting enzyme in remaining viable myocytes of human ventricles after myocardial infarction.
Expression of cardiac angiotensin-converting enzyme after myocardial infarction.
Expression of Renin-Angiotensin System on Dendritic Cells of Patients with Coronary Artery Disease.
Factors associated with actively working in the very long-term following acute coronary syndrome.
Failure of evidence-based medicine in the treatment of hypertension in older patients.
First dose hypotension after angiotensin converting enzyme inhibitor captopril and angiotensin II blocker losartan in patients with acute myocardial infarction.
Follow-up study of patients randomly allocated ramipril or placebo for heart failure after acute myocardial infarction: AIRE Extension (AIREX) Study. Acute Infarction Ramipril Efficacy.
Fourth International Study of Infarct Survival: protocol for a large simple study of the effects of oral mononitrate, of oral captopril, and of intravenous magnesium. ISIS-4 collaborative group.
Frequency of a deletion polymorphism in the gene for angiotensin converting enzyme is increased in African-Americans with hypertension.
From the HOPE to the ONTARGET and the TRANSCEND studies: challenges in improving prognosis.
Gender differences in treatment of heart failure and acute myocardial infarction: a question of quality or epidemiology?
Gene polymorphism but not catalytic activity of angiotensin I-converting enzyme is associated with coronary artery disease and myocardial infarction in low-risk patients.
Gene-gene interaction in the RAS system in the predisposition to myocardial infarction in elder population of St. Petersburg (Russia).
Genetic approaches to common diseases.
Genetic basis of left ventricular remodeling after myocardial infarction.
Genetic polymorphisms of angiotensin converting enzyme (I/D) and endothelial nitric oxide synthase (T(-788)C) genes in Japanese patients with myocardial infarction.
Genotype distribution of angiotensin-converting enzyme polymorphism in Australian healthy and coronary populations and relevance to myocardial infarction and coronary artery disease.
Haemodynamic effects of enalaprilat and preload in acute severe heart failure complicating myocardial infarction.
Health care improvement and cost reduction opportunities in hypertensive Medicaid beneficiaries.
Health outcomes associated with calcium antagonists compared with other first-line antihypertensive therapies: a meta-analysis of randomised controlled trials.
Health-related quality of life in patients 7 months after a myocardial infarction: factors affecting the Short Form-12.
Heart failure complicating acute myocardial infarction.
Heart failure, ventricular remodelling and the renin-angiotensin system: insights from recently completed clinical trials.
Heart rate variability and left ventricular dilatation early after myocardial infarction.
Hemodynamic effect of endothelin antagonists in dogs with myocardial infarction.
Hemodynamic effects of acute and chronic treatment with aladotril, a mixed inhibitor of neutral endopeptidase and angiotensin I-converting enzyme, in conscious rats with myocardial infarction.
High flow and high dose neosynephrine are effective to maintain perfusion pressure for the patient with preoperative angiotensin converting enzyme inhibitor during cardiopulmonary bypass.
High-sensitivity C-reactive protein and left ventricular remodeling in patients with acute myocardial infarction.
How long should angiotensin-converting enzyme inhibitors be given to patients following myocardial infarction: implications of the HOPE trial.
Human vascular reactivity and polymorphisms of the angiotensin-converting enzyme and the angiotensin type 1 receptor genes.
Hypertension and coronary artery disease: a summary of the american heart association scientific statement.
Hypertension treatment and implications of recent cardiovascular outcome trials.
Hypothesis: an angiotensin converting enzyme genotype, present in one in three caucasians, is associated with increased mortality rate.
Imidapril in heart failure.
Impact of ACE inhibitors on mortality and morbidity in patients with AMI: Does tissue selectivity matter?
Impact of Angiotensin II Receptor Blockers on Clinical Outcomes after Percutaneous Coronary Intervention in Patients with Acute Myocardial Infarction Based on Data from the Korean National Health Insurance Database (2005-2014).
Impact of candesartan on nonfatal myocardial infarction and cardiovascular death in patients with heart failure.
Impact of I/D polymorphism of angiotensin-converting enzyme (ACE) gene on myocardial infarction susceptibility among young Moroccan patients.
Impact of ramipril versus other angiotensin-converting enzyme inhibitors on outcome of unselected patients with ST-elevation acute myocardial infarction.
Impact of renin angiotensin system inhibitor on 3-year clinical outcomes in acute myocardial infarction patients with preserved left ventricular systolic function: a prospective cohort study from Korea Acute Myocardial Infarction Registry (KAMIR).
Impact of telmisartan on coronary stenting in patients with acute myocardial infarction compared with enalapril.
Implications of recently published trials of blood pressure-lowering drugs in hypertensive or high-risk patients.
Importance of angiotensin-converting enzyme inhibitors in myocardial infarction and congestive heart failure: implications for clinical practice.
Improved treatment of hospitalized coronary artery disease patients with the get with the guidelines program.
Improving outcomes in post-acute myocardial infarction heart failure: incorporation of aldosterone blockade into combination therapy to optimize neurohormonal blockade.
Improving patient outcomes by pooling resources (the Texas Heart Care Partnership experience).
Improving survival for patients with advanced heart failure: a study of 737 consecutive patients.
Incidence and predictors of angioedema in elderly hypertensive patients at high risk for cardiovascular disease: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Incidence and predictors of ventricular arrhythmias after ST-segment elevation myocardial infarction.
Incidence and prognostic significance of atrial fibrillation in acute myocardial infarction: the GISSI-3 data.
Incidence of and Risk Factors for Severe Adverse Events in Elderly Patients Taking Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers after an Acute Myocardial Infarction.
Incidence of new coronary events in older persons with prior myocardial infarction and systemic hypertension treated with beta blockers, angiotensin-converting enzyme inhibitors, diuretics, calcium antagonists, and alpha blockers.
Incidence of New Stroke or New Myocardial Infarction or Death at 39-Month Follow Up in Patients With Diabetes Mellitus, Hypertension, or Both Treated With and Without Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers.
Incidence, trends, and predictors of ischemic stroke 1 year after an acute myocardial infarction.
Increased angiotensin converting enzyme activity in left ventricular aneurysm of patients after myocardial infarction.
Increased angiotensin-converting enzyme activity in the left ventricle after infarction.
Increased cardiovascular risk in long-term hemodialysis patients carrying deletion allele of ACE gene polymorphism.
Increased Risk of Myocardial Infarction Associated With Angiotensin-Converting Enzyme Gene Polymorphism Is Age Dependent.
Incremental value of left ventricular shape parameters measured by gated SPECT MPI in predicting the super-response to CRT.
Indications for immediate angiotensin-converting enzyme inhibition in patients with acute myocardial infarction.
Influence of a history of arterial hypertension and pretreatment blood pressure on the effect of angiotensin converting enzyme inhibition after acute myocardial infarction. Trandolapril Cardiac Evaluation Study.
Influence of angiotensin II on circulating adhesion molecules and blood leukocyte count in vivo.
Influence of angiotensin-converting enzyme I/D gene polymorphism on the right ventricular myocardial performance index in patients with a first acute anterior myocardial infarction.
Influence of angiotensin-converting enzyme inhibition on cardiac function in myocardial infarction.
Influence of perindopril on left ventricular global performance during the early phase of inferior acute myocardial infarction: assessment by Tei index.
Influence of prior ACE inhibitor therapy on morbidity and mortality following acute myocardial infarction.
Influence of proteinuria on cardiovascular risk and response to angiotensin-converting enzyme inhibition after myocardial infarction.
Influence of statin therapy on circadian variation of acute myocardial infarction.
Influence of tissue affinity of angiotensin-converting enzyme inhibitors on left ventricular remodeling after myocardial infarction.
Inhibiting the renin-angiotensin system in myocardial infarction and heart failure: lessons from SAVE, VALIANT and CHARM, and other clinical trials.
Inhibition of angiotensin-converting enzyme and attenuation of myocardial fibrosis by lisinopril in rats receiving angiotensin II.
Inhibition of both angiotensin-converting enzyme and neutral endopeptidase by S21402 (RB105) in rats with experimental myocardial infarction.
Inhibition of matrix metalloproteinase-9 activity by lisinopril after myocardial infarction in hamsters.
Inhibition of neutrophil-dependent cytotoxicity for human endothelial cells by ACE inhibitors.
Inhibition of p38 mitogen-activated protein kinase protects the heart against cardiac remodeling in mice with heart failure resulting from myocardial infarction.
Inhibition of the renin-angiotensin system: no effect on circulating macrophage colony-stimulating factor levels in acute myocardial infarction.
Inhibitory effect of candesartan cilexetil on left ventricular remodeling after myocardial infarction.
Inhibitory effect of valsartan against progression of left ventricular dysfunction after myocardial infarction.
Insertion/deletion (I/D) polymorphism at the locus for angiotensin I-converting enzyme and myocardial infarction.
Insertion/deletion (I/D) polymorphism at the locus for angiotensin I-converting enzyme and parental history of myocardial infarction.
Insertion/deletion polymorphism in the angiotensin-converting enzyme gene and risk of and prognosis after myocardial infarction.
Insertion/deletion polymorphism in the angiotensin-converting enzyme gene and risk of restenosis after coronary angioplasty.
Insertion/deletion polymorphism in the angiotensin-converting enzyme gene in myocardial infarction survivors.
Insertion/deletion polymorphism of the angiotensin-converting enzyme gene is strongly associated with coronary heart disease in non-insulin-dependent diabetes mellitus.
Integrating traditional and emerging treatment options in heart failure.
Interaction between enalapril and aspirin on mortality after acute myocardial infarction: subgroup analysis of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II)
Interaction between neutral endopeptidase and angiotensin converting enzyme inhibition in rats with myocardial infarction: effects on cardiac hypertrophy and angiotensin and bradykinin peptide levels.
Interaction between polymorphisms in the renin-angiotensin-system and angiotensin-converting enzyme inhibitor or beta-blocker use and the risk of myocardial infarction and stroke.
Interaction of the ACE D allele and the GNB3 825T allele in myocardial infarction.
Interrupting the renin-angiotensin system: the role of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists in the treatment of hypertension.
Interstitial fibrosis and angiotensin-converting enzyme inhibition in patients with end-stage myocardial infarction.
Intervention to improve adherence to ACC/AHA recommended adjunctive medications for the management of patients with an acute myocardial infarction.
Is angiotensin-converting enzyme inhibitor useful in a Japanese population for secondary prevention after acute myocardial infarction? A final report of the Japanese Acute Myocardial Infarction Prospective (JAMP) study.
Is ramipril really better than other angiotensin-converting enzyme inhibitors after acute myocardial infarction?
Is timing everything? Therapeutic potential of modulators of cardiac Na(+) transporters.
Issues concerning the use of angiotensin-converting enzyme inhibitors in the treatment of heart failure and myocardial infarction.
Kidney function and long-term medication adherence after myocardial infarction in the elderly.
Lack of association between ACE and bradykinin B2 receptor gene polymorphisms and ACE inhibitor-induced coughing in hypertensive Koreans.
Lack of association between the insertion/deletion polymorphism of the angiotensin-converting enzyme gene and vasospastic angina.
Lack of association of angiotensin I-converting enzyme gene polymorphism and premature myocardial infarction in Mauritian Indians.
Lack of association of angiotensin-converting enzyme (ACE). Gene insertion/deletion polymorphism with CAD in two Asian populations.
Lack of association of angiotensin-converting enzyme insertion/deletion polymorphism and myocardial infarction at very young ages.
Lack of deleterious interaction between angiotensin receptor blockers and beta-blockers in the treatment of patients with heart failure.
Large-scale test of hypothesised associations between the angiotensin-converting-enzyme insertion/deletion polymorphism and myocardial infarction in about 5000 cases and 6000 controls. International Studies of Infarct Survival (ISIS) Collaborators.
Late coronary artery reperfusion has additive beneficial effects on infarct expansion when combined with early angiotensin converting enzyme inhibitor therapy post myocardial infarction.
Left ventricular remodeling after acute myocardial infarction.
Left ventricular remodeling after acute myocardial infarction: clinical course and beneficial effects of angiotensin-converting enzyme inhibition.
Left ventricular remodelling, neurohormonal activation and early treatment with enalapril (CONSENSUS II) following myocardial infarction.
Left ventricular volumes, ejection fraction, and plasma proatrial natriuretic factor (1-98) after withdrawal of enalapril treatment initiated early after myocardial infarction. CONSENSUS II Multi-Echo Study Group.
Lewis A. Conner Memorial Lecture. Mechanisms leading to myocardial infarction: insights from studies of vascular biology.
Limitation of left ventricular hypertrophy and dysfunction by ACE inhibition after anterior Q-wave myocardial infarction.
Links between hypertension and myocardial infarction.
Lipoprotein(a) and oxygen free radicals in survivors of acute myocardial infarction: effects of captopril.
Long-term adherence to evidence based secondary prevention therapies after acute myocardial infarction.
Long-term anti-ischemic effects of angiotensin-converting enzyme inhibition in patients after myocardial infarction. The Captopril and Thrombolysis Study (CATS) Investigators.
Long-term clinical experience with zofenopril.
Long-term clinical outcome between beta-blocker with ACEI or ARB in patients with NSTEMI who underwent PCI with drug-eluting stents.
Long-term compliance with beta-blockers, angiotensin-converting enzyme inhibitors, and statins after acute myocardial infarction.
Long-term effects on cardiac output and peripheral resistance in patients treated with enalapril after acute myocardial infarction. CONSENSUS II Multi-Echo Study Group. Cooperative New Scandinavian Enalapril Survival Study.
Long-term impact of secondary preventive treatments in patients with stable angina.
Long-term survival after myocardial infarction: relationship with thrombolysis and discharge medication. Results of the Augsburg Myocardial Infarction Follow-up Study 1985 to 1993.
Long-term survival in patients with different combinations of evidence-based medications after incident acute myocardial infarction: results from the MONICA/KORA Myocardial Infarction Registry.
Long-term treatment with trandolapril opposes cardiac remodeling and prolongs survival after myocardial infarction in rats.
Long-Term Use of Cardiovascular Drugs: Challenges for Research and for Patient Care.
Lower mortality in patients with the DD genotype of the angiotensin-converting enzyme gene after acute myocardial infarction.
Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitors or calcium channel blocker vs diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Management of acute coronary syndromes clinical guideline.
Management of postmyocardial infarction in the elderly patient.
Management of the older person with ventricular arrhythmias.
Managing acute coronary syndromes in the elderly.
Mechanisms of myocardial remodeling: ramiprilat blocks the expressional upregulation of protein kinase C-epsilon in the surviving myocardium early after infarction.
Mechanistic lessons from the SAVE Study. Survival and Ventricular Enlargement.
Medical treatment after myocardial infarction. Results of studies using various methods.
Medication undertreatment in assisted living settings.
Mega-trials and management of acute myocardial infarction.
Meta-analysis of angiotensin-converting enzyme insertion/deletion polymorphism and myocardial infarction in Han Chinese.
Moderate cardiac-selective overexpression of angiotensin II type 2 receptor protects cardiac functions from ischaemic injury.
Modern adjunctive pharmacotherapy of myocardial infarction.
Modification of high blood pressure after myocardial infarction.
Modification of myosin gene expression by imidapril in failing heart due to myocardial infarction.
Modification of myosin protein and gene expression in failing hearts due to myocardial infarction by enalapril or losartan.
Modulation of pain perception by ramipril and losartan in human volunteers.
Moexipril and left ventricular hypertrophy.
Molecular variant of angiotensinogen gene is associated with coronary atherosclerosis.
Mortality and Morbidity During and After Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial: Results by Sex.
Mortality benefit of long-term angiotensin-converting enzyme inhibitors or angiotensin receptor blockers after successful percutaneous coronary intervention in non-ST elevation acute myocardial infarction.
Mortality rates in elderly patients who take different angiotensin-converting enzyme inhibitors after acute myocardial infarction: a class effect?
Multivessel percutaneous coronary intervention: a new paradigm for a new century.
Myocardial infarction and stroke associated with diuretic based two drug antihypertensive regimens: population based case-control study.
Myocardial infarction, ventricular remodeling, and angiotensin-converting enzyme inhibition: where we stand today.
Myocardial infarction: when and how should we initiate treatment with ACE inhibitors? GISSI-3 Investigators.
Myocardial microvascular disease and major adverse cardiovascular events in patients with end-stage renal disease: rationale and design of the MICROCARD study.
Nationwide trends in the prescription of beta-blockers and angiotensin-converting enzyme inhibitors after myocardial infarction in Denmark, 1995-2002.
Neural mechanism of angiotensin-converting enzyme inhibitors in improving heart rate variability and sleep disturbance after myocardial infarction.
Neuroendocrine activation in acute myocardial infarction.
Neuroendocrine changes in acute myocardial infarction.
Neurohormonal activation in patients with acute myocardial infarction or chronic congestive heart failure. With special reference to treatment with angiotensin converting enzyme inhibitors.
Neurohormonal changes after acute myocardial infarction. Relationships with haemodynamic indices and effects of ACE inhibition.
Neurohumoral and hemodynamic effects of ibopamine in a rat model of chronic myocardial infarction and heart failure.
New Perspectives in the Renin-Angiotensin-Aldosterone System (RAAS) II: Albumin Suppresses Angiotensin Converting Enzyme (ACE) Activity in Human.
New polymorphisms of the angiotensin II type 1 receptor gene and their associations with myocardial infarction and blood pressure: the ECTIM study. Etude Cas-Témoin de l'Infarctus du Myocarde.
Nifedipine retard prevents hospitalization for angina pectoris better than angiotensin-converting enzyme inhibitors in hypertensive Japanese patients with previous myocardial infarction (JMIC-B substudy).
Nonlipid primary and secondary prevention strategies for coronary heart disease.
NT-proBNP Response to Sacubitril/Valsartan in Hospitalized Heart Failure Patients With Reduced Ejection Fraction: TRANSITION Study.
Omapatrilat limits infarct size and lowers the threshold for induction of myocardial preconditioning through a bradykinin receptor-mediated mechanism.
On Target to Dual Block RASS?
Ongoing clinical trials of angiotensin-converting enzyme inhibitors for treatment of coronary artery disease in patients with preserved left ventricular function.
Ongoing trials of angiotensin-converting enzyme inhibition: what they can tell us.
Opposite effects of amlodipine and enalapril on infarct collagen and remodelling during healing after reperfused myocardial infarction.
Oral nitrates: more than symptomatic therapy in coronary artery disease?
Outcomes with Angiotensin-converting Enzyme Inhibitors vs Other Antihypertensive Agents in Hypertensive Blacks.
Overestimation of genetic risks owing to small sample sizes in cardiovascular studies.
Overview of the relationship between ischemia and congestive heart failure.
Participant recruitment in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Pathophysiological aspects of the renin-angiotensin-aldosterone system in acute myocardial infarction.
Patterns of medical therapy in patients with peripheral artery disease in a tertiary care centre in Canada.
Patterns of prescribing ACE inhibitors after myocardial infarction.
Patterns of Use of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers Among Patients With Acute Myocardial Infarction in China From 2001 to 2011: China PEACE-Retrospective AMI Study.
Perioperative use of cardiac medical therapy among patients undergoing coronary artery bypass graft surgery: a systematic review.
Pharmacodynamic effects of C-domain-specific ACE inhibitors on the renin-angiotensin system in myocardial infarcted rats.
Pharmacodynamic interaction of captopril with garlic in isoproterenol-induced myocardial damage in rat.
Pharmacologic blockade of the renin-angiotensin system: vascular benefits beyond commonly understood pharmacologic actions.
Pharmacologic management of angina and acute myocardial infarction.
Pharmacologic treatment of heart failure with standard drugs.
Pharmacological approaches in the treatment of atrial fibrillation.
Pharmacological therapy for myocardial infarction in the elderly: An 8-year analysis.
Physical working capacity after acute myocardial infarction in patients with low ejection fraction and effect of captopril.
Plasma angiotensin-converting enzyme activity and carotid wall thickening.
Plasma angiotensin-converting enzyme activity and left ventricular dilation after myocardial infarction.
Plasma brain natriuretic peptide as an indicator for angiotensin-converting-enzyme inhibition after myocardial infarction.
Plasma corticotrophin releasing hormone, vasopressin, ACTH and cortisol responses to acute myocardial infarction.
Plasma level and gene polymorphism of angiotensin-converting enzyme in relation to myocardial infarction.
Plasminogen activator inhibitor-1 and angiotensin I converting enzyme gene polymorphism in patients with hypertension.
Polymorphism of the apolipoprotein E and angiotensin I converting enzyme genes in Japanese patients with myocardial infarction.
Polymorphisms of renin-angiotensin system and natriuretic peptide receptor A genes in patients of Greek origin with a history of myocardial infarction.
Polymorphisms of the angiotensin-converting-enzyme gene in subjects who die from coronary heart disease.
Poor short-term survival and low use of cardiovascular medications in elderly dialysis patients after acute myocardial infarction.
Positive association of CYP11B2 gene polymorphism with genetic predisposition to essential hypertension.
Post acute myocardial infarction: the Fosinopril in Acute Myocardial Infarction Study (FAMIS).
Postmyocardial infarction patients: experience from the SAVE trial.
Potential advantages of cell administration on the inflammatory response compared to standard ACE inhibitor treatment in experimental myocardial infarction.
Potential beneficial as well as detrimental effects of chronic treatment with lisinopril and (or) spironolactone on isolated hearts following low-flow ischemia in normal and infarcted rats.
Potential indications for angiotensin-converting enzyme inhibitors in atherosclerotic vascular disease.
Potential molecular mechanism of ACE gene at different time points in STEMI patients based on genome-wide microarray dataset.
Potential proischemic effect of early enalapril in hypotension-prone patients with acute myocardial infarction. The CONSENSUS II Holter Substudy Group.
Potential role of renin-angiotensin system blockade for preventing myocardial ischemia/reperfusion injury and remodeling after myocardial infarction.
Practical issues for the use of ACE inhibitors in acute myocardial infarction.
PREAMI: Perindopril and Remodelling in Elderly with Acute Myocardial Infarction: study rationale and design.
Predictive models for adverse clinical outcomes in Chinese patients with atrial fibrillation undergoing percutaneous coronary intervention with stenting.
Predictors and prognostic implications of major adverse cardiovascular events after renal transplant: 10 years outcomes in 321 patients.
Predictors of Acute Kidney Injury Following Surgical Valve Replacement.
Predictors of Adherence to Performance Measures in Patients with Acute Myocardial Infarction.
Predictors of clinically significant postprocedural hypotension after carotid endarterectomy and carotid angioplasty with stenting.
Predictors of heart failure in patients with stable coronary artery disease: a PEACE study.
Predictors of postoperative acute kidney injury in patients undergoing hip fracture surgery: A systematic review and meta-analysis.
Pregnancy-Associated Myocardial Infarction: A Review of Current Practices and Guidelines.
Prescribing patterns for antihypertensive drugs after the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial: report of experience in a health maintenance organization.
Prescription prevalence and continuing medication use for secondary prevention after myocardial infarction: the reality of care revealed by claims data analysis.
Preservation of left ventricular mechanical function and energy metabolism in rats after myocardial infarction by the angiotensin-converting enzyme inhibitor quinapril.
Prevalent but moderate variation across small geographic regions in patient nonadherence to evidence-based preventive therapies in older adults after acute myocardial infarction.
Prevention of congestive heart failure by ACE inhibition in patients with acute myocardial infarction.
Prevention of left ventricular remodeling with granulocyte colony-stimulating factor after acute myocardial infarction: final 1-year results of the Front-Integrated Revascularization and Stem Cell Liberation in Evolving Acute Myocardial Infarction by Granulocyte Colony-Stimulating Factor (FIRSTLINE-AMI) Trial.
Prevention of remodeling of the heart after myocardial infarction.
Preventive effects of oleuropein against cardiac remodeling after myocardial infarction in Wistar rat through inhibiting angiotensin-converting enzyme activity.
Primary and secondary prevention of ischemic heart disease.
Primary prevention of myocardial infarction with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in hypertensive patients with rheumatoid arthritis-A nationwide cohort study.
Prognostic impact of acute beta-blocker therapy on top of aspirin and angiotensin-converting enzyme inhibitor therapy in consecutive patients with ST-elevation acute myocardial infarction.
Prognostic markers in thrombolytic therapy: looking beyond mortality.
Prognostic value of dobutamine stress echocardiography with early injection of atropine with versus without chronic beta-blocker therapy in patients with known or suspected coronary heart disease.
Progressive ventricular dilation in experimental myocardial infarction and its attenuation by angiotensin-converting enzyme inhibition.
Prospective evaluation comparing the effects of enalapril and losartan in left ventricular remodeling after acute myocardial infarction.
Protection of the cardiovascular system by imidapril, a versatile angiotensin-converting enzyme inhibitor.
Public health, cardiovascular disease and molecular biology.
Quinaprilat increases total body vascular compliance in rats with myocardial infarction.
Racial/Ethnic and gender gaps in the use of and adherence to evidence-based preventive therapies among elderly Medicare Part D beneficiaries after acute myocardial infarction.
Ramipril improves nitric oxide availability in hypertensive rats with failing hearts after myocardial infarction.
Ramipril reduces QT dispersion in patients with acute myocardial infarction and heart failure.
Rationale and design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). ALLHAT Research Group.
Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials.
Real-world use of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers/?-blocks in Chinese patients before acute myocardial infarction occurs: patient characteristics and hospital follow-up.
Recent advances in the secondary prevention of coronary heart disease.
Recommendations for the management of special populations: racial and ethnic populations.
Reducing the cardiovascular consequences of diabetes mellitus.
Reduction of exercise-induced myocardial ischemia during add-on treatment with the angiotensin-converting enzyme inhibitor enalapril in patients with normal left ventricular function and optimal beta blockade.
Reduction of myocardial infarct size in rabbits by ramiprilat: reversal by the bradykinin antagonist HOE 140.
Regulation of beta-adrenoceptors in a rat model of cardiac failure: effect of perindopril.
Regulation of components of the brain and cardiac renin-angiotensin systems by 17beta-estradiol after myocardial infarction in female rats.
Reinforcing a continuum of care: in-hospital initiation of long-term secondary prevention following acute coronary syndromes.
Relation between angiotensin-converting enzyme I/D gene polymorphism and pulse pressure in patients with a first anterior acute myocardial infarction.
Relation between previous angiotensin-converting enzyme inhibitor use and in-hospital outcomes in acute coronary syndromes.
Relation Between Statewide Hospital Performance Reports on Myocardial Infarction and Cardiovascular Outcomes.
Relation of coronary atherosclerosis determined by electron beam computed tomography and plasma levels of n-terminal pro-brain natriuretic peptide in a multiethnic population-based sample (the Dallas Heart Study).
Relation of pre-event use of inhibitors of the renin-angiotensin system with myocardial infarct size in patients presenting with a first ST-segment elevation myocardial infarction.
Relations between deletion polymorphism of the angiotensin-converting enzyme gene and insulin resistance, glucose intolerance, hyperinsulinemia, and dyslipidemia.
Relationship between ACE gene polymorphism and ischemic chronic heart failure in Turkish population.
Relationship between angiotensin-converting enzyme gene insertion/deletion polymorphism, angiographically defined coronary artery disease and myocardial infarction in patients with type 2 diabetes mellitus.
Relationship between Beta-blocker and Angiotensin-converting enzyme inhibitor dose and clinical outcome following acute myocardial infarction.
Relationship between myocardial flow reserve by oxygen-15 water positron emission tomography in the subacute phase of myocardial infarction and left ventricular remodeling in the chronic phase.
Relationship between serum angiotensin-converting enzyme activity and plasma plasminogen activator inhibitor activity in patients with recent myocardial infarction.
Relative contribution of angiotensin II, bradykinin, and prostaglandins to the renal effects of converting enzyme inhibition in rats after chronic myocardial infarction.
Relative effectiveness of angiotensin-converting enzyme inhibitors after acute myocardial infarction.
Renal artery stenosis emerged after angiotensin-converting enzyme inhibitor treatment for myocardial infarction: a case report.
Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Renin-Angiotensin System Antagonists in Patients Without Left Ventricular Dysfunction After Percutaneous Intervention for ST-Segment Elevation Myocardial Infarction.
Renin-Angiotensin System Blockade and Risk of Heart Failure After Myocardial Infarction Based on Left Ventricular Ejection Fraction: A Retrospective Cohort Study.
Renin-Angiotensin System Blockade Improves Cardiac Indices in Acromegaly Patients.
Renin-angiotensin system haplotypes and the risk of myocardial infarction and stroke in pharmacologically treated hypertensive patients.
Renin-angiotensin system inhibitors and troponin elevation in spinal surgery.
Renin-angiotensin system modulation: the weight of evidence.
Renin-angiotensin-aldosterone system: fundamental aspects and clinical implications in renal and cardiovascular disorders.
Reperfusion adjunctive therapy.
Residual risk for coronary heart disease events and mortality despite intensive medical management after myocardial infarction.
Risk factors for acute kidney injury in patients with acute myocardial infarction.
Risk factors for pacemaker implantation following aortic valve replacement: a single centre experience.
Risk of hospitalized gastrointestinal bleeding in persons randomized to diuretic, ACE-inhibitor, or calcium-channel blocker in ALLHAT.
Risks and benefits of early treatment of acute myocardial infarction with an angiotensin-converting enzyme inhibitor in patients with a history of arterial hypertension: analysis of the GISSI-3 database.
Role of angiotensin converting enzyme inhibitors in preventing left ventricular remodelling following myocardial infarction.
Role of angiotensin II in blood pressure regulation and in the pathophysiology of cardiovascular disorders.
Role of angiotensin receptor blockers in diabetes: implications of recent clinical trials.
Role of Angiotensin receptor blockers in the prevention and treatment of arrhythmias.
Role of Angiotensin-Converting Enzyme (ACE) gene polymorphism and ACE activity in predicting outcome after acute myocardial infarction.
Role of angiotensin-converting enzyme inhibitors in myocardial infarction.
Role of basal nitric oxide synthesis in vasoconstrictor hyporeactivity in the perfused rat hindlimb after myocardial infarction: effect of captopril.
Role of intracardiac renin-angiotensin-aldosterone system in extracellular matrix remodeling.
Role of kinins in chronic heart failure and in the therapeutic effect of ACE inhibitors in kininogen-deficient rats.
Role of locally formed angiotensin II and bradykinin in the reduction of myocardial infarct size in dogs.
Role of p90 ribosomal S6 kinase-mediated prorenin-converting enzyme in ischemic and diabetic myocardium.
Role of Rho kinase and oxidative stress in cardiac fibrosis induced by aldosterone and salt in angiotensin type 1a receptor knockout mice.
Role of the cardiac renin-angiotensin system in human heart failure.
Role of the renin-angiotensin system as a risk factor for control of morbidity and mortality in coronary artery disease.
Safety of drugs commonly used to treat hypertension, dyslipidemia, and type 2 diabetes (the metabolic syndrome): part 1.
Sarcoplasmic reticulum Ca2+ transport and gene expression in congestive heart failure are modified by imidapril treatment.
Secondary prevention after acute myocardial infarction and coronary revascularisation: focus on Angiotensin converting enzyme inhibitors.
Secondary prevention in coronary heart disease: baseline survey of provision in general practice.
Secondary prevention of coronary artery disease.
Secondary prevention of myocardial infarction: role of beta-adrenergic blockers and angiotensin-converting enzyme inhibitors.
Serum cholesterol levels on admission and survival in patients with acute myocardial infarction treated with zofenopril: a post hoc analysis of the Survival of Myocardial Infarction Long-term Evaluation trial.
Serum MCP-1 and VEGF levels are not affected by inhibition of the renin-angiotensin system in patients with acute myocardial infarction.
Sex difference in the effect of ACE-DD genotype on the risk of premature myocardial infarction.
Short- and long-term effects of early fosinopril administration in patients with acute anterior myocardial infarction undergoing intravenous thrombolysis: results from the Fosinopril in Acute Myocardial Infarction Study. FAMIS Working Party.
Should angiotensin-converting enzyme inhibitors be used in all patients with coronary artery disease or restricted to those with a history of myocardial infarction or myocardial revascularization?
Should increasing the dose or adding an AT1 receptor blocker follow a relatively low dose of ACE inhibitor initiated in acute myocardial infarction?
Side effects of using nitrates to treat heart failure and the acute coronary syndromes, unstable angina and acute myocardial infarction.
Significance of angiotensin I-converting enzyme and angiotensin II type 1 receptor gene polymorphisms as risk factors for coronary heart disease.
Soluble CD40 ligand in acute and chronic heart failure.
Statin therapy in patients with chronic kidney disease undergoing percutaneous coronary intervention (from the Evaluation of Drug Eluting Stents and Ischemic Events Registry).
Stimulatory effect of dexamethasone on angiotensin-converting enzyme in neonatal rat cardiac myocytes.
Structure and in vitro function of human subcutaneous small arteries in mild heart failure.
Study on early intervention with ACE inhibitor in myocardical infarction and short term outcome.
Subcellular and molecular mechanisms of the effects of cardiac glycosides and angiotensin-converting enzyme inhibitors on contractile function and energy conversion in myocardial myofibrils under normal conditions and during acute cardiac insufficiency.
Suboptimal use of evidence-based medical therapy in patients with acute myocardial infarction from the Korea Acute Myocardial Infarction Registry: prescription rate, predictors, and prognostic value.
Summary of AHRQ's comparative effectiveness review of angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers added to standard medical therapy for treating stable ischemic heart disease.
Survival after myocardial infarction in rats: captopril versus losartan.
Survival after myocardial infarction in the rat. Role of tissue angiotensin-converting enzyme inhibition.
Synergistic effect of angiotensin II type-1 receptor 1166A/C with angiotensin-converting enzyme polymorphism on risk of acute myocardial infarction in north Indians.
Synergistic effects of angiotensin-converting enzyme and angiotensin-II type 1 receptor gene polymorphisms on risk of myocardial infarction.
Telmisartan, ramipril, or both in high-risk Chinese patients: analysis of ONTARGET China data.
Tenascin-C aggravates ventricular dilatation and angiotensin-converting enzyme activity after myocardial infarction in mice.
The angiotensin converting enzyme genetic polymorphism in acute coronary syndrome--ACE polymorphism as a risk factor of acute coronary syndrome.
The angiotensin converting enzyme inhibitor perindopril improves survival after experimental myocardial infarction in pigs.
The angiotensin converting enzyme inhibitor trandolapril has neutral effect on exercise tolerance or functional class in patients with myocardial infarction and reduced left ventricular systolic function.
The angiotensin I-converting enzyme gene polymorphism: implication in hypertension and myocardial infarction.
The angiotensin-converting enzyme (ACE) genetic polymorphism: its relationship with plasma ACE level and myocardial infarction.
The angiotensin-converting enzyme gene I/D polymorphism and heart rate variability following acute myocardial infarction.
The Angiotensin-converting Enzyme Inhibition Post Revascularization Study (APRES).
The anti-ischemic potential of angiotensin-converting enzyme inhibition: insights from the heart outcomes prevention evaluation trial.
The antiatherogenic potential of blocking the renin-angiotensin system.
The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic.
The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Major outomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic.
The brain is a possible target for an angiotensin-converting enzyme inhibitor in the treatment of chronic heart failure.
The concept of cardioreparation: Part 2. Medical implications of cardioreparation.
The D allele of the angiotensin-converting enzyme gene and reperfusion-induced ventricular arrhythmias in patients with acute myocardial infarction.
The D-allele of the ACE polymorphism is related to increased QT dispersion in 609 patients after myocardial infarction.
The DD genotype of the angiotensin converting enzyme gene independently associates with CMR-derived abnormal microvascular perfusion in patients with a first anterior ST-segment elevation myocardial infarction treated with thrombolytic agents.
The DD genotype of the angiotensin-converting enzyme gene is associated with increased mortality in idiopathic heart failure.
The DD genotype of the angiotensin-converting enzyme gene occurs in very low frequency in Australian Aboriginals.
The DD-ACE genotype and cardiovascular disease.
The Divergent Cardiovascular Effects of Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers on Myocardial Infarction and Death.
The effect of ACE gene polymorphisms on Doppler blood flow parameters of carotid and brachial arteries in patients with myocardial infarction.
The Effect of Angiotensin-Converting Enzyme Gene Polymorphisms on the Clinical Efficacy of Perindopril Prescribed for Acute Myocardial Infarction in Chinese Han Patients.
The effect of early perindopril administration on mortality and morbidity in patients with high risk of acute myocardial infarction.
The effect of high plasma levels of angiotensin-converting enzyme (ACE) and plasminogen activator inhibitor (PAI-1) on the reperfusion after thrombolytic therapy in patients presented with acute myocardial infarction.
The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. The Survival of Myocardial Infarction Long-Term Evaluation (SMILE) Study Investigators.
The effects of S-nitrosocaptopril on canine coronary circulation.
The effects of sacubitril/valsartan on coronary outcomes in PARADIGM-HF.
The effects of the angiotensin-converting enzyme inhibitor imidapril on plasma plasminogen activator inhibitor activity in patients with acute myocardial infarction.
The endothelium and the renin-angiotensin system.
The EUROPA trial: design, baseline demography and status of the substudies.
The genetics of hypertension.
The genotype interactions of methylenetetrahydrofolate reductase and renin-angiotensin system genes are associated with myocardial infarction.
The genotype of the angiotensin-converting enzyme gene and global left ventricular dysfunction after myocardial infarction.
The HOPE (Heart Outcomes Prevention Evaluation) Study: the design of a large, simple randomized trial of an angiotensin-converting enzyme inhibitor (ramipril) and vitamin E in patients at high risk of cardiovascular events. The HOPE study investigators.
The I/D polymorphism of angiotensin-converting enzyme gene but not the angiotensinogen gene is associated with insulin response to oral glucose in Japanese.
The II genotype of the angiotensin-converting enzyme gene delays the onset of acute coronary syndromes.
The impact of a dose of the angiotensin receptor blocker valsartan on post-myocardial infarction ventricular remodelling.
The impact of angiotensin-converting-enzyme inhibitors versus angiotensin receptor blockers on 3-year clinical outcomes in patients with acute myocardial infarction without hypertension.
The Impact of Antihypertensive Medications on Bone Mineral Density and Fracture Risk.
The impact of antiplatelet therapy on patients with vasospastic angina: A multicenter registry study of the Japanese Coronary Spasm Association.
THE IMPACT OF CARDIOVASCULAR DRUGS ON GLYCEMIC CONTROL: A REVIEW.
The impact of dose of the angiotensin-receptor blocker valsartan on the post-myocardial infarction ventricular remodeling: study protocol for a randomized controlled trial.
The landscape after PEACE: do all ACE inhibitors act in an identical way?
The long-term impact of the angiotensin-converting enzyme inhibitor trandolapril on mortality and hospital admissions in patients with left ventricular dysfunction after a myocardial infarction: follow-up to 12 years.
The paradoxical association of common polymorphisms of the renin-angiotensin system genes with risk of myocardial infarction.
The place of angiotensin-converting enzyme inhibition after acute myocardial infarction.
The platelet Pl(A2) and angiotensin-converting enzyme (ACE) D allele polymorphisms and the risk of recurrent events after acute myocardial infarction.
The potential use of angiotensin-converting enzyme inhibitors in patients with hyperlipidemia.
The problem of underdosing of angiotensin-converting enzyme inhibitors is markedly overrated: results from a study of patients discharged from hospital after an acute myocardial infarction.
The relationship between angiotensin-converting enzyme (insertion/deletion) gene polymorphism and left ventricular remodeling in acute myocardial infarction.
The relationship between visit-to-visit variability in systolic blood pressure and all-cause mortality in the general population: findings from NHANES III, 1988 to 1994.
The renin angiotensin system and Alzheimer's disease.
The renin-angiotensin system as a risk factor and therapeutic target for cardiovascular and renal disease.
The renin-angiotensin system as a target for therapeutic intervention.
The renin-angiotensin system in left ventricular remodeling.
The renin-angiotensin-aldosterone system: cardiorenal effects and implications for renal and cardiovascular disease states.
The revised role of ACE-inhibition after myocardial infarction in the thrombolytic/primary PCI era.
The role of angiotensin-converting enzyme inhibitors in reducing ventricular remodeling after myocardial infarction.
The role of coronary endothelial function testing in patients suspected for angina pectoris.
The role of existing and newer calcium channel blockers in the treatment of hypertension.
The role of genetic variants in angiotensin I converting enzyme, angiotensinogen and the angiotensin II type-1 receptor in the pathophysiology of heart muscle disease.
The role of locally expressed angiotensin converting enzyme in cardiac remodeling after myocardial infarction in mice.
The Survival and Ventricular Enlargement (SAVE) study: rationale and perspective.
The TRAndolapril Cardiac Evaluation (TRACE) study: rationale, design, and baseline characteristics of the screened population. The Trace Study Group.
The use of angiotensin converting enzyme inhibitors in asymptomatic patients with left ventricular dysfunction after myocardial infarction.
The use of angiotensin-converting enzyme inhibitors after acute myocardial infarction.
The use of angiotensin-converting enzyme inhibitors in patients undergoing coronary artery bypass graft surgery.
The use of angiotensin-converting enzyme inhibitors in patients with acute myocardial infarction in community hospitals. Michigan State University Inter-Institutional Collaborative Heart (MICH) Study Group.
The use of guideline recommended beta-blocker therapy in primary prevention implantable cardioverter defibrillator patients: insight from Danish nationwide registers.
The use of inhibitors of angiotensin-converting enzyme and its relation to events in the postoperative period of CABG.
The value of angiotensin converting enzyme inhibitors for the treatment of patients with left ventricular dysfunction, heart failure or after acute myocardial infarction.
Therapeutic effects of captopril on ischemia and dysfunction of the left ventricle after Q-wave and non-Q-wave myocardial infarction.
Tolerability of ramipril 10 mg daily in high-risk cardiovascular patients in Taiwan: experience from Kaohsiung Medical University Chung-Ho Memorial Hospital.
Towards 2001: will ACE inhibitors have a role in atherosclerosis treatment?
Traditional management of chronic stable angina.
Trandolapril. An update of its pharmacology and therapeutic use in cardiovascular disorders.
Trandolapril: a newer angiotensin-converting enzyme inhibitor.
Translation of clinical trial results into practice.
Treating hypertension and prehypertension in older people: when, whom and how.
Treatment at discharge after myocardial infarction in 2,102 patients. The PRIMA study. Prise en charge de l'Infarctus du Myocarde Aigu.
Treatment of arteriosclerosis.
Treatment of diabetic vasculopathy with rosiglitazone and ramipril: Hype or hope?
Treatment of heart failure.
Treatment of high-risk African American patients: left ventricular dysfunction, heart failure, renal disease, and postmyocardial infarction.
Treatment of hypertension in diabetes mellitus.
Trends and outcomes associated with angiotensin-converting enzyme inhibitors.
Trends in long-term management of survivors of acute myocardial infarction by cardiologists in a government university-affiliated teaching hospital.
Trends in the use of pharmacotherapies for acute myocardial infarction among physicians who design and/or implement randomized trials versus physicians in routine clinical practice: the MILIS-TIMI experience. Multicenter Investigation on Limitation of Infarct Size. Thrombolysis in Myocardial Infarction.
Type 2 diabetes--the pharmacotherapy of glycaemic control and risk factor modification.
UK prospective diabetes study (UKPDS) 14: association of angiotensin-converting enzyme insertion/deletion polymorphism with myocardial infarction in NIDDM.
Underutilization of angiotensin-converting enzyme inhibitors in older patients with Q-wave anterior myocardial infarction in an academic hospital-based geriatrics practice.
Uniformity of captopril benefit in the SAVE Study: subgroup analysis. Survival and Ventricular Enlargement Study.
Update on the management of hypertension: recent clinical trials and the JNC 7.
Update on the use of angiotensin converting enzyme inhibitors and calcium antagonists in postinfarction patients.
Upregulation of cardiac insulin-like growth factor-I receptor by ACE inhibition after myocardial infarction: potential role in remodeling.
Use of angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker therapy to reduce cardiovascular events in high-risk patients: Part 1.
Use of angiotensin-converting enzyme inhibitors at discharge in patients with acute myocardial infarction in the United States: data from the National Registry of Myocardial Infarction 2.
Use of combination evidence-based medical therapy prior to acute myocardial infarction (from the National Registry of Myocardial Infarction-4).
Use of digoxin, diuretics, beta blockers, angiotensin-converting enzyme inhibitors, and calcium channel blockers in older patients in an academic hospital-based geriatrics practice.
Use of Renin-Angiotensin system blockers in acute coronary syndromes: findings from get with the guidelines-coronary artery disease program.
VALIANT (VALsartan In Acute myocardial iNfarcTion) trial.
Validity of cardiovascular prescriptions to the guidelines in the elderly according to the STOPP and START method.
VALsartan In Acute myocardial iNfarcTion (VALIANT) trial: baseline characteristics in context.
Valsartan in the treatment of heart failure or left ventricular dysfunction after myocardial infarction.
Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both.
Valsartan: the past, present and future.
Value of digoxin in heart failure and sinus rhythm: new features of an old drug?
Vascular and haemostatic gene polymorphisms associated with non-fatal myocardial infarction: a critical review.
Vascular remodeling during healing after myocardial infarction in the dog model: effects of reperfusion, amlodipine and enalapril.
Vascular renin-angiotensin-system, endothelial function and atherosclerosis?
Ventricular dilatation in the absence of ACE inhibitors: influence of haemodynamic and neurohormonal variables following myocardial infarction.
Ventricular remodeling after myocardial infarction. Experimental observations and clinical implications.
Ventricular remodeling and transforming growth factor-beta 1 mRNA expression after nontransmural myocardial infarction in rats: effects of angiotensin converting enzyme inhibition and angiotensin II type 1 receptor blockade.
Ventricular remodeling following myocardial infarction.
Voltage-programming-based capillary gel electrophoresis for the fast detection of angiotensin-converting enzyme insertion/deletion polymorphism with high sensitivity.
What can we learn from Europe?
What have the ACE-inhibitor trials in postmyocardial patients with left ventricular dysfunction taught us?
What is the optimal initiation timing of angiotensin converting enzyme inhibitor treatment for maximum benefits in acute myocardial infarction patients?
What is the role of angiotensin-converting enzyme inhibitors in congestive heart failure and after myocardial infarction?
Which patient benefits from early angiotensin-converting enzyme inhibition after myocardial infarction? Results of one-year serial echocardiographic follow-up from the Captopril and Thrombolysis Study (CATS).
[ACE inhibitor or ATII receptor blocker in heart failure and myocardial infarction?]
[ACE inhibitors after myocardial infarction: close-up on zofenopril.]
[ACE inhibitors use in patients with acute coronary syndrome]
[Activation of the cardiac angiotensin-converting enzyme after myocardial infarction and its role in ventricular remodeling]
[Acute myocardial infarct and left ventricular dysfunction. Morphologic bases, clinical aspects and pharmacologic prevention]
[Allelic variants of genes: angiotensin I-converting enzyme (ACE), angiotensin-II type 1 receptor (AT1R), methylenetetrahydrofolate reductase and left ventricular mass in patients with myocardial infarction]
[Analysis of angiotensin converting enzyme (ACE) polymorphism in patients with myocardial infarction in the Polish population]
[Angiotensin converting enzyme inhibitors during acute phase of myocardial infarct]
[Angiotensin converting enzyme inhibitors in acute period of myocardial infarction: the place of zofenopril]
[Angiotensin converting enzyme inhibitors in secondary prevention of myocardial infarction]
[Angiotensin-converting enzyme inhibition and cardiovascular prevention: more than twenty years of clinical success]
[Angiotensin-converting enzyme inhibitors :from vasoactive drugs to cardiovascular prevention tools]
[Angiotensin-converting enzyme inhibitors after a myocardial infarct]
[Angiotensin-converting enzyme inhibitors following a myocardial infarct: clinical abd echographic indications]
[Association between myocardial infarction and angiotensin converting enzyme gene polymorphism in young patients]
[Association of polymorphic markers I/D of gene ACE and A1166C of gene AT2R1 with ischemic chronic heart failure in the Russian and Tatar populations of Bashkortostan Republic]
[Can ventricular dysfunction be prevented or delayed in course?]
[Carboxycathepsin activity in myocardial infarct]
[Clinical sequelae of tissue angiotensin converting enzyme inhibition: practicability of use in ischemic heart disease]
[Comparative eficacy of antihypertensive therapy in patients with arterial hypertension and various sensitivity to salt].
[Converting enzyme inhibitors in acute myocardial infarct and heart failure]
[Cross-sectional study of choice of drug therapy in the acute phase of treatment in acute myocardial infarct--part 1]
[Development and analyses of evaluation criteria for meta-analysis-relationship between renin-angiotensin system inhibitor and diabetes mellitus].
[Early application of angiotensin converting enzyme inhibitors in acute myocardial infarction]
[Effect of angiotensin converting enzyme inhibitor lisinopril on sympathetic heart rate response during exercise in the early phase of acute myocardial infarction]
[Effect of angiotensin converting enzyme inhibitor spirapril on dimensions of experimental myocardial infarction, development of ischemic tachyarrhythmias, and ischemic adaptation of the heart]
[Effect of angiotensin converting enzyme inhibitors on oxidative stress, endothelial function in patients with myocardial infarction]
[Effect of chronic therapy with low dose of angiotensin converting enzyme inhibitors on mortality in patients with left ventricular dysfunction after acute myocardial infarction]
[Effect of combined beta-blocker and angiotensin-converting enzyme inhibitor treatment on 1-year survival after acute myocardial infarction: findings of the PRIAMHO-II registry]
[Effect of perindopril on left ventricular structural and functional parameters in patients with preserved systolic function after myocardial infarction. Relation to polymorphism of angiotensin converting enzyme gene]
[Effect of the angiotensin-converting enzyme inhibitor ramipril on the processes of lipid peroxidation on the status of the endogenous antioxidant system in patients with myocardial infarction]
[Effects of ramipril and spironolactone on ventricular remodeling after acute myocardial infarction: randomized and double-blind study]
[Establishment and validation of a new predictive equation with multiple risk factors for the development of cardiorenal syndrome type 1 in patients with acute myocardial infarction].
[Favorable effect of trimetazidine on clinical state and left ventricular function postinfarction period.]
[GENES ALLELE STATUS OF ANGIOTENSINCONVERTING ENZYME (I/D) AND ENDOTHELIAL NITRIC OXIDE SYNTHASE (894 G > T) IN PATIENTS WITH ACUTE CORONARY SYNDROME].
[Genetic polymorphism of the angiotensin I converting enzyme and morbi-mortality after myocardial infarction]
[Gibbs-Sampler approach for meta-analysis of multiple clinical trials using generalized linear model with random-effects]
[Growth stimulating properties of angiotensin II on the heart: consequences for therapy of heart failure]
[Heart and brain: are the risk factors the same? Are the results of primary and secondary trials comparable?]
[Heart failure in acute myocardial infarction]
[I/D polymorphism in the angiotensin-converting enzyme gene in men with myocardial infarction at young age]
[I/D polymorphism of angiotensin converting enzyme gene and myocardial infarction]
[Interaction between antiplatelet agents and angiotensin-converting enzyme inhibitors]
[Interaction of angiotensin converting enzyme inhibitors with nonsteroidal antiinflammatory drugs]
[JMIC-B study and its sub-analyses: effect of nifedipine in Japanese hypertensive patients with coronary artery disease]
[Left heart insufficiency following acute myocardial infarct]
[Myocardial injury in coronavirus disease 19 (Covid-19): main pathophysiological mechanisms and clinical utility of cardiac biomarkers].
[Neurohumoral activation and remodeling after acute myocardial infarct and the effect of angiotensin-converting enzyme inhibitors]
[Pathogenetic mechanisms of the development of cardiac rhythm disorders in the acute period of myocardial infarction]
[Pharmacological correction of hyperactivity of Renin-Angiotensin-aldosteron system.]
[Polymorphism of the angiotensin I-converting enzyme gene in diabetic retinopathy patients and type 2 diabetes mellitus patients with myocardial infarction]
[Prevention and treatment of ischemic heart disease in patients with diabetes mellitus]
[Rationale, characteristics and study design of PREAMI (Perindopril and Remodelling in the Elderly with Acute Myocardial Infraction)]
[Refractory shock after converting enzyme inhibitor administration. Usefulness of angiotensin II]
[Remodeling of the left ventricle after myocardial infarction]
[Remodeling with angiotensin-converting enzyme inhibitors: from GISSI to PREAMI]
[Renal failure in patients after acute coronary syndrome--does it change the standards? From theory to practice]
[Renin-angiotensin system and its role in cardiovascular physiopathology and therapy]
[Resistance to ACE inhibitors. Myth or reality?]
[Risk factors for mortality in abdominal aortic surgery]
[Role of structural polymorphism of the angiotensin-converting enzyme gene in the development of myocardial infarction]
[Secondary prevention after an acute myocardial infarct. Adrenergic beta-blockers, angiotensin-converting enzyme inhibitors and statins for everyone?]
[Secondary prevention of ischemic heart disease: pharmacological treatment after myocardial infarction according to follow-up protocol]
[Secondary prevention of myocardial infarct]
[Synthesis of renin and angiotensin-converting enzyme in human heart]
[The ALLHAT study (antihypertensive and lipid-lowering treatment to prevent heart attack trial): primary antihypertensive agents - diuretics vs calcium channel blockers vs angiotensin-converting enzyme inhibitors]
[The changes in renin-angiotensin-aldosterone system in acute myocardial infarction and the effects of converting enzyme inhibitor-captopril]
[The changing prognosis of myocardial infarction in the reperfusion era: implications for evaluation and management of ventricular arrhythmias]
[The genes of atherosclerosis and cardiovascular diseases].
[The impact of nitrates and mono-therapy and nitrates combined with angiotensin converting enzyme inhibitors on left ventricular remodeling and exercise capacity in patients after acute myocardial infarction]
[The polymorphism of the angiotensin-converting enzyme gene in patients with hypertension, left ventricular hypertrophy and the development of a myocardial infarct at a young age. Preliminary report]
[The relationship of angiotensin I-converting enzyme gene polymorphism with diabetic retinopathy and diabetes myocardial infarction]
[The role of DNA polymorphism in the renin-angiotensin system and the pathogenesis of cardiovascular diseases]
[The use of angiotensin converting enzyme inhibitors in patients after myocardial infarction]
[The use of angiotensin-converting enzyme inhibitor benazepril in acute period of myocardial infarction]
[Treatment by angiotensin converting enzyme inhibitors after myocardial infarction. What did the clinical trials teach us?]
[Treatment of heart failure with angiotensin converting enzyme inhibitors]
[Treatment of patients with ischemic heart disease and diabetes]
[Treatment with angiotension converting enzyme inhibitors]
[Use of captopril and other angiotensin-converting enzyme inhibitors in patients with myocardial infarction]
[Value of pleiotropic effects of angiotensin-converting enzyme inhibitors].
Myocardial Ischemia
2009 Canadian Hypertension Education Program recommendations: the scientific summary--an annual update.
A prospective evaluation of an angiotensin-converting-enzyme gene polymorphism and the risk of ischemic heart disease.
A simplified approach to the management of non-ST-segment elevation acute coronary syndromes.
Acute effects of the ACE inhibitor lisinopril on cardiac electrophysiological parameters of isolated guinea pig hearts.
Age, comorbidity and hypertensive co-medication do not affect cardiovascular tolerability of 10 mg alfuzosin once daily.
Angiotensin converting enzyme gene polymorphism and the risk and extent of ischemic heart disease among Turkish patients.
Angiotensin gene polymorphism as a determinant of posttransplantation renal dysfunction and hypertension.
Angiotensin II Effects on Ischemic Focal Ventricular Tachycardia are Predominantly Mediated Through Myocardial AT2 Receptor.
Angiotensin-converting enzyme activity in myocardial ischemia during exercise testing.
Angiotensin-converting enzyme gene polymorphism in ischemic heart disease.
Angiotensin-converting enzyme inhibition by enalapril: a novel approach to reduce ischemia/reperfusion damage after experimental liver transplantation.
Angiotensin-converting enzyme inhibitors after myocardial infarction: indications and timing.
Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for treatment of ischemic heart disease: Future research needs prioritization.
Angiotensin-converting-enzyme genotype and ischemic heart disease.
Anti-ischemic effects of angiotensin- converting enzyme inhibition in hypertension.
Antiarrhythmic effects of the angiotensin converting enzyme inhibitor perindoprilat in a pig model of acute regional myocardial ischemia.
Antihypertensive and cardioprotective effects after angiotensin-converting enzyme inhibition: role of kinins.
Association of Angiotensin converting enzyme gene insertion / deletion polymorphism with risk of ischemic heart disease in a population of smokers in southern India.
Association of angiotensin I-converting enzyme gene polymorphism with myocardial ischemia and patency of infarct-related artery in patients with acute myocardial infarction.
Association of angiotensin-converting enzyme inhibitor therapy initiation with a reduction in hemoglobin levels in patients without renal failure.
AT1-receptor blockade in experimental myocardial ischemia/reperfusion.
Beneficial effects of combined benazepril-amlodipine on cardiac nitric oxide, cGMP, and TNF-alpha production after cardiac ischemia.
Candidate genes of cerebral infarction and traditional classification in Koreans with cerebral infarction.
Cardioprotection by angiotensin-converting enzyme (ACE) inhibitors.
Cardioprotective effects of ACE inhibitors: experimental proof and clinical perspectives.
Cardioprotective effects of enalapril in acute myocardial ischemia.
Cardioprotective properties of bradykinin: role of the B(2) receptor.
Combination inhibition of the renin-angiotensin system: is more better?
Combination of a calcium antagonist, verapamil, with an angiotensin converting enzyme inhibitor, trandolapril, in experimental myocardial ischemia and reperfusion: antiarrhythmic and hemodynamic effects of chronic oral pretreatment.
Coronary hemodynamic effects of angiotensin inhibition by captopril and teprotide in patients with congestive heart failure.
Determinants of heart rate variability in chronic hemodialysis patients.
Determinants of Utility Based on the EuroQol Five-Dimensional Questionnaire in Patients with Chronic Heart Failure and Their Change Over Time: Results from the Swedish Heart Failure Registry.
Dilation of epicardial arteries in conscious dogs induced by angiotensin-converting enzyme inhibition with enalaprilat.
Does aspirin attenuate the beneficial effects of angiotensin-converting enzyme inhibition in heart failure?
Effect of acute and chronic zofenopril administration on cardiac gene expression.
Effect of adherence to evidence-based therapy after acute myocardial infarction on all-cause mortality.
Effect of dementia on the use of drugs for secondary prevention of ischemic heart disease.
Effects of angiotensin-converting enzyme inhibition on exercise-induced angina and ST segment depression in patients with microvascular angina.
Effects of antihypertensive therapy on hypertensive heart disease.
Effects of benazeprilat on left ventricular systolic and diastolic function and neurohumoral status in patients with ischemic heart disease.
Effects of early angiotensin-converting enzyme inhibition in a pig model of myocardial ischemia and reperfusion.
Enhanced pressor response to angiotensin I in normotensive men with the deletion genotype (DD) for angiotensin-converting enzyme.
Fibroblast Growth Factor-23, Cardiovascular Prognosis, and Benefit of Angiotensin-Converting Enzyme Inhibition in Stable Ischemic Heart Disease.
From evidence to rationale: cardiovascular protection by angiotensin II receptor blockers compared with angiotensin-converting enzyme inhibitors.
Hydrogen sulfide and vascular regulation - An update.
Impact of opinion leader-endorsed evidence summaries on the quality of prescribing for patients with cardiovascular disease: a randomized controlled trial.
Importance of the flow perfusion deficit in the response to captopril in experimental myocardial infarction.
Increased angiotensin-converting enzyme activity in coronary artery specimens from patients with acute coronary syndrome.
Increased IGF1 levels in relation to heart failure and cardiovascular mortality in an elderly population: impact of ACE inhibitors.
Ineffectiveness of angiotensin converting enzyme inhibition (enalapril) on overt and silent myocardial ischemia in vasospastic angina and comparison with verapamil.
Influence of angiotensin converting enzyme inhibitors on stable myocardial ischemia in menopausal cardiac patients.
Inhibition of the renin-angiotensin-aldosterone system to prevent ischemic and atherothrombotic events.
Insertion/Deletion polymorphism of Angiotensin converting enzyme gene in kawasaki disease.
Left Ventricular global longitudinal strain predicts heart failure readmission in acute decompensated heart failure.
Long-term angiotensin-converting enzyme inhibition reduces plasma asymmetric dimethylarginine and improves endothelial nitric oxide bioavailability and coronary microvascular function in patients with syndrome X.
Long-term anti-ischemic effects of angiotensin-converting enzyme inhibition in patients after myocardial infarction. The Captopril and Thrombolysis Study (CATS) Investigators.
Long-term clinical experience with zofenopril.
Long-term outcomes and independent predictors of mortality in patients presenting to emergency departments with acute heart failure in Beijing: a multicenter cohort study with a 5-year follow-up.
Long-term treatment with perindopril ameliorates dobutamine-induced myocardial ischemia in patients with coronary artery disease.
Management of hypertension in diabetes mellitus.
Marked bradykinin-induced tissue plasminogen activator release in patients with heart failure maintained on long-term angiotensin-converting enzyme inhibitor therapy.
Metabolic therapy for the treatment of ischemic heart disease: reality and expectations.
Myocardial ischemia and angiotensin-converting enzyme inhibition: comparison of ischemia during mental and physical stress.
New aspects on angiotensin-converting enzyme: from gene to disease.
Patterns of use of perioperative angiotensin-converting enzyme inhibitors in coronary artery bypass graft surgery with cardiopulmonary bypass: effects on in-hospital morbidity and mortality.
Perindopril chronically inhibits angiotensin-converting enzyme in both the endothelium and adventitia of the internal mammary artery in patients with ischemic heart disease.
Polymorphism of angiotensin converting enzyme, angiotensinogen, and apolipoprotein E genes in a Japanese population with cerebrovascular disease.
Polymorphism of angiotensin-converting enzyme, angiotensinogen, and apolipoprotein E genes in Korean patients with cerebral infarction.
Polymorphism of the angiotensin I converting enzyme gene in essential hypertensive patients.
Polymorphism of the apolipoprotein E and angiotensin-converting enzyme genes in Japanese subjects with silent myocardial ischemia.
Possible synergic effect of angiotensin-I converting enzyme gene insertion/deletion polymorphism and angiotensin-II type-1 receptor 1166A/C gene polymorphism on ischemic heart disease in patients with Kawasaki disease.
Poststroke dementia : clinical features and risk factors.
Potential role of angiotensin-converting enzyme inhibition in myocardial ischemia and current clinical trials.
Potential role of renin-angiotensin system blockade for preventing myocardial ischemia/reperfusion injury and remodeling after myocardial infarction.
Potential use of ACE inhibitors after acute myocardial infarction.
Pretreatment with captopril improves myocardial recovery after cardioplegic arrest.
Prevalence and Predictors of Statin Treatment Among Patients With Chronic Heart Failure at a Tertiary-Care Center in Thailand.
Protection against ischemia/reperfusion injury and myocardial dysfunction by antisense-oligodeoxynucleotide directed at angiotensin-converting enzyme mRNA.
Protective effect of angiotensin converting enzyme inhibitors (CEI): captopril and perindopril on vulnerability to ventricular fibrillation during myocardial ischemia and reperfusion in rat.
Protective effects of captopril and enalapril on myocardial ischemia and reperfusion damage of rat.
Reduction of exercise-induced myocardial ischemia during add-on treatment with the angiotensin-converting enzyme inhibitor enalapril in patients with normal left ventricular function and optimal beta blockade.
Reduction of myocardial infarct size by ramiprilat is independent of angiotensin II synthesis inhibition.
Reduction of myocardial infarct size in rabbits by ramiprilat: reversal by the bradykinin antagonist HOE 140.
Risk of cardiovascular events after initiation of long-acting bronchodilators in patients with chronic obstructive lung disease: A population-based study.
Role of angiotensin-converting enzyme inhibitors in the coronary artery bypass patient.
Role of coronary vasoconstriction in ischemic heart disease and search for novel therapeutic targets.
Role of inflammation and endothelial dysfunction in the pathogenesis of cardiac syndrome X.
Sublingual administration of captopril in patients with acute myocardial ischemia.
Summary of AHRQ's comparative effectiveness review of angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers added to standard medical therapy for treating stable ischemic heart disease.
Sustained augmentation of parasympathetic tone with angiotensin-converting enzyme inhibition in patients with congestive heart failure.
Syncope caused by iatrogenic hyperkalemia.
Systematic Review: Comparative Effectiveness of Angiotensin-Converting Enzyme Inhibitors or Angiotensin II-Receptor Blockers for Ischemic Heart Disease.
Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors or angiotensin II-receptor blockers for ischemic heart disease.
The antiarrhythmic potential of angiotensin II antagonism: experience with losartan.
The effects of ACE inhibitors on exercise capacity in the treatment of congestive heart failure.
The effects of angiotensin-converting enzyme inhibition on endothelial dysfunction: potential role in myocardial ischemia.
The renin-angiotensin system during acute myocardial ischemia in dogs.
The value of angiotensin-I-converting enzyme determinations in malignant and other diseases.
Therapeutic effects of captopril on ischemia and dysfunction of the left ventricle after Q-wave and non-Q-wave myocardial infarction.
Tissue kallikrein is involved in the cardioprotective effect of AT1-receptor blockade in acute myocardial ischemia.
Tissue-advanced glycation end product concentration in dialysis patients.
Treating the Patient with Kidney Failure to Reduce Cardiovascular Disease Risk.
Treatment of angina and microvascular coronary dysfunction.
Use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in clinical practice.
Variability in Atherosclerotic Disease Progression within the Infrainguinal Arterial Circulation is Dependent on Both Patient and Anatomical Factors.
[Adherence to cardioprotective medications in coronary heart disease]
[Angiotensin converting enzyme gene and exercise-induced silent myocardial ischemia in type 2 diabetes mellitus]
[Angiotensin converting enzyme inhibitors and ischemic heart diseases]
[Angiotensin converting enzyme inhibitors and treatment of stable ischemic heart disease: afterword for the European Society of Cardiology recommendations]
[Angiotensin converting enzyme inhibitors in ischemic heart disease]
[Angiotensin converting enzyme inhibitors in patients with ischemic heart disease: in all cases or in high risk of complications]
[Angiotensin-converting enzyme inhibitors and ischemic heart disease]
[Assessment of effects of angiotensin converting enzyme inhibitor perindopril on function of endothelium of arterial vessels in patients with ischemic heart disease and hypertension]
[Association between myocardial infarction and angiotensin converting enzyme gene polymorphism in young patients]
[Clinical Efficacy of Combination Therapy With Trimetazidine and Angiotensin Converting Enzyme Inhibitors in Patients With Hypertension and Ischemic Heart Disease Associated With Type II Diabetes]
[Clinical sequelae of tissue angiotensin converting enzyme inhibition: practicability of use in ischemic heart disease]
[Clinico-economical efficacy of angiotensin converting enzyme inhibitors in patients with arterial hypertension and ischemic heart disease]
[Control of myocardial ischemia in patients with effort angina and polyvascular atherosclerotic involvement].
[Deletion polymorphism of the angiotensin I-converting enzyme gene associates with increased risk for ischemic heart diseases in the Japanese]
[Effect of the angiotensin converting enzyme inhibitor, perindopril, on heart rhythm variability and adrenoreactivity in patients with ischemic heart disease associated with duodenal ulcer]
[Effects of inhibitors of the angiotensin-converting enzyme on endothelial dysfunction in patients with stable angina pectoris]
[Establishment and validation of a new predictive equation with multiple risk factors for the development of cardiorenal syndrome type 1 in patients with acute myocardial infarction].
[Evaluation of influence of long-term therapy with angiotensin converting enzyme inhibitor lisinopril on morphofunctional parameters of the left ventricle peripheral artery endothelium disfunction, and painless myocardial ischemia in premenopausal women with hypertension]
[Fixed-dose compounds and the secondary prevention of ischemic heart disease].
[Gene loci and polymorphisms of angiotensin II receptor]
[Genes in rennin-angiotensin system]
[Genotypes of ACE gene in Kazakh and Uygur patients with ischemic heart disease]
[Hyperkalemia as a limiting factor in the use of drugs that block the Renin Angiotensin Aldosterone System (RAAS)].
[Ischemic heart disease with low risk of vascular complications -- a novel indication for angiotensin converting enzyme inhibitors (results of EUROPA trial)]
[Pharmacogenomic control of angiotensin converting enzyme gene I/D polymorphism predominant risk factor of development of chronic heart failure and target of enalapril treatment].
[Polymorphism of genes coding for angiotensin I converting enzyme and methylenetetrahydrofolate reductase in patients with ischemic heart disease]
[Polymorphism of the promotor region of the angiotensinogen gene and the gene for angiotensin I-converting enzyme in arterial hypertension and myocardial ischemia of the Kazakh ethnic groups]
[Possibilities of correction of coronary and myocardial reserves in patients with ischemic heart disease by Angiotensin converting enzyme inhibitor perindopril.]
[Prevention and treatment of ischemic heart disease in patients with diabetes mellitus]
[Role of structural polymorphism of the angiotensin-converting enzyme gene in the development of myocardial infarction]
[Stiffness of the Arterial Wall and Central Hemodynamics During Long-Term Combination Antihypertensive Therapy].
[Suppression of angiotensin-converting enzyme and myocardial ischemia]
[The changing prognosis of myocardial infarction in the reperfusion era: implications for evaluation and management of ventricular arrhythmias]
[The use of angiotensin-converting enzyme inhibitors in patients with ischemic heart disease]
Myocardial Reperfusion Injury
Attenuation of myocardial reperfusion injury by sulfhydryl-containing angiotensin converting enzyme inhibitors.
Inhibition of angiotensin-converting enzyme reduces rat liver reperfusion injury via bradykinin-2-receptor.
Myocardial Stunning
Angiotensin converting enzyme inhibitors improve contractile function of stunned myocardium by different mechanisms of action.
Attenuation of myocardial stunning by the ACE inhibitor ramiprilat through a signal cascade of bradykinin and prostaglandins but not nitric oxide.
Cardioprotection by ACE inhibitors in myocardial ischaemia/reperfusion. The importance of bradykinin.
Issues surrounding a local cardiac renin system and the beneficial actions of angiotensin-converting enzyme inhibitors in ischemic myocardium.
Left ventricular function after coronary artery reperfusion.
Report of takotsubo cardiomyopathy occurring during cardiopulmonary bypass.
Takotsubo Cardiomyopathy: Case Series and Literature Review.
Myocarditis
Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists in experimental myocarditis.
Beneficial effects of captopril in acute coxsackievirus B3 murine myocarditis.
Captopril prevents experimental autoimmune myocarditis.
Comparative effects of angiotensin II receptor blockade (candesartan) with angiotensin-converting enzyme inhibitor (quinapril) in rats with dilated cardiomyopathy.
Comparative effects of losartan, captopril, and enalapril on murine acute myocarditis due to encephalomyocarditis virus.
Comparison of angiotensin converting enzyme inhibition and angiotensin II receptor blockade for the prevention of experimental autoimmune myocarditis.
Data-mining analyses of pharmacovigilance signals in relation to relevant comparison drugs.
Dilated Cardiomyopathy Risk in Patients with Coronavirus Disease 2019: How to Identify and Characterise it Early?
Enhanced expression of superoxide dismutase messenger RNA in viral myocarditis. An SH-dependent reduction of its expression and myocardial injury.
Lessons learned from experimental myocarditis.
Prolonged Captopril Therapy in Murine Viral Myocarditis.
Rational drug correction of systemic inflammatory response syndrome in severe experimental heart failure.
Reduction of cardiac endothelin-1 by angiotensin II type 1 receptor antagonist in viral myocarditis of mice.
Treatment of experimental myocarditis via modulation of the renin-angiotensin system.
Viral myocarditis: 1917-2020: From the Influenza A to the COVID-19 pandemics.
[Myocardial injury in coronavirus disease 19 (Covid-19): main pathophysiological mechanisms and clinical utility of cardiac biomarkers].
Myoclonus
[Myoclonus and angiotensin converting enzyme inhibitors]
Myositis
Safety of drugs commonly used to treat hypertension, dyslipidemia, and type 2 diabetes (the metabolic syndrome): part 1.
Myotonic Dystrophy
Management of Cardiac Involvement in NeuroMuscular Diseases: Review.
Nasal Obstruction
Role of neutral endopeptidase and kininase II on substance P-induced increase in nasal obstruction in patients with allergic rhinitis.
Nasal Polyps
The Impact of Angiotensin-Modulating Antihypertensives on Time Interval to Revision Surgery for Nasal Polyps.
Neoplasm Metastasis
Angiotensin-Converting Enzyme Gene Deletion Polymorphism is Associated with Lymph Node Metastasis in Colorectal Cancer Patients in a Chinese Population.
Angiotensin-converting enzyme inhibitors may affect pulmonary function in lymphangioleiomyomatosis.
Associations of angiotensin-converting enzyme inhibitor or angiotensin receptor blocker use with colorectal cancer risk in the Women's Health Initiative.
Changes in the renin angiotensin system during the development of colorectal cancer liver metastases.
Clinical Outcomes of Chemotherapy for Diabetic and Nondiabetic Patients With Pancreatic Cancer: Better Prognosis With Statin Use in Diabetic Patients.
Collagen fibril organization within rat vertebral bone modified with metastatic involvement.
Dickkopf-1 (DKK-1) stimulated prostate cancer growth and metastasis and inhibited bone formation in osteoblastic bone metastases.
Ectopeptidases in tumour biology: a review.
Elevated Microdamage Spatially Correlates with Stress in Metastatic Vertebrae.
Evaluating the effects of mixed osteolytic/osteoblastic metastasis on vertebral bone quality in a new rat model.
Expression and function of the ACE2/angiotensin(1-7)/Mas axis in osteosarcoma cell lines U-2 OS and MNNG-HOS.
Expression of the Local Angiotensin II System in Gastric Cancer May Facilitate Lymphatic Invasion and Nodal Spread.
Impact of Angiotensin I-converting Enzyme Inhibitors and Angiotensin II Type-1 Receptor Blockers on Survival of Patients with NSCLC.
Inhibition of gelatinase A (MMP-2) by batimastat and captopril reduces tumor growth and lung metastases in mice bearing Lewis lung carcinoma.
Interactions of the renin-angiotensin system in colorectal cancer and metastasis.
Intra-arterial infusion of Tc-99m MAA: a case of highly selective targeting of liver metastases and shunting.
Local treatment of mixed osteolytic/osteoblastic spinal metastases: is photodynamic therapy effective?
Löfgren Syndrome with Hypercalcemia and Neuroendocrinological Involvement: A Case Report.
Mechanical behavior of metastatic vertebrae are influenced by tissue architecture, mineral content, and organic feature alterations.
New bone formation and osteolysis by a metastatic, highly invasive canine prostate carcinoma xenograft.
Osteolytic and mixed cancer metastasis modulates collagen and mineral parameters within rat vertebral bone matrix.
Polymorphism of angiotensin I-converting enzyme gene is related to oral cancer and lymph node metastasis in male betel quid chewers.
Predictors of distant metastasis and mortality in patients with stage II colorectal cancer.
Retrospective clinical study of renin-angiotensin system blockers in lung cancer patients with hypertension.
Risk factors for developing hyponatremia in thyroid cancer patients undergoing radioactive iodine therapy.
Risk Factors for Emergency Room and Hospital Care Among Patients With Solid Tumors on Immune Checkpoint Inhibitor Therapy.
The ACE gene polymorphism is associated with the incidence of gastric cancer among H. pylori seropositive subjects with atrophic gastritis.
The ectopeptidases CD10, CD13, CD26, and CD143 are upregulated in gastric cancer.
The Effect of a Histone Deacetylase Inhibitor (AR-42) on Canine Prostate Cancer Growth and Metastasis.
The impact of metastasis on the mineral phase of vertebral bone tissue.
The number of lymph node metastases in gastric cancer correlates with the angiotensin I-converting enzyme gene insertion/deletion polymorphism.
The role of angiotensin II in cancer metastasis: Potential of renin-angiotensin system blockade as a treatment for cancer metastasis.
Zoledronic acid decreased osteolysis but not bone metastasis in a nude mouse model of canine prostate cancer with mixed bone lesions.
Neoplasms
2012 Brazilian Society of Rheumatology Consensus on the management of comorbidities in patients with rheumatoid arthritis.
A case of renin-producing juxtaglomerular tumor: effect of ACE inhibitor or angiotensin II receptor antagonist.
A human GRPr-transfected Ace-1 canine prostate cancer model in mice.
A novel canine model for prostate cancer.
A Novel UDP-Glycosyltransferase of Rhodiola crenulata Converts Tyrosol to Specifically Produce Icariside D2.
A renin-secreting tumour sensitive to changes in central blood volume (presumably via sympathetics) but not to circulating angiotensin II.
A renin-secreting tumour with severe hypertension and cardiovascular disease: a diagnostic and therapeutic challenge.
ACE Inhibitor Therapy Does Not Influence the Survival Outcomes of Patients with Colorectal Liver Metastases Following Liver Resection.
ACE2/Angiotensin-(1-7)/Mas receptor axis in human cancer: Potential role for pediatric tumors.
Acquired Angioedema Associated with Primary Antiphospholipid Syndrome in a Patient with Antithrombin III Deficiency.
Activity of angiotensin-converting enzyme in pleural fluid and serum in non-sarcoid, non-tuberculous pleural effusion.
Activity of serum angiotensin-converting enzyme as a tumour marker of hepatocellular carcinoma.
Adiponectin expression and the cardioprotective role of the vitamin D receptor activator paricalcitol and the angiotensin converting enzyme inhibitor enalapril in ApoE-deficient mice.
Age-Dependent Changes in the Pulmonary Renin-Angiotensin System Are Associated With Severity of Lung Injury in a Model of Acute Lung Injury in Rats.
Amelioration of carcinogenesis and tumor growth in the rat liver by combination of vitamin K2 and angiotensin-converting enzyme inhibitor via anti-angiogenic activities.
Aminopeptidases and angiotensin I-converting enzyme activities in primary human lung tumors and lung parenchyma.
An updated meta-analysis on association between angiotensin I-converting enzyme gene insertion/deletion polymorphism and cancer risk.
Analysis of risk factors for chronic subdural haematoma recurrence after burr hole surgery: Optimal management of patients on antiplatelet therapy.
Angioedema in a patient with renal cell cancer treated with everolimus in combination with an angiotensin-converting enzyme inhibitor.
Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonist attenuate tumor growth via polarization of neutrophils toward an antitumor phenotype.
Angiotensin converting enzyme inhibitors for cancer treatment?
ANGIOTENSIN CONVERTING ENZYME INHIBITORS IMPROVE HEPATIC STEATOSIS BY MODULATING EXPRESSION OF TUMOR NECROSIS FACTOR-Alpha, INTERLEUKIN-6 AND ADIPONECTIN RECEPTOR-2 IN RATS WITH TYPE 2 DIABETES.
Angiotensin converting enzyme inhibitors suppress production of tumor necrosis factor-alpha in vitro and in vivo.
Angiotensin converting enzyme-independent, local angiotensin II-generation in human pancreatic ductal cancer tissues.
Angiotensin converting enzyme: a tumour marker in malignant histiocytosis.
Angiotensin I-converting enzyme gene insertion/deletion polymorphism and endometrial human cancer in normotensive and hypertensive women.
Angiotensin I-converting enzyme gene plays a crucial role in the pathology of carcinomas in colorectal cancer.
Angiotensin I-converting enzyme gene polymorphism modifies the smoking-cancer association: the Hisayama Study.
Angiotensin I-converting enzyme inhibitors/angiotensin II receptor blockers may reduce tumor recurrence in left-sided and early colorectal cancers.
Angiotensin I-Converting Enzyme Insertion/Deletion Polymorphism and Increased Risk of Gall Bladder Cancer in Women.
Angiotensin II Receptor Blockers and Cancer Risk: A Meta-Analysis of Randomized Controlled Trials.
Angiotensin II Type 1 Receptor Antagonist as an Angiogenic Inhibitor in Urogenital Cancer.
Angiotensin II type 1 receptor expression in two cases of juxtaglomerular cell tumor: correlation to negative feedback of renin secretion by angiotensin II.
Angiotensin II-induced hypertension is modulated by nuclear factor-?Bin the paraventricular nucleus.
Angiotensin inhibition and malignancies: a review.
Angiotensin receptors: a new role in cancer?
Angiotensin type 1a receptor signaling-dependent induction of vascular endothelial growth factor in stroma is relevant to tumor-associated angiogenesis and tumor growth.
Angiotensin-converting enzyme and the tumor microenvironment: mechanisms beyond angiogenesis.
Angiotensin-converting enzyme gene polymorphism and digestive system cancer risk: A meta-analysis based on 9656 subjects.
Angiotensin-converting enzyme inhibitor therapy and colorectal cancer risk.
Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers as therapeutic options in the treatment of renal cancer: A meta-analysis.
Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in cancer progression and survival: a systematic review.
Angiotensin-converting enzyme inhibitors and risk of esophageal and gastric cancer: a nested case-control study.
Angiotensin-converting enzyme inhibitors and the risk of cancer: a population-based cohort study in Denmark.
Angiotensin-converting enzyme inhibitors enhance the effect of cyclooxygenase inhibitors on breast cancer: a nationwide case-control study.
Angiotensin-converting enzyme inhibitors may affect pulmonary function in lymphangioleiomyomatosis.
Angiotensin-converting enzyme inhibitors, calcium channel blockers, and breast cancer.
Angiotensin-converting enzyme insertion/deletion gene polymorphisms and the risk of glioma in an Algerian population.
Angiotensin-converting enzyme insertion/deletion gene polymorphisms is associated with risk of glioma in a Chinese population.
Angiotensin-converting-enzyme inhibitors suppress synthesis of tumour necrosis factor and interleukin 1 by human peripheral blood mononuclear cells.
Angiotensin-I converting enzyme inhibitors as potential anti-angiogenic agents for cancer therapy.
Angiotensin-I converting enzyme inhibitors suppress angiogenesis and growth of esophageal carcinoma xenografts.
Angiotensin-I-converting enzyme in cancer patients.
Antecedent cancer in Takotsubo syndrome predicts both cardiovascular and long-term mortality.
Anti-cancer actions of a recombinant antibody (R6313/G2) against the angiotensin II AT1 receptor.
Anti-hypertensive drugs and skin cancer risk: a review of the literature and meta-analysis.
Antihypertensive Drugs and the Risk of Cancer: A Nationwide Cohort Study.
Antihypertensive medication and their impact on cancer incidence: a mixed treatment comparison meta-analysis of randomized controlled trials.
Antihypertensive treatment and risk of cancer: an individual participant data meta-analysis.
Antiproliferative efficacy of angiotensin II receptor blockers in prostate cancer.
Appropriateness of cardiovascular care in elderly adult cancer survivors.
Arguing the misconceptions in allergen-specific immunotherapy.
Arterial aging mediates the effect of TNF-? and ACE polymorphisms on mental health in elderly individuals: insights from IKARIA study.
Assessment of risk factors for mortality in patients with cardiovascular disease and a history of treatment for malignancy.
Association between angiotensin I-converting enzyme gene polymorphism and susceptibility to cancer: a meta analysis.
Association between the polymorphism of the angiotensin-converting enzyme gene and tumor size of breast cancer in premenopausal patients.
Association of ACE inhibitors and angiotensin receptor blockers with keratinocyte cancer prevention in the randomized VATTC trial.
Association of AGTR1 (A1166C) and ACE (I/D) Polymorphisms with Breast Cancer Risk in North Indian Population.
Association of Angiotensin I Converting Enzyme Insertion/287?bp Deletion Polymorphisms and Proliferative Prostatic Diseases among Lebanese Men.
Association of angiotensin I converting enzyme insertion/deletion polymorphism with breast cancer: a meta-analysis.
Association of genetic polymorphisms with acute kidney injury after cardiac surgery in a Southeast Asian population.
Association of the TNF-alpha-308 (G-->A) polymorphism with self-reported history of childhood asthma.
Association of Urine Dipstick Proteinuria and Postoperative Renal Function Following Robotic Partial Nephrectomy.
Associations between disease risk and eight polymorphisms adopted for genotype announcements at Nagoya University Hospital.
Associations of angiotensin-converting enzyme inhibitor or angiotensin receptor blocker use with colorectal cancer risk in the Women's Health Initiative.
Asthma susceptible genes in Chinese population: a meta-analysis.
Beneficial anti-inflammatory effect of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker in the treatment of dextran sulfate sodium-induced colitis in mice.
Bioactive peptides and hydrolysates from pulses and their potential use as functional ingredients.
Biochemical properties of peptides encrypted in bovine milk proteins.
Blockade of angiotensin-converting enzyme or tumor necrosis factor-? reverses maternal high-fat diet-induced sensitization of angiotensin II hypertension in male rat offspring.
Blood-borne interleukin-1? acts on the subfornical organ to upregulate the sympathoexcitatory milieu of the hypothalamic paraventricular nucleus.
Brain endogenous angiotensin II receptor type 2 (AT2-R) protects against DOCA/salt-induced hypertension in female rats.
Butterfly Pea Flower (Clitoria ternatea Linn.) Extract Ameliorates Cardiovascular Dysfunction and Oxidative Stress in Nitric Oxide-Deficient Hypertensive Rats.
Calcium channel blockers and the risk of cancer.
Calcium channel blockers, ACE inhibitors, and the risk of cancer in hypertensive patients: a report from the Department of Health Hypertension Care Computing Project (DHCCP)
Calcium-channel blockers and risk of cancer.
Can cardiovascular drugs support cancer treatment? The rationale for drug repurposing.
Can the epirubicin cardiotoxicity in cancer patients be prevented by angiotensin converting enzyme inhibitors?
Cancer stem cells within moderately differentiated head and neck cutaneous squamous cell carcinoma express components of the renin-angiotensin system.
Cancer Vaccine Therapy Using Tumor Endothelial Cells as Antigens Suppresses Solid Tumor Growth and Metastasis.
Captopril and S-nitrosocaptopril as potent radiosensitizers: Comparative study and underlying mechanisms.
Captopril as a potential inhibitor of lung tumor growth and metastasis.
Captopril, an angiotensin-converting enzyme inhibitor, promotes growth of immunogenic tumors in mice.
Carcinogenicity of antihypertensive therapy.
Carcinogenicity of cardiovascular drugs.
Cardiac toxicity of anticancer agents.
Cardiovascular Drug Use and Risk of Actinic Keratosis: A Case-Control Study.
Cardiovascular Medications and Risk of Cancer.
Cardiovascular Outcomes in Relation to Antihypertensive Medication Use in Women with and Without Cancer: Results from the Women's Health Initiative.
Catecholamine-induced cardiomyopathy.
Chitotriosidase activity in sarcoidosis and some other pulmonary diseases.
Clinical characteristics and outcomes of critically ill patients with COVID-19 in a tertiary community hospital in upstate New York.
Clinical Characterization of Patients With COVID-19 in Primary Care in Catalonia: Retrospective Observational Study.
Clinical features associated with circulating concentration of soluble leptin receptor in patients with diabetes.
Clinical relevance of angiotensin-converting enzyme gene polymorphisms to predict risk of mechanical ventilation after coronary artery bypass graft surgery.
Collagen fibril organization within rat vertebral bone modified with metastatic involvement.
Comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in chemoprevention of hepatocellular carcinoma: a nationwide high-risk cohort study.
Correlation of flow mediated dilation with inflammatory markers in patients with impaired cardiac function. Beneficial effects of inhibition of ACE.
Cost Effectiveness of ACEIs/ARBs versus Amlodipine Monotherapies: A Single-Center Retrospective Chart Review.
COVID-19 and cardiac injury: clinical manifestations, biomarkers, mechanisms, diagnosis, treatment, and follow up.
Cross-sectional associations between angiotensin-converting enzyme inhibitor use and cancer diagnosis in US adults.
CUSP9* treatment protocol for recurrent glioblastoma: aprepitant, artesunate, auranofin, captopril, celecoxib, disulfiram, itraconazole, ritonavir, sertraline augmenting continuous low dose temozolomide.
Cytokine gene polymorphisms and susceptibility to cachexia.
Development of granulomatous common variable immunodeficiency subsequent to infection with Toxoplasma gondii.
Dickkopf-1 (DKK-1) stimulated prostate cancer growth and metastasis and inhibited bone formation in osteoblastic bone metastases.
Differential expression of angiotensin-converting enzyme-2 in human paranasal sinus mucosa in patients with chronic rhinosinusitis.
Differential radiation effect in tumor and normal tissue after treatment with ramipril, an angiotensin-converting enzyme inhibitor.
Differential regulation of tumor necrosis factor-alpha-converting enzyme and angiotensin-converting enzyme by type I and II interferons in human normal and leukemic myeloid cells.
Discovery of Noncancer Drug Effects on Survival in Electronic Health Records of Patients With Cancer: A New Paradigm for Drug Repurposing.
Do calcium channel blockers increase the risk of cancer?
Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer?
Do statins, ACE inhibitors or sartans improve outcome in primary glioblastoma?
Dosimetric Correlate of Cardiac-Specific Survival Among Patients Undergoing Coronary Artery Stenting After Thoracic Radiotherapy For Cancer.
Downregulation of angiotensin converting enzyme by TNF-alpha in differentiating human macrophages.
Downregulation of angiotensin-converting enzyme by tumor necrosis factor-alpha and interleukin-1beta in cultured human endothelial cells.
Drug Therapy of Heart Failure: An Immunologic View.
Drug-induced lupus: an update on its dermatologic aspects.
Drug-related Dysgeusia: A Systematic Review.
Drugs affecting the renin-angiotensin system and survival from cancer: a population based study of breast, colorectal and prostate cancer patient cohorts.
Early Post-Therapy Prescription Drug Usage among Childhood and Adolescent Cancer Survivors.
Ectopeptidases in tumour biology: a review.
Effect of angiotensin receptor blockers on the development of cancer: A nationwide cohort study in korea.
Effect of RAAS inhibition on the incidence of cancer and cancer mortality in patients with glomerulonephritis.
Effects of ACE I/D polymorphism on prostate cancer risk, tumor grade and metastatis.
Effects of angiotensin-converting enzyme inhibitor/angiotensin receptor blocker use on cancer therapy-related cardiac dysfunction: a meta-analysis of randomized controlled trials.
Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor blockers on lymphangiogenesis of gastric cancer in a nude mouse model.
Effects of Rubus occidentalis extract on blood pressure in patients with prehypertension: Randomized, double-blinded, placebo-controlled clinical trial.
Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138 769 individuals.
Effects of the angiotensin-I converting enzyme inhibitor perindopril on tumor growth and angiogenesis in head and neck squamous cell carcinoma cells.
Eighth European meeting on hypertension.
Enalapril to prevent cardiac function decline in long-term survivors of pediatric cancer exposed to anthracyclines.
Endoplasmic reticulum stress increases brain MAPK signaling, inflammation and renin-angiotensin system activity and sympathetic nerve activity in heart failure.
Enhanced tumor localization of monoclonal antibody by treatment with kininase II inhibitor and angiotensin II.
Examining the influence of beta blockers and ACE inhibitors on the risk for breast cancer recurrence: results from the LACE cohort.
Exposure to ACEI/ARB and ?-Blockers Is Associated with Improved Survival and Decreased Tumor Progression and Hospitalizations in Patients with Advanced Colon Cancer.
Expression and activity of angiotensin-regulating enzymes is associated with prognostic outcome in clear cell renal cell carcinoma patients.
Expression and function of the ACE2/angiotensin(1-7)/Mas axis in osteosarcoma cell lines U-2 OS and MNNG-HOS.
Expression of renin-angiotensin system (RAS) components in endometrial cancer.
Expression of the Local Angiotensin II System in Gastric Cancer May Facilitate Lymphatic Invasion and Nodal Spread.
Familiar drugs may prevent cancer.
Gastrin-releasing peptide receptor (GRPr) promotes EMT, growth, and invasion in canine prostate cancer.
Gene polymorphisms in patients below 35 years of age who underwent coronary artery bypass surgery.
Genetic Contributions to Childhood Obesity: Association of Candidate Gene Polymorphisms and Overweight/Obesity in Korean Preschool Children.
Genetic disposition and modifiable factors independently associated with anemia in patients with type 2 diabetes mellitus.
Genetic factors in contact allergy--review and future goals.
Genetic factors in lung disease. Part II: Lung cancer and angiotensin converting enzyme gene.
Genetic predisposition to acute kidney injury induced by severe sepsis.
Genetics of sepsis and pneumonia.
Genomics and the prospects of existing and emerging therapeutics for cardiovascular diseases.
Genotype announcement in a genetic polymorphism study for health checkup examinees at Nagoya University Hospital.
Hemizygous mice for the angiotensin II type 2 receptor gene have attenuated susceptibility to azoxymethane-induced colon tumorigenesis.
HER-2/neu protein-receptor-positive breast carcinoma: an immunologic perspective.
Histotripsy focal ablation of implanted prostate tumor in an ACE-1 canine cancer model.
Human endothelial cells transfected by SV40 T antigens: characterization and potential use as a source of normal endothelial factors.
Human mesenchymal stem cells attenuate hyperoxia-induced lung injury through inhibition of the renin-angiotensin system in newborn rats.
Hypercalcemia associated with an elevated 1,25 dihydroxy vitamin D3 level and an elevated angiotensin-converting enzyme level in a patient without evidence of sarcoidosis or malignancy.
Hypertension as a low-grade systemic inflammatory condition that has its origins in the perinatal period.
Hypertension in childhood cancer: a frequent complication of certain tumor sites.
Imminent Angiotensin-converting Enzyme Inhibitor from Microbial Source for Cancer Therapy.
Immune checkpoint inhibitor-associated acute kidney injury and mortality: An observational study.
Immunological methods for the detection of structural components and metabolites of bacteria and fungi in blood.
Immunomodulatory and anti-cytokine therapeutic potential of curcumin and its derivatives for treating COVID-19 - a computational modeling.
Impact of angiotensin I converting enzyme inhibitors and angiotensin II type 1 receptor blockers on survival in patients with advanced non-small-cell lung cancer undergoing first-line platinum-based chemotherapy.
Impact of Angiotensin I-converting Enzyme Inhibitors and Angiotensin II Type-1 Receptor Blockers on Survival of Patients with NSCLC.
Impact of exercise and angiotensin converting enzyme inhibition on tumor necrosis factor-alpha and leptin in fructose-fed hypertensive rats.
Incidence and Associated Risk Factors of Chemotherapy-Induced Cardiomyopathy in the African American and Afro-Caribbean Populations.
Incidental Receipt of Cardiac Medications and Survival Outcomes Among Patients With Stage III Non-Small-Cell Lung Cancer After Definitive Radiotherapy.
Increased tumor response to neoadjuvant therapy among rectal cancer patients taking angiotensin-converting enzyme inhibitors or angiotensin receptor blockers.
Inflammatory molecular signature associated with infectious agents in psychosis.
Influence of angiotensin I-converting enzyme gene polymorphism on hepatocellular carcinoma risk in China.
Inhibition of gelatinase A (MMP-2) by batimastat and captopril reduces tumor growth and lung metastases in mice bearing Lewis lung carcinoma.
Inhibition of proliferation on some neoplastic cell lines-act of carvedilol and captopril.
Inhibition of renin-angiotensin system affects prognosis of advanced pancreatic cancer receiving gemcitabine.
Inhibition of the renin-angiotensin system downregulates tissue factor and vascular endothelial growth factor in human breast carcinoma cells.
Inhibition of the renin-angiotensin system improves physiological outcomes in mice with mild or severe cancer cachexia.
Inhibitors of angiotensin-I-converting enzyme and risk of cancer.
Insertion/Deletion Polymorphism of Angiotensin I-converting Enzyme Gene Is Linked With Chromophobe Renal Cell Carcinoma.
Interactions of the renin-angiotensin system in colorectal cancer and metastasis.
Involvement of bradykinin, cytokines, sympathetic amines and prostaglandins in formalin-induced orofacial nociception in rats.
Ionizing Radiation Enhances Activity of Angiotensin-Converting Enzyme in Rat Aorta.
Is angiotensin I-converting enzyme a "master" disease gene?
Is preoperative chemoradiation in rectal cancer patients modulated by ACE inhibitors? Results from the Dutch Cancer Registry.
Isolation of the opioid peptide Leu-Val-Val-hemorphin-7 from bronchoalveolar lavage fluid of a patient with non-small cell lung cancer.
Ivabradine in Cancer Treatment-Related Left Ventricular Dysfunction.
Keratinocyte cancer prevention with ACE inhibitors, angiotensin receptor blockers or their combination in renal transplant recipients.
Kininase I, kininase II and aminopeptidase levels in patients with gastrointestinal tumors.
Lack of any association between insertion/deletion (I/D) polymorphisms in the angiotensin-converting enzyme gene and digestive system cancer risk: a meta-analysis.
Lack of association between ACE ID polymorphism and colorectal cancer in Romanian patients.
Lack of association between polymorphisms of eight candidate genes and idiopathic dilated cardiomyopathy: the CARDIGENE study.
Lack of Influence of the ACE1 Gene I/D Polymorphism on the Formation and Growth of Benign Uterine Leiomyoma in Turkish Patients.
Lack of replication of association findings in complex disease: an analysis of 15 polymorphisms in prior candidate genes for sporadic Alzheimer's disease.
Letter to the editor: effect of angiotensin converting enzyme inhibitors on soluble tumor necrosis factor related apoptosis-inducing ligand levels - association with neointimal hyperplasia in drug eluting stents.
Long-term enalapril therapy for left ventricular dysfunction in doxorubicin-treated survivors of childhood cancer.
Long-term use of angiotensin II receptor blockers and risk of cancer: A population-based cohort analysis.
Lowered cancer risk with ace inhibitors/ARBs: a population-based cohort study.
Lung cancer in the older population:Interactive effects of angiotensin converting enzyme gene polymorphism (rs 4340 ID) and tobacco addiction in risk assessment.
Manipulating the angiotensin system--new approaches to the treatment of solid tumours.
Manufacture of low-fat Cheddar cheese by exopolysaccharide-producing Lactobacillus plantarum JLK0142 and its functional properties.
Mechanical behavior of metastatic vertebrae are influenced by tissue architecture, mineral content, and organic feature alterations.
Membrane protein secretases.
Meta-analysis of randomized controlled trials on effect of angiotensin-converting enzyme inhibitors on cancer risk.
Metabolic engineering Escherichia coli for efficient production of icariside D2.
Multifunctional peptides encrypted in milk proteins.
New Insights Regarding Genetic Aspects of Childhood Obesity: A Minireview.
No association with risk for colorectal cancer of the insertion/deletion polymorphism which affects levels of angiotensin-converting enzyme.
Obstructive sleep apnea syndrome susceptible genes in the Chinese population: a meta-analysis of 21 case-control studies.
Omega-3 polyunsaturated fatty acids: their potential role in blood pressure prevention and management.
Optimizing Cardiovascular Health in Patients With Cancer: A Practical Review of Risk Assessment, Monitoring, and Prevention of Cancer Treatment-Related Cardiovascular Toxicity.
Oral formulation of angiotensin-(1-7) improves lipid metabolism and prevents high-fat diet-induced hepatic steatosis and inflammation in mice.
Osteolytic and mixed cancer metastasis modulates collagen and mineral parameters within rat vertebral bone matrix.
Pan-Cancer Analysis of Genomic and Prognostic Characteristics Associated With Coronavirus Disease 2019 Regulators.
Pathophysiologic implications of angiotensin I-converting enzyme as a mechanosensor: diabetes.
Perindopril: possible use in cancer therapy.
Pharmacological modifications of the partial pressure of oxygen in murine tumors: evaluation using in vivo EPR oximetry.
Pharmacology and new perspectives of angiotensin II receptor blocker in prostate cancer treatment.
Pharmacology of Ranolazine versus Common Cardiovascular Drugs in Patients with Early Diastolic Dysfunction Induced by Anthracyclines or Nonanthracycline Chemotherapeutics: A Phase 2b Minitrial.
Polymorphism of angiotensin converting enzyme is associated with severe circulatory compromise in febrile neutropenic children with cancer.
Polymorphism of angiotensin I-converting enzyme gene is related to oral cancer and lymph node metastasis in male betel quid chewers.
Polymorphisms in cytokines and growth factor genes and their association with acute rejection and recurrence of hepatitis C virus disease in liver transplantation.
Potential deployment of angiotensin I converting enzyme inhibitors and of angiotensin II type 1 and type 2 receptor blockers in cancer chemotherapy.
Potential of Plant mucilages in Pharmaceuticals and Therapy.
Predator Scent-Induced Sensitization of Hypertension and Anxiety-like Behaviors.
Predicting the safety and efficacy of buffer therapy to raise tumour pHe: an integrative modelling study.
Predictors of distant metastasis and mortality in patients with stage II colorectal cancer.
Predictors of the early impairment of renal disease in human obesity.
Prevalence and outcome of patients with cancer and acute coronary syndrome undergoing percutaneous coronary intervention: a BleeMACS substudy.
Prevalence of tumor necrosis factor-alpha and angiotensin converting enzyme polymorphisms in mild/moderate and fatal/near-fatal asthma.
Prevention and treatment of cardiomyopathy and heart failure in patients receiving cancer chemotherapy.
Prognonstic impact of renin-angiotensin system blockade in localised upper-tract urothelial carcinoma.
Prognostic factors for adverse outcomes in patients with COVID-19: a field-wide systematic review and meta-analysis.
Proinflammatory cytokines, soluble Fas receptor, nitric oxide and angiotensin converting enzyme in congestive heart failure.
Proteomic profiling for detection of early-stage heart failure in the community.
QRS duration is associated with atrial fibrillation in patients with left ventricular dysfunction.
Quantitative assessment of the association between the angiotensin-converting enzyme gene insertion/deletion polymorphism and digestive system cancer risk.
Rapid isolation of urinary exosomal biomarkers using a nanomembrane ultrafiltration concentrator.
RAS polymorphisms in cancerous and benign breast tissue.
Regulation of aminopeptidase A in human brain tumor vasculature: evidence for a role of transforming growth factor-beta.
Relationship between angiotensin-converting enzyme gene polymorphism and body composition, functional performance, and blood biomarkers in advanced cancer patients.
Relationship between polymorphism of angiotensin-converting enzyme gene insertion/deletion and risk of hepatocellular carcinoma in a Chinese Dai population.
Remote myocardium gene expression after 30 and 120 min of ischaemia in the rat.
Renin gene expression in human kidney biopsies from patients with glomerulonephritis or graft rejection.
Renin-Angiotensin Inhibition in Combating Malignancy: A Review.
Renin-angiotensin system blockade for the risk of cancer and death.
Renin-angiotensin system inhibitors and development of hepatocellular carcinoma: A systematic review and meta-analysis.
Renin-angiotensin system inhibitors, angiotensin I-converting enzyme gene insertion/deletion polymorphism, and cancer: the Rotterdam Study.
Resistance training does not have an effect on cognition or related serum biomarkers in nonagenarians: a randomized controlled trial.
Resistin Level is Positively Correlated with Thrombotic Complications in Southern Chinese Metabolic Syndrome Patients.
Response surface optimization of phenolic compounds extraction from camu-camu (Myrciaria dubia) seed coat based on chemical properties and bioactivity.
Rhodiola: an ordinary plant or a promising future therapy for pulmonary hypertension? a brief review.
Rice bran protein hydrolysates reduce arterial stiffening, vascular remodeling and oxidative stress in rats fed a high-carbohydrate and high-fat diet.
Risk Factors for Falls in Hospital In-Patients: A Prospective Nested Case Control Study.
Role of the RAS in Pancreatic Cancer.
Role of the Renin-Angiotensin System in Gynecologic Cancers.
Role of the Renin-Angiotensin System in Prostate Cancer.
Role of the renin-angiotensin-aldosterone system and proinflammatory mediators in cardiovascular disease.
Safety of drugs commonly used to treat hypertension, dyslipidemia, and type 2 diabetes (the metabolic syndrome): part 1.
Sarcoidosis and granuloma genes: a family-based study in African-Americans.
SARS-CoV-2 and cancer: Are they really partners in crime?
Secretion of renin-angiotensin system (RAS) components by normal and tumoral lactotropes. A comparative study using reverse hemolytic plaque assay (RHPA) and immunoelectron microscopy.
Serum levels of renin, angiotensin-converting enzyme and angiotensin II in patients treated by surgical excision, propranolol and captopril for problematic proliferating infantile haemangioma.
Sex differences exist in brain renin-angiotensin system-regulating aminopeptidase activities in transplacental ethyl-nitrosourea-induced gliomas.
Somatic isoform of angiotensin I-converting enzyme in the pathology of testicular germ cell tumors.
Squid gelatin hydrolysates with antihypertensive, anticancer and antioxidant activity
Strategies to prevent and treat cardiovascular risk in cancer patients.
Streptozotocin-induced diabetic cardiomyopathy in rats: ameliorative effect of PIPERINE via Bcl2, Bax/Bcl2, and caspase-3 pathways.
Stress-Induced Sensitization of Angiotensin II Hypertension Is Reversed by Blockade of Angiotensin-Converting Enzyme or Tumor Necrosis Factor-?.
Structure-activity relationship of hydroxamate-based inhibitors on the secretases that cleave the amyloid precursor protein, angiotensin converting enzyme, CD23, and pro-tumor necrosis factor-alpha.
Study of cardioprotective activity of the methanolic extract of the aerial parts of Bauhinia madagascariensis compared to Bauhinia purpurea against adrenaline-induced myocardial toxicity in rats.
Subacute cutaneous lupus erythematosus in the course of rheumatoid arthritis: a relationship with TNF-? antagonists and rituximab therapy?
Suppression of the renin-angiotensin system attenuates vascular endothelial growth factor-mediated tumor development and angiogenesis in murine hepatocellular carcinoma cells.
Testosterone induces apoptosis in cardiomyocytes by increasing proapoptotic signaling involving tumor necrosis factor-? and renin angiotensin system.
The ACE gene polymorphism is associated with the incidence of gastric cancer among H. pylori seropositive subjects with atrophic gastritis.
The ACE2/Angiotensin-(1-7)/Mas Receptor Axis: Pleiotropic Roles in Cancer.
The angiotensin I-converting enzyme gene insertion/deletion polymorphism is linked to early gastric cancer.
The angiotensin II/angiotensin II receptor system correlates with nodal spread in intestinal type gastric cancer.
The angiotensin receptor blocker, Losartan, inhibits mammary tumor development and progression to invasive carcinoma.
The angiotensin-I-converting enzyme inhibitor enalapril and aspirin delay progression of pancreatic intraepithelial neoplasia and cancer formation in a genetically engineered mouse model of pancreatic cancer.
The angiotensin-I-converting enzyme inhibitor perindopril suppresses tumor growth and angiogenesis: possible role of the vascular endothelial growth factor.
The Association Between Selected Molecular Biomarkers and Ambulatory Blood Pressure Patterns in African Chronic Kidney Disease and Hypertensive Patients Compared With Normotensive Controls: Protocol for a Longitudinal Study.
The ectopeptidases CD10, CD13, CD26, and CD143 are upregulated in gastric cancer.
The effect of angiotensin system inhibitors (angiotensin-converting enzyme inhibitors or angiotensin receptor blockers) on cancer recurrence and survival: a meta-analysis.
The effect of Captopril on benign and malignant reactions in irradiated rat skin.
The effect of low glucose degradation product dialysis solution on epithelial-to-mesenchymal transition in continuous ambulatory peritoneal dialysis patients.
The effect of proinflammatory cytokine gene and angiotensin-converting enzyme polymorphisms on erythropoietin requirements in patients on continuous ambulatory peritoneal dialysis.
The effect of renin-angiotensin system inhibitors on pro- and anti-inflammatory cytokine production.
The EPR effect for macromolecular drug delivery to solid tumors: Improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo.
The gene polymorphism of the angiotensin I-converting enzyme correlates with tumor size and patient survival in colorectal cancer patients.
The impact of host's genetic susceptibility on Helicobacter pylori infection in children.
The impact of metastasis on the mineral phase of vertebral bone tissue.
The incidence of cancer deaths among hypertensive patients in a large Chinese population: a cohort study.
The inhibitory effect of alacepril, an angiotensin-converting enzyme inhibitor, on endothelial inflammatory response induced by oxysterol and TNF-alpha.
The insertion/deletion (I/D) polymorphism in the Angiotensin-converting enzyme gene and cancer risk: a meta-analysis.
The Microbiota and Health Promoting Characteristics of the Fermented Beverage Kefir.
The personalised medicine. A paradigm of evidence-based medicine.
The relationship between angiotensin-converting enzyme gene insertion/deletion polymorphism and digestive cancer risk: Insights from a meta-analysis.
The renin angiotensin system in the regulation of angiogenesis.
The role of angiotensin II in cancer metastasis: Potential of renin-angiotensin system blockade as a treatment for cancer metastasis.
The role of the methacholine inhalation challenge in adult patients presenting with chronic cough.
The role of urinary TGF-?1, TNF-?, IL-6 and microalbuminuria for monitoring therapy in posterior urethral valves.
The secretases that cleave angiotensin converting enzyme and the amyloid precursor protein are distinct from tumour necrosis factor-alpha convertase.
Thrombophilic polymorphisms in preterm delivery.
Treatment of kidney transplant recipients with ACEi/ARB and risk of respiratory tract cancer: a collaborative transplant study report.
Treatment-related cardiotoxicity in survivors of childhood cancer.
Troponins and brain natriuretic peptides for the prediction of cardiotoxicity in cancer patients: a meta-analysis.
Tumor growth-inhibitory effect of an angiotensin-converting enzyme inhibitor (captopril) in a lung cancer xenograft model analyzed using 18F-FDG-PET/CT.
Tumor necrosis factor (TNF)-308, -1031, and angiotensin-converting enzyme (ACE) DD/II polymorphisms' role in Behcet's disease with and without uveitis: a meta-analysis.
Tumor necrosis factor-alpha convertase (ADAM17) mediates regulated ectodomain shedding of the severe-acute respiratory syndrome-coronavirus (SARS-CoV) receptor, angiotensin-converting enzyme-2 (ACE2).
Tumor necrosis factor-alpha gene expression in diabetic nephropathy: relationship with urinary albumin excretion and effect of angiotensin-converting enzyme inhibition.
Tumor-selective blood flow decrease induced by an angiotensin converting enzyme inhibitor, temocapril hydrochloride.
Two-Dimensional Speckle Tracking Echocardiography-Derived Strain Measurements in Survivors of Childhood Cancer on Angiotensin Converting Enzyme Inhibition or Receptor Blockade.
Unaltered cleavage and secretion of angiotensin-converting enzyme in tumor necrosis factor-alpha-converting enzyme-deficient mice.
Unexpected tumor reduction in metastatic colorectal cancer patients during SARS-Cov-2 infection.
Up-Regulation of Angiotensin-Converting Enzyme (ACE) Enhances Cell Proliferation and Predicts Poor Prognosis in Laryngeal Cancer.
Use of angiotensin-converting-enzyme inhibitors or angiotensin-receptor blockers and cancer risk: a meta-analysis of observational studies.
Useful laboratory tests for studying thrombogenesis in acute cardiac syndromes.
Utility of serum activity of angiotensin-converting enzyme as a tumor marker.
What is the place of genetics in the pathogenesis of pre-eclampsia?
Wound healing: captopril, an angiogenesis inhibitor, and Staphylococcus aureus peptidoglycan.
Zinc protects against tumor necrosis factor-induced disruption of porcine endothelial cell monolayer integrity.
[Adipocytokines: implications in the prognosis and drug treatment of cardiovascular diseases]
[Angiotensin II and aldosterone stimulate alpha1-(I) procollagen mRNA expression in hepatic stellate cells via activation of ERK1/2 and AP-1]
[Antihypertensive drugs and malignant neoplasia]
[Application of angiotensin II receptor blocker in prostate cancer]
[Cancer and renin-angiotensin system].
[CD143 expression in testicular germ cell tumors]
[Effects of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers on angiogenesis of gastric cancer in a nude mouse model]
[Effects of angiotensin II and aldosterone on NF-kappaB binding activity in hepatic stellate cells]
[Genetics of contact allergy].
[Pancreatic tumors.]
[Primary mediastinal seminoma--a case report]
[Relationship of single nucleotide polymorphisms and genetic susceptibility to sepsis].
[Role of renin-angiotensin system in prostate cancer]
[Significance of elevated serum ACE in pneumology]
[Study on changes in circulatory renin-angiotensin system in rats with endotoxemia.]
Neoplasms, Germ Cell and Embryonal
Somatic isoform of angiotensin I-converting enzyme in the pathology of testicular germ cell tumors.
[CD143 expression in testicular germ cell tumors]
Nephritis
A meta-analysis of the association between angiotensin-converting enzyme insertion/deletion gene polymorphism and Henoch-Schönlein purpura nephritis risk in Asian children.
A Pooled Study of Angiotensin-Converting Enzyme Insertion/Deletion Gene Polymorphism in Relation to Risk, Pathology and Prognosis of Childhood Immunoglobulin A Vasculitis Nephritis.
ACE inhibition reduces proteinuria, glomerular lesions and extracellular matrix production in a normotensive rat model of immune complex nephritis.
Angiotensin II regulates the synthesis of proinflammatory cytokines and chemokines in the kidney.
Angiotensin II type I receptor antagonist suppresses proteinuria and glomerular lesions in experimental nephritis.
Angiotensin II-mediated renal injury.
Angiotensin-converting enzyme (ACE) gene insertion/deletion polymorphism is not a risk factor for hypertension in SLE nephritis.
Angiotensin-converting enzyme gene insertion/deletion polymorphism in children with Henoch-Schonlein purpua nephritis.
Angiotensin-converting enzyme inhibitor versus angiotensin 2 receptor antagonist therapy and the influence of angiotensin-converting enzyme gene polymorphism in IgA nephritis.
Angiotensin-converting enzyme insertion/deletion gene polymorphism in Egyptian children with systemic lupus erythematosus: a possible relation to proliferative nephritis.
Association of angiotensin-converting enzyme insertion/deletion polymorphism with susceptibility to systemic lupus erythematosus: a meta-analysis.
Association of angiotensin-converting enzyme polymorphisms with systemic lupus erythematosus and nephritis: analysis of 644 SLE families.
Association study of ACE and eNOS single nucleotide polymorphisms with Henoch-Schönlein purpura nephritis.
Blood pressure-independent additive effects of pharmacologic blockade of the renin-angiotensin and endothelin systems on progression in a low-renin model of renal damage.
Comparison of converting enzyme inhibitor and calcium channel blocker in SHR with nephrotoxic serum nephritis.
Deletion insertion polymorphism of the angiotensin converting enzyme gene and progression of diabetic nephropathy.
Deletion polymorphism of the angiotensin converting enzyme gene predicts persistent proteinuria in Henoch-Schönlein purpura nephritis.
Disease progression, response to ACEI/ATRA therapy and influence of ACE gene in IgA nephritis.
Effect of the angiotensin converting enzyme inhibitor, captopril, on proteinuria in chronic glomerular disease.
European consensus-based recommendations for diagnosis and treatment of immunoglobulin A vasculitis-the SHARE initiative.
Expression and activation of STAT3 in chronic proliferative immune complex glomerulonephritis and the effect of fosinopril.
Henoch-Schönlein Purpura in Children: An Updated Review.
IgA nephropathy and Henoch-Schönlein purpura nephritis.
Relationship Between Angiotensin-converting Enzyme Insertion/Deletion Gene Polymorphism and Systemic Lupus Erythematosus/Lupus Nephritis: A Systematic Review and Metaanalysis.
Remission of membranoproliferative nephritis with angiotensin converting enzyme inhibition and receptor blockade.
Renoprotective effects of captopril in hypertension induced by nitric oxide synthase inhibition in experimental nephritis.
Spironolactone in combination with cilazapril ameliorates proteinuria and renal interstitial fibrosis in rats with anti-Thy-1 irreversible nephritis.
Steroid- and immunosuppressant-based protocol of Henoch-Schönlein purpura nephritis without angiotensin inhibitors in the acute phase: case series with correlation to histology.
Studies on mechanisms of antinephritic action of SA-446 an angiotensin I converting enzyme inhibitor (1). A comparison with actions of spironolactone, kallidinogenase and saralasin.
Suppressive Effects of Imidapril on TH1- and TH2-Related Chemokines in Monocytes.
Systemic and renovascular hypertension.
Treatment of radiation nephropathy with ACE inhibitors.
[Antinephritic effect of SA-446, an angiotensin I converting enzyme inhibitor, on crescentic-type anti-GBM nephritis in rats]
[Effect of ACE inhibitors on proteinuria and renal functioning in primary glomerulopathies]
[The antiproteinuric action of angiotensin-converting enzyme inhibitors in chronic glomerulonephritis and diabetic nephropathy]
Nephritis, Hereditary
Angiotensin converting enzyme inhibitor therapy in children with Alport syndrome: effect on urinary albumin, TGF-beta, and nitrite excretion.
Angiotensin-converting enzyme inhibitors in patients with Alport syndrome: can all patients benefit?
Angiotensin-[1-7] attenuates kidney injury in experimental Alport syndrome.
Diagnosis of Alport syndrome-search for proteomic biomarkers in body fluids.
Early angiotensin-converting enzyme inhibition in Alport syndrome delays renal failure and improves life expectancy.
Efficacy and safety of losartan in children with Alport syndrome--results from a subgroup analysis of a prospective, randomized, placebo- or amlodipine-controlled trial.
Enalapril in paediatric patients with Alport syndrome: 2 years' experience.
Endothelial Cell-Specific Collagen IV ?3 Expression Does not Rescue Alport Syndrome in Col4a3-/- Mice.
Familial hematuria: A review.
Feasibility of repairing glomerular basement membrane defects in alport syndrome.
In hereditary nephritis angiotensin-converting enzyme inhibition decreases proteinuria and may slow the rate of progression.
Long-term ACE inhibition in Alport syndrome: are the benefits worth the risks?
Long-term treatment by ACE inhibitors and angiotensin receptor blockers in children with Alport syndrome.
Organoprotective Effects of Spironolactone on Top of Ramipril Therapy in a Mouse Model for Alport Syndrome.
Preclinical Alterations in the Serum of COL(IV)A3(-)/(-) Mice as Early Biomarkers of Alport Syndrome.
The 2014 international workshop on alport syndrome.
Treatment of X-linked hereditary nephritis in Samoyed dogs with angiotensin converting enzyme (ACE) inhibitor.
Nephritis, Interstitial
A curious case of growth failure and hypercalcemia: Answers.
A curious case of growth failure and hypercalcemia: Questions.
Acute kidney injury due to renal sarcoidosis during etanercept therapy: a case report and literature review.
Acute tubulointerstitial nephritis and uveitis with angiotensin-converting enzyme increase.
Angiotensin I-converting enzyme gene insertion/deletion and angiotensinogen M235T polymorphisms: risk of chronic renal failure. End-Stage Renal Disease Study Group.
Endothelin A receptor blocker and calcimimetic in the adenine rat model of chronic renal insufficiency.
Subclinical Choroidal Inflammation Revealed by Indocyanine Green Angiography in Tubulointerstitial Nephritis and Uveitis Syndrome.
Nephrosclerosis
ACE inhibition prevents and reverses L-NAME-exacerbated nephrosclerosis in spontaneously hypertensive rats.
Aldosterone antagonism ameliorates proteinuria and nephrosclerosis independent of glomerular dynamics in L-NAME/SHR model.
Aldosterone as a mediator of progressive renal disease: pathogenetic and clinical implications.
Antihypertensive agents prevent nephrosclerosis and left ventricular hypertrophy induced in rats by prolonged inhibition of nitric oxide synthesis.
Cardiovascular outcomes in the African American Study of Kidney Disease and Hypertension (AASK) Trial.
Clinical experience with labetalol and enalapril in combination in patients with severe essential and renovascular hypertension.
Effects of quinapril hydrochloride in patients with essential hypertension and impaired renal function.
Expression of ACE and ACE2 in Patients with Hypertensive Nephrosclerosis.
Kidney angiotensin receptors and their role in renal pathophysiology.
Linkage analysis between loci in the renin-angiotensin axis and end-stage renal disease in African Americans.
Recovery of renal function in patients with accelerated malignant nephrosclerosis on maintenance dialysis with management of blood pressure by captopril.
Recruitment of African Americans with chronic renal insufficiency into a multicenter clinical trial: the african american study of kidney disease and hypertension.
Renal responses to angiotensin receptor antagonist and angiotensin-converting enzyme inhibitor in partially nephrectomized spontaneously hypertensive rats.
Reversible renal insufficiency due to angiotensin converting enzyme inhibitors in hypertensive nephrosclerosis.
Short-term effects of blood pressure control and antihypertensive drug regimen on glomerular filtration rate: the African-American Study of Kidney Disease and Hypertension Pilot Study.
Nephrosis
Angiotensin converting enzyme inhibitor modulates glomerular function and structure by distinct mechanisms.
Angiotensin I converting enzyme activity in adriamycin induced nephrosis in rats.
Angiotensin-converting enzyme inhibitors improve nephrosis more quickly than calcium antagonists in diabetic patients.
Antiproteinuric effect predicts renal protection by angiotensin-converting enzyme inhibition in rats with established adriamycin nephrosis.
Auxiliary genetic analysis in a Chinese adolescent NPH family by single nucleotide polymorphism screening.
Captopril magnifies the increase in angiotensin I-converting enzyme activity in rats with aminonucleoside nephrosis.
Chronic angiotensin II infusion but not bradykinin blockade abolishes the antiproteinuric response to angiotensin-converting enzyme inhibition in established adriamycin nephrosis.
Dual effects of lisinopril on puromycin aminonucleoside nephrosis in unilaterally nephrectomized rats.
Effect of a specific endothelin receptor A antagonist and an angiotensin-converting enzyme inhibitor on glomerular mRNA levels for extracellular matrix components, metalloproteinases (MMP) and a tissue inhibitor of MMP in aminonucleoside nephrosis.
Effect of captopril on chronic puromycin aminonucleoside nephrosis in rats.
Involvement of angiotensin II in development of spontaneous nephrosis in Dahl salt-sensitive rats.
Irreversible tubulointerstitial damage associated with chronic aminonucleoside nephrosis. Amelioration by angiotensin I converting enzyme inhibition.
Temocapril, a long-acting non-SH group angiotensin converting enzyme inhibitor, modulates glomerular injury in chronic puromycin aminonucleoside nephrosis.
[Relativity of nuclear factor-kappaB (P65/Rel-A) and angiotensin II type 1 receptor expression in early stage of lesions of adriamycin nephrosis in young rats and the effects of intervention]
[The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure]
Nephrosis, Lipoid
Acute kidney injury complicating minimal change disease: the case for careful use of diuretics and angiotensin-converting enzyme inhibitors.
Association of angiotensin-converting enzyme insertion/deletion gene polymorphism with susceptibility of minimal change nephrotic syndrome in Asians: a meta-analysis.
Relationship between Angiotensin-Converting Enzyme Insertion/Deletion Gene Polymorphism and Susceptibility of Minimal Change Nephrotic Syndrome: A Meta-Analysis.
[A decrease in urinary proteins in an elderly patient with refractory minimal change nephrotic syndrome administration of an angiotensin converting enzyme inhibitor in combination with steroids]
Nephrotic Syndrome
A meta-analysis of the association between angiotensin-converting enzyme insertion/deletion gene polymorphism and steroid-sensitive nephrotic syndrome in children.
ACE gene insertion/deletion polymorphism in childhood idiopathic nephrotic syndrome.
ACE gene polymorphism in Egyptian children with idiopathic nephrotic syndrome.
ACE I/D gene polymorphism can't predict the steroid responsiveness in Asian children with idiopathic nephrotic syndrome: a meta-analysis.
Acute renal failure in idiopathic nephrotic syndrome.
Angiotensin converting enzyme gene insertion/deletion polymorphism in idiopathic nephrotic syndrome in Kuwaiti Arab children.
Angiotensin converting enzyme gene polymorphism in Indian children with steroid sensitive nephrotic syndrome.
Angiotensin converting enzyme gene polymorphisms do not predict the course of idiopathic nephrotic syndrome in Swiss children.
Angiotensin converting enzyme inhibitor does not reduce proteinuria in an infant with congenital nephrotic syndrome of the Finnish type.
Angiotensin converting enzyme inhibitor improves nephrotic syndrome associated with cyanotic congenital heart disease.
Angiotensin converting enzyme inhibitors for reduction of proteinuria in children with steroid-resistant nephrotic syndrome.
Angiotensin II up-regulates sodium-glucose co-transporter 2 expression and SGLT2 inhibitor attenuates Ang II-induced hypertensive renal injury in mice.
Angiotensin II-mediated renal injury.
Angiotensin-Converting Enzyme Gene Polymorphism in Children with Idiopathic Nephrotic Syndrome, Effect on Biopsy Findings.
Angiotensin-converting enzyme gene polymorphism in children with idiopathic nephrotic syndrome.
Angiotensin-converting enzyme gene polymorphism in patients with minimal-change nephrotic syndrome and focal segmental glomerulosclerosis.
Angiotensin-converting enzyme genotype is not a significant genetic risk factor for idiopathic nephrotic syndrome in Croatian children.
Association of ACE and MDR1 Gene Polymorphisms with Steroid Resistance in Children with Idiopathic Nephrotic Syndrome.
Association of angiotensin converting enzyme insertion/deletion gene polymorphism with idiopathic nephrotic syndrome susceptibility in children: a meta-analysis.
Association of angiotensin-converting enzyme gene I/D polymorphism with steroid responsiveness in childhood nephrotic syndrome.
Association of Angiotensin-Converting Enzyme Insertion/Deletion Gene Polymorphism with Idiopathic Nephrotic Syndrome Susceptibility in Children: An Updated Meta-Analysis.
Association of angiotensin-converting enzyme insertion/deletion gene polymorphism with susceptibility of minimal change nephrotic syndrome in Asians: a meta-analysis.
Association of nephrotic syndrome with immune reconstitution inflammatory syndrome.
Beneficial effect of triple treatment plus immunoglobulin in experimental nephrotic syndrome.
Captopril magnifies the increase in angiotensin I-converting enzyme activity in rats with aminonucleoside nephrosis.
Comparative study of angiotensin converting enzyme inhibitor and calcium channel blocker in the treatment of steroid-resistant idiopathic nephrotic syndrome.
Comparison of the influence of angiotensin-converting enzyme inhibitor lisinopril and angiotensin II receptor antagonist losartan in patients with idiopathic membranous nephropathy and nephrotic syndrome.
Complete remission of nephrotic syndrome in an infant with focal segmental glomerulosclerosis: is it renin-angiotensin blockade?
Complete Remission of Nephrotic Syndrome of Hepatitis B Virus-associated Membranous Glomerulopathy After Lamivudine Monotherapy.
Congenital nephrotic syndrome responsive to angiotensin-converting enzyme inhibition.
Cyanotic congenital heart disease associated with glomerulomegaly and focal segmental glomerulosclerosis: remission of nephrotic syndrome with angiotensin converting enzyme inhibitor.
Diverse effects of increasing lisinopril doses on lipid abnormalities in chronic nephropathies.
Effect of angiotensin converting enzyme gene I/D polymorphism in South Indian children with nephrotic syndrome.
Effect of angiotensin-converting enzyme gene insertion/deletion polymorphism on steroid resistance in Egyptian children with idiopathic nephrotic syndrome.
Effect of dietary protein restriction and angiotensin converting enzyme inhibition on protein metabolism in the nephrotic syndrome.
Effect of losartan treatment on the proteinuria in normotensive patients having proteinuria due to secondary amyloidosis.
Effectiveness of dietary protein augmentation associated with angiotensin-converting enzyme inhibition in the management of the nephrotic syndrome.
Efficacy of captopril treatment in children with steroid-resistant nephrotic syndrome.
Evidence that some mechanism other than the renin system causes sodium retention in nephrotic syndrome.
Henoch-Schönlein nephritis associated with streptococcal infection and persistent hypocomplementemia: a case report.
IgA Deficiency and Membranoproliferative Glomerulonephritis: A Case Report.
Incidence and factors associated with prescribing renin-angiotensin-system inhibitors in adult idiopathic nephrotic syndrome: A nationwide cohort study.
Increased urinary excretion of angiotensin converting enzyme in patients with renal diseases.
Insertion/Deletion (I/D) Polymorphism of Angiotensin-Converting Enzyme Gene in Steroid-Resistant Nephrotic Syndrome for Children: A Genetic Association Study and Meta-analysis.
Insertion/Deletion (I/D) Polymorphism of Angiotensin-Converting Enzyme Gene in Steroid-Resistant Nephrotic Syndrome for Children: An Updated Meta-analysis.
Interventions for idiopathic steroid-resistant nephrotic syndrome in children.
Lack of effect of captopril on the sodium retention of the nephrotic syndrome.
Long-term benefits of the antiproteinuric effect of angiotensin-converting enzyme inhibition in nondiabetic renal disease.
Management of glomerular diseases of primary and secondary origin.
Neonatal nephrotic presentation of a child with heterozygous NPHS1 mutation.
Nephrotic syndrome and idiopathic membranous nephropathy associated with autosomal-dominant polycystic kidney disease.
Non-immunologic mechanisms of calcineurin inhibitors explain its antiproteinuric effects in genetic glomerulopathies.
Nonimmunosuppressive therapy of membranous nephropathy.
Pathophysiology of experimental nephrotic syndrome induced by puromicyn aminonucleoside in rats. III. Effect of captopril, an angiotensin converting enzyme inhibitor, on proteinuria and sodium retention.
Pentoxifylline: a potential therapy for chronic kidney disease.
Relationship between Angiotensin-Converting Enzyme Insertion/Deletion Gene Polymorphism and Susceptibility of Minimal Change Nephrotic Syndrome: A Meta-Analysis.
Renal effects of captopril, indomethacin and nifedipine in nephrotic patients after an oral protein load.
Serum angiotensin converting enzyme activity and plasma renin activity in experimental models of rats.
Severe hepatic encephalopathy in a patient with liver cirrhosis after administration of angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker combination therapy: a case report.
Successful therapeutic use of rituximab in refractory membranous glomerulonephritis.
Successful treatment of a patient with nephrotic syndrome associated with chronic lymphocytic leukemia.
The renoprotective potential of pentoxifylline in chronic kidney disease.
Treatment of childhood nephrotic syndrome.
Treatment of idiopathic membranous nephropathy with the herb Astragalus membranaceus.
Treatment with candesartan combined with angiotensin-converting enzyme inhibitor for immunosuppressive treatment-resistant nephrotic syndrome after allogeneic stem cell transplantation.
[A decrease in urinary proteins in an elderly patient with refractory minimal change nephrotic syndrome administration of an angiotensin converting enzyme inhibitor in combination with steroids]
[Effect of ACE inhibitors on proteinuria and renal functioning in primary glomerulopathies]
[Effect of the angiotensin-converting enzyme inhibitor ramipril on proteinuria, blood pressure and kidney function in histologically confirmed glomerulonephritis with nephrotic syndrome]
[Kidney insufficiency and persistent hypotension following compromise of the renin-angiotensin system in a fetus and a young infant]
[Nephrotic syndrome due to metabolic disease--special reference to diabetic nephropathy]
Nervous System Diseases
Age-adjusted CSF ?2-microglobulin and lactate are increased and ACE is decreased in patients with multiple sclerosis, but only lactate correlates with clinical disease duration and severity.
Angiotensin I converting enzyme in cerebrospinal fluid of patients with neurological diseases.
Cardiovascular disease genetics: a long and winding road.
Nervous System Malformations
Angiotensin-Converting Enzyme Inhibitors and the Risk of Congenital Malformations.
Neural Tube Defects
Preconception health care for the primary care practitioner.
Neuralgia
Ameliorative potential of angiotensin-converting enzyme inhibitor (ramipril) on chronic constriction injury of sciatic nerve induced neuropathic pain in mice.
Mechanisms Involved in Superiority of Angiotensin Receptor Blockade over ACE Inhibition in Attenuating Neuropathic Pain Induced in Rats.
Neurobehavioral Manifestations
Exploring the evidence implicating the renin- angiotensin system (RAS) in the physiopathology of mood disorders.
Neuroblastoma
Angiotensin-converting enzyme inhibition reduces neuroblastoma cell growth rate.
Biochemical characterization of angiotensin-converting enzyme in human neuroblastoma tissue.
Brain renin.
Comparison of cholecystokinin metabolism by membrane preparations from the human astrocytoma clone D384 and the neuroblastoma line SH-SY5Y.
Degradation of luteinizing hormone-releasing hormone by neuroblastoma cells and their membrane: evidence for the involvement of a thiol protease and angiotensin-converting enzyme.
Enkephalin degradation by enkephalinergic neuroblastoma cells. Involvement of angiotensin-converting-enzyme.
Generation of angiotensinogen by cultured neuroblastoma and glioma cells.
Hydrolysis of atrial and brain natriuretic peptides by the human astrocytoma clone D384 and the neuroblastoma line SH-SY5Y.
Induction of neutral endopeptidase and angiotensin-converting enzyme activity of SK-N-SH cells in vitro by quercetin and resveratrol.
Renin and angiotensin-converting enzyme in human neuroblastoma tissue.
Renin, angiotensins, and angiotensin-converting enzyme in neuroblastoma cells: evidence for intracellular formation of angiotensins.
Subcellular localization of angiotensin-converting enzyme in cultured neuroblastoma cells.
The renin-angiotensin system in hybrid NG108-15 cells. Renin gene is from mouse neuroblastoma, angiotensinogen and angiotensin-converting enzyme genes are of rat glioma origin.
Neurodegenerative Diseases
Functional Foods and Nutraceuticals as Dietary Intervention in Chronic Diseases; Novel Perspectives for Health Promotion and Disease Prevention.
No Association of Angiotensin I Converting Enzyme I/D Polymorphism with Domain-Specific Cognitive Function in Aged Men without Dementia.
The Implications of Angiotensin-Converting Enzymes and Their Modulators in Neurodegenerative Disorders: Current and Future Perspectives.
The Renin-Angiotensin System and the Neurodegenerative Diseases: a brief review.
Neurogenic Inflammation
A comparison of neuropeptide expression in skin with allergic contact dermatitis in human and mouse.
A polymorphic locus in the intron 16 of the human angiotensin-converting enzyme (ACE) gene is not correlated with complex regional pain syndrome I (CRPS I).
Genetic polymorphism of the angiotensin-converting enzyme (ACE) in asthmatic patients.
Inhibition of neutral endopeptidase (NEP) facilitates neurogenic inflammation.
Neutral endopeptidase and kininase II mediate glucocorticoid inhibition of neurogenic inflammation in the rat trachea.
Peptidase inhibitors reverse steroid-induced suppression of neutrophil adhesion in rat tracheal blood vessels.
Pharmacological modulation of neurogenic inflammation.
Neuroinflammatory Diseases
A comparative study of neuroprotective effect of angiotensin converting enzyme inhibitors against scopolamine-induced memory impairments in rats.
Angiotensin Receptor Blockade Modulates NF?B and STAT3 Signaling and Inhibits Glial Activation and Neuroinflammation Better than Angiotensin-Converting Enzyme Inhibition.
Angiotensin-converting enzyme inhibitor treatment early after myocardial infarction attenuates acute cardiac and neuroinflammation without effect on chronic neuroinflammation.
Beneficial effects of angiotensin converting enzyme inhibition on scopolamine-induced learning and memory impairment in rats, the roles of brain-derived neurotrophic factor, nitric oxide and neuroinflammation.
Hydroelectrolytic Disorder in COVID-19 patients: Evidence Supporting the Involvement of Subfornical Organ and Paraventricular Nucleus of the Hypothalamus.
Hypertension exacerbates predisposition to neurodegeneration and memory impairment in the presence of a neuroinflammatory stimulus: Protection by angiotensin converting enzyme inhibition.
Role of brain renin angiotensin system in neurodegeneration: An update.
Usage of Angiotensin-Converting Enzyme Inhibitor or Angiotensin II Receptor Blocker in Hypertension Intracerebral Hemorrhage.
Neuromuscular Diseases
Management of Cardiac Involvement in NeuroMuscular Diseases: Review.
Neutropenia
Captopril-induced bone marrow suppression in two cardiac patients with trisomy 21.
Niemann-Pick Diseases
Angiotensin converting enzyme in cultured fibroblasts in Gaucher and Niemann-Pick diseases.
Non-alcoholic Fatty Liver Disease
De novo nonalcoholic fatty liver disease after liver transplantation.
Emerging Liver-Kidney Interactions in Nonalcoholic Fatty Liver Disease.
Essential hypertension and chronic viral hepatitis.
Liver transcriptional profile of atherosclerosis-related genes in human nonalcoholic fatty liver disease.
Nonalcoholic fatty liver disease and atrial fibrillation: possible pathophysiological links and therapeutic interventions.
Nonalcoholic fatty liver disease and the renin-angiotensin system: Implications for treatment.
Role of Renin-Angiotensin-converting Enzyme Level and ACE Gene Polymorphism in Patients with Nonalcoholic Fatty Liver Disease.
[CURRENT ISSUES IN THE CHOICE OF ANTIHYPERTENSIVE THERAPY IN PATIENTS WITH METABOLIC SYNDROME AND RELATED NON-ALCOHOLIC FATTY LIVER DISEASE].
[Transfection of angiotensin-converting-enzyme 2 gene inhibits hepatic fibrosis in rats with nonalcoholic fatty liver disease].
Non-ST Elevated Myocardial Infarction
Effects of early angiotensin-converting enzyme inhibition in patients with non-ST-elevation acute anterior myocardial infarction.
Frequency of ST-segment elevation myocardial infarction, non-ST-segment myocardial infarction, and unstable angina: results from a Southwest Chinese Registry.
Management and mortality in patients with non-ST-segment elevation vs. ST-segment elevation myocardial infarction. Data from the Malopolska Registry of Acute Coronary Syndromes.
Non-ST-elevation myocardial infarction in the Netherlands: room for improvement!
Patterns of Acute Myocardial Infarction in Taiwan from 2009 to 2015.
Survey of Assessment and MAnagement of CoRonary Heart Disease PaTients (SMART) in India.
Nutrition Disorders
Angiotensin-converting enzyme gene insertion/deletion polymorphism in nutritional disorders in children.
Obesity
A Review of Posttraumatic Stress Disorder and Obesity: Exploring the Link.
A Review of Potential Marine-Derived Hypotensive and Anti-Obesity Peptides.
ACE gene titration in mice uncovers a new mechanism for ACE on the control of body weight.
ACE inhibitors improve nephrin expression in Zucker rats with glomerulosclerosis.
ACE2 and ACE: structure-based insights into mechanism, regulation and receptor recognition by SARS-CoV.
ACE2 exerts anti-obesity effect via stimulating brown adipose tissue and induction of browning in white adipose tissue.
Albuminuria among Alaska Natives - Findings from the Genetics of Coronary Artery Disease in Alaska Natives (GOCADAN) Study.
An update on 'progression promoters' in renal diseases.
Anaesthesia, surgery, and life-threatening allergic reactions: epidemiology and clinical features of perioperative anaphylaxis in the 6th National Audit Project (NAP6).
Angiotensin Converting Enzyme (ACE): A Marker for Personalized Feedback on Dieting.
Angiotensin converting enzyme inhibition lowers body weight and improves glucose tolerance in C57BL/6J mice maintained on a high fat diet.
Angiotensin converting enzyme insertion/deletion polymorphism is associated with increased adiposity and blood pressure in obese children and adolescents.
Angiotensin-converting enzyme gene insertion/deletion polymorphism in nutritional disorders in children.
Angiotensin-converting enzyme gene polymorphisms and obesity: an examination of three black populations.
Angiotensin-converting enzyme inhibition reduces food intake and weight gain and improves glucose tolerance in melanocortin-4 receptor deficient female rats.
Angiotensin-converting enzyme inhibition reverses diet-induced obesity, insulin resistance and inflammation in C57BL/6J mice.
Angiotensin-Converting Enzyme Ins/Del Polymorphism and Body Composition: The Intermediary Role of Hydration Status.
Angiotensin-converting enzyme insertion/deletion polymorphism association with obesity and some related disorders in Egyptian females: a case-control observational study.
Angiotensinogen and blood pressure among blacks: findings from a community survey in Jamaica.
Association of Angiotensin Converting Enzyme Insertion-Deletion Polymorphism with Hypertension in Emiratis with Type 2 Diabetes Mellitus and Its Interaction with Obesity Status.
Association of angiotensin-converting enzyme and angiotensin II type I receptor gene polymorphisms with extreme obesity in Polish individuals.
Association of angiotensin-converting enzyme gene polymorphism with pulse pressure and its interaction with obesity status in Heilongjiang province.
Association of angiotensin-converting enzyme insertion/deletion (ACE I/D) and angiotensinogen (AGT M235T) polymorphisms with the risk of obesity in a Tunisian population.
Association of angiotensin-converting enzyme insertion/deletion polymorphism with obesity, cardiovascular risk factors and exercise-mediated changes in Korean women.
Atypical fatigue.
Cardiovascular protective role of a low-dose antihypertensive combination in obese Zucker rats.
Chronic renal insufficiency in a boy with cystic renal lymphangiectasia: morphological findings and long-term follow-up.
Clinical Characterization of Patients With COVID-19 in Primary Care in Catalonia: Retrospective Observational Study.
Combination of ACTN3 R577X and ACE I/D polymorphisms as a tool for prediction of obesity risk in children.
Daily sodium intake influences the relationship between angiotensin-converting enzyme gene insertion/deletion polymorphism and hypertension in older adults.
Does Genetic Predisposition Contribute to the Exacerbation of COVID-19 Symptoms in Individuals with Comorbidities and Explain the Huge Mortality Disparity between the East and the West?
Does panic disorder increase the risk of coronary heart disease? A cohort study of a national managed care database.
Early pharmacological inhibition of angiotensin-I converting enzyme activity induces obesity in adulthood.
Effect of ramipril on insulin sensitivity in obese patients. Time-course study of glucose infusion rate during euglycaemic hyperinsulinaemic clamp.
Effect of Treatment of Sprague Dawley Rats with AVE7688, Enalapril, or Candoxatril on Diet-Induced Obesity.
Effects of interaction between angiotensin I-converting enzyme polymorphisms and lifestyle on adiposity in adolescent Greeks.
Evaluation of Association of ADRA2A rs553668 and ACE I/D Gene Polymorphisms with Obesity Traits in the Setapak Population, Malaysia.
Hemostatic dysfunction associated with endocrine disorders as a major risk factor and cause of human morbidity and mortality: a comprehensive meta-review.
Impact of obesity and nitric oxide synthase gene G894T polymorphism on essential hypertension.
Increased tissue angiotensin-converting enzyme activity impairs bradykinin-induced dilation of coronary arterioles in obesity.
Inhibition of the renin-angiotensin system ameliorates genetically determined hyperinsulinemia.
Is erectile dysfunction predictive of peripheral vascular disease?
Joint effects of hypertension, smoking, dyslipidemia and obesity and angiotensin-converting enzyme DD genotype on albuminuria in Taiwanese patients with type 2 diabetes mellitus.
Leptin regulates ACE activity in mice.
Long-term protection of obese Zucker rat kidneys from fibrosis and renal failure with an angiotensin-converting enzyme inhibitor/diuretic combination.
Management of obesity cardiomyopathy.
Metabolic effects of low dose angiotensin converting enzyme inhibitor in dietary obesity in the rat.
Modification of the coronary artery disease risk associated with the presence of traditional risk factors by insertion/deletion polymorphism of the ACE gene.
New Insights Regarding Genetic Aspects of Childhood Obesity: A Minireview.
Obesity and chronic kidney disease: prevalence, mechanism, and management.
Obesity is associated with tissue-specific activation of renal angiotensin-converting enzyme in vivo: evidence for a regulatory role of endothelin.
Outcomes for patients with COVID-19 admitted to Australian intensive care units during the first four months of the pandemic.
PATHOGENETIC ADVANCES OF FOSINOPRIL SODIUM WITH HYDROCHLOROTHIAZIDE IN OBESE HYPERTENSIVE PATIENTS.
Patients' need for more counseling on diet, exercise, and smoking cessation: results from the National Ambulatory Medical Care Survey.
Peroxisome proliferator-activated receptor [gamma] agonist provides superior renal protection versus angiotensin-converting enzyme inhibition in a rat model of type 2 diabetes with obesity.
Polymorphisms of the renin-angiotensin system are not associated with overweight and obesity in a general adult population.
Potential role of angiotensin-converting enzyme inhibitors and statins on early podocyte damage in a model of type 2 diabetes mellitus, obesity, and mild hypertension.
Preeclampsia is associated with ACE I/D polymorphism, obesity and oxidative damage in Mexican women.
Prevalence and treatment of cardiovascular risk factors in outpatients with atherothrombosis in the Middle East.
Prevention of atrial fibrillation in cardiac surgery: time to consider a multimodality pharmacological approach.
Regulation of adiposity and obesity risk by dietary calcium: mechanisms and implications.
Renin-angiotensin system polymorphisms in relation to hypertension status and obesity in a Tunisian population.
Roles of Dietary Bioactive Peptides in Redox Balance and Metabolic Disorders.
Sarcopenia, obesity, and inflammation--results from the Trial of Angiotensin Converting Enzyme Inhibition and Novel Cardiovascular Risk Factors study.
Screening of Egyptian obese children and adolescents for insertion/deletion (I/D) polymorphism in angiotensin-converting enzyme gene.
Screening of Obese Offspring of First-Cousin Consanguineous Subjects for the Angiotensin-Converting Enzyme Gene with a 287-bp Alu Sequence.
Sex-dependent association between angiotensin-converting enzyme insertion/deletion polymorphism and obesity in relation to sodium intake in children.
Synergistic effects of ACE (I/D) and Apo E (Hha I) gene polymorphisms on obesity, fat mass, and blood glucose level among the adult Asian Indians: A population-based study from Calcutta, India.
The Antihypertensive, Antimicrobial and Anticancer peptides from Arthrospira with therapeutic potential: A minireview.
The Association between Antihypertensive Medication Use and Blood Pressure Is Influenced by Obesity.
The effect of angiotensin-converting enzyme inhibition using captopril on energy balance and glucose homeostasis.
The effects of dairy components on energy partitioning and metabolic risk in mice: a microarray study.
The effects of epoprostenol on drug disposition. I: A pilot study of the pharmacokinetics of digoxin with and without epoprostenol in patients with congestive heart failure.
The relation between obesity, abdominal fat deposit and the angiotensin-converting enzyme gene I/D polymorphism and its association with coronary heart disease.
The role of adiponectin in renal physiology and development of albuminuria.
The role of the renin-angiotensin-aldosterone system in obesity-related renal diseases.
Therapeutic Insights in Chronic Kidney Disease Progression.
Thrombosis and occlusion of vascular access in hemodialyzed patients.
Twenty years of progress in angiotensin converting enzyme 2 and its link to SARS-CoV-2 disease.
Usefulness of satisfactory control of low-density lipoprotein cholesterol to predict left ventricular remodeling after a first ST-elevation myocardial infarction successfully reperfused.
Weight gain after liver transplantation and the insertion/deletion polymorphism of the angiotensin-converting enzyme gene.
[Consumption of antihypertensive agents in obese patients: a cross-sectional study in a sample of 3,291 wage-earners in the Toulous region]
[The role of angiotensin-converting enzyme gene I/D polymorphism in development of metabolic disorders in patients with cardiovascular pathology]
Obesity, Abdominal
New risk factors for coronary heart disease in Asia.
Obesity, Morbid
No contribution of angiotensin-converting enzyme (ACE) gene variants to severe obesity: a model for comprehensive case/control and quantitative cladistic analysis of ACE in human diseases.
Obesity-related focal and segmental glomerulosclerosis: normalization of proteinuria in an adolescent after bariatric surgery.
Obstetric Labor, Premature
The plasma renin-angiotensin system in preeclampsia: effects of magnesium sulfate.
Ocular Hypertension
Oculohypotensive effect of angiotensin-converting enzyme inhibitors in acute and chronic models of glaucoma.
Use of an angiotensin converting enzyme inhibitor in ocular hypertension and primary open-angle glaucoma.
Oligohydramnios
Fetopathy associated with exposure to angiotensin converting enzyme inhibitors and angiotensin receptor antagonists.
Pregnancy outcome following exposure to angiotensin-converting enzyme inhibitors.
Reversible Fetal Renal Impairment following Angiotensin Receptor Blocking Treatment during Third Trimester of Pregnancy: Case Report and Review of the Literature.
Reversible oligohydramnios in a pregnancy with angiotensin-converting enzyme inhibitor exposure.
[Fetopathy associated with exposure to angiotensin converting enzyme inhibitors]
Oliguria
Chronic renal disease in pregnancy.
Onchocerciasis
Elevated serum angiotensin-converting enzyme activity in onchocerciasis.
Optic Nerve Diseases
Granulomatous optic neuropathy.
Modification of radiation injury by ramipril, inhibitor of angiotensin-converting enzyme, on optic neuropathy in the rat.
Optic Neuritis
Serum Level of the Angiotensin-Converting Enzyme in Patients with Idiopathic Acute Optic Neuritis: A Case-Control Study.
Optic Neuropathy, Ischemic
Renin-angiotensin-aldosterone system genes and nonarteritic anterior ischemic optic neuropathy.
The polymorphisms of ATOH 7, ET-1 and ACE in non-arteritic anterior ischemic optic neuropathy.
The role of angiotensin converting enzyme and angiotensin II type 1 receptor gene polymorphisms in patients with nonarteritic anterior ischemic optic neuropathy.
Osteoarthritis
Angiotensin converting enzyme in human synovium: increased stromal [(125)I]351A binding in rheumatoid arthritis.
Angiotensin-Converting Enzyme Insertion/Deletion Polymorphism and Susceptibility to Osteoarthritis of the Knee: A Case-Control Study and Meta-Analysis.
Association between ACE polymorphisms and osteoarthritis susceptibility.
Captopril, an angiotensin-converting enzyme inhibitor, possesses chondroprotective efficacy in a rat model of osteoarthritis through suppression local renin-angiotensin system.
Carboxypeptidase N (kininase I) activity in blood and synovial fluid from patients with arthritis.
Comparison of conventional NSAIDs and cyclooxygenase-2 inhibitors in outpatients.
DD genotype of ace gene I/D polymorphism is associated in a turkish study population with osteoarthritis.
Effect of indomethacin on the antihypertensive efficacy of valsartan and lisinopril: a multicentre study.
MTHFR gene C677T mutation and ACE gene I/D polymorphism in Turkish patients with osteoarthritis.
Neutral endopeptidase (3.4.24.11) in plasma and synovial fluid of patients with rheumatoid arthritis. A marker of disease activity or a regulator of pain and inflammation?
Serum and synovial fluid levels of angiotensin converting enzyme in polyarthritis.
Spontaneous release of angiotensin converting enzyme and interleukin 1 beta from peripheral blood monocytes from patients with rheumatoid arthritis under a serum free condition.
The insertion and deletion (I28005D) polymorphism of the angiotensin I converting enzyme gene is a risk factor for osteoarthritis in an Asian Indian population.
[Expressions of Renin, angiotensin converting enzyme, angiotensin receptor 1, and angiotensin receptor 2 in synovial tissue of osteoarthritis at different stages].
Osteoarthritis, Hip
Neuropeptide-converting enzymes in cerebrospinal fluid: activities increased in pain from herniated lumbar dis, but not from coxarthrosis.
Osteoarthritis, Knee
Angiotensin converting enzyme gene polymorphism in Korean patients with primary knee osteoarthritis.
Angiotensin-Converting Enzyme Insertion/Deletion Polymorphism and Susceptibility to Osteoarthritis of the Knee: A Case-Control Study and Meta-Analysis.
Association between ACE gene I/D polymorphism and knee osteoarthritis in a Chinese population.
Prevalence of angiotensin-converting enzyme gene insertion-deletion polymorphism in patients with primary knee osteoarthritis.
Osteolysis
Evaluating the effects of mixed osteolytic/osteoblastic metastasis on vertebral bone quality in a new rat model.
Zoledronic acid decreased osteolysis but not bone metastasis in a nude mouse model of canine prostate cancer with mixed bone lesions.
Osteonecrosis
ACE Gene Variant Causing High Blood Pressure May Be Associated With Medication-related Jaw Osteonecrosis.
Osteoporosis
2012 Brazilian Society of Rheumatology Consensus on the management of comorbidities in patients with rheumatoid arthritis.
A comparative study between the effect of 17-? estradiol and angiotensin converting enzyme inhibitor on osteoporosis in ovariectomized rats.
ACE-inhibitors: a preventive measure for bone flap resorption after autologous cranioplasty?
Angiotensin II induces mitochondrial oxidative stress and mtDNA damage in osteoblasts by inhibiting SIRT1–FoxO3a–MnSOD pathway.
Association between the ACE gene I/D polymorphism and osteoporosis in a Turkish population.
Cardiovascular disease genetics: a long and winding road.
Current treatment and management of dystrophinopathies.
Effect of pituitary microsurgery on acromegaly complicated nephrotic syndrome with focal segmental glomerulosclerosis: report of a rare clinical case.
Genetic Scores of eNOS, ACE and VEGFA Genes Are Predictive of Endothelial Dysfunction Associated Osteoporosis in Postmenopausal Women.
Glucocorticoids activate the local renin-angiotensin system in bone: possible mechanism for glucocorticoid-induced osteoporosis.
Identification of inappropriate prescribing in geriatrics at a Veterans Affairs hospital using STOPP/START screening tools.
Impact of antihypertensive therapy on postmenopausal osteoporosis: effects of the angiotensin converting enzyme inhibitor moexipril, 17beta-estradiol and their combination on the ovariectomy-induced cancellous bone loss in young rats.
Medication undertreatment in assisted living settings.
Prevalence and predictors of inappropriate prescribing according to the Screening Tool of Older People's Prescriptions and Screening Tool to Alert to Right Treatment version?2 criteria in older patients discharged from geriatric and internal medicine wards: A prospective observational multicenter study.
Prevention of osteoporosis by angiotensin-converting enzyme inhibitor in spontaneous hypertensive rats.
The angiotensin converting enzyme 2/angiotensin-(1-7)/Mas Receptor axis as a key player in alveolar bone remodeling.
Understanding lupus nephritis: diagnosis, management, and treatment options.
Osteoporosis, Postmenopausal
Impact of antihypertensive therapy on postmenopausal osteoporosis: effects of the angiotensin converting enzyme inhibitor moexipril, 17beta-estradiol and their combination on the ovariectomy-induced cancellous bone loss in young rats.
Otosclerosis
No Evidence for the Expression of Renin-Angiotensin-Aldosterone System in Otosclerotic Stapes Footplates.
Out-of-Hospital Cardiac Arrest
A pilot study of angiotensin converting enzyme (ACE) genotype and return of spontaneous circulation following out-of-hospital cardiac arrest.
Ovarian Hyperstimulation Syndrome
Effect of angiotensin-converting enzyme inhibitor on renal function in ovarian hyperstimulation syndrome in the rabbit.
Effects of angiotensin converting enzyme inhibitor cilazapril and angiotensin II antagonist saralasin in ovarian hyperstimulation syndrome in the rabbit.
Increased angiotensin-converting enzyme activity in a patient with severe ovarian hyperstimulation syndrome.
Inhibition of ovarian-derived prorenin to angiotensin cascade in the treatment of ovarian hyperstimulation syndrome.
Ovarian Neoplasms
Assessment of serum angiotensin-converting enzyme in patients with epithelial ovarian cancer.
Association of angiotensin-converting enzyme I gene I/D polymorphism with endometrial but not with ovarian cancer.
Overweight
ACE inhibition but not angiotensin II antagonism reduces plasma fibrinogen and insulin resistance in overweight hypertensive patients.
Angiotensin-converting enzyme gene polymorphism in overweight and obese Turkish patients with insulin resistance.
Blood pressure control and cardiovascular outcomes in normal-weight, overweight, and obese hypertensive patients treated with three different antihypertensives in ALLHAT.
Controlled study of the effect of angiotensin converting enzyme inhibition versus calcium-entry blockade on insulin sensitivity in overweight hypertensive patients: Trandolapril Italian Study (TRIS).
Effect of chronic ACE inhibition on glucose tolerance and insulin sensitivity in hypertensive type 2 diabetic patients.
Effects of Blood Pressure Lowering Agents on Cardiovascular Outcomes in Weight Excess Patients: A Systematic Review and Meta-analysis.
Genetic Contributions to Childhood Obesity: Association of Candidate Gene Polymorphisms and Overweight/Obesity in Korean Preschool Children.
Increased frequency of angiotensin-converting enzyme DD genotype in Saudi overweight and obese patients.
Metabolic neutrality of perindopril: focus on insulin sensitivity in overweight patients with essential hypertension.
PATHOGENETIC ADVANCES OF FOSINOPRIL SODIUM WITH HYDROCHLOROTHIAZIDE IN OBESE HYPERTENSIVE PATIENTS.
Polymorphisms of the renin-angiotensin system are not associated with overweight and obesity in a general adult population.
Predictors of Recurrent Ischemic Stroke in Obese Patients With Type 2 Diabetes Mellitus: A Population-based Study.
The relation between obesity, abdominal fat deposit and the angiotensin-converting enzyme gene I/D polymorphism and its association with coronary heart disease.
Therapeutic approaches in the prevention of cardiovascular disease in metabolic syndrome and in patients with type 2 diabetes.
[Angiotensin converting enzyme gene polymorphism in type 2 diabetes mellitus]
Pancreatic Cyst
[Pancreatic tumors.]
Pancreatic Diseases
Serum angiotensin converting enzyme levels in pancreatic diseases.
Pancreatic Neoplasms
Angiotensin-Converting Enzyme Gene Insertion/Deletion Polymorphism in Patients with Chronic Pancreatitis and Pancreatic Cancer.
Inhibition of renin-angiotensin system affects prognosis of advanced pancreatic cancer receiving gemcitabine.
Inhibitors of angiotensin-converting enzyme modulate mitosis and gene expression in pancreatic cancer cells.
Role of the RAS in Pancreatic Cancer.
The angiotensin-I-converting enzyme inhibitor enalapril and aspirin delay progression of pancreatic intraepithelial neoplasia and cancer formation in a genetically engineered mouse model of pancreatic cancer.
The therapeutic potential of renin-angiotensin system inhibitors in the treatment of pancreatic cancer.
[Intrinsic angiotensin II-generating system in human pancreatic cancer tissues]
[Pancreatic tumors.]
Pancreatitis
ACE inhibitors and the risk of acute pancreatitis-a population-based case-control study.
Acute pancreatitis associated with the use of lisinopril.
Acute pancreatitis following lisinopril rechallenge.
Angiotensin converting enzyme inhibitor therapy and acute pancreatitis.
Angiotensin-converting enzyme (ACE and ACE2) imbalance correlates with the severity of cerulein-induced acute pancreatitis in mice.
Angiotensin-converting enzyme (ACE) inhibitor-induced acute pancreatitis: in search of the evidence.
Angiotensin-Converting Enzyme (ACE) Inhibitors and Pancreatitis: A Potential Dose-dependent Relationship.
Angiotensin-converting enzyme 2-angiotensin (1-7)-Mas axis prevents pancreatic acinar cell inflammatory response via inhibition of the p38 mitogen-activated protein kinase/nuclear factor-?B pathway.
Angiotensin-converting enzyme gene DD genotype neither increases susceptibility to acute pancreatitis nor influences disease severity.
Angiotensin-converting enzyme inhibitor-induced pancreatitis.
Angiotensin-converting-enzyme inhibitor administration must be monitored for serum amylase and lipase in order to prevent an acute pancreatitis: a case report.
Antihypertensive medication and the risk of acute pancreatitis: the European case-control study on drug-induced acute pancreatitis (EDIP).
Association between ACE inhibitors and acute pancreatitis in the elderly.
Association between angiotensin-converting enzyme gene insertion/deletion polymorphism and pancreatitis risk: A meta-analysis.
Captopril, an Angiotensin-converting enzyme inhibitor, attenuates the severity of acute pancreatitis in rats by reducing expression of matrix metalloproteinase 9.
Cardiovascular homeostasis in hypotension associated with initial stages of severe acute pancreatitis.
Changes of angiotensin-converting enzyme activity in the pancreas of chronic hypoxia and acute pancreatitis.
Differential effects of saralasin and ramiprilat, the inhibitors of renin-angiotensin system, on cerulein-induced acute pancreatitis.
Enalapril increases the local extravasation of macromolecules and nitric oxide synthase in pancreas of the fructose-fed insulin-resistant rat model.
Enalapril-induced acute recurrent pancreatitis.
Epidemiology of Acute Pancreatitis in Southern Israel: A Retrospective Study.
Fulminant pancreatitis associated with lisinopril therapy.
Inhibition of renin-angiotensin system in experimental acute pancreatitis in rats: A new therapeutic target?
Lack of significant association of an insertion/deletion polymorphism in the angiotensin converting enzyme (ACE) gene with tropical calcific pancreatitis.
Mirtazapine-Induced Pancreatitis-A Case Report.
Ritonavir and disulfiram may be synergistic in lowering active interleukin-18 levels in acute pancreatitis, and thereby hasten recovery.
Simultaneous acute pancreatitis and angioedema associated with angiotensin-converting enzyme inhibitor.
[Effect of 8-week administration of enalapril plus additional 2-week administration of furosemide on heart rate and exocrine pancreas secretion in dogs]
[Effect of enalapril on heart rate, arterial blood pressure and exocrine pancreatic secretion in the alert dog]
Pancreatitis, Chronic
Angiotensin-Converting Enzyme Gene Insertion/Deletion Polymorphism in Patients with Chronic Pancreatitis and Pancreatic Cancer.
Angiotensin-converting enzyme inhibitor attenuates pancreatic inflammation and fibrosis in male Wistar Bonn/Kobori rats.
Angiotensin-converting enzyme insertion/deletion polymorphism in patients with acute and chronic pancreatitis.
combination effect of hypertonic disease with chronic pancreatitis on the processes maintain homeostasis.
Combination therapy with an angiotensin-converting enzyme inhibitor and an angiotensin II receptor blocker synergistically suppresses chronic pancreatitis in rats.
The functional angiotensin converting enzyme gene I/D polymorphism does not alter susceptibility to chronic pancreatitis.
Pancytopenia
Captopril inhibits the proliferation of hematopoietic stem and progenitor cells in murine long-term bone marrow cultures.
Panniculitis, Nodular Nonsuppurative
[A case of Weber-Christian disease with elevated angiotensin-converting enzyme (ACE) activity and myopathy]
Panuveitis
Choroidal nonperfusion on optical coherence tomography angiography in a case of unilateral posterior segment ocular sarcoidosis misdiagnosed as MEWDS.
Relevance of Brain MRI in Patients with Uveitis: Retrospective Cohort on 402 Patients.
Sarcoid-related uveitis occurring during etanercept therapy.
Paralysis
Angiotensin converting enzyme inhibitor induced hyperkalaemic paralysis.
Cerebrospinal fluid levels of angiotensin-converting enzyme in Alzheimer's disease, Parkinson's disease and progressive supranuclear palsy.
Facial nerve enhancement on gadolinium-DTPA in a case with neurosarcoidosis.
Renin-angiotensin and development of collateral circulation after renal ischemia.
Parasitic Diseases
[Recurrent transverse myelitis. 2 cases and review of the literature]
Parkinson Disease
A Role for the Brain RAS in Alzheimer's and Parkinson's Diseases.
Angiotensin-converting enzyme inhibition reduces oxidative stress and protects dopaminergic neurons in a 6-hydroxydopamine rat model of Parkinsonism.
Angiotensin-converting enzyme inhibitors and bacterial pneumonia in patients with Parkinson disease.
Association between genetic polymorphism of angiotensin-converting enzyme gene and Parkinson's disease.
Cerebrospinal fluid levels of angiotensin-converting enzyme in Alzheimer's disease, Parkinson's disease and progressive supranuclear palsy.
Cerebrospinal fluid levels of angiotensin-converting enzyme, acetylcholinesterase, and dopamine metabolites in dementia associated with Alzheimer's disease and Parkinson's disease: a correlative study.
Chronic Use of ?-Blockers and the Risk of Parkinson's Disease.
Genetic polymorphism of Angiotensin-Converting Enzyme is not associated with the development of Parkinson's disease and of l-dopa-induced adverse effects.
Genetic polymorphism of the angiotensin converting enzyme and L-dopa-induced adverse effects in Parkinson's disease.
Increased angiotensin-converting enzyme activity in cerebrospinal fluid of treated patients with Parkinson's disease.
Peganum Harmala L. Extract Reduces Oxidative Stress and Improves Symptoms in 6-Hydroxydopamine-Induced Parkinson's Disease in Rats.
Potential protective role of ACE-inhibitors and AT1 receptor blockers against levodopa-induced dyskinesias: a retrospective case-control study.
Reduction of dopaminergic degeneration and oxidative stress by inhibition of angiotensin converting enzyme in a MPTP model of parkinsonism.
Risk Factors for Aspiration Pneumonia in Frail Older People: A Systematic Literature Review.
The angiotensin converting enzyme (ACE) inhibitor, perindopril, modifies the clinical features of Parkinson's disease.
The angiotensin-converting enzyme (ACE) I/D polymorphism in Parkinson's disease.
The Implications of Angiotensin-Converting Enzymes and Their Modulators in Neurodegenerative Disorders: Current and Future Perspectives.
The insertion/deletion polymorphism in the angiotensin-converting enzyme and susceptibility to schizophrenia or Parkinson's disease: A meta-analysis.
The insertion/deletion polymorphism of the angiotensin converting enzyme (ACE) in Parkinson's disease.
Use of antihypertensives and the risk of Parkinson disease.
Parkinsonian Disorders
Angiotensin-converting enzyme inhibition reduces oxidative stress and protects dopaminergic neurons in a 6-hydroxydopamine rat model of Parkinsonism.
Influenza Vaccination Reduces Dementia Risk in Chronic Kidney Disease Patients: A Population-Based Cohort Study.
Reduction of dopaminergic degeneration and oxidative stress by inhibition of angiotensin converting enzyme in a MPTP model of parkinsonism.
The angiotensin converting enzyme inhibitor captopril protects nigrostriatal dopamine neurons in animal models of parkinsonism.
Pediatric Obesity
Angiotensin Converting Enzyme insertion/deletion polymorphism: A potential connection with hypertension in childhood obesity.
Pemphigoid, Bullous
A case of levetiracetam induced bullous pemphigoid.
Oroesophageal Pemphigus vulgaris Secondary to Lisinopril Use: A New Side Effect.
Pemphigus
ACE inhibitors can induce circulating antibodies directed to antigens of the superficial epidermal cells.
Angiotensin-converting enzyme inhibitor-induced pemphigus: three case reports and literature review.
Angiotensin-converting-enzyme inhibitors and angiotensin II receptor blockers induced pemphigus: A case series and literature review.
Cutaneous effects of antihypertensive drugs.
Drug-induced pemphigus related to angiotensin-converting enzyme inhibitors.
Drug-related pemphigus and angiotensin converting enzyme inhibitors.
Enalapril: a powerful in vitro non-thiol acantholytic agent.
Fosinopril as a possible pemphigus-inducing drug.
Increased activity of plasma and tissue kallikreins, plasma kininase II and salivary kallikrein in pemphigus foliaceus (fogo selvagem).
Serum Angiotensin converting enzyme in pemphigus vulgaris.
Peptic Ulcer
A pharmacist-led information technology intervention for medication errors (PINCER): a multicentre, cluster randomised, controlled trial and cost-effectiveness analysis.
Low-Dose Aspirin-Associated Upper and Mid Gastrointestinal Tract Damage and Gene Polymorphism.
Protocol for the PINCER trial: a cluster randomised trial comparing the effectiveness of a pharmacist-led IT-based intervention with simple feedback in reducing rates of clinically important errors in medicines management in general practices.
Renin-Angiotensin System Associated with Risk of Upper GI Mucosal Injury Induced by Low Dose Aspirin : Renin Angiotensin System Genes' Polymorphism.
Serum angiotensin converting enzyme in Crohn's disease, ulcerative colitis and peptic ulceration.
[Risk factors for recurrent hospitalizations of patients with atrial fibrillation].
peptidyl-dipeptidase a deficiency
Congenital angiotensin-converting enzyme deficiency presenting as recurrent angioedema of upper airway in adult life.
Expression of urea transporters and their regulation.
Serum Renin Levels Increase With Age in Boys Resulting in Higher Renin Levels in Young Men Compared to Young Women, and Soluble Angiotensin-Converting Enzyme 2 Correlates With Renin and Body Mass Index.
Tubuloglomerular feedback: mechanistic insights from gene-manipulated mice.
Periapical Abscess
Prevalence of Periapical Abscesses in Patients with Hypertension: A Cross-sectional Study of a Large Hospital Population.
Pericarditis, Constrictive
The Effects of Angiotensin Converting Enzyme Inhibitors (ACE-I) on Human N-Acetyl-Seryl-Aspartyl-Lysyl-Proline (Ac-SDKP) Levels: A Systematic Review and Meta-Analysis.
Perinatal Death
Pregnancy in chronic renal insufficiency and end-stage renal disease.
Perinephritis
Serum angiotensin converting enzyme activity and the capacity to develop hypertention-associated arterial disease. Studies during the induction phase of one-kidney perinephritis hypertension in rabbits.
Periodontal Diseases
Effect of angiotensin-converting enzyme inhibitors on vascular endothelial function in hypertensive patients after intensive periodontal treatment.
Periodontitis
Associations between Pharmacotherapy for Cardiovascular Diseases and Periodontitis.
Peripheral Arterial Disease
2010 guidelines of the Taiwan Society of Cardiology for the management of hypertension.
Adherence to guideline-recommended therapy is associated with decreased major adverse cardiovascular events and major adverse limb events among patients with peripheral arterial disease.
Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers (ACEI/ARB) are Associated with Improved Limb Salvage after Infrapopliteal Interventions for Critical Limb Ischemia.
Angiotensin-converting enzyme genotype and peripheral arterial disease in diabetic patients.
Angiotensin-converting enzyme inhibitor or angiotensin receptor blocker use is associated with reduced major adverse cardiovascular events among patients with critical limb ischemia.
Angiotensin-converting enzyme inhibitors for intermittent claudication associated with peripheral arterial disease.
Effect of angiotensin blockade on the association between albuminuria and peripheral arterial disease in elderly taiwanese patients with type 2 diabetes mellitus.
Effect of ramipril on walking times and quality of life among patients with peripheral artery disease and intermittent claudication: A randomized controlled trial. Journal of the American Medical Association 2013; 309: 453-460.
Effects on Mortality and Cardiovascular Events of Adherence to Guideline-Recommended Therapy 4 Years after Lower Extremity Arterial Revascularization.
How Admission to a Vascular Surgery Department Improves Medical Treatment in Patients with Lower Extremity Peripheral Arterial Disease.
How to treat hypertension in patients with peripheral artery disease.
Improved survival with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in chronic limb-threatening ischemia.
Incomplete inhibition of thromboxane biosynthesis by acetylsalicylic acid: determinants and effect on cardiovascular risk.
Lower progression rate of end-stage renal disease in patients with peripheral arterial disease using statins or Angiotensin-converting enzyme inhibitors.
Office management of peripheral arterial disease.
Optimal medical management of peripheral arterial disease.
Painful legs, aching heart: Reducing cardiovascular risk in patients with peripheral arterial disease with angiotensin-converting enzyme inhibition.
Patient, hospital and country-level risk factors of all-cause mortality among patients with chronic heart failure: Prospective international cohort study.
Peripheral arterial disease versus other localizations of vascular disease: the ATTEST study.
Prevalence of Appropriate Management of Diabetes Mellitus in an Academic General Medicine Clinic.
Prognostic factors for adverse outcomes in patients with COVID-19: a field-wide systematic review and meta-analysis.
Progression of atherosclerosis in patients with peripheral arterial disease as a function of angiotensin-converting enzyme gene insertion/deletion polymorphism.
Reduced arterial stiffness may contribute to angiotensin-converting enzyme inhibitor induced improvements in walking time in peripheral arterial disease patients.
Reduced arterial stiffness may contribute to angiotensin-converting enzyme inhibitor induced improvements in walking time in peripheral arterial disease patients: Retraction.
Risk factors associated with the development of ischemic colitis.
Should all patients with peripheral arterial disease be treated with an angiotensin-converting enzyme inhibitor?
The angiotensin-converting-enzyme insertion/deletion polymorphism is not a risk factor for peripheral arterial disease.
The potential role of angiotensin-converting enzyme inhibition in peripheral arterial disease.
Utilization of Vasculoprotective Therapy for Peripheral Artery Disease: A Systematic Review and Meta-analysis.
Vascular protection in patients with diabetes admitted for vascular surgery in a canadian tertiary care hospital: pilot study.
[Medical treatment in peripheral arterial disease: a professional practice study in 262 patients]
[Possibilities of the use Angiotensin converting enzyme inhibitor in peripheral arterial disease]
Peripheral Nervous System Diseases
Angiotensin-converting enzyme (ACE) gene II genotype protects against the development of diabetic peripheral neuropathy in type 2 diabetes mellitus.
Angiotensin-converting enzyme gene single polymorphism as a genetic biomarker of diabetic peripheral neuropathy: longitudinal prospective study.
Angiotensin-converting enzyme I/D polymorphism and diabetic peripheral neuropathy in type 2 diabetes mellitus: A meta-analysis.
Angiotensin-converting enzyme I/D polymorphism is a genetic biomarker of diabetic peripheral neuropathy: evidence from a meta-analysis.
Early loss of innervation of cornea epithelium in streptozotocin-induced type 1 diabetic rats: improvement with ilepatril treatment.
Effect of combination therapy consisting of enalapril, ?-lipoic acid, and menhaden oil on diabetic neuropathy in a high fat/low dose streptozotocin treated rat.
Efficacy of Administration of an Angiotensin Converting Enzyme Inhibitor for Two Years on Autonomic and Peripheral Neuropathy in Patients with Diabetes Mellitus.
Frequency and risk factors of severe hypoglycaemia in insulin-treated Type 2 diabetes: a cross-sectional survey.
The importance of association between angiotensin-converting enzyme (ACE) Gene I/D polymorphism and diabetic peripheral neuropathy.
[Effects of lisinopril on diabetic peripheral neuropathy: experiment with rats]
Peripheral Vascular Diseases
A perspective on telmisartan and cardiovascular risk.
ACE gene polymorphism in peripheral vascular disease.
An Assessment of the Concentration-Related Prognostic Value of Cardiac Troponin I Following Acute Coronary Syndrome.
Circulating CD40 and sCD40L Predict Changes in Renal Function in Subjects with Chronic Kidney Disease.
Clinical characteristics and predictors of in-hospital mortality in acute heart failure with preserved left ventricular ejection fraction.
Coronary surgery in patients with preexisting chronic atrial fibrillation: early and midterm clinical outcome.
Corrigendum to "Ethnic differences in the association between angiotensin-converting enzyme gene insertion/deletion polymorphism and peripheral vascular disease: A meta-analysis" [CDTM 3/4 (2017) 230-241].
Ethnic differences in the association between angiotensin-converting enzyme gene insertion/deletion polymorphism and peripheral vascular disease: A meta-analysis.
Factors associated with aspirin resistance in patients premedicated with aspirin and clopidogrel for endovascular neurosurgery.
Hypertension: investigation, assessment and diagnosis.
Incidence, predictors and clinical management of hyperkalaemia in new users of mineralocorticoid receptor antagonists.
Lack of association between angiotensin-converting enzyme gene polymorphism and peripheral vascular disease in type 2 diabetic patients in Taiwan.
Mortality and cause of death in patients with heart failure: findings at a specialist multidisciplinary heart failure unit.
Potentially inappropriate prescribing (IP) for elderly medical inpatients in Taiwan: A hospital-based study.
Presentation, surgical intervention, and long-term survival in patients with Marfan syndrome.
Protection: risk ratio of antihypertensive drug treatment in the elderly.
Randomized, placebo-controlled trial of the angiotensin-converting enzyme inhibitor, ramipril, in patients with coronary or other occlusive arterial disease. PART-2 Collaborative Research Group. Prevention of Atherosclerosis with Ramipril.
Urinary albumin excretion and atherosclerosis in essential hypertension.
Peritoneal Fibrosis
The ACE inhibitor, quinapril, ameliorates peritoneal fibrosis in an encapsulating peritoneal sclerosis model in mice.
Peritonitis
Data-mining analyses of pharmacovigilance signals in relation to relevant comparison drugs.
Levels of transforming growth factor ?1 during first six months of peritoneal dialysis.
Predictors of decline of residual renal function in new peritoneal dialysis patients.
The effect of low glucose degradation product dialysis solution on epithelial-to-mesenchymal transition in continuous ambulatory peritoneal dialysis patients.
Pheochromocytoma
Angiotensin II and angiotensin converting enzyme binding in human adrenal gland and pheochromocytomas.
Arginine vasopressin as a rescue vasopressor agent in the operating room.
Captopril improves hypertension and cardiomyopathy in rats with pheochromocytoma.
Catecholamine-induced cardiomyopathy.
Pituitary ACTH Hypersecretion
[Activity of angiotensin converting enzyme (ACE) in cushing's disease]
[The activity of renin-angiotensin-aldosterone system (RAA) and possibilities of application angiotensin converting enzyme inhibitors (ACE I) in selected diseases of endocrine glands]
Pituitary Neoplasms
Presence of renin, angiotensinogen, and converting enzyme in human pituitary lactotroph cells and prolactin adenomas.
Placental Insufficiency
[Proteolytic activity of fetoplacental complex in norm and pathology].
Pleural Effusion
Activity of angiotensin-converting enzyme in pleural fluid and serum in non-sarcoid, non-tuberculous pleural effusion.
Chylothorax associated with tricuspid dysplasia and atrial septal defect in a bullmastiff.
Cilazapril-induced pleural effusion: A case report and review of the literature.
Clinical Characteristics and Factors Associated with Heart Failure Readmission at a Tertiary Hospital in North-Eastern Tanzania.
Effect of acute lung injury on angiotensin converting enzyme in serum, lung lavage, and effusate.
Levels of angiotensin-converting enzyme in pleural effusion.
Perioperative administration of angiotensin converting enzyme inhibitors decreases the severity and duration of pleural effusions following bidirectional cavopulmonary anastomosis.
Pleural fluid beta-2-microglobulin and angiotensin-converting enzyme concentrations in rheumatoid arthritis and tuberculosis.
Significant association of insertion/deletion polymorphism of the angiotensin-converting enzyme gene with rheumatoid arthritis.
Pleural Effusion, Malignant
Calpain and spectrin breakdown products as potential biomarkers in tuberculous pleural effusion.
Pleurisy
Imidapril-induced eosinophilic pleurisy. Case report and review of the literature.
Pneumoconiosis
Serum angiotensin-converting enzyme in coal worker's pneumoconiosis.
Pneumonia
Angiotensin-converting enzyme (ACE) I/D corrected serum ACE activity and severity assessment of community-acquired pneumonia.
Angiotensin-converting enzyme 2 (ACE2): COVID 19 gate way to multiple organ failure syndromes.
Angiotensin-converting enzyme I/D polymorphism is associated with pneumonia risk: A meta-analysis.
Angiotensin-converting enzyme inhibitor captopril attenuates ventilator-induced lung injury in rats.
Angiotensin-converting enzyme inhibitor use and pneumonia risk in a general population.
Angiotensin-converting enzyme inhibitor use and pneumonia risk in community-dwelling older adults: results from a population-based case-control study.
Angiotensin-converting enzyme inhibitor use and protection against pneumonia in patients with diabetes.
Angiotensin-converting enzyme inhibitor/angiotensin II receptor blockers and pneumonia risk among stroke patients.
Angiotensin-converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARBs) may be safe for COVID-19 patients.
Angiotensin-Converting Enzyme Inhibitors and Active Tuberculosis: A Population-Based Study.
Angiotensin-converting enzyme inhibitors and bacterial pneumonia in patients with Parkinson disease.
Angiotensin-converting enzyme inhibitors and pneumonia in elderly patients with intracerebral hemorrhage.
Angiotensin-converting Enzyme Inhibitors Decrease the Incidence of Radiation-induced Pneumonitis Among Lung Cancer Patients: A Systematic Review and Meta-analysis.
Angiotensin-converting enzyme inhibitors, angiotensin-II receptor antagonists, and pneumonia in elderly hypertensive patients with stroke.
Angiotensin-converting enzyme insertion/deletion polymorphism and risk and outcome of pneumonia.
Antihypertensive medications and risk of community-acquired pneumonia.
ARB-Based Combination Therapy for the Clinical Management of Hypertension and Hypertension-Related Comorbidities: A Spotlight on Their Use in COVID-19 Patients.
Association between angiotensin-converting enzyme inhibitors or angiotensin receptor blockers and community-acquired pneumonia: A nationwide population propensity-score matching study.
Association of hydrophilic versus lipophilic angiotensin-converting enzyme inhibitor use on pneumonia-related mortality.
Can angiotensin-converting enzyme inhibitors reduce the risk of pneumonia after stroke?
Cardiac Remodeling and Reversible Pulmonary Hypertension During Pneumonitis in Rats after 13-Gy Partial-Body Irradiation with Minimal Bone Marrow Sparing: Effect of Lisinopril.
Chymase is activated in the pulmonary inflammation and fibrosis induced by paraquat in hamsters.
Comparative effects of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on the risk of pneumonia and severe exacerbations in patients with COPD.
Comparing individual angiotensin-converting enzyme inhibitors with losartan in the risk of hospitalization for pneumonia and related mortality: a nationwide cohort study.
Correlation Between Early Plasma Interleukin 37 Responses With Low Inflammatory Cytokine Levels and Benign Clinical Outcomes in Severe Acute Respiratory Syndrome Coronavirus 2 Infection.
COVID-19 and RAS: Unravelling an Unclear Relationship.
COVID-19-Associated Pneumonia: Radiobiological Insights.
CT visual quantitative evaluation of hypertensive patients with coronavirus disease (COVID-19): Potential influence of angiotensin converting enzyme inhibitors / angiotensin receptor blockers on severity of lung involvement.
Daily Lisinopril vs Placebo for Prevention of Chemoradiation-Induced Pulmonary Distress in Patients With Lung Cancer (Alliance MC1221): A Pilot Double-Blind Randomized Trial.
Decreased Risk of Radiation Pneumonitis With Coincident Concurrent Use of Angiotensin-converting Enzyme Inhibitors in Patients Receiving Lung Stereotactic Body Radiation Therapy.
Deletion allele of the angiotensin-converting enzyme gene as a risk factor for pneumonia in elderly patients.
Disparities in health care are driven by where minority patients seek care: examination of the hospital quality alliance measures.
Do Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers Decrease the Risk of Hospitalization Secondary to Community-Acquired Pneumonia? A Nested Case-Control Study.
Does Low Dose Angiotensin Converting Enzyme Inhibitor Prevent Pneumonia in Older People With Neurologic Dysphagia--A Randomized Placebo-Controlled Trial.
Effect of therapeutic interchange on medication reconciliation during hospitalization and upon discharge in a geriatric population.
Effects of an angiotensin-converting enzyme inhibitor-based regimen on pneumonia risk.
Elevated levels of angiotensin-converting enzyme in Pneumocystis carinii pneumonia.
Examination of selected clinical factors and medication use as risk factors for pneumonia during stroke rehabilitation: a case-control study.
Genetic Association Between CD143 rs4340 Polymorphism and Pneumonia risk: A Meta Analysis.
Genetics in community-acquired pneumonia.
Gram-negative pneumonia among patients undergoing dialysis who were admitted to the hospital with angioedema secondary to angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists.
Impact of angiotensin-converting enzyme inhibitors and statins on viral pneumonia.
Impact of statins and angiotensin-converting enzyme inhibitors on mortality of subjects hospitalised with pneumonia.
Incidence and Outcomes of Pneumonia in Patients With Heart Failure.
Incidence and prognostic implications of Acute Kidney Injury on admission in patients with Community Acquired Pneumonia.
Increased risk of pneumonia associated with angiotensin-converting enzyme (CD143) rs4340 polymorphism.
Interventions to prevent pneumonia among older adults.
Is the use of ACE inb/ARBs associated with higher in-hospital mortality in Covid-19 pneumonia patients?
Lung inflammation in sarcoidosis: comparison of serum angiotensin-converting enzyme levels with bronchoalveolar lavage and gallium-67 scanning assessment of the T lymphocyte alveolitis.
Nicergoline improves dysphagia by upregulating substance P in the elderly.
Perindopril-associated pneumonitis.
Pneumonia Risk and Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers.
Positive association of angiotensin II receptor blockers, not angiotensin-converting enzyme inhibitors, with an increased vulnerability to SARS-CoV-2 infection in patients hospitalized for suspected COVID-19 pneumonia.
Post-Stroke Pneumonia Prevention by Angiotensin-Converting Enzyme Inhibitors: Results of a Meta-analysis of Five Studies in Asians.
Preventive strategies for aspiration pneumonia in elderly disabled persons.
Prognostic value of serum angiotensin-converting enzyme activity for outcome of community-acquired pneumonia.
Pulmonary clearance of Staphylococcus aureus and plasma angiotensin-converting enzyme activity in hydrocarbon pneumonitis.
Pulmonary surfactant itself must be a strong defender against SARS-CoV-2.
Purification and properties of angiotensin I-converting enzyme in human lung and its role on the metabolism of vasoactive peptides in pulmonary circulation.
Radiation exposure and lung disease in today's nuclear world.
Recurrent pneumonia: a review with focus on clinical epidemiology and modifiable risk factors in elderly patients.
Reduction of pneumonia risk by an angiotensin I-converting enzyme inhibitor in elderly Japanese inpatients according to insertion/deletion polymorphism of the angiotensin I-converting enzyme gene.
Reduction of risk of pneumonia associated with use of angiotensin I converting enzyme inhibitors in elderly inpatients.
Risk of pneumonia associated with use of angiotensin converting enzyme inhibitors and angiotensin receptor blockers: systematic review and meta-analysis.
Role of angiotensin-converting enzyme in Bacille Calmette-Guérin-induced granulomatous inflammation. Increased angiotensin-converting enzyme levels in lung lavage and suppression of inflammation with captopril.
Serum angiotensin converting enzyme in pneumonias.
Symptomatic Radiation Pneumonitis in Elderly Patients Receiving Thoracic Irradiation.
The impact of statins, ACE inhibitors and gastric acid suppressants on pneumonia mortality in a UK general practice population cohort.
The value of angiotensin-I-converting enzyme determinations in malignant and other diseases.
Transforming growth factor-beta-1 is a serum biomarker of radiation-induced pneumonitis in esophageal cancer patients treated with thoracic radiotherapy: preliminary results of a prospective study.
Use of ACE inhibitors and risk of community-acquired pneumonia: a review.
Ventilation-induced increases in EGFR ligand mRNA are not altered by intra-amniotic LPS or ureaplasma in preterm lambs.
[Angiotensin I-converting enzyme activity in serum and in the lung of rabbits with experimental pneumonitis (author's transl)]
[Change in activity of angiotensin-converting enzyme in pneumonia and chronic obstructive lung diseases]
[Change of lung lavage levels of angiotensin converting enzyme activity in mice with BCG-induced granulomatous pulmonary inflammation]
[Changes in angiotensin-converting enzyme activity in pneumonia and chronic obstructive lung diseases]
[Hypoxic eosinophilic pneumonia in two patients treated with ACE inhibitors]
[The change in the activity of angiotensin converting enzyme in patients with pneumonia and chronic obstructive pulmonary diseases]
Pneumonia, Aspiration
Association between Angiotensin-Converting Enzyme Inhibitors and Post-Stroke Aspiration Pneumonia.
Exploring the Relation between Glottal Closure and Plasma Substance P: A Study Protocol.
Post-Stroke Pneumonia Prevention by Angiotensin-Converting Enzyme Inhibitors: Results of a Meta-analysis of Five Studies in Asians.
Risk Factors for Aspiration Pneumonia in Frail Older People: A Systematic Literature Review.
[Aural Stimulation with Capsaicin Ointment Improved the Swallowing Function in Patients with Dysphagia: Evaluation by the SMRC Scale].
[Etiology, pathogenesis and management of senile inflammatory pulmonary diseases]
Pneumonia, Bacterial
Angiotensin-converting enzyme inhibitors and bacterial pneumonia in patients with Parkinson disease.
Pneumonia, Pneumocystis
A Previously Healthy 37-Year-Old Man With Acute Hypoxic Respiratory Failure and Fevers.
Elevated levels of angiotensin-converting enzyme in Pneumocystis carinii pneumonia.
Pneumonia, Viral
Biophysical analysis of SARS-CoV-2 transmission and theranostic development via N protein computational characterization.
Impact of angiotensin-converting enzyme inhibitors and statins on viral pneumonia.
Pneumoperitoneum
Effects of enalaprilat on the renin-angiotensin-aldosterone system and on renal function during CO2 pneumoperitoneum.
Pneumothorax
[Angiotensin I converting enzyme activity in patients with spontaneous pneumothorax and in rabbits with artificial pneumothorax (author's transl)]
[Life-threatening displacement of a tracheostomy tube in a patient with severe angiotensin-converting enzyme inhibitor-induced angioedema]
Polyarteritis Nodosa
Acute renal failure induced by angiotensin converting enzyme inhibitor in a patient with polyarteritis nodosa.
The renin-angiotensin system as a primary cause of polyarteritis nodosa in rats.
[Arterial hypertension in periarteritis nodosa. 37 case reports]
Polycystic Kidney Diseases
Angiotensin converting enzyme inhibitor limits pulse wave velocity and aortic calcification in a rat model of cystic renal disease.
Angiotensin-converting enzyme activity and the ACE Alu polymorphism in autosomal dominant polycystic kidney disease.
Association between angiotensin converting enzyme gene polymorphism and clinical features in autosomal dominant polycystic kidney disease.
Calcium channel blockers versus ACE inhibitors as antihypertensives in polycystic kidney disease.
Characterization of sperm surface protein patterns of ejaculated and capacitated boar sperm, with the detection of ZP binding candidates.
Chronic treatment with lisinopril decreases proliferative and apoptotic pathways in autosomal recessive polycystic kidney disease.
Cost-effectiveness of angiotensin-converting enzyme inhibitors versus angiotensin II receptor blockers as first-line treatment in autosomal dominant polycystic kidney disease.
Design and baseline characteristics of participants in the study of antihypertensive therapy in children and adolescents with autosomal dominant polycystic kidney disease (ADPKD).
Diuretics versus angiotensin-converting enzyme inhibitors in autosomal dominant polycystic kidney disease.
Effect of statin and angiotensin-converting enzyme inhibition on structural and hemodynamic alterations in autosomal dominant polycystic kidney disease model.
Evidence for pericyte origin of TSC-associated renal angiomyolipomas and implications for angiotensin receptor inhibition therapy.
Hypertension in patients with chronic kidney disease.
No effect of angiotensin-converting enzyme gene polymorphism on disease progression and left ventricular hypertrophy in autosomal dominant polycystic kidney disease.
Polycystic kidney disease and angiotensin-converting enzyme inhibitors.
Renin-Angiotensin-aldosterone system in autosomal dominant polycystic kidney disease.
Reversal of left ventricular hypertrophy with angiotensin converting enzyme inhibition in hypertensive patients with autosomal dominant polycystic kidney disease.
Reversible renal failure associated with angiotensin-converting enzyme inhibitors in polycystic kidney disease.
The angiotensin-converting enzyme genotype and microalbuminuria in autosomal dominant polycystic kidney disease.
The effect of angiotensin-converting-enzyme inhibitors on progression of advanced polycystic kidney disease.
The effect of sodium and angiotensin-converting enzyme inhibition on the classic circulating renin-angiotensin system in autosomal-dominant polycystic kidney disease patients.
US of renal insufficiency in neonates.
[Reversible panmyelopathy following captopril treatment]
Polycystic Kidney, Autosomal Dominant
ACE inhibitors, left ventricular mass and renal cyst growth in ADPKD.
Angiotensin-converting enzyme activity and the ACE Alu polymorphism in autosomal dominant polycystic kidney disease.
Association between angiotensin converting enzyme gene polymorphism and clinical features in autosomal dominant polycystic kidney disease.
Association of the angiotensin I converting enzyme gene deletion polymorphism with early onset of ESRF in PKD1 adult polycystic kidney disease.
Chymase-like angiotensin II-generating activity in end-stage human autosomal dominant polycystic kidney disease.
Cost-effectiveness of angiotensin-converting enzyme inhibitors versus angiotensin II receptor blockers as first-line treatment in autosomal dominant polycystic kidney disease.
Design and baseline characteristics of participants in the study of antihypertensive therapy in children and adolescents with autosomal dominant polycystic kidney disease (ADPKD).
Diuretics versus angiotensin-converting enzyme inhibitors in autosomal dominant polycystic kidney disease.
Effect of antihypertensive therapy on renal function and urinary albumin excretion in hypertensive patients with autosomal dominant polycystic kidney disease.
Effect of statin and angiotensin-converting enzyme inhibition on structural and hemodynamic alterations in autosomal dominant polycystic kidney disease model.
Effect of statin therapy on disease progression in pediatric ADPKD: Design and baseline characteristics of participants.
Effects of angiotensin converting enzyme inhibition in adult polycystic kidney disease.
Endothelial nitric oxide synthase gene expression is associated with hypertension in autosomal dominant polycystic kidney disease.
Epidemiological study of kidney survival in autosomal dominant polycystic kidney disease.
Hypertension and renal injury in experimental polycystic kidney disease.
Influence of ACE I/D gene polymorphism in the progression of renal failure in autosomal dominant polycystic kidney disease: a meta-analysis.
Influence of angiotensin converting enzyme (
Liver involvement in early autosomal-dominant polycystic kidney disease.
No effect of angiotensin-converting enzyme gene polymorphism on disease progression and left ventricular hypertrophy in autosomal dominant polycystic kidney disease.
Patients with autosomal dominant polycystic kidney disease hyperfiltrate early in their disease.
Prospective change in renal volume and function in children with ADPKD.
Renal volume, renin-angiotensin-aldosterone system, hypertension, and left ventricular hypertrophy in patients with autosomal dominant polycystic kidney disease.
Renin-Angiotensin-aldosterone system in autosomal dominant polycystic kidney disease.
Reversal of left ventricular hypertrophy with angiotensin converting enzyme inhibition in hypertensive patients with autosomal dominant polycystic kidney disease.
The angiotensin-converting enzyme genotype and microalbuminuria in autosomal dominant polycystic kidney disease.
The pathogenesis of hypertension in autosomal dominant polycystic kidney disease.
Therapeutic interventions for autosomal dominant polycystic kidney disease.
Vascular dysfunction in children and young adults with autosomal dominant polycystic kidney disease.
[Hypertension in patients with polycystic kidney disease -? incidence, pathogenesis, prognosis, therapy].
Polycystic Kidney, Autosomal Recessive
Chronic treatment with lisinopril decreases proliferative and apoptotic pathways in autosomal recessive polycystic kidney disease.
Kidney Disease Progression in Autosomal Recessive Polycystic Kidney Disease.
Polycystic Ovary Syndrome
Angiotensin converting enzyme gene insertion/deletion polymorphism in patients with polycystic ovary syndrome.
Angiotensin-converting enzyme D/I and plasminogen activator inhibitor-1 4G/5G gene polymorphisms are associated with increased risk of spontaneous abortions in polycystic ovarian syndrome.
Angiotensin-converting enzyme gene polymorphism and risk of insulin resistance in PCOS.
Association between the angiotensin converting enzyme gene insertion/deletion polymorphism and metabolic disturbances in women with polycystic ovary syndrome.
Association of angiotensin converting enzyme (ACE) gene I/D polymorphism and polycystic ovary syndrome (PCOS).
Association of angiotensin-converting enzyme gene insertion/deletion polymorphism with polycystic ovary syndrome: a meta-analysis.
Association of Angiotensin-Converting Enzyme gene polymorphism in Pakistani women with the atypical steroidogenesis in Polycystic ovarian syndrome: A case-control study.
Effect of hypertension therapy with the angiotensin-converting enzyme inhibitor lisinopril on hyperandrogenism in women with polycystic ovary syndrome.
Increased frequency of the DI genotype of the Angiotensin-I Converting Enzyme (ACE) and association of the II genotype with Insulin Resistance in Polycystic Ovary Syndrome.
Increased total Renin levels but not Angiotensin-converting enzyme activity in obese patients with polycystic ovary syndrome.
Polycystic ovarian syndrome: rs1799752 polymorphism of ACE gene.
Relationship between adipocytokines and angiotensin converting enzyme gene insertion/deletion polymorphism in lean women with and without polycystic ovary syndrome.
Polycythemia
A prospective, randomized, open labeled crossover trial of fosinopril and theophylline in post renal transplant erythrocytosis.
A randomized placebo-controlled study of enalapril in the treatment of erythrocytosis after renal transplantation.
A randomized trial comparing losartan with amlodipine as initial therapy for hypertension in the early post-transplant period.
Angiotensin converting enzyme gene polymorphism and development of post-transplant erythrocytosis.
Angiotensin II stimulates proliferation of normal early erythroid progenitors.
Angiotensin-converting enzyme gene polymorphism significantly affects renal posttransplantation erythrocytosis.
Angiotensin-converting enzyme inhibition in the treatment of renal transplant erythrocytosis. Clinical experience and observation of mechanism.
Angiotensin-converting enzyme inhibition induces apoptosis in erythroid precursors and affects insulin-like growth factor-1 in posttransplantation erythrocytosis.
Angiotensin-converting enzyme inhibitor-induced anemia and treatment for erythrocytosis in renal transplant recipients.
Angiotensin-converting enzyme inhibitors for secondary erythrocytosis.
Angiotensin-converting enzyme inhibitors reduce hemoglobin concentrations, hematocrit, and serum erythropoietin levels in renal transplant recipients without posttransplant erythrocytosis.
Association between activation of the renin-angiotensin system and secondary erythrocytosis in patients with chronic obstructive pulmonary disease.
Association between gene polymorphisms of the components of the renin-angiotensin-aldosteron system, graft function, and the prevalence of hypertension, anemia, and erythrocytosis after kidney transplantation.
Association of post-renal transplant erythrocytosis and microalbuminuria: response to angiotensin-converting enzyme inhibition.
Comparison of the effects of enalapril and theophylline on polycythemia after renal transplantation.
Effect of enalapril on exaggerated erythropoietin response to phlebotomy in erythrocytosic renal transplant patients.
Effect of the angiotensin-converting enzyme inhibitor enalapril on post-transplant erythrocytosis.
Effects of erythropoietin, angiotensin II, and angiotensin-converting enzyme inhibitor on erythroid precursors in patients with posttransplantation erythrocytosis.
Effects of losartan on the treatment of posttransplant erythrocytosis.
Effects of losartan or enalapril on hemoglobin, circulating erythropoietin, and insulin-like growth factor-1 in patients with and without posttransplant erythrocytosis.
Efficacy of enalapril after ineffective theophylline treatment on erythrocytosis after renal transplantation.
Enalapril treatment of posttransplant erythrocytosis: efficacy independent of circulating erythropoietin levels.
Hematocrit-lowering effect following inactivation of renin-angiotensin system with angiotensin converting enzyme inhibitors and angiotensin receptor blockers.
Idiopathic erythrocytosis in dialysis patients: a case report and literature review.
Influence of angiotensin I-converting enzyme polymorphism on development of post-transplant erythrocytosis in renal graft recipients.
Influence of angiotensin-converting enzyme polymorphism gene, IGF-1, and other factors in the response rate of hematocrit to enalapril treatment in patients with posttransplant erythrocytosis.
Long-term therapy for postrenal transplant erythrocytosis with ACE inhibitors: efficacy, safety and action mechanisms.
Losartan, an angiotensin II type 1 receptor antagonist, lowers hematocrit in posttransplant erythrocytosis.
Post renal transplant polycythemia and treatment: A single center study.
Postrenal transplant erythrocytosis and insertion/deletion polymorphism of the angiotensin converting enzyme gene.
Postrenal transplant erythrocytosis: a possible role for testosterone, angiotensin I-converting enzyme, and N-acetyl-seryl-aspartyl-lysyl-proline: reply to Kessler et al.
Posttransplant erythrocytosis in renal transplant recipients at Jeddah Kidney Center, Kingdom of Saudi Arabia.
Treatment of erythrocytosis in a renal transplant recipient by angiotensin converting enzyme inhibition.
Treatment of postrenal transplant erythrocytosis. Long-term efficacy and safety of angiotensin-converting enzyme inhibitors.
[Erythrocytosis post kidney transplantation and its pharmacological treatment: angiotensin converting enzyme inhibitors or angiotensin receptor blockers in a case]
Polycythemia Vera
Beneficial effect of ACE inhibitors on kidney function in polycythemia vera.
Polymyalgia Rheumatica
Polymyalgia rheumatica and giant cell arteritis--rational diagnosis and treatment predicated and disordered prostaglandin metabolism.
Polyneuropathies
Angiotensin-converting enzyme insertion/deletion polymorphism and polyneuropathy in type 2 diabetes without macroalbuminuria.
Disappearance of left ventricular hypertrabeculation/noncompaction after biventricular pacing in a patient with polyneuropathy.
Polyuria
Hyponatremic-hypertensive syndrome associated with renovascular hypertension: a case report.
Nocturnal Polyuria in Older Women with Urge Urinary Incontinence: Role of Sleep Quality, Time in Bed and Medications Used.
Severe polyuria and polydipsia in hyponatremic-hypertensive syndrome associated with Wilms tumor.
[Significance of kallikrein, angiotensin-converting enzyme, and proteolysis inhibitors in vascular complications in diabetes mellitus type 1 in children]
Porphyria, Acute Intermittent
A study of 24-hour ambulatory blood pressure monitoring in cases of intermittent acute porphyria with hypertension: special reference to safety and efficacy of angiotensin-converting enzyme inhibitor (enalapril) therapy.
Post-Exercise Hypotension
Acute and chronic effects of resistance exercise on blood pressure in elderly women and the possible influence of ACE I/D polymorphism.
Pre-Eclampsia
A meta-analysis of eNOS and ACE gene polymorphisms and risk of pre-eclampsia in women.
A novel mechanism of angiotensin II-regulated placental vascular tone in the development of hypertension in preeclampsia.
An insertion-deletion polymorphism in angiotensin-converting enzyme is associated with a reduced risk of preeclampsia: an evidence-based meta-analysis from 44 studies.
Angiotensin converting enzyme intron 16 insertion/deletion genotype is associated with plasma C-reactive protein concentration in uteroplacental dysfunction.
Angiotensin-converting enzyme activity in pre-eclampsia.
Angiotensin-Converting Enzyme and Adducin-1 Polymorphisms in Women With Preeclampsia and Gestational Hypertension.
Angiotensin-converting enzyme gene polymorphism in preeclampsia and normal pregnancy.
Angiotensin-converting enzyme I/D polymorphism and preeclampsia risk: evidence of small-study bias.
Angiotensin-converting enzyme inhibitors during the first trimester of pregnancy increase the incidence of fetal malformation, whereas calcium intake (1.0 to 2.0 g/day) prevents preeclampsia.
Angiotensin-converting enzyme insertion-deletion polymorphism in normotensive and pre-eclamptic pregnancies.
Angiotensin-converting enzyme insertion/deletion (ACE I/D) and angiotensin II type 1 receptor (AT1R) gene polymorphism and its association with preeclampsia in Chinese women.
Assessment of angiotensin converting enzyme gene polymorphism in preeclampsia mothers of Bangladesh.
Assessment of insertion/deletion polymorphism of ACE gene as a genetic risk marker for preeclampsia in pregnant women.
Association of Angiotensin-converting enzyme and angiotensinogen gene polymorphisms with preeclampsia.
Association of angiotensin-converting enzyme insertion-deletion polymorphism with preeclampsia.
Association of Angiotensin-Converting Enzyme Intron 16 Insertion/Deletion and Angiotensin II Type 1 Receptor A1166C Gene Polymorphisms with Preeclampsia in South East of Iran.
Association of angiotensin-converting enzyme intron 16 insertion/deletion polymorphism with history of foetal loss.
Associations of polymorphisms of the angiotensinogen M235 polymorphism and angiotensin-converting-enzyme intron 16 insertion/deletion polymorphism with preeclampsia in Korean women.
Comparison of angiotensin-converting enzyme, malonaldehyde, zinc, and copper levels in preeclampsia.
Endothelial angiotensin II generation induced by placenta-derived factors from preeclampsia.
Endothelial nitric oxide synthase gene influences the risk of pre-eclampsia, the recurrence of negative pregnancy events, and the maternal-fetal flow.
Evaluation of the renin-angiotensin-aldosterone system in pregnancy complicated by preeclampsia with and without intrauterine growth retardation.
Evidence-based management for preeclampsia.
Genetic polymorphisms in vasoactive genes and preeclampsia: a meta-analysis.
Histone deacetylase inhibition disturbs the balance between ACE and chymase expression in endothelial cells: a potential mechanism of chymase activation in preeclampsia.
Hypertension-related gene polymorphisms in pre-eclampsia, eclampsia and gestational hypertension in Black South African women.
Insertion-deletion polymorphism in the gene for angiotensin-converting enzyme is associated with obstetric cholestasis but not with preeclampsia.
Insertion/deletion polymorphism of the angiotensin-converting enzyme gene and preeclampsia in Japanese patients.
Low-molecular-weight heparin lowers the recurrence rate of preeclampsia and restores the physiological vascular changes in angiotensin-converting enzyme DD women.
Meta analysis of angiotensin-converting enzyme I/D polymorphism as a risk factor for preeclampsia in Chinese women.
Meta-analysis of angiotensin-converting enzyme insersion/delection polymorphism and pre-eclampsia susceptibility.
Pathophysiology and therapeutic possibilities of calcitonin gene-related peptide in hypertension.
Polymorphisms in angiotensin-converting enzyme and glutathione s-transferase genes in Turkish population and risk for preeclampsia.
Polymorphisms of the angiotensin converting enzyme gene in early-onset and late-onset pre-eclampsia.
Preeclampsia and angiotensin converting enzyme (ACE) I/D and angiotensin II type-1 receptor (AT1R) A1166C polymorphisms: association with ACE I/D polymorphism.
Preeclampsia in North Indian women: the contribution of genetic polymorphisms.
Preeclampsia is associated with ACE I/D polymorphism, obesity and oxidative damage in Mexican women.
Prolylcarboxypeptidase gene, chronic hypertension, and risk of preeclampsia.
Renin-angiotensin system gene variants and risk of early- and late-onset preeclampsia: A single center case-control study.
Studies on Angiotensin-converting enzyme insertion/deletion polymorphism and genotype distributions in Turkish preeclampsia patients.
Synergistic effect of renin-angiotensin system and nitric oxide synthase genes polymorphisms in pre-eclampsia.
The association between preeclampsia and angiotensin-converting enzyme insertion/deletion polymorphism.
The Gene Variants of Maternal/Fetal Renin-Angiotensin System in Preeclampsia: A Hybrid Case-Parent/Mother-Control Study.
The influence of mode of delivery and ACE genotype on serum angiotensin converting enzyme (ACE) activity in the mother and infant at term.
The influence of normotensive pregnancy and pre-eclampsia on angiotensin-converting enzyme.
The plasma renin-angiotensin system in preeclampsia: effects of magnesium sulfate.
Urinary coagulation-fibrinolysis, kallirein-kinin systems and kininase in cases of preclampsia.
[Detection of insertion/deletion polymorphism of angiotensin converting enzyme gene in preeclampsia]
[Expression and activity change of angiotensin converting enzyme in the placenta of preeclampsia]
[Interaction between GNB3 C825T and ACE I/D polymorphisms in pre-eclampsia].
Prediabetic State
Conflicting and new risk factors for contrast induced nephropathy.
Effects of add-on nebivolol on blood pressure and glucose parameters in hypertensive patients with prediabetes.
Mechanistic and Clinical Aspects of Renin-Angiotensin-Aldosterone System (RAAS) Blockade in the Prevention of Diabetes and Cardiovascular Disease.
Pregnancy Complications
A novel rodent model of pregnancy complications associated with genetically determined angiotensin converting enzyme (ACE) activity.
Genetic polymorphisms of the renin-angiotensin system in preterm delivery and premature rupture of membranes.
The Angiotensin-converting Enzyme Insertion/Deletion Polymorphism as a Common Risk Factor for Major Pregnancy Complications.
The influence of mode of delivery and ACE genotype on serum angiotensin converting enzyme (ACE) activity in the mother and infant at term.
Prehypertension
Effects of aerobic exercise training on ACE and ADRB2 gene expression, plasma angiotensin II level, and flow-mediated dilation: a study on obese postmenopausal women with prehypertension.
Formulation, Characterization and Stability Assessment of a Food-Derived Tripeptide, Leucine-Lysine-Proline Loaded Chitosan Nanoparticles.
Prehypertension exercise training attenuates hypertension and cardiac hypertrophy accompanied by temporal changes in the levels of angiotensin II and angiotensin (1-7).
Premature Birth
Association between angiotensin-converting enzyme gene insertion/deletion polymorphism and susceptibility to preterm birth: A case-control study and meta-analysis.
Correlation of angiotensin converting enzyme activity and the genotypes of the I/D polymorphism in the ACE gene with preterm birth and birth weight.
Genetic Association of Angiotensin-Converting Enzyme (ACE) Gene I/D Polymorphism with Preterm Birth in Korean Women: Case-Control Study and Meta-Analysis.
Genetic basis for necrotizing enterocolitis--risk factors and their relations to genetic polymorphisms.
Serially assessed bisphenol A and phthalate exposure and association with kidney function in children with chronic kidney disease in the US and Canada: A longitudinal cohort study.
Primary Myelofibrosis
Factors Related to Erythropoietin Hyporesponsiveness in Peritoneal Dialysis Patients with Anemia.
Primary Ovarian Insufficiency
Association between polymorphisms in renin-angiotensin system genes and primary ovarian insufficiency in Korean women.
Physical training promotes similar effects to the blockade of angiotensin-converting enzyme on the cardiac morphology and function in old female rats subjected to premature ovarian failure.
Proctitis
Can Angiotensin-Converting Enzyme Inhibitors Reduce the Incidence, Severity, and Duration of Radiation Proctitis?
Prostatic Diseases
Association of Angiotensin I Converting Enzyme Insertion/287?bp Deletion Polymorphisms and Proliferative Prostatic Diseases among Lebanese Men.
Prostatic Hyperplasia
Angiotensin-converting enzyme insertion/deletion and angiotensin type 1 receptor A1166C polymorphisms as genetic risk factors in benign prostatic hyperplasia and prostate cancer.
Association of angiotensin I converting enzyme polymorphism as genetic risk factor in benign prostatic hyperplasia and prostate cancer.
Correlation between angiotensin-converting enzyme activity and histologic patterns in benign prostatic hypertrophy tissue.
Does angiotensin-converting enzyme polymorphism have association with symptomatic benign prostatic hyperplasia?
Doxazosin in the current treatment of hypertension.
Localization of angiotensin-converting enzyme in the human prostate: pathological expression in benign prostatic hyperplasia.
Prescriber and pharmacy variation in patient adherence to five medication classes measured using implementation during persistent episodes.
The angiotensin converting enzyme inhibitor captopril attenuates testosterone-induced benign prostatic hyperplasia in rats; a mechanistic approach.
Transactivation of ErbB1 and ErbB2 receptors by angiotensin II in normal human prostate stromal cells.
Prostatic Neoplasms
3-Phosphoinositide-dependent protein kinase-1/Akt signalling and inhibition in a canine prostate carcinoma cell line.
A human GRPr-transfected Ace-1 canine prostate cancer model in mice.
A novel canine model for prostate cancer.
Angiotensin-converting enzyme insertion/deletion and angiotensin type 1 receptor A1166C polymorphisms as genetic risk factors in benign prostatic hyperplasia and prostate cancer.
Angiotensin-converting enzyme insertion/deletion polymorphism and the risk of prostate cancer in the Han population of China.
Antihypertensive drugs use and the risk of prostate cancer: a meta-analysis of 21 observational studies.
Association between captopril, other antihypertensive drugs and risk of prostate cancer.
Association of angiotensin I converting enzyme polymorphism as genetic risk factor in benign prostatic hyperplasia and prostate cancer.
Canine prostatic cancer cell line (LuMa) with osteoblastic bone metastasis.
Development of an orthotopic canine prostate cancer model expressing human GRPr.
Dickkopf-1 (DKK-1) stimulated prostate cancer growth and metastasis and inhibited bone formation in osteoblastic bone metastases.
Drugs which inhibit osteoclast function suppress tumor growth through calcium reduction in bone.
Effects of ACE I/D polymorphism on prostate cancer risk, tumor grade and metastatis.
Elevated Microdamage Spatially Correlates with Stress in Metastatic Vertebrae.
Evaluating the effects of mixed osteolytic/osteoblastic metastasis on vertebral bone quality in a new rat model.
Linkage of angiotensin I-converting enzyme gene insertion/deletion polymorphism to the progression of human prostate cancer.
Local treatment of mixed osteolytic/osteoblastic spinal metastases: is photodynamic therapy effective?
Nanoparticulate paclitaxel demonstrates antitumor activity in PC3 and Ace-1 aggressive prostate cancer cell lines.
New bone formation and osteolysis by a metastatic, highly invasive canine prostate carcinoma xenograft.
Relationship between angiotensin-converting enzyme insertion/deletion gene polymorphism and prostate cancer susceptibility.
The Incidence and Risk of Biochemical Recurrence Following Radical Radiotherapy for Prostate Cancer in Men on Angiotensin-Converting Enzyme Inhibitors (ACEIs) or Angiotensin Receptor Blockers (ARBs).
Zoledronic acid decreased osteolysis but not bone metastasis in a nude mouse model of canine prostate cancer with mixed bone lesions.
[Phenotyping of angiotensin-converting enzyme in the prostate in patients with prostate cancer and benign prostatic hyperplasia].
Prostatitis
Sperm angiotensin-converting enzyme activity in Chernobyl victims and patients with chronic prostatitis.
[Changes in the level of the angiotensin-converting enzyme activity in the spermatozoa of patients with chronic prostatitis and of participants in the cleanup of the accident at the Chernobyl Atomic Electric Power Station]
Protein C Deficiency
Treatment of sepsis-induced acquired protein C deficiency reverses Angiotensin-converting enzyme-2 inhibition and decreases pulmonary inflammatory response.
Proteinuria
-
'Huang Qi Elixir' for proteinuria in patients with diabetic nephropathy: a study protocol for a randomized controlled pilot trial.
A Case of Nephrotic Syndrome Associated with Buerger's Disease.
A case of neuronal intranuclear inclusion disease associated with lupus nephritis-like nephropathy.
A case of renal sarcoidosis: a special reference to calcium metabolism as a diagnostic and the therapeutic implications.
A case of renovascular hypertension with the nephrotic syndrome.
A Cluster Randomized Trial of an Enhanced eGFR Prompt in Chronic Kidney Disease.
A European Renal Best Practice (ERBP) position statement on the Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guideline for the Management of Blood Pressure in Non-dialysis-dependent Chronic Kidney Disease: an endorsement with some caveats for real-life application.
A pharmacoeconomic model to aid in the allocation of ambulatory clinical pharmacy services.
A pilot study of the effects of eplerenone add-on therapy in patients taking renin-angiotensin system blockers.
A Pilot Trial on the Effect of Levothyroxine on Proteinuria in Patients With Advanced CKD.
A practical approach to achieving recommended blood pressure goals in diabetic patients.
A Randomized, Controlled Trial of Rituximab in IgA Nephropathy with Proteinuria and Renal Dysfunction.
A rare case of reversible acquired AA-type renal amyloidosis in a chronic filariasis patient receiving antifilarial therapy.
A relationship between proteinuria and acute tubulointerstitial disease in rats with experimental nephrotic syndrome.
A reliable radiometric assay for the determination of angiotensin I-converting enzyme activity in urine.
A-20C angiotensinogen gene polymorphism and proteinuria in childhood IgA nephropathy.
Accuracy of retinal changes in predicting microalbuminuria among elderly hypertensive patients: a cross-sectional study from a teaching hospital in South India.
ACE inhibition can improve orthostatic proteinuria associated with nutcracker syndrome.
ACE inhibition prevents renal failure and death in uninephrectomized MWF/Ztm rats.
ACEI/ATRA therapy decreases proteinuria by improving glomerular permselectivity in IgA nephritis.
Achieving maximal renal protection in nondiabetic chronic renal disease.
Activity and responsiveness of the renin-angiotensin system in the aging rat.
Acute haemodynamic and proteinuric effects of prednisolone in patients with a nephrotic syndrome.
Acute kidney injury is a risk factor for subsequent proteinuria.
Acute renal failure during lisinopril and losartan therapy for proteinuria.
Add-on anti-TGF-beta antibody to ACE inhibitor arrests progressive diabetic nephropathy in the rat.
Add-on Protective Effect of Pentoxifylline in Advanced Chronic Kidney Disease Treated with Renin-Angiotensin-Aldosterone System Blockade - A Nationwide Database Analysis.
Addition of AT1 blocker fails to overcome resistance to ACE inhibition in adriamycin nephrosis.
Additive antiproteinuric effect of angiotensin-converting enzyme inhibition and non-steroidal anti-inflammatory drug therapy: a clue to the mechanism of action.
Additive antiproteinuric effect of enalapril and losartan in children with hemolytic uremic syndrome.
Administration of dexamethasone induces proteinuria of glomerular origin in mice.
Adult nephrotic syndrome: non-specific strategies for treatment.
Agalsidase alfa slows the decline in renal function in patients with Fabry disease.
Aggressive blood pressure reduction and renin-angiotensin system blockade in chronic kidney disease: time for re-evaluation?
Aldosterone and progression of renal disease.
Aldosterone and the hypertensive kidney: its emerging role as a mediator of progressive renal dysfunction: a paradigm shift.
Aldosterone antagonists for preventing the progression of chronic kidney disease.
Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic kidney disease.
Aldosterone as a mediator of progressive renal disease: pathogenetic and clinical implications.
Aldosterone as a mediator of progressive renal dysfunction: evolving perspectives.
Aldosterone, mineralocorticoid receptors, and vascular inflammation.
Aliskiren add-on therapy effectively reduces proteinuria in chronic kidney disease: An open-label prospective trial.
Alport syndrome: its effects on the glomerular filtration barrier and implications for future treatment.
Amelioration of diabetic microalbuminuria and lipid peroxidation by captopril.
An evidence-based approach to the treatment of adults with sickle cell disease.
An unusual case of membranous nephropathy associated with an ovarian tumor.
An Update on the Management of Childhood-Onset Systemic Lupus Erythematosus.
Angiotensin antagonists and steroids in the treatment of focal segmental glomerulosclerosis.
Angiotensin blockade and matrix synthesis by glomerular epithelial cells in high glucose: a further experimental insight into the pathophysiology of diabetic nephropathy.
Angiotensin blockade as sole treatment for proteinuric kidney disease in children.
Angiotensin converting enzyme inhibition in non-diabetic nephropathy with non-nephrotic proteinuria.
Angiotensin converting enzyme inhibition in normotensive type II diabetics with persistent mild proteinuria.
Angiotensin converting enzyme inhibition reduces proteinuria in Nigerians with chronic renal disease.
Angiotensin converting enzyme inhibition with a low dose of enalapril in normotensive diabetics with persistent proteinuria.
Angiotensin converting enzyme inhibitor does not reduce proteinuria in an infant with congenital nephrotic syndrome of the Finnish type.
Angiotensin converting enzyme inhibitor therapy in children with Alport syndrome: effect on urinary albumin, TGF-beta, and nitrite excretion.
Angiotensin converting enzyme inhibitors and angiotensin II receptor blockers: evidence for and against the combination in the treatment of hypertension and proteinuria.
Angiotensin converting enzyme inhibitors and calcium antagonists alone or combined: does the progression of diabetic renal disease differ?
Angiotensin converting enzyme inhibitors for reduction of proteinuria in children with steroid-resistant nephrotic syndrome.
Angiotensin converting enzyme inhibitors or angiotensin receptor blockers in nephropathy from type 2 diabetes.
Angiotensin converting enzyme inhibitors, calcium channel blockers, and their combination in the treatment of glomerular disease.
Angiotensin converting-enzyme inhibition restores glomerular glycosaminoglycans in rat puromycin nephrosis.
Angiotensin II increases the cytosolic calcium activity in rat podocytes in culture.
Angiotensin II inhibition attenuates postexercise proteinuria in rats.
Angiotensin II receptor antagonists and treatment of hypertension and renal disease.
Angiotensin inhibition or blockade for the treatment of patients with quiescent lupus nephritis and persistent proteinuria.
Angiotensin receptor blocker protection against podocyte-induced sclerosis is podocyte angiotensin II type 1 receptor-independent.
Angiotensin receptor blocker reduces proteinuria independently of blood pressure in children already treated with Angiotensin-converting enzyme inhibitors.
Angiotensin receptor blockers are associated with lower mortality than ACE inhibitors in predialytic stage 5 chronic kidney disease: A nationwide study of therapy with renin-angiotensin system blockade.
Angiotensin receptor blockers in diabetic nephropathy: renal and cardiovascular end points.
Angiotensin-converting enzyme (ACE) inhibitors for proteinuria and microalbuminuria in people with sickle cell disease.
Angiotensin-converting enzyme gene insertion/deletion, not bradykinin B2 receptor -58T/C gene polymorphism, associated with angiotensin-converting enzyme inhibitor-related cough in Chinese female patients with non-insulin-dependent diabetes mellitus.
Angiotensin-converting enzyme gene polymorphism determines the antiproteinuric and systemic hemodynamic effect of enalapril in patients with proteinuric renal disease. Austrian Study Group of the Effects of Enalapril Treatment in Proteinuric Renal Disease.
Angiotensin-converting enzyme inhibition alters clusterin mRNA expression in the kidney following renal mass reduction.
Angiotensin-converting enzyme inhibition and renal protection in nondiabetic patients: the data of the meta-analyses.
Angiotensin-converting enzyme inhibition and the combination of a beta blocker and a diuretic are equally effective in lowering proteinuria in patients with glomerulonephritis.
Angiotensin-converting enzyme inhibition attenuates proteinuria and renal TGF-beta 1 mRNA expression in rats with chronic renal disease.
Angiotensin-converting enzyme inhibition does not correct early defects in renal and vascular permeability in diabetes mellitus.
Angiotensin-converting enzyme inhibition in experimental in-situ immune complex glomerulonephritis: influence on renal function, proteinuria, and morphology.
Angiotensin-converting enzyme inhibition prevents glomerular-tubule disconnection and atrophy in passive Heymann nephritis, an effect not observed with a calcium antagonist.
Angiotensin-converting enzyme inhibitor therapy for non-diabetic progressive renal disease.
Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for IgA nephropathy.
Angiotensin-converting enzyme inhibitors have adverse effects in anti-angiogenesis therapy for hepatocellular carcinoma.
Angiotensin-converting enzyme inhibitors in chronic renal failure.
Angiotensin-converting enzyme inhibitors in diabetes: effect on the kidney and on blood pressure.
Angiotensin-converting enzyme inhibitors versus calcium antagonists in the progression of renal diseases.
Angiotensin-converting enzyme inhibitors: considerations regarding proteinuria.
Angiotensin-converting enzyme is upregulated in the proximal tubules of rats with intense proteinuria.
Anti-CD20 monoclonal antibody (rituximab) for the treatment of recurrent idiopathic membranous nephropathy in a renal transplant patient.
Anti-proteinuric effects of combination therapy with enalapril and losartan in patients with nephropathy due to type 2 diabetes.
Antihypertensive therapy in the presence of proteinuria.
Antihypertensive therapy prescribing patterns and correlates of blood pressure control among hypertensive patients with chronic kidney disease.
Antiproteinuric effect of angiotensin-converting enzyme inhibitors and an angiotensin II receptor blocker in patients with lupus nephritis.
Antiproteinuric effect predicts renal protection by angiotensin-converting enzyme inhibition in rats with established adriamycin nephrosis.
Antiproteinuric effects of enalapril and losartan: a pilot study.
Antiproteinuric efficacy of fosinopril after renal transplantation is determined by the extent of vascular and tubulointerstitial damage.
Antiproteinuric response to dual blockade of the renin-angiotensin system in primary glomerulonephritis.
Antiproteinuric versus antihypertensive effects of high-dose ACE inhibitor therapy.
Are calcium antagonists effective in preventing complications of hypertension and progression of renal disease?
Are drugs that block the renin-angiotensin system effective and safe in patients with renal insufficiency?
Are two better than one? Angiotensin-converting enzyme inhibitors plus angiotensin receptor blockers for reducing blood pressure and proteinuria in kidney disease.
Arthus C. Corcoran Memorial Lecture. Influence of nitric oxide and angiotensin II on renal involvement in hypertension.
ASK1 contributes to fibrosis and dysfunction in models of kidney disease.
Assessing proteinuria in chronic kidney disease: protein-creatinine ratio versus albumin-creatinine ratio.
Assessment of structure and function in progressive renal disease.
Association of angiotensin I-converting enzyme gene polymorphism with susceptibility to antiproteinuric effect of angiotensin I-converting enzyme inhibitors in patients with proteinuria.
Association of deprivation, ethnicity, and sex with quality indicators for diabetes: population based survey of 53,000 patients in primary care.
Associations between retinal microvascular abnormalities and declining renal function in the elderly population: the Cardiovascular Health Study.
Atypical hemolytic uremic syndrome precipitated by thyrotoxicosis: a case report.
Autonomic dysfunction independently predicts poor cardiovascular outcomes in asymptomatic individuals with type 2 diabetes in the DIAD study.
Benazepril combined with either amlodipine or hydrochlorothiazide is more effective than monotherapy for blood pressure control and prevention of end-organ injury in hypertensive Dahl rats.
Beneficial effect of combination therapy with an angiotensin II receptor antagonist and angiotensin-converting enzyme inhibitor on overt proteinuria in a patient with type 1 diabetic nephropathy.
Beneficial responses to modified diets in treating patients with chronic kidney disease.
Benefits of the RAS blockade: clinical evidence before the ONTARGET study.
Blockade of the renin-angiotensin system increases plasma adiponectin levels in type-2 diabetic patients with proteinuria.
Blood pressure and proteinuria after cessation of a brief renin-angiotensin system blockade in young and adult Lyon hypertensive rats.
Blood pressure reduction associated with preservation of renal function in hypertensive patients with IgA nephropathy: a 3-year follow-up.
Blood pressure-independent impact of antihypertensive agents on cardiovascular and renal disease.
C1q nephropathy in association with Gitelman syndrome: a case report.
C3 Glomerulopathy and Atypical Hemolytic Uremic Syndrome: Two Important Manifestations of Complement System Dysfunction.
Calcium channel blockers in the prevention of end stage renal disease: a review.
Can we further slow down the progression to end-stage renal disease in diabetic hypertensive patients?
Canadian Society of Nephrology commentary on the KDIGO clinical practice guideline for CKD evaluation and management.
Canine glomerulonephritis: new thoughts on proteinuria and treatment.
Captopril and combination therapy of captopril and pentoxifylline in reducing proteinuria in diabetic nephropathy.
Captopril, an angiotensin I-converting enzyme inhibitor, decreases proteinuria in hypertensive patients with renal diseases.
Cardiovascular effects of captopril and enalapril in obese Zucker rats.
Characteristics of children with sporadic hemolytic uremic syndrome in a single Northern California center.
Chronic allograft nephropathy in the rat is improved by angiotensin II receptor blockade but not by calcium channel antagonism.
Chronic angiotensin II infusion but not bradykinin blockade abolishes the antiproteinuric response to angiotensin-converting enzyme inhibition in established adriamycin nephrosis.
Chronic disease management interventions for people with chronic kidney disease in primary care: a systematic review and meta-analysis.
Chronic kidney disease and albuminuria in arterial hypertension.
Chronic kidney disease screening and renoprotection in type 2 diabetes.
Chronic kidney disease: prevention and treatment of common complications.
Chronic proteinuric nephropathies: outcomes and response to treatment in a prospective cohort of 352 patients with different patterns of renal injury.
Chronic renal diseases: renoprotective benefits of renin-angiotensin system inhibition.
Chronic renal insufficiency in a boy with cystic renal lymphangiectasia: morphological findings and long-term follow-up.
Clinical experience with angiotensin receptor blockers with particular reference to valsartan.
Clinical implications of proteinuria in renal transplant recipients switching to rapamycin for chronic allograft dysfunction.
Clinical overview of antihypertensive classes--clinically relevant differences: myths or facts? Based on a presentation by Alan H. Gradman, MD.
Clinical practice recommendations for the diagnosis and management of Alport syndrome in children, adolescents, and young adults-an update for 2020.
Clinicopathologic features, outcome, and therapeutic interventions in four children with isolated C3 mesangial proliferative glomerulonephritis.
Clinicopathological analysis of allogeneic hematopoietic stem cell transplantation-related membranous glomerulonephritis.
Coeliac sprue-associated membranoproliferative glomerulonephritis (MPGN).
Combination ACEI and ARB therapy: additional benefit in renoprotection?
Combination inhibition of the renin-angiotensin system: is more better?
Combination of Renal Angioplasty and Angiotensin-converting-enzyme Inhibitor Can Reduce Proteinuria in Patients with Bilateral Renal Artery Disease.
Combination therapy of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in chronic kidney disease.
Combination therapy of prednisone and ACE inhibitor versus ACE-inhibitor therapy alone in patients with IgA nephropathy: a randomized controlled trial.
Combination therapy with lamivudine and angiotensin-converting enzyme inhibitor/angiotensin receptor blocker for hepatitis B virus-associated glomerulonephritis with mild to moderate proteinuria: a clinical review of 38 cases.
Combined angiotensin inhibition for the treatment of diabetic nephropathy.
Combined effects of an angiotensin converting enzyme inhibitor and a calcium antagonist on renal injury.
Combined renin angiotensin blockade in childhood steroid-resistant nephrotic syndrome.
Combined therapy of enalapril and losartan attenuates histologic progression in immunoglobulin A nephropathy.
Combining an antiproteinuric approach with mycophenolate mofetil fully suppresses progressive nephropathy of experimental animals.
Combining blockers of the renin-angiotensin system or increasing the dose of an angiotensin II receptor antagonist in proteinuric patients: a randomized triple-crossover study.
Comparative effects of antihypertensives on proteinuria: angiotensin-converting enzyme inhibitor versus alpha 1-antagonist.
Comparative effects of captopril versus nifedipine on proteinuria and renal function of type 2 diabetic patients.
Comparative proteinuria management of different angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for normotensive patients with CKD: a Bayesian network meta-analysis.
Comparative study of the effect of ACE-inhibitors and other antihypertensive agents on proteinuria in diabetic patients.
Comparison of antiproteinuric effects of two different combination therapies in children with IgA nephropathy.
Comparison of Effects of ACEIs and ARBs on Albuminuria and Hyperkalemia in Indonesian Hypertensive Type 2 Diabetes Mellitus Patients.
Comparison of higher dose of losartan treatment with losartan plus carvedilol and losartan plus ramipril in patients with glomerulonephritis and proteinuria.
Comparison of the effect of pentoxifylline and captopril on proteinuria in patients with type 2 diabetes mellitus.
Comparison of the effects of angiotensin-converting enzyme inhibition and angiotensin II receptor blockade on the evolution of spontaneous glomerular injury in male MWF/Ztm rats.
Compelling drug indications in diabetic and nondiabetic nephropathy.
Comprehensive suppression of the renin-angiotensin-aldosterone system in chronic kidney disease: covering all of the bases.
Consensus document. Recommendations on assessing proteinuria during the diagnosis and follow-up of chronic kidney disease.
Contemporary issues and new challenges in chronic kidney disease amongst people living with HIV.
Contrasting effects of enalapril and metoprolol on proteinuria in diabetic nephropathy.
Control of glomerular hyperfiltration and renal hypertrophy by an angiotensin converting enzyme inhibitor prevents the progression of renal damage in hypertensive diabetic rats.
Control of hypertension with the angiotensin converting enzyme inhibitor captopril reduces glomerular proteinuria.
Conversion to sirolimus for chronic allograft nephropathy and calcineurin inhibitor toxicity and the adverse effects of sirolimus after conversion.
COQ8B nephropathy: Early detection and optimal treatment.
Delayed kidney injury following coronary angiography.
Deletion polymorphism of the angiotensin converting enzyme gene predicts persistent proteinuria in Henoch-Schönlein purpura nephritis.
Determinants of progression from microalbuminuria to proteinuria in patients who have type 1 diabetes and are treated with angiotensin-converting enzyme inhibitors.
Determining the appropriateness of selected surgical and medical management options in recurrent stroke prevention: A guideline for primary care physicians from the National Stroke Association work group on recurrent stroke prevention.
Development of an electronic health record-based chronic kidney disease registry to promote population health management.
Diabetic nephropathy in children and adolescents: a critical review with particular reference to angiotensin-converting enzyme inhibitors.
Diabetic renal disease: microalbuminuria, implications and intervention.
Different effects between antihypertensive drugs on nephrotic-range proteinuria in renovascular hypertension.
Differential effects of calcium antagonist subclasses on markers of nephropathy progression.
Differential effects of enalapril and atenolol on proteinuria and renal haemodynamics in non-diabetic renal disease.
Dissociation between blood pressure reduction and fall in proteinuria in primary renal disease: a randomized double-blind trial.
Diuretic and enhanced sodium restriction results in improved antiproteinuric response to RAS blocking agents.
Diverse effects of increasing lisinopril doses on lipid abnormalities in chronic nephropathies.
Does angiotensin (1-7) contribute to the anti-proteinuric effect of ACE-inhibitors.
Does antihypertensive treatment prevent progression of microalbuminuria to overt proteinuria in insulin-dependent diabetic patients?
Does renin-angiotensin system blockade protect lupus nephritis patients from atherosclerotic cardiovascular events? A case-control study.
Does the hyperfiltration of minoxidil result in increased proteinuria and loss of renoprotection conferred by angiotensin inhibition?
Double-blind, placebo-controlled study on the effect of the aldosterone receptor antagonist spironolactone in patients who have persistent proteinuria and are on long-term angiotensin-converting enzyme inhibitor therapy, with or without an angiotensin II receptor blocker.
Down-regulation of the intrarenal renin-angiotensin system in the aging rat.
Drug therapies for patients with IgA nephropathy: A network meta-analysis of randomized clinical trials.
Drugs controlling proteinuria of patients with Alport syndrome.
Dual blockade of the renin-angiotensin system compared with a 50% increase in the dose of angiotensin-converting enzyme inhibitor: effects on proteinuria and blood pressure.
Dual blockade of the Renin-Angiotensin system in the progression of renal disease: the need for more clinical trials.
Dual blockade of the renin-angiotensin-aldosterone system: beyond the ACE inhibitor and angiotensin-II receptor blocker combination.
Dual blockade of the rennin-angiotensin system versus maximal recommended dose of angiotensin II receptor blockade in chronic glomerulonephritis.
Dual RAAS Blockade with Aliskiren in Patients with Severely Impaired Chronic Kidney Disease.
Dual renin-angiotensin system blockade for nephroprotection.
Dual renin-angiotensin system blockade for nephroprotection: still under scrutiny.
Dual renin-angiotensin system blockade in the ONTARGET study: clinically relevant risk for the kidney?
Dual renin-angiotensin system blockade plus oral methylprednisone for the treatment of proteinuria in IgA nephropathy.
Early high-dose immunosuppression in Henoch-Schönlein nephrotic syndrome may improve outcome.
Early high-dose immunosuppression in Henoch-Schonlein nephrotic syndrome may improve outcome.
Early markers of renal dysfunction in patients with sickle cell/beta-thalassemia.
Early Proteinuria Lowering by Angiotensin-Converting Enzyme Inhibition Predicts Renal Survival in Children with CKD.
Early, but not late therapy with a vasopressin V1a-antagonist ameliorates the development of renal damage after 5/6 nephrectomy.
Eat Your Broccoli: Oxidative Stress, NRF2, and Sulforaphane in Chronic Kidney Disease.
Effect of ACE inhibition by benazepril, enalapril and captopril on chronic and post exercise proteinuria.
Effect of angiotensin converting enzyme inhibition by perindopril on proteinuria of primary renal diseases.
Effect of angiotensin-converting enzyme inhibitor therapy on proteinuria in children with renal disease.
Effect of antihypertensive therapy on the kidney in patients with diabetes: a meta-regression analysis.
Effect of captopril on heavy proteinuria in azotemic diabetics.
Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria. European Microalbuminuria Captopril Study Group.
Effect of captopril, an angiotensin converting enzyme inhibitor, on the massive proteinuria due to chronic rejection after renal transplantation--a prospective study.
Effect of clonidine on the progression of chronic renal disease in partially nephrectomized rats.
Effect of combining ACE inhibitor and statin in severe experimental nephropathy.
Effect of combining an ACE inhibitor and an angiotensin II receptor blocker on plasma and kidney tissue angiotensin II levels.
Effect of direct renin inhibitor monotherapy on proteinuria in overt diabetic nephropathy.
Effect of efonidipine and ACE inhibitors on proteinuria in human hypertension with renal impairment.
Effect of enalapril on proteinuria after kidney transplantation.
Effect of fosinopril on chemerin and VEGF expression in diabetic nephropathy rats.
Effect of Omega-3 Fatty Acid on the Fatty Acid Content of the Erythrocyte Membrane and Proteinuria in Patients with Diabetic Nephropathy.
Effect of pentoxifylline on GFR decline in CKD: a pilot, double-blind, randomized, placebo-controlled trial.
Effect of proteinuria reduction on prevention of focal glomerulosclerosis by angiotensin-converting enzyme inhibition is modifiable.
Effect of ramipril on blood pressure and protein excretion rate in normotensive nondiabetic patients with proteinuria.
Effect of telmisartan, angiotensin-converting enzyme inhibition, or both, on proteinuria and blood pressure in dogs.
Effect of the angiotensin converting enzyme inhibitor, captopril, on proteinuria in chronic glomerular disease.
Effectiveness of dietary protein augmentation associated with angiotensin-converting enzyme inhibition in the management of the nephrotic syndrome.
Effects of Add-on Fluvastatin Therapy in Patients with Chronic Proteinuric Nephropathy on Dual Renin-Angiotensin System Blockade: The ESPLANADE Trial.
Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy.
Effects of angiotensin converting enzyme inhibitors on the progression of renal failure and proteinuria in humans.
Effects of angiotensin II receptor blocker (irbesartan) on peritoneal membrane functions.
Effects of angiotensin-converting enzyme inhibition on glomerular capillary wall ultrastructure in MWF/Ztm rats.
Effects of angiotensin-converting enzyme inhibitor and steroid therapy on proteinuria in FSGS: a retrospective study in a single clinic.
Effects of angiotensin-converting enzyme inhibitor, angiotensin II receptor antagonist and calcium antagonist on urinary podocytes in patients with IgA nephropathy.
Effects of anti-proteinuric therapy with angiotensin-converting-enzyme inhibition on renal protein catabolism in the adriamycin-induced nephrotic rat.
Effects of antihypertensive drugs on blood pressure and proteinuria in childhood.
Effects of antihypertensive drugs on renal function in patients with diabetic nephropathy.
Effects of calcium channel blockers on proteinuria in patients with diabetic nephropathy.
Effects of captopril on diabetic nephropathy in hypertensive women.
Effects of combined ACE inhibitor and angiotensin II antagonist treatment in human chronic nephropathies.
Effects of dual blockade of renin-angiotensin system in type 2 diabetes mellitus patients with diabetic nephropathy.
Effects of dual blockade of the renin-angiotensin system in primary proteinuric nephropathies.
Effects of efonidipine, nicardipine and captopril on proteinuria in aged spontaneously hypertensive rats.
Effects of lisinopril administration on blood bcl-2 concentrations in patients with immunoglobulin A nephropathy.
Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomised, double blind, placebo controlled trial (the DIABHYCAR study).
Effects of nitrendipine and cilazapril on renal hemodynamics and albuminuria in hypertensive patients with chronic renal failure.
Effects of pentoxifylline on proteinuria and glucose control in patients with type 2 diabetes: a prospective randomized double-blind multicenter study.
Effects of ramipril and valsartan on proteinuria and renal function in patients with nondiabetic proteinuria.
Effects of spironolactone in combination with angiotensin-converting enzyme inhibitors or Angiotensin receptor blockers in patients with proteinuria.
Effects of weight reduction and angiotensin-converting enzyme inhibition on IgA nephropathy-associated proteinuria.
Efficacy and safety of 'rescue therapy' with mycophenolate mofetil in resistant primary glomerulonephritis--a multicenter study.
Efficacy and safety of losartan in children with Alport syndrome--results from a subgroup analysis of a prospective, randomized, placebo- or amlodipine-controlled trial.
Efficacy and safety of Shenyankangfu tablets for primary glomerulonephritis: study protocol for a randomized controlled trial.
Efficacy of captopril treatment in children with steroid-resistant nephrotic syndrome.
Efficacy of pentoxifylline for reduction of proteinuria in type II diabetic patients.
Elevation of von Willebrand factor levels in patients with IgA nephropathy: effect of ACE inhibition.
Enalapril improves albuminuria by preventing glomerular loss of heparan sulfate in diabetic rats.
Enalapril in paediatric patients with Alport syndrome: 2 years' experience.
Enalapril increases antioxidant enzyme activity in renal cortical tissue of five-sixths-nephrectomized rats.
Endothelin receptor antagonists for the treatment of diabetic nephropathy: A meta-analysis and systematic review.
Evaluation and Management of Proteinuria After Kidney Transplantation.
Evaluation of the effects of a therapeutic renal diet to control proteinuria in proteinuric non-azotemic dogs treated with benazepril.
Evaluation of the effects of inhibition of angiotensin converting enzyme with enalapril in dogs with induced chronic renal insufficiency.
Evolving strategies for renoprotection: non-diabetic chronic renal disease.
Expert Consensus on the Management of Adverse Events During Treatment with Lenvatinib for Thyroid Cancer.
Failure of angiotensin converting enzyme inhibition to affect the course of chronic puromycin aminonucleoside nephropathy.
Familial partial lipodystrophy and proteinuric renal disease due to a missense c.1045C?>?T LMNA mutation.
Fatal Renal Failure in a Spinal Cord Injury Patient with Vesicoureteric Reflux Who Underwent Repeated Ureteric Reimplantations Unsuccessfully: Treatment Should Focus on Abolition of High Intravesical Pressures rather than Surgical Correction of Reflux.
Feasibility study of the early detection and treatment of renal disease by mass screening.
Fibrillary glomerulopathy in a 10-year-old female.
Fibroblast growth factor 23 and the antiproteinuric response to dietary sodium restriction during renin-angiotensin-aldosterone system blockade.
Focus on proteinuria.
Following specific podocyte injury captopril protects against progressive long term renal damage.
Fosinopril ameliorates exogenous cholesterol-induced incipient glomerular lesions in obese Zucker rats. Effects on eicosanoid secretion.
Fractional urinary excretion of IgG is the most powerful predictor of renoprotection by ACE inhibitors in IgA nephropathy.
Functional expression of the renin-angiotensin system in human podocytes.
Glomerular damage as a predictor of renal allograft loss.
Guidelines on the care of diabetic nephropathy, retinopathy and foot disease.
Henoch-Schönlein Purpura in Children: An Updated Review.
Hormonal modulation of proteinuria in the nephrotic syndrome.
How to prevent progression to end stage renal disease.
Hyperlipidemia is secondary to proteinuria and is completely normalized by angiotensin-converting enzyme inhibition in hypertensive fawn-hooded rats.
Hypertension in cardiac transplant recipients: tackling a new face of an old foe.
Hypertension in children with chronic kidney disease: pathophysiology and management.
Hypertension: investigation, assessment and diagnosis.
Hyponatremic hypertensive syndrome and massive proteinuria in a patient with renin-producing leiomyosarcoma.
IgA deficiency and membranous glomerulonephritis presenting as nephrotic syndrome.
IgA nephropathy and Henoch-Schönlein purpura nephritis.
IgA nephropathy with severe chronic renal failure: a randomized controlled trial of corticosteroids and azathioprine.
IgACE: a placebo-controlled, randomized trial of angiotensin-converting enzyme inhibitors in children and young people with IgA nephropathy and moderate proteinuria.
Immunoadsorption: a new strategy to induce remission in membranous lupus nephritis.
Immunotactoid glomerulopathy in an HIV-positive African-American man.
Impact of angiotensin II on the kidney: does an angiotensin II receptor blocker make sense?
Impact of angiotensin-converting enzyme gene polymorphism on proteinuria and arterial hypertension.
Impact of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers on renal and mortality outcomes in people with Type 2 diabetes and proteinuria.
Impact of Obesity on IgA Nephropathy: Comparative Ultrastructural Study between Obese and Non-Obese Patients.
Impaired vascular reactivity in African-American patients with type 2 diabetes mellitus and microalbuminuria or proteinuria despite angiotensin-converting enzyme inhibitor therapy.
Implementing KDOQI CKD definition and staging guidelines in Southern California Kaiser Permanente.
Improvement of lipid abnormalities associated with proteinuria using fosinopril, an angiotensin-converting enzyme inhibitor.
Improving the Management of Chronic Kidney Disease in Uruguay: A National Renal Healthcare Program.
In hereditary nephritis angiotensin-converting enzyme inhibition decreases proteinuria and may slow the rate of progression.
Individual titration for maximal blockade of the renin-angiotensin system in proteinuric patients: a feasible strategy?
Influence of proteinuria on cardiovascular risk and response to angiotensin-converting enzyme inhibition after myocardial infarction.
Influence of T-calcium channel blocker treatment on deterioration of renal function in chronic kidney disease.
Insulin-dependent diabetes mellitus as long term complication of haemolytic-uraemic syndrome.
Interaction between ACE and ADD1 gene polymorphisms in the progression of IgA nephropathy in Japanese patients.
Interaction of angiotensin II and mechanical stretch on vascular endothelial growth factor production by human mesangial cells.
Involvement of (pro)renin receptor in the glomerular filtration barrier.
Involvement of angiotensin II in development of spontaneous nephrosis in Dahl salt-sensitive rats.
Involvement of renal ACE activity in proteinuria-associated renal damage in untreated and treated adriamycin nephrotic rats.
Irbesartan in hypertensive non-diabetic advanced chronic kidney disease. Comparative study with ACEI.
Irreversible tubulointerstitial damage associated with chronic aminonucleoside nephrosis. Amelioration by angiotensin I converting enzyme inhibition.
Is Chronic Kidney Disease Progression Influenced by the Type of Renin-Angiotensin-System Blocker Used?
Is microalbuminuria a marker of early intrarenal vascular dysfunction in essential hypertension?
Is proteinuria reduction by angiotensin-converting enzyme inhibition enough to prove its role in renal protection in IgA nephropathy?
Is the antiproteinuric effect of ACE inhibition mediated by interference in the renin-angiotensin system?
Juxtaglomerular apparatus hyperplasia under dual angiotensin blockade. A footprint of adequate RAS inhibition or a concern for renal fibrosis?
Kidney angiotensin receptors and their role in renal pathophysiology.
Kidney Disease Progression in Autosomal Recessive Polycystic Kidney Disease.
Kinins are involved in the antiproteinuric effect of angiotensin-converting enzyme inhibition in experimental diabetic nephropathy.
Lack of cross sensitivity between captopril and enalapril.
Lack of management of cardiovascular risk factors in type 2 diabetic patients.
Late intervention in the remnant kidney model attenuates proteinuria but not glomerular filtration rate decline.
Lessons from large interventional trials on antihypertensive therapy in chronic renal disease.
Long-term beneficial effects of angiotensin-converting enzyme inhibition in patients with nephrotic proteinuria.
Long-term benefits of the antiproteinuric effect of angiotensin-converting enzyme inhibition in nondiabetic renal disease.
Long-term effects of antihypertensive agents on proteinuria and renal function.
Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease.
Long-term safety of high-dose angiotensin receptor blocker therapy in hypertensive patients with chronic kidney disease.
Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients.
Losartan and other angiotensin II antagonists for nephropathy in type 2 diabetes mellitus: a review of the clinical trial evidence.
Losartan in patients with renal insufficiency.
Losartan versus enalapril on cerebral edema and proteinuria in stroke-prone hypertensive rats.
Lovastatin but not enalapril reduces glomerular injury in Dahl salt-sensitive rats.
Low-dose angiotensin-converting-enzyme inhibitor captopril to reduce proteinuria in adult idiopathic membranous nephropathy: a prospective study of long-term treatment.
Management of advanced chronic kidney disease in primary care - current data from Germany.
Management of chronic kidney disease in an academic primary care clinic.
Management of hypertension in renal disease.
Management of hypertensive chronic kidney disease: role of calcium channel blockers.
Management of Proteinuria in Dogs and Cats with Chronic Kidney Disease.
Management of proteinuria in the transplanted patient.
Managing kidney disease with blood-pressure control.
Mechanisms and treatment of CKD.
Mechanisms of disease: The role of aldosterone in kidney damage and clinical benefits of its blockade.
Medical management of vesicoureteral reflux--quiz within the article. Don't overlook placebos.
Membranoproliferative glomerulonephritis related to a streptococcal infection in a girl with IgA deficiency: a case report.
Membranous glomerulonephritis, antiphospholipid syndrome, and persistent low C3 levels associated with meningococcal disease.
Membranous glomerulopathy in a patient with selective IgA deficiency: is there a link?
Membranous lupus nephritis in a renal allograft: response to mycophenolate mofetil therapy.
Meta-analysis: the efficacy and safety of combined treatment with ARB and ACEI on diabetic nephropathy.
Metabolic syndrome and chronic kidney disease.
Mibefradil prevents L-NAME-exacerbated nephrosclerosis in spontaneously hypertensive rats.
Microalbuminuria and tubular proteinuria as risk predictors of cardiovascular morbidity and mortality in essential hypertension: final results of a prospective long-term study (MARPLE Study)*
Microalbuminuria in type II diabetes.
Mineralocorticoid receptor antagonist for renal protection.
Mitochondrial Disease (MELAS Syndrome) Discovered at the Start of Pregnancy in a Patient with Advanced CKD: A Clinical and Ethical Challenge.
Moderate dietary sodium restriction added to angiotensin converting enzyme inhibition compared with dual blockade in lowering proteinuria and blood pressure: randomised controlled trial.
Modulation of albuminuria by dietary protein and converting enzyme inhibition.
Molecular mechanisms of glucose action on angiotensinogen gene expression in rat proximal tubular cells.
Nephrology visits and health care resource use before and after reporting estimated glomerular filtration rate.
Nephropathy of cyanotic congenital heart disease: clinical characteristics and effectiveness of an angiotensin-converting enzyme inhibitor.
Nephrotic hyperlipidemia: primary abnormalities in both lipoprotein catabolism and synthesis.
Nephrotic proteinuria without hypoalbuminemia: clinical characteristics and response to angiotensin-converting enzyme inhibition.
Nephrotic syndrome and Giant cell arthritis concurrently occurring after percutaneous transluminal angioplasty for renal artery stenosis?.
Nephrotic syndrome and IgA nephropathy in polycystic kidney disease.
Nephrotic syndrome in children.
Nephrotic syndrome in infancy can spontaneously resolve.
New classes of antihypertensive drugs and new findings with established agents.
Nifedipine reduces postexercise proteinuria in young volunteers.
No clear evidence of ACEi efficacy on the progression of chronic kidney disease in children with hypodysplastic nephropathy--report from the ItalKid Project database.
No effect of enalapril on progression in autosomal dominant polycystic kidney disease.
Non-immunologic mechanisms of calcineurin inhibitors explain its antiproteinuric effects in genetic glomerulopathies.
Nondihydropyridine Calcium Channel Blockers for the Treatment of Proteinuria: A Review of the Literature.
Obesity and renal disease.
Obesity-related focal and segmental glomerulosclerosis: normalization of proteinuria in an adolescent after bariatric surgery.
Of fads, fashion, surrogate endpoints and dual RAS blockade.
Optimizing therapeutic strategies to achieve renal and cardiovascular risk reduction in diabetic patients with angiotensin receptor blockers.
Outcomes of antiproteinuric RAAS blockade: high-dose compared with dual therapy.
Paradoxical fall in proteinuria during pregnancy in an LCAT-deficient patient-A case report.
Passive Heymann nephritis: evidence that angiotensin-converting enzyme inhibition reduces proteinuria and retards renal structural injury.
Pathophysiology of experimental nephrotic syndrome induced by puromicyn aminonucleoside in rats. III. Effect of captopril, an angiotensin converting enzyme inhibitor, on proteinuria and sodium retention.
Pathophysiology of experimental nephrotic syndrome induced by puromycin aminonucleoside in rats. I. The role of proteinuria, hypoproteinemia, and renin-angiotensin-aldosterone system on sodium retention.
Pentoxifylline plus ACEIs/ARBs for proteinuria and kidney function in chronic kidney disease: a meta-analysis.
Pentoxifylline: a potential therapy for chronic kidney disease.
Pharmacogenomics of angiotensin converting enzyme inhibitors in renal disease--pathophysiological considerations.
Pharmacologic management of adult idiopathic nephrotic syndrome.
Pharmacological strategies for kidney function preservation: are there differences by ethnicity?
Pharmacotherapy of hypertension in patients with diabetes mellitus.
Physician Characteristics and Knowledge of CKD Management.
Pierson syndrome in an adolescent girl with nephrotic range proteinuria but a normal GFR.
Pleiotropic effects of inhibitors of the RAAS in the diabetic population: above and beyond blood pressure lowering.
Podocyturia: A Clue for the Rational Use of Amiloride in Alport Renal Disease.
Posttransplantation proteinuria: an approach to diagnosis and management.
Potential role of angiotensin-converting enzyme inhibitors and statins on early podocyte damage in a model of type 2 diabetes mellitus, obesity, and mild hypertension.
Predictors of incident proteinuria among patients with SLE.
Predictors of the progression of diabetic nephropathy and the beneficial effect of angiotensin-converting enzyme inhibitors in NIDDM patients.
Preserving the diabetic kidney.
Prevalence and pathologic features of sickle cell nephropathy and response to inhibition of angiotensin-converting enzyme.
Prevalence and predictors of epoetin hyporesponsiveness in chronic kidney disease patients.
Prevalence of microalbuminuria in children with sickle cell disease.
Prevalence of proteinuria in rural adult population in Tamil Nadu.
Prevention and slowing down the progression of the diabetic nephropathy through antihypertensive therapy.
Prevention and treatment of diabetic nephropathy: the program for irbesartan mortality and morbidity evaluation.
Prognostic factors associated with poor graft outcomes in renal recipients with post-transplant glomerulonephritis.
Prognostic significance of microalbuminuria.
Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis.
Progression of Renal Damage in Glycogen Storage Disease Type I Is Associated to Hyperlipidemia: A Multicenter Prospective Italian Study.
Prophylaxis of experimental bone marrow transplant nephropathy.
Prostaglandins, angiotension II, and proteinuria.
Protecting the residual renal function: which drugs of choice?
Protective effect of angiotensin-converting enzyme inhibitor therapy among persons with HIV and proteinuria.
Proteinuria after conversion to sirolimus in kidney transplant recipients: impact of pre-existing proteinuria, graft function, and angiotensin-converting enzyme inhibitors/angiotensin-receptor antagonists.
Proteinuria and albumin homeostasis in the nephrotic syndrome: effect of dietary protein intake.
Proteinuria and angiotensin converting enzyme (ACE) gene polymorphism.
Proteinuria and cardiovascular disease.
Proteinuria and focal segmental glomerulosclerosis in severely obese adolescents.
Proteinuria and the expression of the podocyte slit diaphragm protein, nephrin, in diabetic nephropathy: effects of angiotensin converting enzyme inhibition.
Proteinuria as a risk marker for the progression of chronic kidney disease in patients on predialysis care and the role of angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker treatment.
Proteinuria in diabetic patients in a primary health care setting in Sarawak.
Proteinuria in Kidney Transplant Recipients: Prevalence, Prognosis, and Evidence-Based Management.
Proteinuria in renal artery occlusion is related to active renin concentration and contralateral kidney size.
Proteinuria in systemic sclerosis: reversal by ACE inhibition.
Proteinuria lowering needs a multifactorial and individualized approach to halt progression of renal disease.
Proteinuria reduction: mandatory consideration or option when selecting an antihypertensive agent?
Proteinuria versus albuminuria in 24-hour urine collection: prevalence and clinical outcome in non-hypoxemic adult patients with congenital heart disease.
Proteinuria versus albuminuria in chronic kidney disease.
Proteinuria, a modifiable risk factor: angiotensin converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs).
Proteinuria, Chronic Kidney Disease, and the Effect of an Angiotensin Receptor Blocker in Addition to an Angiotensin-Converting Enzyme Inhibitor in Patients With Moderate to Severe Heart Failure.
Proteinuria, hyperlipidemia, and the kidney.
Proteinuria-lowering effect of heparin therapy in diabetic nephropathy without affecting the renin-angiotensin-aldosterone system.
Proteinuria: its clinical importance and role in progressive renal disease.
Pulsatile intermittent intravenous insulin therapy for attenuation of retinopathy and nephropathy in type 1 diabetes mellitus.
QiDiTangShen Granules Reduced Diabetic Kidney Injury by Regulating the Phosphorylation Balance of the Tyrosine and Serine Residues of Insulin Receptor Substrate 1.
Quality of care and mortality are worse in chronic kidney disease patients living in remote areas.
Quinapril decreases renal endothelin-1 expression and synthesis in a normotensive model of immune-complex nephritis.
Ramipril inhibits in vitro human mesangial cell proliferation and platelet-derived growth factor expression.
Ramipril lowers plasma FGF-23 in patients with diabetic nephropathy.
Ramipril versus placebo in kidney transplant patients with proteinuria: a multicentre, double-blind, randomised controlled trial.
Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia)
Randomized controlled crossover study of the effect on proteinuria and blood pressure of adding an angiotensin II receptor antagonist to an angiotensin converting enzyme inhibitor in normotensive patients with chronic renal disease and proteinuria.
Randomized controlled trial: lisinopril reduces proteinuria, ammonia, and renal polypeptide tubular catabolism in patients with chronic allograft nephropathy.
Randomized, double-blind, controlled study of losartan in children with proteinuria.
Rapid decline in renal function after acute myocardial infarction.
Rationale and design of a study to evaluate management of proteinuria in patients at high risk for vascular events: the IMPROVE trial.
Recent Advances in Pharmacological Management of Hypertension in Diabetic Patients with Nephropathy : Effects of Antihypertensive Drugs on Kidney Function and Insulin Sensitivity.
Recent advances in pharmacological management of hypertension in diabetic patients with nephropathy. Effects of antihypertensive drugs on kidney function and insulin sensitivity.
Recent update in the management of hypertension.
Recognition and management of angiotensin converting enzyme inhibitor fetopathy.
Recurrent glomerulonephritis in the renal allograft: an update of selected areas.
Reducing the risks of cardiovascular disease in liver allograft recipients.
Reduction of Mean Arterial Pressure and Proteinuria by the Effect of ACEIs (Lisinopril) in Kurdish Hypertensive Patients in Hawler City.
Reduction of proteinuria and changes of renal function in patients with glomerulonephritis and mild renal insufficiency. Short- versus long-acting angiotensin-converting enzyme inhibitors.
Reduction of proteinuria by angiotensin converting enzyme inhibition.
Reduction of proteinuria during intensified antihypertensive therapy in children after renal transplantation.
Reduction of proteinuria; combined effects of receptor blockade and low dose angiotensin-converting enzyme inhibition.
Relationship between proteinuria and progressive renal disease.
Remission and regression of diabetic nephropathy.
Renal allograft protection with early angiotensin-converting enzyme inhibitors administration.
Renal and cardiovascular effects of angiotensin-converting enzyme inhibitor plus angiotensin II receptor antagonist therapy in children with proteinuria.
Renal and cardiovascular protection in type 2 diabetes mellitus: angiotensin II receptor blockers.
Renal and metabolic disorders depend on the renin-angiotensin system in Lyon hypertensive rats associated with diabetes.
Renal complications in two patients with dentatorubral-pallidoluysian atrophy.
Renal complications of sickle cell disease: managing for optimal outcomes.
Renal effects of captopril, indomethacin and nifedipine in nephrotic patients after an oral protein load.
Renal endothelin-1 and endothelin receptor type B expression in glomerular diseases with proteinuria.
Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial.
Renal protection in hypertensive patients: selection of antihypertensive therapy.
Renal protective effect of angiotensin-converting enzyme inhibition in aging rats.
Renal tubulointerstitial damage caused by persistent proteinuria is attenuated in AT1-deficient mice: role of endothelin-1.
Renin-angiotensin blockade lowers MCP-1 expression in diabetic rats.
Renin-Angiotensin System Blockage and Avoiding High Doses of Calcineurin Inhibitors Prevent Interstitial Fibrosis and Tubular Atrophy in Kidney Transplant Recipients.
Renoprotection by direct renin inhibition: a systematic review and meta-analysis.
Renoprotective Effect of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers in Diabetic Patients with Proteinuria.
Renoprotective effect of contemporary blocking of angiotensin II and endothelin-1 in rats with membranous nephropathy.
Renoprotective effect of early inhibition of the renin-angiotensin system in renal transplant recipients.
Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria.
Resolution of proteinuria in a patient with X-linked Alport syndrome treated with cyclosporine.
Response to inhibition of angiotensin-converting enzyme in human immunodeficiency virus-associated nephropathy: a case report.
Restricted protein diet is associated with decrease in proteinuria: consequences on the progression of renal failure.
Review: Renal protection by inhibition of the renin-angiotensin-aldosterone system.
Risk factors and prognosis for proteinuria in renal transplant recipients.
Risk factors for developing acute kidney injury in older people with diabetes and community-acquired pneumonia: a population-based UK cohort study.
Rituximab for idiopathic membranous nephropathy: who can benefit?
Rituximab treatment of idiopathic membranous nephropathy.
Role of aliskiren in blood pressure control and renoprotection.
Role of diltiazem in pregnant women with chronic renal disease.
Salt blocks the renal benefits of ramipril in diabetic hypertensive rats.
Screening for proteinuria in US adults: a cost-effectiveness analysis.
Screening of Elderly for Chronic Kidney Disease.
Secondary failure of plasma therapy in factor H deficiency.
Secondary focal segmental glomerulosclerosis following kidney transplantation in a patient with type I diabetes mellitus.
Serum angiotensin converting enzyme activity in type 2 (non-insulin-dependent) diabetic patients with chronic glomerulonephritis.
Serum angiotensin-converting enzyme activity and active renin plasma concentrations in insulin-dependent diabetes mellitus.
Severe hepatic encephalopathy in a patient with liver cirrhosis after administration of angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker combination therapy: a case report.
Severe hypertension and massive proteinuria in a newborn with renal artery stenosis.
Sex chromosomes do not influence renal injury in borderline hypertensive rats.
Sickle cell nephropathy: challenging the conventional wisdom.
Sirolimus-associated proteinuria and renal dysfunction.
Slowly progressive, angiotensin II-independent glomerulosclerosis in human (pro)renin receptor-transgenic rats.
Spironolactone in combination with cilazapril ameliorates proteinuria and renal interstitial fibrosis in rats with anti-Thy-1 irreversible nephritis.
Spironolactone in type 2 diabetic nephropathy: Effects on proteinuria, blood pressure and renal function.
Spontaneous remission of nephrotic syndrome in idiopathic membranous nephropathy.
Steroid-responsive nephrotic syndrome and bilateral renal artery stenosis: a possible role for Angiotensin-mediated podocyte injury.
Successful treatment of a patient with nephrotic syndrome associated with chronic lymphocytic leukemia.
Supportive Versus Immunosuppressive Therapy of Progressive IgA nephropathy (STOP) IgAN trial: rationale and study protocol.
Suppressing renal NADPH oxidase to treat diabetic nephropathy.
Targeting inflammation: New therapeutic approaches in chronic kidney disease (CKD).
Telmisartan in the treatment of hypertension in patients with chronic renal insufficiency.
Temocapril, a long-acting non-SH group angiotensin converting enzyme inhibitor, modulates glomerular injury in chronic puromycin aminonucleoside nephrosis.
The African American Study of Kidney Disease: do these results indicate that 140/90 mm hg is good enough?
The antiproteinuric effect of angiotensin antagonism in human IgA nephropathy is potentiated by indomethacin.
The beneficial effect of angiotensin-converting enzyme inhibition with captopril on diabetic nephropathy in normotensive IDDM patients with microalbuminuria. North American Microalbuminuria Study Group.
The best way to manage hypertension after renal transplantation.
The cost-effectiveness of treating all patients with type 2 diabetes with angiotensin-converting enzyme inhibitors.
The Effect of Amiloride on Proteinuria in Patients with Proteinuric Kidney Disease.
The effect of angiotensin-converting enzyme inhibition and dietary protein restriction in the treatment of proteinuria.
The effect of chinese herbal medicine on albuminuria levels in patients with diabetic nephropathy: a systematic review and meta-analysis.
The effect of enalapril and sairei-to on survival-time for the rat with subtotal nephrectomy.
The effect of enalapril on nephrotic proteinuria and determination of serum angiotensin-converting enzyme before and after treatment.
The effect of renal diet in association with enalapril or benazepril on proteinuria in dogs with proteinuric chronic kidney disease.
The effects of amlodipine and enalapril on renal function in adults with hypertension and nondiabetic nephropathies: a 3-year, randomized, multicenter, double-blind, placebo-controlled study.
The effects of angiotensin-converting enzyme inhibitors on peritoneal protein loss and solute transport in peritoneal dialysis patients.
The effects of enalapril on urinary protein excretion in patients with idiopathic membranous nephropathy.
The effects of nonsteroidal anti-inflammatory drugs on glomerular filtration of proteins and their therapeutic utility.
The effects of prolonged angiotensin-converting enzyme inhibition on excretory kidney function and proteinuria in renal allograft recipients with chronic progressive transplant failure.
The future of clinical trials in chronic renal disease: outcome of an NIH/FDA/Physician Specialist Conference. Evaluation of Clinical Trial Endpoints in Chronic Renal Disease Study Group.
The Impact of Lipoic Acid on Endothelial Function and Proteinuria in Quinapril-Treated Diabetic Patients With Stage I Hypertension: Results From the QUALITY Study.
The Irbesartan type II diabetic nephropathy trial: study design and baseline patient characteristics. For the Collaborative Study Group.
The Kidney from Prenatal to Adult Life: Perinatal Programming and Reduction of Number of Nephrons during Development.
The molecular basis of increased glomerulosclerosis after blockade of the renin angiotensin system in growth hormone transgenic mice.
The relationship between magnitude of proteinuria reduction and risk of end-stage renal disease: results of the African American study of kidney disease and hypertension.
The renal functional and structural consequences of corticosteroid and angiotensin-converting enzyme inhibitor therapy in chronic puromycin aminonucleoside nephropathy.
The renin-angiotensin system in lupus: physiology, genes and practice, in animals and humans.
The renin-angiotensin system in progression, remission and regression of chronic nephropathies.
The reno-protective effect of the dual blockade of the renin angiotensin system (RAS).
The renoprotective potential of pentoxifylline in chronic kidney disease.
The renoprotective properties of angiotensin-converting enzyme inhibitors in a chronic model of membranous nephropathy are solely due to the inhibition of angiotensin II: evidence based on comparative studies with a receptor antagonist.
The role of angiotensin II antagonism in type 2 diabetes mellitus: a review of renoprotection studies.
The role of calcium antagonists in chronic kidney disease.
The role of laboratory testing in the diagnosis of renovascular hypertension.
The role of renin-angiotensin-aldosterone system inhibition in chronic kidney disease.
The role of systemic hypertension in the progression of nondiabetic renal disease.
The spectrum of HIV-related nephropathy in children.
The use of calcium antagonists in the treatment of hypertensive persons with kidney disease.
Therapeutic approach of patients with IgA nephropathy.
Therapeutic approaches to slowing the progression of diabetic nephropathy - is less best?
Therapeutic resistance to angiotensin converting enzyme (ACE) inhibition is related to pharmacodynamic and -kinetic factors in 5/6 nephrectomized rats.
Tonsillectomy and steroid pulse therapy significantly impact on clinical remission in patients with IgA nephropathy.
Treatment and landmark clinical trials for renoprotection.
Treatment and prognosis of primary focal segmental glomerulosclerosis.
Treatment of hypertension and renal injury induced by the angiogenesis inhibitor sunitinib: preclinical study.
Treatment of IgA nephropathy based on the severity of clinical and histological features.
Treatment of renal failure and blood pressure.
Treatment of type 2 diabetic nephropathy by blockade of the renin-angiotensin system: a comparison of angiotensin-converting-enzyme inhibitors and angiotensin receptor antagonists.
Treatment with angiotensin-converting enzyme inhibitors in renal transplantation with proteinuria.
Treatment with candesartan combined with angiotensin-converting enzyme inhibitor for immunosuppressive treatment-resistant nephrotic syndrome after allogeneic stem cell transplantation.
Treatment with low-dose angiotensin-converting enzyme inhibitor (ACEI) plus angiotensin II receptor blocker (ARB) in pediatric patients with IgA nephropathy.
Two Pregnancies with a Different Outcome in a Patient with Alport Syndrome.
Type II Diabetes Patients with Proteinuria and the Recovery of Their Metabolic Parameters.
Type II diabetes patients with proteinuria and the recovery of their metabolic parameters.
Underuse of ACE inhibitors and angiotensin II receptor blockers among patients with diabetic nephropathy in Taiwan.
Underuse of ACE inhibitors and angiotensin II receptor blockers in elderly patients with diabetes.
Unusual post-transplantation recurrence of focal segmental glomerulosclerosis which resolved with cyclosporine but not with sirolimus.
Use of Angiotensin Converting Enzyme Inhibitors in Patients Receiving Therapeutic Plasma Exchange with Centrifuge-based Apheresis System.
Use of angiotensin-converting enzyme inhibitors in chronic progressive renal disease.
Use of microalbuminuria testing in persons with type 2 diabetes: are the right patients being tested?
Use of recombinant human erythropoietin in kidney transplant patients with stable graft function.
V1/V2 Vasopressin receptor antagonism potentiates the renoprotection of renin-angiotensin system inhibition in rats with renal mass reduction.
Variability and risk factors for kidney disease progression and death following attainment of stage 4 CKD in a referred cohort.
Variation in the progression of diabetic nephropathy according to racial origin.
Vitamin D, proteinuria, diabetic nephropathy, and progression of CKD.
Weight loss for reduction of proteinuria in diabetic nephropathy: Comparison with angiotensin-converting enzyme inhibitor therapy.
Whether vitamin D3 is effective in reducing proteinuria in type 2 diabetic patients?
Why patients with diabetes, hypertension and/or proteinuria are not on angiotensin converting enzyme inhibitors.
Will the addition of pentoxifylline reduce proteinuria in patients with diabetic glomerulosclerosis refractory to maximal doses of both an angiotensin-converting enzyme inhibitor and an angiotensin receptor blocker?
Wiskott-Aldrich syndrome with IgA nephropathy: a case report and literature review.
[Additive antiproteinuric effect of angiotensin II receptor antagonist and angiotensin-converting enzyme inhibitor in patients with chronic glomerulonephritis]
[Angiotensin converting enzyme inhibitors in the treatment of proteinuria]
[Angiotensin-converting enzyme inhibitors in the treatment of proteinuria]
[Arterial hypertension in renal transplant recipients]
[Clinical features and MYH9 gene variant in two Chinese siblings with Fechtner syndrome].
[Clinical state of a patient with nephrotic proteinuria successfully treated with combined therapy with angiotensin II receptor antagonists and angiotensin II converting enzyme inhibitors and pentoxifylline]
[Critically appraised article].
[Effect of the angiotensin-converting enzyme inhibitor ramipril on proteinuria, blood pressure and kidney function in histologically confirmed glomerulonephritis with nephrotic syndrome]
[Factors of progression and chronic renal insufficiency and their prevention]
[How and when to search for a renal artery atheromatous stenosis in diabetic patients?]
[Hyperkalemia as a limiting factor in the use of drugs that block the Renin Angiotensin Aldosterone System (RAAS)].
[Hypertension and renal insufficiency]
[IgA nephropathy. Significance of immunoglobulin A glycosylation in pathogenesis and clinical presentation]
[Immunosuppressive and non-immunosuppressive agents for patients with IgA nephropathy: guideline from the Italian Society of Nephrology.]
[Impact of antihypertensive treatment on target organs]
[Influence of the angiotensin converting enzyme inhibition on the functional proteinuria in rats]
[Intensive treatment of blood pressure in patients with kidney disease and proteinuria]
[Lack of effect of ACE inhibition on severe proteinuria in diabetic nephropathy--a 6-month-long study]
[Long-term effect of angiotensin-converting inhibitors in children with proteinuria]
[Nephropathy in non-insulin-dependent diabetics]
[Pentoxifylline old drug or new hope for nephrology?]
[Post-transplant nephropathy and arterial hypertension]
[Prevention of hypertensive renal damage by prepubertal treatment with ARB]
[Renoprotective effect of triple therapy with low-dose angiotensin receptor blocker, low-dose diuretic and Ca-antagonist in hypertensive type 2 diabetic patients with overt nephropathy]
[Some metabolic and genetic risk factors and the progression of IgA nephropathy--preliminary report]
[The effect of angiotensin-converting enzyme inhibitors on proteinuria in chronic glomerulonephritis]
[The genetic and biochemical mechanisms of the development of diabetic nephropathy in children].
[The participation of the renin-angiotensin-aldosterone system in the pathogenesis of acute kidney failure in endotoxemia]
[The role of angiotensin II AT1-receptor antagonists in renal and cardiac protection in type-2 diabetes mellitus]
Pruritus
Prolonged generalized pruritus associated with selective elevation of IgA as the presenting symptoms of sarcoidosis.
Pseudolymphoma
Phenytoin Induced Cutaneous B Cell Pseudolymphoma.
Psoriasis
A systematic review and meta-analysis of angiotensin-converting enzyme inhibitor use and psoriasis incidence.
Angiotensin Converting Enzyme and Subclinical Atherosclerosis in Psoriasis: Is there Any Association? A case-control study.
Angiotensin-Converting Enzyme (ACE) D Allele as a Risk Factor for Increase Serum Interleukin-6 and Interleukin-8 in Psoriasis Patients.
Angiotensin-converting enzyme gene insertion/deletion polymorphism and susceptibility to psoriasis: a systematic review and meta-analysis.
Angiotensin-converting enzyme gene polymorphisms and the risk of psoriasis: a meta-analysis.
Angiotensin-converting enzyme inhibitors and psoriasis.
Angiotensin-converting enzyme inhibitors as possible exacerbating drugs in psoriasis.
Angiotensin-converting enzyme insertion/deletion (rs106180) and angiotensin type 1 receptor A1166 C (rs106165) genotypes and psoriasis: Correlation with cellular immunity, lipid profile, and oxidative stress markers.
Angiotensin-converting enzyme insertion/deletion polymorphism and susceptibility to psoriasis in a Chinese population.
Assessment of insertion/deletion polymorphism of the angiotensin converting enzyme gene in psoriasis.
Association between the insertion/deletion polymorphism of the angiotensin I-converting enzyme gene and risk for psoriasis in a Chinese population in Taiwan.
Association of insertion/deletion polymorphism of the angiotensin-converting enzyme gene with psoriasis.
Captopril-induced proteinuria in hypertensive psoriatic patients.
Cutaneous effects of antihypertensive drugs.
Drug exposure and psoriasis vulgaris: case-control and case-crossover studies.
Evaluation of the Association Between CD143 Gene Polymorphism and Psoriasis.
Exacerbation and induction of psoriasis by angiotensin-converting enzyme inhibitors.
Lack of association between angiotensin I-converting enzyme insertion/deletion polymorphism and psoriasis or psoriatic arthritis in Spain.
No increased risk of psoriasis in patients receiving androgen deprivation therapy for prostate cancer: a 17-year population-based study.
Psoriasis After Exposure to Angiotensin-Converting Enzyme Inhibitors: French Pharmacovigilance Data and Review of the Literature.
Psoriasis and risk of the COVID-19: is there a role for angiotensin converting enzyme (ACE)?
Psoriasis associated with ACE inhibitors: an analysis of the FAERS database.
Psoriasis related to angiotensin-converting enzyme inhibitors.
Psoriasis risk in patients with type 2 diabetes in German primary care practices.
Psoriasis: changing clinical patterns.
Serum and tissue angiotensin converting enzyme in patients with psoriasis.
Serum angiotensin converting enzyme activity in patients with psoriasis.
Serum angiotensin converting enzyme in patients with psoriasis.
Serum angiotensin-converting enzyme activity in psoriasis.
Serum angiotensin-converting enzyme in sarcoidosis and psoriasis.
The angiotensin-converting enzyme gene insertion polymorphism: a higher risk for psoriasis in male patients.
The angiotensin-converting enzyme insertion/deletion and the endothelin -134 3A/4A gene polymorphisms in patients with chronic plaque psoriasis.
The angiotensin-converting enzyme insertion/deletion polymorphism and susceptibility to rheumatoid arthritis, vitiligo and psoriasis: A meta-analysis.
Tissue angiotensin-converting enzyme in patients with various clinical forms of psoriasis.
Pterygium
Immunohistochemical analysis of angiotensin converting enzyme in sardinian pterygium.
Puberty, Delayed
Current treatment and management of dystrophinopathies.
Pulmonary Alveolar Proteinosis
[A case of pulmonary alveolar proteinosis with elevated serum angiotensin-converting enzyme activity]
Pulmonary Arterial Hypertension
Analysis of Angiotensin Converting Enzyme, Endothelial Nitric Oxide Synthase & Serotonin Gene Polymorphisms among Atrial Septal Defect Subjects with and without Pulmonary Arterial Hypertension.
Angiotensin converting enzyme 2 and angiotensin (1-7) axis in pulmonary arterial hypertension.
Angiotensin-converting enzyme inhibitor preserves p21 and endothelial nitric oxide synthase expression in monocrotaline-induced pulmonary arterial hypertension in rats.
Losartan attenuates chronic cigarette smoke exposure-induced pulmonary arterial hypertension in rats: possible involvement of angiotensin-converting enzyme-2.
Potential Contribution of Carotid Body-Induced Sympathetic and Renin-Angiotensin System Overflow to Pulmonary Hypertension in Intermittent Hypoxia.
Reduced expression of angiotensin I-converting enzyme in Caveolin-1 knockout mouse lungs.
Research Progress on Pulmonary Arterial Hypertension and the Role of the Angiotensin Converting Enzyme 2-Angiotensin-(1-7)-Mas Axis in Pulmonary Arterial Hypertension.
Scleroderma--clinical and pathological advances.
Systemic and localized scleroderma.
[Treatment of systemic sclerosis].
Pulmonary Disease, Chronic Obstructive
+9/+9 Homozygosity of the bradykinin receptor gene polymorphism is associated with reduced fat-free mass in chronic obstructive pulmonary disease.
?-blocker use in patients after percutaneous coronary interventions: One size fits all? Worse outcomes in patients without myocardial infarction or heart failure.
A multicenter risk index for atrial fibrillation after cardiac surgery.
A Pilot Study Linking Endothelial Injury in Lungs and Kidneys in Chronic Obstructive Pulmonary Disease.
A Randomized Controlled Trial of ACE-inhibition for Skeletal Muscle Dysfunction in Chronic Obstructive Pulmonary Disease.
ACE gene polymorphism is associated with COPD and COPD with pulmonary hypertension: a meta-analysis.
ACE I allele and eNOS G allele crosstalk may have a role in chronic obstructive pulmonary disease.
Activation of angiotensin-converting enzyme 2 (ACE2) attenuates allergic airway inflammation in rat asthma model.
Acute effects of nifedipine administration in pulmonary haemodynamics and oxygen delivery during exercise in patients with chronic obstructive pulmonary disease: implication of the angiotensin-converting enzyme gene polymorphisms.
Adequacy of Therapy for People with Both COPD and Heart Failure in the UK: Historical Cohort Study.
Adherence to Oral Medications for Hypertension and Diabetes in Veterans with Comorbid Airflow Limitation.
Amiodarone for prevention of atrial fibrillation following esophagectomy.
Anaemia in chronic obstructive pulmonary disease. Does it really matter?
Angiotensin converting enzyme genotype and strength in chronic obstructive pulmonary disease.
Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers: A Promising Medication for Chronic Obstructive Pulmonary Disease?
Angiotensin Converting Enzyme Insertion/Deletion Genotype and Strength in Chronic Obstructive Pulmonary Disease Patients: 1715: Board #3 May 31 8:00 AM 9:30 AM.
Angiotensin II blockers in obstructive pulmonary disease: a randomised controlled trial.
Angiotensin-converting enzyme gene polymorphisms and prognosis in chronic thromboembolic pulmonary hypertension.
Angiotensin-converting enzyme genotype and C-reactive protein in patients with COPD.
Angiotensin-converting enzyme I/D polymorphism in chronic obstructive pulmonary disease.
Angiotensin-converting enzyme I/D polymorphism is associated with COPD risk in Asian population: evidence from a meta-analysis.
Angiotensin-Converting Enzyme Inhibition as an Adjunct to Pulmonary Rehabilitation in COPD.
Angiotensin-converting enzyme-2 overexpression attenuates inflammation in rat model of chronic obstructive pulmonary disease.
Angiotensin-converting-enzyme gene polymorphisms, smoking and chronic obstructive pulmonary disease.
Association between activation of the renin-angiotensin system and secondary erythrocytosis in patients with chronic obstructive pulmonary disease.
Association between angiotensin-converting enzyme gene polymorphisms and exercise performance in patients with COPD.
Association between the angiotensin-converting enzyme gene polymorphisms and tissue oxygenation during exercise in patients with COPD.
Association of angiotensin-converting enzyme gene I/D polymorphism with chronic obstructive pulmonary disease: a meta-analysis.
Associations between endothelial nitric oxide synthase A/B, angiotensin converting enzyme I/D and serotonin transporter L/S gene polymorphisms with pulmonary hypertension in COPD patients.
Challenges in the Management of Patients with Chronic Obstructive Pulmonary Disease and Heart Failure With Reduced Ejection Fraction.
Characteristics, treatments and 1-year prognosis of hospitalized and ambulatory heart failure patients with chronic obstructive pulmonary disease in the European Society of Cardiology Heart Failure Long-Term Registry.
Chronic Cough: Evaluation and Management.
Chronic obstructive pulmonary disease and comorbidities.
Chronic obstructive pulmonary disease: an update of treatment related to frequently associated comorbidities.
Chronic obstructive pulmonary disease: moving from symptom relief to mortality reduction.
Clinical Characteristics and Outcomes of Patients With Heart Failure With Reduced Ejection Fraction and Chronic Obstructive Pulmonary Disease: Insights From PARADIGM-HF.
Clinical factors associated with early readmission among acutely decompensated heart failure patients.
Clinical metric and medication persistency effects: evidence from a Medicaid care management program.
Comparative effects of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on the risk of pneumonia and severe exacerbations in patients with COPD.
Deletion polymorphisms in the angiotensin converting enzyme gene are associated with pulmonary hypertension evoked by exercise challenge in patients with chronic obstructive pulmonary disease.
Dysregulation of endocytic machinery and ACE2 in small airways of smokers and COPD patients can augment their susceptibility to SARS-CoV-2 (COVID-19) infections.
Effect of enalapril on exercise cardiopulmonary performance in chronic obstructive pulmonary disease: A pilot study.
Effects of angiotensin converting enzyme inhibition on sodium excretion in patients with hypoxaemic chronic obstructive pulmonary disease.
Effects of angiotensin-converting enzyme inhibitors on spontaneous or stimulated generation of reactive oxygen species by bronchoalveolar lavage cells harvested from patients with or without chronic obstructive pulmonary disease.
Effects of captopril administration on pulmonary haemodynamics and tissue oxygenation during exercise in ACE gene subtypes in patients with COPD: a preliminary study.
Effects of captopril on hemodynamics and blood gases in chronic obstructive lung disease with pulmonary hypertension.
Elevated ACE activity is not associated with asthma, COPD, and COPD co-morbidity.
Future treatments for chronic obstructive pulmonary disease and its comorbidities.
Gene polymorphisms of endothelial nitric oxide synthase enzyme associated with pulmonary hypertension in patients with COPD.
Genetic Polymorphism of Angiotensin-Converting Enzyme and Chronic Obstructive Pulmonary Disease Risk: An Updated Meta-Analysis.
Guideline-recommended secondary prevention drug therapy after acute myocardial infarction: predictors and outcomes of nonadherence.
Heart failure and chronic obstructive pulmonary disease: a review.
Hematocrit-lowering effect following inactivation of renin-angiotensin system with angiotensin converting enzyme inhibitors and angiotensin receptor blockers.
High rate of renal recovery in survivors of COVID-19 associated acute renal failure requiring renal replacement therapy.
Highly positive intraoperative fluid balance during cardiac surgery is associated with adverse outcome.
Identification of independent risk factors for fentanyl-induced cough.
Impact of COPD on the mortality and treatment of patients hospitalized with acute decompensated heart failure: the Worcester Heart Failure Study.
Impact of statins and ACE inhibitors on mortality after COPD exacerbations.
Incidence and Risk Factors of Dry Eye in a Spanish Adult Population: 11-Year Follow-Up From the Salnés Eye Study.
Influence of oxygen administration on pulmonary haemodynamics and tissue oxygenation during exercise in COPD patients with different ACE genotypes.
Inhaled corticosteroids and angiotensin-converting enzyme-2 in COPD.
Insertion/deletion polymorphism of angiotensin-converting enzyme and chronic obstructive pulmonary disease: A case-control study on north Indian population.
Left ventricular output indices in hospitalized heart failure: when "simpler" may not mean "better".
Local Renin-Angiotensin II Systems, Angiotensin-Converting Enzyme and its Homologue ACE2: Their Potential Role in the Pathogenesis of Chronic Obstructive Pulmonary Diseases, Pulmonary Hypertension and Acute Respiratory Distress Syndrome.
Management of Chronic Obstructive Pulmonary Disease in Patients with Cardiovascular Diseases.
Nonsteroidal antiinflammatory drugs and risk of gastrointestinal bleeding among patients on hemodialysis.
Overview of the pharmacological challenges facing physicians in the management of patients with concomitant cardiovascular disease and chronic obstructive pulmonary disease.
Prevalence and prognosis of chronic obstructive pulmonary disease among 8167 Middle Eastern patients with acute coronary syndrome.
Prevention of chronic obstructive pulmonary disease exacerbation by angiotensin-converting enzyme inhibitors in individuals with impaired swallowing.
Prognostic factors for adverse outcomes in patients with COVID-19: a field-wide systematic review and meta-analysis.
Redox status of patients before cardiac surgery.
Reducing mortality for chronic obstructive pulmonary disease: role of statins and angiotensin-converting enzyme inhibitors.
Reduction of morbidity and mortality by statins, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease.
Risk of Sepsis and Mortality Among Patients With Chronic Obstructive Pulmonary Disease Treated With Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers.
Risk prediction for 30-day heart failure-specific readmission or death after discharge: Data from the Korean Acute Heart Failure (KorAHF) registry.
Serum angiotensin converting enzyme values in chronic obstructive pulmonary disease.
Serum angiotensin-converting enzyme activity, concentration, and specific activity in granulomatous interstitial lung disease, tuberculosis, and COPD.
Surprising Results from an Angiotensin-Converting Enzyme Inhibitor Trial in Patients with Chronic Obstructive Pulmonary Disease.
Targeting systemic inflammation: novel therapies for the treatment of chronic obstructive pulmonary disease.
Temporal Trends in Treatment and Outcomes of Acute Myocardial Infarction in Patients With Chronic Obstructive Pulmonary Disease: A Nationwide Population-Based Observational Study.
The association between COPD and heart failure risk: a review.
The D/I Polymorphism in the Angiotensin-Converting Enzyme Gene and Chronic Obstructive Pulmonary Disease Risk: A Meta-Analysis.
The DD genotype of the angiotensin converting enzyme gene is negatively associated with right ventricular hypertrophy in male patients with chronic obstructive pulmonary disease.
The effects of angiotensin-converting enzyme inhibition on sodium handling in patients with advanced chronic obstructive pulmonary disease.
The insertion/deletion polymorphism in the ACE gene and chronic obstructive pulmonary disease.
The link between angiotensin-converting enzyme genotype and pulmonary artery pressure in patients with COPD.
Total management of chronic obstructive pulmonary disease (COPD) as an independent risk factor for cardiovascular disease.
Treatment of COPD: moving beyond the lungs.
Update in diagnosis and therapy of coexistent chronic obstructive pulmonary disease and chronic heart failure.
Vitamin D receptor genotypes influence quadriceps strength in chronic obstructive pulmonary disease.
[Anemias in chronic obstructive pulmonary disease].
[Angiotensin converting enzyme activity in the clinical course and forming of cor pulmonale in patients with chronic obstructive pulmonary diseases]
[Changes in angiotensin-converting enzyme activity in pneumonia and chronic obstructive lung diseases]
[Changes of angiotensin II and angiotensin-converting enzyme in cor pulmonale with respiratory failure]
[Choice of an Optimal Blocker of the Renin-Angiotensin-Aldosterone System in Patients With Concomitant Arterial Hypertension and Chronic Obstructive Pulmonary Disease].
[Clinical efficiency of course and long-term therapy with the angiotensin-converting enzyme inhibitor perindopril in patients with chronic obstructive lung disease and cor pulmonale]
[Effect of captopril on pulmonary arterial hypertension in congestive heart failure associated with chronic obstructive bronchopneumopathy]
[Effects of captopril on hemodynamics, gas exchange and exercise capacity in patients with pulmonary hypertension secondary to chronic obstructive pulmonary disease]
[Pulmonary hypertension and right ventricular failure. Part V. Therapy in the patients with chronic obstructive pulmonary disease]
[The change in the activity of angiotensin converting enzyme in patients with pneumonia and chronic obstructive pulmonary diseases]
[The evaluation of serum angiotensin-converting enzyme in silicosis and silicotuberculosis]
[Variations of angiotensin converting enzyme in chronic obstructive pulmonary disease and chronic respiratory insufficiency]
Pulmonary Edema
Angiotensin-converting enzyme gene insertion/deletion polymorphism and high-altitude pulmonary edema: An updated meta-analysis.
Atrial infarction is a unique and often unrecognized clinical entity.
Decreased serum angiotensin converting enzyme in adult respiratory distress syndrome associated with sepsis: a preliminary report.
Effectiveness of liposomal-N-acetylcysteine against LPS-induced lung injuries in rodents.
Enhanced activity of liposomal polymyxin B against Pseudomonas aeruginosa in a rat model of lung infection.
Existence of leukotoxin 9,10-epoxy-12-octadecenoate in lung lavages from rats breathing pure oxygen and from patients with the adult respiratory distress syndrome.
Inhibition of angiotensin-converting enzyme by perindopril diacid in canine oleic acid pulmonary edema.
Ischemic renal disease: an emerging cause of chronic renal failure and end-stage renal disease.
Lung injury induced by antibody fragments to angiotensin-converting enzyme.
Lung injury mediated by antibodies to endothelium. III. Effect of chlorpromazine in rabbits.
Management of Heart Failure in the Emergency Department Setting: An Evidence-Based Review of the Literature.
Nitrofurantoin-induced pulmonary toxicity. In vivo evidence for oxidative stress-mediated mechanisms.
Noninvasive diagnosis of renovascular disease.
Peritoneal dialysis and cough: ACCP evidence-based clinical practice guidelines.
Polymorphisms of angiotensin converting enzyme and nitric oxide synthase 3 genes as risk factors of high-altitude pulmonary edema: a case-control study and meta-analysis.
Polymorphisms of renin-angiotensin system genes with high-altitude pulmonary edema in Japanese subjects.
Prophylaxis against lipopolysaccharide-induced acute lung injury by alpha-tocopherol liposomes.
Prophylaxis against lipopolysaccharide-induced lung injuries by liposome-entrapped dexamethasone in rats.
Pseudomonas aeruginosa-induced lung injury: role of oxidative stress.
Pulmonary edema induced by angiotensin I in rats.
Rapid improvement of acute pulmonary edema with angiotensin converting enzyme inhibitor under hemodialysis in a patient with renovascular disease.
Renal artery stenosis presenting as preeclampsia.
Renal artery stenosis: a common, treatable cause of renal failure?
Secondary Hypertension: Discovering the Underlying Cause.
Surfactant protein A (SP-A) and angiotensin converting enzyme (ACE) as early biomarkers for pulmonary edema formation in ventilated human lung lobes.
University of Miami Division of Clinical Pharmacology Therapeutic Rounds: ischemic renal disease.
[Protective effect of an angiotensin-converting-enzyme inhibitor on neurogenic pulmonary edema in rabbits].
[Renal artery stenosis: acute congestive heart failure as a possible cause]
Pulmonary Embolism
A new experimental model for measurement of pulmonary arterial haemodynamic variables in conscious rats before and after pulmonary embolism and during general anaesthesia.
Anaesthetic considerations with the metabolic syndrome.
Changes in serum angiotensin-converting enzyme activity after pulmonary embolism.
In the eye of the storm: the right ventricle in COVID-19.
Pulmonary Embolism in a Sarcoidosis Patient Double Heterozygous for Methylenetetrahydrofolate Reductase Gene Polymorphisms and Factor V Leiden and Homozygous for the D-Allele of Angiotensin Converting Enzyme Gene.
The role of angiotensin-converting enzyme gene polymorphism in pulmonary thromboembolism.
The value of angiotensin-I-converting enzyme determinations in malignant and other diseases.
[Angiotensin-converting enzyme in pulmonary thromboembolism as a marker of vascular lesion]
[Cough: differential diagnosis and differentiated treatment].
[Insertion/deletion polymorphsim of the angiotensin I converting enzyme gene and pulmonary thromboembolism in Chinese population]
[Pulmonary embolism mimicking acute anterior myocardial infarction: Diagnostic trap.]
Pulmonary Emphysema
Pulmonary angiotensin converting enzyme activity in elastase induced emphysema.
Pulmonary Fibrosis
Angiotensin II is mitogenic for human lung fibroblasts via activation of the type 1 receptor.
Antifibrotic effect of captopril and enalapril on paraquat-induced lung fibrosis in rats.
Assessment of bleomycin lung toxicity using angiotensin-converting enzyme in pulmonary lavage.
Association between plasma angiotensin-converting enzyme level and radiation pneumonitis.
Captopril inhibits proliferation of human lung fibroblasts in culture: a potential antifibrotic mechanism.
Effect of an angiotensin II receptor blocker and two angiotensin converting enzyme inhibitors on transforming growth factor-beta (TGF-beta) and alpha-actomyosin (alpha SMA), important mediators of radiation-induced pneumopathy and lung fibrosis.
Increased D allele frequency of the angiotensin-converting enzyme gene in pulmonary fibrosis.
Intravenous cyclophosphamide pulse therapy for the treatment of lung disease associated with scleroderma.
Mir-21 Mediates the Inhibitory Effect of Ang (1-7) on AngII-induced NLRP3 Inflammasome Activation by Targeting Spry1 in lung fibroblasts.
Model development and use of ACE inhibitors for preclinical mitigation of radiation-induced injury to multiple organs.
Monocrotaline-induced pulmonary fibrosis in rats: amelioration by captopril and penicillamine.
Osthole Alleviates Bleomycin-Induced Pulmonary Fibrosis via Modulating Angiotensin-Converting Enzyme 2/Angiotensin-(1-7) Axis and Decreasing Inflammation Responses in Rats.
Preliminary results from a cohort of workers exposed to wollastonite in a Finish limestone quarry.
Pulmonary fibrosis and angiotensin I-converting enzyme.
Radiation pneumotoxicity in rats: modification by inhibitors of angiotensin converting enzyme.
Radiation-induced endothelial dysfunction and fibrosis in rat lung: modification by the angiotensin converting enzyme inhibitor CL242817.
Radiation-induced pulmonary endothelial dysfunction and hydroxyproline accumulation in four strains of mice.
Tanshinone IIA attenuates bleomycin-induced pulmonary fibrosis via modulating angiotensin-converting enzyme 2/ angiotensin-(1-7) axis in rats.
The genetic basis of strain-dependent differences in the early phase of radiation injury in mouse lung.
[A study on the inhibition effect of tetrandrine on the pingyangmycinum induced pulmonary fibrosis]
[Livedo-like cutaneous sarcoidosis].
[Perindopril and losartan attenuate bleomycin A5-induced pulmonary fibrosis in rats]
Pulmonary Heart Disease
[Angiotensin converting enzyme activity in the clinical course and forming of cor pulmonale in patients with chronic obstructive pulmonary diseases]
[Changes of angiotensin II and angiotensin-converting enzyme in cor pulmonale with respiratory failure]
[Clinical efficiency of course and long-term therapy with the angiotensin-converting enzyme inhibitor perindopril in patients with chronic obstructive lung disease and cor pulmonale]
[Efficiency of ramipril treatment in patients with chronic obstructive bronchitis complicated by chronic cor pulmonale]
[The drug therapy of chronic cor pulmonale]
Pulmonary Valve Insufficiency
From Other Journals: A Review of Recent Articles in Pediatric Cardiology.
Pulmonary Valve Stenosis
Alpha blocker and angiotensin-converting enzyme inhibitor in the management of severe pulmonary valve stenosis: from bench to bedside.
Angiotensin converting enzyme inhibitor as an additive treatment after successful balloon dilation of a critical pulmonary valve stenosis.
Increased chymase-like activity in a dog with congenital pulmonic stenosis.
Pure Autonomic Failure
Angiotensin converting enzyme inhibition lowers blood pressure in patients with primary autonomic failure independently of plasma renin levels and sympathetic nervous activity.
Purpura
A meta-analysis of the association between angiotensin-converting enzyme insertion/deletion gene polymorphism and Henoch-Schönlein purpura nephritis risk in Asian children.
Angiotensin-converting enzyme insertion/deletion polymorphism and susceptibility to Henoch-Schönlein purpura: a meta-analysis.
Association study of ACE and eNOS single nucleotide polymorphisms with Henoch-Schönlein purpura nephritis.
Deletion polymorphism of the angiotensin converting enzyme gene predicts persistent proteinuria in Henoch-Schönlein purpura nephritis.
Henoch-Schönlein nephritis associated with streptococcal infection and persistent hypocomplementemia: a case report.
IgA nephropathy and Henoch-Schönlein purpura nephritis.
Steroid- and immunosuppressant-based protocol of Henoch-Schönlein purpura nephritis without angiotensin inhibitors in the acute phase: case series with correlation to histology.
Pyelonephritis
Effect of captopril on the progression of induced pyelonephritis in the rat.
[The effect of captopril on the arterial pressure, structural resistance and vascular reactivity of the kidney in rats with nephrogenic hypertension]
Quadriplegia
Effect of hypotensive challenge on systemic hemodynamics and cerebral blood flow in persons with tetraplegia.
Partial angiotensin-converting enzyme inhibition during acute orthostatic stress in persons with tetraplegia.
Radiation Pneumonitis
Angiotensin-converting enzyme inhibitors decrease the risk of radiation pneumonitis after stereotactic body radiation therapy.
Association between plasma angiotensin-converting enzyme level and radiation pneumonitis.
Can angiotensin-converting enzyme inhibitors protect against symptomatic radiation pneumonitis?
Cardiac Remodeling and Reversible Pulmonary Hypertension During Pneumonitis in Rats after 13-Gy Partial-Body Irradiation with Minimal Bone Marrow Sparing: Effect of Lisinopril.
Decreased Risk of Radiation Pneumonitis With Coincident Concurrent Use of Angiotensin-converting Enzyme Inhibitors in Patients Receiving Lung Stereotactic Body Radiation Therapy.
Decreased Risk of Radiation Pneumonitis with Incidental Concurrent Use of Angiotensin-Converting Enzyme Inhibitors and Thoracic Radiation Therapy.
Do angiotensin-converting enzyme inhibitors reduce the risk of symptomatic radiation pneumonitis in patients with non-small cell lung cancer after definitive radiation therapy? Analysis of a single-institution database.
Model development and use of ACE inhibitors for preclinical mitigation of radiation-induced injury to multiple organs.
Radiation pneumonitis in rats and its modification by the angiotensin-converting enzyme inhibitor captopril evaluated by high-resolution computed tomography.
Symptomatic Radiation Pneumonitis in Elderly Patients Receiving Thoracic Irradiation.
Raynaud Disease
Renin-angiotensin system mediators and Raynaud's phenomenon.
Rectal Neoplasms
Increased tumor response to neoadjuvant therapy among rectal cancer patients taking angiotensin-converting enzyme inhibitors or angiotensin receptor blockers.
Is preoperative chemoradiation in rectal cancer patients modulated by ACE inhibitors? Results from the Dutch Cancer Registry.
Red-Cell Aplasia, Pure
Erythropoiesis-stimulating agent hyporesponsiveness.
Reflex, Abnormal
Autonomic and baroreflex function after captopril in hypertension.
Renal Artery Obstruction
(99m)Tc Diethylenetriaminepentacetic Acid Angiotension-coverting Enzyme Inhibitor Renography as Screening Test for Renovascular Hypertension in Unilateral Small Kidney: A Prospective Study.
Acute renal failure after the use of angiotensin-converting-enzyme inhibitors in patients without renal artery stenosis.
Acute renal failure secondary to angiotensin II receptor blockade in a patient with bilateral renal artery stenosis.
Afferent renal nerve-dependent hypertension following acute renal artery stenosis in the conscious rat.
An underused opportunity to introduce ACE inhibitors and influence prognosis: observational study of patients undergoing aortic surgery.
Angiotensin converting enzyme inhibition induces alterations to hippuran renography despite unchanged ipsilateral renal blood flow in conscious two-kidney, one clip Goldblatt hypertensive dogs.
Angiotensin receptor blockade has protective effects on the poststenotic porcine kidney.
Angiotensin-converting enzyme inhibition in renal disease; contrasting effects on renal function in renal artery stenosis and progressive renal injury.
Angiotensin-converting enzyme inhibitor renography. Pathophysiological, diagnostic and therapeutic aspects in renal artery stenosis.
Angiotensin-converting enzyme inhibitor usage in patients with incidental atherosclerotic renal artery stenosis.
Atherosclerotic Renal Artery Stenosis.
Atherosclerotic renal artery stenosis: surgery, percutaneous transluminal angioplasty, or medical therapy?
Captopril renal scintigraphy in renovascular hypertension.
Captopril renography in two kidney and one kidney Goldblatt hypertension in dogs.
Captopril-associated granulocytopenia in hypertension after renal transplantation.
Captopril-enhanced scintigraphy using the method of the expected renogram: improved detection of patients with renin-dependent hypertension due to functionally significant renal artery stenosis.
Captopril-induced acute renal failure in a kidney transplant recipient.
Captopril-induced changes in MAG3 clearance in patients with renal arterial stenosis and the effect of renal angioplasty.
Changes in renal function induced by ACE-inhibition in the conscious two-kidney, one-clip Goldblatt hypertensive dog.
Characteristics of renal tubular atrophy in experimental renovascular hypertension: a model of kidney hibernation.
Clinical characteristics of atherosclerotic renovascular disease.
Contrasting effects of acute angiotensin converting enzyme inhibitors and calcium antagonists in transplant renal artery stenosis.
Converting-enzyme inhibitor enalapril (MK421) in treatment of hypertension with renal artery stenosis.
Diagnosis of renovascular hypertension: feasibility of captopril-sensitized dynamic MR imaging and comparison with captopril scintigraphy.
Diagnostic imaging of renal artery stenosis.
Diagnostic use of angiotensin converting enzyme (ACE)-inhibited renal scintigraphy in the identification of selective renal artery stenosis in the presence of multiple renal arteries: a case report.
Diagnostic use of angiotensin converting enzyme inhibitors in radioisotope evaluation of unilateral renal artery stenosis.
Differential renal function during angiotensin converting enzyme inhibition in renovascular hypertension.
Differentiated response of the sympathetic nervous system to angiotensin-converting enzyme inhibition in hypertension.
Differentiation between renovascular and essential hypertension by means of changes in single kidney 99mTc-DTPA clearance induced by angiotensin-converting enzyme inhibition.
Effect of angiotensin converting enzyme inhibition on the Doppler waveform in dogs with renal artery stenosis.
Effect of captopril (SQ 14225) on blood pressure, plasma renin activity and angiotensin I converting enzyme activity.
Effect of captopril and the nonpeptide angiotensin II antagonists, SK&F 108566 and EXP3174, on renal function in dogs with a renal artery stenosis.
Effect of captopril on 99mTc-diethylenetriaminepentaacetic acid renograms in two-kidney, one clip hypertension.
Effect of captopril on blood pressure and renal function in patients with transplant renal artery stenosis.
Effects of enalapril maleate (MK-421) on renovascular hypertension.
Effects of enalapril maleate on plasma level of inactive renin in renovascular hypertension.
Effects on angiotensin-converting enzyme inhibition on renal hemodynamics in renal artery stenosis.
Enalapril: a new angiotensin converting enzyme inhibitor.
Endothelin and active renin levels in essential hypertension and hypertension with renal artery stenosis before and after percutaneous transluminal renal angioplasty.
Epidemiology, associated factors, and prognostic outcomes of renal artery stenosis in chronic heart failure assessed by magnetic resonance angiography.
European Captopril Radionuclide Test Multicenter Study. Preliminary results. Inspective renographic analysis. The European Captopril Radionuclide Test Multicenter Study Group.
Expression of angiotensin-converting enzyme in renovascular hypertensive rat kidney.
Functional testing: ACEI renography.
General inhibition of renocortical cyclooxygenase-2 expression by the renin-angiotensin system.
Influence of anaesthesia on renal hippurate handling during angiotensin-converting enzyme inhibition in unilateral renal artery stenosis.
Kidney Biopsy Findings in a Patient With Valproic Acid-Associated Fanconi Syndrome.
Kidney scintigraphy after ACE inhibition in the diagnosis of renovascular hypertension.
Labeled lectin studies of renal tubular dysgenesis and renal tubular atrophy of postnatal renal ischemia and end-stage kidney disease.
Losartan renography for the detection of renal artery stenosis: comparison with captopril renography and evaluation of dose and timing.
Ostial renal artery stent placement for atherosclerotic renal artery stenosis in patients with coronary artery disease.
Percutaneous transluminal renal angioplasty and renal function.
Pharmacologic nephrectomy with chronic angiotensin converting enzyme inhibitor treatment in renovascular hypertension in the rat.
Refractory hypertension after renal transplantation.
Renal artery stenosis emerged after angiotensin-converting enzyme inhibitor treatment for myocardial infarction: a case report.
Renal artery stenosis presenting as preeclampsia.
Renal artery stenosis: a common, treatable cause of renal failure?
Renal artery stenosis: evaluation of Doppler US after inhibition of angiotensin-converting enzyme with captopril.
Renal Considerations in Geriatric Patients With Heart Disease.
Renal insufficiency during angiotensin-converting enzyme inhibitor therapy in hypertensive patients with no renal artery stenosis.
Renal physiology of renal artery stenosis. Implications for captopril-stimulated renography.
Renal scintigraphic captopril test in the diagnosis of renovascular hypertension.
Renin-dependent renal parenchymatous hypertension detected by angiotensin-converting enzyme inhibitor renography.
Renovascular hypertension: nuclear medicine techniques.
Risks of angiotensin converting enzyme inhibition in renal artery stenosis.
Role of angiotensin II in the hypertension induced by renal artery stenosis.
Safety of angiotensin-converting enzyme inhibitors in patients with bilateral renal artery stenosis following successful renal artery stent revascularization.
Secondary hypertension in adults.
Selection of patients for renal artery repair using captopril testing.
Severe Infrarenal Atheroma Load in Open Aortic Aneurysm Repair Is Not a Risk Factor for Postoperative Acute Kidney Injury.
Severe paradoxical hypertension with angiotensin-converting enzyme inhibitors: an unusual feature of renal artery stenosis.
State-of-the-art review: captopril renography--pathophysiological considerations and clinical observations.
Taking precautions with angiotensin converting enzyme inhibitors. Screening for unilateral renal artery stenosis cannot be justified.
The 2011 canadian hypertension education program recommendations for the management of hypertension: blood pressure measurement, diagnosis, assessment of risk, and therapy.
The impact of atherosclerotic renovascular disease on diabetic renal failure.
The mechanism and diagnostic value of angiotensin I converting enzyme inhibition renography.
Transient anuria following administration of angiotensin I-converting enzyme inhibitor (SQ 14225) in a patient with renal artery stenosis of the solitary kidney successfully treated with renal autotransplantation.
Use of renin-angiotensin inhibitors in people with renal artery stenosis.
[Acute renal failure, renal artery stenosis and angiotensin-converting enzyme (ACE) inhibitor]
[Acute renal insufficiency secondary to the use of angiotensin converting enzyme inhibitors in 2 patients without renal artery stenosis]
[Angiotensin-converting enzyme inhibitor renography. Physiopathological, diagnostic and therapeutic aspects in renal artery stenosis]
[Hypertension and arteriopathy]
[Hypertension and stenosis of the graft artery: effects of conversion enzyme inhibition]
[Hypertension from the nephrologist's point of view]
[Management of atherosclerotic renal artery stenoses]
[Renal scintigraphy with captopril in the evaluation of renovascular hypertension]
[Revascularization of atherosclerotic stenosis of the renal artery. Indications and results]
[Unnoticed loss of renal function during treatment with angiotensin I converting enzyme inhibitor. A new risk in patients with unrecognized unilateral stenosis of the renal artery]
Renal Insufficiency
A comparative study of the prevalence of hyperkalemia with the use of angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers.
A practical approach to the management of patients with chronic renal failure.
ACE activity is modulated by the enzyme ?-galactosidase A.
ACE inhibition is effective and renoprotective in hypertensive nephrosclerosis: the African American Study of Kidney Disease and Hypertension (AASK) trial.
ACE inhibition or angiotensin receptor blockade: impact on potassium in renal failure. VAL-K Study Group.
ACE inhibition prevents renal failure and death in uninephrectomized MWF/Ztm rats.
ACE inhibitors to prevent end-stage renal disease: when to start and why possibly never to stop: a post hoc analysis of the REIN trial results. Ramipril Efficacy in Nephropathy.
Acute Kidney Injury after Heart Valve Surgery in Elderly Patients: any Risk Factors to Modify?
Acute phosphate nephropathy--an emerging issue.
Acute renal failure during lisinopril and losartan therapy for proteinuria.
Acute renal thrombosis induced by angiotensin-converting enzyme inhibitors in patients with renovascular hypertension.
Add-on angiotensin II receptor blockade lowers urinary transforming growth factor-beta levels.
Adult Care of Children From Pediatric Urology.
Advances and unmet needs in genetic, basic and clinical science in Alport syndrome: report from the 2015 International Workshop on Alport Syndrome.
Adverse cardiac effects of exogenous angiotensin 1-7 in rats with subtotal nephrectomy are prevented by ACE inhibition.
Alport Syndrome in Women and Girls.
Alport syndrome: its effects on the glomerular filtration barrier and implications for future treatment.
Angiotensin antagonists and steroids in the treatment of focal segmental glomerulosclerosis.
Angiotensin converting enzyme genotype and chronic allograft nephropathy in protocol biopsies.
Angiotensin converting enzyme inhibition and protein restriction in progression of experimental chronic renal failure.
Angiotensin converting enzyme inhibition and renal insufficiency in patients with bilateral renovascular disease.
Angiotensin converting enzyme inhibition in renovascular hypertension: frequency of reversible renal failure.
Angiotensin converting enzyme inhibitors and calcium antagonists in the progression of renal insufficiency.
Angiotensin converting enzyme inhibitors and progressive renal insufficiency. Current experience and future directions.
Angiotensin converting enzyme inhibitors in nondiabetic renal disease.
Angiotensin II increases the cytosolic calcium activity in rat podocytes in culture.
Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
Angiotensin-converting enzyme inhibition aggravates renal interstitial injury resulting from partial unilateral ureteral obstruction in the neonatal rat.
Angiotensin-converting enzyme inhibition and anaemia in renal patients.
Angiotensin-converting enzyme inhibition in nondiabetic progressive renal insufficiency: a controlled double-blind trial.
Angiotensin-converting enzyme inhibition in renovascular hypertension: the narrowing gap between functional renal failure and progressive renal atrophy.
Angiotensin-converting enzyme inhibitor use in older patients with heart failure and renal dysfunction.
Angiotensin-converting enzyme inhibitor-induced renal failure: causes, consequences, and diagnostic uses.
Angiotensin-converting enzyme inhibitors and kidney protection: the AIPRI trial. The ACE Inhibition in Progressive Renal Insufficiency (AIPRI) Study Group.
Angiotensin-converting enzyme inhibitors and outcome among patients with heart failure and renal insufficiency: need for a prospective study.
Angiotensin-converting enzyme inhibitors and renal failure in diabetes.
Angiotensin-converting enzyme inhibitors in pregnancy may result in neonatal renal failure.
Angiotensin-converting enzyme inhibitors.
Angiotensin-converting enzyme polymorphism in patients with terminal renal failure.
Antihypertensive agents acting on the renin angiotensin system and the risk of sepsis.
Antihypertensive treatment in renal transplant patients--is there a role for ACE inhibitors?
Antihypertensive treatment with and without benazepril in patients with chronic renal insufficiency: a US economic evaluation.
Are angiotensin converting enzyme inhibitors superior to beta blockers in retarding progressive renal function decline?
Are we inhibited? Renal insufficiency should not preclude the use of ACE inhibitors for patients with myocardial infarction and depressed left ventricular function.
Arteriolar wall thickening, capillary rarefaction and interstitial fibrosis in the heart of rats with renal failure:the effects of ramipril, nifedipine and moxonidine.
Aspirin use in older patients with heart failure and coronary artery disease: national prescription patterns and relationship with outcomes.
Associated effect of hepatic hydroxymethylglutaryl coenzyme A reductase + angiotensin converting enzyme inhibitors on the progression of renal failure in hypertensive subjects.
Association between the A1166C polymorphism of the angiotensin II receptor type 1 and progression of chronic renal insufficiency.
Association between vitamin D receptor gene polymorphisms and tubular citrate handling in calcium nephrolithiasis.
Association of angiotensin-converting enzyme inhibitor therapy initiation with a reduction in hemoglobin levels in patients without renal failure.
Attenuation of nephrotoxic acute renal failure in the dog with angiotensin-converting enzyme inhibitor (SQ-20,881).
Benazepril and the kidney: new indication. No better than the other ACE inhibitors.
Benazepril slows progression of renal dysfunction in patients with non-diabetic renal disease.
Bilateral renal artery stenosis: presenting as a case of scleroderma renal crisis.
Blood Eicosapentaenoic Acid and Docosahexaenoic Acid as Predictors of All-Cause Mortality in Patients With Acute Myocardial Infarction.
Blood pressure, angiotensin-converting enzyme (ACE) inhibitors, and the kidney.
Can we further slow down the progression to end-stage renal disease in diabetic hypertensive patients?
Captopril in patients with type II diabetes and renal insufficiency: systemic and renal hemodynamic alterations.
Cardiomyocyte loss in experimental renal failure: prevention by ramipril.
Cardiorenal disease: a clinical intersection.
Chronic kidney disease screening and renoprotection in type 2 diabetes.
Chronic lead poisoning: a "forgotten" cause of renal disease.
Clearance of imidapril, an Angiotensin-converting enzyme inhibitor, during hemodialysis in hypertensive renal failure patients: comparison with quinapril and enalapril.
Clinical and histopathological features resembling those of human focal segmental glomerulosclerosis in a cat with nonimmune-mediated glomerulonephropathy.
Clinical characteristics of atherosclerotic renovascular disease.
Clinical pharmacokinetics of angiotensin converting enzyme (ACE) inhibitors in renal failure.
Clinical utility of angiotensin converting enzyme inhibitors in hypertension.
Combination therapy with an angiotensin-converting enzyme inhibitor and a vitamin D analog suppresses the progression of renal insufficiency in uremic rats.
Combination therapy with angiotensin-converting enzyme inhibitor and oral adsorbent of uremic toxins can delay the appearance of glomerular sclerosis and interstitial fibrosis in established renal failure.
Combination therapy with benazepril and oral adsorbent ameliorates progressive renal fibrosis in uremic rats.
Combination use of medicines from two classes of renin-angiotensin system blocking agents: risk of hyperkalemia, hypotension, and impaired renal function.
Comparison of Frequency of Cardiovascular Events and Mortality in Patients With Heart Failure Using Versus Not Using Cocaine.
Comparison of frequency of new-onset atrial fibrillation or flutter in patients on statins versus not on statins presenting with suspected acute coronary syndrome.
Comparison of renin-angiotensin to calcium channel blockade in renal disease.
Concomitant administration of isradipine and spirapril prevents reduction of renal function induced by acute administration of spirapril in patients with reduced renal function.
Congenital renal tubular dysplasia and skull ossification defects similar to teratogenic effects of angiotensin converting enzyme (ACE) inhibitors.
Control of hypertension and reversal of renal failure in undifferentiated connective tissue disease by enalapril.
Control of hypertension with captopril affords better renal protection as compared with irbesartan in salt-loaded uremic rats.
Development of hypertension and effects of benazepril hydrochloride in a canine remnant kidney model of chronic renal failure.
Development of hypotension in patients newly diagnosed with heart failure in UK general practice: retrospective cohort and nested case-control analyses.
Diabetic nephropathy.
Diabetic nephropathy: an observational study on patients attending a joint diabetes renal clinic.
Diagnosis of Alport syndrome-search for proteomic biomarkers in body fluids.
Differential regulation of angiotensin converting enzyme 2 and nuclear factor-?B by angiotensin II receptor subtypes in type 2 diabetic kidney.
Disease progression, response to ACEI/ATRA therapy and influence of ACE gene in IgA nephritis.
Does the combination of aprotinin and angiotensin-converting enzyme inhibitor cause renal failure after cardiac surgery?
Early angiotensin-converting enzyme inhibition in Alport syndrome delays renal failure and improves life expectancy.
Effect of angiotensin converting enzyme inhibition on blood pressure and renal function during open heart surgery.
Effect of benazepril monotherapy in subjects with hypertension associated with renal dysfunction.
Effect of enalapril on erythrocytosis in hypertensive patients with renal disease.
Effect of renal insufficiency on the pharmacokinetics and pharmacodynamics of benazepril in cats.
Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group.
Effects of an inhibitor of angiotensin converting enzyme (Captopril) on pulmonary and renal insufficiency due to intravascular coagulation in the rat.
Effects of angiotensin converting enzyme inhibitor on renal function in patients of membranoproliferative glomerulonephritis with mild to moderate renal insufficiency.
Effects of angiotensin converting enzyme inhibitors on the progression of renal failure and proteinuria in humans.
Effects of angiotensin inhibitors on renal injury and angiotensin receptor expression in early hypertensive nephrosclerosis.
Effects of antihypertensive drugs on renal function in patients with diabetic nephropathy.
Effects of antihypertensive therapy on intrarenal angiotensin and bradykinin levels in experimental renal insufficiency.
Effects of captopril on cardiac and renal damage, and metabolic alterations in the nitric oxide-deficient hypertensive rat.
Effects of dual blockade of renin-angiotensin system in type 2 diabetes mellitus patients with diabetic nephropathy.
Effects of the angiotensin converting enzyme inhibitor benazepril in cats with induced renal insufficiency.
Effects of withdrawing vs continuing renin-angiotensin blockers on incidence of acute kidney injury in patients with renal insufficiency undergoing cardiac catheterization: Results from the Angiotensin Converting Enzyme Inhibitor/Angiotensin Receptor Blocker and Contrast Induced Nephropathy in Patients Receiving Cardiac Catheterization (CAPTAIN) trial.
Efficacy and safety of benazepril for advanced chronic renal insufficiency.
Elevations in serum creatinine with RAAS blockade: why isn't it a sign of kidney injury?
Elimination kinetics of quinaprilat and perindoprilat in hypertensive patients with renal failure on haemodialysis.
Enalapril reduces the albuminuria of patients with sickle cell disease.
Enalapril-associated erythema and vasculitis.
End-stage renal disease. Measures to prevent it or slow its progression.
End-stage renal disease: a southern epidemic.
Endothelin in cardiovascular control: the role of endothelin antagonists.
Evaluation of the effects of inhibition of angiotensin converting enzyme with enalapril in dogs with induced chronic renal insufficiency.
Evaluation of the safety and efficacy of telmisartan and enalapril, with the potential addition of frusemide, in moderate-renal failure patients with mild-to-moderate hypertension.
Fabry disease: recent advances in enzyme replacement therapy.
Familial hematuria: A review.
Feasibility of repairing glomerular basement membrane defects in alport syndrome.
Fetal toxic effects of angiotensin II receptor antagonists: case report and follow-up after birth.
Fetopathy associated with exposure to angiotensin converting enzyme inhibitors and angiotensin receptor antagonists.
Gadolinium-based contrast exposure, nephrogenic systemic fibrosis, and gadolinium detection in tissue.
Gene polymorphism of angiotensin II type 1 and type 2 receptors.
Heart failure in subjects with chronic kidney disease: Best management practices.
Heart rate variability (HRV) in kidney failure: measurement and consequences of reduced HRV.
Hematocrit-lowering effect following inactivation of renin-angiotensin system with angiotensin converting enzyme inhibitors and angiotensin receptor blockers.
High calcium diet down-regulates kidney angiotensin-converting enzyme in experimental renal failure.
High serum enalaprilat in chronic renal failure.
How does minor renal dysfunction influence cardiovascular risk and the management of cardiovascular disease?
Hyperkalemia induced failure of atrial and ventricular pacemaker capture.
Hyperkalemia: pathophysiology, risk factors and consequences.
Hypertension in autosomal dominant polycystic kidney disease.
Immunoglobulin A nephropathy: fish oils and beyond.
Implications of nonsteroidal anti-inflammatory drug therapy.
Improved kidney function with cilazapril in hypertensive type II diabetics with chronic renal failure.
Increased angiotensin-converting enzyme activities in diabetes mellitus: analysis of diabetes type, state of metabolic control and occurrence of diabetic vascular disease.
Influence of angiotensin converting enzyme inhibitor treatment on cardiac autonomic modulation in patients receiving haemodialysis.
Influence of renal function on the pharmacokinetics of ramipril (HOE 498).
Insulin-dependent diabetes mellitus as long term complication of haemolytic-uraemic syndrome.
Intensity of hydration changes the role of renin-angiotensin-aldosterone system blockers in contrast-induced nephropathy risk after coronary catheterisation in patients with chronic kidney disease.
Irbesartan reduces creatinine clearance in type 1 diabetic children with renal hyperfunction: a randomized, double-blind, placebo-controlled trial.
Ischemic nephropathy: noninvasive testing.
Ischemic renal disease: an emerging cause of chronic renal failure and end-stage renal disease.
Kidney damage in 'benign' essential hypertension.
Kidney scintigraphy after ACE inhibition in the diagnosis of renovascular hypertension.
Kinetics of angiotensin-converting enzyme inhibitors in renal failure.
Laboratory monitoring of patients treated with antihypertensive drugs and newly exposed to non steroidal anti-inflammatory drugs: a cohort study.
Life threatening hyperkalemia and acidosis secondary to trimethoprim-sulfamethoxazole treatment.
Long-term comparison between captopril and nifedipine in the progression of renal insufficiency.
Long-term preservation of renal function in hypertensive heart transplant recipients treated with enalapril and a diuretic.
Long-term progression of chronic renal insufficiency in the AIPRI Extension Study. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group.
Long-term protection of obese Zucker rat kidneys from fibrosis and renal failure with an angiotensin-converting enzyme inhibitor/diuretic combination.
Low-grade urinary albumin excretion in normotensive/non-diabetic obstructive sleep apnea patients.
Low-protein diets and angiotensin-converting enzyme inhibition in progressive renal failure.
Management of hypertension in diabetes mellitus.
Management of mild chronic hypertension during pregnancy: a review.
Management of severe hypertension in childhood Takayasu's arteritis.
Meeting the challenge to improve the treatment of hypertension in blacks.
Metabolic acidosis in advanced renal failure: differences between diabetic and nondiabetic patients.
Microalbuminuria in type II diabetes.
Modulation of gentamicin nephrotoxicity by chronic inhibition of angiotensin-I-converting enzyme in rat.
Neonatal anuria with maternal angiotensin-converting enzyme inhibition.
Nephrotoxicity in the elderly due to co-prescription of angiotensin converting enzyme inhibitors and nonsteroidal anti-inflammatory drugs.
New insights on effect of kidney insufficiency on disposition of angiotensin-converting enzyme inhibitors: case of enalapril and benazepril in dogs.
Night and day proteinuria in patients with sleep apnea.
No effect of angiotensin-converting enzyme gene polymorphism on disease progression and left ventricular hypertrophy in autosomal dominant polycystic kidney disease.
Noninvasive diagnosis of renovascular disease.
Optimising drug management of individuals with cryptogenic hypertension.
Oropharyngeal angioedema associated with the use of angiotensin-converting enzyme inhibitors.
Patients with autosomal dominant polycystic kidney disease hyperfiltrate early in their disease.
Peripheral artery disease: a cause of refractory hypertension after renal transplantation.
Pharmacokinetics and pharmacodynamics of lisinopril in advanced renal failure. Consequence of dose adjustment.
Pharmacokinetics of temocapril hydrochloride, a novel angiotensin converting enzyme inhibitor, in renal insufficiency.
Pharmacologic management of hypertension in patients with diabetes.
Pharmacotherapy in congestive heart failure: ACE inhibitors and anemia in congestive heart failure.
Phosphate binding reduces aortic angiotensin-converting enzyme and enhances nitric oxide bioactivity in experimental renal insufficiency.
Physicians make different decisions from nephrologists at serum creatinine 2.0 mg/dl.
Pierson Syndrome Associated with Hypothyroidism and Septic Shock.
Possible mechanism for the renoprotective effect of angiotensin converting enzyme inhibitors.
Prescription Habits Related to Chronic Pathologies of Elderly People in Primary Care in the Western Part of Romania: Current Practices, International Recommendations, and Future Perspectives Regarding the Overuse and Misuse of Medicines.
Prevalence and pathologic features of sickle cell nephropathy and response to inhibition of angiotensin-converting enzyme.
Prevalence and risk factors of pre-diabetes after renal transplantation: a single-centre cohort study in 200 consecutive patients.
Prevention and slowing down the progression of the diabetic nephropathy through antihypertensive therapy.
Prevention of progression in non-diabetic chronic renal failure.
Progression of renal failure with anaemia and multiple effects of angiotensin-converting enzyme inhibitor in rats with renal mass reduction.
Progressive renal insufficiency: the role of angiotensin converting enzyme inhibitors.
Prophylaxis of experimental bone marrow transplant nephropathy.
Protecting the residual renal function: which drugs of choice?
Protection of Renal Function with ACE Inhibitors: Experience with Benazepril.
Proteinuria and angiotensin converting enzyme (ACE) gene polymorphism.
QRS duration is associated with atrial fibrillation in patients with left ventricular dysfunction.
Questionnaire study and audit of use of angiotensin converting enzyme inhibitor and monitoring in general practice: the need for guidelines to prevent renal failure.
Quinapril decreases renal endothelin-1 expression and synthesis in a normotensive model of immune-complex nephritis.
Randomised controlled trial of enalapril and beta blockers in non-diabetic chronic renal failure.
Randomized controlled trial: lisinopril reduces proteinuria, ammonia, and renal polypeptide tubular catabolism in patients with chronic allograft nephropathy.
Rapid life-threatening hyperkalemia after addition of amiloride HCl/hydrochlorothiazide to angiotensin-converting enzyme inhibitor therapy.
Reduction of proteinuria and changes of renal function in patients with glomerulonephritis and mild renal insufficiency. Short- versus long-acting angiotensin-converting enzyme inhibitors.
Relationship between proteinuria and progressive renal disease.
Renal artery stenosis presenting as preeclampsia.
Renal Failure Is an Independent Predictor of Mortality in Hospitalized Heart Failure Patients and Is Associated With a Worse Cardiovascular Risk Profile.
Renal failure related to angiotensin-converting enzyme inhibitors.
Renal function in meningomyelocele: risk factors, chronic renal failure, renal replacement therapy and transplantation.
Renal functional alterations induced by angiotensin-converting enzyme inhibitors in heart failure.
Renal insufficiency and mortality in coronary artery disease with reduced ejection fraction.
Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial.
Renal insufficiency as an independent predictor of mortality among women with heart failure.
Renal insufficiency due to angiotensin-converting enzyme inhibitors.
Renal insufficiency during angiotensin-converting enzyme inhibitor therapy in hypertensive patients with no renal artery stenosis.
Renal insufficiency with combinations of angiotensin converting enzyme inhibitors and diuretics.
Renal issues in the management of hypertension.
Renal protection in diabetes: is it affected by glucose control or inhibition of the renin-angiotensin pathway?
Renal protective effects of blocking the intrarenal renin-angiotensin system.
Renal protective potential of antihypertensive drugs.
Renal scintigraphic captopril test in the diagnosis of renovascular hypertension.
Renal therapeutics: patent highlights January to June 2003.
Renoprotective effects of antihypertensive drugs.
Resolution of early stage diabetic nephropathy in an obese diabetic patient after gastric bypass.
Reversible acute renal failure as an atypical presentation of ischemic nephropathy.
Reversible hyperkalemia during antihypertensive therapy in a hypertensive diabetic patient with latent hypoaldosteronism and mild renal failure.
Reversible renal failure after combined treatment with enalapril and frusemide in a patient with congestive heart failure.
Reversible renal failure associated with angiotensin-converting enzyme inhibitors in polycystic kidney disease.
Reversible renal insufficiency and angiotensin-converting enzyme inhibitor therapy.
Reversible renal insufficiency due to angiotensin converting enzyme inhibitors in hypertensive nephrosclerosis.
Risk-benefit assessment of angiotensin II receptor antagonists.
Salt-losing nephrogenic diabetes insipidus caused by fetal exposure to angiotensin receptor blocker.
Serum angiotensin-converting enzyme levels in patients with chronic renal failure.
Shock efficacy of single and dual coil electrodes-new insights from the NORDIC ICD Trial.
Single dose pharmacokinetics of perindopril and its metabolites in hypertensive patients with various degrees of renal insufficiency.
Sodium phosphates and colonoscopy: renal failure.
Spironolactone in severe heart failure: enhances efficacy of diuretic + ACE inhibitor combinations.
Study on pharmacokinetics of a new biliary excreted oral angiotensin converting enzyme inhibitor, temocapril (CS-622) in humans.
Suboptimal medical care of patients with STElevation Myocardial Infarction and Renal Insufficiency: results from the Korea acute Myocardial Infarction Registry.
Successful use of captopril in the treatment of "scleroderma renal crisis".
The African American Study of Kidney Disease and Hypertension (AASK) trial: what more have we learned?
The African American Study of Kidney Disease and Hypertension (AASK): new findings.
The angiotensin converting enzyme inhibitor enalapril in acute ischemic renal failure in rats.
The association among renal insufficiency, pharmacotherapy, and outcomes in 6,427 patients with heart failure and coronary artery disease.
The cardioprotective effects of the angiotensin-converting enzyme inhibitor perindopril in patients with stable coronary artery disease are not modified by mild to moderate renal insufficiency: insights from the EUROPA trial.
The contribution of systemic hypertension to progression of chronic renal failure in the rat remnant kidney: effect of treatment with an angiotensin converting enzyme inhibitor or a calcium inhibitor.
The diversified pharmacology of angiotensin II-receptor blockade.
The impact of diabetes on economic costs in dialysis patients: experiences in Taiwan.
The management of hyperkalaemia in the emergency department.
The molecular basis of increased glomerulosclerosis after blockade of the renin angiotensin system in growth hormone transgenic mice.
The Need to Emphasize Nephrology Knowledge in Residents-in-Training.
The renin-angiotensin system as a risk factor and therapeutic target for cardiovascular and renal disease.
The renoprotective effect of angiotensin-converting enzyme inhibitors in experimental chronic renal failure is not dependent on enhanced kinin activity.
The role of genetic polymorphisms of angiotensin-converting enzyme in the progression of renal diseases.
Therapeutic efficacy and tolerance of ramipril in hypertensive patients with renal failure.
Toxic effects of drugs used in the ICU. Nitroprusside, nitroglycerin, and angiotensin-converting enzyme inhibitors.
Trapped renal arteries: functional renal artery stenosis due to occlusion of the aorta in the arch and below the kidneys.
Treatment at discharge after myocardial infarction in 2,102 patients. The PRIMA study. Prise en charge de l'Infarctus du Myocarde Aigu.
Treatment of human immunodeficiency virus (HIV)-associated nephropathy.
Treatment of renal failure and blood pressure.
University of Miami Division of Clinical Pharmacology Therapeutic Rounds: ischemic renal disease.
University of Miami Division of Clinical Pharmacology Therapeutic Rounds: managing hypertension in patients with kidney disease-implications for preservation of renal function.
Update on the drug treatment of hypertension in patients with cardiovascular disease.
US of renal insufficiency in neonates.
Use of ACE inhibitors or angiotensin receptor blockers and survival in patients on peritoneal dialysis.
Use of angiotensin-converting enzyme inhibitors for the preservation of kidney function. A retrospective study.
Use of angiotensin-converting enzyme inhibitors in heart failure and renal insufficiency.
Use of angiotensin-converting enzyme inhibitors in patients with heart failure and renal insufficiency: how concerned should we be by the rise in serum creatinine?
Vasoactive factors in the immature kidney.
What is the impact of the ACE gene insertion/deletion (I/D) polymorphism on the clinical effectiveness and adverse events of ACE inhibitors?--Protocol of a systematic review.
[Angiotensin-converting enzyme inhibitors and pregnancy. Apropos of 2 cases]
[Association analysis of angiotensin-converting enzyme gene polymorphism with end-stage renal disease]
[Bleeding in the appointment of dabigatran in the patients with renal insufficiency caused by coadministration of spironolactone and ACE inhibitors].
[Cardiac insufficiency: what treatment? what dose? For which patients? Converting enzyme inhibitors and diuretics]
[Clinical state of a patient with nephrotic proteinuria successfully treated with combined therapy with angiotensin II receptor antagonists and angiotensin II converting enzyme inhibitors and pentoxifylline]
[Combined captopril and labetalol treatment of malignant arterial hypertension (author's transl)]
[Comparison of the effects of a low protein diet and angiotensin converting enzyme inhibitors on renal insufficiency in hypertensive rats]
[Drug bradyarrhythmias as a cause of hospital admission. Study of 83 cases]
[Effects of converting enzyme inhibition by enalapril on renal hemodynamics in essential arterial hypertension]
[Fetal angiotensin converting enzyme (ACE) inhibition renal failure]
[Fetopathy associated with exposure to angiotensin converting enzyme inhibitors]
[How and when to search for a renal artery atheromatous stenosis in diabetic patients?]
[Hyperkalemia - Pathophysiology, prognostic significance and treatment options].
[Hypertension and stenosis of the graft artery: effects of conversion enzyme inhibition]
[Hypertension from the nephrologist's point of view]
[Hypertension in diseases of the kidney. Pathogenesis and therapy]
[Intraglomerular hypertension. Physiopathology and therapeutic implications]
[Irreversible renal failure during treatment with angiotensin I converting enzyme inhibitor in bilateral renal stenosis]
[Malignant arrhythmias caused by hyperkalemia: a new area of drug-induced electrolyte abnormalities]
[Microalbuminuria in insulin-dependent diabetics: the prevention of diabetic nephropathy]
[Non SLE connective tissue diseases: general aspects and kidney]
[Pathophysiological and clinical implications of AT(1)/AT(2) angiotensin II receptors in heart failure and coronary and renal failure]
[Pentoxifylline old drug or new hope for nephrology?]
[Pharmacological studies on the diuretic action of azosemide [5-(4'-chloro-5'-sulfamoyl-2'-thenylamino)-phenyltetrazole], a new diuretic (3). Effect of azosemide following pretreatment with SA-446, an angiotensin I converting enzyme inhibitor, or propranolol, a beta-adrenergic blocker, in HgCl2-induced acute renal failure in rats]
[Progressive renal failure. Why blood pressure must now be monitored]
[Pulse pressure in the therapeutic management of hypertension?]
[Renal artery stenosis: acute congestive heart failure as a possible cause]
[Renal effects of angiotensin-converting enzyme inhibitors and their therapeutic use in chronic terminal renal failure]
[Renoprotective effects of antihypertensives]
[Severe kidney failure during treatment with angiotensin-converting enzyme inhibitors]
[Severe renal failure during treatment with angiotensin-converting enzyme inhibitors]
[Significance of elevated serum ACE in pneumology]
[Suppressive effect of angiotensin converting enzyme inhibitor (ACEI) on the progression of renal insufficiency: a propensity score analysis]
[The effect of a low-protein diet and certain pharmaceutical agents on the course of ablation nephropathy in rats]
[The effect of angiotensin-converting enzyme inhibitors on left ventricular hypertrophy in patients with chronic glomerulonephritis and pronounced kidney failure]
[Therapeutic management of systemic sclerosis]
[Treatment with an angiotensin converting enzyme inhibitor may increase the nephrotoxicity of gentamicin in rats]
Renal Insufficiency, Chronic
"Quadruple whammy"- a preventable newly described syndrome of post-operative AKI in CKD II and CKD III patients on combination "Triple whammy" medications: a Mayo Clinic Health System, Eau Claire, Wisconsin experience.
2009 Canadian Hypertension Education Program recommendations: the scientific summary--an annual update.
2010 guidelines of the Taiwan Society of Cardiology for the management of hypertension.
8D.03: EVIDENCE FOR AN ACE-INDEPENDENT TISSUE-SPECIFIC RAS REGULATION AFTER KIDNEY TRANSPLANTATION.
A Prospective Single-Blind Randomized Trial of Ramipril, Eplerenone and Their Combination in Type 2 Diabetic Nephropathy.
A prospective study of frequency and characteristics of cough during ACE inhibitor treatment.
A Quality Improvement Initiative Targeting Chronic Kidney Disease Metrics Through Increased Urinary Albumin Testing.
A real-world cohort study on the quality of potassium and creatinine monitoring during initiation of mineralocorticoid receptor antagonists in patients with heart failure.
A subdepressor low dose of ramipril lowers urinary protein excretion without increasing plasma potassium.
ACE gene polymorphism and its association with serum erythropoietin and hemoglobin ?in Iraqi hemodialysis patients.
ACE Inhibitor Benefit to Kidney and Cardiovascular Outcomes for Patients with Non-Dialysis Chronic Kidney Disease Stages 3-5: A Network Meta-Analysis of Randomised Clinical Trials.
ACE inhibitors and ARBs: Managing potassium and renal function.
ACE-I vs angiotensin II receptor antagonists: prevention of renal injury in chronic rat models.
Acute Kidney Injury in Elderly Patients With Chronic Kidney Disease: Do Angiotensin-Converting Enzyme Inhibitors Carry a Risk?
Acute Kidney Injury in Patients Receiving Systemic Treatment for Cancer: A Population-Based Cohort Study.
Acute phosphate nephropathy.
Add-on angiotensin receptor blockade with maximized ACE inhibition.
Add-on angiotensin receptor blocker in patients who have proteinuric chronic kidney diseases and are treated with angiotensin-converting enzyme inhibitors.
Add-on Protective Effect of Pentoxifylline in Advanced Chronic Kidney Disease Treated with Renin-Angiotensin-Aldosterone System Blockade - A Nationwide Database Analysis.
Add-on therapy with angiotensin II receptor 1 blocker in children with chronic kidney disease already treated with angiotensin-converting enzyme inhibitors.
Addition of vitamin D reverses the decline in GFR following treatment with ACE inhibitors/angiotensin receptor blockers in patients with chronic kidney disease.
Adjunctive therapy with statins reduces residual albuminuria/proteinuria and provides further renoprotection by downregulating the angiotensin II-AT1 pathway in hypertensive nephropathy.
Albuminuria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT): a randomised, double-blind, placebo-controlled trial.
Aldosterone antagonists for preventing the progression of chronic kidney disease.
Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic kidney disease.
Aldosterone blockade in chronic kidney disease.
Aldosterone breakthrough does not alter central hemodynamics.
Aldosterone breakthrough during angiotensin II receptor blockade in hypertensive patients with diabetes mellitus.
An update of the blockade of the renin angiotensin aldosterone system in clinical practice.
Angioedema related to Angiotensin inhibitors.
Angiotensin converting enzyme inhibition reduces proteinuria in Nigerians with chronic renal disease.
Angiotensin converting enzyme inhibitor limits pulse wave velocity and aortic calcification in a rat model of cystic renal disease.
Angiotensin converting enzyme inhibitor therapy in children with Alport syndrome: effect on urinary albumin, TGF-beta, and nitrite excretion.
Angiotensin converting enzyme insertion/deletion polymorphism and renoprotection in diabetic and nondiabetic nephropathies.
Angiotensin gene polymorphism as a determinant of posttransplantation renal dysfunction and hypertension.
Angiotensin II and progressive renal insufficiency.
Angiotensin receptor antagonists in experimental models of chronic renal failure.
Angiotensin receptor blockers in chronic renal disease: the promise of a bright clinical future.
Angiotensin-converting enzyme gene polymorphisms in renal disease: clinically relevant?
Angiotensin-converting enzyme inhibition attenuates proteinuria and renal TGF-beta 1 mRNA expression in rats with chronic renal disease.
Angiotensin-converting enzyme inhibitor therapy for non-diabetic progressive renal disease.
Angiotensin-converting enzyme inhibitor usage and acute kidney injury: A secondary analysis of RENAL study outcomes.
Angiotensin-converting enzyme inhibitor, angiotensin receptor blocker use, and mortality in patients with chronic kidney disease.
Angiotensin-converting enzyme inhibitors and anemia in chronic kidney disease: a complex interaction.
Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for adults with early (stage 1 to 3) non-diabetic chronic kidney disease.
Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in chronic renal disease: safety issues.
Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with congestive heart failure and chronic kidney disease.
Angiotensin-converting enzyme inhibitors and progression of nondiabetic chronic renal disease.
Angiotensin-converting enzyme inhibitors and receptor blockers in heart failure and chronic kidney disease - Demystifying controversies.
Angiotensin-converting enzyme inhibitors in the treatment of hypertension: an update.
Angiotensin-converting enzyme inhibitors or angiotensin receptor blocker monotherapy retard deterioration of renal function in Taiwanese chronic kidney disease population.
Angiotensin-converting enzyme insertion/deletion polymorphism contributes high risk for chronic kidney disease in Asian male with hypertension--a meta-regression analysis of 98 observational studies.
Angiotensin-I converting enzyme inhibition: clinical effects in chronic renal disease.
Antihypertensive and antiproteinuric efficacy of ramipril in children with chronic renal failure.
Antihypertensive treatment in renal transplant patients--is there a role for ACE inhibitors?
Application of direct renin inhibition to chronic kidney disease.
Are differences in calcium antagonists relevant across all stages of nephropathy or only proteinuric nephropathy?
Author Correction: Angiotensin-converting enzyme inhibitors or angiotensin receptor blocker monotherapy retard deterioration of renal function in Taiwanese chronic kidney disease population.
Barriers to ACEI/ARB Use in Proteinuric Chronic Kidney Disease: An Observational Study.
Barriers to blood pressure control and angiotensin enzyme inhibitor use in Canadian patients with chronic renal insufficiency.
Benazepril affects integrin-linked kinase and smooth muscle ?-actin expression in diabetic rat glomerulus and cultured mesangial cells.
Beneficial action of candesartan cilexetil plus amlodipine or ACE inhibitors in chronic nondiabetic renal disease.
Beneficial effects of combination therapy with angiotensin II receptor blocker and angiotensin-converting enzyme inhibitor on vascular endothelial function.
Blood pressure and angiotensin converting enzyme inhibitor use in hypertensive patients with chronic renal insufficiency.
Blood pressure in children with chronic kidney disease: a report from the Chronic Kidney Disease in Children study.
Bradykinin decreases podocyte permeability through ADAM17-dependent epidermal growth factor receptor activation and zonula occludens-1 rearrangement.
Calcium channels blockers and progression of kidney disease.
Captopril slows the progression of chronic renal disease in partially nephrectomized rats.
Cardiac risk factors and the use of cardioprotective medications in patients with chronic renal insufficiency.
Characteristics of atheromatous renovascular disease in Dubai: a single-center experience.
Choosing Wisely: The Canadian Society of Nephrology's List of 5 Items Physicians and Patients Should Question.
Chronic kidney disease screening and renoprotection in type 2 diabetes.
Chronic kidney disease, cardiovascular risk, and response to angiotensin-converting enzyme inhibition after myocardial infarction: the Survival And Ventricular Enlargement (SAVE) study.
Chronic kidney disease: cardiac and renal angiotensin converting enzyme (ACE) 2 expression in rats after subtotal nephrectomy and the effect of ACE inhibition.
Chronic kidney disease: tipping the scale to the benefit of angiotensin-converting enzyme inhibitors in patients with coronary artery disease.
Chronic renal insufficiency: a diagnostic and therapeutic approach.
Cigarette Smoking Attenuates Kidney Protection by Angiotensin-Converting Enzyme Inhibition in Nondiabetic Chronic Kidney Disease.
Cilnidipine is as effective as benazepril for control of blood pressure and proteinuria in hypertensive patients with benign nephrosclerosis.
Cisplatin-induced renal toxicity in elderly people.
Clinical use of angiotensin-converting enzyme inhibitors in patients with renal impairment.
Combination ACEI and ARB therapy: additional benefit in renoprotection?
Combination inhibition of the renin-angiotensin system: is more better?
Combination therapy of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in chronic kidney disease.
Common questions about the initial management of hypertension.
Comparative effects of captopril and enalapril on the progression of chronic renal disease in partially nephrectomized rats.
Comparative proteinuria management of different angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for normotensive patients with CKD: a Bayesian network meta-analysis.
Comparison of the effects of an ACE inhibitor and alphabeta blocker on the progression of renal failure with left ventricular hypertrophy: preliminary report.
Complementary effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in slowing the progression of chronic kidney disease.
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2017 EXECUTIVE SUMMARY.
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2018 EXECUTIVE SUMMARY.
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2019 EXECUTIVE SUMMARY.
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2020 EXECUTIVE SUMMARY.
Conservative management of chronic kidney disease stage 5: role of angiotensin converting enzyme inhibitors.
Contrast-Induced Acute Kidney Injury in Radiologic Management of Acute Ischemic Stroke in the Emergency Setting.
Cost Effectiveness of ACEIs/ARBs versus Amlodipine Monotherapies: A Single-Center Retrospective Chart Review.
Could mycophenolate mofetil combined with benazapril delay tubulointerstitial fibrosis in 5/6 nephrectomized rats?
Current guidelines for using angiotensin-converting enzyme inhibitors and angiotensin II-receptor antagonists in chronic kidney disease: is the evidence base relevant to older adults?
Current Strategies to Achieve Further Cardiac and Renal Protection through Enhanced Renin-Angiotensin-Aldosterone System Inhibition.
Diabetes, hemoglobin A(1c), cholesterol, and the risk of moderate chronic renal insufficiency in an ambulatory population.
Diabetic nephropathy for the primary care provider: new understandings on early detection and treatment.
Dietary protein restriction in combination with angiotensin converting enzyme inhibitor improves insulin resistance in patients with chronic renal disease.
Digoxin and clinical outcomes in systolic heart failure patients on contemporary background heart failure therapy.
Dihydropyridine calcium channel blockers and renal disease.
Direct renin inhibition in a rat model of chronic allograft injury.
Direct Renin Inhibition: Promising Treatment in Renoprotection?
Discontinuation of Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Chronic Kidney Disease.
Does Genetic Predisposition Contribute to the Exacerbation of COVID-19 Symptoms in Individuals with Comorbidities and Explain the Huge Mortality Disparity between the East and the West?
Dose effect of captopril on renal hemodynamics and proteinuria in conscious, partially nephrectomized rats.
Dual blockade of the renin-angiotensin system compared with a 50% increase in the dose of angiotensin-converting enzyme inhibitor: effects on proteinuria and blood pressure.
Dual blockade of the renin-angiotensin system with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in chronic kidney disease.
Dual blockade of the renin-angiotensin-aldosterone system: beyond the ACE inhibitor and angiotensin-II receptor blocker combination.
Dual renin-angiotensin system blockade for nephroprotection.
Dual renin-angiotensin system blockade for nephroprotection: still under scrutiny.
Dual renin-angiotensin system blockade in the ONTARGET study: clinically relevant risk for the kidney?
Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial.
Early recognition and prevention of chronic kidney disease.
Eat Your Broccoli: Oxidative Stress, NRF2, and Sulforaphane in Chronic Kidney Disease.
Economic evaluation of benazepril in chronic renal insufficiency.
Effect of aliskiren on proteinuria in non-diabetic chronic kidney disease: a double-blind, crossover, randomised, controlled trial.
Effect of Angiotensin-Converting Enzyme Inhibitor/Calcium Antagonist Combination Therapy on Renal Function in Hypertensive Patients With Chronic Kidney Disease: Chikushi Anti-Hypertension Trial - Benidipine and Perindopril.
Effect of combining ACE inhibition with aldosterone blockade on proteinuria and renal damage in experimental nephrosis.
Effect of dual compared to no or single renin-angiotensin system blockade on risk of renal replacement therapy or death in predialysis patients: PREPARE-2 study.
Effect of Mineralocorticoid Receptor Antagonism and ACE Inhibition on Angiotensin Profiles in Diabetic Kidney Disease: An Exploratory Study.
Effect of pentoxifylline on proteinuria, markers of tubular injury and oxidative stress in non-diabetic patients with chronic kidney disease - placebo controlled, randomized, cross-over study.
Effect of ramipril on ambulatory blood pressure and albuminuria in renal hypertension.
Effect of spironolactone on left ventricular mass and aortic stiffness in early-stage chronic kidney disease: a randomized controlled trial.
Effect of spironolactone on urinary protein excretion in patients with chronic kidney disease.
Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group.
Effect of valsartan on erythropoietin and hemoglobin levels in stage III-IV chronic kidney disease patients.
Effects of Add-on Fluvastatin Therapy in Patients with Chronic Proteinuric Nephropathy on Dual Renin-Angiotensin System Blockade: The ESPLANADE Trial.
Effects of angiotensin-converting enzyme inhibition on plasma aldosterone concentration, plasma renin activity, and blood pressure in spontaneously hypertensive cats with chronic renal disease.
Effects of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in patients with chronic kidney disease.
Effects of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers on Angiotensin-Converting Enzyme 2 Levels: A Comprehensive Analysis Based on Animal Studies.
Effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on cardiovascular events and residual renal function in dialysis patients: a meta-analysis of randomised controlled trials.
Effects of Angiotensin-Converting Enzyme Inhibitors and Angiotensin-Receptor Blockers in Heart Failure With Chronic Kidney Disease?- Propensity Score Matching Analysis.
Effects of angiotensin-converting enzyme inhibitors in systolic heart failure patients with chronic kidney disease: a propensity score analysis.
Effects of calcium channel blockers comparing to angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with hypertension and chronic kidney disease stage 3 to 5 and dialysis: A systematic review and meta-analysis.
Effects of candesartan on the proteinuria of chronic glomerulonephritis.
Effects of N-acetylcysteine on angiotensin-converting enzyme plasma activity in patients with chronic kidney diseases.
Effects of Renin-Angiotensin-Aldosterone System Blockade in Patients with End-Stage Renal Disease.
Effects of telmisartan and enalapril on renoprotection in patients with mild to moderate chronic kidney disease.
Effects of the Renin-Angiotensin system blockade on hemoglobin levels in type 2 diabetic patients with chronic kidney disease.
Efficacy and Safety of Angiotensin-Converting Enzyme Inhibitor in Combination with Angiotensin-Receptor Blocker in Chronic Kidney Disease Based on Dose: A Systematic Review and Meta-Analysis.
Efficacy and Safety of Angiotensin-Converting Enzyme Inhibitors in Combination with Angiotensin II Receptor Blockers in Non-diabetic Chronic Kidney Disease: a Systematic Review and Meta-Analysis.
Efficacy of low dose spironolactone in chronic kidney disease with resistant hypertension.
Efficacy of statins on renal function in patients with chronic kidney disease: a systematic review and meta-analysis.
Emerging strategies to preserve renal function.
Environmental and individual predictors of medication adherence among elderly patients with hypertension and chronic kidney disease: A geospatial approach.
Evaluation of the 24 h effects of the angiotensin II receptor blockers: means to improve cardiovascular outcomes?
Evaluation of the effects of a therapeutic renal diet to control proteinuria in proteinuric non-azotemic dogs treated with benazepril.
Evaluation of the effects of inhibition of angiotensin converting enzyme with enalapril in dogs with induced chronic renal insufficiency.
Exposure to inhibitors of the renin-angiotensin system is a major independent risk factor for acute renal failure induced by sucrose-containing intravenous immunoglobulins: a case-control study.
Facility variation in utilization of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in patients with diabetes mellitus and chronic kidney disease.
Gene polymorphisms of angiotensin-converting enzyme and angiotensin II Type 1 receptor among chronic kidney disease patients in a Chinese population.
GSTM1 Gene, Diet, and Kidney Disease: Implication for Precision Medicine?: Recent Advances in Hypertension.
Guideline-recommended secondary prevention drug therapy after acute myocardial infarction: predictors and outcomes of nonadherence.
High dose enalapril impairs the response to erythropoietin treatment in haemodialysis patients.
High-dose angiotensin-converting enzyme inhibitor attenuates oxidative stress in patients with chronic kidney disease.
Hyperkalaemia in people with diabetes: occurrence, risk factors and outcomes in a Danish population-based cohort study.
Hyperkalemia Associated with Angiotensin Converting Enzyme Inhibitor or Angiotensin Receptor Blockers in Chronic Kidney Disease.
Hypertension management in patients with chronic kidney disease.
Hypertension, renal disease, and drug considerations.
Hyponatremic Coma after Bowel Preparation.
Impact of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers on Renal Function in Chronic Kidney Disease Patients Undergoing Coronary Angiography.
Impact of the interval between coronary angiography and off-pump coronary bypass surgery on postoperative renal function.
Incidence of and risk factors for severe acute kidney injury in children with heart failure treated with renin-angiotensin system inhibitors.
Incidence, predictors and clinical management of hyperkalaemia in new users of mineralocorticoid receptor antagonists.
Increased expression of transforming growth factor-beta in renal disease.
Increased serum angiotensin-converting enzyme in chronic renal disease.
Increased tyrosine nitration of the brain in chronic renal insufficiency: reversal by antioxidant therapy and angiotensin-converting enzyme inhibition.
Influence of Angiotensin Converting Enzyme I/D Polymorphism on Hemodynamic and Antioxidant Response to Long-Term Intradialytic Resistance Training in Patients With Chronic Kidney Disease: A Randomized Controlled Trial.
Influence of the ACE gene polymorphism in the progression of renal failure in autosomal dominant polycystic kidney disease.
Inhibition of the Renin-Angiotensin System in Chronic Kidney Disease: A Critical Look to Single and Dual Blockade.
Interpreting treatment effects from clinical trials in the context of real-world risk information: end-stage renal disease prevention in older adults.
Interventions for chronic kidney disease in people with sickle cell disease.
Intrarenal Distributions and Changes of Angiotensin-Converting Enzyme and Angiotensin-Converting Enzyme 2 in Feline and Canine Chronic Kidney Disease.
Intrarenal Renin-Angiotensin-System Dysregulation after Kidney Transplantation.
Irbesartan in hypertensive non-diabetic advanced chronic kidney disease. Comparative study with ACEI.
Is Chronic Kidney Disease Progression Influenced by the Type of Renin-Angiotensin-System Blocker Used?
Left ventricular output indices in hospitalized heart failure: when "simpler" may not mean "better".
Lessons from large interventional trials on antihypertensive therapy in chronic renal disease.
Limitations of angiotensin inhibition.
Liver involvement in early autosomal-dominant polycystic kidney disease.
Long-term comparison between captopril and nifedipine in the progression of renal insufficiency.
Long-term effects of enalapril and nicardipine on urinary albumin excretion in patients with chronic renal insufficiency: a 1-year follow-up.
Long-term effects of patiromer for hyperkalaemia treatment in patients with mild heart failure and diabetic nephropathy on angiotensin-converting enzymes/angiotensin receptor blockers: results from AMETHYST-DN.
Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease.
Long-term observation of renal function on combination therapy with prostaglandin and angiotensin-converting enzyme inhibitor for chronic kidney disease.
Long-term progression of chronic renal insufficiency in the AIPRI Extension Study. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group.
Losartan and enalapril are comparable in reducing proteinuria in children.
Low-dose aldosterone blockade as a new treatment paradigm for controlling resistant hypertension.
Management of Renin-Angiotensin-Aldosterone System Blockade in Kidney Transplant Recipients.
Managing hypertension using combination therapy.
Managing progressive renal disease before dialysis.
Meta-Analysis of Risks for Short-Term Readmission in Patients With Heart Failure.
Methylglyoxal stress, the glyoxalase system, and diabetic chronic kidney disease.
Metoprolol Increases Uric Acid and Risk of Gout in African Americans With Chronic Kidney Disease Attributed to Hypertension.
Midkine Regulation of the Renin-Angiotensin System.
Mineralocorticoid Receptor Antagonism and Aldosterone Synthesis Inhibition Do Not Improve Glomerulosclerosis and Renal Interstitial Fibrosis in a Model of Chronic Kidney Allograft Injury.
Mineralocorticoid receptor antagonist for renal protection.
Mineralocorticoid receptor blockade in chronic kidney disease.
Mineralocorticoid Receptor Blockade in Chronic Kidney Disease.
Modern treatment of patients at risk: still a HOPE for ACE inhibitors?
N-Acetyl-seryl-aspartyl-lysyl-proline Alleviates Renal Fibrosis Induced by Unilateral Ureteric Obstruction in BALB/C Mice.
N-acetyl-seryl-aspartyl-lysyl-proline mediates the anti-fibrotic properties of captopril in unilateral ureteric obstructed BALB/C mice.
Neurological diseases as mortality predictive factors for patients with COVID-19: a retrospective cohort study.
No impact of hyperkalaemia with renin-angiotensin system blockades in maintenance haemodialysis patients.
Nonatherosclerotic Vascular Abnormalities Associated with Chronic Kidney Disease.
Not all proteinuria is created equal.
Optimal dose of angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker for renoprotection.
Optimal management of HIV- positive adults at risk for kidney disease in Nigeria (Renal Risk Reduction "R3" Trial): protocol and study design.
Optimizing blood pressure control in patients with chronic kidney disease.
Overexpression of Urinary N-Domain ACE in Chronic Kidney Dysfunction in Wistar Rats.
Patient Awareness, Prevalence, and Risk Factors of Chronic Kidney Disease among Diabetes Mellitus and Hypertensive Patients at Jimma University Medical Center, Ethiopia.
Pentoxifylline plus ACEIs/ARBs for proteinuria and kidney function in chronic kidney disease: a meta-analysis.
Pharmacology of enalapril in children: a review.
Phosphate attenuates the anti-proteinuric effect of very low-protein diet in CKD patients.
Phosphate binding reduces aortic angiotensin-converting enzyme and enhances nitric oxide bioactivity in experimental renal insufficiency.
Physiologic evidence of renoprotection by antihypertensive therapy.
Potassium homeostasis and Renin-Angiotensin-aldosterone system inhibitors.
Predicting the risk of hyperkalemia in patients with chronic kidney disease starting lisinopril.
Predictive models for adverse clinical outcomes in Chinese patients with atrial fibrillation undergoing percutaneous coronary intervention with stenting.
Predictors for neoatherosclerosis: a retrospective observational study from the optical coherence tomography registry.
Predictors of postoperative acute kidney injury in patients undergoing hip fracture surgery: A systematic review and meta-analysis.
Prescribing angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in chronic kidney disease.
Prescriptions for angiotensin-converting enzyme inhibitors/angiotensin receptor blockers and monitoring of serum creatinine and potassium in patients with chronic kidney disease.
Prevalence of and risk factors for reduced serum bicarbonate in chronic kidney disease.
Prevalence of angiotensin converting enzyme (ACE) gene insertion/deletion polymorphism in South Indian population with hypertension and chronic kidney disease.
Prevalence of proteinuria in rural adult population in Tamil Nadu.
Progenitor cell secretory products exert additive renoprotective effects when combined with ace inhibitors in experimental CKD.
Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis.
Progression of chronic renal disease and diabetic nephropathy: a review of clinical studies and current therapy.
Proteinuria as a risk marker for the progression of chronic kidney disease in patients on predialysis care and the role of angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker treatment.
Proteinuria, Chronic Kidney Disease, and the Effect of an Angiotensin Receptor Blocker in Addition to an Angiotensin-Converting Enzyme Inhibitor in Patients With Moderate to Severe Heart Failure.
Quality of Care for Patients With Chronic Kidney Disease in the Primary Care Setting: A Retrospective Cohort Study From Ontario, Canada.
RAAS inhibition and the course of Alport syndrome.
RAAS Inhibition/Blockade in patients with Cardiovascular disease : Implications of recent large scale randomized trials for clinical practice.
Racial differences in the renal response to blood pressure lowering during chronic angiotensin-converting enzyme inhibition: a prospective double-blind randomized comparison of fosinopril and lisinopril in older hypertensive patients with chronic renal insufficiency.
Ramipril and risk of hyperkalemia in chronic hemodialysis patients.
Randomized controlled crossover study of the effect on proteinuria and blood pressure of adding an angiotensin II receptor antagonist to an angiotensin converting enzyme inhibitor in normotensive patients with chronic renal disease and proteinuria.
Randomized placebo-controlled clinical trial of a chewable formulation of amlodipine for the treatment of hypertension in client-owned cats.
Rationale for combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor treatment and end-organ protection in patients with chronic kidney disease.
Recognition and Management of Hypertension in Older Persons: Focus on African Americans.
Renal effects of angiotensin converting enzyme inhibitors: nondiabetic chronic renal disease.
Renal Effects of Sodium-Glucose Co-Transporter Inhibitors.
Renal handling of angiotensin receptor blockers: clinical relevance.
Renal hemodynamic control by endothelin and nitric oxide under angiotensin II blockade in man.
Renal insufficiency due to angiotensin-converting enzyme inhibitors.
Renal outcomes with aliskiren in patients with type 2 diabetes: a prespecified secondary analysis of the ALTITUDE randomised controlled trial.
Renin Inhibition with Aliskiren: A Decade of Clinical Experience.
Renin-Angiotensin Inhibition in Systolic Heart Failure and Chronic Kidney Disease.
Renin-angiotensin system blockade and the risk of hyperkalemia in chronic hemodialysis patients.
Renin-angiotensin system blocker discontinuation and adverse outcomes in chronic kidney disease.
Renin-angiotensin system inhibition in COVID-19 patients.
Renin-Angiotensin System Inhibitors and Kidney and Cardiovascular Outcomes in Patients With CKD: A Bayesian Network Meta-analysis of Randomized Clinical Trials.
Renoprotection by blockade of the renin-angiotensin-aldosterone system in diabetic and non-diabetic chronic kidney disease. Specific involvement of intra-renal angiotensin-converting enzyme activity in therapy resistance?
Renoprotective benefits of RAS inhibition: from ACEI to angiotensin II antagonists.
Renoprotective effect of combining pentoxifylline with angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker in advanced chronic kidney disease.
Renoprotective effect of Renin-Angiotensin-aldosterone system blockade in patients with predialysis advanced chronic kidney disease, hypertension, and anemia.
Renoprotective effects of antihypertensive drugs.
Reporting of the estimated glomerular filtration rate was associated with increased use of angiotensin-converting enzyme inhibitors and angiotensin-II receptor blockers in CKD.
Requirement of drug development for chronic renal disease: Other strategies than blockade of the renin-angiotensin system.
Research on renal endothelin in proteinuric nephropathies dictates novel strategies to prevent progression.
Resistive index as a predictor of acute kidney injury caused by an angiotensin converting enzyme inhibitor or angiotensin II receptor blocker in chronic kidney disease patients.
Resistive index as a predictor of renal progression in patients with moderate renal dysfunction regardless of angiotensin converting enzyme inhibitor or angiotensin receptor antagonist medication.
Risk factors associated with biochemically detected and hospitalised acute kidney injury in patients prescribed renin angiotensin system inhibitors.
Risk factors for acute kidney injury in patients with acute myocardial infarction.
Risk Factors for Emergency Room and Hospital Care Among Patients With Solid Tumors on Immune Checkpoint Inhibitor Therapy.
Risk factors for the development and progression of renal diseases in disadvantaged populations: role of the renin-angiotensin system blockade.
Risk of hyperkalemia in nondiabetic patients with chronic kidney disease receiving antihypertensive therapy.
Risk of hyperkalemia in patients with moderate chronic kidney disease initiating angiotensin converting enzyme inhibitors or angiotensin receptor blockers: a randomized study.
Role of angiotensin converting enzyme inhibitors and angiotensin receptor blockers in hypertension of chronic kidney disease and renoprotection. Study results.
Role of angiotensin-converting enzyme gene polymorphism in progressive loss of renal function in chronic renal diseases.
Role of diltiazem in pregnant women with chronic renal disease.
Scleroderma renal crisis in a newly diagnosed mixed connective tissue disease resulting in dialysis-dependent chronic kidney disease despite angiotensin-converting enzyme inhibition.
Screening and management of patients with early chronic kidney disease.
Selection of the dose of angiotensin converting enzyme inhibitor for patients with diabetic nephropathy depends on the presence or absence of left ventricular hypertrophy.
Serum Cystatin C, Klotho, and Neutrophil Gelatinase-Associated Lipocalin in the Risk Prediction of Acute Kidney Injury after Acute Myocardial Infarction.
Serum Sodium Profile of Congestive Heart Failure Patients and its Impact on Their Outcome at Discharge.
Severe central sleep apnea is associated with atrial fibrillation in patients with left ventricular systolic dysfunction.
Sodium intake, RAAS-blockade and progressive renal disease.
Sodium-Glucose Linked Cotransporter-2 Inhibition Does Not Attenuate Disease Progression in the Rat Remnant Kidney Model of Chronic Kidney Disease.
Stage A: Can Heart Failure Be Prevented?
Successful effect of triple blockade of renin-angiotensin-aldosterone system on massive proteinuria in a patient with chronic kidney disease.
Sympathetic hyperactivity in hypertensive chronic kidney disease patients is reduced during standard treatment.
Sympathetic nervous system function in renal hypertension.
Sympathetic overactivity as a cause of hypertension in chronic renal failure.
Targeting the renin angiotensin system in dialysis patients.
The angiotensin II type 2 receptor in renal disease.
The Association of Losartan and Ramipril Therapy With Kidney and Cardiovascular Outcomes in Patients With Chronic Kidney Disease: A Chinese Nation-Wide Cohort Study in Taiwan.
The effect of aldosterone blockade in patients with Alport syndrome.
The effect of angiotensin-converting enzyme inhibitor/angiotensin receptor blocker use on mortality in patients with chronic kidney disease: a meta-analysis of observational studies.
The effect of losartan on hemoglobin concentration and renal outcome in diabetic nephropathy of type 2 diabetes.
The effect of N-acetylcysteine on proteinuria and markers of tubular injury in non-diabetic patients with chronic kidney disease. A placebo-controlled, randomized, open, cross-over study.
The effect of renal diet in association with enalapril or benazepril on proteinuria in dogs with proteinuric chronic kidney disease.
The frequency of hyperkalemia and its significance in chronic kidney disease.
The Multicomponent, Multitarget Therapy SUC in Cats with Chronic Kidney Disease: A Multicenter, Prospective, Observational, Nonrandomized Cohort Study.
The Need to Emphasize Nephrology Knowledge in Residents-in-Training.
The renin-angiotensin-aldosterone system: cardiorenal effects and implications for renal and cardiovascular disease states.
The safety and tolerability of spironolactone in patients with mild to moderate chronic kidney disease.
Therapeutic advantage of angiotensin-converting enzyme inhibitors in patients with proteinuric chronic kidney disease.
Therapeutic advantages of angiotensin converting enzyme inhibitors in chronic renal disease.
Time to re-evaluate effects of renin-angiotensin system inhibitors on renal and cardiovascular outcomes in diabetic nephropathy.
Tolerability and efficacy of benazepril in cats with chronic kidney disease.
Treating renal disease in India's poor: the art of the possible.
Treatment Effectiveness in Heart Failure with Comorbidity: Lung Disease and Kidney Disease.
Treatment strategies for isolated systolic hypertension in elderly patients.
Treatment strategies in patients with chronic renal disease: ACE inhibitors, angiotensin receptor antagonists, or both?
TREATMENT WITH ANGIOTENSIN II INHIBITORS AND RESIDUAL RENAL FUNCTION IN PERITONEAL DIALYSIS PATIENTS.
University of Miami Division of Clinical Pharmacology Therapeutic Rounds: managing hypertension in patients with kidney disease-implications for preservation of renal function.
Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers During the COVID-19 Pandemic: A Modeling Analysis.
Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers for Geriatric Ischemic Stroke Patients: Are the Rates Right?
Use of angiotensin-converting enzyme inhibitors in patients with diabetic and nondiabetic chronic renal diseases: a need for reassessment.
Use of angiotensin-converting enzyme inhibitors in patients with heart failure and renal insufficiency: how concerned should we be by the rise in serum creatinine?
Use of Antihypertensive Agents and Association With Risk of Adverse Outcomes in Chronic Kidney Disease: Focus on Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers.
Use of medications to reduce cardiovascular risk among individuals with psychotic disorders and Type 2 diabetes.
Use of Renin-Angiotensin System Blockade in Advanced CKD: An NKF-KDOQI Controversies Report.
User of angiotensin-converting-enzyme inhibitor and/or angiotensin II receptor blocker might be associated with vascular calcification in predialysis chronic kidney disease patients: a retrospective single-center observational study : ACEI/ARB and vascular calcification.
Valsartan chronotherapy reverts the non-dipper pattern and improves blood pressure control through mediation of circadian rhythms of the renin-angiotensin system in spontaneous hypertension rats.
Vitamin D, proteinuria, diabetic nephropathy, and progression of CKD.
Wen-pi-tang-Hab-Wu-ling-san reduces ureteral obstructive renal fibrosis by the reduction of oxidative stress, inflammation, and TGF-beta/Smad2/3 signaling.
What every doctor needs to know about chronic kidney disease.
Will the addition of pentoxifylline reduce proteinuria in patients with diabetic glomerulosclerosis refractory to maximal doses of both an angiotensin-converting enzyme inhibitor and an angiotensin receptor blocker?
[Can angiotensin-converting enzyme inhibitor be used in chronic kidney disease patients with serum creatinine level greater than 266 micromol/L?]
[Evaluation of the effectivenes of treatment of patients with renal arterial hypertension with carvedilol]
[Hyperkalemia as a limiting factor in the use of drugs that block the Renin Angiotensin Aldosterone System (RAAS)].
[Nephroprotection by inhibition of the renin-angiotensin system--wish or reality?]
[Progression of chronic renal insufficiency and its prevention using angiotensin converting enzyme inhibitors and angiotensin antagonists]
[Reduced progression, increased mortality in chronic renal disease after treatment with the angiotensin-converting enzyme inhibitor benazepril]
[Serum angiotensin converting enzyme activity in patients with chronic renal insufficiency]
[Use of angiotensin-converting enzyme inhibitors in chronic kidney insufficiency]
Reperfusion Injury
A local kallikrein-kinin system is present in rat hearts.
Aliskiren Reduces Myocardial Ischemia-Reperfusion Injury by a Bradykinin B2 Receptor- and Angiotensin AT2 Receptor-Mediated Mechanism.
Angiotensin-converting enzyme inhibition and food restriction in diabetic mice do not correct the increased sensitivity for ischemia-reperfusion injury.
Anti-free radical mechanisms in captopril protection against reperfusion injury in isolated rat hearts.
Beneficial effects of bradykinin on myocardial energy metabolism and infarct size.
Cardioprotection with angiotensin converting enzyme inhibitor and angiotensin II type 1 receptor antagonist is not abolished by nitric oxide synthase inhibitor in ischemia-reperfused rabbit hearts.
Cardioprotective effect of orally administered angiotensin-converting enzyme inhibitor against ischemia. Reperfusion injury in the isolated rat heart.
Clinical relevance of angiotensin-converting enzyme gene polymorphisms to predict risk of mechanical ventilation after coronary artery bypass graft surgery.
Early antihypertensive treatment and ischemia-induced acute kidney injury.
Effect of ACE inhibitor captopril and L-arginine on the metabolism and on ischemia-reperfusion injury of the isolated rat heart.
Effects of intracoronary low-dose enalaprilat as an adjunct to primary percutaneous transluminal coronary angiography in acute myocardial infarction.
Efficacy Of Zofenopril Alone Or In Combination With Hydrochlorothiazide In Patients With Kidney Dysfunction.
Immunotargeting of the Pulmonary Endothelium via Angiotensin-Converting-Enzyme in Isolated Ventilated and Perfused Human Lung.
Inhibition of angiotensin-converting enzyme by captopril: a novel approach to reduce ischemia-reperfusion injury after lung transplantation.
Inhibition of angiotensin-converting enzyme reduces rat liver reperfusion injury via bradykinin-2-receptor.
Inhibition of neutrophil-dependent cytotoxicity for human endothelial cells by ACE inhibitors.
Lisinopril inhibits endothelin-1 in the early period of hepatic reperfusion injury in a partial hepatectomy model.
Myocardial angiotensin II receptor expression and ischemia-reperfusion injury.
Neuroprotection against retinal ischemia-reperfusion injury by blocking the Angiotensin ll type 1 receptor.
Pretreatment with angiotensin-converting enzyme inhibitors attenuates ischemia-reperfusion injury.
Protective effect of lisinopril against ischemia-reperfusion injury in isolated guinea pig hearts.
Protective effects of captopril and enalapril on myocardial ischemia and reperfusion damage of rat.
Role of angiotensin and endothelin in testicular ischemia reperfusion injury.
The protective effect of calcium inhibitors and of captopril on the renal microcirculation during reperfusion.
Tissue kallikrein is involved in the cardioprotective effect of AT1-receptor blockade in acute myocardial ischemia.
Respiratory Distress Syndrome
Absence of association between angiotensin converting enzyme polymorphism and development of adult respiratory distress syndrome in patients with severe acute respiratory syndrome: a case control study.
ACE Gene Polymorphism in Premature Neonates with Respiratory Distress Syndrome.
ACE I/D but not AGT (-6)A/G polymorphism is a risk factor for mortality in ARDS.
ACE1 polymorphism and progression of SARS.
Activated Protein C has No Effect on Pulmonary Capillary Endothelial Function in Septic Patients with Acute Respiratory Distress Syndrome: Association of Endothelial Dysfunction with Mortality.
Activation of angiotensin-converting enzyme 2 (ACE2) attenuates allergic airway inflammation in rat asthma model.
Acute Kidney Injury in COVID-19 Patients: An Inner City Hospital Experience and Policy Implications.
An experimental study of therapeutic effect of ACEI on chemical-induced ARDS in rats.
Angiotensin converting enzyme and endotoxin induced lung damage in the mouse.
Angiotensin converting enzyme genotypes and mortality from COVID-19: An ecological study.
Angiotensin converting enzyme insertion/deletion polymorphism is associated with susceptibility and outcome in acute respiratory distress syndrome.
Angiotensin-converting enzyme 2 (ACE2): COVID 19 gate way to multiple organ failure syndromes.
Angiotensin-converting enzyme activity in serum and bronchoalveolar lavage fluid after damage to the alveolo-capillary barrier in the human lung.
Angiotensin-converting enzyme I/D polymorphism and acute respiratory distress syndrome.
Angiotensin-converting enzyme in acute respiratory distress syndrome: from bed to bench first… and now back to bed?
Angiotensin-converting enzyme in human adult respiratory distress syndrome.
Angiotensin-converting enzyme insertion/deletion polymorphism associated with acute respiratory distress syndrome among caucasians.
Angiotensin-converting enzyme insertion/deletion polymorphism is not associated with susceptibility and outcome in sepsis and acute respiratory distress syndrome.
Angiotensin-Converting-Enzyme 2 and Renin-Angiotensin System Inhibitors in COVID-19: An Update.
Angiotensin-I-converting enzyme activity in idiopathic respiratory distress syndrome of the newborn infant and in experimental alveolar hypoxia in mice.
Association between insertion/deletion polymorphism in angiotensin-converting enzyme gene and acute lung injury/acute respiratory distress syndrome: a meta-analysis.
Clinical characteristics and outcomes of critically ill patients with COVID-19 in a tertiary community hospital in upstate New York.
Combination of C21 and ARBs with rhACE2 as a therapeutic protocol: A new promising approach for treating ARDS in patients with coronavirus infection.
COVID-19 and cardiac injury: clinical manifestations, biomarkers, mechanisms, diagnosis, treatment, and follow up.
COVID-19-Associated Pneumonia: Radiobiological Insights.
Decreased angiotensin-converting enzyme in the adult respiratory distress syndrome.
Decreased serum angiotensin converting enzyme in adult respiratory distress syndrome associated with sepsis: a preliminary report.
Diabetes, insulin, and development of acute lung injury.
Effect of a fibrin-derived vasoactive peptide on pulmonary angiotensin converting enzyme activity and on pressure responses to bradykinin.
Effect of angiotensin converting enzyme gene I/D polymorphism and its expression on clinical outcome in acute respiratory distress syndrome.
Equilibrium Angiotensin Metabolite Profiling in Patients with Acute Respiratory Distress Syndrome Indicates Angiotensin Converting Enzyme Inhibition.
Ethnic and age-specific acute lung injury/acute respiratory distress syndrome risk associated with angiotensin-converting enzyme insertion/deletion polymorphisms, implications for COVID-19: A meta-analysis.
Genetic basis for necrotizing enterocolitis--risk factors and their relations to genetic polymorphisms.
Genetic Contributions to the Development of Complications in Preterm Newborns.
Imbalance between pulmonary angiotensin-converting enzyme and angiotensin-converting enzyme 2 activity in acute respiratory distress syndrome.
In the eye of the storm: the right ventricle in COVID-19.
Local Renin-Angiotensin II Systems, Angiotensin-Converting Enzyme and its Homologue ACE2: Their Potential Role in the Pathogenesis of Chronic Obstructive Pulmonary Diseases, Pulmonary Hypertension and Acute Respiratory Distress Syndrome.
Neutral endopeptidase in serum samples from patients with adult respiratory distress syndrome. Comparison with angiotensin-converting enzyme.
Peripheral blood microRNAs and the COVID-19 patient: methodological considerations, technical challenges and practice points.
Pharmacovigilance in patients with diabetes: A data-driven analysis identifying specific RAS antagonists with adverse pulmonary safety profiles that have implications for COVID-19 morbidity and mortality.
Polymorphism of the angiotensin converting enzyme gene and angiotensin converting enzyme activity in transient tachypnea of neonate and respiratory distress syndrome.
Polymorphism of the angiotensin-converting enzyme gene affects the outcome of acute respiratory distress syndrome*
Relationship between angiotensin-converting enzyme gene polymorphism and respiratory distress syndrome in premature neonates.
Role of angiotensin-converting enzyme (ACE) and ACE2 in a rat model of smoke inhalation induced acute respiratory distress syndrome.
The Angiotensin Converting Enzyme Deletion/Deletion Genotype Is a Risk Factor for Severe COVID-19: Implication and Utility for Patients Admitted to Emergency Department.
The Role of Angiotensin II Receptor-1 Blockade in the Hypoxic Pulmonary Vasoconstriction Response in Newborn Piglets.
[Angiotensin converting enzyme in the adult respiratory distress syndrome]
[Serum and pulmonary angiotensin converting enzyme as a marker of acute lung injury in an experimental model of adult respiratory distress syndrome]
Respiratory Hypersensitivity
Airway and cough responsiveness and exhaled nitric oxide in non-smoking patients with stable chronic heart failure.
Respiratory Insufficiency
Angiotensin-converting enzyme D allele does not influence susceptibility to acute hypoxic respiratory failure in children.
Anion Gap Was Associated with Inhospital Mortality and Adverse Clinical Outcomes of Coronary Care Unit Patients.
Decreased angiotensin-converting enzyme in the adult respiratory distress syndrome.
Dilated Cardiomyopathy Risk in Patients with Coronavirus Disease 2019: How to Identify and Characterise it Early?
The effect of RAAS inhibitors on acute hypoxemic respiratory failure and in-hospital mortality in the hypertensive Covid-19 patients.
The Impact of Polyphenols-Based Diet on the Inflammatory Profile in COVID-19 Elderly and Obese Patients.
The Ineluctable Role of ACE-2 Receptors in SARS COV-2 Infection and Drug Repurposing as a Plausible SARS COV-2 Therapy : A Concise Treatise.
[ACE Index in patients with respiratory failure]
[Changes of angiotensin II and angiotensin-converting enzyme in cor pulmonale with respiratory failure]
[Variations of angiotensin converting enzyme in chronic obstructive pulmonary disease and chronic respiratory insufficiency]
Respiratory Tract Infections
Acute Cardiac Injury in Coronavirus Disease 2019 and Other Viral Infections-A Systematic Review and Meta-Analysis.
Controversies in the evaluation and management of chronic cough.
Quality of US outpatient care: temporal changes and racial/ethnic disparities.
Top 20 Research Studies of 2014 for Primary Care Physicians.
Retinal Artery Occlusion
Angiotensin-converting enzyme insertion/deletion polymorphism and retinal artery occlusion.
Retinal Detachment
Primary T-cell lymphoma of the retina and cerebellum: immunophenotypic and gene rearrangement confirmation.
Retinal Diseases
Treatment effects of captopril on non-proliferative diabetic retinopathy.
Retinal Neovascularization
Captopril and vascular endothelial growth factor in a mouse model of retinopathy.
Retinal Perforations
Measurement of activities in two different angiotensin II generating systems, chymase and angiotensin-converting enzyme, in the vitreous fluid of vitreoretinal diseases: a possible involvement of chymase in the pathogenesis of macular hole patients.
Retinal Vasculitis
Optic Nerve Head Granuloma, Retinal Vasculitis and Elevated Levels of Angiotensin-converting Enzyme: Dilemma of Forme Fruste Ocular Sarcoidosis.
Relevance of Brain MRI in Patients with Uveitis: Retrospective Cohort on 402 Patients.
Retinal Vein Occlusion
Relationship between angiotensin I-converting enzyme insertion/deletion gene polymorphism and retinal vein occlusion.
Role of angiotensin-converting enzyme insertion/deletion and plasminogen activator inhibitor-1 4G/5G gene polymorphisms in retinal vein occlusion.
Retinopathy of Prematurity
Angiotensin-converting enzyme gene insertion/deletion polymorphism in Kuwaiti children with retinopathy of prematurity.
Association of eNOS and ACE Polymorphisms with Retinopathy of Prematurity: A Systematic Review and Meta-Analysis.
Diabetes and retinal vascular disorders: role of the reninangiotensin system.
Genetic Contributions to the Development of Complications in Preterm Newborns.
Severe ROP in twins after blockage of the renin-angiotensin system during gestation.
Rhabdomyolysis
The management of hyperkalaemia in the emergency department.
Rheumatic Diseases
Renal disease in scleroderma: an update on evaluation, risk stratification, pathogenesis and management.
[Interactions of nonsteroid anti-inflammatory drugs with inhibitors of angiotensin-converting enzyme in patients with rheumatic diseases (a review)]
Rheumatic Fever
Angiotensin-converting enzyme genotype predicts valve damage in acute rheumatic fever.
Rheumatic Heart Disease
Angiotensin converting enzyme DD genotype is associated with development of rheumatic heart disease in Egyptian children.
Angiotensin Converting Enzyme Inhibitors (ACEIs) Decrease the Progression of Cardiac Fibrosis in Rheumatic Heart Disease Through the Inhibition of IL-33/sST2.
Angiotensin-converting enzyme gene insertion/deletion polymorphism in Saudi patients with rheumatic heart disease.
Association between angiotensin I-converting enzyme gene insertion/deletion polymorphism and risk of rheumatic heart disease.
Association of angiotensin I-converting enzyme gene insertion/deletion polymorphism with rheumatic heart disease in Indian population and meta-analysis.
Correlation of angiotensin I-converting enzyme gene insertion/deletion polymorphism with rheumatic heart disease: a meta-analysis.
Expression of extracellular signal-regulated kinase and angiotensin-converting enzyme in human atria during atrial fibrillation.
Reduced testosterone levels in males with lone atrial fibrillation.
Rheumatoid Nodule
Constitutive production of angiotensin converting enzyme from rheumatoid nodule cells under serum free conditions.
Rhinitis
Angiotensin-converting enzyme insertion/deletion polymorphism and susceptibility to allergic rhinitis in Chinese populations: a systematic review and meta-analysis.
Rhinitis, Allergic
ACE gene polymorphism might disclose why some Taiwanese children with allergic rhinitis develop asthma symptoms but others do not.
Angiotensin-converting enzyme (ACE) I/D polymorphism is a risk factor of allergic rhinitis.
Angiotensin-converting enzyme gene insertion/deletion polymorphisms and the susceptibility to allergic rhinitis.
Angiotensin-converting enzyme II expression and its implication in the association between COVID-19 and allergic rhinitis.
Angiotensin-converting enzyme insertion/deletion polymorphism and susceptibility to allergic rhinitis in Chinese populations: a systematic review and meta-analysis.
Angiotensin-converting enzyme insertion/deletion polymorphism associated with allergic rhinitis susceptibility: Evidence from 1410 subjects.
Association between angiotensin-converting enzyme gene polymorphism and childhood allergic rhinitis in Taiwan.
Association between polymorphisms of the angiotensin-converting enzyme and angiotensinogen genes and allergic rhinitis in a Korean population.
Evidence and evidence gaps of medical treatment of non-tumorous diseases of the head and neck.
Pseudoaldosteronism due to the concurrent use of two herbal medicines containing glycyrrhizin: interaction of glycyrrhizin with angiotensin-converting enzyme inhibitor.
Role of neutral endopeptidase and kininase II on substance P-induced increase in nasal obstruction in patients with allergic rhinitis.
[Strong and Deficient Evidence in Drug-Treated, Non-Tumorous Diseases in ENT].
Rotavirus Infections
Protein Malnutrition Alters Tryptophan and Angiotensin-Converting Enzyme 2 Homeostasis and Adaptive Immune Responses in Human Rotavirus-Infected Gnotobiotic Pigs with Human Infant Fecal Microbiota Transplant.
Sarcoidosis
(18)F-FDG PET, genotype-corrected ACE and sIL-2R in newly diagnosed sarcoidosis.
8-Isoprostane, a marker of oxidative stress, is increased in the expired breath condensate of patients with pulmonary sarcoidosis.
A case of Graves' disease developing with exacerbation of sarcoidosis.
A case of renal sarcoidosis showing central necrosis and abnormal expression of angiotensin converting enzyme in the granuloma.
A case of sarcoid reaction associated with papillary thyroid carcinoma.
A case of sarcoidosis associated with bronchial asthma.
A case of sarcoidosis presenting as a non-specific intramedullary lesion.
A case of sarcoidosis that developed three years after the onset of hard metal asthma.
A case of scrotal sarcoidosis that mimicked tuberculosis.
A case report of gastric cancer associated with sarcoid reactions in the regional lymph nodes and liver.
A clinical evaluation of serum angiotensin converting enzyme in sarcoidosis.
A comparison of Blau's syndrome and sarcoidosis.
A Multiple Biomarker Approach in Patients with Cardiac Sarcoidosis.
A patient with sarcoidosis presenting with acute renal failure: implication for granulomatous interstitial nephritis and hypercalcemia.
Abdominal CT findings in sarcoidosis: radiologic and clinical correlation.
ACE and sIL-2R correlate with lung function improvement in sarcoidosis during methotrexate therapy.
ACE gene I/D polymorphism and risk of sarcoidosis development in Turkish patients.
Ace gene I/D polymorphism and sarcoidosis pulmonary disease severity.
ACE I/D-corrected Z-scores to identify normal and elevated ACE activity in sarcoidosis.
ACE levels may affect cystatin C measurements.
Acquired hypogammaglobulinaemia and sarcoidosis.
Active pre-treatment pure pulmonary parenchymal sarcoidosis with raised serum angiotensin converting enzyme level: characteristics on PET with glucose metabolism and cell proliferation tracers and HRCT.
Activity of angiotensin I converting enzyme in sarcoidosis, atopic bronchial asthma and acute bronchitis.
Acute effects of captopril on serum angiotensin-converting enzyme activity, the renin-aldosterone system and blood pressure in patients with sarcoidosis.
Acute reversible dysphagia and dysphonia as initial manifestations of sarcoidosis.
Adverse effect of chronic tonsillitis on clinical course of sarcoidosis.
Amenorrhea-galactorrhea syndrome as an uncommon manifestation of isolated neurosarcoidosis.
Amounts of angiotensin-converting enzyme mRNA reflect the burden of granulomas in granulomatous lung disease.
An 82 year-old patient with sarcoidosis.
An angiotensin-converting enzyme (ACE) inhibitor in human serum. Increased sensitivity of the serum ACE assay for detecting active sarcoidosis.
An assessment of back pain and the prevalence of sacroiliitis in sarcoidosis.
An in vitro model for the induction of angiotensin-converting enzyme in sarcoidosis. Evidence for a soluble ACE-inducing factor.
An in vitro model for the induction of angiotensin-converting enzyme in sarcoidosis: possible parallels to the immune response.
Angiogenic activity of sera from interstitial lung disease patients in relation to Angiotensin-converting enzyme activity.
Angiotensin converting enzyme (ACE) gene polymorphism in sarcoidosis in relation to associated autoimmune diseases.
Angiotensin converting enzyme genotype affects development and course of sarcoidosis in Asian Indians.
Angiotensin converting enzyme I/D polymorphism and sarcoidosis risk.
Angiotensin converting enzyme in bronchoalveolar lavage fluid in pulmonary sarcoidosis.
Angiotensin converting enzyme in cerebrospinal fluid: a new assay.
Angiotensin converting enzyme in sarcoidosis and in silicosis.
Angiotensin converting enzyme levels in sarcoidosis.
Angiotensin converting enzyme. III. Changes in serum level as an indicator of disease activity in untreated sarcoidosis.
Angiotensin converting enzyme. IV. Changes in serum activity and in lysozyme concentrations as indicators of the course of untreated sarcoidosis.
Angiotensin converting enzyme. V. Serum levels as monitors of disease activity in corticosteroid-treated sarcoidosis.
Angiotensin I-converting enzyme in the diagnosis and management of sarcoidosis.
Angiotensin II augmentation of tyrosine kinase activity in human adherent mononuclear cells.
Angiotensin II receptor on BALF macrophages from Japanese patients with active sarcoidosis.
Angiotensin II receptor type 1 1166 A/C and angiotensin converting enzyme I/D gene polymorphisms in a Dutch sarcoidosis cohort.
Angiotensin-converting enzyme (ACE) gene polymorphism in patients with sarcoidosis.
Angiotensin-converting enzyme (ACE) gene polymorphisms and familial occurrence of sarcoidosis.
Angiotensin-converting enzyme activity and steroid therapy in sarcoidosis.
Angiotensin-converting enzyme activity in sarcoidosis and other disorders.
Angiotensin-converting enzyme and its clinical significance--a review.
Angiotensin-converting Enzyme as a Predictor of Extrathoracic Involvement of Sarcoidosis.
Angiotensin-converting enzyme gene polymorphism and risk of sarcoidosis.
Angiotensin-converting enzyme gene polymorphism in relation to HLA-DR in sarcoidosis.
Angiotensin-converting enzyme in bronchoalveolar lavage fluid in sarcoidosis.
Angiotensin-converting enzyme in Crohn's disease and ulcerative colitis.
Angiotensin-converting enzyme in farmer's lung.
Angiotensin-converting enzyme in newly detected sarcoidosis. With special reference to enzyme levels in patients with erythema nodosum.
Angiotensin-converting enzyme in sarcoid and chalazion granulomas of the conjunctiva.
Angiotensin-converting enzyme in sarcoid perivasculitis.
Angiotensin-converting enzyme in sarcoidosis and other pulmonary diseases: a comparison of two methods of determination.
Angiotensin-converting enzyme in sarcoidosis.
Angiotensin-converting enzyme in sarcoidosis: a British study.
Angiotensin-converting enzyme in serum and in bronchoalveolar lavage in sarcoidosis.
Angiotensin-converting enzyme in uveitis and sarcoidosis.
Angiotensin-converting enzyme inhibitors in the treatment of sarcoidosis and association with ACE gene polymorphism: case series.
Angiotensin-converting enzyme levels in chronic sarcoidosis.
Angiotensin-converting enzyme, lysozyme, beta-2-microglobulin and adenosine deaminase in sarcoidosis.
Angiotensin-converting enzyme. I. Activity and correlation with serum lysozyme in sarcoidosis, other chest or lymph node diseases and healthy persons.
Angiotensin-converting enzyme. II. Serum activity in early and newly diagnosed sarcoidosis.
Angiotensin-converting enzyme. Investigation of diurnal variation, the effect of a large dose of prednisolone, and prednisolone pharmacokinetics in patients with sarcoidosis.
Angiotensin-I-converting enzyme and gallium scan in noninvasive evaluation of sarcoidosis.
Angiotensin-I-converting enzyme and sarcoidosis.
Antifungal medication is efficient in treatment of sarcoidosis.
ApoE-deficient mice on cholate-containing high-fat diet reveal a pathology similar to lung sarcoidosis.
Are the pulmonary function tests and the markers of activity helpful to establish the prognosis of sarcoidosis?
Assessing angiotensin-converting enzyme (ACE) protein is more appropriate than ACE activity when investigating sarcoidosis.
Assessment of activity in chronic sarcoidosis: usefulness of serum angiotensin converting enzyme and gallium scan.
Assessment of activity in Sarcoidosis. Sensitivity and specificity of 67Gallium scintigraphy, serum ACE levels, chest roentgenography, and blood lymphocyte subpopulations.
Assessment of serum angiotensin-converting enzyme as a marker of activity in sarcoidosis: a study of 31 patients with erythema nodosum.
Association between ACE gene I/D polymorphism and clinical presentation and prognosis of sarcoidosis.
Association between angiotensin II receptor gene polymorphism and serum angiotensin converting enzyme (SACE) activity in patients with sarcoidosis.
Association between I/D polymorphism in the ACE gene and sarcoidosis in Turkish patients.
Association of angiotensin-converting enzyme/DD genotype with sarcoidosis susceptibility in Slovenian patients.
Association of peripheral multifocal choroiditis with sarcoidosis: a study of thirty-seven patients.
Association of serum amyloid A and oxidative stress with paraoxonase 1 in sarcoidosis patients.
Associations between the angiotensin-converting enzyme insertion/deletion polymorphism and susceptibility to sarcoidosis: A meta-analysis.
Bilateral parotid swelling caused by sarcoidosis.
Biochemical indicators of disordered vitamin D and calcium homeostasis in sarcoidosis.
Biomarkers in Autoimmune Salivary Gland Disorders: A Review.
Blood monocytes and serum and bone marrow lysozyme in sarcoidosis.
Bronchial responsiveness and angiotensin-converting enzyme gene polymorphism in sarcoidosis patients.
Bronchioalveolar angiotensin converting enzyme activity. Value in assessing disease activity in sarcoidosis.
Bronchoalveolar lavage fluid angiotensin-converting enzyme in interstitial lung diseases.
Bronchoalveolar lavage, serum angiotensin-converting enzyme, and gallium-67 scanning in extrathoracic sarcoidosis.
Calcitriol-Mediated Hypercalcemia: Causes and Course in 101 Patients.
Cardiac Sarcoidosis Presenting as Acute Progressive Heart Failure with Abdominal Lymphadenopathy.
Cerebrospinal fluid angiotensin-converting enzyme for diagnosis of central nervous system sarcoidosis.
Characterization of a spectrophotometric assay for angiotensin converting enzyme.
Chest Radiographic Screening for Sarcoidosis in the Diagnosis of Patients with Active Uveitis.
Childhood Sarcoidosis Presenting as Recurrent Facial Palsy.
Chitotriosidase analysis in bronchoalveolar lavage of patients with sarcoidosis.
Choroidal granuloma in sarcoidosis.
Choroidal nonperfusion on optical coherence tomography angiography in a case of unilateral posterior segment ocular sarcoidosis misdiagnosed as MEWDS.
Chronic granulomatous inflammation of the breast as a first clinical manifestation of primary sarcoidosis.
Circulating gamma delta-T-cell-receptor-positive lymphocytes in sarcoidosis.
Circulating soluble intercellular adhesion molecule-1 (sICAM-1) in patients with sarcoidosis.
Cistoid macular edema as first manifestation of sarcoidosis.
Clinical analysis of sarcoidosis presenting with heterochronic cardiac involvement.
Clinical and biochemical aspects of sarcoidosis. With special reference to angiotensin-converting enzyme (ACE).
Clinical and biochemical presentation of sarcoidosis with high and normal serum angiotensin-converting enzyme.
Clinical application of measurement of angiotensin-converting enzyme level.
Clinical correlations of serum angiotensin-converting enzyme (ACE) in sarcoidosis. A longitudinal study of serum ACE, 67gallium scans, chest roentgenograms, and pulmonary function.
Clinical diagnosis of ocular sarcoidosis.
Clinical features of spinal cord sarcoidosis: analysis of 17 neurosarcoidosis patients.
Clinical significance of serum angiotensin-converting enzyme levels in sarcoidosis.
Clinical significance of serum thermolysin-like metalloendopeptidase and its relationship to serum angiotensin converting enzyme in sarcoidosis.
Coexisting Primary Hyperparathyroidism and Sarcoidosis Cause Increased Angiotensin-Converting Enzyme and Decreased Parathyroid Hormone and Phosphate Levels.
Collagenase and fibronectin in bronchoalveolar lavage fluid in patients with sarcoidosis.
Combined application of angiotensin converting enzyme and chitotriosidase analysis improves the laboratory diagnosis of sarcoidosis.
Comparison of clinical parameters, bronchoalveolar lavage, gallium-67 lung uptake, and serum angiotensin converting enzyme in assessing the activity of sarcoidosis.
Comparison of the T lymphocyte-dependent induction of angiotensin-converting enzyme and leucine aminopeptidase in cultured human monocytes.
Comparison of two methods for measurement of serum angiotensin-converting enzyme in sarcoidosis.
Composite Carcinoma of the Stomach Associated with Sarcoid-Like Granulomas.
Concentration of angiotensin-converting enzyme in tears of patients with sarcoidosis.
Conformational Fingerprinting of the Angiotensin I-Converting Enzyme (ACE). 1. Application in Sarcoidosis.
Conjunctival sarcoidosis.
Correlation between 25-hydroxyvitamin D3 1 alpha-hydroxylase gene expression in alveolar macrophages and the activity of sarcoidosis.
Correlation between disease activity, one-year prognosis, and angiotensin-converting enzyme in untreated sarcoidosis.
Correlative analysis of longitudinal changes in bronchoalveolar lavage, 67gallium scanning, serum angiotensin-converting enzyme activity, chest X-ray, and pulmonary function tests in pulmonary sarcoidosis.
Corticosteroid therapy increases HDL-cholesterol concentrations in patients with active sarcoidosis and hypoalphalipoproteinemia.
Corticosteroid treatment in pulmonary sarcoidosis: do serial lavage lymphocyte counts, serum angiotensin converting enzyme measurements, and gallium-67 scans help management?
Corticosteroid-resistant bulbar neurosarcoidosis responsive to intravenous immunoglobulin.
Course and outcome of ocular sarcoidosis.
Cryptogenic Organizing Pneumonia with Sarcoidosis Overlap: An Atypical Case Study.
Cushing's syndrome due to primary adrenocortical nodular dysplasia, cardiac myxomas, and spotty pigmentation, complicated by sarcoidosis.
Deletion polymorphism in the angiotensin I converting enzyme (ACE) gene as a genetic risk factor for sarcoidosis.
Determination of angiotensin-converting enzyme activity in tears. A noninvasive test for evaluation of ocular sarcoidosis.
Determination of serum angiotensin-converting enzyme in sarcoidosis.
Development of a high-resolution melting genotyping assay for the angiotensin I converting enzyme insertion/deletion polymorphism and establishment of genotype-specific reference intervals in a Danish population.
Development of a random forest model to classify sarcoidosis and tuberculosis.
Development of Hypercalcemia in a Patient Receiving Peginterferon alfa-2a Therapy for Polycythemia Vera.
Diagnostic Utility of Angiotensin-Converting Enzyme in Sarcoidosis: A Population-Based Study.
Diagnostic value of blood tests for occult causes of initially idiopathic small-fiber polyneuropathy.
Diagnostic value of serum angiotensin converting enzyme activity in lung diseases.
Differences in clinical findings between Caucasians and African Americans with biopsy-proven sarcoidosis.
Distinguishing Features of Ocular Sarcoidosis in an International Cohort of Uveitis Patients.
Does serum angiotensin converting enzyme reflect intensity of alveolitis in sarcoidosis?
Effects of acute exercise on angiotensin I-converting enzyme (ACE) activity in horses.
Elevated concentrations of soluble interleukin-2 receptors in serum samples and bronchoalveolar lavage fluids in active sarcoidosis.
Elevated levels of angiotensin-converting enzyme in Pneumocystis carinii pneumonia.
Elevated serum angiotensin I converting enzyme in sarcoidosis.
Elevated serum angiotensin-converting enzyme in hyperthyroidism.
Elevated serum BAFF levels in patients with sarcoidosis: association with disease activity.
Elevated serum levels of lysozyme in desquamative interstitial pneumonia.
Elevation of angiotensin-converting enzyme in granulomatous lymph nodes and serum in sarcoidosis: clinical and possible pathogenic significance.
Elevation of granulomatous lymph-node and serum lysozyme in sarcoidosis and correlation with angiotensin-converting enzyme.
Elevation of serum angiotensin-converting enzyme activity in patients with hyperthyroidism.
Elevation of serum angiotensin-converting-enzyme (ACE) level in sarcoidosis.
Elevation of the bronchoalveolar concentration of angiotensin I converting enzyme in sarcoidosis.
Enzymes in sarcoidosis. Angiotensin-converting-enzyme (ACE).
Evaluation of Serum Biomarkers in Patients with Sarcoidosis: Can Visfatin Be a New Biomarker for Sarcoidosis?
Evaluation of soluble CD 14 and neopterin as serum parameters of the inflammatory activity of pulmonary sarcoidosis.
Extreme elevation of serum angiotensin-converting enzyme (ACE) activity: always consider familial ACE hyperactivity.
Familial Mediterranean fever. Another cause of raised serum angiotensin converting enzyme; another abortive attempt at masquerading as sarcoidosis.
Fibroblast growth-stimulating activity in bronchoalveolar lavage fluid of patients with pulmonary sarcoidosis.
Fluorodeoxyglucose positron emission tomography (FDG-PET) is useful in the diagnosis of neurosarcoidosis.
Follow-up on angiotensin-converting enzyme in serum of patients with sarcoidosis.
Foreign Body Granulomatous Reaction to Silica, Silicone, and Hyaluronic Acid in a Patient With Interferon-Induced Sarcoidosis.
FUO due to sarcoidosis-lymphoma syndrome.
Gallium 67 citrate scanning and serum angiotensin converting enzyme levels in sarcoidosis.
Gallium-67 in the evaluation of sarcoidosis: correlations with serum angiotensin-converting enzyme and bronchoalveolar lavage.
Gastrointestinal sarcoidosis presenting with malabsorption at an early age.
Gene polymorphisms of ACE and the angiotensin receptor AT2R1 influence serum ACE levels in sarcoidosis.
Genetic-based reference values for angiotensin-converting enzyme (ACE) according to I/D polymorphism in a Spanish population sample.
Genotype-corrected reference values for serum angiotensin-converting enzyme.
Genotyping increases the yield of angiotensin-converting enzyme in sarcoidosis--a systematic review.
Head and neck manifestations of sarcoidosis.
Hepatic Sarcoidosis: Clinico-pathological characterization of symptomatic cases.
High-dose Vitamin D Supplementation Precipitating Hypercalcemic Crisis in Granulomatous Disorders.
Histiocytosis X. VI. Angiotensin-converting enzyme activity.
Histoplasmosis With Tenosynovitis of the Hand and Hypercalcemia Mimicking Sarcoidosis.
Histoplasmosis: a masquerader of sarcoidosis.
HLA-DRB1 alleles associate with hypercalcemia in sarcoidosis.
Human chitotriosidase: a potential new marker of sarcoidosis severity.
Hypercalcaemia: A portent of sarcoidosis in cystic fibrosis.
Hypercalcemia and renal insufficiency – where can we start?
Hypercalcemia associated with an elevated 1,25 dihydroxy vitamin D3 level and an elevated angiotensin-converting enzyme level in a patient without evidence of sarcoidosis or malignancy.
Hypercalcemia due to excess 1,25-dihydroxyvitamin D in Crohn's disease.
Identification of a thermolysin-like metalloendopeptidase in serum: activity in normal subjects and in patients with sarcoidosis.
Identification of Active Sarcoidosis Using Chitotriosidase and Angiotensin-Converting Enzyme.
Immunofluorescent localization of angiotensin converting enzyme in epithelioid and giant cells of sarcoidosis granulomas.
Immunohistologic diagnosis of sarcoidosis. Detection of angiotensin-converting enzyme in sarcoid granulomas.
Impaired Vascular Function in Sarcoidosis Patients.
In vitro synthesis of angiotensin-converting enzyme by alveolar macrophages is increased in disseminated sarcoidosis.
Increase of KL-6 in sera of uveitis patients with sarcoidosis.
Increased angiotensin-converting enzyme in peripheral blood monocytes from patients with sarcoidosis.
Increased circulating interleukin-12 (IL-12) p40 in pulmonary sarcoidosis.
Increased levels of interleukin-12 and interleukin-18 in bronchoalveolar lavage fluid of patients with pulmonary sarcoidosis.
Increased serum angiotensin converting enzyme activity in sarcoidosis.
Indocyanine green angiographic features in ocular sarcoidosis.
Induction of angiotensin converting enzyme in cultured human monocytes by a factor present in the bronchoalveolar lavage fluid of sarcoidosis patients.
Inflammatory cells in the formation of tumor-related sarcoid reactions.
Influence of angiotensin converting enzyme (ACE) genotype on interpretation of diagnostic tests for serum ACE activity.
Influence of serum amyloid A on the decrease of high density lipoprotein-cholesterol in active sarcoidosis.
Insertion/Deletion Polymorphisms and Serum Angiotensin-converting Enzyme Levels in Iranian Patients with Sarcoidosis.
Interleukin-2 Receptor and Angiotensin-Converting Enzyme as Markers for Ocular Sarcoidosis.
International criteria for the diagnosis of ocular sarcoidosis: results of the first International Workshop On Ocular Sarcoidosis (IWOS).
Intramedullary cervical spinal cord sarcoidosis.
Isolated neurosarcoidosis presenting as headache and multiple brain and spinal cord lesions mimicking central nervous system metastases.
Kininase II in bronchoalveolar lavage fluid and serum of patients with pulmonary disorders.
Lack of correlation between serum angiotensin-converting enzyme activity and bronchoalveolar lymphocytosis in lung sarcoidosis.
Lack of detection of factor VIII in sarcoidal epithelioid cells.
Late-onset and Rare Far-advanced Pulmonary Involvement in Patients with Sarcoidosis in Taiwan.
Leprosy initially misdiagnosed as sarcoidosis, adult-onset still disease, or autoinflammatory disease.
Levels of angiotensin-converting enzyme in pleural effusion.
Levels of transferrin in bronchoalveolar lavage fluid in sarcoidosis.
Localization of angiotensin converting enzyme (ACE) in granulomas of sarcoidosis cutaneous lesions.
Longitudinal observations of serum angiotensin-converting enzyme activity in sarcoidosis with and without treatment.
Low levels of high density lipoprotein cholesterol in patients with active sarcoidosis.
Low-grade B-cell lymphoma and concomitant extensive sarcoidlike granulomas: a case report and review of the literature.
Lower left ventricular ejection fraction and higher serum angiotensin-converting enzyme activity are associated with histopathological diagnosis by endomyocardial biopsy in patients with cardiac sarcoidosis.
Lung inflammation in sarcoidosis: comparison of serum angiotensin-converting enzyme levels with bronchoalveolar lavage and gallium-67 scanning assessment of the T lymphocyte alveolitis.
Markedly elevated angiotensin converting enzyme in lymph nodes containing non-necrotizing granulomas in sarcoidosis.
Markers of activity in sarcoidosis with a special reference to serum angiotensin converting enzyme (SACE).
Measurement of angiotensin-converting enzyme activity in intact human alveolar macrophages and effect of smoking.
Meta-analytical association between angiotensin-converting enzyme gene polymorphisms and sarcoidosis risk.
Minocycline for the treatment of sarcoidosis: is the mechanism of action immunomodulating or antimicrobial effect?
Molecular studies of bronchial asthma, sarcoidosis and angiotensin converting enzyme inhibitor-induced cough.
Multi-Organ Sarcoidosis Treatment with Fumaric Acid Esters: A Case Report and Review of the Literature.
Nephrolithiasis as primary symptom in sarcoidosis.
Neuro-Ophthalmic Manifestations of Sarcoidosis.
Neuro-ophthalmic sarcoidosis: the University of Iowa experience.
Newly diagnosed pulmonary sarcoidosis in HIV-infected patients.
Normal serum angiotensin converting enzyme activity in patients with newly diagnosed sarcoidosis.
Novel ACE mutations mimicking sarcoidosis by increasing blood ACE levels.
Optic Nerve Head Granuloma, Retinal Vasculitis and Elevated Levels of Angiotensin-converting Enzyme: Dilemma of Forme Fruste Ocular Sarcoidosis.
Optimized angiotensin-converting enzyme activity assay for the accurate diagnosis of sarcoidosis.
Optimized determination of angiotensin I-converting enzyme activity with hippuryl-L-histidyl-L-leucine as substrate.
Oral involvement in sarcoidosis: report of 12 cases.
Oro-facial granulomatosis--a clinical and pathological analysis.
Orosomucoid and haptoglobin types in patients with sarcoidosis.
Pathogenesis of sarcoidosis: an hypothetical model.
Peripheral multifocal chorioretinitis: a distinct clinical entity?
Peripheral sea-fan retinal neovascularization as a manifestation of chronic rhegmatogenous retinal detachment and surgical management.
Peritoneal sarcoidosis: A case report.
Plasma angiotensin converting enzyme in the diagnosis and monitoring of disease activity in sarcoidosis.
Plasma chitotriosidase and CCL18 as surrogate markers for granulomatous macrophages in sarcoidosis.
Plasma levels of endothelin-1 increase in patients with sarcoidosis and fall after disease remission.
Polymorphic ventricular tachycardia with cardiac sarcoidosis: treatment with low-dose metoprolol and cibenzoline.
Polymorphism in the angiotensin-converting enzyme (ACE) gene and sarcoidosis.
Polymorphism of angiotensin-converting enzyme gene in sarcoidosis.
Post-partum recurrent sarcoidosis associated with type 1 diabetes mellitus.
Predictors of objective cough frequency in pulmonary sarcoidosis.
Primary presentation of sarcoidosis with profound bilateral sensorineural hearing loss.
Primary Sjögren's syndrome complicated by sarcoidosis.
Primary systemic amyloidosis and high levels of Angiotensin-converting enzyme: two case reports.
Prolonged course of illness in a child with malignant lymphoma mimicking sarcoidosis.
Prolonged generalized pruritus associated with selective elevation of IgA as the presenting symptoms of sarcoidosis.
Prolonged Uhthoff phenomenon in sarcoidosis.
Propeptide levels of type III and type I procollagen in the serum and bronchoalveolar lavage fluid of patients with pulmonary sarcoidosis.
Pulmonary cavitary sarcoidosis: clinico-radiologic characteristics and natural history of a rare form of sarcoidosis.
Pulmonary Embolism in a Sarcoidosis Patient Double Heterozygous for Methylenetetrahydrofolate Reductase Gene Polymorphisms and Factor V Leiden and Homozygous for the D-Allele of Angiotensin Converting Enzyme Gene.
Pulmonary function tests, serum angiotensin-converting enzyme levels, and clinical findings as prognostic indicators in sarcoidosis.
Pulmonary sarcoidosis: correlation of serum angiotensin-converting enzyme with blood and bronchoalveolar lymphocytes.
Quantitative analysis of propionibacterial DNA in bronchoalveolar lavage cells from patients with sarcoidosis.
Reconsideration of the cut-off value of angiotensin-converting enzyme for screening of sarcoidosis in Japanese patients.
Relation between clinical stage of sarcoidosis and serum values of angiotensin converting enzyme and beta2-microglobulin.
Relation between immunocytological features of bronchoalveolar lavage fluid and clinical indices in sarcoidosis.
Relationship between angiotensin-converting enzyme and lysozyme in sarcoidosis.
Relationship between changed alveolar-capillary permeability and angiotensin converting enzyme activity in serum in sarcoidosis.
Relationship between circulating immune complexes and angiotensin-converting enzyme in pulmonary sarcoidosis.
Relationship between CT activity score with lung function and the serum angiotensin converting enzyme in pulmonary sarcoidosis on chest HRCT.
Research on normal values of serum angiotensin-I converting enzyme. Cooperative Group of Sarcoidosis Research.
Respiratory clearance of 99mTc-DTPA and pulmonary involvement in sarcoidosis.
Reversible esophageal motility disorder in a patient with sarcoidosis.
Reversible facial paralysis in sarcoidosis. Confirmation by serum angiotensin-converting enzyme assay.
Role of fluorodeoxyglucose positron emission tomography in the diagnosis of neurosarcoidosis.
Role of serum angiotensin converting enzyme in sarcoidosis.
Sarcoid and erythema nodosum arthropathies.
Sarcoid arthropathy in cystic fibrosis.
Sarcoid granuloma simulating amelanotic melanoma of the iris.
Sarcoid reaction observed in a worker with a history of asbestos exposure.
Sarcoid-like granulomatous orbital inflammation induced by interferon-alpha treatment.
Sarcoid-related uveitis occurring during etanercept therapy.
Sarcoidosis activity: correlation of HRCT findings with those of 67Ga scanning, bronchoalveolar lavage, and serum angiotensin-converting enzyme assay.
Sarcoidosis and granuloma genes: a family-based study in African-Americans.
Sarcoidosis associated with interferon-alpha therapy for chronic hepatitis C.
Sarcoidosis beyond pulmonary involvement: A case series of unusual presentations.
Sarcoidosis detected due to tattoo swellings in an Indian female.
Sarcoidosis following Cushing's syndrome: A report of two cases and review of the literature.
Sarcoidosis in a patient with systemic sclerosis and primary biliary cirrhosis.
Sarcoidosis in chronic granulomatous disease.
Sarcoidosis in the 1990s: avenues for the future.
Sarcoidosis initially manifesting as symptomatic hypercalcemia with the absence of organic involvement.
Sarcoidosis mythology.
Sarcoidosis of the anterior visual pathway: 24 new cases.
Sarcoidosis of the breast.
Sarcoidosis of the breast: a rare case report and a review.
Sarcoidosis of the tongue.
Sarcoidosis Presenting Addison's Disease.
Sarcoidosis presenting as granulomatous colitis.
Sarcoidosis presenting as multiple subcutaneous nodules.
Sarcoidosis Presenting with Bilateral Optic Disc Edema as the Initial Presentation.
Sarcoidosis presenting with stroke.
Sarcoidosis with acute recurrent polyarthritis and hypercalcemia.
Sarcoidosis with Arteriovenous Malformation in a 15-Year-Old Girl - The Rarest of the Rare.
Sarcoidosis with marked necrosis in enlarged lymph nodes mimics mycobacterial infection: a case report.
Sarcoidosis with prominent giant cells.
Sarcoidosis.
Sarcoidosis: a primary care review.
Sarcoidosis: correlation of HRCT findings with results of pulmonary function tests and serum angiotensin-converting enzyme assay.
Sarcoidosis: TNF-alpha release from alveolar macrophages and serum level of sIL-2R are prognostic markers.
Sensitive fluorimetric assay for serum angiotensin-converting enzyme with the natural substrate angiotensin I.
Serial estimation of serum angiotensin converting enzyme activity during and after pregnancy in a woman with sarcoidosis.
Serial investigation of Angiotensin-Converting Enzyme in sarcoidosis patients treated with Angiotensin-Converting Enzyme Inhibitor.
Serial observations of angiotensin-converting enzyme and pulmonary function in sarcoidosis.
Serum activity of angiotensin converting enzyme and pulmonary radiography as prognostic criteria in sarcoidosis.
Serum and lymph-node collagenase in sarcoidosis. Comparison with angiotensin-converting enzyme.
Serum angiotensin converting enzyme (ACE) levels in untreated and treated sarcoidosis.
Serum angiotensin converting enzyme activity in chronic beryllium disease.
Serum angiotensin converting enzyme activity in Crohn's disease and ulcerative colitis.
Serum angiotensin converting enzyme activity in patients with histoplasmosis.
Serum angiotensin converting enzyme activity in patients with psoriasis.
Serum angiotensin converting enzyme activity in pulmonary diseases: correlation with lung function parameters.
Serum angiotensin converting enzyme activity in sarcoidosis and pulmonary tuberculosis.
Serum angiotensin converting enzyme activity in sarcoidosis as measured by a simple radiochemical assay.
Serum angiotensin converting enzyme does not correlate with radiographic stage at initial diagnosis of sarcoidosis.
Serum angiotensin converting enzyme in sarcoidosis--its value in present clinical practice.
Serum angiotensin converting enzyme in sarcoidosis: clinical significance.
Serum angiotensin converting enzyme in sarcoidosis: sensitivity and specificity in diagnosis: correlations with disease activity, duration, extra-thoracic involvement, radiographic type and therapy.
Serum angiotensin converting enzyme in the diagnosis of pulmonary sarcoidosis.
Serum angiotensin converting enzyme, Erythrocyte sedimentation rate and high sensitive-C reactive protein levels in diagnosis of cardiac sarcoidosis- where do we stand?
Serum angiotensin--converting enzyme (SACE) in sarcoidosis and other granulomatous disorders.
Serum angiotensin-converting enzyme (SACE) activity as an indicator of total body granuloma load and prognosis in sarcoidosis.
Serum angiotensin-converting enzyme (SACE) in sarcoidosis and other granulomatous disorders.
Serum angiotensin-converting enzyme activity as an indicator of prognosis in sarcoidosis.
Serum angiotensin-converting enzyme activity in evaluating the clinical course of sarcoidosis.
Serum angiotensin-converting enzyme activity in normal children and in those with sarcoidosis.
Serum angiotensin-converting enzyme activity in sarcoidosis.
Serum angiotensin-converting enzyme activity, concentration, and specific activity in granulomatous interstitial lung disease, tuberculosis, and COPD.
Serum angiotensin-converting enzyme activity. Its use in the evaluation and management of hypercalcemia associated with sarcoidosis.
Serum angiotensin-converting enzyme and bronchoalveolar lavage in sarcoidosis.
Serum angiotensin-converting enzyme and delayed hypersensitivity in pulmonary tuberculosis.
Serum angiotensin-converting enzyme as a marker for the chronic fatigue-immune dysfunction syndrome: a comparison to serum angiotensin-converting enzyme in sarcoidosis.
Serum angiotensin-converting enzyme estimation and the Kveim-Siltzbach test in sarcoidosis.
Serum angiotensin-converting enzyme for diagnosis and therapeutic evaluation of sarcoidosis.
Serum Angiotensin-Converting Enzyme Has a High Negative Predictive Value in the Investigation for Systemic Sarcoidosis.
Serum angiotensin-converting enzyme in leprosy and coccidioidomycosis.
Serum angiotensin-converting enzyme in sarcoidosis and other diseases.
Serum angiotensin-converting enzyme in sarcoidosis and psoriasis.
Serum angiotensin-converting enzyme in sarcoidosis.
Serum angiotensin-converting enzyme is elevated in association with underground coal mining.
Serum angiotensin-converting enzyme levels in patients with chronic renal failure.
Serum angiotensin-converting enzyme levels in patients with pigeon-breeder's disease.
Serum angiotensin-converting enzyme levels in sarcoid arthritis.
Serum angiotensin-converting enzyme: elevations in diabetes mellitus.
Serum angiotensin-I-converting enzyme and lysozyme levels in untreated and unsplenectomized patients with Hodgkin's disease.
Serum beta-2-microglobulin and angiotensin-converting enzyme activity in sarcoidosis.
Serum concentrations of ionized calcium reflect renal function in patients with sarcoidosis.
Serum levels of chitotriosidase as a marker of disease activity and clinical stage in sarcoidosis.
Serum levels of interleukin-8 as a marker of disease activity in patients with chronic sarcoidosis.
Serum lysozyme levels and clinical features of sarcoidosis.
Serum protein electrophoretic pattern and angiotensin-converting enzyme in sarcoidosis.
Serum soluble interleukin-2 receptor level is more sensitive than angiotensin-converting enzyme or lysozyme for diagnosis of sarcoidosis and may be a marker of multiple organ involvement.
Significance of serum angiotensin converting enzyme and gallium scan in noninvasive diagnosis of sarcoidosis.
Significance of the interleukin-1 receptor antagonist/interleukin-1 beta ratio as a prognostic factor in patients with pulmonary sarcoidosis.
Similarity in some properties of serum angiotensin converting enzyme from sarcoidosis patients and normal subjects.
Simple radioassay for measuring serum activity of angiotensin-converting enzyme in sarcoidosis.
Soluble interleukin 2 receptors in patients with sarcoidosis. Possible origin.
Spectrophotometry of angiotensin-converting enzyme in sarcoidosis.
Sphenoid sinus brown tumor, hypercalcemia, and blindness: an unusual presentation of primary hyperparathyroidism.
Studies with an automated kinetic assay for plasma angiotensin-converting enzyme activity and its potentiation by zinc ion.
Subcutaneous sarcoidosis of the upper and lower extremities: A case report and review of the literature.
Systemic and lung protein changes in sarcoidosis. Lymphocyte counts, gallium uptake values, and serum angiotensin-converting enzyme levels may reflect different aspects of disease activity.
Systemic sarcoidosis: a case with a focal hydrocephalus and elevated lysozyme and angiotensin-converting enzyme in the cerebrospinal fluid.
Talc granulomatosis: two unusual presentations.
TARC expression in the circulation and cutaneous granulomas correlates with disease severity and indicates Th2-mediated progression in patients with sarcoidosis.
Tattoo skin reaction as a skin manifestation of systemic sarcoidosis.
Tertiary syphilis and Kaposi sarcoma mistaken for systemic sarcoidosis in an HIV-negative patient.
The ACE gene I/D polymorphism does not affect the susceptibility to or prognosis of PBC.
The angiotensin-converting enzyme DD gene is associated with poor prognosis in Finnish sarcoidosis patients.
The Comparative Value of Serum Angiotensin Converting Enzyme (ACE) and Lysozyme and the Use of Polyclonal Antibody Activation in the Work-up of Ocular Sarcoidosis.
The fine page. Serum angiotensin-converting enzyme activity in sarcoidosis.
The immunocytochemical detection of angiotensin-converting enzyme in alveolar macrophages from patients with sarcoidosis.
The influence of prednisone on serum angiotensin-converting enzyme activity in patients with and without sarcoidosis.
The investigation of nasal septal perforations and ulcers.
The predictive value of serum angiotensin converting enzyme and lysozyme levels in the diagnosis of ocular sarcoidosis.
The predictive value of serum angiotensin-converting enzyme activity in the differential diagnosis of hypercalcemia.
The relationship between fatigue and clinical parameters in pulmonary sarcoidosis.
The roentgenographic staging of sarcoidosis. Historic and contemporary perspectives.
The serum angiotensin converting enzyme and lysozyme levels in patients with ocular involvement of autoimmune and infectious diseases.
The usefulness of serum angiotensin-converting enzyme test in the diagnosis of sarcoidosis.
The value of combined serum angiotensin-converting enzyme and gallium scan in diagnosing ocular sarcoidosis.
Thermolysin-like serum metalloendopeptidase. A new marker for active sarcoidosis that complements serum angiotensin-converting enzyme.
Treatment of pulmonary sarcoidosis: a practical guide.
Tumoral calcinosis associated with hypercalcemia in a patient with chronic renal failure.
Unilateral papilloedema in a 12 year old girl--a surprising diagnosis.
Urinary neopterin in pulmonary sarcoidosis. Relationship to clinical and biologic assessment of the disease.
Usefulness of Combined Measurement of Serum Soluble IL-2R and Angiotensin-Converting Enzyme in the Detection of Uveitis Associated with Japanese Sarcoidosis.
Usefulness of quantifying serum KL-6 levels in the follow-up of uveitic patients with sarcoidosis.
Utility of angiotensin-converting enzyme activity in aqueous humor in the diagnosis of ocular sarcoidosis.
Uveitis associated with sarcoidosis and angiotensin converting enzyme.
Value of measuring serum angiotensin I converting enzyme and serum lysozyme in the management of sarcoidosis.
Value of s-ACE, BAL lymphocytosis, and CD4+/CD8+ and CD103+CD4+/CD4+ T-cell ratios in diagnosis of sarcoidosis.
Value of serial measurement of serum angiotensin converting enzyme in the management of sarcoidosis.
Vascular involvement in cutaneous sarcoidosis.
Verifying Sarcoidosis Activity: Chitotriosidase versus ACE in Sarcoidosis - a Case-control Study.
Vitritis as the primary manifestation of ocular syphilis in patients with HIV infection.
X-linked chronic granulomatous disease (CGD) caused by an intra-exonic splice mutation (CYBB exon 3, c.262G->A) is mimicking juvenile sarcoidosis.
YKL-40, Soluble IL-2 Receptor, Angiotensin Converting Enzyme and C-Reactive Protein: Comparison of Markers of Sarcoidosis Activity.
[A case of elderly onset sarcoidosis]
[A case of palpable nodular type of muscular sarcoidosis with special reference to serum angiotensin-converting enzyme (SACE)]
[A case of pulmonary alveolar proteinosis with elevated serum angiotensin-converting enzyme activity]
[A case of relapsing sarcoidosis with pleurisy 14 years after spontaneous remission]
[A case of sarcoidosis presenting with high fever and rash progressing to acute respiratory failure]
[A case of so-called Lennert's lymphoma, suspected of sarcoidosis due to uveitis occurring first and elevation of serum angiotensin-converting enzyme (ACE)]
[A clinical study on 8 cases of sarcoidosis with a cervical mass as a symptom].
[A male case of primary Sjögren's syndrome with interstitial pneumonitis and interstitial tubulo-nephritis in the absence of dry eye and dry mouth: parotid gland MRI is a useful diagnostic method for Sjögren's syndrome]
[A patient with type ZZ alpha 1-antitrypsin deficiency and hypercalcemia caused by sarcoidosis]
[Activity of angiotensin I converting enzyme in sarcoidosis - personal experience]
[Activity of angiotensin I converting enzyme in serum and bronchoalveolar lavage fluid of patients with sarcoidosis and lung neoplasms]
[Advantage of the serum measurement of angiotensin I converting enzyme in sarcoidosis]
[Angiotensin converting enzyem (ACE) - a blood chemistry parameter in the diagnosis of sarcoidosis]
[Angiotensin converting enzyme (ACE) a bloodtest for diagnosis of sarcoidosis (author's transl)]
[Angiotensin converting enzyme activity in the serum of patients with sarcoidosis]
[Angiotensin converting enzyme and sarcoidosis]
[Angiotensin converting enzyme as a diagnostic aid in newly diagnosed sarcoidosis compared with pulmonary cancer and tuberculosis]
[Angiotensin converting enzyme in sarcoidosis]
[Angiotensin converting enzyme, lysozyme and circulating immune complexes in the serum of patients with sarcoidosis and other interstitial lung diseases]
[Angiotensin I converting enzyme and carboxypeptidase B-like enzymes in sarcoidosis and other lung diseases]
[Angiotensin I-converting enzyme (ACE) for sarcoidosis diagnosis]
[Angiotensin-converting enzyme (ACE) in sarcoidosis, tuberculosis, silicosis, and coal mining workers]
[Angiotensin-converting enzyme (ACE) polymorphism and serum ACE activities in sarcoidosis]
[Angiotensin-converting enzyme as a follow-up parameter in sarcoidosis]
[Angiotensin-converting enzyme in sarcoidosis: diagnostic and prognostic value (author's transl)]
[Angiotensin-converting enzyme in sarcoidosis]
[Assay of angiotensin converting enzyme (ACE) in thoracic forms of sarcoidosis and other pulmonary diseases]
[Berylliosis in Italy: a case of "sarcoidosis" under the threshold limit value]
[Bilateral recurrent blurred vision associated with halos around sources of light and headache].
[Blood serum angiotensin converting enzyme and its clinical significance in treating sarcoidosis]
[Branch retinal vein occlusion and sarcoidosis in a child: A case report.]
[Case of sarcoidosis with squamous cell carcinoma which originated from solitary bronchial papilloma].
[Case report: A case of Hodgkin lymphoma required a differential diagnosis from sarcoidosis due to elevated serum level of angiotensin converting enzyme (ACE)].
[Clinical significance of serum levels of angiotensin-converting enzyme and lysozyme in sarcoidosis, with special reference to its prognosis and reaction to steroids]
[Clinical significance of the angiotensin-converting enzyme in the serum in sarcoidosis]
[Clinical value of the estimation of plasma converting enzyme activity]
[Comparative evolution of bronchoalveolar lavage cells, angiotensin I converting enzyme, serum lysozyme, circulating immune complexes and gallium scintigraphy in mediastinopulmonary sarcoidosis]
[Comparison of angiotensin converting enzyme activity in the serum of patients with sarcoidosis vs. extrinsic pulmonary granulomatosis]
[Conjunctival biopsy: a useful procedure for the diagnosis of sarcoidosis.]
[Correlation between bronchoalveolar lavage fluid angiotensin converting enzyme levels and T cell subsets in patients with sarcoidosis]
[Criteria for the evaluation of the activity of sarcoidosis by bronchoalveolar lavage and angiotensin converting enzyme in the serum]
[Cutaneous lesions during hot-tub hypersensitivity pneumonitis: Pseudomonas folliculitis ?]
[Diagnosis in sarcoidosis. Sensitivity and specificity of 67-gallium scintigraphy, serum angiotensin converting enzyme levels, thoracic radiography and blood lymphocyte subpopulations]
[Diagnostic value of serum angiotensin converting enzyme activity in sarcoidosis (author's transl)]
[Diagnostic, prognostic and developmental value of serum angiotensin converting enzyme in sarcoidosis]
[Early onset pediatric sarcoidosis, diagnostic problems].
[Elevated negative predictive value of angiotensin converting enzyme in the diagnosis of active sarcoidosis]
[Elevation of serum angiotensin converting enzyme (ACE) during treatment]
[Endoscope-assisted biopsy for the diagnosis of neurosarcoidosis]
[Evaluation of measurement of serum angiotensin-converting enzyme (S-ACE) level in sarcoidosis (author's transl)]
[Evaluation of revised diagnosis criteria for sarcoidosis]
[Fasciitis in granulomatous myositis--an atypical manifestation of sarcoidosis?]
[Gallium scintigraphy as an indicator of sarcoidosis activity. Comparison with roentgenographic findings, functional pulmonary tests, cytologic examination of bronchoalveolar fluid and blood levels of angiotensin converting enzyme]
[Immunohistochemical localization of angiotensin converting enzyme in epithelioid sarcoidosis granulomas]
[Increased concentration of angiotensin I converting enzyme in the alveolar fluid of patients with sarcoidosis]
[Increased serum activity of angiotensin-converting enzyme (ACE): indication of sarcoidosis? A 'Bayesian' approach]
[Kininase II (SACE) and renin in sarcoidosis patients and healthy probands in exercise testing]
[Levels of soluble CD4 and soluble CD8 in patients with sarcoidosis]
[Lichenoid sarcoidosis]
[Localization of angiotensin converting enzyme (ACE) in granulomas of sarcoidosis of the skin]
[Lymphocyte subsets of peripheral blood in patients with sarcoidosis]
[Malignant lymphoma and sarcoidosis. Changes in the serum levels of angiotensin-converting enzyme]
[Modern criteria of sarcoidosis activity and approaches to glucocorticoid therapy]
[Neurosarcoidosis presenting with severe hyposmia and polyradiculopathy].
[Orbital sarcoidosis--a case with an unusual course]
[Posterior uveitis: sarcoidosis or tuberculosis]
[Practical value of serum angiotensin converting enzyme levels in sarcoidosis. Current results]
[Practical value of the assay of serum angiotensin converting enzyme activity in sarcoidosis]
[Procollagen III-peptide and angiotensin converting enzyme in bronchoalveolar lavage in sarcoidosis]
[Prognostic value of measuring serum angiotensin I-converting enzyme (ACE) in patients with sarcoidosis]
[Psycho-neurological symptoms and raised angiotensin-converting enzyme in cerebrospinal fluid in a patient with sarcoidosis beginning in the central nervous system]
[Sarcoid uveitis: Diagnostic and therapeutic update.]
[Sarcoidosis and the serum angiotensin-converting enzyme (ACE) level]
[Sarcoidosis in a child disclosed by blindness with major hypercalcemia]
[Sarcoidosis localized in endocrine glands]
[Sarcoidosis presenting as partial seizures. Report of one case]
[Sarcoidosis with hematologic involvement and hypogammaglobulinemia]
[Sarcoidosis-lymphoma syndrome showing abnormal FDG uptake in lymph nodes and muscles upon post-chemotherapy PET/CT imaging].
[Sarcoidosis. Critical review on immunology in sarcoidosis and serum angiotensin converting enzyme in sarcoidosis (author's transl)]
[Scintigraphy of the thoracic lymph nodes and lungs using Ga-67 citrate in combined examination of patients with sarcoidosis]
[Serum adenosine deaminase and angiotensin converting enzyme activity in patients with endogenous uveitis]
[Serum angiotensin converting enzyme (ACE) activity in sarcoidosis]
[Serum angiotensin converting enzyme activity in sarcoidosis. A review of seventy cases]
[Serum angiotensin converting enzyme in sarcoidosis and other diseases. A review based on 2 1/2 years analysis of 1 601 patients]
[Serum angiotensin converting enzyme in the diagnosis of sarcoidosis and other lung diseases]
[Serum angiotensin-converting enzyme and its clinical value in sarcoidosis treatment]
[Serum angiotensin-converting enzyme and serum lysozyme in sarcoidosis and other granulomatous diseases]
[Serum angiotensin-converting enzyme levels in sarcoidosis with cutaneous lesions]
[Serum level of angiotensin-converting enzyme in sarcoidosis. Attempted correlation with the clinical activity of the disease (author's transl)]
[The behavior of angiotensin-converting enzyme in patients with uveitis]
[The diagnosis of sarcoidosis based on ocular manifestations]
[The importance of the angiotensin converting enzyme in evaluating the activity of sarcoidosis]
[The prognostic evaluation of clinical course in sarcoidosis by initial serum angiotensin converting enzyme level (author's transl)]
[The significance of angiotensin-converting enzyme in sarcoidosis]
[The significance of biochemical data of patients with sarcoidosis]
[Two siblings with sarcoidosis diagnosed by younger sister's central nervous symptoms]
[Undifferentiated adenocarcinoma of the lung associated with sarcoidosis--differential diagnosis]
[Unusual case of disseminated sarcoidosis with prominent gastrointestinal symptoms]
[Value of angiotensin I-converting enzyme in the diagnosis of sarcoidosis (author's transl)]
[Value of determining angiotensin converting enzyme activity in the differential diagnosis of sarcoidosis]
[Value of the cytologic and biochemical study of alveolar lavage fluid in the evaluation of the developmental ability of sarcoidosis]
[Variations in plasma angiotensin-converting enzyme and renin in sarcoidosis]
[Weight loss, joint pain and abdominal lymphadenopathy as signs of sarcoidosis, but also of Whipple's disease]
Sarcoidosis, Pulmonary
67Ga scintigraphy, serum lysozyme and angiotensin-converting enzyme in pulmonary sarcoidosis.
Activation of alveolar macrophages in pulmonary sarcoidosis: lack of correlation with serum angiotensin-converting enzyme activity.
Activation of bronchoalveolar lavage T lymphocytes and clinical, functional and radiological features in sarcoidosis.
Angiotensin converting enzyme in bronchoalveolar lavage fluid in pulmonary sarcoidosis.
Angiotensin-converting enzyme and pulmonary sarcoidosis.
Angiotensin-converting enzyme gene polymorphisms in patients with pulmonary sarcoidosis: impact on disease severity.
Annular lesion of the lung in sarcoidosis.
Behaviour of angiotensin converting enzyme, hydroxyproline and some protease inhibitors in pulmonary sarcoidosis.
Characteristics of patients presenting with erythema nodosum and sarcoidosis.
Circulating levels of tartrate-resistant acid phosphatase in macrophage-activated lung disease.
Coexistent sarcoidosis and lymphangioleiomyomatosis in a patient with cystic lung disease.
Comparison of gallium-67 scanning, bronchoalveolar lavage, and serum angiotensin-converting enzyme levels in pulmonary sarcoidosis. Predicting response to therapy.
Correlative analysis of longitudinal changes in bronchoalveolar lavage, 67gallium scanning, serum angiotensin-converting enzyme activity, chest X-ray, and pulmonary function tests in pulmonary sarcoidosis.
Corticosteroid treatment in pulmonary sarcoidosis: do serial lavage lymphocyte counts, serum angiotensin converting enzyme measurements, and gallium-67 scans help management?
Diagnostic aspects of angiotensin converting enzyme in pulmonary sarcoidosis.
Does serum angiotensin converting enzyme reflect intensity of alveolitis in sarcoidosis?
Effects of sarcoid and steroids on angiotensin-converting enzyme.
Hypercalcemia of sarcoidosis treated with cellulose sodium phosphate.
Impaired Vascular Function in Sarcoidosis Patients.
Ionized calcium and 1,25-dihydroxyvitamin D concentration in serum of patients with sarcoidosis.
Lavage versus serum measurements of lysozyme, angiotensin converting enzyme and other inflammatory markers in pulmonary sarcoidosis.
Long-term use of corticosteroid eye drops delays the spontaneous remission of pulmonary sarcoidosis.
Lung inflammation in sarcoidosis: comparison of serum angiotensin-converting enzyme levels with bronchoalveolar lavage and gallium-67 scanning assessment of the T lymphocyte alveolitis.
Prediction of therapeutic response in steroid-treated pulmonary sarcoidosis. Evaluation of clinical parameters, bronchoalveolar lavage, gallium-67 lung scanning, and serum angiotensin-converting enzyme levels.
Predictive value of gallium scan, angiotensin-converting enzyme level, and bronchoalveolar lavage in two-year follow-up of pulmonary sarcoidosis.
Propeptide levels of type III and type I procollagen in the serum and bronchoalveolar lavage fluid of patients with pulmonary sarcoidosis.
Pulmonary sarcoidosis and serum angiotensin-converting enzyme.
Pulmonary sarcoidosis: correlation of serum angiotensin-converting enzyme with blood and bronchoalveolar lymphocytes.
Relationship between circulating immune complexes and angiotensin-converting enzyme in pulmonary sarcoidosis.
Relationship between CT activity score with lung function and the serum angiotensin converting enzyme in pulmonary sarcoidosis on chest HRCT.
Respiratory clearance of 99mTc-DTPA and pulmonary involvement in sarcoidosis.
Retrograde radiographic development in pulmonary sarcoidosis.
Serial measurements of serum angiotensin-converting enzyme and steroid therapy for pulmonary sarcoidosis.
Serum angiotensin converting enzyme in the diagnosis of pulmonary sarcoidosis.
Serum angiotensin-converting enzyme in sarcoidosis and psoriasis.
Sinonasal sarcoidosis: review and report of fifteen cases.
Studies of peripheral blood monocytes in pulmonary sarcoidosis.
The angiotensin converting enzyme in pulmonary sarcoidosis and the relative diagnostic value of serum lysozyme.
The level of angiotensin-converting enzyme as indicator of 2-year prognosis in untreated pulmonary sarcoidosis without erythema nodosum.
The relationship between disease duration and noninvasive pulmonary explorations in sarcoidosis with erythema nodosum.
The value of angiotensin-I-converting enzyme determinations in malignant and other diseases.
Use of likelihood ratios improves interpretation of laboratory testing for pulmonary sarcoidosis.
[A case of pulmonary sarcoidosis complicated with bronchial asthma that proved eosinophilic invasion].
[Clinical significance of serum KL-6 in pulmonary sarcoidosis]
[Determination of angiotensin-converting enzyme activity in internal diseases]
[Diagnosis in sarcoidosis. Sensitivity and specificity of 67-gallium scintigraphy, serum angiotensin converting enzyme levels, thoracic radiography and blood lymphocyte subpopulations]
[Diagnostic, prognostic and developmental value of serum angiotensin converting enzyme in sarcoidosis]
[Evaluation of the activity of angiotensin I converting enzyme (ACE) and of humoral immunity in patients with active pulmonary sarcoidosis]
[Serum level of angiotensin-converting enzyme in sarcoidosis. Attempted correlation with the clinical activity of the disease (author's transl)]
Sarcoma, Kaposi
Advances in the pathobiology and treatment of Kaposi sarcoma.
Increased levels of angiotensin-converting enzyme activity in Kaposi's sarcoma.
Wound healing: captopril, an angiogenesis inhibitor, and Staphylococcus aureus peptidoglycan.
Sarcoma, Yoshida
Tumor-selective blood flow decrease induced by an angiotensin converting enzyme inhibitor, temocapril hydrochloride.
Sarcopenia
An overview of sarcopenia: facts and numbers on prevalence and clinical impact.
Angiotensin-Converting Enzyme Inhibitors and Parameters of Sarcopenia: Relation to Muscle Mass, Strength and Function: Data from the Berlin Aging Study-II (BASE-II).
Comprehensive approach to sarcopenia treatment.
Effects of enalapril or nifedipine on muscle strength or functional capacity in elderly subjects. A double blind trial.
From muscle wasting to sarcopenia and myopenia: update 2012.
Leucine and ACE inhibitors as therapies for sarcopenia (LACE trial): study protocol for a randomised controlled trial.
Reassessing Sarcopenia in Hypertension: STAR and ACE Inhibitors Excel.
Sarcopenia, obesity, and inflammation--results from the Trial of Angiotensin Converting Enzyme Inhibition and Novel Cardiovascular Risk Factors study.
Sarcopenia--a potential target for Angiotensin-converting enzyme inhibition?
Sarcopenia.
The emergence of sarcopenia as an important entity in older people.
Schistosomiasis
Alteration of granuloma angiotensin I-converting enzyme activity by regulatory T lymphocytes in murine schistosomiasis.
Alteration of the granulomatous response in murine schistosomiasis by the chronic administration of captopril, an inhibitor of angiotensin-converting enzyme.
Angiotensin-converting enzyme and other enzymes in livers of mice with experimental schistosomiasis.
Effect of SQ 14225, an inhibitor of angiotensin I-converting enzyme, on the granulomatous response to Schistosoma mansoni eggs in mice.
Enhanced granuloma angiotensin I converting enzyme activity associated with modulation in murine schistosomiasis.
Production of angiotensin I converting enzyme by liver granuloma macrophages of Schistosoma mansoni infected mice.
Schistosoma mansoni: angiotensin converting enzyme activity in mice under the influence of praziquantel and/or captopril.
[Increase in angiotensin converting enzyme levels in schistosomiasis]
Schistosomiasis mansoni
Alteration of granuloma angiotensin I-converting enzyme activity by regulatory T lymphocytes in murine schistosomiasis.
Induction of granuloma-dependent angiotensin-converting enzyme and eosinophil chemotactic factor in the skin of athymic nude mice.
Scleroderma, Diffuse
Deterioration of renal function in hypertensive patients with scleroderma despite blood pressure normalization with captopril.
Scleroderma, Systemic
An International, Web-Based, Prospective Cohort Study to Determine Whether the Use of ACE Inhibitors prior to the Onset of Scleroderma Renal Crisis Is Associated with Worse Outcomes-Methodology and Preliminary Results.
Angiotensin converting enzyme: an in vivo and in vitro marker of endothelial injury.
Angiotensin-converting enzyme gene does not contribute to genetic susceptibility to systemic sclerosis in European Caucasians.
Angiotensin-converting enzyme gene insertion/deletion polymorphism in korean patients with systemic sclerosis.
Angiotensin-converting enzyme I/D polymorphism and macrovascular disease in systemic sclerosis.
Angiotensin-converting enzyme in systemic sclerosis: from endothelial injury to a genetic polymorphism.
Angiotensin-converting enzyme insertion/deletion polymorphism and susceptibility to systemic sclerosis: a meta-analysis.
Arterial hypertension treated with angiotensin converting enzyme inhibitors and glucocorticoids are independent risk factors associated with decreased glomerular filtration rate in systemic sclerosis.
Clinical correlations of plasma angiotensin converting enzyme (ACE) activity in systemic sclerosis: a longitudinal study of plasma ACE level, endothelial injury and lung involvement.
Enalapril (10 mg/day) in systemic sclerosis. One year, double blind, randomised study (ESS-1): ECG exercise testing--three months follow-up.
High prevalence of polymorphisms of angiotensin-converting enzyme (I/D) and endothelial nitric oxide synthase (Glu298Asp) in patients with systemic sclerosis.
Hypertensive crisis in systemic sclerosis: treatment with the new oral angiotensin converting enzyme inhibitor MK, 421 (Enalapril) in captopril-intolerant patients.
Lack of efficacy of quinapril on vascular damage in limited cutaneous systemic sclerosis.
Long-term outcomes of scleroderma renal crisis.
Outcome of renal crisis in systemic sclerosis: relation to availability of angiotensin converting enzyme (ACE) inhibitors.
Polymorphisms of endothelial nitric oxide synthase and angiotensin-converting enzyme in systemic sclerosis.
Prevention of vascular damage in scleroderma and autoimmune Raynaud's phenomenon: A multicenter, randomized, double-blind, placebo-controlled trial of the angiotensin-converting enzyme inhibitor quinapril.
Recovery of renal function in undifferentiated connective tissue disease after treatment with angiotensin-converting enzyme inhibitors.
Reduced angiotensin converting enzyme plasma activity in scleroderma. A marker of endothelial injury?
Renal transplantation in scleroderma.
Scleroderma Renal Crisis: Risk Factors for an Increasingly Rare Organ Complication.
Scleroderma--clinical and pathological advances.
Systemic and localized scleroderma.
Treatment of scleroderma.
Unusual case of pulmonary renal syndrome with autopsy findings.
Vascular injury in systemic sclerosis: angiotensin-converting enzyme insertion/deletion polymorphism.
[Renal involvement in connective tissue diseases]
Scoliosis
Genetic ACE I/D and ACTN3 R577X polymorphisms and adolescent idiopathic scoliosis.
Seizures
Analysis of risk factors for chronic subdural haematoma recurrence after burr hole surgery: Optimal management of patients on antiplatelet therapy.
Effect of ACE inhibitors and AT1 receptor antagonists on pentylenetetrazole-induced convulsions in mice.
Epilepsy Seizures in Spontaneously Hypertensive Rats After Acoustic Stimulation: Role of Renin-Angiotensin System.
Evidence-based management for preeclampsia.
Fosinopril and zofenopril, two angiotensin-converting enzyme (ACE) inhibitors, potentiate the anticonvulsant activity of antiepileptic drugs against audiogenic seizures in DBA/2 mice.
Highlights of the 22nd French pharmacovigilance meeting.
Treatment-resistant bipolar depression: concepts and challenges for novel interventions.
Seminoma
Mediastinal Seminoma with an Elevated Level of Serum Angiotensin-converting Enzyme.
Reduced semen quality in patients with testicular cancer seminoma is associated with alterations in the expression of sperm proteins.
[CD143 expression in testicular germ cell tumors]
Sepsis
Activity of serum angiotensin converting enzyme in septic pigs treated with intrapulmonary corticosteroid.
Angiotensin converting enzyme insertion/deletion polymorphism does not alter sepsis outcome in ventilated very low birth weight infants.
Angiotensin-converting enzyme (ACE) in sepsis.
Angiotensin-converting enzyme insertion/deletion polymorphism is not associated with susceptibility and outcome in sepsis and acute respiratory distress syndrome.
Antihypertensive agents acting on the renin angiotensin system and the risk of sepsis.
Association between angiotensin-converting enzyme I/D polymorphism and sepsis: A meta-analysis.
Association of the ACE I/D gene polymorphism with sepsis susceptibility and sepsis progression.
Chronic Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers Is High Among Intensive Care Unit Patients With Non-COVID-19 Sepsis but Carries a Moderately Increased Risk of Death.
COVID-19 and Kidney Disease: Update on Epidemiology, Clinical Manifestations, Pathophysiology and Management.
Decreased serum angiotensin converting enzyme in adult respiratory distress syndrome associated with sepsis: a preliminary report.
Effect of angiotensin converting enzyme inhibitor and angiotensin II receptor blocker on the patients with sepsis.
Effect of Antihypertensive Medications on Sepsis-Related Outcomes: A Population-Based Cohort Study.
Effects of the angiotensin converting enzyme inhibitor enalapril on bacterial translocation after thermal injury and bacterial challenge.
Genetic basis for necrotizing enterocolitis--risk factors and their relations to genetic polymorphisms.
Genetic Dissection of the Regulatory Mechanisms of Ace2 in the Infected Mouse Lung.
Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers on Acute Kidney Injury in Emergency Medical Admissions.
Increased susceptibility of sepsis associated with CD143 deletion/insertion polymorphism in Caucasians: a meta analysis.
Preadmission Antihypertensive Drug Use and Sepsis Outcome: Impact of Angiotensin-Converting Enzyme Inhibitors (ACEIs) and Angiotensin Receptor Blockers (ARBs).
Pulmonary midkine inhibition ameliorates sepsis induced lung injury.
Risk of Sepsis and Mortality Among Patients With Chronic Obstructive Pulmonary Disease Treated With Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers.
Role of angiotensin-converting enzyme gene polymorphisms in children with sepsis and septic shock.
Systemic and regional hemodynamic effects of enalaprilat infusion in experimental normotensive sepsis.
The protective effects of angiotensin-converting enzyme inhibitor against cecal ligation and puncture-induced sepsis via oxidative stress and inflammation.
Underuse of standard care and outcome of patients with acute myocardial infarction and chronic renal insufficiency.
Vasoplegic syndrome: An update on perioperative considerations.
[Relationship of single nucleotide polymorphisms and genetic susceptibility to sepsis].
Severe Acute Respiratory Syndrome
A Fatal Extrapulmonary Manifestation of COVID-19.
Absence of association between angiotensin converting enzyme polymorphism and development of adult respiratory distress syndrome in patients with severe acute respiratory syndrome: a case control study.
Amino acid substitutions in the s2 region enhance severe acute respiratory syndrome coronavirus infectivity in rat angiotensin-converting enzyme 2-expressing cells.
Angiotensin II receptor blocker or angiotensin-converting enzyme inhibitor use and COVID-19-related outcomes among US Veterans.
Angiotensin-converting enzyme 2, the SARS-CoV-2 cellular receptor, is widely expressed in human myometrium and uterine leiomyoma.
Angiotensin-converting Enzyme 2-containing Small Extracellular Vesicles and Exomeres Bind the Severe Acute Respiratory Syndrome Coronavirus 2 Spike Protein.
Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers Use and COVID-19 Infection Among 824 650 Patients With Hypertension From a US Integrated Healthcare System.
Antecedent Administration of Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Receptor Antagonists and Survival After Hospitalization for COVID-19 Syndrome.
Association of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers With the Risk of Hospitalization and Death in Hypertensive Patients With COVID-19.
Associations Between the Use of Renin-Angiotensin System Inhibitors and the Risks of Severe COVID-19 and Mortality in COVID-19 Patients With Hypertension: A Meta-Analysis of Observational Studies.
Autophagy as an emerging target for COVID-19: lessons from an old friend, chloroquine.
Cardiovascular damage due to COVID-19: what do we need to know?
Classical and Counter-Regulatory Renin-Angiotensin System: Potential Key Roles in COVID-19 Pathophysiology.
Clinical characteristics and outcomes of critically ill patients with COVID-19 in a tertiary community hospital in upstate New York.
Combating sars-cov-2 through lipoxins, proteasome, caveolin and nuclear factor-?b pathways in non-pregnant and pregnant populations.
Considerations on the use of antihypertensive blockers of the renin-angiotensin system in adults and children in the face of the COVID-19 pandemic.
Continuing versus suspending angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: Impact on adverse outcomes in hospitalized patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)--The BRACE CORONA Trial.
Coronavirus Disease 2019 (COVID-19) and Cardiovascular Disease: A Viewpoint on the Potential Influence of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers on Onset and Severity of Severe Acute Respiratory Syndrome Coronavirus 2 Infection.
Coronavirus disease 2019 (COVID-19) and the renin-angiotensin system: A closer look at angiotensin-converting enzyme 2 (ACE2).
Coronavirus Disease 2019 and Nasal Conditions: A Review of Current Evidence.
Correcting the imbalanced protective RAS in COVID-19 with angiotensin AT2-receptor agonists.
COVID-19 and cardiac injury: clinical manifestations, biomarkers, mechanisms, diagnosis, treatment, and follow up.
Decoding the silent walk of COVID-19: Halting its spread using old bullets.
Diabetes and COVID-19: evidence, current status and unanswered research questions.
Differential expression of angiotensin-converting enzyme-2 in human paranasal sinus mucosa in patients with chronic rhinosinusitis.
Dipeptidylpeptidase-4 levels and DPP4 gene polymorphisms in patients with COVID-19. Association with disease and with severity.
Dual function of sialic acid in gastrointestinal SARS-CoV-2 infection.
Effect of COVID-19 on Male Reproductive System - A Systematic Review.
Electronic Cigarette Aerosol Is Cytotoxic and Increases ACE2 Expression on Human Airway Epithelial Cells: Implications for SARS-CoV-2 (COVID-19).
Elevated FiO2 increases SARS-CoV-2 co-receptor expression in respiratory tract epithelium.
Engineered ACE2 receptor traps potently neutralize SARS-CoV-2.
Future Challenges of Covid-19 and Oral Manifestations in Daily Dental Practice: A Literature Review.
Gastrointestinal manifestations of coronavirus disease 2019.
Human Lung Stem Cell-Based Alveolospheres Provide Insights into SARS-CoV-2-Mediated Interferon Responses and Pneumocyte Dysfunction.
Identification of critical active-site residues in angiotensin-converting enzyme-2 (ACE2) by site-directed mutagenesis.
Impact of sex and gender on COVID-19 outcomes in Europe.
Important Management Considerations In Patients With Pituitary Disorders During The Time Of The Covid-19 Pandemic.
Increased susceptibility to SARS-CoV-2 infection in patients with reduced left ventricular ejection fraction.
Influence of aging on deterioration of patients with COVID-19.
Inhibition of endoplasmic reticulum-resident glucosidases impairs severe acute respiratory syndrome coronavirus and human coronavirus NL63 spike protein-mediated entry by altering the glycan processing of angiotensin I-converting enzyme 2.
Interactions between antihyperglycemic drugs and the renin-angiotensin system: Putative roles in COVID-19. A mini-review.
Little to no expression of angiotensin-converting enzyme-2 on most human peripheral blood immune cells but highly expressed on tissue macrophages.
Lower Serum Angiotensin-Converting Enzyme Level in Relation to Hyperinflammation and Impaired Antiviral Immune Response Contributes to Progression of COVID-19 Infection.
Neither ACEIs nor ARBs are associated with respiratory distress or mortality in COVID-19 results of a prospective study on a hospital-based cohort.
Oroxylin A is a severe acute respiratory syndrome coronavirus 2-spiked pseudotyped virus blocker obtained from Radix Scutellariae using angiotensin-converting enzyme II/cell membrane chromatography.
Outcomes of COVID-19 Hospitalized Patients Previously Treated with Renin-Angiotensin System Inhibitors.
Patients taking angiotensin-converting enzyme inhibitors/angiotensin II type I receptor blockers: higher risks of severe acute respiratory syndrome coronavirus 2 infection but milder clinical manifestations?
Peripheral blood microRNAs and the COVID-19 patient: methodological considerations, technical challenges and practice points.
Polycystic ovary syndrome: Pathways and mechanisms for possible increased susceptibility to COVID-19.
Potential benefits of dietary seaweeds as protection against COVID-19.
Prognostic Value of Troponin Elevation in COVID-19 Hospitalized Patients.
Regulation Mechanism for the Binding between the SARS-CoV-2 Spike Protein and Host Angiotensin-Converting Enzyme II.
Renin-Angiotensin System Inhibition in Cardiovascular Patients at the Time of COVID19: Much Ado for Nothing? A Statement of Activity from the Directors of the Board and the Scientific Directors of the Italian Society of Hypertension.
Renin-angiotensin-aldosterone system and COVID-19 infection.
Renin-angiotensin-aldosterone system inhibitors and SARS-CoV-2 infection: an analysis from the veteran's affairs healthcare system.
Renin-angiotensin-system inhibition in the context of corona virus disease-19: experimental evidence, observational studies, and clinical implications.
Retinal Microcirculation as a Correlate of a Systemic Capillary Impairment After Severe Acute Respiratory Syndrome Coronavirus 2 Infection.
Role of the Backbenchers of the Renin-Angiotensin System ACE2 and AT2 Receptors in COVID-19: Lessons From SARS.
Severe acute respiratory syndrome coronavirus 2 infection, angiotensin-converting enzyme 2 and treatment with angiotensin-converting enzyme inhibitors or angiotensin II type 1 receptor blockers.
Severe acute respiratory syndrome coronavirus 2 is penetrating to dementia research.
Sex, Hormones, Immune Functions, and Susceptibility to Coronavirus Disease 2019 (COVID-19)-Related Morbidity.
Single-cell analysis of angiotensin-converting enzyme II expression in human kidneys and bladders reveals a potential route of 2019 novel coronavirus infection.
Smoking Upregulates Angiotensin-Converting Enzyme-2 Receptor: A Potential Adhesion Site for Novel Coronavirus SARS-CoV-2 (Covid-19).
Snake venom-derived bradykinin-potentiating peptides: A promising therapy for COVID-19?
Spironolactone may provide protection from SARS-CoV-2: Targeting androgens, angiotensin converting enzyme 2 (ACE2), and renin-angiotensin-aldosterone system (RAAS).
Stroke Care during the COVID-19 Pandemic: International Expert Panel Review.
Testis and blood-testis barrier in Covid-19 infestation: role of angiotensin-converting enzyme 2 in male infertility.
The Anticoagulant Nafamostat Potently Inhibits SARS-CoV-2 S Protein-Mediated Fusion in a Cell Fusion Assay System and Viral Infection In Vitro in a Cell-Type-Dependent Manner.
Two hits to the renin-angiotensin system may play a key role in severe COVID-19.
Withdrawal Notice: Identification of the Interaction between Angiotensin-converting Enzyme Residues and Severe Acute Respiratory Syndrome Coronavirus 2
[Epidemiological features and mechanism of coronavirus disease 2019 in children].
Sexually Transmitted Diseases
Interstitial keratitis secondary to severe hidradenitis suppurativa: a case report and literature review.
Kimura disease involving a caruncle.
Shock, Cardiogenic
Angiotensin II: a new therapeutic option for vasodilatory shock.
Clinical characteristics and four-year outcomes of patients in the Rhode Island Takotsubo Cardiomyopathy Registry.
Factors associated with actively working in the very long-term following acute coronary syndrome.
Importance of RAA system and the treatment of patients with ACE inhibition after myocardial infarction.
Long-term prognosis after out-of-hospital cardiac arrest with/without ST elevation myocardial infarction.
Underuse of standard care and outcome of patients with acute myocardial infarction and chronic renal insufficiency.
[Primary angioplasty in diabetic and non-diabetic patients with acute myocardial infarction: Predictors of mortality].
[Update cardiology 2006/2007]
Shock, Septic
An observed pressor effect of the cerebellum during endotoxin shock in the dog.
Association between exposure to angiotensin-converting enzyme inhibitors and angiotensin receptor blockers prior to septic shock and acute kidney injury.
Association of angiotensin II type 1 receptor-associated protein (AGTRAP) gene polymorphism with increased mortality in septic shock.
Evaluating the Effects of Chronic Antihypertensives on Vasopressor Dosing in Septic Shock.
Pierson Syndrome Associated with Hypothyroidism and Septic Shock.
Risk of Sepsis and Mortality Among Patients With Chronic Obstructive Pulmonary Disease Treated With Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers.
Role of angiotensin-converting enzyme gene polymorphisms in children with sepsis and septic shock.
Treatment of Renin-Angiotensin-Aldosterone System Dysfunction With Angiotensin II in High-Renin Septic Shock.
[Angiotensin converting enzyme as an indicator of lung damage in septic shock]
Sick Sinus Syndrome
Syncope caused by iatrogenic hyperkalemia.
Sickle Cell Trait
Genetic polymorphisms associated with exertional rhabdomyolysis.
Silicosis
Angiotensin converting enzyme in sarcoidosis and in silicosis.
Angiotensin converting enzyme in the serum of rats with experimental silicosis.
Angiotensin-converting enzyme and lysozyme in silicosis and asbestosis.
Increased activity of serum angiotensin-converting enzyme in progressive silicosis.
Interaction of N-acetyl-seryl-aspartyl-lysyl-proline with the angiotensin-converting enzyme 2-angiotensin-(1-7)-Mas axis attenuates pulmonary fibrosis in silicotic rats.
Serum angiotensin converting enzyme (ACE) in silicosis.
Serum angiotensin converting enzyme activity in silicosis.
Serum angiotensin converting enzyme elevation in association with artificial stone silicosis.
Serum angiotensin-converting enzyme level in silicosis.
Serum angiotensin-converting enzyme levels in patients with silicosis.
Serum Levels of Copper, Ceruloplasmin and Angiotensin Converting Enzyme among Silicotic and Non-Silicotic Workers.
Silica exposure and serum angiotensin converting enzyme activity.
[Angiotensin-converting enzyme (ACE) in sarcoidosis, tuberculosis, silicosis, and coal mining workers]
[Kinin aminopeptidase in lung tissue and activity of kininase II in the serum of patients with silicosis]
[Studies on serum angiotensin-I-converting enzyme activity of experimental silicosis in rats]
[The evaluation of serum angiotensin-converting enzyme in silicosis and silicotuberculosis]
Silicotuberculosis
[The evaluation of serum angiotensin-converting enzyme in silicosis and silicotuberculosis]
Sinusitis
Differential diagnosis of chronic cough.
Skin Diseases
A comparison of Blau's syndrome and sarcoidosis.
ACE inhibitors can induce circulating antibodies directed to antigens of the superficial epidermal cells.
Characterization of angiotensin-converting enzyme expression during epidermis morphogenesis in humans: a potential marker for epidermal stem cells.
Evaluation of the Association Between CD143 Gene Polymorphism and Psoriasis.
Linear IgA dermatosis induced by a new angiotensin-converting enzyme inhibitor.
Tissue angiotensin-converting enzyme and lysosomal enzyme levels in skin diseases.
Skin Neoplasms
Melanoma and Non-Melanoma Skin Cancer Associated with Angiotensin-Converting-Enzyme Inhibitors, Angiotensin-Receptor Blockers and Thiazides: A Matched Cohort Study.
Melanoma incidence and exposure to angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.
Predictors of Basal Cell Carcinoma in High-Risk Patients in the VATTC (VA Topical Tretinoin Chemoprevention) Trial.
The role of drugs and selected dietary factors in cutaneous squamous cell carcinogenesis.
Sleep Apnea Syndromes
Angiotensin-converting enzyme, sleep-disordered breathing, and hypertension.
Deletion Polymorphism of Angiotensin Converting Enzyme Gene is Associated with Left Ventricular Hypertrophy in Uighur Hypertension-Obstructive Sleep Apnea Hypopnea Syndrome (OSAHS) Patients.
Discontinuation of furosemide decreases PaCO(2) in patients with COPD.
Effects of cilazapril on hypertension, sleep, and apnea.
The association of angiotensin converting enzyme (ACE) polymorphisms with sleep apnea and hypertension.
Sleep Apnea, Central
Effects of Heart Failure and its Pharmacological Management on Sleep.
Sleep Apnea, Obstructive
Angiotensin I-converting enzyme gene polymorphism in Chinese patients with obstructive sleep apnea syndrome.
Angiotensin-converting enzyme gene insertion/deletion (I/D) polymorphism in hypertensive patients with different degrees of obstructive sleep apnea.
Angiotensin-converting enzyme gene polymorphism in north Indian population with obstructive sleep apnea.
Angiotensin-converting enzyme inhibitors and obstructive sleep apnea.
Association between blood pressure reduction with antihypertensive treatment and sleep apnea activity.
Association of ACE I/D polymorphism with obstructive sleep apnea susceptibility: evidence based on 2,228 subjects.
Chronic Cough: Evaluation and Management.
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2017 EXECUTIVE SUMMARY.
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2018 EXECUTIVE SUMMARY.
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2019 EXECUTIVE SUMMARY.
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2020 EXECUTIVE SUMMARY.
Deletion Polymorphism of Angiotensin Converting Enzyme Gene is Associated with Left Ventricular Hypertrophy in Uighur Hypertension-Obstructive Sleep Apnea Hypopnea Syndrome (OSAHS) Patients.
Effect of angiotensin converting enzyme inhibition [Cilazapril] on blood pressure recording in hypertensive obstructive sleep apneic patients.
Genetically-reduced serum ACE activity might be a causal risk factor for obstructive sleep apnea syndrome: A meta-analysis.
Insertion/Deletion Polymorphism and Serum Activity of the Angiotensin-Converting Enzyme in Turkish Patients with Obstructive Sleep Apnea Syndrome.
Mineralocorticoid Receptor-Associated Hypertension and Its Organ Damage: Clinical Relevance for Resistant Hypertension.
Prognostic factors for adverse outcomes in patients with COVID-19: a field-wide systematic review and meta-analysis.
Reciprocal interactions of obstructive sleep apnea and hypertension associated with ACE I/D polymorphism in males.
Revised Korean Cough Guidelines, 2020: Recommendations and Summary statements.
Serum angiotensin converting enzyme and the obstructive sleep apnea hypopnea syndrome.
The Korean Cough Guideline: Recommendation and Summary Statement.
[Angiotensin-converting enzyme gene polymorphism in patients with obstructive sleep apnea]
[Association of polymorphisms in the angiotensin system genes with obstructive sleep apnea-hypopnea syndrome]
[Study on the polymorphism of angiotensin converting enzyme genes and serum angiotensin II level in patients with obstructive sleep apnea hypopnea syndrome accompanied hypertension]
Sleep Deprivation
Angiotensin I-converting enzyme (ACE) activity and expression in rat central nervous system after sleep deprivation.
Influence of a functional polymorphism within the angiotensin I-converting enzyme gene on partial sleep deprivation in patients with major depression.
Sleep Initiation and Maintenance Disorders
[Investigation of the factors that contribute to the onset of insomnia in hypertensive patients by using a post-marketing surveillance database].
Sleep Wake Disorders
Influenza Vaccination Reduces Dementia Risk in Chronic Kidney Disease Patients: A Population-Based Cohort Study.
Small Cell Lung Carcinoma
Small Cell Lung Cancer with Sarcoidosis in Spontaneous Remission: A Case Report.
The angiotensin receptor blocker, Losartan, inhibits mammary tumor development and progression to invasive carcinoma.
Solitary Kidney
Acute renal thrombosis induced by angiotensin-converting enzyme inhibitors in patients with renovascular hypertension.
Contrasting acute effects of captopril and nifedipine on renal function in renovascular hypertension.
Deterioration of renal function during angiotensin converting enzyme inhibition in hypertensive patients with a poorly functioning solitary kidney.
Differentiation between renovascular and essential hypertension by means of changes in single kidney 99mTc-DTPA clearance induced by angiotensin-converting enzyme inhibition.
Familial unilateral renal agenesis and focal and segmental glomerulosclerosis.
Pharmacologic nephrectomy with chronic angiotensin converting enzyme inhibitor treatment in renovascular hypertension in the rat.
Renal artery stenosis: a common, treatable cause of renal failure?
Renal function in hypertension.
Transient anuria following administration of angiotensin I-converting enzyme inhibitor (SQ 14225) in a patient with renal artery stenosis of the solitary kidney successfully treated with renal autotransplantation.
Spasm
Angiotensin converting enzyme as a genetic risk factor for coronary artery spasm. Implication in the pathogenesis of myocardial infarction.
Reversal of experimental delayed cerebral vasospasm by angiotensin-converting enzyme inhibition.
Spermatic Cord Torsion
Effect of angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade on apoptotic changes in contralateral testis following unilateral testicular torsion.
Spinal Cord Diseases
Ramipril reduces incidence and prolongates latency time of radiation-induced rat myelopathy after photon and carbon ion irradiation.
[Two siblings with sarcoidosis diagnosed by younger sister's central nervous symptoms]
Spinal Cord Injuries
Fatal Renal Failure in a Spinal Cord Injury Patient with Vesicoureteric Reflux Who Underwent Repeated Ureteric Reimplantations Unsuccessfully: Treatment Should Focus on Abolition of High Intravesical Pressures rather than Surgical Correction of Reflux.
Mitigation of radiation myelopathy and reduction of microglial infiltration by Ramipril, ACE inhibitor.
Spondylarthropathies
Association of angiotensin-converting enzyme (ACE) gene insertion-deletion polymorphism with spondylarthropathies.
Spondylitis, Ankylosing
Serum and synovial fluid levels of angiotensin converting enzyme in polyarthritis.
The serum angiotensin converting enzyme and lysozyme levels in patients with ocular involvement of autoimmune and infectious diseases.
Squamous Cell Carcinoma of Head and Neck
Angiotensin-converting enzymes (ACE and ACE2) as potential targets for Malignant Epithelial Neoplasia: Review and bioinformatics analyses focused in Oral Squamous Cell Carcinoma.
Effects of the angiotensin-I converting enzyme inhibitor perindopril on tumor growth and angiogenesis in head and neck squamous cell carcinoma cells.
ST Elevation Myocardial Infarction
Achieving High Quality in ST-segment Elevation Myocardial Infarction Care: One Urban Academic Medical Center Experience.
Acute Coronary Syndrome: Inpatient Management.
Acute treatment of myocardial infarction in Canada 1999-2002.
Association between the use of renin-angiotensin system blockers and development of in-hospital atrial fibrillation in patients with ST-segment elevation myocardial infarction.
Associations of ACE I/D polymorphism with the levels of ACE, kallikrein, angiotensin II and interleukin-6 in STEMI patients.
Clinical characteristics and outcomes of critically ill patients with COVID-19 in a tertiary community hospital in upstate New York.
Comparison of the risk of left ventricular free wall rupture in Taiwanese patients with ST-elevation acute myocardial infarction undergoing different reperfusion strategies: A medical record review study.
Diagnosis and management of ST elevation myocardial infarction: a review of the recent literature and practice guidelines.
Doses of renin-angiotensin system inhibitors but not beta-blockers predict outcome after ST-elevation myocardial infarction.
Frequency of ST-segment elevation myocardial infarction, non-ST-segment myocardial infarction, and unstable angina: results from a Southwest Chinese Registry.
Guideline Adherence After ST-Segment Elevation Versus Non-ST Segment Elevation Myocardial Infarction.
Improving the management of patients after myocardial infarction, from admission to discharge.
Infarct-related coronary artery patency and medication use prior to ST-segment elevation myocardial infarction.
Long-term prognosis after out-of-hospital cardiac arrest with/without ST elevation myocardial infarction.
Patterns of Acute Myocardial Infarction in Taiwan from 2009 to 2015.
Predictive models for adverse clinical outcomes in Chinese patients with atrial fibrillation undergoing percutaneous coronary intervention with stenting.
Prognostic impact of acute beta-blocker therapy on top of aspirin and angiotensin-converting enzyme inhibitor therapy in consecutive patients with ST-elevation acute myocardial infarction.
Quality of care by classification of myocardial infarction: treatment patterns for ST-segment elevation vs non-ST-segment elevation myocardial infarction.
Survey of Assessment and MAnagement of CoRonary Heart Disease PaTients (SMART) in India.
Total occlusion of the infarct-related coronary artery correlates with brachial artery flow-mediated dilation in patients with ST-elevation myocardial infarction.
Treatment and outcomes of acute coronary syndromes in India (CREATE): a prospective analysis of registry data.
Treatment of ST-elevation myocardial infarction.
[Mortality of myocardial infarction].
Staphylococcal Infections
Comparisons of Staphylococcus aureus infection and other outcomes between users of angiotensin-converting-enzyme inhibitors and angiotensin II receptor blockers: lessons for COVID-19 from a nationwide cohort study.
Starvation
Changes in serum angiotensin-converting enzyme in acutely starved non-obese patients. A possible dissociation between angiotensin-converting enzyme and the thyroid state.
[Effects of stress on indices for assessing zinc nutrition status]
Stomach Neoplasms
Angiotensin-converting enzyme inhibitors and risk of esophageal and gastric cancer: a nested case-control study.
Angiotensin-converting enzyme insertion/deletion polymorphism and gastric cancer: a systematic review and meta-analysis.
Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor blockers on lymphangiogenesis of gastric cancer in a nude mouse model.
Expression of the Local Angiotensin II System in Gastric Cancer May Facilitate Lymphatic Invasion and Nodal Spread.
Influences of chymase and angiotensin I-converting enzyme gene polymorphisms on gastric cancer risks in Japan.
Lack of association between gene polymorphisms of Angiotensin converting enzyme, Nod-like receptor 1, Toll-like receptor 4, FAS/FASL and the presence of Helicobacter pylori-induced premalignant gastric lesions and gastric cancer in Caucasians.
No association between angiotensin I converting enzyme (ACE) I/D polymorphism and gastric cancer risk among Japanese.
Role of renin-angiotensin system in gastric oncogenesis.
The ACE gene polymorphism is associated with the incidence of gastric cancer among H. pylori seropositive subjects with atrophic gastritis.
The angiotensin I-converting enzyme gene insertion/deletion polymorphism is linked to early gastric cancer.
The angiotensin II/angiotensin II receptor system correlates with nodal spread in intestinal type gastric cancer.
The ectopeptidases CD10, CD13, CD26, and CD143 are upregulated in gastric cancer.
The number of lymph node metastases in gastric cancer correlates with the angiotensin I-converting enzyme gene insertion/deletion polymorphism.
[Effects of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers on angiogenesis of gastric cancer in a nude mouse model]
Stomach Ulcer
Effect of angiotensin converting enzyme inhibitor (captopril) on gastric ulcer production in pylorus ligated rats.
Effect of captopril on oxyphenbutazone and ethanol-induced gastric lesions in rats.
The renin-angiotensin system and its vasoactive metabolite angiotensin-(1-7) in the mechanism of the healing of preexisting gastric ulcers. The involvement of Mas receptors, nitric oxide, prostaglandins and proinflammatory cytokines.
Stomatitis, Aphthous
High association of angiotensin-converting enzyme (ACE) gene insertion/deletion (I/D) polymorphism with recurrent aphthous stomatitis.
Streptococcal Infections
Henoch-Schönlein nephritis associated with streptococcal infection and persistent hypocomplementemia: a case report.
Stroke
(Pro)renin Receptor Blockade Ameliorates Cardiac Injury and Remodeling and Improves Function After Myocardial Infarction.
2010 guidelines of the Taiwan Society of Cardiology for the management of hypertension.
A clustering of unfavourable common genetic mutations in stroke cases.
A meta-analysis reporting effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients without heart failure.
A systematic review of angiotensin receptor blockers in preventing stroke.
A Systematic Review on the Efficacy of Amlodipine in the Treatment of Patients With Hypertension With Concomitant Diabetes Mellitus and/or Renal Dysfunction, When Compared With Other Classes of Antihypertensive Medication.
ACE I/D polymorphism in Korean patients with ischemic stroke and silent brain infarction.
ACE inhibition reduces infarction in normotensive but not hypertensive rats: correlation with cortical ACE activity.
ACE inhibitors increase type III collagen synthesis: a potential explanation for reduction in acute vascular events by ACE inhibitors.
ACE-Triggered Hypertension Incites Stroke: Genetic, Molecular, and Therapeutic Aspects.
Action on Vascular Risk Factors: Importance of Blood Pressure and Lipid Lowering in Stroke Secondary Prevention.
Activation of the Neuroprotective Angiotensin-Converting Enzyme 2 in Rat Ischemic Stroke.
Acute ischemic coronary artery disease and ischemic stroke: similarities and differences.
Advances in angiotensin converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs).
ALLHAT: still providing correct answers after 7 years.
Amlodipine: a pharmacoeconomic review.
Angioedema Secondary to tPA Use in Acute Ischemic Stroke Patient with Hypertension: A Case Report.
Angiotensin 2 type 2 receptor activity and ischemic stroke severity.
Angiotensin converting enzyme activity in strains of normo- and hypertensive rats.
Angiotensin converting enzyme inhibition and cerebral circulation--a review.
Angiotensin II and the endothelium: diverse signals and effects.
Angiotensin receptor blockers (ARB) outperform angiotensin-converting enzyme (ACE) inhibitors on ischemic stroke prevention in patients with hypertension and diabetes - A real-world population study in Taiwan.
Angiotensin receptor blockers and cerebral protection in stroke.
Angiotensin receptor blockers and secondary stroke prevention: the MOSES study.
Angiotensin receptor blockers in hypertension. New insights from Japan.
Angiotensin-converting enzyme gene deletion polymorphism. A new risk factor for lacunar stroke but not carotid atheroma.
Angiotensin-converting enzyme gene insertion/deletion polymorphism and small vessel cerebral stroke in Indian population.
Angiotensin-converting enzyme gene polymorphism and middle cerebral artery stenosis in a Chinese Han population.
Angiotensin-converting enzyme gene polymorphism and stroke in type 2 diabetic patients in Taiwan.
Angiotensin-converting enzyme gene polymorphism in hypertensive individuals with parental history of stroke.
Angiotensin-converting enzyme inhibition and regional cerebral blood flow in acute stroke.
Angiotensin-Converting Enzyme Inhibitor in Tube-Fed Patients With Stroke History.
Angiotensin-converting enzyme inhibitor/angiotensin II receptor blockers and pneumonia risk among stroke patients.
Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on prevention of stroke: Which one is better?
Angiotensin-converting enzyme inhibitors and calcium channel blockers for coronary heart disease and stroke prevention.
Angiotensin-converting enzyme inhibitors and stroke prevention: what about the influence of atrial fibrillation and antithrombotic therapy?
Angiotensin-converting enzyme inhibitors and stroke risk: benefit beyond blood pressure reduction?
Angiotensin-converting enzyme inhibitors and stroke: blood pressure reduction is major determinant of risk.
Angiotensin-converting enzyme inhibitors for stroke prevention: is there HOPE for PROGRESS After LIFE?
Angiotensin-Converting Enzyme Inhibitors in Patients With Coronary Artery Disease and Absence of Heart Failure or Left Ventricular Systolic Dysfunction: An Overview of Long-term Randomized Controlled Trials.
Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers are beneficial in normotensive atherosclerotic patients: a collaborative meta-analysis of randomized trials.
Angiotensin-converting enzyme inhibitors reduce mortality compared to angiotensin receptor blockers: Systematic review and meta-analysis.
Angiotensin-converting enzyme inhibitors will help in improving stroke outcome if given immediately after stroke.
Angiotensin-converting enzyme inhibitors will not help in improving stroke outcome if given immediately after stroke.
Angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers and the risk of major adverse cardiac events in patients with diabetes and prior stroke: a nationwide study.
Angiotensin-converting enzyme inhibitors, angiotensin receptor blockers and protection from stroke.
Angiotensin-converting enzyme inhibitors, angiotensin-II receptor antagonists, and pneumonia in elderly hypertensive patients with stroke.
Angiotensin-converting enzyme insertion/deletion polymorphism has no effect on the risk of atherosclerotic stroke or hypertension.
Angiotensinogen Met235Thr polymorphism, angiotensin-converting enzyme inhibitor therapy, and the risk of nonfatal stroke or myocardial infarction in hypertensive patients.
Anticoagulation after anterior myocardial infarction and the risk of stroke.
Antihypertensive and lipid lowering treatment in stroke prevention: current state and future.
Antihypertensive drug use and adherence after stroke: are there sex differences?
Antihypertensive medications for risk reduction of first and recurrent ischemic stroke.
Antiplatelets, ACE inhibitors, and statins combination reduces stroke severity and tissue at risk.
Are beta-blockers efficacious as first-line therapy for hypertension in the elderly?
Are cholesterol-lowering medications and antihypertensive agents preventing stroke in ways other than by controlling the risk factor?
Are the angiotensin-converting enzyme gene and activity risk factors for stroke?
Assessment of the effect of ramipril therapy on direct health care costs for first and recurrent strokes in high-risk cardiovascular patients using data from the Heart Outcomes Prevention Evaluation (HOPE) study.
Association between angiotensin I-converting enzyme genotypes, extracranial artery stenosis, and stroke.
Blockade of central angiotensin AT(1) receptors improves neurological outcome and reduces expression of AP-1 transcription factors after focal brain ischemia in rats.
Blood pressure and lipid lowering in the prevention of stroke: a note to neurologists.
Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren.
Blood pressure lowering in patients with cerebrovascular disease: results of the PROGRESS (Perindopril Protection Against Recurrent Stroke Study) pilot phase.
Blood pressure-lowering treatment for preventing recurrent stroke, major vascular events, and dementia in patients with a history of stroke or transient ischaemic attack.
Blood-pressure reduction and cardiovascular risk in HOPE study.
Calcium antagonists in the treatment of hypertension in patients with ischaemic heart disease.
Calcium channel blockers and cardiovascular outcomes: a meta-analysis of 175,634 patients.
Can the renin-angiotensin system protect against stroke? A focus on angiotensin II receptor blockers.
Captopril treatment reverses erectile dysfunction in male stroke prone spontaneously hypertensive rats.
Carotid artery intima-media thickness and angiotensin-converting enzyme gene polymorphism in the offspring of parents with premature stroke.
Carotid artery intimal-medial thickness: indicator of atherosclerotic burden and response to risk factor modification.
Carotid endarterectomy remains the standard of care, even in high-risk surgical patients.
Cerebroprotection mediated by angiotensin II: a hypothesis supported by recent randomized clinical trials.
Circulating angiotensin-converting enzyme, von Willebrand factor antigen and thrombomodulin in exertional heat stroke.
Clinical efficacies of antihypertensive drugs.
Clinical impact of angiotensin I converting enzyme polymorphisms in subjects with resistant hypertension.
Clinical Implications of Recent Findings from the Antihypertensive and Lipid-Lowering Treatment To Prevent Heart Attack Trial (ALLHAT) and Other Studies of Hypertension.
Cognitive function and the emotional state of stroke patients on antihypertensive therapy.
Community Implementation and Translation of Kaiser Permanente's Cardiovascular Disease Risk-Reduction Strategy.
Comparative effectiveness of cardioprotective drugs in elderly individuals with type 2 diabetes.
Comparison between angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on the risk of myocardial infarction, stroke and death: a meta-analysis.
Comparison between angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on the risk of stroke recurrence and longitudinal progression of white matter lesions and silent brain infarcts on MRI (CEREBRAL study): rationale, design, and methodology.
Comparison of Cardiovascular Events Among Users of Different Classes of Antihypertension Medications: A Systematic Review and Network Meta-analysis.
Complicated orolingual angioedema after recombinant tissue plasminogen activator treatment in stroke patients under angiotensin converting enzyme inhibitor: Report of two cases.
Comprehensive comparative effectiveness and safety of first-line antihypertensive drug classes: a systematic, multinational, large-scale analysis.
Coronary surgery in patients with preexisting chronic atrial fibrillation: early and midterm clinical outcome.
Cost-minimization and the number needed to treat in uncomplicated hypertension.
CSF enzymes in lacunar and cortical stroke.
Dante Pazzanese risk score for non-st-segment elevation acute coronary syndrome.
DD genotype of ACE gene is a risk factor for intracerebral hemorrhage.
DD genotype of the angiotensin-converting enzyme gene and stroke in Slovenian population.
Desirability of immediate surgical standby for coronary angioplasty.
Differential effects of angiotensin converting enzyme inhibition and diuretic therapy on reductions in ambulatory blood pressure, left ventricular mass, and vascular hypertrophy.
Diuretics: a review and update.
Drug therapy of neurovascular disease.
Effect of angiotensin converting enzyme inhibitor (captopril) on cerebral blood flow in hypertensive patients without a history of stroke.
Effect of losartan on nocturnal blood pressure in patients with stroke: comparison with angiotensin converting enzyme inhibitor.
Effect of perindopril on cerebral and renal perfusion in stroke patients with carotid disease.
Effect of perindopril on cerebral and renal perfusion on normotensives in mild early ischaemic stroke: a randomized controlled trial.
Effect of perindopril on vasoreactivity in patients with hypertensive chronic cerebrovascular disease. A comparative analysis of different brain structures.
Effect of pre-stroke use of ACE inhibitors on ischemic stroke severity.
Effect of renin-angiotensin-aldosterone system inhibitors on all-cause mortality and major cardiovascular events in patients with diabetes: A meta-analysis focusing on the number needed to treat and minimal clinical effect.
Effect of single and dual renin-angiotensin blockade on stroke in patients with and without diabetes in VALIANT.
Effect of the angiotensin-converting enzyme inhibitor perindopril on 24-hour blood pressure in patients with lacunar infarction: comparison between dippers and non-dippers.
Effects of angiotensin-converting enzyme inhibition and angiotensin II AT1 receptor antagonism on cardiac parameters in left ventricular hypertrophy.
Effects of blood pressure-lowering on outcome incidence in hypertension: 5. Head-to-head comparisons of various classes of antihypertensive drugs - overview and meta-analyses.
Effects of hydrochlorothiazide on oxidative stress and pulse pressure in hypertensive patients with chronic stroke: the EMINENT study.
Effects of Long- and Intermediate-Acting Dihydropyridine Calcium Channel Blockers in Hypertension: A Systematic Review and Meta-Analysis of 18 Prospective, Randomized, Actively Controlled Trials.
Efficacy of Calcium Channel Blockers Versus Other Classes of Antihypertensive Medication in the Treatment of Hypertensive Patients With Previous Stroke and/or Coronary Artery Disease: A Systematic Review and Meta-Analysis.
Epidemiology of stroke in chronic heart failure patients with normal sinus rhythm: Findings from the DIG stroke sub-study.
Epidemiology, Pathophysiology, and Treatment of Hypertension in Ischaemic Stroke Patients.
Evaluation of the angiotensin-converting enzyme insertion/deletion polymorphism and the risk of ischaemic stroke.
Evidence for age and sex differences in the secondary prevention of stroke in Scottish primary care.
Examination of selected clinical factors and medication use as risk factors for pneumonia during stroke rehabilitation: a case-control study.
Fibrin Clot Permeability as a Predictor of Stroke and Bleeding in Anticoagulated Patients With Atrial Fibrillation.
Fluid matters in choosing antihypertensive therapy: a hypothesis that the data speak volumes.
Gene polymorphism of the renin-angiotensin system associates with risk for lacunar infarction. The Ohasama study.
Genetic polymorphisms in the renin-angiotensin system confer increased risk of stroke independently of blood pressure: a nested case-control study.
Genetic Risk Factors for Arterial Ischemic Stroke in Children: A Possible MTHFR and eNOS Gene-Gene Interplay?
Higher On-admission Serum Triglycerides Predict Less Severe Disability and Lower All-cause Mortality after Acute Ischemic Stroke.
Hypertension and hypertensive encephalopathy.
Hypertension-Related Stroke Prevention in the Elderly.
Incidence of New Stroke or New Myocardial Infarction or Death at 39-Month Follow Up in Patients With Diabetes Mellitus, Hypertension, or Both Treated With and Without Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers.
Incidence, trends, and predictors of ischemic stroke 1 year after an acute myocardial infarction.
Increased cardiovascular risk in long-term hemodialysis patients carrying deletion allele of ACE gene polymorphism.
Inflammation and atherosclerosis: novel insights into plaque formation and destabilization.
Influence of on-going treatment with angiotensin-converting enzyme inhibitor or angiotensin receptor blocker on the outcome of patients treated with intravenous rt-PA for ischemic stroke.
Inhibition of the renin-angiotensin-aldosterone system to prevent ischemic and atherothrombotic events.
Interaction between polymorphisms in the renin-angiotensin-system and angiotensin-converting enzyme inhibitor or beta-blocker use and the risk of myocardial infarction and stroke.
Interaction of angiotensin-converting enzyme and apolipoprotein E gene polymorphisms in ischemic stroke involving large-vessel disease.
Is prestroke use of angiotensin-converting enzyme inhibitors associated with better outcome?
Is the angiotensin II Type 2 receptor cerebroprotective?
Lack of association between angiotensin converting enzyme gene insertion/deletion polymorphism and stroke.
Left ventricular hypertrophy and performance: therapeutic options among the angiotensin-converting enzyme inhibitors.
Left ventricular systolic dysfunction and atrial fibrillation in older people in the community--a need for screening?
Long-term angiotensin-converting enzyme inhibitor perindopril therapy improves cerebral perfusion reserve in patients with previous minor stroke.
Long-term impact of secondary preventive treatments in patients with stable angina.
Long-term outcomes and independent predictors of mortality in patients presenting to emergency departments with acute heart failure in Beijing: a multicenter cohort study with a 5-year follow-up.
Managing hypertension using combination therapy.
Managing the patient at risk for a second stroke.
Mechanisms of hypotension during dobutamine stress echocardiography in patients with coronary artery disease.
Medical prevention of stroke, 2003.
Medication undertreatment in assisted living settings.
Migraine and coronary artery disease: an open study on the genetic polymorphism of the 5, 10 methylenetetrahydrofolate (MTHFR) and angiotensin I-converting enzyme (ACE) genes.
Mineralocorticoid Antagonism and Diabetic Kidney Disease.
Myocardial infarction and stroke associated with diuretic based two drug antihypertensive regimens: population based case-control study.
Neuroprotection by post-stroke administration of an oral formulation of angiotensin-(1-7) in ischaemic stroke.
No Increase in Adverse Events During Aliskiren Use Among Ontario Patients Receiving Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers.
Ongoing clinical outcome studies of calcium antagonists.
Outcomes with Angiotensin-converting Enzyme Inhibitors vs Other Antihypertensive Agents in Hypertensive Blacks.
Patterns of medical therapy in patients with peripheral artery disease in a tertiary care centre in Canada.
Pharmacoeconomic Evaluation of Hypothetical Over-the-counter Angiotensin-converting Enzyme (ACE) Inhibitors for the Prevention of Stroke in Patients with Grade I Hypertension.
Platelet angiotensin II in cerebrovascular accident and the effect of angiotensin-converting enzyme inhibitors.
Possible pathophysiologic mechanisms supporting the superior stroke protection of angiotensin receptor blockers compared to angiotensin-converting enzyme inhibitors: clinical and experimental evidence.
Poststroke dementia : clinical features and risk factors.
Prediction on admission of in-hospital mortality in patients older than 70 years with acute myocardial infarction.
Predictors of Acute Kidney Injury Following Surgical Valve Replacement.
Predictors of clinically significant postprocedural hypotension after carotid endarterectomy and carotid angioplasty with stenting.
Predictors of Recurrent Ischemic Stroke in Obese Patients With Type 2 Diabetes Mellitus: A Population-based Study.
Prevention of dementia: lessons from SYST-EUR and PROGRESS.
Prevention of major cardiovascular events with an angiotensin-converting enzyme inhibitor or an angiotensin receptor blocker early or late after stroke.
Prevention of nephrosclerosis and cardiac hypertrophy by captopril treatment of spontaneously hypertensive rats.
Prevention of stroke in patients with hypertension.
Primary and secondary prevention of stroke by antihypertensive drug treatment.
Primary stroke prevention and hypertension treatment: which is the first-line strategy?
Prior use of angiotensin-converting enzyme inhibitors does not affect outcome in patients with intracerebral hemorrhage.
PROGRESS (perindopril protection against recurrent stroke study): rationale and design. PROGRESS Management Committee [corrected]
PROGRESS (Perindopril Protection Against Recurrent Stroke Study): regional characteristics of the study population at baseline. PROGRESS Management Committee.
PROGRESS - Perindopril Protection Against Recurrent Stroke Study: characteristics of the study population at baseline. Progress Management Committee.
PROGRESS--perindopril protection against recurrent stroke study: status in July 1996. PROGRESS Management Committee.
PROGRESS: Perindopril pROtection aGainst REcurrent Stroke Study: status in March 1997. PROGRESS Management Committee.
Prophylactic effect of imidapril on stroke in stroke-prone spontaneously hypertensive rats.
Prospective evaluation of the angiotensin-converting enzyme insertion/deletion polymorphism and the risk of stroke.
Prospective validation of the dante pazzanese risk score in non-ST-segment elevation acute coronary syndrome.
Protective arms of the renin-angiotensin-system in neurological disease.
Race and ethnicity in trials of antihypertensive therapy to prevent cardiovascular outcomes: a systematic review.
Rapid decline in estimated glomerular filtration rate is common in adults with sickle cell disease and associated with increased mortality.
Rationale, design and baseline data of a randomized, double-blind, controlled trial comparing two antithrombotic regimens (a fixed-dose combination of extended-release dipyridamole plus ASA with clopidogrel) and telmisartan versus placebo in patients with strokes: the Prevention Regimen for Effectively Avoiding Second Strokes Trial (PRoFESS).
Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials.
Recommendations for the management of special populations: racial and ethnic populations.
Reducing the risk of stroke in diabetes: what have we learned that is new?
Relationship of angiotensin converting enzyme genotype with serum triglyceride concentration in stroke patients.
Renin-angiotensin system genetic polymorphisms and cerebral white matter lesions in essential hypertension.
Renin-angiotensin system haplotypes and the risk of myocardial infarction and stroke in pharmacologically treated hypertensive patients.
Renin-Angiotensin system modulators modestly reduce vascular risk in persons with prior stroke.
Resource utilization implications of treatment were able to be assessed from appropriately reported clinical trial data.
Results of carotid endarterectomy in patients with contralateral internal carotid artery occlusion from the Mid-America Vascular Study Group and the Society for Vascular Surgery Vascular Quality Initiative.
Revisiting evidence from the Blood Pressure Lowering Treatment Trialists' Collaboration: Fractional polynomials meta-regression of blood pressure reduction by angiotensin-converting enzyme inhibitors on stroke risk.
Role of angiotensin receptor blockers in diabetes: implications of recent clinical trials.
Role of angiotensin-converting-enzyme inhibitors in stroke prevention.
Role of antihypertensive therapy with angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers in combination with calcium channel blockers for stroke prevention.
Role of Blood Pressure Management in Stroke Prevention: A Systematic Review and Network Meta-Analysis of 93 Randomized Controlled Trials.
Secondary CV Prevention in South America in a Community Setting: The PURE Study.
Secondary prevention of stroke and the expanding role of the neurologist.
Selective Reduction of Central Pulse Pressure Under Angiotensin Blockage in SHR: Role of the Fibronectin-alpha5beta1 Integrin Complex.
Shared genetic risk factors for depression and stroke.
Small but powerful: Short peptide hormones and their role in autoimmune inflammation.
Streptozotocin-induced diabetes enhances protective effects of enalapril on nitric oxide-deficient stroke in stroke-prone rats.
Stroke and cognition.
Stroke in chronic kidney disease: prevention and management.
Stroke prevention therapy beyond antithrombotics: unifying mechanisms in ischemic stroke pathogenesis and implications for therapy: an invited review.
Stroke prevention with losartan in the context of other antihypertensive drugs.
Stroke prevention: managing modifiable risk factors.
Stroke Prevention: Not all Antihypertensive Drugs are Created Equal.
Stroke prevention: what's new?
Stroke risks and patterns of warfarin therapy among atrial fibrillation patients post radiofrequency ablation: A real-world experience.
Stroke: a vascular pathology with inadequate management.
Stroke: development, prevention and treatment with peptidase inhibitors.
Stroke: strategies for primary prevention.
Targeting of renin-angiotensin system in COVID-19 patients affected by stroke: Emerging concerns about detrimental vs. benefit effect.
Targeting the renin-angiotensin system for the reduction of cardiovascular outcomes in hypertension: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.
Telmisartan, ramipril, or both in high-risk Chinese patients: analysis of ONTARGET China data.
The 2011 canadian hypertension education program recommendations for the management of hypertension: blood pressure measurement, diagnosis, assessment of risk, and therapy.
The Association between Hypertension and Dementia in the Elderly.
The diversified pharmacology of angiotensin II-receptor blockade.
The effect of antihypertensive drugs on carotid intima media thickness: an up-to-date review.
The HOPE (Heart Outcomes Prevention Evaluation) Study: the design of a large, simple randomized trial of an angiotensin-converting enzyme inhibitor (ramipril) and vitamin E in patients at high risk of cardiovascular events. The HOPE study investigators.
The I/D polymorphism of the ACE1 gene is not associated with ischaemic stroke in Spanish individuals.
The Implications of Angiotensin-Converting Enzymes and Their Modulators in Neurodegenerative Disorders: Current and Future Perspectives.
The influence of iatrogenic atrial septal defect on the prognosis of patients with atrial fibrillation between cryoablation and radiofrequency ablation.
The PRoFESS trial: future impact on secondary stroke prevention.
The PROGRESS trial: questions about the effectiveness of angiotensin converting enzyme inhibitors. Perindopril pROtection aGainst REcurrent Stroke Study.
The renin angiotensin system in the regulation of angiogenesis.
The Renin-Angiotensin System and the Cerebrovascular Diseases: Experimental and Clinical Evidence.
The renin-angiotensin system as a risk factor and therapeutic target for cardiovascular and renal disease.
The role of angiotensin II receptors in stroke protection.
The role of RAS modification for primary and secondary stroke prevention.
The use of inhibitors of angiotensin-converting enzyme and its relation to events in the postoperative period of CABG.
The Utilization of Spironolactone in Heart Failure Patients at a Tertiary Hospital in Saudi Arabia.
Therapeutic benefit of captopril in salt-loaded stroke-prone spontaneously hypertensive rats is independent of hypotensive effect.
Therapeutic effects of imidapril on cerebral lesions observed by magnetic resonance imaging in malignant stroke-prone spontaneously hypertensive rats.
Thiazide and loop diuretics.
Tolerability of ramipril 10 mg daily in high-risk cardiovascular patients in Taiwan: experience from Kaohsiung Medical University Chung-Ho Memorial Hospital.
Trandolapril's protective effects in stroke-prone spontaneously hypertensive rats persist long after treatment withdrawal.
Transient ischemic attacks: Part II. Treatment.
Treating hypertension and prehypertension in older people: when, whom and how.
Treatment of diabetic vasculopathy with rosiglitazone and ramipril: Hype or hope?
Treatment of high-risk African American patients: left ventricular dysfunction, heart failure, renal disease, and postmyocardial infarction.
Trials on blood pressure-lowering and secondary stroke prevention.
Understanding the PRoFESS Study for Secondary Stroke Prevention.
Update on the drug treatment of hypertension in patients with cardiovascular disease.
Update on the management of hypertension: recent clinical trials and the JNC 7.
Update on the treatment and prevention of ischaemic stroke.
Use of angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker therapy to reduce cardiovascular events in high-risk patients: Part 1.
Use of angiotensin-converting enzyme inhibitors immediately after stroke: Commentary.
Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies.
Use of ramipril in preventing stroke: double blind randomised trial.
Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey.
Use of Secondary Prevention Medications among Adults with Reduced Kidney Function.
Vascular factors and cognition: toward a prevention of dementia?
Ventricular Arrhythmia Risk After Subarachnoid Hemorrhage.
Which drug should be used to treat patients with uncomplicated essential hypertension?
Withholding versus Continuing Angiotensin-converting Enzyme Inhibitors or Angiotensin II Receptor Blockers before Noncardiac Surgery: An Analysis of the Vascular events In noncardiac Surgery patIents cOhort evaluatioN Prospective Cohort.
[Aural Stimulation with Capsaicin Ointment Improved the Swallowing Function in Patients with Dysphagia: Evaluation by the SMRC Scale].
[Clinical study of the month. Secondary prevention of cerebrovascular accident with perindopril: the PROGRESS study]
[Cognitive functions and emotional state of post stroke patients on antihypertensive therapy]
[Comparative eficacy of antihypertensive therapy in patients with arterial hypertension and various sensitivity to salt].
[Discharge prescription for ischemic stroke patients]
[Hypertension in the acute phase and in the secondary prevention of stroke]
[Hyponatremia with somnolence due to indapamide]
[Management of blood pressure for stroke prevention].
[Pharmacological correction of hyperactivity of Renin-Angiotensin-aldosteron system.]
[Reduced risk of stroke recurrence due to hypotensive medication, irrespective of the initial blood pressure]
[Secondary prevention of stroke with effective antihypertensive treatment].
[Stroke and other thromboembolic complications of atrial fibrillation. Part v. The use of drugs without antithrombotic or antiarrhythmic properties.]
[Study on the association of oral contraceptives, angiotensin-converting enzyme gene polymorphisms and risk of stroke in women].
[The effect of calcium channel blockers for hypertension--a survey of a Cochrane review].
[The relationship between angiotensin-converting enzyme gene polymorphism and heart rate variability in cerebral stroke]
[The therapy of complicated forms of essential hypertension with the ACE inhibitor perindopril]
[What is new about stroke prevention?]
Stroke, Lacunar
Angiotensin converting enzyme insertion/deletion genotype is associated with leukoaraiosis in lacunar syndromes.
Angiotensin-converting enzyme gene and lacunar stroke.
Angiotensin-converting enzyme gene deletion polymorphism. A new risk factor for lacunar stroke but not carotid atheroma.
Association between angiotensin I-converting enzyme genotypes, extracranial artery stenosis, and stroke.
CSF enzymes in lacunar and cortical stroke.
Effect of the angiotensin-converting enzyme inhibitor perindopril on 24-hour blood pressure in patients with lacunar infarction: comparison between dippers and non-dippers.
Gene polymorphism of the renin-angiotensin system associates with risk for lacunar infarction. The Ohasama study.
Regional cerebral hemodynamics among hypertensive patients with lacunar infarctions during blood pressure control in subacute and chronic phases.
Subacute Sclerosing Panencephalitis
Angiotensin-converting enzyme and angiotensin II type 1 receptor gene polymorphisms in children with subacute sclerosing panencephalitis.
[Host genetic factors for the development of SSPE]
Subarachnoid Hemorrhage
Alacepril, an angiotensin-converting enzyme inhibitor, prevents cerebral vasospasm in subarachnoid hemorrhage model in rats.
Angiotensin-converting enzyme inhibitor cilazapril prevents chronic morphologic vasospasm in rat.
Cardiac abnormalities after aneurysmal subarachnoid hemorrhage: effects of ?-blockers and angiotensin-converting enzyme inhibitors.
II genotype of the angiotensin-converting enzyme gene increases the risk for subarachnoid hemorrhage from ruptured aneurysm.
Reversal of experimental acute cerebral vasospasm by angiotensin converting enzyme inhibition.
Sunburn
Cardiovascular Drug Use and Risk of Actinic Keratosis: A Case-Control Study.
Predictors of Basal Cell Carcinoma in High-Risk Patients in the VATTC (VA Topical Tretinoin Chemoprevention) Trial.
Supranuclear Palsy, Progressive
Cerebrospinal fluid levels of angiotensin-converting enzyme in Alzheimer's disease, Parkinson's disease and progressive supranuclear palsy.
Syncope
Angiotensin-converting enzyme gene polymorphism in arrhythmogenic right ventricular dysplasia: is DD genotype helpful in predicting syncope risk?
Effects of long-term vasodilator therapy in patients with carotid sinus hypersensitivity.
Efficacy of Oral Tadalafil, a New Long-acting Phosphodiesterase-5 Inhibitor, for the Short-term Treatment of Pulmonary Arterial Hypertension in a Dog.
Emerging low-density lipoprotein (LDL) therapies: Management of severely elevated LDL cholesterol--the role of LDL-apheresis.
Hypoglycemic syncope induced by a combination of cibenzoline and angiotensin converting enzyme inhibitor.
Syncope and COVID-19 disease - A systematic review.
Syncope caused by hyperkalemia during use of a combined therapy with the angiotensin-converting enzyme inhibitor and spironolactone.
Syncope caused by nonsteroidal anti-inflammatory drugs and angiotensin-converting enzyme inhibitors.
Syncope in advanced heart failure: high risk of sudden death regardless of origin of syncope.
Syncope in dilated cardiomyopathy is a predictor of sudden cardiac death.
Unusual Cause of Syncope in a Patient with Ischemic Heart Disease.
Syncope, Vasovagal
Angiotensin converting enzyme insertion/deletion polymorphisms in vasovagal syncope.
Syphilis
Fuchs heterochromic cyclitis and ocular toxocariasis.
Severe uveitis in an HLA-B27-positive patient with ankylosing spondylitis.
The serum angiotensin converting enzyme and lysozyme levels in patients with ocular involvement of autoimmune and infectious diseases.
[Benign tumor of the oral cavity: idiopathic granuloma of the tongue].
Tachycardia
A common angiotensin-converting enzyme polymorphism and preoperative angiotensin-converting enzyme inhibition modify risk of tachyarrhythmias after congenital heart surgery.
Anaphylactoid reaction to recombinant tissue plasminogen activator.
Angiotensin-converting enzyme inhibitor resets baroreceptor reflexes in conscious dogs.
Antihypertensive effects of parenteral nicardipine alone and in combination with captopril.
Association of angiotensin converting enzyme gene polymorphism with tachycardia cardiomyopathy.
Autonomic and baroreflex function after captopril in hypertension.
Captopril attenuates reflex adrenergic response in essential hypertension.
DuP 753 is more effective than captopril on baroreceptor function in high-renin hypertension.
Effect of enalapril at rest and during isometric and dynamic exercise in essential hypertensive patients.
Effects of long-term blockade of angiotensin converting enzyme with captopril (SQ14,225) on hemodynamics and circulating blood volume in SHR.
Electrophysiologic and clinical effects of angiotensin-converting enzyme inhibitors in patients with prior myocardial infarction, nonsustained ventricular tachycardia, and depressed left ventricular function. MUSTT Investigators. Multicenter UnSustained Tachycardia Trial.
Hemodynamic effects of angiotensin-converting enzyme inhibitors in essential hypertension: a review.
Resetting baroreceptors to a lower arterial pressure level by enalapril avoids baroreflex mediated activation of sympathetic nervous system by nifedipine.
Reversal of bradykinin-induced reflex tachycardia to bradycardia by captopril; evidence for prostacyclin involvement.
Risk of cardiovascular events after initiation of long-acting bronchodilators in patients with chronic obstructive lung disease: A population-based study.
Ro 42-5892 is a potent orally active renin inhibitor in primates.
Role of norepinephrine in the lack of reflex tachycardia after angiotensin converting enzyme inhibitor treatment.
Structural requirements and mechanism of the pressor activity of Leu-Val-Val-hemorphin-7, a fragment of hemoglobin beta-chain in rats.
Syncope at SARS-CoV-2 onset.
The effect of captopril on the reflex control heart rate: possible mechanisms.
The influence of naloxone on the circulatory effects of captopril.
[Captopril + hydrochlorothiazide versus captopril + nifedipine in the treatment of arterial hypertension in diabetes mellitus type II]
[Effect of angiotensin converting enzyme inhibitor spirapril on dimensions of experimental myocardial infarction, development of ischemic tachyarrhythmias, and ischemic adaptation of the heart]
[Hemodynamic effects of captopril, an ACE inhibitor, in patients after aortocoronary bypass]
[Hypertensive crisis]
[Regional blood flow in congestive cardiac failure and inhibition of angiotensin converting enzyme]
[Sudden cardiac death (part 2)]
[Treatment of cardiac insufficiency in ischemic heart disease]
Tachycardia, Sinus
Effects of metoprolol in chagasic patients with severe congestive heart failure.
Tachycardia, Ventricular
Acute effects of the ACE inhibitor lisinopril on cardiac electrophysiological parameters of isolated guinea pig hearts.
Comparative electrophysiological effects of captopril or hydralazine combined with nitrate in patients with left ventricular dysfunction and inducible ventricular tachycardia.
Effects of bradykinin on inducible sustained ventricular tachycardia two weeks after myocardial infarction in pigs.
Electrophysiologic and clinical effects of angiotensin-converting enzyme inhibitors in patients with prior myocardial infarction, nonsustained ventricular tachycardia, and depressed left ventricular function. MUSTT Investigators. Multicenter UnSustained Tachycardia Trial.
From Other Journals: A Review of Recent Articles in Pediatric Cardiology.
Inhibition of renin-angiotensin system (RAS) reduces ventricular tachycardia risk by altering connexin43.
Prognostic Impact of Angiotensin Converting Enzyme Inhibitors and Receptor Blockers on Recurrent Ventricular Tachyarrhythmias and ICD Therapies.
Sustained improvement in cardiac function with persistent amyloid deposition in a patient with multiple myeloma-associated cardiac amyloidosis treated with bortezomib.
The management of ventricular arrhythmias in older patients after CAST.
The renin-angiotensin-aldosterone system (RAAS) and cardiac arrhythmias.
The whole nine yards: multiple cardiac surgical and percutaneous interventions in a patient during 30 years of care.
Tachypnea
Polymorphism of the angiotensin converting enzyme gene and angiotensin converting enzyme activity in transient tachypnea of neonate and respiratory distress syndrome.
Takayasu Arteritis
Von Willebrand factor antigen and angiotensin converting enzyme levels in Takayasu arteritis.
Takotsubo Cardiomyopathy
Takotsubo cardiomyopathy associated with Miller-Fisher syndrome.
Takotsubo Cardiomyopathy: Case Series and Literature Review.
What is the recurrence rate of takotsubo syndrome in patients treated with ?-blockers and angiotensin converting enzyme inhibitors/angiotensin receptor blockers?
Zumba-induced Takotsubo cardiomyopathy: a case report.
Tardive Dyskinesia
Angiotensin converting enzyme gene insertion/deletion polymorphism: case-control association studies in schizophrenia, major affective disorder, and tardive dyskinesia and a family-based association study in schizophrenia.
Testicular Neoplasms
Angiotensin I-converting enzyme and potential substrates in human testis and testicular tumours.
Angiotensin-converting enzyme: an indicator of bleomycin-induced pulmonary toxicity in humans?
Tetanus
Families of zinc metalloproteases.
Tetralogy of Fallot
From Other Journals: A Review of Recent Articles in Pediatric Cardiology.
The cause of B-type natriuretic peptide elevation and the dose-dependent effect of angiotensin-converting enzyme inhibitor on patients late after tetralogy of Fallot repair.
Thromboangiitis Obliterans
Determination of kininogens levels and kallikrein/kininase II activities in patients with thromboangiitis obliterans.
Thrombocytopenia
Gemcitabine-induced hemolytic uremic syndrome mimicking scleroderma renal crisis presenting with Raynaud's phenomenon, positive antinuclear antibodies and hypertensive emergency.
Severe refractory sarcoidosis in a 64-year-old man with persistent leucopenia.
Thrombocytopenia and angiotensin converting enzyme inhibitors.
Thrombocytopenia induced by angiotensin converting enzyme inhibitors.
[Process in Citation].
[Successful treatment with enzyme replacement therapy for pelvic fragile fracture in an elderly case of type I Gaucher's disease].
Thrombocytosis
Bartonella henselae Infection: An Uncommon Mimicker of Autoimmune Disease.
Peripheral sea-fan retinal neovascularization as a manifestation of chronic rhegmatogenous retinal detachment and surgical management.
Thromboembolism
Angiotensin-converting enzyme gene polymorphism: I and D alleles from some different countries.
Solitary focal coronary artery aneurysm in a middle aged male with atypical chest pain.
The management of idiopathic nephrotic syndrome in children.
Thrombophilia
Amaurosis fugax caused by hereditary thrombophilia due to mutation of gene.
Induction of a hypercoagulability state and endothelial cell activation by granulocyte colony-stimulating factor in peripheral blood stem cell donors.
Thrombosis
A comparative study of captopril and enalapril on endothelial cell function in congestive heart failure patients.
ACE DD genotype: an independent predisposition factor to venous thromboembolism.
ACE2 Activation Promotes Anti-Thrombotic Activity.
Acute pulmonary and moderate cardiovascular responses of spontaneously hypertensive rats after exposure to single-wall carbon nanotubes.
Acute renal thrombosis induced by angiotensin-converting enzyme inhibitors in patients with renovascular hypertension.
Adverse safety events in patients with chronic kidney disease (CKD).
An evaluation of an angiotensin-converting enzyme gene polymorphism and the risk of arterial thrombosis in patients with the antiphospholipid syndrome.
An updated clinical primer on large artery mechanics: implications of pulse waveform analysis and arterial tonometry.
Angiotensin-converting enzyme gene polymorphism: I and D alleles from some different countries.
Antithrombotic effect of tissue and plasma type angiotensin converting enzyme inhibitors in experimental thrombosis in rats.
Beneficial effect of combined spironolactone and quinapril treatment on thrombosis and hemostasis in 2K1C hypertensive rats.
Cerebral Venous Sinus Thrombosis as an Unexpected Complication of COVID-19 Pneumonia.
Clinical characteristics and outcomes of critically ill patients with COVID-19 in a tertiary community hospital in upstate New York.
COVID-19 Pathogenesis: From Molecular Pathway to Vaccine Administration.
COVID-19 related thrombi in ascending and descending thoracic aorta with peripheral embolization: a case report.
Effects of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers on Prothrombotic Processes and Myocardial Infarction Risk.
Has the controversy over the use of calcium channel blockers in coronary artery disease been resolved?
Imidapril, an angiotensin-converting enzyme inhibitor, inhibits thrombosis via reduction in aortic plasminogen activator inhibitor type-1 levels in spontaneously hypertensive rats.
Ischemic nephropathy: clinical characteristics and treatment.
Lack of association between potential prothrombotic genetic risk factors and arterial and venous thrombosis.
Modulation of arterial thrombosis by angiotensin-converting enzyme inhibition and angiotensin II type 1-receptor blockade.
Potentiation of the inhibitory effect of a thromboxane A2 antagonist (L-640,035) on arterial thrombosis formation in rabbit by the angiotensin converting enzyme inhibitor enalapril.
Prevalence of the fibrinogen beta-chain, angiotensin-converting enzyme and plasminogen activator inhibitor-1 polymorphisms in Costa Rican young adults with thrombotic disease.
Renal artery thrombosis with acute renal failure after withdrawal of angiotensin converting enzyme inhibitor: a case report.
Significant correlation of angiotensin converting enzyme and glycoprotein IIIa genes polymorphisms with unexplained recurrent pregnancy loss in north of Iran.
The presence of PAI-1 4G/5G and ACE DD genotypes increases the risk of early-stage AVF thrombosis in hemodialysis patients.
The prothrombotic paradox of hypertension: role of the renin-angiotensin and kallikrein-kinin systems.
Vulnerable disease may induce neointimal coverage after sirolimus-eluting stent implantation.
What should the role of ACE inhibitors be in the treatment of diabetes? Lessons from HOPE and MICRO-HOPE.
[Gene polymorphisms of rennin-angiotensin system and coronary artery thrombosis disease.]
[Preliminary exploration on effect of yiqi wenyang huoxue lishui treatment on neuroendocrine system in patients with congestive heart failure]
Thrombotic Microangiopathies
Aldosterone plays a pivotal role in the pathogenesis of thrombotic microangiopathy in SHRSP.
Renal involvement in autoimmune connective tissue diseases.
Thrombotic microangiopathy due to malignant hypertension following corticosteroid therapy for microscopic polyangitis.
[Non SLE connective tissue diseases: general aspects and kidney]
Thyroid Diseases
Factors affecting the sensitivity of Tc-99m methoxyisobutylisonitrile dual-phase parathyroid single photon emission computed tomography in primary hyperparathyroidism.
Thyroiditis
Effects of angiotensin II blockade on the development of autoimmune thyroiditis in nonobese diabetic mice.
Elevated serum angiotensin-converting enzyme in hyperthyroidism.
Serum angiotensin-converting enzyme. Alterations in hyperthyroidism, hypothyroidism, and subacute thyroiditis.
Thyroid hormones affect serum angiotensin I converting enzyme levels.
Thyroiditis, Autoimmune
Effects of angiotensin II blockade on the development of autoimmune thyroiditis in nonobese diabetic mice.
Thyroiditis, Subacute
Serum angiotensin-converting enzyme. Alterations in hyperthyroidism, hypothyroidism, and subacute thyroiditis.
Thyrotoxicosis
[Recent parameters for diagnosis of challenging thyroid gland disorders: consequences for diagnosis and therapy]
Tinnitus
Angiotensin-Converting Enzyme (ACE) I/D and Alpha-Adducin (ADD1) G460W Gene Polymorphisms in Turkish Patients with Severe Chronic Tinnitus.
Positive Association between Tinnitus and Arterial Hypertension.
tissue kallikrein deficiency
Kallikrein protects against microalbuminuria in experimental type I diabetes.
Torsades de Pointes
Computer prediction of cardiovascular and hematological agents by statistical learning methods.
Sex, drugs, and heart failure: a sex-sensitive review of the evidence base behind current heart failure clinical guidelines.
Toxoplasmosis
Associations of Fuchs heterochromic iridocyclitis in a South Indian patient population.
Neuroretinitis as a manifestation of Lyme disease in South India: a case report.
Severe uveitis in an HLA-B27-positive patient with ankylosing spondylitis.
Vitritis as the primary manifestation of ocular syphilis in patients with HIV infection.
Transfusion Reaction
Acute hypotensive transfusion reaction during liver transplantation in a patient on angiotensin converting enzyme inhibitors from low aminopeptidase P activity.
Acute Hypotensive Transfusion Reaction With Concomitant Use of Angiotensin-Converting Enzyme Inhibitors: A Case Report and Review of the Literature.
Clinical Pattern in Hypotensive Transfusion Reactions.
Hypotensive Transfusion Reaction Treated With Vasopressin in a Patient Taking an Angiotensin-Converting Enzyme Inhibitor: A Case Report.
Hypotensive transfusion reactions can occur with blood products that are leukoreduced before storage.
Hypotensive transfusion reactions in patients taking angiotensin-converting-enzyme inhibitors.
Tricuspid Valve Insufficiency
Impact of interventricular lead distance and the decrease in septal-to-lateral delay on response to cardiac resynchronization therapy.
Tuberculosis
Acute Kidney Injury Secondary to Necrotizing Sarcoid Granulomatosis.
Angiotensin-converting enzyme in sarcoidosis: a British study.
Angiotensin-Converting Enzyme Inhibitors and Active Tuberculosis: A Population-Based Study.
Brassicasterol with Dual Anti-Infective Properties against HSV-1 and Mycobacterium tuberculosis, and Cardiovascular Protective Effect: Nonclinical In Vitro and In Silico Assessments.
Elevated serum angiotensin I converting enzyme in sarcoidosis.
Pleural fluid beta-2-microglobulin and angiotensin-converting enzyme concentrations in rheumatoid arthritis and tuberculosis.
Revised Korean Cough Guidelines, 2020: Recommendations and Summary statements.
Sarcoidosis mythology.
Serum and lymph-node collagenase in sarcoidosis. Comparison with angiotensin-converting enzyme.
Serum angiotensin-converting enzyme activity, concentration, and specific activity in granulomatous interstitial lung disease, tuberculosis, and COPD.
Serum angiotensin-converting enzyme in sarcoidosis.
The Korean Cough Guideline: Recommendation and Summary Statement.
The usefulness of angiotensin converting enzyme in the differential diagnosis of Crohn's disease and intestinal tuberculosis.
The value of angiotensin-I-converting enzyme determinations in malignant and other diseases.
Vitritis as the primary manifestation of ocular syphilis in patients with HIV infection.
[Angiotensin converting enzyme as a diagnostic aid in newly diagnosed sarcoidosis compared with pulmonary cancer and tuberculosis]
[Angiotensin converting enzyme in the blood serum of patients with tuberculosis and leprosy]
[Angiotensin-converting enzyme (ACE) in sarcoidosis, tuberculosis, silicosis, and coal mining workers]
[Effects of angiotensin-converting enzyme inhibitors and cosaar on quality of life of patients with pulmonary tuberculosis and chronic heart failure]
[Significance of elevated serum ACE in pneumology]
[The evaluation of serum angiotensin-converting enzyme in silicosis and silicotuberculosis]
Tuberculosis, Miliary
[Elevated serum angiotensin-converting enzyme in miliary tuberculosis]
Tuberculosis, Pulmonary
Serum angiotensin converting enzyme activity in sarcoidosis and pulmonary tuberculosis.
Serum angiotensin converting enzyme in the diagnosis of pulmonary sarcoidosis.
Serum angiotensin-converting enzyme and delayed hypersensitivity in pulmonary tuberculosis.
Tests of activity in pulmonary tuberculosis in elderly patients: serum angiotensin converting enzyme and serum albumin.
[Angiotensin converting enzyme in the blood serum of patients with tuberculosis and leprosy]
[Effects of angiotensin-converting enzyme inhibitors and cosaar on quality of life of patients with pulmonary tuberculosis and chronic heart failure]
[Respiratory and renal functions and blood electrolytic composition in patients with pulmonary tuberculosis in the treatment of heart failure]
Twins, Conjoined
Labeled lectin studies of renal tubular dysgenesis and renal tubular atrophy of postnatal renal ischemia and end-stage kidney disease.
Undifferentiated Connective Tissue Diseases
Recovery of renal function in undifferentiated connective tissue disease after treatment with angiotensin-converting enzyme inhibitors.
Uremia
Clinical aspects of cardiomyopathy in dialysis patients.
Effects of benazepril on insulin resistance and glucose tolerance in uremia.
New insights into the epidemiologic and clinical manifestations of atherosclerotic renovascular disease.
Paricalcitol Downregulates Myocardial Renin-Angiotensin and Fibroblast Growth Factor Expression and Attenuates Cardiac Hypertrophy in Uremic Rats.
Prevention of cardiac hypertrophy in experimental chronic renal failure by long-term ACE inhibitor administration: potential role of lysosomal proteinases.
Ureteral Obstruction
Altered regulation of renin-angiotensin, endothelin and natriuretic peptide systems in rat kidney with chronic unilateral ureteral obstruction.
Angiotensin-converting enzyme inhibition aggravates renal interstitial injury resulting from partial unilateral ureteral obstruction in the neonatal rat.
Beneficial effects of a combination of Rho-kinase inhibitor and ACE inhibitor on tubulointerstitial fibrosis induced by unilateral ureteral obstruction.
Effect of unilateral ureteral obstruction and anti-angiotensin II treatment on renal tubule and interstitial cell apoptosis in rats.
Effects of dietary protein on glomerular eicosanoid production in rats with bilateral ureteral obstruction.
Eicosanoid production by isolated glomeruli of rats with unilateral ureteral obstruction.
Enalapril accelerates remodeling of the renal interstitium after release of unilateral ureteral obstruction in rats.
Regulation of the renal angiotensin II receptor gene in acute unilateral ureteral obstruction.
Renal angiotensin converting enzyme promotes renal damage during ureteral obstruction.
Role of ANG II in eicosanoid production by isolated glomeruli from rats with bilateral ureteral obstruction.
Role of angiotensin II in the tubulointerstitial fibrosis of obstructive nephropathy.
The pathophysiology of obstructive nephropathy: the role of vasoactive compounds in the hemodynamic and structural abnormalities of the obstructed kidney.
Zinc deficiency further increases the enhanced expression of endothelin-1 in glomeruli of the obstructed kidney.
[The effect of captopril on the arterial pressure, structural resistance and vascular reactivity of the kidney in rats with nephrogenic hypertension]
[The expression of AT1A receptor and its modulation by benazepril in the renal tubulointerstitial lesions induced by ureteral obstruction]
Urinary Bladder Neoplasms
Prognostic Value of Renin-Angiotensin System Blockade in Non-muscle-invasive Bladder Cancer.
Renin-Angiotensin Inhibitors Decrease Recurrence after Transurethral Resection of Bladder Tumor in Patients with Nonmuscle Invasive Bladder Cancer.
[Influence of Renin-angiotensin System Blockage on Recurrence of Non-muscle-invasive Bladder Cancer].
Urinary Calculi
The mechanistic insight of polyphenols in calcium oxalate urolithiasis mitigation.
Urinary Incontinence
Management of hypertension in older patients.
Nocturnal Polyuria in Older Women with Urge Urinary Incontinence: Role of Sleep Quality, Time in Bed and Medications Used.
Risk Factors for Falls in Hospital In-Patients: A Prospective Nested Case Control Study.
Stress urinary incontinence due to prescription medications: alpha-blockers and angiotensin converting enzyme inhibitors.
The effect of angiotensin inhibition on urinary incontinence: Data from the National Health and Nutrition Examination Survey (2001-2008).
Urinary Incontinence, Urge
The effect of angiotensin inhibition on urinary incontinence: Data from the National Health and Nutrition Examination Survey (2001-2008).
Urinary Tract Infections
Angiotensin-Converting Enzyme Inhibitor Treatment and the Development of Urinary Tract Infections: A Prescription Sequence Symmetry Analysis.
Association between vitamin D receptor gene polymorphisms and tubular citrate handling in calcium nephrolithiasis.
Effects of pentoxifylline on the urinary protein excretion profile of type 2 diabetic patients with microproteinuria: A double-blind, placebo-controlled randomized trial.
Increased urine angiotensin I converting enzyme activity in patients with upper urinary tract infection.
Polymorphisms of the angiotensin converting enzyme and angiotensin II type 1 receptor genes and renal scarring in non-uropathic children with recurrent urinary tract infection.
Relationship of microalbuminuria with the diabetic foot ulcers in type II diabetes.
[ACE gene polymorphism and renal scarring in children with urinary tract infection and vesicoureteric reflux: preliminary results]
Urolithiasis
Antiurolithiatic effects of pentacyclic triterpenes: The distance traveled from therapeutic aspects.
Increased urinary excretion of renal enzymes in idiopathic calcium oxalate nephrolithiasis.
[Beneficial effect of angiotensin converting enzyme inhibitor treatment in severe cystine urolithiasis]
Urologic Diseases
Potential risk factors associated with progressive renal damage in childhood urological diseases: the role of angiotensin-converting enzyme gene polymorphism.
Urticaria
: Angio-oedema and urticaria associated with angiotensin converting enzyme inhibitors.
Angio-oedema and urticaria associated with angiotensin converting enzyme inhibitors.
Angioedema due to angiotensin-converting enzyme inhibitors.
Angioedema.
Angioedema: A Life-threatening Complication of Tissue Plasminogen Activator.
Angiooedema and urticaria with angiotensin converting enzyme inhibitors.
Chronic Urticaria and Recurrent Angioedema: Clues to the Mimics.
Clinical Features and Outcomes Associated with Angioedema in the Emergency Department.
Cold urticaria and angiotensin converting enzyme inhibitor.
Delayed diagnosis of angiotensin-converting enzyme (ACE) inhibitor induced angioedema and urticaria.
Drug-induced urticaria and angioedema caused by non-IgE mediated pathomechanisms.
Drug-induced urticaria.
Management of allergic disease in the elderly: key considerations, recommendations and emerging therapies.
Urticaria and angioedema.
Uterine Cervical Neoplasms
Acute chemoradiotherapy toxicity in cervical cancer patients.
Uveitis
Acute tubulointerstitial nephritis and uveitis with angiotensin-converting enzyme increase.
An 82 year-old patient with sarcoidosis.
Angiotensin-converting enzyme in sarcoid and chalazion granulomas of the conjunctiva.
Angiotensin-converting enzyme in sarcoid uveitis.
Angiotensin-converting enzyme in uveitis and sarcoidosis.
Associations of Fuchs heterochromic iridocyclitis in a South Indian patient population.
Concentration of angiotensin-converting enzyme in tears of patients with sarcoidosis.
Diagnostic Value of Serum-Soluble Interleukin 2 Receptor Levels vs Angiotensin-Converting Enzyme in Patients With Sarcoidosis-Associated Uveitis.
Heerfordt's Syndrome Presenting with Recurrent Facial Nerve Palsy: Case report and 10-year literature review.
Interleukin-2 Receptor and Angiotensin-Converting Enzyme as Markers for Ocular Sarcoidosis.
Limited gallium scans and angiotensin converting enzyme in granulomatous uveitis.
Ocular Manifestations of Biopsy-Proven Pulmonary Sarcoidosis in Korea.
Peripapillary subretinal neovascularization in presumed sarcoidosis.
Relevance of Brain MRI in Patients with Uveitis: Retrospective Cohort on 402 Patients.
Reversible esophageal motility disorder in a patient with sarcoidosis.
Sarcoidosis with marked necrosis in enlarged lymph nodes mimics mycobacterial infection: a case report.
Serum Angiotensin-Converting Enzyme Has a High Negative Predictive Value in the Investigation for Systemic Sarcoidosis.
Subclinical Choroidal Inflammation Revealed by Indocyanine Green Angiography in Tubulointerstitial Nephritis and Uveitis Syndrome.
Tattoo skin reaction as a skin manifestation of systemic sarcoidosis.
The predictive value of serum angiotensin converting enzyme and lysozyme levels in the diagnosis of ocular sarcoidosis.
The value of laboratory testing in uveitis.
Therapeutic targets of renin-angiotensin system in ocular disorders.
Truncal polyradiculopathy due to sarcoidosis.
Tumor necrosis factor (TNF)-308, -1031, and angiotensin-converting enzyme (ACE) DD/II polymorphisms' role in Behcet's disease with and without uveitis: a meta-analysis.
Usefulness of Combined Measurement of Serum Soluble IL-2R and Angiotensin-Converting Enzyme in the Detection of Uveitis Associated with Japanese Sarcoidosis.
Uveitis associated with sarcoidosis and angiotensin converting enzyme.
Uveitis: the collaborative diagnostic evaluation.
[A case of elderly onset sarcoidosis]
[A case of pulmonary sarcoidosis mimicking relapse of pulmonary tuberculosis]
[A case of relapsing sarcoidosis with pleurisy 14 years after spontaneous remission]
[A case of sarcoidosis following chemotherapy for follicular lymphoma].
[A case of sarcoidosis with right pneumothorax and multiple cavities in both lung fields]
[A case of so-called Lennert's lymphoma, suspected of sarcoidosis due to uveitis occurring first and elevation of serum angiotensin-converting enzyme (ACE)]
[Bilateral recurrent blurred vision associated with halos around sources of light and headache].
[Serum adenosine deaminase and angiotensin converting enzyme activity in patients with endogenous uveitis]
[Studies on serum angiotensin converting enzyme in endogenous uveitis (author's transl)]
[The behavior of angiotensin-converting enzyme in patients with uveitis]
Uveitis, Anterior
Long-term use of corticosteroid eye drops delays the spontaneous remission of pulmonary sarcoidosis.
The value of laboratory testing in uveitis.
Uveitis, Intermediate
Relevance of Brain MRI in Patients with Uveitis: Retrospective Cohort on 402 Patients.
Uveitis, Posterior
A comparison of Blau's syndrome and sarcoidosis.
Granulomatous optic neuropathy.
Uveitis: Diagnostic work-up. A literature review and recommendations from an expert committee.
[Uveitis: Diagnostic work-up. Recommendations from an expert committee].
Varicocele
Somatic angiotensin converting enzyme in varicocele.
Vascular Calcification
User of angiotensin-converting-enzyme inhibitor and/or angiotensin II receptor blocker might be associated with vascular calcification in predialysis chronic kidney disease patients: a retrospective single-center observational study : ACEI/ARB and vascular calcification.
Vascular Diseases
A pharmacogenetic analysis of determinants of hypertension and blood pressure response to angiotensin-converting enzyme inhibitor therapy in patients with vascular disease and healthy individuals.
A population study of ethnic variations in the angiotensin-converting enzyme I/D polymorphism: relationships with gender, hypertension and impaired glucose metabolism.
A targetable, injectable adenoviral vector for selective gene delivery to pulmonary endothelium in vivo.
ACE gene polymorphism and survival in atherosclerotic renovascular disease.
Adherence to guideline-recommended therapies among patients with diverse manifestations of vascular disease.
Advances in noninvasive screening for renovascular disease.
Analysis of risk factors for occlusions of a synthetic femoropopliteal bypass graft.
Angiotensin converting enzyme activity and evolution of pulmonary vascular disease in rats with monocrotaline pulmonary hypertension.
Angiotensin I-converting enzyme insertion-related genotypes and allele are associated with higher susceptibility of endometriosis and leiomyoma.
Angiotensin II and monocrotaline-induced pulmonary hypertension: effect of losartan (DuP 753), a nonpeptide angiotensin type 1 receptor antagonist.
Angiotensin-converting enzyme (ACE) inhibition in the secondary prevention of vascular disease: the Heart Outcomes Prevention Evaluation (HOPE) Trial and its substudies.
Angiotensin-converting enzyme gene polymorphism in non-insulin dependent diabetes mellitus and its relationship with diabetic nephropathy.
Angiotensin-converting enzyme inhibition improves vascular function in rheumatoid arthritis.
Angiotensin-converting enzyme inhibitors in patients with vascular disease.
Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers are beneficial in normotensive atherosclerotic patients: a collaborative meta-analysis of randomized trials.
Angiotensin-converting enzyme inhibitors, angiotensin receptor blockers and combined therapy in patients with micro- and macroalbuminuria and other cardiovascular risk factors: a systematic review of randomized controlled trials.
Angiotensin-converting enzyme insertion/deletion polymorphism and cerebrovascular disease.
Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials.
Association of angiotensin-converting enzyme and endothelial Nitric Oxide synthase gene polymorphisms with vascular disease in ESRD patients in a Chinese population.
Cardiovascular protection: a breakthrough for high-risk patients?
Cilazapril delays progression of hypertension and uremia in rat polycystic kidney disease.
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2017 EXECUTIVE SUMMARY.
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2018 EXECUTIVE SUMMARY.
Elevations in serum creatinine concentration: concerning or reassuring?
Endogenous nitric oxide in cardiovascular disease and transplantation.
Endothelial dysfunction: A potential therapeutic target for geriatric depression and brain amyloid deposition in Alzheimer's disease?
Endothelial function studies in pulmonary vascular disease: determination of angiotensin converting enzyme activity in humans (review).
Evaluation of recent fixed-dose combination therapies in the management of hypertension.
Haemoglobin level and vascular access survival in haemodialysis patients.
Hypertension in the elderly with coexisting benign prostatic hyperplasia.
I/D genetic polymorphism of angiotensin-converting enzyme: pathogenesis evaluation for erectile dysfunction by gene ontology.
Imagine how many lives you save: angiotensin-converting enzyme inhibition for atherosclerotic vascular disease in the present era of risk reduction.
In-hospital Initiation of Cardiovascular Protective Therapies to Improve Treatment Rates and Clinical Outcomes: The University of California-Los Angeles, Cardiovascular Hospitalization Atherosclerosis Management Program.
Increased angiotensin-converting enzyme activities in diabetes mellitus: analysis of diabetes type, state of metabolic control and occurrence of diabetic vascular disease.
Lack of association between deletion polymorphism of the ACE gene and ischemic vascular diseases in a Chinese population in Taiwan.
Local renin-angiotensin systems in the genitourinary tract.
Management of diastolic heart failure.
Meta-Analysis of Risks for Short-Term Readmission in Patients With Heart Failure.
Neurological diseases as mortality predictive factors for patients with COVID-19: a retrospective cohort study.
Nitric oxide in atherosclerosis: vascular protector or villain?
Nitric oxide in cardiovascular disorders.
Nitric oxide in coronary artery disease: roles in atherosclerosis, myocardial reperfusion and heart failure.
Novel approach of molecular genetic understanding of iridology: relationship between iris constitution and angiotensin converting enzyme gene polymorphism.
Novel vascular biology of third-generation L-type calcium channel antagonists: ancillary actions of amlodipine.
Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial (ONTARGET): implications for reduced cardiovascular risk.
Pleiotropic effects of angiotensin receptor blockers: addressing comorbidities by optimizing hypertension therapy.
Potential indications for angiotensin-converting enzyme inhibitors in atherosclerotic vascular disease.
Predictors of decline of residual renal function in new peritoneal dialysis patients.
Preservation of renal function following partial or radical nephrectomy using 24-hour creatinine clearance.
Prevalence of renal artery stenosis in patients with peripheral vascular disease and hypertension.
Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis.
Quality of care for acute coronary syndrome patients with known atherosclerotic disease: results from the Get With the Guidelines Program.
RAAS Inhibition/Blockade in patients with Cardiovascular disease : Implications of recent large scale randomized trials for clinical practice.
Re-examining RAS-blocking treatment regimens for abrogating progression of chronic kidney disease.
Retraction. Endothelial function studies in pulmonary vascular disease: determination of angiotensin converting enzyme activity in humans (review).
Short-term effects of angiotensin receptor blockers on blood pressure control, and plasma inflammatory and fibrinolytic parameters in patients taking angiotensin-converting enzyme inhibitors.
Telmisartan, ramipril, or both in patients at high risk for vascular events.
The ACE gene I/D polymorphism is not associated with the blood pressure and cardiovascular benefits of ACE inhibition.
The effectiveness and safety of angiotensin-converting enzyme inhibition or receptor blockade in vascular diseases in patients with hemodialysis.
Tooth loss is associated with an increased risk of hypertension in postmenopausal women.
Update on the ROADMAP clinical trial report: olmesartan for the prevention or delay of microalbuminuria development in Type 2 diabetes.
Vascular surgery and arterial hypertension.
Vasculoprotective and cardioprotective mechanisms of angiotensin-converting enzyme inhibition: the homeostatic balance between angiotensin II and nitric oxide.
Vasopeptidase inhibition: a new direction in cardiovascular treatment.
Which patients have the highest cardiovascular risk? A follow-up study from Turkey.
[ADVANCE study: objectives, design and current status]
[Clinical study of the month. The HOPE study, a two-by-two factorial clinical trial with contrasted results]
[Occurrence of renal artery stenosis in patients with peripheral arteriosclerosis and hypertension]
[ONTARGET: similar protection of telmisartan and ramipril and lack of benefit of combined therapy in patients at high risk for vascular events]
[The renin-angiotensin system and progression of kidney disease]
Vascular System Injuries
Angiotensin converting enzyme inhibitor restrains inflammation-induced vascular injury in mice.
Angiotensin converting enzyme: history and relevance.
Angiotensin I-converting enzyme activity and vascular sensitivity to angiotensin I in rat injured carotid artery.
Angiotensin II type 2 receptor expression after vascular injury: differing effects of angiotensin-converting enzyme inhibition and angiotensin receptor blockade.
Angiotensin-converting enzyme inhibitor cilazapril suppresses expression of basic fibroblast growth factor messenger ribonucleic acid and protein in endothelial and intimal smooth muscle cells in a vascular injury model of spontaneous hypertensive rats.
Association of the D allele of the angiotensin I converting enzyme polymorphism with malignant vascular injury.
Bradykinin receptor antagonists attenuate neointimal proliferation postangioplasty.
Captopril reduces graft coronary artery disease in a rat heterotopic transplant model.
Chymase: a new pharmacologic target in cardiovascular disease.
Effect of aldosterone and mineralocorticoid receptor blockade on vascular inflammation.
Effect of high dose angiotensin-converting enzyme inhibition on restenosis: final results of the MARCATOR Study, a multicenter, double-blind, placebo-controlled trial of cilazapril. The Multicenter American Research Trial With Cilazapril After Angioplasty to Prevent Transluminal Coronary Obstruction and Restenosis (MARCATOR) Study Group.
Effects of angiotensin converting enzyme inhibition with cilazapril on intimal hyperplasia in injured arteries and vascular grafts in the baboon.
Fibroblast growth factor stimulates angiotensin converting enzyme expression in vascular smooth muscle cells. Possible mediator of the response to vascular injury.
Important role of nitric oxide in the effect of angiotensin-converting enzyme inhibitor imidapril on vascular injury.
Increased concentrations of angiotensin-converting enzyme in the intimal hyperplasia of experimental vein grafts.
Induction of angiotensin converting enzyme in the neointima after vascular injury. Possible role in restenosis.
Influence of the status of the renin-angiotensin system on the effect of cilazapril on neointima formation after vascular injury in rats.
Inhibition of injury induced intimal hyperplasia by saralasin in rats.
Inhibitors of angiotensin-converting enzyme prevent myointimal proliferation after vascular injury.
Mechanism Analysis of a Novel Angiotensin-I-Converting Enzyme Inhibitory Peptide from Isochrysis zhanjiangensis Microalgae for Suppressing Vascular Injury in Human Umbilical Vein Endothelial Cells.
Prevention of neointima formation by mibefradil after vascular injury in rats: comparison with ACE inhibition.
Quinapril with high affinity to tissue angiotensin-converting enzyme reduces restenosis after percutaneous transcatheter coronary intervention.
Quinaprilat-eluting stents do not attenuate intimal thickening following stenting in porcine coronary arteries.
Role of angiotensin II in injury-induced neointima formation in rats.
Suppression of vascular transforming growth factor-beta1 and extracellular matrix gene expressions by cilazapril and nifedipine in hypertensive rats.
The proliferative response to vascular injury is suppressed by angiotensin-converting enzyme inhibition.
Vascular injury in systemic sclerosis: angiotensin-converting enzyme insertion/deletion polymorphism.
Vascular remodeling and the kallikrein-kinin system.
[History of the renin-angiotensin system: great men, a great finding].
Vasculitis
A Pooled Study of Angiotensin-Converting Enzyme Insertion/Deletion Gene Polymorphism in Relation to Risk, Pathology and Prognosis of Childhood Immunoglobulin A Vasculitis Nephritis.
Angiotensin converting enzyme a new tool for the follow-up of endothelial injury in paediatric vasculitides.
Associations between the angiotensin-converting enzyme insertion/deletion polymorphism and susceptibility to vasculitis: a meta-analysis.
Clinical features of cardiac lesion in patients with generalized sarcoidosis.
Enalapril-associated erythema and vasculitis.
[Etiologic aspects of acute renal insufficiency in the adult]
Vasculitis, Central Nervous System
Pulmonary vascular involvement in sarcoidosis: granulomatous angiitis and microangiopathy in transbronchial lung biopsies.
Vasoplegia
Early On-Cardiopulmonary Bypass Hypotension and Other Factors Associated With Vasoplegic Syndrome.
Low systemic vascular resistance after cardiopulmonary bypass: incidence, etiology, and clinical importance.
Preoperative methylene blue administration in patients at high risk for vasoplegic syndrome during cardiac surgery.
Risk factors for vasoplegia after coronary artery bypass and valve surgery.
Vasospasm, Intracranial
Alacepril, an angiotensin-converting enzyme inhibitor, prevents cerebral vasospasm in subarachnoid hemorrhage model in rats.
Reversal of experimental acute cerebral vasospasm by angiotensin converting enzyme inhibition.
Reversal of experimental delayed cerebral vasospasm by angiotensin-converting enzyme inhibition.
Venous Thromboembolism
ACE DD genotype: an independent predisposition factor to venous thromboembolism.
Clinical care of pregnant and postpartum women with COVID-19: Living recommendations from the National COVID-19 Clinical Evidence Taskforce.
Clinical characteristics and outcomes of critically ill patients with COVID-19 in a tertiary community hospital in upstate New York.
Effect of the angiotensin-converting enzyme gene deletion polymorphism on the risk of venous thromboembolism.
Inhibition of renin angiotensin axis may be associated with reduced risk of developing venous thromboembolism in patients with atherosclerotic disease.
Meta-Analysis of Association Between Insertion/Deletion Polymorphism of the Angiotensin I-Converting Enzyme Gene and Venous Thromboembolism.
Prognostic factors for adverse outcomes in patients with COVID-19: a field-wide systematic review and meta-analysis.
Risk of venous thromboembolism associated with the insertion/deletion polymorphism in the angiotensin-converting enzyme gene.
The ACE D/D genotype is protective against the development of idiopathic deep vein thrombosis and pulmonary embolism.
The angiotensin-converting enzyme insertion/deletion polymorphism and serum levels of angiotensin-converting enzyme in venous thromboembolism. Data from a case control study.
The deletion polymorphism in the angiotensin-converting enzyme gene is a moderate risk factor for venous thromboembolism.
[The investigation of angiotensin converting enzyme I/D and plasminogen activator inhibitor-1 4G/5G polymorphisms in venous thromboembolism patients].
Venous Thrombosis
2012 Brazilian Society of Rheumatology Consensus on the management of comorbidities in patients with rheumatoid arthritis.
ACE DD genotype: an independent predisposition factor to venous thromboembolism.
Antithrombotic effect of enalapril, an angiotensin-converting enzyme inhibitor, on venous thrombosis in rats.
Clinical characteristics and outcomes of critically ill patients with COVID-19 in a tertiary community hospital in upstate New York.
Deletion polymorphism in the angiotensin-converting enzyme gene as a thrombophilic risk factor after hip arthroplasty.
Genetic factors associated with thrombosis in pregnancy in a United States population.
Nitric oxide and prostacyclin are involved in antithrombotic action of captopril in venous thrombosis in rats.
The angiotensin-converting enzyme gene insertion/deletion polymorphism: insufficient evidence for a role in deep venous thrombosis.
The angiotensin-converting-enzyme insertion/deletion polymorphism is not related to venous thrombosis.
[Update cardiology 2006/2007]
Ventilator-Induced Lung Injury
Angiotensin-converting enzyme inhibitor captopril attenuates ventilator-induced lung injury in rats.
Role of the renin-angiotensin system in ventilator-induced lung injury: an in vivo study in a rat model.
Ventricular Dysfunction
A word on netting of angiotensin-converting enzyme inhibitor therapy in hypoplastic left heart syndrome following stage-I.
Angiotensin II receptor blockade and myocardial fibrosis of the infarcted rat heart.
Angiotensin-converting enzyme inhibitor therapy for ventricular dysfunction in infants, children and adolescents: a review.
Calcium antagonists in patients with left ventricular dysfunction: back on the bridge?
Do cardiologists at a university hospital adopt the guidelines for the treatment of heart failure?
Effect of anti-heart failure therapy on diastolic function in children with single-ventricle circulations.
Effects of angiotensin-converting enzyme inhibitor on plasma B-type natriuretic peptide levels in patients with acute myocardial infarction.
Exercise training reduces cardiac angiotensin II levels and prevents cardiac dysfunction in a genetic model of sympathetic hyperactivity-induced heart failure in mice.
From Other Journals: A Review of Recent Articles in Pediatric Cardiology.
Inhibition of the renin-angiotensin-aldosterone system in heart failure: new insights from basic clinical research.
Managed care patients with heart failure: spectrum of ventricular dysfunction and predictors of medication utilization.
Prevention of remodeling in congestive heart failure due to myocardial infarction by blockade of the renin-angiotensin system.
Safety and efficacy of epoprostenol in patients with severe congestive heart failure. Epoprostenol Multicenter Research Group.
Simultaneous angiotensin converting enzyme inhibition moderates ventricular dysfunction caused by doxorubicin.
The effects of ACE inhibition on progression of atherosclerosis.
[Hospitalized congestive heart failure patients with preserved versus abnormal left ventricular systolic function]
[The treatment of asymptomatic ventricular dysfunction with angiotensin-converting enzyme inhibitors]
Ventricular Dysfunction, Left
"Escape" of aldosterone production in patients with left ventricular dysfunction treated with an angiotensin converting enzyme inhibitor: implications for therapy.
A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group.
A personal perspective on the treatment of heart failure in 1994.
A pharmacoeconomic model to aid in the allocation of ambulatory clinical pharmacy services.
A pragmatic approach to the use of angiotensin-converting enzyme inhibitors in acute myocardial infarction.
A review of Perindopril in the reduction of cardiovascular events.
A systematic review: effect of angiotensin converting enzyme inhibition on left ventricular volumes and ejection fraction in patients with a myocardial infarction and in patients with left ventricular dysfunction.
ACE gene insertion/deletion polymorphism has a mild influence on the acute development of left ventricular dysfunction in patients with ST elevation myocardial infarction treated with primary PCI.
ACE inhibitor intolerance and lessons learned from the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) trials.
ACE inhibitors: myocardial infarction and congestive heart failure.
Acute intervention with captopril during thrombolysis in patients with first anterior myocardial infarction. Results from the Captopril and Thrombolysis Study (CATS).
Additive beneficial effects of beta-blockers to angiotensin-converting enzyme inhibitors in the Survival and Ventricular Enlargement (SAVE) Study. SAVE Investigators.
Administration of angiotensin-converting enzyme inhibitors and ?-blockers during adjuvant trastuzumab chemotherapy for nonmetastatic breast cancer: marker of risk or cardioprotection in the real world?
Adverse effects of combination angiotensin II receptor blockers plus angiotensin-converting enzyme inhibitors for left ventricular dysfunction: a quantitative review of data from randomized clinical trials.
Age- and sex-related bias in the management of heart disease in a district general hospital.
Age-related differences in management of heart disease: a study of cardiac medication use in an older cohort. Pacemaker Selection in the Elderly (PASE) Investigators.
Alteration of intracellular Ca2(+)-handling and receptor regulation in hypertensive cardiac hypertrophy: insights from Ren2-transgenic rats.
An integrated approach to diagnosis and therapeutic management of patients with systolic heart failure in the Copenhagen metropolitan area.
Angina and left ventricular dysfunction.
Angiotensin converting enzyme inhibitors for heart failure with reduced ejection fraction or left ventricular dysfunction: A complementary network meta-analyses.
Angiotensin converting enzyme inhibitors in bone marrow transplant recipients with depressed left ventricular function.
Angiotensin II and angiotensin 1-7: which is their role in atrial fibrillation?
Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
Angiotensin II receptor antagonists in heart failure: rationale and design of the evaluation of losartan in the elderly (ELITE) trial.
Angiotensin receptor blockers: therapeutic targets and cardiovascular protection.
Angiotensin-converting enzyme inhibition after myocardial infarction: the Trandolapril Cardiac Evaluation Study.
Angiotensin-converting enzyme inhibition and angiotensin II subtype-1 receptor blockade during the progression of left ventricular dysfunction: differential effects on myocyte contractile processes.
Angiotensin-converting enzyme inhibition facilitates alveolar-capillary gas transfer and improves ventilation-perfusion coupling in patients with left ventricular dysfunction.
Angiotensin-converting enzyme inhibitor as a risk factor for the development of anemia, and the impact of incident anemia on mortality in patients with left ventricular dysfunction.
Angiotensin-converting enzyme inhibitors and coronary heart disease prevention.
Angiotensin-converting enzyme inhibitors downregulate tissue factor synthesis in monocytes.
Angiotensin-converting enzyme inhibitors in left ventricular dysfunction.
Angiotensin-converting enzyme inhibitors, inhibition of brain and peripheral angiotensin-converting enzymes, and left ventricular dysfunction in rats after myocardial infarction.
Angiotensin-converting enzyme inhibitors, left ventricular dysfunction, and early heart failure.
ASHP therapeutic guidelines on angiotensin-converting-enzyme inhibitors in patients with left ventricular dysfunction. This official ASHP practice standard was developed through the ASHP Commission on Therapeutics and approved by the ASHP Board of Directors on November 16, 1996.
Aspirin and angiotensin-converting enzyme inhibitors are safe when taken together after acute myocardial infarction in patients with left ventricular dysfunction.
Augmented sympathoinhibitory effect of valsartan when added to angiotensin-converting enzyme inhibitor in patients with left ventricular dysfunction.
B1 kinin receptor does not contribute to vascular tone or tissue plasminogen activator release in the peripheral circulation of patients with heart failure.
Beneficial hemodynamic and renal effects of intravenous enalaprilat following coronary artery bypass surgery complicated by left ventricular dysfunction.
Beta-adrenergic blocking agent use and mortality in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a post hoc analysis of the Studies of Left Ventricular Dysfunction.
Beta-adrenergic blocking agents or angiotensin-converting enzyme inhibitors, or both, for postinfarction patients with left ventricular dysfunction.
Beta-adrenergic Receptor Blockers in Heart Failure.
Bioequivalence study of two formulations of enalapril, at a single oral dose of 20 mg (tablets): A randomized, two-way, open-label, crossover study in healthy volunteers.
Blockade of the renin-angiotensin system. Effect on mortality in patients with left ventricular systolic dysfunction.
Blood pressure response to the first dose of angiotensin-converting enzyme inhibitors in congestive heart failure.
Candesartan in the prevention of relapsing atrial fibrillation.
Cardiac effects of combination therapy in hypertension.
Cardiac toxicity of anticancer agents.
Cardiac Toxicity: Using Angiotensin-Converting Enzyme Inhibitors to Prevent Anthracycline-Induced Left Ventricular Dysfunction and Cardiomyopathy.
Cardioembolic stroke: call for a multidisciplinary approach.
Cardiomyopathy Caused by Antineoplastic Therapies.
Cardioreparative effects of lisinopril in rats with genetic hypertension and left ventricular hypertrophy.
Cardiovascular Complications of Neuromuscular Disorders.
Changes in left ventricular mass and volumes in patients receiving angiotensin-converting enzyme inhibitor therapy for left ventricular dysfunction after Q-wave myocardial infarction.
Chemotherapy induced cardiomyopathy: pathogenesis, monitoring and management.
Chronic dual inhibition of angiotensin-converting enzyme and neutral endopeptidase during the development of left ventricular dysfunction in dogs.
Chronic effects of ACE-inhibition (quinapril) and angiotensin-II-type-1 receptor blockade (losartan) on atrial natriuretic peptide in brain nuclei of rats with experimental myocardial infarction.
Chronic effects of enalapril and amlodipine on cardiac remodeling in cardiomyopathic hamster hearts.
Circulating angiotensin-converting enzyme is associated with left ventricular dysfunction, but not with central aortic hemodynamics.
Clinical experience in protecting the failing heart.
Clinical heart failure trials and the design rationale of Studies of Left Ventricular Dysfunction (SOLVD).
Clinical trials evaluating angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in the setting of acute myocardial infarction.
Coenzyme Q10 Modulates Remodeling Possibly by Decreasing Angiotensin-Converting Enzyme in Patients with Acute Coronary Syndrome.
Combination neurohormonal blockade with ACE inhibitors, angiotensin II antagonists and beta-blockers in patients with congestive heart failure: design of the Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) Pilot Study.
Combined effects of low-dose spironolactone and captopril therapy in a rat model of genetic hypertrophic cardiomyopathy.
Comparison between zofenopril and ramipril in combination with acetylsalicylic acid in patients with left ventricular systolic dysfunction after acute myocardial infarction: results of a randomized, double-blind, parallel-group, multicenter, European study (SMILE-4).
Comparison of Outcomes in Patients With Probable Versus Definite Cardiac Sarcoidosis.
Congestive heart failure. New frontiers.
Contemporary medical management of left ventricular dysfunction and congestive heart failure.
Current Treatment Options for CHF Management: Focus on the Renin-Angiotensin-Aldosterone System.
Digoxin use and digoxin toxicity in the post-DIG trial era.
Do angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers have similar effects in the improvement of left ventricular dysfunction after myocardial infarction in Japanese?
Does long-term angiotensin converting enzyme inhibition affect the concentration of tissue-type plasminogen activator-plasminogen activator inhibitor-1 in the blood of patients with a previous myocardial infarction.
Dosing of ACE inhibitors in left ventricular dysfunction: does current clinical dosing provide optimal benefit?
Doxorubicin-induced cardiomyopathy treated with carvedilol.
Dual-chamber pacing or ventricular backup pacing in patients with an implantable defibrillator: the Dual Chamber and VVI Implantable Defibrillator (DAVID) Trial.
Early and late angiotensin-converting enzyme inhibition in acute myocardial infarction.
Early intervention in heart failure.
Early neurohormonal effects of trandolapril in patients with left ventricular dysfunction and a recent acute myocardial infarction: a double-blind, randomized, placebo-controlled multicentre study.
Early prevention of left ventricular dysfunction after myocardial infarction with angiotensin-converting-enzyme inhibition.
Effect of activation and inhibition of the renin-angiotensin system on plasma PAI-1.
Effect of angiotensin converting enzyme inhibition after acute myocardial infarction in patients with arterial hypertension. TRACE Study Group, Trandolapril Cardiac Event.
Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on cardiovascular events in patients with heart failure: a meta-analysis of randomized controlled trials.
Effect of angiotensin-converting enzyme inhibitors in left ventricular dysfunction: results of the studies of left ventricular dysfunction in the context of other similar trials.
Effect of Combined Beta-Blocker and Angiotensin-Converting Enzyme Inhibitor Treatment on 1-Year Survival After Acute Myocardial Infarction: Findings of the PRIAMHO-II Registry.
Effect of comorbidities on outcomes and angiotensin converting enzyme inhibitor effects in patients with predominantly left ventricular dysfunction and heart failure.
Effect of enalapril initiated early after acute myocardial infarction on heart failure parameters, with reference to clinical class and echocardiographic determinants. CONSENSUS II Multi-Echo Study Group.
Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions.
Effect of infarct artery patency on prognosis after acute myocardial infarction. The Survival and Ventricular Enlargement Investigators.
Effect of prophylactic betablocker or ACE inhibitor on cardiac dysfunction & heart failure during anthracycline chemotherapy ± trastuzumab.
Effect of ramipril on postrevascularization prevalence of angina and quality of life.
Effect of the angiotensin-converting enzyme inhibitor trandolapril on mortality and morbidity in diabetic patients with left ventricular dysfunction after acute myocardial infarction. Trace Study Group.
Effectiveness of preload reserve as a determinant of clinical status in patients with left ventricular systolic dysfunction. The SOLVD Investigators.
Effects of a new angiotensin-converting enzyme inhibitor (idrapril) in rats with left ventricular dysfunction after myocardial infarction.
Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators.
Effects of angiotensin-converting enzyme inhibition with perindopril on left ventricular remodeling and clinical outcome: results of the randomized Perindopril and Remodeling in Elderly with Acute Myocardial Infarction (PREAMI) Study.
Effects of captopril therapy on endogenous fibrinolysis in men with recent, uncomplicated myocardial infarction.
Effects of long-term treatment with angiotensin-converting-enzyme inhibitors in the presence or absence of aspirin: a systematic review.
Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dysfunction in patients with heart failure. SOLVD Investigators.
Efficacy and safety of Angiotensin-converting enzyme inhibitors in patients with left ventricular systolic dysfunction and hyponatremia.
Efficacy of angiotensin-converting enzyme inhibition in reducing progression from asymptomatic left ventricular dysfunction to symptomatic heart failure in black and white patients.
Enalapril reduces the incidence of diabetes in patients with chronic heart failure: insight from the Studies Of Left Ventricular Dysfunction (SOLVD).
Enalaprilat decreases plasma endothelin and atrial natriuretic peptide levels and preload in patients with left ventricular dysfunction after cardiac surgery.
Epidemiologic analysis of racial/ethnic disparities: Some fundamental issues and a cautionary example.
Exacerbation of atherosclerosis by hypertension. Potential mechanisms and clinical implications.
Genotype-phenotype associations between chymase and angiotensin-converting enzyme gene polymorphisms in chronic systolic heart failure patients.
Heart failure disease management: impact on hospital care, length of stay, and reimbursement.
Heart failure, ventricular remodelling and the renin-angiotensin system: insights from recently completed clinical trials.
Hydrogen sulfide and vascular regulation - An update.
Hypertension and coronary artery disease: a summary of the american heart association scientific statement.
Imaging-Guided Cardioprotective Treatment in a Community Elderly Population of Stage B Heart Failure.
Impact of chronic kidney disease and anemia on hospitalization expense in patients with left ventricular dysfunction.
Impact of pharmacological treatment on mortality after myocardial infarction in diabetic patients.
Importance of angiotensin-converting enzyme inhibitors in myocardial infarction and congestive heart failure: implications for clinical practice.
Increased angiotensin converting enzyme activity in left ventricular aneurysm of patients after myocardial infarction.
Indications for immediate angiotensin-converting enzyme inhibition in patients with acute myocardial infarction.
Infantile facial haemangioma and subclinical left ventricular dysfunction: the importance of z score in the diagnostic and therapeutic process.
Influence of a history of arterial hypertension and pretreatment blood pressure on the effect of angiotensin converting enzyme inhibition after acute myocardial infarction. Trandolapril Cardiac Evaluation Study.
Influence of renal function on the use of guideline-recommended therapies for patients with heart failure.
Integrating traditional and emerging treatment options in heart failure.
International trials and national practice: a questionnaire survey of current physician practice in the treatment of acute myocardial infarction.
Ischemia Management with Accupril post bypass Graft via Inhibition of angiotensin coNverting enzyme (IMAGINE): a multicentre randomized trial - design and rationale.
Landmark study: the Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction Study (CAPRICORN).
Left ventricular systolic dysfunction and atrial fibrillation in older people in the community--a need for screening?
Lesser response to angiotensin-converting-enzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction.
Long-term combined therapy with losartan and an angiotensin-converting enzyme inhibitor improves functional capacity in patients with left ventricular dysfunction.
Management of hypertension in patients with cardiac disease: use of renin-angiotensin blocking agents.
Managing cardiotoxicity of chemotherapy.
Mechanistic lessons from the SAVE Study. Survival and Ventricular Enlargement.
Modulation of in vivo cardiac hypertrophy with insulin-like growth factor-1 and angiotensin-converting enzyme inhibitor: relationship between change in myosin isoform and progression of left ventricular dysfunction.
Myocardial effects of beta-agonist stimulation in rats with chronic left ventricular dysfunction treated with an angiotensin-converting enzyme inhibitor.
Myocardial infarction: when and how should we initiate treatment with ACE inhibitors? GISSI-3 Investigators.
Myocarditis.
Natriuretic peptides and cyclic guanosine 3',5'-monophosphate in asymptomatic and symptomatic left ventricular dysfunction.
Neurohormonal activation and congestive heart failure: today's experience with ACE inhibitors and rationale for their use.
Neurohormonal and hemodynamic effects of ibopamine.
Neurohormonal mechanisms and the role of angiotensin-converting enzyme (ACE) inhibitors in heart failure.
New information on the role of beta-blockers in cardiac therapy.
Ongoing clinical trials of angiotensin-converting enzyme inhibitors for treatment of coronary artery disease in patients with preserved left ventricular function.
Optimising pharmacotherapy for secondary prevention of non-invasively managed acute coronary syndrome.
Overview of the relationship between ischemia and congestive heart failure.
Performance assessment model for guideline-recommended pharmacotherapy in the secondary prevention of coronary artery disease and treatment of left ventricular dysfunction.
Pharmacologic management of angina and acute myocardial infarction.
Pharmacologic treatment of heart failure with standard drugs.
Pharmacological approaches in the treatment of atrial fibrillation.
Pharmacotherapy for heart failure with left ventricular dysfunction: beyond angiotensin-converting enzyme inhibitors and beta-blockers.
Potential indications for angiotensin-converting enzyme inhibitors in atherosclerotic vascular disease.
Predictors of decreased renal function in patients with heart failure during angiotensin-converting enzyme inhibitor therapy: results from the studies of left ventricular dysfunction (SOLVD)
Preventing congestive heart failure.
Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition.
Primary prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with end-stage renal disease undergoing dialysis.
Prognostic value of neurohumoral activation in patients with an acute myocardial infarction: effect of captopril.
Progression of left ventricular dysfunction secondary to coronary artery disease, sustained neurohormonal activation and effects of ibopamine therapy during long-term therapy with angiotensin-converting enzyme inhibitor.
Progressive left ventricular dysfunction and myocardial fibrosis in Duchenne and Becker muscular dystrophy: a longitudinal cardiovascular magnetic resonance study.
Quantification of the risk and predictors of hyperkalemia in patients with left ventricular dysfunction: a retrospective analysis of the Studies of Left Ventricular Dysfunction (SOLVD) trials.
Racial response to angiotensin-converting enzyme therapy in systolic heart failure.
Reasons for underuse of angiotensin-converting enzyme inhibitors in patients with heart failure and left ventricular dysfunction.
Recruitment strategies in the studies of left ventricular dysfunction (SOLVD): strategies for screening and enrollment in two concurrent but separate trials. The SOLVD Investigators.
Reduced mortality and morbidity with the use of angiotensin-converting enzyme inhibitors in patients with left ventricular dysfunction and congestive heart failure.
Reduction in mortality by pharmacological therapy in congestive heart failure.
Reduction of ischemic events with angiotensin-converting enzyme inhibitors: lessons and controversy emerging from recent clinical trials.
Renin-angiotensin system modulation: the weight of evidence.
Reperfusion adjunctive therapy.
Right vEntricular Dysfunction in tEtralogy of Fallot: INhibition of the rEnin-angiotensin-aldosterone system (REDEFINE) trial: Rationale and design of a randomized, double-blind, placebo-controlled clinical trial.
Role of angiotensin converting enzyme inhibitors in patients with left ventricular dysfunction and congestive heart failure.
Role of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in the management of atrial fibrillation.
Safety and costs of initiating angiotensin converting enzyme inhibitors for heart failure in primary care: analysis of individual patient data from studies of left ventricular dysfunction.
Safety and tolerability of angiotensin-converting enzyme inhibitor versus the combination of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker in patients with left ventricular dysfunction: a systematic review and meta-analysis of randomized controlled trials.
Sex, quality of care, and outcomes of elderly patients hospitalized with heart failure: findings from the National Heart Failure Project.
Should an angiotensin-converting enzyme inhibitor be standard therapy for patients with atherosclerotic disease?
Similar clinical benefits from below-target and target dose enalapril in patients with heart failure in the SOLVD Treatment trial.
Simultaneous angiotensin converting enzyme inhibition moderates ventricular dysfunction caused by doxorubicin.
Stimulation of plasminogen activator inhibitor in vivo by infusion of angiotensin II. Evidence of a potential interaction between the renin-angiotensin system and fibrinolytic function.
Studies of Left Ventricular Dysfunction (SOLVD) Registry: rationale, design, methods and description of baseline characteristics.
Studies of Left Ventricular Dysfunction (SOLVD).
Summary of AHRQ's comparative effectiveness review of angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers added to standard medical therapy for treating stable ischemic heart disease.
Summary of randomized trials of angiotensin converting enzyme inhibitors.
Sustained inhibition of angiotensin I-converting enzyme (ACE) expression and long-term antihypertensive action by virally mediated delivery of ACE antisense cDNA.
Takotsubo cardiomyopathy, or broken-heart syndrome.
The Angiotensin-converting Enzyme Inhibition Post Revascularization Study (APRES).
The beneficial effects of angiotensin-converting enzyme II (ACE2) activator in pulmonary hypertension secondary to left ventricular dysfunction.
The beta1-adrenergic receptor mediates the pharmacogenetic interaction of the ACE D allele and beta-blockers.
The cost and cardioprotective effects of enalapril in hypertensive patients with left ventricular dysfunction.
The Dual Chamber and VVI Implantable Defibrillator (DAVID) Trial: rationale, design, results, clinical implications and lessons for future trials.
The economics of TRACE. A cost-effectiveness analysis of trandolapril in postinfarction patients with left ventricular dysfunction.
The EUROPA trial: design, baseline demography and status of the substudies.
The genotype of the angiotensin-converting enzyme gene and global left ventricular dysfunction after myocardial infarction.
The Heart Outcomes Prevention Evaluation study: angiotensin-converting enzyme inhibitors: are their benefits a class effect or do individual agents differ?
The impact of race on response to RAAS inhibition.
The long-term impact of the angiotensin-converting enzyme inhibitor trandolapril on mortality and hospital admissions in patients with left ventricular dysfunction after a myocardial infarction: follow-up to 12 years.
The QUinapril Ischemic Event Trial (QUIET) design and methods: evaluation of chronic ACE inhibitor therapy after coronary artery intervention.
The renin-angiotensin system as a target for therapeutic intervention.
The renin-angiotensin system: the role of inhibitors, blockers, and genetic polymorphisms in the treatment and prevention of heart failure.
The use of angiotensin converting enzyme inhibitors in asymptomatic patients with left ventricular dysfunction after myocardial infarction.
The value of angiotensin converting enzyme inhibitors for the treatment of patients with left ventricular dysfunction, heart failure or after acute myocardial infarction.
Therapeutic effects of captopril on ischemia and dysfunction of the left ventricle after Q-wave and non-Q-wave myocardial infarction.
Therapeutic interventions to reduce rates of hospitalization and death in patients with heart failure: new clinical evidence.
Towards 2001: will ACE inhibitors have a role in atherosclerosis treatment?
Translation of clinical trial results into practice.
Treating children with idiopathic dilated cardiomyopathy (from the Pediatric Cardiomyopathy Registry).
Under-diagnosis of diabetes mellitus in patients with coronary artery disease.
Underutilization and clinical benefits of angiotensin-converting enzyme inhibitors in patients with asymptomatic left ventricular dysfunction.
Uniformity of captopril benefit in the SAVE Study: subgroup analysis. Survival and Ventricular Enlargement Study.
Use of ACE Inhibitors for Secondary Prevention.
Use of converting enzyme inhibitors in patients with asymptomatic left ventricular dysfunction.
Use of Sacubitril/valsartan in patients with cardio toxicity and heart failure due to chemotherapy.
Using cardiac biomarkers and treating cardiotoxicity in cancer.
Valsartan: the past, present and future.
Vasodilators after myocardial infarction-ISIS IV.
Ventricular remodeling after myocardial infarction. Experimental and clinical studies.
Ventricular remodeling following myocardial infarction.
[Angiotensin-converting enzyme inhibition and cardiovascular prevention: more than twenty years of clinical success]
[Anthracycline-induced cardiomyopathy.]
[Cardiac insufficiency: what treatment? what dose? For which patients? Converting enzyme inhibitors and diuretics]
[Cardioprotection in women with neoplastic disease].
[Effect of angiotensin-converting enzyme inhibitors in congestive heart failure]
[Effect of chronic therapy with low dose of angiotensin converting enzyme inhibitors on mortality in patients with left ventricular dysfunction after acute myocardial infarction]
[Effect of combined beta-blocker and angiotensin-converting enzyme inhibitor treatment on 1-year survival after acute myocardial infarction: findings of the PRIAMHO-II registry]
[Management of the treatment with converting enzyme inhibitors in chronic heart failure]
[Modern therapy of cardiac insufficiency]
[Temporal trends in pharmacological therapy in the IN-CHF registry from 1995 to 2005]
[The use of angiotensin-converting enzyme inhibitors in left ventricular dysfunction (the generalization of the experience of multicenter studies)]
[Treatment after myocardial infarction]
[Treatment of heart failure: guidelines compared to clinical practice]
[Trends in pharmacological treatment of congestive heart failure]
Ventricular Dysfunction, Right
Discontinuation of furosemide decreases PaCO(2) in patients with COPD.
The effect of three major co-morbidities on quality of life and outcome of patients with heart failure with reduced ejection fraction.
Ventricular Fibrillation
Cardioprotective effects of ACE inhibitors: experimental proof and clinical perspectives.
Chronic oral pretreatment with the angiotensin converting enzyme inhibitor, trandolapril decreases ventricular fibrillation in acute ischaemia and reperfusion.
Inhibition of angiotensin-converting enzyme reduces susceptibility of hypertrophied rat myocardium to ventricular fibrillation.
Protective effect of angiotensin converting enzyme inhibitors (CEI): captopril and perindopril on vulnerability to ventricular fibrillation during myocardial ischemia and reperfusion in rat.
The potential mechanisms of reduced incidence of ventricular fibrillation as the presenting rhythm in sudden cardiac arrest.
Underuse of standard care and outcome of patients with acute myocardial infarction and chronic renal insufficiency.
Ventricular Premature Complexes
Differential effects of a long-acting angiotensin converting enzyme inhibitor (temocapril) and a long-acting calcium antagonist (amlodipine) on ventricular ectopic beats in older hypertensive patients.
Prognostic significance of ventricular late potentials in patients with pulmonary sarcoidosis.
Vesico-Ureteral Reflux
Angiotensin Converting Enzyme Gene Insertion/Deletion Polymorphism and Vesicoureteral Reflux in Children: A Meta-Analysis of 14 Case-Control Studies.
Angiotensin converting enzyme gene polymorphism in primary vesicoureteral reflux.
Angiotensin-converting enzyme genotype distribution in familial vesicoureteral reflux.
Association of ACE I/D gene polymorphism with vesicoureteral reflux susceptibility in children: a meta-analysis.
Fatal Renal Failure in a Spinal Cord Injury Patient with Vesicoureteric Reflux Who Underwent Repeated Ureteric Reimplantations Unsuccessfully: Treatment Should Focus on Abolition of High Intravesical Pressures rather than Surgical Correction of Reflux.
Is ACE gene polymorphism a risk factor for renal scarring with low-grade reflux?
Renin-angiotensin system polymorphisms in Taiwanese primary vesicoureteral reflux.
Risk factors for the development of renal parenchymal damage in familial vesicoureteral reflux.
Virus Diseases
A consensus statement on the use of angiotensin receptor blockers and angiotensin converting enzyme inhibitors in relation to COVID-19 (corona virus disease 2019).
Ayurveda and Allopathic Therapeutic Strategies in Coronavirus Pandemic Treatment 2020.
Biophysical analysis of SARS-CoV-2 transmission and theranostic development via N protein computational characterization.
Clinical Practice Guidelines for Diagnosis and Management of Hypersensitivity Reactions to Contrast Media.
Coronavirus Disease 2019 and Nasal Conditions: A Review of Current Evidence.
Correcting the imbalanced protective RAS in COVID-19 with angiotensin AT2-receptor agonists.
COVID-19 and Kidney Disease: Molecular Determinants and Clinical Implications in Renal Cancer.
Current approaches for target-specific drug discovery using natural compounds against SARS-CoV-2 infection.
Emerging SARS-CoV-2 Variants and Impact in Global Vaccination Programs against SARS-CoV-2/COVID-19.
Follow-up of three patients with a large in-frame deletion of exons 45-55 in the Duchenne muscular dystrophy (DMD) gene.
Genetic Dissection of the Regulatory Mechanisms of Ace2 in the Infected Mouse Lung.
Hematologic toxicity of immunosuppressive treatment.
Immune function of an angiotensin-converting enzyme against Rice stripe virus infection in a vector insect.
Immunomodulatory and anti-cytokine therapeutic potential of curcumin and its derivatives for treating COVID-19 - a computational modeling.
Impact of angiotensin-converting enzyme inhibitors and statins on viral pneumonia.
Impairment of olfactory and gustatory sensations in severe acute respiratory syndrome corona virus 2 (SARS-CoV-2 virus) disease.
In the eye of the storm: the right ventricle in COVID-19.
Increased Time Exposure to Tenofovir Is Associated with a Greater Decrease in Estimated Glomerular Filtration Rate in HIV Patients with Kidney Function of Less than 60 ml/min/1.73 m.
Lichen planus.
Nutraceutical management of metabolic syndrome as a palliative and a therapeutic to coronavirus disease (COVID) crisis.
Possible role of angiotensin-converting enzyme polymorphism on progression of hepatic fibrosis in chronic hepatitis C virus infection.
Risk of viral infection in patients using either angiotensin-converting enzyme inhibitors or angiotensin receptor blockers: A nationwide population-based propensity score matching study.
Role of ACE2 in pregnancy and potential implications for COVID-19 susceptibility.
SARS-CoV-2 Infects Human Engineered Heart Tissues and Models COVID-19 Myocarditis.
Serum activity of angiotensin converting enzyme (ACE) is not affected by hepatitis B viral infection.
Serum angiotensin-converting enzyme level is elevated in patients with human immunodeficiency virus infection.
The Effect of Helicobacter pylori on the Presentation and Clinical Course of Coronavirus Disease 2019 Infection.
The Impact of Statin and Angiotensin-Converting Enzyme Inhibitor/Angiotensin Receptor Blocker Therapy on Cognitive Function in Adults With Human Immunodeficiency Virus Infection.
[Pravovirus B19 infection--the cause of severe anaemia after renal transplantation]
Vitamin D Deficiency
Addition of vitamin D reverses the decline in GFR following treatment with ACE inhibitors/angiotensin receptor blockers in patients with chronic kidney disease.
The association of vitamin D deficiency and insufficiency with diabetic nephropathy: implications for health disparities.
Whether vitamin D3 is effective in reducing proteinuria in type 2 diabetic patients?
Vitiligo
An insertion/deletion polymorphism in the gene encoding angiotensin converting enzyme is not associated with generalised vitiligo in an English population.
Angiotensin converting enzyme (ACE) gene polymorphism in vitiligo: protective and predisposing effects of genotypes in disease susceptibility and progression.
Association between IL4 (-590), ACE (I)/(D), CCR5 (Delta32), CTLA4 (+49) and IL1-RN (VNTR in intron 2) gene polymorphisms and vitiligo.
Association of ACE gene I/D polymorphism with vitiligo: a meta-analysis.
Association of angiotensin converting enzyme gene I/D polymorphism of vitiligo in Korean population.
Association of Angiotensin-Converting Enzyme (ACE) Gene Polymorphism with Inflammation and Cellular Cytotoxicity in Vitiligo Patients.
Association of Angiotensin-Converting Enzyme ACE Gene Polymorphism with ACE Activity and Susceptibility to Vitiligo in Egyptian Population.
Associations of Angiotensin-Converting Enzyme Gene Insertion/Deletion (ACE Gene I/D) Polymorphism With Vitiligo: An Updated Systematic Review and Meta-Analysis.
Deleterious effect of angiotensin-converting enzyme gene polymorphism in vitiligo patients.
The angiotensin-converting enzyme gene insertion/deletion polymorphism in Indian vitiligo patients: a case-control study and meta-analysis.
The angiotensin-converting enzyme insertion/deletion polymorphism and susceptibility to rheumatoid arthritis, vitiligo and psoriasis: A meta-analysis.
Vocal Cord Dysfunction
Differential diagnosis of chronic cough.
Werner Syndrome
ACE, PAI-1, decorin and Werner helicase genes are not associated with the development of renal disease in European patients with type 1 diabetes.
Whooping Cough
Differential diagnosis of chronic cough.
Wilms Tumor
Auxiliary genetic analysis in a Chinese adolescent NPH family by single nucleotide polymorphism screening.
Severe polyuria and polydipsia in hyponatremic-hypertensive syndrome associated with Wilms tumor.
Xerostomia
Influence of dual blockade of the renin-angiotensin system on thirst in hemodialysis patients.
Potential oral manifestations of cardiovascular drugs.